PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	COHEN, AR				COHEN, AR			IMAGES IN CLINICAL MEDICINE - COLLOID CYST OF THE 3RD VENTRICLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											COHEN, AR (corresponding author), RAINBOW BABIES & CHILDRENS HOSP,2101 ADELBERT RD,CLEVELAND,OH 44106, USA.								0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 11	1995	332	19					1267	1267		10.1056/NEJM199505113321905	http://dx.doi.org/10.1056/NEJM199505113321905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW600	7708071				2022-12-28	WOS:A1995QW60000005
J	TAN, HL; HOU, CJY; LAUER, MR; SUNG, RJ				TAN, HL; HOU, CJY; LAUER, MR; SUNG, RJ			ELECTROPHYSIOLOGIC MECHANISMS OF THE LONG QT INTERVAL SYNDROMES AND TORSADE-DE-POINTES	ANNALS OF INTERNAL MEDICINE			English	Review							CARDIAC PURKINJE-FIBERS; POLYMORPHOUS VENTRICULAR-TACHYCARDIA; INDUCED EARLY AFTERDEPOLARIZATIONS; MONOPHASIC ACTION-POTENTIALS; PRENYLAMINE-INDUCED TORSADE; III ANTIARRHYTHMIC AGENTS; DEPENDENT PROTEIN-KINASE; DE-POINTES; TRIGGERED ACTIVITY; POTASSIUM CHANNEL	Purpose: To review the current understanding of the mechanisms and treatment of the long QT interval syndromes and torsade de pointes. Data Sources: Personal databases of the authors and a search of the MEDLINE database from 1966 to 1994. Study Selection: Experimental and clinical studies and topical reviews on the electrophysiologic mechanisms and treatment of torsade de pointes were analyzed. Results: The long QT interval syndromes have been classified into acquired and hereditary forms, both of which are associated with a characteristic type of life-threatening polymorphic ventricular tachycardia called torsade de pointes. The acquired form is caused by various agents and conditions that reduce the magnitude of outward repolarizing K+ currents, enhance inward depolarizing Na+ or Ca2+ currents, or both, thereby triggering the development of early afterdepolarizations that initiate the tachyarrhythmia. The hereditary form appears to result from an abnormal response to adrenergic or sympathetic nervous system stimulation. At least some cases of the hereditary long QT interval syndromes may result from a single gene defect that alters the intracellular regulatory proteins responsible for the modulation of K+ channel function. Treatment of the acquired form is primarily directed at identifying and withdrawing the offending agent, although emergent therapy using maneuvers and agents that favorably modulate transmembrane ion currents can be lifesaving. In torsade de pointes associated with the hereditary long QT interval syndromes, early diagnosis leading to treatments designed to both shorten the QT interval and block the beta-adrenergic-induced instability of the QT interval is essential. Conclusions: The long QT interval syndromes and torsade de pointes are potentially life-threatening conditions caused by various agents, conditions, and genetic defects. The mechanisms responsible for these conditions and available treatment options for them are reviewed.	STANFORD UNIV, SCH MED, STANFORD, CA USA	Stanford University								ABINADER EG, 1983, CARDIOLOGY, V70, P37, DOI 10.1159/000173567; ALDARIZ AE, 1986, PACE, V9, P836, DOI 10.1111/j.1540-8159.1986.tb06633.x; [Anonymous], 1989, NEW ENGL J MED, V321, P406; ANTZELEVITCH C, 1994, J AM COLL CARDIOL, V23, P259, DOI 10.1016/0735-1097(94)90529-0; APKON M, 1988, P NATL ACAD SCI USA, V85, P8756, DOI 10.1073/pnas.85.22.8756; ARNSDORF MF, 1976, CIRC RES, V38, P115, DOI 10.1161/01.RES.38.2.115; ATTWELL D, 1988, LANCET, V1, P1136; ATTWELL D, 1979, PFLUG ARCH EUR J PHY, V379, P137, DOI 10.1007/BF00586939; BAILIE DS, 1988, CIRCULATION, V77, P1395, DOI 10.1161/01.CIR.77.6.1395; BANAI S, 1993, J CARDIOVASC ELECTR, V4, P206, DOI 10.1111/j.1540-8167.1993.tb01224.x; BAUER MF, 1994, CHEST, V105, P1876, DOI 10.1378/chest.105.6.1876; BAUMAN JL, 1984, AM HEART J, V107, P425, DOI 10.1016/0002-8703(84)90081-4; BAYER R, 1988, CURR MED RES OPIN, V11, P254, DOI 10.1185/03007998809114244; BEN-HAIM S A, 1992, Pharmacology and Toxicology, V70, P402; BENDAVID J, 1990, CIRCULATION, V82, P225, DOI 10.1161/01.CIR.82.1.225; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BHANDARI AK, 1985, CIRCULATION, V71, P63, DOI 10.1161/01.CIR.71.1.63; BHANDARI AK, 1984, PACE, V7, P341, DOI 10.1111/j.1540-8159.1984.tb04915.x; BONATTI V, 1983, EUR HEART J, V4, P168, DOI 10.1093/oxfordjournals.eurheartj.a061436; BRACHMANN J, 1983, CIRCULATION, V68, P846, DOI 10.1161/01.CIR.68.4.846; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; BRUCKNER R, 1985, J MOL CELL CARDIOL, V17, P639, DOI 10.1016/S0022-2828(85)80063-8; BRUM G, 1983, PFLUG ARCH EUR J PHY, V398, P147, DOI 10.1007/BF00581064; BURSILL JA, 1994, J CARDIOVASC PHARM, V23, P833, DOI 10.1097/00005344-199405000-00021; CARLSSON L, 1993, CARDIOVASC RES, V27, P2186, DOI 10.1093/cvr/27.12.2186; CARLSSON L, 1990, J CARDIOVASC PHARM, V16, P276, DOI 10.1097/00005344-199008000-00014; CARLSSON L, 1992, CIRCULATION, V85, P1491, DOI 10.1161/01.CIR.85.4.1491; CARLSSON L, 1993, J PHARMACOL EXP THER, V267, P1076; CARMELIET E, 1982, CIRC RES, V50, P257, DOI 10.1161/01.RES.50.2.257; CHEN Y W, 1991, Journal of the American College of Cardiology, V17, p140A; COLQUHOUN D, 1981, NATURE, V294, P752, DOI 10.1038/294752a0; COSIO FG, 1991, EUR HEART J, V12, P635, DOI 10.1093/oxfordjournals.eurheartj.a059952; CRANEFIELD PF, 1977, CIRC RES, V41, P415, DOI 10.1161/01.RES.41.4.415; CRANEFIELD PF, 1991, CARDIOVASC DRUG THER, V5, P531, DOI 10.1007/BF03029780; CURRY P, 1976, LANCET, V2, P231; DAMIANO BP, 1984, CIRCULATION, V69, P1013, DOI 10.1161/01.CIR.69.5.1013; DEKEYSER J, 1987, INTENS CARE MED, V13, P76, DOI 10.1007/BF00263564; Dessertenne F, 1966, Arch Mal Coeur Vaiss, V59, P263; DIFRANCESCO D, 1988, J PHYSIOL-LONDON, V405, P477, DOI 10.1113/jphysiol.1988.sp017343; DIPASQUALE G, 1988, INT J CARDIOL, V18, P163, DOI 10.1016/0167-5273(88)90162-3; DISEGNI E, 1980, ARCH INTERN MED, V140, P1036, DOI 10.1001/archinte.140.8.1036; DONATINI B, 1992, CARDIOLOGY, V81, P340, DOI 10.1159/000175827; EISNER DA, 1986, HEART CARDIOVASCULAR, P489; EL-SHERIF N, 1990, Journal of Cardiovascular Electrophysiology, V1, P145, DOI 10.1111/j.1540-8167.1990.tb01057.x; ELSHERIF N, 1988, CIRC RES, V63, P286, DOI 10.1161/01.RES.63.2.286; FAUCHIER JP, 1974, ANN CARDIOL ANGEIOL, V23, P341; FISH FA, 1990, CIRCULATION, V82, P1362, DOI 10.1161/01.CIR.82.4.1362; FREDLUND BO, 1983, ACTA MED SCAND, V213, P231; GINTANT GA, 1984, BIOPHYS J, V45, P509, DOI 10.1016/S0006-3495(84)84187-9; GITLER B, 1994, CHEST, V105, P368, DOI 10.1378/chest.105.2.368; GLASSMAN AH, 1993, JAMA-J AM MED ASSOC, V269, P2673, DOI 10.1001/jama.269.20.2673; GOSS JE, 1993, ARCH INTERN MED, V153, P2705, DOI 10.1001/archinte.1993.00410230129016; GOUGH WB, 1989, CARDIOVASC RES, V23, P554, DOI 10.1093/cvr/23.6.554; HABBAB MA, 1992, PACE, V15, P916, DOI 10.1111/j.1540-8159.1992.tb03082.x; HAN J, 1964, CIRC RES, V14, P516, DOI 10.1161/01.RES.14.6.516; HAN J, 1964, CIRC RES, V14, P44, DOI 10.1161/01.RES.14.1.44; HANICH RF, 1988, CIRCULATION, V77, P1149, DOI 10.1161/01.CIR.77.5.1149; HANLEY SP, 1983, EUR HEART J, V4, P889, DOI 10.1093/oxfordjournals.eurheartj.a061417; HIRAOKA M, 1992, ANN NY ACAD SCI, V644, P33, DOI 10.1111/j.1749-6632.1992.tb31000.x; HOFFMAN BF, 1981, CIRC RES, V49, P1, DOI 10.1161/01.RES.49.1.1; HOHNLOSER SH, 1992, PACE, V15, P2211, DOI 10.1111/j.1540-8159.1992.tb03049.x; HONDEGHEM LM, 1990, CIRCULATION, V81, P686, DOI 10.1161/01.CIR.81.2.686; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; JACKMAN W M, 1990, Journal of Cardiovascular Electrophysiology, V1, P170, DOI 10.1111/j.1540-8167.1990.tb01059.x; JACKMAN WM, 1988, PROG CARDIOVASC DIS, V31, P115, DOI 10.1016/0033-0620(88)90014-X; JANSE MJ, 1992, EUR HEART J, V13, P30, DOI 10.1093/eurheartj/13.suppl_F.30; JANUARY C T, 1990, Journal of Cardiovascular Electrophysiology, V1, P161, DOI 10.1111/j.1540-8167.1990.tb01058.x; JANUARY CT, 1992, ANN NY ACAD SCI, V644, P23, DOI 10.1111/j.1749-6632.1992.tb30999.x; JANUARY CT, 1988, CIRC RES, V62, P563, DOI 10.1161/01.RES.62.3.563; JANUARY CT, 1989, CIRC RES, V64, P977, DOI 10.1161/01.RES.64.5.977; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; JURKIEWICZ NK, 1993, CIRC RES, V72, P75, DOI 10.1161/01.RES.72.1.75; KAPLINSKY E, 1972, CHEST, V62, P764, DOI 10.1378/chest.62.6.764; KASEDA S, 1990, Journal of Cardiovascular Electrophysiology, V1, P31, DOI 10.1111/j.1540-8167.1990.tb01046.x; KASEDA S, 1989, AM HEART J, V118, P458, DOI 10.1016/0002-8703(89)90258-5; KASS RS, 1978, J PHYSIOL-LONDON, V281, P187, DOI 10.1113/jphysiol.1978.sp012416; KATSUKI T, 1994, PACE, V17, P763; KAY GN, 1983, J AM COLL CARDIOL, V2, P806; KEARNEY P, 1993, BRIT HEART J, V70, P473; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; KEMPER AJ, 1983, JAMA-J AM MED ASSOC, V249, P2931, DOI 10.1001/jama.249.21.2931; KEREN G, 1984, J AM COLL CARDIOL, V4, P742, DOI 10.1016/S0735-1097(84)80401-5; KUMAR A, 1987, ANN INTERN MED, V106, P712, DOI 10.7326/0003-4819-106-5-712; KUO CS, 1983, CIRCULATION, V67, P1356, DOI 10.1161/01.CIR.67.6.1356; KURITA T, 1993, PACE, V16, P33, DOI 10.1111/j.1540-8159.1993.tb01532.x; LAZZARA R, 1989, ANN INTERN MED, V111, P549, DOI 10.7326/0003-4819-111-7-549; LAZZARA R, 1990, CARDIAC ELECTROPHYSI, P402; LEENHARDT A, 1994, CIRCULATION, V89, P206, DOI 10.1161/01.CIR.89.1.206; LEVINE JH, 1985, CIRCULATION, V72, P1092, DOI 10.1161/01.CIR.72.5.1092; LINDEMANN JP, 1990, CARDIAC ELECTROPHYSI, P277; LITTLE RE, 1990, PACE, V13, P164, DOI 10.1111/j.1540-8159.1990.tb05066.x; LOPEZ JA, 1987, AM J CARDIOL, V59, P376, DOI 10.1016/0002-9149(87)90824-1; LUDOMIRSKY A, 1982, AM J CARDIOL, V49, P1654, DOI 10.1016/0002-9149(82)90242-9; MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590; MANALAN AS, 1982, J BIOL CHEM, V257, P52; MARBAN E, 1986, J CLIN INVEST, V78, P1185, DOI 10.1172/JCI112701; MASON JW, 1993, NEW ENGL J MED, V329, P452, DOI 10.1056/NEJM199308123290702; MATTIONI TA, 1989, ANN INTERN MED, V111, P574, DOI 10.7326/0003-4819-111-7-574; MAURO VF, 1988, CRIT CARE MED, V16, P200, DOI 10.1097/00003246-198802000-00020; MCKIBBIN JK, 1984, BRIT HEART J, V51, P157; METZGER E, 1993, J CLIN PSYCHOPHARM, V13, P128; MOSS AJ, 1991, CIRCULATION, V84, P1524, DOI 10.1161/01.CIR.84.4.1524; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; NATTEL S, 1988, CARDIOVASC RES, V22, P808, DOI 10.1093/cvr/22.11.808; NAYEBPOUR M, 1990, J CARDIOVASC PHARM, V15, P552, DOI 10.1097/00005344-199004000-00005; NGUYEN PT, 1986, CIRCULATION, V74, P340, DOI 10.1161/01.CIR.74.2.340; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NOBE S, 1993, GEN PHARMACOL, V24, P1187, DOI 10.1016/0306-3623(93)90367-7; NOBLE D, 1992, ANN NY ACAD SCI, V644, P1, DOI 10.1111/j.1749-6632.1992.tb30998.x; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; OHE T, 1990, JPN CIRC J, V54, P1323, DOI 10.1253/jcj.54.10_1323; PEPER K, 1967, PFLUG ARCH GES PHYS, V296, P328, DOI 10.1007/BF00362532; POHJOLASINTONEN S, 1993, EUR J CLIN PHARMACOL, V45, P191, DOI 10.1007/BF00315505; PRINGLE TH, 1983, INT J OBESITY, V7, P253; PRIORI S G, 1990, Journal of Cardiovascular Electrophysiology, V1, P529, DOI 10.1111/j.1540-8167.1990.tb01087.x; PRIORI SG, 1991, CARDIOVASC DRUG THER, V5, P203, DOI 10.1007/BF03029822; PRIORI SG, 1994, CIRCULATION, V89, P1681, DOI 10.1161/01.CIR.89.4.1681; PRIORI SG, 1990, AM J PHYSIOL, V258, pH1796, DOI 10.1152/ajpheart.1990.258.6.H1796; REDWOOD S, 1994, CIRCULATION, V90, P524; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; RODEN DM, 1986, J AM COLL CARDIOL, V8, pA73, DOI 10.1016/S0735-1097(86)80032-8; RODEN DM, 1985, CIRC RES, V56, P857, DOI 10.1161/01.RES.56.6.857; ROMANO C, 1963, Clin Pediatr (Bologna), V45, P656; ROSEN MR, 1992, J CARDIOVASC ELECTR, V3, P487, DOI 10.1111/j.1540-8167.1992.tb00991.x; ROTEM M, 1988, NEUROSURGERY, V23, P89, DOI 10.1227/00006123-198807000-00015; RUBART M, 1993, CIRCULATION, V88, P1832, DOI 10.1161/01.CIR.88.4.1832; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SALLE P, 1985, ANN CARDIOL ANGEIOL, V34, P381; SARELI P, 1987, CLIN CARDIOL, V10, P361, DOI 10.1002/clc.4960100514; SARTORI M, 1984, AM J MED, V77, P388, DOI 10.1016/0002-9343(84)90728-9; SCHOMIG A, 1984, CIRC RES, V55, P689, DOI 10.1161/01.RES.55.5.689; SCHREM SS, 1990, AM HEART J, V120, P980, DOI 10.1016/0002-8703(90)90221-I; SCHWARTZ PJ, 1990, CARDIAC ELECTROPHYSI, P589; SELZER A, 1964, CIRCULATION, V30, P17, DOI 10.1161/01.CIR.30.1.17; SEN S, 1984, INTENS CARE MED, V10, P263; SHAH A, 1988, BIOPHYS J, V54, P219, DOI 10.1016/S0006-3495(88)82950-3; SHIMIZU K, 1992, AM HEART J, V124, P235, DOI 10.1016/0002-8703(92)90954-T; SHIMIZU W, 1994, J CARDIOVASC ELECTR, V5, P438, DOI 10.1111/j.1540-8167.1994.tb01183.x; SINGH BN, 1992, AM J CARDIOL, V69, pD79; SINGH BN, 1978, JAMA-J AM MED ASSOC, V240, P115, DOI 10.1001/jama.240.2.115; SOLTI F, 1987, COR VASA, V29, P428; SONG YJ, 1992, CIRC RES, V70, P743, DOI 10.1161/01.RES.70.4.743; SPINELLI W, 1991, CIRC RES, V68, P1127, DOI 10.1161/01.RES.68.4.1127; STERNS LD, 1994, PACE, V17, P763; SURAWICZ B, 1989, J AM COLL CARDIOL, V14, P172, DOI 10.1016/0735-1097(89)90069-7; SZABO B, 1987, J AM COLL CARDIOL, V9, pA210; SZABO B, 1988, FASEB J, V2, P5710; SZABO B, 1985, FED PROC, V44, P2307; TAKAHASHI N, 1992, CIRCULATION, V86, P1987, DOI 10.1161/01.CIR.86.6.1987; TAKAHASHI N, 1991, CARDIOVASC RES, V25, P445, DOI 10.1093/cvr/25.6.445; THOMPSON KA, 1988, CLIN PHARMACOL THER, V43, P636, DOI 10.1038/clpt.1988.88; TOHSE N, 1987, AM J PHYSIOL, V253, pH1321, DOI 10.1152/ajpheart.1987.253.5.H1321; TSIEN RW, 1972, NATURE-NEW BIOL, V240, P181, DOI 10.1038/newbio240181a0; TSIEN RW, 1985, CARDIAC ELECTROPHYSI, P19; TZIVONI D, 1988, CIRCULATION, V77, P392, DOI 10.1161/01.CIR.77.2.392; VINCENT GM, 1992, J AM COLL CARDIOL, V20, P500, DOI 10.1016/0735-1097(92)90123-5; VOS MA, 1994, J AM COLL CARDIOL, pA282; VOS MA, 1992, CIRCULATION, V86, P560; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; WANG JJ, 1993, CIRCULATION, V88, P1030, DOI 10.1161/01.CIR.88.3.1030; WARD O C, 1964, J Ir Med Assoc, V54, P103; WATANABE AM, 1977, CIRC RES, V40, P596, DOI 10.1161/01.RES.40.6.596; WELD FM, 1980, CIRC RES, V46, P167, DOI 10.1161/01.RES.46.2.167; WESLEY RC, 1992, AM HEART J, V123, P794, DOI 10.1016/0002-8703(92)90525-Z; WHARTON JM, 1987, AM J MED, V83, P571, DOI 10.1016/0002-9343(87)90774-1; Wiggers CJ, 1940, AM HEART J, V20, P399, DOI 10.1016/S0002-8703(40)90874-2; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZAZA A, 1989, J PHARMACOL EXP THER, V250, P397; ZEHENDER M, 1990, CLIN PHYSIOL BIOCH, V8, P90	171	194	195	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					701	714		10.7326/0003-4819-122-9-199505010-00009	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00009			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702233				2022-12-28	WOS:A1995QV15100009
J	FRASER, AM; BROCKERT, JE; WARD, RH				FRASER, AM; BROCKERT, JE; WARD, RH			ASSOCIATION OF YOUNG MATERNAL AGE WITH ADVERSE REPRODUCTIVE OUTCOMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-BIRTH-WEIGHT; TEENAGE PREGNANCY; PRENATAL-CARE; ADOLESCENT PREGNANCY; PRETERM DELIVERY; ADULT WOMEN; RISK; POPULATION; HEALTH; GROWTH	Background. Pregnancy in adolescence is associated with an excess risk of poor outcomes, including low birth weight and prematurity, Whether this association simply reflects the deleterious sociodemographic environment of most pregnant teenagers or whether biologic immaturity is also causally implicated is not known, Methods. To determine whether a young age confers an intrinsic risk of adverse outcomes of pregnancy, we performed stratified analyses of 134,088 white girls and women, 13 to 24 years old, in Utah who delivered singleton, first-born children between 1970 and 1990. Relative risk for subgroups of this study population was examined to eliminate the confounding influence of marital status, educational level, and the adequacy of prenatal care, The adjusted relative risk for the entire study group was calculated as the weighted average of the stratum-specific risks. Results. Among white married mothers with educational levels appropriate for their ages who received adequate prenatal care, younger teenage mothers (13 to 17 years of age) had a significantly higher risk (P<0.001) than mothers who were 20 to 24 years of age of delivering an infant who had low birth weight (relative risk, 1.7; 95 percent confidence interval, 1.5 to 2.0), who was delivered prematurely (relative risk, 1.9; 95 percent confidence interval, 1.7 to 2.1), or who was small for gestational age (relative risk, 1.3; 95 percent confidence interval, 1.2 to 1.4). Older teenage mothers (18 or 19 years of age) also had a significant increase in these risks, Even though sociodemographic variables associated with teenage pregnancy increase the risk of adverse outcomes, the relative risk remained significantly elevated for both younger and older teenage mothers after adjustment for marital status, level of education, and adequacy of prenatal care. Conclusions. In a study of mothers 13 to 24 years old who had the characteristics of most white, middle-class Americans, a younger age conferred an increased risk of adverse pregnancy outcomes that was independent of important confounding sociodemographic factors.	UNIV UTAH,ECCLES INST HUMAN GENET 2100,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UTAH DEPT HLTH,BUR VITAL RECORDS,SALT LAKE CITY,UT	Utah System of Higher Education; University of Utah					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023492] Funding Source: NIH RePORTER; NICHD NIH HHS [1R01 HD23492] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahmed F, 1990, J Community Health, V15, P35, DOI 10.1007/BF01350184; ANNIE E, 1992, KIDS COUNT DATA BOOK, P110; BROWN HL, 1991, SOUTHERN MED J, V84, P46, DOI 10.1097/00007611-199101000-00012; BUCHI KF, 1993, OBSTET GYNECOL, V81, P239; DAVID RJ, 1983, SOUTHERN MED J, V76, P1401, DOI 10.1097/00007611-198311000-00020; DIXON WJ, 1990, BMDP STATISTICAL SOF, V1, P231; DUNN PM, 1985, ACTA PAEDIATR SC   S, V319, P7; EISNER V, 1979, AM J PUBLIC HEALTH, V69, P887, DOI 10.2105/AJPH.69.9.887; ELSTER AB, 1984, AM J OBSTET GYNECOL, V149, P845, DOI 10.1016/0002-9378(84)90602-1; FRIEDE A, 1987, PUBLIC HEALTH REP, V102, P192; GALE R, 1989, J ADOLESCENT HEALTH, V10, P404, DOI 10.1016/0197-0070(89)90219-2; HAIEK L, 1989, J ADOLESCENT HEALTH, V10, P16, DOI 10.1016/0197-0070(89)90041-7; HEDIGER ML, 1989, OBSTET GYNECOL, V74, P6; HORON IL, 1983, AM J OBSTET GYNECOL, V146, P444, DOI 10.1016/0002-9378(83)90826-8; KETTERLINUS RD, 1990, J ADOLESCENT HEALTH, V11, P423, DOI 10.1016/0197-0070(90)90090-O; LEE KS, 1988, AM J OBSTET GYNECOL, V158, P84, DOI 10.1016/0002-9378(88)90783-1; MAKINSON C, 1985, FAM PLANN PERSPECT, V17, P132, DOI 10.2307/2135024; MCANARNEY ER, 1987, AM J DIS CHILD, V141, P1053, DOI 10.1001/archpedi.1987.04460100031017; Rothman K, 1986, MODERN EPIDEMIOLOGY; Scholl T O, 1989, Paediatr Perinat Epidemiol, V3, P357, DOI 10.1111/j.1365-3016.1989.tb00524.x; SCHOLL TO, 1988, LANCET, V1, P701, DOI 10.1016/S0140-6736(88)91494-8; SCHOLL TO, 1987, OBSTET GYNECOL, V69, P312; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; TRUSSELL J, 1988, FAM PLANN PERSPECT, V20, P262, DOI 10.2307/2135482; TURNER RJ, 1990, J HEALTH SOC BEHAV, V31, P43, DOI 10.2307/2137044; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203; 1993, EXECUTIVE SUMMARY MA; 1993, MMWR-MORBID MORTAL W, V42, P230; 1992, 162 UT STAT U DEP SO; 1993, MMWR-MORBID MORTAL W, V42, P255; [No title captured]; 1993, 167 UT STAT U DEP SO; 1993, MON VITAL STAT REP S, V42; 1991, STATISTICAL ABSTRACT, P63	34	609	642	0	46	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	1995	332	17					1113	1117		10.1056/NEJM199504273321701	http://dx.doi.org/10.1056/NEJM199504273321701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QU302	7700283				2022-12-28	WOS:A1995QU30200001
J	AUGUST, P; MUELLER, FB; SEALEY, JE; EDERSHEIM, TG				AUGUST, P; MUELLER, FB; SEALEY, JE; EDERSHEIM, TG			ROLE OF RENIN-ANGIOTENSIN SYSTEM IN BLOOD-PRESSURE REGULATION IN PREGNANCY	LANCET			English	Note							PREECLAMPSIA	We gave captopril (25 mg) to nine pregnant and eight nonpregnant women. From baseline to 60 min post-captopril, mean arterial pressure decreased significantly more in pregnant than in non-pregnant women (mean 15.0 [SE 25] vs 5.2 [1.2] mm Hg; difference 9.8 [95% CI 3.9-1.59] mm Hg, p=0.0036), whereas plasma renin activity increased significantly more in the pregnant group (18.0 [5.5] vs 4.5 [1.9] ng mL(-1) h(-1); difference 13.5 [0.71-26.5], p=0.043). These findings support the hypothesis that stimulation of the renin-angiotensin system in pregnancy maintains blood pressure.	CORNELL UNIV,MED CTR,NEW YORK HOSP,CTR CARDIOVASC,DEPT OBSTET & GYNECOL,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital	AUGUST, P (corresponding author), CORNELL UNIV,MED CTR,NEW YORK HOSP,CTR CARDIOVASC,DEPT MED,NEW YORK,NY 10021, USA.				NHLBI NIH HHS [HL-18323, HL-40152] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040152, P50HL018323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUGUST P, 1990, AM J OBSTET GYNECOL, V163, P1612, DOI 10.1016/0002-9378(90)90639-O; HANSSENS M, 1991, OBSTET GYNECOL, V78, P128; LARAGH JH, 1992, HDB RENAL PHYSL, P1409; LENZ T, 1991, AM J PHYSIOL, V260, pE876, DOI 10.1152/ajpendo.1991.260.6.E876; LINDHEIMER MD, 1992, KIDNEY PHYSL PATHOPH, P3371; MACGREGOR GA, 1981, NATURE, V291, P329, DOI 10.1038/291329a0; MULLER FB, 1986, AM J MED, V80, P633, DOI 10.1016/0002-9343(86)90819-3; SCHRIER RW, 1991, OBSTET GYNECOL, V77, P632; SEALEY JE, 1991, CLIN CHEM, V37, P1811; Skinner SL, 1993, RENIN ANGIOTENSIN SY, V1	10	36	36	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					896	897		10.1016/S0140-6736(95)90012-8	http://dx.doi.org/10.1016/S0140-6736(95)90012-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707813				2022-12-28	WOS:A1995QR06700012
J	GEISSLER, A; ANDUS, T; ROTH, M; KULLMANN, F; CAESAR, I; HELD, P; GROSS, V; FEUERBACH, S; SCHOLMERICH, J				GEISSLER, A; ANDUS, T; ROTH, M; KULLMANN, F; CAESAR, I; HELD, P; GROSS, V; FEUERBACH, S; SCHOLMERICH, J			FOCAL WHITE-MATTER LESIONS IN BRAIN OF PATIENTS WITH INFLAMMATORY BOWEL-DISEASE	LANCET			English	Note							CROHNS-DISEASE	Inflammatory bowel diseases are often associated with extra-intestinal manifestations, such as arthritis and iritis/uveitis. Using magnetic-resonance imaging we found hyperintense focal white-matter lesions in the brain in 20 of 48 (42%) patients with Crohn's disease, in 11 of 24 (46%) patients with ulcerative colitis, but in only 8 of 50 (16%) healthy age-matched controls (relative risk [95% CI] vs controls 2.6 [1.3-5.3] and 2.9 [1.3-6.2], respectively). These findings may represent another extra-intestinal manifestation of inflammatory bowel disease.	UNIV REGENSBURG,DEPT INTERNAL MED 1,D-93042 REGENSBURG,GERMANY; UNIV REGENSBURG,DEPT RADIOL,D-93042 REGENSBURG,GERMANY	University of Regensburg; University of Regensburg								ADAMEK RJ, 1993, LEBER MAGEN DARM, V23, P91; BELL CL, 1991, ARTHRITIS RHEUM, V34, P432, DOI 10.1002/art.1780340408; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; ERDEM E, 1993, NEURORADIOLOGY, V35, P142, DOI 10.1007/BF00593971; HORIKOSHI T, 1993, NEURORADIOLOGY, V35, P151, DOI 10.1007/BF00593975; ISHIKAWA O, 1994, J RHEUMATOL, V21, P87; MEGURO K, 1993, NEURORADIOLOGY, V35, P125, DOI 10.1007/BF00593968; MORRISSEY SP, 1993, BRAIN, V116, P135, DOI 10.1093/brain/116.1.135; RACHMILEWITZ D, 1989, BRIT MED J, V198, P82; WAKEFIELD AJ, 1989, LANCET, V2, P1057	10	96	99	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					897	898						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707814				2022-12-28	WOS:A1995QR06700013
J	LEESE, B; BOSANQUET, N				LEESE, B; BOSANQUET, N			FAMILY DOCTORS AND CHANGE IN PRACTICE STRATEGY SINCE 1986	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To investigate the changes in practice strategy that have taken place since 1986. Design-Comparison of practices in 1986 and 1992. Setting-93% of group practices (26 practices) in a single family health services authority. Main outcome measures-Changes in staffing, premises, equipment, clinic services, and incomes between 1986 and 1992. Results-In 1986, 28% of practices employed a nurse; in 1992, 92% did so. Between 1986 and 1992, 14 cost-rent schemes costing more than pound 10 000 had been started. Certain practices, designated innovators, were more likely to possess specified items of equipment than other practices. Computer ownership was widespread: 77% of practices had a computer, compared with 36% in 1986. In 1992, 16 practices had a manager, compared with 10 in 1986. Clinic services provided by more than half of practices were well established services (antenatal, for example), new services for which a payment had been introduced (such as diabetes, asthma, minor surgery), or the more readily provided ''new'' clinic services (diet, smoking cessation). Gross income increased, but so did practice costs, especially for innovators. Practices in the more affluent area of the family health services authority were still more likely to invest in their premises and staff, and to provide more services than those in the declining area. In the more affluent area, practices had higher costs but also higher incomes. Conclusion-Between 1986 and 1992, practices in this area invested heavily in equipment and services, but differences remain, depending on the location of the practice. Investment has increased, particularly in the more deprived part of the area, so that the inconsistency in standards has been much reduced. Practice incomes have risen, but so also have workload and costs.	UNIV LONDON,ST MARYS HOSP,SCH MED,HLTH POLICY UNIT,LONDON W2 1PG,ENGLAND	Imperial College London; University of London; London School of Hygiene & Tropical Medicine	LEESE, B (corresponding author), UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND.							BOSANQUET N, 1988, BRIT MED J, V296, P1576, DOI 10.1136/bmj.296.6636.1576; BOSANQUET N, 1986, BRIT MED J, V293, P667, DOI 10.1136/bmj.293.6548.667; BOSANQUET N, 1989, FAMILY DOCTORS EC IN; HART JT, 1974, LANCET, V1, P405; HOLLIDAY I, 1993, NHS TRANSFORMED GUID, P19; LEESE B, 1989, BRIT MED J, V298, P932, DOI 10.1136/bmj.298.6678.932; LEESE B, 1994, SETTING PRIORITIES H, P263; 1989, 3 DEP HLTH WORK PAP; 1989, GENERAL PRACTICE NHS; 1987, CMND127	10	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					705	708		10.1136/bmj.310.6981.705	http://dx.doi.org/10.1136/bmj.310.6981.705			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711539	Green Published			2022-12-28	WOS:A1995QN46100022
J	ROBERTS, J				ROBERTS, J			RETHINKING CONSULTANTS - SPECIALISTS IN THE UNITED-STATES - WHAT LESSONS	BRITISH MEDICAL JOURNAL			English	Article								Several pressures are forcing a rethink of the way that consultants in Britain work. Perhaps the most acute pressures come from the current moves to reduce junior doctors' working hours and the Calman proposals for more structured and shorter specialty training programmes. Together these will mean fewer juniors available to do service work within the NHS and a greater load on the consultants who have to reach them. But patients and purchasers are also demanding that more clinical work should be done by fully trained doctors, not trainees, and the requirements of the new NHS require consultants to take part in auditing, contracting, and managing the service. Last week (11 March, p 673) the BMA council heard consultants' anxieties that the numbers of consultants were not growing in line with the demands of the Calman implementation plan. There is a feeling that something will have to give, and the BMA fears the proliferation of subconsultant grades (staff who are not trainees but do not have full clinical autonomy) to fill the growing gap between the work to be done and doctors available to do it. Also, on 6 April the Central Consultants and Specialists Committee of the BMA is holding a conference to discuss consultants' career development in the face of these changes. We have commissioned four articles to contribute to this debate about how consultants should organise themselves and their work in future. In the first of these our North American editor, John Roberts, outlines the effect of similar pressures on the way that specialists in the United States organise their work, and how their working practices are changing.										STARR P, 1982, SOCIAL TRANSFORMATIO, P224; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; 1991, SOCIOECONOMIC CHARAC; 1995, ABMS DIRECTORY BOARD	4	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					724	727		10.1136/bmj.310.6981.724	http://dx.doi.org/10.1136/bmj.310.6981.724			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711543	Green Published			2022-12-28	WOS:A1995QN46100031
J	ORTON, P				ORTON, P			SHARED CARE	LANCET			English	Article							CLINICS				ORTON, P (corresponding author), MATCHING PARSONAGE FARM,NEWMANS END,MATCHING CM17 0QX,ESSEX,ENGLAND.							BAILEY JJ, 1994, BRIT MED J, V308, P1083, DOI 10.1136/bmj.308.6936.1083; Hughes J., 1993, HOSPITALS PRIMARY CA; JACOBS LGH, 1990, BRIT MED J, V301, P470, DOI 10.1136/bmj.301.6750.470; Jones R, 1988, Health Trends, V20, P45; SINGH BM, 1984, BRIT MED J, V289, P726, DOI 10.1136/bmj.289.6447.726; SPENCER NJ, 1993, ARCH DIS CHILD, V68, P496, DOI 10.1136/adc.68.4.496; WOOD J, 1991, BRIT J GEN PRACT, V41, P26; 1992, HLTH PERSONAL SOCIAL; 1991, INTEGRATING PRIMARY; 1993, HLTH PERSONAL SOCIAL; 1993, JOINT REPORT SHARED; 1991, NHS OUTPATIENTS SERV; 1994, BRIT MED J, V308, P1208	13	24	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 19	1994	344	8934					1413	1415						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR786	7695704				2022-12-28	WOS:A1994PR78600014
J	MAYER, B; JAUCH, KW; GUNTHERT, U; FIGDOR, CG; SCHILDBERG, FW; FUNKE, I; JOHNSON, JP				MAYER, B; JAUCH, KW; GUNTHERT, U; FIGDOR, CG; SCHILDBERG, FW; FUNKE, I; JOHNSON, JP			DE-NOVO EXPRESSION OF CD44 AND SURVIVAL IN GASTRIC-CANCER	LANCET			English	Article							LYMPHOCYTE HOMING RECEPTOR; GLYCOPROTEIN; CARCINOMA; MOLECULE; VARIANT; CELLS	We have examined the cell surface molecule CD44, which is attracting interest because of reports that isoforms are associated with metastasis. The prognostic value of CD44 expression has yet to be assessed for a solid tumour. Benign (59) and malignant (primary 61, metastatic 59) gastric tissues were examined with antibodies directed at epitopes common to known CD44 isoforms. Normal mucosa was CD44 negative. In atrophic gastritis and intestinal metaplasia expression was restricted to the epithelial cells of the basal glands and was positively correlated with an increased leucocyte infiltrate and with the expression of HLA DR by mucosal cells. These observations suggest a role for chronic inflammation in the induction of CD44 expression on benign mucosa. No such association was observed between inflammatory infiltrate and CD44 expression on gastric tumours. CD44 expression, observed in only 49% of primary tumours, was associated with distant metastases at time of diagnosis and, among 31 curatively resected patients, with tumour recurrence (p=0.0014) and increased mortality (p=0.001) during follow-up averaging 17 months. When we used an antibody directed against the CD44 variant exon 9v, we found a good correlation between the expression of total CD44 and of exon 9v containing isoforms, and 9v expression in primary tumours was significantly and positively associated with tumour recurrence and mortality.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; NETHERLANDS CANC INST,1066 CX AMSTERDAM,NETHERLANDS; UNIV MUNICH,INST IMMUNOL,D-81366 MUNICH,GERMANY	Netherlands Cancer Institute; University of Munich	MAYER, B (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT SURG,D-81366 MUNICH,GERMANY.		Figdor, Carl G/A-4232-2010	Figdor, Carl G/0000-0002-2366-9212				ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CAMP RL, 1991, J EXP MED, V173, P763, DOI 10.1084/jem.173.3.763; CREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160; DUARTE I, 1981, HUM PATHOL, V12, P237, DOI 10.1016/S0046-8177(81)80124-4; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUNTHERT U, IN PRESS CURR TOP MI; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HOFMANN M, 1991, CANCER RES, V51, P5292; HORST E, 1990, LEUKEMIA, V4, P595; JACKSOND G, 1993, LANCET, V341, P252; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; MACKAY CR, 1988, IMMUNOLOGY, V65, P93; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MAYER B, 1993, CANCER RES, V53, P1690; PALS ST, 1989, J IMMUNOL, V143, P851; SCHMITZMOORMANN P, 1979, GASTRIC CANCER, P172; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; WAHAB ZA, 1985, INT J CANCER, V36, P677, DOI 10.1002/ijc.2910360610	22	229	245	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 23	1993	342	8878					1019	1022		10.1016/0140-6736(93)92879-X	http://dx.doi.org/10.1016/0140-6736(93)92879-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD066	7692200	Green Submitted			2022-12-28	WOS:A1993MD06600010
J	BROCKE, S; GAUR, A; PIERCY, C; GAUTAM, A; GIJBELS, K; FATHMAN, CG; STEINMAN, L				BROCKE, S; GAUR, A; PIERCY, C; GAUTAM, A; GIJBELS, K; FATHMAN, CG; STEINMAN, L			INDUCTION OF RELAPSING PARALYSIS IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS BY BACTERIAL SUPERANTIGEN	NATURE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; STAPHYLOCOCCAL ENTEROTOXIN-B; MYELIN BASIC-PROTEIN; T-CELLS; MICE; ANERGY; INVIVO	THE role of infection in the pathogenesis of clinical relapses that occur in most autoimmune diseases, including multiple sclerosis, remains to be established1,2. Experimental autoimmune encephalomyelitis (EAE) serves as a model for multiple sclerosis, with episodes of relapsing paralysis3-9. In certain strains of mice, T-lymphocytes expressing the Vbeta8 T-cell receptor (TCR)6-8 engage the amino-terminal epitope Ac1-11 of myelin basic protein, leading to EAE. The bacterial superantigen staphylococcal enterotoxin B (SEB) activates Vbeta8-expressing T cells. Here we show that after immunization with Ac1-11, or after transfer of encephalitogenic T-cell lines or clones reactive to Ac1-11, SEB induces exacerbation or relapses of paralytic disease in mice that are in clinical remission following an initial episode of paralysis, and triggers paralysis in mice with subclinical disease. Tumour necrosis factor has a critical role in the mechanism underlying SEB-induced exacerbation of disease, because anti-tumour necrosis factor antibody given in vivo delays the onset of paralysis triggered by SEB. On reactivation of autoaggressive cells through their T-cell receptor, superantigens may induce clinical relapses of autoimmune disease.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305	Stanford University	BROCKE, S (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305, USA.			Steinman, Lawrence/0000-0002-2437-2250				ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ALLEN I, 1991, MCALPINES MULTIPLE S; Alvord EC, 1984, EXPT ALLERGIC ENCEPH; BEHIKE MA, 1986, P NATL ACAD SCI USA, V83, P767; BELL RB, 1993, J IMMUNOL, V150, P4085; BROCKE S, 1991, INFECT IMMUN, V59, P4531, DOI 10.1128/IAI.59.12.4531-4539.1991; GAUR A, 1993, J IMMUNOL, V150, P3062; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; POSER CM, 1992, J NEUROL SCI, V107, P127, DOI 10.1016/0022-510X(92)90280-X; POWELL MB, 1990, INT IMMUNOL, V2, P539, DOI 10.1093/intimm/2.6.539; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; ROTT O, 1992, INT IMMUNOL, V4, P347, DOI 10.1093/intimm/4.3.347; SOOS JM, 1993, J NEUROIMMUNOL, V43, P39, DOI 10.1016/0165-5728(93)90073-8; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; ZAMVIL SS, 1988, J EXP MED, V167, P1586, DOI 10.1084/jem.167.5.1586; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	23	234	244	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					642	644		10.1038/365642a0	http://dx.doi.org/10.1038/365642a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	7692305				2022-12-28	WOS:A1993MB84600057
J	NEUMANSILBERBERG, FS; SCHUPBACH, T				NEUMANSILBERBERG, FS; SCHUPBACH, T			THE DROSOPHILA DORSOVENTRAL PATTERNING GENE GURKEN PRODUCES A DORSALLY LOCALIZED RNA AND ENCODES A TGF-ALPHA-LIKE PROTEIN	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; MATERNAL MESSENGER-RNA; EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; XENOPUS OOCYTES; POSTERIOR DETERMINANT; SIGNAL TRANSDUCTION; TYROSINE KINASE; BICOID RNA; GERM LINE	Cell-cell interactions in the Drosophila ovary play a crucial role in the establishment of dorsoventral polarity of both the egg shell and the future embryo. Torpedo/DER (top/DER), a homolog of the vertebrate epidermal growth factor receptor, is required for this signaling process in the somatic cells of the ovary. In contrast, gurken (grk), which also functions in this pathway, is required in the germline. We cloned the grk gene and found that it encodes a TGFalpha-like protein. Grk is, therefore, likely to be a ligand of top/DER, activating the receptor during oogenesis. During oogenesis, the grk transcript becomes asymmetrically localized to the dorsal corner of the oocyte. We propose that the dorsal localization of grk RNA results in a spatially restricted ligand that asymmetrically activates the receptor.			NEUMANSILBERBERG, FS (corresponding author), PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.		xu, huanfang/I-4315-2012		NIGMS NIH HHS [GM40558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBURNER M, 1990, GENETICS, V126, P679; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1991, PEPTIDE GROWTH FACTO, P69; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHEUNG HK, 1992, DEVELOPMENT, V114, P653; CLIFFORD R, 1992, DEVELOPMENT, V115, P853; CLIFFORD RJ, 1989, GENETICS, V123, P771; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DALBY B, 1992, DEVELOPMENT, V115, P989; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARZA D, 1989, SCIENCE, V246, P641, DOI 10.1126/science.2510296; GOTTLIEB E, 1992, P NATL ACAD SCI USA, V89, P7164, DOI 10.1073/pnas.89.15.7164; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; HAENLIN M, 1987, EMBO J, V6, P801, DOI 10.1002/j.1460-2075.1987.tb04822.x; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KAMMERMEYER KL, 1987, DEVELOPMENT, V100, P201; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; King R. C., 1970, OVARIAN DEV DROSOPHI; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANTZ V, 1992, DEVELOPMENT, V115, P75; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Lindsley D.L., 1968, GENETIC VARIATIONS D; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; Maniatis T, 1989, MOL CLONING; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MONTELL DJ, 1991, SCIENCE, V254, P290, DOI 10.1126/science.1925585; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; PIKE LJ, 1982, J BIOL CHEM, V257, P4628; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; PROST E, 1988, GENE DEV, V2, P891, DOI 10.1101/gad.2.7.891; RAZ E, 1992, DEVELOPMENT, V114, P113; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPACH T, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P163; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STEWARD R, 1988, CELL, V55, P487, DOI 10.1016/0092-8674(88)90035-9; STJOHNSTON D, 1992, CELL, V68, P201; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WIESCHAUS E, 1978, ROUX ARCH DEV BIOL, V184, P75, DOI 10.1007/BF00848670; WIESCHAUS E, 1979, INSERM S, V10, P291; WUSTMANN G, 1989, MOL GEN GENET, V217, P520, DOI 10.1007/BF02464926; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; YUE L, 1992, GENE DEV, V6, P2443, DOI 10.1101/gad.6.12b.2443	73	489	492	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 8	1993	75	1					165	174		10.1016/S0092-8674(05)80093-5	http://dx.doi.org/10.1016/S0092-8674(05)80093-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MB667	7691414				2022-12-28	WOS:A1993MB66700017
J	WHITINGTON, PF; EMOND, JC; HEFFRON, T; THISTLETHWAITE, JR				WHITINGTON, PF; EMOND, JC; HEFFRON, T; THISTLETHWAITE, JR			ORTHOTOPIC AUXILIARY LIVER-TRANSPLANTATION FOR CRIGLER-NAJJAR SYNDROME TYPE-1	LANCET			English	Note								Some diseases that result from inborn errors of critical metabolic or synthetic processes mainly involving the liver do not cause structural liver damage. These disorders can be treated by the addition of liver tissue (auxiliary liver transplantation) rather than liver replacement. We report correction of the metabolic error in a 13-year-old girl with Crigler-Najjar syndrome type 1 by auxiliary (left lateral segment) transplantation. The first graft failed and was replaced successfully. The second graft shows features of chronic rejection, but at 2 years postoperatively bilirubin conjugating ability has not been impaired. Another graft may become necessary in due course.	UNIV CHICAGO,WYLER CHILDRENS HOSP,PRITZKER SCH MED,DEPT SURG,CHICAGO,IL 60637	University of Chicago	WHITINGTON, PF (corresponding author), UNIV CHICAGO,WYLER CHILDRENS HOSP,PRITZKER SCH MED,DEPT PEDIAT,CHICAGO,IL 60637, USA.							BLACK M, 1969, NEW ENGL J MED, V280, P1266, DOI 10.1056/NEJM196906052802303; BLOOMER JR, 1984, HEPATOLOGY, V4, pS18, DOI 10.1002/hep.1840040707; BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015; FUNG JJ, 1991, TRANSPLANT P, V23, P14; JANSEN PLM, 1989, J HEPATOL, V8, P192, DOI 10.1016/0168-8278(89)90007-X; WEISIGER RA, 1985, P NATL ACAD SCI USA, V82, P1563, DOI 10.1073/pnas.82.5.1563; WHITINGTON PF, 1991, J PEDIATR-US, V118, P169, DOI 10.1016/S0022-3476(05)80478-0	7	94	96	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 25	1993	342	8874					779	780		10.1016/0140-6736(93)91543-U	http://dx.doi.org/10.1016/0140-6736(93)91543-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY868	7690444				2022-12-28	WOS:A1993LY86800012
J	CATALONA, WJ; SMITH, DS; RATLIFF, TL; BASLER, JW				CATALONA, WJ; SMITH, DS; RATLIFF, TL; BASLER, JW			DETECTION OF ORGAN-CONFINED PROSTATE-CANCER IS INCREASED THROUGH PROSTATE-SPECIFIC ANTIGEN-BASED SCREENING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIGITAL RECTAL EXAMINATION; ADENOCARCINOMA; VOLUME; BENIGN; STAGE; SERUM	Objective.-To determine whether prostate-specific antigen (PSA)-based screening alters the proportion of organ-confined prostate cancers detected. Design.-A prospective, nonrandomized, serial PSA-based screening trial (follow-up from 6 to 37 months), and a concurrent comparison group. Setting.-General community outpatient screening program based at a university center. Patients.-The study group consisted of 10 251 men aged 50 years and older (mean and median age, 63 years; mean and median age of patients who underwent biopsies, 66 years) who presented to a prostate cancer screening program and consented to phlebotomy. The comparison group consisted of 266 concurrently studied private patients in the same age range (mean and median age, 68 years) who were referred for prostatic ultrasonography and biopsy because of an abnormal digital rectal examination (DRE). Main Outcome Measure.-Proportion detected with clinically or pathologically advanced prostate cancer. Results.-The men were divided into three groups: the comparison group, the initial PSA-based screening group, and the serial PSA-based screening group. The proportions of prostate cancers detected that were clinically or pathologically advanced were as follows: comparison group, 57% (27/47); initial PSA-based screening group, 37% (91/244); and serial PSA-based screening group, 29% (37/129). Screened patients had a lower proportion of advanced cancers than the comparison group (chi2 [2]= 12.3; P=.002); this advantage was observed principally in patients younger than 70 years. Surgical staging revealed that the cancer was microscopically focal and well differentiated (possibly latent cancer) in 2.5% (1/40) of the nonscreened group, 2.9% (7/244) of the initially screened group, and 7.8% (10/129) of the serially screened group (generalized Fisher's Exact Test, P=.08). Conclusion.-Screening based on PSA identifies some men with prostate cancer who have a significantly increased proportion of organ-confined tumors compared with those detected through evaluation for an abnormal DRE alone.	WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110	Washington University (WUSTL)	CATALONA, WJ (corresponding author), WASHINGTON UNIV,SCH MED,DIV UROL SURG,660 S EUCLID,BOX 8109,ST LOUIS,MO 63110, USA.				NCI NIH HHS [P20 CA58193] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P20CA058193] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER RB, 1989, J UROLOGY, V141, P880, DOI 10.1016/S0022-5347(17)41038-X; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; BRAWN PN, 1991, CANCER, V68, P1592, DOI 10.1002/1097-0142(19911001)68:7<1592::AID-CNCR2820680721>3.0.CO;2-M; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P215; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1990, J UROLOGY, V143, P586, DOI 10.1016/S0022-5347(17)40031-0; CATALONA WJ, 1990, J UROLOGY, V143, P528; CHODAK GW, 1989, J UROLOGY, V141, P1136, DOI 10.1016/S0022-5347(17)41192-X; COLBERG JW, 1993, J UROLOGY, V149, P507, DOI 10.1016/S0022-5347(17)36130-X; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; GERBER GS, 1993, JAMA-J AM MED ASSOC, V269, P61, DOI 10.1001/jama.269.1.61; HUDSON MA, 1989, J UROLOGY, V142, P1011, DOI 10.1016/S0022-5347(17)38972-3; LEE F, 1985, PROSTATE, V7, P117, DOI 10.1002/pros.2990070202; Marascuilo L.A., 1977, NONPARAMETRIC DISTRI, P141; MCNEAL JE, 1992, HUM PATHOL, V23, P258, DOI 10.1016/0046-8177(92)90106-D; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; PARTIN AW, 1990, J UROLOGY, V143, P747, DOI 10.1016/S0022-5347(17)40079-6; Simpson K. N., 1993, J UROL S, V149, p413A; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STORMONT TJ, 1993, UROLOGY, V41, P3, DOI 10.1016/0090-4295(93)90233-Z; THOMPSON IM, 1987, J UROLOGY, V137, P424, DOI 10.1016/S0022-5347(17)44055-9	23	801	817	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1993	270	8					948	954		10.1001/jama.270.8.948	http://dx.doi.org/10.1001/jama.270.8.948			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LT567	7688438				2022-12-28	WOS:A1993LT56700025
J	BERRA, E; DIAZMECO, MT; DOMINGUEZ, I; MUNICIO, MM; SANZ, L; LOZANO, J; CHAPKIN, RS; MOSCAT, J				BERRA, E; DIAZMECO, MT; DOMINGUEZ, I; MUNICIO, MM; SANZ, L; LOZANO, J; CHAPKIN, RS; MOSCAT, J			PROTEIN KINASE-C-ZETA ISOFORM IS CRITICAL FOR MITOGENIC SIGNAL-TRANSDUCTION	CELL			English	Article							HYDROLYZING PHOSPHOLIPASE-C; XENOPUS-LAEVIS OOCYTES; T-CELL ACTIVATION; GROWTH-FACTOR; RAS ONCOGENE; PHOSPHATIDYLCHOLINE; DIACYLGLYCEROL; STIMULATION; FIBROBLASTS; EXPRESSION	The requirement of protein kinase C zeta(zetaPKC) for maturation of X. laevis oocytes in response to insulin, p21ras, and phosphatidylcholine-hydrolyzing phospholipase C has recently been shown. Here we present experimental evidence demonstrating that activation of zetaPKC is not only necessary but also sufficient by itself to activate maturation in oocytes and to produce deregulation of growth control in mouse fibroblasts. Furthermore, by using a dominant kinase-defective mutant zetaPKC, we confirm that this kinase is required for mitogenic activation in oocytes and fibroblasts. These results permit us to propose zetaPKC as a critical step downstream of p21ras in mitogenic signal transduction.			BERRA, E (corresponding author), UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,CANTO BLANCO,E-28049 MADRID,SPAIN.		Moscat, Jorge/A-7011-2009; Berra, Edurne/F-9692-2011; Lozano, José/C-2760-2014	Berra, Edurne/0000-0002-3820-5744; Lozano, José/0000-0002-8187-2833; Diaz-Meco, Maria/0000-0003-0147-0998; Chapkin, Robert/0000-0002-6515-3898; /0000-0001-9617-4141				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DIAZMECO MT, 1991, J BIOL CHEM, V266, P22597; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EXTON JH, 1990, J BIOL CHEM, V265, P1; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KALENIC G, 1992, MOL CELL BIOL, V12, P4687; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KONDO T, 1992, J BIOL CHEM, V267, P23609; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PESSIN MS, 1990, J BIOL CHEM, V265, P7959; PRICE BD, 1989, J BIOL CHEM, V264, P16638; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; WAYS DK, 1992, J BIOL CHEM, V267, P4799; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	32	387	390	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					555	563		10.1016/0092-8674(93)80056-K	http://dx.doi.org/10.1016/0092-8674(93)80056-K			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	7688666				2022-12-28	WOS:A1993LT73900016
J	LAFONCAZAL, M; PIETRI, S; CULCASI, M; BOCKAERT, J				LAFONCAZAL, M; PIETRI, S; CULCASI, M; BOCKAERT, J			NMDA-DEPENDENT SUPEROXIDE PRODUCTION AND NEUROTOXICITY	NATURE			English	Article							NITRIC-OXIDE SYNTHASE; AMINO-ACID RELEASE; STRIATAL NEURONS; NERVOUS-SYSTEM; GLUTAMATE; RECEPTORS; ISCHEMIA; QUANTIFICATION; CULTURES; INJURY	NEURONAL injury resulting from acute brain insults and some neurodegenerative diseases implicates N-methyl-D-aspartate (NMDA) glutamate receptors1-4. The fact that antioxidants reduce some types of brain damage suggests that oxygen radicals may have a roles5-7. It has been shown that mutations in Cu/Zn-superoxide dismutase (SOD), an enzyme catalysing superoxide (O2.-) detoxification in the cell, are linked to a familial form of amyotrophic lateral sclerosis (ALS)4. Here we report that O2.- is produced upon NMDA receptor stimulation in cultured cerebellar granule cells. Electron paramagnetic resonance was used to assess O2.- production that was due in part to the release of arachidonic acid. Activation of kainic acid receptors, or voltage-sensitive Ca2+ channels, did not produce detectable O2.-. We also find that the nitrone DMPO (5,5-dimethyl pyrroline 1-oxide), used as a spin trap, is more efficient than the nitric oxide synthase inhibitor, L-N(G)-nitroarginine, in reducing NMDA-induced neuronal death in these cultures.	CRIPDOM,F-34172 CASTELNAU LEZ,FRANCE; UNIV AIX MARSEILLE 1,SREP,CNRS,URA 1412,F-13397 MARSEILLE 4,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	LAFONCAZAL, M (corresponding author), CNRS,INSERM,CTR PHARMACOL ENDOCRINOL,RUE DE LA CARDONILLE,F-34094 MONTPELLIER 5,FRANCE.							BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DIDIER M, 1990, J NEUROSCI RES, V27, P25, DOI 10.1002/jnr.490270105; DIDIER M, 1993, EUR J PHARMACOL, V224, P57; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; FAVARON M, 1990, P NATL ACAD SCI USA, V87, P1983, DOI 10.1073/pnas.87.5.1983; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; LAFONCAZAL M, 1992, BRAIN RES, V593, P63, DOI 10.1016/0006-8993(92)91264-F; LERNERNATOLI M, 1992, J NEUROREPORT, V3, P1109; MARIN P, 1992, EUR J NEUROSCI, V4, P425, DOI 10.1111/j.1460-9568.1992.tb00892.x; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONCADA C, 1992, NEUROREPORT, V3, P530; MONYER H, 1990, NEURON, V5, P121, DOI 10.1016/0896-6273(90)90302-V; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; OLNEY JW, 1989, DRUG DEVELOP RES, V17, P299, DOI 10.1002/ddr.430170406; PAUWELS PJ, 1992, NEUROSCI LETT, V143, P27, DOI 10.1016/0304-3940(92)90225-V; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; POU S, 1989, ANAL BIOCHEM, V177, P1, DOI 10.1016/0003-2697(89)90002-X; POU S, 1992, J BIOL CHEM, V267, P24173; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rosen G.M., 1985, ADV FREE RADIC BIOL, V1, P345, DOI [10.1016/8755-9668(85)90012-2, DOI 10.1016/8755-9668(85)90012-2]; ROSEN GM, 1988, J MED CHEM, V31, P428, DOI 10.1021/jm00397a028; SAEZ JC, 1987, P NATL ACAD SCI USA, V84, P3056, DOI 10.1073/pnas.84.9.3056; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185, DOI 10.1152/jappl.1991.71.4.1185; VANVLIET BJ, 1989, J NEUROCHEM, V52, P1229	29	1098	1113	0	66	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					535	537		10.1038/364535a0	http://dx.doi.org/10.1038/364535a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	7687749				2022-12-28	WOS:A1993LQ66700057
J	STEWARD, WP				STEWARD, WP			GRANULOCYTE AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTORS	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; CHEMOTHERAPY-INDUCED NEUTROPENIA; HIGH-DOSE CHEMOTHERAPY; CELL LUNG-CANCER; ADVANCED MALIGNANCY; GM-CSF; TOXICITY; THERAPY				STEWARD, WP (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,BEATSON ONCOL CTR,CRC,DEPT MED ONCOL,GLASGOW G11 6NT,SCOTLAND.							ANTMAN KS, 1988, NEW ENGL J MED, V319, P593, DOI 10.1056/NEJM198809083191001; BENNETT CL, 1990, BLOOD S1, V76, P132; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BRONCHUD MH, 1987, BRIT J CANCER, V56, P809, DOI 10.1038/bjc.1987.295; CEBON J, 1988, BLOOD, V72, P1340; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; DEVEREUX S, 1989, BRIT J HAEMATOL, V71, P323; DEVRIES EGE, 1991, CANCER RES, V51, P116; EGUCHI K, 1989, CANCER RES, V49, P5221; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; HAMMOND WP, 1989, NEW ENGL J MED, V320, P1306, DOI 10.1056/NEJM198905183202003; KOTAKE T, 1991, CANCER CHEMOTH PHARM, V27, P253, DOI 10.1007/BF00685108; LIESCHKE GJ, 1989, ANN INTERN MED, V110, P357, DOI 10.7326/0003-4819-110-5-357; LIESCHKE GJ, 1989, BLOOD, V74, P2634; METCALF D, 1982, J CELL PHYSIOL, V111, P275, DOI 10.1002/jcp.1041110308; METCALF D, 1986, BLOOD, V67, P257; METCALF D, 1984, HEMOPOIETIC COLONIES; MILES SA, 1991, BLOOD, V77, P2109; MORSTYN G, 1988, LANCET, V1, P667, DOI 10.1016/S0140-6736(88)91475-4; MORSTYN G, 1989, J CLIN ONCOL, V7, P1554, DOI 10.1200/JCO.1989.7.10.1554; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; PLUDA JM, 1990, BLOOD, V76, P463; SACHS L, 1990, CANCER-AM CANCER SOC, V65, P2196, DOI 10.1002/1097-0142(19900515)65:10<2196::AID-CNCR2820651006>3.0.CO;2-Y; SCHUSTER MW, 1990, BLOOD S, V76, P47; SHERIDAN WP, 1992, LANCET, V339, P640, DOI 10.1016/0140-6736(92)90795-5; SHERIDAN WP, 1989, LANCET, V2, P891; SOCINSKI MA, 1988, LANCET, V1, P1194; STEWARD WP, 1990, BRIT J CANCER, V61, P749, DOI 10.1038/bjc.1990.167; STEWARD WP, 1989, BRIT J CANCER, V59, P142, DOI 10.1038/bjc.1989.28; WELTE K, 1987, J EXP MED, V165, P941, DOI 10.1084/jem.165.4.941; WODZINSKI MA, 1991, BRIT J HAEMATOL, V77, P249, DOI 10.1111/j.1365-2141.1991.tb07987.x	31	82	83	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					153	157		10.1016/0140-6736(93)91350-U	http://dx.doi.org/10.1016/0140-6736(93)91350-U			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	7687319				2022-12-28	WOS:A1993LN04200016
J	CATARSI, S; DRAPEAU, P				CATARSI, S; DRAPEAU, P			TYROSINE KINASE-DEPENDENT SELECTION OF TRANSMITTER RESPONSES INDUCED BY NEURONAL CONTACT	NATURE			English	Article							IDENTIFIED LEECH NEURON; ACETYLCHOLINE-RECEPTOR; CULTURE; REINNERVATION; CONNECTIONS; SEROTONIN	TRANSMITTER receptors are localized to discrete cellular sites1 such that only those responses appropriate for a particular pattern of inputs are activated2-4. How neurons select between synaptic and extrasynaptic responses during development is not understood. We have investigated how contact during synapse formation between identified leech neurons5-7 selectively suppresses the modulation of extrasynaptic channels by protein kinase C8-10. A microelectrode with an isolated membrane patch containing channels from an uninnervated target neuron was 'crammed'11 into a similar cell contacted by a presynaptic partner. We report here that within a few minutes, the crammed channels were rendered insensitive to activation of protein kinase C, demonstrating the action of a cytoplasmic signal. Treatment of the neurons with selective inhibitors of tyrosine kinases12, which are signalling molecules during normal and oncogenic cellular differentiation13,14, prevented the loss of channel modulation. Thus, tyrosine kinases mediate early functional changes during specific synapse formation that are induced by neuronal contact.	MONTREAL GEN HOSP,RES INST,MONTREAL H3G 1A4,QUEBEC,CANADA	McGill University	CATARSI, S (corresponding author), MCGILL UNIV,CTR RES NEUROSCI,1650 CEDAR AVE,MONTREAL H3G 1A4,PQ,CANADA.							ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BLOCH RJ, 1988, AM J PHYSIOL, V254, pC345, DOI 10.1152/ajpcell.1988.254.3.C345; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CATARSI S, 1992, NEURON, V8, P275, DOI 10.1016/0896-6273(92)90294-N; COHEN MW, 1987, J NEUROSCI, V7, P2849; DIETZEL ID, 1986, J PHYSIOL-LONDON, V372, P191, DOI 10.1113/jphysiol.1986.sp016004; DRAPEAU P, 1989, J NEUROBIOL, V20, P312, DOI 10.1002/neu.480200505; DRAPEAU P, 1989, J NEUROSCI, V9, P2502; DRAPEAU P, 1988, J NEUROSCI, V8, P4718; DRAPEAU P, 1990, NEURON, V4, P875, DOI 10.1016/0896-6273(90)90140-B; FUCHS PA, 1981, J PHYSIOL-LONDON, V316, P203, DOI 10.1113/jphysiol.1981.sp013783; GERSCHENFELD HM, 1973, PHYSIOL REV, V53, P1, DOI 10.1152/physrev.1973.53.1.1; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; KATZ B, 1972, J PHYSIOL-LONDON, V224, P665, DOI 10.1113/jphysiol.1972.sp009918; KRAMER RH, 1990, NEURON, V2, P335; MERZ DC, 1992, P ROY SOC B-BIOL SCI, V248, P129, DOI 10.1098/rspb.1992.0052; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NEHER E, 1976, J PHYSIOL-LONDON, V258, P705, DOI 10.1113/jphysiol.1976.sp011442; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PURVES D, 1985, PRINCIPLES NEURAL DE; QU Z, 1990, NEURON, V2, P367; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WITZEMANN V, 1991, J CELL BIOL, V114, P125, DOI 10.1083/jcb.114.1.125	29	35	35	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					353	355		10.1038/363353a0	http://dx.doi.org/10.1038/363353a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	7684513				2022-12-28	WOS:A1993LD91700054
J	BREWSTER, JL; DEVALOIR, T; DWYER, ND; WINTER, E; GUSTIN, MC				BREWSTER, JL; DEVALOIR, T; DWYER, ND; WINTER, E; GUSTIN, MC			AN OSMOSENSING SIGNAL TRANSDUCTION PATHWAY IN YEAST	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; NUCLEOTIDE-SEQUENCE; MAP KINASE; PHOSPHORYLATION; PHEROMONE; GENES; DNA; ACCUMULATION; RESISTANCE	Yeast genes were isolated that are required for restoring the osmotic gradient across the cell membrane in response to increased external osmolarity. Two of these genes, HOG1 and PBS2, encode members of the mitogen-activated protein kinase (MAP kinase) and MAP kinase kinase gene families, respectively. MAP kinases are activated by extracellular ligands such as growth factors and function as intermediate kinases in protein phosphorylation cascades. A rapid, PBS2-dependent tyrosine phosphorylation of HOG1 protein occurred in response to increases in extracellular osmolarity. These data define a signal transduction pathway that is activated by changes in the osmolarity of the extracellular environment.	RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA; THOMAS JEFFERSON UNIV, JEFFERSON INST MOLEC MED, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA	Rice University; Jefferson University; Jefferson University				Gustin, Michael/0000-0003-0097-9194; Dwyer, Noelle/0000-0002-1995-7203	NIGMS NIH HHS [GM45772] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLARD MJ, 1991, EMBO J, V10, P3753, DOI 10.1002/j.1460-2075.1991.tb04944.x; BLOMBERG A, 1989, J BACTERIOL, V171, P1087, DOI 10.1128/jb.171.2.1087-1092.1989; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, UNPUB; Chamberlin ME, 1989, AM J PHYSIOL, Vl257, P159; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; EDGELY M, 1983, J GEN MICROBIOL, V129, P3453; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; FIELDS S, 1990, TRENDS BIOCHEM SCI, V15, P270, DOI 10.1016/0968-0004(90)90052-D; FRINGS CS, 1966, ANAL CHIM ACTA, V34, P225, DOI 10.1016/S0003-2670(00)89030-3; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; MEIKLE AJ, 1988, J GEN MICROBIOL, V134, P3049; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; REED RH, 1987, APPL ENVIRON MICROB, V53, P2119, DOI 10.1128/AEM.53.9.2119-2123.1987; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; TATCHELL K, 1986, J BACTERIOL, V166, P364, DOI 10.1128/jb.166.2.364-367.1986; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; [No title captured]	38	1021	1101	3	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	1993	259	5102					1760	1763		10.1126/science.7681220	http://dx.doi.org/10.1126/science.7681220			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	7681220				2022-12-28	WOS:A1993KT81000039
J	ZAMBRANO, MM; SIEGELE, DA; ALMIRON, M; TORMO, A; KOLTER, R				ZAMBRANO, MM; SIEGELE, DA; ALMIRON, M; TORMO, A; KOLTER, R			MICROBIAL COMPETITION - ESCHERICHIA-COLI MUTANTS THAT TAKE OVER STATIONARY PHASE CULTURES	SCIENCE			English	Article							SPONTANEOUS MUTATIONS; STARVATION SURVIVAL; GENERAL RESISTANCE; BACTERIA; KATF; EXPRESSION; SELECTION; EVOLUTION; PROTEINS; SEQUENCE	Many microorganisms, including Escherichia coli, can survive extended periods of starvation. The properties of cells that survived prolonged incubation in stationary phase were studied by mixture of 10-day-old (aged) cultures with 1-day-old (young) cultures of the same strain of Escherichia coli. Mutants from the aged cultures that could grow eventually took over the population, which resulted in the death of the cells from the young cultures. This phenotype was conferred by mutations in rpoS, which encodes a putative stationary phase-specific sigma factor. These rapid population shifts have implications for the studies of microbial evolution and ecology.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School			Zambrano, Maria Mercedes/AAD-2805-2019	Zambrano, Maria Mercedes/0000-0002-0796-4473; Siegele, Deborah/0000-0001-8935-0696				ATWOOD KC, 1951, P NATL ACAD SCI USA, V37, P146, DOI 10.1073/pnas.37.3.146; BENNETT AF, 1990, NATURE, V346, P79, DOI 10.1038/346079a0; BOHANNON DE, 1991, J BACTERIOL, V173, P4482, DOI 10.1128/JB.173.14.4482-4492.1991; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; DYKHUIZEN DE, 1983, MICROBIOL REV, V47, P150, DOI 10.1128/MMBR.47.2.150-168.1983; GROAT RG, 1986, J BACTERIOL, V168, P486, DOI 10.1128/jb.168.2.486-493.1986; HALL BG, 1988, GENETICS, V120, P887; HALL BG, 1991, NEW BIOL, V3, P729; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HENGGEARONIS R, 1991, J BACTERIOL, V173, P7918, DOI 10.1128/jb.173.24.7918-7924.1991; KJELLEBERG S, 1987, ANNU REV MICROBIOL, V41, P25, DOI 10.1146/annurev.mi.41.100187.000325; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LANGE R, 1991, J BACTERIOL, V173, P4474, DOI 10.1128/JB.173.14.4474-4481.1991; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; LOEWEN PC, 1985, ARCH BIOCHEM BIOPHYS, V243, P144, DOI 10.1016/0003-9861(85)90782-9; LOSICK R, 1986, ANNU REV GENET, V20, P625, DOI 10.1146/annurev.ge.20.120186.003205; MATIN A, 1989, ANNU REV MICROBIOL, V43, P293, DOI 10.1146/annurev.mi.43.100189.001453; MATIN A, 1991, MOL MICROBIOL, V5, P3, DOI 10.1111/j.1365-2958.1991.tb01819.x; MCCANN MP, 1991, J BACTERIOL, V173, P4188, DOI 10.1128/jb.173.13.4188-4194.1991; Miller J.H., 1972, EXPT MOL GENETICS; MITTLER JE, 1992, NATURE, V356, P446, DOI 10.1038/356446a0; MULVEY MR, 1989, NUCLEIC ACIDS RES, V17, P9979, DOI 10.1093/nar/17.23.9979; NOVICK A, 1950, P NATL ACAD SCI USA, V36, P708, DOI 10.1073/pnas.36.12.708; SIEGELE DA, 1992, J BACTERIOL, V174, P345, DOI 10.1128/jb.174.2.345-348.1992; SIEGELE DA, IN PRESS STARVATION; Small P. L. C., 1992, ASM B, V74, P38; SPECTOR MP, 1986, J BACTERIOL, V168, P420, DOI 10.1128/jb.168.1.420-424.1986; SYKES RB, 1982, ANTIMICROB AGENTS CH, V21, P85, DOI 10.1128/AAC.21.1.85; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X	29	430	433	1	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1757	1760		10.1126/science.7681219	http://dx.doi.org/10.1126/science.7681219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	7681219				2022-12-28	WOS:A1993KT81000038
J	VISKIN, S; BELHASSEN, B				VISKIN, S; BELHASSEN, B			WHEN YOU ONLY LIVE TWICE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							IDIOPATHIC VENTRICULAR-FIBRILLATION; SUDDEN-DEATH; CARDIAC-ARREST; TACHYCARDIA; ARRHYTHMIAS; SURVIVORS		TEL AVIV UNIV,SOURASKY TEL AVIV MED CTR,DEPT CARDIOL,TEL AVIV,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine								ADHAR GC, 1988, J AM COLL CARDIOL, V12, P159, DOI 10.1016/0735-1097(88)90369-5; BARON RC, 1983, JAMA-J AM MED ASSOC, V250, P2947, DOI 10.1001/jama.250.21.2947; BELHASSEN B, 1987, CIRCULATION, V75, P809, DOI 10.1161/01.CIR.75.4.809; BELHASSEN B, 1993, J CARDIOVASC ELECTR, V4, P356, DOI 10.1111/j.1540-8167.1993.tb01236.x; BRUGADA P, 1983, AM J CARDIOL, V52, P1214, DOI 10.1016/0002-9149(83)90576-3; BRUGADA P, 1992, J AM COLL CARDIOL, V20, P1391, DOI 10.1016/0735-1097(92)90253-J; DEANTONIO HJ, 1990, PACE, V13, P982, DOI 10.1111/j.1540-8159.1990.tb02144.x; ENGEL GL, 1971, ANN INTERN MED, V74, P771, DOI 10.7326/0003-4819-74-5-771; EYSMANN SB, 1986, CIRCULATION, V73, P73, DOI 10.1161/01.CIR.73.1.73; KIM SG, 1990, J AM COLL CARDIOL, V16, P756, DOI 10.1016/0735-1097(90)90371-U; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; MATTANA J, 1992, CHEST, V101, P1386, DOI 10.1378/chest.101.5.1386; MILLER DD, 1982, CIRCULATION, V66, P588, DOI 10.1161/01.CIR.66.3.588; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; RICCI C, 1992, AM J CARDIOL, V70, P1589, DOI 10.1016/0002-9149(92)90462-8; ROBINSON K, 1988, BRIT HEART J, V59, P53; SLAMA R, 1985, CARDIAC ELECTROPHYSI, P545; SWEENEY MO, 1994, CIRCULATION, V89, P1851, DOI 10.1161/01.CIR.89.4.1851; VISKIN S, 1990, AM HEART J, V120, P661, DOI 10.1016/0002-8703(90)90025-S; WANG Y, 1991, J AM COLL CARDIOL, V18, P1711, DOI 10.1016/0735-1097(91)90508-7; WELLENS HJJ, 1992, CIRCULATION S1, V85, P192; WICHTER T, 1992, CIRCULATION, V86, P29, DOI 10.1161/01.CIR.86.1.29; WIESFELD ACP, 1994, AM HEART J, V127, P1421, DOI 10.1016/0002-8703(94)90068-X	23	20	20	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 4	1995	332	18					1221	1225		10.1056/NEJM199505043321809	http://dx.doi.org/10.1056/NEJM199505043321809			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV415	7700318				2022-12-28	WOS:A1995QV41500009
J	VANDAM, J; SCULLY, RE; SCHAPIRO, RB; GRAEMECOOK, FM; SAINI, S				VANDAM, J; SCULLY, RE; SCHAPIRO, RB; GRAEMECOOK, FM; SAINI, S			A 35-YEAR-OLD WOMAN WITH RECURRENT BLEEDING FROM A GASTRIC-ULCER AFTER TREATMENT FOR HELICOBACTER-PYLORI INFECTION - LOW-GRADE GASTRIC B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE (MALT) ORIGIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Discussion							ZOLLINGER-ELLISON SYNDROME; MALIGNANT-LYMPHOMA; ENDOSCOPIC ULTRASONOGRAPHY; SPONTANEOUS REGRESSION; LINITIS PLASTICA; DUODENAL-ULCER; DIAGNOSIS; CARCINOMA; STOMACH; CANCER		HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	VANDAM, J (corresponding author), BRIGHAM & WOMENS HOSP,75 FRANCIS ST,BOSTON,MA 02115, USA.							ABDU RA, 1993, ARCH SURG-CHICAGO, V128, P103; ALAM K, 1994, AM J GASTROENTEROL, V89, P888; ANAI H, 1990, GASTROINTEST ENDOSC, V36, P624, DOI 10.1016/S0016-5107(90)71185-6; ARISTANASR J, 1991, HUM PATHOL, V22, P339, DOI 10.1016/0046-8177(91)90082-Z; AWAD JA, 1990, DIGEST DIS SCI, V35, P317, DOI 10.1007/BF01537408; BLAZQUEZ M, 1992, GUT, V33, P1621, DOI 10.1136/gut.33.12.1621; BORCH K, 1982, ACTA CHIR SCAND, V148, P517; BROOKS JJ, 1983, CANCER, V51, P701, DOI 10.1002/1097-0142(19830215)51:4<701::AID-CNCR2820510425>3.0.CO;2-D; CALETTI G, 1993, SURGERY, V113, P14; CARTER KJ, 1984, ANN SURG, V199, P604, DOI 10.1097/00000658-198405000-00016; CHAN JKC, 1990, AM J PATHOL, V136, P1153; CONTINI S, 1990, GASTROINTEST ENDOSC, V36, P168, DOI 10.1016/S0016-5107(90)70990-X; CRAANEN ME, 1992, AM J GASTROENTEROL, V87, P572; FICH A, 1991, DIGEST DIS SCI, V36, P10, DOI 10.1007/BF01300079; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; GUPTA B, 1990, POSTGRAD MED J, V66, P63, DOI 10.1136/pgmj.66.771.63; HANSON JT, 1980, GASTROINTEST ENDOSC, V26, P33, DOI 10.1016/S0016-5107(80)73262-5; HANSSON LE, 1993, GASTROENTEROLOGY, V105, P1098, DOI 10.1016/0016-5085(93)90954-B; HARRIS NL, 1991, AM J SURG PATHOL, V15, P879, DOI 10.1097/00000478-199109000-00008; HARUMA K, 1992, AM J GASTROENTEROL, V87, P31; HENDRICKS JC, 1986, SURG CLIN N AM, V66, P683; HENKE F, 1926, HDB SPEZIELLEN PATHO, V4, P865; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; ISAACSON P, 1984, CANCER, V53, P2515, DOI 10.1002/1097-0142(19840601)53:11<2515::AID-CNCR2820531125>3.0.CO;2-C; JENSEN RT, 1983, ANN INTERN MED, V98, P59, DOI 10.7326/0003-4819-98-1-59; LABENZ J, 1994, AM J GASTROENTEROL, V89, P726; MASUDA R, 1992, CANCER, V70, P2592, DOI 10.1002/1097-0142(19921201)70:11<2592::AID-CNCR2820701104>3.0.CO;2-W; MATLEY PJ, 1988, ANN SURG, V208, P593, DOI 10.1097/00000658-198811000-00008; MOONKA D, 1993, AM J GASTROENTEROL, V88, P297; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; NOMURA A, 1994, ANN INTERN MED, V120, P977, DOI 10.7326/0003-4819-120-12-199406150-00001; OBRIEN MJ, 1985, AM J MED, V78, P195, DOI 10.1016/0002-9343(85)90426-7; OSBORNE BM, 1992, AM J SURG PATHOL, V16, P838, DOI 10.1097/00000478-199209000-00002; PALMER ED, 1958, J LAB CLIN MED, V52, P231; PANELLA VS, 1988, J CLIN GASTROENTEROL, V10, P327, DOI 10.1097/00004836-198806000-00019; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; RAUTELIN H, 1992, ANTIMICROB AGENTS CH, V36, P163, DOI 10.1128/AAC.36.1.163; RUSKONEFOURMEST.A, 1993, GASTROENTEROLOGY, V105, P1662; SAEED ZA, 1991, DIGEST DIS SCI, V36, P15, DOI 10.1007/BF01300080; SALPETER SR, 1991, WESTERN J MED, V155, P412; SCHWARTZ MS, 1989, AM J GASTROENTEROL, V84, P1555; SEVERSON RK, 1990, CANCER, V66, P1283, DOI 10.1002/1097-0142(19900915)66:6<1283::AID-CNCR2820660631>3.0.CO;2-4; SHARMA S, 1990, J SURG ONCOL, V43, P231, DOI 10.1002/jso.2930430409; STRAUCHEN JA, 1987, CANCER, V60, P1872, DOI 10.1002/1097-0142(19871015)60:8<1872::AID-CNCR2820600833>3.0.CO;2-6; SUEKANE H, 1993, CANCER, V71, P1207, DOI 10.1002/1097-0142(19930215)71:4<1207::AID-CNCR2820710406>3.0.CO;2-O; SUNDEEN JT, 1992, AM J SURG PATHOL, V16, P130, DOI 10.1097/00000478-199202000-00005; SWEENEY JF, 1992, DIGEST DIS SCI, V37, P939, DOI 10.1007/BF01300395; TAKEHARA Y, 1992, ENDOSCOPY, V24, P735, DOI 10.1055/s-2007-1010573; TATSUTA M, 1993, CANCER, V72, P1841, DOI 10.1002/1097-0142(19930915)72:6<1841::AID-CNCR2820720608>3.0.CO;2-I; Ueyama T, 1993, Radiat Med, V11, P167; WESTBLOM TU, 1992, J INFECT DIS, V165, P974; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1992, HISTOPATHOLOGY, V20, P29, DOI 10.1111/j.1365-2559.1992.tb00912.x; YOSHIKANE H, 1993, GASTROINTEST ENDOSC, V39, P375, DOI 10.1016/S0016-5107(93)70109-1	55	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	1995	332	17					1153	1159		10.1056/NEJM199504273321708	http://dx.doi.org/10.1056/NEJM199504273321708			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU302	7700290				2022-12-28	WOS:A1995QU30200008
J	GRUMBACH, K; BODENHEIMER, T				GRUMBACH, K; BODENHEIMER, T			MECHANISMS FOR CONTROLLING COSTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-MAINTENANCE ORGANIZATIONS; PROSPECTIVE PAYMENT SYSTEM; CONTROLLED TRIAL; UNITED-STATES; MANAGED COMPETITION; PROMOTE QUALITY; CARE; PHYSICIANS; INSURANCE; CANADA		UNIV CALIF SAN FRANCISCO, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	GRUMBACH, K (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT FAMILY & COMMUNITY MED, BOX 1364, SAN FRANCISCO, CA 94143 USA.		Grumbach, Kevin/L-9222-2016					BARER ML, 1991, JAMA-J AM MED ASSOC, V265, P2393, DOI 10.1001/jama.265.18.2393; BECK RG, 1980, MED CARE, V18, P787, DOI 10.1097/00005650-198008000-00001; BLUSTEIN J, 1990, JAMA-J AM MED ASSOC, V270, P344; BODENHEIMER T, 1994, JAMA-J AM MED ASSOC, V272, P971, DOI 10.1001/jama.272.12.971; BODENHEIMER T, 1994, JAMA-J AM MED ASSOC, V272, P634, DOI 10.1001/jama.272.8.634; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; BUNKER JP, 1970, NEW ENGL J MED, V282, P135, DOI 10.1056/NEJM197001152820306; DIPPE SE, 1989, WESTERN J MED, V151, P93; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; ENTHOVEN AC, 1993, HEALTH AFFAIR, V12, P24, DOI 10.1377/hlthaff.12.suppl_1.24; EVANS RG, 1989, NEW ENGL J MED, V320, P571, DOI 10.1056/NEJM198903023200906; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; FAHS MC, 1992, HEALTH SERV RES, V27, P25; FITZGERALD JF, 1988, NEW ENGL J MED, V319, P1392, DOI 10.1056/NEJM198811243192106; Folland S, 1990, Med Care Rev, V47, P419, DOI 10.1177/107755879004700403; GABEL JR, 1992, HEALTH AFFAIR, V11, P186, DOI 10.1377/hlthaff.11.4.186; GLASER W, 1991, HLTH INSURANCE PRACT; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GREENFIELD S, 1978, NEW ENGL J MED, V298, P305, DOI 10.1056/NEJM197802092980604; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; GRUMBACH K, 1994, JAMA-J AM MED ASSOC, V272, P1458, DOI 10.1001/jama.272.18.1458; GRUMBACH K, 1990, HEALTH AFFAIR, V9, P120, DOI 10.1377/hlthaff.9.4.120; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HUGHES JS, 1991, JAMA-J AM MED ASSOC, V265, P2347, DOI 10.1001/jama.265.18.2347; LEE PR, 1989, LANCET, V1, P263; LETSCH SW, 1993, HEALTH AFFAIR, V12, P94, DOI 10.1377/hlthaff.12.1.94; LOMAS J, 1989, HEALTH AFFAIR, V8, P80, DOI 10.1377/hlthaff.8.1.80; LUFT HS, 1978, NEW ENGL J MED, V298, P1336, DOI 10.1056/NEJM197806152982404; LUFT HS, 1994, CRITICAL ISSUES US H; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MCPHERSON K, 1989, HLTH CARE FINANCIN S, P9; MERLIS M, 1992, CRS ISSUE BRIEF HLTH; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MUNDINGER MO, 1994, NEW ENGL J MED, V330, P211, DOI 10.1056/NEJM199401203300314; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; NEWHOUSE JP, 1985, MED CARE, V23, P960, DOI 10.1097/00005650-198508000-00003; RELMAN AS, 1993, NEW ENGL J MED, V328, P133, DOI 10.1056/NEJM199301143280212; RICE T, 1993, JAMA-J AM MED ASSOC, V270, P1357, DOI 10.1001/jama.270.11.1357; RICE TH, 1989, J HEALTH POLIT POLIC, V14, P587, DOI 10.1215/03616878-14-3-587; ROBINSON JC, 1988, JAMA-J AM MED ASSOC, V260, P2676, DOI 10.1001/jama.260.18.2676; ROEMER M, 1959, HOSPITAL UTILIZATION; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; RUBLEE DA, 1989, HEALTH AFFAIR, V8, P178, DOI 10.1377/hlthaff.8.3.178; RUSSELL LB, 1989, NEW ENGL J MED, V320, P439, DOI 10.1056/NEJM198902163200706; SINGER DE, 1983, NEW ENGL J MED, V309, P1155, DOI 10.1056/NEJM198311103091905; SIU AL, 1986, NEW ENGL J MED, V315, P1259, DOI 10.1056/NEJM198611133152005; STARR P, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.suppl_1.7; STODDART GL, 1994, USER CHARGES SNARES; WELCH HG, 1994, NEW ENGL J MED, V330, P607, DOI 10.1056/NEJM199403033300906; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; Wickizer T M, 1990, Med Care Rev, V47, P327, DOI 10.1177/107755879004700303; 1991, HLTH CARE SPENDING C; 1993, MANAGED HLTH CARE EF	56	28	28	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1223	1230		10.1001/jama.273.15.1223	http://dx.doi.org/10.1001/jama.273.15.1223			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT100	7707633				2022-12-28	WOS:A1995QT10000035
J	REEVES, RA				REEVES, RA			DOES THIS PATIENT HAVE HYPERTENSION - HOW TO MEASURE BLOOD-PRESSURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ISOLATED SYSTOLIC HYPERTENSION; TREATING MILD HYPERTENSION; BORDERLINE HYPERTENSION; ARTERIAL-PRESSURE; FOLLOW-UP; OBSERVER VARIABILITY; EXERCISE; ERROR; PSEUDOHYPERTENSION; MANAGEMENT		UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT MED, DIV CLIN EPIDEMIOL, TORONTO, ON, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, CLIN EPIDEMIOL UNIT, TORONTO, ON, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center			Zellweger, Michael/AAB-4859-2022					ABELLA M, 1992, J ACOUST SOC AM, V91, P2224, DOI 10.1121/1.403655; [Anonymous], 1980, LANCET, V1, P1261; [Anonymous], 1992, Am J Hypertens, V5, P207; ARMITAGE P, 1966, CLIN SCI, V30, P325; BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; BENOWITZ NL, 1984, CLIN PHARMACOL THER, V36, P74, DOI 10.1038/clpt.1984.142; BLANK SG, 1988, CIRCULATION, V77, P1297, DOI 10.1161/01.CIR.77.6.1297; BRUCE NG, 1990, J HYPERTENS, V8, pS11; BRUCE NG, 1988, J HYPERTENS, V6, P375; BURKE GL, 1987, J CHRON DIS, V40, P83, DOI 10.1016/0021-9681(87)90099-3; CAMPBELL NRC, 1990, CAN MED ASSOC J, V143, P19; CANNER PL, 1991, AM J EPIDEMIOL, V134, P379, DOI 10.1093/oxfordjournals.aje.a116100; CLEMENT DL, 1990, J HYPERTENS, V8, pS39; COHN JN, 1967, J AMER MED ASSOC, V199, P972, DOI 10.1001/jama.1967.03120130058009; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CONCEICAO S, 1976, BRIT MED J, V1, P886, DOI 10.1136/bmj.1.6014.886; CUSHMAN WC, 1990, AM J HYPERTENS, V3, P240, DOI 10.1093/ajh/3.3.240; DEVEREUX RB, 1983, CIRCULATION, V68, P470, DOI 10.1161/01.CIR.68.3.470; DIRIENZO M, 1985, J HYPERTENS, V3, P343; DLIN RA, 1983, AM HEART J, V106, P316, DOI 10.1016/0002-8703(83)90198-9; ELLIS PJ, 1988, LANCET, V2, P902; FAGIUS J, 1989, HYPERTENSION, V14, P511, DOI 10.1161/01.HYP.14.5.511; FROHLICH E D, 1988, Hypertension (Dallas), V11, p210A; FUJII I, 1984, J CHRON DIS, V37, P895, DOI 10.1016/0021-9681(84)90065-1; GIACONI S, 1988, J HYPERTENS, V6, pS64, DOI 10.1097/00004872-198812040-00016; GORDON T, 1976, INT J EPIDEMIOL, V5, P327, DOI 10.1093/ije/5.4.327; GOULD BA, 1984, AMBULATORY BLOOD PRE, P9; GUERRERA G, 1991, AM J HYPERTENS, V4, P271, DOI 10.1093/ajh/4.3.271; HASHIMOTO F, 1984, WESTERN J MED, V141, P189; Haynes R B, 1983, J Hypertens, V1, P91; HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403; HAYNES RB, 1993, CAN MED ASSOC J, V149, P409; HLA KM, 1991, J CLIN EPIDEMIOL, V44, P513, DOI 10.1016/0895-4356(91)90214-T; HLA KM, 1986, ARCH INTERN MED, V146, P2373, DOI 10.1001/archinte.146.12.2373; HOLLEMAN DR, 1993, J GEN INTERN MED, V8, P325, DOI 10.1007/BF02600148; IMAI Y, 1990, CLIN EXP HYPERTENS A, V12, P1095, DOI 10.3109/10641969009073520; IZZO JL, 1990, AM J HYPERTENS, V3, P405, DOI 10.1093/ajh/3.5.405; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; JENNINGS D, 1991, CAN MED ASSOC J, V144, P973; KANNEL WB, 1976, AM J CARDIOL, V37, P269, DOI 10.1016/0002-9149(76)90323-4; KEENAN WF, 1981, JAMA-J AM MED ASSOC, V246, P1088, DOI 10.1001/jama.1981.03320100024013; KENNY RA, 1987, J HYPERTENS       S5, V5, P483; KING GE, 1963, AM HEART J, V65, P303, DOI 10.1016/0002-8703(63)90003-6; KLEINERT HD, 1984, HYPERTENSION, V6, P574, DOI 10.1161/01.HYP.6.4.574; Kraus J F, 1982, J Community Health, V8, P3, DOI 10.1007/BF01324392; KUNES J, 1991, AM J HYPERTENS, V4, P422, DOI 10.1093/ajh/4.5.422; KUWAJIMA I, 1990, J HYPERTENS, V8, P429, DOI 10.1097/00004872-199005000-00006; LAUGHLIN KD, 1980, J CHRON DIS, V33, P197, DOI 10.1016/0021-9681(80)90064-8; LEFEBVRE RC, 1988, ARCH INTERN MED, V148, P1993, DOI 10.1001/archinte.148.9.1993; LITTLER WA, 1975, BRIT MED J, V3, P346, DOI 10.1136/bmj.3.5979.346; LONDE S, 1984, WESTERN J MED, V141, P193; LYNCH JJ, 1982, ISRAEL J MED SCI, V18, P575; MACMAHON SW, 1986, PROG CARDIOVASC DIS, V29, P99, DOI 10.1016/0033-0620(86)90038-1; MADER SL, 1989, ARCH INTERN MED, V149, P2757, DOI 10.1001/archinte.149.12.2757; MALINOW KL, 1986, PSYCHOSOM MED, V48, P95, DOI 10.1097/00006842-198601000-00008; MANCIA G, 1986, HYPERTENSION, V8, P147, DOI 10.1161/01.HYP.8.2.147; MANCIA G, 1987, HYPERTENSION, V9, P209, DOI 10.1161/01.HYP.9.2.209; MAXWELL MH, 1982, LANCET, V2, P33; MCGRADY A, 1990, J BEHAV MED, V13, P93, DOI 10.1007/BF00844901; MCKAY DW, 1990, J HUM HYPERTENS, V4, P639; MENGDEN T, 1990, J HYPERTENS, V8, pS15; MESSERLI FH, 1985, NEW ENGL J MED, V312, P1548, DOI 10.1056/NEJM198506133122405; MIDANIK LT, 1991, PUBLIC HEALTH REP, V106, P85; MILLARCRAIG MW, 1978, LANCET, V1, P795; MILLARCRAIG MW, 1978, CLIN SCI MOL MED, V55, pS391; MITCHELL PL, 1964, NEW ENGL J MED, V271, P72, DOI 10.1056/NEJM196407092710204; MYERS MG, 1982, CAN MED ASSOC J, V127, P365; MYERS MG, 1991, AM J HYPERTENS, V4, P427, DOI 10.1093/ajh/4.5.427; MYERS MG, 1991, AM J HYPERTENS, V4, P844, DOI 10.1093/ajh/4.10.844; NEUFELD PD, 1986, CAN MED ASSOC J, V135, P633; NUESSLE WF, 1956, AM HEART J, V52, P905, DOI 10.1016/0002-8703(56)90158-2; OBRIEN E, 1990, J HYPERTENS, V8, P621, DOI 10.1097/00004872-199007000-00005; OBRIEN ET, 1979, BRIT MED J, V2, P920, DOI 10.1136/bmj.2.6195.920; OBRIEN ET, 1979, BRIT MED J, V2, P851, DOI 10.1136/bmj.2.6194.851; OBRIEN ET, 1979, BRIT MED J, V2, P775, DOI 10.1136/bmj.2.6193.775; OBRIEN ET, 1979, BRIT MED J, V2, P982, DOI 10.1136/bmj.2.6196.982; ORNSTEIN S, 1988, J FAM PRACTICE, V26, P517; OROURKE M, 1985, NEW ENGL J MED, V313, P1300; PADFIELD PL, 1990, J HUM HYPERTENS, V4, P3; PATTERSON HR, 1984, BRIT MED J, V289, P1661, DOI 10.1136/bmj.289.6459.1661; PERLOFF D, 1993, CIRCULATION, V88, P2460, DOI 10.1161/01.CIR.88.5.2460; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V249, P2792, DOI 10.1001/jama.249.20.2792; PERRY HM, 1992, J HYPERTENS, V10, P887; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; PICKERING TG, 1989, J HYPERTENS, V7, pS65; POLEFRONE JM, 1988, PSYCHOSOM MED, V50, P23, DOI 10.1097/00006842-198801000-00004; PORCHET M, 1986, J CARDIOVASC PHARM, V8, P332, DOI 10.1097/00005344-198603000-00016; POTTER JF, 1986, HYPERTENSION, V8, P625, DOI 10.1161/01.HYP.8.7.625; RABKIN SW, 1982, CIRCULATION, V65, P291, DOI 10.1161/01.CIR.65.2.291; REEVES R A, 1991, Clinical and Investigative Medicine, V14, pA69; REEVES RA, 1992, J HYPERTENS, V10, P1249, DOI 10.1097/00004872-199210000-00020; REEVES RA, 1991, CLIN INVEST MED, V14, P251; REEVES RA, 1991, CLIN INVEST MED, V14, P198; REEVES RA, 1991, CLIN INVEST MED, V14, P218; ROBERTSON D, 1981, J CLIN INVEST, V67, P1111, DOI 10.1172/JCI110124; ROCCELLA E, 1990, ARCH INTERN MED, V150, P2270; ROSE G, 1965, LANCET, V1, P673; RUSSELL AE, 1989, J HYPERTENS, V7, P607, DOI 10.1097/00004872-198908000-00002; SAKLAYEN MG, 1988, AM J MED, V84, P794, DOI 10.1016/0002-9343(88)90127-1; SAPIRA JD, 1990, ART SCI BEDSIDE DIAG, P85; SCHERWITZ LW, 1982, MED CARE, V20, P727, DOI 10.1097/00005650-198207000-00008; Scordo K, 1983, Dimens Crit Care Nurs, V2, P75, DOI 10.1097/00003465-198303000-00002; Segall HN, 1940, CAN MED ASSOC J, V42, P311; SHAW A, 1979, BRIT MED J, V1, P789, DOI 10.1136/bmj.1.6166.789; SHEAR CL, 1986, PEDIATRICS, V77, P862; SHEPARD DS, 1981, J CHRON DIS, V34, P191, DOI 10.1016/0021-9681(81)90064-3; SHIMADA K, 1990, CLIN EXP HYPERTENS A, V12, P151, DOI 10.3109/10641969009074725; SILAGY CA, 1990, CLIN EXP PHARMACOL P, V17, P203, DOI 10.1111/j.1440-1681.1990.tb01306.x; SILVERBERG DS, 1972, BRIT MED J, V2, P1331; SMITH TDW, 1990, BMJ-BRIT MED J, V300, P74, DOI 10.1136/bmj.300.6717.74; SPENCE JD, 1978, CLIN SCI MOL MED, V55, pS399, DOI 10.1042/cs055399s; STEINFELD L, 1974, AM J CARDIOL, V33, P107, DOI 10.1016/0002-9149(74)90745-0; SWALES JD, 1989, BMJ-BRIT MED J, V298, P694; SYKES D, 1990, BMJ-BRIT MED J, V300, P162, DOI 10.1136/bmj.300.6718.162; TAGUCHI JT, 1974, JAMA-J AM MED ASSOC, V228, P733, DOI 10.1001/jama.228.6.733; THOMAS CB, 1982, JOHNS HOPKINS MED J, V151, P93; THULIN T, 1975, POSTGRAD MED J, V51, P390, DOI 10.1136/pgmj.51.596.390; TIFFT CP, 1988, ARCH INTERN MED, V148, P518, DOI 10.1001/archinte.148.3.518; TREMBATH CR, 1991, J FAM PRACTICE, V32, P378; TROUT KW, 1956, JAMA-J AM MED ASSOC, V162, P970, DOI 10.1001/jama.1956.72970270001010; VANLOO JM, 1986, J HYPERTENS, V4, P631, DOI 10.1097/00004872-198610000-00017; VEERMAN DP, 1992, J HYPERTENS       S4, V6, pS77; VIOL GW, 1979, AM HEART J, V98, P813, DOI 10.1016/0002-8703(79)90483-6; VONEIFF AW, 1971, AM J OBSTET GYNECOL, V109, P887, DOI 10.1016/0002-9378(71)90802-7; WAALER HT, 1980, J EPIDEMIOL COMMUN H, V34, P53, DOI 10.1136/jech.34.1.53; WALLACE CT, 1975, ANESTHESIOLOGY, V43, P588, DOI 10.1097/00000542-197511000-00023; WARSHAW LJ, 1989, JAMA-J AM MED ASSOC, V262, P1775, DOI 10.1001/jama.1989.03430130049030; WATSON RDS, 1987, J HYPERTENS, V5, P207, DOI 10.1097/00004872-198704000-00012; WATSON RDS, 1980, HYPERTENSION, V2, P333, DOI 10.1161/01.HYP.2.3.333; WEBB CH, 1980, PRIMARY CARE, V7, P637; WEILAND SK, 1991, J HYPERTENS, V9, P131, DOI 10.1097/00004872-199102000-00005; WHITE LJ, 1986, ANN INTERN MED, V104, P275; WHITE WB, 1990, AM J CARDIOL, V65, P60, DOI 10.1016/0002-9149(90)90026-W; WIETLISBACH V, 1988, ACTA MED SCAND, P165; WILKINSON LS, 1991, J ROY COLL PHYS LOND, V25, P116; WILSON NV, 1981, PREV MED, V10, P62, DOI 10.1016/0091-7435(81)90006-2; YAGI S, 1986, NEW ENGL J MED, V315, P836; ZANCHETTI A, 1993, HYPERTENSION, V22, P392; 1977, CIRC RES S1, V40, P106; 1993, ARCH  INTERN MED, V153, P154; 1989, MAIN FINDINGS REPORT, P1; 1978, J CHRON DIS, V31, P651; 1988, CAN MED ASSOC J, V138, P1093; 1977, JAMA-J AM MED ASSOC, V237, P2385	145	131	133	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1211	1218		10.1001/jama.1995.03520390071036	http://dx.doi.org/10.1001/jama.1995.03520390071036			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT100	7707630				2022-12-28	WOS:A1995QT10000031
J	WELSH, JP; LANG, EJ; SUGIHARA, I; LLINAS, R				WELSH, JP; LANG, EJ; SUGIHARA, I; LLINAS, R			DYNAMIC ORGANIZATION OF MOTOR CONTROL WITHIN THE OLIVOCEREBELLAR SYSTEM	NATURE			English	Article							INFERIOR OLIVARY NEURONS; CEREBELLAR; RAT; INVITRO; NUCLEUS; CAT	WHAT is the role of the cerebellum in motor coordination? Such coordination depends upon the integrity of the inferior olive, a major cerebellar afferent, as its lesion produces ataxic and dysmetric movement abnormalities(1,2). Using multiple-microelectrode recordings, we report here that there are domains of Purkinje cell activity that are generated by olivary input during skilled tongue movements in rats, Such activity domains are highly rhythmic and time-locked to movement, Patterns of synchronous olivocerebellar activity are geometrically complex and can change during a sequence of movements. The results support the view that the inferior olive organizes movement in time, by entraining motor-neuronal firing through rhythmic activation of the cerebellum, and in space, by synchronously activating cell ensembles that allow the use of individual muscles. Dynamic repatterning of olivocerebellar synchrony may allow different combinations of muscles to be used for movements intended to have varying spatial structures.			WELSH, JP (corresponding author), NYU,MED CTR,DEPT PHYSIOL & NEUROSCI,550 1ST AVE,NEW YORK,NY 10016, USA.		Lang, Eric J/A-1136-2017	Lang, Eric J/0000-0002-8524-9854				BOX GEP, 1994, TIME SERIES ANAL; Brooks VB, 1981, HDB PHYSL NERVOUS SY, V2, P877; BUISSERETDELMAS C, 1993, PROG NEUROBIOL, V40, P63, DOI 10.1016/0301-0082(93)90048-W; CICERATA F, 1992, EXPL BRAIN RES, V89, P352; DESCLIN JC, 1974, BRAIN RES, V77, P365, DOI 10.1016/0006-8993(74)90628-3; DEZEEUW CI, 1989, J COMP NEUROL, V284, P12, DOI 10.1002/cne.902840103; ECCLES JC, 1966, J PHYSIOL-LONDON, V182, P268, DOI 10.1113/jphysiol.1966.sp007824; GERSTEIN GL, 1960, BIOPHYS J, V1, P15, DOI 10.1016/S0006-3495(60)86872-5; KEEHN JD, 1960, SCIENCE, V132, P739, DOI 10.1126/science.132.3429.739; KING JS, 1976, J COMP NEUROL, V165, P387, DOI 10.1002/cne.901650307; LANG E I, 1990, Society for Neuroscience Abstracts, V16, P894; Larsell O., 1970, COMP ANATOMY HISTOLO; LLINAS R, 1989, EUR J NEUROSCI, V1, P587, DOI 10.1111/j.1460-9568.1989.tb00365.x; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P549, DOI 10.1113/jphysiol.1981.sp013763; LLINAS R, 1986, J PHYSIOL-LONDON, V376, P163, DOI 10.1113/jphysiol.1986.sp016147; LLINAS R, 1991, MOTOR CONTROL CONCEP, P223; MURPHY MG, 1971, ARCH NEUROL-CHICAGO, V24, P145, DOI 10.1001/archneur.1971.00480320073007; SASAKI K, 1989, EUR J NEUROSCI, V1, P572, DOI 10.1111/j.1460-9568.1989.tb00364.x; SOTELO C, 1974, J NEUROPHYSIOL, V37, P541, DOI 10.1152/jn.1974.37.3.541; SOTELO C, 1986, J COMP NEUROL, V252, P32, DOI 10.1002/cne.902520103; SUGIHARA I, 1993, J PHYSIOL-LONDON, V470, P243, DOI 10.1113/jphysiol.1993.sp019857; VALLBO AB, 1993, J PHYSIOL-LONDON, V469, P673, DOI 10.1113/jphysiol.1993.sp019837; WILSON WC, 1945, J COMP NEUROL, V83, P69, DOI 10.1002/cne.900830104; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; ZIEGLER HP, 1991, THIRST PHYSL PSYCHOL, P241	25	500	504	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					453	457		10.1038/374453a0	http://dx.doi.org/10.1038/374453a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700354				2022-12-28	WOS:A1995QP89900058
J	MARSH, GN; DAWES, ML				MARSH, GN; DAWES, ML			ESTABLISHING A MINOR ILLNESS NURSE IN A BUSY GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To study the feasibility of a practice nurse caring for patients with minor illnesses. Design-Nurse given training in dealing with patients with minor illnesses. Patients requesting a same day appointment were offered a nurse consultation. Setting-Group practice in Stockton on Tees. Main outcome measures-Number of consultations which required a doctor contact, treatment, and rate of reconsultation. Results-Of 696 consultations in six months, 602 (86%) required no doctor contact. 549 (79%) patients did not reconsult about that episode of illness, and 343 (50%) patients were given advice on self care only. Conclusion-Trained nurses could diagnose and treat a large proportion of patients currently consulting general practitioners about minor illness provided that the nurse has immediate access to a doctor.			MARSH, GN (corresponding author), NORTON MED CTR,STOCKTON ON TEES TS20 1AN,CLEVELAND,ENGLAND.			Dawes, Martin/0000-0003-3624-2477				ATKIN K, 1993, NURSES COUNT NATIONA; BARNES G, 1985, J ROY COLL GEN PRACT, V35, P447; BOWLING A, 1988, NURSE FAMILY PRACTIC; CHAN CA, 1994, BR J GEN PRACT, V44, P263; JEWELL D, 1988, PRACTITIONER, V232, P484; JEWELL D, 1994, BRIT MED J, V308, P735, DOI 10.1136/bmj.308.6931.735; MARSH GN, 1991, EFFICIENT CARE GENER; READ SM, 1992, BRIT MED J, V305, P1466, DOI 10.1136/bmj.305.6867.1466; ROSS FM, 1994, BRIT J GEN PRACT, V44, P15; WAINE C, 1992, DIABETES GENERAL PRA; 1994, STATISTICAL B, V4	11	42	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	1995	310	6982					778	780		10.1136/bmj.310.6982.778	http://dx.doi.org/10.1136/bmj.310.6982.778			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP609	7711584	Green Published			2022-12-28	WOS:A1995QP60900021
J	MCDONALD, M; MILES, C				MCDONALD, M; MILES, C			MANAGEMENT FOR DOCTORS .11. THE POTENTIAL FOR MARKETING PLANNING IN AN NHS TRUST	BRITISH MEDICAL JOURNAL			English	Article									REDBRIDGE HLTH CARE TRUST,SURG & SPECIALIST SERV,REDBRIDGE,ESSEX,ENGLAND		MCDONALD, M (corresponding author), CRANFIELD SCH MANAGEMENT,CRANFIELD MK43 0AL,BEDS,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					719	724		10.1136/bmj.310.6981.719	http://dx.doi.org/10.1136/bmj.310.6981.719			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QN461	7711542	Green Published			2022-12-28	WOS:A1995QN46100030
J	DAVENPORT, RJ; STATHAM, PFX; WARLOW, CP				DAVENPORT, RJ; STATHAM, PFX; WARLOW, CP			LESSON OF THE WEEK - DETECTION OF BILATERAL ISODENSE SUBDURAL HEMATOMAS	BRITISH MEDICAL JOURNAL			English	Article							COMPUTED-TOMOGRAPHY; HEMATOMAS; CT; CONTRAST; SCAN				DAVENPORT, RJ (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							DCOSTA DF, 1990, BRIT J CLIN PRACT, V44, P666; Dublin A B, 1976, Surg Neurol, V6, P23; FOX AJ, 1992, AM J NEURORADIOL, V13, P1271; GREENHOUSE AH, 1979, ARCH NEUROL-CHICAGO, V36, P305, DOI 10.1001/archneur.1979.00500410083013; GUDEMAN SK, 1979, NEUROSURGERY, V5, P273, DOI 10.1227/00006123-197908000-00016; KAUFMAN HH, 1980, J COMPUT ASSIST TOMO, V4, P557, DOI 10.1097/00004728-198008000-00034; MATTLE H, 1989, J NEUROL NEUROSUR PS, V52, P829, DOI 10.1136/jnnp.52.7.829; MOLLER A, 1979, RADIOLOGY, V130, P149; SHIELDS CB, 1980, J NEUROSURG, V52, P712, DOI 10.3171/jns.1980.52.5.0712; SLOWIKOWSKI JS, 1989, AM J MED, V86, P345, DOI 10.1016/0002-9343(89)90311-2; WEISBERG LA, 1986, COMPUT RADIOL, V10, P245, DOI 10.1016/0730-4862(86)90005-3; WILMS G, 1992, NEURORADIOLOGY, V34, P497, DOI 10.1007/BF00598959; WYBLE SW, 1992, REGION ANESTH, V17, P52	13	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1994	309	6957					792	794		10.1136/bmj.309.6957.792	http://dx.doi.org/10.1136/bmj.309.6957.792			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ282	7695701	Green Published			2022-12-28	WOS:A1994PJ28200031
J	HOHMANN, AW; BOOTH, K; PETERS, V; GORDON, DL; COMACCHIO, RM				HOHMANN, AW; BOOTH, K; PETERS, V; GORDON, DL; COMACCHIO, RM			COMMON EPITOPE ON HIV P24 AND HUMAN PLATELETS	LANCET			English	Note							IMMUNE THROMBOCYTOPENIC PURPURA; HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; GLYCOPROTEINS; DISEASE	Mimicry of human antigen by HIV may underlie the autoreactivity seen in AIDS. A mouse monoclonal antibody (VIC8) raised against HIV p24 cross-reacted with human platelets; binding could be abolished by recombinant p24 antigen. VIC8 bound less well to platelets from patients with HIV than to those from healthy individuals. In the HIV group, binding was not related to p24 antigenaemia, disease stage, or platelet counts. This cross-reactivity is another example of antigenic mimicry by HIV and may be mechanistically important in HIV-associated autoimmune-like thrombocytopenia.	FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT CLIN IMMUNOL,BEDFORD PK,SA 5042,AUSTRALIA; FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT MICROBIOL & INFECT DIS,BEDFORD PK,SA 5042,AUSTRALIA	Flinders University South Australia; Flinders University South Australia				Gordon, David/0000-0003-3276-9685				BALLEM PJ, 1992, NEW ENGL J MED, V327, P1779, DOI 10.1056/NEJM199212173272503; BETTAIEB A, 1992, BLOOD, V80, P162; DEKEYSER F, 1992, CLIN IMMUNOL IMMUNOP, V62, P285, DOI 10.1016/0090-1229(92)90104-V; LOUACHE F, 1991, BLOOD, V78, P1697; MORROW WJW, 1991, CLIN IMMUNOL IMMUNOP, V58, P163, DOI 10.1016/0090-1229(91)90134-V; QUADRI MI, 1992, CLIN LAB HAEMATOL, V14, P109; STRICKER RB, 1991, HEMATOL ONCOL CLIN N, V5, P249, DOI 10.1016/S0889-8588(18)30439-8; ZAULI G, 1991, AIDS, V5, P1345, DOI 10.1097/00002030-199111000-00010	8	36	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1274	1275		10.1016/0140-6736(93)92363-X	http://dx.doi.org/10.1016/0140-6736(93)92363-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7694021				2022-12-28	WOS:A1993MH56600013
J	ABUELMAGD, K; VANTHIEL, DH; JEGASOTHY, BV; JACOBS, JC; CARROLL, P; RODRIGUEZRILO, H; ACKERMAN, CD; FUNG, JJ; STARZL, TE				ABUELMAGD, K; VANTHIEL, DH; JEGASOTHY, BV; JACOBS, JC; CARROLL, P; RODRIGUEZRILO, H; ACKERMAN, CD; FUNG, JJ; STARZL, TE			RESOLUTION OF SEVERE PYODERMA-GANGRENOSUM IN A PATIENT WITH STREAKING LEUKOCYTE FACTOR DISEASE AFTER TREATMENT WITH TACROLIMUS (FK-506)	ANNALS OF INTERNAL MEDICINE			English	Note							STREPTOMYCES		UNIV PITTSBURGH, SCH MED, DEPT SURG, PITTSBURGH, PA 15213 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PEDIAT, NEW YORK, NY 10032 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Columbia University	ABUELMAGD, K (corresponding author), PITTSBURGH TRANSPLANT INST, 3601 5TH AVE, FALK CLIN 5C, PITTSBURGH, PA 15213 USA.		FUNG, John Julian/A-2679-2012	FUNG, John Julian/0000-0002-3038-0441	NIDDK NIH HHS [DK29961, R01 DK029961-19] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029961, R37DK029961] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUELMAGD K, 1991, TRANSPLANT P, V23, P3328; FUNG JJ, 1991, TRANSPLANT P, V23, P3105; GLASS AT, 1991, J AM ACAD DERMATOL, V25, P109, DOI 10.1016/S0190-9622(08)80497-5; JACOBS JC, 1975, PEDIATRICS, V56, P570; JACOBS JC, 1993, PEDIATRIC RHEUMATOLO, P153; JEGASOTHY BV, 1992, ARCH DERMATOL, V128, P781, DOI 10.1001/archderm.128.6.781; KETCHEL MM, 1958, J EXP MED, V107, P211, DOI 10.1084/jem.107.2.211; KINO T, 1987, J ANTIBIOT, V40, P1256, DOI 10.7164/antibiotics.40.1256; KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249; MADERAZO EG, 1979, CLIN IMMUNOL IMMUNOP, V12, P382, DOI 10.1016/0090-1229(79)90043-6; MARTIN RR, 1974, J INFECT DIS, V129, P110, DOI 10.1093/infdis/129.2.110; TAMURA K, 1987, TRANSPLANT P, V19, P23; TODO S, 1990, ANN SURG, V212, P295, DOI 10.1097/00000658-199009000-00008; WARD PA, 1966, J EXP MED, V124, P209, DOI 10.1084/jem.124.2.209; WILKINSON PC, 1990, IMMUNOLOGY, V71, P417	15	39	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	1				595	598		10.7326/0003-4819-119-7_Part_1-199310010-00008	http://dx.doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA291	7689802	Green Accepted			2022-12-28	WOS:A1993MA29100008
J	GIRALT, S; ESCUDIER, S; KANTARJIAN, H; DEISSEROTH, A; FREIREICH, EJ; ANDERSSON, BS; OBRIEN, S; ANDREEFF, M; FISHER, H; CORK, A; HIRSCHGINSBERG, C; TRUJILLO, J; STASS, S; CHAMPLIN, RE				GIRALT, S; ESCUDIER, S; KANTARJIAN, H; DEISSEROTH, A; FREIREICH, EJ; ANDERSSON, BS; OBRIEN, S; ANDREEFF, M; FISHER, H; CORK, A; HIRSCHGINSBERG, C; TRUJILLO, J; STASS, S; CHAMPLIN, RE			PRELIMINARY-RESULTS OF TREATMENT WITH FILGRASTIM FOR RELAPSE OF LEUKEMIA AND MYELODYSPLASIA AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLONY-STIMULATING FACTOR; TOTAL-BODY IRRADIATION; HEMATOLOGICAL MALIGNANCIES; HOST DISEASE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; METHOTREXATE; BUSULFAN; REGIMEN	Background. Patients whose leukemia relapses after allogeneic bone marrow transplantation have a poor prognosis; few respond to further chemotherapy, and almost none survive over the long term. We present preliminary observations on the use of filgrastim (granulocyte colony-stimulating factor) for relapse after transplantation. Methods. Seven female patients with leukemia (one with chronic myelogenous leukemia, five with acute myelogenous leukemia, and one with a myelodysplastic syndrome that transformed into.acute myelogenous leukemia) whose disease relapsed within 360 days after allogeneic bone marrow transplantation received filgrastim (5 mug per kilogram of body weight per day by subcutaneous injection) to reinduce remission by stimulating residual donor marrow cells. Cytogenetic analysis of bone marrow, fluorescence in situ hybridization, and determination of restriction-fragment-length polymorphisms were used to assess response and chimerism. Results. Three of the seven patients had a complete hematologic and cytogenetic remission, with reestablishment of hematopoiesis of donor origin. Mild chronic graft-versus-host disease developed in one patient, and acute graft-versus-host disease in none. One patient had a relapse 12 months after treatment, and two others remained in remission after 10 and 11 months. In two of the patients with a response, fluorescence in situ hybridization demonstrated stimulation of donor cells without differentiation of the leukemic clone. Conclusions. Filgrastim may be effective in selected cases of leukemic relapse after allogeneic bone marrow transplantation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT LAB MED,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center								ARCESE W, 1990, BONE MARROW TRANSPL, V5, P309; BOSTROM B, 1987, J CLIN ONCOL, V5, P376, DOI 10.1200/JCO.1987.5.3.376; FORMAN SJ, 1987, TRANSPLANT P, V19, P2605; FRASSONI F, 1988, BRIT J HAEMATOL, V70, P317, DOI 10.1111/j.1365-2141.1988.tb02488.x; GABRILOVE JL, 1989, HEMATOL ONCOL CLIN N, V3, P427, DOI 10.1016/S0889-8588(18)30539-2; GIRALT S, 1991, BLOOD S1, V78, pA503; HIGANO CS, 1990, TRANSPLANTATION, V50, P175; HOROWITZ MM, 1990, BLOOD, V75, P555; ISCN An international system for human cytogenetic nomen-clature, 1978, CYTOGENET CELL GENET, V21, P309; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; METCALF D, 1980, INT J CANCER, V25, P225, DOI 10.1002/ijc.2910250210; MORTIMER J, 1989, J CLIN ONCOL, V7, P50, DOI 10.1200/JCO.1989.7.1.50; Mortimer J, 1989, J CLIN ONCOL, V7, P5451; PETERSEN FB, 1989, BONE MARROW TRANSPL, V4, P617; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PRZEPIORKA D, 1992, BLOOD S1, V80, pA337; Sambrook J, 1989, MOL CLONING LABORATO; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TRUJILLO JM, 1979, BLOOD, V53, P695; TUTSCHKA PJ, 1987, BLOOD, V70, P1382; VADHANRAJ S, 1987, NEW ENGL J MED, V317, P1545, DOI 10.1056/NEJM198712173172501; WAGNER JE, 1989, BONE MARROW TRANSPL, V4, P115; WELTE K, 1985, P NATL ACAD SCI USA, V82, P1526, DOI 10.1073/pnas.82.5.1526; YAU JC, 1990, BONE MARROW TRANSPL, V5, P269; YAU JC, 1992, AM J HEMATOL, V41, P40, DOI 10.1002/ajh.2830410108; 1989, BONE MARROW TRANSPL, V4, P221	26	100	101	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1993	329	11					757	761		10.1056/NEJM199309093291103	http://dx.doi.org/10.1056/NEJM199309093291103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV642	7688862				2022-12-28	WOS:A1993LV64200003
J	TAN, RY; CHEN, L; BUETTNER, JA; HUDSON, D; FRANKEL, AD				TAN, RY; CHEN, L; BUETTNER, JA; HUDSON, D; FRANKEL, AD			RNA RECOGNITION BY AN ISOLATED ALPHA-HELIX	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SMALL NUCLEAR RIBONUCLEOPROTEIN; HIV-1 REV PROTEIN; TAT PROTEIN; CRYSTAL-STRUCTURE; BINDING DOMAIN; CIRCULAR-DICHROISM; DNA-BINDING; AMINO-ACIDS; SYNTHETASE	A 17 amino acid peptide containing the arginine-rich region of the HIV Rev protein binds specifically to Rev response element (RRE) RNA. Even though it is highly charged, the peptide forms an alpha helix in solution, but only when its N- and C-termini are modified to provide favorable electrostatic interactions with the helix macrodipole. Binding affinity for IIB RNA (the primary binding site within the RRE) increases with alpha helix content, whereas nonspecific binding affinity is independent of helix content. Binding of mutant peptides demonstrates that one threonine, one asparagine, and four arginine side chains are important for sequence-specific recognition. Transactivation of the HIV LTR using Tat-Rev peptide hybrids and the RRE IIB site indicates that the peptide adopts an alpha-helical conformation in vivo. The results suggest that interactions with the RNA backbone may help to orient the alpha helix in the major groove of RNA.	UNIV CALIF SAN FRANCISCO, GLADSTONE INST VIROL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; ARRIS PHARMACEUT, San Francisco, CA 94080 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes	TAN, RY (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.				NIAID NIH HHS [AI29135, AI08591] Funding Source: Medline; NIGMS NIH HHS [GM39589] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029135, F32AI008591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039589] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BOHNLEIN E, 1991, J VIROL, V65, P7051; BUETTNER JA, 1993, IN PRESS PEPTIDES 19; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577; Creighton T. E., 1993, PROTEINS STRUCTURES; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HEAPHY S, 1991, P NATL ACAD SCI USA, V88, P7366, DOI 10.1073/pnas.88.16.7366; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOL WGJ, 1981, NATURE, V294, P532, DOI 10.1038/294532a0; HUANG XJ, 1991, J VIROL, V65, P2131, DOI 10.1128/JVI.65.4.2131-2134.1991; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; PUGLISI JD, 1993, IN PRESS P NATL ACAD, V90; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RIORDAN FA, 1992, J MOL BIOL, V226, P305, DOI 10.1016/0022-2836(92)90947-I; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TAN RY, 1992, BIOCHEMISTRY-US, V31, P10288, DOI 10.1021/bi00157a016; TAO JS, 1993, P NATL ACAD SCI USA, V90, P1571, DOI 10.1073/pnas.90.4.1571; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; Turner DH, 1992, CURR OPIN STRUC BIOL, V2, P334; VANDERGRAAF M, 1992, BIOCHEMISTRY-US, V31, P9177, DOI 10.1021/bi00153a009; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734	58	252	257	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 4	1993	73	5					1031	1040		10.1016/0092-8674(93)90280-4	http://dx.doi.org/10.1016/0092-8674(93)90280-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	7684657				2022-12-28	WOS:A1993LF06100018
J	KOCH, C; HOIBY, N				KOCH, C; HOIBY, N			PATHOGENESIS OF CYSTIC-FIBROSIS	LANCET			English	Article							PSEUDOMONAS-AERUGINOSA; GENE; IDENTIFICATION; LOCALIZATION; INFECTIONS; TRANSPORT; CFTR		UNIV COPENHAGEN,RIGSHOSP,DEPT CLIN MICROBIOL,DK-2100 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen	KOCH, C (corresponding author), UNIV COPENHAGEN,RIGSHOSP,DEPT PEDIAT,DANISH CYST FIBROSIS CTR,BLEGDAMSVEJ 9,DK-2100 COPENHAGEN,DENMARK.							ANDERSON NP, 1992, SCIENCE, V257, P1701; ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER M, 1991, CLIN REV ALLERG, V9, P119; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CHU CS, 1992, J CLIN INVEST, V90, P785, DOI 10.1172/JCI115952; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; COHN JA, 1991, BIOCHEM BIOPH RES CO, V181, P36, DOI 10.1016/S0006-291X(05)81378-6; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; CONG EL, 1989, THORAX, V44, P739; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; CUTTING RC, 1992, AM J HUM GENET, V50, P1185; DORIN JR, 1992, NATURE, V359, P211, DOI 10.1038/359211a0; ENGLEHARDT JF, 1992, PEDIATR PULM S, V8, P185; FINKELSTEIN SM, 1988, J PEDIATR-US, V112, P373, DOI 10.1016/S0022-3476(88)80315-9; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; HJELTE L, 1990, THORAX, V45, P397, DOI 10.1136/thx.45.5.397; HOIBY N, 1990, THORAX, V45, P881, DOI 10.1136/thx.45.11.881; HOIBY N, 1989, ACTA PAEDIATR SCAND, V78, P395, DOI 10.1111/j.1651-2227.1989.tb11099.x; Hoiby N, 1987, Antibiot Chemother (1971), V39, P60; JOHANSEN HK, 1992, THORAX, V47, P109, DOI 10.1136/thx.47.2.109; JOHANSEN HK, 1991, LANCET, V337, P631, DOI 10.1016/0140-6736(91)92449-C; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KILBY JM, 1992, CHEST, V102, P70, DOI 10.1378/chest.102.1.70; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; LANNG S, 1991, ARCH DIS CHILD, V66, P612, DOI 10.1136/adc.66.5.612; LIPUMA JJ, 1990, LANCET, V336, P1094, DOI 10.1016/0140-6736(90)92571-X; MORTENSEN J, IN PRESS CHEST; PEDERSEN SS, 1992, APMIS S28, V100; PETERSEN NT, 1981, ACTA PAEDIATR SCAND, V70, P623, DOI 10.1111/j.1651-2227.1981.tb05757.x; PRESSLER T, 1992, CLIN EXP IMMUNOL, V90, P209; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SAJJAN US, 1992, J CLIN INVEST, V89, P648, DOI 10.1172/JCI115631; SCHAAD UB, 1991, LANCET, V338, P1236, DOI 10.1016/0140-6736(91)92103-9; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; VALERIUS NH, 1991, LANCET, V338, P725, DOI 10.1016/0140-6736(91)91446-2; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, pC332, DOI 10.1152/ajpcell.1991.261.2.C332	41	329	344	1	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 24	1993	341	8852					1065	1069		10.1016/0140-6736(93)92422-P	http://dx.doi.org/10.1016/0140-6736(93)92422-P			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ018	7682274				2022-12-28	WOS:A1993KZ01800015
J	SHIMODA, K; OKAMURA, S; INABA, S; OKAMURA, T; OHGA, S; UEDA, K; NIHO, Y				SHIMODA, K; OKAMURA, S; INABA, S; OKAMURA, T; OHGA, S; UEDA, K; NIHO, Y			GRANULOCYTE COLONY-STIMULATING FACTOR AND PLATELET-AGGREGATION	LANCET			English	Letter									KYUSHU UNIV HOSP,BLOOD TRANSFUS SERV,FUKUOKA 812,JAPAN; KYUSHU UNIV,DEPT PAEDIAT,FUKUOKA 812,JAPAN; KYUSHU UNIV,DEPT INTERNAL MED 1,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University; Kyushu University	SHIMODA, K (corresponding author), KYUSHU UNIV HOSP,CTR CANC,FUKUOKA 812,JAPAN.							CONTI JA, 1992, CANCER, V70, P2699, DOI 10.1002/1097-0142(19921201)70:11<2699::AID-CNCR2820701122>3.0.CO;2-C; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; SHIMODA K, 1991, BLOOD, V77, P2214; SHIMODA K, IN PRESS J CLIN INVE; SOUZA LM, 1986, SCIENCE, V232, P61, DOI 10.1126/science.2420009	5	44	46	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 6	1993	341	8845					633	633		10.1016/0140-6736(93)90394-V	http://dx.doi.org/10.1016/0140-6736(93)90394-V			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ234	7679767				2022-12-28	WOS:A1993KQ23400039
J	NEOTE, K; DIGREGORIO, D; MAK, JY; HORUK, R; SCHALL, TJ				NEOTE, K; DIGREGORIO, D; MAK, JY; HORUK, R; SCHALL, TJ			MOLECULAR-CLONING, FUNCTIONAL EXPRESSION, AND SIGNALING CHARACTERISTICS OF A C-C CHEMOKINE RECEPTOR	CELL			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; MACROPHAGE INFLAMMATORY PROTEIN; NEUTROPHIL CHEMOTACTIC FACTOR; HUMAN INTERLEUKIN-8 RECEPTOR; HUMAN BETA-HEXOSAMINIDASE; CELL-SURFACE RECEPTORS; CYTOKINE FAMILY; LYMPHOCYTES-T; IDENTIFICATION; BINDING	The immunoregulatory proteins C-C chemokines are potent chemoattractants of lymphocytes and monocytes, as well as activators and attractants of eosinophils and basophils. We have isolated a cDNA that encodes a seven transmembrane-spanning receptor, with homology to other chemoattractant receptors, that encodes a protein designated C-C CKR-1 that acts as a receptor for the C-C chemokines. Human and murine macrophage inflammatory protein 1alpha (MIP-1alpha), human macrophage inflammatory protein 1beta (MIP-1beta), human monocyte chemotactic protein 1 (MCP-1), and RANTES all bind to the C-C CKR-1 with varying affinities. Chemokine binding affinity does not predict how well the ligand will transmit a signal through the receptor: RANTES and human MIP-1alpha induce a similar intracellular calcium flux while binding with disparate affinities, while MCP-1 and human MIP-1beta induce calcium mobilization only at high concentrations. Finally, C-C chemokines were shown to bind a C-C CKR-1-related gene product encoded by cytomegalovirus, suggesting a role for C-C chemokines in viral immunity.			NEOTE, K (corresponding author), GENENTECH INC, DEPT IMMUNOL, 460 POINT SAN BRUNO BLVD, San Francisco, CA 94080 USA.							ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Bankier A T, 1991, DNA Seq, V2, P1, DOI 10.3109/10425179109008433; BISCHOFF SC, 1992, J EXP MED, V175, P1271, DOI 10.1084/jem.175.5.1271; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BROWNE H, 1990, J VIROL, V64, P2181; BROXMEYER HE, 1991, J IMMUNOL, V147, P2586; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVATELIS G, 1989, SCIENCE, V243, P1066, DOI 10.1126/science.2646711; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DUNLOP DJ, 1992, BLOOD, V79, P2221; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; GRAHAM GJ, 1992, DEV BIOL, V151, P377, DOI 10.1016/0012-1606(92)90177-I; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1987, J BIOL CHEM, V262, P16275; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KORNELUK RG, 1986, J BIOL CHEM, V261, P8407; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; KUNA P, 1992, J IMMUNOL, V149, P636; LARRICK JW, 1992, TRENDS BIOTECHNOL, V10, P146, DOI 10.1016/0167-7799(92)90202-7; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; MCPHERSON GA, 1983, COMPUT PROG BIOMED, V17, P107, DOI 10.1016/0010-468X(83)90031-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NACCACHE PH, 1989, J IMMUNOL, V142, P2438; NAPOLITANO M, 1990, J EXP MED, V172, P285, DOI 10.1084/jem.172.1.285; NEOTE K, 1990, J BIOL CHEM, V265, P20799; NEOTE K, 1990, J CLIN INVEST, V86, P1524, DOI 10.1172/JCI114871; NGUYEN T, 1991, GENE, V109, P211, DOI 10.1016/0378-1119(91)90611-E; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OH KO, 1991, J IMMUNOL, V147, P2978; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; ROLLINS BJ, 1991, BLOOD, V78, P1112; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1992, EUR J IMMUNOL, V22, P1477, DOI 10.1002/eji.1830220621; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHILD HO, 1973, DRUG RECEPTORS, P29; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SOZZANI S, 1991, J IMMUNOL, V147, P2215; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; VALENTE AJ, 1991, BIOCHEM BIOPH RES CO, V176, P309, DOI 10.1016/0006-291X(91)90925-W; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WOLD WSM, 1991, VIROLOGY, V184, P1, DOI 10.1016/0042-6822(91)90815-S; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YOSHIMURA T, 1990, J IMMUNOL, V145, P292	61	744	885	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 12	1993	72	3					415	425		10.1016/0092-8674(93)90118-A	http://dx.doi.org/10.1016/0092-8674(93)90118-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	7679328				2022-12-28	WOS:A1993KM16200011
J	BAYER, R; STRYKER, J; SMITH, MD				BAYER, R; STRYKER, J; SMITH, MD			TESTING FOR HIV-INFECTION AT HOME	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FALSE POSITIVE RATE; ANTIBODY		UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94105 USA; HENRY J KAISER JR FAMILY FDN, MENLO PK, CA 94024 USA	University of California System; University of California San Francisco	BAYER, R (corresponding author), COLUMBIA UNIV, SCH PUBL HLTH, 600 W 168TH ST, NEW YORK, NY 10032 USA.				NIMH NIH HHS [P50-MH43520] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH043520] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON JE, 1992, AM J PUBLIC HEALTH, V82, P1533, DOI 10.2105/AJPH.82.11.1533; BURKE DS, 1988, NEW ENGL J MED, V319, P961, DOI 10.1056/NEJM198810133191501; Doll Lynda S., 1994, P302; GWINN M, 1992, J ACQ IMMUN DEF SYND, V5, P505; HARRIS HR, 1994, WASH POST       0409, pG1; HENRY K, 1988, JAMA-J AM MED ASSOC, V259, P229, DOI 10.1001/jama.259.2.229; KOOP CE, 1994, FDA BLOOD PRODUCTS A; Leary Warren E, 1994, N Y Times Web, pA18; LEARY WE, 1989, NY TIMES        0316, P15; MEYER KB, 1987, NEW ENGL J MED, V317, P238, DOI 10.1056/NEJM198707233170410; OCAMB K, 1994, POZ              JUN, P48; OSSIPKLEIN DJ, 1991, J CONSULT CLIN PSYCH, V59, P325, DOI 10.1037/0022-006X.59.2.325; PHILLIPS KA, 1995, NEW ENGL J MED, V332, P1308, DOI 10.1056/NEJM199505113321918; ROSIN H, 1994, NEW REPUBLIC    0103, P12; SALBU SR, 1995, HASTINGS LAW J, V46, P403; SCHONBERG SK, 1994, COMMISSIONER FO 0629; Starace F, 1993, Int J Soc Psychiatry, V39, P64, DOI 10.1177/002076409303900107; VALDISERRI RO, 1993, PUBLIC HEALTH REP, V108, P12; WOFSY CB, 1987, SURGEON GENERALS WOR, P32; 1995, FED REGISTER, V60, P10087; 1990, JAMA-J AM MED ASSOC, V264, P2416; 1995, AIDS POLICY LAW, V10, P10; 1989, TIME            0418, P26; 1995, BUS WIRE        0208; 1994, HOME TESTING PRINCIP; 1994, ADV DATA VITAL HLTH, V243; 1995, FED REGISTER, V60, P10086	27	41	41	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 11	1995	332	19					1296	1299		10.1056/NEJM199505113321911	http://dx.doi.org/10.1056/NEJM199505113321911			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QW600	7708077				2022-12-28	WOS:A1995QW60000011
J	ZIEGLER, MG; LEW, P; SINGER, BC				ZIEGLER, MG; LEW, P; SINGER, BC			THE ACCURACY OF DRUG INFORMATION FROM PHARMACEUTICAL SALES REPRESENTATIVES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PROMOTION; ATTITUDES; FACULTY	Objective.-To provide quantitative data about the accuracy of the information about drugs presented to physicians by pharmaceutical sales representatives. Design.-One hundred six statements about drugs made during 13 presentations by pharmaceutical representatives were analyzed for accuracy. Statements were rated inaccurate if they contradicted the 1993 Physicians' Desk Reference or material quoted or handed out by the sales representative. Setting.-University teaching hospital. Results.-Twelve (11%) of 106 statements about drugs were inaccurate. All 12 inaccurate statements were favorable toward the promoted drug, whereas 39 (49%) of 79 accurate statements were favorable (P=.005). None of 15 statements about competitors' drugs were favorable, but all were accurate, significantly (P<.001) differing from statements about promoted drugs. In a survey of 27 physicians who attended these presentations, seven (26%) recalled any false statement made by a pharmaceutical representative, and 10 (37%) said information from the representatives influenced the way they prescribed drugs. Conclusions.-Eleven percent of the statements made by pharmaceutical representatives about drugs contradicted information readily available to them. Physicians generally failed to recognize the inaccurate statements.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARM,SAN DIEGO,CA 92103	University of California System; University of California San Diego	ZIEGLER, MG (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,SCH MED,DEPT MED,200 W ARBOR DR,SAN DIEGO,CA 92103, USA.		Ziegler, Michael/L-4728-2019					AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; BROTZMAN GL, 1993, J GEN INTERN MED, V8, P130, DOI 10.1007/BF02599757; HEMMINKI E, 1977, MED EDUC, V11, P210, DOI 10.1111/j.1365-2923.1977.tb00595.x; LEXCHIN J, 1989, INT J HEALTH SERV, V19, P663, DOI 10.2190/HUFK-5Y54-QX1E-AD62; LICHSTEIN PR, 1992, ARCH INTERN MED, V152, P1009, DOI 10.1001/archinte.152.5.1009; LURIE N, 1990, J GEN INTERN MED, V5, P240, DOI 10.1007/BF02600542; MARGOLIS LH, 1991, PEDIATRICS, V88, P1233; MCKINNEY WP, 1990, JAMA-J AM MED ASSOC, V264, P1693, DOI 10.1001/jama.264.13.1693; MORRIS LA, 1992, J DRUG ISSUES, V22, P245, DOI 10.1177/002204269202200205; PARSONS LJ, 1981, J MARKETING RES, V18, P107, DOI 10.2307/3151321; SKOLNICK AA, 1994, JAMA-J AM MED ASSOC, V271, P332	11	185	188	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	1995	273	16					1296	1298		10.1001/jama.273.16.1296	http://dx.doi.org/10.1001/jama.273.16.1296			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QU571	7715044				2022-12-28	WOS:A1995QU57100035
J	STAMP, T				STAMP, T			GREY HAIRS, FALSE TEETH, AND BAD BONES	LANCET			English	Editorial Material							PHOTON-ABSORPTIOMETRY; RISK-FACTORS; OSTEOPOROSIS; WOMEN				STAMP, T (corresponding author), ROYAL NATL ORTHOPAED HOSP, STANMORE HA7 4LP, MIDDX, ENGLAND.							ARNOLD HL, 1990, ANDREWS DISEASES SKI, P891; COOPER C, 1991, OSTEOPOROSIS INT, V2, P48, DOI 10.1007/BF01627079; GLASSER M, 1991, MED HYPOTHESES, V36, P404, DOI 10.1016/0306-9877(91)90020-Y; HOUKI K, 1994, J BONE MINER RES  S1, V9, pS211; JEFFCOAT MK, 1993, J AM DENT ASSOC, V124, P49, DOI 10.14219/jada.archive.1993.0225; KEOGH EV, 1965, NATURE, V207, P877, DOI 10.1038/207877a0; KLEEREKOPER M, 1989, BONE MINER, V7, P171, DOI 10.1016/0169-6009(89)90074-3; ROSEN CJ, 1994, J CLIN ENDOCR METAB, V79, P854, DOI 10.1210/jc.79.3.854; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; SPECTOR TD, 1992, CURRENT RES OSTEOPOR, V11, P86; 1993, J BONE MINER RES S2, V8, pS443; 1994, REPORT ADVISORY GROU, P76	12	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 8	1995	345	8954					876	876		10.1016/S0140-6736(95)90006-3	http://dx.doi.org/10.1016/S0140-6736(95)90006-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707808				2022-12-28	WOS:A1995QR06700006
J	SHEETS, MD; WU, M; WICKENS, M				SHEETS, MD; WU, M; WICKENS, M			POLYADENYLATION OF C-MOS MESSENGER-RNA AS A CONTROL POINT IN XENOPUS MEIOTIC MATURATION	NATURE			English	Article							3' UNTRANSLATED REGION; MESSENGER-RNA; UNWINDING ACTIVITY; OOCYTE MATURATION; POLY(A) ADDITION; ANTISENSE RNA; CELL-CYCLE; INVITRO	c-mos protein, encoded by a proto-oncogene, is essential for the meiotic maturation of frog oocytes. Polyadenylation of c-mos messenger RNA is shown here to be a pivotal regulatory step in meiotic maturation. Maturation is prevented by selective amputation of polyadenylation signals from c-mos mRNA. Injection of a prosthetic RNA, which restores c-mos polyadenylation signals by base pairing to the amputated mRNA, rescues maturation and can stimulate translation in trans. Prosthetic RNAs may provide a general strategy by which to alter patterns of mRNA expression in vivo.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Berkeley								AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; Bachvarova R, 1985, Dev Biol (N Y 1985), V1, P453; BALLANTYNE S, IN PRESS RNA; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; Bass Brenda L., 1992, Seminars in Developmental Biology, V3, P425; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BILGER A, 1994, GENE DEV, V8, P1106, DOI 10.1101/gad.8.9.1106; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FOX CA, 1992, EMBO J, V11, P5021, DOI 10.1002/j.1460-2075.1992.tb05609.x; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GEBAUER F, 1994, EMBO J, V13, P5712, DOI 10.1002/j.1460-2075.1994.tb06909.x; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; Maller J L, 1985, Dev Biol (N Y 1985), V1, P289; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V333, P519; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; SMITH RC, 1990, DEVELOPMENT, V110, P769; STANDART N, 1994, BIOCHIMIE, V78, P867; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; VANDEWOUDE GF, 1994, NATURE, V370, P20, DOI 10.1038/370020a0; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WICKENS M, 1993, NATURE, V363, P305, DOI 10.1038/363305a0; WICKENS M, 1992, SEM DEV BIOL, V3, P399; Wickens Marvin, 1992, Seminars in Developmental Biology, V3, P363; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	36	202	203	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					511	516		10.1038/374511a0	http://dx.doi.org/10.1038/374511a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700377				2022-12-28	WOS:A1995QR06900042
J	SINGH, P; COE, J; HONG, WJ				SINGH, P; COE, J; HONG, WJ			A ROLE FOR RETINOBLASTOMA PROTEIN IN POTENTIATING TRANSCRIPTIONAL ACTIVATION BY THE GLUCOCORTICOID RECEPTOR	NATURE			English	Article							GENE-PRODUCT; CELL-CYCLE; SUSCEPTIBILITY GENE; ADENOVIRUS E1A; LARGE-T; PHOSPHORYLATION; TRANSFORMATION; EXPRESSION; GROWTH; FAMILY	THE Saccharomyces cerevisiae SNF2/SWI2 protein is essential for the regulated expression of a variety of genes(1,2). A human SW12/SNF2 homologue, hBrm, is a positive participant in glucocorticoid-receptor-mediated transcription(3), but its mechanism of action is not known. The retinoblastoma protein, RB, has also been shown to stimulate the transcription of several genes(4-10), although the target for RB has not been identified in any of these transcriptional events. Here we show that RB upregulates glucocorticoid-receptor-mediated transcription. The effect of either RB or hBrm is dependent on the presence of the other. Furthermore, we demonstrate that RB and hBrm interact with one another in vitro and in vivo. These results highlight a new role for RB, which is to interact with hBrm in order to potentiate glucocorticoid-receptor-activated transcription.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,MEMBRANE BIOL LAB,SINGAPORE 0511,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			HONG, Wanjin/E-9927-2010					BOCCO JL, 1993, ONCOGENE, V8, P2977; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; HARPER JW, 1993, CELL, V75, P805; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LU YM, 1994, ONCOGENE, V9, P1015; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; SCHEFFNER M, 1989, P NATL ACAD SCI USA, V88, P5523; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	26	169	171	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					562	565		10.1038/374562a0	http://dx.doi.org/10.1038/374562a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700385				2022-12-28	WOS:A1995QR06900058
J	YAO, RJ; COOPER, GM				YAO, RJ; COOPER, GM			REQUIREMENT FOR PHOSPHATIDYLINOSITOL-3 KINASE IN THE PREVENTION OF APOPTOSIS BY NERVE GROWTH-FACTOR	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; TRK PROTOONCOGENE PRODUCT; PC12 CELLS; NEURONAL DIFFERENTIATION; TYROSINE KINASE; FACTOR RECEPTOR; PHEOCHROMOCYTOMA CELLS; PDGF RECEPTOR; BINDING-SITE; MAP KINASE	Nerve growth factor (NGF) induces both differentiation and survival of neurons by binding to the Trk receptor protein tyrosine kinase. Although Pas is required for differentiation, it was not required for NGF-mediated survival of rat pheochromocytoma PC-12 cells in serum-free medium. However, the ability of NGF to prevent apoptosis (programmed cell death) was inhibited by wortmannin or LY294002, two specific inhibitors of phosphatidylinositol (PI)-3 kinase. Moreover, platelet-derived growth factor (PDGF) prevented apoptosis of PC-12 cells expressing the wild-type PDGF receptor, but not of cells expressing a mutant receptor that failed to activate PI-3 kinase. Cell survival thus appears to be mediated by a PI-3 kinase signaling pathway distinct from the pathway that mediates differentiation.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NCI NIH HHS [R01 CA 18689] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BORASIO GD, 1993, J CELL BIOL, V121, P665, DOI 10.1083/jcb.121.3.665; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; ROVELLI G, 1993, P NATL ACAD SCI USA, V90, P8717, DOI 10.1073/pnas.90.18.8717; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO R, UNPUB	52	1254	1331	1	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					2003	2006		10.1126/science.7701324	http://dx.doi.org/10.1126/science.7701324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701324				2022-12-28	WOS:A1995QQ06800047
J	LETSOU, A; ARORA, K; WRANA, JL; SIMIN, K; TWOMBLY, V; JAMAL, J; STAEHLINGHAMPTON, K; HOFFMANN, FM; GELBART, WM; MASSAGUE, J; OCONNOR, MB				LETSOU, A; ARORA, K; WRANA, JL; SIMIN, K; TWOMBLY, V; JAMAL, J; STAEHLINGHAMPTON, K; HOFFMANN, FM; GELBART, WM; MASSAGUE, J; OCONNOR, MB			DROSOPHILA DPP SIGNALING IS MEDIATED BY THE PUNT GENE-PRODUCT - A DUAL LIGAND-BINDING TYPE-II RECEPTOR OF THE TGF-BETA RECEPTOR FAMILY	CELL			English	Article							GROWTH-FACTOR-BETA; VISCERAL MESODERM; ACTIVIN RECEPTOR; GERM LAYERS; MELANOGASTER; EXPRESSION; KINASE; EMBRYOS; PATTERN; COMPLEX	Signaling by TGF beta-related factors requires ligand-induced association between type I and type II transmembrane serine/threonine kinases. In Drosophila, the saxophone (sax) and thick veins (tkv) genes encode type I receptors that mediate signaling by decapentaplegic (dpp), a member of the bone morphogenetic protein (BMP) subgroup of TGF beta-type factors. In this report, we demonstrate that the Drosophila punt gene encodes atr-ll, a previously described type II receptor that on its own is able to bind activin but not BMP2, a vertebrate ortholog of dpp. Mutations in punt produce phenotypes similar to those exhibited by tkv, sax, and dpp mutants. Furthermore, punt will bind BMP2 in concert with tkv or sax, forming complexes with these receptors. We suggest that punt functions as a type II receptor for dpp and propose that BMP signaling in vertebrates may also involve sharing of type II receptors by diverse ligands.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; UNIV WISCONSIN,SCH MED,MCARDLE LAB CANC RES,GENET LAB,MADISON,WI 53706	University of California System; University of California Irvine; University of California System; University of California Irvine; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Harvard University; University of Wisconsin System; University of Wisconsin Madison	LETSOU, A (corresponding author), UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.		Wrana, Jeffrey/F-8857-2013; O'Connor, Michael B/C-9977-2014	O'Connor, Michael B/0000-0002-3067-5506; Massague, Joan/0000-0001-9324-8408; Hoffmann, F. Michael/0000-0002-2770-9656				AFFOLTER M, 1994, DEVELOPMENT, V120, P3105; ARORA K, 1992, DEVELOPMENT, V114, P1003; ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAPOVILLA M, 1994, CELL, V76, P461, DOI 10.1016/0092-8674(94)90111-2; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; CHOU TB, 1993, DEVELOPMENT, V119, P1359; DOCTOR JS, 1992, DEV BIOL, V151, P491, DOI 10.1016/0012-1606(92)90188-M; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Maniatis T., 1982, MOL CLONING; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NUSSLEINVOLHARD C, 1984, W ROUXS ARCH DEV BIO, V183, P267; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; REUTER R, 1990, DEVELOPMENT, V110, P1031; ROBERTSON HM, 1988, GENETICS, V118, P461; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; SEGAL D, 1985, GENETICS, V109, P119; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STAEHLINGHAMPTO.K, 1994, DEV BIOL, V164, P502; STAEHLINGHAMPTO.K, 1994, NATURE, V372, P783; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TERRACOL R, 1994, GENETICS, V138, P165; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	50	236	243	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					899	908		10.1016/0092-8674(95)90293-7	http://dx.doi.org/10.1016/0092-8674(95)90293-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697720	Bronze			2022-12-28	WOS:A1995QP61200009
J	PULEO, PR; MEYER, D; WATHEN, C; TAWA, CB; WHEELER, S; HAMBURG, RJ; ALI, N; OBERMUELLER, SD; TRIANA, JF; ZIMMERMAN, JL; PERRYMAN, MB; ROBERTS, R				PULEO, PR; MEYER, D; WATHEN, C; TAWA, CB; WHEELER, S; HAMBURG, RJ; ALI, N; OBERMUELLER, SD; TRIANA, JF; ZIMMERMAN, JL; PERRYMAN, MB; ROBERTS, R			USE OF A RAPID ASSAY OF SUBFORMS OF CREATINE-KINASE MB TO DIAGNOSE OR RULE OUT ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHEST PAIN; INITIAL ELECTROCARDIOGRAM; MARATHON RUNNERS; SKELETAL-MUSCLE; ISOENZYME; PLASMA; EMERGENCY; ADMISSION; SERUM; UNIT	Background. Ruling out myocardial infarction in patients coming to the emergency room with chest pain is hindered by the lack of a specific early diagnostic marker. Less than 30 percent of patients admitted to coronary care units have infarction, resulting in substantial unnecessary expenditures. We developed a rapid assay of the subforms of creatine kinase MB (OK-MB) and prospectively analyzed its sensitivity and specificity in diagnosing myocardial infarction in the first six hours after the onset of chest pain. Methods. In 1110 consecutive patients who came to the emergency room with chest pain, blood samples were collected every 30 to 60 minutes until at least 6 hours after the onset of symptoms; in patients who were then admitted to the hospital, samples were collected every 4 hours for up to 48 hours. The samples were analyzed for CK-MB subforms, and the diagnosis of myocardial infarction was confirmed by conventional CK-MB analysis. Results. Of the 1110 patients evaluated, 121 had myocardial infarction. The sensitivity of the assay of OK-MB subforms to detect myocardial infarction in the first six hours after the onset of symptoms was 95.7 percent, as compared with only 48 percent for the conventional CK-MB assay; the specificity was 93.9 percent among patients hospitalized without myocardial infarction and 96.2 percent among those sent home. Among the patients with myocardial infarction, definitive results of the subform assay were available a mean (+/-SD) of 1.22+/-1.17 hours after their arrival in the emergency room. Conclusions. The assay of CK-MB subforms reliably detected myocardial infarction within the first six hours after the onset of symptoms, and its use could reduce admission to the coronary care unit by 50 to 70 percent, thereby reducing costs.	BAYLOR COLL MED, DEPT MED, CARDIOL SECT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED, CRIT CARE SECT, HOUSTON, TX 77030 USA; CHRIST HOSP, DEPT MED, CARDIOL SECT, CINCINNATI, OH 45219 USA	Baylor College of Medicine; Baylor College of Medicine; Christ Hospital - Ohio					NHLBI NIH HHS [P50-HL42267] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042267] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNESLEY TM, 1985, CLIN CHEM, V31, P402; APPLE FS, 1986, CLIN CHEM, V32, P41; APPLE FS, 1984, CLIN CHEM, V30, P413; Armitage P, 1987, STAT METHODS MED RES, V2, P117; BRUSH JE, 1985, NEW ENGL J MED, V312, P1137, DOI 10.1056/NEJM198505023121801; COLLINSON PO, 1989, J CLIN PATHOL, V42, P1126, DOI 10.1136/jcp.42.11.1126; FESMIRE FM, 1989, ARCH INTERN MED, V149, P1294, DOI 10.1001/archinte.149.6.1294; FINEBERG HV, 1984, NEW ENGL J MED, V310, P1301, DOI 10.1056/NEJM198405173102006; FRIEDMAN DL, 1993, CLIN CHEM, V39, P1598; GASPOZ JM, 1991, AM J CARDIOL, V68, P145, DOI 10.1016/0002-9149(91)90734-3; GEORGE S, 1984, J BIOL CHEM, V259, P2667; GIBLER WB, 1990, ANN EMERG MED, V19, P1359, DOI 10.1016/S0196-0644(05)82598-3; GIBLER WB, 1991, ANN EMERG MED, V20, P420; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRACE A, 1982, CLIN CHIM ACTA, V123, P59, DOI 10.1016/0009-8981(82)90114-0; GRENADIER E, 1983, AM HEART J, V105, P408, DOI 10.1016/0002-8703(83)90357-5; HENRY PD, 1975, CLIN CHEM, V21, P844; HEYNDRICKX GR, 1985, J AM COLL CARDIOL, V6, P1299, DOI 10.1016/S0735-1097(85)80216-3; JAFFE AS, 1986, CIRCULATION, V74, P105, DOI 10.1161/01.CIR.74.1.105; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; LEE TH, 1989, ANN INTERN MED, V110, P957, DOI 10.7326/0003-4819-110-12-957; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LEE TH, 1987, ANN INTERN MED, V106, P181, DOI 10.7326/0003-4819-106-2-181; MARMOR A, 1981, AM J CARDIOL, V48, P603, DOI 10.1016/0002-9149(81)90137-5; MICHAEL LH, 1985, AM J PHYSIOL, V248, pH350, DOI 10.1152/ajpheart.1985.248.3.H350; MORELLI RL, 1983, CIRCULATION, V67, P1283, DOI 10.1161/01.CIR.67.6.1283; OHMAN EM, 1990, CIRCULATION, V82, P1073, DOI 10.1161/01.CIR.82.3.1073; PRAGER NA, 1992, J AM COLL CARDIOL, V20, P414, DOI 10.1016/0735-1097(92)90111-Y; PULEO PR, 1990, CIRCULATION, V82, P759, DOI 10.1161/01.CIR.82.3.759; PULEO PR, 1989, CLIN CHEM, V35, P1452; ROBERTS R, 1988, CHEST, V93, pS3; SELKER HP, 1989, AM J MED, V87, P491; STARK ME, 1987, ARCH INTERN MED, V147, P843, DOI 10.1001/archinte.147.5.843; TURI ZG, 1985, AM J CARDIOL, V55, P1463, DOI 10.1016/0002-9149(85)90954-3; WEINGARTEN SR, 1989, AM J MED, V87, P494, DOI 10.1016/S0002-9343(89)80603-5; WEVERS RA, 1978, CLIN CHIM ACTA, V86, P323, DOI 10.1016/0009-8981(78)90388-1; WU AHB, 1989, CLIN CHEM, V35, P1752; YASMINEH WG, 1978, CLIN CHEM, V24, P1985; YOUNG MJ, 1987, ARCH INTERN MED, V147, P1219, DOI 10.1001/archinte.147.7.1219; 1984, AM HEART ASS MONOGRA, V100, P77	40	246	252	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					561	566		10.1056/NEJM199409013310901	http://dx.doi.org/10.1056/NEJM199409013310901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	7702648				2022-12-28	WOS:A1994PD69900001
J	KANAAR, R; ROCHE, SE; BEALL, EL; GREEN, MR; RIO, DC				KANAAR, R; ROCHE, SE; BEALL, EL; GREEN, MR; RIO, DC			THE CONSERVED PREMESSENGER RNA SPLICING FACTOR-U2AF FROM DROSOPHILA - REQUIREMENT FOR VIABILITY	SCIENCE			English	Article							AUXILIARY FACTOR; CLONING; YEAST; HOMOLOG; GENE; RIBONUCLEOPROTEIN; REGULATORS; PROTEINS; ACCURATE; DOMAIN	The large subunit of the human pre-messenger RNA splicing factor U2 small nuclear ribonucleoprotein auxiliary factor (hU2AF65) is required for spliceosome assembly in vitro. A complementary DNA clone encoding the large subunit of Drosophila U2AF (dU2AF50) has been isolated. The dU2AF50 protein is closely related to its mammalian counterpart and contains three carboxyl-terminal ribonucleoprotein consensus sequence RNA binding domains and an amino-terminal arginine- and serine-rich (R/S) domain. Recombinant dU2AF50 protein complements mammalian splicing extracts depleted of U2AF activity. Germline transformation of Drosophila with the dU2AF50 complementary DNA rescues a lethal mutation, establishing that the dU2AF50 gene is essential for viability. R/S domains have been found in numerous metazoan splicing factors, but their function is unknown. The mutation in Drosophila U2AF will allow in vivo analysis of a conserved R/S domain-containing general splicing factor.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV GENET, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of Massachusetts System; University of Massachusetts Worcester					NICHD NIH HHS [R01-HD28063] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028063] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASHBURNER M, 1989, DROSOPHILA LABORATOR; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P1333, DOI 10.1093/nar/21.5.1333; BIRNEY E, 1992, NUCLEIC ACIDS RES, V20, P4663, DOI 10.1093/nar/20.17.4663; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CONWAY L, 1987, EMBO J, V6, P4177, DOI 10.1002/j.1460-2075.1987.tb02764.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HARLOW E, 1989, ANTIBODIES LABORATOR; JONES KR, 1990, NEURON, V4, P711, DOI 10.1016/0896-6273(90)90197-N; KANAAR R, UNPUB; KIM YJ, 1992, GENE DEV, V6, P2569, DOI 10.1101/gad.6.12b.2569; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MATTOX W, 1992, J BIOL CHEM, V267, P19023; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; MISRA S, 1990, CELL, V62, P269, DOI 10.1016/0092-8674(90)90365-L; MORE M, 1993, RNA WORLD, P303; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; RIO DC, 1988, P NATL ACAD SCI USA, V85, P2904, DOI 10.1073/pnas.85.9.2904; RUBY SW, 1991, TRENDS GENET, V7, P79; RYMOND BC, IN PRESS MOL CELLULA; SAILER A, 1992, NUCLEIC ACIDS RES, V20, P2374, DOI 10.1093/nar/20.9.2374; Sambrook J, 1989, MOL CLONING LABORATO; SMITH V, 1991, EMBO J, V10, P2627, DOI 10.1002/j.1460-2075.1991.tb07805.x; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	41	80	84	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1993	262	5133					569	573		10.1126/science.7692602	http://dx.doi.org/10.1126/science.7692602			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC935	7692602				2022-12-28	WOS:A1993MC93500041
J	NEUHOLD, LA; WOLD, B				NEUHOLD, LA; WOLD, B			HLH FORCED DIMERS - TETHERING MYOD TO E47 GENERATES A DOMINANT POSITIVE MYOGENIC FACTOR INSULATED FROM NEGATIVE REGULATION BY ID	CELL			English	Article							HELIX-LOOP-HELIX; CREATINE-KINASE ENHANCER; MUSCLE-SPECIFIC ENHANCER; LIGATION-MEDIATED PCR; PAN-NEURAL GENE; DNA-BINDING; TRANSCRIPTION FACTORS; CYCLIC AMPLIFICATION; SEX DETERMINATION; NUCLEAR FACTOR	Basic-helix-loop-helix (bHLH) class transcription factors bind DNA as hetero- and homodimers. In murine myogenic cells the HLH network includes multiple members of the E protein, MyoD, and Id families; changes in the network characterize muscle determination and differentiation and have been proposed as causal for these developmental transitions. To test the importance of HLH partner choice in these cellular decisions, we have designed a strategy in which the identity of a bHLH dimer is specified by joining two monomers via a flexible polypeptide linker. A MyoD is similar to E47 polyprotein avidly bound the same DNA target as its unlinked counterpart, but, unlike intermolecular dimers that are very sensitive to inhibition by Id, MyoD is similar E47 was resistant to Id challenge. In cells MyoD is similar to E47 acted as a dominant positive myogenic factor, capable of initiating myogenic determination and also substantially bypassing negative regulation of differentiation by serum growth factors.			NEUHOLD, LA (corresponding author), CALTECH,DIV BIOL,156-29,PASADENA,CA 91125, USA.							ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIER E, 1992, GENE DEV, V6, P2137, DOI 10.1101/gad.6.11.2137; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1991, EUR J BIOCHEM, V198, P187, DOI 10.1111/j.1432-1033.1991.tb16000.x; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CABRERA CV, 1992, DEVELOPMENT, V115, P893; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P6103, DOI 10.1128/MCB.11.12.6103; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FARMER K, 1992, J BIOL CHEM, V267, P5631; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FLORINI JR, 1990, J BIOL CHEM, V265, P13435; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MINER JH, 1992, DEVELOPMENT, V114, P853; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; Sambrook J, 1989, MOL CLONING LABORATO; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STOCKDALE F, 1961, EXP CELL RES, V24, P508, DOI 10.1016/0014-4827(61)90450-5; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, CELL, V66, P423, DOI 10.1016/0092-8674(81)90003-9; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YOUNGERSHEPHERD S, 1992, CELL, V70, P911, DOI 10.1016/0092-8674(92)90242-5; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; YUTSEY KE, 1992, NUCLEIC ACIDS RES, V20, P5105	65	134	136	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					1033	1042		10.1016/0092-8674(93)90725-6	http://dx.doi.org/10.1016/0092-8674(93)90725-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	7691411				2022-12-28	WOS:A1993LY49300010
J	KARLIN, KD				KARLIN, KD			METALLOENZYMES, STRUCTURAL MOTIFS, AND INORGANIC MODELS	SCIENCE			English	Article							DINUCLEAR IRON CENTERS; X-RAY ABSORPTION; DNA-POLYMERASE-I; RIBONUCLEOTIDE REDUCTASE; CRYSTAL-STRUCTURE; ELECTRON-TRANSFER; NITRIC-OXIDE; ACTIVE-SITE; DIOXYGEN BINDING; ESCHERICHIA-COLI	Metalloenzymes effect a variety of important chemical transformations, often involving small molecule substrates or products such as molecular oxygen, hydrogen, nitrogen, and water. A diverse array of ions or metal clusters is observed at the active-site cores, but living systems use basic recurring structures that have been modified or tuned for specific purposes. Inorganic chemists are actively involved in the elucidation of the structure, spectroscopy, and mechanism of action of these biological catalysts, in part through a synthetic modeling approach involving biomimetic studies.			KARLIN, KD (corresponding author), JOHNS HOPKINS UNIV, DEPT CHEM, CHARLES & 34TH ST, BALTIMORE, MD 21218 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028962, R37GM028962, R01GM045971] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45971, GM28962] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG WH, 1983, J AM CHEM SOC, V105, P4837, DOI 10.1021/ja00352a053; ARMSTRONG WH, 1988, METAL CLUSTERS PROTE, P1; ATTA M, 1992, J BIOL CHEM, V267, P20682; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BARTON DHR, 1992, ACCOUNTS CHEM RES, V25, P504, DOI 10.1021/ar00023a004; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; BLACKBURN NJ, 1988, J AM CHEM SOC, V110, P4263, DOI 10.1021/ja00221a027; BOLIN JT, 1993, P NATL ACAD SCI USA, V90, P1078, DOI 10.1073/pnas.90.3.1078; BOLLINGER JM, 1991, J AM CHEM SOC, V113, P6289, DOI 10.1021/ja00016a066; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BRESLOW R, 1982, SCIENCE, V218, P532, DOI 10.1126/science.7123255; BRUICE TC, 1980, BIOMIMETIC CHEM, V191, P89; BURGESON IE, 1991, INORG CHEM, V30, P4299, DOI 10.1021/ic00023a004; BURLEY SK, 1990, P NATL ACAD SCI USA, V87, P6878, DOI 10.1073/pnas.87.17.6878; BURLEY SK, 1991, P NATL ACAD SCI USA, V88, P6916, DOI 10.1073/pnas.88.16.6916; Butler A., 1993, BIOINORGANIC CATALYS, P425; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; Cammack R., 1993, BIOINORGANIC CATALYS, P189; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; Chan S.I., 1993, BIOINORGANIC CHEM CO, P184; CHAUDHURI P, 1985, ANGEW CHEM INT EDIT, V24, P778, DOI 10.1002/anie.198507781; CHIN J, 1991, ACCOUNTS CHEM RES, V24, P145, DOI 10.1021/ar00005a004; CHIOU YM, 1992, J AM CHEM SOC, V114, P7567, DOI 10.1021/ja00045a041; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CHRISTODOULOU D, 1993, J CHEM SOC CHEM COMM, P937, DOI 10.1039/c39930000937; CHRISTODOULOU D, 1993, BIOINORGANIC CHEM CO, P427; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; Collman J.P., 1980, METAL ION ACTIVATION, P1; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; COUCOUVANIS D, 1991, ACCOUNTS CHEM RES, V24, P1, DOI 10.1021/ar00001a001; CRICHTON RR, 1992, BIOCHEMISTRY-US, V31, P11255, DOI 10.1021/bi00161a001; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DAY EP, 1993, INORG CHEM, V32, P634, DOI 10.1021/ic00057a024; DeGrado WF, 1991, CURR OPIN STRUC BIOL, V1, P984, DOI 10.1016/0959-440X(91)90095-B; DEMONTELLANO PRO, 1987, ACCOUNTS CHEM RES, V20, P289; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; Dickerson R.E., 1983, HEMOGLOBIN; Dismukes G.C., 1993, BIOINORGANIC CATALYS, P317; DONG YH, 1993, J AM CHEM SOC, V115, P1851, DOI 10.1021/ja00058a033; DRAGO RS, 1992, COORDIN CHEM REV, V117, P185, DOI 10.1016/0010-8545(92)80024-L; EICHHORN GL, 1993, MODELS INORGANIC BIO, V9; EMPTAGE MH, 1988, ACS SYM SER, V372, P343; ERMACORA MR, 1992, P NATL ACAD SCI USA, V89, P6383, DOI 10.1073/pnas.89.14.6383; EVANS DJ, 1983, BIOINORGANIC CATALYS, P89; FEE JA, 1993, BIOINORGANIC CHEM CO, P485; FELTON DE, J CHEM SOC DA, P1349; FERGUSONMILLER S, 1993, J BIOENERG BIOMEMBR, V25, P69, DOI 10.1007/BF00762848; FIFE TH, 1991, PERSPECTIVES BIOINOR, V1, P43; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; Fox B. G., 1990, BIOL OXIDATION SYSTE, V1, P367; FREEMAN JC, 1993, J AM CHEM SOC, V115, P4923, DOI 10.1021/ja00064a077; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; GOLDBERG DP, 1993, J AM CHEM SOC, V115, P5346, DOI 10.1021/ja00065a077; GUNTER MJ, 1991, COORDIN CHEM REV, V108, P115, DOI 10.1016/0010-8545(91)84001-L; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAN H, 1991, BIOCHEMISTRY-US, V30, P11104, DOI 10.1021/bi00110a012; HANSEN S, 1992, J MOL BIOL, V225, P543, DOI 10.1016/0022-2836(92)90938-G; HARRISON PM, 1991, ADV INORG CHEM, V36, P449, DOI 10.1016/S0898-8838(08)60046-X; HAYASHI Y, 1992, CHEM LETT, P91, DOI 10.1246/cl.1992.91; HENDRICKSON WA, 1992, MACROMOLECULAR STRUC; HENDRY P, 1990, PROG INORG CHEM, V38, P201; HILL HAO, 1976, CHEM BRIT, V12, P119; HOFFMAN BM, 1991, STRUCT BOND, V75, P85; HOLM RH, 1990, PROG INORG CHEM, V38, P1; HOLM RH, 1992, ADV INORG CHEM, V38, P1, DOI 10.1016/S0898-8838(08)60061-6; HOLMES MA, 1991, J MOL BIOL, V218, P583, DOI 10.1016/0022-2836(91)90703-9; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; IBERS JA, 1980, SCIENCE, V209, P223, DOI 10.1126/science.7384796; IGNARRO LJ, 1991, BLOOD VESSELS, V28, P67; INGRAHAM LI, 1985, BIOCH ELEMENTS, V4, P157; JACOBSON RR, 1988, J AM CHEM SOC, V110, P3690, DOI 10.1021/ja00219a071; Karlin K.D., 1993, BIOINORGANIC CHEM CO; Karlin K.D, 1993, BIOINORGANIC CATALYS, P261; KARLIN KD, 1984, J AM CHEM SOC, V106, P2121, DOI 10.1021/ja00319a036; KENNEDY MC, 1992, ADV INORG CHEM RAD, V38, P323, DOI 10.1016/S0898-8838(08)60067-7; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; KIMURA E, 1994, PROG INORG CHEM, V41, P443, DOI 10.1002/9780470166420.ch6; KIMURA E, 1990, J AM CHEM SOC, V112, P5805, DOI 10.1021/ja00171a020; KITAJIMA N, 1990, J AM CHEM SOC, V112, P6402, DOI 10.1021/ja00173a041; KITAJIMA N, 1989, J AM CHEM SOC, V111, P8975, DOI 10.1021/ja00206a062; KITAJIMA N, 1992, J AM CHEM SOC, V114, P1277, DOI 10.1021/ja00030a025; KITAJIMA N, 1992, ADV INORG CHEM, V39, P1, DOI 10.1016/S0898-8838(08)60258-5; KOLODZIEJ AF, 1994, PROG INORG CHEM, V41, P493, DOI 10.1002/9780470166420.ch7; KOVACS JA, 1993, MODELS INORGANIC BIO, V9, P173; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; KURTZ DM, 1990, CHEM REV, V90, P585, DOI 10.1021/cr00102a002; LEE SC, 1993, J AM CHEM SOC, V115, P5833, DOI 10.1021/ja00066a065; LEGALL J, 1988, BIOCHEMISTRY-US, V27, P1636, DOI 10.1021/bi00405a037; LEISING RA, 1991, J AM CHEM SOC, V113, P3988, DOI 10.1021/ja00010a050; LINDAHL PA, 1990, J CLUST SCI, V1, P29; LIPPARD SJ, 1988, ANGEW CHEM INT EDIT, V27, P344, DOI 10.1002/anie.198803441; LIPPARD SJ, 1973, PROG INORG CHEM, V18, pR5; LIU KE, 1993, J AM CHEM SOC, V115, P939, DOI 10.1021/ja00056a018; Magnus K. A., 1993, BIOINORGANIC CHEM CO, P143; MARLETTA M A, 1990, Biofactors, V2, P219; MARONEY MJ, 1991, J AM CHEM SOC, V113, P3962, DOI 10.1021/ja00010a044; Marzilli LG, 1993, BIOINORGANIC CATALYS, P227; Mathews FS, 1991, CURR OPIN STRUC BIOL, V1, P954, DOI 10.1016/0959-440X(91)90091-7; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MCLENDON G, 1993, J AM CHEM SOC, V115, P3665, DOI 10.1021/ja00062a035; MCLENDON G, 1992, CHEM REV, V92, P481, DOI 10.1021/cr00011a007; MCREE DE, 1986, J BIOL CHEM, V261, P277; MEUNIER B, 1992, CHEM REV, V92, P1411, DOI 10.1021/cr00014a008; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; MOURA I, 1992, J BIOL CHEM, V267, P4489; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; MURTHY NN, UNPUB; NANTHAKUMAR A, IN PRESS J AM CHEM S; NASIR MS, 1992, J AM CHEM SOC, V114, P2482, DOI 10.1021/ja00033a024; NORDLUND P, 1992, FEBS LETT, V307, P257, DOI 10.1016/0014-5793(92)80690-I; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; ORMEJOHNSON WH, 1992, SCIENCE, V257, P1639, DOI 10.1126/science.1529351; OSTOVIC D, 1992, ACCOUNTS CHEM RES, V25, P314, DOI 10.1021/ar00019a007; OXENDER DL, 1989, PROTEIN ENG; PECORARO VL, 1992, MANGANESE REDOX ENZY; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; PERUTZ MF, 1979, ANNU REV BIOCHEM, V48, P327, DOI 10.1146/annurev.bi.48.070179.001551; PESSI A, 1993, NATURE, V362, P367, DOI 10.1038/362367a0; Pilato R. S., 1993, BIOINORGANIC CATALYS, P131; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; POYNER RR, 1992, BIOCHEMISTRY-US, V31, P7166, DOI 10.1021/bi00146a020; PRINCE RC, 1993, TRENDS BIOCHEM SCI, V18, P35, DOI 10.1016/0968-0004(93)90047-Q; Que Jr L., 1993, BIOINORGANIC CATALYS, P347; QUE L, 1990, PROG INORG CHEM, V38, P97; QUE L, 1988, ACS S SERIES, V372; QUIOCHO FA, 1993, NATURE, V362, P293, DOI 10.1038/362293a0; RAGSDALE SW, 1991, CRIT REV BIOCHEM MOL, V26, P261, DOI 10.3109/10409239109114070; RANA TM, 1991, J AM CHEM SOC, V113, P1859, DOI 10.1021/ja00005a076; RARDIN RL, 1991, NEW J CHEM, V15, P417; RECZKOWSKI RS, 1992, J AM CHEM SOC, V114, P10992, DOI 10.1021/ja00053a064; Reedijk J., 1993, BIOINORGANIC CATALYS; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; RODERICK SL, 1993, BIOCHEMISTRY-US, V32, P3907, DOI 10.1021/bi00066a009; SANDERSLOEHR J, 1989, J AM CHEM SOC, V111, P8084, DOI 10.1021/ja00203a003; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; SOLOMON EI, 1992, CHEM REV, V92, P521, DOI 10.1021/cr00012a003; SOLOMON EI, 1992, ACCOUNTS CHEM RES, V25, P343, DOI 10.1021/ar00020a004; SOLOMON EI, 1993, SCIENCE, V259, P1575, DOI 10.1126/science.8384374; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STEPHENS T, 1991, J NIH RES, V3, P21; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; Stubbe J, 1991, CURR OPIN STRUC BIOL, V1, P788, DOI 10.1016/0959-440X(91)90180-2; SUH JH, 1992, ACCOUNTS CHEM RES, V25, P273, DOI 10.1021/ar00019a001; SUSLICK KS, 1985, J CHEM EDUC, V62, P974, DOI 10.1021/ed062p974; TAFT KL, 1993, SCIENCE, V259, P1302, DOI 10.1126/science.8446898; TAINER J A, 1992, Current Opinion in Biotechnology, V3, P378, DOI 10.1016/0958-1669(92)90166-G; THEIL EC, 1990, ADV ENZYMOL RAMB, V63, P421; THIEMENS MH, 1991, SCIENCE, V251, P932, DOI 10.1126/science.251.4996.932; TRAYLOR TG, 1991, PURE APPL CHEM, V63, P265, DOI 10.1351/pac199163020265; TRAYLOR TG, 1993, J AM CHEM SOC, V115, P810, DOI 10.1021/ja00055a075; TYEKLAR Z, 1993, J AM CHEM SOC, V115, P2677, DOI 10.1021/ja00060a017; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1993, BIOCHEMISTRY-US, V32, P6493, DOI 10.1021/bi00077a001; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; WATANABE Y, 1992, MECHANISMS CATALYSIS, V20, P405; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WIEGHARDT K, 1983, ANGEW CHEM INT EDIT, V22, P727, DOI 10.1002/anie.198307271; WUENSCHELL GE, 1992, J AM CHEM SOC, V114, P3346, DOI 10.1021/ja00035a028; ZANG Y, 1993, J AM CHEM SOC, V115, P811, DOI 10.1021/ja00055a076; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	178	520	531	0	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1993	261	5122					701	708		10.1126/science.7688141	http://dx.doi.org/10.1126/science.7688141			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	7688141				2022-12-28	WOS:A1993LQ73000026
J	KOBAYASHI, S; AMIKURA, R; OKADA, M				KOBAYASHI, S; AMIKURA, R; OKADA, M			PRESENCE OF MITOCHONDRIAL LARGE RIBOSOMAL-RNA OUTSIDE MITOCHONDRIA IN GERM PLASM OF DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							MATERNAL-EFFECT MUTATIONS; INSITU HYBRIDIZATION; POLAR GRANULES; EMBRYOS; GENE; CELLS; SEGMENTATION; LOCALIZATION; PATTERN; NANOS	Mitochondrial large ribosomal RNA (mtlrRNA) has been identified as a cytoplasmic factor that induces pole cell formation in embryos whose ability to form a germ line has been abolished by treatment with ultraviolet light. In situ hybridization analyses reveal that mtlrRNA is enriched in germ plasm and is tightly associated with polar granules, the distinctive organelles of germ plasm, which supports the idea that mtlrRNA functions in pole cell formation. This suggests that a product from the mitochondrial genome, along with nuclear products, participates in a key event in embryonic development: determination of the germ line.			KOBAYASHI, S (corresponding author), UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN.							BINDER M, 1986, J CELL BIOL, V102, P1646, DOI 10.1083/jcb.102.5.1646; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; CLARY DO, 1985, NUCLEIC ACIDS RES, V13, P4029, DOI 10.1093/nar/13.11.4029; DING DF, COMMUNICATION; EDDY EM, 1975, INT REV CYTOL, V43, P229; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; HAY B, 1988, DEVELOPMENT, V103, P625; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; KOBAYASHI S, 1990, NUCLEIC ACIDS RES, V18, P4592, DOI 10.1093/nar/18.15.4592; KOBAYASHI S, 1989, DEVELOPMENT, V107, P733; KOBAYASHI S, UNPUB; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; MAHOWALD AP, 1968, J EXP ZOOL, V167, P237, DOI 10.1002/jez.1401670211; MAHOWALD AP, 1971, J EXP ZOOL, V176, P329, DOI 10.1002/jez.1401760308; MAHOWALD AP, 1992, SCIENCE, V255, P1216, DOI 10.1126/science.1372132; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1986, GENETICS, V112, P803; OKADA M, 1974, DEV BIOL, V37, P43, DOI 10.1016/0012-1606(74)90168-7; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P489, DOI 10.1007/BF00375889; UNDERWOOD EM, 1980, DEV BIOL, V77, P303, DOI 10.1016/0012-1606(80)90476-5; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K	24	135	138	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1521	1524		10.1126/science.7684857	http://dx.doi.org/10.1126/science.7684857			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	7684857				2022-12-28	WOS:A1993LF05800042
J	GADSBY, DC; RAKOWSKI, RF; DEWEER, P				GADSBY, DC; RAKOWSKI, RF; DEWEER, P			EXTRACELLULAR ACCESS TO THE NA,K PUMP - PATHWAY SIMILAR TO ION CHANNEL	SCIENCE			English	Article							CURRENT-VOLTAGE RELATIONSHIP; NA+/K+-PUMP; SODIUM-PUMP; EXTERNAL K+; NA/K PUMP; TRANSLOCATION; DEPENDENCE; EXCHANGE; POTASSIUM; TRANSPORT	In each normal Na,K pump cycle, first three sodium and then two potassium ions are transported; in both cases, the ions become temporarily occluded in pump conformations that isolate them from internal and external solutions. A major charge movement occurs during sodium translocation and accompanies the deocclusion of sodium ions or their release to the cell exterior, or both. The nature of the charge movement was examined by measurement of the unidirectional sodium-22 efflux mediated by Na(i)-Na(o) exchange (Na(i) and Na(o) are internal and external sodium ions) in voltage-clamped, internally dialyzed squid giant axons in the absence of potassium; in this way the pump activity was restricted to the sodium-translocation pathway. Although electroneutral, the Na(i)-Na(o) exchange was nevertheless voltage-sensitive: increasingly negative potentials enhanced its rate along a saturating sigmoid curve. Such voltage dependence demonstrates that the release and rebinding of external sodium is the predominant charge-moving (hence, voltage-sensitive) step, suggesting that extracellular sodium ions must reach their binding sites deep in the pump molecule through a high-field access channel. This implies that part of the pump molecule is functionally analogous to an ion channel.	MARINE BIOL LAB,WOODS HOLE,MA 02543	Marine Biological Laboratory - Woods Hole					NHLBI NIH HHS [HL-36783] Funding Source: Medline; NINDS NIH HHS [NS-22979, NS-11223] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036783] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022979, R01NS011223] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN OS, 1985, J GEN PHYSIOL, V86, P215, DOI 10.1085/jgp.86.2.215; ANNER BM, 1985, BIOCHIM BIOPHYS ACTA, V832, P335; APELL HJ, 1990, BIOCHIM BIOPHYS ACTA, V1023, P81, DOI 10.1016/0005-2736(90)90012-D; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; BAHINSKI A, 1988, P NATL ACAD SCI USA, V85, P3412, DOI 10.1073/pnas.85.10.3412; CORNELIUS F, 1991, BIOCHIM BIOPHYS ACTA, V1071, P19, DOI 10.1016/0304-4157(91)90011-K; DEWEER P, 1970, J GEN PHYSIOL, V56, P583, DOI 10.1085/jgp.56.5.583; DEWEER P, 1988, ANNU REV PHYSIOL, V50, P225, DOI 10.1146/annurev.physiol.50.1.225; DEWEER P, 1990, REGULATION POTASSIUM, P5; DEWEER P, 1988, NA K PUMP A, P421; DIPOLO R, 1987, J GEN PHYSIOL, V90, P505, DOI 10.1085/jgp.90.4.505; GADSBY DC, 1992, ACTA PHYSIOL SCAND, V146, P111; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P159, DOI 10.1113/jphysiol.1967.sp008294; GLYNN IM, 1971, J PHYSIOL-LONDON, V218, P239, DOI 10.1113/jphysiol.1971.sp009612; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; JENNINGS ML, 1990, J GEN PHYSIOL, V96, P991, DOI 10.1085/jgp.96.5.991; KIM SY, 1991, SODIUM PUMP RECENT D, P505; LAGNADO L, 1988, P NATL ACAD SCI USA, V85, P4548, DOI 10.1073/pnas.85.12.4548; LAUGER P, 1988, BIOCHIM BIOPHYS ACTA, V944, P451, DOI 10.1016/0005-2736(88)90516-0; Lauger P., 1991, ELECTROGENIC ION PUM; LEE KH, 1980, NATURE, V285, P338, DOI 10.1038/285338a0; Mitchell P., 1969, THEORETICAL EXPT BIO, V2, P159; NAKAO M, 1989, J GEN PHYSIOL, V94, P539, DOI 10.1085/jgp.94.3.539; NAKAO M, 1986, NATURE, V323, P628, DOI 10.1038/323628a0; RAKOWSKI RF, 1989, J GEN PHYSIOL, V93, P903, DOI 10.1085/jgp.93.5.903; RAKOWSKI RF, 1991, J MEMBRANE BIOL, V121, P177, DOI 10.1007/BF01870531; RAKOWSKI RF, 1993, J GEN PHYSIOL, V101, P117, DOI 10.1085/jgp.101.1.117; STURMER W, 1991, J MEMBRANE BIOL, V121, P163, DOI 10.1007/BF01870530; VASILETS LA, 1991, J BIOL CHEM, V266, P16285	29	178	179	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					100	103		10.1126/science.7682009	http://dx.doi.org/10.1126/science.7682009			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	7682009				2022-12-28	WOS:A1993KV42300038
J	MILLAUER, B; WIZIGMANNVOOS, S; SCHNURCH, H; MARTINEZ, R; MOLLER, NPH; RISAU, W; ULLRICH, A				MILLAUER, B; WIZIGMANNVOOS, S; SCHNURCH, H; MARTINEZ, R; MOLLER, NPH; RISAU, W; ULLRICH, A			HIGH-AFFINITY VEGF BINDING AND DEVELOPMENTAL EXPRESSION SUGGEST FLK-1 AS A MAJOR REGULATOR OF VASCULOGENESIS AND ANGIOGENESIS	CELL			English	Article							VASCULAR-PERMEABILITY FACTOR; ENDOTHELIAL-CELL MITOGEN; NERVE GROWTH-FACTOR; C-KIT RECEPTOR; TYROSINE KINASE; MAMMALIAN-CELLS; PROTO-ONCOGENE; EGF RECEPTOR; CDNA CLONING; FGF-RECEPTOR	Examination of flk-1 receptor tyrosine kinase mRNA expression by in situ hybridization analysis revealed specific association with endothelial cells at all stages of mouse development, including the blood islands in the yolk sac of day 8.5-10.5 embryos, in which the early progenitors of this lineage originate. flk-1 transcripts were abundant in proliferating endothelial cells of vascular sprouts and branching vessels of embryonic and early postnatal brain, but were drastically reduced in adult brain, where proliferation has ceased. Identification of the angiogenic mitogen, vascular endothelial growth factor (VEGF), as the high affinity ligand of Flk-1 and correlation of the temporal and spatial expression pattern of Flk-1 and VEGF suggest a major role of this ligand-receptor signaling system in vasculogenesis and angiogenesis.	MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM,W-8033 MARTINSRIED,GERMANY; SUGEN INC,DEPT MOLEC BIOL,REDWOOD CITY,CA 94063	Max Planck Society	MILLAUER, B (corresponding author), MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,AM KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY.							AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Bar T., 1980, ADV ANAT EMBRYOL CEL, V59, P1, DOI DOI 10.1007/978-3-642-67432-7_1; BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; BASLER K, 1988, CELL, V54, P299; BREIER G, 1992, DEVELOPMENT, V114, P521; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DUMONT DJ, 1992, ONCOGENE, V7, P1471; ENGERMAN RL, 1967, LAB INVEST, V17, P738; FAHRNER K, 1987, EMBO J, V6, P1497; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENDLY BM, 1990, CANCER RES, V50, P1550; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GINSBURG D, 1985, SCIENCE, V228, P1401, DOI 10.1126/science.3874428; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEUER JG, 1990, NEURON, V5, P283, DOI 10.1016/0896-6273(90)90165-C; HOGAN B, 1986, MANIPULATING MOUSE E; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; KURODA H, 1989, J CELL PHYSIOL, V139, P329, DOI 10.1002/jcp.1041390215; LEPPINK DM, 1989, TRANSPLANTATION, V48, P874, DOI 10.1097/00007890-198911000-00032; Levy AP, 1989, GROWTH FACTORS, V2, P9, DOI 10.3109/08977198909069077; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAHER PA, 1988, J CELL BIOL, V106, P1747, DOI 10.1083/jcb.106.5.1747; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PETERS KG, 1992, DEVELOPMENT, V114, P233; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; RISAU W, 1988, DEV BIOL, V125, P441, DOI 10.1016/0012-1606(88)90225-4; RISAU W, 1990, J CELL BIOL, V110, P1757, DOI 10.1083/jcb.110.5.1757; Risau W., 1991, DEV VASCULAR SYSTEM, P58; ROBERTSON PL, 1985, DEV BRAIN RES, V23, P219, DOI 10.1016/0165-3806(85)90044-6; ROBINSON CJ, 1991, TRENDS PHARMACOL SCI, V12, P123, DOI 10.1016/0165-6147(91)90525-W; RUSSELL ES, 1979, ADV GENET, V20, P257; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SCHNURCH H, 1991, DEVELOPMENT, V111, P1143; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SHIBUYA M, 1990, ONCOGENE, V5, P519; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANAKA A, 1991, DEVELOPMENT, V111, P455; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YEH IT, 1989, LAB INVEST, V61, P1	66	1725	1859	1	58	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					835	846		10.1016/0092-8674(93)90573-9	http://dx.doi.org/10.1016/0092-8674(93)90573-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	7681362				2022-12-28	WOS:A1993KU17500005
J	CONSTANTOULAKIS, P; CAMPBELL, M; FELBER, BK; NASIOULAS, G; AFONINA, E; PAVLAKIS, GN				CONSTANTOULAKIS, P; CAMPBELL, M; FELBER, BK; NASIOULAS, G; AFONINA, E; PAVLAKIS, GN			INHIBITION OF REV-MEDIATED HIV-1 EXPRESSION BY AN RNA-BINDING PROTEIN ENCODED BY THE INTERFERON-INDUCIBLE-9-27 GENE	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL MESSENGER-RNA; INTERFERON-STIMULATED GENES; KAPOSIS-SARCOMA; TARGET SEQUENCE; FUNCTIONAL-ANALYSIS; TRANS-ACTIVATOR; ALPHA; REPLICATION; GAMMA	Interferon inhibits expression of human immunodeficiency virus type-1 (HIV-1) through unknown mechanisms. A gene inducible by interferon-alpha (IFN-alpha) and interferon-gamma (IFN-gamma) was isolated by screening of a human complementary DNA library for proteins binding to the Rev-responsive element (RRE) of HIV-1. The product of this gene, RBP9-27, was shown to bind RNA in vitro and to inhibit HIV-1 expression after transfection into human cells. RBP9-27 primarily inhibited Rev-dependent posttranscriptional steps of viral gene expression. Thus, RBP9-27 is a cellular factor that antagonizes Rev function. These results suggest an interferon-induced antiviral mechanism operating through the induction of RNA binding proteins such as RBP9-27. Elucidation of RBP9-27 function may lead to a better understanding of the mechanism of interferon action during HIV-1 infection.	NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, HUMAN RETROVIRUS SECT, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, HUMAN RETROVIRUS PATHOGENESIS GRP, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N0-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED YF, 1990, GENE DEV, V4, P1014, DOI 10.1101/gad.4.6.1014; AMBRUS JL, 1989, AM J MED, V87, P405, DOI 10.1016/S0002-9343(89)80822-8; ANDERSON KP, 1987, J VIROL, V61, P787, DOI 10.1128/JVI.61.3.787-795.1987; ANDERSON RE, 1989, INT C AIDS STOCKHOLM; ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; BENKO D M, 1990, New Biologist, V2, P1111; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991; CONSTANTOULAKIS P, UNPUB; CULLEN BR, 1991, ADV VIRUS RES, V40, P1; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; DAYTON ET, 1989, SCIENCE, V246, P1625, DOI 10.1126/science.2688093; DEWIT R, 1988, LANCET, V2, P1214; EDLIN BR, 1992, J INFECT DIS, V165, P793, DOI 10.1093/infdis/165.5.793; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FISCHL MA, 1991, AM J MED, V90, pS2, DOI 10.1016/0002-9343(91)90404-L; FOSTER GR, 1991, P NATL ACAD SCI USA, V88, P2888, DOI 10.1073/pnas.88.7.2888; FRANCIS ML, 1992, AIDS RES HUM RETROV, V8, P199, DOI 10.1089/aid.1992.8.199; FRIEDMAN R M, 1990, Journal of Experimental Pathology (New York), V5, P49; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FUCHS D, 1989, J ACQ IMMUN DEF SYND, V2, P158; GENDELMAN HE, 1990, J IMMUNOL, V145, P2669; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GROOPMAN JE, 1991, AM J MED, V90, pS27, DOI 10.1016/0002-9343(91)90408-P; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; Haseltine W. A., 1991, GENETIC STRUCTURE RE; HO DD, 1985, LANCET, V1, P602; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; KERR IM, 1991, FEBS LETT, V285, P194, DOI 10.1016/0014-5793(91)80802-A; KITAJEWSKI J, 1986, CELL, V45, P195, DOI 10.1016/0092-8674(86)90383-1; KORNBLUTH RS, 1990, CLIN IMMUNOL IMMUNOP, V54, P200, DOI 10.1016/0090-1229(90)90082-2; KROWN SE, 1991, HEMATOL ONCOL CLIN N, V5, P311, DOI 10.1016/S0889-8588(18)30443-X; LAIRMORE MD, 1988, J IMMUNOL, V140, P779; LANE HC, 1988, LANCET, V2, P1218; LAWRENCE JB, 1991, NEW BIOL, V3, P1220; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEWIN AR, 1991, EUR J BIOCHEM, V199, P417, DOI 10.1111/j.1432-1033.1991.tb16139.x; MALDARELLI F, 1991, J VIROL, V65, P5732, DOI 10.1128/JVI.65.11.5732-5743.1991; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MELTZER MS, 1990, ANNU REV IMMUNOL, V8, P169, DOI 10.1146/annurev.iy.08.040190.001125; MERIGAN TC, 1991, AM J MED, V90, pS8, DOI 10.1016/0002-9343(91)90405-M; MURRAY HW, 1985, NEW ENGL J MED, V313, P1504, DOI 10.1056/NEJM198512123132403; NARAYAN O, 1985, J EXP MED, V162, P1954, DOI 10.1084/jem.162.6.1954; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; PAVLAKIS GN, 1991, ANN REV AIDS RES, P41; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; POPIK W, 1992, VIROLOGY, V189, P435, DOI 10.1016/0042-6822(92)90567-9; PREBLE OT, 1989, AIDS INFECTIONS HOMO; REICH N, 1988, J VIROL, V62, P114, DOI 10.1128/JVI.62.1.114-119.1988; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; ROSEN CA, 1990, AIDS, V4, P499, DOI 10.1097/00002030-199006000-00002; ROSSOL S, 1989, J INFECT DIS, V159, P815, DOI 10.1093/infdis/159.5.815; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992; SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992; SHIRAZI Y, 1992, J VIROL, V66, P1321, DOI 10.1128/JVI.66.3.1321-1328.1992; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMIN L, 1990, J VIROL, V64, P6010, DOI 10.1128/JVI.64.12.6010-6017.1990; VADHANRAJ S, 1986, CANCER RES, V46, P417; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x; WITT PL, 1991, AIDS, V5, P289, DOI 10.1097/00002030-199103000-00007; ZINK MC, 1989, J VIROL, V63, P2578, DOI 10.1128/JVI.63.6.2578-2584.1989	67	48	51	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	1993	259	5099					1314	1318		10.1126/science.7680491	http://dx.doi.org/10.1126/science.7680491			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	7680491				2022-12-28	WOS:A1993KN88300028
J	TUOMANEN, EI; AUSTRIAN, R; MASURE, HR				TUOMANEN, EI; AUSTRIAN, R; MASURE, HR			MECHANISMS OF DISEASE - PATHOGENESIS OF PNEUMOCOCCAL INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HUMAN ENDOTHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; STREPTOCOCCUS-PNEUMONIAE; ANTIBIOTIC-RESISTANCE; SURFACE COMPONENTS; MENINGITIS; INFLAMMATION; WALL; IDENTIFICATION; INDUCTION		UNIV PENN, DEPT MOLEC & CELLULAR ENGN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	TUOMANEN, EI (corresponding author), ROCKEFELLER UNIV, MOLEC INFECT DIS LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716				ALLOING G, 1989, GENE, V76, P363, DOI 10.1016/0378-1119(89)90177-7; ANDERSSON B, 1983, J EXP MED, V158, P559, DOI 10.1084/jem.158.2.559; AUSTRIAN R, 1986, J ANTIMICROB CHEMOTH, V18, P35, DOI 10.1093/jac/18.Supplement_A.35; Austrian R, 1976, Trans Assoc Am Physicians, V89, P184; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; BOULNOIS GJ, 1991, MOL MICROBIOL, V5, P2611, DOI 10.1111/j.1365-2958.1991.tb01969.x; BROOME CV, 1980, J INFECT DIS, V141, P119, DOI 10.1093/infdis/141.1.119; CABELLOS C, 1992, J CLIN INVEST, V90, P612, DOI 10.1172/JCI115900; CUNDELL DR, 1994, MICROB PATHOGENESIS, V17, P361, DOI 10.1006/mpat.1994.1082; CUNDELL DR, 1995, INFECT IMMUN, V63, P757, DOI 10.1128/IAI.63.3.757-761.1995; Finland M, 1932, J EXP MED, V55, P853, DOI 10.1084/jem.55.6.853; GARCIABUSTOS J, 1990, P NATL ACAD SCI USA, V87, P5415, DOI 10.1073/pnas.87.14.5415; GARCIABUSTOS JF, 1987, J BIOL CHEM, V262, P15400; GEELEN S, 1993, INFECT IMMUN, V61, P1538, DOI 10.1128/IAI.61.4.1538-1543.1993; GEELEN S, 1992, INFECT IMMUN, V60, P4179, DOI 10.1128/IAI.60.10.4179-4183.1992; GIEBINK GS, 1988, ANN OTO RHINOL LARYN, V97, P28, DOI 10.1177/00034894880970S308; Griffith F, 1928, J HYG-CAMBRIDGE, V27, P113, DOI 10.1017/S0022172400031879; HAKANSSON A, 1994, INFECT IMMUN, V62, P2707; Hamburger M, 1940, J EXP MED, V72, P261, DOI 10.1084/jem.72.3.261; HARFORD CG, 1950, J EXP MED, V91, P245, DOI 10.1084/jem.91.3.245; HEUMANN D, 1994, INFECT IMMUN, V62, P2715, DOI 10.1128/IAI.62.7.2715-2721.1994; JENNINGS HJ, 1980, BIOCHEMISTRY-US, V19, P4712, DOI 10.1021/bi00561a026; Kline BS, 1915, J EXP MED, V21, P311, DOI 10.1084/jem.21.4.311; KNECHT JC, 1970, J EXP MED, V132, P475, DOI 10.1084/jem.132.3.475; LOOSLI C, 1940, LANCET, V60, P49; MCCRUMB FR, 1953, AM J MED, V14, P284, DOI 10.1016/0002-9343(53)90040-0; OSLER W, 1897, AM J MED SCI, V113, P1; PEARCE BJ, 1993, MOL MICROBIOL, V9, P1037, DOI 10.1111/j.1365-2958.1993.tb01233.x; PEARCE BJ, 1994, MOL MICROBIOL, V12, P881, DOI 10.1111/j.1365-2958.1994.tb01076.x; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PFISTER HW, 1990, J CEREBR BLOOD F MET, V10, P914, DOI 10.1038/jcbfm.1990.148; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Rake G, 1936, J EXP MED, V63, P191, DOI 10.1084/jem.63.2.191; Rich AR, 1939, B JOHNS HOPKINS HOSP, V64, P434; RIESENFELDORN I, 1989, INFECT IMMUN, V57, P1890, DOI 10.1128/IAI.57.7.1890-1893.1989; SAMPSON JS, 1994, INFECT IMMUN, V62, P319, DOI 10.1128/IAI.62.1.319-324.1994; SAUKKONEN K, 1990, J EXP MED, V171, P439, DOI 10.1084/jem.171.2.439; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Stryker LM, 1916, J EXP MED, V24, P49, DOI 10.1084/jem.24.1.49; Sutliff WD, 1938, J IMMUNOL, V34, P455; TALKINGTON DF, 1991, INFECT IMMUN, V59, P1285, DOI 10.1128/IAI.59.4.1285-1289.1991; TAUBER MG, 1992, J INFECT DIS, V166, P1045, DOI 10.1093/infdis/166.5.1045; TOEWS GB, 1984, AM REV RESPIR DIS, V129, P82; TOMASZ A, 1989, Pediatric Infectious Disease Journal, V8, P902, DOI 10.1097/00006454-198912000-00034; TOMASZ A, 1967, SCIENCE, V157, P694, DOI 10.1126/science.157.3789.694; TOMASZ A, 1981, REV INFECT DIS, V3, P190; TOMASZ A, 1970, NATURE, V227, P138, DOI 10.1038/227138a0; TOMASZ A, 1975, P NATL ACAD SCI USA, V72, P4162, DOI 10.1073/pnas.72.10.4162; TUOMANEN E, 1985, J INFECT DIS, V151, P859, DOI 10.1093/infdis/151.5.859; TUOMANEN E, 1987, J INFECT DIS, V155, P985, DOI 10.1093/infdis/155.5.985; TUOMANEN E, 1987, AM REV RESPIR DIS, V135, P869, DOI 10.1164/arrd.1987.135.4.869; TUOMANEN E, 1989, Pediatric Infectious Disease Journal, V8, P923, DOI 10.1097/00006454-198912000-00047; TUOMANEN E, 1988, J INFECT DIS, V158, P36, DOI 10.1093/infdis/158.1.36; TUREEN JH, 1990, J CLIN INVEST, V85, P577, DOI 10.1172/JCI114475; WAGNER HN, 1956, B JOHNS HOPKINS HOSP, V98, P197; WEISER JN, 1994, INFECT IMMUN, V62, P2582, DOI 10.1128/IAI.62.6.2582-2589.1994; WINKELSTEIN JA, 1978, J IMMUNOL, V120, P174; Winternitz MC, 1913, J EXP MED, V17, P657, DOI 10.1084/jem.17.6.657; WOOD WB, 1946, J EXP MED, V84, P387, DOI 10.1084/jem.84.4.387; WOOD WB, 1952, HARVEY LECT, V47, P72	60	269	283	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 11	1995	332	19					1280	1284		10.1056/NEJM199505113321907	http://dx.doi.org/10.1056/NEJM199505113321907			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW600	7708073				2022-12-28	WOS:A1995QW60000007
J	HRIPCSAK, G; FRIEDMAN, C; ALDERSON, PO; DUMOUCHEL, W; JOHNSON, SB; CLAYTON, PD				HRIPCSAK, G; FRIEDMAN, C; ALDERSON, PO; DUMOUCHEL, W; JOHNSON, SB; CLAYTON, PD			UNLOCKING CLINICAL-DATA FROM NARRATIVE REPORTS - A STUDY OF NATURAL-LANGUAGE PROCESSING	ANNALS OF INTERNAL MEDICINE			English	Article							SYSTEM	Objective: To evaluate the automated detection of clinical conditions described in narrative reports. Design: Automated methods and human experts detected the presence or absence of six clinical conditions in 200 admission chest radiograph reports. Study Subjects: A computerized, general-purpose natural language processor; 6 internists; 6 radiologists; 6 lay persons; and 3 other computer methods. Main Outcome Measures: Intersubject disagreement was quantified by ''distance'' (the average number of clinical conditions per report on which two subjects disagreed) and by sensitivity and specificity with respect to the physicians. Results: Using a majority vote, physicians detected 101 conditions in the 200 reports (0.51 per report); the most common condition was acute bacterial pneumonia (prevalence, 0.14), and the least common was chronic obstructive pulmonary disease (prevalence, 0.03). Pairs of physicians disagreed on the presence of at least 1 condition for an average of 20% of reports. The average intersubject distance among physicians was 0.24 (95% CI, 0.19 to 0.29) out of a maximum possible distance of 6. No physician had a significantly greater distance than the average. The average distance of the natural language processor from the physicians was 0.26 (CI, 0.21 to 0.32; not significantly greater than the average among physicians). Lay persons and alternative computer methods had significantly greater distance from the physicians (all >0.5). The natural language processor had a sensitivity of 81% (CI, 73% to 87%) and a specificity of 98% (CI, 97% to 99%); physicians had an average sensitivity of 85% and an average specificity of 98%. Conclusions: Physicians disagreed on the interpretation of narrative reports, but this was not caused by outlier physicians or a consistent difference in the way internists and radiologists read reports. The natural language processor was not distinguishable from the physicians and was superior to all other comparison subjects. Although the domain of this study was restricted (six clinical conditions in chest radiographs), natural language processing seems to have the potential to extract clinical information from narrative reports in a manner that will support automated decision-support and clinical research.	CUNY QUEENS COLL, DEPT COMP SCI, FLUSHING, NY 11367 USA; COLUMBIA PRESBYTERIAN MED CTR, DEPT RADIOL, NEW YORK, NY 10032 USA	City University of New York (CUNY) System; Queens College NY (CUNY); Columbia University; NewYork-Presbyterian Hospital	HRIPCSAK, G (corresponding author), COLUMBIA PRESBYTERIAN MED CTR, DEPT MED INFORMAT, 161 FT WASHINGTON AVE, AP-1310, NEW YORK, NY 10032 USA.		Mendonca, Eneida/J-8895-2016	Mendonca, Eneida/0000-0003-4297-9221; Johnson, Stephen/0000-0002-6079-8419	NLM NIH HHS [LM05627, LM05397, LM04419] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [G08LM004419, R29LM005627, R29LM005397] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Chinchor N, 1993, COMPUT LINGUIST, V19, P409; Dunn G., 1989, DESIGN ANAL RELIABIL; FRIEDMAN C, 1994, J AM MED INFORM ASSN, V1, P161, DOI 10.1136/jamia.1994.95236146; GABRIELI E R, 1988, Journal of Medical Systems, V12, P135, DOI 10.1007/BF00996636; HAUG PJ, 1990, RADIOLOGY, V174, P543, DOI 10.1148/radiology.174.2.2404321; Hripcsak G., 1991, Software Engineering in Medical Informatics. Proceedings of the IMIA Working Conference, P471; HRIPCSAK G, 1994, COMPUT BIOMED RES, V27, P291, DOI 10.1006/cbmr.1994.1023; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; MCDONALD CJ, 1992, M D COMPUT, V9, P206; MCDONALD CJ, 1981, ACTION ORIENTED DECI; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; PESTOTNIK SL, 1990, AM J MED, V88, P43, DOI 10.1016/0002-9343(90)90126-X; RIND DM, 1994, ARCH INTERN MED, V154, P1511, DOI 10.1001/archinte.154.13.1511; Sager N., 1994, Seventeenth Annual Symposium on Computer Applications in Medical Care. Patient-Centered Computing, P265; SPRENT P, 1993, APPLIED NONPARAMETRI; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; VRIES JK, 1992, COMPUT BIOMED RES, V25, P153, DOI 10.1016/0010-4809(92)90018-6; YERUSHALMY J, 1969, RADIOL CLIN N AM, V7, P381; ZINGMOND D, 1993, COMPUT BIOMED RES, V26, P467, DOI 10.1006/cbmr.1993.1033	20	221	229	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					681	688		10.7326/0003-4819-122-9-199505010-00007	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702231				2022-12-28	WOS:A1995QV15100007
J	RASELL, ME				RASELL, ME			COST-SHARING IN HEALTH-INSURANCE - A REEXAMINATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RANDOMIZED CONTROLLED TRIAL; ARTERY BYPASS-SURGERY; UNITED-STATES; CORONARY ANGIOGRAPHY; RACIAL-DIFFERENCES; CARE; CANADA; APPROPRIATENESS; SERVICES; DEMAND				RASELL, ME (corresponding author), ECON POLICY INST,WASHINGTON,DC 20036, USA.							ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BERK ML, 1992, HEALTH AFFAIR, V11, P145, DOI 10.1377/hlthaff.11.4.145; BLUSTEIN J, 1995, NEW ENGL J MED, V332, P1138, DOI 10.1056/NEJM199504273321706; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; BROWN ML, 1990, ANN INTERN MED, V113, P547, DOI 10.7326/0003-4819-113-7-547; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; CHERKIN DC, 1989, MED CARE, V27, P669, DOI 10.1097/00005650-198907000-00001; Chulis G S, 1993, Health Care Financ Rev, V14, P163; FAHS MC, 1992, HEALTH SERV RES, V27, P25; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; GABEL J, 1990, HEALTH AFFAIR, V9, P161, DOI 10.1377/hlthaff.9.3.161; GREENSPAN AM, 1988, NEW ENGL J MED, V318, P158, DOI 10.1056/NEJM198801213180306; HALL WJ, 1993, HEALTH AFFAIR, V12, P58, DOI 10.1377/hlthaff.12.1.58; KAHN KL, 1988, ANN INTERN MED, V109, P664, DOI 10.7326/0003-4819-109-8-664; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; LEFKOWITZ D, 1991, PHS AHCPR92017 AG HL; Lohr K, 1986, MED CARE S, V24, pS31; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; MANNING WG, 1987, AM ECON REV, V77, P251; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; NEWHOUSE JP, 1994, HEALTH AFFAIR, V13, P132, DOI 10.1377/hlthaff.13.1.132; REDELMEIER DA, 1993, NEW ENGL J MED, V327, P772; RICE T, 1993, HEALTH AFFAIR, V12, P21, DOI 10.1377/hlthaff.12.1.21; RICE TH, 1989, J HEALTH POLIT POLIC, V14, P587, DOI 10.1215/03616878-14-3-587; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; Schieber G J, 1992, Health Care Financ Rev, V13, P1; SCHIEBER GJ, 1993, HEALTH AFFAIR, V12, P120, DOI 10.1377/hlthaff.12.2.120; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; SIU AL, 1986, NEW ENGL J MED, V315, P1259, DOI 10.1056/NEJM198611133152005; SPILLMAN BC, 1992, INQUIRY-J HEALTH CAR, V29, P457; SULLIVAN CB, 1992, HEALTH AFFAIR, V11, P172, DOI 10.1377/hlthaff.11.4.172; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; WOOLHANDLER S, 1993, NEW ENGL J MED, V329, P400, DOI 10.1056/NEJM199308053290606; ZWANZIGER J, 1993, HEALTH AFFAIR, V12, P130, DOI 10.1377/hlthaff.12.2.130; 1993, OTABPH112 OFF TECHN; 1990, EMPLOYEE BENEFITS ME; 1992, EMPLOYEE BENEFITS ME; 1991, HRD929 GEN ACC OFF; 1985, EMPLOYEE BENEFITS ME	43	33	35	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	1995	332	17					1164	1168		10.1056/NEJM199504273321711	http://dx.doi.org/10.1056/NEJM199504273321711			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QU302	7700293				2022-12-28	WOS:A1995QU30200011
J	KARK, JD; GOLDMAN, S; EPSTEIN, L				KARK, JD; GOLDMAN, S; EPSTEIN, L			IRAQI MISSILE ATTACKS ON ISRAEL - THE ASSOCIATION OF MORTALITY WITH A LIFE-THREATENING STRESSOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PERSIAN-GULF-WAR; PSYCHOLOGICAL STRESS; GAS MASKS; DEATH; SUDDEN; EARTHQUAKE	Objective.-The imminent deadline for the 1991 Persian Gulf War and, subsequently, the 18 missile attacks by Iraq on Israel represented an unusual, short-term, life-threatening stressor for an entire nation. We studied mortality in Israel in January and February 1991 to determine whether excess deaths were precipitated on days of missile attacks. Design.-A time-series mortality study. Setting.-The state of Israel. Participants.-All Israelis aged 25 years and older. Main Outcome Measure.-Daily mortality by sex, age, region, underlying cause, and place of death. Results.-On January 18, 1991, the day of the first strike on Israeli cities, a 58% increment in total mortality occurred in the Israeli population (95% confidence interval [Cl], 34% to 86%; P<.0001), a 77% excess (95% Cl, 40% to 120%) in women and a 41% excess (95% Cl, 10% to 79%) in men. This excess mortality occurred largely in the targeted Tel Aviv-central coastal plain and Haifa regions from cardiovascular causes and mainly out of hospital, significantly more so (P<.01) in women than men. Subsequently, on 16 attack days no overall excess was noted, yet a 10% increase in out-of-hospital deaths occurred. Conclusions.-Likely explanations for the initial increase in mortality include acute emotional stress coupled with breathing difficulties induced by gas masks and extended stay in sealed rooms with resultant hypoxia in susceptible individuals. Women were more vulnerable than men. The absence of elevated total mortality in the subsequent attacks suggests a rapid adaptation to the circumstances surrounding the war. The policy of an unventilated sealed room may have been detrimental.	HADASSAH MED ORG,DEPT SOCIAL MED,JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH SCH PUBL HLTH & COMMUNITY MED,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem								ARAD M, 1991, ISRAEL J MED SCI, V27, P636; BLASER DG, 1982, AM J EPIDEMIOL, V115, P684; BLEICH A, 1992, JAMA-J AM MED ASSOC, V268, P613, DOI 10.1001/jama.268.5.613; BORKAN J, 1991, NEW ENGL J MED, V325, P583; CARMELI A, 1991, ISRAEL J MED SCI, V27, P677; CASSEL J, 1976, AM J EPIDEMIOL, V104, P107, DOI 10.1093/oxfordjournals.aje.a112281; DANENBERG HD, 1991, ISRAEL J MED SCI, V27, P627; DOBSON AJ, 1991, MED J AUSTRALIA, V155, P757, DOI 10.5694/j.1326-5377.1991.tb94029.x; ENGEL GL, 1971, ANN INTERN MED, V74, P771, DOI 10.7326/0003-4819-74-5-771; GAL R, 1991, REACTION ISRAELI PUB, P1; HISS J, 1992, BRIT MED J, V304, P92, DOI 10.1136/bmj.304.6819.92; HUMINER D, 1991, NEW ENGL J MED, V325, P582; KARSENTY E, 1991, ISRAEL J MED SCI, V27, P603; LOWN B, 1987, CIRCULATION, V76, P186; MEISEL SR, 1991, LANCET, V338, P660, DOI 10.1016/0140-6736(91)91234-L; PHILLIPS DP, 1990, JAMA-J AM MED ASSOC, V263, P1947, DOI 10.1001/jama.263.14.1947; SLATER PE, 1991, LANCET, V338, P1336, DOI 10.1016/0140-6736(91)92636-G; TRICHOPOULOS D, 1983, LANCET, V1, P441	18	65	68	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1208	1210		10.1001/jama.273.15.1208	http://dx.doi.org/10.1001/jama.273.15.1208			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT100	7707629				2022-12-28	WOS:A1995QT10000030
J	DECOCK, KM				DECOCK, KM			SCREENING FOR TUBERCULOSIS AND HIV IN RESOURCE-POOR COUNTRIES	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; RISK; COHORT				DECOCK, KM (corresponding author), LONDON SCH HYG & TROP MED,LONDON WC1,ENGLAND.							AISU T, IN PRESS AIDS; BRAUN MM, 1991, AM REV RESPIR DIS, V143, P501, DOI 10.1164/ajrccm/143.3.501; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECOCK KM, 1991, BMJ-BRIT MED J, V302, P496, DOI 10.1136/bmj.302.6775.496; ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; GNAORE E, 1993, T ROY SOC TROP MED H, V87, P57, DOI 10.1016/0035-9203(93)90420-U; KASSIM S, 1993, 8TH INT C AIDS AFR 8; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; NUNN P, 1994, TUBERCLE LUNG DIS, V75, P25, DOI 10.1016/0962-8479(94)90098-1; NUNN P, 1991, LANCET, V377, P627; ORMEROD LP, 1994, THORAX, V49, P1085, DOI 10.1136/thx.49.11.1085; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; 1994, TUB LUNG DIS, V75, P94	15	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					873	874		10.1016/S0140-6736(95)90003-9	http://dx.doi.org/10.1016/S0140-6736(95)90003-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707805				2022-12-28	WOS:A1995QR06700003
J	PISACANE, A; DELUCA, U; IMPAGLIAZZO, N; RUSSO, M; DECAPRIO, C; CARACCIOLO, G				PISACANE, A; DELUCA, U; IMPAGLIAZZO, N; RUSSO, M; DECAPRIO, C; CARACCIOLO, G			BREAST-FEEDING AND ACUTE APPENDICITIS	BRITISH MEDICAL JOURNAL			English	Article									OSPED SANTOBONO,DIV CHIRURG,USL REG CAMPANIA 40,NAPLES,ITALY		PISACANE, A (corresponding author), UNIV NAPLES,DEPT PEDIAT,I-80131 NAPLES,ITALY.							BARKER DJP, 1985, BRIT MED J, V290, P1125, DOI 10.1136/bmj.290.6475.1125; COGGON D, 1991, J EPIDEMIOL COMMUN H, V45, P244, DOI 10.1136/jech.45.3.244; GOLDMAN AS, 1993, PEDIATR INFECT DIS J, V12, P664, DOI 10.1097/00006454-199308000-00008; HEATON KW, 1987, BRIT MED J, V294, P1632, DOI 10.1136/bmj.294.6588.1632; NELSON M, 1986, J EPIDEMIOL COMMUN H, V40, P316, DOI 10.1136/jech.40.4.316	5	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 1	1995	310	6983					836	837		10.1136/bmj.310.6983.836	http://dx.doi.org/10.1136/bmj.310.6983.836			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711621	Green Published			2022-12-28	WOS:A1995QQ85700019
J	WEIL, J; COLINJONES, D; LANGMAN, M; LAWSON, D; LOGAN, R; MURPHY, M; RAWLINS, M; VESSEY, M; WAINWRIGHT, P				WEIL, J; COLINJONES, D; LANGMAN, M; LAWSON, D; LOGAN, R; MURPHY, M; RAWLINS, M; VESSEY, M; WAINWRIGHT, P			PROPHYLACTIC ASPIRIN AND RISK OF PEPTIC-ULCER BLEEDING	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTI-INFLAMMATORY DRUGS; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; CONTROLLED TRIAL; MORTALITY; ACID	Objective-To determine the risks of hospitalisation for bleeding peptic ulcer with the current prophylactic aspirin regimens of 300 mg daily or less. Design-A case-control study with hospital and community controls. Setting-Hospitals in Glasgow, Newcastle, Nottingham, Oxford, and Portsmouth. Subjects-1121 patients with gastric or duodenal ulcer bleeding matched with hospital and community controls. Results-144 (12.8%) cases had been regular users of aspirin (taken at least five days a week for at least the previous month) compared with 101 (9.0%) hospital and 77 (7.8%) community controls. Odds ratios were raised for all doses of aspirin taken, whether compared with hospital or community controls (compared with combined controls: 75 mg, 2.3 (95% confidence interval 1.2 to 4.3); 150 mg, 3.2 (1.7 to 6.5); 300 mg, 3.9 (2.5 to 6.3)). Results were not explained by confounding influences of age, sex, prior ulcer history or dyspepsia, or concurrent nonaspirin non-steroidal anti-inflammatory drug use. Risks seemed particularly high in patients who took non-aspirin non-steroidal anti-inflammatory drugs concurrently. Conclusion-No conventionally used prophylactic aspirin regimen seems free of the risk of peptic ulcer complications.	UNIV BIRMINGHAM, QUEEN ELIZABETH HOSP, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; W MIDLANDS REG HLTH AUTHOR, PUBL HLTH MED, BIRMINGHAM, W MIDLANDS, ENGLAND; QUEEN ALEXANDRA HOSP, PORTSMOUTH PO6 3LY, HANTS, ENGLAND; ROYAL INFIRM, GLASGOW G4 0SF, LANARK, SCOTLAND; UNIV NOTTINGHAM, NOTTINGHAM NG7 2UH, ENGLAND; UNIV OXFORD, HLTH CARE EPIDEMIOL UNIT, OXFORD OX2 6HE, ENGLAND; UNIV NEWCASTLE UPON TYNE, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND; UNIV OXFORD, RADCLIFFE INFIRM, OXFORD OX2 6HE, ENGLAND; UNIV BIRMINGHAM, INST CANC STUDIES, BIRMINGHAM B15 2TJ, W MIDLANDS, ENGLAND	University of Birmingham; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; Royal Infirmary of Edinburgh; University of Nottingham; University of Oxford; Newcastle University - UK; Radcliffe Infirmary; University of Oxford; University of Birmingham								ALVAREZ AS, 1958, LANCET, V2, P179; [Anonymous], 1988, Br Med J (Clin Res Ed), V296, P316; [Anonymous], 1991, Lancet, V338, P1345; [Anonymous], 1980, CIRCULATION, V62, P449; BJARNASON I, 1988, GASTROENTEROLOGY, V94, P1070, DOI 10.1016/0016-5085(88)90568-9; BJARNASON I, 1987, GASTROENTEROLOGY, V93, P480, DOI 10.1016/0016-5085(87)90909-7; BOUSSER MG, 1983, STROKE, V14, P5, DOI 10.1161/01.STR.14.1.5; BREDDIN K, 1980, HAEMOSTASIS, V9, P325; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; COGGON D, 1982, GUT, V23, P340, DOI 10.1136/gut.23.4.340; ELWOOD PC, 1974, BRIT MED J, V1, P436, DOI 10.1136/bmj.1.5905.436; ELWOOD PC, 1979, LANCET, V2, P1313; FAULKNER G, 1988, BRIT MED J, V297, P1311, DOI 10.1136/bmj.297.6659.1311; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; LANGMAN MJS, 1985, BRIT MED J, V290, P347, DOI 10.1136/bmj.290.6465.347; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LEVY M, 1988, ARCH INTERN MED, V148, P281, DOI 10.1001/archinte.148.2.281; MEADE TW, 1992, THROMB HAEMOSTASIS, V68, P1; PETERSEN P, 1989, LANCET, V1, P175; PRITCHARD PJ, 1989, BRIT MED J, V298, P493; RODERICK PJ, 1993, BRIT J CLIN PHARMACO, V35, P219, DOI 10.1111/j.1365-2125.1993.tb05689.x; SHORROCK C J, 1992, Gastroenterology, V102, pA165; SOMERVILLE K, 1986, LANCET, V1, P462; SORENSEN PS, 1983, STROKE, V14, P15, DOI 10.1161/01.STR.14.1.15; The Aspirin Myocardial Infarction Study: final results, 1980, CIRCULATION S5, V62, pV79; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; WALLENTIN L, 1990, LANCET, V336, P827; 1976, J CHRON DIS, V29, P625	31	459	480	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	1995	310	6983					827	830		10.1136/bmj.310.6983.827	http://dx.doi.org/10.1136/bmj.310.6983.827			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711618	Green Published			2022-12-28	WOS:A1995QQ85700016
J	DALLOS, P; EVANS, BN				DALLOS, P; EVANS, BN			HIGH-FREQUENCY MOTILITY OF OUTER HAIR-CELLS AND THE COCHLEAR AMPLIFIER	SCIENCE			English	Article							GUINEA-PIG COCHLEA; ELECTROKINETIC SHAPE CHANGES; MECHANICAL RESPONSES; CURRENTS; ELECTROMOTILITY; SENSITIVITY; PHASE; ORGAN; CORTI	Outer hair cells undergo somatic elongation-contraction cycles in vitro when electrically stimulated. This ''electromotile'' response is assumed to underlie the high sensitivity and frequency selectivity of amplification in the mammalian cochlea. This process, presumably operating on a cycle-by-cycle basis at the frequency of the stimulus, is believed to provide mechanical feedback in vivo. However, if driven by the receptor potential of the cell, the mechanical feedback is expected to be severely attenuated at high frequencies because of electrical low-pass filtering by the outer hair cell basolateral membrane. It is proposed that electromotility at high frequencies is driven instead by extracellular potential gradients across the hair cell, and it is shown that this driving voltage is not subject to low-pass filtering and is sufficiently large. It is further shown that if the filtering properties of the cell membrane are canceled, taking advantage of the electrical characteristics of isolated outer hair cells in a partitioning glass microchamber, then the lower bound of the motor's bandwidth is approximately 22 kilohertz, a number determined only by the limitations of our instrumentation.	NORTHWESTERN UNIV,DEPT COMMUN SCI & DISORDERS,EVANSTON,IL 60208	Northwestern University	DALLOS, P (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,AUDIOL PHYSIOL LAB,HUGH KNOWLES CTR,EVANSTON,IL 60208, USA.		Dallos, Peter/Q-9360-2019	Dallos, Peter/0000-0002-9731-6591				Ashmore J. F., 1989, COCHLEAR MECH, P107; ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; ASHMORE JF, 1986, NATURE, V322, P368, DOI 10.1038/322368a0; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; CANNON MW, 1976, THESIS SYRACUSE U SY; CHEATHAM MA, UNPUB; Cooper N. P., 1993, BIOPHYSICS HAIR CELL, P249; CROWLEY DE, 1966, J COMP PHYSIOL PSYCH, V62, P427, DOI 10.1037/h0023953; DALLOS P, 1991, NATURE, V350, P155, DOI 10.1038/350155a0; DALLOS P, 1993, J NEUROPHYSIOL, V70, P299, DOI 10.1152/jn.1993.70.1.299; DALLOS P, 1985, J NEUROSCI, V5, P1591; DALLOS P, 1992, J NEUROSCI, V12, P4575; DALLOS P, 1983, HEARING RES, V12, P89, DOI 10.1016/0378-5955(83)90120-X; DAVIS H, 1983, HEARING RES, V9, P79, DOI 10.1016/0378-5955(83)90136-3; Davis H, 1981, Am J Otolaryngol, V2, P153, DOI 10.1016/S0196-0709(81)80034-8; Evans B.N., 1989, COCHLEAR MECHANISMS, P205; EVANS BN, 1993, P NATL ACAD SCI USA, V90, P8347, DOI 10.1073/pnas.90.18.8347; EVANS BN, 1991, HEARING RES, V52, P288, DOI 10.1016/0378-5955(91)90019-6; Fay R. R., 1988, HEARING VERTEBRATES; FORGE A, 1991, CELL TISSUE RES, V265, P473, DOI 10.1007/BF00340870; GEISLER CD, 1990, HEARING RES, V44, P241, DOI 10.1016/0378-5955(90)90084-3; GITTER AH, 1988, BASIC ISSUES HEARING, P32; HOPKINS CD, 1981, AM ZOOL, V21, P211; HOUSLEY GD, 1992, J PHYSIOL-LONDON, V448, P73, DOI 10.1113/jphysiol.1992.sp019030; HUBBARD AE, 1983, SCIENCE, V222, P510, DOI 10.1126/science.6623090; HUDSPETH AJ, 1977, P NATL ACAD SCI USA, V74, P2407, DOI 10.1073/pnas.74.6.2407; KACHAR B, 1986, NATURE, V322, P365, DOI 10.1038/322365a0; KALINEC F, 1992, P NATL ACAD SCI USA, V89, P8671, DOI 10.1073/pnas.89.18.8671; KOSSL M, 1992, HEARING RES, V60, P156, DOI 10.1016/0378-5955(92)90018-I; KOSSL M, 1992, J NEUROSCI, V12, P1575; MAMMANO F, 1993, NATURE, V365, P838, DOI 10.1038/365838a0; Marmarelis P.Z., 1978, ANAL PHYSL SYSTEMS; Moller A R, 1974, Scand J Rehabil Med Suppl, V3, P37; MOUNTAIN DC, 1993, BIOPHYSICS HAIR CELL, P361; NUTTALL AL, 1993, BIOPHYSICS HAIR CELL, P288; POLLAK G, 1972, SCIENCE, V176, P66, DOI 10.1126/science.176.4030.66; RUSSELL IJ, 1992, P ROY SOC B-BIOL SCI, V247, P97, DOI 10.1098/rspb.1992.0014; SANTOS-SACCHI J, 1988, HEARING RES, V35, P143, DOI 10.1016/0378-5955(88)90113-X; SANTOS-SACCHI J, 1989, J NEUROSCI, V9, P2954; SANTOS-SACCHI J, 1991, J NEUROSCI, V11, P3096, DOI 10.1523/jneurosci.11-10-03096.1991; SANTOS-SACCHI J, 1992, J NEUROSCI, V12, P1906; SELLICK PM, 1982, J ACOUST SOC AM, V72, P131, DOI 10.1121/1.387996; YATES GK, 1993, BIOPHYSICS HAIR CELL, P352; ZENNER HP, 1986, HEARING RES, V22, P83, DOI 10.1016/0378-5955(86)90082-1	44	262	268	0	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					2006	2009		10.1126/science.7701325	http://dx.doi.org/10.1126/science.7701325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701325				2022-12-28	WOS:A1995QQ06800048
J	MARTI, K; KIM, JS; THAKUR, AN; MCCOY, TJ; KEIL, K				MARTI, K; KIM, JS; THAKUR, AN; MCCOY, TJ; KEIL, K			SIGNATURES OF THE MARTIAN ATMOSPHERE IN GLASS OF THE ZAGAMI METEORITE	SCIENCE			English	Article							NOBLE-GASES; SHERGOTTITE METEORITES; SNC METEORITES; ORIGIN; NITROGEN; MARS; PETROGENESIS; EETA-79001; ABUNDANCES; XENON	Isotopic signatures of nitrogen, argon, and xenon have been determined in separated millimeter-sized pockets of shock-melted glass in a recently identified lithology of the meteorite Zagami, a shergottite. The ratio of nitrogen-15 to nitrogen-14, which is at least 282 per mil larger than the terrestrial value, the ratio of xenon-129 to xenon-132 = 2.40, and the argon isotopic abundances match the signatures previously observed in the glassy lithology of the Antarctic shergottite EETA 79001. These results show that the signatures in EETA 79001 are not unique but characterize the trapped gas component in shock-melted glass of shergottites. The isotopic and elemental ratios of nitrogen, argon, and xenon closely resemble the Viking spacecraft data for the martian atmosphere and provide compelling evidence for a martian origin of the two shergottites and, by extension, of the meteorites in the shergottites-nakhlites-chassignites (SNC) group.	UNIV HAWAII MANOA,HAWAII CTR VOLCANOL,HONOLULU,HI 96822; UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,CALIF SPACE INST,LA JOLLA,CA 92093; UNIV HAWAII MANOA,SCH OCEAN & EARTH SCI & TECHNOL,HAWAII INST GEOPHYS & PLANETOL,HONOLULU,HI 96822	University of Hawaii System; University of Hawaii Manoa; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Hawaii System; University of Hawaii Manoa	MARTI, K (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093, USA.			McCoy, Timothy/0000-0002-4573-3553				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BECKER RH, 1984, EARTH PLANET SC LETT, V69, P225, DOI 10.1016/0012-821X(84)90183-3; BECKER RH, 1993, METEORITICS, V28, P637, DOI 10.1111/j.1945-5100.1993.tb00634.x; BIEMANN K, 1976, SCIENCE, V194, P76, DOI 10.1126/science.194.4260.76; BOGARD DD, 1986, J GEOPHYS RES-SOLID, V91, pE99, DOI 10.1029/JB091iB13p00E99; BOGARD DD, 1983, SCIENCE, V221, P651, DOI 10.1126/science.221.4611.651; BOGARD DD, 1984, GEOCHIM COSMOCHIM AC, V48, P1723, DOI 10.1016/0016-7037(84)90028-0; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.earth.21.1.115; Dreibus G., 1982, LUNAR PLANETARY SCI, P186; EPSTEIN S, 1971, GEOCHIM COSM SUPPL, V2, P1421; EUGSTER O, 1994, METEORITICS, V29, P464; JAGOUTZ E, 1989, GEOCHIM COSMOCHIM AC, V53, P2429, DOI 10.1016/0016-7037(89)90363-3; KIM J, UNPUB; KIM JS, 1992, P LUNAR PLANET SCI, V22, P145; KIM JS, 1994, LUNAR PLANET SCI, V25, P701; MCCOY TJ, 1992, GEOCHIM COSMOCHIM AC, V56, P3571, DOI 10.1016/0016-7037(92)90400-D; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MCSWEEN HY, 1983, GEOCHIM COSMOCHIM AC, V47, P1501, DOI 10.1016/0016-7037(83)90309-5; NAKAMURA N, 1982, METEORITICS, V17, P257; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; OTT U, 1988, GEOCHIM COSMOCHIM AC, V52, P1937, DOI 10.1016/0016-7037(88)90017-8; OWEN T, 1976, SCIENCE, V193, P801, DOI 10.1126/science.193.4255.801; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; Owen T., 1977, J GEOPHYS RES, V82, P4635, DOI DOI 10.1029/JS082I028P04635; SHIH CY, 1982, GEOCHIM COSMOCHIM AC, V46, P2323, DOI 10.1016/0016-7037(82)90205-8; STOEFFLER D, 1986, GEOCHIM COSMOCHIM AC, V50, P889; STOLPER E, 1979, GEOCHIM COSMOCHIM AC, V43, P1475, DOI 10.1016/0016-7037(79)90142-X; SWINDLE TD, 1986, GEOCHIM COSMOCHIM AC, V50, P1001, DOI 10.1016/0016-7037(86)90381-9; Wadhwa M., 1993, METEORITICS, V28, P453; WALKER D, 1979, LUNAR PLANET SCI, V10, P1274; Wasson J.T., 1979, ASTEROIDS, P926; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; WIENS RC, 1988, GEOCHIM COSMOCHIM AC, V52, P295, DOI 10.1016/0016-7037(88)90085-3; WIENS RC, 1986, EARTH PLANET SC LETT, V77, P149, DOI 10.1016/0012-821X(86)90156-1	34	96	96	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1981	1984		10.1126/science.7701319	http://dx.doi.org/10.1126/science.7701319			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701319				2022-12-28	WOS:A1995QQ06800040
J	ROGERS, DJ; PACKER, MJ				ROGERS, DJ; PACKER, MJ			VECTOR-BORNE DISEASES, MODELS, AND GLOBAL CHANGE	LANCET			English	Article											ROGERS, DJ (corresponding author), UNIV OXFORD,DEPT ZOOL,S PARKS RD,OXFORD OX1 3PS,ENGLAND.							Anderson RM, 1982, POPULATION DYNAMICS, V368, DOI [10.1007/978-1-4899-2901-3, DOI 10.1007/978-1-4899-2901-3]; MAURICE J, 1993, NEW SCI         1016; RAI KS, 1991, ANNU REV ENTOMOL, V36, P459, DOI 10.1146/annurev.en.36.010191.002331; ROGERS DJ, 1988, PARASITOLOGY, V97, P193, DOI 10.1017/S0031182000066853; ROGERS DJ, 1993, PARASITOL TODAY, V9, P266, DOI 10.1016/0169-4758(93)90074-P; 1990, WHO TDRCTDHH901	6	72	75	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1282	1284		10.1016/0140-6736(93)92367-3	http://dx.doi.org/10.1016/0140-6736(93)92367-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7695661				2022-12-28	WOS:A1993MH56600017
J	HATHCOCK, KS; LASZLO, G; DICKLER, HB; BRADSHAW, J; LINSLEY, P; HODES, RJ				HATHCOCK, KS; LASZLO, G; DICKLER, HB; BRADSHAW, J; LINSLEY, P; HODES, RJ			IDENTIFICATION OF AN ALTERNATIVE CTLA-4 LIGAND COSTIMULATORY FOR T-CELL ACTIVATION	SCIENCE			English	Article							EXPRESSION; PROLIFERATION; ANTIGEN-B7; MOLECULE; INVIVO; B7	Stimulation of T cell proliferation generally requires two signals: The first signal is provided by the T cell receptor binding to antigen, and the second signal or costimulus is provided by a different receptor-ligand interaction. In mouse and human, the CD28-B7 interaction has been identified as a source of costimulatory signals. We have identified a cell surface molecule (GL1) that is distinct from B7 and abundantly expressed on activated B cells. On activated B cells GL1, rather than B7, is the predominant ligand for the T cell-activation molecule CTLA-4. GL1 provides a critical signal for T cell-dependent responses in vitro and in vivo.	NIA,BETHESDA,MD 20892; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Bristol-Myers Squibb	HATHCOCK, KS (corresponding author), NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892, USA.							CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; FREEMAN GJ, 1993, SCIENCE, V262, P907, DOI 10.1126/science.7694362; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; HATHCOCK KS, 1992, J IMMUNOL, V149, P2286; HATHCOCK KS, UNPUB; LASZLO G, 1993, J IMMUNOL, V150, P5252; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; STEINMAN R, UNPUB; TAN RS, 1992, J IMMUNOL, V149, P3217; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102	16	524	555	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					905	907		10.1126/science.7694361	http://dx.doi.org/10.1126/science.7694361			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	7694361				2022-12-28	WOS:A1993MF43800037
J	DEMATTEIS, MA; SANTINI, G; KAHN, RA; DITULLIO, G; LUINI, A				DEMATTEIS, MA; SANTINI, G; KAHN, RA; DITULLIO, G; LUINI, A			RECEPTOR AND PROTEIN KINASE-C-MEDIATED REGULATION OF ARF BINDING TO THE GOLGI-COMPLEX	NATURE			English	Article							ADP-RIBOSYLATION FACTOR; BREFELDIN-A; GUANINE-NUCLEOTIDE; COATED VESICLES; CELL-SURFACE; BETA-COP; SECRETION; INHIBITION; TRANSPORT; MEMBRANES	THE formation of constitutive transport vesicles involves the association of non-clathrin coat proteins to transport organelles1,2 . Here we report that IgE receptors and protein kinase C (PKC) regulate the GTP-dependent binding of the two coat proteins ADP-ribosylation factor (ARF) and beta-COP3-5 to Golgi membranes in rat basophilic leukaemia cells. Activation of IgE receptors and PKC prevented the ARF and beta-COP dissociation from Golgi membranes that occurs in permeabilized cells in the absence of GTP and potentiated the association-promoting effects of GTP and the G protein activator fluoroaluminate. In contrast, PKC downregulation and PKC inhibition abolished the activity of GTP and fluoro-luminate in promoting ARF binding to the Golgi complex. Studies of ARF binding to isolated Golgi membranes gave similiar results. These findings suggest that coat assembly on Golgi membranes, and thus possibly constitutive secretory traffic, is modulated by membrane receptors and second messengers.	IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,MOLEC NEUROBIOL LAB,I-66030 SANTA MARIA IMBAR,ITALY; NCI,DIV CANC TREATMENT,BIOL CHEM LAB,BETHESDA,MD 20892	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	DEMATTEIS, MA (corresponding author), IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,PHYSIOPATHOL SECRET UNIT,I-66030 SANTA MARIA IMBAR,ITALY.		Kahn, Richard/ABD-2666-2020; Luini, Alberto/L-1372-2013; De Matteis, Maria Antonietta/AHE-5161-2022	Kahn, Richard/0000-0002-0259-0601; Luini, Alberto/0000-0002-8729-2549; De Matteis, Maria Antonietta/0000-0003-0053-3061				ALI H, 1989, J IMMUNOL, V143, P2626; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; DEMATTEIS MA, 1991, J BIOL CHEM, V266, P10452; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; HUANG FL, 1989, J BIOL CHEM, V264, P4238; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LOW SH, 1991, J BIOL CHEM, V266, P17729; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Melancon P, 1991, Trends Cell Biol, V1, P165, DOI 10.1016/0962-8924(91)90018-5; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; ORCI L, 1991, CELL, V64, P1183; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STROUS GJ, 1993, J BIOL CHEM, V268, P2341	36	140	143	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					818	821		10.1038/364818a0	http://dx.doi.org/10.1038/364818a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	7689177				2022-12-28	WOS:A1993LU58100060
J	PYLE, AM				PYLE, AM			RIBOZYMES - A DISTINCT CLASS OF METALLOENZYMES	SCIENCE			English	Article							YEAST TRANSFER-RNAPHE; SELF-SPLICING RNA; PHENYLALANINE TRANSFER-RNA; SITE-SPECIFIC CLEAVAGE; HEPATITIS-DELTA-VIRUS; TETRAHYMENA RIBOZYME; METAL-ION; INTERVENING SEQUENCE; SUBSTRATE BINDING; RIBONUCLEASE-P	Ribozymes are an important new class of metalloenzymes that have an unlikely feature: they are made entirely of ribonucleic acid (RNA). Metal ions are essential for efficient chemical catalysis by ribozymes and are often required for the stabilization of ribozyme structure. Most ribozymes catalyze reactions at phosphorus centers through one of two major mechanistic pathways, and reaction has been observed at carbon centers. Creative experiments have revealed the position of metal ions in the active site of two ribozymes. The exploitation of variable metal geometry and reactivity has expanded ribozyme chemistry and has facilitated the application of in vitro selection for the creation of novel ribozymes.			PYLE, AM (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.							AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BEEN MD, 1992, BIOCHEMISTRY-US, V31, P11843, DOI 10.1021/bi00162a024; BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; BRESLOW R, 1991, P NATL ACAD SCI USA, V88, P4080, DOI 10.1073/pnas.88.10.4080; BRIMACOMBE R, 1993, FASEB J, V7, P161, DOI 10.1096/fasebj.7.1.8422963; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1992, J BIOL CHEM, V267, P17479; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; CHOWRIRA BM, 1993, BIOCHEMISTRY-US, V32, P1088, DOI 10.1021/bi00055a014; CHRISTIAN EL, 1993, BIOCHEMISTRY-US, V32, P4475, DOI 10.1021/bi00068a001; CHRISTIAN EL, 1992, J MOL BIOL, V228, P743, DOI 10.1016/0022-2836(92)90861-D; CIESIOLKA J, 1989, EUR J BIOCHEM, V182, P445, DOI 10.1111/j.1432-1033.1989.tb14851.x; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; COLLINS RA, 1993, BIOCHEMISTRY-US, V32, P2795, DOI 10.1021/bi00062a009; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; DANGE V, 1990, SCIENCE, V248, P585, DOI 10.1126/science.2185542; DENG HY, 1992, BIOCHEMISTRY-US, V31, P10518, DOI 10.1021/bi00158a015; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; GUERRIERTAKADA C, 1983, CELL, V35, P848; HAMPEL A, 1989, BIOCHEMISTRY-US, V28, P4929, DOI 10.1021/bi00438a002; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HEUS HA, 1991, J MOL BIOL, V217, P113, DOI 10.1016/0022-2836(91)90615-D; HOLBROOK SR, 1977, NUCLEIC ACIDS RES, V4, P2811, DOI 10.1093/nar/4.8.2811; HOYER D, 1990, J AM CHEM SOC, V112, P3249, DOI 10.1021/ja00164a076; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; JACQUIER A, 1986, SCIENCE, V234, P1099, DOI 10.1126/science.2430332; JARRELL KA, 1988, J BIOL CHEM, V263, P3432; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; JOYCE GF, 1992, SCI AM, V267, P90, DOI 10.1038/scientificamerican1292-90; KAZAKOV S, 1992, P NATL ACAD SCI USA, V89, P7939, DOI 10.1073/pnas.89.17.7939; KAZAKOV S, 1991, P NATL ACAD SCI USA, V88, P9193, DOI 10.1073/pnas.88.20.9193; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LEHMAN N, 1993, NATURE, V361, P182, DOI 10.1038/361182a0; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MCCLOSKEY JA, 1977, ACCOUNTS CHEM RES, V10, P403, DOI 10.1021/ar50119a004; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MEI HY, 1989, P NATL ACAD SCI USA, V86, P9727, DOI 10.1073/pnas.86.24.9727; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MORL M, 1992, CELL, V70, P803, DOI 10.1016/0092-8674(92)90313-2; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; PACE NR, 1990, J BIOL CHEM, V265, P3587; PAN T, 1992, NATURE, V358, P560, DOI 10.1038/358560a0; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; Pan  T., 1993, RNA WORLD, P271; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; RANA TM, 1990, J AM CHEM SOC, V112, P2457, DOI 10.1021/ja00162a077; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; ROSSI JJ, 1991, PHARMACOL THERAPEUT, V50, P245, DOI 10.1016/0163-7258(91)90016-F; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SAKAI H, 1967, J BIOL CHEM, V242, P1458; SAMPSON JR, 1987, COLD SPRING HARB SYM, V52, P267, DOI 10.1101/SQB.1987.052.01.032; SCHEPARTZ A, 1990, J AM CHEM SOC, V112, P3247, DOI 10.1021/ja00164a075; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SMITH D, 1992, J BIOL CHEM, V267, P2429; STEITZ TA, IN PRESS P NATLA CAD; SUGIMOTO N, 1989, NUCLEIC ACIDS RES, V17, P355, DOI 10.1093/nar/17.1.355; SURRATT CK, 1990, J BIOL CHEM, V265, P22513; SYMONS RH, 1989, TRENDS BIOCHEM SCI, V14, P445, DOI 10.1016/0968-0004(89)90103-5; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; TULLIUS TD, 1988, NATURE, V332, P663, DOI 10.1038/332663a0; UCHIMARU T, 1993, FASEB J, V7, P137, DOI 10.1096/fasebj.7.1.8422960; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; WISSINGER B, 1992, TRENDS GENET, V8, P322, DOI 10.1016/0168-9525(92)90265-6; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008; ZAUG AJ, 1986, BIOCHEMISTRY-US, V25, P4478, DOI 10.1021/bi00364a002	88	443	468	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 6	1993	261	5122					709	714		10.1126/science.7688142	http://dx.doi.org/10.1126/science.7688142			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	7688142				2022-12-28	WOS:A1993LQ73000027
J	SIOMI, H; SIOMI, MC; NUSSBAUM, RL; DREYFUSS, G				SIOMI, H; SIOMI, MC; NUSSBAUM, RL; DREYFUSS, G			THE PROTEIN PRODUCT OF THE FRAGILE-X GENE, FMR1, HAS CHARACTERISTICS OF AN RNA-BINDING PROTEIN	CELL			English	Article							HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; ESCHERICHIA-COLI; MESSENGER-RNA; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; NUCLEOLAR PROTEIN; CDNA CLONING; 5S RNA; DNA; HNRNP	Fragile X syndrome is one of the most common human genetic diseases and the most common cause of hereditary mental retardation. The gene that causes fragile X syndrome, FMR1, was recently identified and sequenced and found to encode a putative protein of unknown function. Here we report that FMR1 contains two types of sequence motifs recently found in RNA-binding proteins: an RGG box and two heterogeneous nuclear RNP K homology domains. We also demonstrate that FMR1 binds RNA in vitro. Using antibodies to FMR1, we detect its expression in divergent organisms and in cells of unaffected humans, but fragile X-affected patients express little or no FMR1. These findings demonstrate that FMR1 expression is directly correlated with the fragile X syndrome and suggest that anti-FMR1 antibodies will be important for diagnosis of fragile X syndrome. Furthermore, the RNA binding activity of FMR1 opens the way to understanding the function of FMR1.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	SIOMI, H (corresponding author), UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104, USA.		Dreyfuss, Gideon/D-1218-2013; Siomi, Haruhiko/A-7020-2015	Dreyfuss, Gideon/0000-0001-8129-8774; Siomi, Haruhiko/0000-0001-8690-3822				ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BRAUER D, 1979, FEBS LETT, V106, P352, DOI 10.1016/0014-5793(79)80531-1; BUVOLI M, 1988, NUCLEIC ACIDS RES, V16, P3751, DOI 10.1093/nar/16.9.3751; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CHOI YD, 1984, P NATL ACAD SCI-BIOL, V81, P7471, DOI 10.1073/pnas.81.23.7471; CHRISTENSEN ME, 1988, BIOCHEM BIOPH RES CO, V155, P1278, DOI 10.1016/S0006-291X(88)81279-8; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; CRUZALVAREZ M, 1987, J BIOL CHEM, V262, P13377; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DELAHODDE A, 1986, NUCLEIC ACIDS RES, V14, P9213, DOI 10.1093/nar/14.22.9213; DREYFUSS G, 1988, J CELL BIOL, V106, P1419, DOI 10.1083/jcb.106.5.1419; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GEDEON AK, 1992, NAT GENET, V1, P341, DOI 10.1038/ng0892-341; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; NADLER SG, 1991, BIOCHEMISTRY-US, V30, P2968, DOI 10.1021/bi00225a034; NUSSBAUM RL, 1986, ANNU REV GENET, V20, P109; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; REGNIER P, 1987, J BIOL CHEM, V262, P63; RICHARDS RI, 1992, TRENDS GENET, V8, P249, DOI 10.1016/0168-9525(92)90124-M; RIVA S, 1986, EMBO J, V5, P2267, DOI 10.1002/j.1460-2075.1986.tb04494.x; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; SCHMIDT C, 1992, EUR J BIOCHEM, V206, P625, DOI 10.1111/j.1432-1033.1992.tb16967.x; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH MC, 1988, J BIOL CHEM, V263, P7211; SPIRIDONOVA VA, 1989, CAN J MICROBIOL, V35, P153, DOI 10.1139/m89-023; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Sutherland G, 1985, FRAGILE SITES HUMAN; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WILSON JM, 1983, J CLIN INVEST, V72, P767, DOI 10.1172/JCI111047; WOHRLE D, 1992, AM J HUM GENET, V51, P299; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	56	552	564	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					291	298		10.1016/0092-8674(93)90420-U	http://dx.doi.org/10.1016/0092-8674(93)90420-U			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	7688265				2022-12-28	WOS:A1993LP72600010
J	KURAHASHI, T; YAU, KW				KURAHASHI, T; YAU, KW			COEXISTENCE OF CATIONIC AND CHLORIDE COMPONENTS IN ODORANT-INDUCED CURRENT OF VERTEBRATE OLFACTORY RECEPTOR-CELLS	NATURE			English	Article							CYCLIC-NUCLEOTIDES; ADENYLATE-CYCLASE; GATED CHANNELS; NEURONS; CILIA; ACTIVATION; MEMBRANE; CONDUCTANCE; NEWT; TRANSDUCTION	ODORANT stimulation leads to a depolarization of olfactory receptor neurons1-3. A mechanism underlying this transduction, which occurs in the sensory cilia3-6, involves a G-protein-mediated increase in adenylyl cyclase activity7-10, and therefore a rise in internal cyclic AMP and consequent opening of a cAMP-gated cation channel on the plasma membrane11-22. Another mechanism, not as well established, involves the opening of an inositol trisphosphate-activated cation channel on the plasma membrane23 as a result of phospholipase C activity24,25. In both cases, an influx of cations is thought to generate the depolarizing receptor potential. We now report, however, that the mechanism is actually more complex. The odorant-induced current appears to contain an inward chloride component also, which is triggered by calcium influx through the cation-selective channel. This newly found chloride component can be as large as the cationic component. The co-existence of cationic and chloride components in the odorant response, possibly unique among sensory transduction mechanisms, may serve to reduce variations in the transduction current resulting from changes in external ionic concentrations around the olfactory cilia. Our finding can explain the long-standing puzzle of why removal of most mucosal cations still does not diminish the amplitude of the olfactory receptor cell response26-28.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University								ALVAREZLEEFMANS FJ, 1990, CHLORIDE CHANNELS AND CARRIERS IN NERVE, MUSCLE, AND GLIAL CELLS, P109; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; DIONNE VE, 1992, J GEN PHYSIOL, V99, P415, DOI 10.1085/jgp.99.3.415; FIRESTEIN S, 1989, SCIENCE, V244, P79, DOI 10.1126/science.2704991; FIRESTEIN S, 1991, J NEUROSCI, V11, P3565; FIRESTEIN S, 1991, NEURON, V6, P825, DOI 10.1016/0896-6273(91)90178-3; FIRESTEIN S, 1990, J PHYSIOL-LONDON, V430, P135, DOI 10.1113/jphysiol.1990.sp018286; FRINGS S, 1991, J GEN PHYSIOL, V97, P1, DOI 10.1085/jgp.97.1.1; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; GETCHELL TV, 1986, PHYSIOL REV, V66, P772, DOI 10.1152/physrev.1986.66.3.772; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HUQUE T, 1986, BIOCHEM BIOPH RES CO, V137, P36, DOI 10.1016/0006-291X(86)91172-1; KLEENE SJ, 1991, J MEMBRANE BIOL, V120, P75, DOI 10.1007/BF01868593; KLEENE SJ, 1991, J NEUROSCI, V11, P3624; KOLESNIKOV SS, 1990, FEBS LETT, V266, P96, DOI 10.1016/0014-5793(90)81515-P; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; KURAHASHI T, 1991, NEUROREPORT, V2, P5, DOI 10.1097/00001756-199101000-00001; KURAHASHI T, 1990, J PHYSIOL-LONDON, V430, P355, DOI 10.1113/jphysiol.1990.sp018295; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; LOWE G, 1989, P NATL ACAD SCI USA, V86, P5641, DOI 10.1073/pnas.86.14.5641; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SUZUKI N, 1978, COMP BIOCHEM PHYS A, V61, P461; SUZUKI N, 1989, CHEM SENSES, V1, P469; TUCKER D, 1965, COLD SPRING HARB SYM, V30, P207, DOI 10.1101/SQB.1965.030.01.023; YAMASHITA M, 1991, VISUAL NEUROSCI, V6, P399, DOI 10.1017/S0952523800006635; YOSHII K, 1983, BRAIN RES, V274, P239, DOI 10.1016/0006-8993(83)90701-1; ZUFALL F, 1991, J NEUROSCI, V11, P3573	33	264	266	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 6	1993	363	6424					71	74		10.1038/363071a0	http://dx.doi.org/10.1038/363071a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	7683113				2022-12-28	WOS:A1993LA68200061
J	PODRID, PJ				PODRID, PJ			AMIODARONE - REEVALUATION OF AN OLD DRUG	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE MYOCARDIAL-INFARCTION; SUSTAINED VENTRICULAR-TACHYCARDIA; CONGESTIVE-HEART-FAILURE; LONG-TERM AMIODARONE; CHRONIC ATRIAL-FIBRILLATION; PARKINSON-WHITE SYNDROME; PLACEBO-CONTROLLED TRIAL; LOW-DOSE AMIODARONE; 2-YEAR FOLLOW-UP; CARDIAC-ARRHYTHMIAS	Purpose: To review the pharmacology, electrophysiology, and toxicity of amiodarone and to discuss the clinical results produced when amiodarone is used as therapy for patients with atrial fibrillation, patients with nonsustained ventricular tachycardia and cardiomyopathy, patients who have recently had myocardial infarctions, and patients who have survived out-of-hospital cardiac arrest caused by ventricular tachycardia or ventricular fibrillation. Data Sources: Animal and clinical studies involving the pharmacology and electrophysiology of amiodarone and clinical trials in which amiodarone was used as therapy for the arrhythmias noted above were reviewed. Study Selection: Relevant studies that reported on the efficacy and toxicity of amiodarone and on longterm therapy using amiodarone were reviewed, and their data were summarized. Reports of ongoing trials using amiodarone were also reviewed and summarized. Results: Amiodarone is useful for the treatment of many rhythm disturbances. Although side effects from this agent are common, serious toxicity necessitating discontinuation of therapy is infrequent. Unlike other antiarrhythmic agents, amiodarone has not been shown to increase mortality in any population studied. Conclusion: Amiodarone, a unique antiarrhythmic agent with many pharmacologic actions, is effective in the treatment of a wide range of rhythm abnormalities. Several large, randomized trials will provide further information about the clinical usefulness of this agent.	BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA	Boston University								ADAMS PC, 1985, CIRCULATION, V72, P1064, DOI 10.1161/01.CIR.72.5.1064; ANDERSON KP, 1989, CIRCULATION, V79, P948, DOI 10.1161/01.CIR.79.4.948; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1993, Am J Cardiol, V72, P280; BALSER JR, 1991, CIRC RES, V69, P519, DOI 10.1161/01.RES.69.2.519; BIGGER JT, 1986, AM J CARDIOL, V58, P1151, DOI 10.1016/0002-9149(86)90374-7; BRODSKY MA, 1987, AM J CARDIOL, V60, P572, DOI 10.1016/0002-9149(87)90307-9; BROWN MA, 1986, EUR HEART J, V7, P234, DOI 10.1093/oxfordjournals.eurheartj.a062057; BURCKHARDT D, 1991, J CLIN PHARMACOL, V31, P1105, DOI 10.1002/j.1552-4604.1991.tb03679.x; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; CAIRNS JA, 1993, AM J CARDIOL, V72, pF87, DOI 10.1016/0002-9149(93)90969-J; CAIRNS JA, 1991, CIRCULATION, V84, P550, DOI 10.1161/01.CIR.84.2.550; CAMM AJ, 1993, AM J CARDIOL, V72, pF95, DOI 10.1016/0002-9149(93)90970-N; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; CHADDA K, 1986, CIRCULATION, V73, P503, DOI 10.1161/01.CIR.73.3.503; CHOUE CW, 1994, AM J CARDIOL, V73, P1075, DOI 10.1016/0002-9149(94)90286-0; CLELAND JGF, 1987, BRIT HEART J, V58, P572; CLELAND JGF, 1987, BRIT HEART J, V57, P436; CONNOLLY SJ, 1993, AM J CARDIOL, V72, pF103, DOI 10.1016/0002-9149(93)90972-F; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; CRIJNS HJ, 1991, AM J CARDIOL, V68, P335, DOI 10.1016/0002-9149(91)90828-9; DICARLO LA, 1985, AM J CARDIOL, V55, P372, DOI 10.1016/0002-9149(85)90378-9; DISCH DL, 1994, ANN INTERN MED, V120, P449, DOI 10.7326/0003-4819-120-6-199403150-00001; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; FANANAPAZIR L, 1991, AM J CARDIOL, V67, P169, DOI 10.1016/0002-9149(91)90440-V; FOGOROS RN, 1984, ANN INTERN MED, V100, P699, DOI 10.7326/0003-4819-100-5-699; FOGOROS RN, 1983, CIRCULATION, V68, P88, DOI 10.1161/01.CIR.68.1.88; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GARGUICHEVICH J, 1993, CICULATION S1, V88, P1; GOLD RL, 1986, AM J CARDIOL, V57, P124, DOI 10.1016/0002-9149(86)90964-1; GOSSELINK ATM, 1992, JAMA-J AM MED ASSOC, V267, P3289, DOI 10.1001/jama.267.24.3289; GRABOYS TB, 1983, AM HEART J, V106, P870, DOI 10.1016/0002-8703(83)90009-1; GRADMAN A, 1989, J AM COLL CARDIOL, V14, P564, DOI 10.1016/0735-1097(89)90093-4; GREENE HL, 1983, J AM COLL CARDIOL, V2, P1114, DOI 10.1016/S0735-1097(83)80338-6; GREENE HL, 1992, J AM COLL CARDIOL, V19, P894, DOI 10.1016/0735-1097(92)90267-Q; HAFFAJEE CI, 1983, AM HEART J, V106, P935, DOI 10.1016/0002-8703(83)90019-4; HAISSAGUERRE M, 1989, NEW ENGL J MED, V320, P426, DOI 10.1056/NEJM198902163200704; HAMER AWF, 1989, J AM COLL CARDIOL, V14, P1768, DOI 10.1016/0735-1097(89)90030-2; HANSEN JF, 1990, AM J CARDIOL, V66, P779; HEGER JJ, 1981, NEW ENGL J MED, V305, P539, DOI 10.1056/NEJM198109033051002; HEGER JJ, 1983, AM HEART J, V106, P887, DOI 10.1016/0002-8703(83)90012-1; HERRE JM, 1989, J AM COLL CARDIOL, V13, P442, DOI 10.1016/0735-1097(89)90525-1; HOLT DW, 1983, AM HEART J, V106, P840, DOI 10.1016/0002-8703(83)90006-6; HOROWITZ LN, 1983, AM HEART J, V106, P881, DOI 10.1016/0002-8703(83)90011-X; HOROWITZ LN, 1985, J AM COLL CARDIOL, V6, P1402, DOI 10.1016/S0735-1097(85)80232-1; HOROWITZ LN, 1985, AM J CARDIOL, V55, P367, DOI 10.1016/0002-9149(85)90377-7; Impact Research Group, 1984, J AM COLL CARDIOL, V4, P1148; INGRAM DV, 1983, AM HEART J, V106, P902, DOI 10.1016/0002-8703(83)90014-5; JACKMAN WM, 1991, NEW ENGL J MED, V324, P1605, DOI 10.1056/NEJM199106063242301; KADISH AH, 1987, J AM COLL CARDIOL, V10, P90, DOI 10.1016/S0735-1097(87)80165-1; KERIN NZ, 1988, CLIN CARDIOL, V11, P31; KIM SG, 1991, J AM COLL CARDIOL, V17, P1587, DOI 10.1016/0735-1097(91)90652-P; KLEIN LS, 1988, AM J CARDIOL, V61, P1024, DOI 10.1016/0002-9149(88)90119-1; KOWEY PR, 1993, CIRCULATION, V88, P396; KOWEY PR, 1988, CHEST, V93, P54, DOI 10.1378/chest.93.1.54; LEE MA, 1991, CIRCULATION, V83, P827, DOI 10.1161/01.CIR.83.3.827; MARCUS FI, 1983, AM HEART J, V106, P924, DOI 10.1016/0002-8703(83)90017-0; MARON BJ, 1981, AM J CARDIOL, V48, P252, DOI 10.1016/0002-9149(81)90604-4; MARTIN A, 1986, BRIT J CLIN PRACT, V40, P52; MARTIN WJ, 1988, CHEST, V93, P1067, DOI 10.1378/chest.93.5.1067; MASON JW, 1983, PFLUG ARCH EUR J PHY, V396, P79, DOI 10.1007/BF00584702; MCKENNA WJ, 1985, BRIT HEART J, V53, P412; MEINERTZ T, 1984, AM J CARDIOL, V53, P902, DOI 10.1016/0002-9149(84)90522-8; MEYER BJ, 1993, AM HEART J, V125, P996, DOI 10.1016/0002-8703(93)90106-J; MORADY F, 1989, CIRCULATION, V79, P1160, DOI 10.1161/01.CIR.79.6.1160; MORADY F, 1983, AM J CARDIOL, V51, P156, DOI 10.1016/S0002-9149(83)80027-7; MORADY F, 1983, AM J CARDIOL, V52, P975, DOI 10.1016/0002-9149(83)90515-5; MORGANROTH J, 1991, CIRCULATION, V84, P1977, DOI 10.1161/01.CIR.84.5.1977; MOSTOW ND, 1990, AM HEART J, V120, P1356, DOI 10.1016/0002-8703(90)90248-V; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; MYERS M, 1990, AM HEART J, V119, P8, DOI 10.1016/S0002-8703(05)80074-2; NADEMANEE K, 1983, AM HEART J, V106, P895, DOI 10.1016/0002-8703(83)90013-3; NADEMANEE K, 1986, AM J CARDIOL, V58, P981, DOI 10.1016/S0002-9149(86)80023-6; NAVARROLOPEZ F, 1993, AM J CARDIOL, V72, P1243, DOI 10.1016/0002-9149(93)90291-J; NERI R, 1987, AM HEART J, V113, P707, DOI 10.1016/0002-8703(87)90711-3; NEWMAN D, 1992, AM J CARDIOL, V69, P899, DOI 10.1016/0002-9149(92)90789-2; NICKLAS JM, 1991, AM HEART J, V122, P1016, DOI 10.1016/0002-8703(91)90466-U; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; PETER T, 1983, AM HEART J, V106, P943, DOI 10.1016/0002-8703(83)90020-0; PFISTERER M, 1992, AM J CARDIOL, V69, P1399, DOI 10.1016/0002-9149(92)90889-7; PFISTERER ME, 1993, CIRCULATION, V87, P309, DOI 10.1161/01.CIR.87.2.309; PICHLER WJ, 1988, AM J MED, V85, P197; PODRID PJ, 1981, AM HEART J, V101, P374, DOI 10.1016/0002-8703(81)90124-1; RAEDER EA, 1985, AM HEART J, V109, P975, DOI 10.1016/0002-8703(85)90238-8; RAVID S, 1989, J AM COLL CARDIOL, V14, P1326, DOI 10.1016/0735-1097(89)90436-1; ROSENBAUM MB, 1976, AM J CARDIOL, V38, P934, DOI 10.1016/0002-9149(76)90807-9; SANTINELLI V, 1984, AM J CARDIOL, V53, P1462, DOI 10.1016/S0002-9149(84)91293-1; SCHWARTZ A, 1983, AM HEART J, V106, P848, DOI 10.1016/0002-8703(83)90007-8; SCLAROVSKY S, 1983, AM HEART J, V105, P6, DOI 10.1016/0002-8703(83)90270-3; SIEBELS J, 1993, AM J CARDIOL, V72, pF109, DOI 10.1016/0002-9149(93)90973-G; SINGH BN, 1983, AM HEART J, V106, P788, DOI 10.1016/0002-8703(83)90002-9; SINGH BN, 1970, BRIT J PHARMACOL, V39, P657, DOI 10.1111/j.1476-5381.1970.tb09891.x; SINGH SN, 1993, AM J CARDIOL, V72, pF99, DOI 10.1016/0002-9149(93)90971-E; SINGH SN, 1994, CIRCULATION, V90, P546; SLATER W, 1988, AM J CARDIOL, V61, P349, DOI 10.1016/0002-9149(88)90943-5; SMITH WM, 1986, AM J CARDIOL, V57, P1288, DOI 10.1016/0002-9149(86)90206-7; SOBOL SM, 1982, CIRCULATION, V65, P819, DOI 10.1161/01.CIR.65.4.819; VELTRI EP, 1986, CIRCULATION, V74, P1054, DOI 10.1161/01.CIR.74.5.1054; VELTRI EP, 1985, J AM COLL CARDIOL, V6, P806, DOI 10.1016/S0735-1097(85)80487-3; VENKATESH N, 1986, J CARDIOVASC PHARM, V8, P989, DOI 10.1097/00005344-198609000-00016; VITOLO E, 1981, ACTA CARDIOL, V36, P431; WARD DE, 1980, BRIT HEART J, V44, P91; WELLENS HJJ, 1980, AM J CARDIOL, V46, P665, DOI 10.1016/0002-9149(80)90518-4; WILSON JS, 1991, AM HEART J, V121, P158, DOI 10.1016/0002-8703(91)90969-O; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0; YABEK SM, 1986, J CARDIOVASC PHARM, V8, P197, DOI 10.1097/00005344-198601000-00029; YEE HG, 1984, CIRCULATION S2, V20, P438; ZEHENDER M, 1992, J AM COLL CARDIOL, V19, P1054, DOI 10.1016/0735-1097(92)90294-W; ZEHENDER M, 1990, Journal of the American College of Cardiology, V15, p33A	109	175	181	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					689	700		10.7326/0003-4819-122-9-199505010-00008	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00008			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702232				2022-12-28	WOS:A1995QV15100008
J	FUNATSU, T; HARADA, Y; TOKUNAGA, M; SAITO, K; YANAGIDA, T				FUNATSU, T; HARADA, Y; TOKUNAGA, M; SAITO, K; YANAGIDA, T			IMAGING OF SINGLE FLUORESCENT MOLECULES AND INDIVIDUAL ATP TURNOVERS BY SINGLE MYOSIN MOLECULES IN AQUEOUS-SOLUTION	NATURE			English	Article							ACTIN-FILAMENTS; INVITRO; SUBFRAGMENT-1; MICROSCOPY; HYDROLYSIS; MOVEMENT	VISUALIZATION of single actin filaments by fluorescence microscopy(1) led to the development of new in vitro assays for analysing actomyosin-based motility at the molecular level(2-5). The ability to manipulate actin filaments with a microneedle(6,7) or an optical trap(8) combined with position-sensitive detectors has enabled direct measurements of nanometre displacements and piconewton forces exerted by individual myosin molecules. To elucidate how myosin generates movement, it is necessary to understand how ATP hydrolysis is coupled to mechanical work at the level of the single molecule. But the most sensitive microscopic ATPase assay available still requires over 1,000 myosin(9). To enhance the sensitivity of such assays, we have refined epifluorescence and total internal reflection microscopies to visualize single fluorescent dye molecules. We report here that this approach can be used directly to image single fluorescently labelled myosin molecules and detect individual ATP turnover reactions. In contrast to pre,viously reported single fluorescent molecule imaging methods, which used specimens immobilized on an air-dried surface(10-12), method allows video-rate imaging of single molecules in aqueous solution, and hence can be applied to the study of man types of enzymes and biomolecules.	OSAKA UNIV, DEPT BIOPHYS ENGN, TOYONAKA, OSAKA 560, JAPAN	Osaka University	FUNATSU, T (corresponding author), JRDC, ERATO, BIOMOTRON PROJECT, SENBA HIGASHI 2-4-14, MINO, OSAKA 562, JAPAN.		Funatsu, Takashi/Q-1404-2015; Yanagida, Toshio/D-1919-2009	Funatsu, Takashi/0000-0002-9656-8308; Tokunaga, Makio/0000-0003-4586-8922				AXELROD D, 1989, METHOD CELL BIOL, V30, P245; Bagshaw CR., 1993, MUSCLE CONTRACTION, DOI 10.1007/978-94-015-6839-5; BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HARADA Y, 1988, CELL MOTIL CYTOSKEL, V10, P71, DOI 10.1002/cm.970100112; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; ISHIKAWA M, 1994, JPN J APPL PHYS 1, V33, P1571, DOI 10.1143/JJAP.33.1571; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LINDBERG M, 1975, EUR J BIOCHEM, V53, P481, DOI 10.1111/j.1432-1033.1975.tb04089.x; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; SOUTHWICK PL, 1990, CYTOMETRY, V11, P418, DOI 10.1002/cyto.990110313; SOWERBY AJ, 1993, J MOL BIOL, V234, P114, DOI 10.1006/jmbi.1993.1567; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRAUTMAN JK, 1994, NATURE, V369, P40, DOI 10.1038/369040a0; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; YANAGIDA T, 1993, TRENDS BIOCHEM SCI, V18, P319, DOI 10.1016/0968-0004(93)90064-T	24	835	885	6	263	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	1995	374	6522					555	559		10.1038/374555a0	http://dx.doi.org/10.1038/374555a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700383				2022-12-28	WOS:A1995QR06900056
J	SCOTT, T; JACKSON, P				SCOTT, T; JACKSON, P			MANAGEMENT FOR DOCTORS - USING INFORMATION FOR MANAGING CLINICAL SERVICES EFFECTIVELY .13.	BRITISH MEDICAL JOURNAL			English	Article									HUDDERSFIELD ROYAL INFIRM,DEPT OBSTET & GYNAECOL,HUDDERSFIELD HD3 3EA,W YORKSHIRE,ENGLAND		SCOTT, T (corresponding author), BARNES HOSP,CHEADLE SK8 2NY,CHESHIRE,ENGLAND.							BERWICK DM, 1991, JAMA-J AM MED ASSOC, V266, P841, DOI 10.1001/jama.266.6.841; COULTER A, 1993, BRIT MED J, V306, P236, DOI 10.1136/bmj.306.6872.236; SCHERKENBACK WW, 1991, DEMING ROUTE QUALITY; 1990, SHORT CUUT BETTER SE	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 1	1995	310	6983					848	850		10.1136/bmj.310.6983.848	http://dx.doi.org/10.1136/bmj.310.6983.848			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711625	Green Published			2022-12-28	WOS:A1995QQ85700024
J	LINDSELL, CE; SHAWBER, CJ; BOULTER, J; WEINMASTER, G				LINDSELL, CE; SHAWBER, CJ; BOULTER, J; WEINMASTER, G			JAGGED - A MAMMALIAN LIGAND THAT ACTIVATES NOTCH1	CELL			English	Article							DROSOPHILA NEUROGENIC GENE; ACHAETE-SCUTE HOMOLOG; CELL FATE; TRANSMEMBRANE PROTEIN; SERRATE ENCODES; MOUSE NOTCH; EXPRESSION; DELTA; PATTERN; DIFFERENTIATION	Here we report the isolation of a rat cDNA clone, Jagged, which we show encodes a ligand for vertebrate Notch. Our conclusion is based on three observations. First, sequence analysis reveals substantial homology between Jagged and invertebrate ligands for the LIN-12/Notch proteins. Second, in situ hybridization of rat embryos identifies both distinct and overlapping patterns of gene expression for Jagged with those for Notch1, Notch2, and Notch3. Finally, the biological activity of Jagged was tested using a cell culture assay in which Jagged activates rat Notch1 expressed in myoblasts and prevents muscle cell differentiation. Our data support the hypothesis that Notch-ligand interactions function in maintaining mammalian cells in an undifferentiated state.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,LA JOLLA,CA 92037	University of California System; University of California Los Angeles; Salk Institute	LINDSELL, CE (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031885, R37NS031885] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31885-01] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1984, DEV RAT SPINAL CORD; ARTAVANISTSAKON.S, 1991, TRENDS GENET, V7, P403; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BATE M, 1993, DEVELOPMENT S, V119, P149; BIERKAMP C, 1993, MECH DEVELOP, V43, P87, DOI 10.1016/0925-4773(93)90027-U; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; CUOSO JP, 1994, CELL, V79, P259; DELAMO FF, 1992, DEVELOPMENT, V115, P737; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; GHUYSEN A, 1993, GENE DEV, V7, P723; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KOPAN R, 1993, J CELL BIOL, V121, P631, DOI 10.1083/jcb.121.3.631; KOPAN R, 1994, DEVELOPMENT, V120, P2385; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Muskavitch M.A.T., 1990, Current Topics in Developmental Biology, V24, P289, DOI 10.1016/S0070-2153(08)60091-5; NORNES HO, 1974, BRAIN RES, V73, P121, DOI 10.1016/0006-8993(74)91011-7; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHERSON T, 1993, DEVELOPMENT, V118, P1049; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; THOMAS U, 1991, DEVELOPMENT, V111, P749; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	43	546	583	0	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					909	917		10.1016/0092-8674(95)90294-5	http://dx.doi.org/10.1016/0092-8674(95)90294-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697721	Bronze			2022-12-28	WOS:A1995QP61200010
J	AKIL, M; AMOS, RS				AKIL, M; AMOS, RS			ABC OF RHEUMATOLOGY - RHEUMATOID-ARTHRITIS .2. TREATMENT	BRITISH MEDICAL JOURNAL			English	Article											AKIL, M (corresponding author), NETHER EDGE HOSP,SHEFFIELD CTR RHEUMAT DIS,SHEFFIELD,S YORKSHIRE,ENGLAND.								0	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					652	655		10.1136/bmj.310.6980.652	http://dx.doi.org/10.1136/bmj.310.6980.652			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703756	Green Published			2022-12-28	WOS:A1995QL98400025
J	PIATON, E; GRILLETRAVIGNEAUX, MH; SAUGIER, B; PELLET, H				PIATON, E; GRILLETRAVIGNEAUX, MH; SAUGIER, B; PELLET, H			PROSPECTIVE-STUDY OF COMBINED USE OF BRONCHIAL ASPIRATES AND BIOPSY SPECIMENS IN DIAGNOSIS AND TYPING OF CENTRALLY LOCATED LUNG-TUMORS	BRITISH MEDICAL JOURNAL			English	Article							CANCER; CARCINOMA	Objective-To determine the diagnostic accuracy of examining bronchial secretions in pulmonary cytopathology and whether cytology and histopathology can complement each other in routine practice among lung specialists. Design-A prospective study comparing 1225 cytological and biopsy results, conducted during 1987-93. Tumours were confirmed by histopathology, imaging techniques, or clinical outcome and imaging techniques combined. Setting-11 lung or internal medicine units, France. Subjects-1128 patients (874 men; 254 women) aged 65.3 (SD 13.7) years who underwent fibreoptic bronchoscopy for various pulmonary symptoms. Results-Exact concordance between cytological and biopsy results was obtained in 1036/1187 (87.3%) satisfactory specimens. In all 574 lung tumours were diagnosed. One case (0.08%) was a false positive cytological diagnosis in a patient with tuberculosis. Patients with lung cancer were more likely to have positive cytological results than positive biopsy results than positive biopsy results (P < 0.001). Agreement in tumour typing was observed in 375/424 (88.4%) cases, when non-small cell carcinomas, small cell carcinomas and undifferentiated carcinomas were separated. In the 11 patients with squamous cell carcinomas in situ, eight (72.7%) of the carcinomas were diagnosed cytologically as squamous cell. Unsatisfactory material was obtained in only 20 (1.6%) and 19 (1.6%) cases by cytology and biopsy respectively. Examinations had to be repeated in 86 (7.6%) patients. Conclusions-Examination of bronchial secretions complements histopathology in both diagnosing and typing lung tumours and could be performed more systematically in patients undergoing fibreoptic bronchoscopy.	LYON GRANGE BLANCHE MED FAC,CLIN CYTOPATHOL LAB,F-69373 LYON,FRANCE; GEN HOSP,INTERNAL MED UNIT,F-39016 LONS LE SAUNIER,FRANCE									ATAY Z, 1975, DEUT MED WOCHENSCHR, V100, P1269, DOI 10.1055/s-0028-1106369; DIBONITO L, 1991, DIAGN CYTOPATHOL, V7, P7, DOI 10.1002/dc.2840070104; FOOT NC, 1952, AM J PATHOL, V28, P963; FUSHIMI H, 1992, CANCER, V70, P599, DOI 10.1002/1097-0142(19920801)70:3<599::AID-CNCR2820700310>3.0.CO;2-9; Johnston ww, 1991, COMPREHENSIVE CYTOPA, P320; KHAJOTIA RR, 1991, LANCET, V338, P976, DOI 10.1016/0140-6736(91)91839-M; KOSS LG, 1964, ACTA CYTOL, V8, P104; KREYBERG L, 1981, INT HISTOLOGICAL CLA; LANGE E, 1972, ACTA CYTOL, V16, P327; MOURIQUAND J, 1981, STAIN TECHNOL, V56, P215, DOI 10.3109/10520298109067314; NAGAMOTO N, 1993, AM J SURG PATHOL, V17, P1234, DOI 10.1097/00000478-199312000-00004; PAYNE CR, 1979, THORAX, V34, P294, DOI 10.1136/thx.34.3.294; PIATON E, 1994, J CLIN PATHOL, V47, P447; SHOPLAND DR, 1991, JNCI-J NATL CANCER I, V83, P1142, DOI 10.1093/jnci/83.16.1142; TAFT PD, 1980, AM J CLIN PATHOL, V73, P36; TRUONG LD, 1985, ACTA CYTOL, V29, P379; YOUNG JA, 1993, J CLIN PATHOL, V46, P589, DOI 10.1136/jcp.46.7.589; ZUSMANHARACH SB, 1991, J CLIN PATHOL, V44, P997, DOI 10.1136/jcp.44.12.997	18	16	16	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					624	627		10.1136/bmj.310.6980.624	http://dx.doi.org/10.1136/bmj.310.6980.624			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703748	Green Published			2022-12-28	WOS:A1995QL98400014
J	SOUSA, R; CHUNG, YJ; ROSE, JP; WANG, BC				SOUSA, R; CHUNG, YJ; ROSE, JP; WANG, BC			CRYSTAL-STRUCTURE OF BACTERIOPHAGE-T7 RNA-POLYMERASE AT 3.3-ANGSTROM RESOLUTION	NATURE			English	Article							RIBONUCLEIC-ACID POLYMERASE; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; NUCLEOTIDE-SEQUENCE; BINDING-SITE; TRANSCRIPTION; IDENTIFICATION; DNA; INITIATION; PROMOTER	The crystal structure of T7 RNA polymerase reveals a molecule organized around a cleft that can accommodate a double-stranded DNA template. A portion (approximately 45%) of the molecule displays extensive structural homology to the polymerase domain of Klenow fragment and more limited homology to the human immunodeficiency virus HIV-1 reverse transcriptase. A comparison of the structures and sequences of these polymerases identifies structural elements that may be responsible for discriminating between ribonucleotide and deoxyribonucleotide substrates, and RNA and DNA templates. The relative locations of the catalytic site and a specific promoter recognition residue allow the orientation of the polymerase on the template to be defined.	UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260; UNIV PITTSBURGH,DEPT CRYSTALLOG,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Sousa, Rui/0000-0003-4314-121X				BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BASU A, 1989, J BIOL CHEM, V264, P8746; BASU S, 1986, J MOL BIOL, V190, P425, DOI 10.1016/0022-2836(86)90013-6; BESSE LS, 1993, SCIENCE, V260, P352; BONNER G, 1992, EMBO J, V11, P3767, DOI 10.1002/j.1460-2075.1992.tb05462.x; BURGESS RR, 1969, J BIOL CHEM, V244, P425; BUTLER ET, 1982, J BIOL CHEM, V257, P5772; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CARTER AD, 1981, J MOL BIOL, V153, P825, DOI 10.1016/0022-2836(81)90421-6; CHAMBERL.M, 1970, NATURE, V228, P227, DOI 10.1038/228227a0; CHUNG YJ, 1990, STRUCTURE AND FUNCTION OF NUCLEIC ACIDS AND PROTEINS, P55; CHUNG YJ, 1990, GENE REGULATION AIDS, P3; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DELARUE M, 1990, J PROTEIN ENG, V10, P461; DUNN JJ, 1988, GENE, V68, P259, DOI 10.1016/0378-1119(88)90028-5; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FREEMONT P S, 1986, Proteins Structure Function and Genetics, V1, P66, DOI 10.1002/prot.340010111; GROSS L, 1992, J MOL BIOL, V228, P488, DOI 10.1016/0022-2836(92)90837-A; HANSEN UM, 1980, J BIOL CHEM, V255, P3548; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JENG ST, 1990, J BIOL CHEM, V265, P3823; JOHO KE, 1990, J MOL BIOL, V215, P21; KOHLSTADT LA, 1992, SCIENCE, V258, P1783; KOTANI H, 1987, NUCLEIC ACIDS RES, V15, P2653, DOI 10.1093/nar/15.6.2653; KRUMMEL B, 1989, J BIOCH, V28, P7828; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; OLLIS DL, 1985, NATURE, V313, P765; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; PANDEY VN, 1990, J BIOL CHEM, V265, P3679; PANDEY VN, 1988, J BIOL CHEM, V263, P6068; PATRA D, 1992, J MOL BIOL, V224, P307, DOI 10.1016/0022-2836(92)90996-W; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; RESKIN CA, 1993, J MOL BIOL, V226, P506; RICCHETTI M, 1993, EMBO J, V12, P387, DOI 10.1002/j.1460-2075.1993.tb05670.x; ROSA MD, 1979, CELL, V16, P815, DOI 10.1016/0092-8674(79)90097-7; RUSH J, 1990, J BIOL CHEM, V265, P4821; SANKAR S, 1992, J BIOL CHEM, V267, P10169; SCHINKEL AH, 1989, TRENDS GENET, V5, P149, DOI 10.1016/0168-9525(89)90056-5; SHI Y, 1988, J BIOL CHEM, V363, P527; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; SOUSA R, 1989, PROTEINS, V5, P266, DOI 10.1002/prot.340050403; SOUSA R, 1990, Methods (Orlando), V1, P50, DOI 10.1016/S1046-2023(05)80146-X; SOUSA R, 1991, J CRYST GROWTH, V118, P237; STROTHKAMP RE, 1980, BIOCHEMISTRY-US, V19, P1074, DOI 10.1021/bi00547a005; WONG BC, 1985, METHOD ENZYMOL, V115, P890; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	53	351	364	2	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					593	599		10.1038/364593a0	http://dx.doi.org/10.1038/364593a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	7688864				2022-12-28	WOS:A1993LR77100042
J	BOOKER, GW; GOUT, I; DOWNING, AK; DRISCOLL, PC; BOYD, J; WATERFIELD, MD; CAMPBELL, ID				BOOKER, GW; GOUT, I; DOWNING, AK; DRISCOLL, PC; BOYD, J; WATERFIELD, MD; CAMPBELL, ID			SOLUTION STRUCTURE AND LIGAND-BINDING SITE OF THE SH3 DOMAIN OF THE P85-ALPHA SUBUNIT OF PHOSPHATIDYLINOSITOL 3-KINASE	CELL			English	Article							HETERONUCLEAR NMR-SPECTROSCOPY; SIGNAL TRANSDUCTION; TYROSINE KINASE; MESSENGER-RNA; PROTEINS; CLONING; SRC; SIMILARITY; RESONANCE; DYNAMICS	SH3 domains are found in proteins associated with receptor tyrosine kinase signal transduction complexes. The solution structure of the SH3 domain of the 85 kd regulatory subunit of phosphatidylinositol 3-kinase is shown to be a compact beta barrel consisting of five beta strands arranged in two beta sheets of three and two strands. The structure is similar to that of chicken brain alpha spectrin but represents a distinct class of SH3 domain, with an insertion between the second and third beta strands that may influence binding specificity. H-1 chemical shift changes induced by complex formation with a synthetic peptide derived from the SH3-binding protein dynamin, together with amino acid sequence comparisons, suggest that the ligand-binding site consists of a hydrophobic surface flanked by two charged loops.	LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,LONDON WC1E 6BT,ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London	BOOKER, GW (corresponding author), UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND.		Driscoll, Paul C/B-8007-2010	Driscoll, Paul C/0000-0002-4124-6950				BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1990, XPLOR V2 1 MANUAL; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICHETTI P, 1992, SCIENCE, V257, P803; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DOWNING AK, 1992, J MOL BIOL, V225, P821, DOI 10.1016/0022-2836(92)90403-7; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P3542, DOI 10.1021/bi00466a018; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; KAETO JY, 1986, MOL CELL BIOL, V12, P4155; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LASKOWSKI RA, 1993, IN PRESS J APPL CRYS, V26; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; MAETHEWS DA, 1986, BIOCHEMISTRY-US, V25, P4194; Maniatis T., 1982, MOL CLONING; MANO H, 1990, ONCOGENE, V5, P1781; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MURZIN AG, 1992, NATURE, V360, P635, DOI 10.1038/360635a0; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILGES M, 1991, COMPUTATIONAL ASPECT, P451; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; WUTHRICH K, 1991, FEBS LETT, V285, P237, DOI 10.1016/0014-5793(91)80808-G; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	48	193	200	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 21	1993	73	4					813	822		10.1016/0092-8674(93)90259-S	http://dx.doi.org/10.1016/0092-8674(93)90259-S			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	7684655				2022-12-28	WOS:A1993LD83000018
J	WAKSMAN, G; SHOELSON, SE; PANT, N; COWBURN, D; KURIYAN, J				WAKSMAN, G; SHOELSON, SE; PANT, N; COWBURN, D; KURIYAN, J			BINDING OF A HIGH-AFFINITY PHOSPHOTYROSYL PEPTIDE TO THE SRC SH2 DOMAIN - CRYSTAL-STRUCTURES OF THE COMPLEXED AND PEPTIDE-FREE FORMS	CELL			English	Article							SIGNAL TRANSDUCTION; PROTEIN; REFINEMENT	The crystal structure of the Src SH2 domain complexed with a high affinity 11-residue phosphopeptide has been determined at 2.7 angstrom resolution by X-ray diffraction. The peptide binds in an extended conformation and makes primary interactions with the SH2 domain at six central residues: PQ(pY)EEI. The phosphotyrosine and the isoleucine are tightly bound by two well-defined pockets on the protein surface, resulting in a complex that resembles a two-pronged plug engaging a two-holed socket. The glutamate residues are in solvent-exposed environments in the vicinity of basic side chains of the SH2 domain, and the two N-terminal residues cap the phosphotyrosine-binding site. The crystal structure of Src SH2 in the absence of peptide has been determined at 2.5 angstrom resolution, and comparison with the structure of the high affinity complex reveals only localized and relatively small changes.	HOWARD HUGHES MED INST,NEW YORK,NY 10021; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02115	Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.	WAKSMAN, G (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.		Cowburn, David/A-8448-2008	Cowburn, David/0000-0001-6770-7172				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1988, XPLOR VERSION 2 2 MA; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; ECK M, 1993, IN PRESS; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, IN PRESS MOL CELL BI; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIU X, 1993, IN PRESS ONCOGENE; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OVERDUIN M, 1992, P NATL ACAD SCI USA, V89, P11673, DOI 10.1073/pnas.89.24.11673; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYNE G, IN PRESS; PAYNE G, 1993, IN PRESS P NATL ACAD; PICCIONE E, 1993, IN PRESS BIOCHEMISTR; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; ROSSMANN MG, 1972, INT SCI REV SERIES, V13; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHOELSON SE, 1993, IN PRESS EMBO J, V6; SONGYANG Z, 1993, CELL, V72; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WILLIAMS KP, 1993, IN PRESS J BIOL CHEM; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	45	699	726	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					779	790		10.1016/0092-8674(93)90405-F	http://dx.doi.org/10.1016/0092-8674(93)90405-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	7680960				2022-12-28	WOS:A1993KR43600013
J	LINDSLEY, JE; WANG, JC				LINDSLEY, JE; WANG, JC			STUDY OF ALLOSTERIC COMMUNICATION BETWEEN PROTOMERS BY IMMUNOTAGGING	NATURE			English	Article							TOPOISOMERASE-II; TRANSITION; DNA	LIGAND-INDUCED allosteric changes in proteins are important in their cellular functions and regulation1,2, and both concerted and sequential examples are known3-5. The distinction has entailed elaborate analysis, however, and only a few systems have been unequivocally analysed. We have investigated the coupling between ATP usage and DNA transport by type II DNA topoisomerases6,7, and one key question concerning allostery in these dyadic enzymes is whether ATP binding to one protomer can induce a concerted conformational change in the entire enzyme. Here we use an enzyme with one immunotagged subunit defective in ATP binding and one wild-type subunit to show that it can. Our approach should be generally applicable in the study of allostery and communication between members of a macromolecular assembly.			LINDSLEY, JE (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							DEPEW RE, 1978, J BIOL CHEM, V253, P511; FERSHT A, 1984, ENZYME STRUCTURE MEC, P263; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SCHACHMAN HK, 1988, J BIOL CHEM, V263, P18583	9	61	62	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					749	750		10.1038/361749a0	http://dx.doi.org/10.1038/361749a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	7680110				2022-12-28	WOS:A1993KN78900064
J	OBERTI, F; RUGET, O; CALES, P; CARONPOITREAU, C; TRINCHET, JC; ABOURACHED, A; AJAVON, Y; BEAUGRAND, M; DUMAS, F; COUZIGOU, P; DROUILLARD, J; BALABAUD, C; GRELET, P; GUEBEL, A; MELANGE, M; PRINGOT, J; VANBEERS, B; HADENGUE, A; VILGRAIN, V; ERLINGER, S; DUVOUX, C; MATHIEU, D; DHUMEAUX, D; ZARSKI, JP; DALSOGLIO, S; MION, F; VALETTE, PJ; PALIARD, P; CLAUDELBONVOISIN, S; EMERY, JC; DESCOS, L; DAGENAIS, M; DUFRESNE, MP; LAPOINTE, R; HUET, PM; BAS, V; REGENT, D; BAZIN, C; BIGARD, MA; HUMEAU, B; BURY, A; LERHUN, M; LERAT, F; GIBAUD, H; RYMER, R; LEBODIC, L; MASLIAH, C; POULIQUEN, B; PERRIN, D; CHASTANG, C; CHAZOUILLERES, O; LORIA, A; POUPON, R; PAUWELS, A; MOSTEFAKARA, N; LEVY, VG; BALLADUR, P; DEUTSCH, JP; TUBIANA, JM; POL, S; BERTHELOT, P; VALLA, D; BOUSQUET, JC; OPOLON, P; BOUVRY, M; LABADIE, H; MARTIN, T; BRONOWICKI, JP; VETTER, D; WENGER, JJ; BUSCAIL, L; FREXINOS, J; JOFFRE, F				OBERTI, F; RUGET, O; CALES, P; CARONPOITREAU, C; TRINCHET, JC; ABOURACHED, A; AJAVON, Y; BEAUGRAND, M; DUMAS, F; COUZIGOU, P; DROUILLARD, J; BALABAUD, C; GRELET, P; GUEBEL, A; MELANGE, M; PRINGOT, J; VANBEERS, B; HADENGUE, A; VILGRAIN, V; ERLINGER, S; DUVOUX, C; MATHIEU, D; DHUMEAUX, D; ZARSKI, JP; DALSOGLIO, S; MION, F; VALETTE, PJ; PALIARD, P; CLAUDELBONVOISIN, S; EMERY, JC; DESCOS, L; DAGENAIS, M; DUFRESNE, MP; LAPOINTE, R; HUET, PM; BAS, V; REGENT, D; BAZIN, C; BIGARD, MA; HUMEAU, B; BURY, A; LERHUN, M; LERAT, F; GIBAUD, H; RYMER, R; LEBODIC, L; MASLIAH, C; POULIQUEN, B; PERRIN, D; CHASTANG, C; CHAZOUILLERES, O; LORIA, A; POUPON, R; PAUWELS, A; MOSTEFAKARA, N; LEVY, VG; BALLADUR, P; DEUTSCH, JP; TUBIANA, JM; POL, S; BERTHELOT, P; VALLA, D; BOUSQUET, JC; OPOLON, P; BOUVRY, M; LABADIE, H; MARTIN, T; BRONOWICKI, JP; VETTER, D; WENGER, JJ; BUSCAIL, L; FREXINOS, J; JOFFRE, F			COMPARISON OF LIPIODOL CHEMOEMBOLIZATION AND CONSERVATIVE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSCATHETER ARTERIAL EMBOLIZATION; PROGNOSTIC FACTORS; ETHIODIZED OIL; MULTIVARIATE-ANALYSIS; NATURAL-HISTORY; GELATIN SPONGE; CISPLATIN; THERAPY; LIVER; EXPERIENCE	Background. Chemoembolization with Lipiodol (iodized oil) is widely used to treat patients with unresectable hepatocellular carcinoma, Severe side effects have been reported, and improved survival has not been clearly demonstrated. Methods. Patients with unresectable hepatocellular carcinoma who did not have severe liver disease and who met additional entry criteria were randomly assigned to receive either Lipiodol chemoembolization (70 mg of cisplatin, 10 ml of Lipiodol, and gelatin-sponge [Gelfoam] particles delivered through the hepatic artery) or conservative management involving treatment of complications and pain, Courses of treatment were to be given every two months for a maximum of four courses, The main end point was survival. Results. The study was stopped in December 1992, after a sequential analysis showed the lack of the expected benefit from chemoembolization. As of October 1, 1994, 39 of the 50 patients assigned to chemoembolization and 40 of the 46 patients assigned to conservative management had died. Twenty-six patients assigned to chemoembolization received all four courses of treatment. There was no significant difference in survival between the two groups, although there was a trend favoring the chemoembolization group (estimated relative risk of death in the control group, 1.4, 95 percent confidence interval, 0.9 to 2.2; P = 0.13). The comparison of survival between the two groups was not substantially changed by adjustments for differences in base-line and prognostic characteristics (adjusted relative risk, 1.3; 95 percent confidence interval, 0.8 to 2.1; P = 0.31). At one year, the estimated survival rates were 62 percent in the chemoembolization group (95 percent confidence interval, 48.6 to 75.4 percent) and 43.5 percent in the conservative-management group (95 percent confidence interval, 29.2 to 57.8 percent). In the chemoembolization group, tumor growth, as assessed by tumor size and serum alpha-fetoprotein concentration, was reduced and the incidence of portal obstruction was lower than in the conservative-management group. Liver failure occurred after 47 courses of treatment in 30 patients assigned to chemoembolization. Conclusions. In a group of patients with unresectable hepatocellular carcinoma but without severe liver disease, Lipiodol chemoembolization reduced tumor growth, often caused acute liver failure, and did not significantly improve survival.	CHU ANGERS,ANGERS,FRANCE; HOP HAUT LEVEQUE,PESSAC,FRANCE; HOP ST ANDRE,BORDEAUX,FRANCE; HOP ST LUC,BRUSSELS,BELGIUM; CLIN UNIV MT GODINNE,BRUSSELS,BELGIUM; HOP BEAUJON,CLICHY,FRANCE; HOP HENRI MONDOR,F-94010 CRETEIL,FRANCE; HOP ALBERT MICHALLON,GRENOBLE,FRANCE; HOP EDOUARD HERRIOT,LYON,FRANCE; CTR HOSP LYON SUD,F-69310 PIERRE BENITE,FRANCE; HOP ST LUC,MONTREAL,PQ H2X 1P1,CANADA; CHU VANDOEUVRE LES NANCY,VANDOEUVRE NANCY,FRANCE; HOP GUILLAUME & RENEE LAENNEC,NANTES,FRANCE; HOP HOTEL DIEU,NANTES,FRANCE; HOP ST LOUIS,PARIS,FRANCE; HOP ST ANTOINE,F-75571 PARIS,FRANCE; HOP NECKER ENFANTS MALAD,PARIS,FRANCE; HOP LA PITIE SALPETRIERE,PARIS,FRANCE; CTR HOSP PONTOISE,PONTOISE,FRANCE; CTR HOSP DELAFONTAINE,ST DENIS,FRANCE; CHU STRASBOURG,F-67000 STRASBOURG,FRANCE; CTR HOSP GEN ST NAZAIRE,ST NAZAIRE,FRANCE; CLIN ORANGERIE,STRASBOURG,FRANCE; CHU TOULOUSE,TOULOUSE,FRANCE	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Bordeaux; CHU Bordeaux; Universite Catholique Louvain; Universite Catholique Louvain Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHU Grenoble Alpes; CHU Lyon; CHU Lyon; Universite de Montreal; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre Hospitalier Rene Dubos, Pontoise; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU de Toulouse	OBERTI, F (corresponding author), HOP JEAN VERDIER,SERV HEPATOGASTROENTEROL,AVE 14 JUILLET,F-93143 BONDY,FRANCE.		Duvoux, Christophe/CAF-3432-2022; Van Beers, Bernard/N-2816-2016	Van Beers, Bernard/0000-0001-6429-1140				AKASHI Y, 1991, HEPATOLOGY, V14, P262, DOI 10.1016/0270-9139(91)91413-U; [Anonymous], 1992, DESIGN ANAL SEQUENTI; AOYAMA K, 1992, CANCER CHEMOTH PHARM, V31, pS55, DOI 10.1007/BF00687106; ATTALI P, 1987, CANCER, V59, P2108, DOI 10.1002/1097-0142(19870615)59:12<2108::AID-CNCR2820591225>3.0.CO;2-3; BISMUTH H, 1992, AM J SURG, V163, P387, DOI 10.1016/0002-9610(92)90039-T; BRUIX J, 1994, HEPATOLOGY, V20, P643, DOI 10.1002/hep.1840200315; CALVET X, 1990, J HEPATOL, V10, P311, DOI 10.1016/0168-8278(90)90138-H; CALVET X, 1990, HEPATOLOGY, V12, P753, DOI 10.1002/hep.1840120422; COLOMBO M, 1993, SEMIN LIVER DIS, V13, P374; COX DR, 1972, J R STAT SOC B, V34, P187; DUSHEIKO GM, 1992, LANCET, V340, P285, DOI 10.1016/0140-6736(92)92367-O; ENSMINGER WD, 1984, CANCER TREAT REP, V68, P101; IMAOKA S, 1989, CANCER CHEMOTH PHARM, V23, pS126, DOI 10.1007/BF00647258; KAN ZX, 1993, RADIOLOGY, V186, P861, DOI 10.1148/radiology.186.3.8381552; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASUGAI H, 1989, GASTROENTEROLOGY, V97, P965, DOI 10.1016/0016-5085(89)91505-9; KHAN KN, 1991, CANCER RES, V51, P5667; Liver Cancer Study Group of Japan, 1990, Ann Surg, V211, P277; MATSUI O, 1991, RADIOLOGY, V178, P493, DOI 10.1148/radiology.178.2.1846240; MATSUI O, 1994, CANCER CHEMOTH PHARM, V33, pS84, DOI 10.1007/BF00686674; MIYOSHI S, 1988, J HEPATOL, V6, P332, DOI 10.1016/S0168-8278(88)80050-3; NAKAMURA H, 1983, RADIOLOGY, V147, P401, DOI 10.1148/radiology.147.2.6300959; NAKAMURA H, 1989, RADIOLOGY, V170, P783, DOI 10.1148/radiology.170.3.2536946; NAKAMURA H, 1994, CANCER CHEMOTH PHARM, V33, pS89, DOI 10.1007/BF00686675; NAKAO N, 1992, CANCER CHEMOTH PHARM, V31, pS72, DOI 10.1007/BF00687110; OHNISHI K, 1987, HEPATOLOGY, V7, P1285, DOI 10.1002/hep.1840070618; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; PELLETIER G, 1990, J HEPATOL, V11, P181, DOI 10.1016/0168-8278(90)90110-D; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; RAOUL JL, 1988, RADIOLOGY, V168, P541, DOI 10.1148/radiology.168.2.2839866; SASAKI Y, 1987, CANCER, V60, P1194, DOI 10.1002/1097-0142(19870915)60:6<1194::AID-CNCR2820600607>3.0.CO;2-T; STUART K, 1993, CANCER, V72, P3202, DOI 10.1002/1097-0142(19931201)72:11<3202::AID-CNCR2820721112>3.0.CO;2-4; VENOOK AP, 1990, J CLIN ONCOL, V8, P1108, DOI 10.1200/JCO.1990.8.6.1108; VETTER D, 1991, HEPATOLOGY, V13, P427, DOI 10.1002/hep.1840130308; YAMASHITA Y, 1991, CANCER, V67, P385, DOI 10.1002/1097-0142(19910115)67:2<385::AID-CNCR2820670212>3.0.CO;2-Q; YODONO H, 1989, CANCER CHEMOTH PHARM, V23, pS42, DOI 10.1007/BF00647238; YU YQ, 1993, CANCER, V71, P62, DOI 10.1002/1097-0142(19930101)71:1<62::AID-CNCR2820710111>3.0.CO;2-8	37	684	688	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 11	1995	332	19					1256	1261						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW600	7708069				2022-12-28	WOS:A1995QW60000003
J	EPSTEIN, AM				EPSTEIN, AM			US TEACHING HOSPITALS IN THE EVOLVING HEALTH-CARE SYSTEM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN; REFORM		BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED, HLTH SERV & POLICY RES SECT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	EPSTEIN, AM (corresponding author), HARVARD UNIV, SCH MED, DEPT HLTH CARE POLICY, 25 SHATTUCK ST, 1ST FLOOR, BOSTON, MA 02115 USA.							ANDERS G, 1994, WALL STREET J   0819; ANDERSON GF, 1978, HLTH POLICY, V7, P3; BLUMENTHAL D, 1993, NEW ENGL J MED, V329, P1812, DOI 10.1056/NEJM199312093292413; BROWN JG, 1994, STUDY GRADUATE MED E; COHEN JJ, 1994, JAMA-J AM MED ASSOC, V272, P712, DOI 10.1001/jama.272.9.712; DAVIS K, 1990, HLTH CARE COST CONTA; DOBSON A, 1994, ANAL TEACHING HOSPIT; FOREMAN S, 1994, COMMUNICATION   0414; FOX PD, 1993, HEALTH AFFAIR, V12, P85, DOI 10.1377/hlthaff.12.1.85; HOY EW, 1991, HLTH AFFAIRS     WIN, P18, DOI DOI 10.1377/HLTHAFF.25.6.1568; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; LUTZ S, 1993, MODERN HEALTHCARE, V23, P28; REINHARDT UE, 1994, INQUIRY-J HEALTH CAR, V31, P250; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; SCHROEDER SA, 1993, NEW ENGL J MED, V328, P961, DOI 10.1056/NEJM199304013281312; SCHROEDER SA, 1994, INQUIRY, V28, P266; SHORTELL S, IN PRESS MILBANK Q; SHORTELL SM, 1993, HOSP HEALTH SERV ADM, V38, P447; THORPE KE, 1988, HEALTH SERV RES, V22, P821; Weinber JP, 1994, JAMA-J AM MED ASSOC, V272, P222; Weissman JS., 1994, FALLING SAFETY NET I; 1994, ANN REPORT C 1994; 1994, MEDICARE AM HLTH CAR; 1993, GAOHRD9346 US GEN AC; 1992, MEDICARE AM HLTH CAR; 1992, 3RD REPORT IMPROVING; 1994, MED AM HLTH CARE SYS; 1994, PATTERNS HMO ENROLLM	28	60	62	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1203	1207		10.1001/jama.273.15.1203	http://dx.doi.org/10.1001/jama.273.15.1203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT100	7707628				2022-12-28	WOS:A1995QT10000029
J	TAPPERO, JW; SCHUCHAT, A; DEAVER, KA; MASCOLA, L; WENGER, JD				TAPPERO, JW; SCHUCHAT, A; DEAVER, KA; MASCOLA, L; WENGER, JD			REDUCTION IN THE INCIDENCE OF HUMAN LISTERIOSIS IN THE UNITED-STATES - EFFECTIVENESS OF PREVENTION EFFORTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPORADIC LISTERIOSIS; EPIDEMIC LISTERIOSIS; FOODS; MONOCYTOGENES; ASSOCIATION	Background.-Food-borne transmission is now recognized as a major cause of human listeriosis. Objective.-To assess the impact of prevention efforts, listeriosis rates before interventions were initiated in 1989 were compared with more recent rates (1990 through 1993). Design.-From 1989 through 1993, multistate, laboratory-based active surveillance was conducted to identify all cases in which Listeria monocytogenes was isolated from cultures or ordinarily sterile sites in an aggregate population of more than 19 million. Setting.-All laboratories serving acute care hospitals in up to nine surveillance areas in the United States. Interventions.-In 1989, a well-publicized case report of listeriosis linked to processed poultry led US regulatory agencies to enforce aggressive food monitoring policies and prompted industry to invest in cleanup efforts. In May 1992, consumer guidelines for listeriosis prevention were disseminated. Outcome Measures.-Cases of perinatal and nonperinatal listeriosis. Results.-The rate of listeriosis decreased in all surveillance areas. Projection of these rates to the US population suggests an estimated 1965 cases and 481 deaths occurred in 1989 compared with an estimated 1092 cases and 248 deaths in 1993, a 44% and 48% reduction in illness and death, respectively. Among adults 50 years of age and older, rates declined from 16.2 per 1 million in 1989 to 10.2 per 1 million in 1993 (P=.02). Perinatal disease decreased from 17.4 cases per 100 000 births in 1989 to 8.6 cases per 100 000 births in 1993 (P=.003). Three serotypes (1/2a, 1/2b, and 4b) of L monocytogenes accounted for more than 96% of cases during each year of the study (1989 through 1993). Conclusions. The incidence of listeriosis in study areas was substantially lower in 1993 than in 1989. The temporal association of this reduction with industry, regulatory, and educational efforts suggests these measures were effective.	LOS ANGELES CTY DEPT HLTH SERV, PUBL HLTH PROGRAMS & SERV, LOS ANGELES, CA USA		TAPPERO, JW (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, CHILDHOOD & RESP DIS BRANCH, ATLANTA, GA 30333 USA.				FDA HHS [FDA 224-88-2456] Funding Source: Medline	FDA HHS		ARCHER D L, 1988, Clinical Microbiology Reviews, V1, P377; Bernard D., 1994, Dairy, Food and Environmental Sanitation, V14, P140; BILLE J, 1990, T IND MICR, P71; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; FARBER JM, 1991, MICROBIOL REV, V55, P476, DOI 10.1128/MMBR.55.3.476-511.1991; FARBER JM, 1989, J FOOD PROTECT, V52, P456, DOI 10.4315/0362-028X-52.7.456; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FLEMING DW, 1985, NEW ENGL J MED, V312, P404, DOI 10.1056/NEJM198502143120704; GELLIN BG, 1991, AM J EPIDEMIOL, V133, P392, DOI 10.1093/oxfordjournals.aje.a115893; GELLIN BG, 1989, JAMA-J AM MED ASSOC, V261, P1313, DOI 10.1001/jama.261.9.1313; GILBERT RJ, 1989, LANCET, V1, P383; GOULET V, 1993, B EPIDEMIOL HEBDOM, V4, P13; HEDBERG CW, 1994, CLIN INFECT DIS, V18, P671, DOI 10.1093/clinids/18.5.671; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; MCLAUCHLIN J, 1991, BRIT MED J, V303, P773, DOI 10.1136/bmj.303.6805.773; McLauchlin J., 1990, PHLS Microbiology Digest, V7, P54; Newton L, 1992, Commun Dis Rep CDR Rev, V2, pR142; PINNER RW, 1992, JAMA-J AM MED ASSOC, V267, P2046, DOI 10.1001/jama.267.15.2046; RYSER ET, 1991, LISTERIA LISTERIOSIS, P405; SCHLECH WF, 1983, NEW ENGL J MED, V308, P203, DOI 10.1056/NEJM198301273080407; SCHUCHAT A, 1991, CLIN MICROBIOL REV, V4, P169, DOI 10.1128/CMR.4.2.169-183.1991; SCHUCHAT A, 1992, JAMA-J AM MED ASSOC, V267, P2041, DOI 10.1001/jama.267.15.2041; SCHWARTZ B, 1988, LANCET, V2, P779; Seeliger H.P.R., 1979, METHOD MICROBIOL, V13, P31, DOI [10.1016/S0580-9517(08)70372-6, DOI 10.1016/S0580-9517(08)70372-6]; SMITH JL, 1990, FOODBORNE LISTERIOSI, P137; THOMPSON P, 1990, LANCET, V336, P1557, DOI 10.1016/0140-6736(90)93320-O; TISLER JM, 1991, FOOD TECHNOL-CHICAGO, V45, P125; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WENGER JD, 1990, J FOOD PROTECT, V53, P1015, DOI 10.4315/0362-028X-53.12.1015; 1992, PREVENTING FOOD BORN; 1993, PUTTING CONSUMERS 1S; 1993, COMMUN DIS REP CDR W, V3, P136; 1992, MAKING CONNECTION US, P1; 1992, BACK GROUNDER LISTER; 1985, US PHS FDA229 US DEP; 1987, US PHS MI876 US DEP; 1992, JAMA-J AM MED ASSOC, V268, P180; 1992, PREVENTING FOODBORNE; 1986, MICROORGANISMS FOODS, P92; 1990, FSIS102401 FOOD SAF; 1987, FED REG         0311, V52, P7464; 1989, FED REG         0523, V54, P22345; 1992, MMWR-MORBID MORTAL W, V41, P251; 1988, MMWR-MORBID MORTAL W, V37, P764; 1992, MMWR-MORBID MORTAL W, V41, P257; 1992, FDA922232 PUBL; 1993, HIV AIDS SURVEILLANC, V5, P1; 1989, MMWR-MORBID MORTAL W, V38, P267	48	182	189	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1118	1122		10.1001/jama.273.14.1118	http://dx.doi.org/10.1001/jama.273.14.1118			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR059	7707600				2022-12-28	WOS:A1995QR05900031
J	CHISWICK, M				CHISWICK, M			ANTENATAL TRH	LANCET			English	Editorial Material							THYROTROPIN-RELEASING-HORMONE; INFANTS				CHISWICK, M (corresponding author), ST MARYS HOSP,NW REG PERINATAL CTR,MANCHESTER M13 0JH,LANCS,ENGLAND.							ALTHABE F, 1991, PEDIATR RES, V29, pA200; Althabe O, 1992, PEDIATR RES, V32, P738; BALLARD RA, 1992, LANCET, V339, P510, DOI 10.1016/0140-6736(92)90337-3; CROWTHER CA, 1994, 04749 COCHR DAT SYST; GONZALES LW, 1986, J CLIN ENDOCR METAB, V62, P687; JIKIHARA H, 1990, 6TH P C FED AS OC PE, P87; KNIGHT DB, 1994, AM J OBSTET GYNECOL, V171, P11, DOI 10.1016/S0002-9378(94)70070-2; Knight DB, 1992, P AUSTR PERINATAL SO, pA9; MORALES WJ, 1989, OBSTET GYNECOL, V73, P111; SHELLENBERG JC, 1988, J APPL PHYSIOL, V65, P94	10	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					872	873		10.1016/S0140-6736(95)90002-0	http://dx.doi.org/10.1016/S0140-6736(95)90002-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707804				2022-12-28	WOS:A1995QR06700002
J	MEURMAN, JH; RAJASUO, A; MURTOMAA, H; SAVOLAINEN, S				MEURMAN, JH; RAJASUO, A; MURTOMAA, H; SAVOLAINEN, S			RESPIRATORY-TRACT INFECTIONS AND CONCOMITANT PERICORONITIS OF THE WISDOM TEETH	BRITISH MEDICAL JOURNAL			English	Article							3RD MOLARS	Objective-To discover if there is an association between respiratory tract infections and pericoronitis of erupting third molars in young adults. Design-Data from male military conscripts' medical records w ere collected over five years and the incidence of respiratory tract infection before and after acute pericoronitis (191 cases) and before and after standard (722 cases) and operative (741) extractions compared with that in controls (n=703) who had no infections in the third molar regions. Subjects-14 500 male military conscripts aged 20. Setting-Garrisons in Valkeala and Kouvola, Finland. Results-The incidence of respiratory tract infection was significantly higher during the two weeks before acute pericoronitis was diagnosed compared with that in controls. The highest incidence was observed in the three days before pericoronitis (odds ratio 6.8; 95% confidence interval 3.0 to 15.0). The incidence was also increased in the first week after pericoronitis (odds ratio 3.7; 1.6 to 8.4) and three days before (odds ratio 2.6; 0.9 to 7.5) and during the first week after extraction of third molars (odds ratio 2.6; 1.3 to 5.3). Conclusions-Respiratory tract infection may precipitate and occur concomitantly with acute pericoronitis. Third molar surgery for pericoronitis, on the other hand, may trigger respiratory tract infection.	VALKEALA MIL HOSP,VALKEALA,FINLAND; UNIV HELSINKI,INST DENT,HELSINKI,FINLAND; CENT MIL HOSP,HELSINKI,FINLAND	University of Helsinki	MEURMAN, JH (corresponding author), UNIV KUOPIO,FAC DENT,POB 1627,SF-70211 KUOPIO,FINLAND.			Meurman, Jukka/0000-0001-6702-6836				ALMADORI G, 1988, INT J PEDIATR OTORHI, V15, P157, DOI 10.1016/0165-5876(88)90067-5; BEAN LR, 1971, J AM DENT ASSOC, V83, P1074, DOI 10.14219/jada.archive.1971.0439; DEGRE M, 1986, SCAND J INFECT DIS S, V49, P140; DIXON RE, 1985, AM J MED, V78, P45, DOI 10.1016/0002-9343(85)90363-8; GURALNICK W, 1984, BRIT DENT J, V156, P389, DOI 10.1038/sj.bdj.4805380; GWALTNEY JM, 1981, ANN OTO RHINOL LARYN, V90, P68, DOI 10.1177/00034894810903S216; HURLEN B, 1984, ORAL SURG ORAL MED O, V58, P522, DOI 10.1016/0030-4220(84)90072-0; Kay L W, 1966, Br J Oral Surg, V3, P188; KREKMANOV L, 1986, INT J ORAL MAX SURG, V15, P25, DOI 10.1016/S0300-9785(86)80007-2; LUDWICK WE, 1974, MIL MED, V139, P121; MACGREGOR AJ, 1970, J ORAL SURG, V28, P885; Marsland D W, 1976, J Fam Pract, V3, P25; MOMBELLI A, 1990, J CLIN PERIODONTOL, V17, P48, DOI 10.1111/j.1600-051X.1990.tb01047.x; NITZAN DW, 1985, J ORAL MAXIL SURG, V43, P510, DOI 10.1016/S0278-2391(85)80029-X; PARNELL JL, 1966, NEW ENGL J MED, V274, P979, DOI 10.1056/NEJM196605052741801; PIIRONEN J, 1981, Proceedings of the Finnish Dental Society, V77, P278; RAJASUO A, 1991, MIL MED, V156, P16, DOI 10.1093/milmed/156.1.16; RAJASUO A, 1994, THESIS U HELSINKI; van Cauwenberge P B, 1985, Rhinology, V23, P273; VENTA I, 1993, THESIS U HELSINKI; WADE WG, 1991, ORAL MICROBIOL IMMUN, V6, P310, DOI 10.1111/j.1399-302X.1991.tb00499.x; 1993, ANNUAL REPORTS HLTH; 1977, MANUAL INT STATISTIC, V1	23	14	14	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 1	1995	310	6983					834	836		10.1136/bmj.310.6983.834	http://dx.doi.org/10.1136/bmj.310.6983.834			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711620	Green Published			2022-12-28	WOS:A1995QQ85700018
J	FOURCADE, O; SIMON, MF; VIODE, C; RUGANI, N; LEBALLE, F; RAGAB, A; FOURNIE, B; SARDA, L; CHAP, H				FOURCADE, O; SIMON, MF; VIODE, C; RUGANI, N; LEBALLE, F; RAGAB, A; FOURNIE, B; SARDA, L; CHAP, H			SECRETORY PHOSPHOLIPASE A(2) GENERATES THE NOVEL LIPID MEDIATOR LYSOPHOSPHATIDIC ACID IN MEMBRANE MICROVESICLES SHED FROM ACTIVATED CELLS	CELL			English	Article							HUMAN-ERYTHROCYTES; PLASMA-MEMBRANE; RED-CELL; PURIFIED PHOSPHOLIPASES; ASYMMETRIC DISTRIBUTION; PROCOAGULANT ACTIVITY; PLATELET AGGREGATION; POSSIBLE INVOLVEMENT; II PHOSPHOLIPASE-A2; EXPRESSION	Nonpancreatic secretory phospholipase A(2) (sPLA(2)) displays proinflammatory properties; however, its physiological substrate is not identified. Although inactive toward intact cells, sPLA(2) hydrolyzed phospholipids in membrane microvesicles shed from Ca2+-loaded erythrocytes as well as from platelets and from whole blood cells challenged with inflammatory stimuli. sPLA(2) was stimulated upon degradation of sphingomyelin (SPH) and produced lysophosphatidic acid (LPA), which induced platelet aggregation. Finally, lysophospholipid-containing vesicles and sPLA(2) were detected in inflammatory fluids in relative proportions identical to those used in vitro. We conclude that upon loss of phospholipid asymmetry, cell-derived microvesicles provide a preferential substrate for sPLA(2). SPH hydrolysis, which is provoked by various cytokines, regulates sPLA(2) activity, and the novel lipid mediator LPA can be generated by this pathway.	HOP PURPAN,INSERM,U326,F-31059 TOULOUSE,FRANCE; FAC ST CHARLES,INST CHIM BIOL,F-13331 MARSEILLE 3,FRANCE; HOP PURPAN,SERV RHUMATOL,F-31059 TOULOUSE,FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse								AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; ALLAN D, 1981, BIOCHEM J, V198, P433, DOI 10.1042/bj1980433; ALLAN D, 1975, NATURE, V258, P348, DOI 10.1038/258348a0; ALLAN D, 1980, BIOCHEM J, V188, P881, DOI 10.1042/bj1880881; ALLAN D, 1976, BIOCHEM J, V156, P225, DOI 10.1042/bj1560225; ARDLIE NG, 1970, BRIT J HAEMATOL, V19, P7, DOI 10.1111/j.1365-2141.1970.tb01596.x; ARVAND M, 1990, J BIOL CHEM, V265, P14377; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P4917, DOI 10.1073/pnas.90.11.4917; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BEVERS EM, 1992, BLOOD, V79, P380, DOI 10.1182/blood.V79.2.380.380; BHAKDI S, 1994, MED MICROBIOL IMMUN, V183, P119, DOI 10.1007/BF00196048; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRA R, 1987, BIOCHIM BIOPHYS ACTA, V902, P253, DOI 10.1016/0005-2736(87)90303-8; CHANG CP, 1993, J BIOL CHEM, V268, P7171; CHAP HJ, 1977, BIOCHIM BIOPHYS ACTA, V467, P146, DOI 10.1016/0005-2736(77)90192-4; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; CONNOR J, 1994, J BIOL CHEM, V269, P2399; DEVAUX PF, 1993, CURR OPIN STRUC BIOL, V3, P489, DOI 10.1016/0959-440X(93)90072-S; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FADOK VA, 1992, J IMMUNOL, V149, P4029; FRANKEN PA, 1992, EUR J BIOCHEM, V203, P89, DOI 10.1111/j.1432-1033.1992.tb19832.x; GASSAMADIAGNE A, 1992, J BIOL CHEM, V267, P13418; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; HAMILTON KK, 1990, J BIOL CHEM, V265, P3809; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HIDI R, 1993, J IMMUNOL, V151, P5613; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAUCO G, 1978, BIOCHIMIE, V60, P653, DOI 10.1016/S0300-9084(78)80784-6; MINTA JO, 1983, METHOD ENZYMOL, V93, P375; MIYAKE A, 1994, EUR J PHARMACOL, V253, P155; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; MOUNIER C, 1993, EUR J BIOCHEM, V216, P169, DOI 10.1111/j.1432-1033.1993.tb18129.x; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; NICULESCU F, 1993, J IMMUNOL, V150, P214; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; PFEILSCHIFTER J, 1994, J CLIN INVEST, V92, P2516; RADVANYI F, 1989, ANAL BIOCHEM, V177, P103, DOI 10.1016/0003-2697(89)90022-5; RANSAC S, 1992, EUR J BIOCHEM, V204, P793, DOI 10.1111/j.1432-1033.1992.tb16697.x; RAVAL PJ, 1984, BIOCHIM BIOPHYS ACTA, V772, P192, DOI 10.1016/0005-2736(84)90043-9; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; RUGANI N, 1992, J CHROMATOGR-BIOMED, V583, P246, DOI 10.1016/0378-4347(92)80560-D; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SCHWARTZ RS, 1985, J CLIN INVEST, V75, P1965, DOI 10.1172/JCI111913; SCOTT S, 1984, BIOCHEM J, V224, P285, DOI 10.1042/bj2240285; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHUKLA SD, 1978, BIOCHIM BIOPHYS ACTA, V512, P341, DOI 10.1016/0005-2736(78)90258-4; SIMON MF, 1982, BIOCHEM BIOPH RES CO, V108, P1743, DOI 10.1016/S0006-291X(82)80113-7; STEIN JM, 1991, BIOCHEM J, V274, P381, DOI 10.1042/bj2740381; SUGIURA T, 1994, ARCH BIOCHEM BIOPHYS, V311, P358, DOI 10.1006/abbi.1994.1249; THANNHAUSER TW, 1985, BIOCHEMISTRY-US, V24, P7681, DOI 10.1021/bi00347a027; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; WRIGHT GW, 1990, J BIOL CHEM, V265, P6675; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; ZWAAL RFA, 1975, BIOCHIM BIOPHYS ACTA, V406, P83, DOI 10.1016/0005-2736(75)90044-9; ZWAAL RFA, 1992, BIOCHIM BIOPHYS ACTA, V1180, P1, DOI 10.1016/0925-4439(92)90019-J	70	473	481	0	14	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					919	927		10.1016/0092-8674(95)90295-3	http://dx.doi.org/10.1016/0092-8674(95)90295-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697722	Bronze			2022-12-28	WOS:A1995QP61200011
J	LEVY, MA; ARNOLD, RM; FINE, MJ; KAPOOR, WN				LEVY, MA; ARNOLD, RM; FINE, MJ; KAPOOR, WN			PROFESSIONAL COURTESY - CURRENT PRACTICES AND ATTITUDES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHYSICIANS	Background. Physicians have long provided care free of charge or at a reduced rate as a professional courtesy to other physicians and their families. We conducted a stratified national mail survey to assess the extent to which this practice has changed in recent years. Methods. Using the American Medical Association's 1991 master list of physicians, we selected a random sample of 4800 practicing physicians from 12 direct-care specialties. These physicians were asked about their current policy and opinions regarding professional courtesy. Results. Of the 2224 respondents, 2127 (96 percent) offered professional courtesy, defined as providing free or discounted health care to physicians and their families. Psychiatrists were less likely to offer professional courtesy than physicians in any of the other specialties (80 percent vs. 91 to 99 percent, P<0.05). The forms of free or discounted care offered as a professional courtesy included billing only the insurance company (75 percent), providing care at no charge (49 percent), and giving a partial discount (23 percent). Twenty-three percent of the respondents reported that they had changed their policy regarding professional courtesy since starting to practice. Among those who had changed their policy, the most common changes were to increase the practice of billing only the insurance company (67 percent) and to provide care at no charge less often (58 percent). The majority of physicians responding to the survey thought that professional courtesy solidified bonds between physicians (79 percent) and was sound business practice (62 percent); 12 percent believed that it was too expensive to offer free or discounted care as a professional courtesy, and 14 percent thought that the practice had negative effects on the physician-patient interaction. Conclusions. Our survey of physicians involved in direct patient care indicates that, with the exception of psychiatrists, almost all American physicians off er free or discounted care as a professional courtesy and support the practice.	UNIV PITTSBURGH,CTR MED ETH,DEPT PSYCHIAT,PITTSBURGH,PA 15260; UNIV PITTSBURGH,DEPT MED,DIV GEN INTERNAL MED,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	LEVY, MA (corresponding author), MED CTR CENT MASSACHUSETTS,DIV PRIMARY CARE GENET,119 BELMONT ST,WORCESTER,MA 01605, USA.				NHLBI NIH HHS [R01 HL36735] Funding Source: Medline; PHS HHS [K04L 01899] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036735] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUERBACK A, 1962, AM J PSYCHIAT, V119, P520, DOI 10.1176/ajp.119.6.520; BASS LW, 1980, PEDIATRICS, V65, P751; BASS LW, 1978, NEW ENGL J MED, V299, P772, DOI 10.1056/NEJM197810052991410; BUNCIC JR, 1988, CAN MED ASSOC J, V139, P827; Fowler F. J., 1988, SURVEY RES METHODS; GERBERT B, 1991, JAMA-J AM MED ASSOC, V266, P2837, DOI 10.1001/jama.266.20.2837; GIFFORD JP, 1962, MED ECON, V39, P81; GOLDMAN B, 1985, CAN MED ASSOC J, V132, P422; GOLDMAN B, 1985, CAN MED ASSOC J, V132, P426; LACHS MS, 1990, NEW ENGL J MED, V322, P1599, DOI 10.1056/NEJM199005313222210; MAHEUX B, 1989, AM J PUBLIC HEALTH, V79, P638, DOI 10.2105/AJPH.79.5.638; REUBEN DB, 1991, J AM GERIATR SOC, V39, P799, DOI 10.1111/j.1532-5415.1991.tb02703.x; SHERWOOD HC, 1958, MED ECON, V35, P74; STRAW WE, 1979, NEW ENGL J MED, V300, P325; 1992, J AM DENT ASSOC, V123, P98; 1966, JAMA-J AM MED ASSOC, V195, P299; 1989, CURRENT OPINIONS COU; 1992, SOCIOECONOMIC CHARAC	18	23	23	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1993	329	22					1627	1631		10.1056/NEJM199311253292207	http://dx.doi.org/10.1056/NEJM199311253292207			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MJ546	7695662				2022-12-28	WOS:A1993MJ54600007
J	WU, J; DENT, P; JELINEK, T; WOLFMAN, A; WEBER, MJ; STURGILL, TW				WU, J; DENT, P; JELINEK, T; WOLFMAN, A; WEBER, MJ; STURGILL, TW			INHIBITION OF THE EGF-ACTIVATED MAP KINASE SIGNALING PATHWAY BY ADENOSINE-3',5'-MONOPHOSPHATE	SCIENCE			English	Article							PROTEIN-KINASE; CORONARY-ARTERIES; RECEPTOR; CELLS; RAF	Mitogen-activated protein (MAP) kinases P42mapk and p44mapk are activated in cells stimulated with epidermal growth factor (EGF) and other agents. A principal pathway for MAP kinase (MAPK) activation by EGF consists of sequential activations of the guanine nucleotide exchange factor Sos, the guanosine triphosphate binding protein Ras, and the protein kinases Raf-1, MAPK kinase (MKK), and MAPK. Because adenosine 3',5'-monophosphate (cAMP) does not activate MAPK and has some opposing physiologic effects, the effect of increasing intracellular concentrations of cAMP with forskolin and 3-isobutyl-1-methylxanthine on the EGF-stimulated MAPK pathway was studied. Increased concentrations of cAMP blocked activation of Raf-1, MKK, and MAPK in Rat1hER fibroblasts, accompanied by a threefold increase in Raf-1 phosphorylation on serine 43 in the regulatory domain. Phosphorylation of Raf-1 in vitro and in vivo reduces the apparent affinity with which it binds to Ras and may contribute to the blockade by cAMP.	UNIV VIRGINIA, HLTH SCI CTR, DEPT INTERNAL MED, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; CLEVELAND CLIN EDUC FDN, DEPT CELL BIOL, CLEVELAND, OH 44106 USA	University of Virginia; University of Virginia; University of Virginia; Cleveland Clinic Foundation			Wu, Jie/R-2404-2019	Wu, Jie/0000-0002-2864-1606	NATIONAL CANCER INSTITUTE [R37CA039076, R01CA039076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077] Funding Source: NIH RePORTER; NCI NIH HHS [CA39076] Funding Source: Medline; NIDDK NIH HHS [DK41077] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; ASHWORTH A, 1992, ONCOGENE, V7, P2555; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHOW YL, UNPUB; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CONRAD KE, 1992, ONCOGENE, V7, P1279; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1993, MOL BIOL CELL, V4, P483, DOI 10.1091/mbc.4.5.483; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JIANG H, 1992, J BIOL CHEM, V267, P1015; JOHNSON GS, 1972, NATURE, V263, P247; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; ODA A, 1988, Hokkaido Journal of Medical Science, V63, P747; PARSONS WJ, 1988, MOL PHARMACOL, V34, P37; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1505; RHEE SG, 1993, ADV SEC MESS PHOSPH, V28, P57; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEGER R, 1992, J BIOL CHEM, V267, P14373; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEBER MJ, 1974, P C MECHANISMS VIRUS, P327; WELLS JN, 1975, MOL PHARMACOL, V11, P775; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; Wu J.-Y., UNPUB; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	46	905	924	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	1993	262	5136					1065	1069		10.1126/science.7694366	http://dx.doi.org/10.1126/science.7694366			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	7694366				2022-12-28	WOS:A1993MG18700039
J	KNYRIM, K; WAGNER, HJ; BETHGE, N; KEYMLING, M; VAKIL, N				KNYRIM, K; WAGNER, HJ; BETHGE, N; KEYMLING, M; VAKIL, N			A CONTROLLED TRIAL OF AN EXPANSILE METAL STENT FOR PALLIATION OF ESOPHAGEAL OBSTRUCTION DUE TO INOPERABLE CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							YAG LASER THERAPY; RANDOMIZED TRIAL; GASTROESOPHAGEAL JUNCTION; MALIGNANT DYSPHAGIA; CARCINOMA; RADIOTHERAPY; STRICTURES; INTUBATION; SURGERY	Background. Esophageal obstruction due to cancer can produce debilitating dysphagia. Rapid palliation is usually possible with endoscopic placement of a plastic esophageal prosthesis, but this device has a high rate of complications. A new alternative is a metal-mesh stent that collapses to 3 mm in diameter at placement but can then expand up to 16 mm. Methods. Patients with esophageal carcinoma (39 patients) or malignant extrinsic obstruction (3 patients) were randomly assigned to treatment with either a plastic prosthesis (16 mm in diameter) or an expansile metal-mesh stent. The patients were evaluated every six weeks until death. The degree of palliation was expressed as a dysphagia score and a Karnofsky performance score. Results. Complications were significantly less frequent with the metal stents than with the plastic prostheses (no complications vs. nine; P<0.001). The dysphagia and Karnofsky scores improved significantly and to a similar degree in both treatment groups. The most common causes of recurrent dysphagia were migration of the plastic prostheses (five patients) and ingrowth or overgrowth of the metal stents by tumor (five patients). The rates of reintervention were similar in both treatment groups, as were the 30-day mortality rates. The period of hospitalization after placement of a prosthesis was significantly longer in the group given plastic prostheses than in the group given metal stents (mean +/-SE, 12.5+/-2.1 vs. 5.4+/-1.0 days; P = 0.005). Despite their higher initial cost, the metal stents were cost effective because of the absence of fatal complications and the decrease in the hospital stay. Conclusions. Expansile metal stents are a safe and cost-effective alternative to conventional plastic endoprostheses in the treatment of esophageal obstruction due to inoperable cancer.	STADT KLINIKEN,INST RONTGENDIAGNOST,KASSEL,GERMANY; KREISKRANKENHAUS,MED KLIN,BAD HERSFELD,GERMANY; KRANKENHAUS NEUKOLLN,INNERE ABT 4,BERLIN,GERMANY; UNIV ROCHESTER,MED CTR,ROCHESTER,NY 14642	Klinikum Kassel; University of Rochester	KNYRIM, K (corresponding author), STADT KLINIKEN,MED KLIN,MONCHEBERGSTR 41,W-3500 KASSEL,GERMANY.							ADAM A, 1991, AM J ROENTGENOL, V156, P321, DOI 10.2214/ajr.156.2.1702574; ALBERTSSON M, 1989, ACTA ONCOL, V28, P267, DOI 10.3109/02841868909111261; BARR H, 1990, GUT, V31, P252, DOI 10.1136/gut.31.3.252; BETHGE N, 1992, ENDOSCOPY, V24, P411, DOI 10.1055/s-2007-1010509; BETHGE N, 1992, ENDOSCOPY, V24, P395, DOI 10.1055/s-2007-1010506; CASPERS RJL, 1988, RADIOTHER ONCOL, V12, P15, DOI 10.1016/0167-8140(88)90188-0; CHAVY AL, 1986, CANCER, V57, P1426, DOI 10.1002/1097-0142(19860401)57:7<1426::AID-CNCR2820570731>3.0.CO;2-2; DAVIDS PHP, 1992, LANCET, V340, P1488, DOI 10.1016/0140-6736(92)92752-2; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; Didcott C C, 1973, Ann R Coll Surg Engl, V53, P112; EARLAM R, 1980, BRIT J SURG, V67, P381, DOI 10.1002/bjs.1800670602; FLEISCHER DE, 1992, GASTROINTEST ENDOSC, V38, P494, DOI 10.1016/S0016-5107(92)70484-2; HAHL J, 1991, SCAND J GASTROENTERO, V26, P103, DOI 10.3109/00365529108996490; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; KNYRIM K, 1993, ENDOSCOPY, V25, P207, DOI 10.1055/s-2007-1010294; KOZAREK RA, 1992, GASTROINTEST ENDOSC, V38, P1, DOI 10.1016/S0016-5107(92)70321-6; LINDBERG CG, 1991, ACTA RADIOL, V32, P345; LOIZOU LA, 1991, GASTROENTEROLOGY, V100, P1303; MELLOW MH, 1985, ARCH INTERN MED, V145, P1443, DOI 10.1001/archinte.145.8.1443; REED CE, 1991, ANN THORAC SURG, V51, P552, DOI 10.1016/0003-4975(91)90309-E; RUTGEERTS P, 1988, GASTROINTEST ENDOSC, V34, P87, DOI 10.1016/S0016-5107(88)71269-9; SARGEANT IR, 1992, GUT, V33, P1597, DOI 10.1136/gut.33.12.1597; SCHAER J, 1992, GASTROINTEST ENDOSC, V38, P7, DOI 10.1016/S0016-5107(92)70322-8; SONG HY, 1992, RADIOLOGY, V184, P729, DOI 10.1148/radiology.184.3.1509057; WAGNER HJ, 1992, DEUT MED WOCHENSCHR, V117, P248, DOI 10.1055/s-2008-1062304; WATSON A, 1988, POSTGRAD MED J, V64, P860, DOI 10.1136/pgmj.64.757.860	26	644	663	0	26	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1993	329	18					1302	1307		10.1056/NEJM199310283291803	http://dx.doi.org/10.1056/NEJM199310283291803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD557	7692297				2022-12-28	WOS:A1993MD55700003
J	GAUCHAT, JF; HENCHOZ, S; MAZZEI, G; AUBRY, JP; BRUNNER, T; BLASEY, H; LIFE, P; TALABOT, D; FLORESROMO, L; THOMPSON, J; KISHI, K; BUTTERFIELD, J; DAHINDEN, C; BONNEFOY, JY				GAUCHAT, JF; HENCHOZ, S; MAZZEI, G; AUBRY, JP; BRUNNER, T; BLASEY, H; LIFE, P; TALABOT, D; FLORESROMO, L; THOMPSON, J; KISHI, K; BUTTERFIELD, J; DAHINDEN, C; BONNEFOY, JY			INDUCTION OF HUMAN IGE SYNTHESIS IN B-CELLS BY MAST-CELLS AND BASOPHILS	NATURE			English	Article							MESSENGER-RNA; INTERLEUKIN-4; LIGAND; CD40; IDENTIFICATION; CYCLOSPORINE; LEUKEMIA; LINE	IMMUNOGLOBULIN E (IgE) is central to the induction of allergic diseases through its binding to the high-affinity receptor (FcepsilonR1) on mast cells and basophils. Crosslinking by allergens of the bound IgE leads to the release of various inflammatory mediators. IgE production by B cells requires a physical interaction with T cells1, involving a number of surface adhesion molecules1,2, as well as the soluble factors interleukin-4 (IL-4)3,4 and IL-13 (ref. 5) produced by T cells6,7, basophils8 and mast cells9. Here we report that, in the presence of IL-4, mast and basophilic cell lines can provide the cell contact signals that are required for IgE synthesis. The human cell lines HMC-1 (mast) and KU812 (basophilic) both express the ligand for CD40 (CD40L) which is shown to be responsible for the IgE production. Moreover, freshly isolated purified human lung mast cells and blood basophils are also shown to express CD40L and to induce IgE production. This evidence suggests that mast cells and basophils may therefore play a key role in allergy not only by producing inflammatory mediators, but also by directly regulating IgE production independently of T cells.	GLAXO INST MOLEC BIOL,14 CHEMIN AULX,CH-1228 PLAN LES OUATES,SWITZERLAND; INSELSPITAL BERN,CH-3010 BERN,SWITZERLAND; GLAXO GRP RES LTD,GREENFORD UB6 0HE,MIDDX,ENGLAND; NIIGATA UNIV,NIIGATA 951,JAPAN; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905	GlaxoSmithKline; GlaxoSmithKline; Niigata University; Mayo Clinic								ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; FANSLOW WC, 1992, J IMMUNOL, V149, P655; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; GASCAN H, 1991, J IMMUNOL, V147, P8; GAUCHAT JF, 1989, EUR J IMMUNOL, V19, P1079, DOI 10.1002/eji.1830190618; GAUCHAT JF, 1993, FEBS LETT, V315, P259, DOI 10.1016/0014-5793(93)81175-Y; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; PENE J, 1988, P NATL ACAD SCI USA, V85, P8166; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295	29	569	580	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					340	343		10.1038/365340a0	http://dx.doi.org/10.1038/365340a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	7690905				2022-12-28	WOS:A1993LY49600052
J	SALVESEN, KA; VATTEN, LJ; EIKNES, SH; HUGDAHL, K; BAKKETEIG, LS				SALVESEN, KA; VATTEN, LJ; EIKNES, SH; HUGDAHL, K; BAKKETEIG, LS			ROUTINE ULTRASONOGRAPHY IN-UTERO AND SUBSEQUENT HANDEDNESS AND NEUROLOGICAL DEVELOPMENT	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; DIAGNOSTIC ULTRASOUND; PREGNANCY	Objective-To examine any associations between routine ultrasonography in utero and subsequent brain development as indicated by non-right handedness at primary school age and neurological development during childhood. Design-Follow up of 8 and 9 year old children of women who took part in two randomised, controlled trials of routine ultrasonography during pregnancy. Setting-Clinics of 60 general practitioners in Norway during 1979-81. Maternal and child health centres. Subjects-2161 (89%) of 2428 eligible singletons were followed up, partly through a questionnaire to their parents and partly through information from health centres. Main outcome measures-The dominant hand of the child was assessed by 10 questions. Deficits in attention, motor control, and perception were evaluated by five questions. Impaired neurological development during the first year of life was assessed by an abbreviated version of the Denver developmental screening test. Results-The odds of non-right handedness were higher among children who had been screened in utero than among control children (odds ratio 1.32; 95% confidence interval 1.02 to 1.71). No clear differences were found between the groups with regard to deficits in attention, motor control, and perception or neurological development during the first year of life. Conclusion-Our data suggest a possible association between routine ultrasonography in utero and subsequent non-right handedness, whereas no association with impaired neurological development was found. As the question on non-right handedness was one of six initial hypotheses, the observed results may be due to chance. None the less, the results suggest that the hypothesis may have some merit and should be tested in future studies.	UNIV BERGEN,DEPT BIOL & MED PSYCHOL,N-5014 BERGEN,NORWAY; UNIV TRONDHEIM,DEPT COMMUNITY MED & FAMILY PRACTICE,TRONDHEIM,NORWAY; NATL INST PUBL HLTH,DEPT EPIDEMIOL,OSLO 1,NORWAY	University of Bergen	SALVESEN, KA (corresponding author), UNIV TRONDHEIM,MED CTR,DEPT GYNAECOL & OBSTET,NATL CTR FETAL MED,N-7005 TRONDHEIM,NORWAY.		Vatten, Lars/AAF-9380-2022; Vatten, Lars/AFK-2073-2022					BAKKETEIG LS, 1984, LANCET, V2, P207; BISHOP DVM, 1990, CLIN DEV MED, V110; EIKNES SH, 1984, LANCET, V1, P1347; FRANKENBURG WK, 1967, J PEDIATR-US, V71, P181, DOI 10.1016/S0022-3476(67)80070-2; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P427; GILLBERG NIC, 1987, DEFICITS ATTENTION M; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LIEBESKIND D, 1982, BRIT J CANCER, V45, P176; MOLE R, 1986, BIRTH-ISS PERINAT C, V13, P29, DOI 10.1111/j.1523-536X.1986.tb00999.x; MORTIMER AJ, 1988, ULTRASOUND MED BIOL, V14, P499, DOI 10.1016/0301-5629(88)90111-1; Neilson J., 1989, EFFECTIVE CARE PREGN; RACKOWSKI D, 1974, NEUROPSYCHOLOGIA, V12, P43; RASMUSSEN P, 1983, ACTA PAEDIATR SCAND, V72, P125, DOI 10.1111/j.1651-2227.1983.tb09676.x; Rothman K, 1986, MODERN EPIDEMIOLOGY; SAARIKEMPPAINEN A, 1990, LANCET, V336, P387, DOI 10.1016/0140-6736(90)91941-3; Salvesen K A, 1990, Tidsskr Nor Laegeforen, V110, P1506; SALVESEN KA, 1992, LANCET, V339, P85, DOI 10.1016/0140-6736(92)90998-I; SALVESEN KA, 1992, ULTRASOUND OBST GYN, V2, P243, DOI 10.1046/j.1469-0705.1992.02040243.x; Satz P, 1972, Cortex, V8, P121; SCHEIDT PC, 1978, AM J OBSTET GYNECOL, V131, P743, DOI 10.1016/0002-9378(78)90238-7; STARK CR, 1984, OBSTET GYNECOL, V63, P194; WALDENSTROM U, 1988, LANCET, V2, P585; 1988, J ULTRAS MED, V7, P1; 1985, STATISTICAL PACKAGE; 1984, NIH84667 PHS US DEP	25	97	99	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					159	164		10.1136/bmj.307.6897.159	http://dx.doi.org/10.1136/bmj.307.6897.159			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	7688253	Green Published, Bronze			2022-12-28	WOS:A1993LN18400018
J	ZHU, N; LIGGITT, D; LIU, Y; DEBS, R				ZHU, N; LIGGITT, D; LIU, Y; DEBS, R			SYSTEMIC GENE-EXPRESSION AFTER INTRAVENOUS DNA DELIVERY INTO ADULT MICE	SCIENCE			English	Article							TRANSGENIC ANIMALS; HIGHLY EFFICIENT; TRANSFECTION; INVIVO; LIPOFECTION	Direct gene transfer into adult animals resulting in generalized or tissue-specific expression would facilitate rapid analysis of transgene effects and allow precise in vivo manipulation of biologic processes at the molecular level. A single intravenous injection of expression plasmid:cationic liposome complexes into adult mice efficiently transfected virtually all tissues. In addition to vascular endothelial cells, most of the extravascular parenchymal cells present in many tissues including the lung, spleen, lymph nodes, and bone marrow expressed the transgene without any apparent treatment-related toxicity. The transgene was still expressed in large numbers of cells in multiple tissues for at least 9 weeks after a single injection. Expression could be targeted to specific tissues and cell types, depending on the promoter element used.	UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143; UNIV WASHINGTON,SCH MED,DEPT COMPARAT MED,SEATTLE,WA 98195	University of California System; University of California San Francisco; University of Washington; University of Washington Seattle								ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; BRIGHAM KL, 1989, AM J MED SCI, V298, P278, DOI 10.1097/00000441-198910000-00013; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; DEBS R, 1992, AM J RESP CELL MOL, V7, P406, DOI 10.1165/ajrcmb/7.4.406; DEBS RJ, 1987, BIOCHIM BIOPHYS ACTA, V901, P183, DOI 10.1016/0005-2736(87)90114-3; DEBS RJ, 1990, J BIOL CHEM, V265, P10189; FEINSTEIN SC, 1982, J MOL BIOL, V156, P549, DOI 10.1016/0022-2836(82)90266-2; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HOLT CE, 1990, NEURON, V4, P203, DOI 10.1016/0896-6273(90)90095-W; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JARNAGIN WR, 1992, NUCLEIC ACIDS RES, V20, P4205, DOI 10.1093/nar/20.16.4205; JULIANO RL, 1983, LIPOSOMES, P53; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MARUYAMA K, 1990, P NATL ACAD SCI USA, V87, P5744, DOI 10.1073/pnas.87.15.5744; MERLINO GT, 1991, FASEB J, V5, P2996, DOI 10.1096/fasebj.5.14.1752364; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1992, HUM GENE THER, V3, P649, DOI 10.1089/hum.1992.3.6-649; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; SCHMIDT EV, 1990, MOL CELL BIOL, V10, P4406, DOI 10.1128/MCB.10.8.4406; STEWART MJ, 1992, HUM GENE THER, V3, P267, DOI 10.1089/hum.1992.3.3-267; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; ZHU N, UNPUB	24	683	864	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					209	211		10.1126/science.7687073	http://dx.doi.org/10.1126/science.7687073			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	7687073				2022-12-28	WOS:A1993LL59600040
J	FOULKES, NS; SCHLOTTER, F; PEVET, P; SASSONECORSI, P				FOULKES, NS; SCHLOTTER, F; PEVET, P; SASSONECORSI, P			PITUITARY-HORMONE FSH DIRECTS THE CREM FUNCTIONAL SWITCH DURING SPERMATOGENESIS	NATURE			English	Article							GOLDEN-HAMSTERS; GENE; TRANSCRIPTION; SEQUENCE	THE CREM (cyclic AMP-responsive element modulator) gene encodes multiple regulators of the cAMP-transcriptional response by alternative splicing1. A developmental switch in CREM expression occurs during spermatogenesis, whereby CREM function is converted from an antagonist to an activator (CREMtau; ref. 2) which accumulates to extremely high levels from the premeiotic spermatocyte stage onwards. To define the physiological mechanisms controlling the CREM developmental switch, we have hypophysectomized rats and observed the extinction of CREMtau expression in testis, thereby demonstrating a central role of the pituitary-hypothalamic axis. We then used the seasonal-dependent modulation of spermatogenesis in hamsters to dissect the hormonal programme controlling this developmental process. By this approach, combined with direct administration of pituitary-derived hormones, we have established that follicle-stimulating hormone (FSH) is responsible for the CREM switch. FSH appears to regulate CREM expression by alternative polyadenylation, which results in a dramatic enhancement of transcript stability.	CNRS, URA 1332, F-67000 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS)	SASSONECORSI, P (corresponding author), FAC MED STRASBOURG, CNRS, GENET MOLEC EUCARYOTES LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE.		Foulkes, Nicholas S/K-7003-2013	Foulkes, Nicholas S/0000-0002-1794-9891				Bartke A., 1985, The hamster - reproduction and behavior., P73; CROWLEY WF, 1991, RECENT PROG HORM RES, V47, P27; DESJARDINS C, 1971, ENDOCRINOLOGY, V89, P791, DOI 10.1210/endo-89-3-791; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; JEGOU B, 1992, SCHERING F WORKSHOP, V4, P57; JETTON AE, 1991, ENDOCRINOLOGY, V129, P1025, DOI 10.1210/endo-129-2-1025; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; KLEMCKE HG, 1987, BIOL REPROD, V37, P356, DOI 10.1095/biolreprod37.2.356; MAZLUFF WF, 1986, TRANSCRIPTION TRANSL; PEVET P, 1988, REPROD NUTR DEV, V28, P575; RAYNAUD F, 1991, J NEURAL TRANSM-GEN, V83, P235, DOI 10.1007/BF01253393; Reiter R J, 1980, Endocr Rev, V1, P109; RUBIN MR, 1986, SCIENCE, V233, P663, DOI 10.1126/science.3726554; Santen R. J., 1987, ENDOCRINOL METAB, P821; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; VULLIAMY TJ, 1988, P NATL ACAD SCI USA, V85, P5171, DOI 10.1073/pnas.85.14.5171	19	233	236	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 18	1993	362	6417					264	267		10.1038/362264a0	http://dx.doi.org/10.1038/362264a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	7681549				2022-12-28	WOS:A1993KT02600062
J	ZHOU, SY; SHOELSON, SE; CHAUDHURI, M; GISH, G; PAWSON, T; HASER, WG; KING, F; ROBERTS, T; RATNOFSKY, S; LECHLEIDER, RJ; NEEL, BG; BIRGE, RB; FAJARDO, JE; CHOU, MM; HANAFUSA, H; SCHAFFHAUSEN, B; CANTLEY, LC				ZHOU, SY; SHOELSON, SE; CHAUDHURI, M; GISH, G; PAWSON, T; HASER, WG; KING, F; ROBERTS, T; RATNOFSKY, S; LECHLEIDER, RJ; NEEL, BG; BIRGE, RB; FAJARDO, JE; CHOU, MM; HANAFUSA, H; SCHAFFHAUSEN, B; CANTLEY, LC			SH2 DOMAINS RECOGNIZE SPECIFIC PHOSPHOPEPTIDE SEQUENCES	CELL			English	Article							MIDDLE-T-ANTIGEN; PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; PROTEIN-TYROSINE KINASES; GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; BINDING; POLYOMAVIRUS; PP60C-SRC; GAP; SRC	A phosphopeptide library was used to determine the sequence specificity of the peptide-binding sites of SH2 domains. One group of SH2 domains (Src, Fyn, Lck, Fgr, Abl, Crk, and Nck) preferred sequences with the general motif pTyr-hydrophilic-hydrophilic-Ile/Pro while another group (SH2 domains of p85, phospholipase C-gamma, and SHPTP2) selected the general motif pTyr-hydrophobic-X-hydrophobic. Individual members of these groups selected unique sequences, except the Src subfamily (Src, Fyn, Lck, and Fgr), which all selected the sequence pTyr-Glu-Glu-Ile. The variability in SH2 domain sequences at likely sites of contact provides a structural basis for the phosphopeptide selectivity of these families. Possible in vivo binding sites of the SH2 domains are discussed.	BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA; BRIGHAM & WOMENS HOSP, DEPT MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02115 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; BASF CORP, CAMBRIDGE, MA 02139 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02215 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Harvard University; Beth Israel Deaconess Medical Center; Tufts University; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; BASF; Rockefeller University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Tufts University	ZHOU, SY (corresponding author), HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA.		Cantley, Lewis C/D-1800-2014; Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013	Cantley, Lewis C/0000-0002-1298-7653; 				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1992, J BIOL CHEM, V267, P5408; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, IN PRESS J BIOL CHEM; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; DOMCHEK S, 1993, BIOCHEMISTRY-US, V31, P9865; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; LIU X, 1993, IN PRESS ONCOGENE; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHUMACHER TNM, 1992, EUR J IMMUNOL, V22, P1405, DOI 10.1002/eji.1830220612; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992	41	2487	2701	0	38	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 12	1993	72	5					767	778		10.1016/0092-8674(93)90404-E	http://dx.doi.org/10.1016/0092-8674(93)90404-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	7680959				2022-12-28	WOS:A1993KR43600012
J	MIYATA, T; TAKEDA, J; IIDA, Y; YAMADA, N; INOUE, N; TAKAHASHI, M; MAEDA, K; KITANI, T; KINOSHITA, T				MIYATA, T; TAKEDA, J; IIDA, Y; YAMADA, N; INOUE, N; TAKAHASHI, M; MAEDA, K; KITANI, T; KINOSHITA, T			THE CLONING OF PIG-A, A COMPONENT IN THE EARLY STEP OF GPI-ANCHOR BIOSYNTHESIS	SCIENCE			English	Article							GLYCOSYL-PHOSPHATIDYLINOSITOL ANCHOR; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; VARIANT SURFACE GLYCOPROTEIN; THY-1 GLYCOPROTEIN; MEMBRANE-PROTEIN; CELLS; EXPRESSION; MUTANTS; VECTOR	The glycosylphosphatidylinositol (GPI) anchor is a membrane attachment structure of many proteins and occurs in a wide variety of eukaryotes from yeasts to mammals. The structure of the core of the GPI anchor is conserved in protozoa and mammals and so is its biosynthetic pathway. A complementary DNA encoding a human protein termed PIG-A (phosphatidylinositol glycan-class A) was cloned. PIG-A was necessary for synthesis of N-acetylglucosaminyl-phosphatidylinositol, the very early intermediate in GPI-anchor biosynthesis.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT IMMUNOREGULAT,SUITA,OSAKA 565,JAPAN; NAGOYA UNIV,BRANCH HOSP,SCH MED,DEPT INTERNAL MED,NAGOYA 461,JAPAN; GIFU UNIV,SCH MED,DEPT PEDIAT,GIFU 500,JAPAN	Osaka University; Nagoya University; Gifu University			Takahashi, Minoru/G-4748-2011; Miyata, Toshio/A-4872-2010; Kinoshita, Taroh/C-7353-2009					ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONZELMANN A, 1988, MOL CELL BIOL, V8, P674, DOI 10.1128/MCB.8.2.674; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HYMAN R, 1985, BIOCHEM J, V225, P27, DOI 10.1042/bj2250027; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; HYMAN R, 1980, IMMUNOGENETICS, V10, P261, DOI 10.1007/BF01561574; INOUE N, UNPUB; ISHIHARA A, 1987, P NATL ACAD SCI USA, V84, P1290, DOI 10.1073/pnas.84.5.1290; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; NODA M, 1987, J CELL BIOL, V105, P1671, DOI 10.1083/jcb.105.4.1671; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PUOTI A, 1991, J BIOL CHEM, V266, P21051; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; ROSSE WF, 1991, BLOOD, V78, P547, DOI 10.1182/blood.V78.3.547.bloodjournal783547; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKAHASHI M, UNPUB; UETSUKI T, 1989, J BIOL CHEM, V264, P5791	29	422	430	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 26	1993	259	5099					1318	1321		10.1126/science.7680492	http://dx.doi.org/10.1126/science.7680492			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	7680492				2022-12-28	WOS:A1993KN88300029
J	ALLEN, RC; ARMITAGE, RJ; CONLEY, ME; ROSENBLATT, H; JENKINS, NA; COPELAND, NG; BEDELL, MA; EDELHOFF, S; DISTECHE, CM; SIMONEAUX, DK; FANSLOW, WC; BELMONT, J; SPRIGGS, MK				ALLEN, RC; ARMITAGE, RJ; CONLEY, ME; ROSENBLATT, H; JENKINS, NA; COPELAND, NG; BEDELL, MA; EDELHOFF, S; DISTECHE, CM; SIMONEAUX, DK; FANSLOW, WC; BELMONT, J; SPRIGGS, MK			CD40 LIGAND GENE DEFECTS RESPONSIBLE FOR X-LINKED HYPER-IGM SYNDROME	SCIENCE			English	Article							HUMAN B-CELLS; HYPERIMMUNOGLOBULINEMIA-M; T-CELLS; IMMUNODEFICIENCY; INTERLEUKIN-4; DIFFERENTIATION; SWITCH; PROLIFERATION; LOCALIZATION; ACTIVATION	The ligand for CD40 (CD40L) is a membrane glycoprotein on activated T cells that induces B cell proliferation and immunoglobulin secretion. Abnormalities in the CD40L gene were associated with an X-linked immunodeficiency in humans [hyper-IgM (immunoglobulin M) syndrome]. This disease is characterized by elevated concentrations of serum IgM and decreased amounts of all other isotypes. CD40L complementary DNAs from three of four patients with this syndrome contained distinct point mutations. Recombinant expression of two of the mutant CD40L complementary DNAs resulted in proteins incapable of binding to CD40 and unable to induce proliferation or IgE secretion from normal B cells. Activated T cells from the four affected patients failed to express wild-type CD40L, although their B cells responded normally to wild-type CD40L. Thus, these CD40L defects lead to a T cell abnormality that results in the failure of patient B cells to undergo immunoglobulin class switching.	IMMUNEX RES & DEV CORP, DEPT MOLEC BIOL, SEATTLE, WA 98101 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, INST MOLEC GENET, HOUSTON, TX 77030 USA; IMMUNEX RES & DEV CORP, DEPT IMMUNOL, SEATTLE, WA 98101 USA; ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, MEMPHIS, TN 38105 USA; NCI, FREDERICK CANC RES & DEV CTR, MAMMALIAN GENET LAB, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Washington; University of Washington Seattle; University of Tennessee System; University of Tennessee Health Science Center; Baylor College of Medicine			Belmont, John W/AAI-2494-2019; Belmont, John/AAH-6084-2021	Belmont, John W/0000-0001-7409-3578; 	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; PHS HHS [A125129] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE RJ, 1990, INT IMMUNOL, V2, P1039, DOI 10.1093/intimm/2.11.1039; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARMITAGE RJ, 1990, J IMMUNOL, V144, P938; ARMITAGE RJ, UNPUB; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BRAHMI Z, 1983, J CLIN IMMUNOL, V3, P127, DOI 10.1007/BF00915483; CLAASSEN JL, 1990, J IMMUNOL METHODS, V126, P213, DOI 10.1016/0022-1759(90)90153-M; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; DICKINSON ME, 1990, GENOMICS, V6, P505, DOI 10.1016/0888-7543(90)90480-I; FANSLOW WC, 1992, J IMMUNOL, V149, P655; GALY AHM, 1992, J IMMUNOL, V149, P775; GEHA RS, 1979, J CLIN INVEST, V64, P385, DOI 10.1172/JCI109473; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GREEN EL, 1992, GENETICS PROBABILITY, P77; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HENDRIKS RW, 1990, EUR J IMMUNOL, V20, P2603, DOI 10.1002/eji.1830201212; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JAMIESON WM, 1962, ARCH DIS CHILD, V37, P330, DOI 10.1136/adc.37.193.330; KYONG CU, 1978, PEDIATR RES, V12, P1024, DOI 10.1203/00006450-197810000-00015; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; LEVITT D, 1983, J CLIN INVEST, V72, P1650, DOI 10.1172/JCI111124; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MALISZEWSKI CR, UNPUB; MARTH JD, 1986, P NATL ACAD SCI USA, V83, P7400, DOI 10.1073/pnas.83.19.7400; MAYER L, 1986, NEW ENGL J MED, V314, P409, DOI 10.1056/NEJM198602133140703; MENSINK EJBM, 1987, HUM GENET, V76, P96; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; ROSEN FS, 1961, PEDIATRICS, V28, P182; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WINFIELD JB, 1982, CLIN IMMUNOL IMMUNOP, V23, P58, DOI 10.1016/0090-1229(82)90070-8; ZHANG K, 1991, J IMMUNOL, V146, P1836	40	738	766	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 12	1993	259	5097					990	993		10.1126/science.7679801	http://dx.doi.org/10.1126/science.7679801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	7679801				2022-12-28	WOS:A1993KL80000049
J	HORTON, R				HORTON, R			ESOPHAGEAL CANCER - LASER PALLIATION OF MALIGNANT DYSPHAGIA	LANCET			English	Editorial Material							CARCINOMA						Gandevia, Simon/D-5009-2011	Gandevia, Simon/0000-0002-1345-3821				BARR H, 1991, CANCER, V68, P1660, DOI 10.1002/1097-0142(19911001)68:7<1660::AID-CNCR2820680733>3.0.CO;2-L; GATZINSKY P, 1985, J THORAC CARDIOV SUR, V89, P71; LOIZOU LA, 1992, CANCER, V70, P386, DOI 10.1002/1097-0142(19920715)70:2<386::AID-CNCR2820700203>3.0.CO;2-H; MAUNOURY V, 1992, GUT, V33, P1602, DOI 10.1136/gut.33.12.1602; NAKAYAMA K, 1964, Clin Radiol, V15, P232, DOI 10.1016/S0009-9260(64)80073-8; SARGEANT IR, 1992, GUT, V33, P1597, DOI 10.1136/gut.33.12.1597; SKINNER DB, 1986, ANN SURG, V204, P391, DOI 10.1097/00000658-198610000-00007; WANG M, 1989, INT J RADIAT ONCOL, V16, P325; ZENONE T, 1992, EUR J CANCER, V28A, P1380, DOI 10.1016/0959-8049(92)90525-7	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					348	348		10.1016/0140-6736(93)90145-7	http://dx.doi.org/10.1016/0140-6736(93)90145-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	7679176				2022-12-28	WOS:A1993KK93900013
J	MOORE, PS; CHANG, Y				MOORE, PS; CHANG, Y			DETECTION OF HERPESVIRUS-LIKE DNA-SEQUENCES IN KAPOSIS-SARCOMA IN PATIENTS WITH AND THOSE WITHOUT HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEROLOGICAL ASSOCIATION; ANTIBODY PATTERNS; ENDEMIC AFRICAN; HOMOSEXUAL MEN; AIDS; CYTOMEGALOVIRUS; EPIDEMIC; RISK	Background. Herpesvirus-like DNA sequences have recently been found in lesions from patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS). It is not known whether these sequences are also present in classic Kaposi's sarcoma or in the Kaposi's sarcoma that occurs in homosexual men who are seronegative for the human immunodeficiency virus (HIV). Methods. We analyzed DNA in tissue samples from patients with AIDS-associated Kaposi's sarcoma, patients with classic Kaposi's sarcoma, and HIV-seronegative homosexual men with Kaposi's sarcoma. We also analyzed DNA in samples of uninvolved tissue from these patients and in control tissue from healthy subjects. All samples were tested blindly by polymerase chain reaction (PCR) with specific primers to amplify KS330(233), a herpesvirus-like DNA sequence. Results. The KS330(233) PCR product was found in 20 of 21 tissue samples (95 percent) from the patients with Kaposi's sarcoma, including 10 of the 11 samples from the patients with AIDS-associated Kaposi's sarcoma, all 6 samples from the patients with classic Kaposi's sarcoma, and all 4 samples from the HIV-negative homosexual men with Kaposi's sarcoma. Only 1 of the 21 control samples (5 percent) was positive (odds ratio, 400; 95 percent confidence interval, 19 to 17,300). Of the 14 samples of uninvolved skin from the patients with Kaposi's sarcoma, 3 were positive for KS330(233). Representative PCR-product sequences were more than 98 percent identical for the three types of Kaposi's sarcoma, suggesting that all three are caused by the same agent. Conclusions. The same herpesvirus-like DNA sequences are present in AIDS-associated Kaposi's sarcoma, classic Kaposi's sarcoma, and the Kaposi's sarcoma that occurs in HIV-negative homosexual men. Therefore, this presumably new human herpesvirus is not solely an opportunistic infection in patients with AIDS, and the three forms of Kaposi's sarcoma may be caused by the same infectious agent.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY USA	Columbia University	MOORE, PS (corresponding author), COLUMBIA UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, PH18, 630 W 168TH ST, NEW YORK, NY 10032 USA.		Moore, Patrick/GVR-8294-2022; Moore, Patrick S./F-3960-2011; Chang, Yuan/F-4146-2011	Moore, Patrick S./0000-0002-8132-858X; Chang, Yuan/0000-0003-1125-4041	PHS HHS [U64CCU210852-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMBINDER RF, 1985, J INFECT DIS, V156, P193; ARCHIBALD CP, 1992, EPIDEMIOLOGY, V3, P203, DOI 10.1097/00001648-199205000-00004; BENDSOE N, 1990, EUR J CANCER, V26, P699, DOI 10.1016/0277-5379(90)90120-I; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1992, LANCET, V339, P632, DOI 10.1016/0140-6736(92)90793-3; BERAL V, 1991, BRIT MED J, V302, P624, DOI 10.1136/bmj.302.6777.624; BERAL V, 1991, BRIT MED J, V302, P752; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; DIGIOVANNA JJ, 1981, AM J MED, V71, P779, DOI 10.1016/0002-9343(81)90364-8; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FRIEDMANKIEN AE, 1990, LANCET, V335, P168, DOI 10.1016/0140-6736(90)90041-3; FRIEDMANKIEN AE, 1990, J AM ACAD DERMATOL, V22, P1237, DOI 10.1016/0190-9622(90)70169-I; GAN YJ, 1994, J INFECT DIS, V170, P436, DOI 10.1093/infdis/170.2.436; GIRALDO G, 1978, INT J CANCER, V22, P126, DOI 10.1002/ijc.2910220204; GIRALDO G, 1975, INT J CANCER, V15, P839, DOI 10.1002/ijc.2910150516; HUANG YQ, 1993, J CLIN INVEST, V91, P1191, DOI 10.1172/JCI116279; HUANG YQ, 1995, LANCET, V345, P749; KATZ MH, 1994, J INFECT DIS, V170, P198, DOI 10.1093/infdis/170.1.198; KESTENS L, 1985, INT J CANCER, V36, P49, DOI 10.1002/ijc.2910360109; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; NICOLAIDES A, 1994, ANTICANCER RES, V14, P921; PENN I, 1979, TRANSPLANTATION, V27, P8, DOI 10.1097/00007890-197901000-00003; PETERMAN TA, 1991, CANCER SURV, V10, P23; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5	26	997	1029	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 4	1995	332	18					1181	1185		10.1056/NEJM199505043321801	http://dx.doi.org/10.1056/NEJM199505043321801			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV415	7700310	Bronze			2022-12-28	WOS:A1995QV41500001
J	MCGINNIS, JM; LEE, PR				MCGINNIS, JM; LEE, PR			HEALTHY-PEOPLE-2000 AT MID-DECADE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											MCGINNIS, JM (corresponding author), US PHS,330 C ST SW,ROOM 2132,WASHINGTON,DC 20201, USA.							[Anonymous], 1989, GUIDE CLIN PREVENTIV; [Anonymous], MMWR-MORBID MORTAL W, DOI DOI 10.15585/MMWR; KREUTERMW, 1992, J HLTH ED, V23, P135; LASKER RD, 1994, JAMA-J AM MED ASSOC, V272, P1297, DOI 10.1001/jama.272.16.1297; MCGINNIS JM, 1992, JAMA-J AM MED ASSOC, V268, P2545, DOI 10.1001/jama.268.18.2545; 1990, MMWR-MORBID MORTAL W, V39, P1; 1992, HLTH PEOPLE 2000 STA; [No title captured]; 1994, FED REG         1003, V59, P50253; 1993, MARCH 1993 SUPPLEMEN; 1995, MMWR-MORBID MORTAL W, V44, P142; [No title captured]; 1993, MMWR-MORBID MORTAL W, V42, P258; 1990, HLTH PEOPLE 2000 AM; 1987, VITAL STATISTICS US, V2; 1990, ASSESSMENT PROTOCOL; 1988, NATIONAL HOUSEHOLD S; 1993, HLTH PLAN EMPLOYER D; 1992, HLTH PEOPLE 2000 PUB; 1994, PHS9412321 US DEP HL; 1992 1993 NATIONAL P; 1980, PROMOTING HLTH PREVE; 1990, HLTH PEOPLE 2000 CIT; 1991, HLTH COMMUNITIES 200; 1992, HLTH PEOPLE 2000 CON; 1990, HLTH YOUTH 2000	26	97	97	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1123	1129		10.1001/jama.273.14.1123	http://dx.doi.org/10.1001/jama.273.14.1123			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR059	7707601				2022-12-28	WOS:A1995QR05900032
J	GLYNN, JR; JENKINS, PA; FINE, PEM; PONNIGHAUS, JM; STERNE, JAC; MKANDWIRE, PK; NYASULU, S; BLISS, L; WARNDORFF, DK				GLYNN, JR; JENKINS, PA; FINE, PEM; PONNIGHAUS, JM; STERNE, JAC; MKANDWIRE, PK; NYASULU, S; BLISS, L; WARNDORFF, DK			PATTERNS OF INITIAL AND ACQUIRED ANTITUBERCULOSIS DRUG-RESISTANCE IN KARONGA DISTRICT, MALAWI	LANCET			English	Article							TUBERCULOSIS	There is concern that drug-resistant tuberculosis is increasing and may be concentrated among HIV-positive patients. Little information is available from developing countries, where surveillance studies are often unable to distinguish resistance in previously untreated patients (initial resistance) from resistance acquired following drug therapy, and where information on the HIV status of the patients is rare. Initial resistance patterns reflect the strains being transmitted in the community. We have studied patterns of resistance in northern Malawi, where the Lepra Evaluation Project has been collecting data on drug resistance since 1986. Initial drug sensitivity results were available for 373 new cases of tuberculosis. Initial resistance to at least one drug was found in 44 of these patients (11.8%, 95% CI 8.5-15.1): 13 were resistant to streptomycin alone, 13 to isoniazid alone, and 17 to more than one drug. Only 3 patients showed initial rifampicin resistance-1 in isolation, 1 in combination with streptomycin, and 1 with triple resistance. Drug resistance was not related to age, sex, or HIV status of the patient and there was no evidence of any increase over the period studied. There was no evidence of geographic clustering of the resistant strains, or of any increased risk of resistant strains in households with previous tuberculosis cases. Acquired resistance during follow-up was found in 5 of 329 patients with documented initially fully sensitive strains. 5 patients with initial resistance seemed to show reversion to sensitivity. The absence of an increase in drug resistance, despite an increase in tuberculosis cases over the period, is encouraging for the control programme. It emphasises the need to collect information from many areas before assuming that increases in antituberculosis drug resistance are occurring worldwide.	UNIV WALES HOSP,PHLS MYCOBACTERIUM REFERENCE UNIT,CARDIFF CF4 4XW,S GLAM,WALES; LEPRA,CHLLUMBA,MALAWI	Cardiff University	GLYNN, JR (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,COMMUNICABLE DIS EPIDEMIOL UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Sterne, Jonathan/Z-3106-2019	Sterne, Jonathan/0000-0001-8496-6053				BOHMER PD, 1992, S AFR MED J, V81, P382; Boulahbal F, 1989, Bull Int Union Tuberc Lung Dis, V64, P23; BRAUN MM, 1992, AIDS, V6, P1327, DOI 10.1097/00002030-199211000-00014; COWIE RL, 1990, TUBERCLE, V71, P39, DOI 10.1016/0041-3879(90)90059-H; DECALUWE P, 1989, ANN SOC BELG MED TR, V69, P143; Freiden T.E., 1993, NEW ENGL J MED, V328, P521; GITHUI W, 1992, TUBERCLE LUNG DIS, V73, P203, DOI 10.1016/0962-8479(92)90087-Z; Jenkins P. A., 1985, Isolation and identification of micro-organisms of medical and veterinary importance, P275; LEMMA E, 1984, ETHIOPIAN MED J, V22, P93; MITCHISON DA, 1984, BRIT MED BULL, V40, P84, DOI 10.1093/oxfordjournals.bmb.a071952; NKINDA S J, 1985, Tubercle, V66, P161; NUNN P, 1994, TUBERCLE LUNG DIS, V75, P163, DOI 10.1016/0962-8479(94)90001-9; Nyangulu D S, 1991, Bull Int Union Tuberc Lung Dis, V66, P173; SHENNAN D H, 1964, Tubercle, V45, P1, DOI 10.1016/S0041-3879(64)80080-5; SWAI OB, 1989, TUBERCLE, V70, P5; VARELDZIS BP, 1994, TUBERCLE LUNG DIS, V75, P1, DOI 10.1016/0962-8479(94)90096-5; WEYER K, 1992, TUBERCLE LUNG DIS, V73, P106, DOI 10.1016/0962-8479(92)90064-Q; WOLDE K, 1986, ETHIOPIAN MED J, V24, P15	18	44	45	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					907	910		10.1016/S0140-6736(95)90016-0	http://dx.doi.org/10.1016/S0140-6736(95)90016-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707817				2022-12-28	WOS:A1995QR06700016
J	BENTON, MJ				BENTON, MJ			DIVERSIFICATION AND EXTINCTION IN THE HISTORY OF LIFE	SCIENCE			English	Article							PHANEROZOIC TAXONOMIC DIVERSITY; FOSSIL RECORD; MASS EXTINCTIONS; KINETIC-MODEL; HIGHER TAXA; TETRAPODS; FAMILIES; PATTERNS; ORIGINATION; PERIODICITY	Analysis of the fossil record of microbes, algae, fungi, protists, plants, and animals shows that the diversity of both marine and continental life increased exponentially since the end of the Precambrian. This diversification was interrupted by mass extinctions, the largest of which occurred in the Early Cambrian, Late Ordovician, tate Devonian, Late Permian, Early Triassic, Late Triassic, and end-Cretaceous. Most of these extinctions were experienced by both marine and continental organisms. As for the periodicity of mass extinctions, no support was found: Seven mass extinction peaks in the last 250 million years are spaced 20 to 60 million years apart.			BENTON, MJ (corresponding author), UNIV BRISTOL,DEPT GEOL,WILLS MEM BLDG,BRISTOL BS8 1RJ,AVON,ENGLAND.		Benton, Michael J/A-5639-2008	Benton, Michael J/0000-0002-4323-1824				Benton M. J., 1987, MEM SOC GEOL FR, V150, P21; BENTON MJ, 1987, BIOL REV, V62, P305, DOI 10.1111/j.1469-185X.1987.tb00666.x; BENTON MJ, 1994, GEOLOGY, V22, P111, DOI 10.1130/0091-7613(1994)022<0111:TTQOTF>2.3.CO;2; BENTON MJ, 1994, TRENDS ECOL EVOL, V9, P181, DOI 10.1016/0169-5347(94)90083-3; BENTON MJ, 1989, PHILOS T ROY SOC B, V325, P369, DOI 10.1098/rstb.1989.0094; BENTON MJ, 1985, NATURE, V316, P811, DOI 10.1038/316811a0; BENTON MJ, IN PRESS PHILOS T B; BENTON MJ, 1991, UNITY EVOLUTIONARY B; BENTON MJ, 1989, PALAEONTOLOGY EVOLUT, P218; BENTON MJ, 1993, FOSSIL RECORDS, V2, pR13; BENTON MJ, 1995, IN PRESS GENESIS MAI; BENTON MJ, 1993, FOSSIL RECORD, V2; BOYAJIAN GF, 1986, GEOLOGY, V14, P955, DOI 10.1130/0091-7613(1986)14<955:PTIBEC>2.0.CO;2; ERWIN DH, 1987, EVOLUTION, V41, P1177, DOI 10.1111/j.1558-5646.1987.tb02459.x; FOOTE M, 1994, PALEOBIOLOGY, V20, P424, DOI 10.1017/S0094837300012914; GAUTHIER J, 1988, CLADISTICS, V4, P105, DOI 10.1111/j.1096-0031.1988.tb00514.x; GILINSKY NL, 1987, PALEOBIOLOGY, V13, P427; Harland W. B., 1967, FOSSIL RECORD; Harland W.B., 1990, GEOLOGIC TIME SCALE; HENNIG W, 1999, PHYLOGENETIC SYSTEMA; HOLMAN EW, 1989, PALEOBIOLOGY, V15, P357, DOI 10.1017/S0094837300009556; Jarzembowski Ed, 1993, Geology Today, V9, P218, DOI 10.1111/j.1365-2451.1993.tb01067.x; Kitchell J.A., 1985, P277; Knoll A.H., 1990, P9; LABANDEIRA CC, 1993, SCIENCE, V261, P310, DOI 10.1126/science.11536548; MAXWELL WD, 1990, PALEOBIOLOGY, V16, P322, DOI 10.1017/S0094837300010022; MAY RM, 1990, PHILOS T R SOC B, V330, P293, DOI 10.1098/rstb.1990.0200; Mayr W., 1969, PRINCIPLES SYSTEMATI; MCKINNEY ML, 1987, NATURE, V325, P143, DOI 10.1038/325143a0; NIKLAS KJ, 1983, NATURE, V303, P614, DOI 10.1038/303614a0; Niklas KJ, 1980, EVOLUTIONARY BIOL, V12, P1; NORELL MA, 1992, SCIENCE, V255, P1690, DOI 10.1126/science.255.5052.1690; RAUP D., 1991, ANAL PALEOBIOLOGY, V4, P207; RAUP DM, 1972, SCIENCE, V177, P1065, DOI 10.1126/science.177.4054.1065; RAUP DM, 1986, SCIENCE, V231, P833, DOI 10.1126/science.11542060; RAUP DM, 1984, P NATL ACAD SCI-BIOL, V81, P801, DOI 10.1073/pnas.81.3.801; RAUP DM, 1982, SCIENCE, V215, P1501, DOI 10.1126/science.215.4539.1501; SCHOPF JW, 1993, SCIENCE, V260, P640, DOI 10.1126/science.260.5108.640; Sepkoski J. J., 1982, MILWAUKEE PUBLIC MUS, V51, P1; Sepkoski J. J., 1986, PATT PROC HIST LIF R, P277, DOI DOI 10.1007/978-3-642-70831-2_15; Sepkoski J.J. Jr, 1986, P3; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P43, DOI 10.1017/S0094837300012306; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P168, DOI 10.1017/S0094837300015852; SEPKOSKI JJ, 1978, PALEOBIOLOGY, V4, P223, DOI 10.1017/S0094837300005972; SEPKOSKI JJ, 1989, J GEOL SOC LONDON, V146, P7, DOI 10.1144/gsjgs.146.1.0007; SEPKOSKI JJ, 1981, NATURE, V293, P435, DOI 10.1038/293435a0; SEPKOSKI JJ, 1984, PALEOBIOLOGY, V10, P246, DOI 10.1017/S0094837300008186; SEPKOSKI JJ, 1994, GEOTIMES, V39, P15; SEPKOSKI JJ, 1979, PALEOBIOLOGY, V5, P222, DOI 10.1017/S0094837300006539; SEPKOSKI JJ, IN PRESS BIOEVENTS E; Sepkoski Jr J.J., 1992, MILWAUKEE PUBLIC MUS, V83, P1; Signor P.W. III, 1985, P129; SMITH AB, 1994, SYSTEMATICS FOSSIL R; Valentine J. W., 1969, Palaeontology, V12, P684; VANVALEN LM, 1984, NATURE, V307, P50, DOI 10.1038/307050a0; VANVALEN LM, 1985, EVOL THEOR, V7, P133; [No title captured]; [No title captured]; [No title captured]	59	442	464	6	235	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					52	58		10.1126/science.7701342	http://dx.doi.org/10.1126/science.7701342			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701342	Green Submitted			2022-12-28	WOS:A1995QR45400023
J	STAMPF, DR; FELDER, CE; SUSSMAN, JL				STAMPF, DR; FELDER, CE; SUSSMAN, JL			PDBBROWSE - A GRAPHICS INTERFACE TO THE BROOKHAVEN PROTEIN DATA-BANK	NATURE			English	Article									WEIZMANN INST SCI,DEPT BIOL STRUCT,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	STAMPF, DR (corresponding author), BROOKHAVEN NATL LAB,DEPT CHEM,UPTON,NY 11973, USA.			Sussman, Joel/0000-0003-0306-3878				BARTON GJ, 1994, TRENDS BIOCHEM SCI, V19, P554, DOI 10.1016/0968-0004(94)90060-4; Ousterhout J. K., 1994, TCL TK TOOLKIT; PEITSCH MC, 1995, TRENDS BIOCHEM SCI, V20, P82, DOI 10.1016/S0968-0004(00)88963-X; SCHATZ BR, 1994, SCIENCE, V265, P895, DOI 10.1126/science.265.5174.895; SCHWARTZ RL, 1992, PROGRAMMING PERL; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899	6	27	28	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					572	574		10.1038/374572a0	http://dx.doi.org/10.1038/374572a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700388				2022-12-28	WOS:A1995QR06900061
J	CRAIG, AD; BUSHNELL, MC; ZHANG, ET; BLOMQVIST, A				CRAIG, AD; BUSHNELL, MC; ZHANG, ET; BLOMQVIST, A			A THALAMIC NUCLEUS SPECIFIC FOR PAIN AND TEMPERATURE SENSATION	NATURE			English	Article							NEURONS; AREA; CAT; STIMULI; MONKEY; TRACT	THE existence of a posterolateral thalamic relay nucleus for pain and temperature sensation was postulated in 1911, on the basis of the stroke-induced analgesia and thermanaesthesia found paradoxically in patients with thalamic pain syndrome(1). Pain or temperature sensations can be evoked in humans by electrical stimulation in a vaguely defined region of the posterolateral thalamus(2,3). Here we use anterograde tracing and single unit recordings to demonstrate that there is a distinct nucleus in the posterior thalamus of the macaque monkey that receives a dense, topographic input from spinothalamic lamina I neurons and in which almost all neurons are nociceptive- or thermoreceptive-specific. Immunohistochemical staining showed that this nucleus is defined by a dense calbindin-positive fibre plexus in the macaque, so we applied the same staining method to sections of human thalamus. We found a nearly identical fibre plexus localized within a distinct nucleus that is cytoarchitectonically homologous to the lamina I relay nucleus in the macaque thalamus. The stereotaxic coordinates of this nucleus and its location relative to the main somatosensory representation fit clinical descriptions of the pain-producing region in humans. We conclude that this is a specific thalamic nucleus for pain and temperature sensation in both monkey and human.	UNIV MONTREAL,FAC MED DENT,DEPT STOMATOL,MONTREAL H3C 3J7,PQ,CANADA; UNIV MONTREAL,FAC MED DENT,CTR RECH SCI NEUROL,MONTREAL H3C 3J7,PQ,CANADA; LINKOPING UNIV,FAC HLTH SCI,DEPT CELL BIOL,S-58185 LINKOPING,SWEDEN	Universite de Montreal; Universite de Montreal; Linkoping University	CRAIG, AD (corresponding author), BARROW NEUROL INST,DIV NEUROBIOL,350 W THOMAS RD,PHOENIX,AZ 85013, USA.		Blomqvist, Anders/K-3990-2019	Blomqvist, Anders/0000-0002-6928-4473				ANTAL M, 1990, J COMP NEUROL, V295, P467, DOI 10.1002/cne.902950310; BLOMQVIST A, 1993, J COMP NEUROL, V327, P584, DOI 10.1002/cne.903270409; BOGOUSSLAVSKY J, 1988, NEUROLOGY, V38, P837, DOI 10.1212/WNL.38.6.837; BUSHNELL MC, 1993, J NEUROPHYSIOL, V69, P739, DOI 10.1152/jn.1993.69.3.739; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802, DOI 10.1152/jn.1994.71.2.802; CHRISTENSEN BN, 1970, J NEUROPHYSIOL, V33, P293, DOI 10.1152/jn.1970.33.2.293; COGHILL RC, 1994, J NEUROSCI, V14, P4095; CRAIG AD, 1993, J COMP NEUROL, V331, P517, DOI 10.1002/cne.903310407; CRAIG AD, 1992, J COMP NEUROL, V322, P99, DOI 10.1002/cne.903220108; CRAIG AD, 1985, J PHYSIOL-LONDON, V365, P197, DOI 10.1113/jphysiol.1985.sp015767; CRAIG AD, 1994, SCIENCE, V265, P252, DOI 10.1126/science.8023144; CRAIG AD, 1991, J COMP NEUROL, V308, P56; CRAIG AD, PROGR PAIN RES MAN, V3; Dostrovsky JO, 1992, INT C SERIES, V989, P115; FRIEDMAN DP, 1986, J COMP NEUROL, V252, P348, DOI 10.1002/cne.902520305; Head H, 1911, BRAIN, V34, P102, DOI 10.1093/brain/34.2-3.102; HIRAI T, 1989, BRAIN RES REV, V14, P1, DOI 10.1016/0165-0173(89)90007-6; JEANMONOD D, 1994, NEUROREPORT, V4, P475; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; JONES EG, 1989, EUR J NEUROSCI, V1, P222, DOI 10.1111/j.1460-9568.1989.tb00791.x; LEIJON G, 1989, PAIN, V36, P13, DOI 10.1016/0304-3959(89)90107-3; LENZ FA, 1993, J NEUROPHYSIOL, V70, P200, DOI 10.1152/jn.1993.70.1.200; LENZ FA, 1993, BRAIN RES, V623, P235, DOI 10.1016/0006-8993(93)91433-S; PANNETON WM, 1991, J COMP NEUROL, V313, P377; Perl E. R., 1984, HDB PHYSL 2 1, VIII, P915; RALSTON HJ, 1992, PAIN, V48, P107, DOI 10.1016/0304-3959(92)90137-Z; RICHARDSON DE, 1967, CONFIN NEUROL, V29, P139; White JC., 1969, PAIN NEUROSURGEON, P6	28	417	427	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 22	1994	372	6508					770	773		10.1038/372770a0	http://dx.doi.org/10.1038/372770a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PY212	7695716				2022-12-28	WOS:A1994PY21200050
J	FREIER, JE				FREIER, JE			EASTERN EQUINE ENCEPHALOMYELITIS	LANCET			English	Article											FREIER, JE (corresponding author), USDA,CTR EPIDEMIOL & ANIM HLTH,ANIM & PLANT HLTH INSPECT SERV,VET SERV,555 S HOWES ST,FT COLLINS,CO 80525, USA.							CRANS WJ, 1977, MOSQ NEWS, V37, P85; MORRIS AC, 1989, MED VET ENTOMOL, V3, P1, DOI 10.1111/j.1365-2915.1989.tb00467.x; SCHWARZ D, 1985, SURVEILLANT SCI REMO, P53; TSAI TF, 1987, TXB PEDIATRIC INFECT, V2, P1417	4	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1281	1282		10.1016/0140-6736(93)92366-2	http://dx.doi.org/10.1016/0140-6736(93)92366-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7695660				2022-12-28	WOS:A1993MH56600016
J	ROBBINS, FC				ROBBINS, FC			ERADICATION OF POLIO IN THE AMERICA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									PAN AMER HLTH ORG,INT COMMISS CERTIFICAT ERADICAT POLIO AMER,WASHINGTON,DC	Pan American Health Organization	ROBBINS, FC (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.							CHEN R, 1992, 32ND INT C ANT AG CH; RIORDAN JT, 1961, YALE J BIOL MED, V34, P512; SHALALA DE, 1993, JAMA-J AM MED ASSOC, V269, P144; 1992, MMWR MORB MORTAL WKL, V41, P917; 1993, MMWR MORB MORTAL WKL, V42, P337; 1991, JAMA-J AM MED ASSOC, V266, P1547; 1993, JAMA-J AM MED ASSOC, V269, P1817	7	15	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1993	270	15					1857	1859		10.1001/jama.270.15.1857	http://dx.doi.org/10.1001/jama.270.15.1857			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB464	7692114				2022-12-28	WOS:A1993MB46400031
J	KAMINSKI, MS; ZASADNY, KR; FRANCIS, IR; MILIK, AW; ROSS, CW; MOON, SD; CRAWFORD, SM; BURGESS, JM; PETRY, NA; BUTCHKO, GM; GLENN, SD; WAHL, RL				KAMINSKI, MS; ZASADNY, KR; FRANCIS, IR; MILIK, AW; ROSS, CW; MOON, SD; CRAWFORD, SM; BURGESS, JM; PETRY, NA; BUTCHKO, GM; GLENN, SD; WAHL, RL			RADIOIMMUNOTHERAPY OF B-CELL LYMPHOMA WITH [I-131] ANTI-B1 (ANTI-CD20) ANTIBODY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RADIOLABELED MONOCLONAL-ANTIBODIES; NON-HODGKINS-LYMPHOMA; EXTERNAL BEAM IRRADIATION; CARCINOMA XENOGRAFTS; ANTIGEN; DOSIMETRY; TRIAL; SEROTHERAPY; MALIGNANCIES; COMBINATION	Background. Many patients with non-Hodgkin's lymphomas are not cured by current therapies, and new approaches to treatment are needed. As part of an ongoing phase 1 study, we examined the effect of radioimmunotherapy with I-131-labeled B-cell-specific anti-CD20 monoclonal antibody in 10 patients with CD20-positive B-cell lymphomas in whom primary chemotherapy had failed. Methods and Results. Anti-B1 (anti-CD20) mouse monoclonal antibody trace-labeled with I-131 (15 mg containing 5 mCi) was given intravenously at approximately one-week intervals: first, without pretreatment with unlabeled anti-B1 antibody, to all 10 patients; then, with pretreatment with 135 mg of unlabeled antibody, to 8 patients; and then, with pretreatment with 685 mg, to 2 patients. Serial quantitative gamma-camera images and measures of whole-body radioactivity were obtained after each tracer dose. All known disease sites larger than 2 cm could be imaged. The effect of a pretreatment dose of unlabeled anti-B1 antibody on targeting of the tumor with the radiolabeled antibody was variable. The pretreatment dose of unlabeled antibody that produced the highest ratio of the tumor dose to the whole-body dose in tracer studies was then used to deliver higher doses of radioactivity for radioimmunotherapy in nine patients. Three patients received doses designed to deliver 25 cGy to the whole body (two patients treated twice, six to eight weeks apart), four patients received 35 cGy (one patient treated twice), and two patients received 45 cGy (one patient treated twice); each dose contained 34 to 66 mCi of activity. Six of the nine treated patients had tumor responses, including patients with bulky or chemotherapy-resistant disease: four patients had complete remissions, and two had partial responses. Three patients had objective responses to tracer infusions before they received radioimmunotherapeutic doses. Of the four patients with complete remissions, one remained in remission for eight months and the other three continue to have no disease progression (for 11, 9, and 8 months). There was mild or no myelosuppression. Conclusions. Radioimmunotherapy with [I-131]anti-B1 antibody is a promising new treatment for lymphoma.	COULTER CORP, HIALEAH, FL USA; UNIV MICHIGAN, DEPT INTERNAL MED, DIV NUCL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT INTERNAL MED, DIV HEMATOL ONCOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT RADIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NCI NIH HHS [R01-CA-56794, P01-CA-42768] Funding Source: Medline; NCRR NIH HHS [MO1-RR-00042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056794, P01CA042768] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		[Anonymous], 1975, REPORT TASK GROUP RE; ARMITAGE JO, 1989, BLOOD, V73, P1749; BAST RC, 1983, CANCER RES, V43, P1389; BROWN SL, 1989, BLOOD, V73, P651; BUCHSBAUM DJ, 1992, CANCER RES, V52, P6476; BUCHSBAUM DJ, 1990, INT J RADIAT ONCOL, V18, P1033, DOI 10.1016/0360-3016(90)90438-P; DENARDO GL, 1990, CANCER RES, V50, pS1014; DENARDO SJ, 1988, INT J CANCER, P96; DENARDO SJ, 1988, ANTIBODY IMMUNOCONJ, V1, P17; DEVITA VT, 1989, CANCER PRINCIPLES PR, V2, P1741; DILLMAN LT, NMMIRD10 SOC NUCL ME; DYER MJS, 1989, BLOOD, V73, P1431; ELLET WH, NMMIRD8 SOC NUCL MED; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOLDENBERG DM, 1991, J CLIN ONCOL, V9, P548, DOI 10.1200/JCO.1991.9.4.548; GORDON LI, 1992, NEW ENGL J MED, V327, P1342, DOI 10.1056/NEJM199211053271903; GROSSBARD ML, 1992, BLOOD, V79, P576; GROSSBARD ML, 1993, J CLIN ONCOL, V11, P726, DOI 10.1200/JCO.1993.11.4.726; HALE G, 1988, LANCET, V2, P1394; KAMINSKI MS, 1992, J CLIN ONCOL, V10, P1696, DOI 10.1200/JCO.1992.10.11.1696; KNOX SJ, 1990, CANCER RES, V50, P4935; LINDMO T, 1984, J IMMUNOL METHODS, V72, P77, DOI 10.1016/0022-1759(84)90435-6; MACKLIS RM, 1992, RADIAT RES, V130, P220, DOI 10.2307/3578279; MACKLIS RM, 1992, ANTIBODIES IMMUNOCON, V5, P339; MASON DY, 1990, AM J PATHOL, V136, P1215; MEEKER TC, 1985, BLOOD, V65, P1349, DOI 10.1182/blood.V65.6.1349.bloodjournal6561349; NADLER LM, 1980, CANCER RES, V40, P3147; PRESS OW, 1987, BLOOD, V69, P584; PRESS OW, 1989, J CLIN ONCOL, V7, P1027, DOI 10.1200/JCO.1989.7.8.1027; PRESS OW, 1989, CANCER RES, V49, P4906; SCHEINBERG DA, 1990, J CLIN ONCOL, V8, P792, DOI 10.1200/JCO.1990.8.5.792; SNYDER WS, NMMIRD11 SOC NUCL ME; STASHENKO P, 1980, J IMMUNOL, V125, P1678; STEVENSON GT, 1988, INT J CANCER, P9; VITETTA ES, 1991, CANCER RES, V51, P4052; WAHL RL, 1990, J NUCL MED, V31, P84; WATSON E, 1984, MIRDOSE; WESSELS BW, 1989, INT J RADIAT ONCOL, V17, P1257, DOI 10.1016/0360-3016(89)90534-8	39	557	635	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1993	329	7					459	465		10.1056/NEJM199308123290703	http://dx.doi.org/10.1056/NEJM199308123290703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR443	7687326				2022-12-28	WOS:A1993LR44300003
J	TSUBATA, T; WU, J; HONJO, T				TSUBATA, T; WU, J; HONJO, T			B-CELL APOPTOSIS INDUCED BY ANTIGEN RECEPTOR CROSS-LINKING IS BLOCKED BY A T-CELL SIGNAL THROUGH CD40	NATURE			English	Article							INVITRO TOLERANCE INDUCTION; LYMPHOCYTES-B; TRANSGENIC MOUSE; ACTIVATION; IMMUNOGLOBULIN; LIGAND; EXPRESSION; PROTEIN; DEATH; PROLIFERATION	IN mice transgenic for an autoantibody, self-reactive B cells have been shown to be eliminated upon interaction with membrane-bound self-antigens in the periphery1,2 as well as in the bone marrow3,5, suggesting that both immature and mature B cells are eliminated by multimerization of surface immunoglobulins (sIg). Activation of mature B cells by antigens may thus require a second signal that inhibits sIg-mediated apoptosis. Such a second signal is likely to be provided by T helper cells, because B-cell tolerance is more easily induced in the absence of T helper cells6-9. To assess the molecular nature of the signal that inhibits sIg-mediated apoptosis, we used anti-IgM-induced apoptotic death of WEHI-231 B lymphoma cells10,11 as a model system. Here we report that the signal for abrogating sIg-mediated apoptosis is generated by association of the CD40L molecule on T cells with the CD40 molecule on WEHI-231 cells. T-cell help through CD40 may thus determine whether B cells are eliminated or activated upon interaction with antigens.			TSUBATA, T (corresponding author), KYOTO UNIV, FAC MED, DEPT MED CHEM, KYOTO 606, JAPAN.		Honjo, Tasuku/N-4470-2016; Tsubata, Takeshi/AAI-7489-2021	Tsubata, Takeshi/0000-0003-0760-1258				ARMITAGE RJ, 1992, EUR J IMMUNOL, V22, P2071, DOI 10.1002/eji.1830220817; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; METCALF ES, 1977, J IMMUNOL, V118, P2111; METCALF ES, 1976, J EXP MED, V143, P1327, DOI 10.1084/jem.143.6.1327; MOND JJ, 1981, J IMMUNOL, V127, P881; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; ODAKA C, 1990, J IMMUNOL, V144, P2096; OGASAWARA K, 1989, J IMMUNOL, V142, P1448; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; OZAKI S, 1988, J IMMUNOL, V141, P71; PAULIE S, 1989, J IMMUNOL, V142, P590; ROBB RJ, 1986, P NATL ACAD SCI USA, V83, P3992, DOI 10.1073/pnas.83.11.3992; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SHIMIZU A, 1989, P NATL ACAD SCI USA, V86, P8020, DOI 10.1073/pnas.86.20.8020; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; SUBBARAO B, 1983, J IMMUNOL, V130, P2033; SUBBARAO B, 1984, J EXP MED, V159, P1796, DOI 10.1084/jem.159.6.1796; VAN DE VELDE H, 1991, NATURE, V351, P662	35	386	400	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 12	1993	364	6438					645	648		10.1038/364645a0	http://dx.doi.org/10.1038/364645a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	7688865				2022-12-28	WOS:A1993LR77100058
J	BUTLER, A; TSUNODA, S; MCCOBB, DP; WEI, A; SALKOFF, L				BUTLER, A; TSUNODA, S; MCCOBB, DP; WEI, A; SALKOFF, L			MSLO, A COMPLEX MOUSE GENE ENCODING MAXI CALCIUM-ACTIVATED POTASSIUM CHANNELS	SCIENCE			English	Article							LIPID BILAYERS; ION CHANNELS; K+ CHANNELS; DROSOPHILA; SHAKER; COMPONENTS; PERMEATION; CURRENTS; BLOCKADE; PROTEIN	Complementary DNAs (cDNAs) from mSlo, a gene encoding calcium-activated potassium channels, were isolated from mouse brain and skeletal muscle, sequenced, and expressed in Xenopus oocytes. The mSlo-encoded channel resembled ''maxi'' or BK (high conductance) channel types; single channel conductance was 272 picosiemens with symmetrical potassium concentrations. Whole cell and single channel currents were blocked by charybdotoxin, iberiotoxin, and tetraethylammonium ion. A large number of variant mSlo cDNAs were isolated, indicating that several diverse mammalian BK channel types are produced by a single gene.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NINDS NIH HHS [R01 NS24785-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024785] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BUTLER AR, UNPUB; CAHALAN MD, 1991, CURR TOP MEMBR, V39, P357; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; ELKINS T, 1986, P NATL ACAD SCI USA, V83, P8415, DOI 10.1073/pnas.83.21.8415; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GHO M, 1992, J EXP BIOL, V170, P93; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KIRBER MT, 1992, FEBS LETT, V297, P24, DOI 10.1016/0014-5793(92)80319-C; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1992, NEURON, V8, P483; MARTY A, 1989, TRENDS NEUROSCI, V12, P420, DOI 10.1016/0166-2236(89)90090-8; MEECH RW, 1978, ANNU REV BIOPHYS BIO, V7, P1, DOI 10.1146/annurev.bb.07.060178.000245; PALLOTTA BS, 1981, NATURE, V293, P471, DOI 10.1038/293471a0; PETERSEN OH, 1984, NATURE, V307, P693, DOI 10.1038/307693a0; RUDY B, 1991, Molecular and Cellular Neuroscience, V2, P89, DOI 10.1016/1044-7431(91)90001-5; SAITO M, 1991, J NEUROSCI, V11, P2135; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SALKOFF L, 1987, SCIENCE, V237, P744, DOI 10.1126/science.2441469; SALKOFF L, 1985, J PHYSIOL-PARIS, V80, P275; SALKOFF L, 1983, NATURE, V302, P249, DOI 10.1038/302249a0; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SINGH S, 1989, NEURON, V2, P1325, DOI 10.1016/0896-6273(89)90070-6; TORO L, 1991, AM J PHYSIOL, V260, pH1779, DOI 10.1152/ajpheart.1991.260.6.H1779; TORO L, 1990, J GEN PHYSIOL, V96, P373, DOI 10.1085/jgp.96.2.373; TORO L, 1990, AM J PHYSIOL, V258, P912; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157	35	571	588	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					221	224		10.1126/science.7687074	http://dx.doi.org/10.1126/science.7687074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	7687074				2022-12-28	WOS:A1993LL59600044
J	VALIUS, M; KAZLAUSKAS, A				VALIUS, M; KAZLAUSKAS, A			PHOSPHOLIPASE-C-GAMMA-1 AND PHOSPHATIDYLINOSITOL-3 KINASE ARE THE DOWNSTREAM MEDIATORS OF THE PDGF RECEPTORS MITOGENIC SIGNAL	CELL			English	Article							GROWTH-FACTOR RECEPTOR; GTPASE-ACTIVATING PROTEIN; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; C-GAMMA; DNA-SYNTHESIS; BOVINE BRAIN; RAT-LIVER; ASSOCIATION; 3-KINASE	Upon ligand-induced tyrosine phosphorylation, the platelet-derived growth factor (PDGF) receptor (PDGFR) beta subunit associates with PLC-gamma1, RasGAP, PI3K, and a 64 kd protein. To determine the relative role of each of these associated proteins in PDGFR signaling, we constructed a PDGFR mutant (F5) unable to bind any of them and a panel of ''add-back'' mutants that could bind only one of the receptor-associated proteins. F5 PDGFR failed to activate PLC-gamma1, PI3K, or Ras and was unable to trigger DNA synthesis. Permitting association of F5 PDGFR with either PLC-gamma1 or PI3K restored Ras activation and a mitogenic response. Surprisingly, even though binding of the 64 kd protein almost fully restored Ras activation, it did not rescue the receptor's ability to trigger DNA synthesis. Thus Ras activation is insufficient to trigger PDGF-dependent DNA synthesis, and PLC-gamma1 and PI3K are independent downstream mediators of PDGFs mitogenic signal.	NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206	National Jewish Health			Valius, Mindaugas/F-2734-2012; Valius, Mindaugas/N-1220-2019	Valius, Mindaugas/0000-0001-8478-8517	NCI NIH HHS [CA55063] Funding Source: Medline; NIGMS NIH HHS [GM48339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, J BIOL CHEM, V264, P20181; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, IN PRESS MOL CELL BI; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; LIPS DL, 1989, J BIOL CHEM, V264, P8759; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLLOY CJ, 1989, CELL, V58, P649; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISONGRAHAM K, 1992, DEVELOPMENT, V115, P133; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VALIUS M, 1993, MOL CELL BIOL, V13, P7266; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	68	627	632	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 23	1993	73	2					321	334		10.1016/0092-8674(93)90232-F	http://dx.doi.org/10.1016/0092-8674(93)90232-F			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	7682895				2022-12-28	WOS:A1993KY50500013
J	HENKIN, RI				HENKIN, RI			BODY ODOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HENKIN, RI (corresponding author), TASTE & SMELL CLIN,WASHINGTON,DC, USA.							GOLDBERG RL, 1985, PSYCHOSOMATICS, V26, P326; HENKIN RI, 1993, OTOLARYNGOLOGY, V2, P1; HENKIN RI, 1994, OLFACTION TASTE, V11, P568; Jackson JH., 1871, LANCET, V1, P376; MUNRO A, 1982, CAN J PSYCHIAT, V27, P374, DOI 10.1177/070674378202700504; PERRY TL, 1970, CLIN CHIM ACTA, V30, P721, DOI 10.1016/0009-8981(70)90266-4; PHILLIPS M, 1994, CLIN RES, V42, pA260; POTOLICCHIO SJ, 1986, CLIN RES, V34, P635; PRYSEPHILLIPS W, 1991, ACTA PSYCHIAT SCAND, V47, P484; RUBERT SL, 1961, ARCH GEN PSYCHIAT, V5, P313; SMITH K, 1969, SCIENCE, V166, P398, DOI 10.1126/science.166.3903.398; Taylor RB, 1992, DIFFICULT DIAGNOSIS, P348	12	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1171	1172						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT100	7707616				2022-12-28	WOS:A1995QT10000011
J	AXON, ATR; BELL, GD; JONES, RH; QUINE, MA; MCCLOY, RF				AXON, ATR; BELL, GD; JONES, RH; QUINE, MA; MCCLOY, RF			GUIDELINES ON APPROPRIATE INDICATIONS FOR UPPER GASTROINTESTINAL ENDOSCOPY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EARLY GASTRIC-CANCER; HELICOBACTER-PYLORI; DYSPEPSIA; SEROLOGY	Upper gastrointestinal endoscopy is a valuable diagnostic tool, but for an endoscopy service to be effective it is essential that it is not overloaded with inappropriately referred patients. A joint working party in Britain has considered the available literature on indications for endoscopy, assessed standard practice through a questionnaire, and audited randomly selected cases using an independent panel of experts and an American database system. They used these data to produce guidelines on the appropriate and inappropriate indications for referral for endoscopy, although they emphasise that under certain circumstances there may be reasons to deviate from the advice given. The need for endoscopy is most difficult to judge in patients with dyspepsia, and this aspect is discussed in detail. Early endoscopy will often prove more cost effective than delaying until the indications are clearer.	IPSWICH HOSP NHS TRUST, IPSWICH IP4 5PD, SUFFOLK, ENGLAND; UNITED MED & DENT SCH, DEPT GEN PRACTICE, LONDON SE11 6SP, ENGLAND; ROYAL COLL SURGEONS ENGLAND, LONDON WC2A 3PN, ENGLAND; UNIV MANCHESTER, MANCHESTER ROYAL INFIRM, DEPT SURG, MANCHESTER M13 9WL, LANCS, ENGLAND	Ipswich Hospital NHS Trust; Ipswich Hospital; University of London; King's College London; Royal College of Surgeons of England; University of Manchester	AXON, ATR (corresponding author), GEN INFIRM, CTR DIGEST DIS, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND.							BROOK RH, 1990, NEW ENGL J MED, V323, P1173, DOI 10.1056/NEJM199010253231705; BYTZER P, 1994, LANCET, V343, P811, DOI 10.1016/S0140-6736(94)92023-0; CHASSIN M, 1989, APPROPRIATE INVESTIG, P21; COLINJONES DG, 1988, LANCET, V1, P576; COLLINS JSA, 1992, EUR J GASTROEN HEPAT, V4, P991; DEDOMBAL FT, 1990, GUT, V31, P115, DOI 10.1136/gut.31.1.115; FISCHER A, 1988, ACTA CHIR SCAND, P86; GOULSTON KJ, 1991, MED J AUSTRALIA, V155, P20, DOI 10.5694/j.1326-5377.1991.tb116372.x; HALLISSEY MT, 1990, BRIT MED J, V301, P513, DOI 10.1136/bmj.301.6751.513; HEADING RC, 1991, SCAND J GASTROENTERO, V26, P1, DOI 10.3109/00365529109109529; HEATLEY RV, 1987, LANCET, V2, P779; JOHNSTON BJ, 1990, GUT, V31, pA613; JONES R, 1988, PRACTITIONER, V232, P75; JONES RH, 1990, GUT, V31, P401, DOI 10.1136/gut.31.4.401; LINDBERG G, 1990, GASTROSKOPI VID UTRE; LOGAN RFA, 1983, LANCET, V2, P667; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MARUYAMA K, 1987, WORLD J SURG, V11, P418, DOI 10.1007/BF01655804; MENDALL MA, 1992, EUR J GASTROEN HEPAT, V4, P713; MORGAN AG, 1991, GUT, V32, pA570; Nyren O, 1992, Pharmacoeconomics, V1, P312; OFFERHAUS GJA, 1992, LANCET, V340, P33, DOI 10.1016/0140-6736(92)92433-G; QUINE MA, 1994, GUT, V35, P1209, DOI 10.1136/gut.35.9.1209; SOBALA GM, 1991, LANCET, V338, P94, DOI 10.1016/0140-6736(91)90085-4; SUELING HM, 1992, GUT, V33, P1318, DOI 10.1136/gut.33.10.1318; SUELING HM, 1993, BMJ-BRIT MED J, V307, P591, DOI 10.1136/bmj.307.6904.591; Talley N, 1991, GASTROENTEROL INT, V4, P145; TALLEY NJ, 1993, GASTROENTEROLOGY, V105, P1378, DOI 10.1016/0016-5085(93)90142-Y; TYTGAT GNJ, 1991, J GASTROEN HEPATOL, V6, P103, DOI 10.1111/j.1440-1746.1991.tb01447.x; 1988, GASTROINTEST ENDOSC, V34, pS18	30	114	114	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	1995	310	6983					853	856		10.1136/bmj.310.6983.853	http://dx.doi.org/10.1136/bmj.310.6983.853			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711627	Green Published			2022-12-28	WOS:A1995QQ85700026
J	KOTANIDES, H; REICH, NC				KOTANIDES, H; REICH, NC			REQUIREMENT OF TYROSINE PHOSPHORYLATION FOR RAPID ACTIVATION OF A DNA-BINDING FACTOR BY IL-4	SCIENCE			English	Article							STIMULATORY FACTOR-I; RECOMBINANT INTERLEUKIN-4; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; INTERFERON-ALPHA; IFN-GAMMA; PROTEIN; RECEPTOR; EXPRESSION; PROMOTER	Interleukin-4 (IL-4) is an immunoregulatory cytokine produced by activated T lymphocytes to promote the growth and differentiation of cells that participate in immune defense. This study demonstrates the rapid activation of a specific DNA binding factor by IL-4. The IL-4 nuclear-activated factor (IL-4 NAF) appeared within minutes of IL-4 stimulation and recognized a specific DNA sequence found in the promoters of IL-4-responsive genes. Activation of this putative transcription factor required tyrosine phosphorylation, and antibodies specific for phosphotyrosine recognize the IL-4 NAF-DNA complex. Thus, IL-4 appears to transduce a signal to the nucleus through tyrosine phosphorylation of a latent DNA binding factor.	SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794; SUNY STONY BROOK,GRAD PROGRAM MOLEC & CELLULAR BIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [R29CA050773] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA50773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOOTHBY M, 1988, SCIENCE, V242, P1559, DOI 10.1126/science.3144043; CAO H, 1989, J IMMUNOL, V143, P3524; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GERONDAKIS S, 1990, P NATL ACAD SCI USA, V87, P1581, DOI 10.1073/pnas.87.4.1581; GILMOUR KC, UNPUB; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; GUTCH MJ, UNPUB; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; ILLGES H, 1992, MOL IMMUNOL, V29, P1265, DOI 10.1016/0161-5890(92)90063-4; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KOTANIDES H, UNPUB; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MCGARVIE GM, 1989, IMMUNOL LETT, V22, P221, DOI 10.1016/0165-2478(89)90195-8; MIRESLUIS AR, 1991, J BIOL CHEM, V266, P18113; MOND JJ, 1986, J IMMUNOL, V137, P353; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; PAUL WE, 1991, BLOOD, V77, P1859; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PURKERSON J, 1992, FASEB J, V6, P3245, DOI 10.1096/fasebj.6.14.1385241; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; ROTHMAN P, 1991, MOL CELL BIOL, V11, P5551, DOI 10.1128/MCB.11.11.5551; SARFATI M, 1992, IMMUNOL RES, V11, P260, DOI 10.1007/BF02919132; SHINDLER C, 1992, SCIENCE, V257, P809; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; STUART PM, 1988, J IMMUNOL, V140, P1542; SUTER U, 1989, J IMMUNOL, V143, P3087; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; XU MZ, 1992, EMBO J, V11, P145, DOI 10.1002/j.1460-2075.1992.tb05037.x; YANG Q, 1993, J BIOL CHEM, V268, P6622; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X	40	261	267	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1265	1267		10.1126/science.7694370	http://dx.doi.org/10.1126/science.7694370			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	7694370				2022-12-28	WOS:A1993MH32400039
J	ASHLEY, CT; WILKINSON, KD; REINES, D; WARREN, ST				ASHLEY, CT; WILKINSON, KD; REINES, D; WARREN, ST			FMR1 PROTEIN - CONSERVED RNP FAMILY DOMAINS AND SELECTIVE RNA-BINDING	SCIENCE			English	Article							FRAGILE-X-SYNDROME; ESCHERICHIA-COLI; GENE; DNA; INSTABILITY; SEQUENCE; METHYLATION; REPEAT; SITE	Fragile X syndrome is the result of transcriptional suppression of the gene FMR1 as a result of a trinucleotide repeat expansion mutation. The normal function of the FMR1 protein (FMRP) and the mechanism by which its absence leads to mental retardation are unknown. Ribonucleoprotein particle (RNP) domains were identified within FMRP, and RNA was shown to bind in stoichiometric ratios, which suggests that there are two RNA binding sites per FMRP molecule. FMRP was able to bind to its own message with high affinity (dissociation constant = 5.7 nM) and interacted with approximately 4 percent of human fetal brain messages. The absence of the normal interaction of FMRP with a X syndrome.	EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Emory University; Howard Hughes Medical Institute; Emory University; Emory University			excellency, Your/R-2357-2019; Warren, Stephen T/A-2498-2012	excellency, Your/0000-0003-0832-6243; 	NICHD NIH HHS [HD20521] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020521, R37HD020521] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; BRAUER D, 1979, FEBS LETT, V106, P352, DOI 10.1016/0014-5793(79)80531-1; BROWN WT, 1990, AM J HUM GENET, V47, P175; BUTLER MG, 1991, CLIN GENET, V39, P347; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DELAHODDE A, 1986, NUCLEIC ACIDS RES, V14, P9213, DOI 10.1093/nar/14.22.9213; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GIDEON AK, 1992, NAT GENET, V1, P341; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; HINDS HL, 1993, NAT GENET, V3, P36, DOI 10.1038/ng0193-36; KAO CC, 1992, J VIROL, V66, P6322, DOI 10.1128/JVI.66.11.6322-6329.1992; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; Price D, UNPUB; REGNIER P, 1987, J BIOL CHEM, V262, P63; SCHMIDT C, 1992, EUR J BIOCHEM, V206, P625, DOI 10.1111/j.1432-1033.1992.tb16967.x; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; VERHEIJ C, 1993, NATURE, V363, P722, DOI 10.1038/363722a0; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WOHRLE D, 1992, AM J HUM GENET, V51, P299; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; ZHANG XT, 1990, NUCLEIC ACIDS RES, V18, P6689, DOI 10.1093/nar/18.22.6689	31	599	612	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 22	1993	262	5133					563	566		10.1126/science.7692601	http://dx.doi.org/10.1126/science.7692601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC935	7692601				2022-12-28	WOS:A1993MC93500039
J	THORPE, G				THORPE, G			FORTNIGHTLY REVIEW - ENABLING MORE DYING PEOPLE TO REMAIN AT HOME	BRITISH MEDICAL JOURNAL			English	Article							TERMINAL CARE; DEATH	When it comes to dying there is no place like home. Since earliest times most cultures have accepted that dying people should remain at home. But this was never possible for all. Some were destined to die in accidents, on battlefields, by execution, and from catastrophic illness, maybe many miles away. Nevertheless, with few exceptions people could expect to die in their own beds and in the bosom of their families. In Europe from the Middle Ages until a century ago there was a simplicity about dying. Aware that the end was approaching, people would take to their sickbeds and preside over the ritual. The family, including children, friends, and neighbours would congregate. The ceremony was public and doctors often complained about overcrowding. Death was not regarded as a frightening event and was accepted as an inevitable and integral part of life. Dramatic changes in attitudes to death have taken place since the mid-nineteenth century. The natural acceptance of a biological reality has been lost and people are now unable to come to terms with their own mortality. One consequence is that death has become institutionalised.1 This paper seeks to answer five questions. These refer to where people die, where they would choose to die, where they spend their last year of life, the reasons for admission for terminal care, and whether more dying people could remain at home. Discussion is restricted to adults in the United Kingdom. References are mostly from the past decade.			THORPE, G (corresponding author), MOORGREEN HOSP,COUNTESS MOUNTBATTEN HOUSE,WEST END,SOUTHAMPTON SO3 3JB,ENGLAND.							ADDINGTON-HALL J M, 1991, Palliative Medicine, V5, P207, DOI 10.1177/026921639100500305; ARIES P, 1976, WESTERN ATTITUDES DE; Beck-Friis Barbro, 1993, Palliative Medicine, V7, P93, DOI 10.1177/026921639300700202; CARTWRIGHT A, 1991, BRIT J GEN PRACT, V41, P271; CARTWRIGHT A, 1991, J PUBLIC HEALTH MED, V13, P81; CARTWRIGHT A, 1973, LIFE DEATH; DOYLE D, 1980, PRACTITIONER, V224, P575; DUNLOP RJ, 1989, PALLIAT MED, V0003, P00197, DOI DOI 10.1177/026921638900300305; FIELD D, 1993, FUTURE PALLIATIVE CA, P6; HAINES A, 1986, BRIT MED J, V292, P1051, DOI 10.1136/bmj.292.6527.1051; HERD EB, 1990, BRIT J GEN PRACT, V40, P248; JOHNSON IS, 1990, BRIT MED J, V300, P791, DOI 10.1136/bmj.300.6727.791; JONES R, 1992, EUR J CANCER CARE, V1, P9; JONES RVH, 1993, BRIT MED J, V306, P249, DOI 10.1136/bmj.306.6872.249; Levy B, 1976, J R Coll Gen Pract, V26, P303; PARKES CM, 1980, POSTGRAD MED J, V56, P685, DOI 10.1136/pgmj.56.660.685; Smith Anthony M., 1992, Palliative Medicine, V6, P277, DOI 10.1177/026921639200600403; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415; WILKES E, 1984, LANCET, V1, P950; 1993, MAKING LONDON BETTER; 1992, JOINT REPORT PRINCIP; 1992, HLTH NATION SUMMARY; 1993, CHANGING CHILDBIRTH; 1993, OXFORD TXB PALLIATIV; 1989, CARING PEOPLE COMMUN; 1992, PATIENTS CHARTER	26	91	92	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					915	918		10.1136/bmj.307.6909.915	http://dx.doi.org/10.1136/bmj.307.6909.915			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	7694718	Green Published, Bronze			2022-12-28	WOS:A1993MB84700023
J	QUILL, TE				QUILL, TE			THE AMBIGUITY OF CLINICAL INTENTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											QUILL, TE (corresponding author), UNIV ROCHESTER, SCH MED & DENT, ROCHESTER, NY 14607 USA.							ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; BRODY H, 1993, J CLIN ETHIC, V4, P112; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; VANDERMAAS PJ, 1992, HLTH POLICY MONOGRAP, V2; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1992, JAMA-J AM MED ASSOC, V267, P2229	9	137	138	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					1039	1040		10.1056/NEJM199309303291414	http://dx.doi.org/10.1056/NEJM199309303291414			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY587	7690111				2022-12-28	WOS:A1993LY58700014
J	LOVE, PE; SHORES, EW; JOHNSON, MD; TREMBLAY, ML; LEE, EJ; GRINBERG, A; HUANG, SP; SINGER, A; WESTPHAL, H				LOVE, PE; SHORES, EW; JOHNSON, MD; TREMBLAY, ML; LEE, EJ; GRINBERG, A; HUANG, SP; SINGER, A; WESTPHAL, H			T-CELL DEVELOPMENT IN MICE THAT LACK THE ZETA-CHAIN OF THE T-CELL ANTIGEN RECEPTOR COMPLEX	SCIENCE			English	Article							ETA-CHAIN; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; TRANSGENIC MICE; EXPRESSION; THYMOCYTES; CD4; MUTATIONS; FAMILY; TCR	The zeta subunit of the T cell antigen receptor complex is required for targeting nascent receptor complexes to the cell surface and for receptor-mediated signal transduction. To examine the significance of the zeta subunit in T cell development, mice deficient for zeta expression were generated by gene targeting. These zeta-/- mice had few CD4+CD8+ thymocytes, and the generation of CD4+ and CD8+ single positive T cells was impaired but not completely abrogated. Peripheral T cells were present but were unusual in that they expressed small amounts of CD5 and few T cell receptors. Thus, zeta chain expression influences thymocyte differentiation but is not absolutely required for the generation of single positive T cells.	NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LOVE, PE (corresponding author), NICHHD,MAMMALIAN GENES & DEV LAB,BLDG 6B,ROOM 210,BETHESDA,MD 20892, USA.							Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BAUER A, 1991, P NATL ACAD SCI USA, V88, P3842, DOI 10.1073/pnas.88.9.3842; BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BONIFACINO JS, 1990, NATURE, V344, P247, DOI 10.1038/344247a0; CLAYTON LK, 1991, P NATL ACAD SCI USA, V88, P5202, DOI 10.1073/pnas.88.12.5202; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; HUGO P, 1990, INT IMMUNOL, V2, P209, DOI 10.1093/intimm/2.3.209; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KISHI H, 1993, J IMMUNOL, V150, P1263; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LOVE PE, 1992, P NATL ACAD SCI USA, V89, P9929, DOI 10.1073/pnas.89.20.9929; LOVE PJ, UNPUB; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SHORTMAN K, 1988, CELL IMMUNOL, V113, P462, DOI 10.1016/0008-8749(88)90042-1; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; UNKLESS JC, 1979, J EXP MED, V150, P580; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x	33	200	204	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					918	921		10.1126/science.7688481	http://dx.doi.org/10.1126/science.7688481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	7688481				2022-12-28	WOS:A1993LR89700040
J	GRANT, WE; HOPPER, C; MACROBERT, AJ; SPEIGHT, PM; BOWN, SG				GRANT, WE; HOPPER, C; MACROBERT, AJ; SPEIGHT, PM; BOWN, SG			PHOTODYNAMIC THERAPY OF ORAL-CANCER - PHOTOSENSITIZATION WITH SYSTEMIC AMINOLEVULINIC ACID	LANCET			English	Note								Photodynamic therapy with intravenous photosensitising drugs has been shown to be effective in the ablation of superficial cancers, but long-lasting photosensitivity is a serious disadvantage. Similar photosensitivity is a feature of certain types of porphyria. We present the first report of tumour necrosis brought about by photodynamic activation of a temporary endogenous porphyrin accumulation, after an oral dose of the haem precursor, 5-aminolaevulinic acid. In 4 patients, quantitative fluorescence microscopy showed that accumulation of the photoactive intermediate protoporphyrin IX peaked after 4-6 h in 4 oral cavity squamous cell carcinomas, returning to background in 24 h. Irradiation with non-thermal red laser light caused tumour necrosis in 3 patients.	UNIV LONDON UNIV COLL, SCH MED, DEPT SURG, DIV MAXILLOFACIAL SURG, LONDON WC1E 6JJ, ENGLAND; UCL EASTMAN DENT HOSP, INST DENT SURG, DEPT ORAL PATHOL, LONDON WC1, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	GRANT, WE (corresponding author), UNIV LONDON UNIV COLL, SCH MED, DEPT SURG, NATL MED LASER CTR, LONDON WC1E 6JJ, ENGLAND.		Bown, Stephen G/C-5713-2009; Bown, Stephen/AAX-6573-2020					BARR H, 1987, BRIT J CANCER, V56, P111, DOI 10.1038/bjc.1987.166; BEDWELL J, 1992, BRIT J CANCER, V65, P818, DOI 10.1038/bjc.1992.175; DIVARIS DXG, 1990, AM J PATHOL, V136, P891; DOUGHERTY TJ, 1990, LASER SURG MED, V10, P485, DOI 10.1002/lsm.1900100514; DOUGHERTY TJ, 1966, ACTA MED SCAND, V179, P11; KENNEDY JC, 1992, J PHOTOCH PHOTOBIO B, V14, P275, DOI 10.1016/1011-1344(92)85108-7; LOH CS, 1993, BRIT J CANCER, V68, P41, DOI 10.1038/bjc.1993.284; LOH CS, 1992, BRIT J CANCER, V66, P452, DOI 10.1038/bjc.1992.295; MALIK Z, 1987, BRIT J CANCER, V56, P589, DOI 10.1038/bjc.1987.246; MEYER M, 1991, BRIT J CANCER, V64, P1093, DOI 10.1038/bjc.1991.470	10	228	235	1	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					147	148		10.1016/0140-6736(93)91347-O	http://dx.doi.org/10.1016/0140-6736(93)91347-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	7687318				2022-12-28	WOS:A1993LN04200013
J	HAYMAN, MJ; MEYER, S; MARTIN, F; STEINLEIN, P; BEUG, H				HAYMAN, MJ; MEYER, S; MARTIN, F; STEINLEIN, P; BEUG, H			SELF-RENEWAL AND DIFFERENTIATION OF NORMAL AVIAN ERYTHROID PROGENITOR CELLS - REGULATORY ROLES OF THE TGF-ALPHA/C-ERBB AND SCF/C-KIT RECEPTORS	CELL			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM-CELLS; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; TRANSFORMED ERYTHROBLASTS; MYELOID CELLS; EGF RECEPTOR; TS MUTANTS; VIRUS; ONCOGENE	The c-kit proto-oncogene product is a major regulator of early hematopoiesis in mice. We show here that the avian c-Kit protein, together with the c-erbB proto-oncogene product, regulates self-renewal and differentiation in two types of normal chick erythroid progenitors. A relatively frequent progenitor expressing only c-Kit transiently proliferated in response to avian c-Kit ligand (stem cell factor [SCF]). A second, rare progenitor coexpressed c-Kit and c-ErbB and was induced to long-term self-renewal by SCF or transforming growth factor alpha(TGFalpha), a c-ErbB ligand. In the absence of SFC or TGFalpha, both progenitors underwent erythropoietin (Epo)-dependent terminal differentiation with indistinguishable kinetics. Interestingly, Epo induced differentiation in the SCF progenitors even when SCF was present. In contrast, the c-ErbB-expressing, TGFalpha-induced progenitors continued to self-renew when treated with Epo plus the growth factors SCF, TGFalpha, or both. Expression of c-ErbB thus may be a dominant determinant for the sustained self-renewal of committed erythroid progenitors.	AMGEN CTR,THOUSAND OAKS,CA 91320; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Amgen; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	HAYMAN, MJ (corresponding author), SUNY,DEPT MICROBIOL,STONY BROOK,NY 11794, USA.							ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BEUG H, 1992, NUCLEAR PROCESSES ON, P53; BEUG H, 1985, MODERN TRENDS HUMAN, V6, P284; BEUG H, 1987, ONCOGENES GROWTH CON, P85; BROXMEYER HE, 1991, BLOOD, V77, P2142; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GRAF T, 1977, CANCER RES, V37, P59; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; HARRISON DE, 1988, P NATL ACAD SCI USA, V85, P822, DOI 10.1073/pnas.85.3.822; HAUNG E, 1990, CELL, V63, P225; KELLER G, 1992, CURR OPIN IMMUNOL, V4, P133, DOI 10.1016/0952-7915(92)90002-V; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KENNEDY M, 1992, BLOOD, V79, P180; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KOWENZ E, 1987, MODERN TRENDS HUMAN, V7, P199; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Maniatis T., 1982, MOL CLONING; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TILL JE, 1980, BIOCHIM BIOPHYS ACTA, V605, P431, DOI 10.1016/0304-419X(80)90009-8; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	48	88	91	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					157	169		10.1016/0092-8674(93)90303-8	http://dx.doi.org/10.1016/0092-8674(93)90303-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	7687522				2022-12-28	WOS:A1993LN62500016
J	WALTERS, S; SMITH, EG				WALTERS, S; SMITH, EG			PSEUDOMONAS-CEPACIA IN CYSTIC-FIBROSIS - TRANSMISSIBILITY AND ITS IMPLICATIONS	LANCET			English	Editorial Material									BIRMINGHAM HEARTLANDS HOSP,BIRMINGHAM PUBL HLTH LAB,BIRMINGHAM,ENGLAND	Heart of England NHS Foundation Trust; University of Birmingham	WALTERS, S (corresponding author), UNIV BIRMINGHAM,SCH MED,INST PUBL & ENVIRONM HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							Editorial, 1992, LANCET, V339, P1385; ISLES A, 1984, J PEDIATR-US, V104, P206, DOI 10.1016/S0022-3476(84)80993-2; LIPUMA JJ, 1991, LANCET, V336, P1904; MILLARJONES L, 1992, LANCET, V340, P491, DOI 10.1016/0140-6736(92)91817-R; SIMMONDS EJ, 1990, ARCH DIS CHILD, V65, P674; SMITH DL, 1992, LANCET, V339, P252, DOI 10.1016/0140-6736(92)90063-9; TABIAN OC, 1987, CHEST, V91, P527; THOMASSEN MJ, 1986, AM REV RESPIR DIS, V134, P669	8	26	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					3	4						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	7686240				2022-12-28	WOS:A1993LK98500004
J	WELSH, MJ; SMITH, AE				WELSH, MJ; SMITH, AE			MOLECULAR MECHANISMS OF CFTR CHLORIDE CHANNEL DYSFUNCTION IN CYSTIC-FIBROSIS	CELL			English	Review							MUTATIONS; GENE; TRANSPORT; DISEASE		GENZYME CORP, FRAMINGHAM, MA 01701 USA	Sanofi-Aventis; Genzyme Corporation	WELSH, MJ (corresponding author), UNIV IOWA, COLL MED, DEPT INTERNAL MED, HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA.			Welsh, Michael/0000-0002-1646-6206				ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DORK T, 1991, HUM GENET, V87, P441; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1989, SCIENCE, V245, P1066; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; Tsui L C, 1991, Adv Hum Genet, V20, P153; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K	24	1176	1228	1	238	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 2	1993	73	7					1251	1254		10.1016/0092-8674(93)90353-R	http://dx.doi.org/10.1016/0092-8674(93)90353-R			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LL209	7686820	Bronze			2022-12-28	WOS:A1993LL20900002
J	IMAMOTO, A				IMAMOTO, A			DISRUPTION OF THE CSK GENE, ENCODING A NEGATIVE REGULATOR OF SRC FAMILY TYROSINE KINASES, LEADS TO NEURAL-TUBE DEFECTS AND EMBRYONIC LETHALITY IN MICE	CELL			English	Article							HUMAN-COLON CARCINOMA; PP60C-SRC EXPRESSION; MOUSE-BRAIN; RAT-BRAIN; C-SRC; PHOSPHORYLATION; PROTEIN; ACTIVATION; P60C-SRC; PROTOONCOGENE	All Src family non-receptor tyrosine kinases are negatively regulated by phosphorylation at a carboxy-terminal tyrosine. To analyze the significance of this regulation during development, we have generated mice deficient in Csk, a kinase that phosphorylates this tyrosine, by gene targeting in embryonic stem cells. Homozygous mutant embryos exhibit a complex phenotype that includes defects in the neural tube and die between day 9 and day 10 of gestation. Cells derived from these embryos exhibit an order of magnitude increase in activity of Src and the related Fyn kinase. Phosphorylation at the carboxy-terminal tyrosine of Src was reduced but not eliminated and was accompanied by increased phosphorylation at another key tyrosine residue. These results demonstrate that Src family kinase activity is critically dependent on phosphorylation by Csk and suggest that the regulation of kinase activity may be essential during embryogenesis.	BAYLOR COLL MED, INST MOLEC GENET, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute			Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X				APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOULTER CA, 1991, DEVELOPMENT, V111, P357; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1987, ONCOGENE RES, V1, P297; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; Gluecksohn-Schoenheimer S, 1944, P NATL ACAD SCI USA, V30, P134, DOI 10.1073/pnas.30.6.134; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRUNEBERG H, 1958, J EMBRYOL EXP MORPH, V6, P424; GRUNEBERG H, 1958, J EMBRYOL EXP MORPH, V6, P124; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOHNSTON JG, 1989, P NATL ACAD SCI USA, V86, P1066, DOI 10.1073/pnas.86.3.1066; Kaufman M.H., 1992, ATLAS MOUSE DEV; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; LUMSDEN A, 1991, CELL, V64, P471, DOI 10.1016/0092-8674(91)90226-O; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; MACAULEY A, 1993, ONCOGENE, V8, P117; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MANESS PF, 1986, DEV BIOL, V117, P83, DOI 10.1016/0012-1606(86)90350-7; MARIN O, 1991, J BIOL CHEM, V266, P17798; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; OKADA M, 1991, J BIOL CHEM, V266, P24249; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; OUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696; PARTANEN J, 1991, ONCOGENE, V6, P2013; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SORIANO P, 1986, SCIENCE, V234, P1409, DOI 10.1126/science.3024318; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WIESTLER OD, 1988, MOL CELL BIOL, V8, P502, DOI 10.1128/MCB.8.1.502; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	62	366	373	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 18	1993	73	6					1117	1124		10.1016/0092-8674(93)90641-3	http://dx.doi.org/10.1016/0092-8674(93)90641-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	7685657				2022-12-28	WOS:A1993LH54800008
J	TUVESON, DA; CARTER, RH; SOLTOFF, SP; FEARON, DT				TUVESON, DA; CARTER, RH; SOLTOFF, SP; FEARON, DT			CD19 OF B-CELLS AS A SURROGATE KINASE INSERT REGION TO BIND PHOSPHATIDYLINOSITOL 3-KINASE	SCIENCE			English	Article							FACTOR-I RECEPTOR; PROTEIN TYROSINE PHOSPHORYLATION; GROWTH-FACTOR STIMULATION; LYMPHOCYTES-B; SIGNAL TRANSDUCTION; ANTIGEN RECEPTOR; COMPLEMENT RECEPTOR; PDGF RECEPTOR; MIDDLE-T; ASSOCIATION	Antigen receptors on B and T lymphocytes transduce signals by activating nonreceptor protein tyrosine kinases (PTKs). A family of receptor PTKs contains kinase insert regions with the sequence tyrosine-X-X-methionine (where X is any amino acid) that when phosphorylated mediate the binding and activation of phosphatidylinositol 3-kinase (PI 3-kinase). The CD19 membrane protein of B cells enhances activation through membrane immunoglobulin M (mIgM) and was found to contain a functional analog of the kinase insert region. Ligation of mIgM induced phosphorylation of CD19 and association with PI 3-kinase. Thus, CD19 serves as a surrogate kinase insert region for mIgM by providing the means for PI 3-kinase activation by nonreceptor PTKs.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02215 USA	Johns Hopkins University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	TUVESON, DA (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022833, R01AI028191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28191, AI22833] Funding Source: Medline; NIGMS NIH HHS [5T32GM07309] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1991, J IMMUNOL, V147, P3663; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; ESCOBEDO JA, 1988, NATURE, V335, P85, DOI 10.1038/335085a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1992, J IMMUNOL, V148, P2012; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; HEYMAN B, 1990, J EXP MED, V172, P665, DOI 10.1084/jem.172.2.665; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; NADLER LM, 1983, J IMMUNOL, V131, P244; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PEPYS MB, 1974, J EXP MED, V140, P126, DOI 10.1084/jem.140.1.126; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAMENKOVIC I, 1988, J EXP MED, V168, P1205, DOI 10.1084/jem.168.3.1205; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TEDDER TF, 1989, J IMMUNOL, V143, P712; VANNOESEL CJM, 1991, J IMMUNOL, V146, P3881; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	54	292	298	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1993	260	5110					986	989		10.1126/science.7684160	http://dx.doi.org/10.1126/science.7684160			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB791	7684160				2022-12-28	WOS:A1993LB79100044
J	DUNBAR, CE; NIENHUIS, AW				DUNBAR, CE; NIENHUIS, AW			MULTIPLE-MYELOMA - NEW APPROACHES TO THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MARROW TRANSPLANTATION; CASTLEMANS DISEASE; GENE-TRANSFER; CELL-GROWTH; INTERLEUKIN-6; CHEMOTHERAPY; EXPRESSION; LEUKEMIA				DUNBAR, CE (corresponding author), NHLBI, HEMATOL BRANCH, BLDG 10, ROOM 7C-103, BETHESDA, MD 20892 USA.			Dunbar, Cynthia/0000-0002-7645-838X				ALEXANIAN R, 1980, BLOOD, V56, P521; ALEXANIAN R, 1986, ANN INTERN MED, V105, P8, DOI 10.7326/0003-4819-105-1-8; ALEXANIAN R, 1992, BLOOD, V80, P887; ANDERSON KC, 1991, BLOOD, V77, P712; BARLOGIE B, 1987, BLOOD, V70, P869; BARLOGIE B, 1984, NEW ENGL J MED, V310, P1353, DOI 10.1056/NEJM198405243102104; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; BERENSON RJ, 1991, BLOOD, V77, P1717; BERGSAGEL DE, 1982, CLIN HAEMATOL, V11, P221; BERGSAGEL DE, 1962, CANCER CHEMOTH REP, P87; BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; COOPER MR, 1986, J CLIN ONCOL, V4, P1331, DOI 10.1200/JCO.1986.4.9.1331; GAHRTON G, 1991, NEW ENGL J MED, V325, P1267, DOI 10.1056/NEJM199110313251802; GORE ME, 1989, LANCET, V2, P879; GREGORY WM, 1992, J CLIN ONCOL, V10, P334, DOI 10.1200/JCO.1992.10.2.334; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; JAGANNATH S, 1990, BLOOD, V76, P1860; JAGANNATH S, 1992, BLOOD, V80, P1666; KARLSSON S, 1991, BLOOD, V78, P2481; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KLEIN B, 1989, BLOOD, V73, P517; KLEIN B, 1991, BLOOD, V78, P1198; LOWRY PA, 1992, EXP HEMATOL, V20, P937; MANDELLI F, 1990, NEW ENGL J MED, V322, P1430, DOI 10.1056/NEJM199005173222005; METCALF D, 1991, P NATL ACAD SCI USA, V88, P11310, DOI 10.1073/pnas.88.24.11310; NILSSON K, 1990, CURR TOP MICROBIOL, V166, P3; PREIS P, 1989, ONKOLOGIE, V12, P27, DOI 10.1159/000216593; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; SAKAI A, 1991, NEW ENGL J MED, V324, P1893; STEWART FM, IN PRESS BLOOD; YOSHIZAKI K, 1989, BLOOD, V74, P1360	32	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1993	269	18					2412	2416		10.1001/jama.269.18.2412	http://dx.doi.org/10.1001/jama.269.18.2412			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA675	7683062				2022-12-28	WOS:A1993LA67500037
J	CLARK, CM; LEE, DA				CLARK, CM; LEE, DA			PREVENTION AND TREATMENT OF THE COMPLICATIONS OF DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ALDOSE REDUCTASE INHIBITION; CONVERTING ENZYME-INHIBITION; INSULIN-DEPENDENT DIABETICS; DIETARY-PROTEIN; RENAL-FAILURE; PANCREAS TRANSPLANTATION; CONTROLLED TRIAL; KIDNEY-FUNCTION; DOUBLE-BLIND; SURAL-NERVE		INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN USA	Indiana University System; Indiana University-Purdue University Indianapolis	CLARK, CM (corresponding author), RICHARD L ROUDEBUSH VET AFFAIRS MED CTR, REGENSTRIEF INST HLTH CARE, 1001 W 10TH ST, INDIANAPOLIS, IN 46202 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60DK20542] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAIRA C, 1992, DIABETES CARE, V15, P1560, DOI 10.2337/diacare.15.11.1560; [Anonymous], 1991, Ophthalmology, V98, P757; [Anonymous], 1978, Ophthalmology, V85, P82; [Anonymous], 1985, Arch Ophthalmol, V103, P1644; [Anonymous], 1981, OPHTHALMOLOGY, V88, P583; [Anonymous], 1994, Diabetes Care, V17, P1357; [Anonymous], 1991, PREVENTION TREATMENT; APFEL SC, 1993, DRUG THER, V5, P17; AUBIA J, 1987, CLIN NEPHROL, V27, P15; BAKRIS GL, 1992, KIDNEY INT, V41, P912, DOI 10.1038/ki.1992.139; BANDELLO F, 1992, TRANSPLANT P, V24, P854; BAUDOIN C, 1989, DIABETES, V38, P491; BECKNIELSEN H, 1985, DIABETES CARE, V8, P585, DOI 10.2337/diacare.8.6.585; BERGLUND J, 1985, ACTA MED SCAND, V218, P401; BLACKENSHIP GW, 1985, OPHTHALMOLOGY, V92, P503; BOJESTIG M, 1994, NEW ENGL J MED, V330, P15, DOI 10.1056/NEJM199401063300103; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; CARLSEN JE, 1990, BRIT MED J, V300, P975, DOI 10.1136/bmj.300.6730.975; Christensen C K, 1987, J Diabet Complications, V1, P91, DOI 10.1016/S0891-6632(87)80063-6; CHRISTENSEN JEJ, 1985, ACTA NEUROL SCAND, V71, P164; CHRISTIANSEN JS, 1981, DIABETOLOGIA, V20, P451; COLWELL JA, 1994, DIABETES REV, V2, P277; DAHLJORGENSEN K, 1988, ACTA ENDOCRINOL-COP, V117, P19, DOI 10.1530/acta.0.1170019; DAHLJORGENSEN K, 1985, BRIT MED J, V290, P811, DOI 10.1136/bmj.290.6471.811; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; EDELSTEIN D, 1992, DIABETES, V41, P26, DOI 10.2337/diabetes.41.1.26; ESMATJES E, 1992, TRANSPLANT P, V24, P12; EVANOFF GV, 1987, ARCH INTERN MED, V147, P492, DOI 10.1001/archinte.147.3.492; FAGIUS J, 1985, DIABETOLOGIA, V28, P323; Feldman M, 1987, GASTROENTEROLOGY, V92, P171, DOI 10.1016/0016-5085(87)90854-7; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FITZGERALD M, 1983, PAIN, V15, P109, DOI 10.1016/0304-3959(83)90012-X; GONEN B, 1991, Diabetologia, V34, pA153; GREENE D A, 1990, Diabetologia, V33, pA92; GREENE DA, 1985, CLIN DIABETES, V3, P80; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HAMMES HP, 1992, P NATL ACAD SCI USA, V89, P9364; HOROWITZ M, 1985, DIGEST DIS SCI, V30, P1, DOI 10.1007/BF01318363; HOROWITZ M, 1987, GASTROENTEROLOGY, V92, P1899, DOI 10.1016/0016-5085(87)90622-6; HOROWITZ M, 1990, AM J MED, V88, P195, DOI 10.1016/0002-9343(90)90475-S; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; HOTTA N, 1990, DIABETES S1, V39, pA61; JANSSENS J, 1990, NEW ENGL J MED, V322, P1028, DOI 10.1056/NEJM199004123221502; JOHNSON AG, 1989, SCAND J GASTROENTERO, V24, P36, DOI 10.3109/00365528909091229; JUDZEWITSCH RG, 1983, NEW ENGL J MED, V308, P119, DOI 10.1056/NEJM198301203080302; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; KAYSEN GA, 1986, KIDNEY INT, V29, P572, DOI 10.1038/ki.1986.36; KIHARA M, 1991, P NATL ACAD SCI USA, V88, P6107, DOI 10.1073/pnas.88.14.6107; KLEIN R, 1992, DIABETES CARE, V15, P1875, DOI 10.2337/diacare.15.12.1875; KOHNER M, 1990, DIABETES S1, V39, pA62; LAURITZEN T, 1983, LANCET, V1, P200; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MATTOCK MB, 1992, DIABETES, V41, P736, DOI 10.2337/diabetes.41.6.736; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; MELCHIOR WR, 1993, ANN PHARMACOTHER, V27, P344, DOI 10.1177/106002809302700318; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MOGENSEN CE, 1976, SCAND J CLIN LAB INV, V36, P383, DOI 10.3109/00365517609055274; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MOGENSEN CE, 1992, CLIN NEPHROL, V38, pS28; MURRAY KM, 1991, CLIN PHARMACY, V10, P862; NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306; NEIL A, 1993, DIABETES CARE, V16, P996, DOI 10.2337/diacare.16.7.996; OHARE JP, 1988, DIABETIC MED, V5, P537, DOI 10.1111/j.1464-5491.1988.tb01047.x; PARVING HH, 1985, DIABETOLOGIA, V28, P797, DOI 10.1007/BF00291067; PARVING HH, 1983, LANCET, V1, P1175; PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015; PEDERSEN MM, 1991, DIABETES, V40, P527, DOI 10.2337/diabetes.40.5.527; RASKIN P, 1987, AM J MED, V83, P298, DOI 10.1016/0002-9343(87)90702-9; RASKIN P, 1983, NEW ENGL J MED, V309, P1546, DOI 10.1056/NEJM198312223092504; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; ROWE DJF, 1990, ANN CLIN BIOCHEM, V27, P297, DOI 10.1177/000456329002700404; SCHEIDER A, 1991, Diabetologia, V34, pS95, DOI 10.1007/BF00587630; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHERWIN RS, 1984, NEW ENGL J MED, V311, P365, DOI 10.1056/NEJM198408093110604; SIMA AAF, 1988, NEW ENGL J MED, V319, P548, DOI 10.1056/NEJM198809013190905; SNAPE WJ, 1982, ANN INTERN MED, V96, P444, DOI 10.7326/0003-4819-96-4-444; SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328; STEIN PP, 1991, DIABETES CARE, V14, P425, DOI 10.2337/diacare.14.6.425; SUTHERLAND DER, 1993, AM J SURG, V166, P456, DOI 10.1016/S0002-9610(05)81142-0; TIU SC, 1993, DIABETES CARE, V16, P616, DOI 10.2337/diacare.16.4.616; VANNINI P, 1984, DIABETES CARE, V7, P151, DOI 10.2337/diacare.7.2.151; VIBERTI GC, 1982, LANCET, V1, P1430; VIBERTI GC, 1985, DIABETIC NEPHROPATHY, V4, P32; WALKER JD, 1989, LANCET, V2, P1411; WALKER JD, 1989, LANCET, V2, P1540; WALKER WG, 1985, T AM CLIN CLIMAT ASS, V97, P94; WARD JD, 1986, DRUGS, V32, P279, DOI 10.2165/00003495-198632030-00004; WARRAM JH, 1991, ARCH INTERN MED, V151, P1350, DOI 10.1001/archinte.151.7.1350; YAGIHASHI S, 1990, DIABETES, V39, P690, DOI 10.2337/diabetes.39.6.690; YAGIHASHI S, 1992, DIABETES, V41, P47, DOI 10.2337/diabetes.41.1.47; ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202; 1991, AM J KIDNEY DIS S2, V18; 1993, DIABETES CARE, V16, P16; 1990, ARCH OPHTHALMOL-CHIC, V108, P1577; 1990, ARCH OPHTHALMOL-CHIC, V108, P1234	95	277	284	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 4	1995	332	18					1210	1217		10.1056/NEJM199505043321807	http://dx.doi.org/10.1056/NEJM199505043321807			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV415	7700316				2022-12-28	WOS:A1995QV41500007
J	LOPEZJIMENEZ, J; ODRIOZOLA, J; PEREZOTEYZA, J; GARCIALARANA, J				LOPEZJIMENEZ, J; ODRIOZOLA, J; PEREZOTEYZA, J; GARCIALARANA, J			HEPATITIS-C AND IMMUNE GLOBULIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											LOPEZJIMENEZ, J (corresponding author), HOSP RAMON Y CAJAL,E-28034 MADRID,SPAIN.		de Oteyza, Jaime Perez/K-5514-2012	de Oteyza, Jaime Perez/0000-0002-8338-2037				JANOT C, 1992, REV FR TRANSFUS HEM, V35, P171, DOI 10.1016/S1140-4639(05)80120-0; LOPEZJIMENEZ J, 1994, BLOOD, V84, P665	2	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 4	1995	332	18					1235	1236						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV415	7700324				2022-12-28	WOS:A1995QV41500018
J	BLUSTEIN, J				BLUSTEIN, J			MEDICARE COVERAGE, SUPPLEMENTAL INSURANCE, AND THE USE OF MAMMOGRAPHY BY OLDER WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-CANCER; HEALTH-INSURANCE; PREVENTIVE CARE; CERVICAL-CANCER; UNITED-STATES; DIAGNOSIS; IMPACT; STAGE; RACE	Background. On January 1, 1998, the Medicare program began offering reimbursement for screening mammography every two years. This study examined the use of mammography in women covered by Medicare during the first two years that the screening benefit was offered. Methods. Medicare bills for 1991 and 1992 from a nationally representative sample of 4110 women 65 years of age or older were examined to determine the degree of compliance with recognized guidelines for screening mammography and the extent to which the use of mammography was associated with having supplemental insurance, which shields patients from the out-of-pocket costs associated with using Medicare benefits. Results. A total of 36.9 percent of older U.S. women had mammography during the first two years of the Medicare benefit for screening mammography. Only 14.4 percent of the women lacking supplemental insurance had mammography, as compared with 44.7 percent of those with employer-sponsored supplemental insurance, 40.1 percent of those with self-purchased supplemental insurance, and 23.9 percent of those with Medicaid supplemental insurance. These differences persisted in the stratified and multivariate analyses. As compared with women lacking supplemental insurance, women with employment-based supplemental insurance were more likely to undergo mammography (adjusted odds ratio, 3.03; 95 percent confidence interval, 2.17 to 4.23), as were women with self-purchased supplemental insurance (adjusted odds ratio, 2.97; 95 percent confidence interval, 2.13 to 4.15) and women with Medicaid supplemental insurance (adjusted odds ratio, 1.99; 95 percent confidence interval, 1.30 to 3.07). Conclusions. The use of mammography was substantially below recommended levels during the first two years of Medicare coverage for screening mammography. Women lacking supplemental health insurance were at particularly high risk of failing to undergo mammography. Requiring copayments for preventive services is an obstacle to the effective mass screening of older women for breast cancer.	COLUMBIA UNIV,SCH PUBL HLTH,DIV HLTH POLICY & MANAGEMENT,NEW YORK,NY	Columbia University	BLUSTEIN, J (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DIV GEN MED,PH9 E,630 W 168TH ST,NEW YORK,NY 10032, USA.							[Anonymous], 1989, GUIDE CLIN PREVENTIV; APODACA R, 1992, P SECTION SURVEY RES; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; BERNSTEIN AB, 1991, MED CARE, V29, P196; BOSS LP, 1992, AM J PUBLIC HEALTH, V82, P252, DOI 10.2105/AJPH.82.2.252; Chulis G S, 1993, Health Care Financ Rev, V14, P163; Davis K, 1978, HLTH WAR POVERTY 10; DEGNAN D, 1992, AM J PUBLIC HEALTH, V82, P1386, DOI 10.2105/AJPH.82.10.1386; FOX SA, 1991, ARCH INTERN MED, V51, P150; FRANKS P, 1993, MED CARE, V31, P213, DOI 10.1097/00005650-199303000-00003; Fulton-Kehoe D, 1992, Public Health Rev, V20, P233; GORDILLO C, 1989, JAMA-J AM MED ASSOC, V262, P1155, DOI 10.1001/jama.262.9.1155; HAYWARD RA, 1988, ARCH INTERN MED, V148, P1177, DOI 10.1001/archinte.148.5.1177; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JEPSON C, 1991, AM J PUBLIC HEALTH, V81, P501, DOI 10.2105/AJPH.81.4.501; JUDKINS D, 1992, P SECTION SURVEY RES; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; MORROW B, 1990, LIBR SOFTWARE REV, V9, P57; NATTINGER AB, 1992, ARCH INTERN MED, V152, P922; RICE T, 1985, INQUIRY-J HEALTH CAR, V22, P188; RIMER BK, 1992, J GERONTOL, V47, P85; RIMER BK, 1992, PUBLIC HEALTH REP, V107, P369; RUBENSTEIN L, 1994, CANCER, V74, P2190, DOI 10.1002/1097-0142(19941001)74:7+<2190::AID-CNCR2820741733>3.0.CO;2-T; SHAH BV, 1992, SUDAAN USERS MANUAL; STEIN JA, 1992, HEALTH EDUC QUART, V19, P447, DOI 10.1177/109019819201900409; THOMPSON GB, 1989, AM J PUBLIC HEALTH, V79, P1541, DOI 10.2105/AJPH.79.11.1541; WELLS BL, 1992, AM J PUBLIC HEALTH, V82, P1383, DOI 10.2105/AJPH.82.10.1383; WHITE E, 1993, ANNU REV PUBL HEALTH, V14, P605; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; 1994, ADV DATA VITAL HLTH, V254; 1994, COMING UP SHORT INCR; 1993, UNFINISHED AGENDA IM; 1994, 94375M500894 AM CANC; 1993, RESPONSE RATES MED C; 1994, MEDIGAP CONSUMERS 1	36	224	225	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	1995	332	17					1138	1143		10.1056/NEJM199504273321706	http://dx.doi.org/10.1056/NEJM199504273321706			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QU302	7700288				2022-12-28	WOS:A1995QU30200006
J	ANTMAN, EM; GRUDZIEN, C; SACKS, DB				ANTMAN, EM; GRUDZIEN, C; SACKS, DB			EVALUATION OF A RAPID BEDSIDE ASSAY FOR DETECTION OF SERUM CARDIAC TROPONIN-T	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CREATINE-KINASE; UNSTABLE ANGINA; MB; DIAGNOSIS; INJURY; ISOENZYME	Objective.-To evaluate a rapid, qualitative, bedside immunoassay for cardiac-specific troponin T (cTnT) using a handheld device containing monoclonal antibodies. Design.-Comparison of rapid cTnT assay with clinical standard for diagnosis of myocardial infarction (MI). Setting.-Tertiary care university medical center. Patients.-A cohort of 100 patients admitted for evaluation of chest pain who had sufficient blood samples at presentation for measurement of creatine kinase, creatine kinase MB fraction, and rapid cTnT as well as adequate clinical data to establish the diagnosis of MI. Intervention.-None; treating physicians were blinded to rapid cTnT results. Main Outcome Measures.-Sensitivity and specificity of rapid cTnT assay for MI; likelihood ratios of positive and negative rapid cTnT assay results; relative risk (RR) for serious cardiac events with positive rapid cTnT assay result on admission. Results.-Sensitivity of the rapid cTnT assay increased from 33% within 2 hours from the onset of chest pain to 86% after 8 hours (P<.001); specificity ranged from 86% to 100% during the same time intervals. The odds of an MI increased sixfold with a positive assay result within 2 hours of chest pain and decreased sixfold with a negative assay result after 8 hours. The RR for experiencing death or nonfatal MI was 6.8 for patients presenting with a positive rapid cTnT assay. Conclusions.-The rapid cTnT assay is a simple, efficient test that for the first time provides clinicians with a useful laboratory tool for point-of-care evaluation of patients with chest pain.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,CLIN CHEM LAB,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School	ANTMAN, EM (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.			Sacks, David/0000-0003-3100-0735				ADAMS JE, 1993, CIRCULATION, V88, P750, DOI 10.1161/01.CIR.88.2.750; APPLE FS, 1992, LAB MED, V23, P298, DOI 10.1093/labmed/23.5.298; DSOUZA JP, 1978, CLIN BIOCHEM, V11, P204, DOI 10.1016/S0009-9120(78)80029-0; ELLIS AK, 1991, CIRCULATION, V83, P1107, DOI 10.1161/01.CIR.83.3.1107; FLETCHER RH, 1988, CLIN EPIDEMIOLOGY ES, P42; GERHARDT W, 1991, CLIN CHEM, V37, P1405; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KATUS HA, 1992, CLIN CHEM, V38, P386; MAIR J, 1991, CLIN CHEM, V37, P845; MAIR J, 1992, CRIT REV CL LAB SCI, V29, P31, DOI 10.3109/10408369209105245; PEDOETUNSTALL H, 1994, CIRCULATION, V90, P583; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; SEINO Y, 1993, LANCET, V342, P1236, DOI 10.1016/0140-6736(93)92216-G; WU AHB, 1994, CLIN CHEM, V40, P900	16	121	127	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	1995	273	16					1279	1282		10.1001/jama.273.16.1279	http://dx.doi.org/10.1001/jama.273.16.1279			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU571	7715040				2022-12-28	WOS:A1995QU57100031
J	RICHARDSON, WS; DETSKY, AS				RICHARDSON, WS; DETSKY, AS			USERS GUIDES TO THE MEDICAL LITERATURE .7. HOW TO USE A CLINICAL DECISION-ANALYSIS .A. ARE THE RESULTS OF THE STUDY VALID	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DILATED CARDIOMYOPATHY; MANAGEMENT; POLICY		UNIV ROCHESTER,SCH MED & DENT,DEPT MED,ROCHESTER,NY 14642; UNIV TORONTO,DEPT HLTH ADM,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON M5S 1A1,CANADA; TORONTO HOSP,DIV GEN INTERNAL MED & CLIN EPIDEMIOL,TORONTO,ON M5T 2S8,CANADA	University of Rochester; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto								BAKER DW, 1994, JAMA-J AM MED ASSOC, V272, P1614, DOI 10.1001/jama.272.20.1614; BARZA M, 1980, ANN INTERN MED, V92, P641, DOI 10.7326/0003-4819-92-5-641; BUCHBINDER R, 1992, J RHEUMATOL, V19, P1220; DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307; DISCH DL, 1994, ANN INTERN MED, V120, P449, DOI 10.7326/0003-4819-120-6-199403150-00001; DOLAN JG, 1989, MED DECIS MAKING, V9, P40, DOI 10.1177/0272989X8900900108; ECKMAN MH, 1992, CHEST, V102, pS538, DOI 10.1378/chest.102.4_Supplement.538S; Eddy David M., 1990, JAMA-J AM MED ASSOC, V263, P3081; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P3077, DOI 10.1001/jama.263.22.3077; Eddy DM., 1990, JAMA-J AM MED ASSOC, V263, P3084; FALK RH, 1990, AM J CARDIOL, V65, P914, DOI 10.1016/0002-9149(90)91436-A; GOEL V, 1992, CAN MED ASSOC J, V147, P413; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JASECHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703; KASSIRER JP, 1987, ANN INTERN MED, V106, P275, DOI 10.7326/0003-4819-106-2-275; KATZ DA, 1992, JAMA-J AM MED ASSOC, V268, P2678, DOI 10.1001/jama.268.19.2678; KEENEY RL, 1982, OPER RES, V30, P803, DOI 10.1287/opre.30.5.803; KRAHN M, 1991, ANN INTERN MED, V115, P248, DOI 10.7326/0003-4819-115-4-248; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; LEVINE M, 1994, JAMA-J AM MED ASSOC, V271, P1615, DOI 10.1001/jama.271.20.1615; Llewellyn-Thomas H, 1982, Med Decis Making, V2, P449, DOI 10.1177/0272989X8200200407; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; Sox HC, 1988, MED DECISION MAKING; TSEVAT J, 1989, MED DECIS MAKING, V9, P162, DOI 10.1177/0272989X8900900303; Weinstein MC, 1980, CLIN DECISION ANAL; WONG JB, 1993, NEW ENGL J MED, V328, P971, DOI 10.1056/NEJM199304013281319	29	151	153	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	1995	273	16					1292	1295		10.1001/jama.273.16.1292	http://dx.doi.org/10.1001/jama.273.16.1292			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU571	7715043				2022-12-28	WOS:A1995QU57100034
J	ZHANG, XK; BLENIS, J; LI, HC; SCHINDLER, C; CHENKIANG, S				ZHANG, XK; BLENIS, J; LI, HC; SCHINDLER, C; CHENKIANG, S			REQUIREMENT OF SERINE PHOSPHORYLATION FOR FORMATION OF STAT-PROMOTER COMPLEXES	SCIENCE			English	Article							TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; GROWTH-FACTOR; PROTEIN-PHOSPHORYLATION; INTERFERON-GAMMA; IFN-GAMMA; BINDING; GENE; INTERLEUKIN-6; ACTIVATION	Members of the interleukin-6 family of cytokines bind to and activate receptors that contain a common subunit, gp130. This leads to the activation of Stat3 and Stat1, two cytoplasmic signal transducers and activators of transcription (STATs), by tyrosine phosphorylation. Serine phosphorylation of Stat3 was constitutive and was enhanced by signaling through gp130. In cells of lymphoid and neuronal origins, inhibition of serine phosphorylation prevented the formation of complexes of DNA with Stat3-Stat3 but not with Stat3-Stat1 or Stat1-Stat1 dimers. In vitro serine dephosphorylation of Stat3 also inhibited DNA binding of Stat3-Stat3. The requirement of serine phosphorylation for Stat3-Stat3.DNA complex formation was inversely correlated with the affinity of Stat3-Stat3 for the binding site. Thus, serine phosphorylation appears to enhance or to be required for the formation of stable Stat3-Stat3 DNA complexes.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; CUNY MT SINAI SCH MED,DEPT BIOCHEM,NEW YORK,NY 10029; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard Medical School; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University					NATIONAL CANCER INSTITUTE [R01CA046595, R37CA046595] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER; NCI NIH HHS [CA46595] Funding Source: Medline; NHLBI NIH HHS [HL 21006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HSU W, 1993, MOL CELL BIOL, V13, P2515, DOI 10.1128/MCB.13.4.2515; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LI HC, 1981, ARCH BIOCHEM BIOPHYS, V207, P270, DOI 10.1016/0003-9861(81)90034-5; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P4371; NATKUNAM Y, 1994, J IMMUNOL, V153, P3476; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Zhang X, UNPUB; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	33	517	525	1	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1990	1994		10.1126/science.7701321	http://dx.doi.org/10.1126/science.7701321			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701321				2022-12-28	WOS:A1995QQ06800043
J	SUTTON, RB; DAVLETOV, BA; BERGHUIS, AM; SUDHOF, TC; SPRANG, SR				SUTTON, RB; DAVLETOV, BA; BERGHUIS, AM; SUDHOF, TC; SPRANG, SR			STRUCTURE OF THE FIRST C-2 DOMAIN OF SYNAPTOTAGMIN .1. A NOVEL CA2+/PHOSPHOLIPID-BINDING FOLD	CELL			English	Article							PROTEIN-KINASE-C; CRYSTAL-STRUCTURE; NEUROTRANSMITTER RELEASE; PHOSPHOLIPID-BINDING; ANNEXIN-V; CALCIUM; P65; EXOCYTOSIS; DROSOPHILA; REFINEMENT	C-2 domains are regulatory sequence motifs that occur widely in nature. Synaptotagmin I, a synaptic vesicle protein involved in the Ca2+ regulation of exocytosis, contains two C-2 domains, the first of which acts as a Ca2+ sensor. We now describe the three-dimensional structure of this C-2 domain at 1.9 Angstrom resolution in both the Ca2+-bound and Ca2+-free forms. The C-2 polypeptide forms an eight-stranded beta sandwich constructed around a conserved four-stranded motif designated as a C-2 key. Ca2+ binds in a cup-shaped depression between two polypeptide loops located at the N- and C-termini of the C-2-key motif.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	SUTTON, RB (corresponding author), UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235, USA.		Davletov, Bazbek/ABA-8569-2021; Berghuis, Albert M/A-6495-2008	Davletov, Bazbek/0000-0003-4658-3275; Berghuis, Albert/0000-0002-2663-025X				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CONCHA NO, 1993, SCIENCE, V261, P1321, DOI 10.1126/science.8362244; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DAVLETOV BA, 1994, J BIOL CHEM, V269, P28547; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FLORES TP, 1994, PROTEIN ENG, V7, P31, DOI 10.1093/protein/7.1.31; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEINZ DW, 1993, NATURE, V361, P561, DOI 10.1038/361561a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; HUBER R, 1990, FEBS LETT, V275, P15, DOI 10.1016/0014-5793(90)81428-Q; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NISHIKI T, 1994, J BIOL CHEM, V269, P10498; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PFLUGRATH JW, 1986, J MOL BIOL, V189, P383, DOI 10.1016/0022-2836(86)90520-6; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHARDSON JS, 1978, P NATL ACAD SCI USA, V75, P2574, DOI 10.1073/pnas.75.6.2574; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; WOOLFSON DN, 1993, PROTEIN ENG, V6, P461, DOI 10.1093/protein/6.5.461; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; 1994, ACTA CRYSTALLOGR, V50, P760	56	604	625	0	19	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					929	938		10.1016/0092-8674(95)90296-1	http://dx.doi.org/10.1016/0092-8674(95)90296-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697723	Bronze			2022-12-28	WOS:A1995QP61200012
J	RIAD, H; NICHOLLS, A				RIAD, H; NICHOLLS, A			AN ETHICAL DEBATE - ELECTIVE VENTILATION OF POTENTIAL ORGAN DONORS	BRITISH MEDICAL JOURNAL			English	Article							DONATION	Elective ventilation describes the procedure of transferring selected patients dying from rapidly progressive intracranial haemorrhage from general medical wards to intensive care units for a brief period of ventilation before confirmation of brain stem death and harvesting of organs. This approach in Exeter has led to a rate of kidney retrieval and transplant higher than has been achieved elsewhere in the United Kingdom, with a stabilisation of numbers on patients on dialysis. Recently doubt has been cast on the legality of our practice of elective ventilation on the grounds that relatives are not permitted to consent to treatment of an incompetent person when that treatment is not in the patient's best interests. We are thus faced with the dilemma of a protocol that is ethical, practical, and operates for the greater good but which may be illegal. This article explores various objections to the protocol and calls for public, medical, and legal debate on the issues.	UNIV BRISTOL,BRISTOL ROYAL INFIRM,INTENS THERAPY UNIT,BRISTOL BS2 8HW,AVON,ENGLAND; ROYAL LIVERPOOL UNIV HOSP,RENAL TRANSPLANT UNIT,LIVERPOOL,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,FAC LAW,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; THREE SERJEANTS INN,LONDON EC4Y 1BQ,ENGLAND	Bristol Royal Infirmary; University of Bristol; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of Liverpool	RIAD, H (corresponding author), ROYAL DEVON & EXETER HOSP,EXETER EX2 5DW,DEVON,ENGLAND.		Sano, Michael/E-1715-2011					COLLINS CH, 1992, CARE CRITICALLY ILL, V8, P57; Conference of Medical Royal Colleges and their Faculties in the UK, 1979, LANCET, Vi, P261; FEEST TG, 1990, LANCET, V335, P1133, DOI 10.1016/0140-6736(90)91134-V; NEW B, 1994, 18 KINGS FUND I RES; NICHOLLS A, 1994, BRIT J HOSP MED, V51, P555; NICHOLLS A, 1993, BRIT MED J, V306, P517, DOI 10.1136/bmj.306.6876.517-d; NIELSEN MS, 1994, J ROY COLL PHYS LOND, V28, P85; RIAD H, 1994, BRIT J HOSP MED, V51, P555; RIAD H, 1993, BRIT J HOSP MED, V50, P438; ROBSON JG, 1981, LANCET, V2, P365; ROBSON JG, 1981, BMJ-BRIT MED J, V283, P505, DOI 10.1136/bmj.283.6289.505-a; Routh G, 1992, CARE CRIT ILL, V8, P60; SOMMERVILLE A, 1993, MED ETHICS TODAY ITS; WILLATTS SM, 1994, BRIT J HOSP MED, V51, P554; WILLIAMS R, 1993, J ROY COLL PHYS LOND, V27, P214; 1983, CADAVERIC ORGANS TRA; 1979, BRIT MED J, V1, P332; 1993, ISSUES NURSING SOC, V19	18	38	38	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					714	715		10.1136/bmj.310.6981.714	http://dx.doi.org/10.1136/bmj.310.6981.714			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711541	Green Published			2022-12-28	WOS:A1995QN46100024
J	BRADLOW, A; DAVID, J				BRADLOW, A; DAVID, J			RECENT ADVANCES - RHEUMATOLOGY	BRITISH MEDICAL JOURNAL			English	Article							ARTHRITIS				BRADLOW, A (corresponding author), ROYAL BERKSHIRE & BATTLE HOSP NHS TRUST,DEPT RHEUMATOL,READING RG3 1AG,BERKS,ENGLAND.							BACON PA, 1994, ANN RHEUM DIS, V53, P621, DOI 10.1136/ard.53.10.621; BATEMAN DN, 1994, BRIT MED J, V309, P552, DOI 10.1136/bmj.309.6954.552; BLACKBURN WD, 1991, ARTHRITIS RHEUM, V34, P204, DOI 10.1002/art.1780340212; CASH JM, 1994, NEW ENGL J MED, V330, P1368; COOPER C, 1994, Q J MED, V87, P203; COPE H, 1994, LANCET, V344, P864, DOI 10.1016/S0140-6736(94)92833-9; COSTE J, 1994, BRIT MED J, V308, P577, DOI 10.1136/bmj.308.6928.577; DEYO RA, 1994, NEW ENGL J MED, V331, P115, DOI 10.1056/NEJM199407143310209; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; GORDON M, 1993, Q J MED, V86, P779; GOUGH AKS, 1994, LANCET, V344, P23, DOI 10.1016/S0140-6736(94)91049-9; GSTON JSH, 1994, Q J MED, V87, P647; HILL J, 1994, BRIT J RHEUMATOL, V33, P283; ISAACS JD, 1992, LANCET, V340, P748, DOI 10.1016/0140-6736(92)92294-P; JAYSON MIV, 1994, BRIT MED J, V309, P681, DOI 10.1136/bmj.309.6956.681; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; KREMER JM, 1994, ARTHRITIS RHEUM-US, V37, P316, DOI 10.1002/art.1780370304; LAMBERT CM, 1994, BRIT J RHEUMATOL, V33, P383; LANDEWE RBM, 1994, ARTHRITIS RHEUM, V37, P637, DOI 10.1002/art.1780370506; LEUNG DYM, 1993, LANCET, V342, P1385, DOI 10.1016/0140-6736(93)92752-F; LUQMANI RA, 1994, Q J MED, V87, P671; MAPP PI, 1994, ANN RHEUM DIS, V53, P240, DOI 10.1136/ard.53.4.240; MURPHY EA, 1994, BRIT MED J, V309, P1337, DOI 10.1136/bmj.309.6965.1337; OCALLAGHAN CA, 1994, BRIT MED J, V308, P110, DOI 10.1136/bmj.308.6921.110; Pascual Eliseo, 1994, Current Opinion in Rheumatology, V6, P454, DOI 10.1097/00002281-199407000-00018; PORTER DR, 1994, ANN RHEUM DIS, V53, P812, DOI 10.1136/ard.53.12.812; PRITCHARD MH, 1994, BRIT J RHEUMATOL, V33, P475; PULLAR T, 1985, ANN RHEUM DIS, V44, P134, DOI 10.1136/ard.44.2.134; SAMBROOK PN, 1994, LANCET, V344, P3, DOI 10.1016/S0140-6736(94)91040-5; SHARPE M, 1994, Q J MED, V87, P187; STOKES LT, 1993, OXFORD TXB RHEUMATOL, P367; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; VISCHER TL, 1994, ANN RHEUM DIS, V53, P708, DOI 10.1136/ard.53.11.708; VREUGDENHIL G, 1990, BRIT J RHEUMATOL, V29, P105; WADDELL G, 1993, ANN RHEUM DIS, V52, P317, DOI 10.1136/ard.52.5.317; WALPORT MJ, 1993, OXFORD TXB RHEUMATOL, P292; WEINBLATT ME, 1994, ARTHRITIS RHEUM, V37, P1492, DOI 10.1002/art.1780371013; WINROW VR, 1993, BRIT MED BULL, V49, P506, DOI 10.1093/oxfordjournals.bmb.a072627; WORDSWORTH BP, 1992, SPRINGER SEMIN IMMUN, V14, P59; WORDSWORTH P, 1994, BRIT J RHEUMATOL, V33, P409; 1994, BACK PAIN; 1994, CURRENT PROBLEMS PHA, V20, P9	46	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					637	640		10.1136/bmj.310.6980.637	http://dx.doi.org/10.1136/bmj.310.6980.637			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703753	Green Published			2022-12-28	WOS:A1995QL98400020
J	WYLLIE, HR; DUNN, FG				WYLLIE, HR; DUNN, FG			PREHOSPITAL OPIATE AND ASPIRIN ADMINISTRATION IN PATIENTS WITH SUSPECTED MYOCARDIAL-INFARCTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article									STOBHILL GEN HOSP, DEPT CARDIAC, GLASGOW G21 3UW, SCOTLAND									ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; FORD JL, 1988, TXB PHARM SCI DOSAGE, P362; WILLARD JE, 1992, NEW ENGL J MED, V327, P175; YOUNG LY, 1992, TXB APPLIED THERAPEU, V3, P9	5	16	16	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	1994	308	6931					760	761		10.1136/bmj.308.6931.760a	http://dx.doi.org/10.1136/bmj.308.6931.760a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	7695672	Green Published			2022-12-28	WOS:A1994NC34800021
J	GRAY, DT; FYLER, DC; WALKER, AM; WEINSTEIN, MC; CHALMERS, TC				GRAY, DT; FYLER, DC; WALKER, AM; WEINSTEIN, MC; CHALMERS, TC			CLINICAL OUTCOMES AND COSTS OF TRANSCATHETER AS COMPARED WITH SURGICAL CLOSURE OF PATENT DUCTUS-ARTERIOSUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CATHETER OCCLUSION; LIGATION; OCCLUDER; INFANTS; TRIALS; FLOW; BIAS	Background. Transcatheter implantation of the Rashkind PDA occluder is an alternative to conventional surgical closure of isolated patent ductus arteriosus. Neither the clinical outcomes nor the costs of these procedures have been formally compared. Methods. We performed a retrospective cohort study to evaluate the clinical outcomes within a seven-month period for comparable patients with patent ductus arteriosus who underwent either placement of an occluder or surgical closure. The patients were treated between 1982 and 1987 at 14 major North American centers where patent ductus arteriosus was closed predominantly by a surgical procedure or by the occluder technique. To estimate inpatient and follow-up costs, we multiplied the observed use of resources by 1989 unit costs based on hospital-accounting and physician-reimbursement data. Results. On the basis of cardiac auscultation at follow-up, the initial procedure resulted in closure of the ductus arteriosus in 77.3 percent of 185 patients in whom the occluder was implanted (95 percent confidence interval, 70.6 to 83.1 percent) and 99.8 percent of 446 surgical patients (95 percent confidence interval, 98.8 to 100.0 percent). Second procedures increased the percentage of successful closures to 87.6 percent (95 percent confidence interval, 81.9 to 92.0 percent) and 1 00.0 percent (95 percent confidence interval, 99.3 to 100.0 percent) for patients in the occluder and surgical groups, respectively. There were no deaths. Major complications occurred in 2.7 percent of the patients in whom the occluder was implanted (95 percent confidence interval, 0. 9 to 6.2 percent) and 0.2 percent of the patients who underwent surgery (95 percent confidence interval, 0.0 to 1.2 percent); moderate complications in 16.8 percent (95 percent confidence interval, 11.7 to 22.9 percent) and 15.0 percent (95 percent confidence interval, 11.8 to 18.7 percent), respectively; and minor complications in 11.4 percent (95 percent confidence interval, 7.2 to 16.8 percent) and 24.9 percent (95 percent confidence interval, 20.9 to 29.2 percent). Including the cost of follow-up care, the mean estimated cost per case treated surgically was $8,838 (in 1989 U.S. dollars), as compared with $11,466 per case treated with the occluder technique. Sensitivity analyses based on our data identified no plausible situations in which the costs of surgery and of implantation of the occluder would be equal. Conclusions. The more effective and less costly surgical procedure was superior to transcatheter placement of the occluder for closure of isolated patent ductus arteriosus. Consequently, our results do not support the widespread dissemination of the occluder procedure for the management of this common congenital lesion.	CHILDRENS HOSP MED CTR,DEPT CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	GRAY, DT (corresponding author), MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,200 1ST ST SW,ROCHESTER,MN 55905, USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS006302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007069] Funding Source: NIH RePORTER; AHRQ HHS [1 R03 HS 06302-01] Funding Source: Medline; NIEHS NIH HHS [5T32 ESO7069-11/0021] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS ME, 1992, MED CARE, V30, P231, DOI 10.1097/00005650-199203000-00005; BASH SE, 1984, CIRCULATION S2, V2, P285; BEGG CB, 1983, BIOMETRICS, V39, P207, DOI 10.2307/2530820; BENSON LN, 1988, CATHETER CARDIO DIAG, V14, P82, DOI 10.1002/ccd.1810140204; BENSON LN, 1989, CATHETER CARDIO DIAG, V18, P48, DOI 10.1002/ccd.1810180112; BRIDGES ND, 1991, J AM COLL CARDIOL, V18, P1297, DOI 10.1016/0735-1097(91)90551-J; COHN HE, 1985, PEDIATR CARDIOL, V6, P123, DOI 10.1007/BF02336550; FAN LL, 1989, J THORAC CARDIOV SUR, V98, P611; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FLEMING WH, 1983, PEDIATRICS, V71, P373; Ghani S A, 1989, J R Coll Surg Edinb, V34, P33; GINSBURG PB, 1984, NEW ENGL J MED, V310, P893, DOI 10.1056/NEJM198404053101406; GRAY DT, 1991, MED DECIS MAKING, V11, P335; GRAY DT, 1991, P ANN M INT SOC TECH; GRAY DT, 1989, SOCIOECONOMICS SURGI, P228; GREGORIC I, 1990, CIRCULATION, V82, P76; HLATKY MA, 1988, J AM COLL CARDIOL, V11, P237, DOI 10.1016/0735-1097(88)90086-1; HOLLENBERG J, 1987, SMLTREE VERSION 2 2; HOSKING MCK, 1991, CIRCULATION, V84, P2313, DOI 10.1161/01.CIR.84.6.2313; HOSKING MCK, 1989, CAN J CARDIOL, V5, P340; KARWANDE SV, 1992, ANN THORAC SURG, V54, P164, DOI 10.1016/0003-4975(92)91172-6; KRICHENKO A, 1989, AM J CARDIOL, V63, P877, DOI 10.1016/0002-9149(89)90064-7; LATSON LA, 1991, CIRCULATION, V84, P2591, DOI 10.1161/01.CIR.84.6.2591; LATSON LA, 1989, J PEDIATR-US, V115, P549, DOI 10.1016/S0022-3476(89)80279-3; Miettinen O S, 1983, Stat Med, V2, P267, DOI 10.1002/sim.4780020222; MUSEWE NN, 1989, CIRCULATION, V80, P1706, DOI 10.1161/01.CIR.80.6.1706; RASHKIND WJ, 1987, CIRCULATION, V75, P583, DOI 10.1161/01.CIR.75.3.583; ROTHMAN KJ, 1979, NIH791649 PUBL, P33; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SORENSEN KE, 1991, AM J CARDIOL, V67, P653, DOI 10.1016/0002-9149(91)90911-4; Torrance GW, 1987, METHODS EC EVALUATIO; VITIELLO R, 1991, BRIT HEART J, V65, P211; Weinstein M C, 1981, Med Decis Making, V1, P309, DOI 10.1177/0272989X8100100403; Weinstein MC, 1980, CLIN DECISION ANAL; WESSEL DL, 1988, CIRCULATION, V77, P1068, DOI 10.1161/01.CIR.77.5.1068; WOODS JR, 1992, HEALTH SERV RES, V27, P219; 1988, PRODUCT LINE MANAGER; 1993, CARDIAC SURGERY MORP, V1, P841; 1991, STATXACT STATISTICAL	39	114	118	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1993	329	21					1517	1523		10.1056/NEJM199311183292101	http://dx.doi.org/10.1056/NEJM199311183292101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG188	7695658	Bronze			2022-12-28	WOS:A1993MG18800001
J	KAUFMAN, DL; CLARESALZLER, M; TIAN, JD; FORSTHUBER, T; TING, GSP; ROBINSON, P; ATKINSON, MA; SERCARZ, EE; TOBIN, AJ; LEHMANN, PV				KAUFMAN, DL; CLARESALZLER, M; TIAN, JD; FORSTHUBER, T; TING, GSP; ROBINSON, P; ATKINSON, MA; SERCARZ, EE; TOBIN, AJ; LEHMANN, PV			SPONTANEOUS LOSS OF T-CELL TOLERANCE TO GLUTAMIC-ACID DECARBOXYLASE IN MURINE INSULIN-DEPENDENT DIABETES	NATURE			English	Article							HEAT-SHOCK PROTEIN; AUTOANTIGEN; MOUSE; GAMMA; CD4+; ENCEPHALOMYELITIS; AUTOANTIBODIES; IDENTIFICATION; AUTOIMMUNITY; INDUCTION	INSULIN-DEPENDENT diabetes mellitus (IDDM) in non-obese diabetic (NOD) mice results from the T-lymphocyte-mediated destruction of the insulin-producing pancreatic beta-cells and serves as a model for human IDDM1. Whereas a number of autoantibodies are associated with IDDM2, it is unclear when and to what beta-cell antigens pathogenic T cells become activated during the disease process. We report here that a T-helper-1 (Th1) response to glutamate decarboxylase develops in NOD mice at the same time as the onset of insulitis. This response is initially limited to a confined region of glutamate decarboxylase, but later spreads intramolecularly to additional determinants. Subsequently, T-cell reactivity arises to other beta-cell antigens, consistent with intermolecular diversification of the response. Prevention of the spontaneous anti-glutamate decarboxylase response, by tolerization of glutamate decarboxylase-reactive T cells, blocks the development of T-cell autoimmunity to other beta-cell antigens, as well as insulitis and diabetes. Our data suggest that (1) glutamate decarboxylase is a key target antigen in the induction of murine IDDM; (2) autoimmunity to glutamate decarboxylase triggers T-cell responses to other beta-cell antigens, and (3) spontaneous autoimmune disease can be prevented by tolerization to the initiating target antigen.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,BRAIN RES INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV FLORIDA,COLL MED,DEPT PATHOL & LAB MED,GAINESVILLE,FL 32610	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; State University System of Florida; University of Florida	KAUFMAN, DL (corresponding author), UNIV CALIF LOS ANGELES,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024, USA.		Kaufman, Daniel/AAU-1228-2021; Forsthuber, Thomas/AID-8080-2022	Kaufman, Daniel/0000-0002-9844-5918; /0000-0003-0692-7125	NINDS NIH HHS [R01 NS022256] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO DG, 1989, CELL IMMUNOL, V124, P132, DOI 10.1016/0008-8749(89)90117-2; ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BRADLEY LM, 1992, J IMMUNOL, V148, P324; BU DF, 1992, P NATL ACAD SCI USA, V89, P2115, DOI 10.1073/pnas.89.6.2115; CASTANO L, 1991, J CLIN ENDOCR METAB, V73, P1197, DOI 10.1210/jcem-73-6-1197; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CROFT M, 1992, J EXP MED, V176, P1431, DOI 10.1084/jem.176.5.1431; ELIAS D, 1991, P NATL ACAD SCI USA, V88, P3088, DOI 10.1073/pnas.88.8.3088; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; GAMMON G, 1989, NATURE, V342, P183, DOI 10.1038/342183a0; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; KAUFMAN DL, 1986, SCIENCE, V232, P1138, DOI 10.1126/science.3518061; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; KAUFMAN DL, 1993, TRENDS PHARMACOL SCI, V14, P107, DOI 10.1016/0165-6147(93)90079-Y; LEE DS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P157, DOI 10.1016/0167-4781(93)90056-J; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; LEHMANN PV, 1993, IMMUNOL TODAY, V14, P203, DOI 10.1016/0167-5699(93)90163-F; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; PALMER JP, 1993, DIABETES REV, V1, P104; QIN HY, 1993, J IMMUNOL, V150, P2072; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; TAGUCHI T, 1990, J IMMUNOL, V145, P68; WATANABE R, 1983, NATURE, V305, P150, DOI 10.1038/305150a0; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	29	1039	1080	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					69	72		10.1038/366069a0	http://dx.doi.org/10.1038/366069a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	7694152	Green Accepted			2022-12-28	WOS:A1993MF00700056
J	EGELHOFF, TT; LEE, RJ; SPUDICH, JA				EGELHOFF, TT; LEE, RJ; SPUDICH, JA			DICTYOSTELIUM MYOSIN HEAVY-CHAIN PHOSPHORYLATION SITES REGULATE MYOSIN FILAMENT ASSEMBLY AND LOCALIZATION IN-VIVO	CELL			English	Article							PROTEIN-KINASE-C; NULL MUTANTS; CYCLIC-GMP; DISCOIDEUM; CELLS; CYTOSKELETON; PURIFICATION; TAIL; GENE; COMPLEMENTATION	Three threonine residues in the tall region of Dictyostelium myosin II heavy chain have been implicated previously in control of myosin filament formation. Here we report the in vitro and in vivo consequences of converting these sites to alanine residues, which eliminates phosphorylation at these positions, or to aspartate residues, which mimics the negative charge state of the phosphorylated molecule. Alanine substitution allows in vitro assembly and in vivo contractile activity, although this myosin shows substantial over-assembly in vivo. Aspartate substitution eliminates filament assembly in vitro and renders the myosin unable to drive any tested contractile event in vivo. These results demonstrate that heavy chain phosphorylation plays a key modulatory role in controlling myosin function in vivo.	STANFORD UNIV, MED CTR, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA	Stanford University					NATIONAL CANCER INSTITUTE [T32CA009151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K11AR001829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046551, R37GM046551] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09151] Funding Source: Medline; NIAMS NIH HHS [AR01829] Funding Source: Medline; NIGMS NIH HHS [GM46551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLOT CH, 1987, J BIOL CHEM, V262, P3918; CLARKE M, 1974, J MOL BIOL, V86, P209, DOI 10.1016/0022-2836(74)90013-8; COLLINS JH, 1982, BIOCHEMISTRY-US, V21, P6910, DOI 10.1021/bi00269a045; COTE GP, 1987, J BIOL CHEM, V262, P1065; COTE GP, 1987, J BIOL CHEM, V262, P13033; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; EGELHOFF TT, 1990, DEV BIOL, V137, P359, DOI 10.1016/0012-1606(90)90260-P; EGELHOFF TT, 1989, MOL CELL BIOL, V9, P1965, DOI 10.1128/MCB.9.5.1965; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; GIULIANO KA, 1992, MOL BIOL CELL, V3, P1037, DOI 10.1091/mbc.3.9.1037; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KUBALEK EW, 1992, MOL BIOL CELL, V3, P1455, DOI 10.1091/mbc.3.12.1455; KUCZMARSKI ER, 1987, J CELL BIOL, V105, P2989, DOI 10.1083/jcb.105.6.2989; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; LIU G, 1988, J CELL SCI, V90, P123; LIU G, 1991, J CELL SCI, V98, P483; LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MALCHOW D, 1981, EUR J BIOCHEM, V17, P213; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MARUTA H, 1983, EMBO J, V2, P535, DOI 10.1002/j.1460-2075.1983.tb01459.x; OLIVER JM, 1988, PROG ALLERGY, V42, P185; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; PELTZ G, 1985, J CELL BIOL, V100, P1016, DOI 10.1083/jcb.100.4.1016; RAHMSDORF HJ, 1978, FEBS LETT, V88, P322, DOI 10.1016/0014-5793(78)80203-8; RAVID S, 1992, P NATL ACAD SCI USA, V89, P5877, DOI 10.1073/pnas.89.13.5877; RAVID S, 1989, J BIOL CHEM, V264, P15144; RUPPEL KM, 1990, ANN NY ACAD SCI, V582, P147; Sambrook J, 1989, MOL CLONING LABORATO; SPUDICH A, 1987, METHOD CELL BIOL, V28, P209; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TRUONG T, 1992, J BIOL CHEM, V267, P9767; VAILLANCOURT JP, 1988, J BIOL CHEM, V263, P10082; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002	42	241	244	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					363	371		10.1016/0092-8674(93)80077-R	http://dx.doi.org/10.1016/0092-8674(93)80077-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	7691416				2022-12-28	WOS:A1993MD88500017
J	OLIET, SHR; BOURQUE, CW				OLIET, SHR; BOURQUE, CW			MECHANOSENSITIVE CHANNELS TRANSDUCE OSMOSENSITIVITY IN SUPRAOPTIC NEURONS	NATURE			English	Article							ION CHANNELS; RAT; VASOPRESSIN; OXYTOCIN; ACTIVATION; NUCLEUS; STIMULI	VASOPRESSIN is a peptide hormone synthesized by neurons of the supraoptic and paraventricular nuclei, which project axon terminals to the neurohypophysis. Consistent with its antidiuretic properties, vasopressin release rises as a function of plasma osmolality1-3, a response that results from accelerated action potential discharge4-6. Previous studies have shown that increases in fluid osmolality depolarize supraoptic neurons in the absence of synaptic transmission7-9, suggesting that these cells behave as intrinsic osmoreceptors. The mechanism by which changes in osmolality are transduced into an electrical signal is unknown, however. Here we report that changes in cell volume accompany physiological variations in fluid osmolality and that these modulate the activity of mechanosensitive cation channels in a way that is consistent with the macroscopic regulation of membrane voltage and action potential discharge. These findings define a function for stretch-inactivated channels in mammalian central neurons.	MONTREAL GEN HOSP,CTR RES NEUROSCI,1650 CEDAR AVE,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,MONTREAL H3G 1A4,PQ,CANADA	McGill University; McGill University				Oliet, Stephane/0000-0003-0595-9029; Bourque, Charles/0000-0002-1594-742X				BOURQUE CW, 1989, J PHYSIOL-LONDON, V417, P263, DOI 10.1113/jphysiol.1989.sp017800; BRIMBLE MJ, 1977, J PHYSIOL-LONDON, V271, P253, DOI 10.1113/jphysiol.1977.sp011999; BRIMBLE MJ, 1978, J PHYSIOL-LONDON, V278, P69, DOI 10.1113/jphysiol.1978.sp012293; Darrow DC, 1935, J CLIN INVEST, V14, P266, DOI 10.1172/JCI100674; DUNN FL, 1973, J CLIN INVEST, V52, P3212, DOI 10.1172/JCI107521; FRENCH AS, 1992, ANNU REV PHYSIOL, V54, P135, DOI 10.1146/annurev.physiol.54.1.135; FRIEDMAN JE, 1993, J NEUROSCI, V13, P63; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; LAWRENCE D, 1985, BRAIN RES, V341, P176, DOI 10.1016/0006-8993(85)91486-6; LENG G, 1982, NEUROENDOCRINOLOGY, V34, P75, DOI 10.1159/000123280; MASON WT, 1980, NATURE, V287, P154, DOI 10.1038/287154a0; MORRIS CE, 1990, J MEMBRANE BIOL, V113, P93, DOI 10.1007/BF01872883; MORRIS CE, 1989, SCIENCE, V243, P807, DOI 10.1126/science.2536958; MORRIS CE, 1991, SCIENCE, V251, P1246, DOI 10.1126/science.1706535; OLIET SHR, 1992, J PHYSIOL-LONDON, V455, P291, DOI 10.1113/jphysiol.1992.sp019302; POULAIN DA, 1982, NEUROSCIENCE, V7, P773, DOI 10.1016/0306-4522(82)90044-6; ROBERTSON GL, 1976, KIDNEY INT, V10, P25, DOI 10.1038/ki.1976.76; SOKABE M, 1992, ADV COMP ENV PHYSL, V10, P55; VERNEY EB, 1947, PROC R SOC SER B-BIO, V135, P25, DOI 10.1098/rspb.1947.0037	19	272	275	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					341	343		10.1038/364341a0	http://dx.doi.org/10.1038/364341a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	7687327				2022-12-28	WOS:A1993LN57000058
J	COOPER, JA; HOWELL, B				COOPER, JA; HOWELL, B			THE WHEN AND HOW OF SRC REGULATION	CELL			English	Review							PROTEIN TYROSINE KINASE; C-SRC; PP60C-SRC; PHOSPHORYLATION; OSTEOPETROSIS; ACTIVATION; BINDING; DOMAINS; REGION; CD4				COOPER, JA (corresponding author), FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA.			Howell, Brian/0000-0002-0204-0773				APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MACAULEY A, 1993, ONCOGENE, V8, P117; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUDOL M, 1993, ONCOGENE, V8, P823; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	558	568	0	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 18	1993	73	6					1051	1054		10.1016/0092-8674(93)90634-3	http://dx.doi.org/10.1016/0092-8674(93)90634-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LH548	7685656				2022-12-28	WOS:A1993LH54800001
J	PHILLIPS, KA; FLATT, SJ; MORRISON, KR; COATES, TJ				PHILLIPS, KA; FLATT, SJ; MORRISON, KR; COATES, TJ			USE OF HOME HIV TESTING	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							MODEL; RISK				PHILLIPS, KA (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94105, USA.				NIAID NIH HHS [R29 AI34864] Funding Source: Medline; NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ajzen I., 1980, UNDERSTANDING ATTITU; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; BAYER R, 1995, NEW ENGL J MED, V332, P1296, DOI 10.1056/NEJM199505113321911; CATANIA JA, 1990, HEALTH EDUC QUART, V17, P53, DOI 10.1177/109019819001700107; EDMONDSON B, 1985, AM DEMOGR, V7, P35; GORSKY RD, 1995, PREV MED, V24, P3, DOI 10.1006/pmed.1995.1002; HEDLUND K, 1990, 6TH INT C AIDS SAN F, V2, P290; MONTANO DE, 1991, SOC SCI MED, V32, P733, DOI 10.1016/0277-9536(91)90153-4; PARINGER L, 1991, INQUIRY-J HEALTH CAR, V28, P226; PHILLIPS KA, 1993, AIDS EDUC PREV, V5, P95; PHILLIPS KA, 1994, J ACQ IMMUN DEF SYND, V7, P403; PHILLIPS KA, IN PRESS AM J PREV M; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; 1993, EXTERNAL REV PROGRAM; 1994, ADV DATA VITAL HLTH, V243; 1993, PUBLIC USE FILE DOCU	16	39	39	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 11	1995	332	19					1308	1310		10.1056/NEJM199505113321918	http://dx.doi.org/10.1056/NEJM199505113321918			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QW600	7708086				2022-12-28	WOS:A1995QW60000028
J	TERUEL, JL; LASUNCION, MA				TERUEL, JL; LASUNCION, MA			CUTANEOUS XANTHOMAS IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											TERUEL, JL (corresponding author), HOSP RAMON Y CAJAL,E-28034 MADRID,SPAIN.		Lasunción, Miguel A./K-6167-2014	Lasunción, Miguel A./0000-0003-0299-9391					0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	1995	332	17					1137	1137		10.1056/NEJM199504273321705	http://dx.doi.org/10.1056/NEJM199504273321705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU302	7700287				2022-12-28	WOS:A1995QU30200005
J	CONDRA, JH; SCHLEIF, WA; BLAHY, OM; GABRYELSKI, LJ; GRAHAM, DJ; QUINTERO, JC; RHODES, A; ROBBINS, HL; ROTH, E; SHIVAPRAKASH, M; TITUS, D; YANG, T; TEPPLER, H; SQUIRES, KE; DEUTSCH, PJ; EMINI, EA				CONDRA, JH; SCHLEIF, WA; BLAHY, OM; GABRYELSKI, LJ; GRAHAM, DJ; QUINTERO, JC; RHODES, A; ROBBINS, HL; ROTH, E; SHIVAPRAKASH, M; TITUS, D; YANG, T; TEPPLER, H; SQUIRES, KE; DEUTSCH, PJ; EMINI, EA			IN-VIVO EMERGENCE OF HIV-1 VARIANTS RESISTANT TO MULTIPLE PROTEASE INHIBITORS	NATURE			English	Article							REVERSE-TRANSCRIPTASE; IMMUNODEFICIENCY	INHIBITORS Of the human immunodeficiency virus type 1 (HIV-1) protease have entered clinical study as potential therapeutic agents for HIV-1 infection. The clinical efficacy of HIV-1 reverse transcriptase inhibitors has been limited bg the emergence of resistant viral variants. Similarly, variants expressing resistance to protease inhibitors have been derived in cell culture(1-10). We now report the characterization of resistant variants isolated from patients undergoing therapy with the protease inhibitor MX-639 (formerly designated L-735,524). Five of these variants, isolated from four patients, exhibited cross-resistance to all members of a panel of six structurally diverse protease inhibitors. This suggests that combination therapy with multiple protease inhibitors may not prevent loss of antiviral activity resulting from resistance selection. In addition, previous therapy with one compound may abrogate the benefit of subsequent treatment with a second inhibitor.	MERCK SHARP & DOHME LTD,RES LABS,DEPT CLIN PHARMACOL,W POINT,PA 19486; THOMAS JEFFERSON UNIV,DIV INFECT DIS,PHILADELPHIA,PA 19107; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294	Merck & Company; Jefferson University; University of Alabama System; University of Alabama Birmingham	CONDRA, JH (corresponding author), MERCK SHARP & DOHME LTD,RES LABS,DEPT ANTIVIRAL RES,W POINT,PA 19486, USA.		Rhodes, Andrew/G-4265-2011	Rhodes, Andrew/0000-0002-8737-574X				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; BYRNES VW, 1993, ANTIMICROB AGENTS CH, V37, P1576, DOI 10.1128/AAC.37.8.1576; CHEN CM, J CELL BIOCHEM, V18, P16694; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLONNO RJ, 1988, P NATL ACAD SCI USA, V85, P5449, DOI 10.1073/pnas.85.15.5449; CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S; DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001; ELFARRASH MA, 1994, J VIROL, V68, P233, DOI 10.1128/JVI.68.1.233-239.1994; GETMAN DP, 1993, J MED CHEM, V36, P288, DOI 10.1021/jm00054a014; HO DD, 1994, J VIROL, V68, P2016, DOI 10.1128/JVI.68.3.2016-2020.1994; JACOBSEN H, 1995, VIROLOGY, V206, P527, DOI 10.1016/S0042-6822(95)80069-7; KEMPF DJ, 1993, ABSTR PAP AM CHEM S, V206, P119; KEMPF DJ, 1994, J CELL BIOCHEM, V18, P130; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; MARKOWITZ M, 1995, J VIROL, V69, P701, DOI 10.1128/JVI.69.2.701-706.1995; MYERS G, 1993, HUMAN RETROVIRUSES A; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543; OTTO MJ, 1993, ANTIMICROB AGENTS CH, V37, P2606, DOI 10.1128/AAC.37.12.2606; SAAG MS, 1993, NEW ENGL J MED, V329, P1065, DOI 10.1056/NEJM199310073291502; SINGH M, 1993, J CELL BIOCH E S, V17, P86; TISDALE M, 1994, 3RD INT WORKSH HIV D, P14; TUNG RD, 1994, 10TH INT C AIDS, P33; VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096; WINSLOW DL, 1994, AIDS, V8, P753, DOI 10.1097/00002030-199406000-00005; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	28	890	920	0	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					569	571		10.1038/374569a0	http://dx.doi.org/10.1038/374569a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700387				2022-12-28	WOS:A1995QR06900060
J	BRYCE, FP; NEVILLE, RG; CROMBIE, IK; CLARK, RA; MCKENZIE, P				BRYCE, FP; NEVILLE, RG; CROMBIE, IK; CLARK, RA; MCKENZIE, P			CONTROLLED TRIAL OF AN AUDIT FACILITATOR IN DIAGNOSIS AND TREATMENT OF CHILDHOOD ASTHMA IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; MORBIDITY; CHILDREN; PREVALENCE; EDUCATION; HEALTH; TRENDS; CARE	Objective-To test whether an audit facilitator could alter the pattern of diagnosis and treatment of childhood asthma. Design-Randomised stratified controlled trial. Setting-12 general practices in Tayside. Subjects-3373 children aged 1-15 inclusive who had symptoms suggestive of asthma or possible asthma drawn from a systematic review of 10 725 general practice case records. Intervention-Children were targeted for a clinical review by their general practitioner or practice nurses. Main outcome measures-Asthma related consultations, prescriptions, hospital attendances, and health service costs 12 months before and after study. Results-Compared with controls (n=1563) the intervention group (n=1585) had more practice initiated consultations for asthma (relative risk 2.18 (95% confidence interval 1.74 to 2.73)), new diagnoses of asthma (2.83 (2.26 to 3.54)), and past diagnoses reaffirmed (1.30 (1.08 to 1.58)), and they were more frequently prescribed inhaled cromoglycate (1.52 (1.02 to 2.25)). Hospital inpatient day rates fell from 152 to 122 in the intervention group and rose from 69 to 117 in the control group between the year before and the year after study. Total primary care costs rose from pound 30 118 to pound 37 243 in the intervention group and fell from pound 29 131 to pound 27 990 in the control group. Hospital care cost fell in the intervention group from pound 25 406 to pound 20 727 and rose in the control group from pound 12 699 to pound 19 650. Conclusion-An audit facilitator can favourably influence the pattern of diagnoses and treatment of childhood asthma in general practice. This may have an impact on health service costs.	UNIV DUNDEE,WESTGATE HLTH CTR,TAYSIDE CTR GEN PRACTICE,DUNDEE DD2 4AD,SCOTLAND	University of Dundee								ANDERSON HR, 1990, THORAX, V45, P431, DOI 10.1136/thx.45.6.431; [Anonymous], 1990, BMJ, V301, P797; ARMITAGE P, 1987, STAT METHODS MED RES, P458; BROOKES J, 1992, BRIT J GEN PRACT, V42, P504; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; Carswell F, 1989, Bristol Med Chir J, V104, P11; CHARLTON I, 1991, BRIT J GEN PRACT, V41, P227; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; FULLARD E, 1984, BRIT MED J, V289, P1585, DOI 10.1136/bmj.289.6458.1585; HAY IFC, 1987, LANCET, V2, P609; HILL R, 1991, BRIT MED J, V303, P1169, DOI 10.1136/bmj.303.6811.1169; HILL RA, 1989, ARCH DIS CHILD, V63, P246; HILTON S, 1986, LANCET, V1, P26; HORDER J, 1986, J ROY COLL GEN PRACT, V36, P517; JENKINSON D, 1988, BRIT MED J, V297, P267, DOI 10.1136/bmj.297.6643.267; LEVY M, 1984, BRIT MED J, V289, P1115, DOI 10.1136/bmj.289.6452.1115; MANT D, 1991, BRIT MED J, V304, P652; MITCHELL EA, 1986, ARCH DIS CHILD, V61, P1184, DOI 10.1136/adc.61.12.1184; NEVILLE R, 1990, PRACTITIONER, V234, P417; NEVILLE RG, 1993, BRIT MED J, V306, P559, DOI 10.1136/bmj.306.6877.559; NEVILLE RG, 1992, BR J GEN PRACT, V42, P510; ROBERTSON CF, 1991, BRIT MED J, V302, P116; STORR J, 1987, BRIT MED J, V295, P251, DOI 10.1136/bmj.295.6592.251; STRACHAN DP, 1992, BRIT MED J, V304, P819, DOI 10.1136/bmj.304.6830.819; USHERWOOD TP, 1987, FAM PRACT, V4, P318, DOI 10.1093/fampra/4.4.318; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WARNER JO, 1992, ARCH DIS CHILD, V67, P240; 1990, OCCURRENCE COST ASTH; 1986, 3RD NATIONAL STU MB5; 1993, BRIT MED J, V306, P776; 1990, BRIT MED J, V301, P651	31	59	60	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 1	1995	310	6983					838	842		10.1136/bmj.310.6983.838	http://dx.doi.org/10.1136/bmj.310.6983.838			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711623	Green Published			2022-12-28	WOS:A1995QQ85700021
J	ISENBERG, DA; BLACK, C				ISENBERG, DA; BLACK, C			ABC OF RHEUMATOLOGY - RAYNAUDS-PHENOMENON, SCLERODERMA, AND OVERLAP SYNDROMES	BRITISH MEDICAL JOURNAL			English	Article									ROYAL FREE HOSP, DIV RHEUMATOL, LONDON, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	ISENBERG, DA (corresponding author), UCL, DIV RHEUMATOL, LONDON, ENGLAND.			Isenberg, David/0000-0001-9514-2455					0	16	17	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 25	1995	310	6982					795	798		10.1136/bmj.310.6982.795	http://dx.doi.org/10.1136/bmj.310.6982.795			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP609	7711588	Green Published			2022-12-28	WOS:A1995QP60900028
J	SHAW, CD; COLLINS, CD				SHAW, CD; COLLINS, CD			HEALTH-SERVICE ACCREDITATION - REPORT OF A PILOT PROGRAM FOR COMMUNITY HOSPITALS	BRITISH MEDICAL JOURNAL			English	Article								Voluntary accreditation in the United Kingdom is being used by health care providers to improve and market their services and by commissioners to define and monitor service contracts. In a three year pilot scheme in the south west of England, 43 out of 57 eligible community hospitals volunteered to be surveyed; 37 of them were ultimately accredited for up to two years by the hospital accreditation programme. The main causes for non-accreditation related to safety, clinical records, and medical organisation. Follow up visits in 10 hospitals showed that, overall, 69% of recommendations were implemented. An independent survey of participating hospitals showed the perceived benefits to include team building, review of operational policies, improvement of data systems, and the generation of local prestige. Purchasers are increasingly influenced by accreditation status but are mostly unwilling to finance the process directly. None the less, the concept may become an important factor moderating the quality of service in the new NHS.	MUSGROVE PK HOSP,TAUNTON & SOMERSET NHS TRUST,TAUNTON TA1 5DA,SOMERSET,ENGLAND	Musgrove Park Hospital	SHAW, CD (corresponding author), CASPE RES,LONDON SE1 1LL,ENGLAND.							BROOKS TE, 1990, KINGS FUND ORG AUDIT; HAYES J, 1993, EVALUATION ACCREDITA; PENNINGTON GW, 1991, J PATHOL, V44, P172; SHAW C, 1988, GOOD PRACTICE SMALL; Shaw C D, 1991, Qual Assur Health Care, V3, P133; WHITTAKER S, 1994, S AFR MED J, V84, P193; WHITTAKER S, 1994, S AFR MED J, V84, P130; 1989, COMMUNITY HOSPITALS; 1989, CMD555	9	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	1995	310	6982					781	784		10.1136/bmj.310.6982.781	http://dx.doi.org/10.1136/bmj.310.6982.781			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP609	7711585	Green Published			2022-12-28	WOS:A1995QP60900023
J	ABOUSSEKHRA, A; BIGGERSTAFF, M; SHIVJI, MKK; VILPO, JA; MONCOLLIN, V; PODUST, VN; PROTIC, M; HUBSCHER, U; EGLY, JM; WOOD, RD				ABOUSSEKHRA, A; BIGGERSTAFF, M; SHIVJI, MKK; VILPO, JA; MONCOLLIN, V; PODUST, VN; PROTIC, M; HUBSCHER, U; EGLY, JM; WOOD, RD			MAMMALIAN DNA NUCLEOTIDE EXCISION-REPAIR RECONSTITUTED WITH PURIFIED PROTEIN-COMPONENTS	CELL			English	Article							CELL NUCLEAR ANTIGEN; PIGMENTOSUM GROUP-F; BINDING-PROTEIN; DAMAGED DNA; REPLICATION PROTEIN; POLYMERASE-DELTA; TRANSCRIPTION FACTOR; PRIMATE CELLS; LIGASE-I; PURIFICATION	Nucleotide excision repair is the principal way by which human cells remove UV damage from DNA. Human cell extracts were fractionated to locate active components, including xeroderma pigmentosum (XP) and ERCC factors. The incision reaction was then reconstituted with the purified proteins RPA, XPA, TFIIH (containing XPB and XPD), XPC, UV-DDB, XPG, partially purified ERCC1/XPF complex, and a factor designated IF7. UV-DDB (related to XPE protein) stimulated repair but was not essential. ERCC1- and XPF-correcting activity copurified with an ERCC1-binding polypeptide of 110 kDa that was absent in XP-F cell extract. Complete repair synthesis was achieved by combining these factors with DNA polymerase epsilon, RFC, PCNA, and DNA ligase I. The reconstituted core reaction requires about 30 polypeptides.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; UNIV ZURICH IRCHEL,DEPT VET BIOCHEM,CH-8057 ZURICH,SWITZERLAND; NICHHD,DNA REPLICAT REPAIR & MUTAGENESIS,BETHESDA,MD 20892; TAMPERE UNIV HOSP,DEPT CLIN CHEM,SF-33521 TAMPERE,FINLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Zurich; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Tampere University; Tampere University Hospital			Wood, Richard D/M-6319-2018; MONCOLLIN, Vincent/R-1941-2017	Wood, Richard D/0000-0002-9495-6892; MONCOLLIN, Vincent/0000-0002-4163-0231				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; CALSOU P, 1994, BIOCHEM BIOPH RES CO, V202, P788, DOI 10.1006/bbrc.1994.1999; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; CLUGSTON CK, 1992, CANCER RES, V52, P6375; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FELDBERG RS, 1976, BIOCHEMISTRY-US, V15, P2402, DOI 10.1021/bi00656a024; FLORES O, 1992, J BIOL CHEM, V267, P2786; GEORGAKI A, 1993, NUCLEIC ACIDS RES, V21, P3659, DOI 10.1093/nar/21.16.3659; GERARD M, 1991, J BIOL CHEM, V266, P20940; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; KEENEY S, 1994, P NATL ACAD SCI USA, V91, P4053, DOI 10.1073/pnas.91.9.4053; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MIURA M, 1992, J CELL PHYSIOL, V150, P370, DOI 10.1002/jcp.1041500221; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, pU3559; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PODUST LM, 1994, NUCLEIC ACIDS RES, V22, P2970, DOI 10.1093/nar/22.15.2970; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; REARDON JT, 1993, J BIOL CHEM, V268, P21301; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SEROUSSI E, 1993, J BIOL CHEM, V268, P7147; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22729; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TREIBER DK, 1992, NUCLEIC ACIDS RES, V20, P5805, DOI 10.1093/nar/20.21.5805; VANASSENDELFT GB, 1993, NUCLEIC ACIDS RES, V21, P3399, DOI 10.1093/nar/21.15.3399; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WAGA S, 1994, J BIOL CHEM, V269, P10923; WEEDA G, 1993, SEMIN CANCER BIOL, V4, P105; WOOD RD, 1993, COLD SPRING HARB SYM, V58, P625, DOI 10.1101/SQB.1993.058.01.069; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	57	740	763	5	88	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					859	868		10.1016/0092-8674(95)90289-9	http://dx.doi.org/10.1016/0092-8674(95)90289-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697716	Bronze			2022-12-28	WOS:A1995QP61200005
J	BURNUM, JF				BURNUM, JF			MEDICAL DIAGNOSIS THROUGH SEMIOTICS - GIVING MEANING TO THE SIGN	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CLINICAL DECISION-MAKING; CERTAINTY; QUEST	Physicians are engaged in incorporating quantitative methods for making clinical decisions into their practices. An acquaintance with semiotics, the doctrine of signs, may complement this project. A sign stands for something. We communicate indirectly through signs, and by interpreting what signs mean we make sense of our world and diagnose and understand our patients. Thus, through association and inference, we transform flowers into love, Othello into jealousy, and staring eyes into thyrotoxicosis. Characteristically in diagnosis, beginning with an unstable inference, we test and otherwise ask questions likely to produce signs that support (or discredit) our hypothesis. In a literary sense, we join with the author to clarify and rewrite the text; creative interpretation is the key. Diagnosis is concluded through narration, by the meaning that is revealed by telling the story of the patient. Diagnosis will succeed only to the extent that we respect the principles and caveats of sign interpretation. The sign is both the key to the unknown and the master impersonator. The sign and its meaning are usually not the same; meaning has to be inferred. Because interpretations are made subjectively, they are circumscribed by the experience and bias of the clinician. Moreover, the contexts in which the sign appears shape the meaning of the sign and may change it altogether.										BACON F, 1962, NORTON ANTHOLOGY ENG, P1687; BLOIS MS, 1984, INFORMATION MED NATU, P55; BLOIS MS, 1984, NATURE MED DESCRIPTI, P88; BLOIS MS, 1984, NATURE MED DESCRIPTI, P14; BLOIS MS, 1984, INFORMATION MED NATU, P88; Bronowski J., 1987, READINGS SCI AM, P3; BRONOWSKI J, 1988, NORTON READER ANTHOL, P194; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; BROWN LJ, 1985, PSYCHOANAL REV, V72, P379; Clarke Jr. DS, 1987, PRINCIPLES SEMIOTICS; CUMMINS RO, 1990, J GEN INTERN MED, V5, P375, DOI 10.1007/BF02600411; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P287, DOI 10.1001/jama.263.2.287; FEINSTEIN AR, 1973, YALE J BIOL MED, V46, P264; FLANAGIN A, 1990, JAMA-J AM MED ASSOC, V263, P279, DOI 10.1001/jama.263.2.279; FLETCHER RH, 1983, ANN INTERN MED, V99, P401, DOI 10.7326/0003-4819-99-3-401; Fletcher RH, 1988, CLIN EPIDEMIOLOGY ES, V2nd; FROMM E, 1988, NORTON READER ANTHOL, P325; Gadamer Hans-Georg, 1976, PHILOS HERMENEUTICS; GOGEL EL, 1987, J MED PHILOS, V12, P205, DOI 10.1093/jmp/12.3.205; GOLDMAN L, 1991, HARRISONS PRINCIPLES, P5; GORDIMER N, 1989, NEW YORK REV BO 0928, P59; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; Hayakawa S.I., 1975, P S EL EL RECHN EXH, V56; HAYAKAWA SI, 1964, LANGUAGE THOUGHT ACT, P54; HAYNES RB, 1991, ACP J CLUB, V114, pA18; HUNTER KM, 1985, APPLYING HUMANITIES, P301; KASSIRER JP, 1976, YALE J BIOL MED, V49, P149; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; KASSIRER JP, 1989, ANN INTERN MED, V110, P893, DOI 10.7326/0003-4819-110-11-893; KIMBALL CP, 1969, ANN INTERN MED, V71, P147, DOI 10.7326/0003-4819-71-1-147; KORAN LM, 1975, NEW ENGL J MED, V293, P695, DOI 10.1056/NEJM197510022931405; KORZYBSKI A, 1948, SCI SANITY INTRO NON, P58; KORZYBSKI A, 1948, INTRO NONARISTOTELIA, P76; Leitch Vincent, 1983, DECONSTRUCTIVE CRITI; NARDONE DA, 1990, HOSP PRACT, V25, P72; NIETZSCHE F, 1967, WILL POWER, P267; Panzer RI, 1991, DIAGNOSTIC STRATEGIE; PASTEUR L, 1968, FAMILIAR QUOTATIONS, P718; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; Peirce Charles., 1955, PHILOS WRITINGS, P98; REISS E, 1984, AM J MED, V77, P969, DOI 10.1016/0002-9343(84)90170-0; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SACKETT DL, 1980, CAN MED ASSOC J, V123, P499; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; Sless, 1986, SEARCH SEMIOTICS; SMITH RC, 1991, ANN INTERN MED, V115, P470, DOI 10.7326/0003-4819-115-6-470; SOX HC, 1990, COMMON DIAGNOSTIC TE; VESNIN AG, 1990, VOP ONKOL+, V36, P974; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WHITE JB, 1985, ESSAYS RHETORIC POET, P169; WRIGHT R, 1988, 3 SCI THEIR GODS LOO, P202	52	14	14	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1993	119	9					939	943		10.7326/0003-4819-119-9-199311010-00012	http://dx.doi.org/10.7326/0003-4819-119-9-199311010-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD711	7692781				2022-12-28	WOS:A1993MD71100011
J	SPENCER, K; CARPENTER, P				SPENCER, K; CARPENTER, P			PROSPECTIVE-STUDY OF PRENATAL SCREENING FOR DOWNS-SYNDROME WITH FREE BETA-HUMAN CHORIONIC-GONADOTROPIN	BRITISH MEDICAL JOURNAL			English	Article							SERUM ALPHA-FETOPROTEIN; UNCONJUGATED ESTRIOL; HUMAN CHORIOGONADOTROPIN; PREGNANCY; RISK; AGE; ABNORMALITIES; MARKERS; ASSAY; HCG	Objective-To assess the value and impact of a screening programme for Down's syndrome that uses the two maternal serum markers: alpha fetoprotein and free beta human chorionic gonadotrophin. Design-All women booked into clinics were screened. Further tests were offered to women with a risk of one in 300 or greater of having an affected baby. Follow up of outcome of all pregnancies. Setting-Biochemical screening laboratory serving two health districts. Subjects-8179 women of all ages with singleton pregnancies screened between 15 and 22 weeks' gestation from 1 April 1991 to 31 March 1992. Main outcome measures-Detection rate of Down's syndrome, false positive rate, uptake of screening, uptake of amniocentesis in women identified as at increased risk, prevalence of Down's syndrome at birth. Results-Overall 89% (8317/9345) of women underwent screening. The rate of detection of Down's syndrome was 69% (11/16; 95% confidence interval 41 to 89%) with a 5.2% false positive rate (426/8179; 4.7 to 5.7%). In women under 30 the detection rate was 50% (four out of eight; 32 to 86%) Uptake of amniocentesis was 89% (389/437), resulting in a reduction of prevalence of Down's syndrome at birth from 1.1 per 1000 in previous years (66/59 696) to 0.4 per 1000 during the screening year (4/9345). Additionally, several other abnormalities were identified. Conclusion-The benefit of a high detection rate with this approach and the additional anomalies identified should encourage others to introduce screening programmes for Down's syndrome that use free beta human chorionic gonadotrophin and alpha fetoprotein.			SPENCER, K (corresponding author), OLDCHURCH HOSP,DEPT CLIN BIOCHEM,ENDOCRINE UNIT,ROMFORD RM7 0BE,ESSEX,ENGLAND.							AITKEN DA, IN PRESS PRENAT DIAG; BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; CANICK JA, 1988, BRIT J OBSTET GYNAEC, V95, P330, DOI 10.1111/j.1471-0528.1988.tb06601.x; CHENG EY, 1993, OBSTET GYNECOL, V81, P72; CROSSLEY JA, 1993, PRENATAL DIAG, V13, P271, DOI 10.1002/pd.1970130406; CUCKLE H, 1993, BRIT MED J, V306, P1199, DOI 10.1136/bmj.306.6886.1199; CUCKLE H, 1992, BRIT MED J, V305, P1017, DOI 10.1136/bmj.305.6860.1017; CUCKLE HS, 1984, LANCET, V1, P926; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; CUCKLE HS, 1990, PRENATAL DIAGNOSIS P, P67; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; LAUNDON C, 1993, J MED GENET, V30, P340; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MACRI JN, 1993, ANN CLIN BIOCHEM, V30, P94, DOI 10.1177/000456329303000117; MACRI JN, IN PRESS PRENAT DIAG; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; PARSONS L, 1992, BRIT MED J, V305, P1228, DOI 10.1136/bmj.305.6863.1228-a; PHILLIPS OP, 1992, OBSTET GYNECOL, V80, P353; REYNOLDS T, 1992, CLIN CHEM, V38, P1888; REYNOLDS TM, 1990, ANN CLIN BIOCHEM, V27, P452, DOI 10.1177/000456329002700506; SPENCER K, 1985, BRIT MED J, V290, P1940, DOI 10.1136/bmj.290.6486.1940; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P506, DOI 10.1177/000456329202900504; SPENCER K, 1991, CLIN CHEM, V37, P809; SPENCER K, 1992, LANCET, V339, P1480, DOI 10.1016/0140-6736(92)92073-O; SPENCER K, 1993, ANN CLIN BIOCHEM, V30, P394, DOI 10.1177/000456329303000408; SPENCER K, 1993, BRIT MED J, V306, P1616, DOI 10.1136/bmj.306.6892.1616; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P349, DOI 10.1177/000456329202900319; SPENCER K, 1993, IN PRESS MEASUREMENT; SPENCER K, 1993, IN PRESS BMJ; WALD N, 1993, BRIT MED J, V306, P1198, DOI 10.1136/bmj.306.6886.1198-c; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; 1991, BIRTH STATISTICS 199	34	61	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1993	307	6907					764	769		10.1136/bmj.307.6907.764	http://dx.doi.org/10.1136/bmj.307.6907.764			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ478	7693095	Bronze, Green Published			2022-12-28	WOS:A1993LZ47800021
J	OGASAWARA, J; WATANABEFUKUNAGA, R; ADACHI, M; MATSUZAWA, A; KASUGAI, T; KITAMURA, Y; ITOH, N; SUDA, T; NAGATA, S				OGASAWARA, J; WATANABEFUKUNAGA, R; ADACHI, M; MATSUZAWA, A; KASUGAI, T; KITAMURA, Y; ITOH, N; SUDA, T; NAGATA, S			LETHAL EFFECT OF THE ANTI-FAS ANTIBODY IN MICE	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; MONOCLONAL-ANTIBODY; APOPTOSIS; EXPRESSION; RECEPTOR; CACHECTIN; DEATH; CDNA	DURING mammalian development, many cells are programmed to die1,2 most mediated by apoptosis3. The Fas antigen4 coded by the structural gene for mouse lymphoproliferation mutation (lpr)5,6, is a cell surface protein belonging to the tumour necrosis factor/nerve growth factor receptor family7,8, and mediates apoptosis7. The Fas antigen messenger RNA is expressed in the thymus, liver, heart, lung and ovary8. We prepared a monoclonal antibody against mouse Fas antigen, which immunoprecipitated the antigen (M(r) 45K) and had cytolytic activity against cell lines expressing mouse Fas antigen. We report here that staining of mouse thymocytes with the antibody indicated that thymocytes from the wild-type and lpr(cg) mice expressed the Fas antigen, whereas little expression of the Fas antigen was found in lpr mice. Intraperitoneal administration of the anti-Fas antibody into mice rapidly killed the wild-type mice but neither lpr nor lpr(cg) mice. Biochemical, histological and electron microscope analyses indicated severe damage of the liver by apoptosis. These findings suggest that the Fas antigen is important in programmed cell death in the liver, and may be involved in fulminant hepatitis in some cases.	OSAKA BIOSCI INST, 6-2-4 FURUEDAI, SUITA, OSAKA 565, JAPAN; OSAKA CITY INST PUBL HLTH & ENVIRONM SCI, TENNOJI KU, OSAKA 543, JAPAN; UNIV TOKYO, INST MED SCI, LAB ANIM RES CTR, TOKYO 108, JAPAN; OSAKA UNIV, SCH MED, DEPT PATHOL, SUITA, OSAKA 565, JAPAN	University of Tokyo; Osaka University			Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; BENEDETTI A, 1988, J HEPATOL, V7, P319, DOI 10.1016/S0168-8278(88)80004-7; Chisari F V, 1992, Mol Genet Med, V2, P67; CLIGAN JE, 1991, CURRENT PROTOCOLS IM; DEBATIN KM, 1990, LANCET, V335, P497, DOI 10.1016/0140-6736(90)90735-N; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ESKANDARI MK, 1992, J IMMUNOL, V148, P2724; FALK MH, 1992, BLOOD, V79, P3300; HIRATA Y, 1989, J IMMUNOL, V143, P2900; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KIMURA M, 1992, IMMUNOLOGY, V76, P498; KOBAYASHI N, 1990, P NATL ACAD SCI USA, V87, P9620, DOI 10.1073/pnas.87.24.9620; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; OEHM A, 1992, J BIOL CHEM, V267, P10709; POTTEN CS, 1992, CANCER METASTASIS RE, V11, P95; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SANCHEZMADRID F, 1983, J IMMUNOL, V130, P309; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WAAGE A, 1988, J EXP MED, V167, P1987, DOI 10.1084/jem.167.6.1987; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WATSON J, 1977, J IMMUNOL, V120, P422; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	27	1799	1861	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 26	1993	364	6440					806	809		10.1038/364806a0	http://dx.doi.org/10.1038/364806a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	7689176				2022-12-28	WOS:A1993LU58100057
J	COTE, J; RUIZCARRILLO, A				COTE, J; RUIZCARRILLO, A			PRIMERS FOR MITOCHONDRIAL-DNA REPLICATION GENERATED BY ENDONUCLEASE-G	SCIENCE			English	Article							DISPLACEMENT LOOP REGION; CONSERVED SEQUENCE; NUCLEASE; CELLS; GENE; RNA; TRANSCRIPTION; INITIATION; PROTEIN; SITE	Endonuclease G (Endo G) is widely distributed among animals and cleaves DNA at double-stranded (dG)n.(dC)n and at single-stranded (dC)n tracts. Endo G is synthesized as a propeptide with an amino-terminal presequence that targets the nuclease to mitochondria. Endo G can also be detected in extranucleolar chromatin. In addition to deoxyribonuclease activities, Endo G also has ribonuclease (RNase) and RNase H activities and specifically cleaves mouse mitochondrial RNA and DNA-RNA substrates containing the origin of heavy-strand DNA replication (O(H)). The cleavage sites match those found in vivo, indicating that Endo G is capable of generating the RNA primers required by DNA polymerase gamma to initiate replication of mitochondrial DNA.	HOP HOTEL DIEU,LAVAL UNIV,SCH MED,CANC RES CTR,QUEBEC CITY G1R 2J6,QUEBEC,CANADA; HOP HOTEL DIEU,LAVAL UNIV,SCH MED,DEPT BIOCHEM,QUEBEC CITY G1R 2J6,QUEBEC,CANADA	Laval University; Laval University			Cote, Jacques/I-8901-2014	Cote, Jacques/0000-0001-6751-555X				ANDERSON S, 1982, J MOL BIOL, V156, P683, DOI 10.1016/0022-2836(82)90137-1; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BALL TK, 1987, GENE, V57, P183, DOI 10.1016/0378-1119(87)90121-1; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHOW TYK, 1983, J BIOL CHEM, V258, P2010; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; COTE J, 1989, J BIOL CHEM, V264, P3301; COTE J, UNPUB; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; GILLUM AM, 1979, J MOL BIOL, V135, P353, DOI 10.1016/0022-2836(79)90441-8; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAUSWIRTH WW, 1984, CELL, V37, P1001, DOI 10.1016/0092-8674(84)90434-3; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; KING TC, 1987, J BIOL CHEM, V262, P6214; KING TC, 1987, J BIOL CHEM, V262, P6204; KISS T, 1992, CELL, V70, P11, DOI 10.1016/0092-8674(92)90528-K; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LOW RL, 1987, J BIOL CHEM, V262, P16164; LOW RL, 1988, NUCLEIC ACIDS RES, V16, P6427, DOI 10.1093/nar/16.14.6427; MOOS M, 1988, J BIOL CHEM, V263, P6005; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; PRATS E, 1989, NUCLEIC ACIDS RES, V17, P10097, DOI 10.1093/nar/17.23.10097; ROSE AM, 1992, MOL CELL BIOL, V12, P5652, DOI 10.1128/MCB.12.12.5652; RUIZCARRILLO A, 1987, EMBO J, V6, P401, DOI 10.1002/j.1460-2075.1987.tb04769.x; TOOPER JN, 1992, CELL, V70, P16; VINCENT RD, 1988, NUCLEIC ACIDS RES, V16, P3297, DOI 10.1093/nar/16.8.3297; WALBERG MW, 1981, NUCLEIC ACIDS RES, V9, P5411, DOI 10.1093/nar/9.20.5411; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443; ZASSENHAUS HP, 1988, NUCLEIC ACIDS RES, V16, P3283, DOI 10.1093/nar/16.8.3283	32	189	198	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 6	1993	261	5122					765	769		10.1126/science.7688144	http://dx.doi.org/10.1126/science.7688144			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	7688144				2022-12-28	WOS:A1993LQ73000041
J	NOLAN, JM; BURKE, DH; PACE, NR				NOLAN, JM; BURKE, DH; PACE, NR			CIRCULARLY PERMUTED TRANSFER-RNAS AS SPECIFIC PHOTOAFFINITY PROBES OF RIBONUCLEASE-P RNA STRUCTURE	SCIENCE			English	Article							SUBSTRATE; ENZYME; SEQUENCE; CATALYSIS; MOIETY; SITE; DNA	Regions of Escherichia coli ribonuclease P (RNase P) RNA in proximity to a bound transfer RNA (tRNA) substrate were mapped by photoaffinity. A photoaffinity cross-linking reagent was introduced at specific sites in the interior of the native tRNA structure by modification of the 5' ends of circularly permuted tRNAs (cptRNAs). The polymerase chain reaction was used for the production of cptRNA templates. After the amplification of a segment of a tandemly duplicated tRNA gene, the cptRNA gene was transcribed in vitro to produce cptRNA. Modified cptRNAs were cross-linked to RNase P RNA, and the conjugation sites in RNase P RNA were determined by primer extension. These sites occur in phylogenetically conserved structures and sequences and identify regions of the ribozyme that form part of the tRNA binding site. The use of circularly permuted molecules to position specific modifications is applicable to the study of many inter- and intramolecular interactions.	INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA; UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA	Indiana University System; Indiana University Bloomington; University of Colorado System; University of Colorado Boulder					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034527, R01GM034527] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34527] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman S., 1989, ADV ENZYMOL RAMB, V62, P1; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BROWN JW, 1992, NUCLEIC ACIDS RES, V20, P1451, DOI 10.1093/nar/20.7.1451; BROWN JW, 1993, NUCLEIC ACIDS RES, V21, P671, DOI 10.1093/nar/21.3.671; BUCHWALDER A, 1992, BIOCHEMISTRY-US, V31, P1621, DOI 10.1021/bi00121a006; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GAUSS DH, 1979, TRANSFER RNA STRUCTU, P518; GREEN CJ, 1988, J BIOL CHEM, V263, P652; GUERRIERTAKADA C, 1989, SCIENCE, V246, P1578, DOI 10.1126/science.2480641; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; KAHLE D, 1990, EMBO J, V9, P1929, DOI 10.1002/j.1460-2075.1990.tb08320.x; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NOLAN JM, UNPUB; PACE NR, 1990, J BIOL CHEM, V265, P3587; PAN T, 1991, SCIENCE, V254, P1361, DOI 10.1126/science.1720569; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; REICH CI, 1988, THESIS U BUENOS AIRE; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SMITH D, 1992, J BIOL CHEM, V267, P2429; THURLOW DL, 1991, NUCLEIC ACIDS RES, V19, P885, DOI 10.1093/nar/19.4.885; USMAN N, 1992, TRENDS BIOCHEM SCI, V17, P334, DOI 10.1016/0968-0004(92)90306-T; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671	28	113	114	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1993	261	5122					762	765		10.1126/science.7688143	http://dx.doi.org/10.1126/science.7688143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	7688143				2022-12-28	WOS:A1993LQ73000040
J	JUNTTIBERGGREN, L; LARSSON, O; RORSMAN, P; AMMALA, C; BOKVIST, K; WAHLANDER, K; NICOTERA, P; DYPBUKT, J; ORRENIUS, S; HALLBERG, A; BERGGREN, PO				JUNTTIBERGGREN, L; LARSSON, O; RORSMAN, P; AMMALA, C; BOKVIST, K; WAHLANDER, K; NICOTERA, P; DYPBUKT, J; ORRENIUS, S; HALLBERG, A; BERGGREN, PO			INCREASED ACTIVITY OF L-TYPE CA2+ CHANNELS EXPOSED TO SERUM FROM PATIENTS WITH TYPE-I DIABETES	SCIENCE			English	Article							KILLS IMMATURE THYMOCYTES; LIVER NUCLEI; CELL; CA-2+; ENDONUCLEASE; LINE	Type I diabetes [insulin-dependent diabetes mellitus (IDDM)] is an autoimmune disease associated with the destruction of pancreatic beta cells. Serum from patients with IDDM increased L-type calcium channel activity of insulin-producing cells and of GH3 cells derived from a pituitary tumor. The subsequent increase in the concentration of free cytoplasmic Ca2+ ([Ca2+]i) was associated with DNA fragmentation typical of programmed cell death or apoptosis. These effects of the serum were prevented by adding a blocker of voltage-activated L-type Ca2+ channels. When the serum was depleted of immunoglobulin M (IgM), it no longer affected [Ca2+]i. An IgM-mediated increase in Ca2+ influx may thus be part of the autoimmune reaction associated with IDDM and contribute to the destruction of beta cells in vivo.	KAROLINSKA INST,KAROLINSKA HOSP,ROLF LUFT CTR DIABET RES,DEPT ENDOCRINOL,BOX 60500,S-10401 STOCKHOLM 60,SWEDEN; GOTHENBURG UNIV,DEPT MED PHYS,S-41390 GOTHENBURG,SWEDEN; KAROLINSKA INST,DEPT TOXICOL,S-10401 STOCKHOLM 60,SWEDEN; UNIV HOSP UPPSALA,DEPT INTERNAL MED,S-75185 UPPSALA,SWEDEN	Karolinska Institutet; Karolinska University Hospital; University of Gothenburg; Karolinska Institutet; Uppsala University; Uppsala University Hospital			Rorsman, Patrik/A-4331-2016	Rorsman, Patrik/0000-0001-7578-0767				ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARKHAMMAR P, 1989, BIOCHEM BIOPH RES CO, V159, P223, DOI 10.1016/0006-291X(89)92426-1; ARMSTRONG CM, 1985, SCIENCE, V227, P65, DOI 10.1126/science.2578071; ASHCROFT FM, 1990, PFLUG ARCH EUR J PHY, V415, P504, DOI 10.1007/BF00373633; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BAEKKESKOV S, 1986, IMMUNOLOGY ENDOCRINE, P73; COOKE A, 1990, CURR TOP MICROBIOL I, V164, P126; GEPTS W, 1965, DIABETES, V14, P619, DOI 10.2337/diab.14.10.619; HALLBERG A, UNPUB; HESS P, 1984, NATURE, V311, P588; JUNTTIBERGGREN L, UNPUB; KAMPE O, 1989, DIABETES, V38, P1326, DOI 10.2337/diabetes.38.10.1326; LARSSON O, UNPUB; LERNMARK A, 1985, DIABETOLOGIA, V28, P195; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; NICOTERA P, 1990, CHEM RES TOXICOL, V3, P484, DOI 10.1021/tx00018a001; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; RORSMAN P, 1986, AM J PHYSIOL, V251, pC912, DOI 10.1152/ajpcell.1986.251.6.C912; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; SARA S, 1990, BIOPHYS J, V58, P567; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J	27	183	187	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					86	90		10.1126/science.7686306	http://dx.doi.org/10.1126/science.7686306			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	7686306				2022-12-28	WOS:A1993LK43400037
J	TSUKUMA, H; HIYAMA, T; TANAKA, S; NAKAO, M; YABUUCHI, T; KITAMURA, T; NAKANISHI, K; FUJIMOTO, I; INOUE, A; YAMAZAKI, H; KAWASHIMA, T				TSUKUMA, H; HIYAMA, T; TANAKA, S; NAKAO, M; YABUUCHI, T; KITAMURA, T; NAKANISHI, K; FUJIMOTO, I; INOUE, A; YAMAZAKI, H; KAWASHIMA, T			RISK-FACTORS FOR HEPATOCELLULAR-CARCINOMA AMONG PATIENTS WITH CHRONIC LIVER-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEPATITIS-C VIRUS; NON-B HEPATITIS; NON-A; CIGARETTE-SMOKING; ITALIAN PATIENTS; BLOOD-DONORS; ANTIBODIES; PREVALENCE; CIRRHOSIS; CANCER	Background and Methods. To detect potentially curable cases of hepatocellular carcinoma, outpatients with chronic hepatitis or compensated liver cirrhosis who were seen at the Center for Adult Diseases (Osaka, Japan) were examined periodically by means of ultrasonography and measurement of serum alpha-fetoprotein. Risk factors for hepatocellular carcinoma were identified with a Cox proportional-hazards model. Results. A total of 917 patients, 40 to 69 years old, were registered from May 1987 to March 1991. By the end of September 1991, liver cancer had developed in 54. The three-year cumulative risk of liver cancer was 12.5 percent for 240 patients with liver cirrhosis at enrollment and 3.8 percent for 677 patients with chronic hepatitis. Cox regression analysis showed that the risk of liver cancer was increased almost sevenfold in patients with hepatitis B surface antigen (rate ratio, 6.92; 95 percent confidence interval, 2.92 to 16.39) and fourfold in patients with hepatitis C antibody (rate ratio, 4.09; 95 percent confidence interval, 1.30 to 12.85). A high alpha-fetoprotein value at enrollment was also a risk marker for liver cancer. Conclusions. Patients with hepatitis C virus infection have a greatly increased risk of liver cancer. Further studies are required to clarify the roles of other risk factors, including drinking and smoking habits.	CTR ADULT DIS,RES INST,OSAKA 537,JAPAN; CTR CANC DETECT & PREVENT,OSAKA,JAPAN		TSUKUMA, H (corresponding author), CTR ADULT DIS,DEPT FIELD RES,3-3 NAKAMICHI 1 CHOME,HIGASHINARI KU,OSAKA 537,JAPAN.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257				ADAMI HO, 1992, INT J CANCER, V51, P898, DOI 10.1002/ijc.2910510611; ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; BRUIX J, 1989, LANCET, V2, P1004; COLOMBO M, 1989, LANCET, V2, P1006; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; COX DR, 1972, J R STAT SOC B, V34, P187; HIRAYAMA T, 1989, CANCER CHEMOTH PHARM, V23, pS114, DOI 10.1007/BF00647254; HIRAYAMA T, 1981, BANBURY REPORT, V7, P409; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; HSU HH, 1991, GASTROENTEROLOGY, V101, P1724, DOI 10.1016/0016-5085(91)90413-F; JOHNSON PJ, 1990, J NATL CANCER I, V82, P986, DOI 10.1093/jnci/82.12.986; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASUGAI H, 1985, AM J ROENTGENOL, V144, P243, DOI 10.2214/ajr.144.2.243; KATO N, 1989, P JPN ACAD B-PHYS, V65, P219, DOI 10.2183/pjab.65.219; KEW MC, 1990, LANCET, V335, P873, DOI 10.1016/0140-6736(90)90474-J; KUBO Y, 1989, NUCLEIC ACIDS RES, V17, P1367; LOK ASF, 1991, HEPATOLOGY, V14, P756, DOI 10.1002/hep.1840140503; MCHUTCHISON JG, 1991, GASTROENTEROLOGY, V101, P1117, DOI 10.1016/0016-5085(91)90742-4; MENDENHALL CL, 1991, HEPATOLOGY, V14, P581; OSHIMA A, 1984, INT J CANCER, V34, P775, DOI 10.1002/ijc.2910340607; SHIBATA A, 1986, JPN J CANCER RES, V77, P287; TAKEUCHI K, 1990, GENE, V91, P287, DOI 10.1016/0378-1119(90)90102-W; TAKEUCHI K, 1990, NUCLEIC ACIDS RES, V18, P4626, DOI 10.1093/nar/18.15.4626; TANAKA K, 1991, CANCER RES, V51, P2842; TRICHOPOULOS D, 1980, JNCI-J NATL CANCER I, V65, P111; TSUKUMA H, 1990, INT J CANCER, V45, P231, DOI 10.1002/ijc.2910450205; YU MC, 1990, JNCI-J NATL CANCER I, V82, P1038, DOI 10.1093/jnci/82.12.1038; YU MW, 1991, CANCER RES, V51, P5621; 1991, KOSEI NO SHIHYO, V38, P43; 1991, 5TH OS CANC REG PREF	30	982	1007	0	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1993	328	25					1797	1801		10.1056/NEJM199306243282501	http://dx.doi.org/10.1056/NEJM199306243282501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH210	7684822	Green Published, Green Submitted			2022-12-28	WOS:A1993LH21000001
J	HERWALDT, BL; STOKES, SL; JURANEK, DD				HERWALDT, BL; STOKES, SL; JURANEK, DD			AMERICAN CUTANEOUS LEISHMANIASIS IN UNITED-STATES TRAVELERS	ANNALS OF INTERNAL MEDICINE			English	Article						LEISHMANIASIS, CUTANEOUS; TRAVEL; TREES; MEXICO; CENTRAL AMERICA	DIAGNOSIS; GUATEMALA; WORLD; ULCER	Objective: To characterize the exposures and practices of U.S. travelers who acquired cutaneous leishmaniasis in the Americas and to highlight problems they encountered in seeking medical care from U.S. physicians. Design: A retrospective review of Centers for Disease Control and Prevention Drug Service records and a telephone survey of patients. Patients: Fifty-nine civilian U.S. travelers with American cutaneous leishmaniasis for whom the Drug Service released sodium stibogluconate between 1 January 1985 and 30 April 1990; 58 travelers (98%) were interviewed. Main Measurements: Travel destination, exposure duration, knowledge about leishmaniasis, and time from noticing skin lesions to release of drug. Results: Overall, travelers acquired leishmaniasis in as many as 14 countries; 33 of 59 travelers (56%) were infected in Mexico or Central America. Twenty-seven travelers (46%) were conducting field studies and 23 (39%) were tourists, visitors, or tour guides. At least 15 persons (26% of the 58 interviewed travelers) were in forested areas for 1 week or less; at least 6 of these persons had a maximum exposure of 2 days. Ten persons (17%) were home at least 1 month before they noticed skin lesions. Patients consulted from one to seven physicians (mean, 2.1 physicians) before leishmaniasis was diagnosed. Overall, the median time from noticing lesions to the release of drug was 112 days (range, 13 to 1022 days); however, the median was only 55 days for 13 patients (22%) unusually knowledgeable about leishmaniasis and was a maximum of 60 days for 16 patients (28%) (including 7 of the 13 unusually knowledgeable patients) who generally consulted physicians exceptionally knowledgeable about infectious and tropical diseases. Conclusions: Travelers to forested areas in Central America and Texas and their physicians need to be educated about the risk for acquiring leishmaniasis even during short stays; effective preventive measures; and appropriate medical management.			HERWALDT, BL (corresponding author), CTR DIS CONTROL & PREVENT, PARASIT DIS BRANCH, 4770 BUFORD HIGHWAY NE, ATLANTA, GA 30341 USA.							ANDRADENARVAEZ FJ, 1990, T ROY SOC TROP MED H, V84, P219, DOI 10.1016/0035-9203(90)90262-D; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; BERGER RS, 1987, J AM ACAD DERMATOL, V16, P1096, DOI 10.1016/S0190-9622(87)70142-X; BERMAN JD, 1988, REV INFECT DIS, V10, P560; Chulay J D, 1988, Rev Soc Bras Med Trop, V21, P165, DOI 10.1590/S0037-86821988000400002; COPELAND HW, 1990, AM J TROP MED HYG, V43, P257, DOI 10.4269/ajtmh.1990.43.257; DEDET JP, 1987, T ROY SOC TROP MED H, V81, P748, DOI 10.1016/0035-9203(87)90017-4; Desjeux P, 1991, WHOLEISH9130; GARNHAM P. C. C., 1959, TRANS ROY SOC TROP MED AND HYG, V53, P12, DOI 10.1016/0035-9203(59)90080-X; GRIMALDI G, 1987, AM J TROP MED HYG, V36, P270, DOI 10.4269/ajtmh.1987.36.270; GRIMALDI G, 1989, AM J TROP MED HYG, V41, P687, DOI 10.4269/ajtmh.1989.41.687; HERWALDT BL, 1992, J INFECT DIS, V165, P518, DOI 10.1093/infdis/165.3.518; HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296; LAINSON R., 1963, TRANS ROY SOC TROP MED AND HYG, V57, P242, DOI 10.1016/0035-9203(63)90182-2; MAGUIRE JH, 1983, AM J MED SCI, V285, P32, DOI 10.1097/00000441-198303000-00005; MELBY PC, 1992, CLIN INFECT DIS, V15, P924, DOI 10.1093/clind/15.6.924; MERMEL LA, 1990, J AM ACAD DERMATOL, V23, P1178, DOI 10.1016/S0190-9622(08)80926-7; MORRISJONES SD, 1990, LANCET, V336, P691, DOI 10.1016/0140-6736(90)92187-M; NAVIN TR, 1990, AM J TROP MED HYG, V42, P36, DOI 10.4269/ajtmh.1990.42.36; PARKS A, 1987, J AM ACAD DERMATOL, V17, P855, DOI 10.1016/S0190-9622(87)80295-5; RODGERS MR, 1990, EXP PARASITOL, V71, P267, DOI 10.1016/0014-4894(90)90031-7; SANCHEZ JL, 1992, AM J TROP MED HYG, V47, P47, DOI 10.4269/ajtmh.1992.47.47; TAKAFUJI ET, 1980, AM J TROP MED HYG, V29, P516, DOI 10.4269/ajtmh.1980.29.516; WALTON BC, 1968, AM J TROP MED HYG, V17, P19, DOI 10.4269/ajtmh.1968.17.19; WEIGLE KA, 1987, AM J TROP MED HYG, V36, P489, DOI 10.4269/ajtmh.1987.36.489; 1989, YB TOURISM STATISTIC, V2; 1992, MMWR, V41, P131; 1991, NEW ENGL J MED, V324, P476; 1990, WHO TECHNICAL REPORT, V793; 1990, YB TOURISM STATISTIC, V2	30	68	71	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1993	118	10					779	784		10.7326/0003-4819-118-10-199305150-00004	http://dx.doi.org/10.7326/0003-4819-118-10-199305150-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB649	7682386				2022-12-28	WOS:A1993LB64900004
J	BACSKAI, BJ; HOCHNER, B; MAHAUTSMITH, M; ADAMS, SR; KAANG, BK; KANDEL, ER; TSIEN, RY				BACSKAI, BJ; HOCHNER, B; MAHAUTSMITH, M; ADAMS, SR; KAANG, BK; KANDEL, ER; TSIEN, RY			SPATIALLY RESOLVED DYNAMICS OF CAMP AND PROTEIN KINASE-A SUBUNITS IN APLYSIA SENSORY NEURONS	SCIENCE			English	Article							ACTION-POTENTIAL DURATION; CYCLIC-AMP; BEHAVIORAL SENSITIZATION; ADENOSINE 3'=5'-MONOPHOSPHATE; TRANSMITTER RELEASE; REGULATORY SUBUNIT; WITHDRAWAL REFLEX; CATALYTIC SUBUNIT; FACILITATION; SEROTONIN	Cyclic adenosine monophosphate (cAMP)-dependent protein kinase, labeled with fluorescein and rhodamine on the catalytic and regulatory subunits, respectively, was injected into Aplysia sensory neurons either in culture or in intact cell clusters. Energy transfer between the subunits, a measure of cytosolic cAMP concentration ([cAMP]), and compartmentation of the dissociated subunits were monitored by confocal fluorescence microscopy. Bath application of serotonin produced a much greater elevation of [cAMP] in the processes than in the central bodies of the neurons. The resulting gradients must drive a sizable centripetal flux of cAMP because direct microinjection of cAMP showed that it diffused readily. Perinuclear increases in [cAMP] slowly caused the translocation of the freed catalytic subunit into the nucleus to an extent proportional to the percentage of its dissociation from the regulatory subunit.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Howard Hughes Medical Institute; University of California System; University of California San Diego; Columbia University			Bacskai, Brian/AAE-9583-2021					Adams S.R., 1993, FLUORESCENT PROBES B, P133; ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BAXTER DA, 1990, J NEUROPHYSIOL, V64, P978, DOI 10.1152/jn.1990.64.3.978; BERGOLD PJ, 1990, P NATL ACAD SCI USA, V87, P3788, DOI 10.1073/pnas.87.10.3788; BERNIER L, 1982, J NEUROSCI, V2, P1682; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BRUNELLI M, 1976, SCIENCE, V194, P1178, DOI 10.1126/science.186870; CASTELLUCCI VF, 1980, P NATL ACAD SCI-BIOL, V77, P7492, DOI 10.1073/pnas.77.12.7492; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; COHEN MH, 1975, BIOPHYS J, V15, P753, DOI 10.1016/S0006-3495(75)85852-8; Crank J., 1956, MATH DIFFUSION; DALE N, 1987, J NEUROSCI, V7, P2232; DWORKIN M, 1977, J BIOL CHEM, V252, P864; FROST WN, 1985, P NATL ACAD SCI USA, V82, P9266; GREENBERG SM, 1987, J NEUROSCI, V7, P291; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HAYES JS, 1982, J CYCLIC NUCL PROT, V8, P1; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8410, DOI 10.1073/pnas.83.21.8410; HOCHNER B, UNPUB; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HUANG RC, 1991, J GEN PHYSIOL, V98, P835, DOI 10.1085/jgp.98.4.835; KAANG BK, IN PRESS NEURON; KUPFERMANN I, 1970, SCIENCE, V167, P1743, DOI 10.1126/science.167.3926.1743; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MORIMOTO BH, 1991, P NATL ACAD SCI USA, V88, P10835, DOI 10.1073/pnas.88.23.10835; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OCORR KA, 1985, NEUROSCI LETT, V55, P113, DOI 10.1016/0304-3940(85)90004-7; POTTER RL, 1979, J BIOL CHEM, V254, P2413; SCHACHER S, 1983, J NEUROSCI, V3, P2403; SCHOLZ KP, 1987, SCIENCE, V235, P685, DOI 10.1126/science.2433766; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; TANK DW, 1988, SCIENCE, V242, P773, DOI 10.1126/science.2847315; TERASAKI WL, 1977, J BIOL CHEM, V252, P1041; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1990, P R MICROSCOPICAL SO, V25, pS53	38	389	400	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 9	1993	260	5105					222	226		10.1126/science.7682336	http://dx.doi.org/10.1126/science.7682336			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW452	7682336				2022-12-28	WOS:A1993KW45200041
J	DANIEL, WG; MUGGE, A				DANIEL, WG; MUGGE, A			MEDICAL PROGRESS - TRANSESOPHAGEAL ECHOCARDIOGRAPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TWO-DIMENSIONAL ECHOCARDIOGRAPHY; TRANS-ESOPHAGEAL ECHOCARDIOGRAPHY; CROSS-SECTIONAL ECHOCARDIOGRAPHY; CONGENITAL HEART-DISEASE; PATENT FORAMEN OVALE; MITRAL BALLOON VALVULOPLASTY; THORACIC AORTIC DISSECTION; SPONTANEOUS ECHO CONTRAST; CEREBRAL ISCHEMIC EVENTS; CORONARY-ARTERY STENOSIS		HANNOVER MED SCH, DEPT MED, DIV CARDIOL, W-3000 HANNOVER, GERMANY	Hannover Medical School	DANIEL, WG (corresponding author), UNIV CLIN DRESDEN, DEPT MED, DIV CARDIOL, FETSCHERSTR 74, D-01307 DRESDEN, GERMANY.		Giron, Giampiero/K-2722-2016					ADACHI H, 1991, CIRCULATION, V84, P14; ALAM M, 1990, AM J CARDIOL, V66, P873, DOI 10.1016/0002-9149(90)90373-9; AMARENCO P, 1992, STROKE, V23, P1005, DOI 10.1161/01.STR.23.7.1005; ANSARI A, 1993, PROG CARDIOVASC DIS, V35, P349, DOI 10.1016/0033-0620(93)90011-2; APPELBE AF, 1993, J AM COLL CARDIOL, V21, P754, DOI 10.1016/0735-1097(93)90109-E; BALLAL RS, 1991, CIRCULATION, V84, P1903, DOI 10.1161/01.CIR.84.5.1903; Bansal R C, 1990, J Am Soc Echocardiogr, V3, P348; BARZILAI B, 1992, J THORAC CARDIOV SUR, V104, P1410; BAYER AS, 1987, ARCH INTERN MED, V147, P457, DOI 10.1001/archinte.147.3.457; BEAUPRE PN, 1984, AM HEART J, V107, P1021, DOI 10.1016/0002-8703(84)90844-5; BERGERON GA, 1981, NEW ENGL J MED, V304, P489; BIRMINGHAM GD, 1992, AM HEART J, V123, P774, DOI 10.1016/0002-8703(92)90519-2; BLACK IW, 1993, AM HEART J, V126, P375, DOI 10.1016/0002-8703(93)91054-I; BLACK IW, 1991, J AM COLL CARDIOL, V18, P398, DOI 10.1016/0735-1097(91)90592-W; BLACK IW, 1991, BRIT HEART J, V66, P302; CASTELLO R, 1990, AM J CARDIOL, V65, P1149, DOI 10.1016/0002-9149(90)90330-4; CASTELLO R, 1992, J AM COLL CARDIOL, V19, P1516, DOI 10.1016/0735-1097(92)90612-Q; CASTELLO R, 1991, J AM COLL CARDIOL, V17, P1499, DOI 10.1016/0735-1097(91)90638-P; Chan K L, 1991, J Am Soc Echocardiogr, V4, P577; CHEN C, 1993, J AM COLL CARDIOL, V21, P208, DOI 10.1016/0735-1097(93)90738-M; Chenzbraun A, 1993, J Am Soc Echocardiogr, V6, P417; CIGARROA JE, 1993, NEW ENGL J MED, V328, P35, DOI 10.1056/NEJM199301073280107; Cohen G I, 1991, J Am Soc Echocardiogr, V4, P155; CUJEC B, 1991, STROKE, V22, P727, DOI 10.1161/01.STR.22.6.727; DANIEL WG, 1992, CIRCULATION, V86, P2013, DOI 10.1161/01.CIR.86.6.2013; DANIEL WG, 1991, CIRCULATION, V83, P817, DOI 10.1161/01.CIR.83.3.817; DANIEL WG, 1988, J AM COLL CARDIOL, V11, P1204, DOI 10.1016/0735-1097(88)90283-5; DANIEL WG, 1993, NEW ENGL J MED, V328, P803, DOI 10.1056/NEJM199303183281112; DANIEL WG, 1993, AM J CARDIOL, V71, P210, DOI 10.1016/0002-9149(93)90740-4; DANIEL WG, 1993, AM J CARDIOL, V71, P358, DOI 10.1016/0002-9149(93)90811-P; DANIEL WG, 1991, NEW ENGL J MED, V324, P795, DOI 10.1056/NEJM199103213241203; DANIEL WG, 1993, EUR HEART J, V14; DANIEL WG, 1991, EUR HEART J, V12; DANIEL WG, 1989, CIRCULATION S2, V80, P473; DEROOK FA, 1992, ANN INTERN MED, V117, P922, DOI 10.7326/0003-4819-117-11-922; EISENBERG MJ, 1992, JAMA-J AM MED ASSOC, V268, P210, DOI 10.1001/jama.268.2.210; ENGBERDING R, 1993, EUR HEART J, V14, P1223, DOI 10.1093/eurheartj/14.9.1223; ERBEL R, 1989, LANCET, V1, P457; ERBEL R, 1988, EUR HEART J, V9, P43; ERBEL R, 1990, CIRCULATION, V81, P805, DOI 10.1161/01.CIR.81.3.805; ERBEL R, 1993, CIRCULATION, V87, P1604, DOI 10.1161/01.CIR.87.5.1604; ESSOP MR, 1992, AM J CARDIOL, V70, P962, DOI 10.1016/0002-9149(92)90750-S; FISHER EA, 1991, J AM COLL CARDIOL, V18, P1333, DOI 10.1016/0735-1097(91)90558-Q; FLACHSKAMPF FA, 1992, EUR HEART J, V13, P1201, DOI 10.1093/oxfordjournals.eurheartj.a060338; Foster E, 1990, J Am Soc Echocardiogr, V3, P424; Foster E, 1992, J Am Soc Echocardiogr, V5, P368; FRAZIN L, 1976, CIRCULATION, V54, P220; FREEMAN WK, 1992, J AM COLL CARDIOL, V20, P599, DOI 10.1016/0735-1097(92)90014-E; GEWERTZ BL, 1987, J VASC SURG, V5, P607, DOI 10.1067/mva.1987.avs0050607; GOLDMAN AP, 1991, PACE, V14, P1245, DOI 10.1111/j.1540-8159.1991.tb02863.x; GREENLAND P, 1981, ANN INTERN MED, V95, P51, DOI 10.7326/0003-4819-95-1-51; GRIGG LE, 1992, J AM COLL CARDIOL, V20, P42, DOI 10.1016/0735-1097(92)90135-A; HANRATH P, 1983, BRIT HEART J, V49, P350; HART RG, 1986, ARCH NEUROL-CHICAGO, V43, P71; HASHIMOTO S, 1989, J AM COLL CARDIOL, V14, P1253, DOI 10.1016/0735-1097(89)90424-5; HAUSMANN D, 1992, AM J CARDIOL, V70, P668, DOI 10.1016/0002-9149(92)90210-P; Hausmann D, 1992, J Am Soc Echocardiogr, V5, P481; HAUSMANN D, 1992, CIRCULATION, V86, P251; HAUSMANN D, 1994, ECHOCARDIOGR-J CARD, V11, P553, DOI 10.1111/j.1540-8175.1994.tb01097.x; HISANAGA K, 1980, AM J CARDIOL, V46, P837, DOI 10.1016/0002-9149(80)90437-3; Hisanaga K., 1977, P JPN SOC ULTRASON M, V32, P43; Hoffmann R, 1993, J AM COLL CARDIOL, V22, P529, DOI 10.1016/0735-1097(93)90060-E; HOFMANN T, 1990, LANCET, V336, P1421; HSU TL, 1991, ECHOCARDIOGR-J CARD, V8, P677, DOI 10.1111/j.1540-8175.1991.tb01033.x; ILICETO S, 1991, CIRCULATION, V83, P61, DOI 10.1161/01.CIR.83.1.61; Jaarsma W, 1990, J Am Soc Echocardiogr, V3, P384; JORDAENS J, 1990, PACE, V13, P955, DOI 10.1111/j.1540-8159.1990.tb02138.x; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; KARALIS DG, 1992, AM J CARDIOL, V69, P1310, DOI 10.1016/0002-9149(92)91227-U; KARALIS DG, 1992, CIRCULATION, V86, P353, DOI 10.1161/01.CIR.86.2.353; KAULITZ R, 1990, J AM COLL CARDIOL, V16, P686, DOI 10.1016/0735-1097(90)90361-R; KAWAUCHI M, 1992, J HEART LUNG TRANSPL, V11, P306; Khandheria B K, 1992, J Am Soc Echocardiogr, V5, P285; KHANDHERIA BK, 1991, CIRCULATION, V83, P1956, DOI 10.1161/01.CIR.83.6.1956; KHANDHERIA BK, 1992, AM J CARDIOL, V69, pH61, DOI 10.1016/0002-9149(92)90648-I; Kipel G, 1991, J Am Soc Echocardiogr, V4, P631; KRONZON I, 1991, J AM COLL CARDIOL, V17, P537, DOI 10.1016/S0735-1097(10)80128-7; KRONZON I, 1990, J AM COLL CARDIOL, V16, P1320, DOI 10.1016/0735-1097(90)90572-7; KRONZON I, 1993, PROG CARDIOVASC DIS, V36, P39, DOI 10.1016/0033-0620(93)90021-5; KUECHERER HF, 1990, CIRCULATION, V82, P1127, DOI 10.1161/01.CIR.82.4.1127; KULTURSAY H, 1992, CATHETER CARDIO DIAG, V27, P317, DOI 10.1002/ccd.1810270414; LEE RJ, 1991, STROKE, V22, P734, DOI 10.1161/01.STR.22.6.734; LOVETT JL, 1981, ANN INTERN MED, V95, P1, DOI 10.7326/0003-4819-95-1-1; MANNING WJ, 1993, NEW ENGL J MED, V328, P750, DOI 10.1056/NEJM199303183281102; MANNING WJ, 1992, BRIT HEART J, V67, P170; MATSUMOTO M, 1982, BRIT HEART J, V48, P61; MATSUZAKI M, 1990, CIRCULATION, V82, P709, DOI 10.1161/01.CIR.82.3.709; MATSUZAKI M, 1978, J CARDIOGR, V8, P113; MAURER G, 1991, CIRCULATION, V84, pI250; MEHTA RH, 1990, J AM COLL CARDIOL, V16, P1010, DOI 10.1016/S0735-1097(10)80355-9; MELENDEZ LJ, 1991, J AM COLL CARDIOL, V18, P1650, DOI 10.1016/0735-1097(91)90498-X; MERINO A, 1992, J AM COLL CARDIOL, V20, P1661, DOI 10.1016/0735-1097(92)90463-W; MUGGE A, 1989, AM HEART J, V117, P474, DOI 10.1016/0002-8703(89)90795-3; MUGGE A, 1989, J AM COLL CARDIOL, V14, P631; MUGGE A, 1991, CIRCULATION, V83, P70, DOI 10.1161/01.CIR.83.1.70; MUGGE A, 1993, ECHOCARDIOGR-J CARD, V10, P405, DOI 10.1111/j.1540-8175.1993.tb00052.x; MUGGE A, 1993, CARDIOVASCULAR IMAGI, P271; NANDA NC, 1992, ECHOCARDIOGR-J CARD, V9, P667, DOI 10.1111/j.1540-8175.1992.tb00512.x; NELLESSEN U, 1985, J AM COLL CARDIOL, V5, P1002, DOI 10.1016/S0735-1097(85)80449-6; NELLESSEN U, 1988, CIRCULATION, V78, P848, DOI 10.1161/01.CIR.78.4.848; NIENABER CA, 1992, CIRCULATION, V85, P434, DOI 10.1161/01.CIR.85.2.434; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101; NIENABER CA, 1993, NEW ENGL J MED, V328, P1638; Nikutta P, 1992, J Am Soc Echocardiogr, V5, P168; OH JK, 1990, AM J CARDIOL, V66, P1492, DOI 10.1016/0002-9149(90)90541-8; OMOTO R, 1993, ECHOCARDIOGR-J CARD, V10, P79, DOI 10.1111/j.1540-8175.1993.tb00014.x; OMOTO R, 1989, ECHOCARDIOGR-J CARD, V6, P423; OSHEA JP, 1991, J AM COLL CARDIOL, V17, P1426, DOI 10.1016/S0735-1097(10)80158-5; PANDIAN NG, 1992, ECHOCARDIOGR-J CARD, V9, P649, DOI 10.1111/j.1540-8175.1992.tb00511.x; Pearlman A S, 1992, J Am Soc Echocardiogr, V5, P187; PEARLMAN AS, 1991, NEW ENGL J MED, V324, P841, DOI 10.1056/NEJM199103213241209; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; PEARSON AC, 1990, AM HEART J, V119, P1083, DOI 10.1016/S0002-8703(05)80238-8; PEDERSEN WR, 1991, CHEST, V100, P351, DOI 10.1378/chest.100.2.351; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; RAMONDO A, 1991, INT J CARDIOL, V31, P223, DOI 10.1016/0167-5273(91)90220-J; READ RC, 1993, CIRCULATION, V87, P1426, DOI 10.1161/circ.87.4.8462170; RICHARDSON SG, 1991, ECHOCARDIOGR-J CARD, V8, P293, DOI 10.1111/j.1540-8175.1991.tb01193.x; RITTER SB, 1991, J AM COLL CARDIOL, V18, P569, DOI 10.1016/0735-1097(91)90616-H; Roelandt J R, 1992, J Am Soc Echocardiogr, V5, P361; ROHMANN S, 1991, THORAC CARDIOV SURG, V39, P273, DOI 10.1055/s-2007-1019985; Rohmann S, 1991, J Am Soc Echocardiogr, V4, P465; SAMDARSHI TE, 1992, J AM COLL CARDIOL, V19, P572, DOI 10.1016/S0735-1097(10)80275-X; SCHLUTER M, 1984, AM J CARDIOL, V53, P1173, DOI 10.1016/0002-9149(84)90657-X; SCHLUTER M, 1982, BRIT HEART J, V48, P67; SCHLUTER M, 1981, Z KARDIOL, V70, P797; SCHNEIDER B, 1990, J AM COLL CARDIOL, V16, P1000, DOI 10.1016/S0735-1097(10)80354-7; Seward J B, 1992, J Am Soc Echocardiogr, V5, P288; SEWARD JB, 1990, MAYO CLIN PROC, V65, P1193, DOI 10.1016/S0025-6196(12)62744-X; SEWARD JB, 1993, MAYO CLIN PROC, V68, P523, DOI 10.1016/S0025-6196(12)60367-X; SEWARD JB, 1988, MAYO CLIN PROC, V63, P649, DOI 10.1016/S0025-6196(12)65529-3; Shah P M, 1991, J Cardiothorac Vasc Anesth, V5, P316, DOI 10.1016/1053-0770(91)90152-J; SHEIKH KH, 1991, CIRCULATION, V84, P594, DOI 10.1161/01.CIR.84.2.594; SHEIKH KH, 1990, J AM COLL CARDIOL, V15, P363, DOI 10.1016/S0735-1097(10)80064-6; SHINTANI H, 1990, J CARDIOVASC SURG, V31, P564; SHIVELY BK, 1991, J AM COLL CARDIOL, V18, P391, DOI 10.1016/0735-1097(91)90591-V; SIOSTRZONEK P, 1991, AM J CARDIOL, V68, P1247, DOI 10.1016/0002-9149(91)90206-Z; SMITH JS, 1985, CIRCULATION, V72, P1015, DOI 10.1161/01.CIR.72.5.1015; SMITH MD, 1991, CIRCULATION, V83, P79, DOI 10.1161/01.CIR.83.1.79; SOUQUET J, 1982, IEEE T BIO-MED ENG, V29, P707, DOI 10.1109/TBME.1982.324864; SREERAM N, 1990, J AM COLL CARDIOL, V16, P1205, DOI 10.1016/0735-1097(90)90554-3; STECKELBERG JM, 1991, ANN INTERN MED, V114, P635, DOI 10.7326/0003-4819-114-8-635; STECKELBERG JM, 1991, CIRCULATION, V84, P177, DOI 10.1161/01.CIR.84.1.177; STRATTON JR, 1982, CIRCULATION, V66, P156, DOI 10.1161/01.CIR.66.1.156; STUMPER O, 1991, J AM COLL CARDIOL, V17, P1152; STUMPER O, 1991, J AM COLL CARDIOL, V18, P1506; STUMPER OFW, 1990, J AM COLL CARDIOL, V16, P433; STUMPER OFW, 1990, J AM COLL CARDIOL, V16, P442; TAAMS MA, 1990, BRIT HEART J, V63, P109; TAAMS MA, 1989, J AM COLL CARDIOL, V13, P95, DOI 10.1016/0735-1097(89)90555-X; TAKENAKA K, 1991, AM J CARDIOL, V68, P691, DOI 10.1016/0002-9149(91)90371-Q; TRIBOUILLOY C, 1992, CIRCULATION, V85, P1248, DOI 10.1161/01.CIR.85.4.1248; TUNICK PA, 1991, ANN INTERN MED, V115, P423, DOI 10.7326/0003-4819-115-6-423; VANDAELE MERM, 1990, CIRCULATION, V81, P865, DOI 10.1161/01.CIR.81.3.865; VANDENBRINK RBA, 1989, AM J CARDIOL, V63, P1471, DOI 10.1016/0002-9149(89)90010-6; WEINTRAUB R, 1992, CIRCULATION, V86, P711, DOI 10.1161/01.CIR.86.3.711; Winslow T, 1992, J Am Soc Echocardiogr, V5, P206; Wittlich N, 1992, J Am Soc Echocardiogr, V5, P515; YOSHIDA K, 1990, CIRCULATION, V81, P1271, DOI 10.1161/01.CIR.81.4.1271; YOSHIDA K, 1990, CIRCULATION, V82, P1121, DOI 10.1161/01.CIR.82.4.1121; ZENKER G, 1988, STROKE, V19, P345, DOI 10.1161/01.STR.19.3.345; ZWICKY P, 1988, AM J CARDIOL, V62, P639, DOI 10.1016/0002-9149(88)90671-6	162	120	122	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 11	1995	332	19					1268	1279		10.1056/NEJM199505113321906	http://dx.doi.org/10.1056/NEJM199505113321906			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW600	7708072				2022-12-28	WOS:A1995QW60000006
J	GREEN, J; WINTFELD, N				GREEN, J; WINTFELD, N			REPORT CARDS ON CARDIAC-SURGEONS - ASSESSING NEW-YORK STATES APPROACH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; HOSPITAL MORTALITY; UNSTABLE ANGINA; DISCHARGE DATA; RISK; STRATIFICATION				GREEN, J (corresponding author), NYU,MED CTR,550 1ST AVE,NEW YORK,NY 10016, USA.							Altman LK, 1990, NEW YORK TIMES, pB10; [Anonymous], 1992, CORONARY ARTERY BYPA; BIGGER JT, 1978, AM J CARDIOL, V42, P202, DOI 10.1016/0002-9149(78)90901-3; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; BROOK RH, 1994, ANN INTERN MED, V120, P84, DOI 10.7326/0003-4819-120-1-199401010-00015; BYER MJ, 1992, NY TIMES        0321, pA23; GERSH BJ, 1983, CIRCULATION, V67, P483, DOI 10.1161/01.CIR.67.3.483; GREEN J, 1991, JAMA-J AM MED ASSOC, V265, P1849; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; Green J, 1992, BROOKLYN LAW R, V58, P55; GREEN J, 1994, REPORT CARDS CARDIAC; GROSSI EA, 1994, 20TH M W SOC THOR SU; HAMMERMEISTER KE, 1990, CIRCULATION, V82, P380; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HANNAN EL, 1994, ANN THORAC SURG, V58, P1852, DOI 10.1016/0003-4975(94)91726-4; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; IEZZONI LI, 1991, JAMA-J AM MED ASSOC, V265, P3006, DOI 10.1001/jama.265.22.3006; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; KIRKLIN JW, 1993, CARDIAC SURGERY MORP, P315; KRAKAUER H, 1992, HEALTH SERV RES, V27, P317; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; OMOIGUI N, 1994, CIRCULATION, V90, P93; PARSONNET V, 1989, CIRCULATION, V79, P3; PETERSON ED, 1994, ANN INTERN MED, V121, P919, DOI 10.7326/0003-4819-121-12-199412150-00003; Principal Investigators of CASS and Associates, 1981, CIRCULATION S1, V63, pI1; SELKER HP, 1991, MED CARE, V29, P1196, DOI 10.1097/00005650-199112000-00003; TOPOL EJ, 1994, ANN INTERN MED, V120, P65, DOI 10.7326/0003-4819-120-1-199401010-00011; WASSON JH, 1992, J GEN INTERN MED, V7, P298, DOI 10.1007/BF02598088; Zinman D., 1992, NEW YORK NEWSDA 0512, P87; ZINMAN D, 1991, NEWSDAY         1218, P7; 1993, CORONARY ARTERY BYPA; 1994, HLTH CARE REFORM REP; 1993, NY TIMES        0623, pA19; 1994, ANN THORAC SURG, V58, P271; 1994, OTAH608 OFF TECHN AS; 1991, FORM DOH 2254A	39	300	303	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 4	1995	332	18					1229	1232		10.1056/NEJM199505043321812	http://dx.doi.org/10.1056/NEJM199505043321812			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV415	7700321				2022-12-28	WOS:A1995QV41500012
J	TZOURIO, C; TEHINDRAZANARIVELO, A; IGLESIAS, S; ALPEROVITCH, A; CHEDRU, F; DANGLEJANCHATILLON, J; BOUSSER, MG				TZOURIO, C; TEHINDRAZANARIVELO, A; IGLESIAS, S; ALPEROVITCH, A; CHEDRU, F; DANGLEJANCHATILLON, J; BOUSSER, MG			CASE-CONTROL STUDY OF MIGRAINE AND RISK OF ISCHEMIC STROKE IN YOUNG-WOMEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLATELET AGGREGABILITY; PREVALENCE; FEATURES; ADULTS	Objective-To determine whether migraine is a risk factor for ischaemic stroke in young women. Design-A case-control study. Setting-Five hospitals in Paris and suburbs. Subjects-72 women aged under 45 with ischaemic stroke and 173 controls randomly selected from women hospitalised in the same centres. Main outcome measures-Ischaemic stroke confirmed by cerebral computerised tomography or magnetic resonance imaging; history of headache recorded with structured interview, and diagnosis of migraine assessed by reproducibility study. Results-Ischaemic stroke was strongly associated with migraine, both migraine without aura (odds ratio 3.0 (95% confidence interval 1.5 to 5.8)) and migraine with aura (odds ratio 6.2 (2.1 to 18.0)). The risk of ischaemic stroke was substantially increased for migrainous women who were using oral contraceptives (odds ratio 13.9) or who were heavy smokers (greater than or equal to 20 cigarettes/day) (odds ratio 10.2). Conclusions-These results indicate an independent association between migraine and the risk of ischaemic stroke in young women. Although the absolute risk of ischaemic stroke in young women with migraine is low, the reduction of known risk factors for stroke, in particular smoking and use of oral contraceptives, should be considered in this group.	HOP ST ANTOINE, SERV NEUROL, F-75571 PARIS, FRANCE; HOP MEAUX, SERV NEUROL, MEAUX, FRANCE; HOP VERSAILLES, SERV NEUROL, VERSAILLES, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre Hospitalier de Versailles	TZOURIO, C (corresponding author), INSERM, U360, UNITE RECH EPIDEMIOL NEUROL & PSYCHOPATHOL, F-94807 VILLEJUIF, FRANCE.		Tzourio, christophe/L-6344-2019; Tzourio, Christophe I/B-7459-2008; Tzourio, christophe/B-4015-2009	Tzourio, christophe/0000-0002-6517-2984; Tzourio, christophe/0000-0002-6517-2984				[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718; Breslow N, 1980, STATISTICAL METHODS, V32; COUCH JR, 1977, NEUROLOGY, V27, P843, DOI 10.1212/WNL.27.9.843; Fleiss JL, 1981, STAT METHODS RATES P; Gawel M J, 1982, Adv Neurol, V33, P237; HENRICH JB, 1989, J CLIN EPIDEMIOL, V42, P773, DOI 10.1016/0895-4356(89)90075-9; HENRY P, 1992, CEPHALALGIA, V12, P229, DOI 10.1046/j.1468-2982.1992.1204229.x; KALENDOVSKY Z, 1975, ARCH NEUROL-CHICAGO, V32, P13, DOI 10.1001/archneur.1975.00490430035004; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; LEVINE SR, 1989, ANN NEUROL, V26, P386, DOI 10.1002/ana.410260312; LIDEGAARD O, 1987, ACTA NEUROL SCAND, V75, P427, DOI 10.1111/j.1600-0404.1987.tb05473.x; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; MARINI C, 1993, NEUROEPIDEMIOLOGY, V12, P70, DOI 10.1159/000110303; MONTAGNA P, 1988, NEUROLOGY, V38, P751, DOI 10.1212/WNL.38.5.751; PEARSON AC, 1991, J AM COLL CARDIOL, V18, P1223, DOI 10.1016/0735-1097(91)90539-L; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; SCHOENBERG BS, 1970, NEUROLOGY, V20, P181, DOI 10.1212/WNL.20.2.181; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; TATEMICHI TK, 1992, STROKE PATHOPHYSIOLO, P761; TZOURIO C, 1993, BMJ-BRIT MED J, V307, P289, DOI 10.1136/bmj.307.6899.289; 1990, SAS USERS GUIDE STAT, V1	21	353	364	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	1995	310	6983					830	833		10.1136/bmj.310.6983.830	http://dx.doi.org/10.1136/bmj.310.6983.830			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711619	Green Published			2022-12-28	WOS:A1995QQ85700017
J	AULD, DS; SCHIMMEL, P				AULD, DS; SCHIMMEL, P			SWITCHING RECOGNITION OF 2 TRANSFER-RNA SYNTHETASES WITH AN AMINO-ACID SWAP IN A DESIGNED PEPTIDE	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASE; GLUTAMINYL-TRANSFER RNA; ESCHERICHIA-COLI; BINDING-SITE; ANTICODON BINDING; SEQUENCES; PROTEIN; IDENTIFICATION; AMINOACYLATION; CODON	The genetic code is based on specific interactions between transfer RNA (tRNA) synthetases and their cognate tRNAs. The anticodons for methionine and isoleucine tRNAs differ by a single nucleotide, and changing this nucleotide in an isoleucine tRNA is sufficient to change aminoacylation specificity to methionine. Results of combinatorial mutagenesis of an anticodon-binding-helix loop peptide were used to design a hybrid sequence composed of amino acid residues from methionyl- and isoleucyl-tRNA synthetases. When the hybrid sequence was transplanted into isoleucyl-tRNA synthetase, active enzyme was generated in vivo and in vitro. The transplanted peptide did not confer function to methionyl-tRNA synthetase, but the substitution of a single amino acid within the transplanted peptide conferred methionylation and prevented isoleucylation. Thus, the swap of a single amino acid in the transplanted peptide switches specificity between anticodons that differ by one nucleotide.			AULD, DS (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23562] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER DG, 1982, EUR J BIOCHEM, V127, P449; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BURBAUM JJ, 1991, BIOCHEMISTRY-US, V30, P319, DOI 10.1021/bi00216a002; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1690, DOI 10.1021/bi00869a034; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; GHOSH G, 1990, BIOCHEMISTRY-US, V29, P2220, DOI 10.1021/bi00461a003; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; IACCARINO M, 1971, J BACTERIOL, V105, P527, DOI 10.1128/JB.105.2.527-537.1971; KIM S, 1993, P NATL ACAD SCI USA, V90, P10046, DOI 10.1073/pnas.90.21.10046; KIM SH, 1994, BIOCHEMISTRY-US, V33, P11040, DOI 10.1021/bi00202a025; KIM SH, 1992, J BIOL CHEM, V267, P15563; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRO JA, 1993, P NATL ACAD SCI USA, V90, P2261, DOI 10.1073/pnas.90.6.2261; MEINNEL T, 1991, P NATL ACAD SCI USA, V88, P291, DOI 10.1073/pnas.88.1.291; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; MURAMATSU T, 1988, J BIOL CHEM, V263, P9261; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; SCHIMMEL P, 1992, PROTEIN SCI, V1, P1387, DOI 10.1002/pro.5560011018; SCHMIDT E, 1993, P NATL ACAD SCI USA, V90, P6919, DOI 10.1073/pnas.90.15.6919; SHEPARD A, 1992, P NATL ACAD SCI USA, V89, P9964, DOI 10.1073/pnas.89.20.9964; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; STARZYK RM, 1989, BIOCHEMISTRY-US, V28, P8479, DOI 10.1021/bi00447a031; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; VALENZUELA D, 1986, BIOCHEMISTRY-US, V25, P4555, DOI 10.1021/bi00364a015; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712	25	43	44	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1994	1996		10.1126/science.7701322	http://dx.doi.org/10.1126/science.7701322			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701322				2022-12-28	WOS:A1995QQ06800044
J	SOUTHWOOD, TR				SOUTHWOOD, TR			ABC OF RHEUMATOLOGY - ARTHRITIS IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article											SOUTHWOOD, TR (corresponding author), UNIV BIRMINGHAM,DEPT RHEUMATOL,BIRMINGHAM,W MIDLANDS,ENGLAND.								0	8	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					728	732		10.1136/bmj.310.6981.728	http://dx.doi.org/10.1136/bmj.310.6981.728			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711544	Green Published			2022-12-28	WOS:A1995QN46100034
J	GILMAN, EA; CHENG, KK; WINTER, HR; SCRAGG, R				GILMAN, EA; CHENG, KK; WINTER, HR; SCRAGG, R			TRENDS IN RATES AND SEASONAL DISTRIBUTION OF SUDDEN INFANT DEATHS IN ENGLAND AND WALES, 1988-92	BRITISH MEDICAL JOURNAL			English	Article									UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND	University of Auckland	GILMAN, EA (corresponding author), UNIV BIRMINGHAM,SCH MED,INST PUBL & ENVIRONM HLTH,DEPT EPIDEMIOL & PUBL HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Cheng, Kar/AAL-8899-2021	Cheng, Kar/0000-0002-1516-1857; Scragg, Robert/0000-0003-0013-2620				LITTLE RE, 1990, EPIDEMIOL REV, V12, P241, DOI 10.1093/oxfordjournals.epirev.a036057; MITCHELL EA, 1994, ARCH DIS CHILD, V76, P291; 1993, REPORT CHIEF MED OFF; 1993, DH3932 OPCS MON SER	4	20	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					631	632		10.1136/bmj.310.6980.631	http://dx.doi.org/10.1136/bmj.310.6980.631			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703750	Green Published			2022-12-28	WOS:A1995QL98400016
J	WATSON, JD; SAINSBURY, JRC; DIXON, JM				WATSON, JD; SAINSBURY, JRC; DIXON, JM			BREAST RECONSTRUCTION AFTER SURGERY	BRITISH MEDICAL JOURNAL			English	Article									HUDDERSFIELD ROYAL INFIRM,HUDDERSFIELD,W YORKSHIRE,ENGLAND; ROYAL INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh	WATSON, JD (corresponding author), ST JOHNS HOSP,LIVINGSTON,W LOTHIAN,SCOTLAND.								0	5	5	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					117	121		10.1136/bmj.310.6972.117	http://dx.doi.org/10.1136/bmj.310.6972.117			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7695752	Green Published			2022-12-28	WOS:A1995QC22300034
J	NORGARDSUMNICHT, KE; VARKI, NM; VARKI, A				NORGARDSUMNICHT, KE; VARKI, NM; VARKI, A			CALCIUM-DEPENDENT HEPARIN-LIKE LIGANDS FOR L-SELECTIN IN NONLYMPHOID ENDOTHELIAL-CELLS	SCIENCE			English	Article							LYMPHOCYTE HOMING RECEPTOR; ANTITHROMBIN-BINDING SEQUENCE; ADHESION MOLECULE-1 LAM-1; LEUKOCYTE ADHESION; BASEMENT-MEMBRANE; LINKED OLIGOSACCHARIDES; SULFATE PROTEOGLYCANS; VASCULAR ENDOTHELIUM; HUMAN-NEUTROPHILS; PASTEURELLA-HAEMOLYTICA	L-Selectin is a calcium-dependent mammalian lectin that mediates lymphocyte trafficking by recognizing sialylated ligands on high endothelial venules in lymph nodes. Although L-selectin probably mediates neutrophil extravasation into nonlymphoid tissues, no corresponding ligand has been characterized. Staining of cultured endothelial cells with an L-selectin chimera (LS-Rg) showed an internal pool of ligands. Metabolic labeling with sulfur-35-labeled sulfate revealed heparin lyase-sensitive ligands that bound LS-Rg in a calcium-dependent, sialic acid-independent manner. A fraction of commercial heparin bound to LS-Rg and LS-Rg bound to heparin-agarose, both in a calcium-dependent manner. Thus, L-selectin recognizes endothelial heparin-like chains, which could be physiological ligands mediating leucocyte trafficking.	UNIV CALIF SAN DIEGO,CTR CANC,GLYCOBIOL PROGRAM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA038701] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA38701] Funding Source: Medline; NHLBI NIH HHS [HL07089] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDULLAH KM, 1992, INFECT IMMUN, V60, P56, DOI 10.1128/IAI.60.1.56-62.1992; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BHAVANANDAN VP, 1992, GLYCOCONJUGATES COMP, P167; BRADBURY MG, 1991, IMMUNOLOGY, V72, P231; BRADBURY MG, 1989, IMMUNOLOGY, V66, P546; BRAUER PR, 1990, DEVELOPMENT, V110, P805; DAWSON J, 1992, EUR J IMMUNOL, V22, P1647, DOI 10.1002/eji.1830220646; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; FAKUDA M, 1985, J BIOL CHEM, V260, P12957; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; HUANG K, 1991, J CLIN INVEST, V88, P1778, DOI 10.1172/JCI115498; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; INOUE S, 1989, J HISTOCHEM CYTOCHEM, V37, P597, DOI 10.1177/37.5.2522961; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEY K, 1991, AM J PHYSIOL, V260, pH1667, DOI 10.1152/ajpheart.1991.260.5.H1667; LEY K, 1991, BLOOD, V77, P2553; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MATZNER Y, 1992, J LEUKOCYTE BIOL, V51, P519, DOI 10.1002/jlb.51.6.519; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; NORGARD KE, UNPUB; OSCARSSON LG, 1989, J BIOL CHEM, V264, P296; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; ROUX L, 1988, J BIOL CHEM, V263, P8879; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; SHAKLEE PN, 1986, BIOCHEM J, V235, P225, DOI 10.1042/bj2350225; SIMONASSMANN P, 1989, J CELL BIOL, V109, P1837, DOI 10.1083/jcb.109.4.1837; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPERTINI O, 1992, J EXP MED, V175, P1789, DOI 10.1084/jem.175.6.1789; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; SPERTINI O, 1991, J IMMUNOL, V147, P2565; STOOLMAN LM, 1989, J CLIN INVEST, V84, P1196, DOI 10.1172/JCI114285; STOOLMAN LM, 1992, CELL SURFACE CARBOHY, P71; STOW JL, 1987, J CELL BIOL, V105, P529, DOI 10.1083/jcb.105.1.529; SUTHERLAND DR, 1992, J IMMUNOL, V148, P1458; TANGELDER GJ, 1991, BLOOD, V77, P1565; TODDERUD G, 1992, J LEUKOCYTE BIOL, V52, P85, DOI 10.1002/jlb.52.1.85; TRUE DD, 1990, J CELL BIOL, V111, P2757, DOI 10.1083/jcb.111.6.2757; VANDENHEUVEL LPWJ, 1990, BIOCHIM BIOPHYS ACTA, V1025, P67, DOI 10.1016/0005-2736(90)90191-P; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; WALENGA JM, 1988, THROMB RES, V52, P553, DOI 10.1016/0049-3848(88)90128-4; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; YEDNOCK TA, 1987, J CELL BIOL, V104, P713, DOI 10.1083/jcb.104.3.713; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	67	179	185	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					480	483		10.1126/science.7687382	http://dx.doi.org/10.1126/science.7687382			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	7687382				2022-12-28	WOS:A1993LN62300039
J	JACKSON, RJ				JACKSON, RJ			CYTOPLASMIC REGULATION OF MESSENGER-RNA FUNCTION - THE IMPORTANCE OF THE 3' UNTRANSLATED REGION	CELL			English	Editorial Material							TRANSLATIONAL CONTROL; PICORNAVIRUS RNA; INITIATION; DEADENYLATION; PROTEIN; COMPLEX				JACKSON, RJ (corresponding author), UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND.							BRAUN RE, 1991, ENZYME, V44, P120; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; HARFORD JB, 1991, ENZYME, V44, P28; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; MACDONALD PM, 1992, SEMIN DEV BIOL, V3, P413; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SCHAFER M, 1990, EMBO J, V9, P4519, DOI 10.1002/j.1460-2075.1990.tb07903.x; SIMON R, 1992, GENE DEV, V6, P2580, DOI 10.1101/gad.6.12b.2580; SONENBERG N, 1991, TRENDS GENET, V7, P105, DOI 10.1016/0168-9525(91)90440-2; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; STRIPECKE R, 1992, NUCLEIC ACIDS RES, V20, P5555, DOI 10.1093/nar/20.21.5555; Tafuri Sherrie R., 1993, Trends in Cell Biology, V3, P94, DOI 10.1016/0962-8924(93)90080-K; VARNUM SM, 1992, DEV BIOL, V153, P283, DOI 10.1016/0012-1606(92)90113-U; WICKENS M, 1992, SEM DEV BIOL, V3, P399	24	404	411	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					9	14		10.1016/0092-8674(93)90290-7	http://dx.doi.org/10.1016/0092-8674(93)90290-7			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	7687524				2022-12-28	WOS:A1993LN62500003
J	LITAM, PP; FRIEDMAN, HD; LOUGHRAN, TP				LITAM, PP; FRIEDMAN, HD; LOUGHRAN, TP			SPLENIC EXTRAMEDULLARY HEMATOPOIESIS IN A PATIENT RECEIVING INTERMITTENTLY ADMINISTERED GRANULOCYTE-COLONY-STIMULATING FACTOR	ANNALS OF INTERNAL MEDICINE			English	Note						GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIESIS, EXTRAMEDULLARY; SPLENOMEGALY; LYMPHOMA; SPLECTOMY		A 22-year-old man received four cycles of cyclophosphamide, vincristine, doxorubicin, prednisone, and etoposide with intermittent granulocyte colony-stimulating factor (G-CSF) for the treatment of a high-grade, stage I malignant lymphoma involving the axilla. On re-evaluation, the axillary mass had completely disappeared: however, splenomegaly was present and lactate dehydrogenase levels were elevated 3 weeks after his final chemotherapy and G-CSF treatments. Because refractory disease was a concern, splenectomy was done. Spleen sections showed extramedullary hematopoiesis but no lymphomatous involvement. To our knowledge, we report the first case of splenomegaly with extramedullary hematopoiesis in a patient receiving intermittent G-CSF therapy. Clinicians should be aware that splenomegaly occurring in this setting does not necessarily indicate refractory lymphoma.	VET ADM MED CTR, SYRACUSE, NY 13210 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	LITAM, PP (corresponding author), SUNY HLTH SCI CTR, DEPT MED, 750 E ADAMS ST, SYRACUSE, NY 13210 USA.				NCI NIH HHS [CA 54552, CA 46903] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046903, R01CA054552] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		FUKUSHIMA N, 1992, BLOOD, V80, P1914; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; GLASPY JA, 1992, SEMIN ONCOL, V19, P386; LORD BI, 1989, P NATL ACAD SCI USA, V86, P9499, DOI 10.1073/pnas.86.23.9499; SWAN F, 1989, J CLIN ONCOL, V7, P1518, DOI 10.1200/JCO.1989.7.10.1518	5	37	37	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1993	118	12					954	955		10.7326/0003-4819-118-12-199306150-00007	http://dx.doi.org/10.7326/0003-4819-118-12-199306150-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF937	7683852				2022-12-28	WOS:A1993LF93700007
J	BDESHA, AS; BUNCE, CJ; KELLEHER, JP; SNELL, ME; VUKUSIC, J; WITHEROW, RO				BDESHA, AS; BUNCE, CJ; KELLEHER, JP; SNELL, ME; VUKUSIC, J; WITHEROW, RO			TRANSURETHRAL MICROWAVE TREATMENT FOR BENIGN PROSTATIC HYPERTROPHY - A RANDOMIZED CONTROLLED CLINICAL-TRIAL	BRITISH MEDICAL JOURNAL			English	Article							TRANS-URETHRAL RESECTION; BALLOON DILATATION; FOLLOW-UP; HYPERPLASIA; HYPERTHERMIA; PROSTATECTOMY; OBSTRUCTION	Objectives-To determine whether transurethral microwave treatment for patients with benign prostatic hypertrophy provides significant symptomatic relief, a reduction in residual urine volumes, and improvements in flow rates compared with sham treatment. Design-Prospective double blind randomised study with follow up at three months. Setting-Department of Urology in a London teaching hospital. Patients-40 men completed the study: 22 received microwave treatment and 18 received sham treatment. Entry criteria were symptoms of prostatism of at least six months' duration, a total symptom score > 14, and a peak urine flow rate < 15 ml/s or a residual urine volume > 50 ml. Exclusion criteria were prostatic cancer, a residual urine volume > 200 ml, a very large prostate, an obstructing middle lobe, acute urinary retention, impaired renal function, coexisting urinary tract disease, and previous prostatic surgery. Interventions-A single 90 minute transurethral microwave treatment or sham treatment. Outcome measures-Patients' symptoms (including daytime frequency and nocturia) recorded in a self assessment symptom score questionnaire, peak urinary flow rates, and residual urine volumes. Results-The mean total symptom scores of the patients who received microwave treatment fell from 30 to 11 compared with a fall from 31 to 26 for patients who received sham treatment (p < 0.001). Among patients who received microwave treatment daytime frequency fell from 9.4 to 5.5 voids a day and night time frequency from 3.5 to 1.6 voids a night; residual urine volumes fell from 104 ml to 52 ml; and peak urine flow rates increased by 2.3 ml/s. In the control group there was no improvement in any of these features. Treatment preserved sexual function and antegrade ejaculation. Conclusions-For selected patients with prostatism microwave treatment is effective and has few side effects.	ST MARYS HOSP,DEPT UROL,LONDON W2 1NY,ENGLAND; LASER ELECTROOPT,LONDON SE25,ENGLAND	Imperial College London								BAERT L, 1990, J UROLOGY, V144, P1383, DOI 10.1016/S0022-5347(17)39748-3; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; BOSCH RJLH, 1989, J UROLOGY, V141, P68, DOI 10.1016/S0022-5347(17)40591-X; BRUSKEWITZ RC, 1986, J UROLOGY, V136, P613, DOI 10.1016/S0022-5347(17)44991-3; CAINE M, 1978, BRIT J UROL, V50, P551, DOI 10.1111/j.1464-410X.1978.tb06210.x; CHILTON CP, 1978, BRIT J UROL, V50, P542, DOI 10.1111/j.1464-410X.1978.tb06208.x; FOWLER FJ, 1988, JAMA-J AM MED ASSOC, V259, P3018, DOI 10.1001/jama.259.20.3018; GLYNN RJ, 1985, AM J EPIDEMIOL, V121, P78; KIRBY RS, 1992, BRIT J UROL, V70, P65, DOI 10.1111/j.1464-410X.1992.tb15666.x; KLEIN LA, 1989, UROLOGY, V33, P198, DOI 10.1016/0090-4295(89)90390-7; LADUC R, 1992, EUR UROL UPDATE, V1, P42; LYTTON B, 1968, J UROLOGY, V99, P639, DOI 10.1016/S0022-5347(17)62763-0; NEAL DE, 1989, BRIT MED J, V299, P762, DOI 10.1136/bmj.299.6702.762; NEAL DE, 1991, RECENT ADV UROLOGY A, V5, P149; OGDEN CW, 1993, LANCET, V341, P14, DOI 10.1016/0140-6736(93)92482-9; REDDY PK, 1988, UROL CLIN N AM, V15, P529; SAPOZINK MD, 1990, J UROLOGY, V143, P944, DOI 10.1016/S0022-5347(17)40146-7; SERVADIO C, 1987, UROLOGY, V30, P97, DOI 10.1016/0090-4295(87)90169-5; STAWARZ B, 1991, J UROLOGY, V146, P353, DOI 10.1016/S0022-5347(17)37792-3; VINCENTE J, 1989, J UROLOGY, V142, P1504; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; YERUSHALMI A, 1985, J UROLOGY, V133, P873, DOI 10.1016/S0022-5347(17)49270-6	22	57	57	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1993	306	6888					1293	1296		10.1136/bmj.306.6888.1293	http://dx.doi.org/10.1136/bmj.306.6888.1293			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC722	7686065	Green Published, Bronze			2022-12-28	WOS:A1993LC72200017
J	LU, B; FU, WM; GREENGARD, P; POO, MM				LU, B; FU, WM; GREENGARD, P; POO, MM			CALCITONIN GENE-RELATED PEPTIDE POTENTIATES SYNAPTIC RESPONSES AT DEVELOPING NEUROMUSCULAR-JUNCTION	NATURE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; CHICK SKELETAL-MUSCLE; EMBRYONIC NEURON; RAPID INDUCTION; INITIAL EVENTS; SPINAL-CORD; PHOSPHORYLATION; MYOTUBES; DESENSITIZATION; CULTURE	PROTEIN phosphorylation is important in synaptic transmission and plasticity1. At the neuromuscular junction, phosphorylation of acetylcholine (ACh) receptor-channels increases the rate of agonist-induced channel desensitization2. In contrast, potentiation of ACh channel activity through protein phosphorylation has not been described. We report here that calcitonin gene-related peptide (CGRP), a neuropeptide present at presynaptic motor nerve terminals3,4, enhances the postsynaptic response at developing neuromuscular junctions by increasing the burst duration of embryonic ACh channels. The effect of CGRP on these ACh channels is mimicked by dibutyryl-cyclic AMP and by cAMP-dependent protein kinase (PKA) and prevented by a specific peptide inhibitor of PKA. Moreover, postsynaptic inhibition of PKA reduced the amplitude and decay time of spontaneous synaptic currents, suggesting that endogenous CGRP may act as a potentiating factor during the early phase of synaptogenesis.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University	LU, B (corresponding author), ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021, USA.		Lu, Bai/A-4018-2012	FU, WEN-MEI/0000-0003-4157-8987; Lu, Bai/0000-0001-5418-9759				BREHM P, 1982, DEV BIOL, V91, P93, DOI 10.1016/0012-1606(82)90012-4; BREHM P, 1984, J PHYSIOL-LONDON, V357, P203, DOI 10.1113/jphysiol.1984.sp015497; BREHM P, 1988, ION CHANNEL MODULATO, P345; EUSEBI F, 1985, J CELL BIOL, V100, P1339, DOI 10.1083/jcb.100.4.1339; FERRERMONTIEL AV, 1991, P NATL ACAD SCI USA, V88, P10213, DOI 10.1073/pnas.88.22.10213; FONTAINE B, 1986, NEUROSCI LETT, V71, P59, DOI 10.1016/0304-3940(86)90257-0; GIBSON SJ, 1984, J NEUROSCI, V4, P3101, DOI 10.1523/jneurosci.04-12-03101.1984; GREENGARD P, 1987, MOL NEUROBIOL, V1, P81, DOI 10.1007/BF02935265; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOPFIELD JF, 1988, NATURE, V336, P577; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; JENNINGS CGB, 1989, BRAIN RES, V504, P199, DOI 10.1016/0006-8993(89)91357-7; KIDOKORO Y, 1988, P NATL ACAD SCI USA, V85, P1978, DOI 10.1073/pnas.85.6.1978; LAUFER R, 1987, EMBO J, V6, P901, DOI 10.1002/j.1460-2075.1987.tb04836.x; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; MASON RT, 1984, NATURE, V308, P653, DOI 10.1038/308653a0; MILES K, 1989, NEURON, V2, P1517, DOI 10.1016/0896-6273(89)90198-0; MULLE C, 1988, P NATL ACAD SCI USA, V85, P5728, DOI 10.1073/pnas.85.15.5728; NEW HV, 1986, NATURE, V323, P809, DOI 10.1038/323809a0; PENG HB, 1989, J COMP NEUROL, V290, P533; POPPER P, 1989, BRAIN RES, V496, P180, DOI 10.1016/0006-8993(89)91064-0; ROA M, 1991, NEUROSCIENCE, V41, P563, DOI 10.1016/0306-4522(91)90349-S; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; SALMONS S, 1976, NATURE, V263, P30, DOI 10.1038/263030a0; TABTI N, 1991, CULTURES NERVE CELLS, P37; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOUNG SH, 1983, NATURE, V304, P161, DOI 10.1038/304161a0	28	105	105	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 6	1993	363	6424					76	79		10.1038/363076a0	http://dx.doi.org/10.1038/363076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA682	7683114				2022-12-28	WOS:A1993LA68200063
J	TEEM, JL; BERGER, HA; OSTEDGAARD, LS; RICH, DP; TSUI, LC; WELSH, MJ				TEEM, JL; BERGER, HA; OSTEDGAARD, LS; RICH, DP; TSUI, LC; WELSH, MJ			IDENTIFICATION OF REVERTANTS FOR THE CYSTIC-FIBROSIS DELTA-F508 MUTATION USING STE6-CFTR CHIMERAS IN YEAST	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CFTR CHLORIDE CHANNEL; MULTIDRUG RESISTANCE; STRUCTURAL MODEL; GENE; CELLS; EXPRESSION; TRANSPORT; PROTEIN; PHOSPHORYLATION	Mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) cause cystic fibrosis; the most common mutation is deletion of phenylalanine at position 508 (DELTAF508). We constructed STE6-CFTR chimeras with portions of the first nucleotide-binding domain (NBD1) of the yeast STE6 a-factor transporter replaced by portions of CFTR NBD1. The chimeras were functional in yeast, but mating efficiency decreased when DELTAF508 was introduced into NBD1. We isolated two DELTAF508 revertant mutations (R553M and R553Q) that restored mating; both were located within the CFTR NBD1 sequence. Introduction of these revertant mutations into human CFTR partially corrected the processing and Cl- channel gating defects caused by the DELTAF508 mutation. These results suggest that the NBD1s of CFTR and STE6 share a similar structure and function and that, in CFTR, the regions containing F508 and R553 interact. They also indicate that the abnormal conformation produced by DELTAF508 can be partially corrected by additional alterations in the protein.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; HOSP SICK CHILDREN,DEPT GENET,TORONTO M5G 1X8,ONTARIO,CANADA	Howard Hughes Medical Institute; University of Iowa; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	TEEM, JL (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.		Tsui, Lap-chee/A-1081-2010	Berger, Herbert/0000-0003-4383-2643; Welsh, Michael/0000-0002-1646-6206; Ostedgaard, Lynda/0000-0001-7717-3442				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DORK T, 1991, HUM GENET, V87, P441; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACKETT M, 1985, DNA CLONING PRACTICA, P191; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	40	151	166	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 23	1993	73	2					335	346		10.1016/0092-8674(93)90233-G	http://dx.doi.org/10.1016/0092-8674(93)90233-G			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KY505	7682896				2022-12-28	WOS:A1993KY50500014
J	RODECK, CH				RODECK, CH			PRENATAL-DIAGNOSIS - FETAL DEVELOPMENT AFTER CHORIONIC VILLUS SAMPLING	LANCET			English	Editorial Material							DEFECTS				RODECK, CH (corresponding author), UNIV LONDON UNIV COLL,DEPT OBSTET & GYNAECOL,LONDON WC1E 6BT,ENGLAND.							BURTON BK, 1992, OBSTET GYNECOL, V79, P726; FABRIS C, 1992, PRENATAL DIAG, V12, P1074, DOI 10.1002/pd.1970121216; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; FROSTERISKENIUS UG, 1989, TERATOLOGY, V39, P127, DOI 10.1002/tera.1420390205; KULIEV AM, 1992, IN PRESS PRENAT DIAG; LIN SP, 1992, NOV M AM SOC HUM GEN; QUINTERO RA, 1992, LANCET, V339, P193, DOI 10.1016/0140-6736(92)90272-5; WEBSTER WS, 1990, TERATOLOGY, V41, P689, DOI 10.1002/tera.1420410605; WEBSTER WS, 1987, TERATOLOGY, V35, P253, DOI 10.1002/tera.1420350212	9	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 20	1993	341	8843					468	469		10.1016/0140-6736(93)90213-Z	http://dx.doi.org/10.1016/0140-6736(93)90213-Z			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN137	7679461				2022-12-28	WOS:A1993KN13700010
J	CORTELAZZO, S; FINAZZI, G; RUGGERI, M; VESTRI, O; GALLI, M; RODEGHIERO, F; BARBUI, T				CORTELAZZO, S; FINAZZI, G; RUGGERI, M; VESTRI, O; GALLI, M; RODEGHIERO, F; BARBUI, T			HYDROXYUREA FOR PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND A HIGH-RISK OF THROMBOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYCYTHEMIA-VERA; COMPLICATIONS; MANAGEMENT	Background. Abnormalities in the number and function of platelets may contribute to thromboembolic complications in patients with essential thrombocythemia. We assessed whether maintaining the platelet count below 600,000 per cubic millimeter with hydroxyurea reduces the incidence of thrombosis in patients with essential thrombocythemia and a high risk of thrombosis. Methods. A total of 114 patients with essential thrombocythemia (77 women and 37 men; median age, 68 years; range, 40 to 85) and a median platelet count of 788,000 per cubic millimeter (range, 533,000 to 1,240,000 per cubic millimeter) were randomly assigned to receive hydroxyurea (56 patients) or no myelosuppressive therapy (58 patients). Ninety-seven (85 percent) were over 60 years old, and 52 (46 percent) had had thrombosis, The two groups were matched for age, sex, and platelet count at randomization, Antiplatelet prophylaxis with aspirin or ticlopidine was not stopped. Followup lasted a median of 27 months in both groups. Results. Two patients (3.6 percent) treated with hydroxyurea had thrombotic episodes (one stroke and one myocardial infarction), whereas 14 patients (24 percent) in the control group had thrombotic episodes (one stroke, five transient ischemic attacks, five peripheral arterial occlusions, one deep-vein thrombosis, and two cases of superficial thrombophlebitis). The difference (20.4 percentage points; 95 percent confidence interval, 8.5 to 32 percent) was statistically significant (chi-square with Yates' correction, 8.3; 1 df; P = 0.003). Conclusions. Hydroxyurea is effective in preventing thrombosis in high-risk patients with essential thrombocythemia.	OSPED RIUNITI BERGAMO,DIV EMATOL,I-24100 BERGAMO,ITALY; OSPED CIVILE S BORTOLO VICENZA,DIV HEMATOL,VICENZA,ITALY	Ospedali Riuniti di Bergamo; ULSS 8 Berica; Ospedale San Bortolo di Vicenza								BARBUI T, 1983, EUR J CANCER CLIN ON, V19, P1593, DOI 10.1016/0277-5379(83)90091-3; CORTELAZZO S, 1990, J CLIN ONCOL, V8, P556, DOI 10.1200/JCO.1990.8.3.556; COX DR, 1972, J R STAT SOC B, V34, P187; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN ME, 1986, SEMIN HEMATOL, V23, P167; LEVINE MN, 1986, CHEST, V89, pS16, DOI 10.1378/chest.89.2_Supplement.16S; LOFVENBERG E, 1990, CANCER GENET CYTOGEN, V49, P57, DOI 10.1016/0165-4608(90)90164-6; LOFVENBERG E, 1988, EUR J HAEMATOL, V41, P375; MANTEL N, 1959, J NATL CANCER I, V22, P719; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MURPHY S, 1993, THROMB HAEMOSTASIS, V69, P564; MURPHY S, 1986, SEMIN HEMATOL, V23, P177; Pearson T C, 1987, Baillieres Clin Haematol, V1, P355, DOI 10.1016/S0950-3536(87)80006-9; Schafer A I, 1991, Prog Hemost Thromb, V10, P69; TURLURE P, 1993, BLOOD S, V82, P1979; VANDEPETTE JEW, 1986, BRIT J HAEMATOL, V62, P229; VANGENDEREN PJJ, 1993, ANN HEMATOL, V67, P57, DOI 10.1007/BF01788127; WATSON KV, 1993, BRIT J HAEMATOL, V83, P198, DOI 10.1111/j.1365-2141.1993.tb08272.x	19	621	644	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	1995	332	17					1132	1136		10.1056/NEJM199504273321704	http://dx.doi.org/10.1056/NEJM199504273321704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU302	7700286				2022-12-28	WOS:A1995QU30200004
J	KORDOWER, JH; FREEMAN, TB; SNOW, BJ; VINGERHOETS, FJG; MUFSON, EJ; SANBERG, PR; HAUSER, RA; SMITH, DA; NAUERT, GM; PERL, DP; OLANOW, CW				KORDOWER, JH; FREEMAN, TB; SNOW, BJ; VINGERHOETS, FJG; MUFSON, EJ; SANBERG, PR; HAUSER, RA; SMITH, DA; NAUERT, GM; PERL, DP; OLANOW, CW			NEUROPATHOLOGICAL EVIDENCE OF GRAFT-SURVIVAL AND STRIATAL REINNERVATION AFTER THE TRANSPLANTATION OF FETAL MESENCEPHALIC TISSUE IN A PATIENT WITH PARKINSONS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOPAMINE NEURONS; SUBSTANTIA-NIGRA; CAUDATE-NUCLEUS; IMPLANTS; MPTP	Background. Trials are under way to determine whether fetal nigral grafts can improve motor function in patients with Parkinson's disease. Some studies use fluorodopa uptake on positron-emission tomography (PET) as a marker of graft viability, but fluorodopa uptake does not distinguish between host and grafted neurons. There has been no direct evidence that grafts of fetal tissue can survive and innervate the striatum. Methods. We studied a 59-year-old man with advanced Parkinson's disease who received bilateral grafts of fetal ventral mesencephalic tissue in the postcommissural putamen. The tissue came from seven embryos between 6 1/2 and 9 weeks after conception. The patient died 18 months later from a massive pulmonary embolism. The brain was studied with the use of tyrosine hydroxylase immunohistochemical methods. Results. After transplantation, the patient had sustained improvement in motor function and a progressive increase in fluorodopa uptake in the putamen on PET scanning, On examination of the brain, each of the large grafts appeared to be viable. Each was integrated into the host striatum and contained dense clusters of dopaminergic neurons. Processes from these neurons had grown out of the grafts and provided extensive dopaminergic reinnervation to the striatum in a patch-matrix pattern, Ungrafted regions of the putamen showed sparse dopaminergic innervation. We could not identify any sprouting of host dopaminergic processes, Conclusions. Grafts of fetal mesencephalic tissue can survive for a long period in the human brain and restore dopaminergic innervation to the striatum in patients with Parkinson's disease. In the patient we studied, clinical improvement and enhanced fluorodopa uptake on PET scanning were associated with the survival of the grafts and dopaminergic reinnervation of the striatum.	UNIV S FLORIDA,DEPT NEUROL,TAMPA,FL 33620; UNIV S FLORIDA,DIV NEUROSURG,TAMPA,FL 33620; UNIV BRITISH COLUMBIA,CTR NEURODEGENERAT DISORDERS,VANCOUVER,BC,CANADA; TAMPA WOMENS HLTH CTR,TAMPA,FL; MT SINAI MED CTR,DEPT PATHOL,NEW YORK,NY 10029; MT SINAI MED CTR,DEPT NEUROL,NEW YORK,NY 10029	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of British Columbia; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	KORDOWER, JH (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT NEUROL SCI,2242 W HARRISON ST,CHICAGO,IL 60612, USA.		Perl, Daniel/GPS-9879-2022; Hauser, Robert/I-5372-2012		NINDS NIH HHS [NS33094, NS32842] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033094] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANKIEWICZ KS, 1990, J NEUROSURG, V72, P231, DOI 10.3171/jns.1990.72.2.0231; BERTRAM KJ, 1994, EXP NEUROL, V127, P245, DOI 10.1006/exnr.1994.1100; BJORKLUND A, 1979, BRAIN RES, V177, P555, DOI 10.1016/0006-8993(79)90472-4; BRUNDIN P, 1986, EXP BRAIN RES, V65, P235; COLLIER TJ, 1993, BRAIN RES, V623, P249, DOI 10.1016/0006-8993(93)91435-U; DUAN WM, 1993, NEUROSCIENCE, V57, P261, DOI 10.1016/0306-4522(93)90061-J; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FREED WJ, 1980, ANN NEUROL, V8, P510, DOI 10.1002/ana.410080508; FREEMAN T, 1994, NEUROLOGY, V44, pA324; FREEMAN TB, 1991, EXP NEUROL, V113, P344, DOI 10.1016/0014-4886(91)90025-8; FREEMAN TB, 1995, CELL TRANSPLANT, V4, P141, DOI 10.1016/0963-6897(94)00048-O; FREEMAN TB, 1991, INTRACEREBRAL TRANSP, P163; GRAYBIEL AM, 1984, NEUROSCIENCE, V13, P1157, DOI 10.1016/0306-4522(84)90293-8; GRAYBIEL AM, 1989, J NEUROSCI, V9, P3250; HENDERSON BT, 1992, ARCH NEUROL-CHICAGO, V48, P822; Hitchcock E.H., 1994, EXP NEUROL, V129, P3; KORDOWER JH, 1988, BRAIN RES, V461, P221, DOI 10.1016/0006-8993(88)90253-3; KORDOWER JH, 1991, ANN NEUROL, V29, P405, DOI 10.1002/ana.410290411; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; LINDVALL O, 1992, ANN NEUROL, V31, P155, DOI 10.1002/ana.410310206; NAUERT GM, 1994, CELL TRANSPLANT, V3, P147, DOI 10.1177/096368979400300202; NICHOLAS MK, 1987, J IMMUNOL, V139, P2275; PESCHANSKI M, 1994, BRAIN, V117, P487, DOI 10.1093/brain/117.3.487; REDMOND DE, 1990, LANCET, V336, P820, DOI 10.1016/0140-6736(90)93294-Y; ROSENSTEIN JM, 1988, SCIENCE, V235, P772; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; VERNEY C, 1991, NEUROSCI LETT, V131, P121, DOI 10.1016/0304-3940(91)90351-S; VINGERHOETS FJG, 1994, J NUCL MED, V35, P18; VINGERHOETS FJG, 1994, MOV DISORD S1, V9, P119; WIDNER H, 1992, NEW ENGL J MED, V327, P1556, DOI 10.1056/NEJM199211263272203; YUREK DM, 1990, ANNU REV NEUROSCI, V13, P415, DOI 10.1146/annurev.neuro.13.1.415	32	713	753	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	1995	332	17					1118	1124		10.1056/NEJM199504273321702	http://dx.doi.org/10.1056/NEJM199504273321702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU302	7700284				2022-12-28	WOS:A1995QU30200002
J	LEE, IM; HSIEH, CC; PAFFENBARGER, RS				LEE, IM; HSIEH, CC; PAFFENBARGER, RS			EXERCISE INTENSITY AND LONGEVITY IN MEN - THE HARVARD ALUMNI HEALTH STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; TOTAL ENERGY-INTAKE; TIME PHYSICAL-ACTIVITY; LEISURE-TIME; EPIDEMIOLOGIC ANALYSES; COLLEGE ALUMNI; FINNISH MEN; RISK FACTOR; FOLLOW-UP; MORTALITY	Objective.-To examine the independent associations of vigorous (greater than or equal to 6 resting metabolic rate [MET] score) and nonvigorous (<6 MET score) physical activity with longevity. Design.-Prospective cohort study, following up men from 1962 or 1966 through 1988. Setting/Participants.-Subjects were Harvard University alumni, without self-reported, physician-diagnosed cardiovascular disease, cancer, or chronic obstructive pulmonary disease (n=17 321). Men with a mean age of 46 years reported their physical activities on questionnaires at baseline. Main Outcome Measure.-All-cause mortality (3728 deaths). Results.-Total energy expenditure and energy expenditure from vigorous activities, but not energy expenditure from nonvigorous activities, related inversely to mortality. After adjustment for potential confounders, the relative risks of dying associated with increasing quintiles of total energy expenditure were 1.00 (referent), 0.94, 0.95, 0.91 and 0.91, respectively (P [trend]<.05). The relative risks of dying associated with less than 630, 630 to less than 1680, 1680 to less than 3150, 3150 to less than 6300, and 6300 or more kJ/wk expended on vigorous activities were 1.00 (referent), 0.88, 0.92, 0.87, and 0.87, respectively (P[trend]=.007). Corresponding relative risks for energy expended on nonvigorous activities were 1.00 (referent), 0.89, 1.00, 0.98, and 0.92, respectively (P[trend]=.36). Analyses of vigorous and nonvigorous activities were mutually adjusted. Among men who reported only vigorous activities (259 deaths), we observed decreasing age-standardized mortality rates with increasing activity (P=.05); among men who reported only nonvigorous activities (380 deaths), no trend was apparent (P=.99). Conclusions.-These data demonstrate a graded inverse relationship between total physical activity and mortality. Furthermore, vigorous activities but not nonvigorous activities were associated with longevity. These findings pertain only to all cause mortality; nonvigorous exercise has been shown to benefit other aspects of health.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; STANFORD UNIV, SCH MED, DIV EPIDEMIOL, STANFORD, CA 94305 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Stanford University	LEE, IM (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Lee, I-Min/ABD-5409-2021		NCI NIH HHS [CA 09001, CA 44854] Funding Source: Medline; NHLBI NIH HHS [HL 34174] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044854] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, 1993, J CLIN EPIDEMIOL, V46, P1403, DOI 10.1016/0895-4356(93)90140-V; AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; Albanes D, 1990, Epidemiology, V1, P65, DOI 10.1097/00001648-199001000-00014; ALESSIO HM, 1993, MED SCI SPORT EXER, V25, P218, DOI 10.1249/00005768-199302000-00010; [Anonymous], 1990, NUTR EPIDEMIOLGY; ARMITAGE P, 1987, STATISTICAL METHODS, P91; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; CAULEY JA, 1987, AM J CLIN NUTR, V45, P14, DOI 10.1093/ajcn/45.1.14; COX DR, 1972, J R STAT SOC B, V34, P187; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; FROELICHER VF, 1990, EXERCISE, FITNESS, AND HEALTH, P429; HAGBERG JM, 1990, EXERCISE, FITNESS, AND HEALTH, P455; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HORTON E S, 1986, Diabetes Metabolism Reviews, V2, P1; HOWE GR, 1986, AM J EPIDEMIOL, V124, P157, DOI 10.1093/oxfordjournals.aje.a114365; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; LAKKA TA, 1994, NEW ENGL J MED, V330, P1549, DOI 10.1056/NEJM199406023302201; LAKKA TA, 1992, AM J EPIDEMIOL, V136, P806, DOI 10.1093/aje/136.7.806; LAPORTE RE, 1983, J GERONTOL, V38, P394, DOI 10.1093/geronj/38.4.394; LAPORTE RE, 1982, J CHRON DIS, V35, P787, DOI 10.1016/0021-9681(82)90090-X; LEE IM, 1992, AM J EPIDEMIOL, V135, P169, DOI 10.1093/oxfordjournals.aje.a116269; LEE IM, 1991, J NATL CANCER I, V83, P1324, DOI 10.1093/jnci/83.18.1324; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; LINDSTED KD, 1991, J CLIN EPIDEMIOL, V44, P355, DOI 10.1016/0895-4356(91)90074-J; MAGNUS K, 1979, AM J EPIDEMIOL, V110, P724, DOI 10.1093/oxfordjournals.aje.a112853; MORRIS JN, 1980, LANCET, V2, P1207; MORRIS JN, 1990, BRIT HEART J, V63, P325; NEWSHOLME EA, 1990, EXERCISE, FITNESS, AND HEALTH, P293; OBERMAN A, 1988, HEART DISEASE TXB CA, P1395; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PEKKANEN J, 1987, LANCET, V1, P1473, DOI 10.1016/S0140-6736(87)92218-5; PIKE MC, 1989, AM J EPIDEMIOL, V129, P1312, DOI 10.1093/oxfordjournals.aje.a115254; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P41; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHEKELLE RB, 1987, AM J EPIDEMIOL, V126, P980, DOI 10.1093/oxfordjournals.aje.a114736; SICONOLFI SF, 1985, AM J EPIDEMIOL, V122, P101, DOI 10.1093/oxfordjournals.aje.a114068; Siegel P Z, 1991, MMWR CDC Surveill Summ, V40, P1; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; SMITH GD, 1992, LANCET, V340, P709; Stefanovic-Racic M., 1994, P417; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; WACHOLDER S, 1994, AM J EPIDEMIOL, V140, P848, DOI 10.1093/oxfordjournals.aje.a117333; WASHBURN RA, 1991, J CLIN EPIDEMIOL, V44, P1319, DOI 10.1016/0895-4356(91)90093-O; WOOD PD, 1990, EXERCISE, FITNESS, AND HEALTH, P409; 1992, ALLIED DUNBAR NATION; 1985, GUIDELINES GRADED EX; [No title captured]	50	437	453	1	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1179	1184		10.1001/jama.273.15.1179	http://dx.doi.org/10.1001/jama.273.15.1179			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT100	7707624				2022-12-28	WOS:A1995QT10000025
J	SUMMERFIELD, JA; RYDER, S; SUMIYA, M; THURSZ, M; GORCHEIN, A; MONTEIL, MA; TURNER, MW				SUMMERFIELD, JA; RYDER, S; SUMIYA, M; THURSZ, M; GORCHEIN, A; MONTEIL, MA; TURNER, MW			MANNOSE-BINDING PROTEIN GENE-MUTATIONS ASSOCIATED WITH UNUSUAL AND SEVERE INFECTIONS IN ADULTS	LANCET			English	Article							DEFECTIVE OPSONIZATION; PROCIDIN FUNCTION; OPSONIN; IMMUNODEFICIENCY; SERUM	A defect in opsonisation can cause a common immunodeficiency. A mutation in mannose binding protein (MBP) caused by point mutations in the MBP gene will lead to such a defect, This type of syndrome can cause recurrent infections in infants between 6 and 18 months of age but is not generally believed to predispose to adult infections. We looked at 4 patients with severe and unusual infections in whom MBP gene mutations were the only identified cause of immunodeficiency and one patient with combined MBP and IgA deficiency, We analysed the MBP genotypes of all the patients in whom we suspected an immunodeficiency because of their clinical history. Infections seen were recurrent skin abscesses, chronic cryptosporidial diarrhoea, meningococcal meningitis with recurrent herpes simplex, and fatal klebsiella lobar pneumonia. Both sexes were affected and ages ranged from 15 to 56 years. Two patients were homozygous for codon 54 mutations, one patient bad codon 52 and codon 54 mutations and was phenotypically homozygous, and two patients were heterozygous for codon 54 mutations. Individuals homozygous for MBP mutations are unusual in the general population (approximate frequency 0.3%). The occurrence of three homozygotes for MBP mutations among these five infected patients suggests that MBP deficiency may confer a life-long risk of infection.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT CLIN PHARMACOL,LONDON W2 1NY,ENGLAND; CHARING CROSS & WESTMINSTER MED SCH,DEPT IMMUNOL,LONDON SW10 9NH,ENGLAND; INST CHILD HLTH,MOLEC IMMUNOL UNIT,LONDON WC1N 1EH,ENGLAND	Imperial College London; Imperial College London; University of London; University College London	SUMMERFIELD, JA (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT MED,LONDON W2 1NY,ENGLAND.			Thursz, Mark/0000-0002-8218-192X				BAKER LRI, 1993, J CLIN PATHOL, V46, P398, DOI 10.1136/jcp.46.5.398; FORSTER GE, 1987, GENITOURIN MED, V63, P169; HARTSHORN KL, 1993, J CLIN INVEST, V91, P1414, DOI 10.1172/JCI116345; JACYNA MR, 1990, GUT, V31, P714, DOI 10.1136/gut.31.6.714; JANOFF EN, 1987, J CLIN MICROBIOL, V25, P976; KUHLMAN M, 1989, J EXP MED, V169, P185; KURATA H, 1993, BIOCHEM BIOPH RES CO, V191, P1204, DOI 10.1006/bbrc.1993.1345; LACEY CJN, 1988, LANCET, V1, P185; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; MILLER ME, 1968, LANCET, V2, P60; PARKIN JM, 1991, SCAND J IMMUNOL, V33, P89, DOI 10.1111/j.1365-3083.1991.tb02495.x; RICHARDSON VF, 1983, ARCH DIS CHILD, V58, P799, DOI 10.1136/adc.58.10.799; SALIT IE, 1981, ARCH INTERN MED, V141, P664, DOI 10.1001/archinte.141.5.664; SIEGAL FP, 1981, AM J MED, V71, P1062, DOI 10.1016/0002-9343(81)90343-0; SOOTHILL JF, 1976, ARCH DIS CHILD, V51, P91, DOI 10.1136/adc.51.2.91; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUPER M, 1992, NAT GENET, V2, P50, DOI 10.1038/ng0992-50; SUPER M, 1989, LANCET, V2, P1236; SWEINBERG SK, 1991, J ALLERGY CLIN IMMUN, V88, P96, DOI 10.1016/0091-6749(91)90306-9; Turner M W, 1991, Clin Exp Allergy, V21 Suppl 1, P182, DOI 10.1111/j.1365-2222.1991.tb01725.x; WITTNER M, 1993, INFECT DIS CLIN N AM, V7, P569	22	309	324	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					886	889		10.1016/S0140-6736(95)90009-8	http://dx.doi.org/10.1016/S0140-6736(95)90009-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707811				2022-12-28	WOS:A1995QR06700009
J	SATOKATA, I; BENSON, G; MAAS, R				SATOKATA, I; BENSON, G; MAAS, R			SEXUALLY DIMORPHIC STERILITY PHENOTYPES IN HOXA10-DEFICIENT MICE	NATURE			English	Article							TESTICULAR DESCENT; MOUSE EMBRYOS; GENE; INVITRO	THE Abdominal B (AbdB) genes constitute a distinct subfamily of homeobox genes that exhibit posterior domains of expression(1,2), including the genital imaginal disc in Drosophila and the developing urogenital system in vertebrates(3,4). We have mutated the AbdB gene Hoxa10 in mice, We report here that homozygotes are fully viable and show an anterior homeotic transformation of lumbar vertebrae. All male homozygotes manifest bilateral cryptorchidism resulting in severe defects in spermatogenesis and increasing sterility with age. Female homozygotes ovulate normally, but about 80% are sterile because of death of embryos between days 2.5 and 3.5 post coitum. This coincides spatially and temporally with expression of maternal Hoxa10 in distal oviductal and uterine epithelium. These results indicate a role for AbdB Hox genes in male and female fertility and suggest that maternal Hoxa10 is required to regulate the expression of a factor that affects the viability of preimplantation embryos.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV GENET,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute								ADAMSON ED, 1993, J CELL BIOCHEM, V53, P280, DOI 10.1002/jcb.240530403; BENSON GV, 1995, MOL CELL BIOL, V15, P1591; BOWMAN P, 1970, J EMBRYOL EXP MORPH, V24, P203; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BROWN JJG, 1991, DEVELOPMENT, V112, P99; CLENICKER S, 1987, GENE DEV, V1, P111; DOLLE P, 1991, GENE DEV, V5, P1767, DOI 10.1101/gad.5.10.1767; ERBACH G, 1994, J BIOL REPROD, V50, P1027; Hogan B, 1986, MANIPULATING MOUSE E, P89; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; Kaufman M.H., 1992, ATLAS MOUSE DEV; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LYON MF, 1970, NATURE, V227, P1217, DOI 10.1038/2271217a0; PARK WH, 1991, J PEDIATR SURG, V26, P615, DOI 10.1016/0022-3468(91)90721-5; POLLARD J, 1991, UTERINE EMBRYONIC FA, P109; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; SAKKAS D, 1990, J REPROD FERTIL, V90, P109, DOI 10.1530/jrf.0.0900109; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; Schultz G A, 1993, Oxf Rev Reprod Biol, V15, P43; SHEN MM, 1992, P NATL ACAD SCI USA, V89, P8240, DOI 10.1073/pnas.89.17.8240; WELLS LJ, 1944, ANAT REC, V88, P465; WENSING CJG, 1988, HORM RES, V30, P144, DOI 10.1159/000181051	24	435	456	3	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					460	463		10.1038/374460a0	http://dx.doi.org/10.1038/374460a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700356				2022-12-28	WOS:A1995QP89900060
J	SALI, A; SHAKHNOVICH, E; KARPLUS, M				SALI, A; SHAKHNOVICH, E; KARPLUS, M			HOW DOES A PROTEIN FOLD	NATURE			English	Article							GLOBULAR-PROTEINS; DYNAMICS	THE number of all possible conformations of a polypeptide chain is too large to be sampled exhaustively. Nevertheless, protein sequences do fold into unique native states in seconds (the Levinthal paradox). To determine how the Levinthal parades is resolved, we use a lattice Monte Carlo model in which the global minimum (native state) is known. The necessary and sufficient condition for folding in this model is that the native state be a pronounced global minimum on the potential surface. This guarantees thermodynamic stability of the native state at a temperature where the chain does not get trapped in local minima. Folding starts by a rapid collapse from a random-coil state to a random semi-compact globule. It then proceeds by a slow, rate-determining search through the semicompact states to find a transition state from which the chain folds rapidly to the native state. The elements of the folding mechanism that lead to the resolution of the Levinthal parades are the reduced number of conformations that need to be searched in the semicompact globule (similar to 10(10) versus similar to 10(16) for the random coil) and the existence of many (similar to 10(3)) transition states. The results have evolutionary implications and suggest principles for the folding of real proteins.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University								BRYNGELSON JD, 1987, P NATL ACAD SCI USA, V84, P7524, DOI 10.1073/pnas.84.21.7524; BRYNGELSON JD, 1989, J PHYS CHEM-US, V93, P6902, DOI 10.1021/j100356a007; CREIGHTON TE, 1992, PROTEIN FOLDING; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; DILORIO EE, 1993, P NATL ACAD SCI USA, V90, P2025; GO N, 1984, ADV BIOPHYS, V18, P149, DOI 10.1016/0065-227X(84)90010-8; GO N, 1981, BIOPOLYMERS, V20, P1013; HARDING MM, 1991, BIOCHEMISTRY-US, V30, P3120, DOI 10.1021/bi00226a020; HONEYCUTT JD, 1992, BIOPOLYMERS, V32, P695, DOI 10.1002/bip.360320610; KARPLUS M, 1976, NATURE, V260, P404, DOI 10.1038/260404a0; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; Leventhal C, 1969, MOSSBAUER SPECTROSCO, P22; LONCHARICH RJ, 1990, J MOL BIOL, V215, P439, DOI 10.1016/S0022-2836(05)80363-8; METROPOLIS N, 1953, J CHEM PHYS, V21, P1098; MIYAZAWA S, 1985, MACROMOLECULES, V18, P534, DOI 10.1021/ma00145a039; SALI A, 1994, J MOL BIOL, V235, P1614, DOI 10.1006/jmbi.1994.1110; SHAKHNOVICH E, 1991, PHYS REV LETT, V67, P1665, DOI 10.1103/PhysRevLett.67.1665; SHAKHNOVICH EI, 1989, BIOPHYS CHEM, V34, P187, DOI 10.1016/0301-4622(89)80058-4; STETTER KO, 1992, FRONTIERS OF LIFE, P195; SYKES MF, 1963, J CHEM PHYS, V39, P410, DOI 10.1063/1.1734262; TAKETOMI H, 1975, INT J PEPT PROT RES, V7, P445; WETLAUFE.DB, 1973, P NATL ACAD SCI USA, V70, P697, DOI 10.1073/pnas.70.3.697	22	851	862	3	110	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					248	251		10.1038/369248a0	http://dx.doi.org/10.1038/369248a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	7710478				2022-12-28	WOS:A1994NM06700061
J	FREEMAN, GJ; BORRIELLO, F; HODES, RJ; REISER, H; HATHCOCK, KS; LASZLO, G; MCKNIGHT, AJ; KIM, J; DU, LN; LOMBARD, DB; GRAY, GS; NADLER, LM; SHARPE, AH				FREEMAN, GJ; BORRIELLO, F; HODES, RJ; REISER, H; HATHCOCK, KS; LASZLO, G; MCKNIGHT, AJ; KIM, J; DU, LN; LOMBARD, DB; GRAY, GS; NADLER, LM; SHARPE, AH			UNCOVERING OF FUNCTIONAL ALTERNATIVE CTLA-4 COUNTER-RECEPTOR IN B7-DEFICIENT MICE	SCIENCE			English	Article							T-CELL ACTIVATION; INVIVO; EXPRESSION; MOLECULE; ANTIGEN; CLONES	B7 delivers a costimulatory signal through CD28, resulting in interleukin-2 secretion and T cell proliferation. Blockade of this pathway results in T cell anergy. The in vivo role of B7 was evaluated with B7-deficient mice. These mice had a 70 percent decrease in costimulation of the response to alloantigen. Despite lacking B7 expression, activated B cells from these mice bound CTLA-4 and GL1 monoclonal antibody, demonstrating that alternative CTLA-4 ligand or ligands exist. These receptors are functionally important because the residual allogenic mixed lymphocyte responses were blocked by CTLA4Ig. Characterization of these CTLA-4 ligands should lead to strategies for manipulating the immune response.	BRIGHAM & WOMENS HOSP,DEPT PATHOL,IMMUNOL RES DIV,BOSTON,MA 02115; REPLIGEN CORP,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; NIA,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV LYMPHOCYTE BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616; Borriello, Frank/0000-0003-3957-3685; Lombard, David/0000-0002-4292-0185; Sharpe, Arlene/0000-0002-9736-2109	NCI NIH HHS [CA 40216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORRIELLO F, UNPUB; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; FREEMAN G, UNPUB; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; RAZIWOLF Z, IN PRESS P NATL ACAD; REISER H, 1989, P NATL ACAD SCI USA, V86, P10069, DOI 10.1073/pnas.86.24.10069; SCHREIBER RD, 1985, J IMMUNOL, V134, P1609; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; WILLIAMS IR, 1990, J IMMUNOL, V145, P85; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	21	397	435	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					907	909		10.1126/science.7694362	http://dx.doi.org/10.1126/science.7694362			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	7694362				2022-12-28	WOS:A1993MF43800038
J	BRUGGEMANN, A; PARDO, LA; STUHMER, W; PONGS, O				BRUGGEMANN, A; PARDO, LA; STUHMER, W; PONGS, O			ETHER-A-GO-GO ENCODES A VOLTAGE-GATED CHANNEL PERMEABLE TO K+ AND CA2+ AND MODULATED BY CAMP	NATURE			English	Article							POTASSIUM CHANNEL; XENOPUS OOCYTES; DROSOPHILA-EAG; ION CHANNELS; EXPRESSION; MUTATIONS; CURRENTS; SYSTEM	THE Drosophila ether-a-go-go (eag) mutant is responsible for altered potassium currents in excitable tissue1. These mutants exhibit spontaneous, repetitive firing of action potentials in the motor axons of larval neuromuscular junctions2. The eag gene encodes a polypeptide3 that shares sequence similarities with several different ionic channel proteins, including voltage-gated potassium channels-, an inward rectifier4,5 as well as cyclic-nucleotide-gated channels6. These formal similarities in the derived primary sequences indicate that eag polypeptides might express a new type of ion channel. Here we report the expression by eag RNA in Xenopus oocytes of such a channel which incorporates properties of both voltage- and ligand-gated channels. The permeability of these eag channels to potassium and calcium is dependent on voltage and cyclic AMP. The ability to mediate potassium-outward and calcium-inward currents endows this channel with properties likely to be important in the modulation of synaptic efficiency in both central and peripheral nervous systems.	MAX PLANCK INST EXPTL MED, HERMANN REIN STR 3, D-37075 GOTTINGEN, GERMANY; ZMNH, INST NEURONALE SIGNALVERARBEITUNG, D-20246 HAMBURG, GERMANY; UNIV OVIEDO, DEPT BIOL FUNCT, E-33006 OVIEDO, SPAIN	Max Planck Society; University of Oviedo			Pardo, Luis/C-5066-2013; Stuehmer, Walter/A-2176-2009	Pardo, Luis/0000-0003-1375-4349; Stuehmer, Walter/0000-0002-0642-7764; Bruggemann, Andrea/0000-0002-7325-6715				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; EISENMAN G, 1962, Biophys J, V2, P259; GANETZKY B, 1986, ANNU REV GENET, V20, P13; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HEINEMANN SH, 1992, METHOD ENZYMOL, V207, P131; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; LORY P, 1990, J PHYSIOL-LONDON, V429, P95, DOI 10.1113/jphysiol.1990.sp018246; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; PONGS O, 1992, TRENDS PHARMACOL SCI, V13, P359, DOI 10.1016/0165-6147(92)90109-J; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; STOCKER M, 1991, P ROY SOC B-BIOL SCI, V245, P101, DOI 10.1098/rspb.1991.0094; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; TORO L, 1993, BIOPHYS J, V64, pA2; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WHITE MM, 1990, MOL PHARMACOL, V37, P720; WU CF, 1983, SCIENCE, V220, P1076, DOI 10.1126/science.6302847; ZAGOTTA WN, 1989, NEURON, V3, P773, DOI 10.1016/0896-6273(89)90246-8; ZHONG Y, 1991, SCIENCE, V252, P1562, DOI 10.1126/science.2047864	23	196	202	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1993	365	6445					445	448		10.1038/365445a0	http://dx.doi.org/10.1038/365445a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	7692301				2022-12-28	WOS:A1993LZ63300057
J	DAVIS, S; ALDRICH, TH; IP, NY; STAHL, N; SCHERER, S; FARRUGGELLA, T; DISTEFANO, PS; CURTIS, R; PANAYOTATOS, N; GASCAN, H; CHEVALIER, S; YANCOPOULOS, GD				DAVIS, S; ALDRICH, TH; IP, NY; STAHL, N; SCHERER, S; FARRUGGELLA, T; DISTEFANO, PS; CURTIS, R; PANAYOTATOS, N; GASCAN, H; CHEVALIER, S; YANCOPOULOS, GD			RELEASED FORM OF CNTF RECEPTOR-ALPHA COMPONENT AS A SOLUBLE MEDIATOR OF CNTF RESPONSES	SCIENCE			English	Article							CILIARY NEUROTROPHIC FACTOR; LEUKEMIA-INHIBITORY FACTOR; COLONY-STIMULATING FACTOR; IL-6 SIGNAL TRANSDUCER; MOLECULAR-CLONING; ALLOREACTIVITY INVIVO; REGIONAL DISTRIBUTION; GROWTH-FACTOR; GM-CSF; EXPRESSION	The alpha component of the receptor for ciliary neurotrophic factor (CNTF) differs from other known growth factor receptors in that it is anchored to cell membranes by a glycosyl-phosphatidylinositol linkage. One possible function of this type of linkage is to allow for the regulated release of this receptor component. Cell lines not normally responsive to CNTF responded to treatment with a combination of CNTF and a soluble form of the CNTF alpha receptor component. These findings not only demonstrate that the CNTF receptor alpha chain is a required component of the functional CNTF receptor complex but also reveal that it can function in soluble form as part of a heterodimeric ligand. Potential physiological roles for the soluble CNTF receptor are suggested by its presence in cerebrospinal fluid and by its release from skeletal muscle in response to peripheral nerve injury.	REGENERON PHARMACEUT INC, TARRYTOWN, NY 10591 USA; INSERM, U298, F-49033 ANGERS, FRANCE; HOSP UNIV PENN, DEPT NEUROL, PHILADELPHIA, PA 19104 USA	Regeneron; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; University of Pennsylvania; Pennsylvania Medicine								ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; ASHWORTH A, 1990, NUCLEIC ACIDS RES, V18, P7178, DOI 10.1093/nar/18.23.7178; BARKER PA, 1991, J BIOL CHEM, V266, P19113; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BLOTTNER D, 1989, NEUROSCI LETT, V105, P316, DOI 10.1016/0304-3940(89)90640-X; BRAKENHOFF JPJ, 1987, J IMMUNOL, V139, P4116; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S.M, UNPUB; DISTEFANO PS, IN PRESS J NEUROSCI; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; FANSLOW WC, 1991, J IMMUNOL, V147, P535; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GEARING DP, 1991, CELL, V66, P9, DOI 10.1016/0092-8674(91)90131-H; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1991, J CELL PHYSIOL, V146, P207, DOI 10.1002/jcp.1041460204; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; HONDA M, 1992, J IMMUNOL, V148, P2175; HOUENOU LJ, 1991, J NEUROSCI, V11, P2829; IP NY, 1991, J NEUROSCI, V11, P3124; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; IP NY, IN PRESS PROG GROWTH; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; MALISZEWSKI CR, 1990, J IMMUNOL, V144, P3028; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PERRY VH, 1992, BIOESSAYS, V14, P401, DOI 10.1002/bies.950140610; RENDE M, 1992, GLIA, V5, P25, DOI 10.1002/glia.440050105; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SKAPER SD, 1986, DEV BRAIN RES, V24, P39, DOI 10.1016/0165-3806(86)90171-9; STAHL N, UNPUB; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	51	337	353	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	1993	259	5102					1736	1739		10.1126/science.7681218	http://dx.doi.org/10.1126/science.7681218			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	7681218				2022-12-28	WOS:A1993KT81000032
J	RUBINS, J				RUBINS, J			METASTATIC RENAL-CELL CARCINOMA - RESPONSE TO TREATMENT WITH HUMAN RECOMBINANT ERYTHROPOIETIN	ANNALS OF INTERNAL MEDICINE			English	Note							PHASE-II; INTERLEUKIN-2; CANCER		CANANDAIGUA MED GRP, CANANDAIGUA, NY USA		RUBINS, J (corresponding author), FF THOMPSON HOSP, 350 PARRISH ST, CANANDAIGUA, NY 14424 USA.							BLOOM HJG, 1973, CANCER, V32, P1066, DOI 10.1002/1097-0142(197311)32:5<1066::AID-CNCR2820320507>3.0.CO;2-F; EVERSON TC, 1964, ANN NY ACAD SCI, V114, P721; JANIK JE, 1993, CANCER-AM CANCER SOC, V72, P2656, DOI 10.1002/1097-0142(19931101)72:9<2656::AID-CNCR2820720922>3.0.CO;2-A; MALDAZYS JD, 1986, J UROLOGY, V136, P376, DOI 10.1016/S0022-5347(17)44873-7; NSEYO UO, 1986, UROLOGY, V28, P301, DOI 10.1016/0090-4295(86)90011-7; SLEIJFER DT, 1992, J CLIN ONCOL, V10, P1119, DOI 10.1200/JCO.1992.10.7.1119; WILKINSON MJ, 1993, CANCER, V71, P3601, DOI 10.1002/1097-0142(19930601)71:11<3601::AID-CNCR2820711122>3.0.CO;2-#	7	11	13	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					676	677		10.7326/0003-4819-122-9-199505010-00005	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00005			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702229				2022-12-28	WOS:A1995QV15100005
J	NEASE, RF; KNEELAND, T; OCONNOR, GT; SUMNER, W; LUMPKINS, C; SHAW, L; PRYOR, D; SOX, HC				NEASE, RF; KNEELAND, T; OCONNOR, GT; SUMNER, W; LUMPKINS, C; SHAW, L; PRYOR, D; SOX, HC			VARIATION IN PATIENT UTILITIES FOR OUTCOMES OF THE MANAGEMENT OF CHRONIC STABLE ANGINA - IMPLICATIONS FOR CLINICAL-PRACTICE GUIDELINES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREFERENCES	Objective.-Although practice guidelines sometimes make recommendations based on symptom severity, they rarely account for how patients feel about their symptoms. To investigate the possible importance of patient preferences in treatment of ischemic heart disease, we assessed attitudes toward symptoms in patients with angina pectoris. Design.-Case series. Setting.-Ambulatory cardiology clinics at two tertiary care medical centers. Patients.-A total of 220 subjects were selected from 589 patients with chronic stable angina referred from cardiologists to achieve patient samples balanced for sex, race, and angina severity. Main Outcome Measures.-We measured patients' attitudes toward their angina using the rating scale, time trade-off, and standard gamble utility metrics. Reliability of measurements was evaluated by repeating the assessments 2 weeks later on 50 willing patients. Results.-While the mean responses followed the expected patterns (those with more severe Canadian Cardiovascular Society scores chose lower utilities), attitudes toward symptoms varied substantially among patients with similarly severe angina. For example, there was a 33% chance that a patient with class II angina had a time trade-off utility that was lower (ie, more bothered by symptoms) than a patient with more severe angina (class III/IV). This variation in utilities was not due to random error in the assessments. Conclusions.-Angina patients with similar functional limitation vary considerably in their tolerance for their symptoms, as measured by utilities. Our findings suggest that guidelines for the management of ischemic heart disease should be based on the preferences of the individual patient rather than on symptom severity alone.	DARTMOUTH COLL, SCH MED, DEPT COMMUNITY & FAMILY MED, CTR EVALUAT CLIN SCI, HANOVER, NH 03755 USA; DARTMOUTH COLL, SCH MED, DEPT MED, HANOVER, NH 03755 USA; UNIV KENTUCKY, DEPT FAMILY PRACTICE, LEXINGTON, KY USA; DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOL, DURHAM, NC 27710 USA	Dartmouth College; Dartmouth College; University of Kentucky; Duke University			Sumner, Walton/H-5045-2019		AHRQ HHS [HS06503-04] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CONOVER W. J, 1980, PRACTICAL NONPARAMET; COX J, 1992, ANN INTERN MED, V117, P677, DOI 10.7326/0003-4819-117-8-677; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1737, DOI 10.1001/jama.264.13.1737; GRADY D, 1992, ANN INTERN MED, V117, P1038; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; KIRKLIN JW, 1991, CIRCULATION, V83, P1125; NEASE R, 1993, CLIN RES, V41, pA181; NEASE RF, 1994, MED DECIS MAKING, V11, P382; OCONNOR AMC, 1987, J CHRON DIS, V40, P811, DOI 10.1016/0021-9681(87)90133-0; Owens D K, 1993, Jt Comm J Qual Improv, V19, P248; READ JL, 1984, MED DECIS MAKING, V4, P315, DOI 10.1177/0272989X8400400307; Sox HC, 1988, MED DECISION MAKING; SUMNER W, 1991, 15TH P ANN S COMP AP, P701; Weinstein MC, 1980, CLIN DECISION ANAL	16	254	256	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1185	1190		10.1001/jama.273.15.1185	http://dx.doi.org/10.1001/jama.273.15.1185			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT100	7707625				2022-12-28	WOS:A1995QT10000026
J	SKUSE, GR; LUDLOW, JW				SKUSE, GR; LUDLOW, JW			TUMOR-SUPPRESSOR GENES IN DISEASE AND THERAPY	LANCET			English	Review							WILMS-TUMOR; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; RETINOBLASTOMA GENE; HUMAN CHROMOSOME-11; HUMAN CANCER; P53 GENE; EXPRESSION; TRANSCRIPTS; PROTEIN; HETEROZYGOSITY		UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester	SKUSE, GR (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT MED,DIV GENET,BOX 641,601 ELMWOOD AVE,ROCHESTER,NY 14642, USA.				NATIONAL CANCER INSTITUTE [R29CA056940, R01CA055173, R29CA055173] Funding Source: NIH RePORTER; NCI NIH HHS [CA56940, CA55173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; BENEDICT WF, 1988, CANCER, V62, P1691, DOI 10.1002/1097-0142(19881015)62:1+<1691::AID-CNCR2820621306>3.0.CO;2-5; BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CHANG CY, 1993, CELL GROWTH DIFFER, V4, P1057; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ECCLES MR, 1994, ONCOGENE, V9, P2059; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; FUJIWARA T, 1994, J NATL CANCER I, V86, P1458, DOI 10.1093/jnci/86.19.1458; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOUSMAN DE, 1986, COLD SPRING HARB SYM, V51, P837; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1976, NEW ENGL J MED, V295, P1120, DOI 10.1056/NEJM197611112952007; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; LAWLOR KG, 1992, ANN NY ACAD SCI, V600, P283; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NISHI T, 1991, ONCOGENE, V6, P1555; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; RICCARDI VM, 1986, NEUROFIBROMATOSIS PH, P214; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; SKUSE GR, 1991, AM J HUM GENET, V49, P600; SKUSE GR, 1989, GENE CHROMOSOME CANC, V1, P36, DOI 10.1002/gcc.2870010107; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUZUKI Y, 1991, BIOCHEM BIOPH RES CO, V181, P955, DOI 10.1016/0006-291X(91)92029-J; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; UCHIDA T, 1992, BIOCHEM BIOPH RES CO, V187, P332, DOI 10.1016/S0006-291X(05)81497-4; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERTELECKI W, 1988, NEW ENGL J MED, V319, P278, DOI 10.1056/NEJM198808043190505; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	51	28	28	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					902	906		10.1016/S0140-6736(95)90015-2	http://dx.doi.org/10.1016/S0140-6736(95)90015-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707816	hybrid			2022-12-28	WOS:A1995QR06700015
J	WEST, SG; WOODBURN, J				WEST, SG; WOODBURN, J			ABC OF RHEUMATOLOGY - PAIN IN THE FOOT	BRITISH MEDICAL JOURNAL			English	Article											WEST, SG (corresponding author), UNIV HUDDERSFIELD,SCH HUMAN & HLTH SCI,DEPT PODIATRY,HUDDERSFIELD,W YORKSHIRE,ENGLAND.			Woodburn, James/0000-0002-5497-8739					0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 1	1995	310	6983					860	864		10.1136/bmj.310.6983.860	http://dx.doi.org/10.1136/bmj.310.6983.860			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711628	Green Published			2022-12-28	WOS:A1995QQ85700032
J	KINLEN, LJ; DICKSON, M; STILLER, CA				KINLEN, LJ; DICKSON, M; STILLER, CA			CHILDHOOD LEUKEMIA AND NON-HODGKINS-LYMPHOMA NEAR LARGE RURAL CONSTRUCTION SITES, WITH A COMPARISON WITH SELLAFIELD NUCLEAR SITE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFECTIVE BASIS; YOUNG-PEOPLE; ENGLAND; WALES; MORTALITY; INSTALLATIONS; EXPOSURE; CUMBRIA; EXCESS	Objective-To determine whether population mixing produced by large, non-nuclear construction projects in rural areas is associated with an increase in childhood leukaemia and non-Hoodgkin's lymhoma. Design-A study of the incidence of leukaemia and non-Hodgkin's lymphoma among children living near large construction projects in Britain since 1945, situated more than 20 km from a population centre, involving a workforce of more than 1000, and built over three or more calendar years. For periods before 1962 mortality was studied. Setting-Areas within 10 km of relevant sites, and the highland counties of Scotland with many hydroelectric schemes. Subjects-Children aged under 15. Results-A 37% excess of leukaemia and non-Hodgkin's lymphoma at 0-14 years of age was recorded during construction and the following calendar year. The excesses were greater at times when construction workers and operating staff overlapped (72%), particularly in areas of relatively high social class. For several sites the excesses were similar to or greater than that near the nuclear site of Sellafield (67%), which is distinctive in its large workforce with many construction workers. Seascale, near Sellafield, with a ninefold increase had an unusually high proportion of residents in social class I. The only study parish of comparable social class also showed a significant excess, with a confidence interval that included the Seascale excess. Conclusion-The findings support the infection hypothesis and reinforce the view that the excess of childhood leukaemia and non-Hodgkin's lymphoma near Sellafield has a similar explanation.	UNIV OXFORD, DEPT PAEDIAT,CHILDHOOD CANC RES GRP, OXFORD OX2 6HJ, ENGLAND	University of Oxford	KINLEN, LJ (corresponding author), UNIV OXFORD, RADCLIFFE INFIRM, DEPT PUBL HLTH & PRIMARY CARE, CANC RES CAMPAIGN EPIDEMIOL UNIT, OXFORD OX2 6HE, ENGLAND.			Stiller, Charles/0000-0002-3006-7869				ANDERSON R M, 1991; BITHELL JF, 1994, BRIT MED J, V309, P501, DOI 10.1136/bmj.309.6953.501; BROWN WMC, 1960, BRIT MED J, V2, P1539, DOI 10.1136/bmj.2.5212.1539; BROWN WMC, 1957, LEUKAEMIA APLSTIC AN; COOKMOZAFFARI PJ, 1989, BRIT J CANCER, V59, P476, DOI 10.1038/bjc.1989.99; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; DRAPER GJ, 1993, BRIT MED J, V306, P89, DOI 10.1136/bmj.306.6870.89; FOGARTY MP, 1945, PROSPECTS IND AREAS; FULTON AA, 1952, P I CIVIL ENG PT 1, V1, P248; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1993, BIOMED PHARMACOTHER, V47, P429, DOI 10.1016/0753-3322(93)90338-L; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1993, BRIT MED J, V306, P1718, DOI 10.1136/bmj.306.6894.1718; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; KINLEN LJ, 1993, BRIT MED J, V306, P930, DOI 10.1136/bmj.306.6882.930-a; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; KINLEN LJ, 1994, BRIT MED J, V309, P1197, DOI 10.1136/bmj.309.6963.1197; LANGFORD I, 1991, SOC SCI MED, V33, P435, DOI 10.1016/0277-9536(91)90325-7; MCKAY K, 1989, VISION GREATNESS HIS; Payne P. L., 1988, HYDRO; 1954, BRITAIN OFFICIAL HDB; 1993, HLTH SAFETY EXECUTIV	26	86	86	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 25	1995	310	6982					763	768		10.1136/bmj.310.6982.763	http://dx.doi.org/10.1136/bmj.310.6982.763			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP609	7711579	Green Published			2022-12-28	WOS:A1995QP60900015
J	GIBBONS, RJ; PICKETTS, DJ; VILLARD, L; HIGGS, DR				GIBBONS, RJ; PICKETTS, DJ; VILLARD, L; HIGGS, DR			MUTATIONS IN A PUTATIVE GLOBAL TRANSCRIPTIONAL REGULATOR CAUSE X-LINKED MENTAL-RETARDATION WITH ALPHA-THALASSEMIA (ATR-X SYNDROME)	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIVATOR SNF2; GENE; CHROMATIN; YEAST; EXPRESSION; HELICASES; PROTEIN; FAMILY; REGION	The ATR-X syndrome is an X-linked disorder comprising severe psychomotor retardation, characteristic facial features, genital abnormalities, and alpha-thalassemia. We have shown that ATR-X results from diverse mutations of XH2, a member of a subgroup of the helicase superfamily that includes proteins involved in a wide range of cellular functions, including DNA recombination and repair (RAD16, RAD54, and ERCC6) and regulation of transcription (SWI2/SNF2, MOT1, and brahma). The complex ATR-X phenotype suggests that XH2, when mutated, down-regulates expression of several genes, including the alpha-globin genes, indicating that it could be a global transcriptional regulator, In addition to its role in the ATR-X syndrome, XH2 may be a good candidate for other forms of X-linked mental retardation mapping to Xq13.	JOHN RADCLIFFE HOSP,INST MOLEC MED,MRC,MOLEC HAEMATOL UNIT,OXFORD OX3 9DU,ENGLAND; INSERM,U406,EQUIPE 3,F-13351 MARSEILLE 5,FRANCE	University of Oxford; Institut National de la Sante et de la Recherche Medicale (Inserm)			Villard, Laurent/E-3941-2016; Gibbons, Richard/E-6937-2011	Villard, Laurent/0000-0001-6657-5008; Gibbons, Richard/0000-0002-7680-9311				BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; BROUGHTON BC, 1994, NAT GENET, V7, P189, DOI 10.1038/ng0694-189; BROWN CJ, 1990, NUCLEIC ACIDS RES, V18, P4191, DOI 10.1093/nar/18.14.4191; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DELMAS V, 1993, P NATL ACAD SCI USA, V90, P2414, DOI 10.1073/pnas.90.6.2414; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GECZ J, 1994, HUM MOL GENET, V3, P39, DOI 10.1093/hmg/3.1.39; GECZ J, 1993, HUM MOL GENET, V2, P1389, DOI 10.1093/hmg/2.9.1389; GIBBONS RJ, 1992, AM J HUM GENET, V51, P1136; GIBBONS RJ, IN PRESS AM J MED GE; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GRAEBER MB, 1992, P NATL ACAD SCI USA, V89, P8245, DOI 10.1073/pnas.89.17.8245; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; IOST I, 1994, NATURE, V372, P193, DOI 10.1038/372193a0; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; KOLSTO AB, 1993, J MOL BIOL, V230, P684, DOI 10.1006/jmbi.1993.1185; LEHRACH H., 1990, GENOME ANAL, P39; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; MCPHERSON E, 1995, IN PRESS AM J MED GE; NERI G, 1994, AM J MED GENET, V51, P542, DOI 10.1002/ajmg.1320510451; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; REARDON W, 1995, IN PRESS AM J MED GE; SAMBROOK J, 1989, MOL C LONING LABORAT; SAUGIERVEBER P, 1995, IN PRESS AM J MED GE; SAUGIERVEBER P, 1995, MOL CLONING LABORATO; SCHLESSINGER D, 1993, CYTOGENET CELL GENET, V64, P148; STAYTON CL, 1994, HUM MOL GENET, V3, P1957, DOI 10.1093/hmg/3.11.1957; STRAUSS EJ, 1991, GENE DEV, V5, P629, DOI 10.1101/gad.5.4.629; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THEIN SL, 1991, BRIT J HAEMATOL, V79, P113, DOI 10.1111/j.1365-2141.1991.tb08016.x; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TSUCHIYA E, 1992, EMBO J, V11, P4017, DOI 10.1002/j.1460-2075.1992.tb05495.x; VYAS P, 1992, CELL, V69, P781, DOI 10.1016/0092-8674(92)90290-S; WANG LH, 1994, GENOMICS, V22, P590, DOI 10.1006/geno.1994.1432; WEATHERALL DJ, 1981, NEW ENGL J MED, V305, P607, DOI 10.1056/NEJM198109103051103; WILKIE AOM, 1990, AM J HUM GENET, V46, P1127; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	46	484	496	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					837	845		10.1016/0092-8674(95)90287-2	http://dx.doi.org/10.1016/0092-8674(95)90287-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697714	Bronze			2022-12-28	WOS:A1995QP61200003
J	RYAN, M				RYAN, M			RUSSIAN REPORT - ALCOHOLISM AND RISING MORTALITY IN THE RUSSIAN-FEDERATION	BRITISH MEDICAL JOURNAL			English	Article								In the Russian Federation today the high incidence of alcoholism and drunkenness helps to account for rising death rates, more particularly among the male population. During the mid-1980s a significant reduction in deaths from alcohol related diseases was achieved by state action in curtailing the supply of alcohol. However, official data disclose a pattern of sharply increased consumption per head since 1987, with high proof drinks-especially vodka-now forming a larger share in the total. In current economic conditions the effects of a traditional macho drinking culture are exacerbated by a reduction of state control over the quality of alcohol available for purchase. A substantial increase has occurred in deaths from most principal causes, with a disproportionate increase in deaths from non-natural causes, including deaths caused predominantly by alcohol. Average expectation of life at birth has fallen especially sharply for men; by 1993 it had slumped to 59.0 years-that is, to below the age at which a pension starts to be paid.			RYAN, M (corresponding author), UNIV COLL SWANSEA,CTR RUSSIAN & E EUROPEAN STUDIES,SWANSEA SA2 8PP,W GLAM,WALES.							NEMTSOV A, 1994, IZVESZIYA, P19; RYAN M, 1990, CONT SOVIET SOC STAT, P253; 1993, ROSSIISKIE VESTI, V255, P4; 1994, ZDRAVOOKHRANENIE ROS, V3, P3	4	63	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					646	648						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QL984	7703754				2022-12-28	WOS:A1995QL98400023
J	BRODIE, MJ; RICHENS, A; YUEN, AWC				BRODIE, MJ; RICHENS, A; YUEN, AWC			DOUBLE-BLIND COMPARISON OF LAMOTRIGINE AND CARBAMAZEPINE IN NEWLY-DIAGNOSED EPILEPSY	LANCET			English	Article							DRUG; MECHANISM	Lamotrigine has been licensed widely as adjunctive therapy for partial and secondary generalised seizures. Use of the drug as monotherapy was investigated in a double-blind, randomised, parallel-group comparison with carbamazepine in newly diagnosed epilepsy. After 4 weeks of planned, fixed dose escalation, doses were adjusted according to efficacy, adverse events, and plasma concentrations. 151 of 260 patients (131 lamotrigine, 129 carbamazepine) in eight UK centres completed the 48-week trial. No differences in efficacy between the drugs were found for partial seizures with or without secondary generalisation or for primary generalised tonic-clonic seizures. The proportion of patients maintained seizure-free during the last 24 weeks of treatment was almost the same in both groups (39% lamotrigine, 38% carbamazepine). More patients with primary generalised seizures (47% both groups) than those with a focal onset (35%, 37%) were fully controlled. Overall, fewer patients on lamotrigine than on carbamazepine withdrew because of adverse events (15 vs 27%). The commonest side-effect leading to withdrawal with either drug was rash (9%, 13%). Sleepiness was less common in lamotrigine than in carbamazepine recipients (12 vs 22%, p<0.05). More lamotrigine than carbamazepine recipients (65 vs 51%, p=0.018) completed the study (hazard ratio 1.57 [95% Cl 1.07-2.31]). Lamotrigine and carbamazepine showed similar efficacy against partial onset seizures and primary generalised tonic-clonic seizures in newly diagnosed epilepsy. Lamotrigine, however, was better tolerated.	UNIV WALES HOSP,CARDIFF,S GLAM,WALES; WELLCOME RES LABS,BECKENHAM,KENT,ENGLAND	Cardiff University; GlaxoSmithKline; Wellcome Research Laboratories	BRODIE, MJ (corresponding author), WESTERN INFIRM & ASSOCIATED HOSP,DEPT MED & THERAPEUT,EPILEPSY RES UNIT,GLASGOW G11 6NT,LANARK,SCOTLAND.							[Anonymous], 1981, EPILEPSIA, V22, P489; BRODIE MJ, 1988, BRIT MED J, V296, P1110, DOI 10.1136/bmj.296.6629.1110; BRODIE MJ, 1992, LANCET, V339, P1397, DOI 10.1016/0140-6736(92)91207-O; BRODIE MJ, 1994, EPILIPSIA, V35, P69; BRODIE MJ, IN PRESS N ENGL J ME; CHADWICK D, 1984, J NEUROL NEUROSUR PS, V47, P642, DOI 10.1136/jnnp.47.6.642; GOA KL, 1993, DRUGS, V46, P152, DOI 10.2165/00003495-199346010-00009; LEACH JP, IN PRESS ANTIEPILEPT; LEACH MJ, 1986, EPILEPSIA, V27, P490, DOI 10.1111/j.1528-1157.1986.tb03573.x; LEES G, 1993, BRAIN RES, V612, P190, DOI 10.1016/0006-8993(93)91660-K; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; RAMBECK B, 1993, CLIN PHARMACOKINET, V25, P433, DOI 10.2165/00003088-199325060-00003; RICHENS A, 1994, J NEUROL NEUROSUR PS, V57, P682, DOI 10.1136/jnnp.57.6.682; SMITH D, 1992, J NEUROL NEUROSUR PS, V55, P416; 1989, LANCET, V2, P595	15	531	539	0	31	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					476	479		10.1016/S0140-6736(95)90581-2	http://dx.doi.org/10.1016/S0140-6736(95)90581-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7710545				2022-12-28	WOS:A1995QH92900008
J	MARTENSON, C; STONE, K; REEDY, M; SHEETZ, M				MARTENSON, C; STONE, K; REEDY, M; SHEETZ, M			FAST AXONAL-TRANSPORT IS REQUIRED FOR GROWTH CONE ADVANCE	NATURE			English	Article							NERVE-CELLS; CYTOSKELETON; DYNAMICS; MEMBRANE; TUBULIN; TENSION	GROWTH cones are capable of advancing despite linkage to a stationary axonal cytoskeleton in chick and murine dorsal root ganglion neurites1,2. Several lines of evidence point to the growth cone as the site of cytoskeletal elongation3,4. Fast axonal transport is probably the means by which cytoskeletal elements5 or cofactors are rapidly moved through the axon. We report that direct, but reversible, inhibition of fast axonal transport with laser optical tweezers inhibits growth cone motility if cytoskeletal attachment to the cell body is maintained. Advancement ceases after a distance-dependent lag period which correlates with the rate of fast axonal transport. But severing the axonal cytoskeleton with the laser tweezers allows growth cones to advance considerably further. We suggest that axon elongation requires fast axonal transport but growth cone motility does not.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University								ASHKIN A, 1990, NATURE, V348, P346, DOI 10.1038/348346a0; BAMBURG JR, 1986, NATURE, V321, P788, DOI 10.1038/321788a0; BRAY D, 1979, J CELL SCI, V37, P391; BROWN A, 1992, J CELL BIOL, V119, P867, DOI 10.1083/jcb.119.4.867; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DENNERLL TJ, 1989, J CELL BIOL, V109, P3073, DOI 10.1083/jcb.109.6.3073; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; HOLLENBECK PJ, 1987, J CELL BIOL, V105, P2827, DOI 10.1083/jcb.105.6.2827; KUCIK DF, 1991, J CELL BIOL, V114, P1029, DOI 10.1083/jcb.114.5.1029; LAMOUREUX P, 1989, Nature (London), V340, P159, DOI 10.1038/340159a0; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; OKABE S, 1990, NATURE, V343, P479, DOI 10.1038/343479a0; OKABE S, 1988, J CELL BIOL, V107, P651, DOI 10.1083/jcb.107.2.651; SHAW G, 1977, EXP CELL RES, V104, P55, DOI 10.1016/0014-4827(77)90068-4	14	44	45	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					66	69		10.1038/366066a0	http://dx.doi.org/10.1038/366066a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	7694151				2022-12-28	WOS:A1993MF00700055
J	TAN, YH				TAN, YH			YIN AND YANG OF PHOSPHORYLATION IN CYTOKINE SIGNALING	SCIENCE			English	Editorial Material							OKADAIC ACID MIMICS; TRANSCRIPTION FACTOR; INTERFERON-ALPHA; PROTEIN; TYROSINE; PHOSPHATASE; ACTIVATION; KINASE; CALCINEURIN; EXPRESSION				TAN, YH (corresponding author), NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,10 KENT RIDGE CRESCENT,SINGAPORE 0511,SINGAPORE.							Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CAO XM, 1993, J BIOL CHEM, V268, P16949; CAO XM, 1992, J BIOL CHEM, V267, P12991; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVIDSON WF, 1979, J IMMUNOL, V122, P884; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUESDON F, 1993, J BIOL CHEM, V261, P358; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; GUY GR, 1992, J BIOL CHEM, V267, P1846; GUY GR, 1993, J BIOL CHEM, V268, P2141; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HIGUCHI T, 1990, J INTERFERON RES, V10, P413, DOI 10.1089/jir.1990.10.413; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; KORETZKY GA, 1990, NATURE, V346, P2037; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MENSON SD, IN PRESS J BIOL CHEM; MIRESLUIS AR, 1991, J BIOL CHEM, V266, P18113; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHULTZ LD, 1987, ANNU REV IMMUNOL, V5, P367, DOI 10.1146/annurev.iy.05.040187.002055; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; THOMAS JD, 1993, J BIOL CHEM, V261, P355; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; YAP WH, 1986, SCIENCE, V234, P355, DOI 10.1126/science.2429366; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	31	28	32	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					376	377		10.1126/science.7692598	http://dx.doi.org/10.1126/science.7692598			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	7692598				2022-12-28	WOS:A1993MB85900043
J	KARUPIAH, G; XIE, QW; BULLER, RML; NATHAN, C; DUARTE, C; MACMICKING, JD				KARUPIAH, G; XIE, QW; BULLER, RML; NATHAN, C; DUARTE, C; MACMICKING, JD			INHIBITION OF VIRAL REPLICATION BY INTERFERON-GAMMA-INDUCED NITRIC-OXIDE SYNTHASE	SCIENCE			English	Article							VACCINIA VIRUS; RIBONUCLEOTIDE REDUCTASE; PROTEIN-KINASE; CELLS; MACROPHAGES; BIOCHEMISTRY; MECHANISM; ARGINASE; PRODUCT; SYSTEM	Interferons (IFNs) induce antiviral activity in many cell types. The ability of IFN-gamma to inhibit replication of ectromelia, vaccinia, and herpes simplex-1 viruses in mouse macrophages correlated with the cells' production of nitric oxide (NO). Viral replication was restored in IFN-gamma-treated macrophages exposed to inhibitors of NO synthase. Conversely, epithelial cells with no detectable NO synthesis restricted viral replication when transfected with a complementary DNA encoding inducible NO synthase or treated with organic compounds that generate NO. In mice, an inhibitor of NO synthase converted resolving ectromelia virus infection into fulminant mousepox. Thus, induction of NO synthase can be necessary and sufficient for a substantial antiviral effect of IFN-gamma.	CORNELL UNIV, MED CTR,COLL MED,DEPT MED,DIV HEMATOL ONCOL, BEATRICE & SAMUEL A SEAVER LAB, NEW YORK, NY 10021 USA	Cornell University	KARUPIAH, G (corresponding author), NIAID, VIRAL DIS LAB, BETHESDA, MD 20892 USA.		Karupiah, Gunasegaran/J-4707-2013	Karupiah, Gunasegaran/0000-0001-6306-4405	NCI NIH HHS [CA43610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CONSTANTOULAKIS P, 1993, SCIENCE, V259, P1314, DOI 10.1126/science.7680491; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; DAVIES MV, 1992, J VIROL, V66, P1943, DOI 10.1128/JVI.66.4.1943-1950.1992; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; DING AH, 1988, J IMMUNOL, V141, P2407; DRAPIER JC, 1988, EUR J IMMUNOL, V18, P1587, DOI 10.1002/eji.1830181018; HASSANAIN HH, 1993, J BIOL CHEM, V268, P5077; HECK DE, 1992, J BIOL CHEM, V267, P21277; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1990, INT CONGR SER, V897, P189; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; ISRAEL N, 1992, J IMMUNOL, V149, P3386; KARUPIAH G, 1990, J EXP MED, V172, P1495, DOI 10.1084/jem.172.5.1495; KARUPIAH G, 1993, J VIROL, V67, P4214, DOI 10.1128/JVI.67.7.4214-4226.1993; KARUPIAH G, UNPUB; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LANDER HM, 1993, J IMMUNOL, V150, P1509; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1992, INFLAMMATION BASIC P, P265; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; PAEZ E, 1984, VIROLOGY, V134, P12, DOI 10.1016/0042-6822(84)90268-X; POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; RUBY J, 1991, LYMPHOKINE CYTOK RES, V10, P353; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SEN GC, 1992, J BIOL CHEM, V267, P5017; SETHI KK, 1983, IMMUNOBIOLOGY, V165, P459, DOI 10.1016/S0171-2985(83)80069-2; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; VILCEK J, 1990, PEPTIDE GROWTH FACTO, V2, P3; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WILDY P, 1982, INFECT IMMUN, V37, P40, DOI 10.1128/IAI.37.1.40-45.1982; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; XIE Q, UNPUB; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	40	757	782	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1993	261	5127					1445	1448		10.1126/science.7690156	http://dx.doi.org/10.1126/science.7690156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	7690156				2022-12-28	WOS:A1993LW54900032
J	HAWKEN, M; NUNN, P; GATHUA, S; BRINDLE, R; GODFREYFAUSSETT, P; GITHUI, W; ODHIAMBO, J; BATCHELOR, B; GILKS, C; MORRIS, J; MCADAM, K				HAWKEN, M; NUNN, P; GATHUA, S; BRINDLE, R; GODFREYFAUSSETT, P; GITHUI, W; ODHIAMBO, J; BATCHELOR, B; GILKS, C; MORRIS, J; MCADAM, K			INCREASED RECURRENCE OF TUBERCULOSIS IN HIV-1-INFECTED PATIENTS IN KENYA	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; MORTALITY; KINSHASA; ZAIRE	There is evidence that in human immunodeficiency virus 1 (HIV-1) infected patients with tuberculosis the rate of recurrence of tuberculosis is increased in those patients treated with a standard thiacetazone-containing regimen. To assess the impact of HIV-1 on tuberculosis in Kenya, patients with tuberculosis were studied prospectively. After treatment with either a standard thiacetazone plus isoniazid regimen or a short-course thiacetazone-containing regimen, overall recurrence rate of tuberculosis was 34 times greater in 58 HIV-1-positive patients than in 138 HIV-1-negative patients (adjusted rate ratio 33.8, 95% CI 4.3-264). Recurrence in the HIV-1-positive group was strongly associated with a cutaneous hypersensitivity reaction due to thiacetazone during initial treatment (rate ratio 13.2, 95% CI 3.1-56.2). In all patients with a cutaneous hypersensitivity reaction ethambutol was substituted for thiacetazone. No significant association was found between recurrence among HIV-1-positive patients and initial resistance, initial treatment regimen, a diagnosis of AIDS (WHO definition), or poor compliance. DNA fingerprinting suggested that both relapse and new infection may have produced recurrence of tuberculosis. In patients who had a cutaneous hypersensitivity reaction, increased recurrence rate may have been related to interruption of treatment, subsequent poor compliance, or more advanced immunosuppression. Alternatively, a change to the combination of ethambutol and isoniazid in the continuation phase for 11 months only may not be adequate.	KENYA GOVT MED RES CTR,NAIROBI,KENYA; PUBL HLTH LAB,OXFORD,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND; KENYATTA NATL HOSP,HOSP INFECT DIS,NAIROBI,KENYA	Kenya Medical Research Institute; University of London; London School of Hygiene & Tropical Medicine; Kenyatta National Hospital	HAWKEN, M (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		Gilks, Charles/B-4184-2012	Gilks, Charles/0000-0002-8953-3123	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; CITRON KM, 1983, OXFORD TXB MED, V1; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; GODFREYFAUSSETT P, 1991, LANCET, V337, P176, DOI 10.1016/0140-6736(91)90840-L; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2052; NARAIN JP, IN PRESS TUBERC LUNG; NDINYAACHOLA JO, 1991, 7 INT C AIDS FLOR; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; NUNN P, 1991, LANCET, V337, P627; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; Slutkin G, 1988, Bull Int Union Tuberc Lung Dis, V63, P21; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SORIANO E, 1988, AIDS, V2, P429, DOI 10.1097/00002030-198812000-00003; 1992, WKLY EPIDEMIOL REC, V67, P1; 1990, NATIONAL LEPROSY TUB	17	125	127	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					332	337		10.1016/0140-6736(93)91474-Z	http://dx.doi.org/10.1016/0140-6736(93)91474-Z			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	7687729				2022-12-28	WOS:A1993LQ86800012
J	SATO, Y; NAKATA, K; KATO, Y; SHIMA, M; ISHII, N; KOJI, T; TAKETA, K; ENDO, Y; NAGATAKI, S				SATO, Y; NAKATA, K; KATO, Y; SHIMA, M; ISHII, N; KOJI, T; TAKETA, K; ENDO, Y; NAGATAKI, S			EARLY RECOGNITION OF HEPATOCELLULAR-CARCINOMA BASED ON ALTERED PROFILES OF ALPHA-FETOPROTEIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LECTIN AFFINITY ELECTROPHORESIS; LIVER-DISEASE; CIRRHOSIS; MICROHETEROGENEITY; DIAGNOSIS; ANTIBODY; SERUM; UTILITY; AGAROSE; BENIGN	Background. The sugar-chain structures of circulating alpha-fetoprotein in patients with hepatocellular carcinomas differ from those in patients with cirrhosis. We studied the reactivity of alpha-fetoprotein with two lectins, Lens culinaris agglutinin A and erythroagglutinating phytohemagglutinin, to monitor the evolution of hepatocellular carcinoma in patients with cirrhosis. Methods. Among 361 patients with cirrhosis caused mainly by chronic hepatitis B or hepatitis C virus infection, 33 with base-line serum alpha-fetoprotein concentrations greater-than-or-equal-to 30 ng per milliliter were found to have hepatocellular carcinomas during a mean follow-up of 35 months. The lectin-reactive profiles of the alpha-fetoprotein in the serum of these 33 patients were analyzed and compared with those in the serum of 32 patients with cirrhosis who had increased base-line serum alpha-fetoprotein concentrations and were followed for at least 24 months but in whom hepatocellular carcinoma did not develop. Results. At the time of tumor detection, 24 (73 percent) of the 33 patients with cirrhosis and hepatocellular carcinoma had higher percentages of L. culinaris agglutinin A-reactive alpha-fetoprotein (alpha-fetoprotein L3), erythroagglutinating phytohemagglutinin-reactive alpha-fetoprotein (alpha-fetoprotein P4+P5), or both than the 32 patients with cirrhosis but no hepatocellular carcinoma. Among the 24 patients, one or both of the markers were first elevated 3 to 18 months before the hepatocellular carcinoma was detected by imaging techniques. Conclusions. Measurements of the alpha-fetoprotein L3 and alpha-fetoprotein P4+P5 fractions of serum alpha-fetoprotein allow the differentiation of hepatocellular carcinoma from cirrhosis in some cases and serve as predictive markers for the development of hepatocellular carcinoma during the follow-up of patients with cirrhosis.	NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 1,1-7-1 SAKAMOTO,NAGASAKI 852,JAPAN; SANRAKU HOSP,TOKYO,JAPAN; NAGASAKI UNIV,HLTH RES CTR,NAGASAKI 852,JAPAN; OKAYAMA UNIV,SCH MED,DEPT PUBL HLTH,OKAYAMA 700,JAPAN	Nagasaki University; Nagasaki University; Okayama University				nagataki, shigenobu/0000-0002-9974-3554				ALPERT E, 1978, GASTROENTEROLOGY, V74, P856; ALPERT E, 1972, J BIOL CHEM, V247, P3792; AOYAGI Y, 1988, CANCER-AM CANCER SOC, V61, P769, DOI 10.1002/1097-0142(19880215)61:4<769::AID-CNCR2820610422>3.0.CO;2-M; BLOOMER JR, 1975, JAMA-J AM MED ASSOC, V233, P38, DOI 10.1001/jama.233.1.38; BREBOROWICZ J, 1981, SCAND J IMMUNOL, V14, P15, DOI 10.1111/j.1365-3083.1981.tb00179.x; BUAMAH PK, 1986, CLIN CHEM, V32, P2083; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; DU MQ, 1991, CANCER, V67, P476, DOI 10.1002/1097-0142(19910115)67:2<476::AID-CNCR2820670226>3.0.CO;2-8; EBARA M, 1986, GASTROENTEROLOGY, V90, P289, DOI 10.1016/0016-5085(86)90923-6; FURUKAWA R, 1984, TUMOUR BIOL, V5, P327; HIRAI H, 1987, TUMOR BIOL, V8, P86, DOI 10.1159/000217500; KERCKAERT JP, 1979, BIOCHIM BIOPHYS ACTA, V576, P99, DOI 10.1016/0005-2795(79)90488-4; KUBO Y, 1978, GASTROENTEROLOGY, V74, P578; LOK ASF, 1989, HEPATOLOGY, V9, P110, DOI 10.1002/hep.1840090119; Miyazaki J, 1981, ACTA HEPATOL JPN TOK, V22, P1559; NAKATA K, 1992, CRIT REV ONCOL HEMAT, V13, P93, DOI 10.1016/1040-8428(92)90019-M; NISHIOKA K, 1991, CANCER, V67, P429, DOI 10.1002/1097-0142(19910115)67:2<429::AID-CNCR2820670218>3.0.CO;2-#; OKA H, 1990, HEPATOLOGY, V12, P680, DOI 10.1002/hep.1840120411; OKUDA K, 1986, HEPATOLOGY, V6, P729, DOI 10.1002/hep.1840060432; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; SHIMIZU K, 1993, CLIN CHIM ACTA, V214, P3, DOI 10.1016/0009-8981(93)90297-H; SHINAGAWA T, 1984, GASTROENTEROLOGY, V86, P495; SMITH CJ, 1973, BIOCHIM BIOPHYS ACTA, V317, P231, DOI 10.1016/0005-2795(73)90218-3; TAKETA K, 1985, ELECTROPHORESIS, V6, P492, DOI 10.1002/elps.1150061005; TAKETA K, 1990, GASTROENTEROLOGY, V99, P508, DOI 10.1016/0016-5085(90)91034-4; TAKETA K, 1990, HEPATOLOGY, V12, P1420, DOI 10.1002/hep.1840120625; TAKETA K, 1986, CANCER LETT, V31, P325, DOI 10.1016/0304-3835(86)90155-2; TAKETA K, 1985, TUMOR BIOL, V6, P533; TAKETA K, 1987, ELECTROPHORESIS, V8, P409, DOI 10.1002/elps.1150080908; VANTHIEL DH, 1992, ETIOLOGY PATHOLOGY T, P309; YOSHIMA H, 1980, CANCER RES, V40, P4276	31	387	403	0	29	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1993	328	25					1802	1806		10.1056/NEJM199306243282502	http://dx.doi.org/10.1056/NEJM199306243282502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH210	7684823				2022-12-28	WOS:A1993LH21000002
J	FALANGA, V; EAGLSTEIN, WH				FALANGA, V; EAGLSTEIN, WH			THE TRAP HYPOTHESIS OF VENOUS ULCERATION	LANCET			English	Article							PERICAPILLARY FIBRIN; SKIN CAPILLARIES; GROWTH; LIPODERMATOSCLEROSIS; FIBROBLAST; CELLS; LEG	The pathogenesis of venous ulceration is unknown. We propose that macromolecules leaking into the dermis as a result of venous hypertension bind to or ''trap'' growth factors and matrix material, which then become unavailable for tissue repair and for the maintenance of tissue integrity.			FALANGA, V (corresponding author), UNIV MIAMI,SCH MED,DEPT DERMATOL & CUTANEOUS SURG,POB 016250,MIAMI,FL 33101, USA.			Falanga, Vincent/0000-0003-2292-2017	NATIONAL INSTITUTE ON AGING [R01AG010998] Funding Source: NIH RePORTER; NIA NIH HHS [AG 10998] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALSLEV E, 1992, BRIT J DERMATOL, V126, P582; BROWSE NL, 1982, LANCET, V2, P243; BUCALO B, 1989, J INVEST DERMATOL, V92, P539; BURNAND KG, 1982, BRIT J SURG, V69, P41, DOI 10.1002/bjs.1800690114; BURNAND KG, 1982, BMJ-BRIT MED J, V285, P1071, DOI 10.1136/bmj.285.6348.1071; CHRISTOPOULOS D, 1989, SURGERY, V106, P829; CLAUDY AL, DETECTIONUNDERGRADED; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DODD HJ, 1985, J ROY SOC MED, V78, P373, DOI 10.1177/014107688507800505; FALANGA V, 1987, ARCH DERMATOL, V123, P620, DOI 10.1001/archderm.123.5.620; FALANGA V, 1992, J DERMATOL SURG ONC, V18, P409, DOI 10.1111/j.1524-4725.1992.tb03694.x; FALANGA V, 1992, J DERMATOL SURG ONC, V18, P604, DOI 10.1111/j.1524-4725.1992.tb03514.x; GRINNELL F, 1992, J INVEST DERMATOL, V98, P410, DOI 10.1111/1523-1747.ep12499839; Higley HR, 1992, WOUNDS, V4, P33; HOPKINS NFG, 1983, BRIT MED J, V286, P333, DOI 10.1136/bmj.286.6362.333; KATZ MH, 1991, J AM ACAD DERMATOL, V25, P1054, DOI 10.1016/0190-9622(91)70306-M; PARDES JB, 1990, J INVEST DERMATOL, V94, P563; PARTSCH H, 1984, BRIT J DERMATOL, V110, P249, DOI 10.1111/j.1365-2133.1984.tb07481.x; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; SCOTT HJ, 1991, BRIT J SURG, V78, P210, DOI 10.1002/bjs.1800780226	20	208	213	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 17	1993	341	8851					1006	1008		10.1016/0140-6736(93)91085-Z	http://dx.doi.org/10.1016/0140-6736(93)91085-Z			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY368	7682272	hybrid			2022-12-28	WOS:A1993KY36800016
J	VOGEL, W; LAMMERS, R; HUANG, JT; ULLRICH, A				VOGEL, W; LAMMERS, R; HUANG, JT; ULLRICH, A			ACTIVATION OF A PHOSPHOTYROSINE PHOSPHATASE BY TYROSINE PHOSPHORYLATION	SCIENCE			English	Article							CHIMERIC RECEPTOR; KINASE; DOMAIN; MECHANISM; SUBSTRATE; PROTEINS; SH2	Regulation of cell proliferation, differentiation, and metabolic homeostasis is associated with the phosphorylation and dephosphorylation of specific tyrosine residues of key regulatory proteins. The phosphotyrosine phosphatase 1D (PTP 1D) contains two amino terminally located Src homology 2 (SH2) domains and is similar to the Drosophila corkscrew gene product, which positively regulates the torso tyrosine kinase signal transduction pathway. PTP activity was found to be regulated by physical interaction with a protein tyrosine kinase. PTP 1D did not dephosphorylate receptor tyrosine kinases, despite the fact that it associated with the epidermal growth factor receptor and chimeric receptors containing the extracellular domain of the epidermal growth factor receptor and the cytoplasmic domain of either the HER2-neu, kit-SCF, or platelet-derived growth factor beta (betaPDGF) receptors. PTP 1D was phosphorylated on tyrosine in cells overexpressing the betaPDGF receptor kinase and this tyrosine phosphorylation correlated with an enhancement of its catalytic activity. Thus, protein tyrosine kinases and phosphatases do not simply oppose each other's action; rather, they may work in concert to maintain a fine balance of effector activation needed for the regulation of cell growth and differentiation.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Max Planck Society; New York University								BURGESS WH, 1990, MOL CELL BIOL, V10, P4470; FENG GS, IN PRESS SCIENCE; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; HERBST R, 1991, J BIOL CHEM, V266, P19908; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, NEURON, V9, P1; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; TUNG HYL, 1987, ANAL BIOCHEM, V161, P412; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, UNPUB; YI T, 1992, MOL CELL BIOL, V12, P826; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	27	562	586	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 12	1993	259	5101					1611	1614		10.1126/science.7681217	http://dx.doi.org/10.1126/science.7681217			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	7681217				2022-12-28	WOS:A1993KR54300039
J	VALCARCEL, J; SINGH, R; ZAMORE, PD; GREEN, MR				VALCARCEL, J; SINGH, R; ZAMORE, PD; GREEN, MR			THE PROTEIN SEX-LETHAL ANTAGONIZES THE SPLICING FACTOR U2AF TO REGULATE ALTERNATIVE SPLICING OF TRANSFORMER PREMESSENGER RNA	NATURE			English	Article							DROSOPHILA-MELANOGASTER; BIOCHEMICAL-CHARACTERIZATION; AUXILIARY FACTOR; GENE; INVITRO; SEQUENCE; BINDING; SITE; DIFFERENTIATION; PURIFICATION	SOMATIC sexual differentiation in Drosophila melanogaster involves a cascade of regulated splicing events1,2 and provides an attractive model system for the analysis of alternative splicing mechanisms. The protein Sex-lethal (SXl)3,4 activates a female-specific 3' splice site in the first intron of transformer (tra) pre-mRNA while repressing an alternative non-sex-specific site5-7. We have developed an in vitro system that recapitulates this regulation in a manner consistent with genetic, transfection and fly transformation studies4-8. Using this system, we have determined the molecular basis of the splice site switch. Here we show that Sxl inhibits splicing to the non-sex-specific (default) site by specifically binding to its polypyrimidine tract, blocking the binding of the essential splicing factor U2AF. This enables U2AF to activate the lower-affinity female-specific site. A splicing 'effector' domain present in U2AF but absent from Sxl accounts for the different activities of these two polypyrimidine-tract-binding proteins: addition of the U2AF effector domain to Sxl converts it from a splicing repressor to an activator and renders it unable to mediate splice-site switching.			VALCARCEL, J (corresponding author), UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, 373 PLANTAT ST, WORCESTER, MA 01605 USA.		Valcarcel, Juan/O-9814-2014; Zamore, Phillip D/A-8941-2013	Valcarcel, Juan/0000-0001-5398-3571; Zamore, Phillip/0000-0002-4505-9618				BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1985, ORIGIN EVOLUTION SEX; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRANADINO B, 1990, EMBO J, V9, P2597, DOI 10.1002/j.1460-2075.1990.tb07441.x; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HODGKIN J, 1989, CELL, V56, P905, DOI 10.1016/0092-8674(89)90619-3; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LEFF SE, 1987, CELL, V48, P517, DOI 10.1016/0092-8674(87)90202-9; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; RIO DC, 1988, P NATL ACAD SCI USA, V85, P2904, DOI 10.1073/pnas.85.9.2904; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; SAIKI RK, 1990, PCR PROTOCOLS GUIDE; SAKAMOTO H, 1992, NUCLEIC ACIDS RES, V20, P5533, DOI 10.1093/nar/20.21.5533; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZAPP ML, 1989, NUCLEIC ACIDS RES, V17, P2655, DOI 10.1093/nar/17.7.2655	33	286	310	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	1993	362	6416					171	175		10.1038/362171a0	http://dx.doi.org/10.1038/362171a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	7680770				2022-12-28	WOS:A1993KR02800064
J	HO, K; NICHOLS, CG; LEDERER, WJ; LYTTON, J; VASSILEV, PM; KANAZIRSKA, MV; HEBERT, SC				HO, K; NICHOLS, CG; LEDERER, WJ; LYTTON, J; VASSILEV, PM; KANAZIRSKA, MV; HEBERT, SC			CLONING AND EXPRESSION OF AN INWARDLY RECTIFYING ATP-REGULATED POTASSIUM CHANNEL	NATURE			English	Article							CFTR CHLORIDE CHANNEL; CYSTIC-FIBROSIS GENE; SQUID GIANT-AXON; K+ CHANNELS; SODIUM-CHANNEL; RAT-BRAIN; FUNCTIONAL EXPRESSION; COMPLEMENTARY-DNA; MEMBRANE-PROTEIN; SHAKER LOCUS	A complementary DNA encoding an ATP-regulated potassium channel has been isolated by expression cloning from rat kidney. The predicted 45K protein, which features two potential membrane-spanning helices and a proposed ATP-binding domain, represents a major departure from the basic structural design characteristic of voltage-gated and second messenger-gated ion channels. But the presence of an HS region, which is likely to form the ion conduction pathway, indicates that the protein may share a common origin with voltage-gated potassium channel proteins.	HARVARD UNIV, SCH MED, HARVARD CTR STUDY KIDNEY DIS, 75 FRANCIS ST, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV RENAL, MOLEC PHYSIOL & BIOPHYS LAB, BOSTON, MA 02115 USA; WASHINGTON UNIV, MED CTR, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA; UNIV MARYLAND, DEPT PHYSIOL, BALTIMORE, MD 21201 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV ENDOCRINE & HYPERTENS, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Washington University (WUSTL); University System of Maryland; University of Maryland Baltimore; Harvard University; Brigham & Women's Hospital			Lederer, William/B-1285-2010; Nichols, Colin/D-6336-2012	Lytton, Jonathan/0000-0003-4770-2512				ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; AUGUSTINE CK, 1990, J GEN PHYSIOL, V95, P245, DOI 10.1085/jgp.95.2.245; BAUMANN A, 1987, EMBO J, V6, P3419, DOI 10.1002/j.1460-2075.1987.tb02665.x; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BELLES B, 1988, PFLUG ARCH EUR J PHY, V411, P353, DOI 10.1007/BF00587713; BEZANILLA F, 1986, P NATL ACAD SCI USA, V83, P2743, DOI 10.1073/pnas.83.8.2743; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHANG CF, 1991, J BIOL CHEM, V266, P16395; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; FRACE AM, 1992, PFLUG ARCH EUR J PHY, V421, P94, DOI 10.1007/BF00374739; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAGIWARA S, 1974, J MEMBRANE BIOL, V18, P61, DOI 10.1007/BF01870103; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEBERT SC, 1984, J MEMBRANE BIOL, V80, P221, DOI 10.1007/BF01868440; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Hille B., 1992, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; KIM D, 1991, J PHYSIOL-LONDON, V437, P133, DOI 10.1113/jphysiol.1991.sp018588; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KIRSCH GE, 1992, BIOPHYS J, V62, P136, DOI 10.1016/S0006-3495(92)81800-3; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOPATIN AN, IN PRESS J PHARM EXP; LUNEAU CJ, 1991, P NATL ACAD SCI USA, V88, P3932, DOI 10.1073/pnas.88.9.3932; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; OHNOSHOSAKU T, 1987, PFLUG ARCH EUR J PHY, V408, P133, DOI 10.1007/BF00581342; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEROZO E, 1991, J GEN PHYSIOL, V98, P1, DOI 10.1085/jgp.98.1.1; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; REHM H, 1989, BIOCHEMISTRY-US, V28, P6455, DOI 10.1021/bi00441a044; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROSSIE S, 1987, J BIOL CHEM, V262, P17530; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; STELZER A, 1988, SCIENCE, V241, P339, DOI 10.1126/science.2455347; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TAKANO M, 1990, AM J PHYSIOL, V258, pH45, DOI 10.1152/ajpheart.1990.258.1.H45; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; TRUBE G, 1984, PFLUG ARCH EUR J PHY, V401, P178, DOI 10.1007/BF00583879; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG W, 1992, REV PHYSL, V54, P81; WANG WH, 1991, J GEN PHYSIOL, V98, P35, DOI 10.1085/jgp.98.1.35; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	102	870	906	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 4	1993	362	6415					31	38		10.1038/362031a0	http://dx.doi.org/10.1038/362031a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	7680431				2022-12-28	WOS:A1993KP97600050
J	TROYANOVSKY, SM; ESHKIND, LG; TROYANOVSKY, RB; LEUBE, RE; FRANKE, WW				TROYANOVSKY, SM; ESHKIND, LG; TROYANOVSKY, RB; LEUBE, RE; FRANKE, WW			CONTRIBUTIONS OF CYTOPLASMIC DOMAINS OF DESMOSOMAL CADHERINS TO DESMOSOME ASSEMBLY AND INTERMEDIATE FILAMENT ANCHORAGE	CELL			English	Article							CELL-ADHESION MOLECULES; AMINO-ACID-SEQUENCE; JUNCTIONAL PLAQUE PROTEIN; KIDNEY EPITHELIAL-CELLS; MESSENGER-RNA; GLYCOPROTEIN-3 DESMOCOLLINS; PEMPHIGUS-VULGARIS; HUMAN PLAKOGLOBIN; GAP-JUNCTIONS; CLONED CDNA	To examine the potential of cytoplasmic portions (''tails'') of desmosomal cadherins for assembly of desmosome plaque structures and anchorage of intermediate filaments (IFs), we transfected cultured human A-431 carcinoma cells, abundant in desmosomes and cytokeratin IFs, with constructs encoding chimeric proteins in which the transmembranous region of connexin 32 had been fused with tails of desmocollin (Dsc) or desmoglein (Dsg). The results show that the tail of the long splice form a of Dsc, but not its shorter splice form b, contains sufficient information to recruit desmoplakin and plakoglobin to connexon membrane paracrystals (gap junctions) and to form a novel kind of plaque at which cytokeratin IFs attach. By contrast, chimeras containing a Dsg tail, which accumulated in the plasma membrane, showed a dominant-negative effect: they not only were unable to form gap junction structures and plaques but also led to the disappearance of all endogenous desmosomes and the detachment of IFs from the plasma membrane.			TROYANOVSKY, SM (corresponding author), GERMAN CANC RES CTR,DIV CELL BIOL,W-6900 HEIDELBERG,GERMANY.			Leube, Rudolf/0000-0002-5519-7379; Franke, Werner W./0000-0002-4873-8448				AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; BADER BL, 1991, J CELL BIOL, V115, P1293, DOI 10.1083/jcb.115.5.1293; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BUXTON RS, 1993, IN PRESS J CELL BIOL; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; COWIN P, 1984, J CELL SCI, V70, P41; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Cowin P, 1985, CELL CONTACT, P427; DUDEN R, 1988, J CELL BIOL, V107, P1049, DOI 10.1083/jcb.107.3.1049; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FRANKE WW, 1987, VIRCHOWS ARCH A, V411, P137, DOI 10.1007/BF00712737; FRANKE WW, 1987, EXP CELL RES, V173, P17, DOI 10.1016/0014-4827(87)90328-4; FRANKE WW, 1984, CELL, V36, P813, DOI 10.1016/0092-8674(84)90031-X; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; GREEN KJ, 1990, CELLULAR MOL BIOL IN, P147; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HORST M, 1991, P NATL ACAD SCI USA, V82, P4137; KAPPRELL HP, 1987, EUR J BIOCHEM, V166, P505, DOI 10.1111/j.1432-1033.1987.tb13543.x; KARTENBECK J, 1982, EMBO J, V1, P725, DOI 10.1002/j.1460-2075.1982.tb01237.x; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; KEMLER R, 1990, MORPHOREGULATORY MOL, P41; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KOCH PJ, 1991, DIFFERENTIATION, V47, P29, DOI 10.1111/j.1432-0436.1991.tb00218.x; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KOCH PJ, 1991, EUR J CELL BIOL, V55, P200; KOCH PJ, 1992, P NATL ACAD SCI USA, V89, P353, DOI 10.1073/pnas.89.1.353; KORMAN NJ, 1989, NEW ENGL J MED, V321, P631, DOI 10.1056/NEJM198909073211002; KREIS TE, 1983, CELL, V32, P1125, DOI 10.1016/0092-8674(83)90296-9; LARSEN WJ, 1985, MOD CELL BIOL, V4, P151; LEUBE RE, 1987, EMBO J, V6, P3261, DOI 10.1002/j.1460-2075.1987.tb02644.x; LEUBE RE, 1989, CELL, V59, P433, DOI 10.1016/0092-8674(89)90028-7; LEUBE RE, 1988, J CELL BIOL, V106, P1249, DOI 10.1083/jcb.106.4.1249; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1986, LAB INVEST, V54, P4; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NILLES LA, 1991, J CELL SCI, V99, P809; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PARKER AE, 1991, J BIOL CHEM, V266, P10438; PARRISH EP, 1990, J CELL SCI, V96, P239; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PENN EJ, 1987, J CELL BIOL, V105, P57, DOI 10.1083/jcb.105.1.57; RUPPERT S, 1984, NATURE, V308, P554, DOI 10.1038/308554a0; SCHMELZ M, 1986, EUR J CELL BIOL, V42, P184; SCHWARZ MA, 1990, ANNU REV CELL BIOL, V6, P461, DOI 10.1146/annurev.cb.06.110190.002333; SINGER SJ, 1992, NATURE, V255, P1671; SORKIN BC, 1988, P NATL ACAD SCI USA, V85, P7617, DOI 10.1073/pnas.85.20.7617; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; THEIS DG, 1993, IN PRESS INT J DEV T; TROYANOVSKY SM, 1989, J CELL SCI, V93, P419; TROYANOVSKY SM, 1992, EUR J CELL BIOL, V59, P127; TSUKITA S, 1990, CELL STRUCT FUNCT, V15, P7, DOI 10.1247/csf.15.7; WHEELER GN, 1991, P NATL ACAD SCI USA, V88, P4796, DOI 10.1073/pnas.88.11.4796; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YEAGER M, 1992, J MOL BIOL, V223, P929, DOI 10.1016/0022-2836(92)90253-G	66	172	172	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					561	574		10.1016/0092-8674(93)90075-2	http://dx.doi.org/10.1016/0092-8674(93)90075-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	7679953				2022-12-28	WOS:A1993KP16500011
J	HOOVER, JE; STRICK, PL				HOOVER, JE; STRICK, PL			MULTIPLE OUTPUT CHANNELS IN THE BASAL GANGLIA	SCIENCE			English	Article							PRIMATE MOTOR CORTEX; FREE ARM MOVEMENTS; FRONTAL-LOBE; THALAMIC INPUTS; GLOBUS-PALLIDUS; CORTICOSPINAL PROJECTIONS; NEURONAL POPULATION; 3-DIMENSIONAL SPACE; ARCUATE PREMOTOR; VISUAL TARGETS	The neural circuits that link the basal ganglia with the cerebral cortex are critically involved in the generation and control of voluntary movement. Retrograde transneuronal transport of herpes simplex virus type 1 was used to examine the organization of connections in the cebus monkey between an output nucleus of the basal ganglia, the internal segment of the globus pallidus (GPi), and three cortical areas: the primary motor cortex, the supplementary motor area, and the ventral premotor area. Spatially separate regions of the GPi were labeled after virus injections into each cortical area. The GPi projects to multiple cortical motor areas, and this pallidal output is organized into discrete channels. This information provides a new anatomical framework for examining the function of the basal ganglia in skeletomotor control.	SUNY HLTH SCI CTR, VET ADM MED CTR, RES SERV, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT NEUROSURG, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT PHYSIOL, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024328] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24328, NS2957] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ALLEN GI, 1974, PHYSIOL REV, V54, P957, DOI 10.1152/physrev.1974.54.4.957; Barbeau A., 1986, HDB CLIN NEUROLOGY, P87; BORTOFF GA, UNPUB; COOPER IS, 1958, J NEUROSURG, V15, P244, DOI 10.3171/jns.1958.15.3.0244; DeLong M. R., 1981, HDB PHYSL NERVOUS SY, P1017; DEVITO JL, 1982, EXP BRAIN RES, V46, P107; DUM RP, 1991, J NEUROSCI, V11, P667; EVARTS EV, 1984, TRENDS NEUROSCI, V7, P447, DOI 10.1016/S0166-2236(84)80151-4; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GIGUERE M, 1988, J COMP NEUROL, V277, P195, DOI 10.1002/cne.902770204; GOLDMANRAKIC PS, 1990, TRENDS NEUROSCI, V13, P241, DOI 10.1016/0166-2236(90)90103-H; GOLDMANRAKIC PS, 1985, J COMP NEUROL, V242, P535, DOI 10.1002/cne.902420406; GRAYBIEL AM, 1990, TRENDS NEUROSCI, V13, P244, DOI 10.1016/0166-2236(90)90104-I; HEINDEL WC, 1989, J NEUROSCI, V9, P582; HOLSAPPLE JW, 1991, J NEUROSCI, V11, P2644; HUMPHREY DR, 1991, DAHLEM WORKSHOP REPO, P413; KALASKA JF, 1989, J NEUROSCI, V9, P2080; KEMP JM, 1970, BRAIN, V93, P525, DOI 10.1093/brain/93.3.525; KIM R, 1976, J COMP NEUROL, V169, P263, DOI 10.1002/cne.901690302; KUO JS, 1973, J COMP NEUROL, V151, P201, DOI 10.1002/cne.901510302; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; Manocha S. L., 1968, STEREOTAXIC ATLAS BR; MARSDEN CD, 1982, NEUROLOGY, V32, P514, DOI 10.1212/WNL.32.5.514; MATELLI M, 1989, J COMP NEUROL, V280, P468, DOI 10.1002/cne.902800311; MUSHIAKE H, 1991, J NEUROPHYSIOL, V66, P705, DOI 10.1152/jn.1991.66.3.705; NAMBU A, 1991, EXP BRAIN RES, V84, P279; NAUTA WALLE J. H., 1966, BRAIN RES, V1, P3, DOI 10.1016/0006-8993(66)90103-X; SCHELL GR, 1984, J NEUROSCI, V4, P539; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; STRICK PL, IN PRESS EXPT NEUROA; SVENNILSON E, 1960, ACTA PSYCH NEUROL, V35, P358, DOI 10.1111/j.1600-0447.1960.tb07606.x; UGOLINI G, 1989, SCIENCE, V243, P89, DOI 10.1126/science.2536188; WIESENDANGER R, 1985, EXP BRAIN RES, V59, P91; WISE SP, 1985, ANNU REV NEUROSCI, V8, P1, DOI 10.1146/annurev.ne.08.030185.000245; ZEMANICK MC, 1991, P NATL ACAD SCI USA, V88, P8048, DOI 10.1073/pnas.88.18.8048	38	467	472	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 5	1993	259	5096					819	821		10.1126/science.7679223	http://dx.doi.org/10.1126/science.7679223			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	7679223				2022-12-28	WOS:A1993KL11000035
J	KORF, B				KORF, B			MOLECULAR DIAGNOSIS .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											KORF, B (corresponding author), CHILDRENS HOSP,DIV GENET,BOSTON,MA, USA.								0	15	16	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 4	1995	332	18					1218	1220		10.1056/NEJM199505043321808	http://dx.doi.org/10.1056/NEJM199505043321808			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV415	7700317				2022-12-28	WOS:A1995QV41500008
J	RAUSCHECKER, JP; TIAN, B; HAUSER, M				RAUSCHECKER, JP; TIAN, B; HAUSER, M			PROCESSING OF COMPLEX SOUNDS IN THE MACAQUE NONPRIMARY AUDITORY-CORTEX	SCIENCE			English	Article							RHESUS-MONKEY; VISUAL PROPERTIES; SQUIRREL-MONKEY; MACACA-MULATTA; NEURONS; VOCALIZATIONS; ORGANIZATION; RESPONSES; ANATOMY; SPEECH	Neurons in the superior temporal gyrus of anesthetized rhesus monkeys were exposed to complex acoustic stimuli. Bandpassed noise bursts with defined center frequencies evoked responses that were greatly enhanced over those evoked by pure tons. This finding led to the discovery of at least one new cochleotopic area in the lateral belt of the nonprimary auditory cortex. The best center frequencies of neurons varied along a rostrocaudal axis, and the best bandwidths of the noise bursts varied along a mediolateral axis. When digitized monkey calls were used as stimuli, many neurons showed a preference for some calls over others. Manipulation of the calls' frequency structure and playback of separate components revealed different types of spectral integration. The lateral areas of the monkey auditory cortex appear to be part of a hierarchical sequence in which neurons prefer increasingly complex stimuli and may form an important stage in the preprocessing of communication sounds.	NIMH,NEUROPHYSIOL LAB,POOLESVILLE,MD 20837; HARVARD UNIV,DEPT ANTHROPOL,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT PSYCHOL,PROGRAM NEUROSCI,CAMBRIDGE,MA 02138	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Harvard University; Harvard University			Rauschecker, Josef P/A-4120-2013	Rauschecker, Josef P./0000-0003-4353-9084				BINDER JR, 1994, ANN NEUROL, V35, P662, DOI 10.1002/ana.410350606; BOATMAN D, IN PRESS BRAIN LANGU; Brodmann K., 1908, J PSYCHOL NEUROL, V10, P231; BRUGGE JF, 1973, J NEUROPHYSIOL, V36, P1138, DOI 10.1152/jn.1973.36.6.1138; BURTON H, 1976, J COMP NEUROL, V168, P249, DOI 10.1002/cne.901680204; CREUTZFELDT O, 1989, EXP BRAIN RES, V77, P451, DOI 10.1007/BF00249600; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; DESIMONE R, 1986, J COMP NEUROL, V248, P164, DOI 10.1002/cne.902480203; DESIMONE R, 1987, J NEUROPHYSIOL, V57, P835, DOI 10.1152/jn.1987.57.3.835; FENG AS, 1978, SCIENCE, V202, P645, DOI 10.1126/science.705350; GOUZOULES S, 1984, ANIM BEHAV, V32, P182, DOI 10.1016/S0003-3472(84)80336-X; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; HAUSER MD, 1992, J ACOUST SOC AM, V91, P2175, DOI 10.1121/1.403676; HAUSER MD, 1993, BEHAV ECOL, V4, P194, DOI 10.1093/beheco/4.3.194; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P229, DOI 10.1152/jn.1965.28.2.229; MERZENICH MM, 1973, BRAIN RES, V50, P275, DOI 10.1016/0006-8993(73)90731-2; MILLER JM, 1972, SCIENCE, V177, P449, DOI 10.1126/science.177.4047.449; MOREL A, 1993, J COMP NEUROL, V335, P437, DOI 10.1002/cne.903350312; PANDYA DN, 1994, J COMP NEUROL, V345, P447, DOI 10.1002/cne.903450311; PANDYA DN, 1972, Z ANAT ENTWICKLUNGS, V139, P127; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PETERSEN SE, 1980, BRAIN RES, V197, P507, DOI 10.1016/0006-8993(80)91137-3; RAUSCHECKER JP, 1993, J NEUROSCI, V13, P4538; RAUSCHECKER JP, 1995, ARO ABSTR, V18, P103; SELDON HL, 1985, CEREB CORTEX, V4, P273; SUGA N, 1992, PHILOS T ROY SOC B, V336, P423, DOI 10.1098/rstb.1992.0078; SUGA N, 1978, SCIENCE, V200, P778, DOI 10.1126/science.644320; TIAN B, 1994, J NEUROPHYSIOL, V71, P1959, DOI 10.1152/jn.1994.71.5.1959; VANECONOMO C, 1925, CYTOARCHITEKTONIK HI; VANESSEN DC, 1983, TRENDS NEUROSCI, V6, P370, DOI 10.1016/0166-2236(83)90167-4; WINTER P, 1973, EXP BRAIN RES, V18, P489; WINTER P, 1966, EXP BRAIN RES, V1, P359; WOLLBERG Z, 1972, SCIENCE, V175, P212, DOI 10.1126/science.175.4018.212; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767; ZEKI SM, 1978, NATURE, V274, P423, DOI 10.1038/274423a0	35	664	669	1	21	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					111	114		10.1126/science.7701330	http://dx.doi.org/10.1126/science.7701330			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701330				2022-12-28	WOS:A1995QR45400038
J	LOMBARDI, V; PIAZZESI, G; FERENCZI, MA; THIRLWELL, H; DOBBIE, I; IRVING, M				LOMBARDI, V; PIAZZESI, G; FERENCZI, MA; THIRLWELL, H; DOBBIE, I; IRVING, M			ELASTIC DISTORTION OF MYOSIN HEADS AND REPRIMING OF THE WORKING STROKE IN MUSCLE	NATURE			English	Article							CONTRACTING MUSCLE; STRIATED-MUSCLE; FIBERS; FROG; TRANSIENTS; MECHANISM	MUSCLE contraction is driven by a cyclical interaction between the globular head domain of myosin and the actin filaments(1-6). We used quick stretches of 5 nm per half sarcomere to synchronize the movements of myosin heads in active single muscle fibres(5,7,8). The intensity of the 14.5 nm X-ray reflection decreased during the stretch, showing that the instantaneous elasticity of muscle(1,5) involves distortion of myosin heads. Head movement continued at about 1,500 s(-1) after the stretch, accompanied by partial force recovery. This indicates a reversal of the force-generating 'working stroke' in the myosin heads(5,8,9) that is smaller and faster than assumed previously(5,10,11). By 50 ms after the stretch, myosin heads have regained both their original conformation and the ability to execute a normal working stroke. This 'repriming' process is slower than that following shortening(12) but much faster than the ATP turnover rate per myosin head.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; UNIV LONDON KINGS COLL,RANDALL INST,LONDON WC2B 5RL,ENGLAND	MRC National Institute for Medical Research; University of London; King's College London	LOMBARDI, V (corresponding author), UNIV FLORENCE,DIPARTIMENTO SCI FISIOL,VIALE GB MORGAGNI 63,I-50134 FLORENCE,ITALY.		Ferenczi, Michael/F-9510-2015	Ferenczi, Michael/0000-0002-0349-331X; Dobbie, Ian/0000-0002-5531-5865	Telethon [239] Funding Source: Medline	Telethon(Fondazione Telethon)		Cecchi G, 1976, Boll Soc Ital Biol Sper, V52, P733; Curtin N A, 1975, J Mechanochem Cell Motil, V3, P147; EISENBERG E, 1978, PROG BIOPHYS MOL BIO, V33, P55; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1981, J PHYSIOL-LONDON, V317, pP12; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY AF, 1981, J PHYSIOL-LONDON, V305, pP15; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; HUXLEY HE, 1982, J MOL BIOL, V159, P637; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; KUSHMERICK MJ, 1969, PROC R SOC SER B-BIO, V174, P315, DOI 10.1098/rspb.1969.0096; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; PIAZZESI G, 1992, J PHYSIOL-LONDON, V445, P659, DOI 10.1113/jphysiol.1992.sp018945; PIAZZESI G, 1995, BIOPHYS J, V98, pS92; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765	21	99	101	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					553	555		10.1038/374553a0	http://dx.doi.org/10.1038/374553a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700382				2022-12-28	WOS:A1995QR06900055
J	TECOTT, LH; SUN, LM; AKANA, SF; STRACK, AM; LOWENSTEIN, DH; DALLMAN, MF; JULIUS, D				TECOTT, LH; SUN, LM; AKANA, SF; STRACK, AM; LOWENSTEIN, DH; DALLMAN, MF; JULIUS, D			EATING DISORDER AND EPILEPSY IN MICE LACKING 5-HT2C SEROTONIN RECEPTORS	NATURE			English	Article							MESSENGER-RNA; NERVOUS-SYSTEM; RAT-BRAIN	SEROTONIN (5-hydroxytryptamine, 5-HT) is a monoaminergic neurotransmitter that is believed to modulate numerous sensory, motor and behavioural processes in the mammalian nervous system(1-3). These diverse responses are elicited through the activation of a large family of receptor subtypes(4). The complexity of this signalling system and the paucity of selective drugs have made it difficult to define specific roles for 5-HT receptor subtypes, or to determine bow serotonergic drugs modulate mood and behaviour. To address these issues, we have generated mutant mice lacking functional 5-HT2C receptors (previously termed 5-HT1C), prominent G-protein-coupled receptors that are widely expressed throughout the brain and spinal cord and which have been proposed to mediate numerous central nervous system (CNS) actions of serotonin(3.5-6). Here we show that 5-HT2C receptor-deficient mice are overweight as a result of abnormal control of feeding behaviour, establishing a role for this receptor in the serotonergic control of appetite. Mutant animals are also prone to spontaneous death from seizures, suggesting that 5-HT2C receptors mediate tonic inhibition of neuronal network excitability.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT NEUROL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								BLUNDELL JE, 1992, AM J CLIN NUTR, V55, P155, DOI 10.1093/ajcn/55.1.155s; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; DAILEY JW, 1987, FASEB J, V46, P706; ENGEL J, 1989, SEIZURES EPILEPSY; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; HIMMSHAGEN J, 1991, FRONT NEUROENDOCRIN, V12, P38; HOFFMAN BJ, 1989, FEBS LETT, V247, P453, DOI 10.1016/0014-5793(89)81390-0; JACOBS BL, 1984, HALLUCINOGENS NEUROC, P183; JOBE PC, 1973, LIFE SCI, V13, P1, DOI 10.1016/0024-3205(73)90271-3; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KENNETT GA, 1991, BRIT J PHARMACOL, V103, P2016, DOI 10.1111/j.1476-5381.1991.tb12369.x; KILIAN M, 1973, NEUROPHARMACOLOGY, V12, P681, DOI 10.1016/0028-3908(73)90121-4; KITCHENER SJ, 1994, PSYCHOPHARMACOLOGY, V113, P369, DOI 10.1007/BF02245211; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Milatovich Athena, 1992, Human Molecular Genetics, V1, P681, DOI 10.1093/hmg/1.9.681; MOLINEAUX SM, 1989, P NATL ACAD SCI USA, V86, P6793, DOI 10.1073/pnas.86.17.6793; ORLOFF MJ, 1949, P SOC EXP BIOL MED, V70, P254; PARKINSON WL, 1990, AM J PHYSIOL, V259, pR829, DOI 10.1152/ajpregu.1990.259.4.R829; POMPEIANO M, 1994, MOL BRAIN RES, V23, P163, DOI 10.1016/0169-328X(94)90223-2; SAMANIN R, 1979, N-S ARCH PHARMACOL, V308, P159, DOI 10.1007/BF00499059; SLEIGHT AJ, 1991, SEROTONIN RECEPTOR S, P211; SPARKS DL, 1985, PHARMACOL BIOCHEM BE, V23, P753, DOI 10.1016/0091-3057(85)90067-X; STRACK AM, 1995, AM J PHYSIOL-REG I, V268, pR183, DOI 10.1152/ajpregu.1995.268.1.R183; Tecott L H, 1993, Curr Opin Neurobiol, V3, P310, DOI 10.1016/0959-4388(93)90122-F; TECOTT LH, 1993, P NATL ACAD SCI USA, V90, P1430, DOI 10.1073/pnas.90.4.1430; THOMAS T, 1988, DEV BIOL, V128, P415, DOI 10.1016/0012-1606(88)90303-X; Wilkinson LO, 1991, SEROTONIN RECEPTOR S, P147; WURTMAN J, 1993, NEUROPSYCHOPHARMACOL, V9, P201, DOI 10.1038/npp.1993.56; YU L, 1991, MOL BRAIN RES, V11, P143, DOI 10.1016/0169-328X(91)90116-F	30	1061	1125	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 6	1995	374	6522					542	546		10.1038/374542a0	http://dx.doi.org/10.1038/374542a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700379				2022-12-28	WOS:A1995QR06900052
J	ALDERDICE, F; RENFREW, M; MARCHANT, S; ASHURST, H; HUGHES, P; BERRIDGE, G; GARCIA, J				ALDERDICE, F; RENFREW, M; MARCHANT, S; ASHURST, H; HUGHES, P; BERRIDGE, G; GARCIA, J			LABOR AND BIRTH IN WATER IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article									RADCLIFFE INFIRM,NATL PERINATAL EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford			Renfrew, Mary/A-2440-2010; Alderdice, Fiona A/F-5748-2010	Renfrew, Mary/0000-0003-2905-403X; Alderdice, Fiona/0000-0003-2404-5644				MCCANDLISH R, 1993, BIRTH-ISS PERINAT C, V20, P79, DOI 10.1111/j.1523-536X.1993.tb00421.x; 1992, 2ND HOUS COMM HLTH C	2	30	32	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 1	1995	310	6983					837	837		10.1136/bmj.310.6983.837	http://dx.doi.org/10.1136/bmj.310.6983.837			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QQ857	7711622	Green Published			2022-12-28	WOS:A1995QQ85700020
J	MCHENRY, PM; WILLIAMS, HC; BINGHAM, EA				MCHENRY, PM; WILLIAMS, HC; BINGHAM, EA			FORTNIGHTLY REVIEW - MANAGEMENT OF ATOPIC ECZEMA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTIGEN-AVOIDANCE; CONTROLLED TRIAL; DOUBLE-BLIND; DUST MITE; DERMATITIS; ALLERGY; CYCLOSPORINE; PREVALENCE; CROSSOVER; PREGNANCY		UNIV NOTTINGHAM HOSP, QUEENS MED CTR, DEPT DERMATOL, NOTTINGHAM NG7 2UH, ENGLAND; ROYAL VICTORIA HOSP, DEPT DERMATOL, BELFAST BT12 6BA, ANTRIM, NORTH IRELAND	University of Nottingham	MCHENRY, PM (corresponding author), UNIV GLASGOW, DEPT DERMATOL, ROBERTSON BLDG, GLASGOW G12 8QQ, LANARK, SCOTLAND.			williams, hywel/0000-0002-5646-3093				AGGARWAL RK, 1993, EYE, V7, P664, DOI 10.1038/eye.1993.152; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; ATHERTON DJ, 1978, LANCET, V1, P401; BAMFORD JTM, 1985, J AM ACAD DERMATOL, V13, P959, DOI 10.1016/S0190-9622(85)70245-9; BERTHJONES J, 1989, BRIT J DERMATOL, V121, P635, DOI 10.1111/j.1365-2133.1989.tb08196.x; BERTHJONES J, 1993, LANCET, V341, P1557, DOI 10.1016/0140-6736(93)90697-F; BOGUNIEWICZ M, 1990, AM J MED, V88, P365, DOI 10.1016/0002-9343(90)90490-5; BOS JD, 1994, LANCET, V343, P1338, DOI 10.1016/S0140-6736(94)92473-2; BURR ML, 1983, ARCH DIS CHILD, V58, P561, DOI 10.1136/adc.58.7.561; CHANDRA RK, 1986, CLIN ALLERGY, V16, P563, DOI 10.1111/j.1365-2222.1986.tb01995.x; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; CUBEY RB, 1976, BRIT J DERMATOL, V95, P207, DOI 10.1111/j.1365-2133.1976.tb00830.x; DAVID TJ, 1987, ARCH DIS CHILD, V62, P876, DOI 10.1136/adc.62.9.876; DAVID TJ, 1989, J ROY SOC MED, V82, P420, DOI 10.1177/014107688908200716; DAVID TJ, 1991, ARCH DIS CHILD, V66, P281, DOI 10.1136/adc.66.3.281; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; GEORGE SA, 1993, BRIT J DERMATOL, V128, P49, DOI 10.1111/j.1365-2133.1993.tb00147.x; Golding J, 1987, Paediatr Perinat Epidemiol, V1, P67, DOI 10.1111/j.1365-3016.1987.tb00091.x; GOODYEAR HM, 1991, BRIT J DERMATOL, V125, P604, DOI 10.1111/j.1365-2133.1991.tb14807.x; GRAHAMBROWN R, 1992, LANCET, V340, P673, DOI 10.1016/0140-6736(92)92208-W; HOWELL JB, 1976, ARCH DERMATOL, V112, P1529, DOI 10.1001/archderm.112.11.1529; JECKLER J, 1988, BRIT J DERMATOL, V119, P697, DOI 10.1111/j.1365-2133.1988.tb03490.x; JOHNSON ML, 1984, J AM ACAD DERMATOL, V11, P930, DOI 10.1016/S0190-9622(84)80017-1; JUBLIN L, 1969, ARCH DERMATOL, V100, P12; KEMP JP, 1989, ANN ALLERGY, V63, P621; LEUNG DYM, 1990, J ALLERGY CLIN IMMUN, V85, P927, DOI 10.1016/0091-6749(90)90079-J; LILJA G, 1989, CLIN EXP ALLERGY, V19, P473, DOI 10.1111/j.1365-2222.1989.tb02416.x; LONG CC, 1991, CLIN EXP DERMATOL, V16, P444, DOI 10.1111/j.1365-2230.1991.tb01232.x; LONG CC, 1993, CLIN EXP DERMATOL, V18, P516, DOI 10.1111/j.1365-2230.1993.tb01020.x; MAUCHER OM, 1987, HAUTARZT, V38, P577; MUNRO CS, 1991, BRIT J DERMATOL, V124, P43; NEILD VS, 1986, BRIT J DERMATOL, V114, P117, DOI 10.1111/j.1365-2133.1986.tb02786.x; NORRIS PG, 1988, BRIT J DERMATOL, V118, P435, DOI 10.1111/j.1365-2133.1988.tb02440.x; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; RAJKA G, 1989, ACTA DERM-VENEREOL, P5; ROOK AR, 1986, TXB DERMATOLOGY, P40; Schultz-Larsen F, 1991, HDB ATOPIC ECZEMA, P15; SHEEHAN MP, 1992, BRIT J DERMATOL, V126, P179, DOI 10.1111/j.1365-2133.1992.tb07817.x; SHEEHAN MP, 1992, LANCET, V340, P13, DOI 10.1016/0140-6736(92)92424-E; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; STERN RS, 1984, NEW ENGL J MED, V310, P1156, DOI 10.1056/NEJM198405033101805; STEWART J C M, 1991, Journal of Nutritional Medicine, V2, P9, DOI 10.3109/13590849109084095; WAHLGREN CF, 1990, BRIT J DERMATOL, V122, P545, DOI 10.1111/j.1365-2133.1990.tb14732.x; WEBBER SA, 1989, BRIT J DERMATOL, V121, P91, DOI 10.1111/j.1365-2133.1989.tb01404.x; WILLIAMS HC, 1992, CLIN EXP DERMATOL, V17, P385, DOI 10.1111/j.1365-2230.1992.tb00244.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; WRIGHT S, 1982, LANCET, V2, P1120; YOUNGER IR, 1991, J AM ACAD DERMATOL, V25, P281, DOI 10.1016/0190-9622(91)70196-9; 1994, 27 ROYAL PHARM SOC G, P412	50	62	64	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	1995	310	6983					843	847		10.1136/bmj.310.6983.843	http://dx.doi.org/10.1136/bmj.310.6983.843			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711624	Green Published			2022-12-28	WOS:A1995QQ85700023
J	NUREKI, O; VASSYLYEV, DG; KATAYANAGI, K; SHIMIZU, T; SEKINE, S; KIGAWA, T; MIYAZAWA, T; YOKOYAMA, S; MORIKAWA, K				NUREKI, O; VASSYLYEV, DG; KATAYANAGI, K; SHIMIZU, T; SEKINE, S; KIGAWA, T; MIYAZAWA, T; YOKOYAMA, S; MORIKAWA, K			ARCHITECTURES OF CLASS-DEFINING AND SPECIFIC DOMAINS OF GLUTAMYL-TRANSFER-RNA SYNTHETASE	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASE; THERMUS-THERMOPHILUS HB8; DATA-COLLECTION SYSTEM; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; DIFFRACTION DATA; GLTX-GENE; MACROMOLECULAR CRYSTALLOGRAPHY; 3-DIMENSIONAL STRUCTURE; WEISSENBERG CAMERA	The crystal structure of a class I aminoacyl-transfer RNA synthetase, glutamyl-tRNA synthetase (GluRS) from Thermus thermophilus, was solved and refined at 2.5 Angstrom resolution. The amino-terminal half of GluRS shows a geometrical similarity with that of Escherichia coli glutaminyl-tRNA synthetase (GlnRS) of the same subclass in class I, comprising the class I-specific Rossmann fold domain and the intervening subclass-specific alpha/beta domain. These domains were found to have two GluRS-specific, secondary-structure insertions, which then participated in the specific recognition of the D and acceptor stems of tRNA(Glu) as indicated by mutagenesis analyses based on the docking properties of GluRS and tRNA. In striking contrast to the beta-barrel structure of the GlnRS carboxyl-terminal half, the GluRS carboxyl-terminal half displayed an all-alpha-helix architecture, an alpha-helix cage, and mutagenesis analyses indicated that it had a role in the anticodon recognition.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; UNIV TOKYO,SCH SCI,DEPT BIOCHEM & BIOPHYS,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Yokoyama, Shigeyuki/N-6911-2015; Kigawa, Takanori/A-7679-2010; Vassylyev, Dmitry/A-9005-2008; Sekine, Shun-ichi/N-5450-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Kigawa, Takanori/0000-0003-0146-9719; Sekine, Shun-ichi/0000-0001-8174-8704				BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRETON R, 1990, J BIOL CHEM, V265, P18248; BRETON R, 1986, J BIOL CHEM, V261, P610; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; CAVARELLI J, 1992, NATURE, V362, P181; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DELARUE M, 1994, EMBO J, V13, P3219, DOI 10.1002/j.1460-2075.1994.tb06623.x; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FETT R, 1991, J BIOL CHEM, V266, P1448; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; HARAYOKOYAMA M, 1984, J BIOCHEM, V96, P1599, DOI 10.1093/oxfordjournals.jbchem.a134990; HARAYOKOYAMA M, 1985, THESIS U TOKYO TOKYO; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LABERGE S, 1989, J BACTERIOL, V171, P3926, DOI 10.1128/jb.171.7.3926-3932.1989; LAMOUR V, 1994, P NATL ACAD SCI USA, V91, P8670, DOI 10.1073/pnas.91.18.8670; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P436; NAKAMURA H, 1987, J PHYS SOC JPN, V56, P1609, DOI 10.1143/JPSJ.56.1609; NUREKI O, 1992, EUR J BIOCHEM, V204, P465, DOI 10.1111/j.1432-1033.1992.tb16656.x; NUREKI O, UNPUB; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OTOWINOWSKI Z, 1988, NATURE, V335, P321; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PUTNEY SD, 1981, SCIENCE, V213, P1497, DOI 10.1126/science.7025207; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHON A, 1988, NATURE, V331, P187, DOI 10.1038/331187a0; Sekine S., UNPUB; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; STEIGEMANN W, 1974, THESIS TU MUNCHEN; STEITZ TA, 1982, P NATL ACAD SCI-BIOL, V79, P3097, DOI 10.1073/pnas.79.10.3097; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; TANAKA I, 1990, J APPL CRYSTALLOGR, V23, P334, DOI 10.1107/S0021889890004009; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WHITE BN, 1972, CAN J BIOCHEM CELL B, V50, P600, DOI 10.1139/o72-082; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229; YAMAO F, 1982, J BIOL CHEM, V257, P1639; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	56	132	135	0	33	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1958	1965		10.1126/science.7701318	http://dx.doi.org/10.1126/science.7701318			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701318				2022-12-28	WOS:A1995QQ06800034
J	FISCHER, KD; ZMUIDZINAS, A; GARDNER, S; BARBACID, M; BERNSTEIN, A; GUIDOS, C				FISCHER, KD; ZMUIDZINAS, A; GARDNER, S; BARBACID, M; BERNSTEIN, A; GUIDOS, C			DEFECTIVE T-CELL RECEPTOR SIGNALING AND POSITIVE SELECTION OF VAV-DEFICIENT CD4(+) CD8(+) THYMOCYTES	NATURE			English	Article							TYROSINE KINASE; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; B-CELLS; PHOSPHORYLATION; ACTIVATION; MICE	DURING lymphocyte development, cellular proliferation and positive and negative selection events ensure the production of T and B lymphocytes bearing highly diverse, but self-tolerant, repertoires of antigen receptors(1,2). These processes are initiated when engagement of growth-factor receptors, or the T-3,T-4 and B-5 lymphocyte antigen receptors, induces tyrosine phosphorylation of specific SH2- and SH3-domain-containing cytoplasmic proteins, including Vav(3,6,7). Here we show that vav(-/-) embryonic stern cells generate only limited numbers of immature and mature T and B lymphocytes in the RAG-2 blastocyst complementation assays. Furthermore, Vav-deficient T lymphocytes showed severely impaired antigen receptor signalling. Finally, we demonstrate that Vav-dependent signalling pathways regulate maturation, but not CD4/ CD8 lineage commitment, during T-cell-receptor-mediated positive selection of immature CD4(+)CD8(+) precursors into mature CD4(+)CD8(-) or CD4(-)CD8(+) T cells.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAM MOLEC BIOL & CANC,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A1,CANADA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; HOSP SICK CHILDREN,RES INST,DIV IMMUNOL & CANC,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M5S 1A1,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Bristol-Myers Squibb; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ADAMS JM, 1992, ONCOGENE, V7, P611; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; ASHTONRICKARDT PG, 1994, IMMUNOL TODAY, V15, P362, DOI 10.1016/0167-5699(94)90174-0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; GODFREY DI, 1992, J IMMUNOL, V149, P2281; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; GUIDOS CJ, 1993, MOL MECHANISMS IMMUN, P137; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; ROLINK A, 1991, EUR J IMMUNOL, V21, P2609, DOI 10.1002/eji.1830211044; VANMEERWIJK JPM, 1993, SCIENCE, V261, P911, DOI 10.1126/science.8102208; VONBOEHMER H, CELL, V219, P94; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; ZMUIDZINAS A, 1995, EMBO J, V14, P1	30	282	283	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					474	477		10.1038/374474a0	http://dx.doi.org/10.1038/374474a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700360				2022-12-28	WOS:A1995QP89900064
J	DAWSON, B; IWAMOTO, CK; ROSS, LP; NUNGESTER, RJ; SWANSON, DB; VOLLE, RL				DAWSON, B; IWAMOTO, CK; ROSS, LP; NUNGESTER, RJ; SWANSON, DB; VOLLE, RL			PERFORMANCE ON THE NATIONAL BOARD OF MEDICAL EXAMINERS .1. EXAMINATION BY MEN AND WOMEN OF DIFFERENT RACE AND ETHNICITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENDER DIFFERENCES; INTERNAL-MEDICINE; STUDENTS; SCHOOL; RESIDENTS; EDUCATION; PROGRAM	Objective.-To investigate the performance of men and women from Various racial and ethnic backgrounds on the National Board of Medical Examiners Part I examination, controlling for any differences in measures of educational background and academic performance before entering medical school. Design.-A retrospective analysis of existing records from the National Board of Medical Examiners and the Association of American Medical Colleges. Setting.-National Board of Medical Examiners. Participants.-All students taking the June administration of Part I for the first time in 1986, 1987, or 1988 and who were 2 years from graduation from an accredited medical school. Methods.-Multiple regression methods were used to estimate Part I examination group differences in performance that would be expected if atl students entered medical school with similar Medical College Admission Test scores, undergraduate grade point averages, and other prematriculation measures. Main Outcome Measure.-Performance on the Part I examination. Results.-There were substantial differences in performance, with white students scoring highest, followed by Asian/Pacific Islanders, Hispanics, and blacks; within ail racial and ethnic categories, women scored lower than men. Controlling for dissimilarities in academic background greatly reduced Part I differences among most racial and ethnic groups, except Asian/Pacific Islander men; unexplained differences remained between men and women. Results were consistent for the 3 years examined. Conclusions.-The results of this study do not imply that physician performance varies among racial and ethnic groups or between men and women; no written examination can measure all the abilities that may be desirable to assess. Validity research investigating reasons for the reported gender and racial and ethnic differences in performance on the National Board examinations should be continued.	NATL BOARD MED EXAMINERS,DIV PSYCHOMETR,PHILADELPHIA,PA; NATL BOARD MED EXAMINERS,EVALUAT PROGRAMS,PHILADELPHIA,PA; NATL BOARD MED EXAMINERS,OFF PRESIDENT,PHILADELPHIA,PA		DAWSON, B (corresponding author), SO ILLINOIS UNIV,SCH MED,DEPT INTERNAL MED,POB 19230,SPRINGFIELD,IL 62794, USA.							ALPER J, 1993, SCIENCE, V260, P409, DOI 10.1126/science.260.5106.409; BECKER DF, 1992, ACAD MED, V67, pS16, DOI 10.1097/00001888-199210000-00025; BOREK D, 1989, ACAD MED, V64, P240, DOI 10.1097/00001888-198905000-00004; BRIDGHAM RG, 1992, ACAD MED, V67, pS69, DOI 10.1097/00001888-199210000-00043; CALKINS EV, 1987, J MED EDUC, V62, P682; CASE SM, 1993, ACAD MED, V68, pS51, DOI 10.1097/00001888-199302000-00031; CASE SM, 1992, ACAD MED, V67, pS13, DOI 10.1097/00001888-199210000-00024; CASE SM, 1993, ACAD MED, V68, pS25, DOI 10.1097/00001888-199310000-00035; COHEN J, 1987, STATISTICAL POWER AN, P43; Cole N., 1989, ED MEASUREMENT, P201; DAWSONSAUNDERS B, 1990, ACAD MED, V65, P448, DOI 10.1097/00001888-199007000-00008; DAY SC, 1989, J GEN INTERN MED, V4, P309, DOI 10.1007/BF02597403; GREEN DR, 1975, EDUC URBAN SOC, V8, P33, DOI 10.1177/001312457500800105; JACOBI M, 1991, REV EDUC RES, V61, P505, DOI 10.3102/00346543061004505; JOLLY P, 1992, ACAD MED, V67, P765, DOI 10.1097/00001888-199211000-00014; Messick S. L., 1989, ED MEASUREMENT, V3rd, P13, DOI DOI 10.7203/RELIEVE.22.1.8248; NORCINI JJ, 1985, ANN INTERN MED, V102, P115, DOI 10.7326/0003-4819-102-1-115; NUNGESTER RJ, 1990, ACAD MED, V65, P723, DOI 10.1097/00001888-199012000-00002; PETERSDORF RG, 1990, ACAD MED, V65, P663, DOI 10.1097/00001888-199011000-00001; Sadker M., 1994, FAILING FAIRNESS AM; STILLMAN PL, 1992, MORE DEV ASSESSING C; SWANSON DB, 1993, ACAD MED, V68, pS19, DOI 10.1097/00001888-199310000-00033; SWANSON DB, 1992, ACAD MED, V67, P553, DOI 10.1097/00001888-199209000-00001; SWANSON DB, 1991, ACAD MED, V66, P443, DOI 10.1097/00001888-199108000-00004; VOLLE RL, 1988, JAMA-J AM MED ASSOC, V259, P266, DOI 10.1001/jama.259.2.266; WAGONER NE, 1986, J MED EDUC, V61, P10; WATTS VG, 1989, ACAD MED, V64, P166, DOI 10.1097/00001888-198903000-00013; WEINBERG E, 1973, J MED EDUC, V48, P240; 1992, PROJECT 3000 2000 TE; 1985, STANDARDS ED PSYCHOL; 1989, BETTER UNDERSTANDING	31	56	56	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 7	1994	272	9					674	679		10.1001/jama.272.9.674	http://dx.doi.org/10.1001/jama.272.9.674			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE327	7710487				2022-12-28	WOS:A1994PE32700011
J	MADDEN, DR; GARBOCZI, DN; WILEY, DC				MADDEN, DR; GARBOCZI, DN; WILEY, DC			THE ANTIGENIC IDENTITY OF PEPTIDE-MHC COMPLEXES - A COMPARISON OF THE CONFORMATIONS OF 5 VIRAL PEPTIDES PRESENTED BY HLA-A2	CELL			English	Article							T-CELL RECOGNITION; CRYSTAL-STRUCTURES; VIRUS PEPTIDE; MOLECULES; PROTEIN; RESOLUTION; EPITOPE; HLA-B27; BINDING; CHAINS	Complexes of five peptides (from HIV-1, influenza A virus, HTLV-1, and hepatitis B virus proteins) bound to the human class I MHC molecule HLA-A2 have been studied by X-ray crystallography. While the peptide termini and their second and C-terminal anchor side chains are bound similarly in all five cases, the main chain and side chain conformations of each peptide are strikingly different in the center of the binding site, and these differences are accessible to direct TCR recognition. Each of the central peptide residues is seen to point up for some bound peptides, but down or sideways for others. Thus, although fixed at its ends, the structure of an MHC-bound peptide appears to be a highly complex function of its entire sequence, potentially sensitive to even small sequence differences. In contrast, MHC structural variation is relatively limited. These results offer a structural framework for understanding the role of nonanchor peptide side chains in both peptide-MHC binding affinity and TCR recognition.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Harvard University; Howard Hughes Medical Institute								ALEXANDER J, 1993, J IMMUNOL, V150, P1; BEDNAREK MA, 1991, J IMMUNOL, V147, P4047; BERTOLETTI A, 1993, J VIROL, V67, P2376, DOI 10.1128/JVI.67.4.2376-2380.1993; BLUESTONE JA, 1992, J EXP MED, V176, P1757, DOI 10.1084/jem.176.6.1757; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, XPLOR MANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CATIPOVIC B, 1992, J EXP MED, V176, P1611, DOI 10.1084/jem.176.6.1611; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FOX GC, 1966, ACTA CRYSTALLOGR, V20, P886, DOI 10.1107/S0365110X66002007; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; ISHIOKA GY, 1992, J IMMUNOL, V148, P2446; JAMES MNG, 1983, J APPL CRYSTALLOGR, V11, P268; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KOENIG S, 1993, J IMMUNOL, V156, P3874; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1992, CURR OPIN STRUC BIOL, V2, P300; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MCMICHAEL AJ, 1988, P NATL ACAD SCI USA, V85, P9194, DOI 10.1073/pnas.85.23.9194; NAYERSINA R, 1993, J IMMUNOL, V150, P4659; PARHAM P, 1988, P NATL ACAD SCI USA, V85, P4005, DOI 10.1073/pnas.85.11.4005; PARKER KC, 1992, J IMMUNOL, V149, P3580; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; UTZ U, 1992, J IMMUNOL, V149, P214; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	46	663	696	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					693	708		10.1016/0092-8674(93)90490-H	http://dx.doi.org/10.1016/0092-8674(93)90490-H			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	7694806				2022-12-28	WOS:A1993MH74900015
J	SPENCER, DM; WANDLESS, TJ; SCHREIBER, SL; CRABTREE, GR				SPENCER, DM; WANDLESS, TJ; SCHREIBER, SL; CRABTREE, GR			CONTROLLING SIGNAL-TRANSDUCTION WITH SYNTHETIC LIGANDS	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; LYMPHOCYTE-T ACTIVATION; CYCLOSPORINE-A; ZETA-CHAIN; MATHEMATICAL THEORY; MOLECULAR-CLONING; ATOMIC-STRUCTURE; BINDING SYSTEMS; KINASE-ACTIVITY; PROTEIN	Dimerization and oligomerization are general biological control mechanisms contributing to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. Cell permeable, synthetic ligands were devised that can be used to control the intracellular oligomerization of specific proteins. To demonstrate their utility, these ligands were used to induce intracellular oligomerization of cell surface receptors that lacked their transmembrane and extracellular regions but contained intracellular signaling domains. Addition of these ligands to cells in culture resulted in signal transmission and specific target gene activation. Monomeric forms of the ligands blocked the pathway. This method of ligand-regulated activation and termination of signaling pathways has the potential to be applied wherever precise control of a signal transduction pathway is desired.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; STANFORD UNIV,HOWARD HUGHES MED INST,STANFORD,CA 94305	Harvard University; Howard Hughes Medical Institute; Stanford University								BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FELDMAN H, 1972, ANAL BIOCHEM, V45, P530, DOI 10.1016/0003-2697(72)90216-3; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LYSON T, 1993, CIRC RES, V73, P596, DOI 10.1161/01.RES.73.3.596; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; ORGAN HM, 1993, BIOORG MED CHEM LETT, V3, P657, DOI 10.1016/S0960-894X(01)81248-8; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROSEN MK, 1992, ANGEW CHEM INT EDIT, V31, P384, DOI 10.1002/anie.199203841; ROSEN MK, 1993, J AM CHEM SOC, V115, P821, DOI 10.1021/ja00055a082; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SPENCER DJE, UNPUB; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WAQNDLESS TJ, UNPUB; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081; YU LM, 1992, J IMMUNOL, V148, P633	53	666	775	3	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1019	1024		10.1126/science.7694365	http://dx.doi.org/10.1126/science.7694365			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	7694365				2022-12-28	WOS:A1993MG18700025
J	BERBERIAN, L; GOODGLICK, L; KIPPS, TJ; BRAUN, J				BERBERIAN, L; GOODGLICK, L; KIPPS, TJ; BRAUN, J			IMMUNOGLOBULIN-V(H)3 GENE-PRODUCTS - NATURAL LIGANDS FOR HIV GP120	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CROSS-REACTIVE IDIOTYPE; B-CELL ACTIVATION; STAPHYLOCOCCAL PROTEIN; T-CELLS; CD4 RECEPTOR; INFECTION; ANTIGEN; ANTIBODY; AUTOANTIBODIES	Infection with human immunodeficiency virus-type 1 (HIV-1) depletes T cells expressing CD4 and B cells expressing immunoglobulin (Ig) V(H)3 gene products. A subpopulation of normal B cells from non-HIV-infected individuals was shown to bind to HIV gp120 by means of membrane Ig; most of these B cells expressed V(H)3 family Ig. Serum V(H)3 IgM from uninfected individuals also avidly bound gp120. Finally, gp120 selectively induced Ig secretion by V(H)3 B cells, indicating that the binding of gp120 functionally activated these cells. These results indicate that naturally occurring V(H)3 Ig is a second ligand for gp120 and a candidate superantigen for V(H)3 B cells.	UNIV CALIF LOS ANGELES, DEPT PATHOL & LAB MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California San Diego				Braun, Jonathan/0000-0003-1646-2974	NCI NIH HHS [CA12800] Funding Source: Medline; NIAID NIH HHS [AI28697] Funding Source: Medline; NIGMS NIH HHS [GM08375] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA012800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008375] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMADORI A, 1990, IMMUNOL TODAY, V11, P374, DOI 10.1016/0167-5699(90)90144-X; AULT KA, 1977, J IMMUNOL, V119, P327; AXELROD O, 1991, BLOOD, V77, P1484; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BASS HZ, 1992, CLIN IMMUNOL IMMUNOP, V64, P63, DOI 10.1016/0090-1229(92)90060-2; BERBERIAN L, 1991, BLOOD, V78, P175; BRAUN J, 1992, J CLIN INVEST, V89, P1395, DOI 10.1172/JCI115728; BRIGHTY DW, 1991, P NATL ACAD SCI USA, V88, P7802, DOI 10.1073/pnas.88.17.7802; CASALI P, 1989, IMMUNOL TODAY, V10, P364, DOI 10.1016/0167-5699(89)90268-5; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CROWLEY JJ, 1990, MOL IMMUNOL, V27, P87, DOI 10.1016/0161-5890(90)90063-6; DEFRANCE T, 1992, EUR J IMMUNOL, V22, P2831, DOI 10.1002/eji.1830221112; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GOODGLICK L, UNPUB; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HAIGWOOD NL, 1990, VACCINES 90, P313; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; IVEYHOYLE M, 1991, P NATL ACAD SCI USA, V88, P512, DOI 10.1073/pnas.88.2.512; JEFFERIES LC, 1992, CLIN IMMUNOL IMMUNOP, V65, P119, DOI 10.1016/0090-1229(92)90214-9; JORDAN CA, 1991, J VIROL, V65, P736, DOI 10.1128/JVI.65.2.736-742.1991; KIRKHAM PM, 1992, EMBO J, V11, P603, DOI 10.1002/j.1460-2075.1992.tb05092.x; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LAURENCE J, 1992, NATURE, V358, P255, DOI 10.1038/358255a0; LYDYARD PM, 1990, SCAND J IMMUNOL, V32, P709, DOI 10.1111/j.1365-3083.1990.tb03214.x; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARTIN T, 1992, J EXP MED, V175, P983, DOI 10.1084/jem.175.4.983; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; OLEE T, 1991, J CLIN INVEST, V88, P193, DOI 10.1172/JCI115277; PASCUAL V, 1991, Current Biology, V1, P315, DOI 10.1016/0960-9822(91)90097-G; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; SASSO EH, 1989, J IMMUNOL, V142, P2778; SASSO EH, 1991, J IMMUNOL, V147, P1877; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SCHMID I, 1992, CYTOMETRY, V13, P204, DOI 10.1002/cyto.990130216; SHIRAI A, 1992, J CLIN INVEST, V89, P561, DOI 10.1172/JCI115621; SHOKRI F, 1991, J IMMUNOL, V146, P936; STEIMER KS, 1988, VACCINES, V88, P347; SUTOR GC, 1992, J IMMUNOL, V149, P1452; VALLESAYOUB Y, 1990, BLOOD, V76, P17; WALTER MA, 1991, J EXP MED, V174, P335, DOI 10.1084/jem.174.2.335; YOUNG F, 1990, J IMMUNOL, V145, P2545	45	261	271	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1993	261	5128					1588	1591		10.1126/science.7690497	http://dx.doi.org/10.1126/science.7690497			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	7690497				2022-12-28	WOS:A1993LX47400033
J	NGUYEN, M; STRUBEL, NA; BISCHOFF, J				NGUYEN, M; STRUBEL, NA; BISCHOFF, J			A ROLE FOR SIALYL LEWIS-X/A GLYCOCONJUGATES IN CAPILLARY MORPHOGENESIS	NATURE			English	Article							LEUKOCYTE ADHESION MOLECULE-1; CARBOHYDRATE LIGAND; CELL-ADHESION; ACTIVATION ANTIGEN; E-SELECTIN; ELAM-1; ENDOTHELIUM; RECOGNITION; INDUCTION; INVITRO	To identify cell adhesion molecules required for angiogenesis, we used an in vitro model in which bovine capillary endothelial cells can be induced to form capillary-like tubes. Monoclonal antibodies directed against the carbohydrate epitopes sialyl Lewis-X and sialyl Lewis-A inhibited capillary formation. We postulated that a member of the selectin family of adhesion molecules may be involved in capillary formation because these proteins bind to sialyl Lewis-X/A-containing ligands. We isolated a 2.8-kilobase complementary DNA from a bovine capillary endothelial cell cDNA library which encodes a polypeptide with 71% identity to human E-selectin. We report here that antibody directed against the bovine E-selectin inhibited capillary formation, suggesting that in addition to its role in leukocyte adhesion to endothelium, a form of E-selectin is involved in capillary morphogenesis.	CHILDRENS HOSP MED CTR,SURG RES LAB,300 LONGWOOD AVE,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			BISCHOFF, JOYCE/K-3354-2019	BISCHOFF, JOYCE/0000-0002-6367-1974; Strubel, Naomi/0000-0002-4394-2108				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BERG EL, 1991, J BIOL CHEM, V266, P14869; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; Heusser C H, 1981, Methods Enzymol, V73, P406; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MCEVER RP, 1991, THROMB HAEMOSTASIS, V66, P80; MESSADI DV, 1987, J IMMUNOL, V139, P1557; NGUYEN M, 1992, J BIOL CHEM, V267, P26157; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; Sambrook J, 1989, MOL CLONING LABORATO; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; STRUBEL NA, 1993, BIOCHEM BIOPH RES CO, V192, P338, DOI 10.1006/bbrc.1993.1420; TAKADA A, 1991, BIOCHEM BIOPH RES CO, V179, P713, DOI 10.1016/0006-291X(91)91875-D; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	27	207	214	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					267	269		10.1038/365267a0	http://dx.doi.org/10.1038/365267a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	7690465				2022-12-28	WOS:A1993LX47100059
J	KETCHEM, RR; HU, W; CROSS, TA				KETCHEM, RR; HU, W; CROSS, TA			HIGH-RESOLUTION CONFORMATION OF GRAMICIDIN-A IN A LIPID BILAYER BY SOLID-STATE NMR	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; TRANSMEMBRANE ION-CHANNEL; PHASE PEPTIDE-SYNTHESIS; C-13 CHEMICAL-SHIFT; RIGHT-HANDED HELIX; PHOSPHOLIPID-BILAYERS; MEMBRANE-PROTEINS; SIDE-CHAINS; TRYPTOPHAN; SPECTROSCOPY	Solid-state nuclear magnetic resonance spectroscopy of uniformly aligned preparations of gramicidin A in lipid bilayers has been used to elucidate a high-resolution dimeric structure of the cation channel conformation solely on the basis of the amino acid sequence and 144 orientational constraints. This initial structure defines the helical pitch as single-stranded, fixes the number of residues per turn at six to seven, specifies the helix sense as right-handed, and identifies the hydrogen bonds. Refinement of this initial structure yields reasonable hydrogen-bonding distances with only minimal changes in the torsion angles.	FLORIDA STATE UNIV,INST MOLEC BIOPHYS,NATL HIGH MAGNET FIELD LAB,TALLAHASSEE,FL 32306; FLORIDA STATE UNIV,DEPT CHEM,TALLAHASSEE,FL 32306	State University System of Florida; Florida State University; State University System of Florida; Florida State University			Ketchem, Randal/AAB-4372-2020; Ketchem, Randal R/K-2258-2017	Ketchem, Randal/0000-0002-7821-2682; Ketchem, Randal R/0000-0002-7821-2682; Cross, Timothy/0000-0002-9413-0505	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023007] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23007] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECKER MD, 1991, BIOCHEMISTRY-US, V30, P8830, DOI 10.1021/bi00100a015; BOUCHARD M, 1993, BIOPHYS J, V64, pA61; BYSTROV VF, 1987, B MAGN RESON, V8, P84; CHIU SW, 1993, BIOPHYS J, V64, P98, DOI 10.1016/S0006-3495(93)81344-4; CORNELL BA, 1988, BIOPHYS J, V53, P67, DOI 10.1016/S0006-3495(88)83066-2; Deisenhofer, 1990, CURRENT TOPICS MEMBR, V36, P53; FIELDS CG, 1989, INT J PEPT PROT RES, V33, P298; FIELDS CG, 1989, THESIS FLORIDA STATE; FIELDS GB, 1988, P NATL ACAD SCI USA, V85, P1384, DOI 10.1073/pnas.85.5.1384; GARBOW JR, 1993, J AM CHEM SOC, V115, P238, DOI 10.1021/ja00054a034; HING AW, 1990, BIOCHEMISTRY-US, V29, P4144, DOI 10.1021/bi00469a018; HU W, 1993, BIOCHEMISTRY-US, V32, P7035, DOI 10.1021/bi00078a032; KATSARAS J, 1992, BIOPHYS J, V61, P827, DOI 10.1016/S0006-3495(92)81888-X; KILLIAN JA, 1992, BIOCHEMISTRY-US, V31, P11283, DOI 10.1021/bi00161a004; KINSEY RA, 1981, J BIOL CHEM, V256, P9028; KVICK A, 1977, ACTA CRYSTALLOGR B, V33, P3796, DOI 10.1107/S0567740877012102; LANGS DA, 1991, P NATL ACAD SCI USA, V88, P5345, DOI 10.1073/pnas.88.12.5345; LANGS DA, 1988, SCIENCE, V241, P188, DOI 10.1126/science.2455345; LEE KC, IN PRESS BIOPHYS J; LOGRASSO PV, 1989, J AM CHEM SOC, V111, P1910, DOI 10.1021/ja00187a072; LOMIZE AL, 1992, BIOORG KHIM+, V18, P182; MAI W, 1993, PROTEIN SCI, V2, P532; NICHOLSON LK, 1989, BIOCHEMISTRY-US, V28, P9379, DOI 10.1021/bi00450a019; PROSSER RS, 1991, BIOCHEMISTRY-US, V30, P4687, DOI 10.1021/bi00233a008; ROUX B, 1988, BIOPHYS J, V53, P297, DOI 10.1016/S0006-3495(88)83107-2; SCHIFFER M, 1992, PROTEIN ENG, V5, P213, DOI 10.1093/protein/5.3.213; SEPAROVIC F, 1991, CHEM PHYS LETT, V181, P157, DOI 10.1016/0009-2614(91)90348-D; SMITH R, 1989, BIOPHYS J, V56, P307, DOI 10.1016/S0006-3495(89)82677-3; TAKEUCHI H, 1990, BIOCHEMISTRY-US, V29, P1572, DOI 10.1021/bi00458a031; TENG Q, 1992, J AM CHEM SOC, V114, P5312, DOI 10.1021/ja00039a048; TENG Q, 1991, J MOL BIOL, V218, P607, DOI 10.1016/0022-2836(91)90705-B; THOMPSON LK, 1992, BIOCHEMISTRY-US, V31, P7931, DOI 10.1021/bi00149a026; URRY DW, 1971, P NATL ACAD SCI USA, V68, P672, DOI 10.1073/pnas.68.3.672; WALLACE BA, 1988, SCIENCE, V241, P182, DOI 10.1126/science.2455344; WEINSTEIN S, 1979, P NATL ACAD SCI USA, V76, P4230, DOI 10.1073/pnas.76.9.4230; ZHANG ZL, 1992, BIOCHEMISTRY-US, V31, P8822, DOI 10.1021/bi00152a019	37	624	628	1	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 10	1993	261	5127					1457	1460		10.1126/science.7690158	http://dx.doi.org/10.1126/science.7690158			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	7690158				2022-12-28	WOS:A1993LW54900036
J	BOUGHTONSMITH, NK; EVANS, SM; HAWKEY, CJ; COLE, AT; BALSITIS, M; WHITTLE, BJR; MONCADA, S				BOUGHTONSMITH, NK; EVANS, SM; HAWKEY, CJ; COLE, AT; BALSITIS, M; WHITTLE, BJR; MONCADA, S			NITRIC-OXIDE SYNTHASE ACTIVITY IN ULCERATIVE-COLITIS AND CROHNS-DISEASE	LANCET			English	Note								Excessive nitric oxide (NO) production by an isoform of NO synthase that can be induced by inflammatory stimuli leads to changes in vascular permeability and to tissue injury. We measured NO synthase activities in mucosa and muscle from the colons of control patients (n=11) and patients with ulcerative colitis (6) or Crohn's disease (4). NO synthase activity in colonic mucosa of ulcerative colitis patients was 0.55 (median interquartile range 0.32-0.57) nmol/min per g tissue, which was about eightfold higher than the value in control mucosa, with no individual overlap (p<0.001). With colonic muscle there was no difference in NO synthase activity between ulcerative colitis patients and controls. In the patients with Crohn's disease, mucosal NO synthase activity did not differ from control values and activity in the colonic muscle was low. Thus, induction of colonic NO synthase may be involved in the mucosal vasodilation and increased vascular permeability of active ulcerative colitis, and could also contribute to the impaired motility that accompanies toxic dilation.	WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; University of Nottingham								BOUGHTONSMITH NK, 1992, BRIT J PHARMACOL, V107, pP79; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; JENKINS D, 1990, GUT, V31, P426, DOI 10.1136/gut.31.4.426; MAHIDA YR, 1989, GUT, V30, P835, DOI 10.1136/gut.30.6.835; MIDDLETON SJ, 1993, LANCET, V341, P465, DOI 10.1016/0140-6736(93)90211-X; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; WAKEFIELD AJ, 1989, LANCET, V2, P1057	10	414	426	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 7	1993	342	8867					338	340		10.1016/0140-6736(93)91476-3	http://dx.doi.org/10.1016/0140-6736(93)91476-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ868	7687730				2022-12-28	WOS:A1993LQ86800014
J	CHEN, TY; PENG, YW; DHALLAN, RS; AHAMED, B; REED, RR; YAU, KW				CHEN, TY; PENG, YW; DHALLAN, RS; AHAMED, B; REED, RR; YAU, KW			A NEW SUBUNIT OF THE CYCLIC NUCLEOTIDE-GATED CATION CHANNEL IN RETINAL RODS	NATURE			English	Article							VERTEBRATE PHOTORECEPTORS; ACTIVATED CONDUCTANCE; FUNCTIONAL EXPRESSION; ION CHANNELS; TEA BLOCKADE; K+ CHANNELS; GMP; EXCITATION; SEGMENTS; CALCIUM	RETINAL rods respond to light with a membrane hyperpolarization produced by a G-protein-mediated signalling cascade that leads to cyclic GMP hydrolysis and the consequent closure of a cGMP-gated channel that is open in darkness1-7. A protein that forms this channel has recently been purified from bovine retina8 and molecularly cloned9, suggesting that the native cGMP-gated channel might be a homo-oligomer10. Here we report the cloning of another protein from human retina which has only about 30% overall identity to the rod channel subunit. This protein, immunocytochemically localized to rod outer segments, does not form functional channels by itself. However, when co-expressed with the cloned human rod channel protein'', it introduces rapid flickers to the channel openings that are characteristic of the native channel12-16. The hetero-oligomeric channel is also highly sensitive to the blocker L-CiS-diltiazem, like the native channel15,17,18. This new protein thus seems to be another subunit of the native rod channel. The hetero-oligomeric nature of the rod channel means that it is no exception to a common motif shared by other ligand-gated channels.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, 725 N WOLFE ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOMED ENGN, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University								BEAN BP, 1990, J NEUROSCI, V10, P11; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; DHALLAN RS, 1992, J NEUROSCI, V12, P3248, DOI 10.1523/JNEUROSCI.12-08-03248.1992; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HAYNES LW, 1992, J GEN PHYSIOL, V100, P783, DOI 10.1085/jgp.100.5.783; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KAUPP UB, 1991, TRENDS NEUROSCI, V14, P150; KAUPP UB, 1992, REV PHYSL, V54, P153; KOCH KW, 1985, J BIOL CHEM, V260, P6788; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LUHRING H, 1990, NATO ADV SCI I A-LIF, V194, P169; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MATTHEWS G, 1986, J NEUROSCI, V6, P2521; MATTHEWS G, 1988, J PHYSIOL-LONDON, V403, P389, DOI 10.1113/jphysiol.1988.sp017255; MCNAUGHTON PA, 1990, PHYSIOL REV, V70, P847, DOI 10.1152/physrev.1990.70.3.847; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; PENG YW, 1991, NEURON, V6, P525, DOI 10.1016/0896-6273(91)90055-5; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; QUANDT FN, 1991, NEUROSCIENCE, V42, P629, DOI 10.1016/0306-4522(91)90032-J; SHIELLS RA, 1992, P ROY SOC B-BIOL SCI, V247, P21, DOI 10.1098/rspb.1992.0004; STERN JH, 1986, P NATL ACAD SCI USA, V83, P1163, DOI 10.1073/pnas.83.4.1163; STRYER L, 1991, J BIOL CHEM, V266, P10711; TORRE V, 1992, P ROY SOC B-BIOL SCI, V250, P209, DOI 10.1098/rspb.1992.0151; WOHLFART P, 1992, J BIOL CHEM, V267, P644; Yau K W, 1991, Curr Opin Neurobiol, V1, P252, DOI 10.1016/0959-4388(91)90086-M; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; YAU KW, 1986, MEMBRANE CONTROL CEL, P343; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	38	299	305	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 22	1993	362	6422					764	767		10.1038/362764a0	http://dx.doi.org/10.1038/362764a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY450	7682292				2022-12-28	WOS:A1993KY45000061
J	OKSENBERG, JR; PANZARA, MA; BEGOVICH, AB; MITCHELL, D; ERLICH, HA; MURRAY, RS; SHIMONKEVITZ, R; SHERRITT, M; ROTHBARD, J; BERNARD, CCA; STEINMAN, L				OKSENBERG, JR; PANZARA, MA; BEGOVICH, AB; MITCHELL, D; ERLICH, HA; MURRAY, RS; SHIMONKEVITZ, R; SHERRITT, M; ROTHBARD, J; BERNARD, CCA; STEINMAN, L			SELECTION FOR T-CELL RECEPTOR V-BETA-D-BETA-J-BETA GENE REARRANGEMENTS WITH SPECIFICITY FOR A MYELIN BASIC-PROTEIN PEPTIDE IN BRAIN-LESIONS OF MULTIPLE-SCLEROSIS	NATURE			English	Article							NONRADIOACTIVE OLIGONUCLEOTIDE PROBES; AMPLIFIED DNA; SEQUENCE; POLYMORPHISM	MULTIPLE sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system in which a restricted cellular immune response has been observed. In order to establish whether such T cell responses are likely to be antigen-specific particularly with regard to myelin basic protein (MBP), we analysed T-cell receptor (TCR) gene rearrangements directly from MS brain plaques, using the polymerase chain reaction on reverse transcribed messenger RNA, and compared these with TCR of previously described MBP-specific T cell clones from MS and the rat model experimental allergic encephalomyelitis. Rearranged Vbeta5.2 genes were detected in the brains of all patients who were HLA DRB1*1501, DQA1*0102, DQB1*0602, DPB1*0401. The Vbeta5.2-Dbeta-Jbeta sequences in these MS brain plaques revealed five motifs. One of the common motifs was identical to that described for the VDJ region of a Vbeta5.2 T-cell clone. This clone was from an MS patient who was HLA DRB1*1501, DQB1*0602, DPB1*0401, and it was cytotoxic towards targets containing the MBP peptide 89-106 (ref. 1). The deduced amino-acid sequence of this VDJ rearrangement, Leu-Arg-Gly, has also been described in rat T cells cloned from experimental allergic encephalomyelitis lesions, which are specific for MBP peptide 87-99 (ref. 2). VDJ sequences with specificity for this MBP epitope constitute a large fraction (40%) of the TCR Vbeta5.2 N(D)N rearrangements in MS lesions. The capacity of rat T cells with these VDJ sequences to cause experimental allergic encephalomyelitis2 and the prevalence of such sequences in demyelinated human lesions indicate that T cells with this rearranged TCR may be critical in MS.	ROCHE MOLEC SYST,DEPT HUMAN GENET,EMERYVILLE,CA 94608; ROCKY MT MS CTR,ENGLEWOOD,CO 80150; LA TROBE UNIV,NEUROIMMUNOL LAB,BUNDOORA,VIC 3083,AUSTRALIA; IMMULOG PHARMACEUT CORP,PALO ALTO,CA 94304	La Trobe University	OKSENBERG, JR (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT NEUROL & NEUROL SCI,STANFORD,CA 94305, USA.			Steinman, Lawrence/0000-0002-2437-2250; Panzara, Michael/0000-0003-2810-4832				BEGOVICH AB, 1992, J IMMUNOL, V148, P249; BUGAWAN TL, 1991, IMMUNOGENETICS, V33, P163, DOI 10.1007/BF01719235; BUGAWAN TL, 1990, IMMUNOGENETICS, V32, P231; GAUTAM AM, 1992, J EXP MED, V176, P605, DOI 10.1084/jem.176.2.605; GIEGERICH G, 1992, EUR J IMMUNOL, V22, P753, DOI 10.1002/eji.1830220319; GOLD DP, 1992, J IMMUNOL, V148, P1712; HELMUTH R, 1990, AM J HUM GENET, V47, P515; JAHNKE U, 1985, SCIENCE, V229, P282, DOI 10.1126/science.2409602; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KOTZIN BL, 1991, P NATL ACAD SCI USA, V88, P9161, DOI 10.1073/pnas.88.20.9161; MARTIN R, 1991, J EXP MED, V173, P19, DOI 10.1084/jem.173.1.19; MORAHAN G, 1989, IMMUNOGENETICS, V30, P311, DOI 10.1007/BF02421337; OKSENBERG JR, 1990, CURR OPIN IMMUNOL, V2, P619, DOI 10.1016/0952-7915(90)90021-8; OKSENBERG JR, 1990, NATURE, V345, P344, DOI 10.1038/345344a0; PANZARA MA, 1992, BIOTECHNIQUES, V12, P728; SCHARF SJ, 1991, HUM IMMUNOL, V30, P190, DOI 10.1016/0198-8859(91)90034-7; TERASAKI PI, 1986, SCIENCE, V193, P1245; TILLINGHAST JP, 1986, SCIENCE, V233, P879, DOI 10.1126/science.3755549	18	422	433	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					68	70		10.1038/362068a0	http://dx.doi.org/10.1038/362068a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	7680433				2022-12-28	WOS:A1993KP97600062
J	WEINER, HL; MACKIN, GA; MATSUI, M; ORAV, EJ; KHOURY, SJ; DAWSON, DM; HAFLER, DA				WEINER, HL; MACKIN, GA; MATSUI, M; ORAV, EJ; KHOURY, SJ; DAWSON, DM; HAFLER, DA			DOUBLE-BLIND PILOT TRIAL OF ORAL TOLERIZATION WITH MYELIN ANTIGENS IN MULTIPLE-SCLEROSIS	SCIENCE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; COLLAGEN-INDUCED ARTHRITIS; BASIC-PROTEIN; II COLLAGEN; SUPPRESSION; TOLERANCE; DISEASE; RATS	Multiple sclerosis (MS) is thought to be an autoimmune disease mediated by T lymphocytes that recognize myelin components of the central nervous system. In a 1-year double-blind study, 30 individuals with relapsing-remitting MS received daily capsules of bovine myelin or a control protein to determine the effect of oral tolerization to myelin antigens on the disease. Six of 15 individuals in the myelin-treated group had at least one major exacerbation; 12 of 15 had an attack in the control group. T cells reactive with myelin basic protein were reduced in the myelin-treated group. No toxicity or side effects were noted. Although conclusions about efficacy cannot be drawn from these data, they open an area of investigation for MS and other autoimmune diseases	HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	WEINER, HL (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV NEUROL,CTR NEUROL DIS,BOSTON,MA 02115, USA.			khoury, samia/0000-0003-3198-6063	NINDS NIH HHS [NS24247, NS23132] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024247, R37NS024247, R01NS023132] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AL-SABBAGH A, 1992, Neurology, V42, P346; Alvord EC, 1984, EXPT ALLERGIC ENCEPH; BITAR DM, 1988, CELL IMMUNOL, V112, P364, DOI 10.1016/0008-8749(88)90305-X; BORNSTEIN MB, 1987, NEW ENGL J MED, V317, P408, DOI 10.1056/NEJM198708133170703; BROD SA, 1991, ANN NEUROL, V29, P615, DOI 10.1002/ana.410290608; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; HANCOCK WW, IN PRESS TRANSPLANTA; HIGGINS PJ, 1988, J IMMUNOL, V140, P440; JOHNSON D, 1986, J NEUROIMMUNOL, V13, P99, DOI 10.1016/0165-5728(86)90053-6; JOHNSON K P, 1990, Neurology, V40, P261; KHOURY SJ, 1990, CELL IMMUNOL, V131, P302, DOI 10.1016/0008-8749(90)90256-Q; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; LIDER O, 1989, J IMMUNOL, V142, P748; MCFARLIN DE, 1982, NEW ENGL J MED, V307, P1183, DOI 10.1056/NEJM198211043071905; MILLER A, 1991, J EXP MED, V174, P791, DOI 10.1084/jem.174.4.791; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MILLER A, 1992, J NEUROIMMUNOL, V39, P243, DOI 10.1016/0165-5728(92)90258-M; MOWAT A, 1987, IMMUNOL TODAY, V8, P193; NAGLERANDERSON C, 1986, P NATL ACAD SCI USA, V83, P7443, DOI 10.1073/pnas.83.19.7443; NUSSENBLATT RB, 1990, J IMMUNOL, V144, P1689; NUSSENBLATT RB, COMMUNICATION; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; SALK J, 1980, PROGR MULTIPLE SCLER, P429; THOMPSON HSG, 1986, CLIN EXP IMMUNOL, V64, P581; TRENTHAM DE, COMMUNICATION; WEINER HL, 1988, ANN NEUROL, V23, P211, DOI 10.1002/ana.410230302; WEINER HL, IN PRESS NEUROLOGY; Wells HG, 1911, J INFECT DIS, V9, P147, DOI 10.1093/infdis/9.2.147; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252; ZHANG ZYJ, 1990, J IMMUNOL, V145, P2489	31	568	596	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 26	1993	259	5099					1321	1324		10.1126/science.7680493	http://dx.doi.org/10.1126/science.7680493			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN883	7680493				2022-12-28	WOS:A1993KN88300030
J	PFEIFER, JD; WICK, MJ; ROBERTS, RL; FINDLAY, K; NORMARK, SJ; HARDING, CV				PFEIFER, JD; WICK, MJ; ROBERTS, RL; FINDLAY, K; NORMARK, SJ; HARDING, CV			PHAGOCYTIC PROCESSING OF BACTERIAL-ANTIGENS FOR CLASS-I MHC PRESENTATION TO T-CELLS	NATURE			English	Article							MEMBRANE PROTEIN; LYMPHOCYTES-T; SALMONELLA; INDUCTION; MOLECULES; TOPOLOGY; SURFACE; EPITOPE; INVIVO	CLASS I major histocompatibility complex (MHC) molecules present antigens that are produced within the presenting cell or penetrate from the vacuolar system into the cytosol for processing. Most studies of exogenous antigen processing have used soluble antigens, which are not efficiently presented by class I MHC molecules1 and do not elicit CD8 T-cell responses in vivo. But particulate antigen preparations with no known mechanism for cytosolic penetration can also elicit CD8 T-cell responses in vivo2-7. We report here that phagocytosis of bacteria with no mechanism for cytosolic penetration also results in presentation of bacterial antigens by class I MHC molecules. Moreover, this mechanism is resistant to cycloheximide and Brefeldin A, which block the classical class I processing pathway. These results suggest a novel vacuolar class I processing pathway for exogenous phagocytic antigens.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								AGGARWAL A, 1990, J EXP MED, V172, P1083, DOI 10.1084/jem.172.4.1083; ARNQVIST A, 1992, MOL MICROBIOL, V6, P2443; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BRUNT LM, 1990, J IMMUNOL, V145, P3540; BURGERT HG, 1989, J EXP MED, V170, P1887, DOI 10.1084/jem.170.6.1887; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CHARBIT A, 1986, EMBO J, V5, P3029, DOI 10.1002/j.1460-2075.1986.tb04602.x; CHARBIT A, 1991, J BACTERIOL, V173, P262, DOI 10.1128/jb.173.1.262-275.1991; COLLINS DS, 1992, J IMMUNOL, V148, P3336; DEBRICK JE, 1991, J IMMUNOL, V147, P2846; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FARRELL JP, 1989, J IMMUNOL, V142, P2052; FINLAY BB, 1989, MOL MICROBIOL, V3, P1833, DOI 10.1111/j.1365-2958.1989.tb00170.x; FLYNN JL, 1990, MOL MICROBIOL, V4, P2111, DOI 10.1111/j.1365-2958.1990.tb00572.x; GAO XM, 1992, INFECT IMMUN, V60, P3780, DOI 10.1128/IAI.60.9.3780-3789.1992; GOODING LR, 1980, J IMMUNOL, V124, P1258; GRANT EP, 1992, J IMMUNOL, V148, P13; HARDING CV, 1992, EUR J IMMUNOL, V22, P1865, DOI 10.1002/eji.1830220728; HARDING CV, 1991, J IMMUNOL, V147, P2860; HARDING CV, 1991, J IMMUNOL, V147, P767; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; MCREYNOLDS L, 1978, NATURE, V273, P723, DOI 10.1038/273723a0; MISRA R, 1988, J BACTERIOL, V170, P528, DOI 10.1128/jb.170.2.528-533.1988; OLSEN A, 1989, NATURE, V338, P652, DOI 10.1038/338652a0; PFEIFER JD, 1992, J IMMUNOL, V149, P2576; REDDY R, 1992, J IMMUNOL, V148, P1585; ROCK KL, 1990, SCIENCE, V249, P918, DOI 10.1126/science.2392683; SARMIENTO M, 1982, IMMUNOL REV, V68, P133; SMITH JD, 1992, P NATL ACAD SCI USA, V89, P7767, DOI 10.1073/pnas.89.16.7767	31	561	586	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					359	362		10.1038/361359a0	http://dx.doi.org/10.1038/361359a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	7678924				2022-12-28	WOS:A1993KJ59000060
J	WONG, JB; KOFF, RS; TINE, F; PAUKER, SG				WONG, JB; KOFF, RS; TINE, F; PAUKER, SG			COST-EFFECTIVENESS OF INTERFERON-ALPHA-2B TREATMENT FOR HEPATITIS-BE ANTIGEN-POSITIVE CHRONIC HEPATITIS-B	ANNALS OF INTERNAL MEDICINE			English	Review						COST-BENEFIT ANALYSIS; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; INTERFERON ALFA2B	CHRONIC ACTIVE HEPATITIS; RECOMBINANT ALPHA-INTERFERON; CHRONIC VIRAL-HEPATITIS; TERM FOLLOW-UP; PRIMARY HEPATOCELLULAR-CARCINOMA; POLYMERASE CHAIN-REACTION; VIRUS-INFECTION; SURFACE-ANTIGEN; CONTROLLED TRIAL; NATURAL-HISTORY	Objective: To estimate the cost-effectiveness of interferon-alpha 2B for the treatment of patients with chronic hepatitis B infection who are positive for hepatitis B e antigen (HBeAg). Design: Meta-analysis of nine randomized controlled trials and cost-effectiveness analysis, projecting the clinical and economic outcomes expected from changes in serologic markers of hepatitis B viral replication. Data Sources: MEDLINE search, expert panel opinion, hospital cost data, and adjusted physician charges. Patients: 552 patients with confirmed chronic hepatitis B infection who were positive for HBeAg. Intervention: Interferon-alpha 2b. Measurements: Lifetime incidence of cirrhosis and hepatocellular carcinoma; life expectancy; quality-adjusted life expectancy; and costs and marginal cost-effectiveness ratios from a societal perspective. Results: Interferon-alpha 2b increases the likelihood of becoming negative for HBeAg from 9.1% to 45.6% (difference, 36.5%; 95% CI, 23.7% to 49.2%) and of becoming negative for hepatitis B surface antigen from 1.7% to 7.7% (difference, 6.0%; CI, 2.8% to 9.3%) in the first year. For a 35-year-old person with chronic hepatitis B who is HBeAg positive, our analysis suggests that interferon-alpha 2b will increase life expectancy by 3.1 years or 3.4 quality-adjusted life-years and will decrease projected lifetime costs, even if future savings are discounted; thus, interferon-alpha 2b is the dominant strategy. Even with the model biased strongly in favor of standard care, the marginal cost-effectiveness ratio of interferon did not exceed $12 000 per life-year gained. Conclusions: Interferon-alpha 2b should prolong life and lower costs for patients with chronic hepatitis B who are HBeAg positive.	TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; METROWEST MED CTR, FRAMINGHAM, MA 01701 USA; V CERVELLO HOSP, I-90146 PALERMO, ITALY	Tufts University	WONG, JB (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, 750 WASHINGTON ST, BOX 302, BOSTON, MA 02111 USA.			Wong, John/0000-0003-4203-9010	NLM NIH HHS [LM04493] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [R01LM004493] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ALTER MJ, 1993, GUT, V34, pS17, DOI 10.1136/gut.34.2_Suppl.S17; ALWARD WLM, 1985, J INFECT DIS, V151, P604, DOI 10.1093/infdis/151.4.604; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; AREVALO JA, 1988, JAMA-J AM MED ASSOC, V259, P365, DOI 10.1001/jama.259.3.365; BAYRAKTAR Y, 1993, GUT, V34, pS101, DOI 10.1136/gut.34.2_Suppl.S101; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BEASLEY RP, 1982, HEPATOLOGY, V2, pS21; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BLOOM BS, 1993, ANN INTERN MED, V118, P298, DOI 10.7326/0003-4819-118-4-199302150-00009; BONINO F, 1986, GASTROENTEROLOGY, V90, P1268, DOI 10.1016/0016-5085(86)90395-1; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BROOK MG, 1989, HEPATOLOGY, V10, P761, DOI 10.1002/hep.1840100502; BROOK MG, 1989, J HEPATOL, V8, P218, DOI 10.1016/0168-8278(89)90010-X; BRUNETTO MR, 1989, HEPATOLOGY, V10, P198, DOI 10.1002/hep.1840100213; CARRENO V, 1992, J HEPATOL, V15, P102, DOI 10.1016/0168-8278(92)90019-L; COLOMBO M, 1992, J HEPATOL, V15, P225, DOI 10.1016/0168-8278(92)90041-M; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; DAMICO G, 1986, DIGEST DIS SCI, V31, P468, DOI 10.1007/BF01320309; DAVIS GL, 1984, GASTROENTEROLOGY, V86, P230; DEANCOS JLG, 1990, J HEPATOL, V11, pS11, DOI 10.1016/0168-8278(90)90157-M; DEFRANCHIS R, 1993, ANN INTERN MED, V118, P191, DOI 10.7326/0003-4819-118-3-199302010-00006; DEFRANCHIS R, 1980, GASTROENTEROLOGY, V79, P521, DOI 10.1016/0016-5085(80)90378-9; DEJONGH FE, 1992, GASTROENTEROLOGY, V103, P1630, DOI 10.1016/0016-5085(92)91188-A; DEMOURA MC, 1991, J HEPATOL, V13, pS12, DOI 10.1016/0168-8278(91)91714-R; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; DIBISCEGLIE AM, 1990, HEPATOLOGY, V11, P266, DOI 10.1002/hep.1840110217; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; DIBISCEGLIE AM, 1993, AM J GASTROENTEROL, V88, P1887; DIBISCEGLIE AM, 1987, GASTROENTEROLOGY, V93, P1236, DOI 10.1016/0016-5085(87)90250-2; DIBISCEGLIE AM, 1990, AM J GASTROENTEROL, V85, P650; DIBISCEGLIE AM, 1989, SEMIN LIVER DIS, V9, P254, DOI 10.1055/s-2008-1040519; DRAGOSICS B, 1987, HEPATOLOGY, V7, P302, DOI 10.1002/hep.1840070215; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; EVERHART JE, 1992, GASTROENTEROLOGY, V103, P1692, DOI 10.1016/0016-5085(92)91198-D; FATTOVICH G, 1986, HEPATOLOGY, V6, P167, DOI 10.1002/hep.1840060203; FATTOVICH G, 1991, GUT, V32, P294, DOI 10.1136/gut.32.3.294; FATTOVICH G, 1993, 7TH EUR WORKSH PAR; FEVERY J, 1990, J HEPATOL, V11, pS108, DOI 10.1016/0168-8278(90)90174-P; FRIEDMAN B, 1992, HLTH EC WORLDWIDE, V1992, P161; HADZIYANNIS S, 1990, J HEPATOL, V11, pS133, DOI 10.1016/0168-8278(90)90180-Y; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; HOOFNAGLE JH, 1987, HEPATOLOGY, V7, P758, DOI 10.1002/hep.1840070424; HOOFNAGLE JH, 1981, ANN INTERN MED, V94, P744, DOI 10.7326/0003-4819-94-6-744; HOOFNAGLE JH, 1993, GASTROENTEROLOGY, V104, P1116, DOI 10.1016/0016-5085(93)90281-G; HOOFNAGLE JH, 1991, JAMA-J AM MED ASSOC, V266, P849, DOI 10.1001/jama.266.6.849; IHDE DC, 1974, AM J MED, V56, P83, DOI 10.1016/0002-9343(74)90753-0; KAKUMU S, 1991, J MED VIROL, V35, P32, DOI 10.1002/jmv.1890350108; KANE MA, 1993, GUT, V34, pS10, DOI 10.1136/gut.34.2_Suppl.S10; KANE MA, 1989, AM J MED, V87, pS11, DOI 10.1016/0002-9343(89)90524-X; KANEKO S, 1990, GASTROENTEROLOGY, V99, P799; KASSIRER JP, 1981, NEW ENGL J MED, V305, P1465, DOI 10.1056/NEJM198112103052409; KORENMAN J, 1991, ANN INTERN MED, V114, P629, DOI 10.7326/0003-4819-114-8-629; KRAHN M, 1993, MED DECIS MAKING, V13, P4, DOI 10.1177/0272989X9301300103; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LANGE W, 1987, POSTGRAD MED J, V63, P21; LASHNER BA, 1988, AM J MED, V85, P609; LAU JYN, 1991, J MED VIROL, V34, P184, DOI 10.1002/jmv.1890340310; LIAW YF, 1989, LIVER, V9, P235; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; LIAW YF, 1983, GASTROENTEROLOGY, V84, P216; LISKERMELMAN M, 1989, ANN INTERN MED, V111, P479, DOI 10.7326/0003-4819-111-6-479; LO KJ, 1982, J INFECT DIS, V146, P205, DOI 10.1093/infdis/146.2.205; LOK ASF, 1990, HEPATOLOGY, V12, P1266, DOI 10.1002/hep.1840120603; LOK ASF, 1987, GASTROENTEROLOGY, V92, P1839, DOI 10.1016/0016-5085(87)90613-5; LOK ASF, 1992, GASTROENTEROLOGY, V102, P2091, DOI 10.1016/0016-5085(92)90337-X; MARCELLIN P, 1990, ANN INTERN MED, V112, P227, DOI 10.7326/0003-4819-112-3-227; MARGOLIS HS, 1991, SEMIN LIVER DIS, V11, P84, DOI 10.1055/s-2008-1040427; MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599; MCMAHON BJ, 1990, ARCH INTERN MED, V150, P1051, DOI 10.1001/archinte.150.5.1051; MORENOOTERO R, 1991, AM J GASTROENTEROL, V86, P560; MULLER R, 1991, HEPATO-GASTROENTEROL, V38, P4; MULLER R, 1990, J HEPATOL, V11, pS137, DOI 10.1016/0168-8278(90)90181-P; MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103; OBATA H, 1980, INT J CANCER, V25, P741, DOI 10.1002/ijc.2910250609; PASTORE G, 1992, J HEPATOL, V14, P221, DOI 10.1016/0168-8278(92)90161-H; PEREZ V, 1993, GUT, V34, pS91, DOI 10.1136/gut.34.2_Suppl.S91; Perrillo R P, 1981, Semin Liver Dis, V1, P15, DOI 10.1055/s-2008-1063926; PERRILLO RP, 1989, GASTROENTEROLOGY, V96, P532, DOI 10.1016/0016-5085(89)91583-7; PERRILLO RP, 1989, SEMIN LIVER DIS, V9, P240, DOI 10.1055/s-2008-1040517; PERRILLO RP, 1993, GUT, V34, pS48, DOI 10.1136/gut.34.2_Suppl.S48; PERRILLO RP, 1991, ANN INTERN MED, V115, P113, DOI 10.7326/0003-4819-115-2-113; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; PERRILLO RP, 1993, DIGEST DIS SCI, V38, P577, DOI 10.1007/BF01316785; PERRILLO RP, 1993, NEW ENGL J MED, V329, P1885, DOI 10.1056/NEJM199312163292512; PERRILLO RP, 1990, HEPATOLOGY, V12, P1433, DOI 10.1002/hep.1840120626; PERRILLO RP, 1991, GASTROENTEROLOGY, V100, P277; PERRILLO RP, 1993, J HEPATOL, pS56; REALDI G, 1980, GASTROENTEROLOGY, V79, P195; REDEKER AG, 1975, AM J MED SCI, V270, P9, DOI 10.1097/00000441-197507000-00003; RENAULT PF, 1987, ARCH INTERN MED, V147, P1577, DOI 10.1001/archinte.147.9.1577; RIZZETTO M, 1991, J HEPATOL, V13, P5, DOI 10.1016/0168-8278(91)90855-6; Rizzetto Mario, 1992, Journal of Hepatology, V17, pS3; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SAKUMA K, 1982, GASTROENTEROLOGY, V83, P114; SAMPLINER RE, 1979, AM J MED SCI, V277, P17, DOI 10.1097/00000441-197901000-00002; SEEFF LB, 1986, SEMIN LIVER DIS, V6, P11, DOI 10.1055/s-2008-1040788; SHELL JC, 1985, CANCER, V56, P660, DOI 10.1002/1097-0142(19850801)56:3<660::AID-CNCR2820560338>3.0.CO;2-F; SHERLOCK S, 1992, LANCET, V339, P802, DOI 10.1016/0140-6736(92)91916-V; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; TAKANO S, 1992, DIGEST DIS SCI, V37, P1633, DOI 10.1007/BF01299851; THOMAS HC, 1991, J HEPATOL, V13, pS4, DOI 10.1016/0168-8278(91)91712-P; TINE F, 1993, J HEPATOL, V18, P154, DOI 10.1016/S0168-8278(05)80241-7; VIOLA LA, 1981, LANCET, V2, P1156; WAKED I, 1990, J CHEMOTHERAPY, V2, P310, DOI 10.1080/1120009X.1990.11739035; WANDS JR, 1991, NEW ENGL J MED, V325, P729, DOI 10.1056/NEJM199109053251010; WASSERMAN Y, 1993, PHYSICIANS FEE REFER; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; WONG JB, 1990, ENDOCRIN METAB CLIN, V19, P741, DOI 10.1016/S0889-8529(18)30319-0; 1992, ST ANTHONYS DRG WORK; 1985, MMWR-MORBID MORTAL W, V34, P329; 1991, VITAL STATISTICS U A, V2; 1985, MMWR-MORBID MORTAL W, V34, P313; 1993, 1993 RED BOOK; 1993, MMWR-MORBID MORTAL W, V41, P969	119	180	185	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					664	675		10.7326/0003-4819-122-9-199505010-00004	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00004			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702228				2022-12-28	WOS:A1995QV15100004
J	SCHWAB, TM; CALLAHAM, ML; MADSEN, CD; UTECHT, TA				SCHWAB, TM; CALLAHAM, ML; MADSEN, CD; UTECHT, TA			A RANDOMIZED CLINICAL-TRIAL OF ACTIVE COMPRESSION-DECOMPRESSION CPR VS STANDARD CPR IN OUT-OF-HOSPITAL CARDIAC-ARREST IN 2 CITIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERPOSED ABDOMINAL COMPRESSION; CARDIOPULMONARY-RESUSCITATION; RACIAL-DIFFERENCES; BLOOD-FLOW; SURVIVAL; DEFIBRILLATION; VENTILATION; PREDICTION; PERFUSION; PIGS	Objective.-To compare the effectiveness of active compression-decompression (ACD) cardiopulmonary resuscitation (CPR) with a handheld suction device vs standard manual CPR in victims of out-of-hospital cardiopulmonary arrest. Design.-Prospective randomized clinical trial with crossover group design. Setting.-Emergency medical services (EMS) of a large (San Francisco) and medium-sized (Fresno) city in California. Patients.-All normothermic adult victims of out-of-hospital, nontraumatic cardiac arrest on whom CPR was performed by first responders. Intervention.-Patients were randomized to receive either standard manual CPR according to American Heart Association guidelines or ACD CPR, on first-responder contact. Main Outcome Measures.-Return of spontaneous circulation, admission to the intensive care unit, survival to hospital discharge, and neurological function at hospital discharge. Results.-The ACD group (n=117 in Fresno; n=297 in San Francisco) and standard group (n=136 in Fresno; n=310 in San Francisco) were similar with regard to demographic and prognostic variables, such as age, witnessed arrest and bystander CPR frequency, and initial cardiac rhythm. Average interval from 911 call activation to EMS responder arrival was 6.4 minutes in Fresno and 4.0 minutes in San Francisco, In Fresno, there was no difference between the ACD group and standard CPR group in return of spontaneous circulation (17% vs 20%; P=.68), hospital admission (16% vs 20%; P=.56), hospital discharge (5% vs 7%; P=.64), or cerebral performance category score at discharge (1.5 vs 1.6; P=.90). Similarly, in San Francisco there was no difference between the ACD group and standard CPR group in return of spontaneous circulation (19% vs 21%; P=.65), hospital admission (13.5% vs 14.5%; P=.79), hospital discharge (4.7% vs 5.5%; P=.80), or cerebral performance category score at discharge (2.2 vs 2.6; P=.31). There was no increase in significant complications associated with the use of ACD CPR. Conclusion.-There was no improvement in outcome with ACD CPR in out-of-hospital cardiac arrest in these two cities. Differences in study design, demographics, EMS systems, response intervals, training, and technique performance may contribute to the lack of improvement in initial resuscitation with ACD CPR compared with previous studies. Future research needs to control these variables to determine the reason for these differences in outcome.	UNIV CALIF SAN FRANCISCO,DIV EMERGENCY MED,SAN FRANCISCO,CA	University of California System; University of California San Francisco	SCHWAB, TM (corresponding author), UNIV CALIF SAN FRANCISCO,VALLEY MED CTR,SAN JOSE MED EDUC PROGRAM,DEPT EMERGENCY MED,FRESNO,CA 93702, USA.			Callaham, Michael/0000-0003-2284-256X				BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; BECKER LB, 1993, ANN EMERG MED, V22, P86, DOI 10.1016/S0196-0644(05)80257-4; BERRYMAN CR, 1984, ANN EMERG MED, V13, P226, DOI 10.1016/S0196-0644(84)80467-9; CALLAHAM M, 1990, CRIT CARE MED, V18, P358, DOI 10.1097/00003246-199004000-00002; CHANDRA N, 1980, LANCET, V1, P175; CHANG MW, 1992, CIRCULATION, V86, P233; COHEN TJ, 1992, JAMA-J AM MED ASSOC, V267, P2916, DOI 10.1001/jama.267.21.2916; COHEN TJ, 1992, AM HEART J, V124, P1145, DOI 10.1016/0002-8703(92)90393-A; COHEN TJ, 1993, NEW ENGL J MED, V329, P1918, DOI 10.1056/NEJM199312233292603; CORDELL WH, 1994, ANN EMERG MED, V23, P1032, DOI 10.1016/S0196-0644(94)70099-0; COWIE MR, 1993, AM J PUBLIC HEALTH, V83, P955, DOI 10.2105/AJPH.83.7.955; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; CUMMINS RO, 1990, ANN EMERG MED, V19, P1245, DOI 10.1016/S0196-0644(05)82282-6; DELGUERCIO LR, 1963, NEW ENGL J MED, V269, P1398, DOI 10.1056/NEJM196312262692603; EISENBERG MS, 1986, CIRCULATION, V74, P9; HALLSTROM A, 1993, AM J PUBLIC HEALTH, V83, P245, DOI 10.2105/AJPH.83.2.245; HOWARD M, 1987, ANN EMERG MED, V16, P253, DOI 10.1016/S0196-0644(87)80169-5; KERN KB, 1992, ANN EMERG MED, V21, P1066, DOI 10.1016/S0196-0644(05)80646-8; KRISCHER JP, 1989, CRIT CARE MED, V17, P1263, DOI 10.1097/00003246-198912000-00005; LINDNER KH, 1990, ANESTHESIOLOGY, V72, P675, DOI 10.1097/00000542-199004000-00017; LINDNER KH, 1993, CIRCULATION, V88, P1254, DOI 10.1161/01.CIR.88.3.1254; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; LURIE KG, 1994, JAMA-J AM MED ASSOC, V271, P1405, DOI 10.1001/jama.271.18.1405; LURIE KG, 1990, JAMA-J AM MED ASSOC, V264, P1661, DOI 10.1001/jama.1990.03450130031020; MATEER JR, 1985, AM J EMERG MED, V3, P143, DOI 10.1016/0735-6757(85)90038-5; SACK JB, 1992, CIRCULATION, V86, P1692, DOI 10.1161/01.CIR.86.6.1692; SANDERS AB, 1984, JAMA-J AM MED ASSOC, V252, P3283, DOI 10.1001/jama.252.23.3283; SHULTZ JJ, 1994, CIRCULATION, V89, P684, DOI 10.1161/01.CIR.89.2.684; TUCKER KJ, 1993, J AM COLL CARDIOL, V22, P1485, DOI 10.1016/0735-1097(93)90561-E; TUCKER KJ, 1994, J AM COLL CARDIOL, V24, P201, DOI 10.1016/0735-1097(94)90564-9; 1992, JAMA-J AM MED ASSOC, V268, P2199; 1992, JAMA-J AM MED ASSOC, V268, P2184; 1992, JAMA-J AM MED ASSOC, V268, P2171; 1986, AM J EMERG MED, V4, P72	34	110	111	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	1995	273	16					1261	1268		10.1001/jama.273.16.1261	http://dx.doi.org/10.1001/jama.273.16.1261			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU571	7715038				2022-12-28	WOS:A1995QU57100028
J	KOTTKE, TE; TRAPP, MA; FORES, MM; KELLY, AW; JUNG, SH; NOVOTNY, PJ; PANSER, LA				KOTTKE, TE; TRAPP, MA; FORES, MM; KELLY, AW; JUNG, SH; NOVOTNY, PJ; PANSER, LA			CANCER SCREENING BEHAVIORS AND ATTITUDES OF WOMEN IN SOUTHEASTERN MINNESOTA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OLDER WOMEN; MAMMOGRAPHY; PHYSICIANS; SMEAR	Objectives.-To determine the rates at which women received screening Papanicolaou tests, clinical breast examinations, and mammography and to determine the extent to which these women might be expected to respond to screening recommendations from their physicians. Design.-Random-digit-dial telephone interviews conducted in January 1993. Setting.-Fifteen counties in southeastern Minnesota. Subjects.-A sample of 1019 women who completed the telephone interview. Main Outcome Measures.-Self-reported Papanicolaou test, clinical breast examination, acid mammography screening rates, with verification from medical records for a randomly selected subsample of 200 respondents who reported having had a test within 1 year of the interview. Results.-For women aged 18 years and older, 60% (95% confidence interval, +/-3.4%) reported having had a Papanicolaou test within the preceding year. For women 40 years of age and older, 57% (95% confidence interval, +/-3,5%) reported having had a clinical breast examination in the past year, and 46% (95% confidence interval, +/-3,6%) reported having had a screening mammogram within 1 year. The verified 1-year Papanicolaou test and mammogram rates were 35% and 33%, respectively. More than 90% of the respondents expressed a willingness to have these tests if their physicians were to advise them that the tests were indicated. However, 53% and 54% of the respondents, respectively, said that they either did not care or did not want their physicians to remind them when they were due for a Papanicolaou test or a mammogram. Conclusions.-Although self-reported screening rates in this population meet Healthy People 2000 goals, verified rates were significantly below target levels. A substantial proportion of women in this population remain ambivalent about participating in cancer detection programs.			KOTTKE, TE (corresponding author), MAYO CLIN & MAYO FDN,NCI,DESIGNATED MAYO COMPREHENS CANC CTR,HARWICK 6,ROCHESTER,MN 55905, USA.				NCI NIH HHS [CA 57825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R25CA057825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackermann S P, 1992, MMWR CDC Surveill Summ, V41, P17; Akaike H, 1973, P 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15; BANDURA A, 1977, SOCIAL LEARNING THEO, P50; CUMMINGS KM, 1983, J FAM PRACTICE, V17, P1029; FREIDSON E, 1970, PROFESSION MED STUDY, P355; KAHNEMAN D, 1982, SCI AM, V246, P160, DOI 10.1038/scientificamerican0182-160; Kee F, 1992, Eur J Cancer Prev, V1, P311, DOI 10.1097/00008469-199206000-00006; KING ES, 1990, AM J PUBLIC HEALTH, V80, P1386, DOI 10.2105/AJPH.80.11.1386; KOTTKE T E, 1990, Journal of General Internal Medicine, V5, pS62, DOI 10.1007/BF02600845; KOTTKE TE, 1993, MAYO CLIN PROC, V68, P785, DOI 10.1016/S0025-6196(12)60638-7; KOTTKE TE, 1994, TOB CONTROL, V3, P46; LERMAN C, 1990, PREV MED, V19, P279, DOI 10.1016/0091-7435(90)90028-I; MOLLEMAN E, 1984, SOC SCI MED, V18, P475, DOI 10.1016/0277-9536(84)90003-0; MOODIE PJS, 1989, NEW ZEAL MED J, V102, P374; MOSELEY R, 1985, J MED PHILOS, V10, P163, DOI 10.1093/jmp/10.2.163; MURRAY M, 1993, J PUBLIC HEALTH MED, V15, P147; RATZAN RM, 1985, J MED PHILOS, V10, P147, DOI 10.1093/jmp/10.2.147; RESNIK MD, 1987, CHOICES INTRO DECISI, P8; Rimer B K, 1990, J Am Board Fam Pract, V3, P26; ROGERS EM, 1983, DIFFUSION INNOVATION, P250; SAWYER JA, 1989, AM J PUBLIC HEALTH, V79, P1036, DOI 10.2105/AJPH.79.8.1036; SKINNER BF, 1959, CUMULATIVE RECORD, P21; STEPTOE A, 1991, SOC SCI MED, V32, P627, DOI 10.1016/0277-9536(91)90141-X; WARNECKE RB, 1976, CANCER, V37, P2015, DOI 10.1002/1097-0142(197604)37:4<2015::AID-CNCR2820370453>3.0.CO;2-X; WEINBERGER M, 1991, J AM GERIATR SOC, V39, P22, DOI 10.1111/j.1532-5415.1991.tb05901.x; ZAPKA JG, 1992, J GERONTOL, V47, P93; 1989, GUIDE CLIN PREVENTIV, P39; 1990, SAS STAT USERS GUIDE, V2, P1071; 1991, PHS9150212 DEP HLTH; 1993, MMWR-MORBID MORTAL W, V42, P1	30	65	66	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1099	1105		10.1001/jama.273.14.1099	http://dx.doi.org/10.1001/jama.273.14.1099			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QR059	7707597				2022-12-28	WOS:A1995QR05900028
J	WARDEN, J				WARDEN, J			OMBUDSMAN IN A WHITE COAT	BRITISH MEDICAL JOURNAL			English	Editorial Material																		WARDEN J, 1995, BRIT MED J, V310, P824, DOI 10.1136/bmj.310.6983.824a	1	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 1	1995	310	6983					826	826		10.1136/bmj.310.6983.826a	http://dx.doi.org/10.1136/bmj.310.6983.826a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711617				2022-12-28	WOS:A1995QQ85700015
J	RUBERTE, E; MARTY, T; NELLEN, D; AFFOLTER, M; BASLER, K				RUBERTE, E; MARTY, T; NELLEN, D; AFFOLTER, M; BASLER, K			AN ABSOLUTE REQUIREMENT FOR BOTH THE TYPE-II AND TYPE-I RECEPTORS, PUNT AND THICK VEINS, FOR DPP SIGNALING IN-VIVO	CELL			English	Article							SERINE THREONINE KINASE; DAUER LARVA DEVELOPMENT; DORSAL VENTRAL AXIS; DROSOPHILA EMBRYO; ACTIVIN RECEPTOR; TGF-BETA; GERM LAYERS; EXPRESSION CLONING; VISCERAL MESODERM; GENE	TGF beta elicits diverse cellular responses by signaling through receptor complexes formed by two distantly related transmembrane serine/threonine kinases called type II and type I receptors. Previous studies have indicated that the product of the Drosophila thick veins (tkv) gene is a type I receptor for decapentaplegic (dpp). Here, we show that the Drosophila gene punt encodes a homolog of a vertebrate type II receptor, and we demonstrate that punt, like tkv, is essential in vivo for dpp-dependent patterning processes. Because no dpp-related signaling is apparent in the absence of either the punt or tkv receptor, we infer that both receptors act in concert to transduce the dpp signal and that their functions cannot be replaced by the other extant type II and I receptors.	UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich	RUBERTE, E (corresponding author), UNIV BASEL,BIOCTR,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.			Basler, Konrad/0000-0003-3534-1529; Affolter, Markus/0000-0002-5171-0016				AFFOLTER M, 1994, DEVELOPMENT, V120, P3105; AFFOLTER M, 1993, DEVELOPMENT, V117, P1199; AZPLAZU N, 1993, GENE DEV, V7, P1325; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BASSING CH, 1994, J BIOL CHEM, V269, P14831; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BODMER R, 1993, DEVELOPMENT, V118, P719; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; CHOU TB, 1993, DEVELOPMENT, V119, P1359; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HARTENSTEIN V, 1992, ROUX ARCH DEV BIOL, V201, P194, DOI 10.1007/BF00188752; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KARPEN GH, 1992, GENETICS, V132, P737; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Manning Gerards, 1993, P609; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; RAY RP, 1991, DEVELOPMENT, V113, P35; REUTER R, 1990, DEVELOPMENT, V110, P1031; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837	51	247	258	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					889	897		10.1016/0092-8674(95)90292-9	http://dx.doi.org/10.1016/0092-8674(95)90292-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697719	Green Accepted, Bronze			2022-12-28	WOS:A1995QP61200008
J	RAMSAHOYE, BH; DAVIES, SV; ELGAYLANI, N; SANDEMAN, D; SCANLON, MF				RAMSAHOYE, BH; DAVIES, SV; ELGAYLANI, N; SANDEMAN, D; SCANLON, MF			LESSON OF THE WEEK - THE MINERALOCORTICOID EFFECTS OF HIGH-DOSE HYDROCORTISONE	BRITISH MEDICAL JOURNAL			English	Article									UNIV WALES HOSP,DEPT CARDIOL,CARDIFF CF4 4XW,S GLAM,WALES; UNIV WALES HOSP,DEPT MED,CARDIFF CF4 4XW,S GLAM,WALES	Cardiff University; Cardiff University	RAMSAHOYE, BH (corresponding author), UNIV WALES HOSP,DEPT HAEMATOL,HEATH PK,CARDIFF CF4 4XW,S GLAM,WALES.							ANDREOLI EA, 1992, CECIL TXB MED, P499; DUBBELD P, 1991, NETH J MED, V39, P6; HAYNES RC, 1990, GOODMAN GILMANS PHAR, P1446; HEATON FW, 1962, LANCET, V2, P802; KALBFLEISCH JM, 1963, J CLIN INVEST, V42, P1471, DOI 10.1172/JCI104831; MYERBURG RJ, 1990, HARRISONS PRINCIPLES, P850; WHANG R, 1985, ARCH INTERN MED, V145, P1686	7	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					656	657		10.1136/bmj.310.6980.656	http://dx.doi.org/10.1136/bmj.310.6980.656			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703757	Green Published			2022-12-28	WOS:A1995QL98400026
J	RASHID, A; ALLEN, J; STYLES, B; GRAY, DP				RASHID, A; ALLEN, J; STYLES, B; GRAY, DP			CAREERS IN ACADEMIC GENERAL-PRACTICE - PROBLEMS, CONSTRAINTS, AND OPPORTUNITIES	BRITISH MEDICAL JOURNAL			English	Article							UNDERGRADUATE MEDICAL-EDUCATION; FUTURE; BASE	Changing priorities in the NHS have underlined the crucial importance of academic general practice in providing quality training and research to underpin developments in general practice. Unfortunately, several problems and constraints mean that the full potential of general practitioners to make a contribution to teaching and research has not been realised. These issues are examined and recommendations for improvements are made. Obstacles to career development for academics in general practice should be removed. The funding of academic general practice should be the same as for other medical disciplines. Vocational training for general practice should be extended to include research and audit methods, particularly for doctors interested in an academic career. Above all, the long term objective should be to integrate undergraduate and postgraduate general practice to increase the overall effectiveness of teaching and research and hence the quality of service general practice.	COUNTESTHORPE HLTH CTR,LEICESTER LE8 3QJ,LEICS,ENGLAND		RASHID, A (corresponding author), ROYAL COLL GEN PRACTIONERS,LONDON SW7 1PU,ENGLAND.			PEREIRA GRAY, DENIS/0000-0001-7917-3841				ALLEN J, 1993, BRIT MED J, V307, P719, DOI 10.1136/bmj.307.6906.719; EDWARDS B, 1987, DISTINCTION MERIT AW; FRASER RC, 1991, BRIT MED J, V303, P41, DOI 10.1136/bmj.303.6793.41; Fraser RC, 1988, 42 ROYAL COLL GEN PR; GRAY DP, 1991, BRIT MED J, V302, P1380, DOI 10.1136/bmj.302.6789.1380; HARRIES BJ, 1987, LANCET, V2, P746; HART JT, 1985, J ROY COLL GEN PRACT, V35, P63; HOOPER J, 1990, BR J GEN PRACT, V336, P268; HOWIE JER, 1986, MACKENZIE REPORT; MACAVOY PA, 1990, MED TEACH, V12, P33; OBYRNE GA, 1988, BRIT MED J, V296, P838, DOI 10.1136/bmj.296.6625.838; OSWALD N, 1989, LANCET, V2, P148; OSWALD N, 1991, BRIT MED J, V303, P71, DOI 10.1136/bmj.303.6794.71; Pereira Gray D., 1993, POSTGRADUATE ED GENE, V4, P85; PETERS DK, 1992, BRIT MED J, V304, P651, DOI 10.1136/bmj.304.6828.651; WILLIAMS AHE, 34 ROYAL COLL GEN PR; WILLIAMS WO, 1990, BRIT J GEN PRACT, V40, P491; 1990, 49 ROYAL COLL GEN PR; 1994, ED TRAINING GENERAL	19	6	6	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 12	1994	309	6964					1270	1272		10.1136/bmj.309.6964.1270	http://dx.doi.org/10.1136/bmj.309.6964.1270			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7710564	Green Published			2022-12-28	WOS:A1994PT03300024
J	HINTON, A; MOOREGILLON, V				HINTON, A; MOOREGILLON, V			RECENT ADVANCES - OTORHINOLARYNGOLOGY	BRITISH MEDICAL JOURNAL			English	Article							OTOACOUSTIC EMISSIONS; CHILDREN; LASER; IMPLANTS; SURGERY; BONE				HINTON, A (corresponding author), ST GEORGE HOSP,DEPT OTORHINOLARYNGOL,LONDON SW17 0QT,ENGLAND.							ANHOLT RRH, 1993, CRIT REV NEUROBIOL, V7, P1; Cain P, 1993, Biomed Sci Instrum, V29, P291; COHEN NL, 1993, NEW ENGL J MED, V328, P233, DOI 10.1056/NEJM199301283280403; COTICCHIA JM, 1993, AM J OTOL, V14, P230; CROFT CB, 1990, J LARYNGOL OTOL, V104, P871, DOI 10.1017/S0022215100114215; Earnshaw R. A., 1993, VIRTUAL REALITY SYST, P327; ELLIS PDM, 1993, ANN ROY COLL SURG, V75, P286; GOODE R, 1991, MED CLIN N AM, V75, P1261, DOI 10.1016/S0025-7125(16)30386-8; GREEN DC, 1992, LARYNGOSCOPE, V102, P14; HAGEN R, 1990, LARYNGO RHINO OTOL, V69, P213, DOI 10.1055/s-2007-998177; HERDMAN RCD, 1993, J LARYNGOL OTOL, V107, P908, DOI 10.1017/S0022215100124764; JACOBSSON M, 1992, INT J PEDIATR OTORHI, V24, P235, DOI 10.1016/0165-5876(92)90021-G; Kaluskar S. K., 1993, Rhinology (Utrecht), V31, P49; KOIVUKANGAS J, 1993, J NEUROSURG, V79, P36, DOI 10.3171/jns.1993.79.1.0036; KORFF M, 1992, OTOLARYNG HEAD NECK, V106, P345, DOI 10.1177/019459989210600405; LEIGHTON SEJ, 1993, CLIN OTOLARYNGOL, V18, P215; LUETJE CM, 1992, LARYNGOSCOPE, V102, P23; LUND VJ, 1994, J ROY SOC MED, V87, P70; MCGEE TM, 1991, LARYNGOSCOPE, V101, P355; Migueis A, 1991, Rev Laryngol Otol Rhinol (Bord), V112, P269; NORTON SJ, 1993, EAR HEARING, V14, P64, DOI 10.1097/00003446-199302000-00009; OWENS JJ, 1993, AM J OTOL, V14, P34; PROOPS DW, 1993, J LARYNGOL OTOL, V107, P99, DOI 10.1017/S0022215100122327; ZOROWKA PG, 1993, EUR J PEDIATR, V152, P626, DOI 10.1007/BF01955236	24	3	3	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					651	654		10.1136/bmj.309.6955.651	http://dx.doi.org/10.1136/bmj.309.6955.651			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	7695693	Green Published			2022-12-28	WOS:A1994PG02000032
J	BAUMHUETER, S; SINGER, MS; HENZEL, W; HEMMERICH, S; RENZ, M; ROSEN, SD; LASKY, LA				BAUMHUETER, S; SINGER, MS; HENZEL, W; HEMMERICH, S; RENZ, M; ROSEN, SD; LASKY, LA			BINDING OF L-SELECTIN TO THE VASCULAR SIALOMUCIN CD34	SCIENCE			English	Article							LYMPHOCYTE HOMING RECEPTOR; ENDOTHELIAL LIGAND; IGG CHIMERA; CELLS; ADHESION; ANTIGEN; INFLAMMATION; VENULES; LECAM-1; INVIVO	The adhesive interactions between leukocyte L-selectin and the endothelium are involved in the migration of lymphocytes through peripheral lymph nodes and of neutrophils to sites of inflammation. A recombinant L-selectin stains high endothelial venules (HEVs) in lymph nodes and recognizes sulfated carbohydrates found on two endothelial glycoproteins, Sgp50 and Sgp90. Amino acid sequencing of purified Sgp90 revealed a protein core identical to that of CD34, a sialomucin expressed on hematopoietic stem cells and endothelium. A polyclonal antiserum to recombinant murine CD34 stains peripheral lymph node endothelium and recognizes Sgp90 that is functionally bound by L-selectin. Thus, an HEV glycoform of CD34 can function as a ligand for L-selectin.	GENENTECH INC, DEPT IMMUNOL, San Francisco, CA 94080 USA; GENENTECH INC, DEPT PROT CHEM, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, PROGRAM IMMUNOL, SAN FRANCISCO, CA 94143 USA	Roche Holding; Genentech; Roche Holding; Genentech; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Henzel, William/0000-0003-2940-3797	NIGMS NIH HHS [GM 23547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023547, R01GM023547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUMHUETER S, UNPUB; BERENSON RJ, 1988, J CLIN INVEST, V81, P951, DOI 10.1172/JCI113409; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BRADY HR, 1992, J IMMUNOL, V149, P2437; BROWN J, 1991, INT IMMUNOL, V3, P175, DOI 10.1093/intimm/3.2.175; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CIVIN CI, 1984, J IMMUNOL, V133, P157; DELIA D, 1993, BLOOD, V81, P1001; FINA L, 1990, BLOOD, V75, P2417; HENZEL WJ, 1990, ANAL BIOCHEM, V187, P228, DOI 10.1016/0003-2697(90)90448-I; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1993, NATURE, V361, P555; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KATZ RC, 1986, J BEHAV MED, V9, P191, DOI 10.1007/BF00848477; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEY K, 1991, BLOOD, V77, P2553; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SUTHERLAND DR, 1988, LEUKEMIA, V2, P793; TRUE DD, 1990, J CELL BIOL, V111, P2757, DOI 10.1083/jcb.111.6.2757; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0	27	594	616	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1993	262	5132					436	438		10.1126/science.7692600	http://dx.doi.org/10.1126/science.7692600			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	7692600				2022-12-28	WOS:A1993MB85900063
J	SHUAI, K; STARK, GR; KERR, IM; DARNELL, JE				SHUAI, K; STARK, GR; KERR, IM; DARNELL, JE			A SINGLE PHOSPHOTYROSINE RESIDUE OF STAT91 REQUIRED FOR GENE ACTIVATION BY INTERFERON-GAMMA	SCIENCE			English	Article							ALPHA-INTERFERON; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; BINDING PROTEIN; MUTANT	Interferon-gamma (IFN-gamma) stimulates transcription of specific genes by inducing tyrosine phosphorylation of a 91-kilodalton cytoplasmic protein (termed STAT for signal transducer and activator of transcription). Stat91 was phosphorylated on a single site (Tyr701), and phosphorylation of this site was required for nuclear translocation, DNA binding, and gene activation. Stat84, a differentially spliced product of the same gene that lacks the 38 carboxyl-terminal amino acids of Stat91, did not activate transcription, although it was phosphorylated and translocated to the nucleus and bound DNA. Thus, Stat91 mediates activation of transcription in response to IFN-gamma.	ROCKEFELLER UNIV, MOLEC CELL BIOL LAB, NEW YORK, NY 10021 USA; CLEVELAND CLIN FDN, RES INST, CLEVELAND, OH 44195 USA; IMPERIAL CANC RES FDN, LONDON, ENGLAND	Rockefeller University; Cleveland Clinic Foundation					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32489-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; IMPROTA T, UNPUB; KAWASAKI E, 1990, PRC PROTOCOLS GUIDE, P119; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MULLER M, IN PRESS EMBO J; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, UNPUB; WALAAS SI, 1989, J MOL NEUROSCI, V1, P117, DOI 10.1007/BF02918897	17	718	738	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	1993	261	5129					1744	1746		10.1126/science.7690989	http://dx.doi.org/10.1126/science.7690989			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	7690989				2022-12-28	WOS:A1993LY58400029
J	ZHANG, JW; MEDAER, R; STINISSEN, P; HAFLER, D; RAUS, J				ZHANG, JW; MEDAER, R; STINISSEN, P; HAFLER, D; RAUS, J			MHC-RESTRICTED DEPLETION OF HUMAN MYELIN BASIC-PROTEIN REACTIVE T-CELLS BY T-CELL VACCINATION	SCIENCE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; LYMPHOCYTE-T; SELECTION; REGION	Activated autoreactive T cells are potentially pathogenic and regulated by clonotypic networks. Experimental autoimmune diseases can be treated by inoculation with autoreactive T cells (T cell vaccination). In the present study, patients with multiple sclerosis were inoculated with irradiated myelin basic protein (MBP)-reactive T cells. T cell responses to the inoculates were induced to deplete circulating MBP-reactive T cells in the recipients. Regulatory T cell lines isolated from the recipients inhibited T cells used for vaccination. The cytotoxicity of the CDB+ T cell lines was restricted by major histocompatibility antigens. Thus, clonotypic interactions regulating autoreactive T cells in humans can be induced by T cell vaccination.	DR L WILLEMS INST,DEPT IMMUNOL,B-3590 DIEPENBEEK,BELGIUM; BRIGHAM & WOMENS HOSP,DEPT MED,DIV NEUROL,CTR NEUROL DIS,BOSTON,MA 02115; LIMBURGS UNIV CENTRUM,B-3590 DIEPENBEEK,BELGIUM; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Hasselt University; Harvard University; Brigham & Women's Hospital; Hasselt University; Harvard University; Harvard Medical School	ZHANG, JW (corresponding author), DR L WILLEMS INST,MULTIPLE SCLEROSIS RES UNIT,B-3590 DIEPENBEEK,BELGIUM.							ALLEGRETTA M, 1990, SCIENCE, V247, P718, DOI 10.1126/science.1689076; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; COHEN IR, 1992, IMMUNOL TODAY, V13, P441, DOI 10.1016/0167-5699(92)90071-E; HAFLER DA, 1992, CLIN IMMUNOL IMMUNOP, V62, P307, DOI 10.1016/0090-1229(92)90108-Z; LAMB JR, 1982, NATURE, V300, P456, DOI 10.1038/300456a0; LEFKOVITS I, 1984, IMMUNOL TODAY, V5, P265, DOI 10.1016/0167-5699(84)90137-3; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; LOHSE AW, 1989, SCIENCE, V244, P820, DOI 10.1126/science.2471264; LOHSE AW, 1991, AUTOIMMUNITY, V9, P119, DOI 10.3109/08916939109006747; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; SARUHANDIRESKENELI G, 1993, EUR J IMMUNOL, V23, P530, DOI 10.1002/eji.1830230235; SCHLUESENER HJ, 1985, J IMMUNOL, V135, P3128; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; ZAMVIL S, 1985, NATURE, V317, P355, DOI 10.1038/317355a0; Zhang J, 1992, Int Rev Immunol, V9, P183, DOI 10.3109/08830189209061790; ZHANG J, UNPUB; ZHANG JW, 1992, ANN NEUROL, V32, P330	21	239	269	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 10	1993	261	5127					1451	1454		10.1126/science.7690157	http://dx.doi.org/10.1126/science.7690157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	7690157				2022-12-28	WOS:A1993LW54900034
J	HORUK, R; CHITNIS, CE; DARBONNE, WC; COLBY, TJ; RYBICKI, A; HADLEY, TJ; MILLER, LH				HORUK, R; CHITNIS, CE; DARBONNE, WC; COLBY, TJ; RYBICKI, A; HADLEY, TJ; MILLER, LH			A RECEPTOR FOR THE MALARIAL PARASITE PLASMODIUM-VIVAX - THE ERYTHROCYTE CHEMOKINE RECEPTOR	SCIENCE			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; KNOWLESI MALARIA; CYTOKINE FAMILY; SPECIFICITY; ANTIGEN; PROTEIN	Plasmodium vivax and P. falciparum are the major causes of human malaria, except in sub-Saharan Africa where people lack the Duffy blood group antigen, the erythrocyte receptor for P. vivax. Duffy negative human erythrocytes are resistant to invasion by P. vivax and the related monkey malaria, P. knowlesi. Several lines of evidence in the present study indicate that the Duffy blood group antigen is the erythrocyte receptor for the chemokines interleukin-8 (IL-8) and melanoma growth stimulatory activity (MGSA). First, IL-8 binds minimally to Duffy negative erythrocytes. Second, a monoclonal antibody to the Duffy blood group antigen blocked binding of IL-8 and other chemokines to Duffy positive erythrocytes. Third, both MGSA and IL-8 blocked the binding of the parasite ligand and the invasion of human erythrocytes by P. knowlesi, suggesting the possibility of receptor blockade for anti-malarial therapy.	NIH,MALARIA RES LAB,BETHESDA,MD 20892; MONTEFIORE MED CTR,BRONX,NY 10467; JG BROWN CANC CTR,DIV MED ONCOL HEMATOL,LOUISVILLE,KY 40292	National Institutes of Health (NIH) - USA; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	HORUK, R (corresponding author), GENENTECH INC,S SAN FRANCISCO,CA 94080, USA.			Chitnis, Chetan/0000-0002-8773-9865	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041382] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 41382] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARINAGA M, 1992, SCIENCE, V258, P1730, DOI 10.1126/science.1334571; BRADLEY DJ, 1987, OXFORD TXB MED, V1, pCH5; BROUN GO, 1966, NEW ENGL J MED, V275, P1410, DOI 10.1056/NEJM196612222752504; CHAUDHURI A, 1989, J BIOL CHEM, V264, P13770; DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442; DARBONNE WC, UNPUB; GOODING LR, 1992, CELL, V71, P5; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HADLEY TJ, 1984, SCIENCE, V223, P597, DOI 10.1126/science.6695171; HAYNES JD, 1988, J EXP MED, V167, P1873, DOI 10.1084/jem.167.6.1873; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1993, BIOCHEMISTRY-US, V32, P5733, DOI 10.1021/bi00073a002; HORUK R, 1993, J BIOL CHEM, V268, P541; HORUK R, UNPUB; LEE J, 1992, J BIOL CHEM, V267, P16283; MARSH W L, 1975, Critical Reviews in Clinical Laboratory Sciences, V5, P387, DOI 10.3109/10408367509107049; MILLER LH, 1975, SCIENCE, V189, P561, DOI 10.1126/science.1145213; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; MILLER LH, 1977, J EXP MED, V146, P277, DOI 10.1084/jem.146.1.277; MURPHY GS, 1993, LANCET, V341, P96, DOI 10.1016/0140-6736(93)92568-E; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, J BIOL CHEM, V268, P12247; NICHOLS ME, 1987, J EXP MED, V166, P776, DOI 10.1084/jem.166.3.776; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; WASNIOWSKA K, 1993, BIOCHEM BIOPH RES CO, V192, P366, DOI 10.1006/bbrc.1993.1424	27	479	497	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1182	1184		10.1126/science.7689250	http://dx.doi.org/10.1126/science.7689250			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	7689250	Green Submitted			2022-12-28	WOS:A1993LU58600036
J	DESAI, SA; KROGSTAD, DJ; MCCLESKEY, EW				DESAI, SA; KROGSTAD, DJ; MCCLESKEY, EW			A NUTRIENT-PERMEABLE CHANNEL ON THE INTRAERYTHROCYTIC MALARIA PARASITE	NATURE			English	Article							HOST-CELL MEMBRANE; PLASMODIUM-FALCIPARUM; MITOCHONDRIAL-MEMBRANE; ERYTHROCYTIC STAGES; PRECURSORS; TRANSPORT; PATHWAY; CULTURE	DURING its 48-hour cycle inside the red blood cell, the human malaria parasite, Plasmodium falciparum, increases its volume 25-fold and divides asexually. This rapid growth demands large amounts of nutrients, a problem exacerbated by the lower metabolic rate and relative ionic impermeability of the host red blood cell. Direct passage of small nutrients across the two membranes that separate the parasite from the erythrocyte cytosol may be important for parasite development, and has been demonstrated for radiolabelled glucose2, amino acids3,4 and purine nucleosides4-6. Flux studies on plasmodia are limited, however, to suspensions of erythrocyte-free parasites and so cannot be used to examine the individual transport properties of the two membranes involved. Here we use the cell-attached patch clamp method7 to overcome this limitation. After removing the intervening red blood cell membrane and forming gigaohm seals on the small (3-5 mum) parasite, we studied transport across the parasitophorous vacuole membrane (PVM), the outer of the two membranes that separate the parasite from the erythrocyte cytosol. A 140-pS channel which is permeable to both cations and anions was identified on the PVM. This channel is present at high density, is open more than 98 per cent of the time at the resting potential of the PVM, and is permeable to lysine and glucuronate. The channel can readily transport amino acids and monosaccharides across the PVM and may be essential for fulfilling the parasite's metabolic demands.	WASHINGTON UNIV,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT MECH ENGN,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Desai, Sanjay A/B-7110-2009	Desai, Sanjay/0000-0003-2150-2483				BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BENZ R, 1985, CRC CR REV BIOCH MOL, V19, P145, DOI 10.3109/10409238509082542; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; FRANCIOLINI F, 1987, J GEN PHYSIOL, V90, P453, DOI 10.1085/jgp.90.4.453; GERO AM, 1991, ADV EXP MED BIOL, V309, P169; GINSBERG H, 1990, COMP BIOCHEM PHYS A, V95, P31, DOI 10.1016/0300-9629(90)90006-E; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; HALDAR K, 1992, MOL BIOCHEM PARASIT, V50, P161, DOI 10.1016/0166-6851(92)90253-G; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANSEN BD, 1980, J PARASITOL, V66, P205, DOI 10.2307/3280805; HUNTER M, 1987, NATURE, V327, P522, DOI 10.1038/327522a0; IZUMO A, 1988, COMP BIOCHEM PHYS B, V91, P735, DOI 10.1016/0305-0491(88)90201-5; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; KANAANI J, 1989, J BIOL CHEM, V264, P3194; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LANGRETH SG, 1977, B WORLD HEALTH ORGAN, V55, P171; LEE P, 1988, AM J TROP MED HYG, V39, P157, DOI 10.4269/ajtmh.1988.39.157; MIKKELSEN RB, 1986, MOL BIOCHEM PARASIT, V21, P83, DOI 10.1016/0166-6851(86)90082-4; POUVELLE B, 1991, NATURE, V353, P73, DOI 10.1038/353073a0; SCHROEDER JE, 1991, NEURON, V6, P13, DOI 10.1016/0896-6273(91)90117-I; SHERMAN IW, 1977, B WORLD HEALTH ORGAN, V55, P211; SHERMAN IW, 1988, PARASITOLOGY, V96, pS57, DOI 10.1017/S003118200008598X; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; TANABE K, 1990, PARASITOL TODAY, V6, P225, DOI 10.1016/0169-4758(90)90199-E; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRAGER W, 1971, J PROTOZOOL, V18, P392, DOI 10.1111/j.1550-7408.1971.tb03341.x; WIBO M, 1981, J CELL BIOL, V89, P456, DOI 10.1083/jcb.89.3.456; YAMADA KA, 1981, MOL BIOCHEM PARASIT, V3, P253, DOI 10.1016/0166-6851(81)90056-6	29	174	181	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 15	1993	362	6421					643	646		10.1038/362643a0	http://dx.doi.org/10.1038/362643a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX438	7681937				2022-12-28	WOS:A1993KX43800052
J	ANDERSEN, B; SCHONEMANN, MD; FLYNN, SE; PEARSE, RV; SINGH, H; ROSENFELD, MG				ANDERSEN, B; SCHONEMANN, MD; FLYNN, SE; PEARSE, RV; SINGH, H; ROSENFELD, MG			SKN-1A AND SKN-1I - 2 FUNCTIONALLY DISTINCT OCT-2-RELATED FACTORS EXPRESSED IN EPIDERMIS	SCIENCE			English	Article							NF-KAPPA-B; STEROID BINDING DOMAIN; PREVENTS DNA-BINDING; POU-SPECIFIC DOMAIN; TRANSCRIPTION FACTOR; GLUCOCORTICOID RECEPTOR; CELL IDENTITY; C-ELEGANS; PROTEIN; GENE	Two forms of a member of the POU domain family of transcriptional regulators, highly related to Oct-2, are selectively expressed in terminally differentiating epidermis and hair follicles. One form, referred to as Skn-1i, contains an amino-terminal domain that inhibits DNA binding and can inhibit transactivation by Oct-1. A second form, Skn-1a, contains an alternative amino terminus and serves to activate cytokeratin 10 (K10) gene expression. The pattern of expression of the Skn-1a/i gene products and the effect of the alternative products on the expression of other genes suggest that these factors serve regulatory functions with respect to epidermal development.	UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	Howard Hughes Medical Institute; University of Chicago	ANDERSEN, B (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,EUKARYOT REGULATORY BIOL PROGRAM,LA JOLLA,CA 92093, USA.			Pearse, Richard/0000-0003-3972-1457	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039949, R37DK039949] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39949] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN BM, UNPUB; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DAVIDSON P, 1952, J ANAT, V86, P342; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; FISHER GJ, 1991, J INVEST DERMATOL, V96, P699, DOI 10.1111/1523-1747.ep12470632; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; FUCHS E, 1988, TRENDS GENET, V4, P277, DOI 10.1016/0168-9525(88)90169-2; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOLDSBOROUGH A, 1990, NUCLEIC ACIDS RES, V18, P1634, DOI 10.1093/nar/18.6.1634; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HOGAN B, 1986, MANIPULATING MOUSE E; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; INGRAHAM HA, 1988, NATURE, V55, P505; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; KOPAN R, 1989, GENE DEV, V3, P1, DOI 10.1101/gad.3.1.1; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; PRATT WB, 1988, J BIOL CHEM, V263, P267; RIEGER M, 1988, J MOL BIOL, V204, P841, DOI 10.1016/0022-2836(88)90045-9; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; VERRIJZER CP, 1992, MOL CELL BIOL, V12, P542, DOI 10.1128/MCB.12.2.542; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	59	105	107	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					78	82		10.1126/science.7682011	http://dx.doi.org/10.1126/science.7682011			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	7682011				2022-12-28	WOS:A1993KV42300031
J	ROBERT, LM; CHAMBERLAND, ME; CLEVELAND, JL; MARCUS, R; GOOCH, BF; SRIVASTAVA, PU; CULVER, DH; JAFFE, HW; MARIANOS, DW; PANLILIO, AL; BELL, DM				ROBERT, LM; CHAMBERLAND, ME; CLEVELAND, JL; MARCUS, R; GOOCH, BF; SRIVASTAVA, PU; CULVER, DH; JAFFE, HW; MARIANOS, DW; PANLILIO, AL; BELL, DM			INVESTIGATIONS OF PATIENTS OF HEALTH-CARE WORKERS INFECTED WITH HIV - THE CENTERS-FOR-DISEASE-CONTROL AND PREVENTION DATABASE	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HEALTH PERSONNEL; DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT; ACQUIRED IMMUNODEFICIENCY SYNDROME; RISK	HUMAN-IMMUNODEFICIENCY-VIRUS; LOOK-BACK; TRANSMISSION; SURGEON; DENTISTS; ABSENCE; RISK	Objective: To assess the risk for transmission of the human immunodeficiency virus (HIV) from an infected health care worker to patients. Design: Survey of investigators from health departments, hospitals, and other agencies who had elected to notify patients who had received care from health care workers infected with HIV. Measurements: Information was collected about infected health care workers, their work practices, their patients' HIV test results, procedures that they did on those of their patients who were tested for HIV, and patient notification procedures. Results: As of 1 January 1995, information about investigations of 64 health care workers infected with HIV was reported to the Centers for Disease Control and Prevention; HIV test results were available for approximately 22 171 patients of 51 of the 64 health care workers. For 37 of the 51 workers, no seropositive patients were reported among 13 063 patients tested for HIV. For the remaining 14 health care workers, 113 seropositive patients were reported among 9108 patients. Epidemiologic and laboratory follow-up did not show any health care worker to have been a source of HIV for any of the patients tested. Conclusion: Despite limitations, these data are consistent with previous assessments that state that the risk for transmission of HIV from a health care worker to a patient is very small. These data also support current recommendations that state that retrospective patient notification need not be done routinely.	CTR DIS CONTROL & PREVENT, CTR PREVENT SERV, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	ROBERT, LM (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, HOSP INFECT PROGRAM, 1600 CLIFTON RD, MAILSTOP E-68, ATLANTA, GA 30333 USA.			Marcus, Ruthanne/0000-0002-9094-0674				[Anonymous], 1991, MMWR Recomm Rep, V40, P1; ARMSTRONG FP, 1987, MIL MED, V152, P414; ARNOW PM, 1993, PUBLIC HEALTH REP, V108, P273; BABINCHAK TJ, 1994, CHEST, V106, P681, DOI 10.1378/chest.106.3.681; BEK M, 1994, NEW S WALES PUBLIC H, V5, P83; BELL DM, 1992, INFECT AGENT DIS, V1, P263; CARDO D, 1994, INTERSCIENCE C ANTIM; CHAMBERLAND ME, 1992, ANN INTERN MED, V116, P871, DOI 10.7326/0003-4819-116-10-871; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; CIESIELSKI CA, 1994, ANN INTERN MED, V121, P886, DOI 10.7326/0003-4819-121-11-199412010-00011; Comer R W, 1991, J Dent Educ, V55, P187; Cottone J A, 1992, J Dent Educ, V56, P536; Crawshaw S C, 1994, Commun Dis Rep CDR Rev, V4, pR125; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; DICKINSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1802, DOI 10.1001/jama.269.14.1802; Heuer M A, 1992, J Dent Educ, V56, P528; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; LONGFIELD JN, 1994, J INFECT DIS, V169, P1, DOI 10.1093/infdis/169.1.1; MISHU B, 1993, JAMA-J AM MED ASSOC, V269, P1843, DOI 10.1001/jama.269.14.1843; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; ROGERS AS, 1993, JAMA-J AM MED ASSOC, V269, P1795, DOI 10.1001/jama.269.14.1795; TAPPER ML, 1992, INFECT CONT HOSP EP, V13, P482, DOI 10.1086/646577; Taylor M, 1992, J Dent Educ, V56, P540; VONREYN CF, 1993, JAMA-J AM MED ASSOC, V269, P1807, DOI 10.1001/jama.269.14.1807; YORK AK, 1993, J AM DENT ASSOC, V124, P74, DOI 10.14219/jada.archive.1993.0141	27	64	65	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					653	657		10.7326/0003-4819-122-9-199505010-00002	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702226				2022-12-28	WOS:A1995QV15100002
J	BIROS, MH; LEWIS, RJ; OLSON, CM; RUNGE, JW; CUMMINS, RO; FOST, N				BIROS, MH; LEWIS, RJ; OLSON, CM; RUNGE, JW; CUMMINS, RO; FOST, N			INFORMED CONSENT IN EMERGENCY RESEARCH - CONSENSUS STATEMENT FROM THE COALITION CONFERENCE OF ACUTE RESUSCITATION AND CRITICAL CARE RESEARCHERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEFERRED CONSENT; CLINICAL-TRIALS; ETHICS	Objective.-A coalition conference of acute resuscitation researchers was held to discuss the feasibility of applying current federal research regulations regarding informed consent to the emergency setting. This article presents consensus recommendations for regulatory changes for consent in emergency research. Participants.-Representatives from the Society for Academic Emergency Medicine and the American Heart Association identified several professional organizations as stakeholders in this issue, including research, clinical, bioethics, legal, and patient advocacy groups. The Office for Protection From Research Risks (OPRR), the Food And Drug Administration (FDA), and staff from specific legislative offices were also invited to observe. Forty-three participants attended, including representatives from 12 professional organizations, five medical institutions, and the FDA and OPRR. This was a closed meeting. Participants were self-funded or sponsored by their professional organizations. Evidence.-Before the meeting, a draft of a position statement was developed by the conference organizers based on the current literature and discussions with experts in the field. This draft, copies of the current federal research regulations, and supporting articles were distributed before the conference. Consensus Process.-Participants rotated through moderated discussion sessions to comment on subsections of the draft. Following discussion, a working draft was developed and distributed to each participant and represented organizational board for final review. All comments were considered in the final version of the document. Conclusions.-We believe there are circumstances when it is not feasible to obtain prospective or proxy consent for enrollment into an emergency research protocol. In these circumstances, patients are vulnerable, not only to research risks, but also to being denied potentially beneficial therapy when there is no known effective treatment for their life-threatening condition. We offer recommendations that should be met when the critical nature of the illness or injury or the need to apply an investigational therapy rapidly precludes prospective consent for participation in emergency research.	UNIV CALIF LOS ANGELES,HARBOR MED CTR,DEPT EMERGENCY MED,LOS ANGELES,CA 90024; UNIV WASHINGTON,EMERGENCY MED SERV,SEATTLE,WA 98195; CAROLINAS MED CTR,DEPT EMERGENCY MED,CHARLOTTE,NC 28203; UNIV WISCONSIN,PROGRAM MED ETH,MADISON,WI	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Washington; University of Washington Seattle; Carolinas Medical Center; University of Wisconsin System; University of Wisconsin Madison	BIROS, MH (corresponding author), HENNEPIN CTY MED CTR,DEPT EMERGENCY MED,701 PK AVE S,MINNEAPOLIS,MN 55415, USA.							ABRAMSON NS, 1990, ANN EMERG MED, V19, P781, DOI 10.1016/S0196-0644(05)81703-2; CARDON PV, 1976, NEW ENGL J MED, V295, P650, DOI 10.1056/NEJM197609162951205; ELLIS GB, 1993, OPRR933 REP; LEVINE RJ, 1993, CANCER-AM CANCER SOC, V72, P2805, DOI 10.1002/1097-0142(19931101)72:9+<2805::AID-CNCR2820721506>3.0.CO;2-8; LEVINE RJ, 1991, CONTROL CLIN TRIALS, V12, P546, DOI 10.1016/0197-2456(91)90012-B; LURIE KG, 1994, JAMA-J AM MED ASSOC, V271, P1405, DOI 10.1001/jama.271.18.1405; MILLER BL, 1993, ANN EMERG MED, V22, P118, DOI 10.1016/S0196-0644(05)80264-1; MORRIS WT, 1989, NEW ZEAL MED J, V102, P472; OLSON CM, 1994, JAMA-J AM MED ASSOC, V271, P1445, DOI 10.1001/jama.271.18.1445; PRENTICE AD, 1993, IRB REV HUM SUBJ RES, V15, P1; Prentice Ernest D, 1994, IRB, V16, P16, DOI 10.2307/3563576; 1979, OPRR887806 OFF PROT; 1991, FED REG         0618, V56, P28002	13	133	134	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	1995	273	16					1283	1287		10.1001/jama.273.16.1283	http://dx.doi.org/10.1001/jama.273.16.1283			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU571	7715041				2022-12-28	WOS:A1995QU57100032
J	CLEAVER, JE; LAYHER, SK				CLEAVER, JE; LAYHER, SK			IF THE SHOE FITS - CLUES ON STRUCTURAL RECOGNITION OF DNA-DAMAGE	CELL			English	Review							ESCHERICHIA-COLI; N-GLYCOSIDASE; BINDING; PROTEIN				CLEAVER, JE (corresponding author), UNIV CALIF SAN FRANCISCO,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143, USA.							DUNCAN BK, 1981, ENZYMES, P565; FRIEDBERG EC, 1975, J VIROL, V16, P315, DOI 10.1128/JVI.16.2.315-321.1975; GROSSMAN L, 1994, ANN NY ACAD SCI, V726, P252, DOI 10.1111/j.1749-6632.1994.tb52823.x; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; JIRICNY J, 1994, TRENDS GENET, V10, P164, DOI 10.1016/0168-9525(94)90093-0; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LATHAM KA, 1994, ANN NY ACAD SCI, V726, P181, DOI 10.1111/j.1749-6632.1994.tb52813.x; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MORIKAWA K, 1994, ANN NY ACAD SCI, V726, P198, DOI 10.1111/j.1749-6632.1994.tb52815.x; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; PARK HW, 1993, J MOL BIOL, V231, P1122, DOI 10.1006/jmbi.1993.1356; REARDON JT, 1993, J BIOL CHEM, V268, P21301; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x	20	15	15	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					825	827		10.1016/0092-8674(95)90283-X	http://dx.doi.org/10.1016/0092-8674(95)90283-X			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697713	Bronze			2022-12-28	WOS:A1995QP61200001
J	EGHOLM, M; BUCHARDT, O; CHRISTENSEN, L; BEHRENS, C; FREIER, SM; DRIVER, DA; BERG, RH; KIM, SK; NORDEN, B; NIELSEN, PE				EGHOLM, M; BUCHARDT, O; CHRISTENSEN, L; BEHRENS, C; FREIER, SM; DRIVER, DA; BERG, RH; KIM, SK; NORDEN, B; NIELSEN, PE			PNA HYBRIDIZES TO COMPLEMENTARY OLIGONUCLEOTIDES OBEYING THE WATSON-CRICK HYDROGEN-BONDING RULES	NATURE			English	Article							PEPTIDE NUCLEIC-ACIDS; DNA; RECOGNITION; REPLICATION; ANTISENSE; STABILITY; THYMINE; HELICES	DNA ANALOGUES are currently being intensely investigated owing to their potential as gene-targeted drugs1-3. Furthermore, their properties and interaction with DNA and RNA could provide a better understanding of the structural features of natural DNA that determine its unique chemical, biological and genetic properties3,4. We recently designed a DNA analogue, PNA, in which the backbone is structurally homomorphous with the deoxyribose backbone and consists of N-(2-aminoethyl)glycine units to which the nucleobases are attached5-9. We showed that PNA oligomers containing solely thymine and cytosine can hybridize to complementary oligonucleotides, presumably by forming Watson-Crick-Hoogsteen (PNA)2-DNA triplexes, which are much more stable than the corresponding DNA-DNA duplexes5-7, and bind to double-stranded DNA by strand displacement5,8. We report here that PNA containing all four natural nucleobases hybridizes to complementary oligonucleotides obeying the Watson-Crick base-pairing rules, and thus is a true DNA mimic in terms of base-pair recognition.	PANUM INST,MED BIOTECHNOL RES CTR,DEPT BIOCHEM B,BLEGDAMSVEJ 3C,DK-2200 COPENHAGEN N,DENMARK; HC ORSTED INST,DEPT ORGAN CHEM,DK-2100 COPENHAGEN 0,DENMARK; ISIS PHARMACEUT,CARLSBAD,CA 92008; RISO NATL LAB,DEPT MAT,POLYMER GRP,DK-4000 ROSKILDE,DENMARK; CHALMERS UNIV TECHNOL,DEPT PHYS CHEM,S-41296 GOTHENBURG,SWEDEN	University of Copenhagen; Isis Pharmaceuticals Inc; Technical University of Denmark; Chalmers University of Technology			Berg, Rolf H/C-6339-2009; Norden, Bengt/ABE-3675-2020	Norden, Bengt/0000-0002-7946-200X; /0000-0001-8771-330X				BORER PN, 1974, J MOL BIOL, V86, P843, DOI 10.1016/0022-2836(74)90357-X; CECH TR, 1986, P NATL ACAD SCI USA, V83, P4360, DOI 10.1073/pnas.83.12.4360; CHERNY DY, 1993, P NATL ACAD SCI USA, V90, P1667, DOI 10.1073/pnas.90.5.1667; Crooke Stanley T., 1992, Current Opinion in Biotechnology, V3, P656, DOI 10.1016/0958-1669(92)90012-8; EGHOLM M, 1993, J CHEM SOC CHEM COMM, P800, DOI 10.1039/c39930000800; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EGHOLM M, 1992, J AM CHEM SOC, V114, P9677, DOI 10.1021/ja00050a068; ESCHENMOSER A, 1992, CHEM SOC REV, V21, P1, DOI 10.1039/cs9922100001; FREIER SM, 1983, BIOCHEMISTRY-US, V22, P6198, DOI 10.1021/bi00295a025; FREIER SM, 1983, BIOPOLYMERS, V22, P1107, DOI 10.1002/bip.360220408; Goodchild J, 1990, BIOCONJUGATE CHEM, V1, P165, DOI 10.1021/bc00003a001; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; Maniatis T., 1982, MOL CLONING; MILLER SL, 1953, SCIENCE, V117, P528, DOI 10.1126/science.117.3046.528; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1993, ANTI-CANCER DRUG DES, V8, P53; ORGEL LE, 1992, NATURE, V358, P203, DOI 10.1038/358203a0; ORO J, 1960, BIOCHEM BIOPH RES CO, V2, P407, DOI 10.1016/0006-291X(60)90138-8; UHLMANN E, 1990, CHEM REV, V90, P544; VESNAVER G, 1991, P NATL ACAD SCI USA, V88, P3569, DOI 10.1073/pnas.88.9.3569	21	1708	2219	4	252	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 7	1993	365	6446					566	568		10.1038/365566a0	http://dx.doi.org/10.1038/365566a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA661	7692304				2022-12-28	WOS:A1993MA66100061
J	TSUCHIHASHI, Z; KHOSLA, M; HERSCHLAG, D				TSUCHIHASHI, Z; KHOSLA, M; HERSCHLAG, D			PROTEIN ENHANCEMENT OF HAMMERHEAD RIBOZYME CATALYSIS	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; TETRAHYMENA-THERMOPHILA RIBOZYME; RNA ANNEALING ACTIVITIES; PRIMER TRANSFER-RNA; NUCLEOCAPSID PROTEIN; RIBONUCLEASE-P; NUCLEIC-ACIDS; VIRAL-RNA; KINETIC DESCRIPTION	When the recognition sequence of a ribozyme is extended beyond a certain length, turnover is slowed and specificity is decreased. Here, it is shown that a protein can help a ribozyme overcome these general limitations on ribozyme activity. Cleavage of an RNA oligonucleotide by a hammerhead ribozyme is enhanced 10- to 20-fold upon addition of a protein derived from the p7 nucleocapsid (NC) protein of human immunodeficiency virus-type 1. The NC protein also enhances the ability of the ribozyme to discriminate between cleavage of RNA oligonucleotides with differing sequences. These catalytic improvements can be attributed to the strand exchange activity of this RNA binding protein. It is conceivable that endogenous or added proteins may provide analogous increases in ribozyme activity and specificity in vivo.	STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305; STANFORD UNIV,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University								ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BUZAYAN JM, 1986, NATURE, V323, P349, DOI 10.1038/323349a0; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; DEROCQUIGNY H, 1993, NUCLEIC ACIDS RES, V21, P823; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FERSHT A, 1985, ENZYME STRUCTURE MEC, P111; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1991, P NATL ACAD SCI USA, V88, P6921, DOI 10.1073/pnas.88.16.6921; HERSCHLAG D, UNPUB; HERTEL KJ, UNPUB; JOSEPH S, 1993, GENE DEV, V7, P130, DOI 10.1101/gad.7.1.130; JOYCE G, COMMUNICATION; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KHAN R, 1992, J BIOL CHEM, V267, P6689; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LEIS JP, 1978, VIROLOGY, V84, P87, DOI 10.1016/0042-6822(78)90220-9; MERIC C, 1989, J VIROL, V63, P1558; MERIC C, 1984, J MOL BIOL, V173, P531, DOI 10.1016/0022-2836(84)90396-6; MILLER PS, 1987, ANTI-CANCER DRUG DES, V2, P117; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; NISSENMEYER J, 1980, J MOL BIOL, V142, P19, DOI 10.1016/0022-2836(80)90203-X; OERTLE S, 1990, J VIROL, V64, P5757, DOI 10.1128/JVI.64.12.5757-5763.1990; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; ROSSI JJ, 1990, TRENDS BIOTECHNOL, V8, P179, DOI 10.1016/0167-7799(90)90169-X; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; SMITH BJ, 1979, NUCLEIC ACIDS RES, V7, P2055; SMITH D, 1992, J BIOL CHEM, V267, P2429; SUROVOY A, 1993, J MOL BIOL, V229, P94, DOI 10.1006/jmbi.1993.1011; TALLSJO A, 1993, NUCLEIC ACIDS RES, V21, P51, DOI 10.1093/nar/21.1.51; TSUCHIHASHI Z, UNPUB	44	196	201	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 1	1993	262	5130					99	102		10.1126/science.7692597	http://dx.doi.org/10.1126/science.7692597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ635	7692597				2022-12-28	WOS:A1993LZ63500031
J	MUSIL, LS; GOODENOUGH, DA				MUSIL, LS; GOODENOUGH, DA			MULTISUBUNIT ASSEMBLY OF AN INTEGRAL PLASMA-MEMBRANE CHANNEL PROTEIN, GAP JUNCTION CONNEXIN43, OCCURS AFTER EXIT FROM THE ER	CELL			English	Article							TRANS-GOLGI NETWORK; VIRUS G-PROTEIN; BREFELDIN-A; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; INFLUENZA HEMAGGLUTININ; PRE-GOLGI; ORGANELLE STRUCTURE; LIGAND-BINDING; CELL-SURFACE	Connexin43 (Cx43) is an integral plasma membrane protein that forms gap junctions between vertebrate cells. We have used sucrose gradient fractionation and chemical cross-linking to study the first step in gap junction assembly, oligomerization of Cx43 monomers into connexon channels. In contrast with other plasma membrane proteins, multisubunit assembly of Cx43 was specifically and completely blocked when endoplasmic reticulum (ER)-to-Golgi transport was inhibited by 15-degrees-C incubation, carbonyl cyanide m-chlorophenylhydrazone, or brefeldin A or in CHO cell mutants with temperature-sensitive defects in secretion. Additional experiments indicated that connexon assembly occurred intracellularly, most likely in the trans-Golgi network. These results describe a post-ER assembly pathway for integral membrane proteins and have implications for the relationship between membrane protein oligomerization and intracellular transport.			MUSIL, LS (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.				NEI NIH HHS [EY-02430] Funding Source: Medline; NIGMS NIH HHS [GM-18974] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018974, R01GM018974] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BERTHOUD VM, 1992, EUR J CELL BIOL, V57, P40; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BONATTI S, 1989, J BIOL CHEM, V264, P12590; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Caspar DLD, 1988, GAP JUNCTIONS, P117; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COLLEY KJ, 1987, J BIOL CHEM, V262, P10296; COLLINS PL, 1991, J GEN VIROL, V72, P3095, DOI 10.1099/0022-1317-72-12-3095; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DEMELLO W, 1987, INTERCELLULAR COMMUN, P29; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; DEVRIES SH, 1992, J PHYSIOL-LONDON, V445, P201, DOI 10.1113/jphysiol.1992.sp018920; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DORAN JE, 1981, INFECT IMMUN, V33, P683, DOI 10.1128/IAI.33.3.683-689.1981; FISHER AS, 1992, THESIS MIT CAMBRIDGE; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GUTHRIE SC, 1989, TRENDS NEUROSCI, V12, P12, DOI 10.1016/0166-2236(89)90150-1; HENDRIX EM, 1992, MOL REPROD DEV, V33, P27, DOI 10.1002/mrd.1080330105; HILLE A, 1990, J CELL BIOL, V110, P963, DOI 10.1083/jcb.110.4.963; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JASCUR T, 1991, BIOCHEMISTRY-US, V30, P1908, DOI 10.1021/bi00221a025; JI TH, 1979, BIOCHIM BIOPHYS ACTA, V559, P39, DOI 10.1016/0304-4157(79)90007-8; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kumar N M, 1992, Semin Cell Biol, V3, P3; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MATTER K, 1991, BIOCHEMISTRY-US, V30, P1916, DOI 10.1021/bi00221a026; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; POTTER TA, 1985, P NATL ACAD SCI USA, V82, P2950, DOI 10.1073/pnas.82.9.2950; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; RAHMAN S, 1993, J BIOL CHEM, V268, P1260; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; RICKWOOD D, 1984, CENTRIFUGATION PRACT, P95; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTUNDO RL, 1984, P NATL ACAD SCI-BIOL, V81, P479, DOI 10.1073/pnas.81.2.479; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SHITE S, 1990, J BIOL CHEM, V265, P17385; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; STAROS JV, 1989, METHOD ENZYMOL, V172, P609; STIEGER B, 1988, J CELL BIOL, V106, P1853, DOI 10.1083/jcb.106.6.1853; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; TARTAKOFF A, 1979, J CELL BIOL, V83, P284, DOI 10.1083/jcb.83.2.284; TARTAKOFF AM, 1986, EMBO J, V5, P1477, DOI 10.1002/j.1460-2075.1986.tb04385.x; VALDIMARSSON G, 1991, MOL REPROD DEV, V30, P18, DOI 10.1002/mrd.1080300103; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YAMADA A, 1988, VIROLOGY, V165, P268, DOI 10.1016/0042-6822(88)90681-2; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838	73	405	411	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 24	1993	74	6					1065	1077		10.1016/0092-8674(93)90728-9	http://dx.doi.org/10.1016/0092-8674(93)90728-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	7691412				2022-12-28	WOS:A1993LY49300013
J	MUNRO, S; THOMAS, KL; ABUSHAAR, M				MUNRO, S; THOMAS, KL; ABUSHAAR, M			MOLECULAR CHARACTERIZATION OF A PERIPHERAL RECEPTOR FOR CANNABINOIDS	NATURE			English	Article							RAT-BRAIN; INSITU HYBRIDIZATION; CLONING; INVITRO; CDNA	THE major active ingredient of marijuana, DELTA9-tetrahydrocannabinol (DELTA9-THC), has been used as a psychoactive agent for thousands of years. Marijuana, and DELTA9-THC, also exert a wide range of other effects including analgesia, anti-inflammation, immunosuppression, anticonvulsion, alleviation of intraocular pressure in glaucoma, and attenuation of vomiting1. The clinical application of cannabinoids has, however, been limited by their psychoactive effects, and this has led to interest in the biochemical bases of their action. Progress stemmed initially from the synthesis of potent derivatives of DELTA9-THC4,5, and more recently from the cloning of a gene encoding a G-protein-coupled receptor for cannabinoids6. This receptor is expressed in the brain but not in the periphery, except for a low level in testes. It has been proposed that the non-psychoactive effects of cannabinoids are either mediated centrally or through direct interaction with other, non-receptor proteins1,7,8. Here we report the cloning of a receptor for cannabinoids that is not expressed in the brain but rather in macrophages in the marginal zone of spleen.			MUNRO, S (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Thomas, Kerrie L/A-6509-2010	Thomas, Kerrie L/0000-0003-3355-9583; Munro, Sean/0000-0001-6160-5773				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; COLLINS SJ, 1987, BLOOD, V70, P1233; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DALLMAN MJ, 1982, EUR J IMMUNOL, V12, P511, DOI 10.1002/eji.1830120612; DEVANE WA, 1992, J MED CHEM, V35, P2065, DOI 10.1021/jm00089a018; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEWEY WL, 1986, PHARMACOL REV, V38, P151; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HOLLISTER LE, 1992, J PSYCHOACTIVE DRUGS, V24, P159, DOI 10.1080/02791072.1992.10471635; HOLLISTER LE, 1986, PHARMACOL REV, V38, P1; HOWLETT AC, 1990, TRENDS NEUROSCI, V13, P420, DOI 10.1016/0166-2236(90)90124-S; HUMPHREY JH, 1981, EUR J IMMUNOL, V11, P221, DOI 10.1002/eji.1830110311; JANSEN EM, 1992, BRAIN RES, V575, P93, DOI 10.1016/0006-8993(92)90428-C; KESHAV S, 1991, J EXP MED, V174, P1049, DOI 10.1084/jem.174.5.1049; KRAAL G, 1992, INT REV CYTOL, V132, P31, DOI 10.1016/S0074-7696(08)62453-5; LEE J, 1992, J BIOL CHEM, V267, P16283; LOPEZCEPERO M, 1986, J LEUKOCYTE BIOL, V39, P679, DOI 10.1002/jlb.39.6.679; MAILLEUX P, 1992, NEUROSCIENCE, V48, P655, DOI 10.1016/0306-4522(92)90409-U; MARTIN BR, 1986, PHARMACOL REV, V38, P45; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MUNSON AE, 1983, ADVERSE HLTH BEHAVIO, P257; RAZDAN RK, 1986, PHARMACOL REV, V38, P75; REICHMAN M, 1991, MOL PHARMACOL, V40, P547; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; SCHATZ AR, 1992, LIFE SCI, V51, P25; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHIRASAWA T, 1992, NUCLEIC ACIDS RES, V20, P909, DOI 10.1093/nar/20.4.909; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	34	3812	4012	6	245	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					61	65		10.1038/365061a0	http://dx.doi.org/10.1038/365061a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	7689702				2022-12-28	WOS:A1993LV64600054
J	WANG, N; BUTLER, JP; INGBER, DE				WANG, N; BUTLER, JP; INGBER, DE			MECHANOTRANSDUCTION ACROSS THE CELL-SURFACE AND THROUGH THE CYTOSKELETON	SCIENCE			English	Article							VASCULAR ENDOTHELIAL-CELLS; RAT CARDIAC MYOCYTES; MECHANICAL FORCES; PC-12 NEURITES; SHEAR-STRESS; STRETCH; TENSION; MATRIX; ORGANIZATION; STIMULATION	Mechanical stresses were applied directly to cell surface receptors with a magnetic twisting device. The extracellular matrix receptor, integrin beta1, induced focal adhesion formation and supported a force-dependent stiffening response, whereas nonadhesion receptors did not. The cytoskeletal stiffness (ratio of stress to strain) increased in direct proportion to the applied stress and required intact microtubules and intermediate filaments as well as microfilaments. Tensegrity models that incorporate mechanically interdependent struts and strings that reorient globally in response to a localized stress mimicked this response. These results suggest that integrins act as mechanoreceptors and transmit mechanical signals to the cytoskeleton. Mechanotransduction, in turn, may be mediated simultaneously at multiple locations inside the cell through force-induced rearrangements within a tensionally integrated cytoskeleton.	CHILDRENS HOSP MED CTR,DEPT SURG,ENDERS 1007,300 LONGWOOD AVE,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,RESP BIOL PROGRAM,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Ingber, Donald E/AAC-5894-2019; Wang, Ning/B-6966-2008		NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033009] Funding Source: NIH RePORTER; NCI NIH HHS [CA45548] Funding Source: Medline; NHLBI NIH HHS [HL-33009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; [Anonymous], 1956, MATH THEORY ELASTICI; BIZAL CL, 1991, J LEUKOCYTE BIOL, V50, P240, DOI 10.1002/jlb.50.3.240; BRODLAND GW, 1991, J BIOMECH ENG, V112, P319; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUXBAUM RE, 1988, J THEOR BIOL, V134, P379, DOI 10.1016/S0022-5193(88)80068-7; CIPRIANO LF, 1991, PHYSIOLOGIST, V34, P72; DEGROOT RP, 1990, J CELL SCI, V97, P33; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; FOLKMAN J, 1989, CELL, V58, P803; FOLKMAN J, 1989, J CELL BIOL, V109, P317; FRANKE RP, 1984, NATURE, V307, P648, DOI 10.1038/307648a0; Fuller B., 1961, PORTFOLIO ARTNEWS AN, V4, P112; FUNG YC, 1988, BIOMECHANICS; FUNG YCB, 1967, AM J PHYSIOL, V213, P1532, DOI 10.1152/ajplegacy.1967.213.6.1532; HARRIS RC, 1992, LAB INVEST, V66, P548; HAY M, 1991, CELL MOTIL CYTOSKEL, V18, P63, DOI 10.1002/cm.970180107; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; Ingber D., 1993, PHYSICAL FORCES MAMM, P61; Ingber D. E, 1989, CELL SHAPE DETERMINA, P3; INGBER DE, 1993, J CELL SCI, V104, P613; Ingber DE., 1985, GENE EXPRESSION NORM, P13; INGBER DE, 1972, P NATL ACAD SCI USA, V69, P3579; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; JOSHI HC, 1985, J CELL BIOL, V101, P697, DOI 10.1083/jcb.101.3.697; KACAHR B, 1990, HEARING RES, V45, P179; Koch JC, 1917, AM J ANAT, V21, P177, DOI 10.1002/aja.1000210202; KOLEGA J, 1986, J CELL BIOL, V102, P1400, DOI 10.1083/jcb.102.4.1400; KOMURO I, 1991, J BIOL CHEM, V266, P1265; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; McMahon T.A., 1984, MUSCLES REFLEXES LOC; MURTI KG, 1992, EXP CELL RES, V202, P36, DOI 10.1016/0014-4827(92)90401-S; NICKOLLS GH, 1992, J CELL SCI, V102, P753; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; PETERSEN NO, 1982, P NATL ACAD SCI-BIOL, V79, P5327, DOI 10.1073/pnas.79.17.5327; PIENTA KJ, 1991, MED HYPOTHESES, V34, P88, DOI 10.1016/0306-9877(91)90072-7; PINTO JG, 1973, J BIOMECH, V6, P597, DOI 10.1016/0021-9290(73)90017-1; RYAN TJ, 1989, J AM ACAD DERMATOL, V21, P115, DOI 10.1016/S0190-9622(89)70156-0; SAMUEL JL, 1990, IN VITRO CELL DEV B, V26, P905; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SIMS JR, 1992, J CELL SCI, V103, P1215; STAMENOVIC D, 1990, PHYSIOL REV, V70, P1117, DOI 10.1152/physrev.1990.70.4.1117; SUMPIO BE, 1988, ARCH SURG-CHICAGO, V123, P1233; TERRACIO L, 1988, IN VITRO CELL DEV B, V24, P53; VALBERG PA, 1984, SCIENCE, V224, P513, DOI 10.1126/science.6710153; VALBERG PA, 1985, J CELL BIOL, V101, P130, DOI 10.1083/jcb.101.1.130; VALBERG PA, 1987, BIOPHYS J, V52, P537, DOI 10.1016/S0006-3495(87)83243-5; WAGNER VT, 1992, P NATL ACAD SCI USA, V89, P3644, DOI 10.1073/pnas.89.8.3644; WARD IM, 1983, MECHANICAL PROPERTIE; WATSON PA, 1990, J BIOL CHEM, V265, P6569; WAYNE R, 1992, J CELL SCI, V101, P611; WILSON LJ, 1990, J COMP NEUROL, V296, P343, DOI 10.1002/cne.902960302; WIRTZ HRW, 1990, SCIENCE, V250, P1266, DOI 10.1126/science.2173861; WOLOSEWICK JJ, 1979, J CELL BIOL, V82, P114, DOI 10.1083/jcb.82.1.114; YAHARA I, 1972, P NATL ACAD SCI USA, V69, P608, DOI 10.1073/pnas.69.3.608; ZANER KS, 1989, J CELL BIOL, V109, P2233, DOI 10.1083/jcb.109.5.2233; [No title captured]; [No title captured]; [No title captured]	61	2330	2418	20	565	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 21	1993	260	5111					1124	1127		10.1126/science.7684161	http://dx.doi.org/10.1126/science.7684161			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC942	7684161				2022-12-28	WOS:A1993LC94200029
J	DECAMPOSLIMA, PO; GAVIOLI, R; ZHANG, QJ; WALLACE, LE; DOLCETTI, R; ROWE, M; RICKINSON, AB; MASUCCI, MG				DECAMPOSLIMA, PO; GAVIOLI, R; ZHANG, QJ; WALLACE, LE; DOLCETTI, R; ROWE, M; RICKINSON, AB; MASUCCI, MG			HLA-A11 EPITOPE LOSS ISOLATES OF EPSTEIN-BARR-VIRUS FROM A HIGHLY A11+ POPULATION	SCIENCE			English	Article							DETECTED MEMBRANE ANTIGEN; BURKITTS-LYMPHOMA CELLS; EBV LATENT GENES; RESTRICTED EXPRESSION; STRUCTURAL PROTEINS; BACTERIOPHAGE-T4; CLEAVAGE; LINES; HEAD	Cytotoxic T lymphocytes (CTLs) control viral infections by recognizing viral peptides presented by major histocompatibility complex (MHC) class I molecules. Human leukocyte antigen (HLA)-A11-restricted CTLs that recognize peptide residues 416 to 424 of the Epstein-Barr virus (EBV) nuclear antigen-4 frequently dominate EBV-induced responses in A11+ Caucasian donors. This epitope is conserved in type A EBV strains from Caucasians and central African populations, where A11 is relatively infrequent. However, strains from highly A11+ populations in New Guinea carry a lysine-to-threonine mutation at residue 424 that abrogates CTL recognition and binding of the peptide to nascent A11 molecules. The results suggest that evolution of a widespread and genetically stable virus such as EBV is influenced by pressure from MHC-restricted CTL responses.	KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM 60,SWEDEN; UNIV BIRMINGHAM,SCH MED,DEPT CANC STUDIES,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND	Karolinska Institutet; University of Birmingham			de Campos-Lima, Pedro Otavio/I-3495-2013; Gavioli, Riccardo/K-7594-2016; Masucci, Maria G/B-8588-2009; Dolcetti, Riccardo/O-3832-2015; Rowe, Martin/B-2880-2009; Masucci, Maria/AAC-6666-2019	de Campos-Lima, Pedro Otavio/0000-0001-8024-8628; Gavioli, Riccardo/0000-0002-7805-4290; Dolcetti, Riccardo/0000-0003-1625-9853; Rowe, Martin/0000-0003-4139-7326; Masucci, Maria/0000-0002-5541-2809	NATIONAL CANCER INSTITUTE [R01CA030264] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA30264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATIA K, 1989, HUM BIOL, V61, P45; COLOMBANI J, 1982, TISSUE ANTIGENS, V20, P161; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DUMAS B, 1975, CLIN CHEM, V21, P1159; GAVIOLI R, 1992, P NATL ACAD SCI USA, V89, P5862, DOI 10.1073/pnas.89.13.5862; GAVIOLI R, 1993, J VIROL, V67, P1572, DOI 10.1128/JVI.67.3.1572-1578.1993; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HIRS C, 1977, ENZYME STRUCTURE, V47, P501; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENOIR GM, 1985, IARC SCI PUBL, V60, P309; MASUCCI MG, 1992, INT IMMUNOL, V4, P1283, DOI 10.1093/intimm/4.11.1283; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; MORRIS PJ, 1973, HISTOCOMPATIBILITY T, P267; MOSS D, 1978, INT J CANCER, V23, P618; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIZZO PA, 1978, NATURE, V272, P629, DOI 10.1038/272629a0; POPE JH, 1968, AUST J EXP BIOL MED, V46, P643, DOI 10.1038/icb.1968.171; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; ROWE M, 1989, J VIROL, V63, P1031, DOI 10.1128/JVI.63.3.1031-1039.1989; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SAMPLE J, 1990, J VIROL, V64, P4084, DOI 10.1128/JVI.64.9.4084-4092.1990; SERJEANTSON S, 1989, COLONIZATION PACIFIC, V7, P120; TORSTEINSDOTTIR S, 1986, P NATL ACAD SCI USA, V83, P5620, DOI 10.1073/pnas.83.15.5620; WALLACE LE, 1982, NATURE, V297, P413, DOI 10.1038/297413a0; ZHANG QJ, 1993, P NATL ACAD SCI USA, V90, P2217, DOI 10.1073/pnas.90.6.2217; ZIMBER U, 1986, VIROLOGY, V154, P56, DOI 10.1016/0042-6822(86)90429-0	31	225	226	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					98	100		10.1126/science.7682013	http://dx.doi.org/10.1126/science.7682013			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	7682013				2022-12-28	WOS:A1993KV42300037
J	MACFARLANE, DE; DAHLE, CE				MACFARLANE, DE; DAHLE, CE			ISOLATING RNA FROM WHOLE-BLOOD - THE DAWN OF RNA-BASED DIAGNOSIS	NATURE			English	Article							POLYMERASE CHAIN-REACTION; BONE-MARROW TRANSPLANTATION; LEUKEMIA PATIENTS		UNIV IOWA,IOWA BIOTECHNOL CORP,INST TECHNOL INNOVAT,IOWA CITY,IA 52242	University of Iowa	MACFARLANE, DE (corresponding author), UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.			Macfarlane, Donald/0000-0001-8785-5690				AUBELSADRON G, 1961, BIOCHIM BIOPHYS ACTA, V53, P11, DOI 10.1016/0006-3002(61)90789-2; CHROMCZYNSKI P, 1991, CURRENT PROTOCOLS S, V14; DALLMAN MJ, 1991, IMMUNOL REV, V119, P163, DOI 10.1111/j.1600-065X.1991.tb00583.x; DELFAU MH, 1990, LEUKEMIA, V4, P1; Hayakawa K., 1991, CATIONIC SURFACTANTS; HIGUCHI R, 1989, PCR TECHNOLOGY; JONES AS, 1953, BIOCHIM BIOPHYS ACTA, V10, P607, DOI 10.1016/0006-3002(53)90304-7; KOWK S, 1992, PERKIN ELMER BIOTECH; MACFARLANE DE, 1989, ANAL BIOCHEM, V176, P457, DOI 10.1016/0003-2697(89)90342-4; MACFARLANE DE, 1991, Patent No. 5010183; NICHOLS J, 1992, BLOOD, V80, P2953; RALPH RK, 1984, BIOCHIM BIOPHYS ACTA, V87, P9; RECK RA, 1982, ENCY CHEM TECHNOLOGY, V19, P521; REDDI KK, 1976, P NATL ACAD SCI USA, V73, P2308, DOI 10.1073/pnas.73.7.2308; SAWYERS CL, 1990, P NATL ACAD SCI USA, V87, P563, DOI 10.1073/pnas.87.2.563; [No title captured]	16	49	58	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					186	188		10.1038/362186a0	http://dx.doi.org/10.1038/362186a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	7680772				2022-12-28	WOS:A1993KR02800069
J	JAMES, JM; BURKS, AW; ROBERSON, PK; SAMPSON, HA				JAMES, JM; BURKS, AW; ROBERSON, PK; SAMPSON, HA			SAFE ADMINISTRATION OF THE MEASLES-VACCINE TO CHILDREN ALLERGIC TO EGGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RUBELLA VACCINE; MUMPS; HYPERSENSITIVITY; IMMUNIZATION; IGE; PROTEIN	Background. The safety of administering the combined measles-mumps-rubella (MMR) vaccine to patients who are allergic to eggs has been debated for decades because of concern about potential anaphylaxis, since the live attenuated virus used in the vaccine is grown in cultured chick-embryo fibroblasts. Methods. We recruited 54 children (mean age, 18.5 months) who had not previously been vaccinated and were allergic to eggs. The children's histories of allergy were confirmed with skin tests and double-blind, placebo-controlled food-challenge tests; some children also underwent skin testing with the MMR vaccine. We then routinely administered the vaccine to the children in one subcutaneous (0.5-ml) dose. Results. All 54 children had positive results on skin testing with egg. Allergy to eggs was confirmed in 26 of the children by convincing histories of anaphylaxis after the ingestion of eggs, in 22 children by food-challenge tests, and in 6 patients by convincing histories of recent allergic reactions occurring after the ingestion of eggs. Of the 17 children who underwent skin testing with the MMR vaccine, 3 had positive results. All 54 children received the MMR vaccine as a single subcutaneous injection; none had an immediate or delayed adverse reaction. Conclusions. The MMR vaccine can be safely administered in a single dose to children with allergy to eggs, even those with severe hypersensitivity.	ARKANSAS CHILDRENS HOSP,DEPT PEDIAT,DIV PEDIAT ALLERGY,LITTLE ROCK,AR 72202; ARKANSAS CHILDRENS HOSP,DEPT PEDIAT,DIV IMMUNOL,LITTLE ROCK,AR 72202; UNIV ARKANSAS MED SCI HOSP,LITTLE ROCK,AR 72205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DIV ALLERGY IMMUNOL,BALTIMORE,MD 21205	Arkansas Children's Hospital; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; Johns Hopkins University; Johns Hopkins University	JAMES, JM (corresponding author), ARKANSAS CHILDRENS HOSP,CTR APPL RES & EVALUAT,800 MARSHALL ST,LITTLE ROCK,AR 72202, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024439] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00052] Funding Source: Medline; NIAID NIH HHS [AI 24439] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AICKIN R, 1994, BRIT MED J, V309, P223, DOI 10.1136/bmj.309.6949.223; AUKRUST L, 1980, ALLERGY, V35, P581, DOI 10.1111/j.1398-9995.1980.tb01808.x; BECK SA, 1991, PEDIATRICS, V88, P913; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BROWN FR, 1967, J PEDIATR-US, V71, P868, DOI 10.1016/S0022-3476(67)80013-1; BRUNO G, 1990, LANCET, V335, P739, DOI 10.1016/0140-6736(90)90863-Z; Businco L, 1991, PEDIATR ALLERGY IMMU, V4, P195; DANNAEUS A, 1977, ACTA PAEDIATR SCAND, V66, P31, DOI 10.1111/j.1651-2227.1977.tb07803.x; FASANO MB, 1992, J PEDIATR-US, V120, P878, DOI 10.1016/S0022-3476(05)81953-5; FORD RPK, 1982, ARCH DIS CHILD, V57, P649, DOI 10.1136/adc.57.9.649; FREIGANG B, 1994, ANN ALLERGY, V73, P486; GREENBERG MA, 1988, J PEDIATR-US, V113, P504, DOI 10.1016/S0022-3476(88)80639-5; HERMAN JJ, 1983, J PEDIATR-US, V102, P196, DOI 10.1016/S0022-3476(83)80519-8; JUNTUNENBACKMAN K, 1987, AM J DIS CHILD, V141, P1103, DOI 10.1001/archpedi.1987.04460100081032; KAMIN PB, 1963, JAMA-J AM MED ASSOC, V185, P647, DOI 10.1001/jama.1963.03060080043012; KAMIN PB, 1965, J AMER MED ASSOC, V193, P1125; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; KEMP A, 1990, AM J DIS CHILD, V144, P33, DOI 10.1001/archpedi.1990.02150250039027; LAVI S, 1990, JAMA-J AM MED ASSOC, V263, P269, DOI 10.1001/jama.263.2.269; MCEWEN J, 1983, MED J AUSTRALIA, V2, P503, DOI 10.5694/j.1326-5377.1983.tb122619.x; MILLER JR, 1983, J ALLERGY CLIN IMMUN, V71, P568; OBRIEN TC, 1971, APPL MICROBIOL, V21, P780, DOI 10.1128/AEM.21.4.780-782.1971; POLLOCK TM, 1983, LANCET, V1, P753; PUVVADA L, 1993, PEDIATRICS, V91, P835; SAMPSON HA, 1988, ANN ALLERGY, V60, P262; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V82, P718, DOI 10.1016/0091-6749(88)90070-X; THURSTON A, 1987, J ROY COLL GEN PRACT, V37, P41; TROTTER AC, 1994, ANN ALLERGY, V72, P25; VANASPEREN PP, 1981, MED J AUSTRALIA, V2, P330; VOORHORST R, 1973, ANN ALLERGY, V31, P195; 1994, 1994 RED BOOK REPORT, P36; 1995, PHYSICIANS DESK REFE, P1573; 1982, 1982 RED BOOK REPORT	33	122	128	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 11	1995	332	19					1262	1266		10.1056/NEJM199505113321904	http://dx.doi.org/10.1056/NEJM199505113321904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW600	7708070				2022-12-28	WOS:A1995QW60000004
J	OWENS, DK; HARRIS, RA; SCOTT, PM; NEASE, RF				OWENS, DK; HARRIS, RA; SCOTT, PM; NEASE, RF			SCREENING SURGEONS FOR HIV-INFECTION - A COST-EFFECTIVENESS ANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review						COST-BENEFIT ANALYSIS; SURGEONS; HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT; MASS SCREENING	HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; HEALTH-CARE WORKERS; UNITED-STATES-ARMY; HEPATITIS-B VIRUS; CONTROLLED TRIAL; SEXUAL-BEHAVIOR; AIDS EDUCATION; CONDOM USE; TRIMETHOPRIM SULFAMETHOXAZOLE	Objective To determine the cost-effectiveness of a policy to screen surgeons for human immunodeficiency virus (HIV) infection to prevent transmission of HIV to patients having invasive procedures. Design: Cost-effectiveness analysis. Results: A one-time national screening program would identify approximately 137 surgeons with HIV infection (range, 28 to 423 surgeons) and would prevent approximately 4.3 infections (range, 1.9 to 21.3 infections) in patients treated by infected surgeons and 0.9 infections (range, 0 to 12.9 infections) in sexual partners of infected surgeons at a direct cost of $8.1 million and an induced cost of approximately $44 million. It would result in expenditures of $458 000 per year of life saved (range, $147 000 to $687 000 per year of life saved), whereas an annual screening program would result in expenditures of approximately $1.1 million per year of life saved (range, $338 000 to $1 886 000 per year of life saved). If the prevalence of HIV infection in surgeons is estimated to be three times our base-case estimate (an increase from 0.1% to 0.3%), annual screening would result in expenditures of approximately $741 000 per year of life saved. If the probability of seroconversion after a patient is exposed to a contaminated instrument is increased to 5.0% from our base-case estimate of 0.29%, an annual screening program would still cost more than $228 000 per year of life saved. Conclusion: Screening surgeons for HIV to prevent transmission of HIV to patients having invasive procedures requires expenditures per year of life saved that are considerably in excess of those of most accepted health interventions. Surveillance studies of patients treated by surgeons infected with HIV should be continued to confirm that transmission of HIV to patients having invasive procedures is rare.	STANFORD UNIV, STANFORD, CA 94305 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, HANOVER, NH 03756 USA	Stanford University; Dartmouth College	OWENS, DK (corresponding author), DEPT VET AFFAIRS MED CTR, GEN INTERNAL MED SECT 111A, 3801 MIRANDA AVE, PALO ALTO, CA 94304 USA.				AHRQ HHS [RD3 HSO7232-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; ANDRULIS DP, 1992, JAMA-J AM MED ASSOC, V267, P2482, DOI 10.1001/jama.267.18.2482; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; ARNO PS, 1989, JAMA-J AM MED ASSOC, V262, P1493, DOI 10.1001/jama.262.11.1493; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BELL DM, 1992, INFECT AGENT DIS, V1, P263; BENNETT CL, 1992, J ACQ IMMUN DEF SYND, V5, P1; BIDDLECOM AE, 1992, J ACQ IMMUN DEF SYND, V5, P1131; BILLY JOG, 1993, FAM PLANN PERSPECT, V25, P52, DOI 10.2307/2136206; BUIRA E, 1992, J ACQ IMMUN DEF SYND, V5, P737; CALSYN DA, 1992, AM J PUBLIC HEALTH, V82, P573, DOI 10.2105/AJPH.82.4.573; CAMPBELL LS, 1991, SOUTHERN MED J, V84, P22, DOI 10.1097/00007611-199101000-00007; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P337; CHAMBERLAND ME, 1992, ANN INTERN MED, V116, P871, DOI 10.7326/0003-4819-116-10-871; CHAVEY WE, 1994, J FAM PRACTICE, V38, P249; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; COWAN DN, 1991, JAMA-J AM MED ASSOC, V265, P2826, DOI 10.1001/jama.265.21.2826; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; ELSADR W, 1994, PHS AHCPR940572 US D; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; FUCHS VR, 1986, HEALTH ECON, P49; GAFNI A, 1993, CAN MED ASSOC J, V148, P913; GALLANT JE, 1994, ANN INTERN MED, V120, P932, DOI 10.7326/0003-4819-120-11-199406010-00006; GARCIA A, 1992, 8 HARV U DUTCH F AID, pC348; GERBERDING JL, 1991, INFECT CONT HOSP EP, V12, P443, DOI 10.1086/646376; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GRAHAM D, 1988, DETAILED DIAGNOSES P; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; Hahn B., 1992, ANN EXPENSES SOURCES; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HEDLUND K, 1990, AIDS 90S SCI POLICY, P256; HELLINGER FJ, 1992, INQUIRY-J HEALTH CAR, V29, P356; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; HENDERSON DK, 1994, INFECT CONT HOSP EP, V15, P631, DOI 10.2307/30145273; HIATT RA, 1990, ARCH INTERN MED, V150, P833, DOI 10.1001/archinte.150.4.833; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; HILTS PJ, 1991, NY TIMES        0927, pA8; HUNT AJ, 1991, AIDS, V5, P723, DOI 10.1097/00002030-199106000-00012; JEWETT JF, 1993, JAMA-J AM MED ASSOC, V269, P1144, DOI 10.1001/jama.269.9.1144; KAMENGA M, 1989, AIDS SCI SOCIAL CHAL, V1, P703; KU LC, 1992, FAM PLANN PERSPECT, V24, P100, DOI 10.2307/2135538; LAUPACIS A, 1993, CAN MED ASSOC J, V148, P927; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LETTAU LA, 1992, INFECT CONT HOSP EP, V13, P336, DOI 10.1086/646541; LETTAU LA, 1986, JAMA-J AM MED ASSOC, V255, P934, DOI 10.1001/jama.255.7.934; LIFSON A, 1989, 5 INT C AIDS MONTR, P60; LINDAN C, 1990, AIDS 90S SCI POLICY, P256; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; LONGINI IM, 1989, STAT MED, V8, P831, DOI 10.1002/sim.4780080708; MACDONALD KL, 1989, ANN INTERN MED, V110, P617, DOI 10.7326/0003-4819-110-8-617; MASUR H, 1992, NEW ENGL J MED, V327, P1853, DOI 10.1056/NEJM199212243272606; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P462, DOI 10.2105/AJPH.78.4.462; MCLEOD GX, 1992, ANN INTERN MED, V117, P487, DOI 10.7326/0003-4819-117-6-487; MISHU B, 1993, JAMA-J AM MED ASSOC, V269, P1843, DOI 10.1001/jama.269.14.1843; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; NAYLOR CD, 1993, CAN MED ASSOC J, V148, P921; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; OWENS DK, 1992, AM J MED, V92, P503, DOI 10.1016/0002-9343(92)90747-Y; OWENS DK, 1994, MODELING THE AIDS EPIDEMIC: PLANNING, POLICY, AND PREDICTION, P153; OWENS DK, 1990, AIDS 90S SCI POLICY, V3, P308; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PADIAN NS, 1991, JAMA-J AM MED ASSOC, V266, P1664; PADIAN NS, 1990, AM J PUBLIC HEALTH, V80, P990, DOI 10.2105/AJPH.80.8.990; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; PHILLIPS KA, 1994, JAMA-J AM MED ASSOC, V271, P851, DOI 10.1001/jama.271.11.851; ROBACK G, 1992, PHYSICIAN CHARACTERI; ROBERT L, 1993, 1ST NAT F INF DIS NA, P1; ROSENTHAL E, 1991, NY TIMES        1020, pB5; RUSSELL LB, 1989, SCIENCE, V246, P892, DOI 10.1126/science.2510299; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SCHULMAN KA, 1994, INFECT CONT HOSP EP, V15, P147, DOI 10.1086/646882; SCHWARTZ JS, 1990, JAMA-J AM MED ASSOC, V264, P1704, DOI 10.1001/jama.264.13.1704; SELL RL, 1994, INFECT CONT HOSP EP, V15, P635, DOI 10.2307/30145274; SMITH TW, 1991, FAM PLANN PERSPECT, V23, P102, DOI 10.2307/2135820; SONENSTEIN FL, 1989, FAM PLANN PERSPECT, V21, P152, DOI 10.2307/2135805; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V268, P489, DOI 10.1001/jama.268.4.489; VALDISERRI RO, 1988, AM J PUBLIC HEALTH, V78, P801, DOI 10.2105/AJPH.78.7.801; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; VITTECOQ D, 1992, 8 HARV U DUTCH F AID, P45; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WELCH J, 1989, LANCET, V1, P205; WENGER NS, 1991, AM J PUBLIC HEALTH, V81, P1580, DOI 10.2105/AJPH.81.12.1580; WENGER NS, 1992, ANN INTERN MED, V117, P905, DOI 10.7326/0003-4819-117-11-905; WITHERS BG, 1992, MIL MED, V157, P80, DOI 10.1093/milmed/157.2.80; WOOD FW, 1990, AM PROFILE OPINIONS; Yawn B P, 1992, Fam Med, V24, P355; 1991, MMWR-MORBID MORTAL W, V40, P377; 1988, MMWR-MORBID MORTAL W, V37, P229; 1992, MMWR-MORBID MORTAL W, V41, P344; 1988, MMWR-MORBID MORTAL W, V37, P239; 1993, STATISTICAL ABSTRACT; 1994, PHYSICIAN CHARACTERI; 1991, NY TIMES        1020, P7; 1992, 8 HARV U DUTCH F AID, pC348; 1993, MMWR-MORBID MORTAL W, V42, P329; 1990, MMWR-MORBID MORTAL W, V39, P489; 1994, SOCIOECONOMIC CHARAC; 1992, STATISTICAL ABSTRACT; 1990, VITAL STATISTICS US; 1990, MMWR-MORBID MORTAL W, V39, P380	108	39	39	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					641	652		10.7326/0003-4819-122-9-199505010-00001	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00001			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702225				2022-12-28	WOS:A1995QV15100001
J	SERVICE, FJ				SERVICE, FJ			MEDICAL PROGRESS - HYPOGLYCEMIC DISORDERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INSULIN-INDUCED HYPOGLYCEMIA; PLASMA-GLUCOSE CONCENTRATION; CHRONIC-RENAL-FAILURE; GROWTH-HORMONE; REACTIVE HYPOGLYCEMIA; POSTPRANDIAL HYPOGLYCEMIA; GLYCEMIC THRESHOLDS; ADRENERGIC-BLOCKADE; AUTOIMMUNE SYNDROME; DIABETES-MELLITUS				SERVICE, FJ (corresponding author), MAYO CLIN & MAYO FDN,DIV ENDOCRINOL & METAB,200 1ST ST SW,ROCHESTER,MN 55905, USA.							AHLQUIST DA, 1980, ANN INTERN MED, V93, P281, DOI 10.7326/0003-4819-93-2-281; ALMIRALL J, 1989, NEPHRON, V53, P273, DOI 10.1159/000185757; ANDREANI D, 1987, HYPOGLYCEMIA, V38, P312; [Anonymous], 1987, DIABETES CARE, V10, P95; ARCHAMBEAUDMOUV.F, 1989, BIOMED PHARMACOTHER, V43, P581; AREM R, 1983, ARCH INTERN MED, V143, P827, DOI 10.1001/archinte.143.4.827; BARRETT CT, 1968, NEW ENGL J MED, V278, P1260, DOI 10.1056/NEJM196806062782304; BEARD CM, 1983, MAYO CLIN PROC, V58, P802; BENZING G, 1969, CIRCULATION, V40, P209, DOI 10.1161/01.CIR.40.2.209; BLOCK MB, 1977, MIL MED, V142, P32; BLOCK MB, 1972, LANCET, V2, P736; BOUCHARD P, 1982, DIABETES, V31, P40, DOI 10.2337/diabetes.31.1.40; BOYLE PJ, 1991, AM J PHYSIOL, V260, pE395, DOI 10.1152/ajpendo.1991.260.3.E395; BOYLE PJ, 1989, AM J PHYSIOL, V256, pE651, DOI 10.1152/ajpendo.1989.256.5.E651; BRESSLER R, 1969, PHARMACOL REV, V21, P105; CHALEW SA, 1984, JAMA-J AM MED ASSOC, V251, P612, DOI 10.1001/jama.251.5.612; CHEN YT, 1984, NEW ENGL J MED, V310, P171, DOI 10.1056/NEJM198401193100306; CLARKE WL, 1979, AM J PHYSIOL, V236, pE147, DOI 10.1152/ajpendo.1979.236.2.E147; COHEN MM, 1971, AM J DIS CHILD, V122, P515, DOI 10.1001/archpedi.1971.02110060085015; COLLINS JE, 1990, ARCH DIS CHILD, V65, P1118, DOI 10.1136/adc.65.10.1118; CONNOR H, 1979, POSTGRAD MED J, V55, P735, DOI 10.1136/pgmj.55.648.735; COX DJ, 1993, DIABETES CARE, V16, P519, DOI 10.2337/diacare.16.2.519; Cryer PE, 1993, HYPOGLYCAEMIA DIABET, P34; DAUGHADAY WH, 1989, ENDOCRIN METAB CLIN, V18, P91, DOI 10.1016/S0889-8529(18)30390-6; DAVIS MR, 1991, J CLIN ENDOCR METAB, V72, P788, DOI 10.1210/jcem-72-4-788; DEFEO P, 1989, AM J PHYSIOL, V256, pE835, DOI 10.1152/ajpendo.1989.256.6.E835; DEFEO P, 1989, AM J PHYSIOL, V257, pE35, DOI 10.1152/ajpendo.1989.257.1.E35; DEFRONZO RA, 1972, DIABETES, V26, P445; DEVIVO DC, 1991, NEW ENGL J MED, V325, P703, DOI 10.1056/NEJM199109053251006; DOHERTY GM, 1991, SURGERY, V110, P989; DOPPMAN JL, 1991, RADIOLOGY, V178, P237, DOI 10.1148/radiology.178.1.1984311; DOPPMAN JL, 1993, RADIOLOGY, V187, P880; FELIG P, 1982, NEW ENGL J MED, V306, P895, DOI 10.1056/NEJM198204153061503; FELIG P, 1970, NEW ENGL J MED, V283, P1436, DOI 10.1056/NEJM197012242832604; FISCHER KF, 1986, NEW ENGL J MED, V315, P1245, DOI 10.1056/NEJM198611133152002; FUSHIMI H, 1980, ENDOCRINOL JAPON, V27, P679; GALIBER AK, 1988, RADIOLOGY, V166, P405, DOI 10.1148/radiology.166.2.2827232; GARBER AJ, 1974, DIABETES, V23, P982, DOI 10.2337/diab.23.12.982; GERICH J, 1979, AM J PHYSIOL, V236, pE380, DOI 10.1152/ajpendo.1979.236.4.E380; GLASGOW AM, 1973, AM J DIS CHILD, V125, P809, DOI 10.1001/archpedi.1973.04160060021004; GOLDMAN J, 1979, J CLIN INVEST, V63, P1050, DOI 10.1172/JCI109374; GOODENOW TJ, 1977, JAMA-J AM MED ASSOC, V237, P1961, DOI 10.1001/jama.237.18.1961; GRANT CS, 1988, WIEN KLIN WOCHENSCHR, V100, P376; Heard C R, 1978, World Rev Nutr Diet, V30, P107; HECHT A, 1959, METABOLISM, V8, P418; HEINIG RE, 1979, ARCH INTERN MED, V139, P1229, DOI 10.1001/archinte.139.11.1229; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; HEPBURN DA, 1991, DIABETES CARE, V14, P949, DOI 10.2337/diacare.14.11.949; Hepburn DA, 1993, HYPOGLYCAEMIA DIABET, P93; HIRATA Y, 1983, LANCET, V2, P1037; HOFELDT FD, 1972, AM J CLIN NUTR, V25, P1193; HOGAN MJ, 1983, MAYO CLIN PROC, V58, P491; JOHANSSON C, 1978, ACTA MED SCAND, V204, P509; JOHNSON DD, 1980, JAMA-J AM MED ASSOC, V243, P1151, DOI 10.1001/jama.243.11.1151; KANE LA, 1993, DIABETES CARE, V16, P1298, DOI 10.2337/diacare.16.9.1298; KAO PC, 1994, J CLIN ENDOCR METAB, V78, P1048, DOI 10.1210/jc.78.5.1048; KOGUT MD, 1969, J PEDIATR-US, V74, P853, DOI 10.1016/S0022-3476(69)80220-9; KOJAK G, 1969, AM J PSYCHIAT, V126, P573, DOI 10.1176/ajp.126.4.573; LAMBERTS SWJ, 1990, NEW ENGL J MED, V323, P1246, DOI 10.1056/NEJM199011013231805; LEVIN H, 1990, CAN J ANAESTH, V37, P477, DOI 10.1007/BF03005631; LEVRAN A, 1981, DIABETES, V30, P996, DOI 10.2337/diabetes.30.12.996; LIMBURG PJ, 1993, ANN INTERN MED, V119, P218, DOI 10.7326/0003-4819-119-3-199308010-00007; LIU D, 1992, DIABETOLOGIA, V35, P287, DOI 10.1007/BF00400932; LUYCKX AS, 1971, DIABETES, V20, P435, DOI 10.2337/diab.20.6.435; MACARON CI, 1981, DIABETES CARE, V4, P113, DOI 10.2337/diacare.4.1.113; Madison L L, 1968, Adv Metab Disord, V3, P85; MCCALL AL, 1993, HYPOGLYCAEMIA DIABET, P56; MCMAHON MM, 1989, MAYO CLIN PROC, V64, P1481, DOI 10.1016/S0025-6196(12)65703-6; MERIMEE TJ, 1973, J CLIN ENDOCR METAB, V37, P698, DOI 10.1210/jcem-37-5-698; MERIMEE TJ, 1971, J CLIN INVEST, V50, P574, DOI 10.1172/JCI106527; MILLER DR, 1977, NEW ENGL J MED, V297, P339; MILLER SI, 1980, AM J MED, V68, P649, DOI 10.1016/0002-9343(80)90250-8; MITRAKOU A, 1991, AM J PHYSIOL, V260, pE67, DOI 10.1152/ajpendo.1991.260.1.E67; MITRAKOU A, 1993, NEW ENGL J MED, V329, P834, DOI 10.1056/NEJM199309163291203; NAPPI JM, 1983, WESTERN J MED, V138, P95; NELSON RL, 1983, HYPOGLYCEMIC DISORDE, P97; NORTON JA, 1990, ANN SURG, V212, P615, DOI 10.1097/00000658-199011000-00009; OBRIEN T, 1993, J CLIN ENDOCR METAB, V77, P448, DOI 10.1210/jc.77.2.448; OOI TC, 1980, J ENDOCRINOL INVEST, V3, P45, DOI 10.1007/BF03348216; PALARDY J, 1989, NEW ENGL J MED, V321, P1421, DOI 10.1056/NEJM198911233212101; PEDERSEN J, 1954, ACTA ENDOCRINOL-COP, V15, P33, DOI 10.1530/acta.0.0150033; PHILLIPS RE, 1986, BRIT MED J, V292, P1319, DOI 10.1136/bmj.292.6531.1319; RASCHKE R, 1991, ARCH INTERN MED, V151, P591, DOI 10.1001/archinte.151.3.591; RICH LM, 1990, ARCH INTERN MED, V150, P894, DOI 10.1001/archinte.150.4.894; RIZZA RA, 1979, J CLIN INVEST, V64, P62, DOI 10.1172/JCI109464; ROSCH T, 1992, NEW ENGL J MED, V326, P1721, DOI 10.1056/NEJM199206253262601; ROSEN SG, 1984, J CLIN INVEST, V73, P405, DOI 10.1172/JCI111226; SANTIAGO JV, 1980, J CLIN ENDOCR METAB, V51, P877, DOI 10.1210/jcem-51-4-877; SCHWARTZ NS, 1987, J CLIN INVEST, V79, P777, DOI 10.1172/JCI112884; SERVICE FJ, 1992, J CLIN ENDOCR METAB, V74, P204, DOI 10.1210/jc.74.1.204; SERVICE FJ, 1989, NEW ENGL J MED, V321, P1472, DOI 10.1056/NEJM198911233212109; SERVICE FJ, 1974, ARCH INTERN MED, V134, P336, DOI 10.1001/archinte.134.2.336; SERVICE FJ, 1991, MAYO CLIN PROC, V66, P711, DOI 10.1016/S0025-6196(12)62083-7; SERVICE FJ, 1976, MAYO CLIN PROC, V51, P417; SERVICE FJ, 1993, J CLIN ENDOCR METAB, V76, P655, DOI 10.1210/jc.76.3.655; Service FJ., 1995, ENDOCRINOLOGY, P1605; SERVICE FJ, 1978, AM J MED, V64, P698; Service FJ, 1992, ENDOCRINOLOGIST, V2, P173; SERVICE FJ, 1987, HYPOGLYCEMIA, V38, P45; SKETRIS I, 1984, DRUG INTEL CLIN PHAR, V18, P142, DOI 10.1177/106002808401800210; SNORGAARD O, 1990, BRIT MED J, V300, P16, DOI 10.1136/bmj.300.6716.16; SOVIK O, 1989, ACTA PAEDIATR SCAND, V78, P161, DOI 10.1111/j.1651-2227.1989.tb11052.x; STARKE AAR, 1983, DIABETOLOGIA, V25, P336; Takei M, 1980, J TOKYO WOMENS MED C, V50, P54; TALENTE GM, 1994, ANN INTERN MED, V120, P218, DOI 10.7326/0003-4819-120-3-199402010-00008; TOWLER DA, 1993, DIABETES, V42, P1791, DOI 10.2337/diabetes.42.12.1791; TREEM WR, 1988, NEW ENGL J MED, V319, P1331, DOI 10.1056/NEJM198811173192006; TSALIKIAN E, 1983, HYPOGLYCEMIC DISORDE, P35; TSE TF, 1983, J CLIN INVEST, V72, P278, DOI 10.1172/JCI110967; VENEMAN T, 1993, DIABETES, V42, P1233, DOI 10.2337/diabetes.42.9.1233; VINIK AI, 1991, SURGERY, V109, P1; Whipple AO, 1938, J INT CHIR, V3, P237; WHITE NJ, 1983, NEW ENGL J MED, V309, P61, DOI 10.1056/NEJM198307143090201; ZIMMERMAN BR, 1983, HYPOGLYCERMIA PATHOG	114	340	349	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	1995	332	17					1144	1152		10.1056/NEJM199504273321707	http://dx.doi.org/10.1056/NEJM199504273321707			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU302	7700289				2022-12-28	WOS:A1995QU30200007
J	RIDKER, PM; STAMPFER, MJ; HENNEKENS, CH				RIDKER, PM; STAMPFER, MJ; HENNEKENS, CH			PLASMA-CONCENTRATION OF LIPOPROTEIN(A) AND THE RISK OF FUTURE STROKE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; APOLIPOPROTEIN-A-I; MYOCARDIAL-INFARCTION; CEREBROVASCULAR-DISEASE; SERUM LIPOPROTEIN(A); CEREBRAL INFARCTION; LP(A) LIPOPROTEIN; ARTERY DISEASE; ATHEROSCLEROSIS; MEN	Objective.-To assess prospectively the risk of future stroke associated with baseline concentration of lipoprotein(a), abbreviated Lp(a). Design.-Nested case-control study using baseline plasma samples. Setting.-Men in the Physicians' Health Study. Participants.-A cohort of 14 916 male physicians with no prior history of stroke, transient ischemic attack, or myocardial infarction provided plasma samples at baseline and were followed prospectively for 7.5 years. Samples from 198 physicians who subsequently developed stroke (155 thromboembolic, 35 hemorrhagic, eight indeterminate) were analyzed for Lp(a) concentration together with paired controls, matched for age and smoking habit. Main Outcome Measure.-Fatal and nonfatal stroke. Results.-Median Lp(a) concentration (8.88 mg/dL [0.23 mmol/L] vs 8.55 mg/dL [0.22 mmol/L]), P=.69) and overall distributions of Lp(a) (P=.54) were similar at baseline in men who did and did not develop future stroke. In analyses controlling for age, smoking status, blood pressure, obesity, and the presence of diabetes, the relative risks (RRs) associated with baseline Lp(a) concentration exceeding the 25th, 50th, 75th, 90th, and 95th percentiles of the control distribution were 1.26, 0.99, 1.06, 0.90, and 1.03 (all P values nonsignificant). There was likewise no association in analyses limited to thromboembolic events. For example, among subjects with baseline Lp(a) values exceeding the 95th percentile of the control distribution, the RR of future thromboembolic stroke was 1.01 (P=.9). No evidence of association between Lp(a) and stroke risk was found in analyses limited to individuals with hypercholesterolemia. Conclusions.-Among nearly 15 000 predominantly white, healthy, middle-aged men followed in the Physicians' Health Study for a period of 7.5 years, we found no evidence of association between baseline plasma concentration of Lp(a) and future risk of total or thromboembolic stroke.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV CARDIOVASC DIS, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	RIDKER, PM (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV PREVENT MED, 900 COMMONWEALTH AVE, BOSTON, MA 02115 USA.				NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-26490, HL-34595] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; BERG K, 1974, CLIN GENET, V6, P230; BOSTOM AG, 1994, CIRCULATION, V90, P1688, DOI 10.1161/01.CIR.90.4.1688; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HOLLANDERS FD, 1975, POSTGRAD MED J, V51, P386, DOI 10.1136/pgmj.51.596.386; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JOVICIC A, 1993, ATHEROSCLEROSIS, V98, P59, DOI 10.1016/0021-9150(93)90223-H; JURGENS G, 1987, NEUROLOGY, V37, P513, DOI 10.1212/WNL.37.3.513; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KOLTRINGER P, 1985, ATHEROSCLEROSIS, V58, P187, DOI 10.1016/0021-9150(85)90065-6; KOSTNER GM, 1986, EUR NEUROL, V25, P346, DOI 10.1159/000116033; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P51, DOI 10.1016/0021-9150(81)90103-9; KOSTNER GM, 1991, ARCH DIS CHILD, V66, P1054, DOI 10.1136/adc.66.9.1054; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MENDEZ I, 1987, NEUROLOGY, V37, P507, DOI 10.1212/WNL.37.3.507; MURAI A, 1986, ATHEROSCLEROSIS, V59, P199, DOI 10.1016/0021-9150(86)90048-1; NAGAYAMA M, 1994, STROKE, V25, P74, DOI 10.1161/01.STR.25.1.74; PEDROBOTET J, 1992, STROKE, V23, P1556, DOI 10.1161/01.STR.23.11.1556; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SANDKAMP M, 1990, CLIN CHEM, V36, P20; SCANU AM, 1992, JAMA-J AM MED ASSOC, V267, P3326, DOI 10.1001/jama.267.24.3326; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SCHEINER PJ, 1994, ANN EPIDEMIOL, V4, P351; SCHREINER PJ, 1993, ARTERIOSCLER THROMB, V13, P826, DOI 10.1161/01.ATV.13.6.826; SHINTANI S, 1993, STROKE, V24, P965, DOI 10.1161/01.STR.24.7.965; SIGURDSSON G, 1992, AM J CARDIOL, V69, P1251, DOI 10.1016/0002-9149(92)91215-P; SLUNGA L, 1992, SCAND J CLIN LAB INV, V52, P95, DOI 10.3109/00365519209088771; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WOO J, 1990, STROKE, V21, P1407, DOI 10.1161/01.STR.21.10.1407; WOO J, 1991, STROKE, V22, P203, DOI 10.1161/01.STR.22.2.203; ZENKER G, 1986, STROKE, V17, P942, DOI 10.1161/01.STR.17.5.942; ZHUANG YY, 1993, CHINESE MED J-PEKING, V106, P597	39	108	117	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	1995	273	16					1269	1273		10.1001/jama.273.16.1269	http://dx.doi.org/10.1001/jama.273.16.1269			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU571	7715039				2022-12-28	WOS:A1995QU57100029
J	VALDIVIA, HH; KAPLAN, JH; ELLISDAVIES, GCR; LEDERER, WJ				VALDIVIA, HH; KAPLAN, JH; ELLISDAVIES, GCR; LEDERER, WJ			RAPID ADAPTATION OF CARDIAC RYANODINE RECEPTORS - MODULATION BY MG2+ AND PHOSPHORYLATION	SCIENCE			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE CHANNEL; DEPENDENT PROTEIN-KINASE; RAT VENTRICULAR MYOCYTES; SKELETAL-MUSCLE; ADENINE-NUCLEOTIDE; SINGLE-CHANNEL; CA-2+ RELEASE; HEART-MUSCLE; CA2+ RELEASE	Channel adaptation is a fundamental feature of sarcoplasmic reticulum calcium release channels (called ryanodine receptors, RyRs). It permits successive increases in the intracellular concentration of calcium (Ca2+) to repeatedly but transiently activate channels. Adaptation of RyRs in the absence of magnesium (Mg2+) and adenosine triphosphate is an extremely slow process (taking seconds). Photorelease of Ca2+ from nitrophenyl-EGTA, a photolabile Ca2+ chelator, demonstrated that RyR adaptation is rapid (milliseconds) in canine heart muscle when physiological Mg2+ concentrations are present. Phosphorylation of the RyR by protein kinase A increased the responsiveness of the channel to Ca2+ and accelerated the kinetics of adaptation. These properties of the RyR from heart may also be relevant to other cells in which multiple agonist-dependent triggering events regulate cellular functions.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR MED BIOTECHNOL,BALTIMORE,MD 21201; UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Pennsylvania			Lederer, William/B-1285-2010	Kaplan, Jack/0000-0002-7048-6574	NHLBI NIH HHS [HL25675, R01 HL025675, R01 HL036974, R01 HL030315, HL36974, R37 HL036974, HL30315] Funding Source: Medline; NIGMS NIH HHS [R01 GM053395, R01 GM039500] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030315, R01HL036974, R01HL025675, R37HL036974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500, R01GM053395] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARO I, 1993, J PHYSIOL-LONDON, V465, P21, DOI 10.1113/jphysiol.1993.sp019664; BERS DM, 1989, AM J PHYSIOL, V256, pC109, DOI 10.1152/ajpcell.1989.256.1.C109; BEUCKELMANN DJ, 1988, J PHYSIOL-LONDON, V405, P233, DOI 10.1113/jphysiol.1988.sp017331; CALLEWAERT G, 1988, P NATL ACAD SCI USA, V85, P2009, DOI 10.1073/pnas.85.6.2009; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; HOLMBERG SRM, 1990, BIOCHIM BIOPHYS ACTA, V1022, P187, DOI 10.1016/0005-2736(90)90113-3; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEDERER WJ, 1990, SCIENCE, V251, P1371; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; OBRIEN PJ, 1986, CAN J VET RES, V50, P318; ONEILL SC, 1990, AM J PHYSIOL, V258, pC1165, DOI 10.1152/ajpcell.1990.258.6.C1165; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SPURGEON HA, 1990, AM J PHYSIOL, V258, pH574, DOI 10.1152/ajpheart.1990.258.2.H574; STRAND MA, 1993, BIOCHIM BIOPHYS ACTA, V1175, P319, DOI 10.1016/0167-4889(93)90224-D; TAKASAGO T, 1989, J BIOCHEM-TOKYO, V106, P872, DOI 10.1093/oxfordjournals.jbchem.a122945; TATE CA, 1985, J BIOL CHEM, V260, P9618; TINKER A, 1992, J GEN PHYSIOL, V100, P479, DOI 10.1085/jgp.100.3.479; VALDIVIA HH, 1991, J BIOL CHEM, V266, P19135; VALDIVIA HH, 1992, P NATL ACAD SCI USA, V89, P12185, DOI 10.1073/pnas.89.24.12185; VALDIVIA HH, UNPUB; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; YATANI A, 1988, J BIOL CHEM, V263, P9887	32	312	322	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1997	2000		10.1126/science.7701323	http://dx.doi.org/10.1126/science.7701323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701323	Green Accepted			2022-12-28	WOS:A1995QQ06800045
J	SHAWLOT, W; BEHRINGER, RR				SHAWLOT, W; BEHRINGER, RR			REQUIREMENT FOR LIM1 IN HEAD-ORGANIZER FUNCTION	NATURE			English	Article							HOMEO-BOX GENE; MOUSE EMBRYOS; EXPRESSION PATTERN; FROG EMBRYOS; INDUCTION; DOMAIN; CELLS; GASTRULATION; HOMEODOMAIN; ELEGANS	Lim1 is a homeobox gene expressed in the organizer region of mouse embryos. To investigate the role of Lim1 during embryogenesis, a targeted deletion of the Lim1 gene was generated in embryonic stem cells. Embryos homozygous for the null allele lacked anterior head structures but the remaining body axis developed normally. A partial secondary axis developed anteriorly in some mutant embryos. Lim1 is thus an essential regulator of the vertebrate head organizer.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, DEVELOPMENT, V120, P2979; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; BEDDINGTON RSP, 1992, POSTIMPLANTATION DEV, P55; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CONLON FL, 1994, DEVELOPMENT, V120, P1919; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; DOWNS KM, 1993, DEVELOPMENT, V118, P1255; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GERHART J, 1991, GASTRULATION MOVEMEN, P57; GONT LK, 1993, DEVELOPMENT, V119, P991; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; JURAND A, 1974, J EMBRYOL EXP MORPH, V32, P1; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEIR S, 1982, DIFFERENTIATION, V117, P96; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; SASAKI H, 1993, DEVELOPMENT, V118, P47; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SORIANO P, 1991, CELL, V64, P694; Spemann H, 1927, NATURWISSENSCHAFTEN, V15, P946, DOI 10.1007/BF01506755; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPEMANN H, 1931, ROUX ARCH ENTW MECH, V123, P389; TAIRA M, 1994, DEVELOPMENT, V120, P1525; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; TAM PPL, 1992, POSTIMPLANTATION DEV, P27; THEILER K, 1989, HOUSE MOUSE; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WADDINGTON CH, 1932, J EXP BIOL, V10, P38; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YAMADA T, 1994, DEVELOPMENT, V120, P3051; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	50	644	655	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					425	430		10.1038/374425a0	http://dx.doi.org/10.1038/374425a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700351				2022-12-28	WOS:A1995QP89900049
J	YANG, YZ; NISWANDER, L				YANG, YZ; NISWANDER, L			INTERACTION BETWEEN THE SIGNALING MOLECULES WNT7A AND SHH DURING VERTEBRATE LIMB DEVELOPMENT - DORSAL SIGNALS REGULATE ANTEROPOSTERIOR PATTERNING	CELL			English	Article							APICAL ECTODERMAL RIDGE; CHICK-EMBRYO; BUD CELLS; MOUSE; GENES; EXPRESSION; SPECIFICATION; DROSOPHILA	Growth and patterning of the vertebrate limb are controlled by the ridge, posterior mesenchyme, and nonridge ectoderm. Fibroblast growth factor 4 (FGF4) and Sonic hedgehog (SHH) can mediate signaling from the ridge and posterior mesenchyme, respectively. Here we show that do rsal ectoderm is required together with FGF4 to maintain Shh expression. Removal of dorsal ectoderm results in loss of posterior skeletal elements, which can be rescued by exogenous SHH. Wnt7a, which is expressed in dorsal ectoderm, provides the signal required for Shh expression and formation of posterior structures. These results provide evidence that all three axes (dorsoventral, proximodistal, and anteroposterior) are intimately linked by the respective signals WNT7a, FGF4, and SHH during limb outgrowth and patterning.	MEM SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University			Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON R, 1993, DEVELOPMENT, V117, P1421; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FEKETE DM, 1993, P NATL ACAD SCI USA, V90, P2350, DOI 10.1073/pnas.90.6.2350; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HELMS J, 1994, DEVELOPMENT, V120, P3267; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MARTIN P, 1986, DEV BIOL, V118, P233, DOI 10.1016/0012-1606(86)90091-6; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PARR BA, 1993, DEVELOPMENT, V119, P247; PARR BA, 1995, IN PRESS NATURE; PAUTOU MP, 1977, VERTEBRATE LIMB SOMI, P257; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VOGEL A, 1993, DEVELOPMENT, V119, P199	41	271	279	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					939	947		10.1016/0092-8674(95)90297-X	http://dx.doi.org/10.1016/0092-8674(95)90297-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697724	hybrid			2022-12-28	WOS:A1995QP61200013
J	OKEEFFE, ST; SMITH, T; VALACIO, R; JACK, CIA; PLAYFER, JR; LYE, M				OKEEFFE, ST; SMITH, T; VALACIO, R; JACK, CIA; PLAYFER, JR; LYE, M			A COMPARISON OF 2 TECHNIQUES FOR ANKLE JERK ASSESSMENT IN ELDERLY SUBJECTS	LANCET			English	Article							RELIABILITY	The reported prevalence of absent ankle jerks in elderly people varies greatly. This variation may be due to differences in the method of testing. Eight physicians examined 12 patients for the presence of ankle jerks using two techniques: plantar strike acid tendon strike. Both intra-observer agreement (kappa 0.47 vs 0.20; p = 0.01) and inter-observer agreement (0.57 vs 0.21; p < 0.001) were greater with plantar strike. Reliability of ankle jerk assessment was greater for more experienced examiners. Differences in technique may explain some of the discrepancy between studies examining the prevalence of absent ankle jerks in elderly people.			OKEEFFE, ST (corresponding author), ROYAL LIVERPOOL UNIV HOSP,DEPT GERIATR MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.			O'Keeffe, Shaun/0000-0002-7682-5004				Altman DG, 1991, PRACTICAL STATISTICS; BARTKO JJ, 1976, J NERV MENT DIS, V163, P307, DOI 10.1097/00005053-197611000-00003; Critchley M, 1931, LANCET, V1, P1119; IMPALLOMENI M, 1984, LANCET, V1, P670; ROSS RT, 1985, EXAMINE NERVOUS SYST, P212; VANGIJN J, 1977, J NEUROL NEUROSUR PS, V40, P787, DOI 10.1136/jnnp.40.8.787; VOGEL HP, 1992, NEUROLOGY, V42, P2076, DOI 10.1212/WNL.42.11.2076; WOLFSON L, 1992, PRINCIPLES GERIATRIC, P75	8	21	21	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1619	1620		10.1016/S0140-6736(94)90411-1	http://dx.doi.org/10.1016/S0140-6736(94)90411-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7695707				2022-12-28	WOS:A1994PW05100014
J	WEEKS, KM; CROTHERS, DM				WEEKS, KM; CROTHERS, DM			MAJOR GROOVE ACCESSIBILITY OF RNA	SCIENCE			English	Article							INTERNAL LOOPS; NUCLEIC-ACIDS; BINDING-SITE; FREE-ENERGY; RECOGNITION; SYNTHETASE; OLIGORIBONUCLEOTIDES; MISMATCHES	Chemical acylation experiments showed that the RNA major groove, often assumed to be too deep and narrow to permit recognition interactions, is accessible at duplex termini. Reactivity extended further into the helix in the 5' than in the 3' direction. Asymmetric and large loops between helices uncoupled them, which yielded both enhanced reactivity at terminal base pairs and weaker stabilization enthalpy compared to that in small loops or symmetric loops of the same size. Uncoupled helices have effective helix ends with accessible major grooves; such motifs are attractive contributors to protein recognition, tertiary folding, and catalysis.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511	Yale University					NIGMS NIH HHS [GM21966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021966, R01GM021966] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDEN CJ, 1979, J MOL BIOL, V132, P411, DOI 10.1016/0022-2836(79)90268-7; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; CANTOR CR, 1980, BIOPHYSICAL CHEM, P1205; CHOW CS, 1992, BIOCHEMISTRY-US, V31, P3534, DOI 10.1021/bi00128a030; Fasman GD., 1975, HDB BIOCH MOL BIOL N, V1, P589; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GRALLA J, 1973, J MOL BIOL, V78, P301, DOI 10.1016/0022-2836(73)90118-6; HAASNOOT CAG, 1986, J BIOMOL STRUCT DYN, V3, P843, DOI 10.1080/07391102.1986.10508468; HOLBROOK SR, 1983, BIOPOLYMERS, V22, P1145, DOI 10.1002/bip.360220410; JACOBSON H, 1950, J CHEM PHYS, V18, P1600, DOI 10.1063/1.1747547; Kim S H, 1976, Prog Nucleic Acid Res Mol Biol, V17, P181, DOI 10.1016/S0079-6603(08)60070-7; LONGFELLOW CE, 1990, BIOCHEMISTRY-US, V29, P278, DOI 10.1021/bi00453a038; LUTTER LC, 1978, J MOL BIOL, V124, P391, DOI 10.1016/0022-2836(78)90306-6; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; PEATTIE DA, 1980, P NATL ACAD SCI-BIOL, V77, P4679, DOI 10.1073/pnas.77.8.4679; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PERITZ AE, 1991, BIOCHEMISTRY-US, V30, P6428, DOI 10.1021/bi00240a013; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SANTALUCIA J, 1991, BIOCHEMISTRY-US, V30, P8242, DOI 10.1021/bi00247a021; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; VINCZE A, 1973, J AM CHEM SOC, V95, P2677, DOI 10.1021/ja00789a045; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1992, CELL, V70, P1069; WEEKS KM, UNPUB; YARUS M, 1991, NUCLEIC ACIDS RES, V19, P1297, DOI 10.1093/nar/19.6.1297	28	191	197	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 17	1993	261	5128					1574	1577		10.1126/science.7690496	http://dx.doi.org/10.1126/science.7690496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	7690496				2022-12-28	WOS:A1993LX47400029
J	VANDEUREN, M; VANDIJKE, B; KOOPMAN, RJJ; HORREVORTS, AM; MEIS, JFGM; SANTMAN, FW; VANDERMEER, JWM				VANDEUREN, M; VANDIJKE, B; KOOPMAN, RJJ; HORREVORTS, AM; MEIS, JFGM; SANTMAN, FW; VANDERMEER, JWM			RAPID DIAGNOSIS OF ACUTE MENINGOCOCCAL INFECTIONS BY NEEDLE ASPIRATION OR BIOPSY OF SKIN-LESIONS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BACTERIAL-MENINGITIS; PROGNOSIS; DISEASE; PURPURA; SHOCK	Objectives-To evaluate the usefulness of Gram staining and culture of skin lesions in patients with acute meningococcal infections. Design-Retrospective study. Setting-Community hospital and intensive care unit of a teaching hospital. Subjects-51 patients admitted from 1989 to 1993 with proved meningococcal infections and microbiological examination of specimens from skin lesions. Interventions-Needle aspiration of a skin lesion before start of antibiotic treatment in 26 patients in the community hospital; punch biopsy of skin lesion after start of antibiotic treatment in 25 patients in the teaching hospital. Main outcome measures-Detection of meningococci by Gram staining of specimens from skin lesions according to category of infection (meningococcaemia, meningitis, meningitis with shock, or septic shock without meningitis). Results-Bacteria were detected in the specimen from haemorrhagic skin lesions by culture or Gram staining, or both in 32 (63%) patients. The sensitivity of the Gram stain was 51% and did not differ significantly from its sensitivity in detecting bacteria in cerebrospinal fluid. In meningococcal sepsis, however, a Gram stained skin lesion was significantly more sensitive (72%) than Gram stained cerebrospinal fluid (22%). In patients with meningitis skin lesions gave positive results on staining more often if shock was present. The results for punch biopsy specimens were not affected by antibiotics as Gram staining gave positive results up to 45 hours after the start of treatment and culture gave positive results up to 13 hours. Conclusion-Microbiological examination of skin lesions is informative, especially in patients with sepsis and inconclusive results from cerebrospinal fluid, and may provide a diagnosis in such patients within 45 minutes. It differentiates well between meningitis with and without haemodynamic complications, and the result is not affected by previous antibiotic treatment.	UNIV HOSP NIJMEGEN, DEPT DERMATOL, 6500 HB NIJMEGEN, NETHERLANDS; UNIV HOSP NIJMEGEN, DEPT MED MICROBIOL, 6500 HB NIJMEGEN, NETHERLANDS; UNIV HOSP NIJMEGEN, DEPT INTENS CARE, 6500 HB NIJMEGEN, NETHERLANDS; ST LAURENTIUS HOSP, DEPT MED MICROBIOL, ROERMOND, NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	VANDEUREN, M (corresponding author), UNIV HOSP NIJMEGEN, DEPT INTERNAL MED, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.		Meis, Jacques F/A-9241-2010; van der Meer, Jos W.M./C-8521-2013	Meis, Jacques F/0000-0003-3253-6080; van der Meer, Jos W.M./0000-0001-5120-3690				[Anonymous], NIPH ANN; APICELLA MA, 1990, PRINCIPLES PRACTICE, P1600; ARGENBRIGHT LW, 1992, J CLIN INVEST, V89, P259, DOI 10.1172/JCI115570; BAXTER P, 1988, LANCET, V1, P1166; BEGG N, 1992, BRIT MED J, V305, P133, DOI 10.1136/bmj.305.6846.133; Bernhard WG, 1944, J LAB CLIN MED, V29, P273; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BRANDTZAEG P, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P183; CAHALANE SF, 1975, LANCET, V2, P120; DAHLE J S, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P49; DAVIS CE, 1974, J EXP MED, V140, P159, DOI 10.1084/jem.140.1.159; EMPARANZA JI, 1988, CRIT CARE MED, V16, P168, DOI 10.1097/00003246-198802000-00015; GEDDEDAHL TW, 1990, REV INFECT DIS, V12, P359; GIRAUD T, 1991, ARCH INTERN MED, V151, P310, DOI 10.1001/archinte.151.2.310; HALSTENSEN A, 1987, SCAND J INFECT DIS, V19, P35, DOI 10.3109/00365548709032375; HILL WR, 1947, JAMA-J AM MED ASSOC, V134, P513, DOI 10.1001/jama.1947.02880230023006; HOALIN NI, 1992, LANCET, V340, P1432; HOYNE AL, 1948, ANN INTERN MED, V28, P248, DOI 10.7326/0003-4819-28-2-248; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; MANIOS S G, 1971, Scandinavian Journal of Infectious Diseases, V3, P127, DOI 10.3109/inf.1971.3.issue-2.06; MCGEJEE WG, 1967, ANN INTERN MED, V67, P250, DOI 10.7326/0003-4819-67-2-250; McLean S, 1931, AM J DIS CHILD, V42, P1053, DOI 10.1001/archpedi.42.5.1053; MERCIER JC, 1988, CRIT CARE MED, V16, P27, DOI 10.1097/00003246-198801000-00006; MOVAT HZ, 1985, HDB ENDOTOXIN, V3, P260; NETTER A, 1917, BRIT J CHILD DIS, V14, P101; NETTER A, 1917, BRIT J CHILD DIS, V14, P264; NIKLASSON P-M, 1971, Scandinavian Journal of Infectious Diseases, V3, P17, DOI 10.3109/inf.1971.3.issue-1.03; Rubenstein R, 1986, Pediatr Dermatol, V3, P414, DOI 10.1111/j.1525-1470.1986.tb00553.x; SINCLAIR JF, 1987, LANCET, V2, P38; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; TALAN DA, 1988, REV INFECT DIS, V10, P365; TOEWS WH, 1974, AM J DIS CHILD, V127, P173, DOI 10.1001/archpedi.1974.02110210023003; TOMPKINS LS, 1992, NEW ENGL J MED, V327, P1290; TOMPKINS V. N., 1943, Journal of the American Medical Association, V123, P31; TONJUM T, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P175; VANDEUREN M, 1992, CLIN INFECT DIS, V15, P424, DOI 10.1093/clind/15.3.424; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333	37	63	64	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	1993	306	6887					1229	1232		10.1136/bmj.306.6887.1229	http://dx.doi.org/10.1136/bmj.306.6887.1229			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB804	7684633	Green Published, Bronze			2022-12-28	WOS:A1993LB80400013
J	KATZ, AM				KATZ, AM			MECHANISMS OF DISEASE - CARDIAC ION CHANNELS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POTASSIUM CHANNELS; CALCIUM CHANNELS; SODIUM-CHANNEL; ACTIVATION; GROWTH; GENE				KATZ, AM (corresponding author), UNIV CONNECTICUT, DEPT MED, DIV CARDIOL, 263 FARMINGTON AVE, FARMINGTON, CT 06030 USA.				NHLBI NIH HHS [HL-33026] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL033026] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGNEW WS, 1988, NATURE, V331, P114, DOI 10.1038/331114a0; ALDRICH RW, 1990, NATURE, V345, P475, DOI 10.1038/345475a0; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1991, Circulation, V84, P1831; BEAN B, 1990, NATURE, V348, P192, DOI 10.1038/348192a0; CARMELIET E, 1992, CARDIOVASC DRUG THER, V6, P305; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHANDY KG, 1991, NATURE, V352, P26, DOI 10.1038/352026b0; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; KATZ AM, 1990, CARDIOLOGY, V77, P346, DOI 10.1159/000174624; KATZ AM, 1992, J CARDIOVASC ELECTR, V3, P150, DOI 10.1111/j.1540-8167.1992.tb01104.x; KATZ AM, 1990, J MOL CELL CARDIOL, V22, P739, DOI 10.1016/0022-2828(90)90086-H; KATZ AM, 1988, J MOL CELL CARDIOL, V20, P355, DOI 10.1016/S0022-2828(88)80069-5; KATZ AM, 1989, CIRCULATION, V79, P712, DOI 10.1161/01.CIR.79.3.712; KATZ AM, 1992, PHYSL HEART, P415; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LAZDUNSKI M, 1992, CARDIOVASC DRUG THER, V6, P313; LUE WM, 1992, CIRCULATION, V85, P1175, DOI 10.1161/01.CIR.85.3.1175; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NUNOKI K, 1989, P NATL ACAD SCI USA, V86, P6816, DOI 10.1073/pnas.86.17.6816; RENKIN J, 1990, CIRCULATION, V82, P913, DOI 10.1161/01.CIR.82.3.913; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; STRONG M, 1993, MOL BIOL EVOL, V10, P221; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TENEICK RE, 1992, FASEB J, V6, P2568, DOI 10.1096/fasebj.6.8.1375569; TIMPE LC, 1988, NATURE, V331, P143, DOI 10.1038/331143a0; VANDERVUSSE GJ, 1992, PHYSIOL REV, V72, P881, DOI 10.1152/physrev.1992.72.4.881; Vaughan Wiliams EM, 1970, S CARDIAC ARRHYTHMIA, P449	32	71	74	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 29	1993	328	17					1244	1251						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ061	7681934				2022-12-28	WOS:A1993KZ06100007
J	FISHER, RI; GAYNOR, ER; DAHLBERG, S; OKEN, MM; GROGAN, TM; MIZE, EM; GLICK, JH; COLTMAN, CA; MILLER, TP				FISHER, RI; GAYNOR, ER; DAHLBERG, S; OKEN, MM; GROGAN, TM; MIZE, EM; GLICK, JH; COLTMAN, CA; MILLER, TP			COMPARISON OF A STANDARD REGIMEN (CHOP) WITH 3 INTENSIVE CHEMOTHERAPY REGIMENS FOR ADVANCED NON-HODGKINS-LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIFFUSE HISTIOCYTIC LYMPHOMA; SOUTHWEST-ONCOLOGY-GROUP; LARGE-CELL LYMPHOMA; MACOP-B CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; INTERMEDIATE-GRADE; M-BACOD; UNDIFFERENTIATED LYMPHOMA; AGGRESSIVE LYMPHOMAS; MALIGNANT-LYMPHOMAS	Background. CHOP is a first-generation, combination-chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone that has cured approximately 30 percent of patients with advanced stages of intermediate-grade or high-grade non-Hodgkin's lymphoma in national cooperative-group trials. However, studies at single institutions have suggested that 55 to 65 percent of such patients might be cured by third-generation regimens such as ones consisting of low-dose methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD); prednisone, doxorubicin, cyclophosphamide, and etoposide, followed by cytarabine, bleomycin, vincristine, and methotrexate with leucovorin rescue (ProMACE-CytaBOM); and methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide; vincristine, prednisone, and bleomycin (MACOP-B). Methods. To make a valid comparison of these regimens, the Southwest Oncology Group and the Eastern Cooperative Oncology Group initiated a prospective, randomized phase III trial. The study end points were the response rate, time to treatment failure, overall survival, and incidence of severe or life-threatening toxicity. Dose intensity was calculated and analyzed. Results. Of the 1138 patients registered for the trial, 899 were eligible. Each treatment group contained at least patients. Known prognostic factors were equally distributed among the groups. There were no significant differences among the groups in the rates of partial and complete response. At three years, 44 percent of all patients were alive without disease; there were no significant differences between the groups (41 percent in the CHOP and MACOP-B groups and 46 percent in the m-BACOD and ProMACE-CytaBOM groups; P = 0.35). Overall survival at three years was 52 percent (50 percent in the ProMACE-CytaBOM and MACOP-B groups, 52 percent in the m-BACOD group, and 54 percent in the CHOP group; P = 0.90). There was no subgroup of patients in which survival was improved by a third-generation regimen. Fatal toxic reactions occurred in 1 percent of the CHOP group, 3 percent of the ProMACE-CytaBOM group, 5 percent of the m-BACOD group, and 6 percent of the MACOP-B group (P = 0.09). Conclusions. CHOP remains the best available treatment for patients with advanced-stage intermediate-grade or high-grade non-Hodgkin's lymphoma.	LOYOLA UNIV, STRITCH SCH MED, MAYWOOD, IL 60153 USA; SW ONCOL GRP, CTR STAT, SEATTLE, WA USA; ABBOTT NW HOSP, VIRGINIA PIPER CANC INST, MINNEAPOLIS, MN USA; UNIV ARIZONA, TUCSON, AZ 85721 USA; UNIV PENN, PHILADELPHIA, PA 19104 USA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78284 USA	Loyola University Chicago; Southwest Oncology Group; University of Arizona; University of Pennsylvania; University of Texas System; University of Texas Health San Antonio					NCI NIH HHS [CA-37429, CA-13612, CA-46282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA013612, U10CA037429, U10CA046282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARDE P, 1991, ANN ONCOL, V2, P431, DOI 10.1093/oxfordjournals.annonc.a057979; CHISESI T, 1991, LEUKEMIA, V5, P107; COIFFIER B, 1989, BLOOD, V74, P558; COLEMAN M, 1985, ANN INTERN MED, V103, P140, DOI 10.7326/0003-4819-103-1-140; COLTMAN CA, 1988, CANCER CHEMOTHERAPY, P194; CONNORS JM, 1988, SEMIN HEMATOL, V25, P41; COOPER IA, 1991, P AN M AM SOC CLIN, V10, P271; COX DR, 1975, BIOMETRIKA, V62, P269, DOI 10.2307/2335362; COX DR, 1972, J R STAT SOC B, V34, P187; DANA BW, 1990, J CLIN ONCOL, V8, P1155, DOI 10.1200/JCO.1990.8.7.1155; DANIEU L, 1986, CANCER RES, V46, P5372; DEVITA VT, 1975, LANCET, V1, P248; DIXON DO, 1986, J CLIN ONCOL, V4, P295, DOI 10.1200/JCO.1986.4.3.295; FEDERICO M, 1991, LEUKEMIA, V5, P95; FISHER RI, 1977, AM J MED, V63, P177, DOI 10.1016/0002-9343(77)90230-3; FISHER RI, 1981, BLOOD, V58, P45; FISHER RI, 1983, ANN INTERN MED, V98, P304, DOI 10.7326/0003-4819-98-3-304; FISHER RI, 1984, P AN M AM SOC CLIN, V3, P242; GAYNOR ER, 1985, J CLIN ONCOL, V3, P1596, DOI 10.1200/JCO.1985.3.12.1596; GORDON LI, 1992, NEW ENGL J MED, V327, P1342, DOI 10.1056/NEJM199211053271903; JAGANNATH S, 1985, J CLIN ONCOL, V3, P39, DOI 10.1200/JCO.1985.3.1.39; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; LAURENCE J, 1982, ANN INTERN MED, V97, P190, DOI 10.7326/0003-4819-97-2-190; LONGO, 1991, J CLIN ONCOL, V9, P710, DOI 10.1200/JCO.1991.9.4.710; LONGO DL, 1991, J CLIN ONCOL, V9, P25, DOI 10.1200/JCO.1991.9.1.25; LOWENTHAL DA, 1987, P AN M AM SOC CLIN, V6, P201; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MILLER TP, 1990, J CLIN ONCOL, V8, P1951, DOI 10.1200/JCO.1990.8.12.1951; MONTSERRAT E, 1991, BLOOD S, V78, pA127; ORADELL JN, 1992, DRUG TOPICS RED BOOK; ROSENBERG SA, 1982, CANCER, V49, P2112; SCHEIN PS, 1976, ANN INTERN MED, V85, P417, DOI 10.7326/0003-4819-85-4-417; SCHNEIDER AM, 1990, J CLIN ONCOL, V8, P94, DOI 10.1200/JCO.1990.8.1.94; SHIPP M, 1992, P AN M AM SOC CLIN, V11, P319; SHIPP MA, 1986, ANN INTERN MED, V104, P757, DOI 10.7326/0003-4819-104-6-757; SKARIN AT, 1983, J CLIN ONCOL, V1, P91, DOI 10.1200/JCO.1983.1.2.91; WEICK JK, 1991, J CLIN ONCOL, V9, P748, DOI 10.1200/JCO.1991.9.5.748	38	1759	1850	1	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					1002	1006		10.1056/NEJM199304083281404	http://dx.doi.org/10.1056/NEJM199304083281404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW282	7680764				2022-12-28	WOS:A1993KW28200004
J	LUSSO, P; MALNATI, MS; GARZINODEMO, A; CROWLEY, RW; LONG, EO; GALLO, RC				LUSSO, P; MALNATI, MS; GARZINODEMO, A; CROWLEY, RW; LONG, EO; GALLO, RC			INFECTION OF NATURAL-KILLER-CELLS BY HUMAN HERPESVIRUS-6	NATURE			English	Article							CHRONIC FATIGUE SYNDROME; HUMAN-IMMUNODEFICIENCY-VIRUS; INVITRO; AIDS; DEFICIENCY; MECHANISM; ANTIGEN	NATURAL killer (NK) cells are a functionally defined subset of non-T, non-B lymphocytes of bone marrow origin, which induce lysis of selected target cells, including neoplastic and virus-infected cells1-3. The NK cell function provides an important mechanism of primary defence against viruses in vivo, as demonstrated by the occurrence of multiple herpesvirus infections in patients congenitally lacking NK cells4,5. Here we show that functionally competent CD3- NK clones can be productively infected by human herpesvirus 6 (HHV-6)6, a T-lymphotropic DNA virus7 that may play a role in the acquired immunodeficiency syndrome (AIDS)8 and in the chronic fatigue syndrome9, two disorders associated with a defective NK cell activity10-15. The infection is cytopathic and induces de novo expression of CD4, an antigen not expressed within the NK lineage16,17, thereby predisposing NK cells to infection by human immunodeficiency virus type 1 (HIV-1). These results provide evidence that a herpesvirus can directly target and kill NK cells, a potential strategy to suppress the natural anti-viral immunity of the host.	NIAID, IMMUNOGENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	LUSSO, P (corresponding author), NCI, TUMOR CELL BIOL LAB, BETHESDA, MD 20892 USA.		Malnati, Mauro/AAN-4207-2020; Long, Eric O/G-5475-2011	Long, Eric O/0000-0002-7793-3728; Garzino-Demo, Alfredo/0000-0002-4095-6950; Malnati, mauro/0000-0001-5355-1680				AOKI T, 1987, NAT IMMUN CELL GROW, V6, P116; BALACHANDRAN N, 1989, J VIROL, V63, P2835, DOI 10.1128/JVI.63.6.2835-2840.1989; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BONAVIDA B, 1986, J IMMUNOL, V137, P1157; BUCHWALD D, 1992, ANN INTERN MED, V116, P103, DOI 10.7326/0003-4819-116-2-103; CALIGIURI M, 1987, J IMMUNOL, V139, P3306; CHEHIMI J, 1991, J VIROL, V65, P1812, DOI 10.1128/JVI.65.4.1812-1822.1991; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FLEISHER G, 1982, J PEDIATR-US, V100, P727, DOI 10.1016/S0022-3476(82)80572-6; HERBERMAN RB, 1981, SCIENCE, V214, P24, DOI 10.1126/science.7025208; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KLIMAS NG, 1990, J CLIN MICROBIOL, V28, P1403, DOI 10.1128/JCM.28.6.1403-1410.1990; LANIER LL, 1986, LEUKOCYTE TYPING 2, V3, P157; LUSSO P, 1991, J IMMUNOL, V147, P685; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; LUSSO P, 1988, J EXP MED, V167, P1659, DOI 10.1084/jem.167.5.1659; LUSSO P, 1992, HUMAN HERPESVIRUS, V6, P121; MORETTA A, 1983, J EXP MED, V157, P743, DOI 10.1084/jem.157.2.743; MORETTA A, 1990, J EXP MED, V171, P695, DOI 10.1084/jem.171.3.695; OLDSTONE MBA, 1991, J VIROL, V65, P6381, DOI 10.1128/JVI.65.12.6381-6386.1991; RITZ J, 1988, ADV IMMUNOL, V42, P181, DOI 10.1016/S0065-2776(08)60845-7; ROBERTSON MJ, 1990, BLOOD, V76, P2421; ROBINSON WE, 1988, HUM PATHOL, V19, P535, DOI 10.1016/S0046-8177(88)80200-4; ROOK AH, 1983, J CLIN INVEST, V72, P398, DOI 10.1172/JCI110981; RUSCETTI FW, 1986, J IMMUNOL, V136, P3619; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SIRIANNI MC, 1988, J IMMUNOL, V140, P2565; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1	29	172	174	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	1993	362	6419					458	462		10.1038/362458a0	http://dx.doi.org/10.1038/362458a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	7681936				2022-12-28	WOS:A1993KV42400087
J	HERRERO, C; VICENTE, A; BRUGUERA, M; ERCILLA, MG; BARRERA, JM; VIDAL, J; TERES, J; MASCARO, JM; RODES, J				HERRERO, C; VICENTE, A; BRUGUERA, M; ERCILLA, MG; BARRERA, JM; VIDAL, J; TERES, J; MASCARO, JM; RODES, J			IS HEPATITIS-C VIRUS-INFECTION A TRIGGER OF PORPHYRIA-CUTANEA-TARDA	LANCET			English	Note							HEPATOCELLULAR-CARCINOMA; PATHOLOGY; LIVER	The causes of liver disease, ranging from fatty changes to cirrhosis and hepatocellular carcinoma, in prophyria cutanea tarda (PCT) remain unclear. We tested 100 consecutive PCT patients for antibodies to hepatitis C virus (HCV) by enzyme-linked immunosorbent assay and a recombinant immunoblot assay. 75 (79%) patients with sporadic PCT but none of 5 with familial PCT were positive. HCV RNA was found in serum of all 18 anti-HCV-positive patients tested. There were no significant differences in the prevalence of anti-HCV between treated and untreated patients or between those with and without various HCV risk factors. The frequency of anti-HCV increased with the severity of liver histology. These findings implicate HCV in the aetiology of PCT-associated liver disease.	UNIV BARCELONA,HOSP CLIN,LIVER UNIT,VILLARROEL 170,E-08036 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN,SERV IMMUNOL,E-08036 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN,SERV MICROBIOL,E-08036 BARCELONA,SPAIN; UNIV BARCELONA,HOSP CLIN,DEPT DERMATOL,E-08036 BARCELONA,SPAIN	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona								BRUGUERA M, 1986, SEMIN DERMATOL, V5, P178; BRUIX J, 1989, LANCET, V2, P1004; CORTES JM, 1980, HISTOPATHOLOGY, V4, P471, DOI 10.1111/j.1365-2559.1980.tb02942.x; ELDER GH, 1990, RECENT ADV DERMATOLO, P55; LEEVY CM, 1979, DISEASES LIVER BILIA; LEFKOWITCH JH, 1983, LIVER, V3, P19; Lentner C, 1982, GEIGY SCI TABLES; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; SALATA H, 1985, J HEPATOL, V1, P477, DOI 10.1016/S0168-8278(85)80746-7; SUAREZ M, 1992, GASTROENTEROL HEPATO, V15, P272	10	198	205	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 27	1993	341	8848					788	789		10.1016/0140-6736(93)90562-U	http://dx.doi.org/10.1016/0140-6736(93)90562-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU900	7681135				2022-12-28	WOS:A1993KU90000005
J	AZZOPARDI, P; COWEY, A				AZZOPARDI, P; COWEY, A			PREFERENTIAL REPRESENTATION OF THE FOVEA IN THE PRIMARY VISUAL-CORTEX	NATURE			English	Article							CORTICAL MAGNIFICATION FACTOR; LATERAL GENICULATE-NUCLEUS; GANGLION-CELL DENSITY; MACAQUE MONKEYS; STRIATE CORTEX; RETINA; FIELD; UNIFORMITY; NEURONS; VISION	THE retinal fovea, which corresponds to the central degree or so of vision, is spatially over-represented in the visual cortex. It is about 0.01% of retina area, but at least 8% of the striate cortex1-3. Does this simply reflect an equivalently uneven distribution of ganglion cells in the retina4-7, or is the cortical representation of the fovea preferentially expanded8-13? The answer hinges on the resolution of long-standing discrepancies between the retinal and cortical magnification factors. We approached the problem in a different way, using a retrograde transneuronal tracer from cortex to retina to relate directly the number of ganglion cells projecting to marked areas of striate cortex. We report here that ganglion cells near the fovea were allocated 3.3 to 5.9 times more cortical tissue than more peripheral ones, and conclude that the cortical representation of the most central retina is much greater than expected from the density of its ganglion cells.			AZZOPARDI, P (corresponding author), UNIV OXFORD,DEPT EXPTL PSYCHOL,S PARKS RD,OXFORD OX1 3UD,ENGLAND.		Azzopardi, Paul/C-5694-2013	Azzopardi, Paul/0000-0001-7386-8191				[Anonymous], 1941, AM J OPHTHALMOL, DOI [10.1016/S0002-9394(41)91363-6, DOI 10.1016/S0002-9394(41)91363-6]; CONNOLLY M, 1984, J COMP NEUROL, V226, P544, DOI 10.1002/cne.902260408; COWEY A, 1964, J NEUROPHYSIOL, V27, P366, DOI 10.1152/jn.1964.27.3.366; DANIEL PM, 1961, J PHYSIOL-LONDON, V159, P203, DOI 10.1113/jphysiol.1961.sp006803; DOW BM, 1981, EXP BRAIN RES, V44, P213; DRASDO N, 1977, NATURE, V266, P554, DOI 10.1038/266554a0; FENDICK M, 1983, VISION RES, V23, P145, DOI 10.1016/0042-6989(83)90137-2; HUBEL DH, 1974, J COMP NEUROL, V158, P295, DOI 10.1002/cne.901580305; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; Kulikowski J. J., 1989, SEEING CONTOUR COLOU, P274; LEVAY S, 1990, EXP BRAIN RES, V82, P77; LEVI DM, 1984, VISION RES, V24, P789, DOI 10.1016/0042-6989(84)90150-0; LEVI DM, 1987, VISION RES, V27, P581, DOI 10.1016/0042-6989(87)90044-7; MALPELI JG, 1975, J COMP NEUROL, V161, P569, DOI 10.1002/cne.901610407; MYERSON J, 1977, SCIENCE, V192, P855; OKUSKY J, 1982, J COMP NEUROL, V210, P278, DOI 10.1002/cne.902100307; PERRY VH, 1985, VISION RES, V25, P1795, DOI 10.1016/0042-6989(85)90004-5; PERRY VH, 1981, NEUROSCIENCE, V6, P931, DOI 10.1016/0306-4522(81)90174-3; PERRY VH, 1984, NEUROSCIENCE, V12, P1125, DOI 10.1016/0306-4522(84)90007-1; PERRY VH, 1988, NEUROSCIENCE, V25, P225, DOI 10.1016/0306-4522(88)90021-8; POTTS AM, 1972, INVEST OPHTH VISUAL, V11, P980; POWELL TPS, 1981, BRAIN RES, V216, P409, DOI 10.1016/0006-8993(81)90142-6; ROCKEL AJ, 1980, BRAIN, V103, P221, DOI 10.1093/brain/103.2.221; ROLLS ET, 1970, EXP BRAIN RES, V10, P298; ROVAMO J, 1979, EXP BRAIN RES, V37, P495, DOI 10.1007/bf00236819; SCHEIN SJ, 1988, J COMP NEUROL, V269, P479, DOI 10.1002/cne.902690403; SILVEIRA LCL, 1989, VISION RES, V29, P1471, DOI 10.1016/0042-6989(89)90131-4; STRASBURGER H, 1991, PERCEPT PSYCHOPHYS, V49, P495, DOI 10.3758/BF03212183; WASSLE H, 1989, NATURE, V341, P643, DOI 10.1038/341643a0; WASSLE H, 1990, VISION RES, V30, P1897, DOI 10.1016/0042-6989(90)90166-I	30	134	135	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					719	721		10.1038/361719a0	http://dx.doi.org/10.1038/361719a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	7680108				2022-12-28	WOS:A1993KN78900054
J	CHOW, YK; HIRSCH, MS; MERRILL, DP; BECHTEL, LJ; ERON, JJ; KAPLAN, JC; DAQUILA, RT				CHOW, YK; HIRSCH, MS; MERRILL, DP; BECHTEL, LJ; ERON, JJ; KAPLAN, JC; DAQUILA, RT			USE OF EVOLUTIONARY LIMITATIONS OF HIV-1 MULTIDRUG RESISTANCE TO OPTIMIZE THERAPY	NATURE			English	Article							REVERSE-TRANSCRIPTASE INHIBITORS; VIRUS; REPLICATION; ZIDOVUDINE; DERIVATIVES; SENSITIVITY; INVITRO; MUTANTS; AZT	WILD-TYPE reverse transcriptase has evolved for the survival of human immunodeficiency virus type 1 (HIV-1) by natural selection1. In contrast, therapy relying on inhibitors of reverse transcriptase by nucleosides like zidovudine (AZT) or dideoxyinosine (ddI), and by non-nucleosides like pyridinones or nevirapine2-6, may exert different selection pressures on this enzyme. Therefore the acquisition of resistance to reverse transcriptase inhibitors by selection of mutations in the pol gene7-15 may require compromises in enzyme function that affect viral replication. As single mutations are unlikely to confer broad resistance when combinations of reverse transcriptase inhibitors are used, multiple mutations may occur that result in further compromises. Certain drug combinations may prevent the co-existence of adequate reverse transcription function and multi-drug resistance (MDR). Unlike bacterial or eukaryotic drug resistance, retroviral drug resistance is conferred only by mutations in its own genome16 and is limited by genome size. Combining drugs directed against the same essential viral protein may thus prevent HIV-1 MDR, whereas the conventional approach of targeting different HIV-1 proteins for combination therapy may not, because genomes with resistance mutations in different HIV-1 genes might recombine to develop MDR17. Here we show that several mutations in the HIV-1 reverse transcriptase gene that confer resistance to inhibitors of this enzyme can attenuate viral replication. We tested whether combinations of mutations giving rise to single-agent resistance might further compromise or even abolish viral replication, and if multidrug-resistant viruses could be constructed. Certain combinations of mutations conferring resistance to AZT, ddI and pyridinone are incompatible with viral replication. These results indicate that evolutionary limitations exist to restrict development of MDR. Furthermore, a therapeutic strategy exploiting these limitations by using selected multidrug regimens directed against the same target may prevent development of MDR. This approach, which we call convergent combination therapy, eliminated HIV-1 replication and virus breakthrough in vitro, and may be applicable to other viral targets. Moreover, elimination of reverse transcription by convergent combination therapy may also limit MDR.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	CHOW, YK (corresponding author), MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,GRAY 5,BOSTON,MA 02114, USA.							ALBERT J, 1992, J VIROL, V66, P5627, DOI 10.1128/JVI.66.9.5627-5630.1992; BALZARINI J, 1992, ANTIMICROB AGENTS CH, V36, P1073, DOI 10.1128/AAC.36.5.1073; BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; COEN DM, 1986, J ANTIMICROB CHEMOTH, V18, P1; ERON JJ, 1992, P NATL ACAD SCI USA, V89, P3241, DOI 10.1073/pnas.89.8.3241; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; GAO Q, 1992, J VIROL, V66, P12, DOI 10.1128/JVI.66.1.12-19.1992; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; Johnson V., 1990, TECHNIQUES HIV RES; JOHNSON VA, 1991, J INFECT DIS, V164, P646, DOI 10.1093/infdis/164.4.646; JOHNSON VA, 1990, J INFECT DIS, V161, P1057; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KORNFELD H, 1987, NATURE, V326, P610, DOI 10.1038/326610a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAND S, 1992, J INFECT DIS, V166, P1139, DOI 10.1093/infdis/166.5.1139; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MELLORS JW, 1992, MOL PHARMACOL, V41, P446; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TEMIN HM, 1989, J ACQ IMMUN DEF SYND, V2, P1; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106	30	154	166	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 18	1993	361	6413					650	654		10.1038/361650a0	http://dx.doi.org/10.1038/361650a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	7679778				2022-12-28	WOS:A1993KM77600068
J	SMIT, JW; WIJNNE, HJ; SCHOBBEN, F; SITSEN, A; DEBRUIN, TW; ERKELENS, DW				SMIT, JW; WIJNNE, HJ; SCHOBBEN, F; SITSEN, A; DEBRUIN, TW; ERKELENS, DW			EFFECTS OF ALCOHOL AND FLUVASTATIN ON LIPID-METABOLISM AND HEPATIC-FUNCTION	ANNALS OF INTERNAL MEDICINE			English	Note							MODERATE HYPERCHOLESTEROLEMIA; PLASMA-LIPOPROTEINS; DENSITY-LIPOPROTEIN; LOVASTATIN; CARCINOGENS; CHOLESTEROL; ETHANOL; DRUGS; LIVER	Objective: To determine the effects of fluvastatin, a synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, combined with moderate alcohol consumption on lipid profiles and hepatic function in patients with primary hypercholesterolemia. Design: Randomized, placebo-controlled, crossover study. Setting: Lipid clinic of a university hospital. Patients: 31 patients with primary hypercholesterolemia (low-density lipoprotein cholesterol levels greater than or equal to 4.2 mmol/L) who had previously received a lipid-lowering diet. Interventions: After a dietary baseline period, 26 patients were randomly assigned to receive 6 weeks of treatment with either 1) fluvastatin, 40 mg/d, added to 20 g of ethanol and diluted to 20% with orange juice or 2) fluvastatin added to orange juice alone. After a 6-week washout period, the two groups crossed over. Main Outcome Measures: Plasma fluvastatin levels, lipid levels, and clinical variables were determined at the end of each treatment period. Results: Six patients left the study prematurely. The remaining patients (15 men, 5 women; mean age +/- SD, 49.1 +/- 14.5 years; mean body mass index +/- SD 24.5 +/- 2.2 kg/m(2)) completed the study. Fluvastatin, alone and combined with alcohol, resulted in similar decreases in levels of total cholesterol (22% and 23%, respectively; P < 0.001 when compared with baseline), low-density lipoprotein cholesterol (28% and 29%, respectively; P < 0.001 compared with baseline), and apolipoprotein B (17% and 20%, respectively; P < 0.001 compared with baseline). High-density lipoprotein cholesterol and triglyceride levels were not changed. Fluvastatin with alcohol resulted in a significantly greater area under the plasma concentration curve (23.4 +/- 4.7 compared with 18.2 +/- 3.2 x 10(3) ng . min/mL) and in a greater time to maximum concentration (187.5 +/- 16.6 min compared with 130.9 +/- 7.0 min) than fluvastatin alone. Terminal half-life tended to increase. No important adverse clinical effects were observed. Conclusion: Six weeks of daily, moderate alcohol consumption influenced the metabolism of fluvastatin but did not interfere with its lipid-lowering efficacy and had no adverse effects.	UNIV UTRECHT HOSP, DEPT PHARM, 3508 GA UTRECHT, NETHERLANDS; UNIV UTRECHT HOSP, DEPT PHARMACOL, 3508 GA UTRECHT, NETHERLANDS	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	SMIT, JW (corresponding author), UNIV UTRECHT HOSP, DEPT INTERNAL MED, ROOM F02126, POB 85500, 3508 GA UTRECHT, NETHERLANDS.							ANDERSON P, 1986, STRESS MEDICINE, V2, P99, DOI 10.1002/smi.2460020205; BENET LZ, 1990, PHARMACOL BASIS THER, P22; BILHEIMER DW, 1990, CARDIOLOGY, V77, P58, DOI 10.1159/000174684; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; CROUSE JR, 1984, J LIPID RES, V25, P486; EAST C, 1988, NEW ENGL J MED, V318, P47; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GRUNDY SM, 1985, J LIPID RES, V26, P1464; GRUNDY SM, 1988, NEW ENGL J MED, V319, P24; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; KALAFSKY G, 1993, J CHROMATOGR-BIOMED, V614, P307, DOI 10.1016/0378-4347(93)80323-V; KEYS A, 1980, LANCET, V1, P145, DOI 10.1016/S0140-6736(80)90620-0; LEITERSDORF E, 1993, EUR J CLIN PHARMACOL, V45, P513, DOI 10.1007/BF00315307; LIEBER CS, 1983, PHARMACOL BIOCHEM BE, V18, P181, DOI 10.1016/0091-3057(83)90169-7; LIEBER CS, 1988, NEW ENGL J MED, V319, P1639; LIEBER CS, 1990, ALCOHOL ALCOHOLISM, V25, P157, DOI 10.1093/oxfordjournals.alcalc.a044990; PETERS TJ, 1982, BRIT MED BULL, V38, P17, DOI 10.1093/oxfordjournals.bmb.a071726; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; WANG RW, 1991, ARCH BIOCHEM BIOPHYS, V290, P355, DOI 10.1016/0003-9861(91)90551-S	20	15	18	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					678	680		10.7326/0003-4819-122-9-199505010-00006	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702230				2022-12-28	WOS:A1995QV15100006
J	SCHNEEWIND, O; FOWLER, A; FAULL, KF				SCHNEEWIND, O; FOWLER, A; FAULL, KF			STRUCTURE OF THE CELL-WALL ANCHOR OF SURFACE-PROTEINS IN STAPHYLOCOCCUS-AUREUS	SCIENCE			English	Article							MALTOSE-BINDING-PROTEIN; GRAM-POSITIVE BACTERIA; SEQUENCE; GENE; RESISTANCE; REGION; LYSOSTAPHIN; ATTACHMENT; MEMBRANE	Many surface proteins are anchored to the cell wall of Gram-positive bacteria and are involved in the pathogenesis of these organisms. A hybrid molecule was designed that, when expressed in Staphylococcus aureus, was anchored to the cell wall and could be released by controlled enzymatic digestion. By a combination of molecular biology and mass spectrometry techniques, the structure of the cell wall anchor of surface proteins in S. aureus was revealed. After cleavage of surface proteins between threonine and glycine of the conserved LPXTG motif, the carboxyl of threonine is amide-linked to the free amino group of the pentaglycine crossbridge in the staphylococcal cell wall.	UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST NEUROPSYCHIAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SCHNEEWIND, O (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024, USA.				NIAID NIH HHS [AI 33985] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033985] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWDER HP, 1965, BIOCHEM BIOPH RES CO, V19, P383, DOI 10.1016/0006-291X(65)90473-0; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; DUPLAY P, 1984, J BIOL CHEM, V259, P606; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FORSGREN A, 1969, ACTA PATHOL MIC SC, V75, P481; FOSTER TJ, 1994, FEMS MICROBIOL LETT, V118, P199, DOI 10.1016/0378-1097(94)90504-5; GAREN A, 1955, VIROLOGY, V1, P347, DOI 10.1016/0042-6822(55)90030-1; GHUYSEN J. M., 1965, BIOCHEMISTRY, V4, P2245, DOI 10.1021/bi00886a043; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; GUSS B, 1984, EUR J BIOCHEM, V138, P413, DOI 10.1111/j.1432-1033.1984.tb07931.x; JONES CL, 1986, J BACTERIOL, V166, P29, DOI 10.1128/jb.166.1.29-33.1986; KEHOE MA, 1994, BACTERIAL CELL WALL, P217; LYON BR, 1987, MICROBIOL REV, V51, P88, DOI 10.1128/MMBR.51.1.88-134.1987; MOKS T, 1986, EUR J BIOCHEM, V156, P3577; MUNOZ E, 1967, BIOCHEMISTRY-US, V6, P3659, DOI 10.1021/bi00864a007; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; PANCHOLI V, 1989, J EXP MED, V170, P2119, DOI 10.1084/jem.170.6.2119; PANCHOLI V, 1988, J BACTERIOL, V170, P2618, DOI 10.1128/jb.170.6.2618-2624.1988; PATEL AH, 1987, INFECT IMMUN, V55, P3103, DOI 10.1128/IAI.55.12.3103-3110.1987; PETIT JF, 1966, BIOCHEMISTRY-US, V5, P2765; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; RECSEI PA, 1987, P NATL ACAD SCI USA, V84, P1127, DOI 10.1073/pnas.84.5.1127; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; SCHOCKMAN GD, 1983, ANNU REV MICROBIOL, V37, P501; SJOQUIST J, 1972, EUR J BIOCHEM, V29, P572, DOI 10.1111/j.1432-1033.1972.tb02023.x; SJOQUIST J, 1972, EUR J BIOCHEM, V30, P190, DOI 10.1111/j.1432-1033.1972.tb02086.x; SLOAN GL, 1977, BIOCHEM J, V167, P293, DOI 10.1042/bj1670293; STROMINGER JL, 1967, SCIENCE, V156, P213, DOI 10.1126/science.156.3772.213; STROMINGER JL, 1967, FED PROC, V26, P9; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; UHLEN M, 1984, J BIOL CHEM, V259, P1695; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747; YOKOGAWA K, 1974, ANTIMICROB AGENTS CH, V6, P156, DOI 10.1128/AAC.6.2.156	38	372	408	0	36	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					103	106		10.1126/science.7701329	http://dx.doi.org/10.1126/science.7701329			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701329				2022-12-28	WOS:A1995QR45400036
J	BENTLEY, GA; BOULOT, G; KARJALAINEN, K; MARIUZZA, RA				BENTLEY, GA; BOULOT, G; KARJALAINEN, K; MARIUZZA, RA			CRYSTAL-STRUCTURE OF THE BETA-CHAIN OF A T-CELL ANTIGEN RECEPTOR	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; COMPLEX; RESOLUTION; REGION; FAB; IMMUNOGLOBULINS; RECOGNITION; SPECIFICITY; REFINEMENT; EXPRESSION	The crystal structure of the extracellular portion of the beta chain of a murine T cell antigen receptor (TCR), determined at a resolution of 1.7 angstroms, shows structural homology to immunoglobulins. The structure of the first and second hypervariable loops suggested that, in general, they adopt more restricted sets of conformations in TCR beta chains than those found in immunoglobulins; the third hypervariable loop had certain structural characteristics in common with those of immunoglobulin heavy chain variable domains. The variable and constant domains were in close contact, presumably restricting the flexibility of the beta chain. This may facilitate signal transduction from the TCR to the associated CD3 molecules in the TCR-CD3 complex.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850		BENTLEY, GA (corresponding author), INST PASTEUR,CNRS,UNITE IMMUNOL STRUCT 359,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Karjalainen, Klaus/A-2206-2011; Bentley, Graham/B-3623-2011					[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BOULOT G, 1994, J MOL BIOL, V235, P795, DOI 10.1006/jmbi.1994.1037; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1991, J MOL BIOL, V211, P239; CASORATI G, 1993, EUR J IMMUNOL, V23, P586, DOI 10.1002/eji.1830230246; CAZENAVE PA, 1990, CELL, V63, P717, DOI 10.1016/0092-8674(90)90138-5; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; FIELDS BA, 1994, J MOL BIOL, V239, P339, DOI 10.1006/jmbi.1994.1373; FISCHMANN TO, 1991, J BIOL CHEM, V266, P12915; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOCHSTENBACH F, 1990, J CLIN IMMUNOL, V10, P1, DOI 10.1007/BF00917493; JORES R, 1990, P NATL ACAD SCI USA, V87, P9138, DOI 10.1073/pnas.87.23.9138; Kabat EA, 1991, SEQUENCES PROTEINS I; KANG JS, 1994, J IMMUNOL, V152, P5305; KARJALAINEN K, 1994, CURR OPIN IMMUNOL, V6, P9, DOI 10.1016/0952-7915(94)90027-2; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; KUBO RT, 1989, J IMMUNOL, V142, P2736; LESK AM, 1988, NATURE, V335, P188, DOI 10.1038/335188a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PATTEN P, 1984, NATURE, V312, P40, DOI 10.1038/312040a0; PATTEN PA, 1993, J IMMUNOL, V150, P2281; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SAUL FA, 1992, PROTEINS, V14, P363, DOI 10.1002/prot.340140305; SCHIFFER M, 1973, BIOCHEMISTRY-US, V12, P4620, DOI 10.1021/bi00747a013; SIMON T, 1990, EMBO J, V9, P1056; TRAUNECKER A, 1991, TRENDS BIOTECHNOL, V9, P109, DOI 10.1016/0167-7799(91)90038-J; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	39	257	259	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 31	1995	267	5206					1984	1987		10.1126/science.7701320	http://dx.doi.org/10.1126/science.7701320			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QQ068	7701320				2022-12-28	WOS:A1995QQ06800041
J	KRAMER, BS; BROWN, ML; PROROK, PC; POTOSKY, AL; GOHAGAN, JK				KRAMER, BS; BROWN, ML; PROROK, PC; POTOSKY, AL; GOHAGAN, JK			PROSTATE-CANCER SCREENING - WHAT WE KNOW AND WHAT WE NEED TO KNOW	ANNALS OF INTERNAL MEDICINE			English	Review							DIGITAL RECTAL EXAMINATION; DETECTION-PROJECT; ANTIGEN LEVELS; MEN; CARCINOMA; MARKER; PROTEIN; DISEASE; SERUM	Objective: To critically evaluate the evidence for recommending the screening of asymptomatic men for prostate cancer with a blood test to detect a prostate-specific antigen (PSA). Data Sources: Relevant articles on screening for prostate cancer were identified from MEDLINE searches, from the authors' files, and from the bibliographies of identified articles. Study Selection: In the absence of controlled prospective trials, the studies are primarily retrospective and contain information about the sensitivity, specificity, and predictive values of tests used to screen for prostate cancer; the natural history of untreated prostate cancer; the morbidity, mortality, and costs of definitive treatment; and reviews of screening study biases. Data Extraction: Potential treatment-related mortality and costs that could be incurred by screening were estimated using defined assumptions. Results: Although screening for prostate cancer has the potential to save lives, because of possible over-diagnosis, screening and subsequent therapy could actually have a net unfavorable effect on mortality or quality of life or both. Given the performance characteristics of the test, widespread screening efforts would probably cost billions of dollars. Conclusions: The net benefit from widespread screening is unclear. A randomized prospective study of the effect of screening on prostate cancer mortality has therefore been initiated by the National Cancer Institute.			KRAMER, BS (corresponding author), NCI, DIV CANC PREVENT & CONTROL, BETHESDA, MD 20892 USA.							ADOLFSSON J, 1993, J UROLOGY, V149, P326, DOI 10.1016/S0022-5347(17)36071-8; BABAIAN RJ, 1992, CANCER, V69, P1195; Boorstin Daniel J., 1983, DISCOVERERS; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; BREUL J, 1993, J UROLOGY, V148, pA302; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA W, 1993, J UROLOGY, V148, pA301; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHODAK G, 1991, ACTA ONCOL, V30, P285, DOI 10.3109/02841869109092372; CHU TM, 1989, CLIN ASPECTS PROSTAT; EDWARDS CN, 1953, CANCER, V6, P531, DOI 10.1002/1097-0142(195305)6:3<531::AID-CNCR2820060311>3.0.CO;2-9; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; FONTANA RS, 1986, LUNG CANCER BASIC CL; FRIEDMAN GD, 1991, LANCET, V337, P1526, DOI 10.1016/0140-6736(91)93207-P; FRISELL J, 1987, BREAST CANCER RES TR, V9, P219, DOI 10.1007/BF01806383; GERBER GS, 1993, JAMA-J AM MED ASSOC, V269, P61, DOI 10.1001/jama.269.1.61; GRAVES HCB, 1985, NEW ENGL J MED, V312, P338, DOI 10.1056/NEJM198502073120603; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HAAS GP, 1992, J UROLOGY, V147, P311; Hara M., 1971, JPN J LEGAL MED, V25, P322; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; HINMAN F, 1991, J UROLOGY, V145, P126, DOI 10.1016/S0022-5347(17)38267-8; HORM JW, 1989, AM J PUBLIC HEALTH, V79, P1490, DOI 10.2105/AJPH.79.11.1490; HULKA BS, 1988, CANCER, V62, P1776, DOI 10.1002/1097-0142(19881015)62:1+<1776::AID-CNCR2820621314>3.0.CO;2-V; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KANE RA, 1992, CANCER-AM CANCER SOC, V69, P1201; KRAHN M, 1993, J UROLOGY, V148, pA299; KURIYAMA M, 1980, CANCER RES, V40, P4568; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; Lawrence R, 1989, GUIDE CLIN PREVENTIV; LEO ME, 1991, J UROLOGY, V145, P802, DOI 10.1016/S0022-5347(17)38456-2; LITTRUP PJ, 1993, CA-CANCER J CLIN, V43, P134, DOI 10.3322/canjclin.43.3.134; LITTRUP PJ, 1992, CA-CANCER J CLIN, V42, P198, DOI 10.3322/canjclin.42.4.198; LUNDBERG S, 1970, Scandinavian Journal of Urology and Nephrology, V4, P93, DOI 10.3109/00365597009137581; METTLIN C, 1991, CANCER, V67, P2949, DOI 10.1002/1097-0142(19910615)67:12<2949::AID-CNCR2820671202>3.0.CO;2-X; MOLD JW, 1992, J FAM PRACTICE, V34, P561; MORRISON AS, 1991, INT J EPIDEMIOL, V20, P642, DOI 10.1093/ije/20.3.642; NADJI M, 1981, CANCER, V48, P1229, DOI 10.1002/1097-0142(19810901)48:5<1229::AID-CNCR2820480529>3.0.CO;2-L; OESTERLING JE, 1992, JAMA-J AM MED ASSOC, V267, P2236, DOI 10.1001/jama.267.16.2236; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; OPTENBERG SA, 1990, UROL CLIN N AM, V17, P719; PAPSIDERO LD, 1980, CANCER RES, V40, P2428; RIEHMANN M, 1993, J UROLOGY, V148, pA449; RIES LAG, 1991, CANCER STATISTICS RE; SCHIFFMAN RM, 1993, J UROL 2, V148, pA495; SENSABAUGH GF, 1978, J FORENSIC SCI, V23, P106; Sherman C R, 1992, Int J Technol Assess Health Care, V8, P683; STEMMERMANN GN, 1992, CANCER EPIDEM BIOMAR, V1, P189; TULINIUS H, 1982, CANCER EPIDEMIOLOGY; VALLANCIEN G, 1991, J UROLOGY, V146, P1308, DOI 10.1016/S0022-5347(17)38076-X; WANG MC, 1979, INVEST UROL, V17, P159; WANG MC, 1981, PROSTATE, V2, P89, DOI 10.1002/pros.2990020109; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WHITMORE WJ, 1987, PROSTATE CANCER IMAG; 1988, CONSENSUS DEV C MANA; 1991, MEDICARE HOSPITAL MO; 1991, STATISTICAL ABSTRACT; 1987, JAMA-J AM MED ASSOC, V258, P2727; 1991, CAN MED ASSOC J, V145, P413	60	224	230	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1993	119	9					914	923		10.7326/0003-4819-119-9-199311010-00009	http://dx.doi.org/10.7326/0003-4819-119-9-199311010-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD711	7692780				2022-12-28	WOS:A1993MD71100009
J	SHENKER, A; LAUE, L; KOSUGI, S; MERENDINO, JJ; MINEGISHI, T; CUTLER, GB				SHENKER, A; LAUE, L; KOSUGI, S; MERENDINO, JJ; MINEGISHI, T; CUTLER, GB			A CONSTITUTIVELY ACTIVATING MUTATION OF THE LUTEINIZING-HORMONE RECEPTOR IN FAMILIAL MALE PRECOCIOUS PUBERTY	NATURE			English	Article							ALPHA-1B-ADRENERGIC RECEPTOR; CHORIONIC-GONADOTROPIN; SEXUAL PRECOCITY; GENE; SUBSTITUTIONS; RHODOPSIN; RAT; LH	FAMILIAL male precocious puberty (FMP) is a gonadotropin-independent disorder that is inherited in an autosomal dominant, male-limited pattern1-5. Affected males generally exhibit signs of puberty by age 4. Testosterone production and Leydig cell hyperplasia occur in the context of prepubertal levels of luteinizing hormone (LH)3-5. The LH receptor is a member of the family of G-protein-coupled receptors6,7, and we hypothesized that FMPP might be due to a mutant receptor that is activated in the presence of little or no agonist8-12 . A single A --> G base change that results in substitution of glycine for aspartate at position 578 in the sixth transmembrane helix of the LH receptor was found in affected individuals from eight different families. Linkage of the mutation to FMPP was supported by restriction-digest analysis. COS-7 cells expressing the mutant LH receptor exhibited markedly increased cyclic AMP production in the absence of agonist, suggesting that autonomous Leydig cell activity in FMPP is caused by a constitutively activated LH receptor.	NIDDK,BIOCHEM & METAB LAB,CELL REGULAT SECT,BETHESDA,MD 20892; NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD 20892; KYOTO UNIV,SCH MED,DEPT LAB MED,KYOTO 606,JAPAN; GUNMA UNIV,SCH MED,DEPT OBSTET & GYNECOL,MAEBASHI,GUNMA 371,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Kyoto University; Gunma University	SHENKER, A (corresponding author), NIDDK,MOLEC PATHOPHYSIOL BRANCH,BLDG 10,ROOM 8C-101,BETHESDA,MD 20892, USA.		KOSUGI, Shinji/GYR-2946-2022					ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; HOLLAND FJ, 1991, ENDOCRIN METAB CLIN, V20, P191, DOI 10.1016/S0889-8529(18)30288-3; HUNZICKERDUNN M, 1985, LUTEINIZING HORMONE, P57; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOSUGI S, 1993, MOL ENDOCRINOL, V7, P1009, DOI 10.1210/me.7.8.1009; LAUE L, 1989, NEW ENGL J MED, V320, P496, DOI 10.1056/NEJM198902233200805; LAUE L, 1993, J CLIN ENDOCR METAB, V76, P151, DOI 10.1210/jc.76.1.151; MINEGISH T, 1990, BIOCHEM BIOPH RES CO, V172, P1049, DOI 10.1016/0006-291X(90)91552-4; Myers R, 1989, PCR TECHNOLOGY PRINC, P71; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; OERTER KE, 1990, J CLIN ENDOCR METAB, V71, P1251, DOI 10.1210/jcem-71-5-1251; REN Q, 1993, J BIOL CHEM, V268, P16483; RIESNER D, 1989, ELECTROPHORESIS, V10, P377, DOI 10.1002/elps.1150100516; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; ROSENTHAL SM, 1983, J CLIN ENDOCR METAB, V57, P571, DOI 10.1210/jcem-57-3-571; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHEDEWIE HK, 1981, J CLIN ENDOCR METAB, V52, P271, DOI 10.1210/jcem-52-2-271; SKLAR CA, 1981, J CLIN ENDOCR METAB, V53, P656, DOI 10.1210/jcem-53-3-656; STONE RK, 1852, AM J M SC, V24, P561; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; WALKER SH, 1952, J PEDIATR-US, V41, P251, DOI 10.1016/S0022-3476(52)80001-0; YAGHMAI R, 1992, P NATL ACAD SCI USA, V89, P7890, DOI 10.1073/pnas.89.17.7890	30	597	624	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 14	1993	365	6447					652	654		10.1038/365652a0	http://dx.doi.org/10.1038/365652a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB846	7692306	Green Published			2022-12-28	WOS:A1993MB84600060
J	SAAG, MS; EMINI, EA; LASKIN, OL; DOUGLAS, J; LAPIDUS, WI; SCHLEIF, WA; WHITLEY, RJ; HILDEBRAND, C; BYRNES, VW; KAPPES, JC; ANDERSON, KW; MASSARI, FE; SHAW, GM				SAAG, MS; EMINI, EA; LASKIN, OL; DOUGLAS, J; LAPIDUS, WI; SCHLEIF, WA; WHITLEY, RJ; HILDEBRAND, C; BYRNES, VW; KAPPES, JC; ANDERSON, KW; MASSARI, FE; SHAW, GM			A SHORT-TERM CLINICAL-EVALUATION OF L-697,661, A NONNUCLEOSIDE INHIBITOR OF HIV-1 REVERSE-TRANSCRIPTASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED COMPLEX; HIGH-LEVEL RESISTANCE; PHASE-I TRIAL; ZIDOVUDINE AZT; 2',3'-DIDEOXYINOSINE DDI; ANTIVIRAL ACTIVITY; INFECTION; TYPE-1; DIDEOXYCYTIDINE	Background. The non-nucleoside reverse transcriptase inhibitors are novel antiretroviral agents with selective activity in vitro against human immunodeficiency virus type 1 (HIV-1). They act through direct inhibition of reverse transcriptase and are not incorporated into DNA. Methods. We evaluated a pyridinone non-nucleoside reverse transcriptase inhibitor, L-697,661, in separate six-week double-blind trials in patients with HIV-1 infection whose CD4 counts ranged from 200 to 500 cells per cubic millimeter (68 patients) or less than 200 cells per cubic millimeter (67 patients). Eligible patients were randomly assigned to receive L-697,661 orally in one of three doses (25 mg twice a day, 100 mg three times a day, or 500 mg twice a day) or zidovudine (100 mg five times a day). Clinical and laboratory assessments were performed weekly. Viral isolates were obtained from a subgroup of patients before and after treatment and were evaluated for in vitro sensitivity to L-697,661. Results. Both L-697,661 and zidovudine were well tolerated. Transient increases in CD4 counts were noted in the patients with fewer than 200 CD4 cells per cubic millimeter who received the two higher doses of L-697,661, but not in those who received the lowest dose or zidovudine. Patients who received L-697,661 had rapid, dose-related decreases in plasma p24 antigen levels. However, this response virtually disappeared after six weeks in some patients receiving L-697,661, coincidently with the emergence of resistant viruses. This change in susceptibility was more frequent among patients receiving the higher doses of L-697,661 and was associated with amino acid substitutions at positions 103 and 181 in the HIV-1 reverse transcriptase gene. Conclusions. L-697,661 is safe and well tolerated and has significant dose-related activity against HIV-1. However, resistant strains of the virus emerge rapidly and may limit the effectiveness of non-nucleoside reverse transcriptase inhibitors as monotherapy for HIV-1 infection.	MERCK RES LABS,W POINT,PA	Merck & Company	SAAG, MS (corresponding author), UNIV ALABAMA,DEPT MED,908 S 20TH ST,245B,BIRMINGHAM,AL 35294, USA.				NCRR NIH HHS [NCRR 5M01-RR00032] Funding Source: Medline; NIAID NIH HHS [AI-27290, AI-27767] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI027290, P30AI027767] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHOW YK, 1993, NATURE, V361, P650, DOI 10.1038/361650a0; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; CONDRA JH, 1992, ANTIMICROB AGENTS CH, V36, P1441, DOI 10.1128/AAC.36.7.1441; COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DUEWEKE TJ, 1993, ANTIMICROB AGENTS CH, V37, P1127, DOI 10.1128/AAC.37.5.1127; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; GOLDMAN ME, 1992, ANTIMICROB AGENTS CH, V36, P1019, DOI 10.1128/AAC.36.5.1019; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; LAIRD N, 1987, J AM STAT ASSOC, V82, P97, DOI 10.2307/2289129; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MERIGAN TC, 1989, ANN INTERN MED, V110, P189, DOI 10.7326/0003-4819-110-3-189; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MOHRI H, 1993, P NATL ACAD SCI USA, V90, P25, DOI 10.1073/pnas.90.1.25; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; PANG S, 1992, AIDS, V6, P453, DOI 10.1097/00002030-199205000-00003; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PAUWELS R, 1993, P NATL ACAD SCI USA, V90, P1711, DOI 10.1073/pnas.90.5.1711; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PRASAD VR, 1989, J BIOL CHEM, V264, P16689; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; SAAG MS, 1991, J INFECT DIS, V164, P72, DOI 10.1093/infdis/164.1.72; SCHNITTMAN SM, 1991, AIDS RES HUM RETROV, V7, P361, DOI 10.1089/aid.1991.7.361; SHAW GM, 1992, RETROVIRUSES HUMAN A, P73; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; YARCHOAN R, 1988, LANCET, V1, P76	38	160	170	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1993	329	15					1065	1072		10.1056/NEJM199310073291502	http://dx.doi.org/10.1056/NEJM199310073291502			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ640	7690462				2022-12-28	WOS:A1993LZ64000002
J	LOWREY, CH; NIENHUIS, AW				LOWREY, CH; NIENHUIS, AW			TREATMENT WITH AZACITIDINE OF PATIENTS WITH END-STAGE BETA-THALASSEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							SICKLE-CELL-ANEMIA; FETAL HEMOGLOBIN PRODUCTION; GAMMA-GLOBIN SYNTHESIS; 5-AZACYTIDINE; ALLOANTIBODIES; DISEASE; HBF		NHLBI,CLIN HEMATOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	LOWREY, CH (corresponding author), DARTMOUTH HITCHCOCK MED CTR,DEPT MED,HEMATOL & ONCOL SECT,1 MED CTR DR,LEBANON,NH 03756, USA.							BRITTENHAM GM, 1982, NEW ENGL J MED, V307, P1671, DOI 10.1056/NEJM198212303072703; CHARACHE S, 1983, P NATL ACAD SCI-BIOL, V80, P4842, DOI 10.1073/pnas.80.15.4842; CHITAMBAR CR, 1991, AM J HEMATOL, V37, P100, DOI 10.1002/ajh.2830370207; DOVER GJ, 1985, BLOOD, V66, P527; DUNBAR C, 1989, BRIT J HAEMATOL, V72, P467, DOI 10.1111/j.1365-2141.1989.tb07734.x; ECONOMIDOU J, 1971, VOX SANG, V20, P252, DOI 10.1111/j.1423-0410.1971.tb00436.x; GIBLETT ER, 1965, VOX SANG, V10, P448, DOI 10.1111/j.1423-0410.1965.tb04358.x; GLOVER AB, 1987, CANCER TREAT REP, V71, P737; HUMPHRIES RK, 1985, J CLIN INVEST, V75, P547, DOI 10.1172/JCI111731; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; LERNER N, 1990, AM J PEDIAT HEMATOL, V12, P56; LEY TJ, 1991, BLOOD, V77, P1146; LEY TJ, 1983, BLOOD, V62, P370; LEY TJ, 1982, NEW ENGL J MED, V307, P1469, DOI 10.1056/NEJM198212093072401; MCDONAGH KT, 1990, CLIN RES, V38, pA346; NIENHUIS AW, 1985, ANN NY ACAD SCI, V445, P198, DOI 10.1111/j.1749-6632.1985.tb17189.x; NOTARI RE, 1975, J PHARM SCI, V64, P1148, DOI 10.1002/jps.2600640704; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172/JCI111464; RACHMILEWITZ EA, 1991, BLOOD, V78, P1145; REBULLA P, 1991, LANCET, V337, P277, DOI 10.1016/0140-6736(91)90881-O; RODGERS GP, 1993, NEW ENGL J MED, V328, P73, DOI 10.1056/NEJM199301143280201; SANDS JM, 1985, ANN INTERN MED, V102, P59, DOI 10.7326/0003-4819-102-1-59; SPANOS T, 1990, VOX SANG, V58, P50, DOI 10.1111/j.1423-0410.1990.tb02055.x; STAMATOYANNOPOULOS JA, 1992, ANNU REV MED, V43, P497; TORREALBADERON AT, 1984, BLOOD, V63, P201; WOLFE L, 1985, NEW ENGL J MED, V312, P1600, DOI 10.1056/NEJM198506203122503	27	105	111	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1993	329	12					845	848		10.1056/NEJM199309163291205	http://dx.doi.org/10.1056/NEJM199309163291205			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW551	7689171				2022-12-28	WOS:A1993LW55100005
J	FAIRBAIRN, LJ; COWLING, GJ; REIPERT, BM; DEXTER, TM				FAIRBAIRN, LJ; COWLING, GJ; REIPERT, BM; DEXTER, TM			SUPPRESSION OF APOPTOSIS ALLOWS DIFFERENTIATION AND DEVELOPMENT OF A MULTIPOTENT HEMATOPOIETIC-CELL LINE IN THE ABSENCE OF ADDED GROWTH-FACTORS	CELL			English	Article							COLONY-STIMULATING FACTORS; HEMATOPOIETIC PROGENITOR CELLS; SELF-RENEWAL; STEM-CELLS; GENE-EXPRESSION; NA+/H+ EXCHANGE; SURVIVAL; DEATH; BCL-2; PROTEIN	In the absence of growth factors, hemopoietic cells die rapidly by the process of apoptosis. Transfection of the human bcl-2 gene into an interleukin-3 (IL-3)-dependent, multipotent hemopoietic cell line allowed these cells to survive in the absence of IL-3, both in serum-containing and serum-deprived conditions, and this survival was accompanied by multilineage differentiation. Moreover, single cell experiments showed that differentiation could occur in the absence of cell division. While these data do not rule out the possibility that growth factors can influence the lineage choice of multipotent cells, they suggest that exposure to growth factors may not be obligatory for the differentiation of stem cells. The data also support the hypothesis that differentiation is intrinsically determined and that the role of the hemopoietic growth factors is enabling rather than inductive.	CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,DEPT BIOPHYS,CANC RES CAMPAIGN,MANCHESTER M20 9BX,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	FAIRBAIRN, LJ (corresponding author), CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,DEPT EXPTL HAEMATOL,CANC RES CAMPAIGN,MANCHESTER M20 9BX,LANCS,ENGLAND.							BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BEGLEY CG, 1986, BLOOD, V68, P162; BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; BROXMEYER HE, 1992, AM J PEDIAT HEMATOL, V14, P22; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COOK N, 1989, EMBO J, V8, P2967, DOI 10.1002/j.1460-2075.1989.tb08446.x; CROSS M, 1988, P NATL ACAD SCI USA, V85, P6232, DOI 10.1073/pnas.85.17.6232; CURRY JL, 1967, SCIENCE, V236, P1229; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FAIRBAIRN LJ, 1993, HAEMOPOIESIS PRACTIC, P175; FORD AM, 1992, P NATL ACAD SCI USA, V89, P3424, DOI 10.1073/pnas.89.8.3424; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; HEBERLEIN C, 1990, ONCOGENE, V5, P1799; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; Heyworth C M, 1991, Growth Factors, V5, P87, DOI 10.3109/08977199109000274; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; KAN O, 1993, HAEMOPOIESIS PRACTIC, P123; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KORN A P, 1973, Experimental Hematology (Charlottesville), V1, P362; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; Maniatis T, 1989, DECONTAMINATION DILU; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; METCALF D, 1991, P NATL ACAD SCI USA, V88, P11310, DOI 10.1073/pnas.88.24.11310; METCALF D, 1984, COLONY STIMULATING F; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUDA T, 1984, P NATL ACAD SCI-BIOL, V81, P2520, DOI 10.1073/pnas.81.8.2520; TESTA NG, 1993, HAEMOPOIESIS PRACTIC; TESTA NG, 1991, CYTOKINES PRACTICAL, P229; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WHETTON AD, 1988, BIOCHEM J, V256, P585, DOI 10.1042/bj2560585; WHETTON AD, 1988, BIOCHEM BIOPH RES CO, V152, P1173, DOI 10.1016/S0006-291X(88)80408-X; WHETTON AD, 1989, BIOCHIM BIOPHYS ACTA, V989, P11; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	57	357	359	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					823	832		10.1016/0092-8674(93)90462-Y	http://dx.doi.org/10.1016/0092-8674(93)90462-Y			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	7690686				2022-12-28	WOS:A1993LX29200008
J	UTZ, U; BIDDISON, WE; MCFARLAND, HF; MCFARLIN, DE; FLERLAGE, M; MARTIN, R				UTZ, U; BIDDISON, WE; MCFARLAND, HF; MCFARLIN, DE; FLERLAGE, M; MARTIN, R			SKEWED T-CELL RECEPTOR REPERTOIRE IN GENETICALLY IDENTICAL-TWINS CORRELATES WITH MULTIPLE-SCLEROSIS	NATURE			English	Article							MYELIN BASIC-PROTEIN; GENES; GLYCOPROTEIN; INDIVIDUALS; DISEASE; CLONES; USAGE; ACID	ALTHOUGH the cause of multiple sclerosis (MS) is unknown, it is thought to involve a T cell-mediated autoimmune mechanism. Susceptibility to the disease is influenced by genetic factors such as genes of the HLA and T-cell receptor (TCR) complex1-6. Other evidence for a genetic influence includes the low incidence in certain ethnic groups7, the increased risk if there are affected family members8 and the increased concordance rate for disease in monozygotic twin pairs (26%)9, compared to dizygotic twins. Epidemiological studies indicate that there may be an additional role for envirommental factors. Although the target antigen(s) are not yet identified, several myelin or myelin-associated proteins have been suspected10-12, among them myelin basic protein. A lack of genetically comparable controls has impaired the analysis of the T-cell response in MS patients and caused disagreement on TCR usage in the disease13-15. Here we analyse the role of TCR genes in MS by comparing TCR usage in discordant versus concordant monozygotic twins in response to-self and foreign antigens. We find that after stimulation with myelin basic protein or tetanus toxoid, control twin sets as well as concordant twin sets select similar Valpha chains. Only the discordant twin sets select different TCRs after stimulation with antigens. Thus exogenous factors or the disease shape the TCR repertoire in MS patients, as seen by comparison with unaffected genetically identical individuals. This skewing of the TCR repertoire could contribute to the pathogenesis of MS and other T-cell-mediated diseases.	UNIV TUBINGEN,SCH MED,DEPT NEUROL,W-7400 TUBINGEN 1,GERMANY	Eberhard Karls University of Tubingen	UTZ, U (corresponding author), NINCDS,NEUROIMMUNOL BRANCH,BLDG 10,RM 5B-16,BETHESDA,MD 20892, USA.			Martin, Roland/0000-0002-0982-1329				ALLEGRETTA M, 1990, SCIENCE, V247, P718, DOI 10.1126/science.1689076; BEALL SS, 1989, J NEUROIMMUNOL, V21, P59, DOI 10.1016/0165-5728(89)90159-8; BENNUN A, 1991, P NATL ACAD SCI USA, V88, P2466, DOI 10.1073/pnas.88.6.2466; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHEN D, 1984, P NATL ACAD SCI-BIOL, V81, P1774, DOI 10.1073/pnas.81.6.1774; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; GULWANIAKOLKAR B, 1991, J EXP MED, V174, P1139, DOI 10.1084/jem.174.5.1139; JOHNSON D, 1986, J NEUROIMMUNOL, V13, P99, DOI 10.1016/0165-5728(86)90053-6; KOTZIN BL, 1991, P NATL ACAD SCI USA, V88, P9161, DOI 10.1073/pnas.88.20.9161; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; MALHOTRA U, 1992, J IMMUNOL, V149, P1802; MARTIN R, 1992, J IMMUNOL, V148, P1359; OKSENBERG JR, 1990, NATURE, V345, P344, DOI 10.1038/345344a0; OLERUP O, 1989, P NATL ACAD SCI USA, V86, P7113, DOI 10.1073/pnas.86.18.7113; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; SADOVNICK AD, 1988, AM J MED GENET, V29, P533, DOI 10.1002/ajmg.1320290310; SEBOUN E, 1989, CELL, V57, P1095, DOI 10.1016/0092-8674(89)90046-9; SUN JB, 1991, J IMMUNOL, V146, P1490; Tiwari JL, 1985, HLA DIS ASS, P152; VARTDAL F, 1989, HUM IMMUNOL, V25, P103, DOI 10.1016/0198-8859(89)90074-8; WAKSMAN BH, 1984, P SOC EXP BIOL MED, V175, P282; WUCHERPFENNIG KW, 1990, SCIENCE, V248, P1016, DOI 10.1126/science.1693015	22	124	126	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					243	247		10.1038/364243a0	http://dx.doi.org/10.1038/364243a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	7686632				2022-12-28	WOS:A1993LM68300059
J	GOULDING, EH; TIBBS, GR; LIU, D; SIEGELBAUM, SA				GOULDING, EH; TIBBS, GR; LIU, D; SIEGELBAUM, SA			ROLE OF H5 DOMAIN IN DETERMINING PORE DIAMETER AND ION PERMEATION THROUGH CYCLIC NUCLEOTIDE-GATED CHANNELS	NATURE			English	Article							K+ CHANNEL; TEA BLOCKADE; CHARYBDOTOXIN; INHIBITOR; RECEPTOR; REGION; MUSCLE; SITE	ION permeation through membrane channels is thought to be governed by a narrow region of the channel pore termed the selectivity filter1, which has been proposed to discriminate among ions by both specific binding and molecular sieving, as determined by pore diameter. Recent evidence suggests that a conserved domain (known as H5, P or SS1-SS2) in voltage-gated potassium2-8, sodium9-13 and calcium12channels contributes to the lining of the pore. Here we investigate whether the H5 domain determines pore diameter and examine the role of pore diameter in controlling ion permeation. These studies rely on differences in single channel conductance, ion selectivity and apparent pore diameter between cyclic nucleotide-gated channels cloned from bovine retina14 and catfish olfactory neurons15. Using chimaeric retinal-olfactory channels, we find that the H5 domain determines these differences in permeation properties, providing structural evidence that the cyclic nucleotide-gated channels are indeed members of the voltage-gated channel family15-17. Moreover, these results show directly that the H5 domain helps form the selectivity filter and that molecular sieving is important in controlling ion permeation.	COLUMBIA UNIV,DEPT PHARMACOL,NEW YORK,NY 10032; COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Columbia University; Howard Hughes Medical Institute	GOULDING, EH (corresponding author), COLUMBIA UNIV,DEPT PHYSIOL,CTR NEUROBIOL & BEHAV,722 W 168 ST,NEW YORK,NY 10032, USA.							BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEIGENBOTHAM L, 1992, SCIENCE, V258, P1152; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 1991, IONIC CHANNELS EXCIT; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; NODDA M, 1989, FEBS LETT, V258, P213; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	22	108	108	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					61	64		10.1038/364061a0	http://dx.doi.org/10.1038/364061a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	7686276				2022-12-28	WOS:A1993LK81800057
J	MACCHIA, D; ALMERIGOGNA, F; PARRONCHI, P; RAVINA, A; MAGGI, E; ROMAGNANI, S				MACCHIA, D; ALMERIGOGNA, F; PARRONCHI, P; RAVINA, A; MAGGI, E; ROMAGNANI, S			MEMBRANE TUMOR-NECROSIS-FACTOR-ALPHA IS INVOLVED IN THE POLYCLONAL B-CELL ACTIVATION-INDUCED BY HIV-INFECTED HUMAN T-CELLS	NATURE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNE-DEFICIENCY SYNDROME; HOMOSEXUAL MEN; BINDING; CLONES	INFECTION of CD4+ T cells by human immune deficiency virus-1 (HIV-1) causes severe dysfunction of cellular immunity1-3, but paradoxically results in intense polyclonal activation of B cells, possibly accounting for both hypergammaglobulinaemia and frequent development of B-cell malignancies seen in HIV-infected patients4-7. We have reported that human CD4+ T-cell clones infected with HIV in vitro markedly stimulate immunoglobulin synthesis by B cells through a non-cognate, contact-dependent mechanism8. We show here that HIV-infected T-cell clones do not express the CD40 ligand (CD40L), a molecule critical for non-cognate B-cell activation9, but a small proportion of them do express membrane tumour-necrosis factor (TNF)-alpha. The ability of HIV-infected T-cell clones to induce polyclonal B-cell activation appears to be restricted to TNF-alpha-positive T blasts and is inhibited by antibodies against both TNF-alpha and TNF-alpha receptor. Freshly isolated CD4+ T cells from HIV-infected individuals express TNF-alpha on the cell membrane and induce TNF-alpha-mediated immunoglobulin production by B cells. Thus, membrane TNF-alpha seems to be involved in the polyclonal B-cell activation induced by HIV-infected T cells.	UNIV FLORENCE,DIV CLIN IMMUNOL & ALLERGOL,VIALE MORGAGNI 85,I-50134 FLORENCE,ITALY; UNIV PISA,POLICLIN SANTA CHIARA,IST CLIN MED 1,I-56100 PISA,ITALY	University of Florence; University of Pisa			Almerigogna, Fabio/AAL-4583-2020; Parronchi, Paola/AAE-5422-2022; Almerigogna, Fabio/A-4636-2012; Maggi, Enrico/AAA-8045-2019	Parronchi, Paola/0000-0002-9184-5089; Maggi, Enrico/0000-0002-1824-3583; Macchia, Donatella/0000-0001-9143-4186				AMADORI A, 1990, IMMUNOL TODAY, V11, P374, DOI 10.1016/0167-5699(90)90144-X; AMMANN AJ, 1983, CLIN IMMUNOL IMMUNOP, V27, P315, DOI 10.1016/0090-1229(83)90084-3; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BOWEN DL, 1985, ANN INTERN MED, V103, P704, DOI 10.7326/0003-4819-103-5-704; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EULER HH, 1985, CLIN EXP IMMUNOL, V59, P267; FAHEY JL, 1984, AM J MED, V76, P95, DOI 10.1016/0002-9343(84)90756-3; KINKHABWALA M, 1990, J EXP MED, V171, P941, DOI 10.1084/jem.171.3.941; KOPELMAN RG, 1988, AM J MED, V84, P82, DOI 10.1016/0002-9343(88)90012-5; KULCZYCK.A, 1974, J EXP MED, V140, P1676, DOI 10.1084/jem.140.6.1676; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; MACCHIA D, 1991, J IMMUNOL, V146, P3413; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; TERPSTRA FG, 1989, EUR J IMMUNOL, V19, P667, DOI 10.1002/eji.1830190415	17	158	158	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					464	466		10.1038/363464a0	http://dx.doi.org/10.1038/363464a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	7684824				2022-12-28	WOS:A1993LE93800063
J	LYAMICHEV, V; BROW, MAD; DAHLBERG, JE				LYAMICHEV, V; BROW, MAD; DAHLBERG, JE			STRUCTURE-SPECIFIC ENDONUCLEOLYTIC CLEAVAGE OF NUCLEIC-ACIDS BY EUBACTERIAL DNA-POLYMERASES	SCIENCE			English	Article							SINGLE-STRANDED-DNA; CHAIN-REACTION; THERMUS-AQUATICUS; 5'->3' EXONUCLEASE; AMPLIFICATION; PURIFICATION; GENERATION	Previously known 5' exonucleases of several eubacterial DNA polymerases have now been shown to be structure-specific endonucleases that cleave single-stranded DNA or RNA at the bifurcated end of a base-paired duplex. Cleavage was not coupled to synthesis, although primers accelerated the rate of cleavage considerably. The enzyme appeared to gain access to the cleavage site by moving from the free end of a 5' extension to the bifurcation of the duplex, where cleavage took place. Single-stranded 5' arms up to 200 nucleotides long were cleaved from such a duplex. Essentially any linear single-stranded nucleic acid can be targeted for specific cleavage by the 5' nuclease of DNA polymerase through hybridization with an oligonucleotide that converts the desired cleavage site into a substrate.	UNIV WISCONSIN,SCH MED,DEPT BIOMOLEC CHEM,1300 UNIV AVE,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					PHS HHS [30220] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANTAO VP, 1991, NUCLEIC ACIDS RES, V19, P5901, DOI 10.1093/nar/19.21.5901; BARGSEID M, 1991, STRATEGIES, V4, P34; CARBALLEIRA N, 1990, BIOTECHNIQUES, V9, P276; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; Hayashi K, 1991, PCR Methods Appl, V1, P34; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KALEDIN A S, 1981, Biokhimiya, V46, P1576; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LEHMAN IR, 1978, ENZYME, V14, P15; LINDAHL T, 1969, P NATL ACAD SCI USA, V62, P597, DOI 10.1073/pnas.62.2.597; LONGLEY MJ, 1990, NUCLEIC ACIDS RES, V18, P7317, DOI 10.1093/nar/18.24.7317; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; LYAMICHEV V, UNPUB; MATHUR EJ, 1991, NUCLEIC ACIDS RES, V19, P6952, DOI 10.1093/nar/19.24.6952; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7661, DOI 10.1021/bi00245a001; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PEDRINI AM, 1983, J BIOL CHEM, V258, P1536; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SETLOW P, 1972, J BIOL CHEM, V247, P232; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377	31	306	382	2	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 7	1993	260	5109					778	783		10.1126/science.7683443	http://dx.doi.org/10.1126/science.7683443			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LA744	7683443				2022-12-28	WOS:A1993LA74400021
J	LASSOUED, K; NUNEZ, CA; BILLIPS, L; KUBAGAWA, H; MONTEIRO, RC; LEBIEN, TW; COOPER, MD				LASSOUED, K; NUNEZ, CA; BILLIPS, L; KUBAGAWA, H; MONTEIRO, RC; LEBIEN, TW; COOPER, MD			EXPRESSION OF SURROGATE LIGHT CHAIN RECEPTORS IS RESTRICTED TO A LATE STAGE IN PRE-B CELL-DIFFERENTIATION	CELL			English	Article							LAMBDA-LIKE GENES; HEAVY-CHAIN; BONE-MARROW; BINDING-PROTEIN; MU-CHAIN; MONOCLONAL-ANTIBODY; SUPPRESSED MICE; LINEAGE CELLS; VPREB GENE; SURFACE	Surrogate light chain (psiLC) genes are transcriptionally active in progenitor B (pro-B) cells before immunoglobulin genes are rearranged. Current hypothetical models suggest that the psiLC proteins may couple with surrogate or conventional heavy chain proteins to form cell surface receptors that signal the progressive differentiation of pro-B, precursor B (pre-B), and immature B cells. Monoclonal antibodies were produced and used to examine the synthesis, expression, intermolecular interaction, and function of psiLC during B cell differentiation. The results indicate that, while psiLC production spans several developmental stages, cell surface expression is confined to a relatively late stage in normal pre-B cell differentiation, during which receptor cross-linkage does not impede cell growth or B cell differentiation.	UNIV ALABAMA, DEPT PEDIAT, DIV DEV & CLIN IMMUNOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT PATHOL, DIV DEV & CLIN IMMUNOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT MICROBIOL, DIV DEV & CLIN IMMUNOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, HOWARD HUGHES MED INST, BIRMINGHAM, AL 35294 USA; UNIV MINNESOTA, SCH MED, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham; University of Minnesota System; University of Minnesota Twin Cities	LASSOUED, K (corresponding author), UNIV ALABAMA, DEPT MED, DIV DEV & CLIN IMMUNOL, BIRMINGHAM, AL 35294 USA.		Monteiro, Renato C/U-8633-2017	Monteiro, Renato C/0000-0001-5202-5646; LeBien, Tucker/0000-0001-5011-2199	NCI NIH HHS [CA13148, CA31685] Funding Source: Medline; NIAID NIH HHS [AI30879] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148, R01CA031685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030879] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; BAUER SR, 1988, EMBO J, V7, P111, DOI 10.1002/j.1460-2075.1988.tb02789.x; BAUER SR, 1991, BLOOD, V78, P1581; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOSSY D, 1991, INT IMMUNOL, V3, P1081, DOI 10.1093/intimm/3.11.1081; Burrows P D, 1990, Semin Immunol, V2, P189; BURROWS PD, 1978, J IMMUNOL, V120, P1526; CHANG H, 1986, J EXP MED, V163, P425, DOI 10.1084/jem.163.2.425; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; CIVIN CI, 1984, J IMMUNOL, V133, P157; COOPER MD, 1980, IMMUNOL REV, V52, P29, DOI 10.1111/j.1600-065X.1980.tb00329.x; COOPER MD, 1990, IMMUNOGLOBULIN GENES, P1; DEFRANCO AL, 1982, B T CELL TUMORS BIOL, P445; DORKEN B, 1989, LEUCOCYTE TYPING, V4, P46; EWERT DL, 1984, J IMMUNOL, V132, P2524; FAHEY JL, 1971, ANN NY ACAD SCI, V190, P221, DOI 10.1111/j.1749-6632.1971.tb13537.x; FINDLEY HW, 1982, BLOOD, V60, P1305; FULOP GM, 1983, CELL IMMUNOL, V75, P91, DOI 10.1016/0008-8749(83)90308-8; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HOLLIS GF, 1989, P NATL ACAD SCI USA, V86, P5552, DOI 10.1073/pnas.86.14.5552; ISHIGAMI T, 1992, J IMMUNOL, V148, P360; Ishihara K, 1991, Dev Immunol, V1, P149, DOI 10.1155/1991/79721; JUSTEMENT LB, 1990, J IMMUNOL, V144, P3272; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; Kerr W G, 1989, Int Immunol, V1, P355, DOI 10.1093/intimm/1.4.355; KIM KM, 1992, J IMMUNOL, V148, P29; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KIYOTAKI M, 1987, J IMMUNOL, V138, P4150; KLEIN E, 1968, CANCER RES, V28, P1300; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KORSMEYER SJ, 1983, J CLIN INVEST, V71, P301, DOI 10.1172/JCI110770; KUBAGAWA H, 1989, P NATL ACAD SCI USA, V86, P2356, DOI 10.1073/pnas.86.7.2356; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; KUDO A, 1989, PROGR IMMUNOLOGY, V7, P339; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIEN TW, 1990, LEUKEMIA, V4, P354; MARTIN D, 1991, J EXP MED, V173, P639, DOI 10.1084/jem.173.3.639; MARUYAMA S, 1985, J IMMUNOL, V135, P192; MASON DY, 1991, J IMMUNOL, V147, P2474; MISENER V, 1991, INT IMMUNOL, V3, P1129, DOI 10.1093/intimm/3.11.1129; NAKAMURA T, 1992, P NATL ACAD SCI USA, V89, P8522, DOI 10.1073/pnas.89.18.8522; NISHIMOTO N, 1991, P NATL ACAD SCI USA, V88, P6284, DOI 10.1073/pnas.88.14.6284; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; PILLAI S, 1988, CURR TOP MICROBIOL, V137, P136; PULVERTAFT RJV, 1964, LANCET, V1, P238; RALPH P, 1973, J IMMUNOL, V110, P1470; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SAKAGUCHI N, 1986, EMBO J, V5, P2139, DOI 10.1002/j.1460-2075.1986.tb04477.x; SCHIFF C, 1991, BLOOD, V78, P1516; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SMITH RG, 1981, J IMMUNOL, V126, P596; STONG RC, 1985, BLOOD, V65, P21, DOI 10.1182/blood.V65.1.21.21; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUBATA T, 1991, EUR J IMMUNOL, V21, P1359, DOI 10.1002/eji.1830210605; TSUBATA T, 1992, INT IMMUNOL, V4, P637, DOI 10.1093/intimm/4.6.637; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; VILLABLANCA JG, 1990, J EXP MED, V172, P325, DOI 10.1084/jem.172.1.325; WORMANN B, 1989, J IMMUNOL, V142, P110; YELLEN AJ, 1991, J IMMUNOL, V146, P1446	71	156	157	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 9	1993	73	1					73	86		10.1016/0092-8674(93)90161-I	http://dx.doi.org/10.1016/0092-8674(93)90161-I			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	7681728				2022-12-28	WOS:A1993KW75300009
J	MARSHALL, WS; CARUTHERS, MH				MARSHALL, WS; CARUTHERS, MH			PHOSPHORODITHIOATE DNA AS A POTENTIAL THERAPEUTIC DRUG	SCIENCE			English	Article							VIRUS REVERSE-TRANSCRIPTASE; LAC OPERATOR DNA; GENE-EXPRESSION; DINUCLEOSIDE PHOSPHORODITHIOATES; ESCHERICHIA-COLI; TRANSFER RNALYS; INHIBITORS; ANTISENSE; SEQUENCE; OLIGODEOXYNUCLEOTIDES	This article summarizes methods for the synthesis of phosphorodithioate-linked deoxyoligonucleotides and details an analysis of one of the distinctive properties of phosphorodithioate DNA oligomers, their ability to strongly inhibit human immunodeficiency virus type-1 reverse transcriptase (HIV-1 RT). Mechanistic studies indicate that oligomers of this type interfere with enzyme function by binding tightly to the active site for primer-template, which results in low or subnanomolar inhibitory constants. Although many of these studies have used deoxyoligocytidine analogs, a rationally designed approach has led to the discovery of a very active phosphorodithioate deoxyoligonucleotide inhibitor. This type of inhibitor, which binds strongly to the primer-template active site of HIV-1 RT, provides another type of potential therapeutic agent against HIV-1.	UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021120, R01GM025680] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21120, GM25680] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL S, 1992, TIBTECH, V10, P152; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BEATON G, 1991, OLIGONUCLEOTIDES ANA, P109; BEAUCAGE SL, 1992, TETRAHEDRON, V48, P2223, DOI 10.1016/S0040-4020(01)88752-4; BILHEIMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P4124, DOI 10.1073/pnas.80.13.4124; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BOERINGER M, IN PRESS TETRAHEDRON; BORDIER B, 1990, NUCLEIC ACIDS RES, V18, P429, DOI 10.1093/nar/18.3.429; BORMAN S, 1992, CHEM ENG NEWS, V70, P18, DOI 10.1021/cen-v070n032.p018; BRILL WKD, 1991, J AM CHEM SOC, V113, P3972, DOI 10.1021/ja00010a045; CALABRETTA B, 1991, CANCER RES, V51, P4505; CARUTHERS MH, 1991, NUCLEOS NUCLEOT, V10, P47, DOI 10.1080/07328319108046435; CARUTHERS MH, 1987, METHOD ENZYMOL, V154, P287; COSSTICK R, 1990, NUCLEIC ACIDS RES, V18, P829, DOI 10.1093/nar/18.4.829; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; Dahl O., 1991, SULFUR REP, V11, P167; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; ENGLISCH U, 1991, ANGEW CHEM INT EDIT, V30, P613, DOI 10.1002/anie.199106133; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOEDDEL DV, 1979, NATURE, V281, P544, DOI 10.1038/281544a0; GOEDDEL DV, 1979, P NATL ACAD SCI USA, V76, P106, DOI 10.1073/pnas.76.1.106; Goodchild J, 1990, BIOCONJUGATE CHEM, V1, P165, DOI 10.1021/bc00003a001; GRANDAS A, 1989, TETRAHEDRON LETT, V30, P543, DOI 10.1016/S0040-4039(00)95248-1; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HEYNEKER HL, 1976, NATURE, V263, P748, DOI 10.1038/263748a0; HITCHINGS GH, 1974, ADV ENZYME REGUL, V9, P121; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; IVERSEN P, 1991, ANTI-CANCER DRUG DES, V6, P531; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LESNIKOWSKI ZJ, 1990, NUCLEIC ACIDS RES, V18, P2109, DOI 10.1093/nar/18.8.2109; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; MAJUMDAR C, 1989, BIOCHEMISTRY-US, V28, P1340, DOI 10.1021/bi00429a060; MARIANS KJ, 1976, NATURE, V263, P744, DOI 10.1038/263744a0; Marshall W. G., UNPUB; MARSHALL WS, 1992, P NATL ACAD SCI USA, V89, P6265, DOI 10.1073/pnas.89.14.6265; MILLER PS, 1987, ANTI-CANCER DRUG DES, V2, P117; MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273; NIELSEN J, 1988, TETRAHEDRON LETT, V29, P2911, DOI 10.1016/0040-4039(88)85045-7; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; Ohlendorf D H, 1985, Adv Biophys, V20, P137, DOI 10.1016/0065-227X(85)90034-6; OWENS RA, 1991, BIOCHEM BIOPH RES CO, V181, P402, DOI 10.1016/S0006-291X(05)81433-0; PORRITT GM, 1989, TETRAHEDRON LETT, V30, P4713, DOI 10.1016/S0040-4039(01)80782-6; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; RYAZNOV SM, 1992, NUCLEIC ACIDS RES, V20, P3403; SADLER JR, 1977, GENE, V1, P305, DOI 10.1016/0378-1119(77)90036-1; SALLAFRANQUEANDREOLA ML, 1989, EUR J BIOCHEM, V184, P367, DOI 10.1111/j.1432-1033.1989.tb15028.x; Segel I.H., 1975, ENZYME KINETICS; SOUZA LM, 1986, SCIENCE, V232, P61, DOI 10.1126/science.2420009; STEC WJ, 1991, NUCLEIC ACIDS RES, V19, P5883, DOI 10.1093/nar/19.21.5883; STEIN CA, 1988, CANCER RES, V48, P2659; STEIN CA, 1991, PHARMACOL THERAPEUT, V52, P365, DOI 10.1016/0163-7258(91)90032-H; TIDD DM, 1990, ANTICANCER RES, V10, P1169; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WIESLER WT, IN PRESS METHODS MOL; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280	62	198	232	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	1993	259	5101					1564	1569		10.1126/science.7681216	http://dx.doi.org/10.1126/science.7681216			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	7681216				2022-12-28	WOS:A1993KR54300027
J	SADOWSKI, HB; GILMAN, MZ				SADOWSKI, HB; GILMAN, MZ			CELL-FREE ACTIVATION OF A DNA-BINDING PROTEIN BY EPIDERMAL GROWTH-FACTOR	NATURE			English	Article							SERUM RESPONSE ELEMENT; SIGNAL TRANSDUCTION; 3T3 CELLS; FOS; TRANSCRIPTION; RECEPTORS; INSULIN; EXPRESSION; INDUCTION; COMPLEX	GROWTH factors such as platelet-derived growth factor and epidermal growth factor (EGF) bind to and activate cell-surface receptors with intrinsic tyrosine kinase activities1. Receptor activation elicits multiple physiological changes in target cells, including alterations in gene expression2-4. Receptor tyrosine kinase signalling involves recruitment of proteins into a signalling complex through interactions between receptor autophosphorylation sites and the src-homology region-2 (SH2) domains on these signalling proteins5-9. Diverse signals can subsequently be generated, depending on the specific receptor and Cell type 2,10. How such signals are transmitted to the nucleus is poorly understood, but because the transcriptional activation of many genes by growth factors occurs in the absence of new protein synthesis4, one or more signals emanating from growth factor receptors must directly affect transcription factors. We report here the activation by EGF of a DNA-binding protein in a cell-free system where activation of DNA binding requires ligand, receptor, ATP and phosphotyrosine-SH2 interactions.	COLD SPRING HARBOR LAB,BOX 100,1 BUNGTOWN RD,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory								CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KANAKURA Y, 1990, BLOOD, V76, P706; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; Treisman R, 1990, Semin Cancer Biol, V1, P47; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	30	246	252	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					79	83		10.1038/362079a0	http://dx.doi.org/10.1038/362079a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	7680434				2022-12-28	WOS:A1993KP97600066
J	TIELSCH, JM; JAVITT, JC; COLEMAN, A; KATZ, J; SOMMER, A				TIELSCH, JM; JAVITT, JC; COLEMAN, A; KATZ, J; SOMMER, A			THE PREVALENCE OF BLINDNESS AND VISUAL IMPAIRMENT AMONG NURSING-HOME RESIDENTS IN BALTIMORE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL RESEARCH; POPULATION; ACUITY; EYE	Background. Although the prevalence of blindness and visual impairment increases with age, most surveys of ocular disease do not include nursing home residents. Methods. We conducted a population-based prevalence survey of persons 40 years of age or older residing in nursing homes in the Baltimore area. Of 738 eligible subjects in 30 nursing homes, 499 (67.6 percent) participated in the study. They had their eyes examined and their visual acuity tested and were interviewed in detail. The nonparticipants were more likely to be older, to be white, and to have lower scores on the Mini-Mental State Examination. Results. The prevalence of bilateral blindness (visual acuity less than or equal to 20/200) was 17.0 percent. The prevalence of visual impairment (<20/40 but >20/200) was 18.8 percent. The frequency of blindness increased from 15.2 percent among those under 60 years of age to 28.6 percent among those 90 or older. The age-adjusted prevalence of blindness was 50 percent higher among blacks than among whites (P<0.01). As compared with the noninstitutionalized population from the same communities, the rate of blindness among nursing home residents was 13.1 times higher for blacks and 15.6 times higher for whites. Cataract was the leading cause of blindness, followed by corneal opacity, macular degeneration, and glaucoma. We judged that 20 percent of the functional blindness and 37 percent of the visual impairment could be remedied by adequate refractive correction. Conclusions. Blindness and visual impairment are highly prevalent among nursing home residents. Much of this loss of vision could be treated or prevented with appropriate ophthalmologic care.	JOHNS HOPKINS UNIV,SCH MED,DANA CTR PREVENT OPHTHALMOL,BALTIMORE,MD; GEORGETOWN UNIV,SCH MED,WORTHEN CTR,DEPT OPHTHALMOL,WASHINGTON,DC; UNIV CALIF LOS ANGELES,DEPT OPHTHALMOL,LOS ANGELES,CA; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,OFF DEAN,BALTIMORE,MD	Johns Hopkins University; Georgetown University; University of California System; University of California Los Angeles; Johns Hopkins University	TIELSCH, JM (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,615 N WOLFE ST,ROOM 5515,BALTIMORE,MD 21205, USA.		Javitt, Jonathan/AAJ-5574-2021	Javitt, Jonathan/0000-0003-2371-1609; Katz, Joanne/0000-0002-5997-7823; Tielsch, James/0000-0002-1151-060X	NCRR NIH HHS [RR-04060] Funding Source: Medline; NEI NIH HHS [EY-05091, EY-09672] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004060] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009672] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASTON SJ, 1986, LOW VISION PRINCIPLE, P502; BERGMAN B, 1992, ACTA OPHTHALMOL, V70, P33; CHARMAN WN, 1985, OPHTHAL PHYSL OPT, V5, P211, DOI 10.1111/j.1475-1313.1985.tb00658.x; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2; FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HING EE, 1989, VITAL HLTH STATIS 13, V97; KAHN HA, 1973, DHEW NIH73427 PUBL; KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310; KORNZWEIG AL, 1957, AM J OPHTHALMOL, V44, P29, DOI 10.1016/0002-9394(57)91952-9; LAPLANTE MP, 1989, DISABILITY STAT REP, V2, P1; Leibowitz H M, 1980, Surv Ophthalmol, V24, P335; NEWELL SW, 1985, ANN OPHTHALMOL, V17, P186; PETERSON R, 1980, J VISUAL IMPAIR BLIN, V74, P323; SALIVE ME, 1992, OPHTHALMOLOGY, V99, P1840; SALIVE ME, 1993, AM J PUBLIC HEALTH, V83, P1765, DOI 10.2105/AJPH.83.12.1765; SALIVE ME, 1994, J AM GERIATR SOC, V42, P287, DOI 10.1111/j.1532-5415.1994.tb01753.x; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; WHITMORE WG, 1989, OPHTHALMOLOGY, V96, P393, DOI 10.1016/S0161-6420(89)32880-6; WOODRUFF ME, 1980, CAN J PUBLIC HEALTH, V71, P413; 1966, EPIDEMIOL VITAL STAT, V19, P437; 1977, MANUAL INT STATISTIC, V1	23	195	197	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 4	1995	332	18					1205	1209		10.1056/NEJM199505043321806	http://dx.doi.org/10.1056/NEJM199505043321806			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV415	7700315				2022-12-28	WOS:A1995QV41500006
J	SNELLER, MC				SNELLER, MC			WEGENERS GRANULOMATOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; HUMAN ENDOTHELIAL-CELLS; ANTICYTOPLASMIC AUTOANTIBODIES; TRIMETHOPRIM-SULFAMETHOXAZOLE; NEUTROPHILS; DIAGNOSIS; ANTIGEN; INFECTION; GLOMERULONEPHRITIS; MYELOPEROXIDASE				SNELLER, MC (corresponding author), NIAID,IMMUNOREGULAT LAB,BLDG 10,ROOM IIB-13,BETHESDA,MD 20892, USA.							CHURG J, 1989, MODERN PATHOL, V2, P144; COHEN TJW, 1989, ARCH INTERN MED, V149, P2461; DAVENPORT A, 1992, CLIN NEPHROL, V37, P124; DAVIES DJ, 1982, BRIT MED J, V2, P606; DECLERCK LS, 1989, CLIN RHEUMATOL, V8, P512, DOI 10.1007/BF02032106; DEREMEE RA, 1985, MAYO CLIN PROC, V60, P27, DOI 10.1016/S0025-6196(12)65279-3; DURAND JM, 1993, AUTOIMMUNITY, V15, P81, DOI 10.3109/08916939309004843; EFTHIMIOU J, 1991, LANCET, V337, P1037, DOI 10.1016/0140-6736(91)92694-W; EWERT BH, 1992, KIDNEY INT, V41, P375, DOI 10.1038/ki.1992.52; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; FALK RJ, 1988, NEW ENGL J MED, V318, P1651, DOI 10.1056/NEJM198806233182504; FAUCI AS, 1973, MEDICINE, V52, P535, DOI 10.1097/00005792-197311000-00002; FAUCI AS, 1993, ANN INTERN MED, V98, P76; GOLDSCHMEDING R, 1989, J CLIN INVEST, V84, P1577, DOI 10.1172/JCI114335; Gross Wolfgang L., 1994, Current Opinion in Rheumatology, V6, P11, DOI 10.1097/00002281-199401000-00003; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; HOFFMAN GS, 1990, AM J MED, V89, P403, DOI 10.1016/0002-9343(90)90367-M; Hoffman GS, 1992, ARTHRITIS RHEUM, V35, P6112; HOLLANDER D, 1967, ANN INTERN MED, V67, P393, DOI 10.7326/0003-4819-67-2-393; ISRAEL HL, 1988, ARCH INTERN MED, V148, P2293, DOI 10.1001/archinte.148.10.2293; KERR GS, 1993, ARTHRITIS RHEUM, V36, P365, DOI 10.1002/art.1780360312; Klinger H, 1931, FRANKFURT Z PATHOL, V42, P455; KODERISCH J, 1990, LANCET, V335, P1227, DOI 10.1016/0140-6736(90)92755-7; LEAVITT RY, 1988, ARTHRITIS RHEUM, V31, P1073, DOI 10.1002/art.1780310822; LEBOVICS RS, 1992, LARYNGOSCOPE, V102, P1341, DOI 10.1288/00005537-199212000-00005; LUDEMANN G, 1987, CLIN EXP IMMUNOL, V69, P350; LUDEMANN J, 1990, J EXP MED, V171, P357, DOI 10.1084/jem.171.1.357; LUDEMANN J, 1988, J IMMUNOL METHODS, V114, P167, DOI 10.1016/0022-1759(88)90169-X; MAYET WJ, 1993, BLOOD, V82, P1221; NILES JL, 1989, BLOOD, V74, P1888; NILES JL, 1991, J AM SOC NEPHROL, V2, P27; NOLLE B, 1989, ANN INTERN MED, V111, P28, DOI 10.7326/0003-4819-111-1-28; REINHOLDKELLER E, 1994, ARTHRITIS RHEUM, V37, P919, DOI 10.1002/art.1780370622; SNELLER MC, IN PRESS ARTHRITIS R; SPECKS U, 1989, MAYO CLIN PROC, V64, P28, DOI 10.1016/S0025-6196(12)65300-2; STEGEMAN CA, 1994, ANN INTERN MED, V120, P12, DOI 10.7326/0003-4819-120-1-199401010-00003; ULMER M, 1992, CLIN NEPHROL, V37, P161; VANDERWOUDE FJ, 1985, LANCET, V1, P425; WALTON EW, 1958, BRIT MED J, V2, P265, DOI 10.1136/bmj.2.5091.265; WEGENER F, 1939, BEITR PATHOL ANAT AL, V29, P36; WEST BC, 1987, ANN INTERN MED, V106, P840, DOI 10.7326/0003-4819-106-6-840; YUASA K, 1988, AM J MED, V84, P371, DOI 10.1016/0002-9343(88)90450-0	42	27	27	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	1995	273	16					1288	1291						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU571	7715042				2022-12-28	WOS:A1995QU57100033
J	KEMP, KB				KEMP, KB			PUBLIC INFORMATION ON OSTEOPOROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											KEMP, KB (corresponding author), US CONGRESS, OFF TECHNOL ASSESSMENT, WASHINGTON, DC 20510 USA.							1994, PUBLIC INFORMATION O, P70801	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1082	1082		10.1001/jama.273.14.1082	http://dx.doi.org/10.1001/jama.273.14.1082			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR059	7707584				2022-12-28	WOS:A1995QR05900006
J	DOHERTY, PC				DOHERTY, PC			CELL-MEDIATED CYTOTOXICITY	CELL			English	Review							LYMPHOCYTES-T; PERFORIN; PEPTIDES; EPITOPES; VIRUS				DOHERTY, PC (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, MEMPHIS, TN 38101 USA.		Doherty, Peter Charles/C-4185-2013	Doherty, Peter Charles/0000-0002-5028-3489				Ahmed R, 1992, Semin Immunol, V4, P105; BERKE G, 1991, IMMUNOL TODAY, V12, P396, DOI 10.1016/0167-5699(91)90138-J; BERKE G, 1993, IMMUNOLOGY, V78, P105; BJORKMAN PJ, 1985, J MOL BIOL, V186, P205, DOI 10.1016/0022-2836(85)90271-2; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; BURKHARDT JK, 1993, J CELL SCI, V104, P151; CEROTTINI JC, 1993, CYTOTOXIC CELLS, P5; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DOHERTY PC, 1993, CURR OPIN IMMUNOL, V5, P479, DOI 10.1016/0952-7915(93)90026-O; DOHERTY PC, 1990, IMMUNOL TODAY, V11, P55; DROGE W, 1992, IMMUNOL TODAY, V13, P221; DUPUIS M, 1993, J EXP MED, V177, P1, DOI 10.1084/jem.177.1.1; HWU P, 1993, J EXP MED, V178, P361, DOI 10.1084/jem.178.1.361; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KYBURZ D, 1993, EUR J IMMUNOL, V23, P1540, DOI 10.1002/eji.1830230722; LUKACHER AE, 1984, J EXP MED, V160, P814, DOI 10.1084/jem.160.3.814; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PETERS PJ, 1990, IMMUNOL TODAY, V11, P28; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; RAMSAY AJ, 1993, IMMUNOL TODAY, V14, P155, DOI 10.1016/0167-5699(93)90277-R; Redegeld F., 1993, CYTOTOXIC CELLS, P307; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SHER A, 1992, IMMUNOL REV, V127, P183, DOI 10.1111/j.1600-065X.1992.tb01414.x; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; STAUSS HJ, 1992, P NATL ACAD SCI USA, V89, P7871, DOI 10.1073/pnas.89.17.7871; SU MWC, 1993, J IMMUNOL, V151, P658; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TSCHOPP J, 1990, ANNU REV IMMUNOL, V8, P279, DOI 10.1146/annurev.immunol.8.1.279; WATANABEFUKUNAG.S, 1992, NATURE, V356, P314; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0	35	105	105	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 19	1993	75	4					607	612		10.1016/0092-8674(93)90480-E	http://dx.doi.org/10.1016/0092-8674(93)90480-E			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	7694805	Bronze			2022-12-28	WOS:A1993MH74900005
J	LERNBECHER, T; MULLER, U; WIRTH, T				LERNBECHER, T; MULLER, U; WIRTH, T			DISTINCT NF-KAPPA-B REL TRANSCRIPTION FACTORS ARE RESPONSIBLE FOR TISSUE-SPECIFIC AND INDUCIBLE GENE ACTIVATION	NATURE			English	Article							DNA-BINDING ACTIVITY; KAPPA-B; PROTO-ONCOGENE; P65 SUBUNIT; C-REL; ENHANCER; INTERACT; CLONING; SEQUENCES; PROMOTER	THE NF-kappaB/Rel family is a growing class of transcriptional regulators1-11 whose members share the conserved Rel-homology domain, involved in specific DNA binding and dimerization. They interact with the regulatory elements of many different genes and are involved in the regulation of lymphoid-specific and inducible transcription12. We tested whether these factors could alone activate a gene in transgenic mice. We report here that a minimal promoter containing three copies of a binding site for these proteins allows tissue-specific and inducible transgene activation. In lymphoid tissues constitutive transgene expression correlates with the presence of a constitutively active p50/RelB heterodimer. Other organs that only contain the p50 homodimer do not express the transgene. In contrast to this constitutive activity mediated by p50/RelB, the p50/p65 heterodimer (which is NF-kappaB) could confer inducible transgene activation in embryo fibroblasts. Thus two different members of the NF-kappaB/Rel family of transcriptional activators are involved in tissue-specific and inducible gene activation in transgenic mice.	ZENTRUM MOLEK BIOL HEIDELBERG,NEUENHEIMER FELD 282,W-6900 HEIDELBERG,GERMANY; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	Ruprecht Karls University Heidelberg			Wirth, Thomas/X-7172-2019					ANNWEILER A, 1992, NUCLEIC ACIDS RES, V20, P1503, DOI 10.1093/nar/20.7.1503; ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, HORMONAL CONTROL REG, P423; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOSH S, 1990, CELL, V62, P1019; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	29	195	198	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					767	770		10.1038/365767a0	http://dx.doi.org/10.1038/365767a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	7692309				2022-12-28	WOS:A1993MC81200068
J	SASSANFAR, M; SZOSTAK, JW				SASSANFAR, M; SZOSTAK, JW			AN RNA MOTIF THAT BINDS ATP	NATURE			English	Article							MOLECULAR RECOGNITION; RECEPTOR	RNAs that contain specific high-affinity binding sites for small molecule ligands immobilized on a solid support are present at a frequency of roughly one in 10(10)-10(11) in pools of random sequence RNA molecules1,2. Here we describe a new in vitro selection procedure designed to ensure the isolation of RNAs that bind the ligand of interest in solution as well as on a solid support. We have used this method to isolate a remarkably small RNA motif that binds ATP, a substrate in numerous biological reactions and the universal biological high-energy intermediate. The selected ATP-binding RNAs contain a consensus sequence, embedded in a common secondary structure. The binding properties of ATP analogues and modified RNAs show that the binding interaction is characterized by a large number of close contacts between the ATP and RNA, and by a change in the conformation of the RNA.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	SASSANFAR, M (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.							ARNOLD FH, 1986, J CHROMATOGR, V355, P1, DOI 10.1016/S0021-9673(01)97299-1; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BRESLOW R, 1989, J AM CHEM SOC, V111, P8296, DOI 10.1021/ja00203a050; CARCANAGUE DR, 1992, J AM CHEM SOC, V114, P1515, DOI 10.1021/ja00030a077; CHANG SK, 1991, J AM CHEM SOC, V113, P7640, DOI 10.1021/ja00020a027; ECHAVARREN A, 1989, J AM CHEM SOC, V111, P4994, DOI 10.1021/ja00195a071; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; FAN E, 1993, J AM CHEM SOC, V115, P369, DOI 10.1021/ja00054a066; FERSHT A, 1985, ENZYME STRUCTURE MEC, P186; GOSWAMI S, 1989, J AM CHEM SOC, V111, P3425, DOI 10.1021/ja00191a048; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; REBEK J, 1987, SCIENCE, V235, P1478, DOI 10.1126/science.3823899; ROTELLO VM, 1993, J AM CHEM SOC, V115, P797, DOI 10.1021/ja00055a066; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; YOON SS, 1993, J AM CHEM SOC, V115, P823, DOI 10.1021/ja00055a083	17	500	541	5	77	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					550	553		10.1038/364550a0	http://dx.doi.org/10.1038/364550a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	7687750				2022-12-28	WOS:A1993LQ66700062
J	JOHNSON, A; TOWNSHEND, P; YUDKIN, P; BULL, D; WILKINSON, AR				JOHNSON, A; TOWNSHEND, P; YUDKIN, P; BULL, D; WILKINSON, AR			FUNCTIONAL ABILITIES AT AGE 4 YEARS OF CHILDREN BORN BEFORE 29 WEEKS OF GESTATION	BRITISH MEDICAL JOURNAL			English	Article							LOW-BIRTH-WEIGHT; GEOGRAPHICALLY DEFINED POPULATION; INFANTS; TRENDS; SURVIVAL; METAANALYSIS; RESIDENTS; MORBIDITY; PRETERM; REGION	Objectives-To assess the rate of impairment and disability among babies born very preterm and to investigate the association between such impairment and gestational age at birth. Design--Cohort study of a geographically defined population of babies. Setting-Oxford Regional Health Authority. Subjects-All babies born alive before 29 weeks of gestation to mothers resident in the region during 1984-6. Main outcome measures-Survival rates and rates of impairment and disability among survivors at the age of 4 years. Results-Of the 342 babies, half (170) survived to be discharged home. Of the 164 survivors to age 4 years, 153 (93%) were assessed. A total of 35 (23%; 95% confidence interval 16% to 30%) were severely disabled and only 54 (35%; 28% to 43%) were unimpaired. The risk of impairment and disability increased with decreasing gestational age at birth (p < 0.003). Conclusions-With the increasing survival rate among babies born before 29 weeks of gestation, we need urgently to establish reliable ways of monitoring the proportion of survivors who have a disability.	UNIV OXFORD,JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND; RADCLIFFE INFIRM,CANC EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND	University of Oxford; University of Oxford; Radcliffe Infirmary; University of Oxford	JOHNSON, A (corresponding author), RADCLIFFE INFIRM,NATL PERINATAL EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.			Johnson, Anne/0000-0003-1330-7100				ALBERMAN E, 1991, ARCH DIS CHILD, V66, P1304, DOI 10.1136/adc.66.11.1304; AYLWARD GP, 1989, J PEDIATR-US, V115, P515, DOI 10.1016/S0022-3476(89)80273-2; CHALMERS I, 1981, LANCET, V1, P1415; COOKE RWI, 1988, BRIT MED BULL, V44, P1133, DOI 10.1093/oxfordjournals.bmb.a072293; DENNIS J, 1989, AM J OBSTET GYNECOL, V161, P213, DOI 10.1016/0002-9378(89)90269-X; EGAN DF, 1984, CHILD CARE HLTH DEV, V10, P163, DOI 10.1111/j.1365-2214.1984.tb00175.x; ESCOBAR GJ, 1991, ARCH DIS CHILD, V66, P204, DOI 10.1136/adc.66.2.204; Griffiths R., 1970, ABILITIES YOUNG CHIL; HEINONEN K, 1988, LANCET, V2, P204; Henderson S., 1992, MOVEMENT ASSESSMENT; MACFARLANE A, 1988, BRIT MED BULL, V44, P861, DOI 10.1093/oxfordjournals.bmb.a072298; MARLOW N, 1989, ARCH DIS CHILD, V64, P839, DOI 10.1136/adc.64.6.839; PANETH N, 1993, CLIN DEV MED, V123, P232; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; POWELL TG, 1986, LANCET, V1, P539; SAIGAL S, 1984, J PEDIATR-US, V105, P969, DOI 10.1016/S0022-3476(84)80093-1; SAIGAL S, 1989, J PEDIATR-US, V114, P839, DOI 10.1016/S0022-3476(89)80150-7; SCHECHNER S, 1980, CLIN PERINATOL, V7, P135, DOI 10.1016/S0095-5108(18)31134-5; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; VANZEBENVANDERAA TM, 1989, LANCET, V1, P253; VERLOOVEVANHORICK SP, 1986, LANCET, V1, P55; WARIYAR U, 1989, ARCH DIS CHILD, V64, P678, DOI 10.1136/adc.64.5.678; YU VYH, 1986, BRIT MED J, V293, P1200, DOI 10.1136/bmj.293.6556.1200; 1992, ARCH DIS CHILD, V67, P675; 1991, ARCH DIS CHILD, V66, P765; [No title captured]; 1991, SCOTTISH STILLBIRTH	27	109	111	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1715	1718		10.1136/bmj.306.6894.1715	http://dx.doi.org/10.1136/bmj.306.6894.1715			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	7688251	Green Published, Bronze			2022-12-28	WOS:A1993LK36700017
J	SPOHR, HL; WILLMS, J; STEINHAUSEN, HC				SPOHR, HL; WILLMS, J; STEINHAUSEN, HC			PRENATAL ALCOHOL EXPOSURE AND LONG-TERM DEVELOPMENTAL CONSEQUENCES	LANCET			English	Article							FOLLOW-UP; MATCHED CONTROLS; FETAL; CHILDREN; MOTHERS; IMPACT; GROWTH	Fetal alcohol syndrome (FAS) is a leading cause of congenital mental retardation but little is known about the long-term development and adolescent outcome of children with FAS. In a 10-year follow-up study of 60 patients diagnosed as having FAS in infancy and childhood, we investigated the long-term sequelae of intrauterine alcohol exposure. We found that the characteristic craniofacial malformations of FAS diminish with time, but microcephaly and, to a lesser degree, short stature and underweight (in boys) persist; in female adolescents body weight normalises. Persistent mental retardation is the major sequela of intrauterine alcohol exposure in many cases, and environmental and educational factors do not have strong compensatory effects on the intellectual development of affected children.	UNIV ZURICH,DEPT CHILD & ADOLESCENT PSYCHIAT,CH-8006 ZURICH,SWITZERLAND	University of Zurich	SPOHR, HL (corresponding author), GERMAN RED CROSS,RITTBERG HOSP,DEPT PEDIAT,CARSTENNSTR 58,W-1000 BERLIN 45,GERMANY.							Abel E. L., 1983, FETAL ALCOHOL SYNDRO; ABEL EL, 1987, DRUG ALCOHOL DEPEN, V19, P51, DOI 10.1016/0376-8716(87)90087-1; ARONSON M, 1985, ACTA PAEDIATR SCAND, V74, P27, DOI 10.1111/j.1651-2227.1985.tb10916.x; CLARREN SK, 1978, NEW ENGL J MED, V298, P1036; DEHAENE P, 1977, REV ALCOOL, P145; JONES KL, 1973, LANCET, V1, P1267; JONES KL, 1973, LANCET, V2, P999; KYLLERMAN M, 1985, ACTA PAEDIATR SCAND, V74, P20, DOI 10.1111/j.1651-2227.1985.tb10915.x; LANDESMANDWYER S, 1981, NEUROBEH TOXICOL TER, V3, P187; LARGO RH, 1980, HELV PAEDIATR ACTA, V35, P419; LEMOINE P, 1968, QUEST MED, V8, P476; Majewski F, 1976, MMW Munch Med Wochenschr, V118, P1635; NESTLER V, 1981, ALKOHOLEMBRYOPATHIE; QUELETTE EM, 1977, NEW ENGL J MED, V297, P528; SOKOL RJ, 1989, ALCOHOL CLIN EXP RES, V13, P597, DOI 10.1111/j.1530-0277.1989.tb00384.x; SPOHR HL, 1987, NEUROPEDIATRICS, V18, P13, DOI 10.1055/s-2008-1052428; STEINHAUSEN HC, 1982, J DEV BEHAV PEDIATR, V3, P49, DOI 10.1097/00004703-198206000-00001; STREISSGUTH AP, 1985, LANCET, V2, P85; STREISSGUTH AP, 1991, JAMA-J AM MED ASSOC, V265, P1961, DOI 10.1001/jama.265.15.1961; STREISSGUTH AP, 1991, J AM ACAD CHILD PSY, V30, P584, DOI 10.1097/00004583-199107000-00009	20	201	202	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 10	1993	341	8850					907	910		10.1016/0140-6736(93)91207-3	http://dx.doi.org/10.1016/0140-6736(93)91207-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW981	7681518				2022-12-28	WOS:A1993KW98100001
J	ZHOU, AM; HASSEL, BA; SILVERMAN, RH				ZHOU, AM; HASSEL, BA; SILVERMAN, RH			EXPRESSION CLONING OF 2-5A-DEPENDENT RNASE - A UNIQUELY REGULATED MEDIATOR OF INTERFERON ACTION	CELL			English	Article							ENCEPHALOMYOCARDITIS VIRUS-REPLICATION; ESCHERICHIA-COLI; MESSENGER-RNA; PROTEIN-SYNTHESIS; RIBOSOMAL-RNA; TREATED CELLS; 2'-5'-OLIGOADENYLATE SYNTHETASE; PPP(A2'P)NA-DEPENDENT RNASE; CONSTITUTIVE EXPRESSION; MOLECULAR-CLONING	2-5A-dependent RNAase, an interferon-induced enzyme that is activated by 5'-phosphorylated, 2',5'-linked oligoadenylates (2-SA), is implicated in both the molecular mechanisms of interferon action and the fundamental control of RNA stability in mammalian cells. Here we report the expression cloning and analysis of murine and human 2-5A-dependent RNAases. The 2-5A binding properties and RNAase activities of recombinant and naturally occurring forms of 2-5A-dependent RNAase were identical. Interferon induction of 2-5A-dependent RNAase expression was demonstrated by measuring the mRNA levels in cells treated with interferon and cycloheximide. Analysis of aligned murine and human 2-5A-dependent RNAase sequences revealed several intriguing features, including similarity to RNAase E, which is implicated in the control of mRNA stability in E. coli. Interestingly, a duplicated phosphate-binding loop motif was determined by deletion analysis and site-directed mutagenesis to function in the binding of 2-5A.	UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA	ZHOU, AM (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT CANC BIOL,CLEVELAND,OH 44195, USA.				NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NCI NIH HHS [2RO1 CA44059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APIRION D, 1978, J BIOL CHEM, V253, P1738; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; Brown R E, 1985, Prog Clin Biol Res, V202, P3; CAYLEY PJ, 1982, BIOCHEM BIOPH RES CO, V108, P1243, DOI 10.1016/0006-291X(82)92133-7; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; ETIENNESMEKENS M, 1983, P NATL ACAD SCI-BIOL, V80, P4609, DOI 10.1073/pnas.80.15.4609; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FLOYDSMITH G, 1981, SCIENCE, V212, P1020; FLOYDSMITH G, 1988, J CELL BIOCHEM, V38, P12; GRIBAUDO G, 1991, J VIROL, V65, P1748, DOI 10.1128/JVI.65.4.1748-1757.1991; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOVANESSIAN AG, 1977, NATURE, V268, P537, DOI 10.1038/268537a0; HOVANESSIAN AG, 1987, EMBO J, V6, P1273, DOI 10.1002/j.1460-2075.1987.tb02364.x; HOVANESSIAN AG, 1900, VIROLOGY, V101, P81; IMAI J, 1985, J BIOL CHEM, V260, P1390; JACOBSEN H, 1983, P NATL ACAD SCI-BIOL, V80, P4954, DOI 10.1073/pnas.80.16.4954; JACOBSEN H, 1983, VIROLOGY, V125, P496, DOI 10.1016/0042-6822(83)90222-2; JOHNSTON MI, 1987, J BIOL CHEM, V262, P8377; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; KNIGHT M, 1980, NATURE, V288, P189, DOI 10.1038/288189a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAUSE D, 1986, J BIOL CHEM, V261, P6836; KRAUSE D, 1985, EUR J BIOCHEM, V146, P611, DOI 10.1111/j.1432-1033.1985.tb08695.x; KUMAR R, 1988, J VIROL, V62, P3175, DOI 10.1128/JVI.62.9.3175-3181.1988; MARIE I, 1992, J BIOL CHEM, V267, P9933; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; NOLANSORDEN NL, 1990, ANAL BIOCHEM, V184, P298, DOI 10.1016/0003-2697(90)90684-2; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; ROZEN F, 1989, MOL CELL BIOL, V9, P4061, DOI 10.1128/MCB.9.9.4061; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SILVERMAN RH, 1983, J VIROL, V46, P1051, DOI 10.1128/JVI.46.3.1051-1055.1983; SILVERMAN RH, 1985, ANAL BIOCHEM, V144, P450, DOI 10.1016/0003-2697(85)90141-1; SILVERMAN RH, 1988, J BIOL CHEM, V263, P7336; SILVERMAN RH, 1982, EUR J BIOCHEM, V126, P333; SILVERMAN RH, 1982, EUR J BIOCHEM, V124, P131, DOI 10.1111/j.1432-1033.1982.tb05915.x; SILVERMAN RH, 1987, LYMPHOKINES INTERFER, P149; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SLATTERY E, 1979, P NATL ACAD SCI USA, V76, P4778, DOI 10.1073/pnas.76.10.4778; STARK GR, 1979, NATURE, V278, P471, DOI 10.1038/278471a0; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P581; TRUJILLO MA, 1987, EUR J BIOCHEM, V169, P167, DOI 10.1111/j.1432-1033.1987.tb13594.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATLING D, 1985, EMBO J, V4, P431, DOI 10.1002/j.1460-2075.1985.tb03647.x; WELLS JA, 1984, J BIOL CHEM, V259, P1363; WILLIAMS BRG, 1978, EUR J BIOCHEM, V92, P455, DOI 10.1111/j.1432-1033.1978.tb12767.x; WILLIAMS BRG, 1979, NATURE, V282, P582, DOI 10.1038/282582a0; WRESCHNER DH, 1982, EUR J BIOCHEM, V124, P261; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; WRESCHNER DH, 1981, NUCLEIC ACIDS RES, V9, P1571, DOI 10.1093/nar/9.7.1571; XIA ZG, 1990, J BIOL CHEM, V265, P6517	62	430	458	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					753	765		10.1016/0092-8674(93)90403-D	http://dx.doi.org/10.1016/0092-8674(93)90403-D			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	7680958	Bronze			2022-12-28	WOS:A1993KR43600011
J	KROLEWSKI, AS; LAFFEL, LMB; KROLEWSKI, M; QUINN, M; WARRAM, JH				KROLEWSKI, AS; LAFFEL, LMB; KROLEWSKI, M; QUINN, M; WARRAM, JH			GLYCOSYLATED HEMOGLOBIN AND THE RISK OF MICROALBUMINURIA IN PATIENTS WITH INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STATISTICAL-METHOD; GLUCOSE CONTROL; COMPLICATIONS; NEPHROPATHY; DISEASE	Background. The risk of microalbuminuria in patients with insulin-dependent diabetes mellitus (IDDM) is thought to depend on the degree of hyperglycemia, but the relation between the degree of hyperglycemia and urinary albumin excretion has not been defined. Methods. We measured urinary albumin excretion in three random urine samples obtained at least one month apart from 1613 patients with IDDM. Microalbuminuria or overt albuminuria was considered to be present if the ratio of albumin (in micrograms) to creatinine (in milligrams) was 17 to 299 or greater than or equal to 300, respectively, for men and 25 to 299 or greater than or equal to 300, respectively, for women. Measurements of glycosylated hemoglobin (hemoglobin A(1)) obtained up to four years before the urine testing were used as an index of hyperglycemia. Twelve percent of the patients had overt albuminuria and were excluded from subsequent analyses. Results. The prevalence of microalbuminuria was 18 percent in patients with IDDM. It increased with increasing postpubertal duration of diabetes and, within each six-year interval of disease duration, it increased nonlinearly with the hemoglobin A(1) value. For hemoglobin A(1) values below 10.1 percent, the slope of the relation was almost flat, whereas for values above 10.1 percent, the prevalence of microalbuminuria rose steeply (P<0.001). For example, as the hemoglobin A(1) value increased from 8.1 to 10.1 percent, the odds of microalbuminuria increased by a factor of 1.3, but as the value increased from 10.1 to 12.1 percent, the odds were increased by a factor of 2.4. Conclusions. The risk of microalbuminuria in patients with IDDM increases abruptly above a hemoglobin A(1) value of 10.1 percent (equivalent to a hemoglobin A(1c) value of 8.1 percent), suggesting that efforts to reduce the frequency of diabetic nephropathy should be focused on reducing hemoglobin A(1) values that are above this threshold.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	KROLEWSKI, AS (corresponding author), JOSLIN DIABET CTR, EPIDEMIOL & GENET SECT, 1 JOSLIN PL, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041526] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK41526] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRASS CK, 1994, KIDNEY INT, V46, P613, DOI 10.1038/ki.1994.313; [Anonymous], 1988, SAS STAT GUIDE PERSO; BIRKETT NJ, 1992, AM J EPIDEMIOL, V136, P356, DOI 10.1093/oxfordjournals.aje.a116500; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; COONROD BA, 1993, DIABETES CARE, V16, P1376, DOI 10.2337/diacare.16.10.1376; DAHLJORGENSEN K, 1992, KIDNEY INT, V41, P920, DOI 10.1038/ki.1992.140; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; ERIKSSON J, 1992, DIABETIC MED, V9, P654, DOI 10.1111/j.1464-5491.1992.tb01862.x; JANNER M, 1994, EUR J PEDIATR, V153, P403; JONES RH, 1984, ANAL BIOCHEM, V141, P287, DOI 10.1016/0003-2697(84)90458-5; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; KROLEWSKI AS, 1987, NEW ENGL J MED, V317, P1390; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; LARKINS R, 1992, DIABETOLOGIA, V35, P1100; LARKINS RG, 1992, DIABETOLOGIA, V35, P499, DOI 10.1007/BF00400475; LIEVENS MM, 1988, CLIN CHEM, V34, P992; LITTLE RR, 1992, CLIN CHEM, V38, P2472; MACLURE M, 1992, AM J EPIDEMIOL, V135, P96; MENARD L, 1980, CLIN CHEM, V26, P1598; MOGENSEN CE, 1983, DIABETES, V32, P64, DOI 10.2337/diab.32.2.S64; NESTLER JE, 1990, DIABETES, V39, P1212, DOI 10.2337/diabetes.39.10.1212; PUGLIESE G, 1991, DIABETES METAB REV, V7, P35, DOI 10.1002/dmr.5610070106; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; Rothman K, 1986, MODERN EPIDEMIOLOGY; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIEGEL JE, 1992, J AM SOC NEPHROL, V3, pS111; ULM K, 1991, STAT MED, V10, P341, DOI 10.1002/sim.4780100306; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; WARRAM JH, 1995, NEW ENGL J MED, V332, P1305, DOI 10.1056/NEJM199505113321915; Wilson R M, 1985, Diabet Med, V2, P167; YIP J, 1993, BRIT MED J, V306, P1235; 1990, P200 SAS I TECHN REP	33	385	393	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 11	1995	332	19					1251	1255		10.1056/NEJM199505113321902	http://dx.doi.org/10.1056/NEJM199505113321902			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW600	7708068				2022-12-28	WOS:A1995QW60000002
J	PLOTZ, PH; RIDER, LG; TARGOFF, IN; RABEN, N; OHANLON, TP; MILLER, FW				PLOTZ, PH; RIDER, LG; TARGOFF, IN; RABEN, N; OHANLON, TP; MILLER, FW			MYOSITIS - IMMUNOLOGICAL CONTRIBUTIONS TO UNDERSTANDING CAUSE, PATHOGENESIS, AND THERAPY	ANNALS OF INTERNAL MEDICINE			English	Discussion							TRANSFER-RNA-SYNTHETASE; IDIOPATHIC INFLAMMATORY MYOPATHIES; INCLUSION-BODY MYOSITIS; T-CELL RECEPTOR; INTERSTITIAL LUNG-DISEASE; ANTIGEN PM-SCL; D REGION GENES; POLYMYOSITIS-DERMATOMYOSITIS; CONTROLLED TRIAL; AUTOANTIBODIES	The myositis syndromes, the most common forms of which are polymyositis and dermatomyositis, are defined by idiopathic chronic inflammation in skeletal muscle. Although initially described more than a century ago, these diseases are so rare and heterogeneous that we have only a limited understanding of their causes and treatment. Recently, autoimmune responses to nuclear and cytoplasmic autoantigens that are unique to patients with myositis, the myositis-specific autoantibodies, have proved clinically useful in helping predict signs and symptoms of myositis, immunogenetics, responses to therapy, and prognosis. We summarize this new information on the variety and nature of these autoantibodies, their target epitopes, and their possible use in identifying causes, pathogenetic mechanisms, and better therapies for these increasingly recognized disorders.			PLOTZ, PH (corresponding author), NIH, BLDG 10, ROOM 9N228, BETHESDA, MD 20892 USA.		Rider, Lisa G/C-7083-2018; Miller, Frederick/D-2431-2019	Rider, Lisa G/0000-0002-6912-2458; Miller, Frederick/0000-0003-2831-9593				BAROHN RJ, 1993, SEMIN NEUROL, V13, P247, DOI 10.1055/s-2008-1041131; BIRDI N, 1993, ARTHRITIS RHEUM, V36, P410, DOI 10.1002/art.1780360318; BOHAN A, 1977, MEDICINE, V56, P255, DOI 10.1097/00005792-197707000-00001; BOWYER SL, 1983, J PEDIATR-US, V103, P882, DOI 10.1016/S0022-3476(83)80706-9; BUNN CC, 1986, J EXP MED, V163, P1281, DOI 10.1084/jem.163.5.1281; CARROLL GJ, 1987, J RHEUMATOL, V14, P995; CHMIEL JF, 1995, IN PRESS J RHEUMATOL; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CUKIER J, 1993, ANN INTERN MED, V118, P920, DOI 10.7326/0003-4819-118-12-199306150-00002; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; DANON MJ, 1989, CAN J NEUROL SCI, V16, P436, DOI 10.1017/S031716710002953X; DEVITA S, 1992, ACTA NEUROL BELG, V92, P215; DOHLMAN JG, 1993, BIOCHEM BIOPH RES CO, V195, P686, DOI 10.1006/bbrc.1993.2100; EMSLIESMITH AM, 1990, ANN NEUROL, V27, P343, DOI 10.1002/ana.410270402; ENGEL AG, 1990, RES P ARNMD, V68, P141; ENZ LA, 1992, ARTHRITIS RHEUM, V35, pS52; ESPINOZA LR, 1991, RHEUM DIS CLIN N AM, V17, P117; FETT R, 1991, J BIOL CHEM, V266, P1448; GARCIADELATORRE I, 1991, ARTHRITIS RHEUM, V34, P744; GE Q, 1994, J BIOL CHEM, V269, P28790; GOLDSTEIN R, 1990, ARTHRITIS RHEUM, V33, P1240; HANISSIAN AS, 1982, J RHEUMATOL, V9, P390; HICKS JH, 1987, POLYMYOSITIS DERMATO, P293; Hiketa Takeshi, 1992, Journal of Dermatology (Tokyo), V19, P470; HIRAKATA M, 1992, ARTHRITIS RHEUM, V35, P449, DOI 10.1002/art.1780350415; HOHLFELD R, 1991, ANN NEUROL, V29, P498, DOI 10.1002/ana.410290509; ISAACSON G, 1991, ARCH OTOLARYNGOL, V117, P103; JABLONSKA S, 1992, CLIN DERMATOL, V10, P457, DOI 10.1016/0738-081X(92)90091-C; JOFFE MM, 1993, AM J MED, V94, P379, DOI 10.1016/0002-9343(93)90148-I; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; Kalovidouris Apostolos E., 1992, Current Opinion in Rheumatology, V4, P809; LEFF RL, 1993, MEDICINE, V72, P225, DOI 10.1097/00005792-199307000-00002; LEFF RL, 1992, LANCET, V339, P1192, DOI 10.1016/0140-6736(92)91134-T; LEFF RL, 1991, ARTHRITIS RHEUM, V34, P1391; LEQUINTREC JS, 1991, BAILLIERE CLIN RHEUM, V5, P21, DOI 10.1016/S0950-3579(05)80294-8; LOVE LA, 1992, ARTHRITIS RHEUM, V35, pS46; LOVE LA, 1991, MEDICINE, V70, P360, DOI 10.1097/00005792-199111000-00002; LOVE LA, 1992, ARTHRITIS RHEUM, V35, pS40; Love Lori A., 1993, Current Opinion in Rheumatology, V5, P712; MACCIONI FJ, 1990, AUST NZ J MED, V20, P806, DOI 10.1111/j.1445-5994.1990.tb00428.x; MANTEGAZZA R, 1993, J CLIN INVEST, V91, P2880, DOI 10.1172/JCI116533; MARGUERIE C, 1990, Q J MED, V77, P1019, DOI 10.1093/qjmed/77.1.1019; MARGUERIE C, 1992, MEDICINE, V71, P327, DOI 10.1097/00005792-199211000-00001; MATHEWS MB, 1984, J EXP MED, V160, P420, DOI 10.1084/jem.160.2.420; MATHEWS MB, 1983, NATURE, V304, P177, DOI 10.1038/304177a0; MEDSGER TA, 1970, AM J MED, V48, P715, DOI 10.1016/S0002-9343(70)80006-7; MILLER F W, 1991, Current Opinion in Rheumatology, V3, P902, DOI 10.1097/00002281-199112000-00002; MILLER F W, 1988, Arthritis and Rheumatism, V31, pS60; MILLER FW, 1990, P NATL ACAD SCI USA, V87, P9933, DOI 10.1073/pnas.87.24.9933; MILLER FW, 1993, JAMA-J AM MED ASSOC, V270, P1846, DOI 10.1001/jama.270.15.1846; MILLER FW, 1992, NEW ENGL J MED, V326, P1380, DOI 10.1056/NEJM199205213262102; MILLER FW, 1990, CLIN EXP IMMUNOL, V81, P373; MILLER LC, 1988, ARCH PHYS MED REHAB, V69, P610; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MORGAN OS, 1989, LANCET, V2, P1184; NAGAR H, 1993, EUR J SURG, V159, P187; NAGARAJA D, 1992, ACTA NEUROL SCAND, V86, P230, DOI 10.1111/j.1600-0404.1992.tb05076.x; ODDIS C V, 1991, Current Opinion in Rheumatology, V3, P919, DOI 10.1097/00002281-199112000-00004; ODDIS CV, 1990, J RHEUMATOL, V17, P1329; ODDIS CV, 1992, ARTHRITIS RHEUM, V35, P1211, DOI 10.1002/art.1780351014; OHANLON TP, 1994, J IMMUNOL, V152, P2569; OHANLON TP, 1994, J AUTOIMMUN, V7, P321, DOI 10.1006/jaut.1994.1023; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PACHMAN LM, 1994, SAMTERS IMMUNOLOGICA, P791; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; PARODI A, 1989, J AM ACAD DERMATOL, V21, P433, DOI 10.1016/S0190-9622(89)80053-2; PLOTZ PH, 1989, ANN INTERN MED, V111, P143, DOI 10.7326/0003-4819-111-2-143; PLUSCHKE G, 1992, J EXP MED, V176, P1785, DOI 10.1084/jem.176.6.1785; RABEN N, 1992, NUCLEIC ACIDS RES, V20, P1075, DOI 10.1093/nar/20.5.1075; RABEN N, 1994, J BIOL CHEM, V269, P24277; REIMERS CD, 1993, J NEUROL, V240, P278, DOI 10.1007/BF00838161; RIDER LG, 1994, ARTHRITIS RHEUM, V37, P1534, DOI 10.1002/art.1780371019; Rider Lisa G., 1994, Current Opinion in Rheumatology, V6, P575, DOI 10.1097/00002281-199411000-00005; RIGGS JE, 1989, J CHILD NEUROL, V4, P283, DOI 10.1177/088307388900400406; SEIDENBERG KB, 1990, AM J OPHTHALMOL, V109, P13, DOI 10.1016/S0002-9394(14)75571-0; SHERRY DD, 1993, PEDIATR NEUROL, V9, P155, DOI 10.1016/0887-8994(93)90055-H; SINGSEN BH, 1977, J PEDIATR-US, V90, P893, DOI 10.1016/S0022-3476(77)80555-6; SINOWAY PA, 1993, ARTHRITIS RHEUM, V36, P319, DOI 10.1002/art.1780360305; STOMMEL EW, 1993, ARCH NEUROL-CHICAGO, V50, P571, DOI 10.1001/archneur.1993.00540060013009; TANEJA V, 1990, ARTHRITIS RHEUM, V33, P1445, DOI 10.1002/art.1780330922; TARGOFF IN, 1992, ARTHRITIS RHEUM, V35, P821, DOI 10.1002/art.1780350718; TARGOFF IN, 1993, J CLIN INVEST, V91, P2556, DOI 10.1172/JCI116493; TARGOFF IN, 1989, J CLIN INVEST, V84, P162, DOI 10.1172/JCI114136; TARGOFF IN, 1985, ARTHRITIS RHEUM, V28, P796, DOI 10.1002/art.1780280711; TARGOFF IN, 1987, J IMMUNOL, V138, P2874; TARGOFF IN, 1990, J IMMUNOL, V144, P1737; TARGOFF IN, 1990, ARTHRITIS RHEUM, V33, P1361, DOI 10.1002/art.1780330908; TARGOFF IN, 1992, RHEUM DIS CLIN N AM, V18, P455	88	139	142	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					715	724		10.7326/0003-4819-122-9-199505010-00010	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00010			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702234				2022-12-28	WOS:A1995QV15100010
J	MOON, RE				MOON, RE			FASTING BEFORE SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							GASTRIC FLUID VOLUME; GUIDELINES; CHILDREN; PH; INGESTION; LIQUIDS				MOON, RE (corresponding author), DUKE UNIV,MED CTR,DURHAM,NC, USA.		Moon, Richard/AAF-2170-2019	Moon, Richard/0000-0003-4432-0332				COTE CJ, 1990, ANESTHESIOLOGY, V72, P589, DOI 10.1097/00000542-199004000-00001; GOODWIN APL, 1991, ANAESTHESIA, V46, P1066, DOI 10.1111/j.1365-2044.1991.tb09926.x; GORESKY GV, 1990, CAN J ANAESTH, V37, P493, DOI 10.1007/BF03006313; KALLAR SK, 1993, ANESTH ANALG, V77, P171; MALTBY JR, 1991, CAN J ANAESTH, V38, P425, DOI 10.1007/BF03007577; MENDELSON CL, 1946, AM J OBSTET GYNECOL, V52, P191; MINAMI H, 1984, GASTROENTEROLOGY, V86, P1592; MOORE JG, 1981, DIGEST DIS SCI, V26, P16, DOI 10.1007/BF01307971; PHILLIPS S, 1993, BRIT J ANAESTH, V70, P6, DOI 10.1093/bja/70.1.6; SANDHAR BK, 1989, ANESTHESIOLOGY, V71, P327, DOI 10.1097/00000542-198909000-00001; SCARR M, 1989, CAN MED ASSOC J, V141, P1151; SCHREINER MS, 1990, ANESTHESIOLOGY, V72, P593, DOI 10.1097/00000542-199004000-00002; SNOW J, 1847, INHALATION VAPOUR ET, P43; SPLINTER WM, 1990, CAN J ANAESTH, V37, P36, DOI 10.1007/BF03007481; STRUNIN L, 1993, BRIT J ANAESTH, V70, P1, DOI 10.1093/bja/70.1.1	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1171	1171						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT100	7707615				2022-12-28	WOS:A1995QT10000010
J	BOTVIN, GJ; BAKER, E; DUSENBURY, L; BOTVIN, EM; DIAZ, T				BOTVIN, GJ; BAKER, E; DUSENBURY, L; BOTVIN, EM; DIAZ, T			LONG-TERM FOLLOW-UP RESULTS OF A RANDOMIZED DRUG-ABUSE PREVENTION TRIAL IN A WHITE MIDDLE-CLASS POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMOKING PREVENTION; PSYCHOSOCIAL APPROACH; BEHAVIORAL-APPROACH; META-ANALYSIS; SELF-REPORTS; YOUTH; PROGRAM; ADOLESCENTS; STRATEGIES; EDUCATION	Objective.-To evaluate the long-term efficacy of a school-based approach to drug abuse prevention. Design.-Randomized trial involving 56 public schools that received the prevention program with annual provider training workshops and ongoing consultation, the prevention program with videotaped training and no consultation, or ''treatment as usual'' (ie, controls). Follow-up data were collected 6 years after baseline using school, telephone, and mailed surveys. Participants.-A total of 3597 predominantly white, 12th-grade students who represented 60.41% of the initial seventh-grade sample. Intervention.-Consisted of 15 classes in seventh grade, 10 booster sessions in eighth grade, and five booster sessions in ninth grade, and taught general ''life skills'' and skills for resisting social influences to use drugs. Measures.-Six tobacco, alcohol, and marijuana use self-report scales were recoded to create nine dichotomous drug use outcome variables and eight polydrug use variables. Results.-Significant reductions in both drug and polydrug use were found for the two groups that received the prevention program relative to controls. The strongest effects were produced for individuals who received a reasonably complete version of the intervention-there were up to 44% fewer drug users and 66% fewer polydrug (tobacco, alcohol, and marijuana) users. Conclusions.-Drug abuse prevention programs conducted during junior high school can produce meaningful and durable reductions in tobacco, alcohol, and marijuana use if they (1)teach a combination of social resistance skills and general life skills, (2) are properly implemented, and (3) include at least 2 years of booster sessions.			BOTVIN, GJ (corresponding author), CORNELL UNIV, MED CTR, COLL MED, INST PREVENT RES, 411 E 69TH ST, NEW YORK, NY 10021 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006230] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33865] Funding Source: Medline; NIDA NIH HHS [DA06230] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BANGERTDROWNS RL, 1988, J DRUG EDUC, V18, P243, DOI 10.2190/8U40-WP3D-FFWC-YF1U; BAUMAN KE, 1982, INT J ADDICT, V17, P1131, DOI 10.3109/10826088209056345; BIGLAN A, 1985, PREVENTION RES DETER, P170; BOTVIN EM, 1984, PSYCHOL REP, V55, P379, DOI 10.2466/pr0.1984.55.2.379; Botvin G J, 1989, Crisis, V10, P62; BOTVIN GJ, 1989, PUBLIC HEALTH REP, V104, P573; BOTVIN GJ, 1992, HEALTH PSYCHOL, V11, P290, DOI 10.1037/0278-6133.11.5.290; BOTVIN GJ, 1992, J DEV BEHAV PEDIATR, V13, P290; BOTVIN GJ, 1990, J CONSULT CLIN PSYCH, V58, P437, DOI 10.1037/0022-006X.58.4.437; BOTVIN GJ, 1990, ADDICT BEHAV, V15, P47, DOI 10.1016/0306-4603(90)90006-J; BOTVIN GJ, 1983, J BEHAV MED, V6, P359, DOI 10.1007/BF00846324; BOTVIN GJ, 1986, J SCHOOL HEALTH, V56, P369, DOI 10.1111/j.1746-1561.1986.tb05775.x; BOTVIN GJ, 1989, J BEHAV MED, V12, P279, DOI 10.1007/BF00844872; BOTVIN GJ, 1992, SUBSTANCE ABUSE COMP, P910; BOTVIN GJ, 1988, 14 OUNCES PREVENTION, P98, DOI DOI 10.1037/10064-008; BOTVIN GJ, 1987, PSYCHO ED INTERVENTI, P70801; Cook T.C., 1979, QUASIEXPERIMENTATION; DWYER JH, 1989, AM J EPIDEMIOL, V130, P781, DOI 10.1093/oxfordjournals.aje.a115399; ELLICKSON PL, 1990, SCIENCE, V247, P1299, DOI 10.1126/science.2180065; ELLICKSON PL, 1993, AM J PUBLIC HEALTH, V83, P856, DOI 10.2105/AJPH.83.6.856; EVANS RI, 1977, J APPL PSYCHOL, V62, P521, DOI 10.1037/0021-9010.62.4.521; FLAY BR, 1989, AM J PUBLIC HEALTH, V79, P1371, DOI 10.2105/AJPH.79.10.1371; FLAY BR, 1985, HEALTH PSYCHOL, V4, P449, DOI 10.1037/0278-6133.4.5.449; GOODSTADT M, 1974, RES METHODS PROGRAMS; HANSEN WB, 1992, HEALTH EDUC RES, V7, P403, DOI 10.1093/her/7.3.403; JOHNSTON LD, 1994, NATIONAL SURVEY RESU, P70801; Johnston LD, 1988, ILLICIT DRUG USE SMO; LUEPKER RV, 1983, J BEHAV MED, V6, P53, DOI 10.1007/BF00845276; MCALISTER A, 1980, AM J PUBLIC HEALTH, V70, P719, DOI 10.2105/AJPH.70.7.719; MURRAY DM, 1990, J CONSULT CLIN PSYCH, V58, P458, DOI 10.1037/0022-006X.58.4.458; MURRAY DM, 1989, HEALTH EDUC QUART, V16, P315, DOI 10.1177/109019818901600214; MURRAY DM, 1988, J BEHAV MED, V11, P395, DOI 10.1007/BF00844938; MURRAY DM, 1989, J BEHAV MED, V12, P207, DOI 10.1007/BF00846551; RESNICOW K, 1993, PREV MED, V22, P484, DOI 10.1006/pmed.1993.1039; SNOW DL, 1992, J CONSULT CLIN PSYCH, V60, P804, DOI 10.1037/0022-006X.60.5.804; TELCH MJ, 1982, J BEHAV MED, V5, P1, DOI 10.1007/BF00845253; TOBLER NS, 1986, J DRUG ISSUES, V16, P537, DOI 10.1177/002204268601600405; TORTU S, 1989, PREV MED, V18, P280, DOI 10.1016/0091-7435(89)90075-3; WINER J, 1971, STATISTICAL PRINCIPL, P247; 1989, SAS STAT USERS GUIDE	40	543	553	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1106	1112		10.1001/jama.273.14.1106	http://dx.doi.org/10.1001/jama.273.14.1106			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QR059	7707598				2022-12-28	WOS:A1995QR05900029
J	STOKOLS, D; PELLETIER, KR; FIELDING, JE				STOKOLS, D; PELLETIER, KR; FIELDING, JE			INTEGRATION OF MEDICAL-CARE AND WORKSITE HEALTH PROMOTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROGRAMS; WELLNESS; IMPACT; COSTS; RISK		STANFORD UNIV,MED CTR,SCH MED,CTR RES DIS PREVENT,STANFORD,CA 94305; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,LOS ANGELES,CA 90024	Stanford University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	STOKOLS, D (corresponding author), UNIV CALIF IRVINE,SCH SOCIAL ECOL,IRVINE,CA 92717, USA.			Stokols, Daniel/0000-0002-3008-3009				[Anonymous], 1989, GUIDE CLIN PREVENTIV; BICKMAN L, 1987, USING PROGRAM THEORY; BLAIR SN, 1986, JAMA-J AM MED ASSOC, V255, P921, DOI 10.1001/jama.255.7.921; BLY JL, 1986, JAMA-J AM MED ASSOC, V256, P3235, DOI 10.1001/jama.256.23.3235; Brill M., 1984, USING OFFICE DESIGN; CAPLAN RD, 1993, J SOC ISSUES, V49, P253, DOI 10.1111/j.1540-4560.1993.tb01192.x; Carayon-Sainfort P., 1989, INT J IND ERGONOM, V4, P67, DOI DOI 10.1016/0169-8141(89)90051-6; Danko S., 1990, J INTERIOR DESIGN ED, V16, P19, DOI https://doi.org/10.1111/j.1939-1668.1990.tb00051.x; DENNIS C, 1988, JAMA-J AM MED ASSOC, V260, P214, DOI 10.1001/jama.260.2.214; DOOLEY D, 1988, J SOC ISSUES, V44, P1, DOI 10.1111/j.1540-4560.1988.tb02088.x; ERFURT JC, 1991, J OCCUP ENVIRON MED, V33, P962; FIELDING J, 1994, JAMA-J AM MED ASSOC, V272, P1292, DOI 10.1001/jama.272.16.1292; FIELDING JE, 1994, JAMA-J AM MED ASSOC, V271, P525, DOI 10.1001/jama.271.7.525; FOOTE A, 1991, JAMA-J AM MED ASSOC, V265, P1283, DOI 10.1001/jama.265.10.1283; Fries J F, 1992, Am J Health Promot, V6, P364; Fries J F, 1994, Am J Health Promot, V8, P216; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; Gottlieb N, 1994, HLTH PROMOTION WORKP, P459; GREEN LW, 1994, HLTH PROMOTION WORKP, P497; Harvey M R, 1993, Am J Health Promot, V7, P296; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; JONES JW, 1992, STRESS & WELL-BEING AT WORK, P239, DOI 10.1037/10116-016; KAPLAN RM, 1993, HIPPOCRATIC PREDICAM; Karasek R., 1990, HLTH WORK STRESS PRO; KARASEK RA, 1979, ADMIN SCI QUART, V24, P285, DOI 10.2307/2392498; LANDY FJ, 1983, PERFORMANCE MEASUREM; LEVI L, 1992, WORK AND WELL-BEING, P199, DOI 10.1037/10108-006; LEWIN AY, 1986, MANAGE SCI, V32, P514, DOI 10.1287/mnsc.32.5.514; Liem J. H., 1990, STRESS WORK FAMILY, P175; LOCKE SE, 1992, JAMA-J AM MED ASSOC, V268, P1301, DOI 10.1001/jama.268.10.1301; MAIDA C, 1989, CRISIS COMPETENCE TR; MASLACH C, 1981, J OCCUP BEHAV, V2, P99, DOI 10.1002/job.4030020205; Maslach C., 1984, APPLIED SOCIAL PSYCH, V5, P133, DOI DOI 10.1037/0021-9010.93.3.5688; McKinlay J. B., 1975, APPL BEHAV SCI CARDI, P9; OCKENE JK, 1994, HEALTH PSYCHOL, V13, P278, DOI 10.1037/0278-6133.13.3.278; Pelletier K R, 1991, Am J Health Promot, V5, P311; Riley AW, 1987, OCCUPATIONAL STRESS; SAAL JA, 1989, SPINE, V14, P431, DOI 10.1097/00007632-198904000-00018; Sauter S. L., 1989, JOB CONTROL WORKER H; SCHULTZ EE, 1994, WALL ST J       0919, pA1; SPILMAN MA, 1986, J OCCUP ENVIRON MED, V28, P285; STOKOLS D, 1992, AM PSYCHOL, V47, P6, DOI 10.1037/0003-066X.47.1.6; Sundstrom E, 1986, WORK PLACES PSYCHOL; VAUGHAN E, 1993, HEALTH PSYCHOL, V12, P74, DOI 10.1037/0278-6133.12.1.74; Vernon SW, 1992, HEALTH VALUES, V16, P3; VINOKUR AD, 1991, AM J COMMUN PSYCHOL, V19, P543, DOI 10.1007/BF00937991; Wallerstein N, 1992, Am J Health Promot, V6, P197; WARNER KE, 1988, J OCCUP ENVIRON MED, V30, P106; WARNER KE, 1990, HEALTH AFFAIR, V9, P63, DOI 10.1377/hlthaff.9.2.63; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; Williams AF., 1982, HEALTH PSYCHOL, V1, P399, DOI [10.1037/h0090242, DOI 10.1037/H0090242]; Winett R., 1989, HLTH PSYCHOL PUBLIC; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; 1994, BUSINESS WEEK   1017, P74; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	92	43	43	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1136	1142		10.1001/jama.273.14.1136	http://dx.doi.org/10.1001/jama.273.14.1136			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QR059	7707603				2022-12-28	WOS:A1995QR05900034
J	DICKINSON, MH; LIGHTON, JRB				DICKINSON, MH; LIGHTON, JRB			MUSCLE EFFICIENCY AND ELASTIC STORAGE IN THE FLIGHT MOTOR OF DROSOPHILA	SCIENCE			English	Article							INSECT FLIGHT; POWER OUTPUT; MELANOGASTER; METABOLISM	Insects could minimize the high energetic costs of flight in two ways: by employing high-efficiency muscles and by using elastic elements within the thorax to recover energy expended accelerating the wings. However, because muscle efficiency and elastic storage have proven difficult variables to measure, it is not known which of these strategies is actually used. By comparison of mechanical power measurements based on gas exchange with simultaneously measured flight kinematics in Drosophila, a method was developed for determining both the mechanical efficiency and the minimum degree of elastic storage within the flight motor. Muscle efficiency values of 10 percent suggest that insects may minimize energy use in flight by employing an elastic flight motor rather than by using extraordinarily efficient muscles. Further, because of the trade-off between inertial and aerodynamic power throughout the wing stroke, an elastic storage capacity as low as 10 percent may be enough to minimize the energetic costs of flight.	UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah	DICKINSON, MH (corresponding author), UNIV CHICAGO,DEPT ORGANISMAL BIOL & ANAT,CHICAGO,IL 60637, USA.		Lighton, John R B/A-9691-2009	Lighton, John/0000-0002-9264-924X				ALEXANDER RM, 1977, NATURE, V265, P114, DOI 10.1038/265114a0; CASEY T, 1988, INSECT FLIGHT, pCH11; CASEY TM, 1981, J EXP BIOL, V91, P117; DICKINSON MH, 1993, J EXP BIOL, V182, P173; ELLINGTON CP, 1985, J EXP BIOL, V115, P293; ELLINGTON CP, 1991, J EXP BIOL, V160, P71; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P145, DOI 10.1098/rstb.1984.0054; FREEMAN P, 1965, 12 INT C ENT LOND, P186; GOTZ K, COMMUNICATION; GOTZ KG, 1968, KYBERNETIK, V4, P199, DOI 10.1007/BF00272517; GOTZ KG, 1987, J EXP BIOL, V128, P35; HEISENBERG M, 1984, VISION DROSOPHILA; Kammer A.E., 1978, Advances in Insect Physiology, V13, P133, DOI 10.1016/S0065-2806(08)60266-0; LAURIEAHLBERG CC, 1985, GENETICS, V111, P845; LEHRMANN FO, 1994, THESIS EBERHARD KARL; LIGHTON JRB, 1991, CONCISE ENCY BIOL BI, P201; PENNYCUICK CJ, 1984, J EXP BIOL, V108, P377; WEISFOGH T, 1960, J EXP BIOL, V37, P889; WEISFOGH T, 1964, 12 INT C ENT; ZANKER JM, 1990, PHILOS T ROY SOC B, V327, P19, DOI 10.1098/rstb.1990.0041	20	171	173	1	27	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					87	90		10.1126/science.7701346	http://dx.doi.org/10.1126/science.7701346			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701346				2022-12-28	WOS:A1995QR45400030
J	MURRAY, K; SELLECK, P; HOOPER, P; HYATT, A; GOULD, A; GLEESON, L; WESTBURY, H; HILEY, L; SELVEY, L; RODWELL, B; KETTERER, P				MURRAY, K; SELLECK, P; HOOPER, P; HYATT, A; GOULD, A; GLEESON, L; WESTBURY, H; HILEY, L; SELVEY, L; RODWELL, B; KETTERER, P			A MORBILLIVIRUS THAT CAUSED FATAL DISEASE IN HORSES AND HUMANS	SCIENCE			English	Article							COMPARATIVE SEQUENCE-ANALYSIS; RESPIRATORY SYNCYTIAL VIRUS; PHOCINE DISTEMPER VIRUS; AMINO-ACID-SEQUENCES; NUCLEOTIDE-SEQUENCE; MATRIX PROTEIN; MOLECULAR-CLONING; RINDERPEST VIRUS; GENE; PARAMYXOVIRUSES	A morbillivirus has been isolated and added to an increasing list of emerging viral diseases. This virus caused an outbreak of fatal respiratory disease in horses and humans. Genetic analyses show it to be only distantly related to the classic morbilliviruses rinderpest, measles, and canine distemper. When seen by electron microscopy, viruses had 10- and 18-nanometer surface projections that gave them a ''double-fringed'' appearance. The virus induced syncytia that developed in the endothelium of blood vessels, particularly the lungs.	QUEENSLAND DEPT HLTH,CTR PUBL HLTH SCI,BRISBANE,QLD 4000,AUSTRALIA; QUEENSLAND DEPT PRIMARY IND,ANIM RES INST,YEERONGPILLY,QLD 4105,AUSTRALIA; QUEENSLAND HLTH,BRISBANE,QLD 4000,AUSTRALIA	Queensland Health; Queensland Department of Agriculture & Fisheries; Queensland Health	MURRAY, K (corresponding author), CSIRO,AUSTRALIAN ANIM HLTH LAB,RYRIE ST,GEELONG,VIC 3220,AUSTRALIA.		Selvey, Linda/B-8473-2017	Selvey, Linda/0000-0001-8493-0974				BARON MD, 1994, VIROLOGY, V200, P121, DOI 10.1006/viro.1994.1170; BARRETT T, 1993, VIROLOGY, V193, P1010, DOI 10.1006/viro.1993.1217; BEARD CW, 1983, DISEASES POULTRY, P452; BELLINI WJ, 1986, J VIROL, V58, P408, DOI 10.1128/JVI.58.2.408-416.1986; BLUMBERG BM, 1984, J VIROL, V52, P656, DOI 10.1128/JVI.52.2.656-663.1984; CATTANEO R, 1989, VIROLOGY, V173, P415, DOI 10.1016/0042-6822(89)90554-0; CURRAN MD, 1992, ARCH VIROL, V126, P159, DOI 10.1007/BF01309692; DIALLO A, COMMUNICATION; ENAMI M, 1989, J GEN VIROL, V70, P2191, DOI 10.1099/0022-1317-70-8-2191; Felsenstein J., 1989, PHYLIP 3 2 MANUAL; FINCH JT, 1970, J GEN VIROL, V6, P141, DOI 10.1099/0022-1317-6-1-141; GALINSKI MS, 1987, VIROLOGY, V157, P24, DOI 10.1016/0042-6822(87)90309-6; HSU D, 1988, VIROLOGY, V166, P149, DOI 10.1016/0042-6822(88)90156-0; HYATT AD, UNPUB; HYATT AD, 1991, ELECTRON MICROS, P59; JONES TC, 1983, VET PATHOL, P435; Lederberg J., 1992, EMERGING INFECTIONS; LIMO M, 1990, VIROLOGY, V175, P323, DOI 10.1016/0042-6822(90)90216-E; MIYAHARA K, 1992, ARCH VIROL, V124, P255, DOI 10.1007/BF01309807; MONATH TP, 1994, SEMIN VIROL, V5, P133, DOI 10.1006/smvy.1994.1014; MURPHY FA, 1994, SEMIN VIROL, V5, P85, DOI 10.1006/smvy.1994.1009; MURPHY FA, 1993, ADV VIRUS RES, V43, P1; NATHANSON N, 1993, VIRUS RES, V29, P3, DOI 10.1016/0168-1702(93)90122-4; NORRBY E, 1990, P1013; PALMER EL, 1988, ELECT MICROSCOPY VIR, P111; PRINGLE CR, 1991, CLASSIFICATION NOMEN, P242; SAMAL SK, 1991, J GEN VIROL, V72, P1715, DOI 10.1099/0022-1317-72-7-1715; SATAKE M, 1984, J VIROL, V50, P92, DOI 10.1128/JVI.50.1.92-99.1984; SCHEID A, 1987, ANIMAL VIRUS STRUCTU, P233; VANDEUSEN RA, 1983, AVIAN DIS, V27, P745, DOI 10.2307/1590317; VISSER IKG, 1993, J GEN VIROL, V74, P631, DOI 10.1099/0022-1317-74-4-631	31	528	572	1	45	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					94	97		10.1126/science.7701348	http://dx.doi.org/10.1126/science.7701348			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701348				2022-12-28	WOS:A1995QR45400033
J	PERKINS, TT; SMITH, DE; LARSON, RG; CHU, S				PERKINS, TT; SMITH, DE; LARSON, RG; CHU, S			STRETCHING OF A SINGLE TETHERED POLYMER IN A UNIFORM-FLOW	SCIENCE			English	Article							PARTICLES; DNA	The stretching of single, tethered DNA molecules by a flow was directly visualized with fluorescence microscopy. Molecules ranging in length (L) from 22 to 84 micrometers were held stationary against the flow by the optical trapping of a latex microsphere attached to one end. The fractional extension x/L is a universal function of eta vL(0.54+/-0.05), where eta and v are the viscosity and velocity of the flow, respectively. This relation shows that the DNA is not ''free-draining'' (that is, hydrodynamic coupling within the chain is not negligible) even near full extension (similar to 80 percent). This function has the same form over a lone range as the fractional extension versus force applied at the ends of a worm-like chain. For small deformations (<30 percent of full extension), the extension increases with velocity as x similar to v(0.70+/-0.08). The relative size of fluctuations in extension decreases as sigma(x)/x congruent to 0.42 exp(-4.9 x/L). Video images of the fluctuating chain have a cone-like envelope and show as sharp increase in intensity at the free end.	STANFORD UNIV,DEPT PHYS,STANFORD,CA 94305; AT&T BELL LABS,MURRAY HILL,NJ 07974	Stanford University; AT&T; Nokia Corporation; Nokia Bell Labs			Smith, Douglas E/A-3131-2017	Smith, Douglas E/0000-0002-8206-3632; Perkins, Thomas/0000-0003-4826-9490	PHS HHS [33289] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1980, VISCOELASTIC PROPERT; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; BENSIMON D, UNPUB; BIRD RB, 1987, DYNAMICS POLYM LIQUI, V2, P19; BROCHARDWYART F, 1993, EUROPHYS LETT, V23, P105, DOI 10.1209/0295-5075/23/2/005; BROCHARDWYART F, 1994, EUROPHYS LETT, V23, P511; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; CHU S, 1991, SCIENCE, V253, P861, DOI 10.1126/science.253.5022.861; DEBYE P, 1948, J CHEM PHYS, V16, P573, DOI 10.1063/1.1746948; Doi M., 1988, THEORY POLYM DYNAMIC; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FIXMAN M, 1973, J CHEM PHYS, V58, P1564, DOI 10.1063/1.1679396; KIRKWOOD JG, 1954, J CHEM PHYS, V22, P1626, DOI 10.1063/1.1740494; KIRKWOOD JG, 1948, J CHEM PHYS, V16, P565, DOI 10.1063/1.1746947; KIRKWOOD JG, 1953, J POLYM SCI, V12, P1; Kuhn W, 1934, KOLLOID Z, V68, P2, DOI 10.1007/BF01451681; Larson R. G., 1988, CONSTITUTIVE EQUATIO; LARSON RG, 1989, MACROMOLECULES, V22, P3004, DOI 10.1021/ma00197a022; LARSON RG, UNPUB; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; SCHURR JM, 1990, BIOPOLYMERS, V29, P1161, DOI 10.1002/bip.360290806; SIMMONS RF, UNPUB; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; VOLOGODSKII A, 1994, MACROMOLECULES, V27, P5623, DOI 10.1021/ma00098a016; ZIMM BH, 1956, J CHEM PHYS, V24, P269, DOI 10.1063/1.1742462; ZIMM BH, 1992, Q REV BIOPHYS, V25, P171, DOI 10.1017/S0033583500004662; ZIMM BH, COMMUNICATION	30	514	526	1	96	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					83	87		10.1126/science.7701345	http://dx.doi.org/10.1126/science.7701345			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701345				2022-12-28	WOS:A1995QR45400029
J	SCHABERT, FA; HENN, C; ENGEL, A				SCHABERT, FA; HENN, C; ENGEL, A			NATIVE ESCHERICHIA-COLI OMPF PORIN SURFACES PROBED BY ATOMIC-FORCE MICROSCOPY	SCIENCE			English	Article							OUTER-MEMBRANE	Topographs of two-dimensional porin OmpF crystals reconstituted in the presence of lipids were recorded in solution by atomic force microscopy (AFM) to a lateral resolution of 10 angstroms and a vertical resolution of 1 angstrom. Protein-protein interactions were demonstrated on the basis of the AFM results and earlier crystallographic findings, To assess protein-lipid interactions, the bilayer was modeled with kinked lipids by fitting the head groups to contours determined with AFM. Finally, two conformations of the extracellular porin surface were detected at forces of 0.1 nanonewton, demonstrating the potential of AFM to monitor conformational changes with high resolution.	UNIV BASEL,BIOZENTRUM,INST MICROSCOP STRUCT BIOL,CH-4056 BASEL,SWITZERLAND	University of Basel								BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BUEHLER LK, 1991, J BIOL CHEM, V266, P2446; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; ENGEL A, 1985, NATURE, V317, P643, DOI 10.1038/317643a0; HOENGER A, 1993, J MOL BIOL, V233, P400, DOI 10.1006/jmbi.1993.1520; HOH JH, 1991, SCIENCE, V253, P1405, DOI 10.1126/science.1910206; JAP BK, 1990, Q REV BIOPHYS, V23, P367, DOI 10.1017/S003358350000559X; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; RADMACHER M, 1994, SCIENCE, V265, P1577, DOI 10.1126/science.8079171; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; SAXTON WO, 1992, ULTRAMICROSCOPY, V46, P287, DOI 10.1016/0304-3991(92)90020-K; SCHABERT FA, 1994, BIOPHYS J, V67, P2394, DOI 10.1016/S0006-3495(94)80726-X; SEELIG A, 1974, BIOCHEMISTRY-US, V13, P4893; TODT JC, 1992, BIOCHEMISTRY-US, V31, P10471, DOI 10.1021/bi00158a009	15	262	266	1	35	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					92	94		10.1126/science.7701347	http://dx.doi.org/10.1126/science.7701347			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701347				2022-12-28	WOS:A1995QR45400032
J	TARAKHOVSKY, A; TURNER, M; SCHAAL, S; MEE, PJ; DUDDY, LP; RAJEWSKY, K; TYBULEWICZ, VLJ				TARAKHOVSKY, A; TURNER, M; SCHAAL, S; MEE, PJ; DUDDY, LP; RAJEWSKY, K; TYBULEWICZ, VLJ			DEFECTIVE ANTIGEN RECEPTOR-MEDIATED PROLIFERATION OF B-CELLS AND T-CELLS IN THE ABSENCE OF VAV	NATURE			English	Article							TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; SIGNALING PROTEINS; MICE; GENE; ACTIVATION; LACKING; DOMAIN; SH2	CROSSLINKING of B- or T-cell antigen receptors results in the rapid tyrosine phosphorylation of a number of proteins, including Vav, a protein expressed in cells of the haematopoietic system contains an array of structural motifs that include Src-homology domains SH2/SH3(4) and regions of homology to the guanine-nucleotide-exchange nucleotide-exchange protein Dbl, pleckstrin and protein kinase C (refs 5-9). Using the RAG-complementation approach(10), we have analysed in vivo differentiation and in vitro responses of B- and T-lineage cells generated by injection of embryonic stem cells homozygous for a null mutation in the vav gene into blastocysts of RAG-1- or RAG-2-deficient mice. Here we report that antigen receptor-mediated proliferative responses of B and T cells in vitro are severely reduced in the absence of Vav. We also suggest a direct link between the low proliferative response of Vav-deficient B and T cells and the reduced number of these cells in peripheral lymphoid organs of chimaeric mice.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	TARAKHOVSKY, A (corresponding author), UNIV COLOGNE,INST GENET,WEYERTAL 121,D-50931 COLOGNE,GERMANY.		Turner, Martin/N-9976-2014	Turner, Martin/0000-0002-3801-9896; Tybulewicz, Victor/0000-0003-2439-0798; Rajewsky, Klaus/0000-0002-6633-6370				ADAMS JM, 1992, ONCOGENE, V7, P611; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BOGUSKI MS, 1992, NATURE, V358, P113, DOI 10.1038/358113a0; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHEN J, 1994, TRANSGENESIS TARGETE, P35; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; GALLAND F, 1992, ONCOGENE, V7, P585; GRUTZMANN R, 1981, THESIS U COLOGNE GER; JUNG S, 1994, J EXP MED, V179, P2023, DOI 10.1084/jem.179.6.2023; KANTOR AB, 1992, P NATL ACAD SCI USA, V89, P3320, DOI 10.1073/pnas.89.8.3320; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; PARSON M, 1986, GENETICS MOL IMMUNOL, V3; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SMITH L, 1986, GENETICS MOL IMMUNOL, V3; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	30	397	403	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					467	470		10.1038/374467a0	http://dx.doi.org/10.1038/374467a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700358				2022-12-28	WOS:A1995QP89900062
J	THORNTON, JG; LILFORD, RJ				THORNTON, JG; LILFORD, RJ			MANAGEMENT FOR DOCTORS - DECISION-ANALYSIS FOR MEDICAL MANAGERS .12.	BRITISH MEDICAL JOURNAL			English	Article							DOWNS-SYNDROME; PREGNANCY		UNIV LEEDS,INST EPIDEMIOL & HLTH SERV,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND	University of Leeds	THORNTON, JG (corresponding author), UNIV LEEDS,DEPT OBSTET & GYNAECOL,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.		Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876				BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P417, DOI 10.1001/jama.266.3.417; French S., 1988, DECISION THEORY INTR; Hayek FriedrichA., 1960, CONSTITUTION LIBERTY; JOHNSON N, 1993, LANCET, V342, P91, DOI 10.1016/0140-6736(93)91290-3; MARTEAU TM, 1989, BRIT MED J, V300, P1527; MENNIE ME, 1992, LANCET, V304, P214; NEUHAUSER D, 1975, NEW ENGL J MED, V293, P226, DOI 10.1056/NEJM197507312930504; Pauker S P, 1987, Birth Defects Orig Artic Ser, V23, P151; PECKHAM CS, 1992, PRENATAL SCREENING T; Raiffa H, 1968, DECISION ANAL INTRO, P271; SHAPIRA MM, 1993, ANN INTERN MED, V118, P838; SHELDON TA, 1991, BRIT MED J, V302, P1133, DOI 10.1136/bmj.302.6785.1133; STRAYPEDERSEN B, 1993, BAILLIERE CLIN OB GY, V7, P107, DOI 10.1016/S0950-3552(05)80149-X; THORNTON JG, 1991, AM J OBSTET GYNECOL, V164, P154, DOI 10.1016/0002-9378(91)90647-A; THORNTON JG, 1990, MED DECIS MAKING, V10, P288, DOI 10.1177/0272989X9001000407; THORNTON JG, 1992, BRIT MED J, V304, P1099, DOI 10.1136/bmj.304.6834.1099; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; 1989, ECONOMIST, P119	19	20	20	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	1995	310	6982					791	794		10.1136/bmj.310.6982.791	http://dx.doi.org/10.1136/bmj.310.6982.791			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP609	7711587	Green Published			2022-12-28	WOS:A1995QP60900027
J	VANDUIJN, CM; HAVEKES, LM; VAN BROECKHOVEN, C; DEKNIJFF, P; HOFMAN, A				VANDUIJN, CM; HAVEKES, LM; VAN BROECKHOVEN, C; DEKNIJFF, P; HOFMAN, A			APOLIPOPROTEIN-E GENOTYPE AND ASSOCIATION BETWEEN SMOKING AND EARLY-ONSET ALZHEIMERS-DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PARKINSONS-DISEASE; BINDING; DEMENTIA; ALLELE	Objective-To investigate the hypothesis that differential survival between smokers and nonsmokers leading to a decrease in the frequency of the e4 allele of the apolipoprotein E gene may explain the inverse relation between smoking history and early onset Alzheimer's disease. Design-A population based case-control study. Setting-The four northern provinces of the Netherlands and metropolitan Rotterdam. Subjects-175 patients with early onset Alzheimer's disease and two independent control groups of 159 and 457 subjects. Main outcome measures-Frequencies of the apolipoprotein e4 allele and relative risk of early onset Alzheimer's disease, Results-The inverse association between smoking history and early onset Alzheimer's disease could not be explained by a decrease in the frequency the apolipoprotein e4 allele, Among of this allele with a family history of dementia subjects with a history of smoking had a strongly reduced risk of early onset Alzheimer's disease (odds ratio 0.10 (95% confidence interval 0.01 to 0.87)). Conclusions-The results suggest that the inverse relation between smoking history and early onset Alzheimer's disease cannot be explained by an increased mortality in carriers of the apolipoprotein e4 allele who smoke, The association is strongly modified by the presence of the apolipoprotein e4 allele as well as by a family history of dementia.	TNO, INST PREVENT & HLTH RES, GAUBIUS LAB, LEIDEN, NETHERLANDS; UNIV ANTWERP, DEPT BIOCHEM, BORN BUNGE FDN, NEUROGENET LAB, B-2020 ANTWERP, BELGIUM	Netherlands Organization Applied Science Research; University of Antwerp	VANDUIJN, CM (corresponding author), ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Van Broeckhoven, Christine/M-7853-2019; de Knijff, Peter/Y-2519-2018; Van Broeckhoven, Christine/G-8362-2017	Van Broeckhoven, Christine/0000-0003-0183-7665; de Knijff, Peter/0000-0002-0899-771X; Van Broeckhoven, Christine/0000-0003-0183-7665				BENSHLOMO Y, 1993, LANCET, V342, P1239; BENWELL MEM, 1988, J NEUROCHEM, V50, P1243, DOI 10.1111/j.1471-4159.1988.tb10600.x; BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293; BRESLOW NE, 1987, INT AGENCY RES CANCE, V82; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Elston RC, 1987, ESSENTIALS BIOSTATIS; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRAVES AB, 1991, INT J EPIDEMIOL, V20, pS48, DOI 10.1093/ije/20.Supplement_2.S48; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; HAVEKES LM, 1987, J LIPID RES, V28, P455; HOFMAN A, 1989, NEUROLOGY, V39, P1589, DOI 10.1212/WNL.39.12.1589; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; LARRICK JW, 1993, LANCET, V342, P1238, DOI 10.1016/0140-6736(93)92219-J; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORENS DM, 1994, LANCET, V343, P356, DOI 10.1016/S0140-6736(94)91194-0; POIRIER I, 1994, P SPRINGF M ALZH DIS, P72; RIGGS JE, 1993, LANCET, V342, P793, DOI 10.1016/0140-6736(93)91547-Y; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANDUIJN CM, 1991, BRIT MED J, V302, P1491, DOI 10.1136/bmj.302.6791.1491; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	25	75	76	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 11	1995	310	6980					627	631		10.1136/bmj.310.6980.627	http://dx.doi.org/10.1136/bmj.310.6980.627			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703749	Green Submitted, Green Published			2022-12-28	WOS:A1995QL98400015
J	FODOR, SPA; RAVA, RP; HUANG, XHC; PEASE, AC; HOLMES, CP; ADAMS, CL				FODOR, SPA; RAVA, RP; HUANG, XHC; PEASE, AC; HOLMES, CP; ADAMS, CL			MULTIPLEXED BIOCHEMICAL ASSAYS WITH BIOLOGICAL CHIPS	NATURE			English	Article							HYBRIDIZATION		AFFYMAX,PALO ALTO,CA 94304		FODOR, SPA (corresponding author), AFFYMETRIX,3380 CENT EXPRESSWAY,SANTA CLARA,CA 95051, USA.							BAINS W, 1988, J THEOR BIOL, V135, P303, DOI 10.1016/S0022-5193(88)80246-7; DRMANAC R, 1993, SCIENCE, V260, P1649, DOI 10.1126/science.8503011; DRMANAC R, 1989, GENOMICS, V4, P114; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; HOLMES CP, 1993, PERSPECTIVES MED CHE, P489; HUANG X, UNPUB; LYSOV YP, 1988, DOKL AKAD NAUK SSSR, V303, P1508; PEASE AJ, UNPUB; SOUTHERN EM, 1992, GENOMICS, V13, P1008, DOI 10.1016/0888-7543(92)90014-J	9	603	972	2	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					555	556		10.1038/364555a0	http://dx.doi.org/10.1038/364555a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	7687751				2022-12-28	WOS:A1993LQ66700064
J	MUEGGE, K; VILA, MP; DURUM, SK				MUEGGE, K; VILA, MP; DURUM, SK			INTERLEUKIN-7 - A COFACTOR FOR V(D)J REARRANGEMENT OF THE T-CELL RECEPTOR BETA-GENE	SCIENCE			English	Article							MURINE INTERLEUKIN-7; RECOMBINATION; RAG-1; IL-7; THYMOCYTES; REGION	The diversity of the T cell receptor repertoire is generated by rearrangement of gene elements in immature thymocytes. To identify a thymic signal that induces this rearrangement, a variety of agents were tested for their ability to induce rearrangement of the T cell receptor beta gene in suspensions of thymocytes from mouse embryos at day 14 of gestation. Of 16 agents tested, only interleukin-7 (IL-7) induced V(D)J gene rearrangement and sustained expression of the RAG-1 and RAG-2 genes, which are known to control rearrangement. These data implicate IL-7, a cytokine that is abundantly expressed in embryonic thymus, in driving gene rearrangement during early T cell development.	NCI,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MUEGGE, K (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702, USA.			durum, scott/0000-0003-1307-9582				ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BLACKWELL TK, 1989, ANNU REV GENET, V23, P605, DOI 10.1146/annurev.ge.23.120189.003133; BORN W, 1985, P NATL ACAD SCI USA, V82, P2925, DOI 10.1073/pnas.82.9.2925; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; GASCOIGNE NRJ, 1984, NATURE, V310, P387, DOI 10.1038/310387a0; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HENNEY CS, 1989, IMMUNOL TODAY, V10, P170, DOI 10.1016/0167-5699(89)90175-8; KAVALER J, 1984, NATURE, V310, P421, DOI 10.1038/310421a0; KINGSTON R, 1985, NATURE, V317, P811, DOI 10.1038/317811a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; MUEGGE K, UNPUB; MUEGGE K, IN PRESS P NATL ACAD; Murray R, 1989, Int Immunol, V1, P526, DOI 10.1093/intimm/1.5.526; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PARK LS, 1990, J EXP MED, V171, P1073, DOI 10.1084/jem.171.4.1073; SAMARIDIS J, 1991, EUR J IMMUNOL, V21, P453, DOI 10.1002/eji.1830210230; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SUDA T, 1991, J IMMUNOL, V146, P3068; WATSON JD, 1989, J IMMUNOL, V143, P1215; WILES MV, 1992, EUR J IMMUNOL, V22, P1037, DOI 10.1002/eji.1830220424; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	25	204	206	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					93	95		10.1126/science.7686307	http://dx.doi.org/10.1126/science.7686307			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	7686307	Green Submitted			2022-12-28	WOS:A1993LK43400039
J	WAGNER, RW; MATTEUCCI, MD; LEWIS, JG; GUTIERREZ, AJ; MOULDS, C; FROEHLER, BC				WAGNER, RW; MATTEUCCI, MD; LEWIS, JG; GUTIERREZ, AJ; MOULDS, C; FROEHLER, BC			ANTISENSE GENE INHIBITION BY OLIGONUCLEOTIDES CONTAINING C-5 PROPYNE PYRIMIDINES	SCIENCE			English	Article							EXPRESSION; RNA	Phosphorothioate oligodeoxynucleotides containing the C-5 propyne analogs of uridine and cytidine bind RNA with high affinity and are potent antisense inhibitors of gene expression. In a cellular assay, gene-specific antisense inhibition occurred at nanomolar concentrations of oligonucleotide, was dose-dependent and exquisitely sensitive to sequence mismatches, and was correlated with the melting temperature and length of oligonucleotide. Activity was independent of RNA target site and cell type but was detectable only when the oligonucleotides were microinjected or delivered with cell-permeabilizing agents. These oligonucleotides may have important applications in therapy and in studies of gene function.			WAGNER, RW (corresponding author), GILEAD SCI INC,353 LAKESIDE DR,FOSTER CITY,CA 94404, USA.							ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BISCHOFBERGER N, 1992, SEMIN VIROL, V3, P57; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; DRAPER KG, 1991, Patent No. 12811; FISEHR TL, IN PRESS NUCLEIC ACI; FROEHLER BC, 1992, TETRAHEDRON LETT, V33, P5307, DOI 10.1016/S0040-4039(00)79079-4; FROEHLER BC, 1993, TETRAHEDRON LETT, V34, P1003, DOI 10.1016/S0040-4039(00)77476-4; FROEHLER BC, 1993, PROTOCOLS OLIGONUCLE, P63; GRAESSMANN M, 1991, NUCLEIC ACIDS RES, V19, P53, DOI 10.1093/nar/19.1.53; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; IRIBARREN AM, 1990, P NATL ACAD SCI USA, V87, P7747, DOI 10.1073/pnas.87.19.7747; ROSOLEN A, 1990, CANCER RES, V50, P6316; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; STEIN CA, 1991, PHARMACOL THERAPEUT, V52, P365, DOI 10.1016/0163-7258(91)90032-H; TACK LC, 1989, J VIROL, V63, P3962; YOUNG S, 1991, NUCLEIC ACIDS RES, V19, P2463, DOI 10.1093/nar/19.9.2463	17	401	456	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 4	1993	260	5113					1510	1513		10.1126/science.7684856	http://dx.doi.org/10.1126/science.7684856			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF058	7684856				2022-12-28	WOS:A1993LF05800038
J	MURGATROYD, FD; CAMM, AJ				MURGATROYD, FD; CAMM, AJ			ATRIAL ARRHYTHMIAS	LANCET			English	Article							SINUS RHYTHM; ANTIARRHYTHMIC DRUGS; VENTRICULAR RATE; FIBRILLATION; FLUTTER; FLECAINIDE; THERAPY; CARDIOVERSION; MAINTENANCE; FRAMINGHAM		ST GEORGE HOSP, SCH MED, DEPT CARDIOL SCI, CRANMER TERR, LONDON SW17 0RE, ENGLAND	St Georges University London								Allessie M, 1985, CARDIAC ELECTROPHYSI, P265, DOI DOI 10.1016/J.HRTHM.2012.03.008; ANDERSON JL, 1989, CIRCULATION, V80, P1557, DOI 10.1161/01.CIR.80.6.1557; [Anonymous], 1989, NEW ENGL J MED, V321, P406; ANTMAN EM, 1990, J AM COLL CARDIOL, V15, P698, DOI 10.1016/0735-1097(90)90649-A; ARNOLD AZ, 1992, J AM COLL CARDIOL, V19, P851, DOI 10.1016/0735-1097(92)90530-Z; BAILY D, 1992, J AM COLL CARDIOL, V19, P41; BIGGER JT, 1985, AM J CARDIOL, V55, P623, DOI 10.1016/0002-9149(85)90125-0; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; COUMEL P, 1978, ARCH MAL COEUR VAISS, V71, P645; COX JL, 1991, J THORAC CARDIOV SUR, V101, P569, DOI 10.1016/s0022-5223(19)36684-x; COX JL, 1991, J THORAC CARDIOV SUR, V101, P406, DOI 10.1016/s0022-5223(19)36723-6; CRAWFORD W, 1989, AM J MED, V86, P663, DOI 10.1016/0002-9343(89)90440-3; FALK RH, 1991, ANN INTERN MED, V114, P573, DOI 10.7326/0003-4819-114-7-573; FISHER JD, 1990, ATRIAL ARRHYTHMIAS C, P400; FLEG JL, 1982, CHEST, V81, P302, DOI 10.1378/chest.81.3.302; GILLETTE PC, 1985, JAMA-J AM MED ASSOC, V253, P391, DOI 10.1001/jama.253.3.391; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; LEVY S, 1992, CIRCULATION, V86, P1415, DOI 10.1161/01.CIR.86.5.1415; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MOE GK, 1962, ARCH INT PHARMACOD T, V140, P183; MURGATROYD FD, 1993, J AM COLL CARDIOL, V21, P380; MURGATROYD FD, 1993, J AM COLL CARDIOL, V21, P478; NATHAN AW, 1987, CLIN CARDIOL, V10, P317, DOI 10.1002/clc.4960100505; OLSHANSKY B, 1990, J AM COLL CARDIOL, V16, P1639, DOI 10.1016/0735-1097(90)90314-F; OLSHANSKY B, 1988, J AM COLL CARDIOL, V11, P359, DOI 10.1016/0735-1097(88)90102-7; PETERSEN P, 1989, LANCET, V1, P175; PRITCHETT ELC, 1991, AM J CARDIOL, V67, P976, DOI 10.1016/0002-9149(91)90170-P; RAWLES JM, 1990, BRIT HEART J, V63, P225; RAWLES JM, 1990, BRIT HEART J, V63, P157; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; SUTTORP MJ, 1990, J AM COLL CARDIOL, V16, P1722, DOI 10.1016/0735-1097(90)90326-K; VANGELDER IC, 1991, AM J CARDIOL, V68, P41, DOI 10.1016/0002-9149(91)90707-R; WELLS JL, 1979, CIRCULATION, V60, P665, DOI 10.1161/01.CIR.60.3.665; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973	37	117	120	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 22	1993	341	8856					1317	1322						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD253	7684105				2022-12-28	WOS:A1993LD25300012
J	TAUB, DD; CONLON, K; LLOYD, AR; OPPENHEIM, JJ; KELVIN, DJ				TAUB, DD; CONLON, K; LLOYD, AR; OPPENHEIM, JJ; KELVIN, DJ			PREFERENTIAL MIGRATION OF ACTIVATED CD4+ AND CD8+ T-CELLS IN RESPONSE TO MIP-1-ALPHA AND MIP-1-BETA	SCIENCE			English	Article							LANGERHANS CELLS; FLUORESCEIN ISOTHIOCYANATE; ADHESION RECEPTORS; CYTOKINE FAMILY; DENDRITIC CELLS; LYMPHOCYTES-T; ANTIGEN; INHIBITION; CHEMOTAXIS; SKIN	Recombinant human macrophage inflammatory protein-1alpha (rhMIP-1alpha) and rhMIP-1beta were potent chemoattractants of human T lymphocytes. These rhMIP-1 cytokines attracted only T cells activated by monoclonal antibody to CD3 and did not attract unstimulated lymphocytes. Phenotypic analysis revealed that CD4+ T cells were capable of migrating in response to rhMIP-1beta, whereas rhMIP-1alpha induced chemotaxis of predominantly CD8+ T lymphocytes. Activated naive and memory T cells also migrated in response to rhMIP-1 cytokines. Furthermore, these cytokines enhanced the ability of T cells to bind to an endothelial cell monolayer. These results suggest that rhMIP-1 cytokines preferentially recruit specific T cell subsets during the evolution of the immune response.	NCI,FCRDC,BIOL RESPONSE MODIFIER PROGRAM,EXPTL IMMUNOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TAUB, DD (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIER PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702, USA.		Lloyd, Andrew/AAF-6071-2022; Lloyd, Andrew/AFJ-8960-2022; Lloyd, Andrew/E-7334-2017	Lloyd, Andrew/0000-0001-6277-8887; Lloyd, Andrew/0000-0001-6277-8887; 	PHS HHS [N01-C0-74102] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIBA S, 1990, J IMMUNOL, V145, P2791; BACON KB, 1989, BIOCHEM BIOPH RES CO, V165, P349, DOI 10.1016/0006-291X(89)91076-0; CENTER DM, 1983, J IMMUNOL, V128, P2563; CONLON KC, 1992, J IMMUNOL, V149, P3278; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; HYENS RO, 1992, CELL, V69, P11; KORNFELD H, 1985, J IMMUNOL, V134, P3887; KUDO C, 1991, J IMMUNOL, V147, P2196; LARSEN C, 1990, PROG CLIN BIOL RES, V349, P419; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; MACATONIA SE, 1986, IMMUNOLOGY, V59, P509; MACATONIA SE, 1987, J EXP MED, V166, P1654, DOI 10.1084/jem.166.6.1654; MIOSSEC P, 1984, J IMMUNOL, V133, P2007; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NAPOLITANO M, 1990, J EXP MED, V173, P285; OH KO, 1991, J IMMUNOL, V147, P2978; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PILARO AM, 1990, J IMMUNOL METHODS, V135, P213, DOI 10.1016/0022-1759(90)90275-Z; RUSSELL RJ, 1975, NATURE, V256, P646, DOI 10.1038/256646a0; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SILBERBERGSINAKIN I, 1976, CELL IMMUNOL, V25, P137, DOI 10.1016/0008-8749(76)90105-2; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAUB DD, UNPUB; TURKA LA, 1990, J IMMUNOL, V144, P1646	28	742	752	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 16	1993	260	5106					355	358		10.1126/science.7682337	http://dx.doi.org/10.1126/science.7682337			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KX800	7682337				2022-12-28	WOS:A1993KX80000039
J	NURCOMBE, V; FORD, MD; WILDSCHUT, JA; BARTLETT, PF				NURCOMBE, V; FORD, MD; WILDSCHUT, JA; BARTLETT, PF			DEVELOPMENTAL REGULATION OF NEURAL RESPONSE TO FGF-1 AND FGF-2 BY HEPARAN-SULFATE PROTEOGLYCAN	SCIENCE			English	Article							FIBROBLAST GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; CELL-SURFACE; BASEMENT-MEMBRANE; PRECURSOR CELLS; EXPRESSION; RECEPTOR; DIFFERENTIATION; NEURONS	Murine neural precursor cells and cell lines derived from them are stimulated by members of the heparin-binding fibroblast growth factor (FGF) family. The activity of FGF is regulated by heparan sulfate proteoglycans (HSPGs), and this interaction is an essential prerequisite for the binding of growth factor to the signal transducing receptors. Messenger RNA for FGF-2 was detectable in the neuroepithelium at embryonic day 9, and the HSPGs produced by these cells at this time preferentially bound FGF-2. However, at embryonic day 11, when messenger RNA for FGF-1 was first detectable, there was a switch in the binding specificity of the HSPG to FGF-1. Thus, a single species of HSPG undergoes a rapid, tightly controlled change in growth factor-binding specificity concomitant with the temporal expression of the FGFs.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute	NURCOMBE, V (corresponding author), UNIV MELBOURNE,DEPT ANAT & CELL BIOL,PARKVILLE,VIC 3052,AUSTRALIA.		Bartlett, Perry/F-3813-2012					ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ANY AH, 1990, BIOCHEM J, V265, P461; BARTLETT PF, 1988, P NATL ACAD SCI USA, V85, P3255, DOI 10.1073/pnas.85.9.3255; BERNFIELD ME, 1992, ANN REV CELL BIOL, V8, P1; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; COLE GJ, 1989, EXP CELL RES, V182, P44, DOI 10.1016/0014-4827(89)90278-4; EDGAR D, 1988, J CELL BIOL, V106, P1299, DOI 10.1083/jcb.106.4.1299; ELDE R, 1991, NEURON, V7, P349, DOI 10.1016/0896-6273(91)90288-B; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; Flaumenhaft R, 1991, CURR OPIN CELL BIOL, V3, P817, DOI 10.1016/0955-0674(91)90055-4; FU YM, 1991, NEURON, V114, P1261; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KILPATRICK T, 1993, NEURON, V10, P1; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; MATTHEW WD, 1985, J NEUROSCI, V5, P1842; MURPHY M, 1990, J NEUROSCI RES, V25, P463, DOI 10.1002/jnr.490250404; NOONAN DM, 1988, J BIOL CHEM, V263, P16379; NURCOMBE V, 1991, SOC NEUR ABSTR, V105, P553; NURCOMBE V, UNPUB; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHNURCH H, 1991, DEVELOPMENT, V111, P1143; SOROKA CJ, 1991, J CELL BIOL, V113, P1231, DOI 10.1083/jcb.113.5.1231; THOMAS D, 1991, DEV BRAIN RES, V59, P117, DOI 10.1016/0165-3806(91)90091-V; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	35	386	406	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					103	106		10.1126/science.7682010	http://dx.doi.org/10.1126/science.7682010			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	7682010				2022-12-28	WOS:A1993KV42300039
J	GETHER, U; JOHANSEN, TE; SNIDER, RM; LOWE, JA; NAKANISHI, S; SCHWARTZ, TW				GETHER, U; JOHANSEN, TE; SNIDER, RM; LOWE, JA; NAKANISHI, S; SCHWARTZ, TW			DIFFERENT BINDING EPITOPES ON THE NK1 RECEPTOR FOR SUBSTANCE-P AND A NONPEPTIDE ANTAGONIST	NATURE			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTORS; LIGAND-BINDING; SPECIFICITY; EXPRESSION; INHIBITORS; AGONIST; SITES; CDNA	NON-PEPTIDE ligands for peptide receptors have been discovered in several systems through file screening programs1-6, but the mechanism of action for these candidate drugs is obscure as they do not chemically resemble the native peptides. The compound CP 96345 is a high-affinity, non-peptide antagonist of the substance P (NK1) receptor4,5,7, which is important in pain perception and neurogenic inflammation8-11. Here we identify epitopes on the NK1 receptor responsible for the specific binding of CP 96345 by systematic exchange of corresponding segments between the NK1 receptor and the homologous NK3 (neurokinin B) receptor, which does not bind the non-peptide ligand. Non-conserved residues, in two epitopes around the top of transmembrane segment V and in one epitope at the top of transmembrane segment VI, are essential for the specific action of CP 96345 on the NK1 receptor, but are surprisingly not important for the binding of the natural peptide ligand, substance P. Susceptibility to the non-peptide antagonists can be conveyed to the previously unresponsive NK3 receptor by mutational transfer of this discontinuous epitope from the NK1 receptor.	PFIZER INC, DIV CENT RES, DEPT EXPLORATORY MED CHEM, GROTON, CT 06340 USA; KYOTO UNIV, FAC MED, INST IMMUNOL, KYOTO 606, JAPAN	Pfizer; Kyoto University	GETHER, U (corresponding author), UNIV COPENHAGEN, DEPT CLIN BIOCHEM, MOLEC ENDOCRINOL LAB, RIGSHOSP 6321, BLEGDAMSVEJ 9, DK-2100 COPENHAGEN, DENMARK.			Schwartz, Thue W./0000-0002-0261-6904; Gether, Ulrik/0000-0002-0020-3807				BUCK SH, 1986, TRENDS PHARMACOL SCI, V7, P65, DOI 10.1016/0165-6147(86)90256-7; CHANG RSL, 1990, MOL PHARMACOL, V37, P347; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; DOHIMAWN HG, 1991, REV BIOCH, V60, P653; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; ENGBERG G, 1981, NATURE, V293, P222, DOI 10.1038/293222a0; FONG TM, 1992, J BIOL CHEM, V267, P25664; FREIDINGER RM, 1990, ALFRED BENZON SYMP S, V29, P389; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GETHER U, 1992, FEBS LETT, V296, P241, DOI 10.1016/0014-5793(92)80295-R; IVERSEN LL, 1990, ALFRED BENZON SYMP S, V29, P363; JOHANSEN TE, 1990, BIOCHEM BIOPH RES CO, V172, P1384, DOI 10.1016/0006-291X(90)91603-P; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAUFER R, 1985, P NATL ACAD SCI USA, V82, P7444, DOI 10.1073/pnas.82.21.7444; MCGILLIS JP, 1990, ANN NY ACAD SCI, V594, P85; MCLEAN S, 1991, SCIENCE, V251, P437, DOI 10.1126/science.1703324; MIZRAHI J, 1984, EUR J PHARMACOL, V99, P193, DOI 10.1016/0014-2999(84)90241-3; PERNOW B, 1983, PHARMACOL REV, V35, P85; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIGEMOTO R, 1990, J BIOL CHEM, V265, P623; SNIDER RM, 1991, P NATL ACAD SCI USA, V88, P10042, DOI 10.1073/pnas.88.22.10042; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; STRADER CD, 1988, J BIOL CHEM, V263, P10267; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WESS J, 1992, MOL PHARMACOL, V41, P369; YAMAMURA Y, 1991, SCIENCE, V252, P572, DOI 10.1126/science.1850553; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	28	235	235	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	1993	362	6418					345	348		10.1038/362345a0	http://dx.doi.org/10.1038/362345a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	7681152				2022-12-28	WOS:A1993KU17600061
J	SCHEITHAUER, W; ROSEN, H; KORNEK, GV; SEBESTA, C; DEPISCH, D				SCHEITHAUER, W; ROSEN, H; KORNEK, GV; SEBESTA, C; DEPISCH, D			RANDOMIZED COMPARISON OF COMBINATION CHEMOTHERAPY PLUS SUPPORTIVE CARE WITH SUPPORTIVE CARE ALONE IN PATIENTS WITH METASTATIC COLORECTALCANCER	BRITISH MEDICAL JOURNAL			English	Article							CANCER-PATIENTS; FOLINIC ACID; CELL-LINES; 5-FLUOROURACIL; LEUCOVORIN; CISPLATIN; FLUOROURACIL; CARCINOMA; QUALITY; HEAD	Objectives-To compare the length of survival and quality of life in patients given combination chemotherapy in addition to supportive care and in patients given only supportive care. Design-Randomised study. Setting-Gastrointestinal oncology departments. Patients-40 previously untreated patients with histologically confirmed, measurable colorectal cancer that was locally recurrent or metastatic. Interventions-Patients were allocated randomly to receive chemotherapy or only supportive care in a ratio of 2:1 according to performance status, metastatic disease of the liver, and weight loss in the six months before entering the study. Chemotherapy consisted of four week cycles of intravenous leucovorin (200 mg/m2/day) followed by 5-fluorouracil (550 mg/m2/day) and cisplatin (20 mg/m2/day), each drug being given on the first four days of the cycle. Main outcome measures-Length of survival and quality of life score with an optimised functional living index-cancer scale. Results-Overall survival was significantly longer for patients given chemotherapy (11.0 months) than for those receiving supportive care alone (5.0 months; p=0.006). Despite common association of chemotherapy with mild to moderate gastrointestinal symptoms, there was no significant difference between the two groups in global or subgroup quality of life scores. In patients with abnormal scores before treatment, quality of life seemed better in the chemotherapy arm. Conclusions-In this sample of patients with disseminated colorectal cancer the chemotherapy regimen was an effective form of palliative treatment.	HANUSCH HOSP,DEPT GASTROENTEROL,A-1140 VIENNA,AUSTRIA; WEINER NEUSTADT GEN HOSP,DEPT SURG,A-2700 WIENER NEUSTADT,AUSTRIA	WGKK - Hanusch Hospital	SCHEITHAUER, W (corresponding author), UNIV VIENNA,DEPT INTERNAL MED 1,DIV ONCOL,A-1090 VIENNA,AUSTRIA.							ARBUCK SG, 1989, CANCER, V63, P1036, DOI 10.1002/1097-0142(19890315)63:6+<1036::AID-CNCR2820631309>3.0.CO;2-K; DAVIS HL, 1982, CANCER-AM CANCER SOC, V50, P2638; ERLICHMAN C, 1988, J CLIN ONCOL, V6, P469, DOI 10.1200/JCO.1988.6.3.469; ETIENNE MC, 1991, BRIT J CANCER, V63, P372, DOI 10.1038/bjc.1991.88; GANZ PA, 1989, CANCER, V63, P1271, DOI 10.1002/1097-0142(19890401)63:7<1271::AID-CNCR2820630707>3.0.CO;2-6; HART L, 1989, P AN M AM SOC CLIN, V8, P43; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAVIN P, 1980, CANCER, V46, P1536, DOI 10.1002/1097-0142(19801001)46:7<1536::AID-CNCR2820460707>3.0.CO;2-K; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Moertel C.G., 1982, CANCER MED, P1830; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; POON MA, 1989, J CLIN ONCOL, V7, P1407, DOI 10.1200/JCO.1989.7.10.1407; PRESANT CA, 1990, J NATL CANCER I, V82, P322, DOI 10.1093/jnci/82.4.322; SCHEITHAUER W, 1991, CANCER, V67, P1294, DOI 10.1002/1097-0142(19910301)67:5<1294::AID-CNCR2820670504>3.0.CO;2-M; SCHEITHAUER W, 1989, ANTICANCER RES, V9, P1793; SCHEITHAUER W, 1992, P AN M AM SOC CLIN, V11, P195; SCHIPPER H, 1984, J CLIN ONCOL, V2, P472, DOI 10.1200/JCO.1984.2.5.472; VOKES EE, 1990, J CLIN ONCOL, V8, P241, DOI 10.1200/JCO.1990.8.2.241; 1992, J CLIN ONCOL, V6, P904	19	532	538	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1993	306	6880					752	755		10.1136/bmj.306.6880.752	http://dx.doi.org/10.1136/bmj.306.6880.752			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU173	7683942	Bronze, Green Published			2022-12-28	WOS:A1993KU17300021
J	HART, AC; KRAMER, H; ZIPURSKY, SL				HART, AC; KRAMER, H; ZIPURSKY, SL			EXTRACELLULAR DOMAIN OF THE BOSS TRANSMEMBRANE LIGAND ACTS AS AN ANTAGONIST OF THE SEV RECEPTOR	NATURE			English	Article							TYROSINE-KINASE RECEPTOR; DROSOPHILA RETINA; SEVENLESS PROTEIN; GROWTH-FACTOR; CELL FATE; SI-LOCUS; BRIDE; GENE; ENCODES; MOUSE	THE fate of the R7 photoreceptor cell in the Drosophila compound eye is established by a specific inductive interaction between the R8 photoreceptor neuron and the R7 precursor cell1. This induction is mediated by two cell-surface proteins: the ligand, bride of sevenless2 (boss), and sevenless (sev), a tyrosine-kinase receptor3-5 The structure of boss is unique for a ligand of a tyrosine-kinase receptor. It contains a large extracellular domain, seven transmembrane segments, and a carboxy-terminal cytoplasmic tail6,7. Here we report that: (1) boss activates tyrosine phosphorylation of the sev receptor; (2) the seven transmembrane domain of boss is necessary for its function; and (3) a soluble form of boss acts as an antagonist of the sev receptor both in vivo and in vitro.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT BIOL CHEM,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024	Howard Hughes Medical Institute; University of California System; University of California Los Angeles				Kramer, Helmut/0000-0002-1167-2676; Zipursky, Stephen/0000-0001-5630-7181				ANKELESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, SCIENCE, V243, P931, DOI 10.1126/science.2493159; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CAGAN RC, 1992, CELL, V69, P309; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JI I, 1991, J BIOL CHEM, V266, P13076; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	21	36	37	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 25	1993	361	6414					732	736		10.1038/361732a0	http://dx.doi.org/10.1038/361732a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KN789	7680109				2022-12-28	WOS:A1993KN78900059
J	UNWIN, N				UNWIN, N			NEUROTRANSMITTER ACTION - OPENING OF LIGAND-GATED ION CHANNELS	CELL			English	Review							NICOTINIC ACETYLCHOLINE-RECEPTOR; INHIBITORY GLYCINE RECEPTOR; AFFINITY BINDING-SITE; FUNCTIONAL EXPRESSION; TORPEDO-CALIFORNICA; H-3 CHLORPROMAZINE; ALPHA-SUBUNIT; AMINO-ACIDS; NONCOMPETITIVE BLOCKERS; PHOTOAFFINITY LIGAND				UNWIN, N (corresponding author), MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND.				NIGMS NIH HHS [GM44149] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANAND R, 1991, J BIOL CHEM, V266, P11192; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BETZ H, 1992, Q REV BIOPHYS, V25, P381, DOI 10.1017/S0033583500004340; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DANI JA, 1989, J NEUROSCI, V9, P884; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DENNIS M, 1986, FEBS LETT, V207, P243, DOI 10.1016/0014-5793(86)81497-1; DINGLEDINE R, 1992, J NEUROSCI, V12, P4080; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HERZ JM, 1989, J BIOL CHEM, V264, P12439; HEUSER JE, 1979, J CELL BIOL, V82, P150, DOI 10.1083/jcb.82.1.150; Hille B., 1992, IONIC CHANNELS EXCIT; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HUCHO F, 1986, FEBS LETT, V205, P137, DOI 10.1016/0014-5793(86)80881-X; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LANGOSCH D, 1991, BIOCHIM BIOPHYS ACTA, V1063, P36, DOI 10.1016/0005-2736(91)90350-H; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONTAL M, 1990, P NATL ACAD SCI USA, V87, P6929, DOI 10.1073/pnas.87.18.6929; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NODA M, 1983, NATURE, V301, P251, DOI 10.1038/301251a0; OIKI S, 1988, P NATL ACAD SCI USA, V85, P8703, DOI 10.1073/pnas.85.22.8703; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; PEDERSEN SE, 1992, J BIOL CHEM, V267, P10489; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; Role L W, 1992, Curr Opin Neurobiol, V2, P254, DOI 10.1016/0959-4388(92)90112-X; SCHMIEDEN V, 1992, EMBO J, V11, P2025, DOI 10.1002/j.1460-2075.1992.tb05259.x; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TIBBITTS TT, 1990, BIOPHYS J, V57, P1025, DOI 10.1016/S0006-3495(90)82621-7; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; UNWIN N, 1993, IN PRESS J MOL BIOL; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; VILLARROEL A, 1992, BIOPHYS J, V62, P209; WADA K, 1988, SCIENCE, V240, P330, DOI 10.1126/science.2832952; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0	72	185	185	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN	1993	72			S			31	41		10.1016/S0092-8674(05)80026-1	http://dx.doi.org/10.1016/S0092-8674(05)80026-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KL707	7679054				2022-12-28	WOS:A1993KL70700002
J	HARGREAVES, MR; FIROOZAN, S; FORFAR, JC				HARGREAVES, MR; FIROOZAN, S; FORFAR, JC			PRESCRIPTION OF REGULAR ASPIRIN IN PATIENTS WITH CHEST PAIN REFERRED TO A CARDIOLOGY OUTPATIENT-CLINIC	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANGINA; TRIAL				HARGREAVES, MR (corresponding author), JOHN RADCLIFFE HOSP, DEPT CARDIAC, OXFORD OX3 9DU, ENGLAND.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; CANNON PJ, 1988, LANCET, V1, P979; JUULMOLLER S, 1992, LANCET, V340, P1421, DOI 10.1016/0140-6736(92)92619-Q; RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835	4	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 25	1995	310	6982					777	777		10.1136/bmj.310.6982.777	http://dx.doi.org/10.1136/bmj.310.6982.777			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP609	7711583	Green Published			2022-12-28	WOS:A1995QP60900019
J	AZUMA, M; ITO, D; YAGITA, H; OKUMURA, K; PHILLIPS, JH; LANIER, LL; SOMOZA, C				AZUMA, M; ITO, D; YAGITA, H; OKUMURA, K; PHILLIPS, JH; LANIER, LL; SOMOZA, C			B70 ANTIGEN IS A 2ND LIGAND FOR CTLA-4 AND CD28	NATURE			English	Article							T-CELL ACTIVATION; COSTIMULATORY SIGNAL; LYMPHOCYTES-T; B-CELLS; EXPRESSION; AMPLIFICATION; SUPERFAMILY; MECHANISM; RECEPTOR; B7/BB-1	THE membrane antigen B7/BB1 (refs 1, 2) is expressed on activated B cells, macrophages and dendritic cells, and binds to a counter-receptor, CD28, expressed on T lymphocytes and thymocytes3. Interaction between CD28 and B7 results in potent costimulation of T-cell activation initiated through the CD3/T-cell receptor complex4,5. Discrepancies between results with anti-CD28 and anti-B7 antibodies have suggested the existence of a second ligand for CD28 and CTLA-4 (refs 3, 6-8). We have generated a monoclonal antibody, IT2, that reacts with a 70K glycoprotein (B70). B70 complementary DNA was cloned from a B-lymphoblastoid cell line library and encodes a new protein of the immunoglobulin superfamily with limited homology to B7. B70 is expressed on resting monocytes and dendritic cells and on activated, but not resting, T, NK and B lymphocytes. IT2 substantially inhibited the binding of a CTLA4-immunoglobulin fusion protein to human B-lymphoblastoid cell lines and, together with anti-B7 antibody, completely blocked CTLA-4 binding. Further IT2 efficiently inhibited primary allogeneic mixed lymphocyte responses. These findings indicate that B70 is a second ligand for CD28 and CTLA-4 and may play an important role for costimulation of T cells in a primary immune response.	UNIV TOKYO,FAC MED,DEPT ORAL & MAXILLOFACIAL SURG,BUNKYO KU,TOKYO 113,JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304	University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	AZUMA, M (corresponding author), JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,HONGO 2-1-1,BUNKYO KU,TOKYO 113,JAPAN.		Azuma, Miyuki/AAT-8928-2021; Lanier, Lewis L/E-2139-2014	Azuma, Miyuki/0000-0002-3529-4585; Lanier, Lewis L/0000-0003-1308-3952				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; AZUMA M, 1992, J IMMUNOL, V149, P1115; AZUMA M, 1993, J IMMUNOL, V150, P2091; AZUMA M, 1993, J EXP MED, V177, P845, DOI 10.1084/jem.177.3.845; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; DOMLO NK, 1991, EUR J IMMUNOL, V21, P1277; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LANIER L L, 1991, Methods (Orlando), V2, P192, DOI 10.1016/S1046-2023(05)80061-1; LANIER LL, 1988, J IMMUNOL, V141, P3478; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; NORTON SD, 1992, J IMMUNOL, V149, P1556; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; VALLE A, 1991, INT IMMUNOL, V3, P229, DOI 10.1093/intimm/3.3.229; YOKOCHI T, 1982, J IMMUNOL, V128, P823; YOUNG JW, 1992, J CLIN INVEST, V90, P229, DOI 10.1172/JCI115840	24	910	981	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					76	79		10.1038/366076a0	http://dx.doi.org/10.1038/366076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	7694153				2022-12-28	WOS:A1993MF00700058
J	LARDER, BA; KELLAM, P; KEMP, SD				LARDER, BA; KELLAM, P; KEMP, SD			CONVERGENT COMBINATION THERAPY CAN SELECT VIABLE MULTIDRUG-RESISTANT HIV-1 IN-VITRO	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITORS; HIGH-LEVEL RESISTANCE; NONNUCLEOSIDE INHIBITORS; ZIDOVUDINE AZT; TYPE-1; SENSITIVITY; REPLICATION; MUTATION; SUSCEPTIBILITIES	THE reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1) is the target for many inhibitors1. Amino-acid substitutions in functional regions of the enzyme that abolish reverse transcriptase activity also prevent HIV-1 replication2,3. But selection pressure by drugs such as AZT (3'-azido-3'-deoxythymidine, zidovudine)4-6, ddI(2',3'-dideoxyinosine)7,8 and non-nucleoside reverse transcriptase inhibitors (NNRTIs)9-14 causes outgrowth of resistant variants due to non-lethal mutations in the enzyme7,9-16. Reports of synergy17-19 and lack of cross-resistance between reverse transcriptase inhibitors (refs 7, 9, 10, 12-14, 17, 18, 20, 21), plus the reversal of AZT resistance by mutations induced by ddI7 and NNRTIs14, have indicated that specific drug combinations directed at reverse transcriptase might curtail resistance. Chow et al.22 extended this concept in a report that specific multiple combinations of resistance mutations in the reverse transcriptase can significantly impair HIV-1 replication. They concluded that evolutionary limitations may exist to prevent the emergence of multidrug resistance to inhibitors of reverse transcriptase22. We report here that HIV-1 co-resistant to AZT, ddI and the NNRTI nevirapine23 can be readily selected in cell culture starting with dual AZT- and ddI-resistant virus. We found no evidence for 'replication incompatible' combinations of resistance mutations, although a mutation (M184-->V) conferring oxathiolane-cytosine nucleoside resistance in reverse transcriptase24,25 completely suppressed AZT resistance in a triple-resistant background. These in vitro observations suggest that triple drug combination therapy might ultimately result in co-resistant HIV-1, although they do not preclude assessment of such combinations for treatment of HIV-1 disease.			LARDER, BA (corresponding author), WELLCOME RES LABS,ANTIVIRAL THERAPEUT RES UNIT,LANGLEY COURT,BECKENHAM BR3 3BS,KENT,ENGLAND.		Larder, Brendan/AAB-3106-2020	Kellam, Paul/0000-0003-3166-4734				BALZARINI J, 1993, VIROLOGY, V192, P246, DOI 10.1006/viro.1993.1027; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; CHOW YK, 1993, NATURE, V361, P650, DOI 10.1038/361650a0; CHOW YK, 1993, NATURE, V364, P679, DOI 10.1038/364679a0; DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119; DUEWEKE TJ, 1993, P NATL ACAD SCI USA, V90, P4713, DOI 10.1073/pnas.90.10.4713; EMINI EA, 1993, NATURE, V364, P679, DOI 10.1038/364679b0; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; JOHNSON VA, 1991, J INFECT DIS, V164, P646, DOI 10.1093/infdis/164.4.646; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1992, ANTIMICROB AGENTS CH, V36, P2664, DOI 10.1128/AAC.36.12.2664; LARDER BA, 1990, ANTIMICROB AGENTS CH, V34, P436, DOI 10.1128/AAC.34.3.436; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Larder Brendan A., 1993, P527; MCLEOD GX, 1992, ANTIMICROB AGENTS CH, V36, P920, DOI 10.1128/AAC.36.5.920; MELLORS JW, 1992, MOL PHARMACOL, V41, P446; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653	29	145	155	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					451	453		10.1038/365451a0	http://dx.doi.org/10.1038/365451a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	7692302				2022-12-28	WOS:A1993LZ63300059
J	FUKUNAGA, R; ISHIZAKAIKEDA, E; NAGATA, S				FUKUNAGA, R; ISHIZAKAIKEDA, E; NAGATA, S			GROWTH AND DIFFERENTIATION SIGNALS MEDIATED BY DIFFERENT REGIONS IN THE CYTOPLASMIC DOMAIN OF GRANULOCYTE-COLONY-STIMULATING FACTOR-RECEPTOR	CELL			English	Article							HEMATOPOIETIC-CELLS; HUMAN MYELOPEROXIDASE; MOLECULAR-CLONING; MYELOID-LEUKEMIA; CHROMOSOMAL GENE; EXPRESSION; MACROPHAGE; CDNA; IDENTIFICATION; PROLIFERATION	Granulocyte colony-stimulating factor (G-CSF) is a cytokine that regulates the proliferation and differentiation of neutrophils. The G-CSF receptor (G-CSFR) is a member of the hemopoietic growth factor receptor family. A G-CSFR expression plasmid was introduced into interleukin-3 (IL-3)-dependent mouse myeloid precursor FDC-P1 cells that normally do not respond to G-CSF. G-CSF stimulated proliferation of the transformants, down-regulated Thy-1 and F4/80 antigens on the cell surface, and induced expression of neutrophil-specific genes such as myeloperoxidase (MPO) and leukocyte elastase. On the other hand, neither granulocyte/macrophage colony-stimulating factor (GM-CSF) nor IL-3 induced MPO gene expression, but they inhibited G-CSFR-mediated MPO gene expression. These results suggested that the G-CSFR, but not the IL-3/GM-CSF receptors, transduced the neutrophilic differentiation signal into cells. Mutational analysis of the G-CSFR indicated that the N-terminal region of its cytoplasmic domain is sufficient to transduce the proliferation signal into cells, while the C-terminal region plays an essential role in transducing the differentiation signal.	OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN				Fukunaga, Rikiro/CAG-2891-2022; Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BAINTON DF, 1990, HEMATOLOGY, P761; BASCH RS, 1982, EUR J IMMUNOL, V12, P359, DOI 10.1002/eji.1830120502; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P1556; DEMETRI GD, 1991, BLOOD, V78, P2791; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; HOLMES KL, 1988, IMMUNOL TODAY, V9, P344, DOI 10.1016/0167-5699(88)91335-7; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P1232; LEE KH, 1991, J EXP MED, V173, P1257, DOI 10.1084/jem.173.5.1257; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; METCALF D, 1992, P NATL ACAD SCI USA, V89, P2819, DOI 10.1073/pnas.89.7.2819; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORISHITA K, 1987, J BIOL CHEM, V262, P15208; MORISHITA K, 1987, J BIOL CHEM, V262, P3844; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAGATA S, 1993, GROWTH FACTORS, V8, P99, DOI 10.3109/08977199309046930; NAGATA S, 1991, Progress in Growth Factor Research, V3, P131, DOI 10.1016/S0955-2235(05)80004-3; NAGATA S, 1990, HDB EXPT PHARM, V95, P699; NICOLA NA, 1983, J BIOL CHEM, V258, P9017; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; OKANO K, 1987, J BIOCHEM-TOKYO, V102, P13, DOI 10.1093/oxfordjournals.jbchem.a122024; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAKAHASHI H, 1988, J BIOL CHEM, V263, P2543; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TESHIMA T, 1990, EXP HEMATOL, V18, P316; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VENTURELLI D, 1989, NUCLEIC ACIDS RES, V17, P5852, DOI 10.1093/nar/17.14.5852; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	45	255	258	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 24	1993	74	6					1079	1087		10.1016/0092-8674(93)90729-A	http://dx.doi.org/10.1016/0092-8674(93)90729-A			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LY493	7691413				2022-12-28	WOS:A1993LY49300014
J	BENNETT, MK; GARCIAARRARAS, JE; ELFERINK, LA; PETERSON, K; FLEMING, AM; HAZUKA, CD; SCHELLER, RH				BENNETT, MK; GARCIAARRARAS, JE; ELFERINK, LA; PETERSON, K; FLEMING, AM; HAZUKA, CD; SCHELLER, RH			THE SYNTAXIN FAMILY OF VESICULAR TRANSPORT RECEPTORS	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; SYNAPTIC VESICLES; GOLGI-COMPLEX; RAT-BRAIN; YEAST; SECRETION; CLEAVAGE; ER; SYNAPTOBREVIN; PURIFICATION	Syntaxins A and B are nervous system-specific proteins implicated in the docking of synaptic vesicles with the presynaptic plasma membrane. A family of syntaxin-related proteins from rat has been identified that shares 23%-84% amino acid identity. Each of the six syntaxins terminate with a carboxy-terminal hydrophobic domain that anchors the protein on the cytoplasmic surface of cellular membranes. The syntaxins display a broad tissue distribution and, when expressed in COS cells, are targeted to different subcellular compartments. Microinjection studies suggest that the nervous system-specific syntaxin 1A is important for calcium-regulated secretion from neuroendocrine PC12 cells. These results indicate that the syntaxins are a family of receptors for intracellular transport vesicles and that each target membrane may be identified by a specific member of the syntaxin family.			BENNETT, MK (corresponding author), STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305, USA.							ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHIN A, 1993, IN PRESS GENE; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; ELFERINK LA, 1992, J BIOL CHEM, V267, P5768; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FENG ZH, 1992, J BIOL CHEM, V267, P21808; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HIRAI Y, 1992, CELL, V69, P471, DOI 10.1016/0092-8674(92)90448-L; HIRAI Y, 1993, CELL, V73, P426, DOI 10.1016/0092-8674(93)90129-E; INOUE A, 1992, J BIOL CHEM, V267, P10613; JONES E, 1976, GENETICS, V85, P23; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MORITA T, 1992, BIOMED RES-TOKYO, V13, P357, DOI 10.2220/biomedres.13.357; ORPINS A, 1993, J CELL BIOL, V121, P49; PELHAM HRB, 1993, CELL, V73, P425, DOI 10.1016/0092-8674(93)90128-D; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPRING J, 1993, TRENDS BIOCHEM SCI, V18, P124, DOI 10.1016/0968-0004(93)90018-I; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WARREN G, 1989, NATURE, V342, P857, DOI 10.1038/342857a0	41	609	623	1	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					863	873		10.1016/0092-8674(93)90466-4	http://dx.doi.org/10.1016/0092-8674(93)90466-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	7690687				2022-12-28	WOS:A1993LX29200012
J	WEISSMAN, JS; KIM, PS				WEISSMAN, JS; KIM, PS			EFFICIENT CATALYSIS OF DISULFIDE BOND REARRANGEMENTS BY PROTEIN DISULFIDE-ISOMERASE	NATURE			English	Article							PANCREATIC TRYPSIN-INHIBITOR; DISULFIDE ISOMERASE; ENDOPLASMIC-RETICULUM; PEPTIDE BINDING; KINETIC ROLE; INTERMEDIATE; RESONANCE; BPTI	PROTEIN disulphide isomerase (PDI)1,2 is a highly abundant and ubiquitous eukaryotic protein that is essential for viability in yeast3,4. Although PDI is thought to catalyse disulphide bond formation and isomerization during protein biosynthesis, PDI has been found previously to have only moderate effects (approximately 25-fold) on the rate of oxidative folding of proteins in vitro. In addition, PDI has been implicated in several apparently unrelated cellular functions3. For example, PDI is the beta-subunit of prolyl 4-hydroxylase 5 and is part of the trigylceride transfer complex6. The oxidative folding of bovine pancreatic trypsin inhibitor (BPTI) is slow and inefficient in vitro7-11. Here we report that PDI increases by a factor of 3,000-6,000 the rates of folding of kinetically trapped BPTI folding intermediates, in which native structure impedes disulphide bond formation. By contrast, PDI has only small effects on the rate of disulphide bond formation in intermediates that are oxidized readily in the absence of PDI. These results suggest that an important function of PDI is to catalyse disulphide bond formation and rearrangements within kinetically trapped, structured folding intermediates.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	WEISSMAN, JS (corresponding author), MIT,DEPT PHYS,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02139, USA.							CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1987, J MOL BIOL, V194, P11, DOI 10.1016/0022-2836(87)90711-X; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; DEISENHOFER J, 1975, ACTA CRYSTALLOGR B, V31, P238, DOI 10.1107/S0567740875002415; EIGENBROT C, 1990, PROTEIN ENG, V3, P591, DOI 10.1093/protein/3.7.591; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREEDMAN RB, 1992, PROTEIN FOLDING, P481; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KAJI EH, IN PRESS J BIOL CHEM; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MORJANA NA, 1993, P NATL ACAD SCI USA, V90, P2107, DOI 10.1073/pnas.90.6.2107; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; STASSINOPOULOU CI, 1984, EUR J BIOCHEM, V145, P423, DOI 10.1111/j.1432-1033.1984.tb08571.x; STATES DJ, 1984, J MOL BIOL, V174, P411, DOI 10.1016/0022-2836(84)90345-0; VANMIERLO CPM, 1991, J MOL BIOL, V222, P353, DOI 10.1016/0022-2836(91)90216-S; VENETIANER P, 1963, BIOCHIM BIOPHYS ACTA, V67, P166; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	28	191	195	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					185	188		10.1038/365185a0	http://dx.doi.org/10.1038/365185a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	7690463				2022-12-28	WOS:A1993LW44200055
J	WJST, M; REITMEIR, P; DOLD, S; WULFF, A; NICOLAI, T; VONLOEFFELHOLZCOLBERG, EF; VONMUTIUS, E				WJST, M; REITMEIR, P; DOLD, S; WULFF, A; NICOLAI, T; VONLOEFFELHOLZCOLBERG, EF; VONMUTIUS, E			ROAD TRAFFIC AND ADVERSE-EFFECTS ON RESPIRATORY HEALTH IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							AIR-POLLUTION; LUNG-FUNCTION; PULMONARY-FUNCTION; PASSIVE SMOKING; SYMPTOMS; ENVIRONMENT; CHILDHOOD; EXPOSURE	Objectives-To examine whether road traffic in a big city has a direct effect on pulmonary function and respiratory symptoms in children. Design-Cross sectional study. Setting-Of all 7445 fourth grade children (aged 9-11 years) in Munich, 6537 were examined. Of the children with German nationality and the same residence during the past five years and known exposure data, 4678 questionnaires and 4320 pulmonary function tests could be analysed. Main outcome measures-Variables of pulmonary function by forced expiration and respiratory symptoms reported in a questionnaire; census data on car traffic collected in the school district. Results-Density of car traffic ranged from 7000 to 125000 cars per 24 hours. Multiple regression analysis of peak expiratory flow showed a significant decrease of 0.71% (95% confidence interval 1.08% to 0.33%) per increase of 25000 cars daily passing through the school district on the main road. Maximum expiratory flow when 25% vital capacity had been expired was decreased by 0.68% (1.11% to 0.25%). In contrast, response to cold air challenge was not increased. The adjusted odds ratio for the cumulative prevalence of recurrent wheezing with the same exposure was 1.08 (1.01 to 1.16). Cumulative prevalence of recurrent dyspnoea was increased, with an odds ratio of 1.10 (1.00 to 1.20). Lifetime prevalence of asthma (odds ratio 1.04; 0.89 to 1.21) and recurrent bronchitis (1.05; 0.98 to 1.12) were not significantly increased. Conclusions-High rates of road traffic diminish forced expiratory flow and increase respiratory symptoms in children.	TECH UNIV MUNICH,INST UMWELTHYG & TOXIKOL,D-80636 MUNICH,GERMANY; UNIV MUNICH,DR VON HAUNERSCHE KINDERKLIN,D-80337 MUNICH,GERMANY; STADT GESUNDHEITSBEHORDE,D-80335 MUNICH,GERMANY	Technical University of Munich; University of Munich	WJST, M (corresponding author), GSF,FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT,INST MED INFORMAT & SYST FORSCH,POB 1129,D-85758 OBERSCHLEISSHEIM,GERMANY.							AMES RG, 1984, ARCH ENVIRON HEALTH, V39, P389, DOI 10.1080/00039896.1984.10545870; AROSSA W, 1987, ARCH ENVIRON HEALTH, V42, P170, DOI 10.1080/00039896.1987.9935817; Atkinson R., 1988, AIR POLLUTION AUTOMO, P99; BROMBERG PA, 1988, AIR POLLUTION AUTOMO, P465; BURCHFIEL CM, 1986, AM REV RESPIR DIS, V133, P966; CHARPIN D, 1988, ARCH ENVIRON HEALTH, V43, P22, DOI 10.1080/00039896.1988.9934369; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; DOLD S, 1992, MONATSSCHR KINDERH, V140, P763; EVANS RG, 1988, AM J IND MED, V14, P25, DOI 10.1002/ajim.4700140105; FARLEY JM, 1992, ANNU REV PHARMACOL, V32, P67, DOI 10.1146/annurev.pharmtox.32.1.67; GAMBLE J, 1987, ENVIRON RES, V42, P201, DOI 10.1016/S0013-9351(87)80022-1; GODLEE F, 1991, BRIT MED J, V303, P1539, DOI 10.1136/bmj.303.6816.1539; GOREN AI, 1988, ENVIRON RES, V46, P107, DOI 10.1016/S0013-9351(88)80025-2; HIGGINS ITT, 1990, AM REV RESPIR DIS, V141, P1136, DOI 10.1164/ajrccm/141.5_Pt_1.1136; HOPPENBROUWERS T, 1990, LUNG S, V68, P35; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; KOENIG JQ, 1988, J ALLERGY CLIN IMMUN, V81, P1055, DOI 10.1016/0091-6749(88)90180-7; MURAKAMI M, 1990, Journal of Human Ergology, V19, P101; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204, DOI 10.1093/oxfordjournals.aje.a116073; NGANGA LW, 1992, AM REV RESPIR DIS, V145, P48, DOI 10.1164/ajrccm/145.1.48; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565, DOI 10.1164/ajrccm/147.3.565; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53, DOI 10.1080/00039896.1993.9938393; ROMIEU I, 1992, AM J EPIDEMIOL, V136, P1524, DOI 10.1093/oxfordjournals.aje.a116474; SAMET JM, 1933, TOXICOLOGY LUNG, P311; SAMSON PJ, 1988, POLLUTION AUTOMOBILE, P77; SCHWARTZ J, 1992, ARCH ENVIRON HEALTH, V47, P116, DOI 10.1080/00039896.1992.10118764; SPEIZER FE, 1973, ARCH ENVIRON HEALTH, V26, P313, DOI 10.1080/00039896.1973.10666289; ULFVARSON U, 1990, AM J IND MED, V17, P341, DOI 10.1002/ajim.4700170306; VEDAL S, 1987, AM J PUBLIC HEALTH, V77, P694, DOI 10.2105/AJPH.77.6.694; VONMUTIUS E, 1991, MUNCHEN MED WOCHEN, V133, P675; WARDLAW AJ, 1993, CLIN EXP ALLERGY, V23, P81, DOI 10.1111/j.1365-2222.1993.tb00303.x; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; Yokoyama Y, 1985, Tokai J Exp Clin Med, V10, P379; 1989, SAS USERS GUIDE STAT; 1987, AIR QUALITY GUIDELIN; 1990, UMWELTATLAS MUNCHEN; 1990, BELASTUNGSBEBIET MUN; 1988, BERICHT IMMISSIONSME; 1985, AM REV RESPIR DIS, V131, P666; 1990, STATISCHE TASCHENBUC	40	325	330	0	35	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1993	307	6904					596	600		10.1136/bmj.307.6904.596	http://dx.doi.org/10.1136/bmj.307.6904.596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW149	7691304	Green Published, Bronze			2022-12-28	WOS:A1993LW14900016
J	MULLIGAN, MS; PAULSON, JC; DEFREES, S; ZHENG, ZL; LOWE, JB; WARD, PA				MULLIGAN, MS; PAULSON, JC; DEFREES, S; ZHENG, ZL; LOWE, JB; WARD, PA			PROTECTIVE EFFECTS OF OLIGOSACCHARIDES IN P-SELECTIN-DEPENDENT LUNG INJURY	NATURE			English	Article							ADHESION; NEUTROPHILS; GMP-140; ACTIVATION	NEUTROPHIL recruitment into tissues is a multistep process involving sequential engagement of adhesion molecules, including selectins (E,P,L), which are reactive with oligosaccharides, and the family of beta2 integrins which are reactive with endothelial intercellular adhesion molecules1-3. These processes result in the initial rolling of leukocytes along the endothelial surfaces, followed by the firm attachment of leukocytes to the endothelium. The intravenous infusion of cobra venom factor into rats results in acute lung injury that is neutrophil-dependent, oxygen radical mediated and P-selectin-dependent4,5. Here we report that infusion of sialyl-Lewis X, a ligand for P-selectin6-9, dramatically reduced lung injury and diminished the tissue accumulation of neutrophils, whereas irrelevant oligosaccharides had no such effects. These results suggest that sialyl-Lewis X carbohydrates maybe used as a new strategy for anti-inflammatory therapy.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,1301 CATHERINE RD,ANN ARBOR,MI 48109; CYTEL CORP,SAN DIEGO,CA 92121; UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan			Paulson, James/AAG-3565-2019					BALL GE, 1992, J AM CHEM SOC, V114, P5449, DOI 10.1021/ja00039a080; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; ICHIKAWA Y, IN PRESS J AM CHEM S; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; PAULSON JC, 1992, ADHESION ITS ROLE IN, P19; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SPRAGG RG, 1991, LUNG SCI F, P2003; TILL GO, 1982, J CLIN INVEST, V69, P1126, DOI 10.1172/JCI110548; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	14	323	361	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					149	151		10.1038/364149a0	http://dx.doi.org/10.1038/364149a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	7686631	Green Published			2022-12-28	WOS:A1993LL36700050
J	ROHAN, PJ; DAVIS, P; MOSKALUK, CA; KEARNS, M; KRUTZSCH, H; SIEBENLIST, U; KELLY, K				ROHAN, PJ; DAVIS, P; MOSKALUK, CA; KEARNS, M; KRUTZSCH, H; SIEBENLIST, U; KELLY, K			PAC-1 - A MITOGEN-INDUCED NUCLEAR-PROTEIN TYROSINE PHOSPHATASE	SCIENCE			English	Article							PURIFICATION; ACTIVATION; RECEPTOR; FAMILY; GENES; CELLS	Tyrosine phosphorylation of proteins is required for signal transduction in cells and for growth regulation. A mitogen-induced gene (PAC-1) has been cloned from human T cells and encodes a 32-kilodalton protein that contains a sequence that defines the enzymatic site of known protein phosphotyrosine phosphatases (PTPases). Other than this sequence, PAC-1 is different from several other known related PTPases exemplified by PTP-1b. PAC-1 is similar to a phosphatase induced by mitogens or heat shock in fibroblasts, a yeast gene, and a vaccinia virus-encoded serine-tyrosine phosphatase (VH1). PAC-1 was predominantly expressed in hematopoietic tissues and localized to the nucleus in transfected COS-7 cells and in mitogen-stimulated T cells.	NCI,PATHOL LAB,BETHESDA,MD 20892; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BUCKHOLZ RG, 1991, YEAST, V7, P913, DOI 10.1002/yea.320070903; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARLES CH, 1992, ONCOGENE, V7, P187; DAVIS P, UNPUB; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; IRVING SG, 1989, MOL CELL BIOL, V9, P1034, DOI 10.1128/MCB.9.3.1034; KELLY K, 1992, ONCOGENE, V7, P1463; Kelly K. J., UNPUB; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; POT DA, 1992, J BIOL CHEM, V267, P140; ROHAN PJ, UNPUB; Sambrook J, 1989, MOL CLONING LABORATO; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tonks NK, 1990, CURR OPIN CELL BIOL, V2, P1114, DOI 10.1016/0955-0674(90)90165-B; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	23	281	290	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 19	1993	259	5102					1763	1766		10.1126/science.7681221	http://dx.doi.org/10.1126/science.7681221			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT810	7681221	Green Submitted			2022-12-28	WOS:A1993KT81000040
J	ECK, MJ; SHOELSON, SE; HARRISON, SC				ECK, MJ; SHOELSON, SE; HARRISON, SC			RECOGNITION OF A HIGH-AFFINITY PHOSPHOTYROSYL PEPTIDE BY THE SRC HOMOLOGY-2 DOMAIN OF P56(LCK)	NATURE			English	Article							SIGNAL TRANSDUCTION; PDGF RECEPTOR; KINASE; PROTEINS; GENE	THE Src homology-2 (SH2) domains are modules of about 100 amino-acid residues that are found in many intracellular signal-transduction proteins1,2. They bind phosphotyrosine-containing sequences with high affinity and specificity1-4, recognizing phosphotyrosine in the context of the immediately adjacent polypeptide sequence3-12. The protein p56lck (Lck) is a Src-like, lymphocyte-specific tyrosine kinase13-15. A phosphopeptide library screen has recently been used to deduce an 'optimal' binding sequence for the Lck SH2 domain16. There is selectivity for the residues Glu, Glu and Ile in the three positions C-terminal to the phosphotyrosine. An 11-residue phosphopeptide derived from the hamster polyoma middle-T antigen, EPQpYEEIPIYL, binds with an approximately 1 nM dissociation constant to the Lck SH2 (ref. 17), an affinity equivalent to that of the tightest known SH2-phosphopeptide complex. We report here the high-resolution crystallographic analysis of the Lck SH2 domain in complex with this phosphopeptide. Recent crystallographically derived structures of the Src SH2 domain in complex with low-affinity peptides18, which do not contain the EEI consensus, and NMR-derived structures of unliganded Abl (ref. 19) and p85 (ref. 20) SH2 domains have revealed the conserved fold of the SH2 domain and the properties of a phosphotyrosine binding pocket. Our high-affinity complex shows the presence of a second pocket for the residue (pY + 3) three positions C-terminal to the phosphotyrosine (pY). The peptide is anchored by insertion of the pY and pY + 3 side chains into their pockets and by a network of hydrogen bonds to the peptide main chain. In the low-affinity phosphopeptide/Src complexes18, the pY + 3 residues do not insert into the homologous binding pocket and the peptide main chain remains displaced from the surface of the domain.	CHILDRENS HOSP MED CTR,MOLEC MED LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02115; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University	ECK, MJ (corresponding author), CHILDRENS HOSP MED CTR,HOWARD HUGHES MED INST,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							AUGER KR, 1992, J BIOL CHEM, V267, P5408; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BRUNGER A, 1992, XPLOR VERSION 3 0 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COUGHLIN SR, 1989, SCIENCE, V243, P1191; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, IN PRESS MOL CELL BI; FOX GC, 1966, ACTA CRYSTALLOGR, V20, P886, DOI 10.1107/S0365110X66002007; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LESLIE AGW, 1992, MOSFLM PROGRAM PACKA; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MMAYER BJ, 1992, MOL CELL BIOL, V12, P609; OKADA M, 1991, J BIOL CHEM, V266, P24249; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYNE G, IN PRESS P NATN ACAD; PEREGO R, 1991, ONCOGENE, V6, P1899; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PICCIONE E, IN PRESS BIOCHEMISTR; Rossmann M. G., 1972, MOL REPLACEMENT METH; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SONGYANG Z, IN PRESS CELL; STEFTON BM, 1991, ONCOGENE, V6, P683; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WAKSMAN G, IN PRESS CELL; WILLIAMS KP, IN PRESS J BIOL CHEM	39	489	498	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					87	91		10.1038/362087a0	http://dx.doi.org/10.1038/362087a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	7680435				2022-12-28	WOS:A1993KP97600068
J	GOODMAN, NW				GOODMAN, NW			TOO MANY WORDS - MOZART 1, EMPEROR 0	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											GOODMAN, NW (corresponding author), UNIV BRISTOL,BRISTOL,AVON,ENGLAND.							GOODMAN NW, 1991, MED WRITING PRESCRIP; ROBERTS JC, 1994, JAMA-J AM MED ASSOC, V272, P119, DOI 10.1001/jama.272.2.119; ROCHON PA, 1994, JAMA-J AM MED ASSOC, V272, P108, DOI 10.1001/jama.272.2.108; ZEIGER M, 1991, WRITING BIOMEDICAL R	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1087	1088		10.1001/jama.1995.03520380023014	http://dx.doi.org/10.1001/jama.1995.03520380023014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR059	7707588				2022-12-28	WOS:A1995QR05900011
J	ALEXANDER, RM				ALEXANDER, RM			SPRINGS FOR WINGS	SCIENCE			English	Editorial Material							FLIGHT-MUSCLE; EFFICIENCY; POWER				ALEXANDER, RM (corresponding author), UNIV LEEDS,DEPT PURE & APPL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.							Casey T. M., 1989, ENERGY TRANSFORMATIO, P200; DEHAAN A, 1989, J EXP BIOL, V141, P327; DICKINSON MH, 1995, SCIENCE, V268, P87, DOI 10.1126/science.7701346; ELLINGTON CP, 1985, J EXP BIOL, V115, P293; GILMOUR KM, 1993, J EXP BIOL, V183, P101; HUXLEY AF, 1971, J PHYSIOL-LONDON, V218, pP59; JOSEPHSON RK, 1991, J PHYSIOL-LONDON, V442, P413, DOI 10.1113/jphysiol.1991.sp018800; MACHIN KE, 1959, PROC R SOC SER B-BIO, V151, P204, DOI 10.1098/rspb.1959.0060; WEISFOGH T, 1973, J EXP BIOL, V59, P169	9	7	7	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					50	51		10.1126/science.7701341	http://dx.doi.org/10.1126/science.7701341			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701341				2022-12-28	WOS:A1995QR45400022
J	KRIEG, AM; YI, AK; MATSON, S; WALDSCHMIDT, TJ; BISHOP, GA; TEASDALE, R; KORETZKY, GA; KLINMAN, DM				KRIEG, AM; YI, AK; MATSON, S; WALDSCHMIDT, TJ; BISHOP, GA; TEASDALE, R; KORETZKY, GA; KLINMAN, DM			CPG MOTIFS IN BACTERIAL-DNA TRIGGER DIRECT B-CELL ACTIVATION	NATURE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; BINDING; OLIGONUCLEOTIDES; PHOSPHOROTHIOATE; STIMULATION; LYMPHOCYTES; FRAGMENTS; MICE	UNMETHYLATED CpG dinucleotides are more frequent in the genomes of bacteria and viruses than of vertebrates. We report here that bacterial DNA and synthetic oligodeoxynucleotides containing unmethylated CPG dinucleotides induce murine B cells to proliferate and secrete immunoglobulin in vitro and in vivo. This activation is enhanced by simultaneous signals delivered through the antigen receptor. Optimal B-cell activation requires a DNA motif in which an unmethylated CpG dinucleotide is flanked by two 5' purines and two 3' py,rimidines. Oligodeoxynucleotides containing this CpG motif induce more than 95% of all spleen B cells to enter the cell cycle. These data suggest a possible evolutionary link between immune defence based on the recognition of microbial DNA and the phenomenon of CpG suppression' in vertebrates. The potent immune activation by CpG oligonucleotides has implications for the design and interpretation of studies using 'antisense' oligonucleotides and points to possible new applications as adjuvants.	UNIV IOWA,COLL MED,DEPT PATHOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT MICROBIOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL,IOWA CITY,IA 52242; VET AFFAIRS MED CTR,IOWA CITY,IA 52246; US FDA,CTR BIOL EVALUAT & RES,RETROVIRAL IMMUNOL SECT,BETHESDA,MD 20892	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; US Food & Drug Administration (FDA)	KRIEG, AM (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.		Koretzky, Gary/AAU-5381-2021; Krieg, Arthur M/K-8109-2019; Krieg, Art/R-6166-2019	Teasdale, Rebecca M./0000-0002-1981-7032; Waldschmidt, Thomas/0000-0001-6147-6991; Bishop, Gail/0000-0002-1291-5078				AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; Agrawal S, 1992, Antisense Res Dev, V2, P261; Bayever E, 1992, Antisense Res Dev, V2, P109; Bayever E, 1993, Antisense Res Dev, V3, P383; BENNETT RM, 1985, J CLIN INVEST, V76, P2182, DOI 10.1172/JCI112226; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BISHOP GA, 1991, J IMMUNOL, V147, P1107; CARDON LR, 1994, P NATL ACAD SCI USA, V91, P3799, DOI 10.1073/pnas.91.9.3799; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; DARZYNKIEWICZ Z, 1976, P NATL ACAD SCI USA, V73, P2881, DOI 10.1073/pnas.73.8.2881; DEFRANCO AL, 1982, J EXP MED, V155, P1523, DOI 10.1084/jem.155.5.1523; HAN J, 1994, ANTISENSE RES DEV, V4, P53, DOI 10.1089/ard.1994.4.53; KLINMAN DM, 1990, J IMMUNOL, V144, P506; KRAPF F, 1989, CLIN EXP IMMUNOL, V75, P336; KRIEG AM, 1989, J IMMUNOL, V143, P2448; KRIEG AM, 1992, IMMUNOMETHODS, V1, P191; LEIBSON HJ, 1981, J EXP MED, V154, P1681, DOI 10.1084/jem.154.5.1681; LISZIEWICZ J, 1994, P NATL ACAD SCI USA, V91, P7942, DOI 10.1073/pnas.91.17.7942; MARRACK P, 1994, CELL, V76, P323, DOI 10.1016/0092-8674(94)90339-5; Matson S, 1992, Antisense Res Dev, V2, P325; MESSINA JP, 1991, J IMMUNOL, V147, P1759; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; RICHARDSON B, 1990, ARTHRITIS RHEUM, V33, P1665, DOI 10.1002/art.1780331109; SANO H, 1989, SCAND J IMMUNOL, V30, P51, DOI 10.1111/j.1365-3083.1989.tb01188.x; SANO H, 1983, J IMMUNOL, V130, P187; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Zhao Q, 1993, Antisense Res Dev, V3, P53	29	2871	3399	7	171	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					546	549		10.1038/374546a0	http://dx.doi.org/10.1038/374546a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700380				2022-12-28	WOS:A1995QR06900053
J	ZHANG, R; ALT, FW; DAVIDSON, L; ORKIN, SH; SWAT, W				ZHANG, R; ALT, FW; DAVIDSON, L; ORKIN, SH; SWAT, W			DEFECTIVE SIGNALING THROUGH THE T-CELL AND B-CELL ANTIGEN RECEPTORS IN LYMPHOLD CELLS LACKING THE VAV PROTOONCOGENE	NATURE			English	Article							TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; CROSS-LINKING; EXPRESSION; KINASE; CD40; REARRANGEMENT; STIMULATION; REQUIREMENT	THE product of the vav proto-oncogene(1), p95(vav) or Vav, is tyrosine phosphorylated upon stimulation of T and B cells by antigen(2-4) and other(5-8) receptors, and contains motifs associated,vith signal transduction(1,9-11). To determine its role in vivo, we used vav-gene-targeted embryonic stem(12) cells and RAG-2(-/-) blastocyst complementation(13). The vav(-/-)-RAG-2(-/-) chimaeras displayed thymic atrophy with reduced numbers of peripheral T cells. Whereas the total number of B cells was normal, the subset of peritoneal B-1 (CD5(+))(14) cells was missing. The vav(-/-) T and B cells were hyporeactive when stimulated through antigen receptors, but vav(-/-) T cells proliferated on exposure to phorbol ester and calcium ionophore(15), whereas B cells responded normally to bacterial mitogen, lipopolysaccharide or the CD40 ligand(16-18). Thus, we have established here a functional role for vav in the control of T- and B-cell development and activation.	CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; CTR BLOOD RES,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)								ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BOGUSKI MS, 1992, NATURE, V358, P113, DOI 10.1038/358113a0; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; HERZENBERG LA, 1993, IMMUNOL TODAY, V14, P79, DOI 10.1016/0167-5699(93)90063-Q; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KIENER PA, 1993, J BIOL CHEM, V268, P24442; LANE P, 1993, J EXP MED, V177, P1209, DOI 10.1084/jem.177.4.1209; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; MANDLER R, 1993, J EXP MED, V178, P1577, DOI 10.1084/jem.178.5.1577; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; PIATANIAS LC, 1994, J BIOL CHEM, V269, P3143; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TESTI R, 1989, J IMMUNOL, V142, P1854; VONBOEHMER H, 1981, IMMUNOL REV, V54, P27; Weiss A, 1991, Semin Immunol, V3, P313; ZHANG R, 1994, P NATL ACAD SCI USA, V91, P12755, DOI 10.1073/pnas.91.26.12755	26	377	383	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					470	473		10.1038/374470a0	http://dx.doi.org/10.1038/374470a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700359				2022-12-28	WOS:A1995QP89900063
J	CONTER, V; CORTINOVIS, I; ROGARI, P; RIVA, L				CONTER, V; CORTINOVIS, I; ROGARI, P; RIVA, L			WEIGHT GROWTH IN INFANTS BORN TO MOTHERS WHO SMOKED DURING PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							MATERNAL SMOKING; BIRTH-WEIGHT; AGE; CHILD	Objective-To determine whether maternal smoking during pregnancy causes impairment in grow-th after birth. Design-Longitudinal study. Setting-Six medical university centres of six towns of north, central, and south Italy. Subjects-12 987 babies (10 238 born from nonsmoking mothers, 2276 from mothers smoking one to nine cigarettes a day, and 473 from mothers smoking greater than or equal to 10 cigarettes a day) entered the study. Main outcome measures-Difference in weight gain between children born to smoking mothers and those born to non-smoking mothers. Weight was measured at birth and at 3 and 6 months of age. Maternal smoking habit was derived from interview on third or fourth day after delivery. Results-Compared with children born to mothers who did not smoke during pregnancy, the birth weights of children born to mothers who smoked up to nine cigarettes a day were 88 g (girls) and 107 g (boys) lower; in children born to mothers who smoked greater than or equal to 10 cigarettes a day weights were 168 g and 247 g lower. At six months of age for the first group the mean weight for girls was 9 g (95% confidence interval -47 g to 65 g) higher and for boys 64 g (-118 g to -10 g) lower than that of children born to mothers who did not smoke. The corresponding figures for the second group were 38 g (-141 g to 85 g) lower for girls and 24 g (-136 g to 88 g) lower for boys. Conclusions-The deficits of weight at birth in children born to mothers who smoked during pregnancy are overcome by 6 months of age. These deficits are probably not permanent when smoking habit during pregnancy is not associated with other unfavourable variables (such as lower socioeconomic class).	UNIV MILAN,IST STAT MED & BIOMETRIA,I-20133 MILAN,ITALY; OSPED SAN GERARDO,DEPT PAEDIAT,MONZA,ITALY; OSPED MELEGNANO,DEPT PAEDIAT,MELEGNANO,ITALY	University of Milan; San Gerardo Hospital			Ivan, Cortinovis/M-9301-2017	Ivan, Cortinovis/0000-0001-8750-302X				BARR HM, 1984, PEDIATRICS, V74, P336; BORACCHI P, 1986, Genus, V42, P53; BUTLER NR, 1972, BMJ-BRIT MED J, V2, P127, DOI 10.1136/bmj.2.5806.127; BUTLER NR, 1973, BRIT MED J, V4, P573, DOI 10.1136/bmj.4.5892.573; Cortinovis I., 1993, Acta Medica Auxologica (Milan), V25, P13; CORTINOVIS I, 1986, Genus, V42, P13; De Scrilli A, 1986, Genus, V42, P37; FOGELMAN KR, 1988, BRIT MED J, V297, P1233, DOI 10.1136/bmj.297.6658.1233; FOX NL, 1990, INT J EPIDEMIOL, V19, P66, DOI 10.1093/ije/19.1.66; HARDY JB, 1972, LANCET, V2, P1332; MILANI S, 1983, SOC SCI MED, V17, P803, DOI 10.1016/0277-9536(83)90031-X; RANTAKALLIO P, 1983, ACTA PAEDIATR SCAND, V72, P747, DOI 10.1111/j.1651-2227.1983.tb09805.x; RONA RJ, 1985, INT J EPIDEMIOL, V2, P402; SEXTON M, 1984, JAMA-J AM MED ASSOC, V251, P911, DOI 10.1001/jama.251.7.911; 1982, B MENSILE STATISTI S	15	70	70	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	1995	310	6982					768	771		10.1136/bmj.310.6982.768	http://dx.doi.org/10.1136/bmj.310.6982.768			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP609	7711580	Green Published			2022-12-28	WOS:A1995QP60900016
J	CHONG, JHA; TAPIARAMIREZ, J; KIM, S; TOLEDOARAL, JJ; ZHENG, YC; BOUTROS, MC; ALTSHULLER, YM; FROHMAN, MA; KRANER, SD; MANDEL, G				CHONG, JHA; TAPIARAMIREZ, J; KIM, S; TOLEDOARAL, JJ; ZHENG, YC; BOUTROS, MC; ALTSHULLER, YM; FROHMAN, MA; KRANER, SD; MANDEL, G			REST - A MAMMALIAN SILENCER PROTEIN THAT RESTRICTS SODIUM-CHANNEL GENE-EXPRESSION TO NEURONS	CELL			English	Article							NERVE GROWTH-FACTOR; RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; AMPLIFICATION; INITIATION; REPRESSION; EUKARYOTES; ELEMENT; CELLS; YEAST	Expression of the type II voltage-dependent sodium channel gene is restricted to neurons by a silencer element active in nonneuronal cells. We have cloned cDNA coding for a transcription factor (REST) that binds to this silencer element. Expression of a recombinant REST protein confers the ability to silence type II reporter genes in neuronal cell types lacking the native REST protein, whereas expression of a dominant negative form of REST in nonneuronal cells relieves silencing mediated by the native protein. REST transcripts in developing mouse embryos are detected ubiquitously outside of the nervous system. We propose that expression of the type II sodium channel gene in neurons reflects a default pathway that is blocked in nonneuronal cells by the presence of REST.	SUNY STONY BROOK,DEPT PHARMACOL,STONY BROOK,NY 11794; UNIV PENN,SCH MED,DEPT NEUROSCI,PHILADELPHIA,PA 19104	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Pennsylvania	CHONG, JHA (corresponding author), SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794, USA.		Toledo-Aral, Juan J/F-2613-2015; IBIS, TERAPIA CELULA/P-3297-2015; Boutros, Michael/C-3566-2008	Toledo-Aral, Juan J/0000-0001-7512-7135; Boutros, Michael/0000-0002-9458-817X; Tapia, Jose/0000-0002-4641-7181				BARTEL PL, 1994, CELLULAR INTERACTION, P153; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DARCANGELO G, 1993, J CELL BIOL, V4, P915; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GREEN JBA, 1994, CELL, V77, P317, DOI 10.1016/0092-8674(94)90145-7; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; JAN YN, 1995, NEURON, V14, P1; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KRANER S, 1991, BIOMED RES-TOKYO, V12, P27; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LEWIN G, 1994, CELL, V79, P935; LI KJ, 1993, SCIENCE, V262, P1870; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LINDSELL P, 1994, J PHYSL, V480, P405; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; NEDIVI E, 1992, J NEUROSCI, V12, P691; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P998; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sherman F., 1986, METHODS YEAST GENETI; TOLEDOARAL JJ, 1995, NEURON, V14, P607, DOI 10.1016/0896-6273(95)90317-8; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X; ZHAO C, 1995, NATURE, V373, P74, DOI 10.1038/373074a0	46	898	917	1	31	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					949	957		10.1016/0092-8674(95)90298-8	http://dx.doi.org/10.1016/0092-8674(95)90298-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697725	hybrid			2022-12-28	WOS:A1995QP61200014
J	WADSWORTH, E; SHIELD, J; HUNT, L; BAUM, D				WADSWORTH, E; SHIELD, J; HUNT, L; BAUM, D			INSULIN-DEPENDENT DIABETES IN CHILDREN UNDER 5 - INCIDENCE AND ASCERTAINMENT VALIDATION FOR 1992	BRITISH MEDICAL JOURNAL			English	Article							MELLITUS; PREVALENCE	Objective-To establish the incidence of insulin dependent diabetes diagnosed in children under 5 years of age in the British Isles during 1992, comparing the national and regional results with those of our 1988 national study, and estimating the 1992 study's level of case ascertainment. Design-Active monthly reporting of cases by consultant paediatricians through the framework of the British Paediatric Surveillance Unit, with additional reports from specialist diabetes nurses and regional health authorities. Subjects-All children diagnosed under the age of 5 years with primary insulin dependent diabetes from 1 January to 31 December 1992 (inclusive) and resident in the British Isles at diagnosis. Results-387 children (208 boys and 179 girls) were confirmed to have insulin dependent diabetes, giving a national incidence of 9 . 3/100 000/year. This is similar to the 9 . 9/100 000/year found in 1988. Three sample capture-recapture analysis, which could only be applied across the 12 (out of 18) regions supplying regional information to the study, suggested ascertainment rates of 78% for the British Paediatric Surveillance Unit, 67% for specialist nurses, 69% for regional health authorities, and 99% for the aggregated registry. Conclusions-The national incidence of diabetes in the under 5s in the British Isles did not differ between 1988 and 1992. Nearly complete (99%) ascertainment of cases was possible only for regions for which three data sources were available. Capture-recapture analysis highlighted both the need for more than one data source and for each data source to be complete for the whole study area.			WADSWORTH, E (corresponding author), INST CHILD HLTH,BRISTOL BS2 8BJ,AVON,ENGLAND.		Wadsworth, Emma/D-1679-2009; Shield, Julian PH/D-6297-2014	Shield, Julian PH/0000-0003-2601-7575				BEGON M., 1979, INVESTIGATING ANIMAL; BINGLEY PJ, 1989, BRIT MED J, V298, P558, DOI 10.1136/bmj.298.6673.558; BISHOP YMM, 1976, DISCRETE MULTIVARIAT, P229; BLOOM A, 1975, BRIT MED J, V3, P580, DOI 10.1136/bmj.3.5983.580; BRUNO G, 1994, DIABETES CARE, V17, P548, DOI 10.2337/diacare.17.6.548; BRUNO G, 1992, DIABETOLOGIA, V35, P851, DOI 10.1007/BF00399931; FISHER N, 1994, BRIT MED J, V308, P27, DOI 10.1136/bmj.308.6920.27; FREEDMAN LS, 1979, J EPIDEMIOL COMMUNIT, V33, P233; FRISCHER M, 1991, INT J EPIDEMIOL, V20, P997, DOI 10.1093/ije/20.4.997; GREEN A, 1992, LANCET, V339, P905, DOI 10.1016/0140-6736(92)90938-Y; Hall S M, 1988, Arch Dis Child, V63, P344; HOOK EB, 1980, AM J EPIDEMIOL, V112, P750, DOI 10.1093/oxfordjournals.aje.a113047; MCCARTY DJ, 1993, INT J EPIDEMIOL, V22, P559, DOI 10.1093/ije/22.3.559; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; PATTERSON CC, 1988, DIABETIC MED, V5, P160, DOI 10.1111/j.1464-5491.1988.tb00964.x; PATTERSON CC, 1983, DIABETOLOGIA, V24, P238, DOI 10.1007/BF00282706; SOLTESZ G, 1990, DIABETIC MED, V7, P111, DOI 10.1111/j.1464-5491.1990.tb01343.x; SWIFT PGF, 1993, BRIT MED J, V306, P96; TUOMILEHTO J, 1992, INT J EPIDEMIOL, V21, P518, DOI 10.1093/ije/21.3.518; 1993, EGRET REFERENCE MANU	20	25	25	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					700	703		10.1136/bmj.310.6981.700	http://dx.doi.org/10.1136/bmj.310.6981.700			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711537	Green Published			2022-12-28	WOS:A1995QN46100019
J	OWEN, AV				OWEN, AV			MANAGEMENT FOR DOCTORS - GETTING THE BEST FROM PEOPLE	BRITISH MEDICAL JOURNAL			English	Article											OWEN, AV (corresponding author), BUPA,HLTH SERV,LONDON WC2R 3AU,ENGLAND.							Bevan S., 1991, PERS MANAGE, V23, P37; Bowen D. E., 1991, ACAD MANAGEMENT EXEC, V5, P35, DOI DOI 10.5465/AME.1991.4274747; Deming William E., 1986, OUT CRISIS QUALITY P; HANDY C, 1985, UNDERSTANDING ORG; HARPER SC, 1983, BUS HORIZONS, V26, P68, DOI 10.1016/0007-6813(83)90108-8; Herzberg FrederickI., 1966, WORK NATURE MAN; HUBERMAN J, 1964, HARVARD BUS REV, V42, P62; KEEP E, 1989, NEW PERSPECTIVES HUM, P109; KOHN A, 1993, HARVARD BUS REV, V71, P54; Locke EA, 1984, GOAL SETTING MOTIVAT; Maslow A.H., 1954, MOTIVATION PERSONALI; MCCLELLAND DC, 1963, ACHIEVEMENT ENTREPRE; McGregor D., 1960, HUMAN SIDE ENTERPRIS; WALL T, 1984, PERS MANAGE, V16, P27; 1994, GUIDANCE GOOD PRACTI	15	3	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					648	651						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703755				2022-12-28	WOS:A1995QL98400024
J	BELLA, J; EATON, M; BRODSKY, B; BERMAN, HM				BELLA, J; EATON, M; BRODSKY, B; BERMAN, HM			CRYSTAL-STRUCTURE AND MOLECULAR-STRUCTURE OF A COLLAGEN-LIKE PEPTIDE AT 1.9-ANGSTROM RESOLUTION	SCIENCE			English	Article							TRIPLE-HELICAL PEPTIDE; CIRCULAR-DICHROISM; N-PROTEINASE; SUBSTITUTION; CHAIN; CONFORMATION; REFINEMENT; KINK; PARAMETERS; CYSTEINE	The structure of a protein triple helix has been determined at 1.9 angstrom resolution by x-ray crystallographic studies of a collagen-like peptide containing a single substitution of the consensus sequence. This peptide adopts a triple-helical structure that confirms the basic features determined from fiber diffraction studies on collagen: supercoiling of polyproline II helices and interchain hydrogen bonding that follows the model II of Rich and Crick. In addition, the structure provides new information concerning the nature of this protein fold. Each triple helix is surrounded by a cylinder of hydration, with an extensive hydrogen bonding network between water molecules and peptide acceptor groups. Hydroxyproline residues have a critical role in this water network. The interaxial spacing of triple helices in the crystal is similar to that in collagen fibrils, and the water networks linking adjacent triple helices in the crystal structure are likely to be present in connective tissues. The breaking of the repeating (X-Y-Gly), pattern by a Gly-->Ala substitution results in a subtle alteration of the conformation, with a local untwisting of the triple helix. At the substitution site, direct interchain hydrogen bonds are replaced with interstitial water bridges between the peptide groups. Similar conformational changes may occur in Gly-->X mutated collagens responsible for the diseases osteogenesis imperfecta, chondrodysplasias, and Ehlers-Danlos syndrome IV.	RUTGERS STATE UNIV,DEPT CHEM,PISCATAWAY,NJ 08855; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,WAKSMAN INST,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick			Bella, Jordi/F-3794-2018	Bella, Jordi/0000-0003-0443-4562; Berman, Helen/0000-0002-3337-0660	NIAMS NIH HHS [AR 19626] Funding Source: Medline; NIGMS NIH HHS [GM 21589] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019626] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021589] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN FH, 1983, ACCOUNTS CHEM RES, V16, P146, DOI 10.1021/ar00089a001; BELLA J, UNPUB; BERG RA, 1970, J BIOL CHEM, V245, P5759; BOGAERT R, 1992, J BIOL CHEM, V267, P22522; BRODSKYDOYLE B, 1976, BIOCHEM J, V159, P279, DOI 10.1042/bj1590279; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, X PLOR VERSION 3 1; CAMPBELLSMITH PJ, 1978, ACTA CRYSTALLOGR A, V34, P3; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Fair C K, 1990, MOLEN; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRASER RDB, 1979, J MOL BIOL, V129, P463, DOI 10.1016/0022-2836(79)90507-2; FRASER RDB, 1983, J MOL BIOL, V167, P497, DOI 10.1016/S0022-2836(83)80347-7; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KILCHHERR E, 1985, J MOL BIOL, V186, P403, DOI 10.1016/0022-2836(85)90114-7; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LEIKIN S, 1994, P NATL ACAD SCI USA, V91, P276, DOI 10.1073/pnas.91.1.276; LI MH, 1993, BIOCHEMISTRY-US, V32, P7377, DOI 10.1021/bi00080a007; LIGHTFOOT SJ, 1992, J BIOL CHEM, V267, P25521; LONG CG, 1992, J MOL BIOL, V225, P1, DOI 10.1016/0022-2836(92)91020-P; LONG CG, 1993, BIOCHEMISTRY-US, V32, P11688, DOI 10.1021/bi00094a027; MACRAE TP, 1973, CONFORMATION FIBROUS; MILLER MH, 1976, J POLYM SCI POL SYM, P171; OKUYAMA K, 1981, J MOL BIOL, V152, P427, DOI 10.1016/0022-2836(81)90252-7; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; RAMACHANDRAN GN, 1955, NATURE, V176, P593, DOI 10.1038/176593a0; RICH A, 1961, J MOL BIOL, V3, P483, DOI 10.1016/S0022-2836(61)80016-8; RICH A, 1955, NATURE, V176, P915, DOI 10.1038/176915a0; SAKAKIBARA S, 1973, BIOCHIM BIOPHYS ACTA, V303, P198, DOI 10.1016/0005-2795(73)90164-5; SAKAKIBARA S, 1972, J MOL BIOL, V65, P371, DOI 10.1016/0022-2836(72)90288-4; VENUGOPAL MG, 1994, BIOCHEMISTRY-US, V33, P7948, DOI 10.1021/bi00191a023; VOGEL BE, 1988, J BIOL CHEM, V263, P19249	35	845	866	2	168	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					75	81		10.1126/science.7695699	http://dx.doi.org/10.1126/science.7695699			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7695699				2022-12-28	WOS:A1994PK58200028
J	PEAD, L; MASKELL, R				PEAD, L; MASKELL, R			STUDY OF URINARY-TRACT INFECTION IN CHILDREN IN ONE HEALTH DISTRICT	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD; WOMEN	Objective-To determine the number of children who had urine specimens sent for culture, who had infections or sterile pyuria, and who were investigated further. To relate the laboratory findings to the results of imaging. Design-One year survey of urine specimens submitted to a laboratory; review of previous and subsequent laboratory reports; review of the findings of imaging of the urinary tract. Setting-Portsmouth and South East Hampshire health district. Subjects-An estimated population of 89 086 children aged 12 years or under. Main outcome measures-Urine bacterial count and results of imaging. Results-12 551 urine specimens were submitted from 7450 children, 3138 boys and 4312 girls. 2238 children had infection or sterile pyuria at least once during the study (13.9/1000 boys, 37/1000 girls). 996 (45%) of the children with infection or sterile pyuria underwent some form of imaging. 128 children who;had infection or sterile pyuria were already known to have urinary tract abnormalities and 114 children had newly identified abnormalities (1.0/1000 boys, 1.5/1000 girls). 50 (44%) of the children with newly detected abnormalities had no pyuria and 48 (42%) had bacterial counts below 10(8)/1. Eight children who had sterile pyuria on presentation were found to have abnormalities on imaging. Conclusions-Urinary tract infection is much commoner in children than is widely believed. Low bacterial counts, the absence of pyuria, or a finding of sterile pyuria should not be disregarded.	ST MARYS HOSP,PUBL HLTH LAB,PORTSMOUTH PO3 6AQ,HANTS,ENGLAND									ASSCHER AW, 1973, LANCET, V2, P1; BUYS H, 1994, BRIT MED J, V308, P690, DOI 10.1136/bmj.308.6930.690; CHIU N-C, 1989, Acta Paediatrica Sinica, V30, P225; JADRESIC L, 1993, BRIT MED J, V307, P761, DOI 10.1136/bmj.307.6907.761; KASS EH, 1956, T ASSOC AM PHYSICIAN, V69, P56; KASS EH, 1957, ARCH INTERN MED, V100, P709, DOI 10.1001/archinte.1957.00260110025004; KUNIN CM, 1964, MEDICINE, V43, P91; KUNIN CM, 1993, ANN INTERN MED, V119, P454, DOI 10.7326/0003-4819-119-6-199309150-00002; MASKELL R, 1989, J INFECTION, V19, P207, DOI 10.1016/S0163-4453(89)90669-5; MASKELL R, 1989, BRIT J UROL, V63, P7, DOI 10.1111/j.1464-410X.1989.tb05113.x; MASKELL R, 1982, URINARY TRACT INFECT, P24; RICKWOOD AMK, 1992, BRIT MED J, V304, P663, DOI 10.1136/bmj.304.6828.663; STAMM WE, 1980, NEW ENGL J MED, V303, P409, DOI 10.1056/NEJM198008213030801; 1975, ARCH DIS CHILD, V50, P90; 1991, JR COLL PHYSICIANS L, V25, P36	15	17	17	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					631	634		10.1136/bmj.309.6955.631	http://dx.doi.org/10.1136/bmj.309.6955.631			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	7695692	Green Published			2022-12-28	WOS:A1994PG02000017
J	MEYER, RM; QUIRT, IC; SKILLINGS, JR; CRIPPS, MC; BRAMWELL, VHC; WEINERMAN, BH; GOSPODAROWICZ, MK; BURNS, BF; SARGEANT, AM; SHEPHERD, LE; ZEE, B; HRYNIUK, WM				MEYER, RM; QUIRT, IC; SKILLINGS, JR; CRIPPS, MC; BRAMWELL, VHC; WEINERMAN, BH; GOSPODAROWICZ, MK; BURNS, BF; SARGEANT, AM; SHEPHERD, LE; ZEE, B; HRYNIUK, WM			ESCALATED AS COMPARED WITH STANDARD DOSES OF DOXORUBICIN IN BACOP THERAPY FOR PATIENTS WITH NON-HODGKINS-LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LARGE-CELL LYMPHOMA; DIFFUSE HISTIOCYTIC LYMPHOMA; COMBINATION CHEMOTHERAPY; MALIGNANT-LYMPHOMA; ONCOLOGY-GROUP; SURVIVAL; TRIAL; CHOP; ADRIAMYCIN; INTENSITY	Background and Methods. In 1981 the Clinical Trials Group of the National Cancer Institute of Canada completed a pilot study in patients with advanced-stage non-Hodgkin's lymphoma with aggressive tumor histology. That study demonstrated the potential efficacy of escalating the dose of doxorubicin used in a regimen of bleomycin, doxorubicin, cyclophosphamide, vincristine, and prednisone (BACOP). In the present study, we compared standard BACOP (s-BACOP) with BACOP that included escalated doses of doxorubicin (esc-BACOP) in 238 patients 16 to 70 years old with previously untreated, advanced-stage intermediate- or high-grade non-Hodgkin's lymphoma. During the first 28-day cycle all patients received doxorubicin in a dose of 25 mg per square meter of body-surface area on days 1 and 8. Patients randomly assigned to receive s-BACOP subsequently received five identical cycles, whereas those assigned to receive esc-BACOP received 40 mg of doxorubicin per square meter on days 1 and 8 of five subsequent cycles if granulocytopenia (<1000 cells per cubic millimeter) had not developed during the first cycle. Results. The 119 patients assigned to the esc-BACOP regimen received doxorubicin at a significantly higher mean weekly dose intensity (13.5 vs. 10.4 mg per square meter per week, P<0.001) and mean total dose (296 vs. 231 mg per square meter, P<0.001). Because of granulocytopenia during the first cycle of therapy, only 56 of these patients (47 percent) received the escalated doses of doxorubicin. During a median follow-up of 65 months, there were no differences between the s-BACOP and esc-BACOP groups in response rate, overall survival, or survival without disease progression. When the patients who actually received the escalated doses of doxorubicin were compared with the patients in the s-BACOP group in whom neutropenia did not develop during the first treatment cycle, no difference between their outcomes was observed. Toxicity was greater in the esc-BACOP group. Conclusions. In patients with advanced-stage intermediate- or high-grade non-Hodgkin's lymphoma, escalating the dose of doxorubicin in the BACOP regimen increases toxicity but does not improve the rate of response or survival.	HAMILTON CIVIC HOSP, HAMILTON, ON, CANADA; MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA; PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA; NOVA SCOTIA CANC TREATMENT RES FDN, HALIFAX, NS, CANADA; DALHOUSIE UNIV, HALIFAX B3H 4H2, NS, CANADA; UNIV OTTAWA, OTTAWA REG CANC CTR, OTTAWA K1N 6N5, ONTARIO, CANADA; UNIV OTTAWA, OTTAWA CIVIC HOSP, OTTAWA K1N 6N5, ONTARIO, CANADA; LONDON REG CANC CTR, LONDON, ON, CANADA; UNIV WESTERN ONTARIO, LONDON N6A 3K7, ONTARIO, CANADA; UNIV MANITOBA, WINNIPEG R3T 2N2, MANITOBA, CANADA; MANITOBA CANC TREATMENT & RES FDN, WINNIPEG, MB, CANADA; NATL CANC INST CANADA, CLIN TRIALS GRP, KINGSTON, ON, CANADA; QUEENS UNIV, KINGSTON K7L 3N6, ONTARIO, CANADA; UNIV CALIF SAN DIEGO, GILDRED CANC CTR, LA JOLLA, CA 92093 USA	McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; Dalhousie University; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Western University (University of Western Ontario); Western University (University of Western Ontario); University of Manitoba; Queens University - Canada; Canadian Cancer Trials Group; Queens University - Canada; University of California System; University of California San Diego			Zee, Benny Chung Ying/G-5606-2017	Zee, Benny Chung Ying/0000-0002-7238-845X				CARBONE PP, 1971, CANCER RES, V31, P1860; COOPER IA, 1991, P AN M AM SOC CLIN, V10, P271; COX DR, 1972, J R STAT SOC B, V34, P187; DEVITA VT, 1975, LANCET, V1, P248; DEVITA VT, 1987, CANCER RES, V47, P5810; EPELBAUM R, 1988, ISRAEL J MED SCI, V24, P533; Fisher R I, 1990, Important Adv Oncol, P217; FISHER RA, 1970, STATISTICAL METHODS, P76; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FISHER RI, 1983, ANN INTERN MED, V98, P304, DOI 10.7326/0003-4819-98-3-304; FLEISS JL, 1973, STATISTICAL METHODS; FRIEDMAN LM, 1985, FUNDAMENTALS CLIN TR, P196; GAMS RA, 1985, J CLIN ONCOL, V3, P1188, DOI 10.1200/JCO.1985.3.9.1188; GORDON LI, 1992, NEW ENGL J MED, V327, P1342, DOI 10.1056/NEJM199211053271903; HAGBERG H, 1985, EUR J CANCER CLIN ON, V21, P175, DOI 10.1016/0277-5379(85)90169-5; Hryniuk W M, 1988, Important Adv Oncol, P121; HRYNIUK WM, 1982, P AN M AM SOC CLIN, V1, P156; JONES SE, 1983, CANCER, V51, P1083, DOI 10.1002/1097-0142(19830315)51:6<1083::AID-CNCR2820510619>3.0.CO;2-M; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; KWAK LW, 1990, J CLIN ONCOL, V8, P963, DOI 10.1200/JCO.1990.8.6.963; LONGO, 1991, J CLIN ONCOL, V9, P710, DOI 10.1200/JCO.1991.9.4.710; LONGO DL, 1991, J CLIN ONCOL, V9, P25, DOI 10.1200/JCO.1991.9.1.25; MCKELVEY EM, 1976, CANCER, V38, P1484, DOI 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I; MEYER RM, 1991, J CLIN ONCOL, V9, P339, DOI 10.1200/JCO.1991.9.2.339; MOOD AM, 1973, INTRO THEORY STATIST; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; RAPPAPORT H, 1966, ATLAS TUMOR PATHOLOG; ROSENBERG SA, 1982, CANCER, V49, P2112; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2.2S; SCHEIN PS, 1976, ANN INTERN MED, V85, P417, DOI 10.7326/0003-4819-85-4-417; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SKARIN AT, 1983, J CLIN ONCOL, V1, P91, DOI 10.1200/JCO.1983.1.2.91	35	58	59	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1993	329	24					1770	1776		10.1056/NEJM199312093292404	http://dx.doi.org/10.1056/NEJM199312093292404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK096	7694148				2022-12-28	WOS:A1993MK09600004
J	BELFORT, M				BELFORT, M			AN EXPANDING UNIVERSE OF INTRONS	SCIENCE			English	Editorial Material							GROUP-I INTRON; TETRAHYMENA				BELFORT, M (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,DAVID AXELROD INST PUBL HLTH,ALBANY,NY 12201, USA.			Belfort, Marlene/0000-0002-1592-5618				AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; COPERTINO DW, 1991, EMBO J, V10, P433, DOI 10.1002/j.1460-2075.1991.tb07965.x; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; KUHSEL MG, 1990, SCIENCE, V250, P1570, DOI 10.1126/science.2125748; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MORI M, 1990, CELL, V60, P629; MORI M, 1992, CELL, V70, P803; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747	14	29	31	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1009	1010		10.1126/science.7694364	http://dx.doi.org/10.1126/science.7694364			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	7694364				2022-12-28	WOS:A1993MG18700023
J	BERENDES, R; VOGES, D; DEMANGE, P; HUBER, R; BURGER, A				BERENDES, R; VOGES, D; DEMANGE, P; HUBER, R; BURGER, A			STRUCTURE-FUNCTION ANALYSIS OF THE ION-CHANNEL SELECTIVITY FILTER IN HUMAN ANNEXIN-V	SCIENCE			English	Article							MOLECULAR-STRUCTURE; BILAYER-MEMBRANES; RECEPTOR CHANNELS; CALCIUM; CRYSTAL; RESOLUTION; PROTEINS; BINDING; FAMILY	Electrophysiology and structural studies were performed on an annexin V variant c containing a mutation of glutamic acid-95 to serine in the center of the pore region. The mutation resulted in a lower single channel conductance for calcium and a strongly increased conductance for sodium and potassium, indicating that glutamic acid-95 is a crucial constituent of the ion selectivity filter. There were only minor differences in the crystal structures of mutant and wild-type annexin V around the mutation site; however, the mutant showed structural differences elsewhere, including the presence of a calcium binding site in domain III unrelated to the mutation. Analysis of the membrane-bound form of annexin V by electron microscopy revealed no differences between the wild type and mutant.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society			demange, pascal JP/U-3561-2018	demange, pascal JP/0000-0002-9572-9990				AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; BERENDES R, UNPUB; BRUNGER AT, 1990, X PLOR MANUAL; BURGER A, 1993, FEBS LETT, V329, P25, DOI 10.1016/0014-5793(93)80185-W; Burger A., UNPUB; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CONCHA NO, 1993, SCIENCE, V2261, P1321; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; DINGLEDINE R, 1992, J NEUROSCI, V12, P4080; EGJEBERG J, 1993, P NATL ACAD SCI USA, V90, P755; FATT P, 1958, J PHYSIOL-LONDON, V142, P516, DOI 10.1113/jphysiol.1958.sp006034; FERRERMONTIEL AV, 1993, FEBS LETT, V324, P185, DOI 10.1016/0014-5793(93)81390-L; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HOPPE W, 1957, Z ELEKTROCHEM, V61, P1076; HUBER R, 1965, ACTA CRYSTALLOGR, V19, P353, DOI 10.1107/S0365110X65003444; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; HUBER R, 1990, FEBS LETT, V275, P15, DOI 10.1016/0014-5793(90)81428-Q; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KARSHIKOV A, 1992, EUR BIOPHYS J BIOPHY, V20, P337, DOI 10.1007/BF00196592; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P50; LEWITBENTLEY A, 1992, EUR J BIOCHEM, V210, P73, DOI 10.1111/j.1432-1033.1992.tb17392.x; MEALY T, 1993, BIOCHEMISTRY-US, V32, P5411; MEERS P, 1990, BIOCHEMISTRY-US, V29, P3325, DOI 10.1021/bi00465a025; Moss S. E, 1992, ANNEXINS; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; POLLARD HB, 1988, P NATL ACAD SCI USA, V85, P2974, DOI 10.1073/pnas.85.9.2974; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; ROJAS E, 1990, J BIOL CHEM, V265, P21207; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; SOPKOVA J, IN PRESS J MOL BIOL; Steigemann W., 1974, THESIS TU MUNCHEN GE; UZGIRIS EE, 1983, NATURE, V301, P125, DOI 10.1038/301125a0	37	102	103	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 15	1993	262	5132					427	430		10.1126/science.7692599	http://dx.doi.org/10.1126/science.7692599			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB859	7692599				2022-12-28	WOS:A1993MB85900060
J	SUSEK, RE; AUSUBEL, FM; CHORY, J				SUSEK, RE; AUSUBEL, FM; CHORY, J			SIGNAL-TRANSDUCTION MUTANTS OF ARABIDOPSIS UNCOUPLE NUCLEAR CAB AND RBCS GENE-EXPRESSION FROM CHLOROPLAST DEVELOPMENT	CELL			English	Article							MESSENGER-RNA ACCUMULATION; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PLANT-CELLS; LIGHT; THALIANA; CHLOROPHYLL; PROTEIN; BINDING; MAIZE	Chloroplast development requires coordinate nuclear and chloroplast gene expression. A putative signal from the chloroplast couples the transcription of certain nuclear genes encoding photosynthesis-related proteins with chloroplast function. We have identified at least three Arabidopsis nuclear genes (GUN1, GUN2, and GUN3) necessary for coupling the expression of some nuclear genes to the functional state of the chloroplast. Homozygous recessive gun mutations allow nuclear gene expression in the absence of chloroplast development and furthermore may interfere with the switch from dark-grown to light-grown development. Other reports suggest this intracellular cross-stalk also involves mitochondrial interactions. The GUN genes thus define steps in one specific branch of a complex interorganellar regulatory network.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT EXTRATERR PHYS,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	SUSEK, RE (corresponding author), SALK INST BIOL STUDIES,PLANT BIOL LAB,SAN DIEGO,CA 92186, USA.				NCRR NIH HHS [RR05595] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AN G, 1987, MOL GEN GENET, V270, P210; BARKAN A, 1993, PLANT CELL, V5, P389, DOI 10.1105/tpc.5.4.389; BATSCHAUER A, 1986, EUR J BIOCHEM, V154, P625, DOI 10.1111/j.1432-1033.1986.tb09444.x; BURGESS DG, 1987, PLANTA, V170, P520, DOI 10.1007/BF00402986; CHAMOVITZ D, 1991, PLANT MOL BIOL, V16, P967, DOI 10.1007/BF00016069; CHORY J, 1989, PLANT CELL, V1, P867, DOI 10.1105/tpc.1.9.867; CHORY J, 1991, NEW BIOL, V3, P538; CHORY J, 1990, P NATL ACAD SCI USA, V87, P8776, DOI 10.1073/pnas.87.22.8776; CHORY J, 1989, CELL, V58, P991, DOI 10.1016/0092-8674(89)90950-1; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; DATTA N, 1989, PLANT CELL, V1, P1069, DOI 10.1105/tpc.1.11.1069; DENG XW, 1992, PLANT J, V2, P83, DOI 10.1111/j.1365-313X.1992.00083.x; DENG XW, 1987, CELL, V49, P379, DOI 10.1016/0092-8674(87)90290-X; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; GILMARTIN PM, 1990, PLANT CELL, V2, P369, DOI 10.1105/tpc.2.5.369; GOODWIN TW, 1985, INTRO PLANT BIOCH; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HA SB, 1988, P NATL ACAD SCI USA, V85, P8017, DOI 10.1073/pnas.85.21.8017; HARPSTER MH, 1984, PLANT MOL BIOL, V3, P59, DOI 10.1007/BF00040030; HERRERAESTRELLA L, 1983, EMBO J, V2, P987, DOI 10.1002/j.1460-2075.1983.tb01532.x; HOWE CJ, 1991, NATURE, V349, P109, DOI 10.1038/349109c0; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; JOHANNINGMEIER U, 1984, J BIOL CHEM, V259, P3541; Kendrick RE., 2012, PHOTOMORPHOGENESIS P, P333; Kirk J., 1978, PLASTIDS THEIR CHEM, V2nd ed.; KLAFF P, 1991, PLANT CELL, V3, P517, DOI 10.1105/tpc.3.5.517; KUCHKA MR, 1989, CELL, V58, P869, DOI 10.1016/0092-8674(89)90939-2; LAUER M, 1990, New Biologist, V2, P179; LEAVER CJ, 1980, GENOME ORG EXPRESSIO; LEUTWILER LS, 1986, NUCLEIC ACIDS RES, V14, P4051, DOI 10.1093/nar/14.10.4051; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MARTINEAU B, 1986, PLANT PHYSIOL, V78, P399; MARTINEZZAPATER JM, 1992, PLANT CELL, V4, P889, DOI 10.1105/tpc.4.8.889; MATHEWS DE, 1990, J BIOL CHEM, V265, P493; MAYFIELD SP, 1984, EUR J BIOCHEM, V144, P79, DOI 10.1111/j.1432-1033.1984.tb08433.x; MILLAR AJ, 1991, PLANT CELL, V3, P541, DOI 10.1105/tpc.3.5.541; MITRA A, 1989, PLANT MOL BIOL, V12, P169, DOI 10.1007/BF00020502; NGERNPRASIRTSIRI J, 1990, CELL STRUCT FUNCT, V15, P273, DOI 10.1247/csf.15.273; OELMULLER R, 1990, PLANT PHYSIOL, V92, P434, DOI 10.1104/pp.92.2.434; OELMULLER R, 1986, PLANTA, V168, P482, DOI 10.1007/BF00392267; OELMULLER R, 1989, PHOTOCHEM PHOTOBIOL, V49, P229, DOI 10.1111/j.1751-1097.1989.tb04101.x; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; OWEN J, 1987, PLANT MITOCHONDRIA S, P211; PLUMLEY FG, 1989, P NATL ACAD SCI USA, V86, P2678, DOI 10.1073/pnas.86.8.2678; RAPP JC, 1991, PLANT MOL BIOL, V17, P813, DOI 10.1007/BF00037063; RAPP JC, 1992, J BIOL CHEM, V267, P21404; REDEI G P, 1973, Mutation Research, V18, P149, DOI 10.1016/0027-5107(73)90031-6; ROUSSELL DL, 1991, PLANT PHYSIOL, V96, P232, DOI 10.1104/pp.96.1.232; SCHINDLER U, 1990, EMBO J, V9, P3415, DOI 10.1002/j.1460-2075.1990.tb07549.x; SCHWARTZ B W, 1991, Plant Physiology (Rockville), V96, P120; SIMPSON J, 1986, SCIENCE, V233, P34, DOI 10.1126/science.233.4759.34; STUMPF P, 1980, BIOCH PLANTS LIPIDS; SUSEK RE, 1992, AUST J PLANT PHYSIOL, V19, P387, DOI 10.1071/PP9920387; TAYLOR WC, 1987, DEV GENET, V8, P305, DOI 10.1002/dvg.1020080503; TAYLOR WC, 1989, ANNU REV PLANT PHYS, V40, P211, DOI 10.1146/annurev.pp.40.060189.001235; Taylor WC, 1986, CURRENT TOPICS PLANT, V5, P117; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WELLBURN A, 1984, CHLOROPLAST BIOGENES; WHITTAKER PA, 1978, MITOCHONDRIA STRUCTU	62	468	487	3	73	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					787	799		10.1016/0092-8674(93)90459-4	http://dx.doi.org/10.1016/0092-8674(93)90459-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	7690685				2022-12-28	WOS:A1993LX29200005
J	MACNICOL, AM; MUSLIN, AJ; WILLIAMS, LT				MACNICOL, AM; MUSLIN, AJ; WILLIAMS, LT			RAF-1 KINASE IS ESSENTIAL FOR EARLY XENOPUS DEVELOPMENT AND MEDIATES THE INDUCTION OF MESODERM BY FGF	CELL			English	Article							PROTEIN-KINASE; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; ACTIVIN-A; C-RAF; ACTIVATION; EMBRYOS; RECEPTOR; HOMOLOG	Animal cap explants from Xenopus embryos injected with a dominant negative Raf-1 mutant, termed NAF (not a functional Raf), demonstrated a complete block to basic fibroblast growth factor (FGF)-stimulated mesoderm induction. Activin induction of mesoderm was normal in embryos that expressed NAF. Injection of NAF RNA into 2-cell stage embryos blocked normal development during neurula stages and caused severe posterior truncations in tadpoles. The phenotype induced by NAF could be rescued by coinjection of wild-type raf-I RNA. The NAF mutant functioned by specifically blocking the activation of endogenous Raf kinase activity. These findings suggest that Raf-1 mediates FGF, but not activin, receptor signaling during mesoderm induction and implicate Raf-1 as a key signaling molecule in the development of posterior structure.			MACNICOL, AM (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,PROGRAM EXCELLENCE MOLEC BIOL,SAN FRANCISCO,CA 94143, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002571, P01HL043821] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43821, K11HL02571-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTABA AR, 1989, NATURE, V341, P33; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AMBROSIO L, 1989, DEVELOPMENT, V106, P145; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BRUDERJT, 1992, GENE DEV, V6, P545; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COUGHLIN SR, 1988, J BIOL CHEM, V263, P1; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRELL JE, 1991, MOL CELL BIOL, V11, P1965, DOI 10.1128/MCB.11.4.1965; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; HOPWOOD ND, 1990, BIOESSAYS, V12, P465, DOI 10.1002/bies.950121003; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEGUELLEC R, 1991, BIOL CELL, V72, P39, DOI 10.1016/0248-4900(91)90076-Y; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MATTHEWS LS, 1991, CELL, V65, P973; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; OHMICHI M, 1992, J BIOL CHEM, V267, P14604; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAPP UR, 1991, ONCOGENE, V6, P495; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SYMES K, 1987, DEVELOPMENT, V101, P339; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; UENO H, 1992, J BIOL CHEM, V267, P1470; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	62	182	182	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					571	583		10.1016/0092-8674(93)90143-E	http://dx.doi.org/10.1016/0092-8674(93)90143-E			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	7683975				2022-12-28	WOS:A1993LA74300017
J	LONG, MY; LANGLEY, CH				LONG, MY; LANGLEY, CH			NATURAL-SELECTION AND THE ORIGIN OF JINGWEI, A CHIMERIC PROCESSED FUNCTIONAL GENE IN DROSOPHILA	SCIENCE			English	Article							MOLECULAR EVOLUTION; DNA; PSEUDOGENES; AMPLIFICATION; DUPLICATION; TRANSCRIPTS; RETROPOSONS; POLYMERASE; PRIMER	The origin of new genes includes both the initial molecular events and subsequent population dynamics. A processed Drosophila alcohol dehydrogenase (Adh) gene, previously thought to be a pseudogene, provided an opportunity to examine the two phases of the origin of a new gene. The sequence of the processed Adh messenger RNA became part of a new functional gene by capturing several upstream exons and introns of an unrelated gene. This novel chimeric gene, jingwei, differs from its parent Adh gene in both its pattern of expression and rate of molecular evolution. Natural selection participated in the origin and subsequent evolution of this gene.	UNIV CALIF DAVIS,EVOLUT & ECOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,CTR POPULAT BIOL,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis	LONG, MY (corresponding author), UNIV CALIF DAVIS,GENET SECT,DAVIS,CA 95616, USA.							ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; ASHWORTH A, 1990, EMBO J, V9, P1529, DOI 10.1002/j.1460-2075.1990.tb08271.x; BANYAI L, 1983, FEBS LETT, V163, P37, DOI 10.1016/0014-5793(83)81157-0; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GOLDBERG DA, 1982, CELL, V34, P59; Haldane JB., 1990, CAUSES EVOLUTION; HIGUCHI RG, 1989, NUCLEIC ACIDS RES, V17, P5865, DOI 10.1093/nar/17.14.5865; HOLLIS GF, 1982, NATURE, V296, P321, DOI 10.1038/296321a0; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUDSON RR, 1987, GENETICS, V116, P153; JEFFS P, 1991, P ROY SOC B-BIOL SCI, V244, P151, DOI 10.1098/rspb.1991.0064; JUKES T H, 1969, P21; Kimura M., 1983, NEUTRAL THEORY MOL E; KREITMAN M, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P204; LACHAISE D, 1988, EVOL BIOL, V22, P159; LANGLEY CH, 1982, P NATL ACAD SCI-BIOL, V79, P5631, DOI 10.1073/pnas.79.18.5631; LANGLEY CH, 1990, POPULATION BIOL GENE, P75; Li W.-H., 1983, P14; LI WH, 1981, NATURE, V292, P237, DOI 10.1038/292237a0; LI WH, 1991, FUNDAMENTALS MOL EVO; LONG MW, UNPUB; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; MORIYAMA EN, 1992, GENETICS, V130, P855; NEI M, 1981, GENETICS, V97, P145; NEI M, 1987, MOL EVOLUTIONARY GEN, P276; Ohno S., 1970, EVOLUTION GENE DUPLI; OHTA T, 1989, GENOME, V31, P304, DOI 10.1139/g89-048; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP PM, 1989, J MOL EVOL, V28, P398, DOI 10.1007/BF02603075; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P1255, DOI 10.1093/nar/18.5.1255; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; SULLIVAN DT, 1990, EVOL BIOL, V24, P107; WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; [No title captured]	43	307	318	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 2	1993	260	5104					91	95		10.1126/science.7682012	http://dx.doi.org/10.1126/science.7682012			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV423	7682012				2022-12-28	WOS:A1993KV42300035
J	ANDRADE, SE; WALKER, AM; GOTTLIEB, LK; HOLLENBERG, NK; TESTA, MA; SAPERIA, GM; PLATT, R				ANDRADE, SE; WALKER, AM; GOTTLIEB, LK; HOLLENBERG, NK; TESTA, MA; SAPERIA, GM; PLATT, R			DISCONTINUATION OF ANTIHYPERLIPIDEMIC DRUGS - DO RATES REPORTED IN CLINICAL-TRIALS REFLECT RATES IN PRIMARY-CARE SETTINGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; PRIMARY HYPERCHOLESTEROLEMIA; ATHEROSCLEROSIS-REGRESSION; COST-EFFECTIVENESS; SERUM-CHOLESTEROL; LOVASTATIN; GEMFIBROZIL; THERAPY; CHOLESTYRAMINE; DYSLIPIDEMIA	Background. Discontinuation rates for drugs used to treat chronic conditions may affect the success of therapy. However, the discontinuation rates reported in clinical trials may not reflect those in primary care settings. Methods. We conducted a cohort study using computerized research files and medical records on 2369 new users of antihyperlipidemic therapy at two health maintenance organizations (HMOs) from 1988 through 1990. The rates of drug discontinuation in these primary care settings were compared with the rates reported in clinical trials published from 1975 through 1993, located with the Medline data base. Results. In the HMOs, the one-year probability of drug discontinuation was 41 percent for bile acid sequestrants (95 percent confidence interval, 38 to 44 percent), 46 percent for niacin (95 percent confidence interval, 42 to 51 percent), 15 percent for lovastatin (95 percent confidence interval, 11 to 19 percent), and 37 percent for gemfibrozil (95 percent confidence interval, 31 to 43 percent), For the bile acid sequestrants, niacin, and gemfibrozil, the risks of discontinuation were substantially higher in the HMOs than in randomized clinical trials, in which the summary estimates of this risk were 31 percent, 4 percent, and 15 percent, respectively, for trials of one year or longer, The rates of discontinuation in open-label studies were similar to those in the HMOs. Conclusions. The discontinuation rates reported in randomized clinical trials may not reflect the rates actually observed in primary care settings, The effectiveness and tolerability of antihyperlipidemic medications should be Studied further in populations that typically use the agents.	HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD COMMUNITY HLTH PLAN, CLIN QUAL MANAGEMENT, BROOKLINE, MA USA; BRIGHAM & WOMENS HOSP, DEPT RADIOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; FALLON CLIN INC, DIV CARDIOL, WORCESTER, MA USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA; CHANNING LABS, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	ANDRADE, SE (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Testa, Marianna/L-9768-2019		AHRQ HHS [5 R01 HS07767-02] Funding Source: Medline; OHS HRSA HHS [ST32 ES07067] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); OHS HRSA HHS		[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; [Anonymous], 1993, Arch Intern Med, V153, P1321; BATES MC, 1990, ARCH INTERN MED, V150, P1947, DOI 10.1001/archinte.150.9.1947; BETTERIDGE DJ, 1992, BRIT MED J, V304, P1335, DOI 10.1136/bmj.304.6838.1335; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; CALDWELL JR, 1970, J CHRON DIS, V22, P579, DOI 10.1016/0021-9681(70)90034-2; COOPER EE, 1975, SOUTHERN MED J, V68, P303, DOI 10.1097/00007611-197503000-00011; CREPALDI G, 1991, ARCH INTERN MED, V151, P146, DOI 10.1001/archinte.151.1.146; CURB JD, 1985, JAMA-J AM MED ASSOC, V253, P3263, DOI 10.1001/jama.253.22.3263; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; EISALO A, 1976, P ROY SOC MED, V69, P49, DOI 10.1177/00359157760690S213; ENGELLAND AL, 1979, AM J PUBLIC HEALTH, V69, P25, DOI 10.2105/AJPH.69.1.25; FARMER JA, 1992, CLIN THER, V14, P708; FRICK MH, 1993, ANN MED, V25, P41, DOI 10.3109/07853899309147855; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GALLUP G, 1986, AM J MED, V81, P20, DOI 10.1016/0002-9343(86)90524-3; GERMAN PS, 1988, HYPERTENSION, V11, pS56; Gillum R F, 1979, J Community Health, V5, P94, DOI 10.1007/BF01324011; GOLDBERG R, 1990, AM J CARDIOL, V66, pB16, DOI 10.1016/0002-9149(90)90436-5; GOTTO AM, 1993, AM J CARDIOL, V71, P1057, DOI 10.1016/0002-9149(93)90573-U; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HAYNES RB, 1976, LANCET, V1, P1265; INUI TS, 1980, MED CARE, V18, P986, DOI 10.1097/00005650-198010000-00002; ITSKOVITZ HD, 1989, CLIN THER, V11, P862; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KANNEL WB, 1990, AM J CARDIOL, V66, pB1, DOI 10.1016/0002-9149(90)90434-3; KNOPP RH, 1985, METABOLISM, V34, P642, DOI 10.1016/0026-0495(85)90092-7; KOSKINEN P, 1992, ARCH INTERN MED, V152, P90, DOI 10.1001/archinte.152.1.90; Kundu S C, 1990, J Assoc Physicians India, V38, P156; LURIA MH, 1988, ARCH INTERN MED, V148, P2493, DOI 10.1001/archinte.148.11.2493; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLSSON AG, 1976, P ROY SOC MED, V69, P28; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RYAN JR, 1975, CLIN PHARMACOL THER, V17, P83; SAHNI R, 1991, AM HEART J, V121, P1600, DOI 10.1016/0002-8703(91)90002-Y; SCHECTMAN G, 1993, AM J CARDIOL, V71, P759, DOI 10.1016/0002-9149(93)90820-3; SCHULMAN KA, 1990, JAMA-J AM MED ASSOC, V264, P3025, DOI 10.1001/jama.264.23.3025; THURMER HL, 1994, J HYPERTENS, V12, P481; Varthakavi P K, 1990, J Assoc Physicians India, V38, P136; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WIREBAUGH SR, 1992, PHARMACOTHERAPY, V12, P445; WIREBAUGH SR, 1993, PHARMACOL THERAPEUT, V18, P559; YOVOS JG, 1982, J CLIN ENDOCR METAB, V54, P1210, DOI 10.1210/jcem-54-6-1210	46	332	385	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 27	1995	332	17					1125	1131		10.1056/NEJM199504273321703	http://dx.doi.org/10.1056/NEJM199504273321703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU302	7700285				2022-12-28	WOS:A1995QU30200003
J	BERNSTEIN, DI; GLASS, RI; RODGERS, G; DAVIDSON, BL; SACK, DA				BERNSTEIN, DI; GLASS, RI; RODGERS, G; DAVIDSON, BL; SACK, DA			EVALUATION OF RHESUS ROTAVIRUS MONOVALENT AND TETRAVALENT REASSORTANT VACCINES IN US CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENEZUELAN INFANTS; FIELD TRIAL; DIARRHEA; PROTECTION; SEROTYPE-1; EFFICACY; IMMUNOGENICITY; LIVE; WC3; REACTOGENICITY	Objective.-To determine the safety and relative efficacy of two reassortant rhesus rotavirus vaccines over two rotavirus seasons. Design.-A prospective, double-masked, placebo-controlled trial. Setting.-Twenty-three centers in the United States. Participants.-A total of 1006 healthy infants between 4 and 26 weeks of age were enrolled, and 898 received three doses of vaccine or placebo. Main Outcome Measures.-Reactogenicity was determined by comparing the incidence of fever, diarrhea, and/or vomiting for 5 days after each dose of vaccine. Rotavirus IgA and neutralizing antibody to rhesus rotavirus and four rotavirus serotypes were measured in a subset of subjects. Relative efficacy was determined by comparing the incidence of rotavirus gastroenteritis after three doses of vaccine or placebo over two rotavirus seasons. Results.-Adverse reactions were mild and limited to a small but significant increase in the incidence of fever after the first dose of tetravalent but not monovalent vaccine. The relative efficacy against rotavirus disease over the 2 years of observation was 40% (98.3% confidence interval, 7% to 62%) for the monovalent and 57% (98.3% confidence interval, 29% to 74%) for the tetravalent vaccine. In post hoc analyses, the relative efficacy against very severe rotavirus gastroenteritis was 73% and 82% for monovalent and tetravalent vaccine recipients, respectively. Also, a 67% and 78% reduction in medical visits for rotavirus gastroenteritis was observed. Both vaccines protected against disease caused by serotype 1 rotavirus, but only the tetravalent vaccine reduced the incidence of disease caused by non-serotype 1 rotavirus infection detected in the second season. It is unclear, however, whether this result represents serotype-specific protection or a difference in the duration of protection. Conclusions.-Vaccination with both vaccines was safe and significantly reduced the incidence of rotavirus gastroenteritis, but only the tetravalent vaccine provided protection against disease caused by non-serotype 1 rotaviruses during the second year of follow-up.	CTR DIS CONTROL & PREVENT,VIRAL GASTROENTERITIS UNIT,ATLANTA,GA 30341; UNIV LOUISVILLE,SCH MED,DEPT PEDIAT,LOUISVILLE,KY 40292; WYETH AYERST,PHILADELPHIA,PA; JOHNS HOPKINS UNIV,DEPT INT HLTH,BALTIMORE,MD	Centers for Disease Control & Prevention - USA; University of Louisville; Pfizer; Johns Hopkins University	BERNSTEIN, DI (corresponding author), JAMES N GAMBLE INST MED RES,DIV CLIN VIROL,2141 AUBURN AVE,CINCINNATI,OH 45219, USA.							BERNSTEIN DI, 1989, J MED VIROL, V28, P90, DOI 10.1002/jmv.1890280207; BERNSTEIN DI, 1990, J INFECT DIS, V162, P1055, DOI 10.1093/infdis/162.5.1055; BISHOP RF, 1993, VACCINE, V11, P247, DOI 10.1016/0264-410X(93)90025-S; CHIBA S, 1986, LANCET, V2, P417; CHRISTY C, 1988, PEDIATR INFECT DIS J, V7, P645, DOI 10.1097/00006454-198809000-00009; CLARK HF, 1990, J INFECT DIS, V161, P1099, DOI 10.1093/infdis/161.6.1099; CLARK HF, 1988, J INFECT DIS, V158, P570, DOI 10.1093/infdis/158.3.570; DAGAN R, 1992, PEDIATR INFECT DIS J, V11, P991, DOI 10.1097/00006454-199211120-00001; DEMOL P, 1986, LANCET, V2, P108; EDELMAN R, 1987, PEDIATR INFECT DIS J, V6, P704, DOI 10.1097/00006454-198708000-00002; FLORES J, 1989, J CLIN MICROBIOL, V27, P512, DOI 10.1128/JCM.27.3.512-518.1989; FLORES J, 1987, LANCET, V1, P882; FLORES J, 1993, J CLIN MICROBIOL, V31, P2439, DOI 10.1128/JCM.31.9.2439-2445.1993; GOTHEFORS L, 1989, J INFECT DIS, V159, P753, DOI 10.1093/infdis/159.4.753; GREEN KY, 1990, J INFECT DIS, V161, P667, DOI 10.1093/infdis/161.4.667; HANLON P, 1987, LANCET, V1, P1342; HO MS, 1989, PEDIATR INFECT DIS J, V8, P692, DOI 10.1097/00006454-198910000-00006; HO MS, 1988, J INFECT DIS, V158, P1112, DOI 10.1093/infdis/158.5.1112; ING DJ, 1991, AM J DIS CHILD, V145, P892, DOI 10.1001/archpedi.1991.02160080070023; KAPIKIAN AZ, 1986, J INFECT DIS, V153, P815, DOI 10.1093/infdis/153.5.815; KAPIKIAN AZ, 1990, VIROLOGY, P1353; MADORE HP, 1992, J INFECT DIS, V166, P235, DOI 10.1093/infdis/166.2.235; MIDTHUN K, 1985, J VIROL, V53, P949, DOI 10.1128/JVI.53.3.949-954.1985; PEREZSCHAEL I, 1990, J MED VIROL, V30, P219, DOI 10.1002/jmv.1890300315; PEREZSCHAEL I, 1990, J CLIN MICROBIOL, V28, P553, DOI 10.1128/JCM.28.3.553-558.1990; RENNELS MB, 1990, AM J DIS CHILD, V144, P601, DOI 10.1001/archpedi.1990.02150290095037; SANTOSHAM M, 1991, J INFECT DIS, V163, P483, DOI 10.1093/infdis/163.3.483; UHNOO I, 1990, J VIROL, V64, P361, DOI 10.1128/JVI.64.1.361-368.1990; VESIKARI T, 1993, VACCINE, V11, P255, DOI 10.1016/0264-410X(93)90026-T; VESIKARI T, 1984, LANCET, V1, P977; VESIKARI T, 1992, PEDIATR INFECT DIS J, V11, P535, DOI 10.1097/00006454-199207000-00006; WARD RL, 1991, J CLIN MICROBIOL, V29, P1915, DOI 10.1128/JCM.29.9.1915-1923.1991; WARD RL, 1993, J VIROL, V67, P464, DOI 10.1128/JVI.67.1.464-468.1993; WARD RL, 1992, J INFECT DIS, V166, P1251, DOI 10.1093/infdis/166.6.1251; 1989, SAS STAT USERS GUIDE, V1, P871; 1986, NEW VACCINE DEV ESTA, V2, P308	36	213	218	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1191	1196		10.1001/jama.273.15.1191	http://dx.doi.org/10.1001/jama.273.15.1191			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT100	7707626				2022-12-28	WOS:A1995QT10000027
J	ESPINAL, MA; REINGOLD, AL; KOENIG, E; LAVANDERA, M; SANCHEZ, S				ESPINAL, MA; REINGOLD, AL; KOENIG, E; LAVANDERA, M; SANCHEZ, S			SCREENING FOR ACTIVE TUBERCULOSIS IN HIV TESTING CENTER	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS-DRUG-USERS; INFECTED PATIENTS; OUTBREAK	In industrialised nations HIV-seropositive individuals can be offered shin testing for tuberculosis (TB) and isoniazid prophylaxis, but this approach is neither practicable nor affordable in most developing countries. in Santo Domingo, Dominican Republic, we offered skin testing and a brief clinical examination for active TB to people requesting HIV testing at one centre. 200 newly detected HIV-positive individuals and 200 age and sex-matched HIV-negative ones were compared. 39 (9.7%) of the 400 individuals seeking HIV testing had active TB; 29 were HIV positive and 10 were HIV negative (adjusted odds ratio 3.3, 95% CI 1.3-8.7; p=0.01). In multivariate analysis, the strongest independent predictors of active TB were 10 mm or more of induration on skin testing, a history of chronic cough, lymphadenopathy, and HIV infection. Of the patients diagnosed with TB, 85% had one or more symptoms readily ascertainable in a brief screening questionnaire. Screening for TB at HIV-testing sites could be an effective approach to early detection of active TB among not just HIV-positive but also HIV-negative people. integrating screening for TB into HIV testing schemes could help to reduce the spread of TB and allow patients with TB to be diagnosed and treated earlier.	UNIV CALIF BERKELEY,SCH PUBL HLTH,DIV PUBL HLTH BIOL & EPIDEMIOL,BERKELEY,CA 94720; NATL LAB PUBL HLTH,SANTO DOMINGO,DOMINICAN REP; MINIST HLTH,NATL TB CONTROL PROGRAM,SANTO DOMINGO,DOMINICAN REP	University of California System; University of California Berkeley					FOGARTY INTERNATIONAL CENTER [D43TW000003] Funding Source: NIH RePORTER; FIC NIH HHS [D43-TW00003-03] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		BOUVET E, 1993, AIDS, V7, P1453, DOI 10.1097/00002030-199311000-00008; CHAISSON RE, 1992, AM REV RESPIR DIS, V146, P285, DOI 10.1164/ajrccm/146.2.285; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DIPERRI G, 1989, LANCET, V2, P1502; DUCOS J, 1992, 7 INT C AIDS AMST; Espinal M, 1994, Bol Oficina Sanit Panam, V116, P452; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; GARCIA V, 1993, NEUMOS, V8, P169; GARCIA V, 1992, NEUMOS, V7, P9; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; HARRIES AD, 1990, LANCET, V335, P390; JOHNSON MP, 1992, J INFECT DIS, V166, P194, DOI 10.1093/infdis/166.1.194; LONG R, 1991, AM REV RESPIR DIS, V143, P69, DOI 10.1164/ajrccm/143.1.69; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; SANCHEZ S, 1993, NEUMOS, V8, P55; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SNIDER DE, 1994, TUBERCULOSIS PATHOGE; Sutherland I, 1976, Adv Tuberc Res, V19, P1; 1994, TUBER LUNG DIS, V75, P96; 1989, MMWR-MORBID MORTAL W, V38, P243; 1989, MMWR-MORBID MORTAL W, V38, P236	21	23	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					890	893		10.1016/S0140-6736(95)90010-1	http://dx.doi.org/10.1016/S0140-6736(95)90010-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707812				2022-12-28	WOS:A1995QR06700010
J	CHRIST, WJ; ASANO, O; ROBIDOUX, ALC; PEREZ, M; WANG, YA; DUBUC, GR; GAVIN, WE; HAWKINS, LD; MCGUINNESS, PD; MULLARKEY, MA; LEWIS, MD; KISHI, Y; KAWATA, T; BRISTOL, JR; ROSE, JR; ROSSIGNOL, DP; KOBAYASHI, S; HISHINUMA, L; KIMURA, A; ASAKAWA, N; KATAYAMA, K; YAMATSU, I				CHRIST, WJ; ASANO, O; ROBIDOUX, ALC; PEREZ, M; WANG, YA; DUBUC, GR; GAVIN, WE; HAWKINS, LD; MCGUINNESS, PD; MULLARKEY, MA; LEWIS, MD; KISHI, Y; KAWATA, T; BRISTOL, JR; ROSE, JR; ROSSIGNOL, DP; KOBAYASHI, S; HISHINUMA, L; KIMURA, A; ASAKAWA, N; KATAYAMA, K; YAMATSU, I			E5531, A PURE ENDOTOXIN ANTAGONIST OF HIGH POTENCY	SCIENCE			English	Article							GRAM-NEGATIVE ENDOTOXIN; LIPID-A; ESCHERICHIA-COLI; SEPTIC SHOCK; INFLAMMATORY MEDIATORS; LIPOPOLYSACCHARIDE; SEPSIS; BIOSYNTHESIS; NEUTROPHILS; MACROPHAGES	Shock due to Gram-negative bacterial sepsis is a consequence of acute inflammatory response to lipopolysaccharide (LPS) or endotoxin released from bacteria. LPS is a major constituent of the outer membrane of Gram-negative bacteria, and its terminal disaccharide phospholipid (lipid A) portion contains the key structural features responsible for toxic activity. Based on the proposed structure of nontoxic Rhodobacter capsulatus lipid A, a fully stabilized endotoxin antagonist E5531 has been synthesized. In vitro, E5531 demonstrated potent antagonism of LPS-mediated cellular activation in a variety of systems. In vivo, E5531 protected mice from LPS-induced lethality and, in cooperation with an antibiotic, protected mice from a lethal infection of viable Escherichia coli.	EISAI RES INST,ANDOVER,MA 01810; EISAI & CO LTD,TSUKUBA RES LABS,TSUKUBA,IBARAKI 30026,JAPAN	Eisai Co Ltd; Eisai Co Ltd								BILLIAU A, 1991, EUR J CLIN INVEST, V21, P559, DOI 10.1111/j.1365-2362.1991.tb01410.x; BONE RC, 1993, CLIN MICROBIOL REV, V6, P57, DOI 10.1128/CMR.6.1.57-68.1993; BONE RC, 1991, CHEST, V100, P802, DOI 10.1378/chest.100.3.802; BULAWA CE, 1984, J BIOL CHEM, V259, P4846; BUNNELL E, 1995, 24TH ED SCI S SOC CR; CHRIST WJ, 1994, J AM CHEM SOC, V116, P3637, DOI 10.1021/ja00087a075; CHRIST WJ, 1836, Patent No. 935050; CHRIST WJ, UNPUB; CROSBY HA, 1994, J MED MICROBIOL, V40, P23, DOI 10.1099/00222615-40-1-23; DANNER RL, 1990, PHARMACEUT RES, V7, P260, DOI 10.1023/A:1015874012484; DANNER RL, 1987, J CLIN INVEST, V80, P605, DOI 10.1172/JCI113112; DOFFERHOFF ASM, 1991, SCAND J INFECT DIS, V23, P745, DOI 10.3109/00365549109024303; ENDO S, 1992, CIRC SHOCK, V38, P264; FELBER BK, 1988, SCIENCE, V239, P184, DOI 10.1126/science.3422113; GALANOS C, 1985, EUR J BIOCHEM, V148, P1, DOI 10.1111/j.1432-1033.1985.tb08798.x; GLAUSER MP, 1994, J CLIN INFECT DIS S2, V18, pS205; GOLENBOCK DT, 1987, INFECT IMMUN, V55, P2471, DOI 10.1128/IAI.55.10.2471-2476.1987; IMOTO M, 1985, TETRAHEDRON LETT, V26, P1545, DOI 10.1016/S0040-4039(00)98548-4; KAWATA T, 1992, 32ND INT C ANT AG CH, P1360; KRAUSS JH, 1989, EUR J BIOCHEM, V180, P519, DOI 10.1111/j.1432-1033.1989.tb14677.x; LOPPNOW H, 1990, INFECT IMMUN, V58, P3743, DOI 10.1128/IAI.58.11.3743-3750.1990; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PRINS JM, 1994, ANTIMICROB AGENTS CH, V38, P1211, DOI 10.1128/AAC.38.6.1211; PROCTOR RA, 1986, INFECT IMMUN, V52, P905, DOI 10.1128/IAI.52.3.905-907.1986; QURESHI N, 1988, J BIOL CHEM, V263, P5502; RAY BL, 1984, J BIOL CHEM, V259, P4852; Rokke O, 1988, Prog Clin Biol Res, V272, P247; ROSSIGNOL D, 1992, 3IND INT C ANT AG CH, P1361; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; VOGEL SN, 1980, J IMMUNOL, V124, P2004; WANG SC, 1994, SURGERY, V116, P339; WELBOURN CRB, 1992, BRIT J SURG, V79, P998, DOI 10.1002/bjs.1800791006	33	297	313	0	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					80	83		10.1126/science.7701344	http://dx.doi.org/10.1126/science.7701344			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701344				2022-12-28	WOS:A1995QR45400028
J	TJOELKER, LW; WILDER, C; EBERHARDT, C; STAFFORINI, DM; DIETSCH, G; SCHIMPF, B; HOOPER, S; LETRONG, H; COUSENS, LS; ZIMMERMAN, GA; YAMADA, Y; MCINTYRE, TM; PRESCOTT, SM; GRAY, PW				TJOELKER, LW; WILDER, C; EBERHARDT, C; STAFFORINI, DM; DIETSCH, G; SCHIMPF, B; HOOPER, S; LETRONG, H; COUSENS, LS; ZIMMERMAN, GA; YAMADA, Y; MCINTYRE, TM; PRESCOTT, SM; GRAY, PW			ANTIINFLAMMATORY PROPERTIES OF A PLATELET-ACTIVATING-FACTOR ACETYLHYDROLASE	NATURE			English	Article							PAF ACETYLHYDROLASE; PLASMA; CELLS; PHOSPHOLIPIDS; SECRETE; RELEASE	PLATELET-ACTIVATING factor (PAF) is a potent pro-inflammatory phospholipid that activates cells involved in inflammation(1,2). The biological activity of PAF depends on its structural features, namely an ether linkage at the sn-1 position and an acetate group at the sn-2 position. The actions of PAF are abolished by hydrolysis of the acetyl residue, a reaction catalysed by PAF acetylhydrolase. There are at least two forms of this enzyme-one intracellular and another that circulates in plasma and is likely to regulate inflammation. Here we report the molecular cloning and characterization of the human plasma PAF acetylhydrolase. The unique sequence contains a Gly-Xaa-Ser-Xaa-Gly motif commonly found in lipases. Recombinant PAF acetylhydrolase has the substrate specificity and lipoprotein association of the native enzyme, and blocks inflammation in vivo: it markedly decreases vascular leakage in pleurisy and paw oedema, suggesting that PAF acetylhydrolase might be a useful therapy for severe acute inflammation.	UNIV UTAH,ECCLES INST HUMAN GENET,PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,INST CARDIOVASC RES & TRAINING,SALT LAKE CITY,UT 84112; ICOS CORP,BOTHELL,WA 98021	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Icos Corporation								BLANK ML, 1981, J BIOL CHEM, V256, P175; CHAPUS C, 1988, BIOCHIMIE, V70, P1223, DOI 10.1016/0300-9084(88)90188-5; CYGLER M, 1993, PROTEIN SCI, V2, P366; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; GRAHAM RM, 1994, CRIT CARE MED, V22, P204, DOI 10.1097/00003246-199402000-00009; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HENRIQUES MGMO, 1992, BRIT J PHARMACOL, V106, P579, DOI 10.1111/j.1476-5381.1992.tb14378.x; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; MAKI N, 1988, P NATL ACAD SCI USA, V85, P728, DOI 10.1073/pnas.85.3.728; MIOZZARI GF, 1978, J BACTERIOL, V133, P1457, DOI 10.1128/JB.133.3.1457-1466.1978; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; NARAHARA H, 1993, ARCH BIOCHEM BIOPHYS, V301, P275, DOI 10.1006/abbi.1993.1144; PATEL KD, 1992, J BIOL CHEM, V267, P15168; SATOH K, 1991, J CLIN INVEST, V87, P476, DOI 10.1172/JCI115020; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; STAFFORINI DM, 1990, J BIOL CHEM, V265, P9682; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TANAKA T, 1993, BIOCHIM BIOPHYS ACTA, V1166, P264, DOI 10.1016/0005-2760(93)90107-K; TARBET EB, 1991, J BIOL CHEM, V266, P16667; TETTA C, 1990, INT ARCH ALLER A IMM, V91, P244, DOI 10.1159/000235124; VENABLE ME, 1993, J LIPID RES, V34, P691; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YOSHIDA JI, 1986, J PHARM PHARMACOL, V38, P878, DOI 10.1111/j.2042-7158.1986.tb03375.x; ZIMMERMAN GA, 1992, INFLAMMATION BASIC P, V2, P149	27	447	482	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					549	553		10.1038/374549a0	http://dx.doi.org/10.1038/374549a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700381				2022-12-28	WOS:A1995QR06900054
J	REES, J				REES, J			RETHINKING CONSULTANTS - WHERE MEDICAL SCIENCE AND HUMAN-BEHAVIOR MEET .3.	BRITISH MEDICAL JOURNAL			English	Article								Although we may be wrong about the details, we should try to imagine what the future holds for hospital consultants. The days of the independent consultant in the same post for 30 years are over, and there will be a change from ''the'' consultant to a few tiers of senior staff. Patients will increasingly demand to see specialists, so more specialists will be needed. As patients and their advocates become better informed the traditional rationing of clinical care to patients in Britain, such as restricting access to specialists, cannot continue. There is a current trend for evidence based health care, but the idea that each element of medical practice can be dictated by systematic evidence based research will prove to be naive-such research informs practice rather than dictates it. Science will continue to act as the guide to medical practice but specialists will not be turned into a set of logical operators running programs designed by health planners.			REES, J (corresponding author), UNIV NEWCASTLE UPON TYNE,DEPT DERMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							1977, SENSE FUTURE ESSAYS; 1961, SCI HUMAN VALUES	2	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 1	1995	310	6983					850	853		10.1136/bmj.310.6983.850	http://dx.doi.org/10.1136/bmj.310.6983.850			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711626	Green Published			2022-12-28	WOS:A1995QQ85700025
J	COOPER, DMF; MONS, N; KARPEN, JW				COOPER, DMF; MONS, N; KARPEN, JW			ADENYLYL CYCLASES AND THE INTERACTION BETWEEN CALCIUM AND CAMP SIGNALING	NATURE			English	Article							CALMODULIN-BINDING DOMAIN; PROTEIN-KINASE-C; RAT-BRAIN; DICTYOSTELIUM-DISCOIDEUM; REGULATORY PROTEINS; NCB-20 CELLS; EXPRESSION; CLONING; OSCILLATIONS; STIMULATION	Adenylyl cyclase is the prototypical second messenger generator. Nearly all of the eight cloned adenylyl cyclases are regulated by one or other arm of the phospholipase C pathway. Functional and ultrastructural investigations have shown that adenylyl cyclases are intimately associated with sites of calcium ion entry into the cell. Oscillations in cellular cyclic AMP levels are predicted to arise because of feedback inhibition of adenylyl cyclase by Ca2+. Such findings inextricably intertwine cellular signalling by cAMP and internal Ca2+ and extend the known regulatory modes available to cAMP.	UNIV COLORADO, HLTH SCI CTR, DEPT PHYSIOL, DENVER, CO 80262 USA; UNIV BORDEAUX 1, FUNCT NEUROCYTOCHEM LAB, CNRS, URA 399, F-33405 TALENCE, FRANCE	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	COOPER, DMF (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, DENVER, CO 80262 USA.		Mons, Nicole/AAD-5541-2019					BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BROOKER G, 1973, SCIENCE, V182, P933, DOI 10.1126/science.182.4115.933; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CARR DW, 1992, P NATL ACAD SCI USA, V89, P16816; CATTERALL WA, 1994, CURR OPIN CELL BIOL, V6, P607, DOI 10.1016/0955-0674(94)90083-3; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHLONO M, 1995, J BIOL CHEM, V270, P1149; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; COOPER DMF, 1995, J NEUROCHEM, V64, P79; CUTHBERTSON KSR, 1991, CELL CALCIUM, V12; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; HELLEVUO K, IN PRESS J BIOL CHEM, V270; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MONK PB, 1989, PHILOS T R SOC B, V323, P185, DOI 10.1098/rstb.1989.0005; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; MONS N, 1993, SYNAPSE, V14, P51, DOI 10.1002/syn.890140108; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PENNER R, 1988, J EXP BIOL, V139, P329; PETRALIA RS, 1994, J NEUROSCI, V14, P667; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; RAPP PE, 1977, J THEOR BIOL, V66, P497, DOI 10.1016/0022-5193(77)90299-5; Rasmussen H, 1980, Ann N Y Acad Sci, V356, P346, DOI 10.1111/j.1749-6632.1980.tb29622.x; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBISON GA, 1968, ANNU REV BIOCHEM, V37, P149, DOI 10.1146/annurev.bi.37.070168.001053; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; ROOS W, 1977, NATURE, V266, P259, DOI 10.1038/266259a0; SCHLEGEL W, 1979, J BIOL CHEM, V254, P5168; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SIEGEL SJ, 1994, P NATL ACAD SCI USA, V91, P564, DOI 10.1073/pnas.91.2.564; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TRAUTWEIN W, 1990, REV PHYSL, V52, P257; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WU ZF, 1992, ADV SEC MESS PHOSPH, V25, P29; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; WU ZL, 1993, J BIOL CHEM, V268, P23766; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; YAU KW, 1994, P NATL ACAD SCI USA, V91, P3481, DOI 10.1073/pnas.91.9.3481; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604; YU HJ, 1993, MOL PHARMACOL, V44, P689	66	543	555	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 30	1995	374	6521					421	424		10.1038/374421a0	http://dx.doi.org/10.1038/374421a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700350				2022-12-28	WOS:A1995QP89900048
J	ROSEN, MK; YAMAZAKI, T; GISH, GD; KAY, CM; PAWSON, T; KAY, LE				ROSEN, MK; YAMAZAKI, T; GISH, GD; KAY, CM; PAWSON, T; KAY, LE			DIRECT DEMONSTRATION OF AN INTRAMOLECULAR SH2-PHOSPHOTYROSINE INTERACTION IN THE CRK PROTEIN	NATURE			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; SH3 DOMAINS; V-CRK; BINDING; SRC; IDENTIFICATION; PRODUCT; PEPTIDE	MANY signal transduction processes are mediated by the binding Of Src-homology-2 (SH2) domains to phosphotyrosine (pTyr)-containing proteins(1). Although most SH2-pTyr interactions occur between tao different types of molecules, some appear to involve only a single molecular type. It has been proposed that the enzymatic activity and substrate recognition of the Src-family kinases(2-4), and the protein-binding and transforming activity of Crk-family adaptor proteins(5), are regulated by intramolecular SH2-pTyr interactions. In addition, the DNA-binding activity of Stat transcription factors seems to be regulated by SH2-mediated homodimerization(6). Here we examine the phosphorylated and non-phosphorylated forms of murine Crk II (p-mCrk and mCrk, respectively)(7-9) using a combination of physical techniques. The Crk protein contains a single SH2 domain and two SH3 domains in the order SH2-SH3-SH3. There is a tyrosine-phosphorylation site between the two SH3 domains at residue 221 which is phosphorylated in vivo by the Abl tyrosine kinase(5). Using NMR spectroscopic analysis, we show here that the SH2 domain of purified p-mCrk is bound to pTyr, and by hydrodynamic measurements that the phosphorylated protein is monomeric, These results provide direct demonstration of an intramolecular SH2-pTyr interaction in a signalling molecule.	UNIV TORONTO, DEPT MED GENET, TORONTO, ON M5S 1A8, CANADA; UNIV TORONTO, DEPT CHEM & BIOCHEM, TORONTO, ON M5S 1A8, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAMME MOLEC BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV ALBERTA, DEPT BIOCHEM, MRC, PROT STRUCT & FUNCT GRP, EDMONTON, AB T6G 2H7, CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Alberta	ROSEN, MK (corresponding author), UNIV TORONTO, PROT ENGN NETWORK CTR EXCELLENCE, MED SCI BLDG, TORONTO, ON M5S 1A8, CANADA.		Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013					BABUL J, 1969, ANAL BIOCHEM, V28, P216, DOI 10.1016/0003-2697(69)90172-9; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; ODA T, 1994, J BIOL CHEM, V269, P22925; OGAWA S, 1994, ONCOGENE, V9, P1669; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; VOGEL HJ, 1989, METHOD ENZYMOL, V177, P263; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YU HT, 1994, NAT STRUCT BIOL, V1, P417, DOI 10.1038/nsb0794-417; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	27	106	108	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 30	1995	374	6521					477	479		10.1038/374477a0	http://dx.doi.org/10.1038/374477a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700361				2022-12-28	WOS:A1995QP89900065
J	BARKER, DJP; MARTYN, CN; OSMOND, C; WIELD, GA				BARKER, DJP; MARTYN, CN; OSMOND, C; WIELD, GA			ABNORMAL LIVER GROWTH IN-UTERO AND DEATH FROM CORONARY HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							ADULT LIFE				BARKER, DJP (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BOCHNER CJ, 1987, AM J OBSTET GYNECOL, V157, P703, DOI 10.1016/S0002-9378(87)80033-9; Gruenwald P, 1974, CIBA F S, V27, P3; MARTYN CN, 1995, BRIT J HAEMATOL, V89, P142, DOI 10.1111/j.1365-2141.1995.tb08920.x	5	72	74	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					703	704		10.1136/bmj.310.6981.703	http://dx.doi.org/10.1136/bmj.310.6981.703			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711538	Green Published			2022-12-28	WOS:A1995QN46100020
J	IMAI, K; NAKACHI, K				IMAI, K; NAKACHI, K			CROSS-SECTIONAL STUDY OF EFFECTS OF DRINKING GREEN TEA ON CARDIOVASCULAR AND LIVER-DISEASES	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BODY IRON STORES; (-)-EPIGALLOCATECHIN GALLATE; ULTRAVIOLET-LIGHT; FREE-RADICALS; CANCER; CHOLESTEROL; CONSUMPTION; RISK; FLAVONOIDS	Objective-To investigate the association between consumption of green tea and various serum markers in a Japanese population, with special reference to preventive effects of green tea against cardiovascular disease and disorders of the liver. Design-Cross sectional study. Setting-Yoshimi, Japan. Subjects-1371 men aged over 40 years resident in Yoshimi and surveyed on their living habits including daily consumption of green tea. Their peripheral blood samples were subjected to several biochemical assays. Results-Increased consumption of green tea was associated with decreased serum concentrations of total cholesterol (P for trend <0.001) and triglyceride (P for trend=0 . 02) and an increased proportion of high density lipoprotein cholesterol together with a decreased proportion of low and very low lipoprotein cholesterols (P for trend=0 . 02), which resulted in a decreased atherogenic index (P for trend=0.02). Moreover, increased consumption of green tea, especially more than 10 cups a day, was related to decreased concentrations of hepatological markers in serum, aspartate aminotransferase (P for trend=0 . 06), alanine transferase (P for trend=0 . 07), and ferritin (P for trend=0 . 02). Conclusion-The inverse association between consumption of green tea and various serum markers shows that green tea may act protectively against cardiovascular disease and disorders of the liver.			IMAI, K (corresponding author), SAITAMA CANC CTR,RES INST,DEPT EPIDEMIOL,KOMURO 818,INA,SAITAMA 362,JAPAN.							BROWN CA, 1993, J EPIDEMIOL COMMUN H, V47, P171, DOI 10.1136/jech.47.3.171; CHISAKA T, 1988, CHEM PHARM BULL, V36, P227; CONNEY AH, 1992, PREV MED, V21, P361, DOI 10.1016/0091-7435(92)90043-H; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; FUJIKI H, 1992, PREV MED, V21, P503, DOI 10.1016/0091-7435(92)90057-O; GREEN MS, 1992, PREV MED, V21, P532, DOI 10.1016/0091-7435(92)90061-L; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; HUSAIN SR, 1987, PHYTOCHEMISTRY, V26, P2489, DOI 10.1016/s0031-9422(00)83860-1; IKEDA I, 1992, BIOCHIM BIOPHYS ACTA, V1127, P141, DOI 10.1016/0005-2760(92)90269-2; KONO S, 1992, PREV MED, V21, P526, DOI 10.1016/0091-7435(92)90060-U; MURAMATSU K, 1986, J NUTR SCI VITAMINOL, V32, P613, DOI 10.3177/jnsv.32.613; NAKACHI K, 1992, JPN J CANCER RES, V83, P798, DOI 10.1111/j.1349-7006.1992.tb01983.x; NAKACHI K, 1991, CANCER RES, V51, P5177; NAKACHI K, 1993, CANCER RES, V53, P2994; NAKAYAMA T, 1994, CANCER RES S, V54; OSAWA T, 1990, BASIC LIFE SCI, V52, P139; SANO M, 1986, CHEM PHARM BULL, V34, P221; SELBY JV, 1988, INT J CANCER, V41, P677, DOI 10.1002/ijc.2910410507; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STENSVOLD I, 1992, PREV MED, V21, P546, DOI 10.1016/0091-7435(92)90062-M; STEVENS RG, 1986, J NATL CANCER I, V76, P605, DOI 10.1093/jnci/76.4.605; STEVENS RG, 1988, NEW ENGL J MED, V319, P1047, DOI 10.1056/NEJM198810203191603; WANG ZY, 1992, CANCER RES, V52, P1162; WANG ZY, 1989, MUTAT RES, V223, P273, DOI 10.1016/0165-1218(89)90120-1; YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038; Yoshizawa S., 1987, PHYTOTHER RES, V1, P44, DOI [10.1002/ptr.2650010110, DOI 10.1002/PTR.2650010110]; YOUNG W, 1967, NATURE, V216, P1015, DOI 10.1038/2161015a0; ZHAO BL, 1989, CELL BIOPHYS, V14, P175, DOI 10.1007/BF02797132	30	340	343	1	31	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					693	696		10.1136/bmj.310.6981.693	http://dx.doi.org/10.1136/bmj.310.6981.693			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711535	Green Published			2022-12-28	WOS:A1995QN46100017
J	MACKINNON, R; ALDRICH, RW; LEE, AW				MACKINNON, R; ALDRICH, RW; LEE, AW			FUNCTIONAL STOICHIOMETRY OF SHAKER POTASSIUM CHANNEL INACTIVATION	SCIENCE			English	Article								Shaker potassium channels from Drosophila are composed of four identical subunits. The contribution of a single subunit to the inactivation gating transition was investigated. Channels carrying a specific mutation in a single subunit can be labeled in a heterogeneous population and studied quantitatively with scorpion toxin sensitivity as a selection tag. Linkage within a single subunit of a mutation that removes the inactivation gate to a second mutation that affects scorpion toxin sensitivity demonstrates that only a single gate is necessary to produce inactivation. The inactivation rate constant for channels with a single gate was one-fourth that of channels with four gates. In contrast, the rate of recovery from inactivation was independent of the number of gates. It appears that each of the four open inactivation gates in a Shaker potassium channel is independent, but only one of the four gates closes in a mutually exclusive manner.	STANFORD UNIV,MED CTR,SCH MED,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University	MACKINNON, R (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115, USA.				NINDS NIH HHS [NS23294] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023294] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	8	162	168	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					757	759		10.1126/science.7694359	http://dx.doi.org/10.1126/science.7694359			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	7694359				2022-12-28	WOS:A1993MD95200047
J	SAMBROOK, P; BIRMINGHAM, J; KELLY, P; KEMPLER, S; NGUYEN, T; POCOCK, N; EISMAN, J				SAMBROOK, P; BIRMINGHAM, J; KELLY, P; KEMPLER, S; NGUYEN, T; POCOCK, N; EISMAN, J			PREVENTION OF CORTICOSTEROID OSTEOPOROSIS - A COMPARISON OF CALCIUM, CALCITRIOL, AND CALCITONIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLUCOCORTICOID-INDUCED OSTEOPENIA; BONE LOSS; POSTMENOPAUSAL OSTEOPOROSIS; SALMON-CALCITONIN; MINERAL METABOLISM; VITAMIN-D; THERAPY; WOMEN; ABSORPTION; HISTOMORPHOMETRY	Background. Prolonged corticosteroid therapy increases the risk of osteoporosis and fracture. We studied whether corticosteroid-induced osteoporosis could be prevented by treatment with calcium, calcitriol (1,25-dihydroxyvitamin D3), and calcitonin. Methods. One hundred three patients starting long-term corticosteroid therapy were randomly assigned to receive 1000 mg of calcium per day orally and either calcitriol (0.5 to 1.0 mug per day orally) plus salmon calcitonin (400 IU per day intranasally), calcitriol plus a placebo nasal spray, or double placebo for one year. Data on treatment efficacy were available for 92 of these patients. Bone density was measured every four months for two years by photon absorptiometry. There were no significant differences between groups with respect to age, underlying disease, initial bone density, or corticosteroid dose during the first year. Results. Calcitriol (mean dose, 0.6 mug per day), with or without calcitonin, prevented more bone loss from the lumbar spine (mean rates of change, -0.2 and -1.3 percent per year, respectively) than calcium alone (-4.3 percent per year, P = 0.0035). Bone loss at the femoral neck and distal radius was not significantly affected by any treatment. In the second year, lumbar bone loss did not occur in the group previously treated with calcitonin plus calcitriol (+0.7 percent per year), but it did occur in the group given calcium alone (-2.3 percent per year). The calcitriol group also lost lumbar bone (-3.6 percent per year) but received more corticosteroid in the second year than the other two groups. Conclusions. Calcitriol and calcium, used prophylactically with or without calcitonin, prevent corticosteroid-induced bone loss in the lumbar spine.	ST VINCENTS HOSP,DEPT ENDOCRINOL,SYDNEY,NSW 2010,AUSTRALIA; ST VINCENTS HOSP,DEPT NUCL MED,SYDNEY,NSW 2010,AUSTRALIA; ST VINCENTS HOSP,DEPT RHEUMATOL,SYDNEY,NSW 2010,AUSTRALIA; ST VINCENTS HOSP,DEPT GERONTOL,SYDNEY,NSW 2010,AUSTRALIA; UNIV NEW S WALES,SCH MED,KENSINGTON,NSW 2033,AUSTRALIA; UNIV NEW S WALES,SCH COMMUNITY MED,KENSINGTON,NSW 2033,AUSTRALIA	St Vincents Hospital Sydney; St Vincents Hospital Sydney; St Vincents Hospital Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney; University of New South Wales Sydney	SAMBROOK, P (corresponding author), ST VINCENTS HOSP,GARVAN INST MED RES,DIV BONE & MINERAL RES,DARLINGHURST,NSW 2010,AUSTRALIA.		Nguyen, Tuan V/B-6147-2008; Eisman, John A/C-2886-2014; Nguyen, Thao/GWN-0419-2022; Nguyen, Thao/HCH-9537-2022	Nguyen, Tuan V/0000-0002-3246-6281; 				ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; ANGUS RM, 1989, J AM DIET ASSOC, V89, P209; AVIOLI LV, 1984, ADV EXP MED BIOL, V171, P81; BAYLINK DJ, 1983, NEW ENGL J MED, V309, P306, DOI 10.1056/NEJM198308043090509; BIJLSMA JWJ, 1988, CLIN EXP RHEUMATOL, V6, P113; BRAUN JJ, 1983, CLIN ENDOCRINOL, V19, P265, DOI 10.1111/j.1365-2265.1983.tb02989.x; BRESSOT C, 1979, METAB BONE DIS RELAT, V1, P303, DOI 10.1016/0221-8747(79)90024-9; DYKMAN TR, 1984, ARTHRITIS RHEUM, V27, P1336, DOI 10.1002/art.1780271203; GALLAGHER JC, 1990, ANN INTERN MED, V113, P649, DOI 10.7326/0003-4819-113-9-649; Gennari C, 1986, Clin Rheum Dis, V12, P637; HAHN TJ, 1981, J CLIN ENDOCR METAB, V52, P111, DOI 10.1210/jcem-52-1-111; HODGKINSON A, 1982, J CLIN PATHOL, V35, P807, DOI 10.1136/jcp.35.8.807; JOWELL PS, 1987, ENDOCRINOLOGY, V120, P531, DOI 10.1210/endo-120-2-531; KELLY PJ, 1989, J CLIN ENDOCR METAB, V69, P1160, DOI 10.1210/jcem-69-6-1160; KELLY PJ, 1991, J CLIN ENDOCR METAB, V72, P808, DOI 10.1210/jcem-72-4-808; KLEIN RG, 1977, J CLIN INVEST, V60, P253, DOI 10.1172/JCI108762; LOCASCIO V, 1990, BONE MINER, V8, P39, DOI 10.1016/0169-6009(91)90139-Q; LUENGO M, 1990, AM REV RESPIR DIS, V142, P104, DOI 10.1164/ajrccm/142.1.104; MEUNIER PJ, 1984, ADV EXP MED BIOL, V171, P191; MONTEMURRO L, 1991, CALCIFIED TISSUE INT, V49, P71, DOI 10.1007/BF02565124; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; NIELSEN HK, 1991, J BONE MINER RES, V6, P435; NORDIN BEC, 1978, CLIN ENDOCRINOL, V8, P55, DOI 10.1111/j.1365-2265.1978.tb01350.x; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; OVERGAARD K, 1989, BRIT MED J, V299, P477, DOI 10.1136/bmj.299.6697.477; POCOCK NA, 1987, MED J AUSTRALIA, V146, P293, DOI 10.5694/j.1326-5377.1987.tb120264.x; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; REGINSTER JY, 1987, BONE MINER, V2, P133; REID IR, 1987, HORM RES, V27, P200, DOI 10.1159/000180820; REID IR, 1986, J CLIN ENDOCR METAB, V62, P379, DOI 10.1210/jcem-62-2-379; REID IR, 1986, AM J CLIN NUTR, V44, P287, DOI 10.1093/ajcn/44.2.287; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; RINGE JD, 1987, EUR J CLIN PHARMACOL, V33, P35, DOI 10.1007/BF00610377; Rizzato G, 1988, Sarcoidosis, V5, P99; SAMBROOK P, 1992, J RHEUMATOL, V19, P357; SAMBROOK P, 1990, J BONE MINER RES, V5, P1211; SAMBROOK PN, 1988, ARTHRITIS RHEUM, V31, P973, DOI 10.1002/art.1780310805; SEEMAN E, 1982, J CLIN INVEST, V69, P1302, DOI 10.1172/JCI110570; SMITH PL, 1979, AM STAT, V33, P57, DOI 10.2307/2683222; SUZUKI Y, 1983, METABOLISM, V32, P151, DOI 10.1016/0026-0495(83)90221-4; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; Wicks J., 1983, GUIDE EXERCISE, P70	45	480	490	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1993	328	24					1747	1752		10.1056/NEJM199306173282404	http://dx.doi.org/10.1056/NEJM199306173282404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LG038	7684512				2022-12-28	WOS:A1993LG03800004
J	CAPEL, B; SWAIN, A; NICOLIS, S; HACKER, A; WALTER, M; KOOPMAN, P; GOODFELLOW, P; LOVELLBADGE, R				CAPEL, B; SWAIN, A; NICOLIS, S; HACKER, A; WALTER, M; KOOPMAN, P; GOODFELLOW, P; LOVELLBADGE, R			CIRCULAR TRANSCRIPTS OF THE TESTIS-DETERMINING GENE SRY IN ADULT-MOUSE TESTIS	CELL			English	Article							SEX-DETERMINING REGION; MESSENGER-RNA; TRANSLATION; DROSOPHILA; EXPRESSION; ENCODES; PROTEIN; LETHAL; INITIATION; SEQUENCE	Sry is expressed at higher levels in the adult testis, where no function has been determined, than in the genital ridge, its critical site of action. cDNA and 5' RACE clones isolated from testis or from Sry-transfected cell lines have an unusual structure, with 3' sequences located in a 5' position. RNAase protection assays and reverse transcription polymerase chain reactions confirmed that these unusual RNA molecules represent the most abundant transcript in testis. Furthermore, oligonucleotide hybridization and RNAase H digestion proved that these Sry RNA molecules are circular. Similar transcripts were detected in the testes of mice with Mus musculus musculus, Mus musculus domesticus, and Mus spretus Sry genes. The circular RNA is found in the cytoplasm but is not substantially bound to polysomes. We suggest that the circles arise from normal splicing processes as a consequence of the unusual genomic structure surrounding the Sry locus in the mouse.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND	University of Cambridge	CAPEL, B (corresponding author), NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND.		Koopman, Peter A/C-9416-2009	Koopman, Peter A/0000-0001-6939-0914; Swain, Amanda/0000-0001-8666-1608; Lovell-Badge, Robin/0000-0001-9364-4179; NICOLIS, SILVIA KIRSTEN/0000-0003-0378-3808	Medical Research Council [MC_U117562207] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BERTA P, 1990, NATURE, V348, P248; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BRUZIK JP, 1992, NATURE, V360, P692, DOI 10.1038/360692a0; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHANG DD, 1990, SCIENCE, V249, P614, DOI 10.1126/science.2143313; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCQUERELLE C, 1992, EMBO J, V11, P1095, DOI 10.1002/j.1460-2075.1992.tb05148.x; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; FOSTER JW, 1992, NATURE, V359, P531, DOI 10.1038/359531a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLD P, 1981, BIOCHEMISTRY-US, V20, P4871; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HAWKINS JR, 1992, HUM GENET, V88, P471, DOI 10.1007/BF00215684; HAWKINS JR, 1992, AM J HUM GENET, V51, P979; HAYFLICK JS, 1989, NUCLEIC ACIDS RES, V17, P6403, DOI 10.1093/nar/17.15.6403; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREIG PA, 1987, METHOD ENZYMOL, V155, P397; LAYTON MG, 1984, BRIT J CANCER, V49, P415, DOI 10.1038/bjc.1984.67; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; Mattaj IW, 1990, CURR OPIN CELL BIOL, V2, P528, DOI 10.1016/0955-0674(90)90138-5; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; RIO D C, 1992, Current Opinion in Cell Biology, V4, P444, DOI 10.1016/0955-0674(92)90010-A; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SAMUELS ME, 1991, MOL CELL BIOL, V11, P3584, DOI 10.1128/MCB.11.7.3584; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAFURI SR, 1993, IN PRESS J CELL BIOC; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	49	815	884	3	77	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 4	1993	73	5					1019	1030		10.1016/0092-8674(93)90279-Y	http://dx.doi.org/10.1016/0092-8674(93)90279-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LF061	7684656	Bronze			2022-12-28	WOS:A1993LF06100017
J	GABRIEL, SE; CLARKE, LL; BOUCHER, RC; STUTTS, MJ				GABRIEL, SE; CLARKE, LL; BOUCHER, RC; STUTTS, MJ			CFTR AND OUTWARD RECTIFYING CHLORIDE CHANNELS ARE DISTINCT PROTEINS WITH A REGULATORY RELATIONSHIP	NATURE			English	Article							CYSTIC-FIBROSIS GENE; CL CHANNELS; KINASE-C; CONDUCTANCE; CELLS; CAMP; EXPRESSION; EPITHELIA; DISEASE	IN cystic fibrosis (CF), numerous epithelial cell functions are abnormal, including Cl- conductance, sodium absorption, mucin sulphation and enzyme secretion1-4. Although the CF gene product, the cystic fibrosis transmembrane conductance regulator (CFTR), functions as a small linear Cl- channel5-8, it is difficult to attribute such pleiotropic disease manifestations solely to a defect in Cl-conductance. This has led to speculation that CFTR regulates the activity of other proteins. One possible example is the protein kinase A activation of outward rectifying Cl- channels (ORCC), which is defective in membrane patches excised from CF cells9-16. Whether CFTR regulates the activity of an independent anion channel is debatable, because ORCC occur exclusively in excised membrane patches and could be an excision-induced molecular derivative of CFTR. 'Knockout' mice that lack CFTR17,18 provide a means to define the relationship between CFTR and ORCC. Here we report that ORCC are present in CFTR(-/-) mouse nasal epithelial cells and thus cannot be a derivative of the CFTR molecule. Also ORCC were regulated by protein kinase A in membrane patches from normal but not CFTR(-/-) cells. These observations are the first, to our knowledge definitive demonstration that CFTR regulates the activity of another protein.			GABRIEL, SE (corresponding author), UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599, USA.		Clarke, Lane L/AAK-2866-2020	Clarke, Lane L/0000-0002-4938-6261				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; CHEN JH, 1989, SCIENCE, V243, P657, DOI 10.1126/science.2464852; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; DEJONGE HR, 1989, BIOCHEM SOC T, V17, P816, DOI 10.1042/bst0170816; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FISCHER H, IN PRESS PFLUEGERS A; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; FRIZZELL RA, 1987, TRENDS NEUROSCI, V10, P190, DOI 10.1016/0166-2236(87)90144-5; GABRIEL SE, 1992, AM J PHYSIOL, V263, pC708, DOI 10.1152/ajpcell.1992.263.3.C708; HAWS C, 1992, PEDIATR PULM S, V8, P253; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JETTEN AM, 1989, SCIENCE, V244, P1472, DOI 10.1126/science.2472008; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KRAUSS RD, 1992, EMBO J, V11, P875, DOI 10.1002/j.1460-2075.1992.tb05125.x; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LUCKACS GL, 1992, J BIOL CHEM, V267, P14568; MORRIS AP, 1992, J BIOL CHEM, V267, P5575; MORRIS AP, 1992, PULMONOL S, V8, P247; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TABCHARANI JA, 1991, AM J PHYSIOL-GASTR L, V261, P992; WARD CL, 1991, P NATL ACAD SCI USA, V88, P5277, DOI 10.1073/pnas.88.12.5277	32	253	260	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 20	1993	363	6426					263	266		10.1038/363263a0	http://dx.doi.org/10.1038/363263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LC866	7683773				2022-12-28	WOS:A1993LC86600053
J	KIM, KJ; LI, B; WINER, J; ARMANINI, M; GILLETT, N; PHILLIPS, HS; FERRARA, N				KIM, KJ; LI, B; WINER, J; ARMANINI, M; GILLETT, N; PHILLIPS, HS; FERRARA, N			INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR-INDUCED ANGIOGENESIS SUPPRESSES TUMOR-GROWTH INVIVO	NATURE			English	Article							PERMEABILITY FACTOR; CELL MITOGEN	THE development of new blood vessels (angiogenesis) is required for many physiological processes including embryogenesis, wound healing and corpus luteum formation1,2. Blood vessel neoformation is also important in the pathogenesis of many disorders1-5, particularly rapid growth and metastasis of solid tumours3-5. There are several potential mediators of tumour angiogenesis, including basic and acidic fibroblast growth factors, tumour necrosis factor-alpha and transforming factors-alpha and -beta1,2. But it is unclear whether any of these agents actually mediates angiogenesis and tumour growth in vivo. Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen and an angiogenesis inducer released by a variety of tumour cells and expressed in human tumours in situ. To test whether VEGF may be a tumour angiogenesis factor in vivo, we injected human rhabdomyosarcoma, glioblastoma multiforme or leiomyosarcoma cell lines into nude mice. We report here that treatment with a monoclonal antibody specific for VEGF inhibited the growth of the tumours, but had no effect on the growth rate of the tumour cells in vitro. The density of vessels was decreased in the antibody-treated tumours. These findings demonstrate that inhibition of the action of an angiogenic factor spontaneously produced by tumour cells may suppress tumour growth in vivo.	GENENTECH INC,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BERMAN PW, 1989, J VIROL, V63, P3489, DOI 10.1128/JVI.63.8.3489-3498.1989; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BREIER G, 1992, DEVELOPMENT, V114, P521; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1991, J NATL CANCER I, V82, P4; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIEBERMANN TA, 1987, EMBO J, V6, P1627; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; RAVINDRANATH N, 1992, ENDOCRINOLOGY, V131, P254, DOI 10.1210/en.131.1.254; RIZZINO A, 1987, METHOD ENZYMOL, V146, P341; ROSENTHAL R, 1990, J GROWTH FACTORS, V4, P53; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SENGER DR, 1986, CANCER RES, V46, P5629; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Tisher E, 1991, J BIOL CHEM, V266, P11947; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WESTPHAL M, 1987, EXP CELL BIOL, V55, P152	32	3112	3563	2	205	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 29	1993	362	6423					841	844		10.1038/362841a0	http://dx.doi.org/10.1038/362841a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	7683111				2022-12-28	WOS:A1993KZ56300057
J	WANG, JF; DOWNS, WD; CECH, TR				WANG, JF; DOWNS, WD; CECH, TR			MOVEMENT OF THE GUIDE SEQUENCE DURING RNA CATALYSIS BY A GROUP-I RIBOZYME	SCIENCE			English	Article							SELF-SPLICING RNA; TETRAHYMENA RIBOZYME; INTERVENING SEQUENCE; ENDORIBONUCLEASE ACTIVITY; RIBONUCLEASE-P; RIBOSOMAL-RNA; SUBSTRATE; YEAST; CLEAVAGE; INVITRO	Ribozymes derived from the self-splicing pre-ribosomal RNA of Tetrahymena act as sequence-specific endonucleases. The reaction involves binding an RNA or DNA substrate by base pairing to the internal guide sequence (IGS) to form helix P1. Site-specific photo-crosslinking localized the 5' end of the IGS in helix P1 to the vicinity of conserved bases between helices P4 and P5, supporting a major feature of the Michel-Westhof three-dimensional structure model. The crosslinked ribozyme retained catalytic activity. When not base-paired, the IGS was still specifically crosslinked, but the major site was 37 angstrom distant from the reactive site in the experimentally supported three-dimensional model. The data indicate that a substantial induced-fit conformational change accompanies P1 formation, and they provide a physical basis for understanding the transport of oligonucleotides to the catalytic core of the ribozyme. The ability of RNA to orchestrate large-scale conformational changes may help explain why the ribosome and the spliceosome are RNA-based machines.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder								BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; BURGIN AB, 1990, EMBO J, V9, P4111, DOI 10.1002/j.1460-2075.1990.tb07633.x; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; DOWNS WD, 1990, BIOCHEMISTRY-US, V29, P5605, DOI 10.1021/bi00475a027; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HERSCHLAG D, COMMUNICATION; HERSCHLAG D, UNPUB; KAO TH, 1980, P NATL ACAD SCI-BIOL, V77, P3360, DOI 10.1073/pnas.77.6.3360; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P4411; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LECUYER KA, IN PRESS BIOCHEMISTR; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MICHEL F, 1992, GENE DEV, V6, P1373, DOI 10.1101/gad.6.8.1373; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; Quiocho F A, 1971, Adv Protein Chem, V25, P1, DOI 10.1016/S0065-3233(08)60278-8; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SCHUSTER GB, 1989, NATO ADV SCI I C-MAT, V272, P31; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; WANG JF, 1992, SCIENCE, V256, P526, DOI 10.1126/science.1315076; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; Williams K., COMMUNICATION; WILLIAMS KP, 1992, P NATL ACAD SCI USA, V89, P10400, DOI 10.1073/pnas.89.21.10400; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	48	101	106	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 23	1993	260	5107					504	508		10.1126/science.7682726	http://dx.doi.org/10.1126/science.7682726			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KY504	7682726				2022-12-28	WOS:A1993KY50400022
J	KOHDA, D; HATANAKA, H; ODAKA, M; MANDIYAN, V; ULLRICH, A; SCHLESSINGER, J; INAGAKI, F				KOHDA, D; HATANAKA, H; ODAKA, M; MANDIYAN, V; ULLRICH, A; SCHLESSINGER, J; INAGAKI, F			SOLUTION STRUCTURE OF THE SH3 DOMAIN OF PHOSPHOLIPASE C-GAMMA	CELL			English	Article							SIGNAL TRANSDUCTION; PROTEIN-STRUCTURE; TYROSINE KINASE; VIRAL ONCOGENE; PC12 CELLS; GROWTH; DIFFERENTIATION; SPECTROSCOPY; REQUIREMENT; EXCHANGE	SH3 (Src homology 3) domains are found in many signaling proteins and appear to function as binding modules for cytoplasmic target proteins. The solution structure of the SH3 domain of human phospholipase C-gamma (PLC-gamma) was determined by two-dimensional H-1 NMR analysis. This SH3 domain is composed of eight antiparallel beta strands consisting of two successive ''Greek key'' motifs, which form a barrel-like structure. The conserved aliphatic and aromatic residues form a hydrophobic pocket on the molecular surface, and the conserved carboxylic residues are localized to the periphery. The hydrophobic pocket may serve as a binding site for target proteins. Analysis of the slowly exchanging amide protons by NMR measurements indicates that despite containing a high content of beta structure, the SH3 domain of PLC-gamma is flexible.	NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	New York University; Max Planck Society	KOHDA, D (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC PHYS,18-22 HONKOMAGOME 3-CHOME,BUNKYO KU,TOKYO 113,JAPAN.		Odaka, Masafumi/C-2378-2013; Kohda, Daisuke/I-4990-2019	Kohda, Daisuke/0000-0001-8234-3776				BRUNGER AT, 1990, X PLOR VERSION 2 1 M; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAVANAGH J, 1992, J MAGN RESON, V96, P670, DOI 10.1016/0022-2364(92)90357-D; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLORE GM, 1986, J MOL BIOL, V191, P523, DOI 10.1016/0022-2836(86)90146-4; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZUIDERWEG ERP, 1986, J MAGN RESON, V70, P336, DOI 10.1016/0022-2364(86)90020-X	29	116	118	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					953	960		10.1016/0092-8674(93)90583-C	http://dx.doi.org/10.1016/0092-8674(93)90583-C			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	7681365				2022-12-28	WOS:A1993KU17500015
J	KOYAMA, S; YU, HT; DALGARNO, DC; SHIN, TB; ZYDOWSKY, LD; SCHREIBER, SL				KOYAMA, S; YU, HT; DALGARNO, DC; SHIN, TB; ZYDOWSKY, LD; SCHREIBER, SL			STRUCTURE OF THE PI3K SH3 DOMAIN AND ANALYSIS OF THE SH3 FAMILY	CELL			English	Article							MULTIPLE QUANTUM COHERENCE; RECEPTOR TYROSINE KINASES; PROTEINS; SPECTROSCOPY; SPECTRA	Src homology 3 (SH3) domains, which are found in many proteins involved in intracellular signal transduction, mediate specific protein-protein interactions. The three-dimensional structure of the SH3 domain in the p85 subunit of the phosphatidylinositol 3-kinase (Pl3K) has been determined by multidimensional NMR methods. The molecule consists of four short helices, two beta turns, and two antiparallel beta sheets. The beta sheets are highly similar to corresponding regions in the SH3 domain of the tyrosine kinase Src, even though the sequence identity of the two domains is low. There is a unique 15 amino acid insert in Pl3K that contains three short helices. There are substantial differences in the identity of the amino acids that make up the receptor site of SH3 domains. The results suggest that while the overall structures of the binding sites in the Pl3K and Src SH3 domains are similar, their ligand binding properties may differ.	ARIAD PHARMACEUT INC,CAMBRIDGE,MA 02139	Takeda Pharmaceutical Company Ltd; Takeda Oncology	KOYAMA, S (corresponding author), HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138, USA.			Yu, Hongtao/0000-0002-8861-049X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044993] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-44993] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1983, J AM CHEM SOC, V105, P7188, DOI 10.1021/ja00362a038; BRUNGER AT, 1992, X PLOR VERSION 3 0 M; BRUNGER AT, 1988, X PLOR VERSION 2 0 M; CARTER AN, 1992, J BIOL CHEM, V267, P14563; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EICH G, 1982, J AM CHEM SOC, V104, P3731, DOI 10.1021/ja00377a036; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACFERRIN KD, 1993, METHOD ENZYMOL, V217, P79; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REDFIELD AG, 1983, CHEM PHYS LETT, V96, P537, DOI 10.1016/0009-2614(83)80443-6; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAGNER G, 1983, BIOCHEM BIOPH RES CO, V113, P854, DOI 10.1016/0006-291X(83)91077-X; Williams Lewis T., 1992, Current Biology, V2, P601, DOI 10.1016/0960-9822(92)90169-B; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	30	143	150	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 26	1993	72	6					945	952		10.1016/0092-8674(93)90582-B	http://dx.doi.org/10.1016/0092-8674(93)90582-B			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	7681364				2022-12-28	WOS:A1993KU17500014
J	OCHS, A; ROSSLE, M; HAAG, K; HAUENSTEIN, KH; DEIBERT, P; SIEGERSTETTER, V; HUONKER, M; LANGER, M; BLUM, HE				OCHS, A; ROSSLE, M; HAAG, K; HAUENSTEIN, KH; DEIBERT, P; SIEGERSTETTER, V; HUONKER, M; LANGER, M; BLUM, HE			THE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC STENT-SHUNT PROCEDURE FOR REFRACTORY ASCITES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERITONEOVENOUS SHUNTS; INTRAVENOUS ALBUMIN; PROSPECTIVE TRIAL; CIRRHOSIS; PARACENTESIS; SURVIVAL; LEVEEN	Background. Previous studies have suggested that the transjugular placement of an intrahepatic stent to establish a portosystemic shunt is an effective treatment of uncomplicated ascites accompanying variceal bleeding. We studied the stent shunt for use in patients with liver cirrhosis and ascites refractory to medical treatment. Methods. Fifty of 62 consecutive patients with cirrhosis and refractory ascites were treated with the stent shunt - an expandable stent of metallic mesh placed between a major branch of the portal vein and one of the hepatic veins. Patients were followed for a mean (+/-SD) of 426+/-333 days. Results. The stent shunt was successfully placed in all patients and reduced the pressure gradient between the portal vein and the inferior vena cava by an average of 63 percent. Thirty-seven patients (74 percent) had complete responses (total remission of ascites within three months), and nine patients (18 percent) had partial responses. Four patients did not respond, including two who died within two weeks of shunt placement. After the procedure, 25 patients had hepatic encephalopathy, as compared with 20 patients before the procedure; although encephalopathy improved in 3 patients, new encephalopathy developed in 8 patients. In the 28 of the 33 patients followed for more than six months who were evaluated, the mean serum creatinine concentration was 1.5+/-0.09 mg per deciliter (133+/-8 mu mol per liter) before placement of the stent shunt, 1.5+/-1.6 mg per deciliter (133+/-141 mu mol per liter) one week after the procedure, and 0.9+/-0.3 mg per deciliter (80+/-27 mu mol per liter) after six months (P=0.008 for the comparison of concentrations before and six months after the procedure). Renal function did not improve in the six patients with organic kidney disease. Procedure-related complications developed in 16 patients. During followup, an additional 29 patients died - 10 of progressive liver disease and 19 of other causes. Survival for at least one year was associated with a patient's being under 60 years of age, having a serum bilirubin level before placement of the stent shunt of less than 1.3 mg per deciliter (22 mu mol per liter), and having a complete response. Conclusions. Our findings in an uncontrolled prospective study suggest that the transjugular intrahepatic portosystemic stent-shunt procedure was an effective treatment for many patients with liver cirrhosis and refractory ascites, but mortality from underlying diseases was substantial.	UNIV FREIBURG,SCH MED,DEPT MED,D-79106 FREIBURG,GERMANY; UNIV FREIBURG,SCH MED,DEPT RADIOL,D-79106 FREIBURG,GERMANY	University of Freiburg; University of Freiburg			Deibert, Peter/AAE-4623-2020					ARROYO V, 1986, SEMIN LIVER DIS, V6, P353, DOI 10.1055/s-2008-1040617; Arroyo V, 1989, GASTROENTEROL INT, V2, P195; BERNHOFT RA, 1982, ARCH SURG-CHICAGO, V117, P631; BORIES P, 1986, J HEPATOL, V3, P212, DOI 10.1016/S0168-8278(86)80028-9; BURCHELL AR, 1968, ANN SURG, V168, P655, DOI 10.1097/00000658-196810000-00012; CAMPBELL DP, 1973, AM J SURG, V126, P748, DOI 10.1016/S0002-9610(73)80062-5; CAPONE RR, 1978, DIGEST DIS SCI, V23, P867; ELCHEROTH J, 1994, WORLD J SURG, V18, P240; EPSTEIN M, 1994, J AM SOC NEPHROL, V4, P1735; EPSTEIN M, 1989, NEW ENGL J MED, V321, P1675, DOI 10.1056/NEJM198912143212410; FERRAL H, 1993, RADIOLOGY, V189, P795, DOI 10.1148/radiology.189.3.8234706; FERRO D, 1992, SCAND J GASTROENTERO, V27, P852, DOI 10.3109/00365529209000153; FRANCO D, 1988, ARCH SURG-CHICAGO, V123, P987; FULENWIDER JT, 1986, ARCH SURG-CHICAGO, V121, P351; GINES P, 1988, GASTROENTEROLOGY, V94, P1493, DOI 10.1016/0016-5085(88)90691-9; GINES P, 1991, NEW ENGL J MED, V325, P829, DOI 10.1056/NEJM199109193251201; HAUENSTEIN KH, 1995, INTERVENTIONAL RADIO, V194, P175; KELLERMAN PS, 1990, ANN INTERN MED, V112, P889, DOI 10.7326/0003-4819-112-12-889; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; LAKE JR, 1993, TRANSPLANT P, V25, P1766; LEVEEN HH, 1974, ANN SURG, V180, P580, DOI 10.1097/00000658-197410000-00023; LLOVET JM, 1993, AM J GASTROENTEROL, V88, P388; MARTINET JP, 1994, HEPATOLOGY, V20, pA113; MOSKOVITZ M, 1990, AM J GASTROENTEROL, V85, P917; OCHS A, 1993, J HEPATOL, V18, P217, DOI 10.1016/S0168-8278(05)80249-1; ORLOFF MJ, 1970, ANN NY ACAD SCI, V170, P213, DOI 10.1111/j.1749-6632.1970.tb37015.x; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; ROSSLE M, 1994, NEW ENGL J MED, V330, P165, DOI 10.1056/NEJM199401203300303; RUNYON BA, 1994, NEW ENGL J MED, V330, P337, DOI 10.1056/NEJM199402033300508; SALERNO F, 1993, AM J GASTROENTEROL, V88, P514; SAUNDERS JB, 1981, BRIT MED J, V282, P263, DOI 10.1136/bmj.282.6260.263; SCHOLZ DG, 1989, AM J GASTROENTEROL, V84, P540; SMART HL, 1990, J HEPATOL, V10, P191, DOI 10.1016/0168-8278(90)90051-R; STANLEY MM, 1989, NEW ENGL J MED, V321, P1632, DOI 10.1056/NEJM198912143212403; Tamaki A, 1968, Surg Forum, V19, P324; VILLARREAL LG, 1993, GASTROENTEROL HEPATO, V16, P18	36	387	389	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 4	1995	332	18					1192	1197		10.1056/NEJM199505043321803	http://dx.doi.org/10.1056/NEJM199505043321803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV415	7700312				2022-12-28	WOS:A1995QV41500003
J	SIMMONS, RM				SIMMONS, RM			MOLECULAR BIOPHYSICS - TAKING A SHINE TO MYOSIN	NATURE			English	Editorial Material											SIMMONS, RM (corresponding author), UNIV LONDON KINGS COLL,RANDALL INST,MRC,MUSCLE & CELL MOTIL UNIT,26-29 DRURY LANE,LONDON WC2B 5RL,ENGLAND.							FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; HIRSCHFELD T, 1976, APPL OPTICS, V15, P2965, DOI 10.1364/AO.15.002965; IRVING M, 1991, NATURE, V352, P284, DOI 10.1038/352284a0; NIE SM, 1994, SCIENCE, V266, P1018, DOI 10.1126/science.7973650; PECK K, 1989, P NATL ACAD SCI USA, V86, P4087, DOI 10.1073/pnas.86.11.4087; SOWERBY AJ, 1993, J MOL BIOL, V234, P114, DOI 10.1006/jmbi.1993.1567; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TELLINGHUISEN J, 1994, ANAL CHEM, V66, P64, DOI 10.1021/ac00073a013	9	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					496	496		10.1038/374496a0	http://dx.doi.org/10.1038/374496a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700371	Bronze			2022-12-28	WOS:A1995QR06900026
J	WAGENKNECHT, LE; FURBERG, CD; HAMMON, JW; LEGAULT, C; TROOST, BT				WAGENKNECHT, LE; FURBERG, CD; HAMMON, JW; LEGAULT, C; TROOST, BT			SURGICAL BLEEDING - UNEXPECTED EFFECT OF A CALCIUM-ANTAGONIST	BRITISH MEDICAL JOURNAL			English	Article									WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT CARDIOTHORAC SURG,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT NEUROL,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	WAGENKNECHT, LE (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27157, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR007122] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR-07122] Funding Source: Medline; NINDS NIH HHS [5-P01-NS2500] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BECKER RC, 1993, AM HEART J, V126, P11, DOI 10.1016/S0002-8703(07)80004-4; BLAUTH CI, 1988, J THORAC CARDIOV SUR, V95, P668; Frishman W H, 1994, Curr Probl Cardiol, V19, P637; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; WOODMAN RC, 1990, BLOOD, V76, P1680; YUSUF S, 1991, AM J CARDIOL, V67, P1295, DOI 10.1016/0002-9149(91)90944-G	6	72	72	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	1995	310	6982					776	777		10.1136/bmj.310.6982.776	http://dx.doi.org/10.1136/bmj.310.6982.776			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP609	7711582	Green Published			2022-12-28	WOS:A1995QP60900018
J	PUTTERILL, J; ROBSON, F; LEE, K; SIMON, R; COUPLAND, G				PUTTERILL, J; ROBSON, F; LEE, K; SIMON, R; COUPLAND, G			THE CONSTANS GENE OF ARABIDOPSIS PROMOTES FLOWERING AND ENCODES A PROTEIN SHOWING SIMILARITIES TO ZINC-FINGER TRANSCRIPTION FACTORS	CELL			English	Article							FLORAL HOMEOTIC GENES; LIGHT QUALITY; THALIANA; MUTANTS; VERNALIZATION; BIOSYNTHESIS; GIBBERELLIN; ACTIVATION; RESPONSES; MUTATIONS	The vegetative and reproductive (flowering) phases of Arabidopsis development are clearly separated. The onset of flowering is promoted by long photoperiods, but the constans (co) mutant flowers later than wild type under these conditions. The CO gene was isolated, and two zinc fingers that show a similar spacing of cysteines, but little direct homology, to members of the GATA1 family were identified in the amino acid sequence. co mutations were shown to affect amino acids that are conserved in both fingers. Some transgenic plants containing extra copies of CO flowered earlier than wild type, suggesting that CO activity is limiting On flowering time. Double mutants were constructed containing co and mutations affecting gibberellic acid responses, meristem identity, or phytochrome function, and their phenotypes suggested a model for the role of CO in promoting flowering.	JOHN INNES INST,JOHN INNES CTR PLANT SCI RES,NORWICH RES PK,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Lee, Karen/GVT-9602-2022; Coupland, George/AAP-8609-2020; Simon, Rudiger/T-6755-2018	Coupland, George/0000-0001-6988-4172; Simon, Rudiger/0000-0002-1317-7716; Lee, Karen/0000-0003-4544-5217				BAGNALL DJ, 1993, ANN BOT-LONDON, V71, P75, DOI 10.1006/anbo.1993.1009; BERNIER G, 1993, PLANT CELL, V5, P1147, DOI 10.1105/tpc.5.10.1147; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; CLARKE JH, 1994, MOL GEN GENET, V242, P81, DOI 10.1007/BF00277351; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DANIELVEDELE F, 1993, MOL GEN GENET, V240, P365, DOI 10.1007/BF00280388; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOTO N, 1991, PHYSIOL PLANTARUM, V83, P209, DOI 10.1111/j.1399-3054.1991.tb02144.x; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; KOORNNEEF M, 1980, THEOR APPL GENET, V58, P257, DOI 10.1007/BF00265176; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LANGRIDGE J, 1957, NATURE, V180, P36, DOI 10.1038/180036a0; LEE I, 1994, PLANT CELL, V6, P75, DOI 10.1105/tpc.6.1.75; Martinez-Zapater JM, 1994, ARABIDOPSIS, P403; MARTINEZZAPATER JM, 1990, PLANT PHYSIOL, V92, P770, DOI 10.1104/pp.92.3.770; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; PARKS BM, 1991, PLANT CELL, V3, P1177, DOI 10.1105/tpc.3.11.1177; PENG JR, 1993, PLANT CELL, V5, P351, DOI 10.1105/tpc.5.3.351; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PUTTERILL J, 1993, MOL GEN GENET, V239, P145, DOI 10.1007/BF00281613; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; REDEI GP, 1962, GENETICS, V47, P443; REED JW, 1993, PLANT CELL, V5, P147, DOI 10.1105/tpc.5.2.147; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHULTZ EA, 1993, DEVELOPMENT, V119, P745; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; STIEKEMA WJ, 1988, PLANT MOL BIOL, V11, P255, DOI 10.1007/BF00027383; SUN TP, 1992, PLANT CELL, V4, P119, DOI 10.1105/tpc.4.2.119; SUNG ZR, 1992, SCIENCE, V258, P1645, DOI 10.1126/science.258.5088.1645; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VALVEKENS D, 1988, P NATL ACAD SCI USA, V87, P5536; VETRILOVA M, 1973, BIOL PLANTARUM, V15, P391, DOI 10.1007/BF02922758; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WILSON RN, 1992, PLANT PHYSIOL, V100, P403, DOI 10.1104/pp.100.1.403; ZAGOTTA MT, 1992, AUST J PLANT PHYSIOL, V19, P411, DOI 10.1071/PP9920411; ZEEVAART JAD, 1993, PLANT PHYSIOL, V101, P25, DOI 10.1104/pp.101.1.25; ZINN KN, 1957, Z IND ABSTAMM VERERB, V88, P253	42	998	1142	10	195	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					847	857		10.1016/0092-8674(95)90288-0	http://dx.doi.org/10.1016/0092-8674(95)90288-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697715	Bronze			2022-12-28	WOS:A1995QP61200004
J	ZABNER, J; COUTURE, LA; GREGORY, RJ; GRAHAM, SM; SMITH, AE; WELSH, MJ				ZABNER, J; COUTURE, LA; GREGORY, RJ; GRAHAM, SM; SMITH, AE; WELSH, MJ			ADENOVIRUS-MEDIATED GENE-TRANSFER TRANSIENTLY CORRECTS THE CHLORIDE TRANSPORT DEFECT IN NASAL EPITHELIA OF PATIENTS WITH CYSTIC-FIBROSIS	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ELECTROLYTE TRANSPORT; EXPRESSION; PATHOGENESIS; PERMEABILITY; CHANNEL; CELLS	To evaluate the potential of direct transfer of cystic fibrosis transmembrane conductance regulator (CFTR) cDNA for the treatment of cystic fibrosis (CF), we administered an E1-deficient adenovirus, encoding CFTR, to a defined area of nasal airway epithelium of three individuals with CF. This treatment corrected the Cl- transport defect that is characteristic of CF-affected epithelia. After treatment, there was a decrease in the elevated basal transepithelial voltage, and the normal response to a cAMP agonist was restored. We found no evidence of viral replication or virus-associated adverse effects, even at the highest dose tested (25 MOI). These data represent a small step in achieving long-term improvement of CF lung function by gene therapy.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT OTOLARYNGOL,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Sanofi-Aventis; Genzyme Corporation	ZABNER, J (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.			Graham, Scott/0000-0003-2969-2998; Zabner, Joseph/0000-0002-9606-1339; Welsh, Michael/0000-0002-1646-6206				ALTON EWF, 1987, THORAX, V342, P815; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; CHASSE JF, 1989, M S-MED SCI, V5, P331, DOI 10.4267/10608/3974; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DICKSON D, 1993, NATURE, V365, P4; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; GRAHAM FL, 1992, VACCINES NEW APPROAC, P363; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; JOHNSON LG, 1992, NAT GENET, V2, P21, DOI 10.1038/ng0992-21; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; MARIASSY AT, 1992, COMP BIOL NORMAL LUN, P63; MASTRANGELI A, 1993, J CLIN INVEST, V91, P225, DOI 10.1172/JCI116175; MATSUSE T, 1992, AM REV RESPIR DIS, V146, P177, DOI 10.1164/ajrccm/146.1.177; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1993, HUM GENE THER, V4, P461, DOI 10.1089/hum.1993.4.4-461; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; TAUSSIG LM, 1973, J PEDIATR-US, V82, P380, DOI 10.1016/S0022-3476(73)80110-6; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; Tsui Lap-Chee, 1992, Human Mutation, V1, P197, DOI 10.1002/humu.1380010304; Weibel E.R., 1963, MORPHOMETRY HUMAN LU, DOI DOI 10.1007/978-3-642-87553-3; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WIDDICOMBE JH, 1985, P NATL ACAD SCI USA, V82, P6167, DOI 10.1073/pnas.82.18.6167; ZABNER J, 1993, IN PRESS NATURE GENE	32	583	664	1	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 22	1993	75	2					207	216		10.1016/0092-8674(93)80063-K	http://dx.doi.org/10.1016/0092-8674(93)80063-K			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	7691415				2022-12-28	WOS:A1993MD88500003
J	PRESS, OW; EARY, JF; APPELBAUM, FR; MARTIN, PJ; BADGER, CC; NELP, WB; GLENN, S; BUTCHKO, G; FISHER, D; PORTER, B; MATTHEWS, DC; FISHER, LD; BERNSTEIN, ID				PRESS, OW; EARY, JF; APPELBAUM, FR; MARTIN, PJ; BADGER, CC; NELP, WB; GLENN, S; BUTCHKO, G; FISHER, D; PORTER, B; MATTHEWS, DC; FISHER, LD; BERNSTEIN, ID			RADIOLABELED-ANTIBODY THERAPY OF B-CELL LYMPHOMA WITH AUTOLOGOUS BONE-MARROW SUPPORT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; MONOCLONAL-ANTIBODY; ANTI-CD37 ANTIBODY; TRANSPLANTATION; DOSIMETRY; RADIOIMMUNOTHERAPY; TOXICITY; ANTIGEN; DISEASE; TARGET	Background. Radiolabeled monoclonal antibodies recognizing B-lymphocyte surface antigens represent a potentially effective new therapy for lymphomas. We assessed the biodistribution, toxicity, and efficacy of anti-CD20 (B1 and 1F5) and anti-CD37 (MB-1) antibodies labeled with iodine-131 in 43 patients with B-cell lymphoma in relapse. Methods. Sequential biodistribution studies were performed with escalating doses of antibody (0.5, 2.5, and 10 mg per kilogram of body weight) trace-labeled with 5 to 10 mCi of I-131. The doses of radiation absorbed by tumors and normal organs were estimated by serial gamma-camera imaging and tumor biopsies. Patients whose tumors were estimated to receive greater doses of radiation than the liver, lungs, or kidneys (i.e., patients with a favorable biodistribution) were eligible for therapeutic infusion of I-131-labeled antibodies according to a phase 1 dose-escalation protocol. Results. Twenty-four patients had a favorable biodistribution, and 19 received therapeutic infusions of 234 to 777 mCi of I-131-labeled antibodies (58 to 1168 mg) followed by autologous marrow reinfusion, resulting in complete remission in 16, a partial response in 2, and a minor response (25 to 50 percent regression of tumor) in 1. Nine patients have remained in continuous complete remission for 3 to 53 months. Toxic effects included myelosuppression, nausea, infections, and two episodes of cardiopulmonary toxicity, and were moderate in patients treated with doses of I-131-labeled antibodies that delivered less than 27.25 Gy to normal organs. Conclusions. High-dose radioimmunotherapy with I-131-labeled antibodies is associated with a high response rate in patients with B-cell lymphoma in whom antibody biodistribution is favorable.	COULTER CORP, MIAMI, FL USA; FIRST HILL DIAGNOST RADIOL, SEATTLE, WA USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT RADIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOL STRUCT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98195 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; PACIFIC NW LAB, RICHLAND, WA 99352 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; United States Department of Energy (DOE); Pacific Northwest National Laboratory				Press, Oliver/0000-0002-3147-8037	NCI NIH HHS [P01CA44991] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPELBAUM FR, 1987, J CLIN ONCOL, V5, P1340, DOI 10.1200/JCO.1987.5.9.1340; ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; BADGER CC, 1987, NUCL MED BIOL, V14, P605, DOI 10.1016/0883-2897(87)90033-X; BEARMAN SI, 1988, J CLIN ONCOL, V6, P1562, DOI 10.1200/JCO.1988.6.10.1562; CZUCZMAN MS, 1990, BLOOD S, V76, pA345; DENARDO GL, 1990, CANCER RES, V50, pS1014; EARY JF, 1990, J NUCL MED, V31, P1257; EARY JF, 1989, MED PHYS, V16, P382, DOI 10.1118/1.596347; FISHER DR, 1991, RADIOPHARM, V4, P655; FREEDMAN AS, 1990, J CLIN ONCOL, V8, P784, DOI 10.1200/JCO.1990.8.5.784; GOLDENBERG DM, 1991, J CLIN ONCOL, V9, P548, DOI 10.1200/JCO.1991.9.4.548; GROSSBARD ML, 1992, BLOOD, V80, P863; HAGAN PL, 1986, J NUCL MED, V27, P422; KAMINSKI MS, 1992, J CLIN ONCOL, V10, P1696, DOI 10.1200/JCO.1992.10.11.1696; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; KNOX SJ, 1990, CANCER RES, V50, P4935; LISTER, 1990, J CLIN ONCOL, V8, P1602; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; NOURIGAT C, 1990, J NATL CANCER I, V82, P47, DOI 10.1093/jnci/82.1.47; PARKER BA, 1990, CANCER RES, V50, pS1022; PRESS OW, 1987, BLOOD, V69, P584; PRESS OW, 1989, J CLIN ONCOL, V7, P1027, DOI 10.1200/JCO.1989.7.8.1027; PRESS OW, 1989, CANCER RES, V49, P4906; ROSEN ST, 1989, NUCL MED BIOL, V16, P667, DOI 10.1016/0883-2897(89)90093-7; SCHEINBERG DA, 1990, J CLIN ONCOL, V8, P792, DOI 10.1200/JCO.1990.8.5.792; VRIESENDORP, 1991, J CLIN ONCOL, V9, P1516, DOI 10.1200/JCO.1991.9.8.1516; VRIESENDORP HM, 1991, J CLIN ONCOL, V9, P918, DOI 10.1200/JCO.1991.9.6.918; WALDMANN TA, 1992, ANN INTERN MED, V116, P148, DOI 10.7326/0003-4819-116-2-148; ZIMMER AM, 1988, ANTIBODY IMMUNOCONJ, V1, P291	29	601	663	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1993	329	17					1219	1224		10.1056/NEJM199310213291702	http://dx.doi.org/10.1056/NEJM199310213291702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB988	7692295				2022-12-28	WOS:A1993MB98800002
J	WOOD, D; HALFON, N; SCARLATA, D; NEWACHECK, P; NESSIM, S				WOOD, D; HALFON, N; SCARLATA, D; NEWACHECK, P; NESSIM, S			IMPACT OF FAMILY RELOCATION ON CHILDRENS GROWTH, DEVELOPMENT, SCHOOL FUNCTION, AND BEHAVIOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTIDIMENSIONAL ASSESSMENT; LIFE EVENTS; FOSTER-CARE; HEALTH; MORBIDITY; HOMELESS; POOR	Objective.-The United States is a highly mobile society, with family relocation rates double those of Great Britain and Germany. The objective of this study was to describe the impact of frequent family moves on reported rates of delay in growth or development, learning disorders, school failure, and frequent behavioral problems in US school-age children. Design and Setting.-We analyzed data on 9915 six- to 17-year-old children of families responding to the 1988 National Health Interview Survey, a nationally representative sample of families and children. Outcome Measures.-Parents were asked to report the total number of moves the index child had experienced during his or her lifetime. Total moves were adjusted for the child's age in years. Children were divided into two groups: never moved/infrequent relocation (below the 90th percentile for age-adjusted moves) and frequent relocation (above the 90th percentile for age-adjusted moves). The parent was asked if the child had ever had a learning disability or a delay in growth or development, had ever failed a grade, or had four or more frequently occurring behavioral problems as described by a behavioral problems checklist. Results.-The measures of both child dysfunction and family relocation were independently associated with multiple sociodemographic characteristics such as poverty, race, and family structure. Frequent relocation was associated with higher rates of all measures of child dysfunction; 23% of children who moved frequently had repeated a grade vs 12% of children who never or infrequently moved. Eighteen percent of children who moved frequently had four or more behavioral problems vs 7% of children who never or infrequently moved. Use of logistic regression to control for potential confounding covariates demonstrated that children who moved frequently were 77% more likely to be reported to have four or more behavioral problems (odds ratio, 1.77; 95% confidence interval, 1.37 to 2.29) and were 35% more likely to have failed a grade (odds ratio, 1.35; 95% confidence interval, 1.06 to 1.72), but no more likely to have had delays in growth or development or a learning disorder. Conclusions.-After adjusting for other covariates, frequent family relocation was associated with an increased risk of children failing a grade in school and four or more frequently occurring behavioral problems.	UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, LOS ANGELES, CA USA; UCSF, SCH MED, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DIV BIOSTAT, SCI & CLIN COMP SERV, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; University of California System; University of California Los Angeles	WOOD, D (corresponding author), CEDARS SINAI MED CTR, AHAMANSON DEPT PEDIAT, DIV PRIMARY CARE PEDIAT, 310 N SAN VICENTE D, LOS ANGELES, CA 90048 USA.							ACHENBACH TM, 1981, MONOGR SOC RES CHILD, V46, P1, DOI 10.2307/1165983; ADAMS PF, 1989, VITAL HLTH STAT 10, V173, P1; ADAMS PF, 1989, VITAL HLTH STAT, V173, P133; BASSUK EL, 1988, YALE LAW POLICY REV, V6, P309; BEAUTRAIS AL, 1982, PEDIATRICS, V70, P774; CAMPBELL SB, 1982, J ABNORM CHILD PSYCH, V10, P569, DOI 10.1007/BF00920755; CHAMBERLAIN P, 1987, BEHAV ASSESS, V9, P97; DIAZ C, 1986, MED CARE, V24, P848, DOI 10.1097/00005650-198609000-00006; Eisen M., 1980, R2313HEW RAND; EMERY RF, 1988, MARRIAGE DIVORCE CHI, P14; GOULD MS, 1981, J AM ACAD CHILD PSY, V20, P462, DOI 10.1016/S0002-7138(09)61640-X; Haggerty RJ, 1975, CHILD HLTH COMMUNITY; HOCHSTADT NJ, 1987, CHILD ABUSE NEGLECT, V11, P53, DOI 10.1016/0145-2134(87)90033-0; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; Jones Jacqueline, 1992, DISPOSSESSED AM UNDE; LEVINE M, 1966, COMMUNITY MENT HLT J, V2, P61, DOI 10.1007/BF01420324; Levy J. E., 1992, FUTURE CHILD, V2, P44; LOCHMAN JE, 1986, J CHILD ADOL PSYCHOL, V3, P91; MCGAUHEY PJ, 1991, PEDIATRICS, V88, P943; MCLANAHAN S, 1988, FOCUS, V2, P16; MCMAHON RC, 1979, J CLIN PSYCHOL, V35, P757, DOI 10.1002/1097-4679(197910)35:4<757::AID-JCLP2270350413>3.0.CO;2-B; NEWACHECK PW, 1988, AM J PUBLIC HEALTH, V78, P927, DOI 10.2105/AJPH.78.8.927; NEWCOMB MD, 1981, J HEALTH SOC BEHAV, V22, P400, DOI 10.2307/2136681; PAVENSTEDT E, 1967, DRIFTERS CHILDREN DI; REYNOLDS AJ, 1989, J EDUC PSYCHOL, V81, P594, DOI 10.1037/0022-0663.81.4.594; REYNOLDS AJ, 1991, ED334019; ROSSI PH, 1980, WHY FAMILIES MOVE, P32; SAMEROFF AJ, 1987, PEDIATRICS, V79, P343; SCHOR EL, 1982, PEDIATRICS, V69, P521; SHAF BV, 1992, SUDAAN USERS MANUAL; STANTON WR, 1991, PEDIATRICS, V88, P954; STOKOLS D, 1982, J SOC ISSUES, V38, P149, DOI 10.1111/j.1540-4560.1982.tb01776.x; STUBBLEFIELD RL, 1955, AM J ORTHOPSYCHIAT, V25, P12; Tyack D., 1992, FUTURE CHILD, V2, P19, DOI DOI 10.2307/1602459; WHALEN TE, 1973, J EDUC RES, V67, P163, DOI 10.1080/00220671.1973.10884593; WHITE KR, 1982, PSYCHOL BULL, V91, P461, DOI 10.1037/0033-2909.91.3.461; WOOD D, 1990, AM J PUBLIC HEALTH, V80, P1049, DOI 10.2105/AJPH.80.9.1049; WOOD DL, 1990, PEDIATRICS, V86, P858; 1989, US CHILDREN THEIR FA; 1992, FUTURE CHILD, V2, P6; 1989, CURRENT POPULATI P60, V166; 1990, 19R01 NAT ASS ED PRO; 1985, SAS USERS GUIDE BASI; 1989, CURRENT POPULATI P20, V430; [No title captured]	45	203	204	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1334	1338		10.1001/jama.270.11.1334	http://dx.doi.org/10.1001/jama.270.11.1334			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	7689659				2022-12-28	WOS:A1993LW34500031
J	BERLIN, C; BERG, EL; BRISKIN, MJ; ANDREW, DP; KILSHAW, PJ; HOLZMANN, B; WEISSMAN, IL; HAMANN, A; BUTCHER, EC				BERLIN, C; BERG, EL; BRISKIN, MJ; ANDREW, DP; KILSHAW, PJ; HOLZMANN, B; WEISSMAN, IL; HAMANN, A; BUTCHER, EC			ALPHA-4-BETA-7-INTEGRIN MEDIATES LYMPHOCYTE BINDING TO THE MUCOSAL VASCULAR ADDRESSIN MADCAM-1	CELL			English	Article							ENDOTHELIAL-CELL RECOGNITION; MONOCLONAL-ANTIBODIES; HOMING RECEPTOR; RECIRCULATING LYMPHOCYTES; ADHESION MOLECULE-1; DIVALENT-CATIONS; INTEGRIN VLA-4; IMMUNE-SYSTEM; FIBRONECTIN; LIGAND	The mucosal vascular addressin, MAdCAM-1, is an immunoglobulin superfamily adhesion molecule for lymphocytes that is expressed by mucosal venules and helps direct lymphocyte traffic into Peyer's patches (PP) and the intestinal lamina propria. We demonstrate that the lymphocyte integrin alpha4beta7, also implicated in homing to PP, is a receptor for MAdCAM-1. Certain antibodies to alpha4 and beta7 integrin chains but not to the beta2 integrin LFA-1 inhibit lymphocyte binding to purified MAdCAM-1 and to MAdCAM-1 transfectants. Lymph node lymphocytes, alpha4beta7+ TK1 lymphoma cells, and a beta7-transfected variant of an alpha4 + B cell line, 38C13, bind constitutively to MAdCAM-1. Binding is enhanced by Mn++-induced integrin activation. The related integrin alpha4beta1 supports efficient binding to VCAM-1 but not to MAdCAM-1, even after integrin activation, indicating that MAdCAM-1 is a preferential ligand for alpha4beta7. alpha4beta7 can also bind VCAM-1, but this requires greater integrin activation than binding to MAdCAM-1. The findings imply a selective role for the interaction of alpha4beta7 and MAdCAM-1 lymphocyte in homing to mucosal sites.	STANFORD UNIV,CTR DIGEST DIS,STANFORD,CA 94305; VET ADM MED CTR,FOOTHILL RES CTR,CTR MOLEC BIOL & MED,PALO ALTO,CA 94304; AFRC,INST ANIM PHYSIOL & GENET RES,DEPT CELL BIOL,CAMBRIDGE CB2 4AT,ENGLAND; TECH UNIV MUNICH,INST MED MICROBIOL,W-8000 MUNICH 80,GERMANY; STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; UNIV HAMBURG,KRANKENHAUS EPPENDORF,MED 1 KLIN,DIV IMMUNOL,W-2000 HAMBURG 20,GERMANY	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Technical University of Munich; Stanford University; Stanford University; University of Hamburg	BERLIN, C (corresponding author), STANFORD UNIV,DEPT PATHOL,IMMUNOL & VASC BIOL LAB,STANFORD,CA 94305, USA.		Berg, Ellen/D-9076-2014; Berg, Ellen/T-8827-2019	Berg, Ellen/0000-0001-5149-6665; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037734, R37GM037734] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19957] Funding Source: Medline; NIDDK NIH HHS [DK45448] Funding Source: Medline; NIGMS NIH HHS [GM37734] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGER A, 1990, INT IMMUNOL, V2, P921, DOI 10.1093/intimm/2.10.921; BARGATZE RF, 1993, IN PRESS J EXP MED; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1991, VASCULAR ADHESION MO, V2, P111; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1986, CURR TOP MICROBIOL, V128, P85; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; FRUTIGER S, 1986, J BIOL CHEM, V261, P6673; GABRIELMASSON CS, 1992, THESIS PENNSYLVANIA; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HAMANN A, 1988, J IMMUNOL, V140, P693; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HU MCT, 1992, P NATL ACAD SCI USA, V89, P8254, DOI 10.1073/pnas.89.17.8254; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; KILSHAW PJ, 1991, EUR J IMMUNOL, V21, P2591, DOI 10.1002/eji.1830211041; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MACKAY CR, 1993, IN PRESS ANN REV IMM; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; NAKACHE M, 1989, NATURE, V337, P179, DOI 10.1038/337179a0; ONEILL JK, 1991, IMMUNOLOGY, V72, P520; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMPER HB, 1976, J EXP MED, V144, P828, DOI 10.1084/jem.144.3.828; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STEPHENS PE, 1989, NUCLEIC ACIDS RES, V17, P7110, DOI 10.1093/nar/17.17.7110; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WOODRUFF JJ, 1987, ANNU REV IMMUNOL, V5, P201, DOI 10.1146/annurev.immunol.5.1.201; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; YUAN Q, 1992, J BIOL CHEM, V267, P7352; Zatz M M, 1970, Cell Immunol, V1, P3, DOI 10.1016/0008-8749(70)90057-2	61	1244	1303	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					185	195		10.1016/0092-8674(93)90305-A	http://dx.doi.org/10.1016/0092-8674(93)90305-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	7687523				2022-12-28	WOS:A1993LN62500018
J	HYDE, SC; GILL, DR; HIGGINS, CF; TREZISE, AEO; MACVINISH, LJ; CUTHBERT, AW; RATCLIFF, R; EVANS, MJ; COLLEDGE, WH				HYDE, SC; GILL, DR; HIGGINS, CF; TREZISE, AEO; MACVINISH, LJ; CUTHBERT, AW; RATCLIFF, R; EVANS, MJ; COLLEDGE, WH			CORRECTION OF THE ION-TRANSPORT DEFECT IN CYSTIC-FIBROSIS TRANSGENIC MICE BY GENE-THERAPY	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; RESPIRATORY EPITHELIUM; CHLORIDE CHANNELS; LUNG-DISEASE; ACTIVATION; EXPRESSION; AMILORIDE; CFTR; MEMBRANE; CALCIUM	CYSTIC fibrosis (CF) is a lethal inherited disorder affecting about 1 in 2,000 Caucasians. The major cause of morbidity is permanent lung damage resulting from ion transport abnormalities in airway epithelia that lead to mucus accumulation and bacterial colonization. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene1 that encodes a cyclic-AMP-regulated chloride channel2,3. Cyclic-AMP-regulated chloride conductances are altered in airway epithelia from CF patients4-6, suggesting that the functional expression of CFTR in the airways of CF patients may be a strategy for treatment. Transgenic mice7-9 With a disrupted cftr gene are appropriate for testing gene therapy protocols. Here we report the use of liposomes to deliver a CFTR expression plasmid to epithelia of the airway and to alveoli deep in the lung, leading to the correction of the ion conductance defects found in the trachea of transgenic (cf/cf) mice. These studies illustrate the feasibility of gene therapy for the pulmonary aspects of CF in humans.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND; UNIV CAMBRIDGE,DEPT PHARMACOL,CAMBRIDGE CB2 1QJ,ENGLAND; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,WELLCOME CRC INST CANC & DEV BIOL,CAMBRIDGE CB2 1QR,ENGLAND	Cancer Research UK; University of Oxford; University of Cambridge; University of Cambridge; University of Cambridge			Colledge, William/X-4976-2019	Colledge, William/0000-0002-9603-4429; Hyde, Stephen/0000-0002-8877-4005; Gill, Deborah/0000-0002-5264-054X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; APP EM, 1990, AM REV RESPIR DIS, V141, P605, DOI 10.1164/ajrccm/141.3.605; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CHAN HC, 1992, AM J PHYSIOL, V262, pC1273, DOI 10.1152/ajpcell.1992.262.5.C1273; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; COLLEDGE WH, 1992, LANCET, V340, P680, DOI 10.1016/0140-6736(92)92223-3; COTTON CU, 1987, J CLIN INVEST, V79, P80, DOI 10.1172/JCI112812; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; CUTHBERT AW, 1990, BRIT J CLIN PHARMACO, V29, P227, DOI 10.1111/j.1365-2125.1990.tb03624.x; DORIN JR, 1992, NATURE, V359, P211, DOI 10.1038/359211a0; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MCCANN JD, 1990, AM J PHYSIOL, V258, pL334, DOI 10.1152/ajplung.1990.258.6.L334; RATCLIFF R, IN PRESS NATURE GENE; RIORDAN JR, 1989, SCIENCE, V245, P1066; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SMITH SN, 1992, CLIN SCI, V82, P667, DOI 10.1042/cs0820667; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; TREZISE AEO, 1991, NATURE, V353, P434, DOI 10.1038/353434a0; TREZISE AEO, 1992, EMBO J, V11, P4291, DOI 10.1002/j.1460-2075.1992.tb05528.x; TREZISE AEO, IN PRESS HUM MOL GEN; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226, DOI 10.1152/ajpcell.1989.256.2.C226; YOSHIMURA K, 1992, NUCLEIC ACIDS RES, V20, P3233, DOI 10.1093/nar/20.12.3233; ZEITLIN PL, 1991, P NATL ACAD SCI USA, V89, P1344	33	360	424	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 18	1993	362	6417					250	255		10.1038/362250a0	http://dx.doi.org/10.1038/362250a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	7681548				2022-12-28	WOS:A1993KT02600058
J	STUART, J				STUART, J			SICKLE-CELL DISEASE - ACUTE-PHASE RESPONSE AND SICKLE CRISIS	LANCET			English	Editorial Material											STUART, J (corresponding author), UNIV BIRMINGHAM,DEPT HAEMATOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							AKINOLA NO, 1992, J CLIN PATHOL, V45, P902, DOI 10.1136/jcp.45.10.902; AKINOLA NO, 1992, BRIT J HAEMATOL, V81, P598, DOI 10.1111/j.1365-2141.1992.tb02998.x; BALLAS SK, 1992, BLOOD, V79, P2154, DOI 10.1182/blood.V79.8.2154.2154; FRANCIS RB, 1991, BLOOD, V77, P1405; MURRAY N, 1988, BRIT MED J, V297, P452, DOI 10.1136/bmj.297.6646.452; RICHARDSON SGN, 1979, BRIT J HAEMATOL, V41, P95, DOI 10.1111/j.1365-2141.1979.tb03685.x; STUART J, 1981, J CLIN PATHOL, V34, P464, DOI 10.1136/jcp.34.5.464; 1988, J CLIN PATHOL, V41, P1203	8	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					664	664		10.1016/0140-6736(93)90425-G	http://dx.doi.org/10.1016/0140-6736(93)90425-G			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	7680739				2022-12-28	WOS:A1993KR61300009
J	KUBO, Y; BALDWIN, TJ; JAN, YN; JAN, LY				KUBO, Y; BALDWIN, TJ; JAN, YN; JAN, LY			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION OF A MOUSE INWARD RECTIFIER POTASSIUM CHANNEL	NATURE			English	Article							GUINEA-PIG HEART; EGG CELL-MEMBRANE; K+ CHANNEL; VENTRICULAR CELLS; ANOMALOUS RECTIFICATION; XENOPUS OOCYTES; MAGNESIUM BLOCK; MAMMALIAN BRAIN; INTERNAL MG-2+; MESSENGER-RNA	A complementary DNA encoding an inward rectifier K+ channel (IRK1) was isolated from a mouse macrophage cell line by expression cloning. This channel conducts inward K+ current below the K+ equilibrium potential but passes little outward K+ current. The IRK1 channel contains only two putative transmembrane segments per subunit and corresponds to the inner core structure of voltage-gated K+ channels. The IRK1 channel and an ATP-regulated K+ channel show extensive sequence similarity and constitute a new superfamily.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Jan, Lily/0000-0003-3938-8498; Kubo, Yoshihiro/0000-0001-6707-0837				ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; Barres B A, 1991, Curr Opin Neurobiol, V1, P354, DOI 10.1016/0959-4388(91)90052-9; BIERMANS G, 1987, PFLUG ARCH EUR J PHY, V410, P604, DOI 10.1007/BF00581320; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; HAGIWARA S, 1979, ANNU REV BIOPHYS BIO, V8, P385, DOI 10.1146/annurev.bb.08.060179.002125; HAGIWARA S, 1977, J GEN PHYSIOL, V70, P269, DOI 10.1085/jgp.70.3.269; HAGIWARA S, 1976, J GEN PHYSIOL, V67, P621, DOI 10.1085/jgp.67.6.621; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HORIE M, 1987, J PHYSIOL-LONDON, V387, P251, DOI 10.1113/jphysiol.1987.sp016572; HORIE M, 1989, J PHYSIOL-LONDON, V408, P313, DOI 10.1113/jphysiol.1989.sp017461; INOUE M, 1988, J PHYSIOL-LONDON, V407, P177, DOI 10.1113/jphysiol.1988.sp017409; ITO H, 1991, J GEN PHYSIOL, V98, P517, DOI 10.1085/jgp.98.3.517; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; KATZ B, 1949, ARCH SCI PHYSIOL, V3, P285; KURACHI Y, 1992, PROG NEUROBIOL, V39, P229, DOI 10.1016/0301-0082(92)90017-9; LEWIS DL, 1991, FEBS LETT, V290, P17, DOI 10.1016/0014-5793(91)81215-T; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; MATSUDA H, 1991, ANNU REV PHYSIOL, V53, P289, DOI 10.1146/annurev.ph.53.030191.001445; MAYER ML, 1983, J PHYSIOL-LONDON, V340, P19, DOI 10.1113/jphysiol.1983.sp014747; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; MCKINNEY LC, 1988, J MEMBRANE BIOL, V103, P41, DOI 10.1007/BF01871931; MEYUHAS O, 1979, CELL, V16, P139, DOI 10.1016/0092-8674(79)90195-8; MIHARA S, 1987, J PHYSIOL-LONDON, V390, P335, DOI 10.1113/jphysiol.1987.sp016704; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; NOMA A, 1979, PFLUG ARCH EUR J PHY, V381, P255, DOI 10.1007/BF00583257; OHMORI H, 1980, J MEMBRANE BIOL, V53, P143, DOI 10.1007/BF01870582; OKAMOTO H, 1976, J PHYSIOL-LONDON, V254, P607, DOI 10.1113/jphysiol.1976.sp011249; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P659, DOI 10.1113/jphysiol.1984.sp015089; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SILVER MR, 1990, J GEN PHYSIOL, V96, P109, DOI 10.1085/jgp.96.1.109; STANDEN NB, 1978, J PHYSIOL-LONDON, V280, P169, DOI 10.1113/jphysiol.1978.sp012379; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WILLIAMS JT, 1988, J NEUROSCI, V8, P3499; YEATES TO, 1987, P NATL ACAD SCI USA, V84, P6438, DOI 10.1073/pnas.84.18.6438; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7	52	979	1012	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					127	133		10.1038/362127a0	http://dx.doi.org/10.1038/362127a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	7680768				2022-12-28	WOS:A1993KR02800049
J	GOVERMAN, J; WOODS, A; LARSON, L; WEINER, LP; HOOD, L; ZALLER, DM				GOVERMAN, J; WOODS, A; LARSON, L; WEINER, LP; HOOD, L; ZALLER, DM			TRANSGENIC MICE THAT EXPRESS A MYELIN BASIC PROTEIN-SPECIFIC T-CELL RECEPTOR DEVELOP SPONTANEOUS AUTOIMMUNITY	CELL			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ANTIGEN RECEPTOR; EXTRATHYMIC TOLERANCE; CLONAL ELIMINATION; VIRUS-INFECTION; SELF-TOLERANCE; LYMPHOCYTES-T; INDUCTION; THYMUS; ANERGY	We constructed a transgenic mouse model that mimics the human autoimmune disease multiple sclerosis in its spontaneous induction and pathology. Transgenic mice were constructed expressing genes encoding a rearranged T cell receptor specific for myelin basic protein (MBP). T cell tolerance was not induced in the periphery, and functional, autoreactive T cells were found in the spleen and lymph nodes of these mice. Transgenic mice developed experimental allergic encephalomyelitis (EAE) following immunization with MBP and adjuvant plus pertussis toxin as well as with administration of pertussis toxin alone. Spontaneous EAE can develop in transgenic mice housed in a nonsterile facility but not in those maintained in a sterile, specific pathogen-free facility. This model system affords a unique opportunity to dissect the genetic and environmental variables that may contribute to the development of spontaneous autoimmune disease.	UNIV SO CALIF, SCH MED, DEPT NEUROBIOL, LOS ANGELES, CA 90033 USA; MERCK SHARP & DOHME LTD, DEPT MOLEC IMMUNOL, RAHWAY, NJ 07065 USA	University of Southern California; Merck & Company	GOVERMAN, J (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.			Goverman, Joan/0000-0002-7361-9424				Alvord E C Jr, 1984, Prog Clin Biol Res, V146, P503; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BROWN AM, 1981, LAB INVEST, V45, P278; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; FRITZ RB, 1989, CHEM IMMUNOL, V46, P101; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; HAMMERLING GJ, 1991, RES IMMUNOL, V142, P417, DOI 10.1016/0923-2494(91)90040-P; JAHNKE U, 1985, SCIENCE, V229, P282, DOI 10.1126/science.2409602; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; JONES LA, 1990, THYMUS, V16, P195; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KAMRADT T, 1991, J IMMUNOL, V147, P3296; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1991, IMMUNOL REV, V122, P69, DOI 10.1111/j.1600-065X.1991.tb00597.x; KOH DR, 1992, SCIENCE, V256, P1210, DOI 10.1126/science.256.5060.1210; LINTHICUM DS, 1982, IMMUNOBIOLOGY, V162, P211, DOI 10.1016/S0171-2985(11)80001-X; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; LUBLIN FD, 1981, J IMMUNOL, V126, P819; MCFARLIN DE, 1982, NEW ENGL J MED, V307, P1183, DOI 10.1056/NEJM198211043071905; MILICH DR, 1991, P NATL ACAD SCI USA, V88, P4348, DOI 10.1073/pnas.88.10.4348; MILLER JFAP, 1991, IMMUNOL REV, V122, P103, DOI 10.1111/j.1600-065X.1991.tb00599.x; MORAHAN G, 1989, NATURE, V339, P622, DOI 10.1038/339622a0; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; PIRCHER H, 1992, EUR J IMMUNOL, V22, P399, DOI 10.1002/eji.1830220217; Raine C. S., 1983, MULTIPLE SCLEROSIS P, P413; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROMAN LM, 1990, CELL, V61, P383, DOI 10.1016/0092-8674(90)90521-F; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; STAERZ UD, 1985, J IMMUNOL, V134, P3994; Suckling A J, 1984, Prog Clin Biol Res, V146, P75; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	40	585	596	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 26	1993	72	4					551	560		10.1016/0092-8674(93)90074-Z	http://dx.doi.org/10.1016/0092-8674(93)90074-Z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	7679952				2022-12-28	WOS:A1993KP16500010
J	LUAN, DD; KORMAN, MH; JAKUBCZAK, JL; EICKBUSH, TH				LUAN, DD; KORMAN, MH; JAKUBCZAK, JL; EICKBUSH, TH			REVERSE TRANSCRIPTION OF R2BM RNA IS PRIMED BY A NICK AT THE CHROMOSOMAL TARGET SITE - A MECHANISM FOR NON-LTR RETROTRANSPOSITION	CELL			English	Article							R HYBRID DYSGENESIS; DROSOPHILA-MELANOGASTER; TRANSPOSABLE ELEMENT; MAMMALIAN LINES; BOMBYX-MORI; RETROVIRAL PROTEINS; I-FACTOR; DNA; SEQUENCE; INSERTION	R2 is a non-LTR retrotransposable element that inserts at a specific site in the 28S rRNA genes of most insects. We have expressed the open reading frame of the R2 element from Bombyx mori, R2Bm, in E. coli and shown that it encodes both sequence-specific endonuclease and reverse transcriptase activities. The R2 protein makes a specific nick in one of the DNA strands at the insertion site and uses the 3' hydroxyl group exposed by this nick to prime reverse transcription of its RNA transcript. After reverse transcription, cleavage of the second DNA strand occurs. A similar mechanism of insertion may be used by other non-LTR retrotransposable elements as well as short interspersed nucleotide elements.			LUAN, DD (corresponding author), UNIV ROCHESTER, DEPT BIOL, ROCHESTER, NY 14627 USA.				NIGMS NIH HHS [GM42790] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DS, 1986, J MOL BIOL, V187, P465, DOI 10.1016/0022-2836(86)90327-X; BELL L, 1983, ANAL BIOCHEM, V130, P527, DOI 10.1016/0003-2697(83)90628-0; BERG JM, 1990, J BIOL CHEM, V265, P6513; BOEKE JD, 1989, ANNU REV MICROBIOL, V43, P403, DOI 10.1146/annurev.micro.43.1.403; BOEKE JD, 1989, MOBILE DNA, P335; BRADFIELD JY, 1985, DNA-J MOLEC CELL BIO, V4, P357, DOI 10.1089/dna.1985.4.357; Brown N L, 1980, Methods Enzymol, V65, P391; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUCHETON A, 1990, TRENDS GENET, V6, P16, DOI 10.1016/0168-9525(90)90044-7; BURKE WD, 1987, MOL CELL BIOL, V7, P2221, DOI 10.1128/MCB.7.6.2221; BURKE WD, 1993, IN PRESS MOL BIOL EV, V10; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; CHABOISSIER MC, 1990, EMBO J, V9, P3557, DOI 10.1002/j.1460-2075.1990.tb07566.x; DAWID IB, 1981, NUCLEIC ACIDS RES, V9, P5011, DOI 10.1093/nar/9.19.5011; Deininger PL, 1989, MOBILE DNA, P619; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; EICKBUSH TH, 1992, NEW BIOL, V4, P430; EICKBUSH TH, 1985, EMBO J, V4, P2281, DOI 10.1002/j.1460-2075.1985.tb03927.x; EVANS JP, 1991, P NATL ACAD SCI USA, V88, P8792, DOI 10.1073/pnas.88.19.8792; FAWCETT DH, 1986, CELL, V47, P1007, DOI 10.1016/0092-8674(86)90815-9; FINNEGAN DJ, 1989, MOBILE DNA, P503; GABRIEL A, 1991, P NATL ACAD SCI USA, V88, P9794, DOI 10.1073/pnas.88.21.9794; HANSEN LJ, 1988, MOL CELL BIOL, V8, P5245, DOI 10.1128/MCB.8.12.5245; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; IVANOV VA, 1991, EMBO J, V10, P2489, DOI 10.1002/j.1460-2075.1991.tb07788.x; JAKUBCZAK JL, 1991, P NATL ACAD SCI USA, V88, P3295, DOI 10.1073/pnas.88.8.3295; JAKUBCZAK JL, 1990, J MOL BIOL, V212, P37, DOI 10.1016/0022-2836(90)90303-4; JENSEN S, 1991, EMBO J, V10, P1927, DOI 10.1002/j.1460-2075.1991.tb07719.x; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KIMMEL BE, 1987, MOL CELL BIOL, V7, P1465, DOI 10.1128/MCB.7.4.1465; Maniatis T., 1982, MOL CLONING; MARLOR RL, 1986, MOL CELL BIOL, V6, P1129, DOI 10.1128/MCB.6.4.1129; Martin SL, 1991, CURR OPIN GENET DEV, V1, P505, DOI 10.1016/S0959-437X(05)80199-6; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MINCHIOTTI G, 1991, MOL CELL BIOL, V11, P5171, DOI 10.1128/MCB.11.10.5171; MIZROKHI LJ, 1988, CELL, V54, P685, DOI 10.1016/S0092-8674(88)80013-8; MOUNT SM, 1985, MOL CELL BIOL, V5, P1630, DOI 10.1128/MCB.5.7.1630; NISSON PE, 1988, NUCLEIC ACIDS RES, V16, P1431, DOI 10.1093/nar/16.4.1431; OKADA N, 1991, TRENDS ECOL EVOL, V6, P358, DOI 10.1016/0169-5347(91)90226-N; PELISSON A, 1991, P NATL ACAD SCI USA, V88, P4907, DOI 10.1073/pnas.88.11.4907; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; ROIHA H, 1981, NATURE, V290, P749, DOI 10.1038/290749a0; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZSOMMER Z, 1987, EMBO J, V6, P3873, DOI 10.1002/j.1460-2075.1987.tb02727.x; SINGER MF, 1985, TRENDS BIOCHEM SCI, V10, P119, DOI 10.1016/0968-0004(85)90271-3; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; TEMIN HM, 1989, NATURE, V339, P254, DOI 10.1038/339254a0; VARMUS H, 1989, MOBILE DNA, P53; VOYTAS DF, 1988, NATURE, V336, P242, DOI 10.1038/336242a0; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; XIONG Y, 1988, MOL CELL BIOL, V8, P114, DOI 10.1128/MCB.8.1.114; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; XIONG Y, 1988, CELL, V55, P235, DOI 10.1016/0092-8674(88)90046-3; [No title captured]	56	900	929	1	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 26	1993	72	4					595	605		10.1016/0092-8674(93)90078-5	http://dx.doi.org/10.1016/0092-8674(93)90078-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	7679954				2022-12-28	WOS:A1993KP16500014
J	VIVILLE, S; NEEFJES, J; LOTTEAU, V; DIERICH, A; LEMEUR, M; PLOEGH, H; BENOIST, C; MATHIS, D				VIVILLE, S; NEEFJES, J; LOTTEAU, V; DIERICH, A; LEMEUR, M; PLOEGH, H; BENOIST, C; MATHIS, D			MICE LACKING THE MHC CLASS II-ASSOCIATED INVARIANT CHAIN	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL DETERMINANTS; HLA-DR MOLECULES; ANTIGEN PRESENTATION; MONOCLONAL-ANTIBODIES; SURFACE EXPRESSION; IA ANTIGENS; INTRACELLULAR-TRANSPORT; EXOGENOUS ANTIGEN; PEPTIDE BINDING	The invariant chain (Ii) has aroused much interest because of its close association with major histocompatibility complex (MHC) class II molecules. Various functions have been proposed for it; several of these have received experimental support, but most have not been definitively proven, owing largely to uncertainties inherent in the experimental systems employed. We have now generated a line of mice devoid of the invariant chain by introducing a drastic mutation into the Ii gene. Cells from mutant animals show aberrant transport of MHC class II molecules, resulting in reduced levels of class II complexes at the surface, and these do not have the typical compact conformation indicative of tight peptide binding. Consequently, mutant cells present protein antigens very poorly and mutant mice are deficient in producing and at negatively selecting CD4+ T cells.	NETHERLANDS CANC INST,1066 CX AMSTERDAM,NETHERLANDS; FAC MED PARIS,INST CORDELIERS,F-75006 PARIS,FRANCE	Netherlands Cancer Institute; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	VIVILLE, S (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,F-67085 STRASBOURG,FRANCE.		Neefjes, Jacques J.C./H-8780-2017; lotteau, vincent/M-8143-2014	Neefjes, Jacques J.C./0000-0001-6763-2211; Lotteau, Vincent/0000-0003-0997-3282; Viville, Stephane/0000-0002-5088-3003				ADORINI L, 1988, J EXP MED, V168, P2091, DOI 10.1084/jem.168.6.2091; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BECK BN, 1986, J IMMUNOL, V136, P2953; BERTOLINO P, 1991, INT IMMUNOL, V3, P435, DOI 10.1093/intimm/3.5.435; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BIKOFF EK, 1991, EUR J IMMUNOL, V21, P1411, DOI 10.1002/eji.1830210613; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BROOKS A, 1991, P NATL ACAD SCI USA, V88, P3290, DOI 10.1073/pnas.88.8.3290; CHEN BP, 1990, J EXP MED, V172, P779, DOI 10.1084/jem.172.3.779; CLEASSONWELSH L, 1985, J IMMUNOL, V135, P3551; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CRESSWELL P, 1992, CURR OPIN IMMUNOL, V4, P87, DOI 10.1016/0952-7915(92)90131-W; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; ELLIOTT WL, 1987, J IMMUNOL, V138, P2949; FISCH A, 1992, EUR J IMMUNOL, V22, P1413, DOI 10.1002/eji.1830220613; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; HACKETT CJ, 1991, J IMMUNOL, V146, P2944; HAMMERLING GJ, 1990, IMMUNOL TODAY, V11, P337; HAMMERLING GJ, 1979, IMMUNOGENETICS, V8, P433, DOI 10.1007/BF01561454; JACOB MC, 1991, CYTOMETRY, V12, P550, DOI 10.1002/cyto.990120612; JANEWAY CA, 1984, J IMMUNOL, V132, P662; JIN Y, 1988, J EXP MED, V168, P293, DOI 10.1084/jem.168.1.293; JONES PP, 1979, MOL IMMUNOL, V16, P51, DOI 10.1016/0161-5890(79)90027-0; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOBORI JA, 1992, P NATL ACAD SCI USA, V89, P2940, DOI 10.1073/pnas.89.7.2940; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; KOCH N, 1991, CURR OPIN IMMUNOL, V3, P10, DOI 10.1016/0952-7915(91)90069-D; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LEMEUR M, 1985, NATURE, V316, P38, DOI 10.1038/316038a0; LEMKE H, 1979, IMMUNOL REV, V47, P175, DOI 10.1111/j.1600-065X.1979.tb00293.x; LORENZ RG, 1988, J IMMUNOL, V141, P4124; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MICHALEK MT, 1992, J IMMUNOL, V148, P1016; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORENO J, 1991, J IMMUNOL, V147, P3306; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; OZATO K, 1980, J IMMUNOL, V124, P533; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; PETERSON M, 1992, NATURE, V357, P596, DOI 10.1038/357596a0; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; RATH S, 1992, EUR J IMMUNOL, V22, P2121, DOI 10.1002/eji.1830220824; REGNIERVIGOUROX A, 1988, J IMMUNOL, V140, P1069; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SALAMERO J, 1990, EMBO J, V9, P3489, DOI 10.1002/j.1460-2075.1990.tb07557.x; SCHAIFF WT, 1991, J IMMUNOL, V147, P603; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SEKALY RP, 1988, P NATL ACAD SCI USA, V85, P1209, DOI 10.1073/pnas.85.4.1209; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; SIMONIS S, 1989, J IMMUNOL, V143, P3619; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; STOCKINGER B, 1989, CELL, V56, P683, DOI 10.1016/0092-8674(89)90590-4; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; Teyton L, 1992, Trends Cell Biol, V2, P52, DOI 10.1016/0962-8924(92)90163-H; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WEI BY, 1991, INT IMMUNOL, V3, P833, DOI 10.1093/intimm/3.8.833; WEISS S, 1991, CELL, V64, P797; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787	72	350	353	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					635	648		10.1016/0092-8674(93)90081-Z	http://dx.doi.org/10.1016/0092-8674(93)90081-Z			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	7679955				2022-12-28	WOS:A1993KP16500017
J	MORROW, JD; FREI, B; LONGMIRE, AW; GAZIANO, JM; LYNCH, SM; SHYR, Y; STRAUSS, WE; OATES, JA; ROBERTS, LJ				MORROW, JD; FREI, B; LONGMIRE, AW; GAZIANO, JM; LYNCH, SM; SHYR, Y; STRAUSS, WE; OATES, JA; ROBERTS, LJ			INCREASE IN CIRCULATING PRODUCTS OF LIPID-PEROXIDATION (F-2-ISOPROSTANES) IN SMOKERS - SMOKING AS A CAUSE OF OXIDATIVE DAMAGE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DENSITY LIPOPROTEIN; HUMAN-BLOOD-PLASMA; VITAMIN-C STATUS; CIGARETTE-SMOKING; PROSTANOIDS F2-ISOPROSTANES; ANTIOXIDANT; MACROPHAGES; METABOLITES; CAROTENES; MECHANISM	Background. It has been hypothesized that the pathogenesis of diseases induced by cigarette smoking involves oxidative damage by free radicals. However, definitive evidence that smoking causes the oxidative modification of target molecules in vivo is lacking. We conducted a study to determine whether the production of F-2-isoprostanes, which are novel products of lipid peroxidation, is enhanced in persons who smoke. Methods. We measured the levels of free F-2-isoprostanes in plasma, the levels of F-2-isoprostanes esterified to plasma lipids, and the urinary excretion of metabolites of F-2-isoprostanes in 10 smokers and 10 nonsmokers matched for age and sex. The short-term effects of smoking (three cigarettes smoked over 30 minutes) and the effects of two weeks of abstinence from smoking on levels of F-2-isoprostanes in the circulation were also determined in the smokers. Results. Plasma levels of free and esterified F-2-isoprostanes were significantly higher in the smokers (mean +/-SD, 242+/-147 and 574+/-217 pmol per liter, respectively) than in the nonsmokers (103+/-19 and 345+/-65 pmol per liter; P = 0.02 for free F-2-isoprostanes and P = 0.03 for esterified F-2-isoprostanes). Smoking had no short-term effects on the circulating levels of F-2-isoprostanes. However, the levels of free and esterified F-2-isoprostanes fell significantly after two weeks of abstinence from smoking (250+/-156 and 624+/-214 pmol per liter, respectively, before the cessation of smoking, as compared with 156+/-67 and 469+/-108 pmol per liter after two weeks' cessation; P=0.03 for free F-2-isoprostanes and P = 0.02 for esterified F-2-isoprostanes). Conclusions. The increased levels of F-2-isoprostanes in the circulation of persons who smoke support the hypothesis that smoking can cause the oxidative modification of important biologic molecules in vivo.	VANDERBILT UNIV, DEPT MED, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, DEPT PREVENT MED, DIV BIOSTAT, NASHVILLE, TN 37232 USA; BOSTON UNIV, SCH MED, WHITAKER CARDIOVASC INST, BOSTON, MA 02118 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, CARDIOL SECT, BOSTON, MA USA	Vanderbilt University; Vanderbilt University; Boston University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University	MORROW, JD (corresponding author), VANDERBILT UNIV, DEPT PHARMACOL, 221 KIRKLAND HALL, 506 MRB, NASHVILLE, TN 37232 USA.		Lynch, Sean M/A-9354-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, R01GM042056, R37GM042056] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49954] Funding Source: Medline; NIGMS NIH HHS [GM-15431, GM-42056] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AWAD JA, 1993, J BIOL CHEM, V268, P4161; Bridges A B, 1993, Eur J Med, V2, P205; CAILLEUX A, 1993, FREE RADICAL RES COM, V18, P323, DOI 10.3109/10715769309147499; CANTIN A, 1985, EUR J RESPIR DIS, V66, P7; CHOW CK, 1993, ANN NY ACAD SCI, V686, P289, DOI 10.1111/j.1749-6632.1993.tb39189.x; CHOW CK, 1986, J AM COLL NUTR, V5, P305; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; DOLL R, 1978, J EPIDEMIOL COMMUN H, V32, P303, DOI 10.1136/jech.32.4.303; DUTHIE GG, 1991, AM J CLIN NUTR, V53, pS1061, DOI 10.1093/ajcn/53.4.1061S; FREI B, 1991, BIOCHEM J, V277, P133, DOI 10.1042/bj2770133; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; HARATS D, 1989, ATHEROSCLEROSIS, V79, P245, DOI 10.1016/0021-9150(89)90130-5; HESS D, 1991, INT J VITAM NUTR RES, V61, P232; HOIDAL JR, 1983, CHEST, V83, P679, DOI 10.1378/chest.83.4.679; KALRA J, 1991, INT J EXP PATHOL, V72, P1; KANNEL WB, 1981, AM HEART J, V101, P319, DOI 10.1016/0002-8703(81)90197-6; KYEREMATEN GA, 1982, CLIN PHARMACOL THER, V32, P769, DOI 10.1038/clpt.1982.235; LEHR HA, 1993, FREE RADICAL BIO MED, V14, P573, DOI 10.1016/0891-5849(93)90138-K; LONGMIRE AW, 1994, BIOCHEM PHARMACOL, V47, P1173, DOI 10.1016/0006-2952(94)90389-1; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; MOHLER ER, 1992, CIRCULATION, V86, P865; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MORROW JD, 1994, METHOD ENZYMOL, V233, P163; OBRIEN PJ, 1988, FREE RADICAL BIO MED, V4, P169, DOI 10.1016/0891-5849(88)90025-1; PELLETIER O, 1970, AM J CLIN NUTR, V23, P520; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROBERTS LJ, 1987, CRC HDB EICOSANOIDS, V1, P233; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SCHONFELD G, 1989, ENDOCRINOLOGY, V3, P2424; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; YOKODE M, 1988, P NATL ACAD SCI USA, V85, P2344, DOI 10.1073/pnas.85.7.2344	34	1167	1190	2	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 4	1995	332	18					1198	1203		10.1056/NEJM199505043321804	http://dx.doi.org/10.1056/NEJM199505043321804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV415	7700313	Bronze			2022-12-28	WOS:A1995QV41500004
J	THOMPSON, RS; TAPLIN, SH; MCAFEE, TA; MANDELSON, MT; SMITH, AE				THOMPSON, RS; TAPLIN, SH; MCAFEE, TA; MANDELSON, MT; SMITH, AE			PRIMARY AND SECONDARY PREVENTION SERVICES IN CLINICAL-PRACTICE - 20 YEARS EXPERIENCE IN DEVELOPMENT, IMPLEMENTATION, AND EVALUATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY CARE PRACTICE; BICYCLE SAFETY HELMETS; CONTROLLED TRIAL; COST-EFFECTIVENESS; RANDOMIZED TRIAL; CANCER; PHYSICIAN; SMOKING; INTERVENTIONS; PROGRAM	This article reviews lessons from 20 years of experience in development and provision of clinical preventive services at Group Health Cooperative of Puget Sound, a large health maintenance organization. Critical factors for enhancing service include the use of a population-based epidemiologic viewpoint coupled with specific evidence-based criteria to examine issues; involvement of practitioners in the process; a systems approach to implementation focused on predisposing factors of the practitioners and enabling factors in the practice, organizational, and community environments; feedback of program outcomes; and the use of automated clinical information systems. Outcome results from our clinical prevention efforts include a 32% decrease in late-stage breast cancer (1989 to 1990); 89% of 2-year-old children with complete immunizations (1994); decrease in adult smokers from 25% to 17% (1985 to 1994); and an increase in bicycle safety helmet use among children from 4% to 48% along with a 67% decrease in bicycle-related head injuries (1987 to 1992). Systematic population-based approaches to the development and provision of clinical preventive services targeting the one-to-one level of primary care and multiple infrastructure levels of care are forging a synthesis of clinical medicine and public health approaches. This approach will become pervasive as clinical information systems improve, risk information is captured routinely, and practitioners gain skills in the art of patient risk behavior change and population-based care.	GRP HLTH COOPERAT PUGET SOUND, CTR HLTH PROMOT, SEATTLE, WA 98121 USA	Group Health Cooperative	THOMPSON, RS (corresponding author), GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, DEPT PREVENT CARE, 1730 MINOR AVE, SUITE 1600, SEATTLE, WA 98101 USA.							[Anonymous], 1989, GUIDE CLIN PREVENTIV; BELCHER DW, 1990, ARCH INTERN MED, V150, P2533, DOI 10.1001/archinte.150.12.2533; BERGMAN AB, 1994, ARCH PEDIAT ADOL MED, V144, P727; BRESLOW L, 1977, NEW ENGL J MED, V296, P601, DOI 10.1056/NEJM197703172961104; BRITT J, 1994, HEALTH EDUC QUART, V21, P55, DOI 10.1177/109019819402100107; CHENEY C, 1987, AM J MED, V83, P129, DOI 10.1016/0002-9343(87)90507-9; COHEN SJ, 1987, AM J PUBLIC HEALTH, V77, P313, DOI 10.2105/AJPH.77.3.313; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DIETRICH AJ, 1992, BRIT MED J, V304, P687, DOI 10.1136/bmj.304.6828.687; DIGUISEPPI CG, 1990, AM J DIS CHILD, V144, P83, DOI 10.1001/archpedi.1990.02150250093041; DOUBILET P, 1986, NEW ENGL J MED, V314, P253, DOI 10.1056/NEJM198601233140421; DURBIN WA, 1981, JAMA-J AM MED ASSOC, V246, P1796, DOI 10.1001/jama.246.16.1796; EPSTEIN AM, 1983, NEW ENGL J MED, V309, P464, DOI 10.1056/NEJM198308253090805; FRAME PS, 1984, J FAM PRACTICE, V19, P341; GEHLBACH SH, 1984, MED CARE, V22, P193, DOI 10.1097/00005650-198403000-00002; GLYNN TJ, 1991, NCI PHS NIH923064 US; GOLDBLOOM R, 1988, CAN MED ASSOC J, V138, P618; GREEN L, 1991, APPLICATION PRECEDE; GREEN L W, 1988, American Journal of Preventive Medicine, V4, P101; JOHNS MB, 1992, AM J PREV MED, V8, P135, DOI 10.1016/S0749-3797(18)30820-1; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KOTTKE TE, 1988, JAMA-J AM MED ASSOC, V259, P2882, DOI 10.1001/jama.1988.03720190050031; KOTTKE TE, 1992, J FAM PRACTICE, V34, P701; KOTTKE TE, 1993, MAYO CLIN PROC, V68, P785, DOI 10.1016/S0025-6196(12)60638-7; LAWRENCE R S, 1990, Journal of General Internal Medicine, V5, pS99, DOI 10.1007/BF02600852; LERMAN C, 1992, J CLIN ONCOL, V10, P330, DOI 10.1200/JCO.1992.10.2.330; LEWIS C E, 1988, American Journal of Preventive Medicine, V4, P9; LIN EHB, 1995, MED CARE, V33, P67, DOI 10.1097/00005650-199501000-00006; MAIMAN LA, 1988, AM J DIS CHILD, V142, P773, DOI 10.1001/archpedi.1988.02150070087033; MARTIN SG, 1982, MED CARE, V20, P21, DOI 10.1097/00005650-198201000-00003; MCBRIDE C, 1993, ANN BEHAV MED, V12, pS128; MCDOWELL I, 1989, MED CARE, V27, P297, DOI 10.1097/00005650-198903000-00008; MCKEOWN T, 1968, SCRENING MED CARE RE; MCPHEE SJ, 1989, ARCH INTERN MED, V149, P1866, DOI 10.1001/archinte.149.8.1866; MYERS LP, 1981, MILBANK FUND Q, V59, P481, DOI 10.2307/3349738; NATTINGER AB, 1989, ARCH INTERN MED, V149, P2087, DOI 10.1001/archinte.149.9.2087; NISSINEN A, 1986, MED CARE, V24, P767, DOI 10.1097/00005650-198608000-00012; ORLEANS CT, 1991, J CONSULT CLIN PSYCH, V59, P439, DOI 10.1037/0022-006X.59.3.439; PAYNE T, 1993, AM J PREV MED, V9, P96, DOI 10.1016/S0749-3797(18)30747-5; PEARSON DC, 1994, PUBLIC HEALTH REP, V109, P571; Perry C.L., 1990, INDIVIDUALS ENV HLTH; POMMERENKE FA, 1992, J FAM PRACTICE, V34, P86; POMMERENKE FA, 1992, J FAM PRACTICE, V34, P92; RIVARA FP, 1994, PEDIATRICS, V93, P567; SAVAGE B, 1991, 26TH ANN USPHS PROF; SCOTT CS, 1992, AM J PREV MED, V8, P241, DOI 10.1016/S0749-3797(18)30812-2; SOX HC, 1994, NEW ENGL J MED, V330, P1589, DOI 10.1056/NEJM199406023302208; Stuart M E, 1991, HMO Pract, V5, P198; Stuart M E, 1992, HMO Pract, V6, P5; SUGG NK, 1992, JAMA-J AM MED ASSOC, V267, P3157, DOI 10.1001/jama.267.23.3157; TAPLIN SH, 1990, CANCER, V66, P812, DOI 10.1002/1097-0142(19900815)66:4<812::AID-CNCR2820660436>3.0.CO;2-1; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; THOMPSON RS, 1986, MED CARE, V24, P904, DOI 10.1097/00005650-198610000-00004; THOMPSON RS, 1993, PEDIATRICS, V91, P902; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; THOMPSON RS, 1989, CANCER-AM CANCER SOC, V64, P2682, DOI 10.1002/1097-0142(19891215)64:2+<2682::AID-CNCR2820641412>3.0.CO;2-T; THOMPSON RS, 1988, MED CARE, V26, P62, DOI 10.1097/00005650-198801000-00007; VOELKER R, 1994, JAMA-J AM MED ASSOC, V271, P1301; WAGNER EH, IN PRESS MED CARE; WAGNER EH, 1992, IOM WORKSHOP P CHANG, P51; WALSH JME, 1992, HEALTH EDUC QUART, V19, P157, DOI 10.1177/109019819201900202; WARD VM, 1991, EVALUATION REV, V15, P266, DOI 10.1177/0193841X9101500207; Warner KE, 1982, COST BENEFIT COST EF; WEISBROD WR, 1979, HLTH CARE MANAGE REV, V4, P7; WILLIAMS PA, 1987, CANCER, V60, P1970, DOI 10.1002/1097-0142(19901015)60:8+<1970::AID-CNCR2820601508>3.0.CO;2-M; WINICKOFF RN, 1984, MED CARE, V22, P527, DOI 10.1097/00005650-198406000-00003; [No title captured]; 1980, PERIODIC HLTH EXAMIN; 1994, OFFICE SYSTEMS PROMO; 1994, PATTERNS HMO ENROLLM	71	130	132	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1130	1135		10.1001/jama.273.14.1130	http://dx.doi.org/10.1001/jama.273.14.1130			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QR059	7707602				2022-12-28	WOS:A1995QR05900033
J	WEINSTEIN, BD; MOSS, AH				WEINSTEIN, BD; MOSS, AH			ROLE MODELS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1076	1076		10.1001/jama.273.14.1076	http://dx.doi.org/10.1001/jama.273.14.1076			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR059	7707580				2022-12-28	WOS:A1995QR05900001
J	DENHEIJER, M; BLOM, HJ; GERRITS, WBJ; ROSENDAAL, FR; HAAK, HL; WIJERMANS, PW; BOS, GMJ				DENHEIJER, M; BLOM, HJ; GERRITS, WBJ; ROSENDAAL, FR; HAAK, HL; WIJERMANS, PW; BOS, GMJ			IS HYPERHOMOCYSTEINAEMIA A RISK FACTOR FOR RECURRENT VENOUS THROMBOSIS	LANCET			English	Article							PLASMA HOMOCYSTEINE; HOMOCYSTINURIA; DEFICIENCY; ARTERIAL; DISEASE	Several studies have shown a relation between hyperhomocysteinaemia and arterial Vascular disease. We looked at the association between hyperhomocysteinaemia and Venous thrombosis which could be clinically important as hyperhomocysteinaemia is easily corrected by Vitamin supplementation. We studied 185 patients with a history of recurrent venous thrombosis and 220 controls from the general population. Homocysteine concentrations were measured before and 6 h after oral methionine loading. We defined hyperhomocysteinaemia as the homocysteine concentration above the fasting or the postmethionine Value found for the 90th percentile of the controls. Of the 185 patients with recurrent thrombosis, 46 (25%) had fasting homocysteine concentrations above the 90th percentile or the controls (odds ratio is 3.1 [1.8-5.5]). After adjustment for age, sex, and menopausal status the odds ratio was 2.0 (1.5-2.7). Similar results were found for the post-methionine Value (unadjusted odds ratio 3.1 [1.7-5.5], adjusted 2.6 [1.9-3.5]). Hyperhomocysteinaemia is a common risk factor for recurrent Venous thrombosis and can lead to a two-fold or three-fold increase in risk.	UNIV NIJMEGEN HOSP,PAEDIAT & NEUROL LAB,6500 HB NIJMEGEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT HEMATOL,2333 AA LEIDEN,NETHERLANDS	Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	DENHEIJER, M (corresponding author), MUNICIPAL HOSP LEYENBURG,DEPT HEMATOL,THE HAGUE,NETHERLANDS.		Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496; Blom, Henk/0000-0001-5202-9241				ANDERSSON A, 1992, EUR J CLIN INVEST, V22, P79, DOI 10.1111/j.1365-2362.1992.tb01940.x; [Anonymous], 1985, THEORETICAL EPIDEMIO; BIENVENU T, 1991, PRESSE MED, V20, P985; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BRATTSTROM L, 1991, HAEMOSTASIS, V21, P51; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; FISKERSTRAND T, 1993, CLIN CHEM, V39, P263; FRANKEN DG, 1994, ARTERIOSCLER THROMB, V14, P465, DOI 10.1161/01.ATV.14.3.465; HEIJEER M, 1994, FIBRINOLYSIS S2, V8, P91; MCCULLY KS, 1987, RES COMMUN CHEM PATH, V56, P349; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MIETTINEN OS, 1974, AM J EPIDEMIOL, V99, P352; MUDD SH, 1985, AM J HUM GENET, V37, P1; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RODGERS GM, 1990, BLOOD, V75, P895; RODGERS GM, 1988, J CLIN INVEST, V81, P1911, DOI 10.1172/JCI113538; Schlesselman JJ, 1982, CASE CONTROL STUDIES; STAMPFER MJ, 1993, JAMA-J AM MED ASSOC, V270, P2726, DOI 10.1001/jama.270.22.2726; UBBINK JB, 1993, CLIN INVESTIGATOR, V71, P993, DOI 10.1007/BF00180030; UELAND PM, 1993, ATHEROSCLEROTIC CARD, P183	20	320	321	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					882	885		10.1016/S0140-6736(95)90008-X	http://dx.doi.org/10.1016/S0140-6736(95)90008-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707810	Green Submitted			2022-12-28	WOS:A1995QR06700008
J	BYSKOV, AG; ANDERSEN, CY; NORDHOLM, L; THOGERSEN, H; XIA, GL; WASSMANN, O; ANDERSEN, JV; GUDDAL, E; ROED, T				BYSKOV, AG; ANDERSEN, CY; NORDHOLM, L; THOGERSEN, H; XIA, GL; WASSMANN, O; ANDERSEN, JV; GUDDAL, E; ROED, T			CHEMICAL-STRUCTURE OF STEROLS THAT ACTIVATE OOCYTE MEIOSIS	NATURE			English	Article							FOLLICULAR-FLUID; GRANULOSA-CELLS; MATURATION; INVITRO; HYPOXANTHINE; ZYMOSTEROL; SUBSTANCE; REDUCTASE	GONADOTROPHINS and various growth factors, but not sex steroids, can induce resumption of meiosis in vitro, but only in oocytes enclosed by cumulus-granulosa cells(1). Follicular purines prevent resumption of meiosis(2,3). This process can be overcome, in vitro, by a transient elevation of cyclic AMP resulting in the production of a diffusible meiosis-inducing substance secreted by the cumulus cells(4). A meiosis-inducing activity has been detected in gonads of different species, for example, in preovulatory follicular fluid of women(5) and in mouse testes(6). We report here the isolation and characterization of meiosis-activating sterols from human follicular fluid and bull testes and the synthesis of two closely related C-29 sterols. All these sterols induce a resumption of meiosis in cultured cumulus-enclosed and naked mouse oocytes indicating their nonspecificity across species and sex. This family of sterols is for the first time considered crucial to meiosis.	NOVO NORDISK AS, DK-2760 MALOV, DENMARK	Novo Nordisk	BYSKOV, AG (corresponding author), UNIV COPENHAGEN HOSP, RIGSHOSP,DEPT OBSTET & GYNECOL,REPROD BIOL LAB, SECT 5712, BLEGDAMSVEJ 9, DK-2100 COPENHAGEN, DENMARK.			Andersen, Claus Yding/0000-0001-7681-253X				ABERNETHY D, 1976, STEROIDS, V27, P297, DOI 10.1016/0039-128X(76)90052-0; ANDERSEN CY, 1990, J CLIN ENDOCR METAB, V71, P1375, DOI 10.1210/jcem-71-5-1375; AOYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P659, DOI 10.1016/S0006-291X(86)80470-3; BYSKOV AG, 1976, DEV BIOL, V52, P193, DOI 10.1016/0012-1606(76)90239-6; BYSKOV AG, 1993, MOL REPROD DEV, V34, P47, DOI 10.1002/mrd.1080340108; COULON J, 1986, CAN J MICROBIOL, V32, P738, DOI 10.1139/m86-134; DOLLE RE, 1989, J AM CHEM SOC, V111, P278, DOI 10.1021/ja00183a042; DONAHOE PK, 1987, RECENT PROG HORM RES, V43, P431; DOWNS SM, 1985, P NATL ACAD SCI USA, V82, P454, DOI 10.1073/pnas.82.2.454; DOWNS SM, 1993, MOL REPROD DEV, V35, P82, DOI 10.1002/mrd.1080350114; DURHAM CR, 1985, MOL CELL ENDOCRINOL, V40, P211, DOI 10.1016/0303-7207(85)90177-7; EMMONS GT, 1989, MAGN RESON CHEM, V27, P1012, DOI 10.1002/mrc.1260271103; EPPIG JJ, 1978, J REPROD FERTIL, V53, P99, DOI 10.1530/jrf.0.0530099; JOSSO N, 1986, PHYSIOL REV, V66, P1038, DOI 10.1152/physrev.1986.66.4.1038; MAITRA U S, 1989, Steroids, V53, P597, DOI 10.1016/0039-128X(89)90034-2; MCNATTY KP, 1979, J CLIN ENDOCR METAB, V49, P687, DOI 10.1210/jcem-49-5-687; PONSINET G, 1965, B SOC CHIM FR, P3682; RICE C, 1981, J REPROD FERTIL, V62, P245, DOI 10.1530/jrf.0.0620245; SCHROEPFER GJ, 1988, CHEM PHYS LIPIDS, V47, P187, DOI 10.1016/0009-3084(88)90012-6; SMITH DM, 1980, J REPROD FERTIL, V60, P331, DOI 10.1530/jrf.0.0600331; TAYLOR UF, 1981, J LIPID RES, V22, P171; Wassarman Paul M., 1994, P79; WESTERGAARD L, 1985, FERTIL STERIL, V44, P663; XIA GL, 1994, MOL REPROD DEV, V39, P17, DOI 10.1002/mrd.1080390104	24	281	304	1	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 6	1995	374	6522					559	562		10.1038/374559a0	http://dx.doi.org/10.1038/374559a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	QR069	7700384				2022-12-28	WOS:A1995QR06900057
J	SABERI, K; HAFTER, ER				SABERI, K; HAFTER, ER			A COMMON NEURAL CODE FOR FREQUENCY-MODULATED AND AMPLITUDE-MODULATED SOUNDS	NATURE			English	Article							INFERIOR COLLICULUS; AUDITORY-CORTEX; VISUAL-SYSTEM; NEURONS; SENSITIVITY; CAT; AM; RESPONSES; PATTERNS; STIMULI	MOST naturally occurring sounds are modulated in amplitude or frequencg; important examples include animal vocalizations and species-specific communication signals in mammals, insects, reptiles, birds and amphibians(1-9). Deciphering the information from amplitude-modulated (AM) sounds is a well-understood process, requiring a phase locking of primary auditory afferents to the modulation envelopes(10-12). The mechanism for decoding frequency modulation (FM) is not as clear because the FM envelope is flat (Fig. 1). One biological solution is to monitor amplitude fluctuations in frequency-tuned cochlear filters as the instantaneous frequency of the FM sweeps through the passband of these filters, This view postulates an FM-to-AM transduction whereby a change in frequency is transmitted as a change in amplitude(13,14). This is an appealing idea because, if such transduction occurs early in the auditory pathway, it provides a neurally economical solution to how the auditory system encodes these important sounds. Here we illustrate that an FM and AM sound must be transformed into a common neural code in the brain stem. Observers can accurately determine if the phase of an FM presented to one ear is leading or lagging, by only a fraction of a millisecond, the phase of an AM presented to the other ear. A single intracranial image is perceived, the spatial position of which is a function of this phase difference.	UNIV CALIF BERKELEY,DEPT PSYCHOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	SABERI, K (corresponding author), UNIV FLORIDA,DEPT PSYCHOL,CTR HEARING RES,GAINESVILLE,FL 32611, USA.		Saberi, Kourosh/GXG-0944-2022					BAILEY WJ, 1993, J INSECT BEHAV, V6, P141, DOI 10.1007/BF01051500; BRILLET C, 1991, Bioacoustics, V3, P33; CARLSON C R, 1980, Investigative Ophthalmology and Visual Science, P165; CARR CE, 1990, J NEUROSCI, V10, P3227; COSCIA E M, 1991, Bioacoustics, V3, P275; DEAR SP, 1993, NATURE, V364, P620, DOI 10.1038/364620a0; HENNING GB, 1975, VISION RES, V15, P887, DOI 10.1016/0042-6989(75)90228-X; HENNING GB, 1980, J ACOUST SOC AM, V68, P446, DOI 10.1121/1.384756; HUBER F, 1985, SCI AM, V253, P60, DOI 10.1038/scientificamerican1285-60; JAMAR JHT, 1984, VISION RES, V24, P243, DOI 10.1016/0042-6989(84)90126-3; JAVEL E, 1980, J ACOUST SOC AM, V68, P133, DOI 10.1121/1.384639; KLUMP GM, 1992, ADV BIOSCI, V83, P353; KUWADA S, 1979, SCIENCE, V206, P586, DOI 10.1126/science.493964; Rayleigh,, 1907, PHILOS MAG, V13, P214, DOI 10.1080/14786440709463595; MASATAKA N, 1983, Primates, V24, P40, DOI 10.1007/BF02381452; MENDELSON JR, 1985, BRAIN RES, V327, P331, DOI 10.1016/0006-8993(85)91530-6; RAYLEIGH, 1976, NATURE, V14, P32; REES A, 1983, HEARING RES, V10, P301, DOI 10.1016/0378-5955(83)90095-3; ROBISSON P, 1993, ETHOLOGY, V94, P279; RYAN MJ, 1988, SCIENCE, V240, P1786, DOI 10.1126/science.240.4860.1786; Schreiner CE, 1988, AUDITORY FUNCTION, P337; SHU ZJ, 1993, NATURE, V364, P721, DOI 10.1038/364721a0; SIMMONS JA, 1979, SCIENCE, V203, P16, DOI 10.1126/science.758674; SMITH RL, 1980, HEARING RES, V2, P123, DOI 10.1016/0378-5955(80)90034-9; WHITFIEL.IC, 1965, J NEUROPHYSIOL, V28, P655, DOI 10.1152/jn.1965.28.4.655; YIN TCT, 1990, J NEUROPHYSIOL, V64, P465, DOI 10.1152/jn.1990.64.2.465; ZHOU YX, 1993, SCIENCE, V261, P98, DOI 10.1126/science.8316862; Zwicker E, 1952, ACUSTICA          S3, V2, P125	28	78	78	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					537	539		10.1038/374537a0	http://dx.doi.org/10.1038/374537a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700378				2022-12-28	WOS:A1995QR06900050
J	CARROLL, D; SMITH, GD; SHEFFIELD, D; SHIPLEY, MJ; MARMOT, MG				CARROLL, D; SMITH, GD; SHEFFIELD, D; SHIPLEY, MJ; MARMOT, MG			PRESSOR REACTIONS TO PSYCHOLOGICAL STRESS AND PREDICTION OF FUTURE BLOOD-PRESSURE - DATA FROM THE WHITEHALL-II STUDY	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR REACTIVITY; ESSENTIAL-HYPERTENSION; MENTAL STRESS; STABILITY; DISEASE	Objective-To examine whether reactions of blood pressure to future blood pressure. Design-Blood pressure was recorded at a medical screening examination after which presser reactions to a psychological stress task were determined. Follow up measurement of blood pressure was undertaken, on average, 4.9 years later. Setting-20 civil service departments in London. Subjects-1003 male civil servants aged between 35 and 55 years at entry to the study. Main outcome measure-Blood pressure at follow up screening. Results-Reactions of systolic blood pressure to stress correlated positively with systolic blood pressure at follow up screening (r = 0.22, P < 0.01). The dominant correlate of follow up blood pressure was blood pressure at initial screening (r = 0.60 P < 0.01 between initial and follow up systolic blood pressure; r = 0.59, P < 0.01 between initial and follow up diastolic blood pressure). Stepwise multiple regression analysis indicated that reactions to the stressor provided minimal prediction of follow up blood pressure over and above that afforded by blood pressure at initial screening. In the case of follow up systolic blood pressure, systolic reactions to stress accounted for only 1% of follow up variance; systolic blood pressure at initial screening accounted for 34%. With regard to diastolic blood pressure at follow up, the independent contribution from diastolic reactions to stress was less than 1%. Conclusion-Pressor reactions to psychological stress provide minimal independent prediction of blood pressure at follow up. Measurement of reactivity is not a useful clinical index of the course of future blood pressure.	UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,BRISTOL BS8 2PR,AVON,ENGLAND; UNIV LONDON UNIV COLL,UNIV COLL & MIDDLESEX SCH MED,DEPT EPIDEMIOL & PUBL HLTH,LONDON WC1E 6BT,ENGLAND	University of Bristol; University of London; University College London	CARROLL, D (corresponding author), GLASGOW CALDONIAN UNIV,DEPT PSYCHOL,GLASGOW G4 0BA,LANARK,SCOTLAND.		Marmot, M G/Y-3920-2019; Davey Smith, George/A-7407-2013	Marmot, M G/0000-0002-2431-6419; Davey Smith, George/0000-0002-1407-8314; Sheffield, David/0000-0001-9121-1783	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER; Medical Research Council [G8802774] Funding Source: Medline; NHLBI NIH HHS [2 ROI HL36310-04] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome Trust)		[Anonymous], 1981, CARDIOVASCULAR PSYCH, DOI DOI 10.4324/9781315081762; ARMSTRONG HG, 1950, AM HEART J, V39, P484, DOI 10.1016/0002-8703(50)90246-8; BORGHI C, 1986, J CARDIOVASC PHARM, V8, pS138, DOI 10.1097/00005344-198608005-00030; CARROLL D, 1991, PSYCHOPHYSIOLOGY, V28, P438, DOI 10.1111/j.1469-8986.1991.tb00728.x; CARROLL D, 1986, PSYCHOPHYSIOLOGY, V23, P174, DOI 10.1111/j.1469-8986.1986.tb00613.x; CORESH J, 1992, HYPERTENSION, V19, P218; DITTO B, 1986, PSYCHOPHYSIOLOGY, V23, P62, DOI 10.1111/j.1469-8986.1986.tb00596.x; DRUMMOND PD, 1985, PSYCHOPHYSIOLOGY, V22, P621, DOI 10.1111/j.1469-8986.1985.tb01656.x; EICH RH, 1967, J CHRON DIS, V20, P583, DOI 10.1016/0021-9681(67)90035-5; FALKNER B, 1981, HYPERTENSION, V3, P521, DOI 10.1161/01.HYP.3.5.521; FREDRIKSON M, 1982, BIOL PSYCHOL, V15, P63, DOI 10.1016/0301-0511(82)90031-X; FREDRIKSON M, 1990, Annals of Behavioral Medicine, V12, P30, DOI 10.1207/s15324796abm1201_3; GALLACHER JEJ, 1985, J EPIDEMIOL COMMUNIT, V39, P200; HARLAN WR, 1964, AM J CARDIOL, V13, P683, DOI 10.1016/0002-9149(64)90205-X; HASTRUP JL, 1980, PSYCHOPHYSIOLOGY, V17, P317; HAYES RJ, 1988, STAT MED, V7, P915, DOI 10.1002/sim.4780070903; HOROWITZ RI, 1984, HYPERTENSION, V6, P295; KEYS A, 1971, ARCH INTERN MED, V128, P201, DOI [10.1001/archinte.128.2.201, 10.1001/archinte.1971.00310200037002]; LIGHT KC, 1981, PSYCHOPHYSIOLOGY, V18, P216, DOI 10.1111/j.1469-8986.1981.tb03021.x; LIGHT KC, 1992, PSYCHOSOM MED, V54, P217, DOI 10.1097/00006842-199203000-00007; LLABRE MM, 1991, PSYCHOPHYSIOLOGY, V28, P701, DOI 10.1111/j.1469-8986.1991.tb01017.x; MANUCK S B, 1990, Annals of Behavioral Medicine, V12, P17, DOI 10.1207/s15324796abm1201_2; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MATTHEWS KA, 1993, HYPERTENSION, V22, P479, DOI 10.1161/01.HYP.22.4.479; MCKINNEY ME, 1985, PSYCHOPHYSIOLOGY, V22, P453, DOI 10.1111/j.1469-8986.1985.tb01632.x; MENKES MS, 1989, HYPERTENSION, V14, P524, DOI 10.1161/01.HYP.14.5.524; MURPHY JK, 1991, PSYCHOPHYSIOLOGY, V28, P447, DOI 10.1111/j.1469-8986.1991.tb00730.x; OLDHAM PD, 1962, J CHRON DIS, V15, P969, DOI 10.1016/0021-9681(62)90116-9; PARATI G, 1988, J HYPERTENS, V6, P481, DOI 10.1097/00004872-198806000-00008; PICKERING T G, 1990, Annals of Behavioral Medicine, V12, P3, DOI 10.1207/s15324796abm1201_1; Pickering TG, 1991, AM J HYPERTENS, V4, P611; Raven J.C., 1960, GUIDE STANDARD PROGR; ROGERS S, 1988, J EPIDEMIOL COMMUN H, V42, P321, DOI 10.1136/jech.42.4.321; SHERWOOD A, 1990, INT J PSYCHOPHYSIOL, V10, P95, DOI 10.1016/0167-8760(90)90050-N; THOMAS CB, 1982, JOHNS HOPKINS MED J, V151, P93; Turner J., 1992, INDIVIDUAL DIFFERENC; WOOD DL, 1984, HYPERTENSION, V6, P301, DOI 10.1161/01.HYP.6.3.301	37	111	112	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	1995	310	6982					771	776		10.1136/bmj.310.6982.771	http://dx.doi.org/10.1136/bmj.310.6982.771			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QP609	7711581	Green Published			2022-12-28	WOS:A1995QP60900017
J	KLEINMAN, LC; KOSECOFF, J; DUBOIS, RW; BROOK, RH				KLEINMAN, LC; KOSECOFF, J; DUBOIS, RW; BROOK, RH			THE MEDICAL APPROPRIATENESS OF TYMPANOSTOMY TUBES PROPOSED FOR CHILDREN YOUNGER THAN 16 YEARS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC OTITIS-MEDIA; MIDDLE-EAR EFFUSION; CAROTID ENDARTERECTOMY; CONTROLLED TRIAL; SURGICAL-PROCEDURES; PRONE CHILD; GLUE EAR; SURGERY; MYRINGOTOMY; EFFICACY	Objective.-To describe the clinical reasons tympanostomy tubes are proposed for children and to assess their appropriateness. Design.-Analysis of data previously collected prospectively by a national utilization review (UR) firm during a two-step UR process to assess the medical appropriateness of tympanostomy tube placement. Nurses interviewed otolaryngologists' and primary care physicians' office staff to collect clinical data. For a randomly selected subsample of cases found inappropriate, we reviewed subsequent interviews of the otolaryngologists by physician reviewers, who looked for possible extenuating clinical circumstances or additional clinical data that might have changed the appropriateness category. Setting.-Otolaryngologists' practices from 49 states and the District of Columbia. Patients.-All 6611 children younger than 16 years who were insured by three clients of the UR firm and whose proposal to receive tympanostomy tubes was reviewed by this system from January 1, 1990, through July 31, 1991. The insurance companies in the study insured 5.6 million Americans at the time of the study. Main Outcome Measure.-The medical appropriateness of tympanostomy tube surgery according to explicit criteria developed by an expert panel using the RAND/University of California-Los Angeles modified Delphi method. Results.-A total of 6429 (97%) of the cases were proposed for recurrent acute otitis media, otitis media with effusion, or both. Making generous clinical assumptions, 41% of the proposals for these reasons had appropriate indications, 32% had equivocal indications, and 27% had inappropriate ones. Considering the additional information available from the subsample review, the proportion appropriate was 42%, equivocal 35%, and inappropriate 23%. Conclusion.-About one quarter of tympanostomy tube insertions for children in this study were proposed for inappropriate indications and another third for equivocal ones.	HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DIV HOSP EPIDEMIOL & QUAL IMPROVEMENT,BOSTON,MA 02115; VALUE HLTH SCI,SANTA MONICA,CA; RAND CORP,HLTH SCI PROGRAM,SANTA MONICA,CA; UNIV CALIF LOS ANGELES,SCH MED,DIV GEN INTERNAL MED,LOS ANGELES,CA; UNIV CALIF LOS ANGELES,SCH MED,DIV GERIATR,LOS ANGELES,CA; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT HLTH SERV,LOS ANGELES,CA 90024	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; RAND Corporation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	KLEINMAN, LC (corresponding author), CHILDRENS HOSP MED CTR,DIV GEN PEDIAT,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		Kleinman, Lawrence/AAS-6934-2021					BERNARD PAM, 1991, PEDIATRICS, V88, P215; BLACK NA, 1990, BRIT MED J, V300, P1551, DOI 10.1136/bmj.300.6739.1551; BLUESTONE CD, 1988, OTITIS MEDIA INFANTS, P175; BLUESTONE CD, 1990, PEDIATRIC OTOLARYNGO, P408; BLUESTONE CD, 1988, PEDIAT INFECT J, V7, P146; BODNER EE, 1991, J LARYNGOL OTOL, V105, P812, DOI 10.1017/S0022215100117426; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; BROSTOFF LM, 1985, LARYNGOSCOPE, V95, P428; CASSELBRANT ML, 1992, PEDIATR INFECT DIS J, V11, P278, DOI 10.1097/00006454-199204000-00004; FINK A, 1987, WESTERN J MED, V147, P609; GEBHART DE, 1981, LARYNGOSCOPE, V91, P849; GRAY D, 1990, LANCET, V335, P1317, DOI 10.1016/0140-6736(90)91196-H; HEALD MM, 1990, OTOLARYNG HEAD NECK, V102, P334, DOI 10.1177/019459989010200406; HOEKELMAN RA, 1977, PEDIATRICS, V59, P119; KAHN KL, 1988, MED CARE, V26, P415, DOI 10.1097/00005650-198804000-00010; KALEIDA PH, 1992, AM J DIS CHILD, V146, P433, DOI 10.1001/archpedi.1992.02160160053013; KARMA PH, 1989, INT J PEDIATR OTORHI, V17, P37, DOI 10.1016/0165-5876(89)90292-9; KOSECOFF J, 1987, MED CARE, V25, P196, DOI 10.1097/00005650-198703000-00003; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2538, DOI 10.1001/jama.258.18.2538; LE CT, 1991, PEDIATR INFECT DIS J, V10, P2, DOI 10.1097/00006454-199101000-00002; LOHR KN, 1983, MEASUREMENT PHYSL HL; MANDEL EM, 1987, NEW ENGL J MED, V316, P432, DOI 10.1056/NEJM198702193160803; MANDEL EM, 1992, PEDIATR INFECT DIS J, V11, P270, DOI 10.1097/00006454-199204000-00003; MANDEL EM, 1989, ARCH OTOLARYNGOL, V115, P1217; MERRICK NJ, 1986, JAMA-J AM MED ASSOC, V256, P2531, DOI 10.1001/jama.256.18.2531; MERRICK NJ, 1987, AM J PUBLIC HEALTH, V77, P187, DOI 10.2105/AJPH.77.2.187; MOSS AI, 1988, USE SELECTED MED DEV, P191; PADEN EP, 1989, J SPEECH HEAR DISORD, V54, P94, DOI 10.1044/jshd.5401.94; PADGHAM N, 1989, J LARYNGOL OTOL, V103, P1034, DOI 10.1017/S0022215100110898; PARADISE JL, 1980, PEDIATRICS, V65, P917; PARADISE JL, 1977, PEDIATRICS, V60, P86; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; PICHICHERO ME, 1989, PEDIATR INFECT DIS J, V8, P780, DOI 10.1097/00006454-198911000-00010; SCHAPPERT SM, 1992, OFFICE VISITS OTITIS, P214; SCHWARTZ RH, 1982, ARCH DIS CHILD, V57, P590, DOI 10.1136/adc.57.8.590; SKINNER DW, 1988, CLIN OTOLARYNGOL, V13, P341, DOI 10.1111/j.1365-2273.1988.tb00763.x; TEELE DW, 1980, ANN OTO RHINOL LARYN, V89, P5, DOI 10.1177/00034894800890S304; TEELE DW, 1984, PEDIATRICS, V74, P282; VAUGHAN VC, 1979, NELSON TXB PEDIATRIC; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; YOON TH, 1990, AM J OTOLARYNG, V11, P10, DOI 10.1016/0196-0709(90)90164-Q; 1991, SAS VERSION607	42	135	137	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	1994	271	16					1250	1255		10.1001/jama.271.16.1250	http://dx.doi.org/10.1001/jama.271.16.1250			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG362	7710469				2022-12-28	WOS:A1994NG36200024
J	COOK, SJ; MCCORMICK, F				COOK, SJ; MCCORMICK, F			INHIBITION BY CAMP OF RAS-DEPENDENT ACTIVATION OF RAF	SCIENCE			English	Article							CYCLIC-AMP; PROTEIN-KINASE; TYROSINE KINASES; CHOLERA-TOXIN; MAP KINASE; CELL-PROLIFERATION; GROWTH; PATHWAY; SHC; EXPRESSION	Activation of the Raf and extracellular signal-regulated kinases (ERKs) (or mitogen-activated protein kinases) are key events in mitogenic signaling, but little is known about interactions with other signaling pathways. Agents that raise levels of intracellular cyclic adenosine 3',5'-monophosphate (cAMP) blocked DNA synthesis and signal transduction in Rat1 cells exposed to epidermal growth factor (EGF) or lysophosphatidic acid. In the case of EGF, receptor tyrosine kinase activity and association with the signaling molecules Grb2 and Shc were unaffected by cAMP. Likewise, EGF-dependent accumulation of the guanosine 5'-triphosphate-bound form of Ras was unaffected. In contrast, activation of Raf-1 and ERK kinases was inhibited. Thus, cAMP appears to inhibit signal transmission from Ras by preventing Ras-dependent activation of Raf-1.			COOK, SJ (corresponding author), ONYX PHARMACEUT,3031 RES DR,RICHMOND,CA 94806, USA.				NCI NIH HHS [UO1 CA51992-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA051992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; COOK S, UNPUB; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOTTESMAN MM, 1986, CANCER SURV, V5, P291; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KAUR G, 1992, CANCER RES, V52, P3340; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P88; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACDONALD SG, IN PRESS MOL CELL BI; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; NODA N, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RALL TW, 1957, J BIOL CHEM, V224, P463; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAKODA T, 1992, ONCOGENE, V7, P1705; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SUTHERLAND EW, 1972, SCIENCE, V177, P401, DOI 10.1126/science.177.4047.401; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANDOP C, 1984, J BIOL CHEM, V259, P696; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITFIELD JF, 1987, CANCER METAST REV, V5, P205, DOI 10.1007/BF00046999; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	46	932	948	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 12	1993	262	5136					1069	1072		10.1126/science.7694367	http://dx.doi.org/10.1126/science.7694367			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG187	7694367				2022-12-28	WOS:A1993MG18700040
J	GALIONE, A; WHITE, A; WILLMOTT, N; TURNER, M; POTTER, BVL; WATSON, SP				GALIONE, A; WHITE, A; WILLMOTT, N; TURNER, M; POTTER, BVL; WATSON, SP			CGMP MOBILIZES INTRACELLULAR CA2+ IN SEA-URCHIN EGGS BY STIMULATING CYCLIC ADP-RIBOSE SYNTHESIS	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CALCIUM; ACTIVATION; RELEASE; ENZYME	MANY hormones or neurotransmitters act at cell surface receptors to increase the intracellular free calcium concentration, triggering a wide range of cellular responses1. As the source of this Ca2+ is often internal stores, additional messengers are required to convey the hormonal message from the plasma membrane. Cyclic ADP-ribose (cADPR) has been proposed as the endogenous activator of Ca2+-induced Ca2+ release by the ryanodine receptor in sea urchin eggs and in several mammalian cell types2-8,22. A second messenger role for cADPR requires that its intracellular levels be under the control of extracellular stimuli. Here we demonstrate a novel action of 3',5'-cyclic guanosine monophosphate (cGMP) in stimulating the synthesis of cADPR from beta-NAD+ by activating its synthetic enzyme ADP-ribosyl cyclase9-11 in sea urchin eggs and egg homogenates. We suggest that cADPR may transduce signals generated by cell surface receptors or gaseous transmitters linked to cGMP production.	UNIV BATH,SCH PHARM & PHARMACOL,BATH BA2 7AY,AVON,ENGLAND; UNIV BATH,INST LIFE SCI,BATH BA2 7AY,AVON,ENGLAND	University of Bath; University of Bath	GALIONE, A (corresponding author), UNIV OXFORD,DEPT PHARMACOL,MANSFIELD RD,OXFORD OX1 3QT,ENGLAND.		Watson, Stephen P/Q-6292-2016; Galione, Antony/E-5884-2011; Potter, Barry/AAX-4781-2020; Potter, Barry VL/A-1845-2012	Watson, Stephen P/0000-0002-7846-7423; Galione, Antony/0000-0002-4132-7646				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P504; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HOFMANN F, 1985, EUR J BIOCHEM, V150, P85, DOI 10.1111/j.1432-1033.1985.tb08991.x; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1993, J BIOL CHEM, V268, P293; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; POTTER BVL, 1992, INTRACELLULAR MESSEN, V20, P273; RUSKINO N, 1989, J BIOL CHEM, V264, P11725; SWANN K, 1987, MOL BIOL INVERTEBRAT, P45; TAKESAWA S, 1993, SCIENCE, V259, P370; WHALLEY T, 1992, MOL BIOL CELL, V3, P373, DOI 10.1091/mbc.3.3.373; WHITAKER M, 1993, DEVELOPMENT, V117, P1; Whitaker M.J., 1989, MECHANISMS EGG ACTIV, P159; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X	22	272	276	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 30	1993	365	6445					456	459		10.1038/365456a0	http://dx.doi.org/10.1038/365456a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ633	7692303				2022-12-28	WOS:A1993LZ63300061
J	FERAT, JL; MICHEL, F				FERAT, JL; MICHEL, F			GROUP-II SELF-SPLICING INTRONS IN BACTERIA	NATURE			English	Article							DNA BINDING-PROTEIN; ESCHERICHIA-COLI; PURPLE BACTERIA; CHLOROPLASTS; SEQUENCES; ORIGINS	LIKE nuclear premessenger introns, group II self-splicing introns are excised from primary transcripts as branched molecules, containing a 2'-5' phosphodiester bond. For this reason, it is widely believed that the ribozyme (catalytic RNA) core of group II introns, or some evolutionarily related molecule, gave rise to the RNA components of the spliceosomal splicing machinery of the eukaryotic nucleus1. One difficulty with this hypothesis has been the restricted distribution of group II introns. Unlike group I self-splicing introns, which interrupt not only organelle primary transcripts, but also some bacterial and nuclear genes2-5, group II introns seemed to be confined to mitochondrial and chloroplast genomes (reviewed in ref. 6). We now report the discovery of group II introns both in cyanobacteria (the ancestors of chloroplasts7) and the gamma subdivision of purple bacteria, or proteobacteria8, whose alpha subdivision probably gave rise to mitochondria9. At least one of these introns actually self-splices in vitro.			FERAT, JL (corresponding author), CNRS,CTR GENET MOLEC,F-91190 GIF SUR YVETTE,FRANCE.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1988, MOL REPROD DEV; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CHASE JW, 1983, P NATL ACAD SCI-BIOL, V80, P5480, DOI 10.1073/pnas.80.18.5480; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; HERDMAN M, 1973, J GEN MICROBIOL, V79, P233, DOI 10.1099/00221287-79-2-233; HIOM K, 1991, J BACTERIOL, V173, P7368, DOI 10.1128/jb.173.22.7368-7373.1991; JACQUIER A, 1990, J MOL BIOL, V213, P437, DOI 10.1016/S0022-2836(05)80206-2; KUCK U, 1989, MOL GEN GENET, V218, P257, DOI 10.1007/BF00331276; KUHSEL MG, 1990, SCIENCE, V250, P1570, DOI 10.1126/science.2125748; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; MICHEL F, 1992, GENE DEV, V6, P1373, DOI 10.1101/gad.6.8.1373; OCHMAN H, 1984, J BACTERIOL, V157, P690, DOI 10.1128/JB.157.2.690-693.1984; PEEBLES CL, 1987, COLD SPRING HARB SYM, V52, P223, DOI 10.1101/SQB.1987.052.01.027; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; SCHWARTZ RM, 1978, SCIENCE, V199, P395, DOI 10.1126/science.202030; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SKELLY PJ, 1991, CURR GENET, V20, P115, DOI 10.1007/BF00312773; STACKEBRANDT E, 1988, INT J SYST BACTERIOL, V38, P321, DOI 10.1099/00207713-38-3-321; TIRANTI V, 1991, NUCLEIC ACIDS RES, V19, P4291, DOI 10.1093/nar/19.15.4291; WOESE CR, 1985, SYST APPL MICROBIOL, V6, P25, DOI 10.1016/S0723-2020(85)80007-2; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; XU MQ, 1990, SCIENCE, V250, P1566, DOI 10.1126/science.2125747; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	26	205	209	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					358	361		10.1038/364358a0	http://dx.doi.org/10.1038/364358a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	7687328				2022-12-28	WOS:A1993LN57000064
J	GOVAN, JRW; BROWN, PH; MADDISON, J; DOHERTY, CJ; NELSON, JW; DODD, M; GREENING, AP; WEBB, AK				GOVAN, JRW; BROWN, PH; MADDISON, J; DOHERTY, CJ; NELSON, JW; DODD, M; GREENING, AP; WEBB, AK			EVIDENCE FOR TRANSMISSION OF PSEUDOMONAS-CEPACIA BY SOCIAL CONTACT IN CYSTIC-FIBROSIS	LANCET			English	Article								Pulmonary colonisation with Pseudomonas cepacia in patients with cystic fibrosis can be associated with increased morbidity and mortality. The modes of transmission of P cepacia are, however, unclear. We used selective media and phenotypic and genomic typing systems to investigate the acquisition of P cepacia by adults with cystic fibrosis. An analysis of isolates from 210 patients attending regional clinics in Edinburgh and Manchester between 1986 and 1992 showed that the main cause of increased isolations of P cepacia from 1989 was the emergence of an epidemic strain that had spread between patients in both clinics. Epidemiological evidence indicated that social contact was important in spread of the epidemic strain within and between clinics. We suggest that guidelines to limit the acquisition of P cepacia should not be restricted to patients in hospital, and that intimate or frequent social contact is associated with a high risk of cross-infection.	MONSAL HOSP,DEPT CHEST DIS,MANCHESTER,ENGLAND; WESTERN GEN HOSP,RESP UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	GOVAN, JRW (corresponding author), UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							ANDERSON DJ, 1991, J CLIN MICROBIOL, V29, P648, DOI 10.1128/JCM.29.3.648-649.1991; Brown P, 1993, THORAX, V48, P425; BUTLER SL, 1992, 11TH INT CYST FIBR C; Editorial, 1992, LANCET, V339, P1385; GILLIGAN PH, 1991, CLIN MICROBIOL REV, V4, P35, DOI 10.1128/CMR.4.1.35-51.1991; GLADMAN G, 1992, ARCH DIS CHILD, V67, P192, DOI 10.1136/adc.67.2.192; GOVAN JRW, 1985, J CLIN MICROBIOL, V22, P490, DOI 10.1128/JCM.22.4.490-494.1985; GOVAN JRW, 1992, BRIT MED BULL, V48, P912, DOI 10.1093/oxfordjournals.bmb.a072585; ISLES A, 1984, J PEDIATR-US, V104, P206, DOI 10.1016/S0022-3476(84)80993-2; LEWIN C, 1993, ANTIMICROB AGENTS CH, V37, P123, DOI 10.1128/AAC.37.1.123; LIPUMA JJ, 1990, LANCET, V336, P1094, DOI 10.1016/0140-6736(90)92571-X; MILLARJONES L, 1992, LANCET, V340, P491, DOI 10.1016/0140-6736(92)91817-R; NELSON JW, 1991, LANCET, V338, P1525, DOI 10.1016/0140-6736(91)92342-Y; NELSON JW, IN PRESS J MED MICRO; SIMMONDS EJ, 1990, ARCH DIS CHILD, V65, P874, DOI 10.1136/adc.65.8.874; SMITH DL, 1992, LANCET, V339, P252, DOI 10.1016/0140-6736(92)90063-9; TABLAN OC, 1987, CHEST, V91, P527, DOI 10.1378/chest.91.4.527; 1992, NEWSLETTER ASS C APR, P2	18	381	385	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 3	1993	342	8862					15	19		10.1016/0140-6736(93)91881-L	http://dx.doi.org/10.1016/0140-6736(93)91881-L			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK985	7686239				2022-12-28	WOS:A1993LK98500010
J	WYSOWSKI, DK; FREIMAN, JP; TOURTELOT, JB; HORTON, ML				WYSOWSKI, DK; FREIMAN, JP; TOURTELOT, JB; HORTON, ML			FATAL AND NONFATAL HEPATOTOXICITY ASSOCIATED WITH FLUTAMIDE	ANNALS OF INTERNAL MEDICINE			English	Article						FLUTAMIDE; HEPATITIS, TOXIC; JAUNDICE; PROSTATIC NEOPLASMS; PROSTATIC HYPERTROPHY	CARCINOMA; HEPATITIS; PROSTATE; FAILURE; CANCER	Objective: To identify and describe patients with hepatotoxicity possibly caused by flutamide, an antiandrogen drug. Design: Case series of reports, submitted to the Adverse Drug Event Reporting System of the Food and Drug Administration. Setting. Outpatient clinics and physicians' offices in the United States. Patients: Nineteen patients treated with flutamide for prostate cancer or benign prostatic hypertrophy (for Investigation of a New Drug or off-label use). Measurements: Evidence of increased liver enzyme levels, hyperbilirubinemia, associated clinical symptoms, and diagnoses of cholestatic hepatitis. Autopsy reports were used when available. Results: From the time of marketing of flutamide in February 1989 through March 1991, the Food and Drug Administration received reports of 19 patients in the United States who developed serious hepatotoxicity while using flutamide. Fourteen patients had resolution of abnormal liver function test results after discontinuing or decreasing the dose of flutamide, but five patients died of progressive liver disease. Autopsy reports from three patients and abnormal pathologic results from three other patients (reported to the Food and Drug Administration or in the medical literature) showed hepatocellular necrosis and possibly cholestasis. Thorough work-ups excluded other possible causes than flutamide. Conclusions: Flutamide appears to cause hepatotoxic effects in certain patients. Physicians should tell patients to immediately report to physicians nausea, vomiting, fatigue, jaundice, and other signs and symptoms of liver injury.	OAKLAND NAVAL HOSP, OAKLAND, CA USA		WYSOWSKI, DK (corresponding author), US FDA, DIV EPIDEMIOL & SURVEILLANCE, HFD-733, 5600 FISHERS LANE, ROOM 15B-18, ROCKVILLE, MD 20857 USA.							ALPERINE M, 1991, PRESSE MED, V20, P1459; COPPERE H, 1990, GASTROEN CLIN BIOL, V14, P105; CORKERY JC, 1991, J CLIN GASTROENTEROL, V13, P364, DOI 10.1097/00004836-199106000-00025; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; FAICH GA, 1986, NEW ENGL J MED, V314, P1589, DOI 10.1056/NEJM198606123142427; FOURCADE R O, 1990, Journal of Urology, V143, p220A; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; HART W, 1989, ANN INTERN MED, V110, P943, DOI 10.7326/0003-4819-110-11-943_2; HOLDAWAY I, 1990, Journal of Urology, V143, p220A; IVERSEN P, 1989, Journal of Urology, V141, p348A; KEATING MA, 1986, J UROLOGY, V135, pA203; LUND F, 1988, BRIT J UROL, V61, P140, DOI 10.1111/j.1464-410X.1988.tb05062.x; LUNDGREN R, 1987, BRIT J UROL, V59, P156; MOLLER S, 1990, J HEPATOL, V10, P346, DOI 10.1016/0168-8278(90)90144-G; ROBINSON MRG, 1990, CANCER, V66, P1022; ZIMMERMAN HJ, 1978, DRUGS, V16, P25, DOI 10.2165/00003495-197816010-00002; 1992, PHYSICIANS DESK REFE; 1989, MED LETT DRUGS THER, V31, P72; 1989, NATIONAL PRESCRIPTIO	19	153	157	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1993	118	11					860	864		10.7326/0003-4819-118-11-199306010-00006	http://dx.doi.org/10.7326/0003-4819-118-11-199306010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LD252	7683180				2022-12-28	WOS:A1993LD25200006
J	HAYGOOD, MG; DISTEL, DL				HAYGOOD, MG; DISTEL, DL			BIOLUMINESCENT SYMBIONTS OF FLASHLIGHT FISHES AND DEEP-SEA ANGLERFISHES FORM UNIQUE LINEAGES RELATED TO THE GENUS VIBRIO	NATURE			English	Article							16S RIBOSOMAL-RNA; LUMINOUS BACTERIA; KRYPTOPHANARON-ALFREDI; EVOLUTION; ANOMALOPIDAE; PHYLOGENY; SEAWATER; GENES	BIOLUMINESCENT symbioses range from facultative associations to highly adapted. apparently obligate ones1. The family Anomalopidae (flashlight fishes) encompasses five genera of tropical reef fishes that have large suborbital light organs2. The suborder Ceratioidei (deep-sea anglerfishes) contains 11 families. In nine of these, females have a bioluminescent lure3,4 that contains bacterial symbionts5. In all other fish light-organ symbioses (occuring in 10 families in 5 orders6), the symbionts belong to three Photobacterium species7; nonsymbiotic luminous bacteria are Vibrio species8. The bacteria are extracellular and tightly packed in tubules that communicate with the exterior7, releasing bacteria into the gut of the host or the surrounding sea water. The released bacteria are usually cultivable and can contribute to planktonic populations9,10. Although anomalopids release bacteria9 and ceratioids have pores that would allow release, the fate of these bacteria is unknown and they cannot be cultured by standard isolation techniques. We report here phylogenetic analysis of 16S ribosomal RNA gene sequences from light organs that show that anomalopid and ceratioid symbionts are not known luminous bacteria, but are new groups related to Vibrio spp. They are characterized by host specificity, deep divergence between symbionts from different genera (anomalopids) or families (ceratioids) and, possibly, parallel divergence of hosts and symbionts.			HAYGOOD, MG (corresponding author), UNIV CALIF SAN DIEGO, SCRIPPS INST OCEANOG, DIV MARINE BIOL RES, 0202, LA JOLLA, CA 92093 USA.		Distel, Daniel/A-8047-2017	Distel, Daniel/0000-0002-3860-194X				Bertelsen E., 1986, P1371; BERTELSEN E, 1984, SPEC PUBL AM SOC ICH, V1, P323; DISTEL DL, 1988, J BACTERIOL, V170, P2506, DOI 10.1128/jb.170.6.2506-2510.1988; DORSCH M, 1992, INT J SYST BACTERIOL, V42, P58, DOI 10.1099/00207713-42-1-58; EDWARDS DB, 1991, APPL ENVIRON MICROB, V57, P1082, DOI 10.1128/AEM.57.4.1082-1088.1991; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; HAYGOOD MG, 1986, GENE, V45, P203, DOI 10.1016/0378-1119(86)90255-6; HAYGOOD MG, 1984, MAR BIOL, V78, P249, DOI 10.1007/BF00393010; HAYGOOD MG, 1992, J MAR BIOL ASSOC UK, V72, P149, DOI 10.1017/S0025315400048852; HAYGOOD MG, 1990, ARCH MICROBIOL, V154, P496, DOI 10.1007/BF00245234; Herring P.J., 1987, Journal of Bioluminescence and Chemiluminescence, V1, P147, DOI 10.1002/bio.1170010303; HERRING PJ, 1982, OCEANOGR MAR BIOL, V20, P415; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; LEISMAN G, 1980, SCIENCE, V208, P1271, DOI 10.1126/science.208.4449.1271; MACDONELL MT, 1985, SYST APPL MICROBIOL, V6, P171, DOI 10.1016/S0723-2020(85)80051-5; NEALSON K, 1981, ANN NY ACAD SCI, V361, P76, DOI 10.1111/j.1749-6632.1981.tb46512.x; NEALSON KH, 1984, MICROBIAL ECOL, V10, P69, DOI 10.1007/BF02011596; OLSEN GJ, 1988, METHOD ENZYMOL, V164, P793; OLSEN GJ, 1991, NUCLEIC ACIDS RES, V19, P2017, DOI 10.1093/nar/19.suppl.2017; OLSEN GJ, 1987, COLD SPRING HARB SYM, V52, P825, DOI 10.1101/SQB.1987.052.01.090; OLSEN GJ, 1986, ANNU REV MICROBIOL, V40, P337, DOI 10.1146/annurev.mi.40.100186.002005; OLSEN GJ, 1992, FASTDNAML; ROSENBLATT RH, 1991, P BIOL SOC WASH, V104, P328; ROWAN R, 1991, SCIENCE, V251, P1348, DOI 10.1126/science.251.4999.1348; Stackebrandt E, 1990, NUCL ACID TECHNIQUES, P115; Swofford D., 1990, PAUP PHYLOGENETIC AN; VALLE O, 1990, SYST APPL MICROBIOL, V13, P257, DOI 10.1016/S0723-2020(11)80195-5; WOLFE CJ, 1991, BIOL BULL, V181, P135, DOI 10.2307/1542496	28	65	67	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	1993	363	6425					154	156		10.1038/363154a0	http://dx.doi.org/10.1038/363154a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LB801	7683390				2022-12-28	WOS:A1993LB80100045
J	SINGHAL, A; DOHERTY, JF; RAYNES, JG; MCADAM, KPWJ; THOMAS, PW; SERJEANT, BE; SERJEANT, GR				SINGHAL, A; DOHERTY, JF; RAYNES, JG; MCADAM, KPWJ; THOMAS, PW; SERJEANT, BE; SERJEANT, GR			IS THERE AN ACUTE-PHASE RESPONSE IN STEADY-STATE SICKLE-CELL DISEASE	LANCET			English	Article							GROWTH; CHILDREN; ANEMIA	Metabolic and serum changes during steady-state homozygous sickle cell (SS) disease are consistent with an acute-phase response and raise the possibility that inflammation occurs in SS disease even during the steady state. To test this hypothesis, we measured concentrations of acute phase reactants in patients with SS disease, in patients with sickle cell haemoglobin C (SC) disease, and in normal (AA) control subjects. The concentrations of C-reactive protein and serum amyloid A were increased above 10 mg/L and 5 mg/L, respectively (our definition of an acute-phase response) in 18% (26/143) of subjects with SS disease even when they were symptom free, in 17% (6/35) of subjects with SC disease, and in 1% (1/80) of AA controls (p < 0.001). We suggest that subclinical vaso-occlusion may generate a covert inflammatory response and that the cytokine mediators of this response may contribute to the metabolic abnormalities and growth failure in sickle cell disease.	UNIV W INDIES,TROP METAB RES UNIT,KINGSTON 7,JAMAICA; UNIV LONDON LONDON SCH HYG & TROP MED,DIV CLIN SCI,LONDON WC1E 7HT,ENGLAND	University West Indies Mona Jamaica; University of London; London School of Hygiene & Tropical Medicine	SINGHAL, A (corresponding author), UNIV W INDIES,MRC LABS,KINGSTON 7,JAMAICA.		Raynes, John G/G-7932-2011	Raynes, John G/0000-0002-8536-1328; Thomas, Peter/0000-0003-2478-4324				AKINOLA NO, 1992, J CLIN PATHOL, V45, P902, DOI 10.1136/jcp.45.10.902; BADALOO A, 1989, CLIN SCI, V77, P93, DOI 10.1042/cs0770093; BECTON DL, 1989, J PEDIATR-US, V115, P99, DOI 10.1016/S0022-3476(89)80339-7; BETKE GH, 1959, J CLIN PATHOL, V184, P1877; COOPER ES, 1990, EUR J CLIN NUTR, V44, P285; ENWONWU CO, 1990, AM J MED SCI, V300, P366, DOI 10.1097/00000441-199012000-00005; GILLESPIE SH, 1991, J CLIN PATHOL, V44, P228, DOI 10.1136/jcp.44.3.228; GRIMBLE R F, 1990, Nutrition Research Reviews, V3, P193, DOI 10.1079/NRR19900012; HEYMAN MB, 1985, LANCET, V1, P903; JACKSON AA, 1988, EUR J CLIN NUTR, V42, P491; KELTS DG, 1979, GASTROENTEROLOGY, V76, P720; KRAEMER R, 1978, ACTA PAEDIATR SCAND, V67, P33, DOI 10.1111/j.1651-2227.1978.tb16273.x; LUCAS GS, 1985, BRIT J HAEMATOL, V59, P363, DOI 10.1111/j.1365-2141.1985.tb03001.x; ODONKOR P O, 1982, IRCS (International Research Communications System) Medical Science Library Compendium, V10, P303; ODONKOR PO, 1984, HUM NUTR-CLIN NUTR, V38C, P23; PEPYS MB, 1981, LANCET, V1, P653; PETERSON CM, 1975, BLOOD, V46, P583; PHEBUS CK, 1988, AM J HEMATOL, V29, P67, DOI 10.1002/ajh.2830290203; PRASAD AS, 1976, JAMA-J AM MED ASSOC, V235, P2396, DOI 10.1001/jama.235.22.2396; STEVENS MCG, 1986, PEDIATRICS, V78, P124; TANGNEY CC, 1989, AM J HEMATOL, V32, P161, DOI 10.1002/ajh.2830320302; 1988, J CLIN PATHOL, V41, P1203	22	58	60	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 13	1993	341	8846					651	653		10.1016/0140-6736(93)90418-G	http://dx.doi.org/10.1016/0140-6736(93)90418-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR613	7680738				2022-12-28	WOS:A1993KR61300003
J	RAMING, K; KRIEGER, J; STROTMANN, J; BOEKHOFF, I; KUBICK, S; BAUMSTARK, C; BREER, H				RAMING, K; KRIEGER, J; STROTMANN, J; BOEKHOFF, I; KUBICK, S; BAUMSTARK, C; BREER, H			CLONING AND EXPRESSION OF ODORANT RECEPTORS	NATURE			English	Article							BETA-ADRENERGIC RECEPTORS; 2ND MESSENGER PATHWAYS; INFECTED INSECT CELLS; SIGNAL TRANSDUCTION	MYRIADS of odorous molecules that vary widely in structure are nevertheless readily detected and discriminated by the sense of smell, but how this is achieved by the olfactory system has been a long-standing puzzle. Several different models have been proposed1, and previous observations indicate that the recognition sites for odorous molecules could be G-protein-coupled receptor proteins2-4, an idea supported by the discovery of a new gene family that probably encodes a diversity of odorant receptors5. Here we report the identification of new members of the gene family encoding putative odorant receptors and demonstrate that they are indeed transcribed in olfactory receptor neurons. Furthermore, the receptor-encoding complementary DNA is expressed in non-neuronal surrogate cells, which generate second messenger responses upon stimulation with appropriate odorants, indicating that the receptors recognize odorants and couple to G proteins of the host cells.	UNIV STUTTGART,INST ZOOPHYSIOL,GARBENSTR 30,W-7000 STUTTGART 70,GERMANY	University of Stuttgart								AMOORE JE, 1977, CHEM SENS FLAV, V2, P267, DOI 10.1093/chemse/2.3.267; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P11983, DOI 10.1073/pnas.89.24.11983; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P471, DOI 10.1073/pnas.89.2.471; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREER H, 1991, CHEM SENSES, V16, P19, DOI 10.1093/chemse/16.1.19; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; DADI HK, 1984, EUR J BIOCHEM, V144, P617, DOI 10.1111/j.1432-1033.1984.tb08510.x; DAHMEN N, 1992, J NEUROCHEM, V58, P1176, DOI 10.1111/j.1471-4159.1992.tb09379.x; GEORGE ST, 1989, BIOCHEM BIOPH RES CO, V163, P1265, DOI 10.1016/0006-291X(89)91114-5; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; LANGRIDGE J, 1980, ANAL BIOCHEM, V103, P264, DOI 10.1016/0003-2697(80)90266-3; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; Liebich H G, 1975, Anat Anz, V138, P170; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; ONEIL BS, 1989, MERCK INDEX; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; PARKER EM, 1991, J BIOL CHEM, V266, P519; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEINER AL, 1972, J BIOL CHEM, V247, P1114; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; WONG SKF, 1990, J BIOL CHEM, V265, P6219	25	250	276	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					353	356		10.1038/361353a0	http://dx.doi.org/10.1038/361353a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	7678922				2022-12-28	WOS:A1993KJ59000058
J	SAAH, AJ; HOOVER, DR; PENG, Y; PHAIR, JP; VISSCHER, B; KINGSLEY, LA; SCHRAGER, LK				SAAH, AJ; HOOVER, DR; PENG, Y; PHAIR, JP; VISSCHER, B; KINGSLEY, LA; SCHRAGER, LK			PREDICTORS FOR FAILURE OF PNEUMOCYSTIS-CARINII PNEUMONIA PROPHYLAXIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MULTICENTER AIDS COHORT; VIRUS HIV INFECTION; CULTURED LUNG-CELLS; TRIMETHOPRIM-SULFAMETHOXAZOLE; AEROSOLIZED PENTAMIDINE; CIGARETTE-SMOKING; SECONDARY PROPHYLAXIS; CONTROLLED TRIAL; HOMOSEXUAL MEN	Objective.-To identify clinical and epidemiological factors associated with failure of Pneumocystis carinii pneumonia (PCP) prophylaxis in those receiving primary and secondary prophylaxis. Design.-Longitudinal cohort study of participants infected with human immunodeficiency virus type 1 in the Multicenter AIDS Cohort Study who used PCP prophylaxis regimens after their T-helper lymphocyte counts had decreased to less than 0.200x10(9)/L (200/mu L). Main Outcome Measure.-Occurrence or recurrence of PCP. Results.-A total of 476 participants reported taking one or more of the following regimens: trimethoprim-sulfamethoxazole (TMP-SMX), dapsone, and/or aerosolized pentamidine-367 as primary prophylaxis and 109 as secondary prophylaxis after a previous episode of PCP. A total of 92 (20%) developed PCP despite prophylaxis. The mean failure rates per person-year of follow-up were 16.0% for those receiving primary prophylaxis and 12.1% for those receiving secondary prophylaxis (P=.19). Median times to death after initiation of primary or secondary prophylaxis were 2.0 and 1.2 years, respectively. The main predictor for failure of PCP prophylaxis was profound T-helper lymphocytopenia; 86% of failures occurred after T-helper cell counts decreased to less than 0.075 x 10(9)/L and 76% occurred after counts decreased to less than 0.050x10(9)/L. In multivariate time-dependent analysis, when compared with counts between 0.100 x 10(9)/L and 0.200 x 10(9)/L, the risk ratio for failure with counts less than 0.050 x 10(9)/L was 2.90 (P<.001). Once T-helper cell counts were considered, fever was the only other health status indicator that predicted subsequent PCP (ie, a time-dependent risk ratio of 2.22; P=.01). Use of TMP-SMX as the prophylaxis regimen was protective but did not eliminate failure tie, a time-dependent risk ratio of 0.55; P=.03). Conclusions.-These findings strongly support identifying improved methods of PCP prophylaxis once T-helper cell counts decrease to less than 0.075 x 10(9)/L or 0.100 x 10(9)/L. Given this severe degree of immunosuppression, an inherently more effective regimen against P carinii is required.	NORTHWESTERN UNIV,SCH MED,CHICAGO,IL; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,LOS ANGELES,CA 90024; UNIV PITTSBURGH,GRAD SCH PUBL HLTH,PITTSBURGH,PA; NIAID,DIV AIDS,BETHESDA,MD 20892	Northwestern University; University of California System; University of California Los Angeles; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	SAAH, AJ (corresponding author), JOHNS HOPKINS UNIV,SCH PUBL HLTH,624 N BROADWAY,ROOM 896,BALTIMORE,MD 21205, USA.			Kingsley, Lawrence/0000-0002-7000-8556	NIAID NIH HHS [UQI-AI-35043, UQI-AI-35042, UQI-AI-35039] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035043, U01AI035042, U01AI035039] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APOLONIO EG, IN PRESS J INFECT DI; BLASCHKE E, 1990, SCAND J CLIN LAB INV, V50, P619, DOI 10.3109/00365519009089179; BURNS DN, 1991, J ACQ IMMUN DEF SYND, V4, P76; BUSKIN SE, 1992, 8TH INT C AIDS AMST; CASALE L, 1993, CHEST, V103, P342, DOI 10.1378/chest.103.2.342; CHMIEL JS, 1987, AM J EPIDEMIOL, V126, P568, DOI 10.1093/oxfordjournals.aje.a114696; COATES RA, 1990, AM J EPIDEMIOL, V132, P717, DOI 10.1093/oxfordjournals.aje.a115713; CONLEY LJ, 1995, 2ND NAT C HUM RETR R; CRAIB KJP, 1992, CLIN INVEST MED, V15, P301; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; HUGHES WT, 1979, ANTIMICROB AGENTS CH, V16, P333, DOI 10.1128/AAC.16.3.333; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KIRBY AJ, 1994, J ACQ IMMUN DEF SYND, V7, P1242; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MONTANER JSG, 1991, ANN INTERN MED, V114, P948, DOI 10.7326/0003-4819-114-11-948; NIEMAN RB, 1993, AIDS, V7, P705, DOI 10.1097/00002030-199305000-00015; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; POTTRATZ ST, 1990, J CLIN INVEST, V85, P351, DOI 10.1172/JCI114445; POTTRATZ ST, 1991, J CLIN INVEST, V88, P403, DOI 10.1172/JCI115318; POTTRATZ ST, 1994, J LAB CLIN MED, V123, P273; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; 1991, SAS STAT SOFTWARE PH; 1993, DEC ANN M AIDS CLIN; 1987, MMWER MORB MORTA S1S, V36, pS1; 1986, MMWR-MORBID MORTAL W, V35, P17; 1989, MMWR-MORBID MORTAL W, V38, P1; 1992, MMWR-MORBID MORTAL W, V41, P1	32	80	80	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	1995	273	15					1197	1202		10.1001/jama.273.15.1197	http://dx.doi.org/10.1001/jama.273.15.1197			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT100	7707627				2022-12-28	WOS:A1995QT10000028
J	BLAIR, SN; KOHL, HW; BARLOW, CE; PAFFENBARGER, RS; GIBBONS, LW; MACERA, CA				BLAIR, SN; KOHL, HW; BARLOW, CE; PAFFENBARGER, RS; GIBBONS, LW; MACERA, CA			CHANGES IN PHYSICAL-FITNESS AND ALL-CAUSE MORTALITY - A PROSPECTIVE-STUDY OF HEALTHY AND UNHEALTHY MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; FOLLOW-UP; PREDICTOR	Objective.-To evaluate the relationship between changes in physical fitness and risk of mortality in men. Design.-Prospective study, with two clinical examinations (mean internal between examinations, 4.9 years) to assess change or lack of change in physical fitness as associated with risk of mortality during follow-up after the subsequent examination (mean follow-up from subsequent examination, 5.1 years). Setting.-Preventive medicine clinic. Study Participants.-Participants were 9777 men given two preventive medical examinations, each of which included assessment of physical fitness by maximal exercise tests and evaluation of health status. Main Outcome Measures.-All-cause (n=223) and cardiovascular disease (n=87) mortality. Results.-The highest age-adjusted all-cause death rate was observed in men who were unfit at both examinations (122.0/10000 man-years); the lowest death rate was in men who were physically fit at both examinations (39.6/10000 man-years). Men who improved from unfit to fit between the first and subsequent examinations had an age-adjusted death rate of 67.7/10 000 man-years. This is a reduction in mortality risk of 44% (95% confidence internal, 25% to 59%) relative to men who remained unfit at both examinations, Improvement in fitness was associated With lower death rates after adjusting for age, health status, and other risk factors of premature mortality, For each minute increase in maximal treadmill time between examinations, there was a corresponding 7.9% (P=.001) decrease in risk of mortality. Similar results were seen when the group was stratified by health status, and for cardiovascular disease mortality. Conclusions.-Men who maintained or improved adequate physical fitness were less likely to die from all causes and from cardiovascular disease during follow-up than persistently unfit men. Physicians should encourage unfit men to improve their fitness by starting a physical activity program.	COOPER CLIN,DALLAS,TX; STANFORD UNIV,SCH MED,STANFORD,CA 94305; UNIV S CAROLINA,SCH PUBL HLTH,COLUMBIA,SC 29208	Cooper Institute; Stanford University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	BLAIR, SN (corresponding author), COOPER INST AEROB RES,DIV EPIDEMIOL,12330 PRESTON RD,DALLAS,TX 75230, USA.		wright, beth/V-7496-2019		NATIONAL INSTITUTE ON AGING [R01AG006945, R37AG006945] Funding Source: NIH RePORTER; NIA NIH HHS [AG06945] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American College of Sports Medicine position stand, 1990, MED SCI SPORTS EXERC, V22, P265; BALKE B, 1959, U S Armed Forces Med J, V10, P675; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Bond, 1989, AGING HLTH CARE SOCI, P27; Bouchard C., 1994, PHYSICAL ACTIVITY FI, P106; BOUCHARD C, 1994, PHYSICAL ACTIVITY FI; BRUCE RA, 1983, J AM COLL CARDIOL, V2, P565, DOI 10.1016/S0735-1097(83)80286-1; COX DR, 1972, J R STAT SOC B, V34, P187; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; ERIKSSEN J, 1986, ACTA MED SCAND S, V711, P189; HEIN HO, 1992, J INTERN MED, V232, P471, DOI 10.1111/j.1365-2796.1992.tb00619.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES, P300; LIE H, 1985, EUR HEART J, V6, P147, DOI 10.1093/oxfordjournals.eurheartj.a061829; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1994, MED SCI SPORT EXER, V26, P857; PETERS RK, 1983, JAMA-J AM MED ASSOC, V249, P3052, DOI 10.1001/jama.249.22.3052; POLLOCK ML, 1976, AM HEART J, V92, P39, DOI 10.1016/S0002-8703(76)80401-2; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SLATTERY ML, 1988, AM J EPIDEMIOL, V127, P571, DOI 10.1093/oxfordjournals.aje.a114832; SOBOLSKI J, 1987, AM J EPIDEMIOL, V125, P601, DOI 10.1093/oxfordjournals.aje.a114573; WILHELMSEN L, 1981, CARDIOLOGY, V68, P1, DOI 10.1159/000173310	23	1415	1456	0	103	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1093	1098		10.1001/jama.273.14.1093	http://dx.doi.org/10.1001/jama.273.14.1093			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR059	7707596				2022-12-28	WOS:A1995QR05900027
J	FRASCH, M				FRASCH, M			INDUCTION OF VISCERAL AND CARDIAC MESODERM BY ECTODERMAL DPP IN THE EARLY DROSOPHILA EMBRYO	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; HOMEOBOX-CONTAINING GENE; VENTRALIZING FACTOR; BETA FAMILY; GERM LAYERS; CELL FATES; XENOPUS; EXPRESSION; PATTERN; REPRESSION	AFTER gastrulation, progenitor cells of the cardiac, visceral and body wall musculature arise at defined positions within the mesodermal layer of the Drosophila embryo(1-4). The regulatory mechanisms underlying this process of pattern formation are largely unknown, although ablation experiments carried out in other insects indicate that inductive influences from ectodermal cells have major roles in embryonic mesoderm differentiation(5,6). An early and important event in the regional subdivision of the mesoderm is the restriction of tinman expression to dorsal mesodermal cells(2,3). Genetic analysis has shown that this homeobox gene controls the formation of the visceral musculature and the heart from dorsal portions of the mesoderm(3,7). We now show that an inductive signal from dorsal ectodermal cells is required for activation of tinman in the underlying mesoderm and present evidence that Decapentaplegic (Dpp), a member of the transforming growth factor-beta superfamily(8), serves as a signalling molecule in this process. This demonstrates that the spatial expression of dpp in the ectoderm determines which cells of the mesoderm become competent to develop into visceral mesoderm and the heart.			FRASCH, M (corresponding author), CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029, USA.		Frasch, Manfred/H-7002-2013	Frasch, Manfred/0000-0003-1373-9798				ANDERSON MG, 1995, GENE DEV, V9, P123, DOI 10.1101/gad.9.1.123; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Bate Michael, 1993, P1013; BODMER R, 1990, DEVELOPMENT, V110, P661; BODMER R, 1993, DEVELOPMENT, V118, P719; BRAND AH, 1993, DEVELOPMENT, V118, P401; DALE L, 1992, DEVELOPMENT, V115, P573; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; Haget A., 1953, Bulletin Biol Paris, V87, P123; HOCH M, 1990, EMBO J, V9, P2587, DOI 10.1002/j.1460-2075.1990.tb07440.x; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IP YT, 1991, CELL, V64, P439; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; JONES CM, 1992, DEVELOPMENT, V115, P639; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LOGAN M, 1993, DEVELOPMENT, V118, P865; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; Poulson D. F., 1950, BIOL DROSOPHILA, P168; Seidel F, 1940, NATURWISSENSCHAFTEN, V28, P433, DOI 10.1007/BF01557878; SMITH JC, 1987, DEVELOPMENT, V99, P3; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; TONISSEN KF, 1994, DEV BIOL, V162, P325, DOI 10.1006/dbio.1994.1089; WHARTON KA, 1993, DEVELOPMENT, V117, P807	30	352	355	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					464	467		10.1038/374464a0	http://dx.doi.org/10.1038/374464a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700357				2022-12-28	WOS:A1995QP89900061
J	WILLIS, MC; HICKE, BJ; UHLENBECK, OC; CECH, TR; KOCH, TH				WILLIS, MC; HICKE, BJ; UHLENBECK, OC; CECH, TR; KOCH, TH			PHOTO-CROSS-LINKING OF 5-IODOURACIL SUBSTITUTED RNA AND DNA TO PROTEINS	SCIENCE			English	Article							PHOTOCHEMICAL CROSS-LINKING; LAC REPRESSOR PROTEIN; 5-BROMOURACIL-SUBSTITUTED DNA; RIBONUCLEIC-ACID; OPERATOR DNA; BROMODEOXYURIDINE; IDENTIFICATION; COMPLEX; REGION; SITE	5-Iodouracil-substituted RNA and DNA were crosslinked regiospecifically to associated proteins in yields of 70 to 94% of bound nucleic acid. Irradiation of the iodouracil chromophore with monochromatic, long-wavelength ultraviolet radiation (325 nanometers) eliminates excitation of other nucleic acid and protein chromophores. The combination of high crosslinking yields, excellent specificity, and elimination of photodamage to other chromophores represents an important advance toward the precise identification of contacts in nucleoprotein complexes.	UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; UNIV COLORADO,HOWARD HUGHES MED INST,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder					NIGMS NIH HHS [GM-36944, GM-28039] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028039, R01GM036944, R01GM028039, R37GM036944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN TD, 1991, J BIOL CHEM, V266, P6113; BARBIER B, 1984, BIOCHEMISTRY-US, V23, P2933, DOI 10.1021/bi00308a013; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; CAREY J, 1983, BIOCHEMISTRY-US, V22, P4723, DOI 10.1021/bi00289a017; DIETZ TM, 1987, J AM CHEM SOC, V109, P1793, DOI 10.1021/ja00240a032; DIETZ TM, 1987, PHOTOCHEM PHOTOBIOL, V46, P971, DOI 10.1111/j.1751-1097.1987.tb04879.x; FANG GW, 1993, GENE DEV, V7, P870, DOI 10.1101/gad.7.5.870; GOTT JM, 1991, BIOCHEMISTRY-US, V30, P6290, DOI 10.1021/bi00239a030; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; HICKE BJ, UNPUB; Hutchinson F., 1980, PROG MOL SUBCELL BIO, V7, P1; KATOUZIANSAFADI M, 1991, PHOTOCHEM PHOTOBIOL, V53, P611, DOI 10.1111/j.1751-1097.1991.tb08487.x; KATOUZIANSAFADI M, 1991, NUCLEIC ACIDS RES, V19, P4937, DOI 10.1093/nar/19.18.4937; KHALILI K, 1988, EMBO J, V7, P1205, DOI 10.1002/j.1460-2075.1988.tb02932.x; LIN SY, 1974, P NATL ACAD SCI USA, V71, P947, DOI 10.1073/pnas.71.3.947; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; OGATA R, 1977, P NATL ACAD SCI USA, V74, P4973, DOI 10.1073/pnas.74.11.4973; SAITO I, 1990, BIOORGANIC PHOTOCHEM, V1, P317; Shetlar M.D., 1980, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V5, P105; TANNER NK, 1988, BIOCHEMISTRY-US, V27, P8852, DOI 10.1021/bi00424a025; UHLENBECK C, 1988, NUCLEIC ACIDS, V16, P11725; WEINTRAUB H, 1973, COLD SPRING HARB SYM, V38, P247, DOI 10.1101/SQB.1974.038.01.028; WICK KL, 1991, J BIOL CHEM, V266, P6106; WILLIS M, UNPUB; WOLFES H, 1986, EUR J BIOCHEM, V159, P267, DOI 10.1111/j.1432-1033.1986.tb09863.x	25	175	197	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1255	1257		10.1126/science.7694369	http://dx.doi.org/10.1126/science.7694369			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	7694369				2022-12-28	WOS:A1993MH32400036
J	BARTEL, DP; SZOSTAK, JW				BARTEL, DP; SZOSTAK, JW			ISOLATION OF NEW RIBOZYMES FROM A LARGE POOL OF RANDOM SEQUENCES	SCIENCE			English	Article							COMPLEMENTARY-STRAND RNA; CATALYSIS; POLYMERASE; SELECTION; EVOLUTION; DIVERSITY; TEMPLATE; CLEAVAGE; ORIGINS; LIFE	An iterative in vitro selection procedure was used to isolate a new class of catalytic RNAs (ribozymes) from a large pool of random-sequence RNA molecules. These ribozymes ligate two RNA molecules that are aligned on a template by catalyzing the attack of a 3'-hydroxyl on an adjacent 5'-triphosphate-a reaction similar to that employed by the familiar protein enzymes that synthesize RNA. The corresponding uncatalyzed reaction also yields a 3',5'-phosphodiester bond. In vitro evolution of the population of new ribozymes led to improvement of the average ligation activity and the emergence of ribozymes with reaction rates 7 million times faster than the uncatalyzed reaction rate.			BARTEL, DP (corresponding author), MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA.							BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; BRIDSON PK, 1980, J MOL BIOL, V144, P567, DOI 10.1016/0022-2836(80)90337-X; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; DAWSON RMC, 1986, DATA BIOCH RES, P486; DOUDNA JA, 1991, SCIENCE, V251, P1605, DOI 10.1126/science.1707185; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; GOLOMB M, 1974, J BIOL CHEM, V249, P2858; GREEN R, 1991, Methods (Orlando), V2, P75, DOI 10.1016/S1046-2023(05)80127-6; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HONJO T, 1985, ANNU REV BIOCHEM, V54, P803, DOI 10.1146/annurev.bi.54.070185.004103; INOUE T, 1982, J MOL BIOL, V162, P201, DOI 10.1016/0022-2836(82)90169-3; JANDA KD, 1990, J AM CHEM SOC, V112, P1274, DOI 10.1021/ja00159a074; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JOYCE GF, 1993, RNA WORLD, pCH1; LEHMAN N, 1993, NATURE, V361, P182, DOI 10.1038/361182a0; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LOHRMANN R, 1975, J MOL EVOL, V6, P237, DOI 10.1007/BF01794633; LORSCH JR, UNPUB; MICHEL F, 1992, GENE DEV, V6, P1373, DOI 10.1101/gad.6.8.1373; MORI M, 1982, CELL, V70, P803; NINIO J, 1978, J MOL EVOL, V12, P91, DOI 10.1007/BF01733260; ORGEL LE, 1986, J THEOR BIOL, V123, P127, DOI 10.1016/S0022-5193(86)80149-7; PAN T, 1992, NATURE, V358, P560, DOI 10.1038/358560a0; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; SZOSTAK JW, 1992, TRENDS BOCH SCI, V17, P3; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAMONTANO A, 1988, J AM CHEM SOC, V110, P2282, DOI 10.1021/ja00215a045; VOLCKAERT G, 1977, ANAL BIOCHEM, V83, P228, DOI 10.1016/0003-2697(77)90531-0; WIRSCHING P, 1991, SCIENCE, V252, P680, DOI 10.1126/science.2024120; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467	32	646	940	0	111	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1993	261	5127					1411	1418		10.1126/science.7690155	http://dx.doi.org/10.1126/science.7690155			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	7690155				2022-12-28	WOS:A1993LW54900023
J	CHO, CY; MORAN, EJ; CHERRY, SR; STEPHANS, JC; FODOR, SPA; ADAMS, CL; SUNDARAM, A; JACOBS, JW; SCHULTZ, PG				CHO, CY; MORAN, EJ; CHERRY, SR; STEPHANS, JC; FODOR, SPA; ADAMS, CL; SUNDARAM, A; JACOBS, JW; SCHULTZ, PG			AN UNNATURAL BIOPOLYMER	SCIENCE			English	Article							SOLID-PHASE SYNTHESIS; PROTECTED PEPTIDE-FRAGMENTS; DRUG DISCOVERY; NUCLEIC-ACIDS; ALCOHOL RESIN; LIBRARIES; ANTISENSE; ANALOGS	A highly efficient method has been developed for the solid-phase synthesis of an ''unnatural biopolymer'' consisting of chiral aminocarbonate monomers linked via a carbamate backbone. Oligocarbamates were synthesized from N-protected p-nitrophenyl carbonate monomers, substituted with a variety of side chains, with greater than 99 percent overall coupling efficiencies per step. A spatially defined library of oligocarbamates was generated by using photochemical methods and screened for binding affinity to a monoclonal antibody. A number of high-affinity ligands were then synthesized and analyzed in solution with respect to their inhibition concentration values, water/octanol partitioning coefficients, and proteolytic stability. These and other unnatural polymers may provide new frameworks for drug development and for testing theories of protein and peptide folding and structure.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; AFFYMAX RES INST,PALO ALTO,CA 94304	University of California System; University of California Berkeley				cherry, sara/0000-0003-3956-6610	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014681] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 F32 GM14681] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER BR, 1965, J PHARM SCI, V54, P987, DOI 10.1002/jps.2600540708; BLAKE J, 1992, BIOCONJUGATE CHEM, V3, P510, DOI 10.1021/bc00018a008; BRAY AM, 1990, TETRAHEDRON LETT, V31, P5811, DOI 10.1016/S0040-4039(00)97966-8; CARPINO LA, 1972, J ORG CHEM, V37, P3404, DOI 10.1021/jo00795a005; COULL JM, 1987, TETRAHEDRON LETT, V28, P745, DOI 10.1016/S0040-4039(01)80978-3; ESCHENMOSER A, 1992, HELV CHIM ACTA, V75, P218, DOI 10.1002/hlca.19920750120; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; HAGIHARA M, 1992, J AM CHEM SOC, V114, P6568, DOI 10.1021/ja00042a052; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KING DS, 1990, INT J PEPT PROT RES, V36, P255; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEE CM, 1961, J AM CHEM SOC, V83, P4596, DOI 10.1021/ja01483a022; LU G, 1981, J ORG CHEM, V46, P3433, DOI 10.1021/jo00330a009; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; MUNGALL WS, 1977, J ORG CHEM, V42, P703, DOI 10.1021/jo00424a028; NEEDELS MC, IN PRESS P NATL ACAD; NIKAWA J, 1979, CHEM LETT, P981, DOI 10.1246/cl.1979.981; OKI M, 1971, B CHEM SOC JPN, V44, P3148, DOI 10.1246/bcsj.44.3148; PATCHORNIK CA, 1970, J AM CHEM SOC, V92, P6333; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SIMON RJ, 1992, P NATL ACAD SCI USA, V89, P9367, DOI 10.1073/pnas.89.20.9367; SMITH AB, 1992, J AM CHEM SOC, V114, P10672, DOI 10.1021/ja00052a093; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; VANDERWERF S, 1967, TETRAHEDRON LETT, P689; WANG SS, 1973, J AM CHEM SOC, V95, P1328, DOI 10.1021/ja00785a602; WELLER DD, 1991, J ORG CHEM, V56, P6000, DOI 10.1021/jo00021a009	32	293	634	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1303	1305		10.1126/science.7689747	http://dx.doi.org/10.1126/science.7689747			3	Multidisciplinary Sciences	Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	7689747				2022-12-28	WOS:A1993LV65600021
J	OESTERLING, JE; JACOBSEN, SJ; CHUTE, CG; GUESS, HA; GIRMAN, CJ; PANSER, LA; LIEBER, MM				OESTERLING, JE; JACOBSEN, SJ; CHUTE, CG; GUESS, HA; GIRMAN, CJ; PANSER, LA; LIEBER, MM			SERUM PROSTATE-SPECIFIC ANTIGEN IN A COMMUNITY-BASED POPULATION OF HEALTHY-MEN - ESTABLISHMENT OF AGE-SPECIFIC REFERENCE RANGES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; MARKER; ADENOCARCINOMA; HYPERPLASIA; IMMUNOASSAY; DISEASE; DENSITY	Objective.-To define the characteristics of serum prostate-specific antigen (PSA) in a population of healthy men without clinically evident prostate cancer, but who are at risk for developing the malignancy. The influence of patient age and prostatic size on the serum PSA concentration was assessed in order to use PSA more appropriately to detect clinically significant prostate cancer at an early, potentially curable stage. Design.-Prospective, community-based study. Participants.-Between December 1989 and March 1991, 2119 healthy men aged 40 to 79 years from Olmsted County, Minnesota, were entered into a prospective study to assess the natural history of benign prostatic hyperplasia. Of these, 537 (25%) were randomly chosen to participate in a detailed clinical examination that included a serum PSA determination (Tandem-R PSA assay), digital rectal examination, and transrectal ultrasonography. Four hundred seventy-one (88%) completed the prostatic evaluation and had no evidence of prostate cancer by any of these three diagnostic tests; these men formed the study population on which all analyses were performed. Main Outcome Measure.-Serum PSA concentration, prostatic volume, and PSA density (serum PSA level/prostatic volume) as a function of patient age. Results.-The serum PSA concentration is correlated with patient age (r=.43; P<.0001) and prostatic volume (r=.55; P<.0001). Prostatic volume, in turn, is directly correlated with patient age (r=.43; P<.0001), whereas the PSA density value is only weakly correlated with patient age (r=.25; P<.001). For a healthy 60-year-old man with no evidence of prostate cancer, the serum PSA concentration increases by approximately 3.2% per year (0.04 ng/mL per year). The recommended reference range for serum PSA (95th percentile) for men aged 40 to 49 years is 0.0 to 2.5 ng/mL; for 50 to 59 years, 0.0 to 3.5 ng/mL; 60 to 69 years, 0.0 to 4.5 ng/mL; and 70 to 79 years, 0.0 to 6.5 ng/mL. Conclusions.-The serum PSA concentration is directly correlated with patient age and prostatic volume, the latter of which also is directly related to age. Thus, rather than rely on a single reference range for men of all age groups, it is more appropriate to have age-specific reference ranges. These age-specific reference ranges have the potential to make serum PSA a more discriminating tumor marker for detecting clinically significant cancers in older men (increasing specificity) and to find more potentially curable cancers in younger men (increasing sensitivity).	MERCK RES LABS, DEPT EPIDEMIOL, BLUE BELL, PA USA; MAYO CLIN & MAYO FDN, CLIN EPIDEMIOL SECT, ROCHESTER, MN 55905 USA	Merck & Company; Mayo Clinic	OESTERLING, JE (corresponding author), MAYO CLIN & MAYO FDN, DEPT UROL, 200 1ST ST SW, ROCHESTER, MN 55905 USA.			Jacobsen, Steven/0000-0002-8174-8533	NIAMS NIH HHS [AR30582] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENSON MC, 1992, J UROLOGY, V147, P815, DOI 10.1016/S0022-5347(17)37393-7; BENSON MC, 1992, J UROLOGY, V147, P817, DOI 10.1016/S0022-5347(17)37394-9; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BRAWER MK, 1989, UROLOGY, V34, P62; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CHAN DW, 1987, CLIN CHEM, V33, P1916; CHUTE CG, 1993, J UROLOGY, V150, P85, DOI 10.1016/S0022-5347(17)35405-8; COLLINS GN, IN PRESS BR J RADIOL; COONER WH, 1993, CAMPBELLS UROLOGY, P1; ELVEBACK LR, 1970, J AMER MED ASSOC, V211, P69, DOI 10.1001/jama.211.1.69; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; GLENSKI WJ, 1992, MAYO CLIN PROC, V67, P249, DOI 10.1016/S0025-6196(12)60101-3; KLEE GG, IN PRESS J UROL; KLEER E, IN PRESS AM J RADIOL; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; METTLIN C, 1993, CA-CANCER J CLIN, V43, P42, DOI 10.3322/canjclin.43.1.42; OESTERLING JE, 1988, J UROLOGY, V139, P766, DOI 10.1016/S0022-5347(17)42630-9; OESTERLING JE, 1992, JAMA-J AM MED ASSOC, V267, P2236, DOI 10.1001/jama.267.16.2236; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; Oesterling JE, 1991, AM UROLOGICAL ASS UP, V10, P137; PANSER LA, IN PRESS AM J EPIDEM; ROBLES JM, 1988, EUR UROL, V14, P360; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; TERRIS MK, 1991, J UROLOGY, V145, P984, DOI 10.1016/S0022-5347(17)38508-7; VESSELLA RL, 1992, CLIN CHEM, V38, P2044; WEBER JP, 1989, J UROLOGY, V141, P987, DOI 10.1016/S0022-5347(17)41083-4; WHITMORE WF, 1993, JAMA-J AM MED ASSOC, V269, P2676, DOI 10.1001/jama.269.20.2676; 1992, AM UROLOGICAL ASS 19, V4, P20	29	1027	1064	0	45	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					860	864		10.1001/jama.270.7.860	http://dx.doi.org/10.1001/jama.270.7.860			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	7688054				2022-12-28	WOS:A1993LR61200033
J	SACHS, AB				SACHS, AB			MESSENGER-RNA DEGRADATION IN EUKARYOTES	CELL			English	Review							3' UNTRANSLATED REGION; SACCHAROMYCES-CEREVISIAE; C-FOS; CODING REGION; ENDONUCLEOLYTIC CLEAVAGE; 5'->3' EXORIBONUCLEASE; TRANSLATION INITIATION; BINDING-PROTEINS; RICH SEQUENCES; YEAST-CELLS				SACHS, AB (corresponding author), UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.				NIGMS NIH HHS [R29 GM-43164] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043164] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; ALTAMURA N, 1992, J MOL BIOL, V224, P575, DOI 10.1016/0022-2836(92)90545-U; ASTROM J, 1992, J BIOL CHEM, V267, P18154; Belasco J.G., 2012, CONTROL MESSENGER RN; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BINDER R, 1989, J BIOL CHEM, V264, P16910; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CAPONIGRO G, 1993, IN PRESS MOL CELL BI, V13; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; DECKER CJ, 1993, IN PRESS GENES DEV, V7; GILLIS P, 1991, J BIOL CHEM, V266, P3172; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HE F, 1993, IN PRESS P NATL ACAD, V90; HEATON B, 1992, NUCLEIC ACIDS RES, V20, P5365, DOI 10.1093/nar/20.20.5365; HELMS SR, 1990, NUCLEIC ACIDS RES, V18, P255, DOI 10.1093/nar/18.2.255; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; IWAI Y, 1991, J BIOL CHEM, V266, P17959; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; Kearsey S, 1991, Trends Cell Biol, V1, P110, DOI 10.1016/0962-8924(91)90101-E; KENNA M, 1993, MOL CELL BIOL, V13, P341, DOI 10.1128/MCB.13.1.341; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LARIMER FW, 1992, GENE, V120, P51, DOI 10.1016/0378-1119(92)90008-D; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; LIM SK, 1992, EMBO J, V11, P3271, DOI 10.1002/j.1460-2075.1992.tb05405.x; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LOMBARDO A, 1992, MOL CELL BIOL, V12, P2941, DOI 10.1128/MCB.12.7.2941; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; PARKER R, 1990, P NATL ACAD SCI USA, V87, P2780, DOI 10.1073/pnas.87.7.2780; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PELTZ SW, 1992, MOL CELL BIOL, V12, P5778, DOI 10.1128/MCB.12.12.5778; PELTZ SW, 1993, IN PRESS GENES DEV, V7; PETERSEN R, 1988, GENE, V72, P161, DOI 10.1016/0378-1119(88)90138-2; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Sachs A, 1990, CURR OPIN CELL BIOL, V2, P1092, DOI 10.1016/0955-0674(90)90161-7; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STEVENS A, 1988, MOL CELL BIOL, V8, P2005, DOI 10.1128/MCB.8.5.2005; STOECKLE MY, 1989, MOL CELL BIOL, V9, P4738, DOI 10.1128/MCB.9.11.4738; STOECKLE MY, 1992, NUCLEIC ACIDS RES, V20, P1123, DOI 10.1093/nar/20.5.1123; TAKAHAMA Y, 1992, SCIENCE, V258, P1456, DOI 10.1126/science.1439838; THEODORAKIS NG, 1992, MOL CELL BIOL, V12, P791, DOI 10.1128/MCB.12.2.791; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VREKEN P, 1992, MOL CELL BIOL, V12, P2986, DOI 10.1128/MCB.12.7.2986; VREKEN P, 1992, NUCLEIC ACIDS RES, V20, P2503, DOI 10.1093/nar/20.10.2503; WELLINGTON CL, 1993, IN PRESS MOL CELL BI, V13; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931	69	853	868	1	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					413	421		10.1016/0092-8674(93)80043-E	http://dx.doi.org/10.1016/0092-8674(93)80043-E			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	7688664				2022-12-28	WOS:A1993LT73900003
J	DODWELL, D; BOND, M; ELWELL, C; GILDERSLEVE, J; PARMAR, S; OWENS, J; BULMAN, A; CRELLIN, A; ASH, D				DODWELL, D; BOND, M; ELWELL, C; GILDERSLEVE, J; PARMAR, S; OWENS, J; BULMAN, A; CRELLIN, A; ASH, D			EFFECT OF MEDICAL AUDIT ON PRESCRIPTION OF PALLIATIVE RADIOTHERAPY	BRITISH MEDICAL JOURNAL			English	Article											DODWELL, D (corresponding author), COOKRIDGE HOSP,YORKSHIRE REG CTR CANC TREATMENT,LEEDS LS16 6QB,W YORKSHIRE,ENGLAND.							CRELLIN AM, 1990, CLIN ONCOLOGY, V1, P63; Maher E J, 1990, Health Trends, V22, P78; PRICE P, 1986, RADIOTHER ONCOL, V6, P247, DOI 10.1016/S0167-8140(86)80191-8; Priestman T J, 1989, Clin Oncol (R Coll Radiol), V1, P39, DOI 10.1016/S0936-6555(89)80010-X; 1991, BRIT J CANCER, V63, P265	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					24	25		10.1136/bmj.307.6895.24	http://dx.doi.org/10.1136/bmj.307.6895.24			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	7688252	Green Published, Bronze			2022-12-28	WOS:A1993LL36900021
J	JOHNSTON, MI; HOTH, DF				JOHNSTON, MI; HOTH, DF			PRESENT STATUS AND FUTURE-PROSPECTS FOR HIV THERAPIES	SCIENCE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITORS; AIDS-RELATED COMPLEX; PLACEBO-CONTROLLED TRIAL; RECOMBINANT SOLUBLE CD4; CHRONICALLY INFECTED-CELLS; DEFICIENCY SYNDROME AIDS; BLOOD MONONUCLEAR-CELLS; MURINE LEUKEMIA-VIRUS; REV TRANS-ACTIVATOR	Since the discovery of human immunodeficiency virus (HIV) in 1983, significant progress has been made toward the discovery, development, and licensing of anti-HIV drugs. In vitro screens against whole virus are now being complemented by screens against specific viral targets, resulting in the development of clinical candidates acting at several critical stages of the viral life cycle. Despite these advances, clinical therapy remains largely palliative. In addition, it has recently been recognized that HIV resistance to most drugs may pose even greater obstacles. Moreover, emerging data on immunopathogenesis raise the possibility that even if virus was eliminated from an infected individual, the patient's immune system might not be capable of restoration to normal function. In the face of such obstacles, deeper insights into the pathogenic mechanisms of disease, aggressive exploitation of those mechanisms for therapeutic gain, and continued commitment of both public and private sectors to support and collaborate in this research are needed.			JOHNSTON, MI (corresponding author), NIAID, DIV AIDS, BASIC RES & DEV PROGRAM, BETHESDA, MD 20892 USA.							ABOULKER JP, 1993, LANCET, V341, P980; ABRAMOVA TV, 1991, NUCLEOS NUCLEOT, V10, P419, DOI 10.1080/07328319108046493; ADLEMAN LM, 1993, J ACQ IMMUN DEF SYND, V6, P144; AGARWAL RP, 1991, BIOCHEM PHARMACOL, V42, P905, DOI 10.1016/0006-2952(91)90052-7; AMBRUS JL, 1992, BLOOD, V79, P535; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; ANDERSON R E, 1992, pWE47; AOKI S, 1990, AIDS RES HUM RETROV, V6, P1331, DOI 10.1089/aid.1990.6.1331; ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; ASHORN P, 1990, P NATL ACAD SCI USA, V87, P8889, DOI 10.1073/pnas.87.22.8889; BABE LM, 1991, BIOCHEMISTRY-US, V30, P106, DOI 10.1021/bi00215a016; BACH MC, 1990, NEW ENGL J MED, V323, P275; BALZARINI J, 1989, P NATL ACAD SCI USA, V86, P332, DOI 10.1073/pnas.86.1.332; BALZARINI J, 1991, AIDS, V5, P21, DOI 10.1097/00002030-199101000-00003; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BENARTZI H, 1992, P NATL ACAD SCI USA, V89, P927, DOI 10.1073/pnas.89.3.927; BENARTZI H, 1992, NUCLEIC ACIDS RES, V20, P5115, DOI 10.1093/nar/20.19.5115; BLAIR ED, 1993, J CELL BIOCH E S, V17, P74; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; BOUCHER CAB, 1992, AIDS, V6, P1259, DOI 10.1097/00002030-199211000-00003; BRETT-SMITH H, 1992, pB88; BROWNE MJ, 1993, J INFECT DIS, V167, P21, DOI 10.1093/infdis/167.1.21; BRYANT ML, 1991, P NATL ACAD SCI USA, V88, P2055, DOI 10.1073/pnas.88.6.2055; BRYANT ML, 1989, P NATL ACAD SCI USA, V86, P8655, DOI 10.1073/pnas.86.22.8655; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHADA S, IN PRESS J VIROL, V67; CHANG PS, 1990, CLIN BIOTECHNOL, V2, P23; CHATTERJEE S, 1992, SCIENCE, V258, P1485, DOI 10.1126/science.1359646; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; CHOW YK, 1993, NATURE, V361, P650, DOI 10.1038/361650a0; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P733, DOI 10.1128/AAC.36.4.733; COHEN J, 1992, SCIENCE, V258, P388, DOI 10.1126/science.1357750; COLEBUNDERS R, 1992, pB89; CONANT MA, 1992, AIDS, V6, P1335, DOI 10.1097/00002030-199211000-00016; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; CONWAY B, 1993, J CELL BIOCH E S, V17, P13; COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; COREY L, 1982, AM J MED, V73, P326, DOI 10.1016/0002-9343(82)90117-6; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S; CRAIGIE R, 1991, NUCLEIC ACIDS RES, V19, P2729, DOI 10.1093/nar/19.10.2729; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; CURIEL DT, 1992, HUM GENE THER, V3, P147, DOI 10.1089/hum.1992.3.2-147; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DALGLEISH AG, 1992, LANCET, V339, P824, DOI 10.1016/0140-6736(92)90277-A; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DARBYSHIRE JH, 1992, LANCET, V340, P1356; DAVEY RT, 1991, J INFECT DIS, V164, P43, DOI 10.1093/infdis/164.1.43; DAVIES WL, 1964, SCIENCE, V144, P862, DOI 10.1126/science.144.3620.862; DEBOUCK C, 1990, DRUG DEVELOP RES, V21, P1, DOI 10.1002/ddr.430210102; DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451; DECREE J, 1992, 8TH INT C AIDS AMST, pB89; DESOLMS SJ, 1991, J MED CHEM, V34, P2852, DOI 10.1021/jm00113a025; DEVREESE K, 1992, VIROLOGY, V188, P900, DOI 10.1016/0042-6822(92)90550-9; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; DREYER GB, 1989, P NATL ACAD SCI USA, V86, P9752, DOI 10.1073/pnas.86.24.9752; DUEWEKE TJ, 1992, J BIOL CHEM, V267, P27; DUEWEKE TJ, IN PRESS P NATL ACAD; Dunn BM, 1990, ANTIVIR CHEM CHEMOTH, V1, P3, DOI 10.1177/095632029000100102; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FAZELY F, 1991, BLOOD, V77, P1653; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1496; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; FITZPATRICK EA, 1992, J IMMUNOL, V148, P3377; FLEXNER C, 1991, ANTIMICROB AGENTS CH, V35, P2544, DOI 10.1128/AAC.35.12.2544; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; GALLO RC, 1983, SCIENCE, V220, P865, DOI 10.1126/science.6601823; GAO Q, 1992, J VIROL, V66, P12, DOI 10.1128/JVI.66.1.12-19.1992; GAO WY, IN PRESS J CLIN INVE, V91; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GOLDING H, 1989, J CLIN INVEST, V83, P1430, DOI 10.1172/JCI114034; GOLDING H, 1988, J EXP MED, V167, P914, DOI 10.1084/jem.167.3.914; GOLDMAN ME, 1992, ANTIMICROB AGENTS CH, V36, P1019, DOI 10.1128/AAC.36.5.1019; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; GOODCHILD J, 1988, P NATL ACAD SCI USA, V85, P5507, DOI 10.1073/pnas.85.15.5507; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HABESHAW JA, 1990, IMMUNOL TODAY, V11, P418, DOI 10.1016/0167-5699(90)90162-3; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HANSEN BD, 1992, J VIROL, V66, P7543, DOI 10.1128/JVI.66.12.7543-7548.1992; HASELTINE WA, 1991, GENETIC STRUCTURE RE, P560; HASSELOFF J, 1988, NATURE, V334, P585; HAYNES BF, 1993, SCIENCE, V260, P1289; HEUCKEROTH RO, 1990, J LIPID RES, V31, P1121; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1985, LANCET, V1, P602; HOLODNIY M, 1993, J CELL BIOCH E S, V17, P3; HSU MC, 1991, SCIENCE, V254, P1799, DOI 10.1126/science.1763331; HSU MC, IN PRESS P NATL ACAD; HUDSON JB, 1991, ANTIVIR RES, V15, P101, DOI 10.1016/0166-3542(91)90028-P; IZANT JG, 1985, SCIENCE, V229, P345, DOI 10.1126/science.2990048; JACOBSEN H, 1993, J CELL BIOCH E S, V17, P90; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; JANSSEN P A J, 1992, pB90; JOHNSON VA, 1992, J INFECT DIS, V166, P1143, DOI 10.1093/infdis/166.5.1143; JOHNSTON MI, 1989, TRENDS PHARMACOL SCI, V10, P305, DOI 10.1016/0165-6147(89)90060-6; Jolly D J, 1990, Semin Immunol, V2, P329; KAGEYAMA S, 1992, ANTIMICROB AGENTS CH, V36, P926, DOI 10.1128/AAC.36.5.926; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KAHN JO, 1990, ANN INTERN MED, V112, P254, DOI 10.7326/0003-4819-112-4; KALAYJIAN R, 1992, pB162; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KAPPES J, 1992, pB90; KASHMAN Y, 1992, J MED CHEM, V35, P2735, DOI 10.1021/jm00093a004; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KEMPF DJ, 1990, J MED CHEM, V33, P2687, DOI 10.1021/jm00172a002; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KONG XB, 1992, ANTIMICROB AGENTS CH, V36, P808, DOI 10.1128/AAC.36.4.808; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; KOUP RA, 1991, J INFECT DIS, V163, P966, DOI 10.1093/infdis/163.5.966; KOUTTAB N, 1992, pB161; KOZAL MJ, 1993, J INFECT DIS, V167, P526, DOI 10.1093/infdis/167.3.526; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; LAGAKOS SW, 1992, ANN INTERN MED, V116, P599, DOI 10.7326/0003-4819-116-7-599; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LAND S, 1992, J INFECT DIS, V166, P1139, DOI 10.1093/infdis/166.5.1139; LANE HC, 1991, SEMIN ONCOL, V18, P46; LANE HC, 1990, ANN INTERN MED, V112, P805, DOI 10.7326/0003-4819-112-11-805; LANE HC, 1990, ANN INTERN MED, V113, P512, DOI 10.7326/0003-4819-113-7-512; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1992, ANTIMICROB AGENTS CH, V36, P2664, DOI 10.1128/AAC.36.12.2664; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEE JS, 1991, J ACQ IMMUN DEF SYND, V4, P833; LIEBERMAN J, 1992, J IMMUNOL, V148, P2738; LINETTE GP, 1988, SCIENCE, V241, P573, DOI 10.1126/science.2899908; LOUIS JM, 1989, BIOCHEM BIOPH RES CO, V164, P30, DOI 10.1016/0006-291X(89)91678-1; LOYA S, 1990, ANTIMICROB AGENTS CH, V34, P2009, DOI 10.1128/AAC.34.10.2009; MALIM MH, 1992, J EXP MED, V176, P1197, DOI 10.1084/jem.176.4.1197; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARCUZZI A, 1992, J VIROL, V66, P4536, DOI 10.1128/JVI.66.7.4536-4539.1992; MARCUZZI A, 1992, J VIROL, V66, P4228, DOI 10.1128/JVI.66.7.4228-4232.1992; MARSH K, 1992, 32ND INT C ANT AG CH, P163; MARSHALL WS, 1993, SCIENCE, V259, P1564, DOI 10.1126/science.7681216; MARTIN LN, IN PRESS J INFECT DI; MATTHES E, 1988, BIOCHEM BIOPH RES CO, V153, P825, DOI 10.1016/S0006-291X(88)81170-7; MAYERS D, 1992, 30TH INF DIS SOC AM, P25; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; MELLORS JW, 1992, MOL PHARMACOL, V41, P446; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MERIGAN TC, 1990, AM J MED, V88, P11; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MERUELO D, 1988, P NATL ACAD SCI USA, V85, P5230, DOI 10.1073/pnas.85.14.5230; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MICHAEL NL, 1992, J VIROL, V66, P310, DOI 10.1128/JVI.66.1.310-316.1992; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MITTLER RS, 1989, SCIENCE, V245, P1380, DOI 10.1126/science.2571187; MOHRI H, 1993, P NATL ACAD SCI USA, V90, P25, DOI 10.1073/pnas.90.1.25; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; MORGAN RA, 1990, AIDS RES HUM RETROV, V6, P183, DOI 10.1089/aid.1990.6.183; NASR M, 1992, NATURAL PRODUCTS AS ANTIVIRAL AGENTS, P31; NASR M, 1990, ANTIVIR RES, V14, P125, DOI 10.1016/0166-3542(90)90030-B; NASR M, 1992, AIDS RES HUM RETROV, V8, P153; NORBECK D, 1992, 8TH INT C AIDS AMST, pTH66; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; OJWANG JO, 1992, P NATL ACAD SCI USA, V89, P10802, DOI 10.1073/pnas.89.22.10802; ORLOFF SL, 1993, J VIROL, V67, P1461, DOI 10.1128/JVI.67.3.1461-1471.1993; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PAUWELS R, 1993, P NATL ACAD SCI USA, V90, P1711, DOI 10.1073/pnas.90.5.1711; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PENG C, 1989, J VIROL, V63, P2550, DOI 10.1128/JVI.63.6.2550-2556.1989; PERNO CF, 1988, J EXP MED, V168, P111; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; PETERSEN E, 1992, pB90; PIALOUX G, 1991, LANCET, V338, P140, DOI 10.1016/0140-6736(91)90135-C; PIATAK JM, 1993, SCIENCE, V259, P1749; PITHA PM, 1979, J GEN VIROL, V42, P467, DOI 10.1099/0022-1317-42-3-467; PLUDA J, 1992, 8TH INT C AIDS AMST; POLI G, 1992, AIDS RES HUM RETROV, V8, P191, DOI 10.1089/aid.1992.8.191; POLI G, 1989, SCIENCE, V244, P575, DOI 10.1126/science.2470148; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; POLSKY B, 1992, pB91; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; PRINCIPI N, 1992, pTH75; PROCHASKA HJ, 1993, P NATL ACAD SCI USA, V90, P3953, DOI 10.1073/pnas.90.9.3953; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; RICH DH, 1990, J MED CHEM, V33, P1285, DOI 10.1021/jm00167a003; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; RICHMAN D, 1991, J VIROL, V65, P11241; RICHMAN D D, 1992, pB183; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RIECKMAN P, 1991, J EXP MED, V175, P1; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; ROSENBERG M, COMMUNICATION; ROSENBERG PS, 1991, J ACQ IMMUN DEF SYND, V4, P392; ROSENBERG ZF, 1989, AIDS RES HUM RETROV, V5, P1, DOI 10.1089/aid.1989.5.1; ROSSI JJ, 1992, ADV EXP MED BIOL, V312, P95; SAARI WS, 1991, J MED CHEM, V34, P2922, DOI 10.1021/jm00113a036; SAKAI H, 1993, J VIROL, V67, P1169, DOI 10.1128/JVI.67.3.1169-1174.1993; SARDANA VV, 1992, J BIOL CHEM, V267, P17526; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P672, DOI 10.1128/AAC.36.3.672; SCHNITTMAN SM, 1991, AIDS RES HUM RETROV, V7, P361, DOI 10.1089/aid.1991.7.361; SCHOOLEY RT, 1990, ANN INTERN MED, V112, P247, DOI 10.7326/0003-4819-112-4-247; SCHWARTZ DH, 1991, J ACQ IMMUN DEF SYND, V4, P11; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878; SINGH M, 1993, J CELL BIOCH E S, V17, P86; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; STEFFY KR, 1993, J VIROL, V67, P1854, DOI 10.1128/JVI.67.4.1854-1859.1993; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; STRIETER RM, 1988, BIOCHEM BIOPH RES CO, V155, P1230, DOI 10.1016/S0006-291X(88)81271-3; SULLENGER BA, 1991, J VIROL, V65, P6811, DOI 10.1128/JVI.65.12.6811-6816.1991; TAN CK, 1991, BIOCHEMISTRY-US, V30, P4831, DOI 10.1021/bi00234a001; TEPPLER H, 1993, J EXP MED, V177, P483, DOI 10.1084/jem.177.2.483; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TERSMETTE M, 1989, LANCET, V1, P983; TERSMETTE M, 1993, J CELL BIOCH S E, V17, P24; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; TSAI CC, IN PRESS J ACQUIR IM; TSAI CC, UPUB; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TURNER S, 1992, P NATL ACAD SCI USA, V89, P1335, DOI 10.1073/pnas.89.4.1335; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; VANLEEUWEN R, 1992, AIDS, V6, P1471, DOI 10.1097/00002030-199212000-00008; VARMUS H, 1989, MOBILE DNA, P53; VASUDEVACHARI MB, 1992, VIROLOGY, V190, P269, DOI 10.1016/0042-6822(92)91213-E; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WARNER JF, 1991, AIDS RES HUM RETROV, V7, P645, DOI 10.1089/aid.1991.7.645; WHITLEY RJ, 1977, NEW ENGL J MED, V297, P289, DOI 10.1056/NEJM197708112970601; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wong-Staal F, 1992, Mol Genet Med, V2, P189; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; YARCHOAN R, 1992, 8TH INT C AIDS AMST; YARCHOAN R, 1990, LANCET, V336, P1515	257	190	239	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1993	260	5112					1286	1293		10.1126/science.7684163	http://dx.doi.org/10.1126/science.7684163			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE025	7684163				2022-12-28	WOS:A1993LE02500035
J	HU, QJ; KLIPPEL, A; MUSLIN, AJ; FANTL, WJ; WILLIAMS, LT				HU, QJ; KLIPPEL, A; MUSLIN, AJ; FANTL, WJ; WILLIAMS, LT			RAS-DEPENDENT INDUCTION OF CELLULAR-RESPONSES BY CONSTITUTIVELY ACTIVE PHOSPHATIDYLINOSITOL-3 KINASE	SCIENCE			English	Article							DIFFERENT SIGNALING PATHWAYS; PROTEIN; 3-KINASE; YEAST; DOWNSTREAM; RAPAMYCIN	Phosphatidylinositol (PI)-3 kinase is one of many enzymes stimulated by growth factors. A constitutively activated mutant, p110*, that functions independently of growth factor stimulation was constructed to determine the specific responses regulated by PI-3 kinase. The p110* protein exhibited high specific activity as a PI-3 kinase and as a protein kinase. Expression of p110* in NIH 3T3 cells induced transcription from the fos promoter. Coexpression of dominant negative Ras blocked this response. When expressed in Xenopus laevis oocytes, p110* increased the amount of guanosine 5'-triphosphate-bound Ras, caused activation of the Ras effector Raf-1, and induced Ras-dependent oocyte maturation. These findings show that PI-3 kinase can Stimulate diverse Ras-dependent cellular processes, including oocyte maturation and fos transcription.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [R01 HL32898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032898] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FANTL WJ, UNPUB; FISH TM, 1987, MOL CELL BIOL, V7, P3490; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; Hu Q-L, UNPUB; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2685; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MULSIN AJ, UNPUB; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	33	514	529	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					100	102		10.1126/science.7701328	http://dx.doi.org/10.1126/science.7701328			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701328				2022-12-28	WOS:A1995QR45400035
J	SCHIPANI, E; KRUSE, K; JUPPNER, H				SCHIPANI, E; KRUSE, K; JUPPNER, H			A CONSTITUTIVELY ACTIVE MUTANT PTH-PTHRP RECEPTOR IN JANSEN-TYPE METAPHYSEAL CHONDRODYSPLASIA	SCIENCE			English	Article							RHODOPSIN; MUTATIONS; GENE	A single heterozygous nucleotide exchange in exon M2 of the gene encoding the parathyroid hormone-parathyroid hormone-related peptide (PTH-PTHrP) receptor was identified in a patient with Jansen-type metaphyseal chondrodysplasia, which changes a strictly conserved histidine residue at position 223 in the receptor's first intracellular loop to arginine. Constitutive, ligand-independent adenosine 3',5'-monophosphate accumulation was observed in COS-7 cells expressing the mutant PTH-PTHrP receptor but not in cells expressing the wild-type receptor. This finding explains the severe ligand-independent hypercalcemia and hypophosphatemia, and most likely the abnormal formation of endochondral bone, in this rare form of short-limbed dwarfism.	MASSACHUSETTS GEN HOSP,DEPT MED,ENDOCRINE UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CHILDRENS SERV,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114; UNIV LUBECK,PADIATRIE KLIN,D-23538 LUBECK,GERMANY	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Lubeck					PHS HHS [R01 46718] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; Broadus Arthur E., 1994, P259; de Haas W H, 1969, J Bone Joint Surg Br, V51, P290; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; Frame B, 1980, PEDIAT DIS RELATED C, P269; GRAM PB, 1959, J BONE JOINT SURG AM, V41, P951, DOI 10.2106/00004623-195941050-00015; HOLT JF, 1969, CLIN DELINEATION BIR, V5, P73; Jansen M, 1934, Z ORTHOP CHIR, V61, P253; Juppner H, 1994, Curr Opin Nephrol Hypertens, V3, P371; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KIKUCHI S, 1976, J BONE JOINT SURG BR, V58, P102, DOI 10.1302/0301-620X.58B1.1270485; KRONENBERG HM, 1993, HDB EXPT PHARM, P185; KRUSE K, 1993, EUR J PEDIATR, V152, P912, DOI 10.1007/BF01957529; LANSKE B, 1994, BONE MINER RES S1, V9, P121; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LEE K, 1994, ENDOCRINOLOGY, V134, P441, DOI 10.1210/en.134.1.441; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; Rao DS, 1979, VITAMIN D BASIC RES, P1173; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SCHIPANI E, 1992, P NATL ACAD SCI USA, V89, P2732; SCHIPANI E, IN PRESS J CLIN ENDO; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0	27	495	517	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					98	100		10.1126/science.7701349	http://dx.doi.org/10.1126/science.7701349			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701349				2022-12-28	WOS:A1995QR45400034
J	DONAHUE, TM				DONAHUE, TM			EVOLUTION OF WATER RESERVOIRS ON MARS FROM D/H RATIOS IN THE ATMOSPHERE AND CRUST	NATURE			English	Article							MARTIAN ATMOSPHERE; ESCAPE; ABUNDANCE; HYDROGEN; HDO	ANCIENT fluvial networks on the surface of Mars suggest that it was warm and wet over three billion years ago. Surface features resembling massive outflow channels provide evidence that, even more recently, the martian crust contained the equivalent of a planet-wide reservoir of water several hundred metres deep(1,2). But arguments based on the isotopic fractionation(3,4) and present-day escape rate of hydrogen in the martian atmosphere require only 0.5 metres of crustal water today and about six metres in the past(5). An additional constraint on the evolution of the isotopic composition of martian water has recently been obtained(6) from measurements of the deuterium to hydrogen ratio of hydrous minerals in the SNC meteorites-meteorites that almost certainly originated on Mars. Here I show that these new data require that the modern crustal reservoirs of martian water must be quite large, at least several metres in global-equivalent depth. The deuterium enrichment of the present martian atmosphere then implies that the reservoir of crustal water on ancient Mars was several hundred metres deep, consistent with the geological evidence(3,4).			DONAHUE, TM (corresponding author), UNIV MICHIGAN,DEPT ATMOSPHER OCEAN & SPACE SCI,ANN ARBOR,MI 48109, USA.							ATREYA SK, 1994, J GEOPHYS RES-PLANET, V99, P13133, DOI 10.1029/94JE01085; Bjoraker G. L., 1989, B AM ASTRON SOC, V21, P990; CARR MH, 1987, NATURE, V326, P30, DOI 10.1038/326030a0; CARR MH, 1990, ICARUS, V87, P210, DOI 10.1016/0019-1035(90)90031-4; CARR MH, 1979, J GEOPHYS RES, V84, P2995, DOI 10.1029/JB084iB06p02995; FOX JL, 1993, GEOPHYS RES LETT, V20, P1747, DOI 10.1029/93GL01118; HUNTEN DM, 1973, J ATMOS SCI, V30, P1481, DOI 10.1175/1520-0469(1973)030<1481:TEOLGF>2.0.CO;2; HUNTEN DM, 1973, J ATMOS SCI, V30, P736; JAKOSKY BM, 1994, ICARUS, V111, P271, DOI 10.1006/icar.1994.1145; JAKOSKY BM, 1990, J GEOPHYS RES-SOLID, V95, P1475, DOI 10.1029/JB095iB02p01475; KASTING JF, 1991, ICARUS, V94, P1, DOI 10.1016/0019-1035(91)90137-I; KRASNOPOLSKY VA, 1993, ICARUS, V101, P33, DOI 10.1006/icar.1993.1003; LIU SC, 1976, ICARUS, V28, P231, DOI 10.1016/0019-1035(76)90035-X; LUHMANN JG, 1992, GEOPHYS RES LETT, V19, P2151, DOI 10.1029/92GL02485; MCELROY MB, 1972, SCIENCE, V177, P986, DOI 10.1126/science.177.4053.986; NAIR H, 1994, ICARUS, V111, P124, DOI 10.1006/icar.1994.1137; OWEN T, 1988, SCIENCE, V240, P1767, DOI 10.1126/science.240.4860.1767; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; YUNG YL, 1988, ICARUS, V76, P146, DOI 10.1016/0019-1035(88)90147-9	19	52	52	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					432	434		10.1038/374432a0	http://dx.doi.org/10.1038/374432a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700352	Green Submitted			2022-12-28	WOS:A1995QP89900051
J	BROWN, NL; SATTLER, CA; PADDOCK, SW; CARROLL, SB				BROWN, NL; SATTLER, CA; PADDOCK, SW; CARROLL, SB			HAIRY AND EMC NEGATIVELY REGULATE MORPHOGENETIC FURROW PROGRESSION IN THE DROSOPHILA EYE	CELL			English	Article							POLARITY GENE HEDGEHOG; CELL-INTERACTIONS; PATTERN-FORMATION; NERVOUS-SYSTEM; PRONEURAL GENE; ACHAETE; EXTRAMACROCHAETAE; DIFFERENTIATION; EXPRESSION; RETINA	The initial steps of pattern formation in the developing Drosophila eye involve the coordination of cell cycles, changes in cell shape, and the specification of the R8 photoreceptor cell. These events begin several cell rows ahead of the morphogenetic furrow and are positively regulated by secreted signaling proteins and the proneural HLH transcription factor atonal (ate). Two HLH regulatory proteins that function to suppress neuronal development in other tissues, extra macrochaetae (emc) and hairy (h), are expressed ahead of the morphogenetic furrow. While neither h nor emc is required for photoreceptor cell determination, in emc-h-clones the morphogenetic furrow and differentiated eye field advance up to eight ommatidial rows ahead of adjacent wild-type tissue. This indicates that morphogenetic furrow progression and neuronal differentiation are negatively regulated by a combination of anteriorly expressed HLH regulatory proteins.	UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI 53706; UNIV WISCONSIN,BOCK LABS,MADISON,WI 53706; UNIV WISCONSIN,MCARDLE LAB,MADISON,WI 53706	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			, Nadean/HCH-9314-2022		NCI NIH HHS [CA-07175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA007175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BLAIR S, 1992, DEVELOPMENT, V119, P339; BODENSTEIN D, 1953, INSECT PHYSL, P822; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BOTAS J, 1982, EMBO J, V1, P307, DOI 10.1002/j.1460-2075.1982.tb01165.x; BROWN NL, 1991, DEVELOPMENT, V113, P1245; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CARROLL SB, 1989, GENE DEV, V3, P905, DOI 10.1101/gad.3.6.905; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; CUBAS P, 1992, EMBO J, V11, P3385, DOI 10.1002/j.1460-2075.1992.tb05417.x; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P246; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; ELLIS HM, 1994, MECH DEVELOP, V47, P65, DOI 10.1016/0925-4773(94)90096-5; GARCIAALONSO L, 1988, ROUX ARCH DEV BIOL, V197, P328; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JARMAN AP, 1994, NATURE, V369, P398, DOI 10.1038/369398a0; LEBOVITZ RM, 1986, DEV BIOL, V117, P663, DOI 10.1016/0012-1606(86)90335-0; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; NOWEL MS, 1980, J EMBRYOL EXP MORPH, V60, P329; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; ORENIC TV, 1993, DEVELOPMENT, V118, P9; PADDOCK SW, 1993, BIOTECHNIQUES, V1, P442; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; SHELTON PMJ, 1974, J EMBRYOL EXP MORPH, V32, P337; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; WHITE RH, 1963, J EXP ZOOL, V148, P223; WOLFF T, 1991, DEVELOPMENT, V113, P841; Wolff Tanya, 1993, P1277; XU T, 1993, DEVELOPMENT, V117, P1223; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	43	121	122	1	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 24	1995	80	6					879	887		10.1016/0092-8674(95)90291-0	http://dx.doi.org/10.1016/0092-8674(95)90291-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697718	Bronze			2022-12-28	WOS:A1995QP61200007
J	BRADLEY, DJ; WARHURST, DC				BRADLEY, DJ; WARHURST, DC			FORTNIGHTLY REVIEW - MALARIA PROPHYLAXIS - GUIDELINES FOR TRAVELERS FROM BRITAIN	BRITISH MEDICAL JOURNAL			English	Article											BRADLEY, DJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,PUBL HLTH LAB SERV,MALARIA REFERENCE LAB,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		warhurst, david c/C-3428-2013					BRADLEY D, 1993, BRIT MED J, V306, P1247, DOI 10.1136/bmj.306.6887.1247	1	60	60	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					709	714		10.1136/bmj.310.6981.709	http://dx.doi.org/10.1136/bmj.310.6981.709			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711540	Green Published			2022-12-28	WOS:A1995QN46100023
J	SHAW, AD; SJOLIN, SU; MCQUEEN, MM				SHAW, AD; SJOLIN, SU; MCQUEEN, MM			LESSON OF THE WEEK - CRUSH SYNDROME FOLLOWING UNCONSCIOUSNESS - NEED FOR URGENT ORTHOPEDIC REFERRAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE-RENAL-FAILURE; TRAUMATIC RHABDOMYOLYSIS; LIMB COMPRESSION		ROYAL INFIRM, ORTHOPAED TRAUMA UNIT, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND	Royal Infirmary of Edinburgh								BETTER OS, 1990, NEW ENGL J MED, V322, P825; Bywaters EGL, 1941, BRIT MED J, V1941, P427, DOI 10.1136/bmj.1.4185.427; HEPPENSTALL RB, 1988, CLIN ORTHOP RELAT R, V226, P138; KIKTA MJ, 1987, ARCH SURG-CHICAGO, V122, P1078; MATSEN FA, 1975, CLIN ORTHOP RELAT R, P8, DOI 10.1097/00003086-197511000-00003; MUBARAK S, 1975, CLIN ORTHOP RELAT R, P81, DOI 10.1097/00003086-197511000-00012; OWEN CA, 1979, NEW ENGL J MED, V300, P1169, DOI 10.1056/NEJM197905243002101; RON D, 1984, ARCH INTERN MED, V144, P277, DOI 10.1001/archinte.144.2.277; RORABECK CH, 1981, J TRAUMA, V21, P446; [No title captured]	10	32	33	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	1994	309	6958					857	859		10.1136/bmj.309.6958.857	http://dx.doi.org/10.1136/bmj.309.6958.857			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7695702	Green Published			2022-12-28	WOS:A1994PK50100028
J	ROSBASH, M; SINGER, RH				ROSBASH, M; SINGER, RH			RNA TRAVEL - TRACKS FROM DNA TO CYTOPLASM	CELL			English	Review							PRE-MESSENGER-RNA; NASCENT TRANSCRIPTS; NUCLEAR-RNA; CELL-CYCLE; LOCALIZATION; SITES		UNIV MASSACHUSETTS,DEPT CELL BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst	ROSBASH, M (corresponding author), BRANDEIS UNIV,DEPT BIOL,HOWARD HUGHES MED INST,WALTHAM,MA 02254, USA.							BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; ELLIOTT DJ, 1992, EMBO J, V11, P3731, DOI 10.1002/j.1460-2075.1992.tb05458.x; FAKAN S, 1976, EXP CELL RES, V99, P155, DOI 10.1016/0014-4827(76)90690-X; FAKAN S, 1978, EXP CELL RES, V113, P327, DOI 10.1016/0014-4827(78)90373-7; GALL JG, 1991, SCIENCE, V252, P1499, DOI 10.1126/science.1828621; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEMAIRE MF, 1990, MOL CELL BIOL, V10, P6059, DOI 10.1128/MCB.10.11.6059; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; PENMAN S, 1970, P NATL ACAD SCI USA, V67, P1878, DOI 10.1073/pnas.67.4.1878; PRYOR KN, 1992, ANNU REV BIOCHEM, V61, P471; ROSBASH M, 1972, J MOL BIOL, V65, P413, DOI 10.1016/0022-2836(72)90198-2; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; SERAPHIN B, 1989, CELL, V59, P319; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; ZACHAR Z, 1993, J CELL BIOL, V121, P729, DOI 10.1083/jcb.121.4.729	25	75	75	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 5	1993	75	3					399	401		10.1016/0092-8674(93)90373-X	http://dx.doi.org/10.1016/0092-8674(93)90373-X			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MF830	7693353				2022-12-28	WOS:A1993MF83000001
J	TABCHARANI, JA; ROMMENS, JM; HOU, YX; CHANG, XB; TSUI, LC; RIORDAN, JR; HANRAHAN, JW				TABCHARANI, JA; ROMMENS, JM; HOU, YX; CHANG, XB; TSUI, LC; RIORDAN, JR; HANRAHAN, JW			MULTIION PORE BEHAVIOR IN THE CFTR CHLORIDE CHANNEL	NATURE			English	Article							CYSTIC-FIBROSIS GENE; CALCIUM CHANNELS; CONDUCTANCE; CELLS; SELECTIVITY; MUTAGENESIS; EXPRESSION; INVITRO	CYSTIC fibrosis transmembrane conductance regulator (CFTR) is a non-rectifying, low-conductance channel1,2 regulated by ATP3 and phosphorylation, which mediates apical chloride conductance in secretory epithelia5,6 and malfunctions in cystic fibrosis (CF)7,8. Mutations at Lys 335 and Arg 347 in the sixth predicted transmembrane helix of CFTR alter its halide selectivity in whole-cell studies9 and its single channel conductance10, but the physical basis of these alterations is unknown and permeation in CFTR is poorly understood. Here we present evidence that wild-type CFTR can contain more than one anion simultaneously. The conductance of CFTR passes through a minimum when channels are bathed in mixtures of two permeant anions. This anomalous mole fraction effect can be abolished by replacing Arg 347 with an aspartate and can be toggled on or off by varying the pH after the same residue is replaced with a histidine. Thus the CFTR channel should provide a convenient model in which to study multi-ion pore behaviour and conduction. The loss of multiple occupancy may explain how naturally occurring CF mutations at this site cause disease.	MCGILL UNIV,DEPT PHYSIOL,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM & CLIN BIOCHEM,TORONTO M5S 1A1,ONTARIO,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA	McGill University; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Hanrahan, John/AGG-1926-2022; Tsui, Lap-chee/A-1081-2010	Hanrahan, John/0000-0001-9080-2039; 				ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; AUDREZET MP, 1993, HUM MOL GENET, V2, P51, DOI 10.1093/hmg/2.1.51; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CHANG XB, 1993, J BIOL CHEM, V268, P11304; Cremonesi Laura, 1992, Human Mutation, V1, P314, DOI 10.1002/humu.1380010409; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hille B., 1992, IONIC CHANNELS EXCIT; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1989, J MEMBRANE BIOL, V112, P109, DOI 10.1007/BF01871272; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687	21	209	209	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 4	1993	366	6450					79	82		10.1038/366079a0	http://dx.doi.org/10.1038/366079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF007	7694154				2022-12-28	WOS:A1993MF00700059
J	MURPHY, JG; GERSH, BJ; MAIR, DD; FUSTER, V; MCGOON, MD; ILSTRUP, DM; MCGOON, DC; KIRKLIN, JW; DANIELSON, GK				MURPHY, JG; GERSH, BJ; MAIR, DD; FUSTER, V; MCGOON, MD; ILSTRUP, DM; MCGOON, DC; KIRKLIN, JW; DANIELSON, GK			LONG-TERM OUTCOME IN PATIENTS UNDERGOING SURGICAL REPAIR OF TETRALOGY OF FALLOT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN-DEATH; FOLLOW-UP; VENTRICULAR ARRHYTHMIAS; SURVIVAL; AGE	Background. Although corrective surgery for tetralogy of Fallot has been available for more than 30 years, the occurrence of late sudden death in patients in whom surgery was apparently successful remains worrisome. Methods. We studied long-term survival among 163 patients who survived 30 days after complete repair of tetralogy of Fallot, examining follow-up hospital records and death certificates when relevant. Results. The overall 32-year actuarial survival rate among all patients who survived surgery was 86 percent, as compared with an expected rate of 96 percent in a control population matched for age and sex (P<0.01). Thirty-year actuarial survival rates were calculated for the patient subgroups. The survival rates among patients less than 5 years old, 5 to 7 years old, and 8 to 11 years old were 90, 93, and 91 percent, respectively - slightly less than the expected rates (P<0.001, P = 0.06, and P = 0.02). Among patients 12 years old or older at the time of surgery, the survival rate was 76 percent, as compared with an expected rate of 93 percent (P<0.001). The performance of a palliative Blalock-Taussig shunt procedure before repair, unlike the performance of a Waterston or Potts shunt procedure, was not associated with reduced long-term survival, nor was the need for a trans-annular patch at the time of surgery. Independent predictors of long-term survival were older age at operation (P = 0.02) and a higher ratio of right ventricular to left ventricular systolic pressure after surgery (P = 0.008). Late sudden death from cardiac causes occurred in 10 patients during the 32-year period. Conclusions. Among patients with surgically repaired tetralogy of Fallot, the rate of long-term survival after the postoperative period is excellent but remains lower than that in the general population. The risk of late sudden death is small.	MAYO CLIN & MAYO FDN, PEDIAT CARDIOL SECT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT BIOSTAT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DIV THORAC & CARDIOVASC SURG, ROCHESTER, MN 55905 USA; MASSACHUSETTS GEN HOSP, DIV CARDIOL, BOSTON, MA 02114 USA; UNIV ALABAMA, MED CTR, DEPT SURG, BIRMINGHAM, AL 35233 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Harvard University; Massachusetts General Hospital; University of Alabama System; University of Alabama Birmingham	MURPHY, JG (corresponding author), MAYO CLIN & MAYO FDN, DIV CARDIOVASC DIS & INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA.		Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986				AZAR H, 1969, ARCH SURG-CHICAGO, V99, P281; BERGSTRALH EJ, 1988, TECHNICAL REPORT SER, V37; COLE RB, 1971, CIRCULATION, V43, P263, DOI 10.1161/01.CIR.43.2.263; COX DR, 1972, J R STAT SOC B, V34, P187; DEANFIELD JE, 1991, INT J CARDIOL, V30, P143, DOI 10.1016/0167-5273(91)90088-7; DEANFIELD JE, 1984, BRIT HEART J, V52, P77; DEANFIELD JE, 1986, PEDIATR CARDIOL, P467; FUSTER V, 1980, AM J CARDIOL, V46, P635, DOI 10.1016/0002-9149(80)90514-7; GARSON A, 1980, AM J CARDIOL, V46, P1006, DOI 10.1016/0002-9149(80)90359-8; GARSON A, 1985, J AM COLL CARDIOL, V6, P221, DOI 10.1016/S0735-1097(85)80279-5; GARSON A, 1987, ADULT CONGENITAL HEA, P493; GILLETTE PC, 1977, CIRCULATION, V56, P566, DOI 10.1161/01.CIR.56.4.566; HARRINGTON DP, 1982, BIOMETRIKA, V69, P553, DOI 10.2307/2335991; HORNEFFER PJ, 1990, ANN THORAC SURG, V50, P179, DOI 10.1016/0003-4975(90)90728-O; HU DCK, 1985, J AM COLL CARDIOL, V5, P40, DOI 10.1016/S0735-1097(85)80083-8; JAMES FW, 1975, CIRCULATION, V52, P691, DOI 10.1161/01.CIR.52.4.691; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATZ NM, 1982, CIRCULATION, V65, P403, DOI 10.1161/01.CIR.65.2.403; KIRKLIN JK, 1989, ANN THORAC SURG, V48, P783, DOI 10.1016/0003-4975(89)90671-1; KIRKLIN JW, 1955, P STAFF M MAYO CLIN, V30, P201; KLINNER W, 1984, THORAC CARDIOV SURG, V32, P244, DOI 10.1055/s-2007-1023394; LILLEHEI CW, 1986, ANN SURG, V204, P490, DOI 10.1097/00000658-198610000-00017; QUATTLEBAUM TG, 1976, CIRCULATION, V54, P289, DOI 10.1161/01.CIR.54.2.289; SHEN WK, 1990, CIRCULATION, V81, P128, DOI 10.1161/01.CIR.81.1.128; VAKSMANN G, 1990, AM J CARDIOL, V66, P346, DOI 10.1016/0002-9149(90)90847-T; ZHAO HX, 1985, J THORAC CARDIOV SUR, V89, P204	26	670	701	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					593	599		10.1056/NEJM199308263290901	http://dx.doi.org/10.1056/NEJM199308263290901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU217	7688102				2022-12-28	WOS:A1993LU21700001
J	WYNICK, D; HAMMOND, PJ; AKINSANYA, KO; BLOOM, SR				WYNICK, D; HAMMOND, PJ; AKINSANYA, KO; BLOOM, SR			GALANIN REGULATES BASAL AND ESTROGEN-STIMULATED LACTOTROPH FUNCTION	NATURE			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; RAT PITUITARY-CELLS; THYROTROPIN-RELEASING-HORMONE; ANTERIOR-PITUITARY; PROLACTIN SECRETION; POSSIBLE INVOLVEMENT; ESTROGEN; IMMUNOREACTIVITY; POLYPEPTIDE; TUMOR	OESTROGEN, an essential physiological regulator of reproductive function1, controls lactotroph proliferation and prolactin release2. The neuropeptide galanin co-localizes to the lactotroph3, but its physiological function is largely unknown. Pituitary galanin expression is extremely sensitive to the oestrogen status of the animal. A marked elevation occurs during pregnancy and lactation 4, and exogenous 17beta-oestradiol can cause a 4,000-fold increase in messenger RNA levels5. Here we report that galanin is secreted by a minority of lactotrophs and is essential for the regulation of basal and vasoactive-intestinal-polypeptide-stimulated prolactin release. Hyperoestrogenization increases the number of galanin-secreting cells and the resulting increase in basal prolactin release is completely abolished by treatment with galanin antiserum. Galanin is a potent lactotroph growth factor and galanin-immunoneutralization completely inhibits the previously reported6-8 mitogenic effects of oestrogen on the lactotroph. These findings represent direct evidence for paracrine regulation of lactotroph function and demonstrate that the effect of oestrogen on lactotroph proliferation and prolactin release are mediated by locally secreted galanin.	HAMMERSMITH HOSP, DEPT MED, DUCANE RD, LONDON W12 0NN, ENGLAND	Imperial College London								AIZAWA T, 1985, ENDOCRINOLOGY, V116, P909, DOI 10.1210/endo-116-3-909; BAUER FE, 1986, GASTROENTEROLOGY, V91, P877, DOI 10.1016/0016-5085(86)90689-X; BJORO T, 1987, MOL CELL ENDOCRINOL, V49, P119, DOI 10.1016/0303-7207(87)90205-X; BJORO T, 1990, BIOSCIENCE REP, V10, P189, DOI 10.1007/BF01116578; CARRILLO AJ, 1992, ENDOCRINOLOGY, V131, P964, DOI 10.1210/en.131.2.964; DENEF C, 1989, METHOD ENZYMOL, V168, P47; FRANKS S, 1983, CLIN SCI, V65, P457, DOI 10.1042/cs0650457; GABRIEL SM, 1990, NEUROENDOCRINOLOGY, V51, P168, DOI 10.1159/000125333; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; Inagaki H, 1989, No To Shinkei, V41, P593; KAPLAN LM, 1988, P NATL ACAD SCI USA, V85, P7408, DOI 10.1073/pnas.85.19.7408; KENDALL ME, 1987, ENDOCRINOLOGY, V121, P2260, DOI 10.1210/endo-121-6-2260; Knobil E, 1980, Recent Prog Horm Res, V36, P53; KOSHIYAMA H, 1987, NEUROSCI LETT, V75, P49, DOI 10.1016/0304-3940(87)90073-5; KROWN KA, 1992, ENDOCRINOLOGY, V131, P595, DOI 10.1210/en.131.2.595; LAM KSL, 1989, ENDOCRINOLOGY, V124, P1077, DOI 10.1210/endo-124-2-1077; MELANDER T, 1987, ACTA PHYSIOL SCAND, V131, P25, DOI 10.1111/j.1748-1716.1987.tb08201.x; MOREL G, 1982, NEUROENDOCRINOLOGY, V34, P85, DOI 10.1159/000123282; OHALLORAN DJ, 1990, ENDOCRINOLOGY, V127, P467, DOI 10.1210/endo-127-1-467; PHELPS C, 1983, NEUROENDOCRINOLOGY, V37, P23, DOI 10.1159/000123511; REYMOND MJ, 1984, ACTA ENDOCRINOL-COP, V106, P459, DOI 10.1530/acta.0.1060459; ROTSZTEJN WH, 1981, P NATL ACAD SCI-BIOL, V78, P7584, DOI 10.1073/pnas.78.12.7584; SHIMATSU A, 1983, NEUROSCI LETT, V43, P259, DOI 10.1016/0304-3940(83)90198-2; STEEL JH, 1989, HISTOCHEMISTRY, V93, P183, DOI 10.1007/BF00315973; TATAR P, 1991, EXP CLIN ENDOCRINOL, V97, P29, DOI 10.1055/s-0029-1211034; TROUILLAS J, 1990, CANCER RES, V50, P4081; VRONTAKIS ME, 1987, J BIOL CHEM, V262, P16755; WYNICK D, 1993, P NATL ACAD SCI USA, V90, P4231, DOI 10.1073/pnas.90.9.4231; WYNICK D, 1990, J ENDOCRINOL, V128, P269	29	122	123	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1993	364	6437					529	532		10.1038/364529a0	http://dx.doi.org/10.1038/364529a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	7687748				2022-12-28	WOS:A1993LQ66700055
J	RESSLER, KJ; SULLIVAN, SL; BUCK, LB				RESSLER, KJ; SULLIVAN, SL; BUCK, LB			A ZONAL ORGANIZATION OF ODORANT RECEPTOR GENE-EXPRESSION IN THE OLFACTORY EPITHELIUM	CELL			English	Article							2-DEOXYGLUCOSE METHOD; BULB; RAT; PROJECTIONS; PATTERNS; NEURONS; NERVES; MOUSE; MODEL; DIFFERENTIATION	The mechanisms by which mammals discriminate a vast array of diverse odors are poorly understood. To gain insight into the organizational strategies underlying this discriminatory capacity, we have examined the spatial distribution of odorant receptor RNAs in the mouse olfactory epithelium. We have observed topographically distinct patterns of receptor RNAs suggesting that the nasal cavity is divided into a series of expression zones. The zones exhibit bilateral symmetry in the two nasal cavities and are organized along the dorsal-ventral and medial-lateral axes. Within each zone, a neuron may select a gene for expression from a zonal gene set via a stochastic mechanism. The observed zonal patterning may serve as an initial organizing step in olfactory sensory information coding.			RESSLER, KJ (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115, USA.		Ressler, Kerry J/N-8741-2018	Ressler, Kerry J/0000-0002-5158-1103	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001662] Funding Source: NIH RePORTER; NIDCD NIH HHS [1-R01-DC01662-01] Funding Source: Medline; NIGMS NIH HHS [2-T32GM07753-14, T32 GM007753] Funding Source: Medline; NINDS NIH HHS [5T32NS07009-18] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS DR, 1972, J MORPHOL, V137, P161, DOI 10.1002/jmor.1051370204; ADRIAN ED, 1950, BRIT MED BULL, V6, P330, DOI 10.1093/oxfordjournals.bmb.a073625; ADRIAN ED, 1956, J LARYNGOL OTOL, V70, P1; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; AMOORE JE, 1964, SCI AM, V210, P42, DOI 10.1038/scientificamerican0264-42; [Anonymous], [No title captured]; ASTIC L, 1983, DEV BRAIN RES, V10, P257, DOI 10.1016/0165-3806(83)90142-6; ASTIC L, 1987, BRAIN RES, V424, P144, DOI 10.1016/0006-8993(87)91204-2; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Buck L B, 1992, Curr Opin Neurobiol, V2, P282, DOI 10.1016/0959-4388(92)90116-3; Buck LB, 1992, CURR OPIN GENET DEV, V2, P467, DOI 10.1016/S0959-437X(05)80159-5; CALOF AL, 1989, NEURON, V3, P115, DOI 10.1016/0896-6273(89)90120-7; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CLANCY AN, 1985, CHEM SENSES, V10, P399; CLARK WEL, 1951, J NEUROL NEUROSUR PS, V14, P1, DOI 10.1136/jnnp.14.1.1; COOPERSMITH R, 1986, DEV BRAIN RES, V27, P191, DOI 10.1016/0165-3806(86)90245-2; COSTANZO RM, 1978, BRAIN RES, V139, P327, DOI 10.1016/0006-8993(78)90932-0; CUSCHIERI A, 1975, J ANAT, V119, P277; CUSCHIERI A, 1975, J ANAT, V119, P471; DANCIGER E, 1989, P NATL ACAD SCI USA, V86, P8565, DOI 10.1073/pnas.86.21.8565; DASTON MM, 1990, BRAIN RES, V537, P69, DOI 10.1016/0006-8993(90)90340-H; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EDWARDS DA, 1988, EXPERIENTIA, V44, P208, DOI 10.1007/BF01941707; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FREEMAN WJ, 1987, BIOL CYBERN, V56, P139, DOI 10.1007/BF00317988; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; GREER CA, 1981, BRAIN RES, V217, P279, DOI 10.1016/0006-8993(81)90004-4; HABERLY LB, 1989, TRENDS NEUROSCI, V12, P258, DOI 10.1016/0166-2236(89)90025-8; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JOURDAN F, 1980, BRAIN RES, V188, P139, DOI 10.1016/0006-8993(80)90563-6; KAUER JS, 1991, TRENDS NEUROSCI, V14, P79, DOI 10.1016/0166-2236(91)90025-P; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LAND LJ, 1973, BRAIN RES, V63, P153, DOI 10.1016/0006-8993(73)90084-X; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MACKAYSIM A, 1991, EUR J NEUROSCI, V3, P209, DOI 10.1111/j.1460-9568.1991.tb00081.x; MACKAYSIM A, 1991, J NEUROSCI, V11, P979; MACKAYSIM A, 1982, J NEUROPHYSIOL, V48, P584, DOI 10.1152/jn.1982.48.2.584; MOZELL MM, 1970, J GEN PHYSIOL, V56, P46, DOI 10.1085/jgp.56.1.46; NEF P, 1992, P NATL ACAD SCI USA, V89, P8948, DOI 10.1073/pnas.89.19.8948; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; Sambrook J, 1989, MOL CLONING LABORATO; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SAUCIER D, 1986, BRAIN RES BULL, V16, P455, DOI 10.1016/0361-9230(86)90173-5; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SCHOTZINGER RJ, 1988, NATURE, V335, P637, DOI 10.1038/335637a0; SCHWARTING GA, 1991, BRAIN RES, V547, P239, DOI 10.1016/0006-8993(91)90967-Z; SCHWOB JE, 1986, J NEUROSCI, V6, P3393; SHARP FR, 1977, J NEUROPHYSIOL, V40, P800, DOI 10.1152/jn.1977.40.4.800; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; Shepherd G.M., 2004, SYNAPTIC ORG BRAIN, V3rd Edn, P133; SKEEN LC, 1977, BRAIN RES, V124, P147, DOI 10.1016/0006-8993(77)90871-X; STEWART WB, 1979, J COMP NEUROL, V185, P715, DOI 10.1002/cne.901850407; STEWART WB, 1987, BRAIN RES, V411, P248, DOI 10.1016/0006-8993(87)91076-6; STROTMANN J, 1992, NEUROREPORT, V3, P1053, DOI 10.1097/00001756-199212000-00005; THOMMESEN G, 1977, ACTA PHYSIOL SCAND, V99, P270, DOI 10.1111/j.1748-1716.1977.tb10380.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0	61	849	868	0	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 7	1993	73	3					597	609		10.1016/0092-8674(93)90145-G	http://dx.doi.org/10.1016/0092-8674(93)90145-G			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	7683976				2022-12-28	WOS:A1993LA74300019
J	NABEL, EG; YANG, ZY; PLAUTZ, G; FOROUGH, R; ZHAN, X; HAUDENSCHILD, CC; MACIAG, T; NABEL, GJ				NABEL, EG; YANG, ZY; PLAUTZ, G; FOROUGH, R; ZHAN, X; HAUDENSCHILD, CC; MACIAG, T; NABEL, GJ			RECOMBINANT FIBROBLAST GROWTH FACTOR-I PROMOTES INTIMAL HYPERPLASIA AND ANGIOGENESIS IN ARTERIES INVIVO	NATURE			English	Article							GENE-EXPRESSION INVIVO; ENDOTHELIAL-CELLS; PROLIFERATION; SEQUENCE; CORONARY; VESSELS; INJURY; WALL	THE prototype members of the heparin-binding fibroblast growth factor (FGF) family1-6, acidic FGF (FGF-1) and basic FGF (FGF-2), are among the growth factors that act directly on vascular cells to induce endothelial cell growth and angiogenesis. In vivo, the role of the FGF prototypes in vascular pathology has been difficult to determine. We report here the introduction, by direct gene transfer into porcine arteries, of a eukaryotic expression vector encoding a secreted form of FGF-1. This somatic transgenic model defines gene function in the arterial wall in vivo. FGF-1 expression induced intimal thickening in porcine arteries 21 days after gene transfer, in contrast to control arteries transduced with an Escherichia coli beta-galactosidase gene. Where there was substantial intimal hyperplasia, neocapillary formation was detected in the expanded intima. These findings suggest that FGF-1 induces intimal hyperplasia in the arterial wall in vivo and, through its ability to stimulate angiogenesis in the neointima, FGF-1 could stimulate neovascularization of atherosclerotic plaques. Potentially, gene transfer of FGF-1 could also be used as a genetic intervention to improve blood flow to ischaemic tissues in selected clinical settings.	UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT BIOL CHEM,ANN ARBOR,MI 48109; AMER RED CROSS,HOLLAND LAB,DEPT MOLEC BIOL,ROCKVILLE,MD 20855; AMER RED CROSS,HOLLAND LAB,DEPT EXPTL PATHOL,ROCKVILLE,MD 20855	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; American Red Cross; American Red Cross	NABEL, EG (corresponding author), UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,DEPT INTERNAL MED,ANN ARBOR,MI 48109, USA.		Christian, Haudenschild C/D-1602-2009					ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAPMAN GD, 1992, CIRC RES, V71, P27, DOI 10.1161/01.RES.71.1.27; CLOWES AW, 1986, LAB INVEST, V54, P295; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; GAJDUSEK CM, 1989, J CELL PHYSIOL, V139, P570, DOI 10.1002/jcp.1041390317; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; LECLERC G, 1992, J CLIN INVEST, V90, P936, DOI 10.1172/JCI115970; LIM CS, 1991, CIRCULATION, V83, P2007, DOI 10.1161/01.CIR.83.6.2007; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; NABEL EG, 1992, P NATL ACAD SCI USA, V89, P5157, DOI 10.1073/pnas.89.11.5157; PLAUTZ G, 1991, CIRCULATION, V83, P578, DOI 10.1161/01.CIR.83.2.578; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; YANAGISAWAMIWA A, 1992, SCIENCE, V257, P1401, DOI 10.1126/science.1382313	26	335	369	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 29	1993	362	6423					844	846		10.1038/362844a0	http://dx.doi.org/10.1038/362844a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KZ563	7683112	Green Published			2022-12-28	WOS:A1993KZ56300058
J	GILLMAN, MW; CUPPLES, LA; GAGNON, D; POSNER, BM; ELLISON, RC; CASTELLI, WP; WOLF, PA				GILLMAN, MW; CUPPLES, LA; GAGNON, D; POSNER, BM; ELLISON, RC; CASTELLI, WP; WOLF, PA			PROTECTIVE EFFECT OF FRUITS AND VEGETABLES ON DEVELOPMENT OF STROKE IN MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; SPONTANEOUSLY HYPERTENSIVE RATS; BLOOD-PRESSURE; PLASMA HOMOCYST(E)INE; JAPANESE MEN; CARDIOVASCULAR MORTALITY; RISK-FACTORS; DIETARY; CONSUMPTION; ALCOHOL	Objective.-To examine the effect of fruit and vegetable intake on risk of stroke among middle-aged men over 20 years of follow-up. Design.-Cohort. Setting.-The Framingham Study, a population-based longitudinal study. Participants.-All 832 men, aged 45 through 65 years, who were free of cardiovascular disease at baseline (1966 through 1969). Measurements and Data Analysis.-The diet of each subject was assessed at baseline by a single 24-hour recall. The estimated total number of servings per day of fruits and vegetables was the exposure variable for this analysis. Using Kaplan-Meier survival analysis, we examined age-adjusted cumulative incidence of stroke by quintile of servings per day. To adjust for multiple covariates, we used proportional hazards regression to calculate the relative risk (RR) of stroke for each increment of three servings per day. Main Outcome Measure.-Incidence of completed strokes and transient ischemic attacks. Results.-At baseline, the mean (+/-SD) number of fruit and vegetable servings per day was 5.1 (+/-2.8). During follow-up there were 97 incident strokes, including 73 completed strokes and 24 transient ischemic attacks. Age-adjusted risk of stroke decreased across increasing quintile of servings per day (log rank P for trend, .01). Age-adjusted RR for all stroke, including transient ischemic attack, was 0.78 (95% confidence interval [CI], 0.62 to 0.98) for each increase of three servings per day. For completed stroke the RR was 0.74 (95% CI, 0.57 to 0.96); for completed stroke of ischemic origin the RR was 0.76 (95% CI, 0.57 to 1.02); and for completed stroke of hemorrhagic origin, 0.49 (95% CI, 0.25 to 0.95). Adjustment for body mass index, cigarette smoking, glucose intolerance, physical activity, blood pressure, serum cholesterol, and intake of energy, ethanol, and fat did not materially change the results. Conclusion.Intake of fruits and vegetables may protect against development of stroke in men.	HARVARD UNIV,COMMUNITY HLTH PLAN,BOSTON,MA 02215; BOSTON UNIV,SCH PUBL HLTH,BOSTON,MA; BOSTON UNIV,SCH MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,EVANS DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02118; FRAMINGHAM HEART DIS EPIDEMIOL STUDY,FRAMINGHAM,MA	Harvard University; Boston University; Boston University; Boston University; Boston University; Framingham Heart Study	GILLMAN, MW (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,126 BROOKLINE AVE,SUITE 200,BOSTON,MA 02215, USA.			Ellison, Robert Curtis/0000-0002-0582-7467; Gagnon, David/0000-0002-6367-3179; Wolf, Philip/0000-0002-3628-301X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL048236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01 HC 38038, R29 HL 48236] Funding Source: Medline; NINDS NIH HHS [R01 NS 17950] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELL LL, 1952, J BIOL CHEM, V195, P357; ACHESON RM, 1983, LANCET, V1, P1191; ATKINS D, 1993, ANN INTERN MED, V119, P136, DOI 10.7326/0003-4819-119-2-199307150-00008; BENFANTE R, 1994, STROKE, V25, P814, DOI 10.1161/01.STR.25.4.814; BRATTSTROM L, 1992, NEUROL RES, V14, P81, DOI 10.1080/01616412.1992.11740017; COULL BM, 1990, STROKE, V21, P572, DOI 10.1161/01.STR.21.4.572; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; GARCIAPALMIERI MR, 1980, AM J CLIN NUTR, V33, P1818, DOI 10.1093/ajcn/33.8.1818; GENEST JJ, 1990, J AM COLL CARDIOL, V16, P1114, DOI 10.1016/0735-1097(90)90542-W; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GORDON T, 1981, CIRCULATION, V63, P500, DOI 10.1161/01.CIR.63.3.500; IKEDA K, 1987, J NUTR SCI VITAMINOL, V33, P31, DOI 10.3177/jnsv.33.31; KAGAN A, 1985, STROKE, V16, P390, DOI 10.1161/01.STR.16.3.390; KANNEL WB, 1987, AM HEART J, V113, P1489, DOI 10.1016/0002-8703(87)90666-1; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; Klag M J, 1993, Ann Epidemiol, V3, P571; KLATSKY AL, 1987, J AM COLL CARDIOL, V9, P78; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LEE CN, 1988, NEW ENGL J MED, V318, P995; MANN GV, 1962, AM J CLIN NUTR, V11, P200, DOI 10.1093/ajcn/11.3.200; MANSON JE, 1993, J AM COLL NUTR, V12, P426, DOI 10.1080/07315724.1993.10718332; MANSON JE, 1994, CIRCULATION, V89, P932; MANSON JE, 1993, CIRCULATION, V87, P678; MARMOT MG, 1992, LANCET, V339, P344, DOI 10.1016/0140-6736(92)91659-V; MCGEE D, 1985, INT J EPIDEMIOL, V14, P97, DOI 10.1093/ije/14.1.97; OMURA T, 1987, SOC SCI MED, V24, P401, DOI 10.1016/0277-9536(87)90212-7; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; POSNER BM, 1991, ARCH INTERN MED, V151, P1181, DOI 10.1001/archinte.151.6.1181; ROUSE IL, 1983, LANCET, V1, P5; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SACKS FM, 1988, AM J CLIN NUTR, V48, P795, DOI 10.1093/ajcn/48.3.795; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; SWAIN JF, 1990, NEW ENGL J MED, V322, P147, DOI 10.1056/NEJM199001183220302; SYME SL, 1975, AM J EPIDEMIOL, V102, P477, DOI 10.1093/oxfordjournals.aje.a112185; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; TILLOTSON JL, 1973, AM J CLIN NUTR, V26, P177, DOI 10.1093/ajcn/26.2.177; TOBIAN L, 1986, J HYPERTENS        S, V5, pS205; VERLANGIERI AJ, 1985, MED HYPOTHESES, V16, P7, DOI 10.1016/0306-9877(85)90035-0; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011; WOLF PA, 1986, NEW ENGL J MED, V315, P1087, DOI 10.1056/NEJM198610233151709; YAMORI Y, 1984, HYPERTENSION, V6, P49, DOI 10.1161/01.HYP.6.1.49; 1994, HEART STROKE FACTS 1; 1991, HLTH PEOPLE 2000 NAT; 1989, RECOMMENDED DIETARY	47	368	376	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1113	1117		10.1001/jama.273.14.1113	http://dx.doi.org/10.1001/jama.273.14.1113			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR059	7707599				2022-12-28	WOS:A1995QR05900030
J	STRYKER, J; COATES, TJ; DECARLO, P; HAYNESSANSTAD, K; SHRIVER, M; MAKADON, HJ				STRYKER, J; COATES, TJ; DECARLO, P; HAYNESSANSTAD, K; SHRIVER, M; MAKADON, HJ			PREVENTION OF HIV-INFECTION - LOOKING BACK, LOOKING AHEAD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIDS; BEHAVIORS; IMPACT	For some, the occurrence of as many as 40 000 new human immunodeficiency virus (HIV) infections in the United States each year is evidence that HIV education and prevention efforts have failed. To the contrary, more than a decade of experience with HIV has demonstrated that lasting changes in behavior needed to avoid infection can occur as a result of carefully tailored, targeted, credible, and persistent HIV risk-reduction efforts. Given experience in other health behavior change endeavors, no interventions are likely to reduce the incidence of HIV infection to zero; indeed, insisting on too high a standard for HIV risk-reduction programs may actually undermine their effectiveness. A number of social, cultural, and attitudinal barriers continue to thwart the implementation of promising HIV risk-reduction programs. The remote prospects for a successful prophylactic vaccine for HIV and the difficulty in finding effective drug treatments have underscored the importance of sustained attention to HIV prevention and education. A series of ''correlates of immunity'' are identified-precedents that must exist to establish effective HIV prevention programs. These include sound policies promoting HIV risk reduction; access to health and social services, condoms, needles, and syringes; interventions shown to motivate behavioral change; organizations capable of reaching those at risk; and development and diffusion of technologies to interrupt the spread of the virus.	MOBILIZAT AGAINST AIDS,SAN FRANCISCO,CA; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV GEN MED & PRIMARY CARE,BOSTON,MA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	STRYKER, J (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,CTR AIDS PREVENT STUDIES,74 NEW MONTGOMERY,SUITE 600,SAN FRANCISCO,CA 94105, USA.				NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; BAYER R, 1994, AM J PUBLIC HEALTH, V84, P895, DOI 10.2105/AJPH.84.6.895; BURRIS S, 1993, AIDS LAW TODAY NEW G; CATANIA JA, 1993, SCIENCE, V258, P1101; CATES W, 1992, NEW ENGL J MED, V327, P492, DOI 10.1056/NEJM199208133270711; CHOI KH, 1994, NEW ENGL J MED, V331, P406, DOI 10.1056/NEJM199408113310619; CHOI KH, 1994, AIDS, V8, P1371, DOI 10.1097/00002030-199410000-00003; COHEN J, 1993, SCIENCE, V259, P1112, DOI 10.1126/science.8438161; EKSTRAND ML, 1990, AM J PUBLIC HEALTH, V80, P973, DOI 10.2105/AJPH.80.8.973; FERREROS C, 1990, 6TH INT C AIDS SAN F; FIFE D, 1992, J ACQ IMMUN DEF SYND, V6, P1111; FISHBEIN M, 1993, J APPL SOC PSYCHOL, V23, P687, DOI 10.1111/j.1559-1816.1993.tb01110.x; GERBERT B, 1990, AM J PUBLIC HEALTH, V80, P467, DOI 10.2105/AJPH.80.4.467; Gorman M, 1989, Med Anthropol, V10, P159; HAHN RA, 1991, SOC SCI MED, V33, P1, DOI 10.1016/0277-9536(91)90444-H; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; JARLAIS DCD, 1992, ANN AM ACAD POLIT SS, V521, P42; KAMENGA M, 1991, AIDS, V5, P61, DOI 10.1097/00002030-199101000-00009; KAPLAN EH, 1989, EVALUATION REV, V13, P107, DOI 10.1177/0193841X8901300201; KEGELES SM, IN PRESS AM J PUBLIC; KELLY JA, 1993, AM PSYCHOL, V48, P1023, DOI 10.1037/0003-066X.48.10.1023; KIRBY D, 1994, PUBLIC HEALTH REP, V109, P339; LIFSON AR, 1994, LANCET, V343, P1306, DOI 10.1016/S0140-6736(94)92462-7; Lurie P, 1993, PUBLIC HLTH IMPACT N; MASCOLA JR, 1994, JAMA-J AM MED ASSOC, V272, P488, DOI 10.1001/jama.272.6.488; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MERSON M, 1994, 10TH INT C AIDS YOK; MOATTI JP, 1992, HEALTH POLICY, V21, P233, DOI 10.1016/0168-8510(92)90021-3; Perrow Charles, 1990, AIDS DISASTER FAILUR; PHILIPSON TJ, 1994, ISSUES SCI TECHNOL, V10, P33; RABIN SA, 1994, PUBLIC HLTH REP, V195, P42; RAMAH M, 1992, IDS PREVENTION ED WO; ROSENBERG PS, 1994, NEW ENGL J MED, V330, P789, DOI 10.1056/NEJM199403173301114; SHRIVER M, 1994, 5 CORRELATES IMMUNIT; STALL R, 1994, BRIT MED J, V309, P685, DOI 10.1136/bmj.309.6956.685; STEVENSON HC, 1994, AIDS EDUC PREV, V6, P126; STRYKER J, 1994, AM J PUBLIC HEALTH, V84, P1901, DOI 10.2105/AJPH.84.12.1901; WASSERFALLEN F, 1993, 9TH INT C AIDS BERL; WIEBEL W, 1993, 9 INT C AIDS BERL; 1990, MMWR-MORBID MORTAL W, V39, P1; 1995, MMWR-MORBID MORTAL W, V44, P64; 1994, NEW HLTH STRATEGY AI; 1993, MMWR-MORBID MORTAL W, V41, P1; 1992, EFFECTIVE APPROACHES; 1993, BEHAVIORAL SOCIAL SC; 1994, HIV PREVENTIVE VACCI; 1994, MMWR-MORBID MORTAL W, V42, P988; 1994, EFFECTIVENESS AIDS O; 1993, CHALLENGE HIV AID CO; 1992, HIV INCIDENCE PREVAL	50	54	54	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	1995	273	14					1143	1148		10.1001/jama.273.14.1143	http://dx.doi.org/10.1001/jama.273.14.1143			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QR059	7707604				2022-12-28	WOS:A1995QR05900035
J	EIDT, S; BAYERDORFFER, E; STOLTE, M				EIDT, S; BAYERDORFFER, E; STOLTE, M			TREAT THE INFECTION AND CURE THE CANCER	LANCET			English	Editorial Material							HELICOBACTER-PYLORI; LYMPHOID-TISSUE		UNIV MUNICH,DEPT MED 2,W-8000 MUNICH,GERMANY; CLIN BAYREUTH,INST PATHOL,BAYREUTH,GERMANY	University of Munich; Klinikum Bayreuth	EIDT, S (corresponding author), UNIV COLOGNE,INST PATHOL,W-5000 COLOGNE,GERMANY.							ALBRECHT S, 1991, J AM ACAD DERMATOL, V24, P621, DOI 10.1016/0190-9622(91)70095-J; BAYERDORFFER E, 1994, GASTROENTEROLOGY, V106, pA370; CALVERT R, 1995, LANCET, V345, P9; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; KAMEL OW, 1993, NEW ENGL J MED, V328, P1317, DOI 10.1056/NEJM199305063281806; LOGAN RPH, 1994, LANCET, V344, P1078, DOI 10.1016/S0140-6736(94)91729-9; OROURKE EA, 1994, J PATHOL, V173, P166; ROONEY CM, 1995, LANCET, V345, P26; STOLTE M, 1993, LANCET, V342, P568, DOI 10.1016/0140-6736(93)91404-A; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; Young L S, 1992, Semin Cancer Biol, V3, P273	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					874	875		10.1016/S0140-6736(95)90004-7	http://dx.doi.org/10.1016/S0140-6736(95)90004-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707806				2022-12-28	WOS:A1995QR06700004
J	GIDER, S; AWSCHALOM, DD; DOUGLAS, T; MANN, S; CHAPARALA, M				GIDER, S; AWSCHALOM, DD; DOUGLAS, T; MANN, S; CHAPARALA, M			CLASSICAL AND QUANTUM MAGNETIC PHENOMENA IN NATURAL AND ARTIFICIAL FERRITIN PROTEINS	SCIENCE			English	Article							MAMMALIAN FERRITIN; ANTIFERROMAGNETS; ABSORPTION; PARTICLES	Artificial ferritin has been synthesized with control of both the magnetic state (antiferromagnetic or ferrimagnetic) and the particle size over an order of magnitude in the number of iron atoms. The magnetic properties of the artificial ferritin were compared with those of natural horse spleen ferritin in a range of temperatures (20 millikelvin to 300 kelvin) and fields (1 nanotesla to 27 tesla). In the classical regime, the blocking temperature was found to correlate with the average particle size. A correlation was also observed in the quantum regime between the resonance frequency of macroscopic quantum tunneling of the Neel vector and the particle size. At high magnetic fields (to 27 tesla), a spin flop transition with a strong dependence on orientation was seen in the natural ferritin, providing evidence of antiferromagnetism in this system.	UNIV CALIF SANTA BARBARA,DEPT PHYS,SANTA BARBARA,CA 93106; UNIV BATH,SCH CHEM,BATH BA2 7AY,AVON,ENGLAND; NATL HIGH MAGNET FIELD LAB,TALLAHASSEE,FL 32306	University of California System; University of California Santa Barbara; University of Bath; State University System of Florida; Florida State University			Douglas, Trevor/F-2748-2011; Mann, Stephen/D-1332-2012; Douglas, Trevor/GRS-0012-2022	Mann, Stephen/0000-0003-3012-8964; Douglas, Trevor/0000-0002-7882-2704				AWSCHALOM DD, 1992, PHYS REV LETT, V68, P3092, DOI 10.1103/PhysRevLett.68.3092; AWSCHALOM DD, 1992, SCIENCE, V258, P414, DOI 10.1126/science.258.5081.414; AWSCHALOM DD, 1993, PHYS REV LETT, V71, P4276, DOI 10.1103/PhysRevLett.71.4276; BARBARA B, 1990, PHYS LETT A, V145, P205, DOI 10.1016/0375-9601(90)90682-E; BAUMINGER ER, 1989, HYPERFINE INTERACT, V50, P489, DOI 10.1007/BF02407681; BELL SH, 1984, BIOCHIM BIOPHYS ACTA, V787, P227, DOI 10.1016/0167-4838(84)90313-3; BLAISE A, 1973, INT C MAGNETISM, P280; BULTE JWM, 1994, INVEST RADIOL, V29, pS214, DOI 10.1097/00004424-199406001-00071; CERDAN S, 1989, MAGN RESON MED, V12, P151, DOI 10.1002/mrm.1910120202; CHANTRELL RW, 1991, IEEE T MAGN, V27, P3570, DOI 10.1109/20.102929; CHAPARALA M, 1992, AIP C P, V273; CHAPARALA M, 1992, SUPERCONDUCTIVITY IT, P407; CHARLES SW, 1990, J MAGN MAGN MATER, V85, P277, DOI 10.1016/0304-8853(90)90066-Y; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; FRANKEL RB, 1991, HYPERFINE INTERACT, V66, P71, DOI 10.1007/BF02395857; GIRARDET JL, 1970, J APPL PHYS, V41, P1002, DOI 10.1063/1.1658785; GITTLEMA.JI, 1974, PHYS REV B, V9, P3891, DOI 10.1103/PhysRevB.9.3891; HARRISON PM, 1973, INORGANIC BIOCHEMIST, V1, P253; HUNT C, 1994, HYPERFINE INTERACT, V91, P821, DOI 10.1007/BF02064613; KEFFER F, 1973, PHYS REV LETT, V31, P1061, DOI 10.1103/PhysRevLett.31.1061; KEFFER F, 1966, HDB PHYSIK FERROMAGN, V18, P134; KRIVE IV, 1990, J PHYS-CONDENS MAT, V2, P9457, DOI 10.1088/0953-8984/2/47/020; MACARA IG, 1972, BIOCHEM J, V126, P151, DOI 10.1042/bj1260151; MACKLE P, 1993, J AM CHEM SOC, V115, P8471, DOI 10.1021/ja00071a076; MANN S, 1987, J MOL BIOL, V198, P405, DOI 10.1016/0022-2836(87)90290-7; MELDRUM FC, 1991, NATURE, V349, P684, DOI 10.1038/349684a0; MELDRUM FC, 1992, SCIENCE, V257, P522, DOI 10.1126/science.1636086; MILLS DL, 1968, PHYS REV LETT, V20, P18, DOI 10.1103/PhysRevLett.20.18; PANKHURST QA, 1993, J PHYS-CONDENS MAT, V5, P8487, DOI 10.1088/0953-8984/5/45/002; SERVICE RF, 1994, SCIENCE, V264, P510, DOI 10.1126/science.264.5158.510; STPIERRE TG, 1989, BIOMINERALIZATION CH, P295; TEJADA J, 1994, Z PHYS CONDENS MATTE, V6, P263; TREFFRY A, 1978, BIOCHEM J, V171, P313, DOI 10.1042/bj1710313	33	221	223	1	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 7	1995	268	5207					77	80		10.1126/science.7701343	http://dx.doi.org/10.1126/science.7701343			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR454	7701343				2022-12-28	WOS:A1995QR45400027
J	HE, ZG; HENRICKSEN, LA; WOLD, MS; INGLES, CJ				HE, ZG; HENRICKSEN, LA; WOLD, MS; INGLES, CJ			RPA INVOLVEMENT IN THE DAMAGE-RECOGNITION AND INCISION STEPS OF NUCLEOTIDE EXCISION-REPAIR	NATURE			English	Article							REPLICATION PROTEIN-A; DNA BINDING-PROTEIN; SIMIAN VIRUS-40 DNA; PIGMENTOSUM GROUP-G; XERODERMA-PIGMENTOSUM; INVITRO; COMPLEMENTATION; SUBUNIT; VP16; P53	HUMAN replication protein (RPA) functions in DNA replication(1-4), homologous recombination(5) and nucleotide excision repair(6). This multisubunit single-stranded DNA-binding protein(1,2) may be required to make unique protein-protein contacts because heterologous single-stranded binding proteins cannot substitute for RPA in these diverse DNA transactions(5-7). We report here that, by using affinity chromatography and immunoprecipitation, we found that human RPA bound specifically and directly to two excision repair proteins, the xeroderma pigmentosum damage-recognition protein XPA (refs 8, 9) and the endonuclease XPG (refs 10-13). Although it had been suggested that RPA might function before the DNA synthesis repair stage(14.15), our finding that a complex of RPA and XPA showed a striking cooperativity in binding to DNA lesions indicates that RPA may function at the very earliest stage of excision repair. In addition, by binding XPG, RPA may target this endonuclease to damaged DNA.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5G 1L6,CANADA; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Toronto; University of Toronto; University of Iowa			Wold, Marc/F-5806-2010	Wold, Marc/0000-0002-4580-1624				ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CLUGSTON CK, 1992, CANCER RES, V52, P6375; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; ODONOVAN A, 1993, NATURE, V363, P185, DOI 10.1038/363185a0; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	30	370	383	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 6	1995	374	6522					566	569		10.1038/374566a0	http://dx.doi.org/10.1038/374566a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QR069	7700386				2022-12-28	WOS:A1995QR06900059
J	BAILEY, J				BAILEY, J			RETHINKING CONSULTANTS - TIME FOR CHANGE IN TRADITIONAL WORKING PRACTICES .2.	BRITISH MEDICAL JOURNAL			English	Article								Consultants in Britain are under pressure to change the way they organise their work. Many rely on formal, but unwritten, rules and a culture of ''learning by doing.'' Unlike their counterparts in Sweden, they are often not well integrated into the management systems of their hospitals. The result is wide differences in the NHS workloads of individual consultants and, for a minority, conflicts of interest with their private work. The training received by junior doctors varies because it is largely left to individual consultants. Clinical directorates should provide a more effective mechanism for consultants to influence trust policies and for consultants to implement these policies. Consultants must not only recognise the need for change but also seize the initiative.			BAILEY, J (corresponding author), AUDIT COMMISS,LONDON SW1P 2PN,ENGLAND.							CAMPLING EA, 1993, 1991 I NCEPOD REP; SCRIVENS E, 1988, SOC POLICY ADMIN, V22, P22, DOI 10.1111/j.1467-9515.1988.tb00288.x; 1995, DOCTORS TALE WORK HO; 1994, DOH EL9413 DEP HLTH; 1994, HOSPITAL MED DENTAL	5	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 25	1995	310	6982					788	790		10.1136/bmj.310.6982.788	http://dx.doi.org/10.1136/bmj.310.6982.788			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QP609	7711586	Green Published			2022-12-28	WOS:A1995QP60900025
J	BARTON, JS; TRIPP, JH; MCNINCH, AW				BARTON, JS; TRIPP, JH; MCNINCH, AW			NEONATAL VITAMIN-K PROPHYLAXIS IN THE BRITISH-ISLES - CURRENT PRACTICE AND TRENDS	BRITISH MEDICAL JOURNAL			English	Article							HEMORRHAGIC-DISEASE; NEWBORN				BARTON, JS (corresponding author), ROYAL DEVON & EXETER HOSP,DEPT CHILD HLTH,EXETER EX2 5DW,DEVON,ENGLAND.							CHAMBERLAIN R, 1975, BRIT BIRTHS 1970, V1; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; HANDEL J, 1991, BRIT MED J, V303, P1109, DOI 10.1136/bmj.303.6810.1109; MCNINCH AW, 1991, BRIT MED J, V303, P1105, DOI 10.1136/bmj.303.6810.1105; 1992, VITAMIN K PROPHYLAXI	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					632	633		10.1136/bmj.310.6980.632	http://dx.doi.org/10.1136/bmj.310.6980.632			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703751	Green Published			2022-12-28	WOS:A1995QL98400017
J	MAYADAS, TN; JOHNSON, RC; RAYBURN, H; HYNES, RO; WAGNER, DD				MAYADAS, TN; JOHNSON, RC; RAYBURN, H; HYNES, RO; WAGNER, DD			LEUKOCYTE ROLLING AND EXTRAVASATION ARE SEVERELY COMPROMISED IN P-SELECTIN-DEFICIENT MICE	CELL			English	Article							GRANULE MEMBRANE-PROTEIN; HUMAN-ENDOTHELIAL-CELLS; WEIBEL-PALADE BODIES; ACTIVATED PLATELETS; VONWILLEBRAND-FACTOR; ADHESION DEFICIENCY; MONOCLONAL-ANTIBODY; PLASMA-MEMBRANE; LUNG INJURY; STEM-CELLS	P selectin, expressed on surfaces of activated endothelial cells and platelets, is an adhesion receptor for leukocytes. We report that P selectin-deficient mice, generated by gene targeting in embryonic stem cells, exhibit a number of defects in leukocyte behavior, including elevated numbers of circulating neutrophils, virtually total absence of leukocyte rolling in mesenteric venules, and delayed recruitment of neutrophils to the peritoneal cavity upon experimentally induced inflammation. These results clearly demonstrate a role for P selectin in leukocyte interactions with the vessel wall and in the early steps of leukocyte recruitment at sites of inflammation. These mutant mice should prove useful in deciphering the contributions of P selectin in various inflammatory responses as well as in platelet functions.	TUFTS UNIV NEW ENGLAND MED CTR,BOSTON,MA 02111; TUFTS UNIV,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02111; MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CTR CANC RES,CAMBRIDGE,MA 02139	Tufts Medical Center; Tufts University; Tufts University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484, P01HL042443, T32HL007437] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07437, P01 HL42443, HL41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARNAOUT MA, 1993, CURR OPIN HEMATOL, V1, P113; ATHERTON A, 1973, J PHYSIOL-LONDON, V233, P157, DOI 10.1113/jphysiol.1973.sp010303; ATHERTON A, 1972, J PHYSIOL-LONDON, V222, P447, DOI 10.1113/jphysiol.1972.sp009808; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BONFANTI R, 1989, BLOOD, V73, P1109; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CARLOS TM, 1990, IMMUNOL REV, V114, P5, DOI 10.1111/j.1600-065X.1990.tb00559.x; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FRIES JWU, 1993, IN PRESS AM J PATHOL; FRYDMAN M, 1993, AM J MED GENET, V44, P297; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; JOHNSTON GI, 1990, J BIOL CHEM, V265, P21381; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KOUTTS J, 1978, J CLIN INVEST, V62, P1255, DOI 10.1172/JCI109246; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, INFLAMMATION BASIC P; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LEY K, 1991, BLOOD, V77, P2553; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; PATEL KD, 1991, J CELL BIOL, V112, P749, DOI 10.1083/jcb.112.4.749; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; Sambrook J, 1989, MOL CLONING LABORATO; SANDERS WE, 1992, BLOOD, V80, P795; SCHMIDSCHONBEIN GW, 1980, MICROVASC RES, V19, P45, DOI 10.1016/0026-2862(80)90083-7; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; VONANDRIAN UH, 1993, IN PRESS J CLIN INVE; WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355; Wagner R., 1839, ERLAUTERUNGSTAFELN P; WATSON ML, 1990, J EXP MED, V172, P263, DOI 10.1084/jem.172.1.263; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WEIBEL ER, 1964, J CELL BIOL, V23, P101, DOI 10.1083/jcb.23.1.101; WELLER A, 1992, J BIOL CHEM, V267, P15176	55	922	954	2	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					541	554		10.1016/0092-8674(93)80055-J	http://dx.doi.org/10.1016/0092-8674(93)80055-J			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	7688665				2022-12-28	WOS:A1993LT73900015
J	SIGMAN, DS; CHEN, CB; GORIN, MB				SIGMAN, DS; CHEN, CB; GORIN, MB			SEQUENCE-SPECIFIC SCISSION OF DNA BY RNAS LINKED TO A CHEMICAL NUCLEASE	NATURE			English	Article							1,10-PHENANTHROLINE COPPER-ION; DELTA-1 CRYSTALLIN GENE; CLEAVAGE; CONVERSION; SITE		UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV PITTSBURGH,DEPT OPHTHALMOL,PITTSBURGH,PA 15213; UNIV PITTSBURGH,DEPT HUMAN GENET,PITTSBURGH,PA 15213; EYE & EAR INST,PITTSBURGH,PA 15213	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	SIGMAN, DS (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.							BRUICE TW, 1991, J AM CHEM SOC, V113, P5446, DOI 10.1021/ja00014a042; CHEN CHB, 1988, J AM CHEM SOC, V110, P6570, DOI 10.1021/ja00227a052; CHEN CHB, 1986, P NATL ACAD SCI USA, V83, P7147, DOI 10.1073/pnas.83.19.7147; CHEN CHB, 1993, P NATL ACAD SCI USA, V90, P4206, DOI 10.1073/pnas.90.9.4206; CHEN CHB, 1993, BIOCONJUGATE CHEM, V4, P69, DOI 10.1021/bc00019a010; COREY DR, 1989, BIOCHEMISTRY-US, V28, P8277, DOI 10.1021/bi00447a004; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; DERVAN PB, 1992, NATURE, V359, P87, DOI 10.1038/359087a0; EBRIGHT RH, 1990, P NATL ACAD SCI USA, V87, P2882, DOI 10.1073/pnas.87.8.2882; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; GOYNE TE, 1987, J AM CHEM SOC, V109, P2846, DOI 10.1021/ja00243a060; KOOB M, 1990, SCIENCE, V250, P271, DOI 10.1126/science.2218529; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LONGMIRE JL, 1987, NUCLEIC ACIDS RES, V15, P859, DOI 10.1093/nar/15.2.859; NICKERSON JM, 1985, J BIOL CHEM, V260, P9100; NICKERSON JM, 1986, J BIOL CHEM, V261, P552; PENDERGRAST PS, 1993, J CELL BIOCHEM, V17, P156; Rosbash M, 1979, Methods Enzymol, V68, P454; SIGMAN DS, 1986, ACCOUNTS CHEM RES, V19, P180, DOI 10.1021/ar00126a004; SIGMAN DS, 1979, J BIOL CHEM, V254, P2269; SIGMAN DS, 1990, ANNU REV BIOCHEM, V59, P207, DOI 10.1146/annurev.biochem.59.1.207; SIGMAN DS, 1993, ACCOUNTS CHEM RES, V26, P98, DOI 10.1021/ar00027a004; SUTTON CL, 1993, BIOCHEMISTRY-US, V32, P4225, DOI 10.1021/bi00067a009; THOMAS M, 1976, P NATL ACAD SCI USA, V73, P2294, DOI 10.1073/pnas.73.7.2294	24	20	21	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 3	1993	363	6428					474	475		10.1038/363474a0	http://dx.doi.org/10.1038/363474a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LE938	7684825				2022-12-28	WOS:A1993LE93800067
J	GARNICK, MB				GARNICK, MB			PROSTATE-CANCER - SCREENING, DIAGNOSIS, AND MANAGEMENT	ANNALS OF INTERNAL MEDICINE			English	Review						PROSTATIC NEOPLASMS; PROSTATE-SPECIFIC ANTIGEN; NEOPLASM STAGING; HORMONES; NEOPLASM METASTASIS	DIGITAL RECTAL EXAMINATION; POST-IRRADIATION BIOPSY; FINE NEEDLE ASPIRATION; RADICAL PROSTATECTOMY; RADIATION-THERAPY; TREATED PATIENTS; PROGNOSTIC-SIGNIFICANCE; PELVIC LYMPHADENECTOMY; LYMPHATIC METASTASES; COMPUTED-TOMOGRAPHY	Objective: To provide physicians with a review of diagnosis, screening, staging evaluation, treatment options, prognosis, psychosocial issues, economic considerations, and future research directions in the management of patients with all stages of prostate cancer. Data Sources:A MEDLINE search of articles relating to the diagnosis, staging, screening, surgery, radiation therapy, medical management, and research in prostate cancer. Emphasis on information reported from government- and nongovernment-sponsored large cooperative trials, consensus development conferences, and proceedings of prostate cancer organ site workshops. Study Selection: Results of randomized treatment trials and consensus summary statements are reported where long-term results (> 5 years follow-up) are available for localized prostate cancer treatment and where survival outcomes are available for metastatic disease treatment. Data Synthesis: Both qualitative and quantitative data are reported. Information on staging, management, and prognosis of localized prostate cancer is based on studies that are predominantly nonrandomized, include heterogeneous patient groups, and often use differing outcome measures. Information on management of metastatic prostate cancer is more quantitative and includes side effects of treatment and survival results obtained from randomized, prospective, multi-institutional studies. Conclusions: Despite the increase in prostate cancer incidence and detection, substantial controversy still exists about the advisability and effectiveness of screening programs, the most appropriate staging evaluation, and the optimal management of patients with all stages of prostate cancer, Although randomized, prospective studies attempt to address some of these issues, physicians must appreciate inherent ambiguities involved in recommending staging and treatment choices.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	GARNICK, MB (corresponding author), GENET INST INC, 87 CAMBRIDGE PK DR, CAMBRIDGE, MA 02140 USA.							ADAMI S, 1985, J UROLOGY, V134, P1152, DOI 10.1016/S0022-5347(17)47663-4; ANDRIOLE GL, 1989, J UROLOGY, V142, P1259, DOI 10.1016/S0022-5347(17)39050-X; ARAI Y, 1990, J UROLOGY, V144, P1415, DOI 10.1016/S0022-5347(17)39757-4; Bagshaw M A, 1988, NCI Monogr, P47; BAGSHAW MA, 1980, CANCER, V45, P1912, DOI 10.1002/cncr.1980.45.s7.1912; BAILAR JC, 1970, CANCER, V26, P257, DOI 10.1002/1097-0142(197008)26:2<257::AID-CNCR2820260203>3.0.CO;2-9; BELAND G, 1990, CANCER-AM CANCER SOC, V66, P1074; BENSON MC, 1992, J UROLOGY, V147, P817, DOI 10.1016/S0022-5347(17)37394-9; BENSON RC, 1979, J UROLOGY, V121, P452, DOI 10.1016/S0022-5347(17)56820-2; Blackard C E, 1973, Urology, V1, P553, DOI 10.1016/0090-4295(73)90515-3; BLACKARD CE, 1970, CANCER, V26, P249, DOI 10.1002/1097-0142(197008)26:2<249::AID-CNCR2820260202>3.0.CO;2-7; BLACKARD CE, 1975, CANCER CHEMOTH REP 1, V59, P225; BOGDEN AE, 1990, CANCER RES, V50, P2646; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BRUCE AW, 1978, CAN MED ASSOC J, V119, P1077; Byar D P, 1980, Scand J Urol Nephrol Suppl, V55, P99; BYAR DP, 1973, CANCER, V32, P1126, DOI 10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO;2-C; BYAR DP, 1977, UROLOGIC PATHOLOGY P, P241; CAIN M, 1992, AUA TODAY, V12, P9; CAREY PO, 1988, UROLOGY, V32, P403, DOI 10.1016/0090-4295(88)90410-4; CARTER HB, 1990, PROSTATE, V16, P39; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHADWICK DJ, 1991, BRIT J UROL, V67, P616, DOI 10.1111/j.1464-410X.1991.tb15226.x; CHANG PJ, 1991, CURR OPIN RADIOL, V3, P687; CHIARODO A, 1991, CANCER RES, V51, P2498; CHODAK GW, 1986, J UROLOGY, V135, P951, DOI 10.1016/S0022-5347(17)45935-0; CHYBOWSKI FM, 1991, J UROLOGY, V145, P313, DOI 10.1016/S0022-5347(17)38325-8; COONER WH, 1988, J UROLOGY, V139, P758, DOI 10.1016/S0022-5347(17)42624-3; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; COONER WH, 1991, MONOGR UROL, V12, P2; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; CRAWFORD ED, 1993, JAMA-J AM MED ASSOC, V43, P42; DANIEL F, 1990, BRIT J UROL, V65, P275, DOI 10.1111/j.1464-410X.1990.tb14726.x; EGGLESTON JC, 1985, J UROLOGY, V134, P1146, DOI 10.1016/S0022-5347(17)47661-0; EISENBERGER M, 1992, P AN M AM SOC CLIN, V11, P201; EISENBERGER MA, 1985, J CLIN ONCOL, V3, P827, DOI 10.1200/JCO.1985.3.6.827; ELDER JS, 1982, J UROLOGY, V127, P704, DOI 10.1016/S0022-5347(17)54005-7; FAIR WR, 1992, AUA TODAY, V5, P16; FLANIGAN RC, 1985, J UROLOGY, V134, P84, DOI 10.1016/S0022-5347(17)46992-8; FLOCKS RH, 1959, J UROLOGY, V81, P194, DOI 10.1016/S0022-5347(17)65988-3; FREIHA FS, 1979, J UROLOGY, V122, P176, DOI 10.1016/S0022-5347(17)56312-0; FREIHA FS, 1984, PROSTATE, V5, P19, DOI 10.1002/pros.2990050103; GARNICK MB, 1984, NEW ENGL J MED, V311, P1281; GARNICK MB, 1989, CLIN ASPECTS PROSTAT, P220; GERBER GS, 1991, J NATL CANCER I, V83, P329, DOI 10.1093/jnci/83.5.329; GIBBONS R P, 1988, NCI (National Cancer Institute) Monographs, P123; GIBBONS RP, 1984, J UROLOGY, V131, P73, DOI 10.1016/S0022-5347(17)50210-4; GIRI PGS, 1982, INT J RADIAT ONCOL, V8, P283; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; GOLIMBU M, 1987, UROLOGY, V30, P427, DOI 10.1016/0090-4295(87)90373-6; GRESKOVICH FJ, 1991, J UROLOGY, V145, P798, DOI 10.1016/S0022-5347(17)38455-0; GUINAN P, 1980, NEW ENGL J MED, V303, P499, DOI 10.1056/NEJM198008283030906; Hanks G E, 1992, Oncology (Williston Park), V6, P79; HANKS GE, 1987, INT J RADIAT ONCOL, V13, P499, DOI 10.1016/0360-3016(87)90063-0; HANKS GE, 1988, CANCER, V61, P2153, DOI 10.1002/1097-0142(19880601)61:11<2153::AID-CNCR2820611104>3.0.CO;2-0; HANKS GE, 1986, INT J RADIAT ONCOL, V12, P1879, DOI 10.1016/0360-3016(86)90334-2; HANKS GE, 1988, INT J RADIAT ONCOL, V14, P1053, DOI 10.1016/0360-3016(88)90033-8; HINMAN F, 1991, J UROLOGY, V145, P126, DOI 10.1016/S0022-5347(17)38267-8; HODGE KK, 1989, J UROLOGY, V142, P71, DOI 10.1016/S0022-5347(17)38664-0; HRICAK H, 1987, RADIOLOGY, V162, P331, DOI 10.1148/radiology.162.2.3797645; HUDSON MA, 1989, J UROLOGY, V142, P1011, DOI 10.1016/S0022-5347(17)38972-3; Huggins C, 1941, CANCER RES, V1, P293; ISAACS JT, 1984, PROSTATE, V5, P1, DOI 10.1002/pros.2990050102; JOHANSSON JE, 1989, LANCET, V1, P799; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; JOHNS WD, 1990, CLIN NUCL MED, V15, P485, DOI 10.1097/00003072-199007000-00006; KEUPPENS F, 1990, CANCER-AM CANCER SOC, V66, P1045; KRAMOLOWSKY EV, 1988, J UROLOGY, V139, P1242, DOI 10.1016/S0022-5347(17)42879-5; KUBAN DA, 1991, UROL CLIN N AM, V18, P131; Labrie F, 1985, Important Adv Oncol, P193; LAWTON CA, 1992, CANCER, V69, P2761, DOI 10.1002/1097-0142(19920601)69:11<2761::AID-CNCR2820691122>3.0.CO;2-K; LEE F, 1987, RADIOLOGY, V163, P515, DOI 10.1148/radiology.163.2.3550883; LEE F, 1989, RADIOLOGY, V170, P609, DOI 10.1148/radiology.170.3.2644656; LEE F, 1988, RADIOLOGY, V168, P389, DOI 10.1148/radiology.168.2.3293108; LEO ME, 1991, J UROLOGY, V145, P802, DOI 10.1016/S0022-5347(17)38456-2; LEPOR H, 1988, NATL CANCER I MONOGR, V7, P117; LEVINE MS, 1981, AM J ROENTGENOL, V137, P207, DOI 10.2214/ajr.137.2.207; LEWINGTON VJ, 1991, EUR J CANCER, V27, P954, DOI 10.1016/0277-5379(91)90257-E; LIDDELL HT, 1986, J UROLOGY, V135, P716, DOI 10.1016/S0022-5347(17)45828-9; MCLAUGHLIN AP, 1976, J UROLOGY, V115, P89, DOI 10.1016/S0022-5347(17)59078-3; MCNEAL JE, 1986, LANCET, V1, P60; MELLINGER GT, 1967, SURG GYNECOL OBSTET, V124, P1011; MYERS CE, 1991, MOL F ONCOLOGY, P419; NADJI M, 1981, CANCER, V48, P1229, DOI 10.1002/1097-0142(19810901)48:5<1229::AID-CNCR2820480529>3.0.CO;2-L; NARAYAN P, 1989, J UROLOGY, V141, P560, DOI 10.1016/S0022-5347(17)40894-9; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; PARTIN AW, 1990, J UROLOGY, V143, P747, DOI 10.1016/S0022-5347(17)40079-6; PAULSON DF, 1980, UROL CLIN N AM, V7, P615; PAULSON DF, 1982, J UROLOGY, V128, P502, DOI 10.1016/S0022-5347(17)53016-5; PEDERSEN KV, 1990, BRIT MED J, V300, P1041, DOI 10.1136/bmj.300.6731.1041; PEREZ CA, 1989, RADIOTHER ONCOL, V16, P1, DOI 10.1016/0167-8140(89)90066-2; PIENTA KJ, 1993, ANN INTERN MED, V118, P793, DOI 10.7326/0003-4819-118-10-199305150-00007; PILEPICH MV, 1987, INT J RADIAT ONCOL, V13, P351, DOI 10.1016/0360-3016(87)90008-3; PLATT JF, 1987, AM J ROENTGENOL, V149, P315, DOI 10.2214/ajr.149.2.315; POLLEN JJ, 1981, CANCER, V47, P2585, DOI 10.1002/1097-0142(19810601)47:11<2585::AID-CNCR2820471113>3.0.CO;2-U; PONT A, 1982, ARCH INTERN MED, V142, P2137, DOI 10.1001/archinte.142.12.2137; RESNICK MI, 1988, J UROLOGY, V139, P754, DOI 10.1016/S0022-5347(17)42623-1; RESNICK MI, 1988, MULTIDISCIPLINARY AN, P299; RIFKIN MD, 1986, RADIOLOGY, V158, P85, DOI 10.1148/radiology.158.1.3510030; Scardino P T, 1988, NCI Monogr, P95; SCARDINO PT, 1986, J UROLOGY, V135, P510, DOI 10.1016/S0022-5347(17)45712-0; SCARDINO PT, 1989, UROL CLIN N AM, V16, P635; SCHELLHAMMER PF, 1988, UROLOGY, V31, P191, DOI 10.1016/0090-4295(88)90137-9; SCHELLHAMMER PF, 1987, J UROLOGY, V137, P897, DOI 10.1016/S0022-5347(17)44289-3; SCHER HI, 1987, CANCER TREAT REP, V71, P887; SCHNAARS SP, 1990, INT J FORECASTING, V6, P1, DOI 10.1016/0169-2070(90)90092-P; SCHNALL MD, 1991, RADIOLOGY, V178, P797, DOI 10.1148/radiology.178.3.1994421; SCHUESSLER WW, 1991, J UROLOGY, V145, P988, DOI 10.1016/S0022-5347(17)38509-9; Shipley W U, 1987, Prog Clin Biol Res, V243B, P199; Shipley W U, 1988, NCI Monogr, P67; SILBERSTEIN EB, 1985, J NUCL MED, V26, P345; SMITH PH, 1990, CANCER, V66, P1009; SOGANI PC, 1984, CANCER, V54, P744, DOI 10.1002/1097-0142(1984)54:4<744::AID-CNCR2820540426>3.0.CO;2-P; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STAMEY TA, 1989, J UROLOGY, V141, P1084, DOI 10.1016/S0022-5347(17)41176-1; STAMEY TA, 1989, J UROLOGY, V141, P1088, DOI 10.1016/S0022-5347(17)41177-3; STAMEY TA, 1989, J UROLOGY, V141, P1070; STAMEY TA, 1989, J UROLOGY, V141, P1076, DOI 10.1016/S0022-5347(17)41175-X; STEIN CA, 1989, J CLIN ONCOL, V7, P499, DOI 10.1200/JCO.1989.7.4.499; SWANSON LJ, 1988, CRIT REV ONCOL HEMAT, V8, P1, DOI 10.1016/S1040-8428(88)80003-9; TENNVALL J, 1988, ACTA ONCOL, V27, P365, DOI 10.3109/02841868809093556; TKACZUK K, 1992, P AN M AM SOC CLIN, V11, P201; TORTI FM, 1985, GENITOURINARY CANCER, P125; TRACHTENBERG J, 1983, J UROLOGY, V130, P152, DOI 10.1016/S0022-5347(17)51007-1; VANAUBEL OGJM, 1985, J UROLOGY, V134, P292, DOI 10.1016/S0022-5347(17)47128-X; WALSH PC, 1980, CANCER, V45, P1906, DOI 10.1002/cncr.1980.45.s7.1906; WEINERMAN PM, 1983, AM J ROENTGENOL, V140, P95, DOI 10.2214/ajr.140.1.95; WILSON CS, 1977, J UROLOGY, V117, P197, DOI 10.1016/S0022-5347(17)58396-2; WINFIELD HN, 1992, J ENDOUROL, V6, P103, DOI 10.1089/end.1992.6.103; WINKLER HZ, 1988, MAYO CLIN PROC, V63, P103, DOI 10.1016/S0025-6196(12)64942-8; WORGUL TJ, 1983, J UROLOGY, V129, P51, DOI 10.1016/S0022-5347(17)51916-3; ZINCKE H, 1992, CANCER-AM CANCER SOC, V70, P311, DOI 10.1002/1097-0142(19920701)70:1+<311::AID-CNCR2820701320>3.0.CO;2-T; Zincke H, 1990, Semin Urol, V8, P175; 1988, NATL CANCER I MONOGR, V7, P3; 1990, CANCER S5, V66; 1968, J UROLOGY, V100, P59; 1992, MMWR, V41, P401	138	145	160	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1993	118	10					804	818		10.7326/0003-4819-118-10-199305150-00008	http://dx.doi.org/10.7326/0003-4819-118-10-199305150-00008			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB649	7682387				2022-12-28	WOS:A1993LB64900008
J	RUPPERT, S; WANG, EH; TJIAN, R				RUPPERT, S; WANG, EH; TJIAN, R			CLONING AND EXPRESSION OF HUMAN TAF(II)250 - A TBP-ASSOCIATED FACTOR IMPLICATED IN CELL-CYCLE REGULATION	NATURE			English	Article							BINDING-PROTEIN; TFIID COMPLEX; MUTANTS; TRANSCRIPTION; COACTIVATORS; PROGRESSION; ACTIVATION; SYSTEM; GENES; CCG1	BASAL transcription by human RNA polymerase II requires the coordinate action of several ancillary factors (TFIIA-J)1 and can be regulated by various promoter-specific DNA binding proteins. An additional class of factors, called coactivators, are dispensable for basal transcription but are indispensable for regulation by transcriptional activators2-4. Biochemical studies established that some coactivators are associated with the TATA-binding protein (TBP) to form the TFIID complex3-6. We therefore set out to define the relationship between TBP and these TBP-associated factors (TAFs). Here we describe the cloning, expression and properties of the first human TAF, hTAF(II)250. The hTAF(II)250 gene is identical to a gene, CCG1 (refs 7, 8), implicated in cell-cycle progression. Recombinant hTAF(II)250 binds directly to TBP both in vitro and in yeast, and participates in the formation of the TFIID complex. This largest TAF may therefore play a central role in TFIID assembly by interacting with both TBP and other TAFs, as well as serving to link the control of transcription to the cell cycle.			RUPPERT, S (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,401 BARKER HALL,BERKELEY,CA 94720, USA.							CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HOEY T, 1993, CELL, V72, P1; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LIU HT, 1985, J BIOL CHEM, V260, P3269; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	22	223	252	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					175	179		10.1038/362175a0	http://dx.doi.org/10.1038/362175a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	7680771				2022-12-28	WOS:A1993KR02800065
J	IMAI, Y; LASKY, LA; ROSEN, SD				IMAI, Y; LASKY, LA; ROSEN, SD			SULFATION REQUIREMENT FOR GLYCAM-1, AN ENDOTHELIAL LIGAND FOR L-SELECTIN	NATURE			English	Article							LYMPHOCYTE HOMING RECEPTOR; LEUKOCYTE ADHESION MOLECULE-1; CARBOHYDRATE LIGAND; CELL-ADHESION; SIALYL-LEX; RECOGNITION; ELAM-1; RECIRCULATION; CDNA	L-SELECTIN participates in the initial attachment of leukocytes to the vascular endothelium1-3. On lymphocytes, it mediates binding to high endothelial venules of lymph nodes. As a selectin 4-6 it functions as a calcium-dependent lectin7,8 recognizing carbohydrate-bearing ligands on endothelial cells9-11. Two lymph node ligands for L-selectin have been identified as sulphated glycoproteins of M(r) approximately 50K and approximately 90K, called Sgp50 and Sgp90 (ref. 10). The recently cloned Sgp50 (ref 12), now designated GlyCAM-1, is a high endothelial venule-associated, mucin-like glycoprotein containing predominantly O-linked carbohydrate chains. Sialylation of GlyCAM-1 is necessary for its ligand activity9,10,13 and a role for fucosylation is suspected13. We have used chlorate as a metabolic inhibitor of sulphation, and report here that GlyCAM-1 has an additional requirement for sulphate.	UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM IMMUNOL,SAN FRANCISCO,CA 94143; GENENTECH INC,DEPT IMMUNOBIOL,S SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Roche Holding; Genentech			Imai, Yasuyuki/E-8701-2010	Imai, Yasuyuki/0000-0002-8937-0221				BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BRUSTEIN M, 1992, J EXP MED, V176, P1415, DOI 10.1084/jem.176.5.1415; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; IMAI Y, IN PRESS GLYCOCONJUG; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPERTINI O, 1992, J EXP MED, V175, P1789, DOI 10.1084/jem.175.6.1789; STOOLMAN LM, 1983, J CELL BIOL, V96, P722, DOI 10.1083/jcb.96.3.722; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725	29	338	350	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 11	1993	361	6412					555	557						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	7679207				2022-12-28	WOS:A1993KL71400067
J	KORPI, ER; KLEINGOOR, C; KETTENMANN, H; SEEBURG, PH				KORPI, ER; KLEINGOOR, C; KETTENMANN, H; SEEBURG, PH			BENZODIAZEPINE-INDUCED MOTOR IMPAIRMENT LINKED TO POINT MUTATION IN CEREBELLAR GABA(A) RECEPTOR	NATURE			English	Article							ANT RAT LINE; <H-3>RO 15-4513; PLASMID DNA; CELLS; SENSITIVITY; CHANNELS; BINDING; INVERSE; BRAIN	THE selectively outbred alcohol-non-tolerant (ANT) rat line1 is highly susceptible to impairment of postural reflexes by benzodiazepine agonists2 such as diazepam. ANT cerebella are generally devoid3 of diazepam-insensitive high-affinity binding of the benzodiazepine [H-3]Ro15-4513 (refs 4, 5), whereas in non-selected strains such binding marks a granule-cell-specific GABA(A) (gamma-aminobutyric acid) receptor containing the alpha6 subunit5,6. A critical determinant for diazepam insensitivity of this 'wild-type' cerebellar GABA(A) receptor is an arginine residue7 in alpha6 position 100, where other alpha subunits carry a histidine8. Here we report that the alpha6 gene of ANT rats is expressed at wild-type levels but carries a point mutation generating an arginine-to-glutamine substitution at position 100. In consequence, alpha6(Q100)beta2gamma2 receptors show diazepam-mediated potentiation of GABA-activated currents and diazepam-sensitive binding of [H-3]Ro15-4513. Our results suggest that cerebellar motor control may be a distinct behavioural correlate of the alpha6-subunit-containing GABA(A) receptor subtype.	ALKO LTD,BIOMED RES CTR,SF-00101 HELSINKI,FINLAND; UNIV HEIDELBERG,DEPT NEUROBIOL,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg	KORPI, ER (corresponding author), UNIV HEIDELBERG,CTR MOLEC BIOL,MOLEC NEUROENDOCRINOL LAB,NEUENHEIMER FELD 282,W-6900 HEIDELBERG,GERMANY.		Kettenmann, Helmut/AAJ-5142-2021	Kettenmann, Helmut/0000-0001-8208-0291				CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Eriksson K., 1981, DEV ANIMAL MODELS PH, P87; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS RA, 1989, FASEB J, V3, P1689, DOI 10.1096/fasebj.3.6.2467834; HELLEVUO K, 1989, PHARMACOL BIOCHEM BE, V34, P399, DOI 10.1016/0091-3057(89)90333-X; KLEINGOOR C, 1991, NEUROSCI LETT, V130, P169, DOI 10.1016/0304-3940(91)90389-B; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MALMINIEMI O, 1989, EUR J PHARMACOL, V169, P53, DOI 10.1016/0014-2999(89)90816-9; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; ROTHSTEIN JD, 1992, J NEUROCHEM, V58, P2102, DOI 10.1111/j.1471-4159.1992.tb10952.x; SANGAMESWARAN L, 1985, P NATL ACAD SCI USA, V82, P5560, DOI 10.1073/pnas.82.16.5560; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SIEGHART W, 1987, J NEUROCHEM, V48, P46, DOI 10.1111/j.1471-4159.1987.tb13125.x; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; TUOMINEN K, 1991, PHARMACOL BIOCHEM BE, V40, P409, DOI 10.1016/0091-3057(91)90572-J; UUSIOUKARI M, 1990, J NEUROCHEM, V54, P1980, DOI 10.1111/j.1471-4159.1990.tb04901.x; UUSIOUKARI M, 1991, ALCOHOL CLIN EXP RES, V15, P241, DOI 10.1111/j.1530-0277.1991.tb01864.x; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y; WISDEN W, 1992, J NEUROSCI, V12, P1040	24	220	224	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					356	359		10.1038/361356a0	http://dx.doi.org/10.1038/361356a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	7678923				2022-12-28	WOS:A1993KJ59000059
J	CESARMAN, E; CHANG, Y; MOORE, PS; SAID, JW; KNOWLES, DM				CESARMAN, E; CHANG, Y; MOORE, PS; SAID, JW; KNOWLES, DM			KAPOSIS SARCOMA-ASSOCIATED HERPESVIRUS-LIKE DNA-SEQUENCES IN AIDS-RELATED BODY-CAVITY-BASED LYMPHOMAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; EPITHELIAL MEMBRANE ANTIGEN; NON-HODGKIN LYMPHOMA; LARGE-CELL LYMPHOMAS; HOMOSEXUAL MEN; GENOME; REARRANGEMENTS; MALIGNANCIES; ACTIVATION	Background. DNA fragments that appeared to belong to an unidentified human herpesvirus were recently found in more than 90 percent of Kaposi's sarcoma lesions associated with the acquired immunodeficiency syndrome (AIDS). These fragments were also found in 6 of 39 tissue samples without: Kaposi's sarcoma, including 3 malignant lymphomas, from patients with AIDS, but not in samples from patients without AIDS. Methods. We examined the DNA of 193 lymphomas from 42 patients with AIDS and 151 patients who did not have AIDS. We searched the DNA for sequences of Kaposi's sarcoma-associated herpesvirus (KSHV) by Southern blot hybridization, the polymerase chain reaction (PCR), or both. The PCR products in the positive samples were sequenced and compared with the KSHV sequences in Kaposi's sarcoma tissues from patients with AIDS. Results. KSHV sequences were identified in eight lymphomas in patients infected with the human immunodeficiency virus. All eight, and only these eight, were body-cavity-based lymphomas - that is, they were characterized by pleural, pericardial, or peritoneal lymphomatous effusions. All eight lymphomas also contained the Epstein-Barr viral genome, KSHV sequences were not found in the other 185 lymphomas. KSHV sequences were 40 to 80 times more abundant in the body-cavity-based lymphomas than in the Kaposi's sarcoma lesions. A high degree of conservation of KSHV sequences in Kaposi's sarcoma and in the eight lymphomas suggests the presence of the same agent in both lesions. Conclusions. The recently discovered KSHV DNA sequences occur in an unusual subgroup of AIDS-related B-cell lymphomas, but not in any other lymphoid neoplasm studied thus far. Our finding strongly suggests that a novel herpesvirus has a pathogenic role in AIDS-related body-cavity-based lymphomas.	COLUMBIA UNIV, SCH PUBL HLTH, DEPT PATHOL, NEW YORK, NY USA; COLUMBIA UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, NEW YORK, NY USA; CEDARS SINAI MED CTR, DEPT PATHOL & LAB MED, DIV ANAT PATHOL, LOS ANGELES, CA 90048 USA	Columbia University; Columbia University; Cedars Sinai Medical Center	CESARMAN, E (corresponding author), CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT PATHOL, 525 E 68TH ST, NEW YORK, NY 10021 USA.		Moore, Patrick S./F-3960-2011; Chang, Yuan/F-4146-2011; Moore, Patrick/GVR-8294-2022	Moore, Patrick S./0000-0002-8132-858X; Chang, Yuan/0000-0003-1125-4041; 	NEI NIH HHS [EY06337] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; ARCHIBALD CP, 1992, EPIDEMIOLOGY, V3, P203, DOI 10.1097/00001648-199205000-00004; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BALLERINI P, 1993, BLOOD, V81, P166; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1992, LANCET, V339, P632, DOI 10.1016/0140-6736(92)90793-3; BERAL V, 1991, LANCET, V337, P805, DOI 10.1016/0140-6736(91)92513-2; BERAL V, 1991, BRIT MED J, V302, P624, DOI 10.1136/bmj.302.6777.624; BERAL V, 1991, BRIT MED J, V302, P752; BERAL V, 1991, CANCER HIV AIDS, P5; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BIGGAR RJ, 1990, SEMIN ONCOL, V17, P251; BIGGAR RJ, 1994, AM J EPIDEMIOL, V139, P362, DOI 10.1093/oxfordjournals.aje.a117008; BORISCH B, 1992, J PATHOL, V168, P229, DOI 10.1002/path.1711680212; BOYLE MJ, 1991, BLOOD, V78, P3004; CHADBURN A, 1993, CANCER, V72, P3078, DOI 10.1002/1097-0142(19931115)72:10<3078::AID-CNCR2820721033>3.0.CO;2-F; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DELSOL G, 1984, LANCET, V2, P1124; DELSOL G, 1988, AM J PATHOL, V130, P59; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLAMAND L, 1993, J VIROL, V67, P6768, DOI 10.1128/JVI.67.11.6768-6777.1993; FLECKENSTEIN B, 1982, HERPESVIRUSES, V1, P253; FOITL DR, 1992, NEOPLASTIC HEMATOPAT, P869; FRANK D, 1995, BLOOD, V85, P1396, DOI 10.1182/blood.V85.5.1396.bloodjournal8551396; GREEN I, 1995, MODERN PATHOL, V8, P39; HARRIS NL, 1994, BLOOD, V84, P1361; INGHIRAMI G, 1990, AM J PATHOL, V136, P357; JAFFE HW, 1983, ANN INTERN MED, V99, P145, DOI 10.7326/0003-4819-99-2-145; KARCHER DS, 1992, LAB INVEST, V66, P80; KNOWLES DM, 1988, ANN INTERN MED, V108, P744, DOI 10.7326/0003-4819-108-5-744; KNOWLES DM, 1989, BLOOD, V73, P792; KNOWLES DM, 1992, NEOPLASTIC HEMATOPAT, P773; LASSOUED K, 1991, AIDS, V5, P877, DOI 10.1097/00002030-199107000-00013; LEVINE AM, 1993, JNCI-J NATL CANCER I, V85, P1382, DOI 10.1093/jnci/85.17.1382; LIN JC, 1993, BLOOD, V81, P3372; LIN JC, 1993, BLOOD, V82, P2268; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; Maniatis T., 1982, MOL CLONING; MARTIN RW, 1993, MEDICINE, V72, P245, DOI 10.1097/00005792-199307000-00004; MILLER G, 1990, FIELDS VIROLOGY, V2, P1921; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; PELICCI PG, 1985, J EXP MED, V162, P1015, DOI 10.1084/jem.162.3.1015; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; ROIZMAN B, 1990, FIELDS VIROLOGY, V2, P1787; SAFAI B, 1980, CANCER, V45, P1472, DOI 10.1002/1097-0142(19800315)45:6<1472::AID-CNCR2820450629>3.0.CO;2-A; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUBAR M, 1988, BLOOD, V72, P667; WALTS AE, 1990, AM J CLIN PATHOL, V94, P170, DOI 10.1093/ajcp/94.2.170	50	2322	2379	0	49	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 4	1995	332	18					1186	1191		10.1056/NEJM199505043321802	http://dx.doi.org/10.1056/NEJM199505043321802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV415	7700311				2022-12-28	WOS:A1995QV41500002
J	BLAKE, JM; NORMAN, GR; SMITH, EKM				BLAKE, JM; NORMAN, GR; SMITH, EKM			REPORT CARD FROM MCMASTER - STUDENT EVALUATION AT A PROBLEM-BASED MEDICAL-SCHOOL	LANCET			English	Article							ASSESSMENTS; EDUCATION		MCMASTER UNIV,PROGRAMME EDUC DEV,HAMILTON,ON L8N 3Z5,CANADA; MCMASTER UNIV,DEPT MED,HAMILTON,ON L8N 3Z5,CANADA	McMaster University; McMaster University	BLAKE, JM (corresponding author), MCMASTER UNIV,FAC HLTH SCI,MD PROGRAM,ROOM 2E18,1200 MAIN ST W,HAMILTON,ON L8N 3Z5,CANADA.							ARNOLD L, 1990, ACAD MED, V65, P515, DOI 10.1097/00001888-199008000-00005; BIENENSTOCK A, 1993, NOV RES MED ED ANN C; GORDON MJ, 1991, ACAD MED, V66, P762, DOI 10.1097/00001888-199112000-00012; HARDEN RM, 1975, BRIT MED J, V1, P447, DOI 10.1136/bmj.1.5955.447; MITCHELL R, 1992, AM ED RES ASS M SAN; NEUFELD VR, 1989, ACAD MED, V64, P423, DOI 10.1097/00001888-198908000-00001; NEWBLE DI, 1983, MED EDUC, V17, P165, DOI 10.1111/j.1365-2923.1983.tb00657.x; PAINVIN C, 1979, 18TH P C RES MED ED; PERKINS DN, 1989, ED RES           JAN, P16; PICKERING G, 1979, MED TEACH, V1, P84; VANHEESEN PAW, 1989, TEACHING ASSESSING C; WOODWARD CA, 1983, MED EDUC, V17, P54, DOI 10.1111/j.1365-2923.1983.tb01094.x; WOODWARD CA, 1989, MEDUCS, V2, P64	13	43	45	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					899	902		10.1016/S0140-6736(95)90014-4	http://dx.doi.org/10.1016/S0140-6736(95)90014-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QR067	7707815				2022-12-28	WOS:A1995QR06700014
J	JOHNSON, BR				JOHNSON, BR			IMPLEMENTING THE CAIRO AGENDA	LANCET			English	Editorial Material											JOHNSON, BR (corresponding author), IPAS,CARRBORO,NC 27510, USA.							[Anonymous], 1994, INT C POPULATION DEV; BONGAARTS J, 1991, STUD FAMILY PLANN, V21, P299; BUTLER C, 1994, LANCET, V343, P582, DOI 10.1016/S0140-6736(94)91526-1; HAUB C, 1994, WORLD POPULATION DAT; KING M, 1994, LANCET, V344, P528, DOI 10.1016/S0140-6736(94)91906-2; MCCARTHY M, 1994, LANCET, V343, P227; PHAROAH POD, 1994, LANCET, V344, P1382, DOI 10.1016/S0140-6736(94)90565-7; Sen Gita, 1994, POPULATION POLICIES; SENANAYAKE P, 1994, LANCET, V343, P1031, DOI 10.1016/S0140-6736(94)90146-5; SNOW R, 1994, LANCET, V344, P459, DOI 10.1016/S0140-6736(94)91777-9; STEFANSKI D, 1994, LANCET, V344, P936, DOI 10.1016/S0140-6736(94)92277-2; 1992, UN E92133 PUBL; 1994, LANCET, V344, P697; 1993, 1993 WORLD BANK WORL; 1988, UN E89134 PUBL; 1994, LANCET, V344, P557	16	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					875	876		10.1016/S0140-6736(95)90005-5	http://dx.doi.org/10.1016/S0140-6736(95)90005-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707807				2022-12-28	WOS:A1995QR06700005
J	ACHESON, A; CONOVER, JC; FANDL, JP; DECHIARA, TM; RUSSELL, M; THADANI, A; SQUINTO, SP; YANCOPOULOS, GD; LINDSAY, RM				ACHESON, A; CONOVER, JC; FANDL, JP; DECHIARA, TM; RUSSELL, M; THADANI, A; SQUINTO, SP; YANCOPOULOS, GD; LINDSAY, RM			A BDNF AUTOCRINE LOOP IN ADULT SENSORY NEURONS PREVENTS CELL DEATH	NATURE			English	Article							NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; NEUROTROPHIC FACTOR; MESSENGER-RNA; DOPAMINERGIC-NEURONS; BRAIN; RECEPTOR; TRKB; NGF; CELLS	DURING the initial phase of their development, sensory neurons of the dorsal root ganglion (DRG) require target-derived trophic support for their survival(1-3), but as they mature they lose this requirement. Because many of these neurons express BDNF (brain-derived neurotrophic factor) messenger RNA(4,5) we hypothesized that BDNF might act as an autocrine survival factor in adult DRG neurons, thus explaining their lack of dependence on exogenous growth factors. When cultured adult DRG cells were treated with antisense oligonucleotides to BDNF, expression of BDNF protein was reduced by 80%, and neuronal survival was reduced by 35%. These neurons could be rescued by exogenous BDNF or neurotrophin-3, but not by other growth factors. Similar results were obtained with single-neuron microcultures, whereas microcultures derived from mutant mice lacking BDNF were unaffected by antisense oligonucleotides. Our results strongly support an autocrine role for BDNF in mediating the survival of a subpopulation of adult DRG neurons.			ACHESON, A (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Lindsay, Ronald/GQP-8001-2022	Conover, Joanne/0000-0003-0375-0141				ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; AGRIS CH, 1986, BIOCHEMISTRY-US, V25, P6268, DOI 10.1021/bi00368a065; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; DOHERTY P, 1987, J NEUROCHEM, V49, P1676, DOI 10.1111/j.1471-4159.1987.tb02425.x; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; GALL CM, 1992, MOL CELL NEUROSCI, V3, P56, DOI 10.1016/1044-7431(92)90009-Q; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, J NEUROSCI, V13, P3394; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOHNSON EM, 1986, TRENDS NEUROSCI, V9, P33, DOI 10.1016/0166-2236(86)90012-3; JOHNSON EM, 1985, NATURE, V314, P751, DOI 10.1038/314751a0; JONES KR, 1994, CELL, V76, P889; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOKAIA Z, 1993, P NATL ACAD SCI USA, V90, P6711, DOI 10.1073/pnas.90.14.6711; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; Lindsay RM, 1992, SENSORY NEURONS DIVE, P404; MCMAHON SB, 1994, NEURON, V12, P1161, DOI 10.1016/0896-6273(94)90323-9; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORRISON RS, 1991, J BIOL CHEM, V266, P728; PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; WETMORE C, 1990, EXP NEUROL, V109, P141, DOI 10.1016/0014-4886(90)90068-4; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x; WUPONG S, 1992, PHARMACEUT RES, V9, P1010, DOI 10.1023/A:1015846209681; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280	30	621	641	2	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					450	453		10.1038/374450a0	http://dx.doi.org/10.1038/374450a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700353				2022-12-28	WOS:A1995QP89900057
J	QIU, RG; CHEN, J; KIRN, D; MCCORMICK, F; SYMONS, M				QIU, RG; CHEN, J; KIRN, D; MCCORMICK, F; SYMONS, M			AN ESSENTIAL ROLE FOR RAC IN RAS TRANSFORMATION	NATURE			English	Article							EXPRESSION; CELLS	THE GTPase Rac(1) is a key component in the reorganization of the actin cytoskeleton that is induced by growth factors or oncogenic Ras(1). Here we investigate the role of Rac(1) in cell transformation and show that Rat(1) fibroblasts expressing activated Val-12 Rac(1) (Rac(1) with valine at residue 12) display all the hallmarks of malignant transformation. In a focus-forming assay in NIH3T3 fibroblasts to measure the efficiency of transformation, we found that dominant-negative Asn-17 Rac(1) inhibited focus formation by oncogenic Ras, but not by RafCAAX, a Raf kinase targeted to the plasma membrane by virtue of the addition of a carboxyterminal localization signal from K-Ras. This indicates that Rac is essential for transformation by Ras. In addition, Val-12 Rac(1) synergizes strongly with RafCAAX in focus-formation assays, indicating that oncogenic Ras drives both the Rac and MAP-kinase pathways, which cooperate to cause transformation.			QIU, RG (corresponding author), ONYX PHARMACEUT,3031 RES DR,RICHMOND,CA 94806, USA.							AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; HAWKINS PT, IN PRESS CURR BIOL; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SELF AJ, 1993, ONCOGENE, V8, P655; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320	19	771	781	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 30	1995	374	6521					457	459		10.1038/374457a0	http://dx.doi.org/10.1038/374457a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP899	7700355				2022-12-28	WOS:A1995QP89900059
J	GRECO, L; POWER, C; PECKHAM, C				GRECO, L; POWER, C; PECKHAM, C			ADULT OUTCOME OF NORMAL-CHILDREN WHO ARE SHORT OR UNDERWEIGHT AT AGE 7 YEARS	BRITISH MEDICAL JOURNAL			English	Article							GROWTH; NEWCASTLE; TYNE; COMMUNITY; HEIGHT; BIRTH	Objectives-To evaluate the adult growth outcome (at age 23) of children who are short or underweight at age 7 years in whom no identifiable pathological cause exists for their poor growth. Design-Longitudinal follow up of a birth cohort. Setting-The national child development study (1958 birth cohort) of Great Britain. Subjects-523 children with a height or a weight below the fifth centile at age 7. Of these, 70 (13 . 4%) were excluded because they had a longstanding illness that could account for their poor growth. The remaining 453 subjects, who were followed to age 23, provided the base group from which those with additional data, such as parental height, were obtained. Results-55/174 (31 . 6%) boys who were short at age 7 became short men; 60/211 (28 . 4%) girls who were short at age 7 became short women. Among boys who were underweight at age 7, 46/160 (28 . 7%) were still underweight at age 23, while 61/200 (30 . 5%) girls underweight at age 7 became underweight women. Having short parents did not increase the probability of being small as an adult. Children with delayed puberty were as likely to remain small as those in whom puberty was not delayed. Conclusions-One in three normal children who was short or underweight at age 7 became a short or underweight adult. This informs the management of short children and may be valuable when prolonged growth hormone treatment for short stature is being considered.	INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,LONDON WC1 1EH,ENGLAND	University of London; University College London	GRECO, L (corresponding author), UNIV NAPLES FEDERICO II,VIA PANSINI,I-80131 NAPLES,ITALY.							ALBERMAN E, 1991, ANN HUM BIOL, V18, P27; BAILEY BJR, 1994, ANN HUM BIOL, V21, P1, DOI 10.1080/03014469400003032; BLAND JM, 1994, BRIT MED J, V309, P780, DOI 10.1136/bmj.309.6957.780; BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499; BROOK CGD, 1991, ARCH DIS CHILD, V66, P85, DOI 10.1136/adc.66.1.85; BUTLER GE, 1990, ANN HUM BIOL, V17, P177, DOI 10.1080/03014469000000952; FERRI E, 1993, LIFE 3O 5TH FOLLOW U; FOGELMAN K, 1983, GROWING UP GREAT BRI; GOLDSTEIN H, 1971, HUM BIOL, V43, P92; GRECO L, 1990, ARCH DIS CHILD-FETAL, V65, P373, DOI 10.1136/adc.65.4_Spec_No.373; GULLIFORD MC, 1991, ARCH DIS CHILD, V66, P235, DOI 10.1136/adc.66.2.235; HERMANUSSEN M, 1988, ANN HUM BIOL, V15, P103, DOI 10.1080/03014468800009521; HINDMARSH PC, 1988, ACTA PEDIATR SCAND S, V343, P73; KNIGHT I, 1984, HEIGHTS WEIGHTS ADUL; LACEY KA, 1974, ARCH DIS CHILD, V49, P417, DOI 10.1136/adc.49.6.417; LACEY KA, 1974, LANCET, V1, P42; MILLER FJW, 1972, BRIT J PREV SOC MED, V26, P224; MILNER RDG, 1986, LANCET, V1, P483; PINTOR C, 1989, LANCET, V1, P1226; POWER C, 1988, INT J OBESITY, V2, P445; Power C., 1991, HLTH CLASS EARLY YEA; RONA RJ, 1981, BRIT MED BULL, V37, P265, DOI 10.1093/oxfordjournals.bmb.a071713; ROSENBAUM S, 1986, ANN HUM BIOL, V12, P115; SKUSE DH, 1985, ARCH DIS CHILD, V60, P173, DOI 10.1136/adc.60.2.173; STARK O, 1981, BMJ-BRIT MED J, V283, P13, DOI 10.1136/bmj.283.6283.13; VOSS LD, 1992, BMJ-BRIT MED J, V305, P1400, DOI 10.1136/bmj.305.6866.1400	26	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					696	700		10.1136/bmj.310.6981.696	http://dx.doi.org/10.1136/bmj.310.6981.696			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711536	Green Published			2022-12-28	WOS:A1995QN46100018
J	THIBAULT, GE				THIBAULT, GE			THE APPROPRIATE DEGREE OF DIAGNOSTIC CERTAINTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							DECISION-MAKING; ASTHMA				THIBAULT, GE (corresponding author), VET AFFAIRS MED CTR,1400 VFW PKY,BOSTON,MA 02132, USA.							BURR ML, 1993, MONOGR ALLERGY, V31, P80; DETRANO R, 1988, AM J MED, V84, P699, DOI 10.1016/0002-9343(88)90107-6; GIANROSSI R, 1989, CIRCULATION, V80, P87, DOI 10.1161/01.CIR.80.1.87; KEMP JP, 1993, ARCH INTERN MED, V153, P805, DOI 10.1001/archinte.153.7.805; McFadden ER, 1994, HARRISONS PRINCIPLES, V2, P1167; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; PAUKER SG, 1975, NEW ENGL J MED, V293, P229, DOI 10.1056/NEJM197507312930505	7	9	9	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1216	1220		10.1056/NEJM199411033311809	http://dx.doi.org/10.1056/NEJM199411033311809			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN806	7695696				2022-12-28	WOS:A1994PN80600009
J	WRIGHT, TL; LAU, JYN				WRIGHT, TL; LAU, JYN			CLINICAL ASPECTS OF HEPATITIS-B VIRUS-INFECTION	LANCET			English	Article							ORTHOTOPIC LIVER-TRANSPLANTATION; ALPHA-INTERFERON THERAPY; CONTROLLED TRIAL; PILOT TRIAL; COMBINATION; ANTIGEN; DNA; SURVIVAL; PATIENT; HBSAG		DEPT VET AFFAIRS MED CTR, DEPT MED, SAN FRANCISCO, CA 94121 USA; UNIV FLORIDA, DEPT MED, DIV GASTROENTEROL HEPATOL & NUTR, HEPATOBILLARY DIS SECT, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida	WRIGHT, TL (corresponding author), DEPT VET AFFAIRS MED CTR, GASTROENTEROL SECT, SAN FRANCISCO, CA 94121 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032242] Funding Source: NIH RePORTER; NIAID NIH HHS [R29AI32242] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER GJM, 1987, LANCET, V2, P66; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; BENNER KG, 1992, GASTROENTEROLOGY, V103, P1307, DOI 10.1016/0016-5085(92)91521-5; BLOOM BS, 1993, ANN INTERN MED, V118, P298, DOI 10.7326/0003-4819-118-4-199302150-00009; BLUM HE, 1991, HEPATOLOGY, V14, P56, DOI 10.1002/hep.1840140110; BROOK MG, 1989, HEPATOLOGY, V10, P761, DOI 10.1002/hep.1840100502; CARMAN W, 1993, LANCET, V341, P349, DOI 10.1016/0140-6736(93)90146-8; CASELMANN WH, 1989, GASTROENTEROLOGY, V96, P449, DOI 10.1016/0016-5085(89)91570-9; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; DEFRANCHIS R, 1993, ANN INTERN MED, V118, P191, DOI 10.7326/0003-4819-118-3-199302010-00006; DEGOS F, 1988, GASTROENTEROLOGY, V94, P151, DOI 10.1016/0016-5085(88)90623-3; FANG JWS, 1993, IN PRESS GASTROENTER, V105; FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P; FRIED MW, 1992, HEPATOLOGY, V16, pA127; GARCIA G, 1987, ANN INTERN MED, V107, P278, DOI 10.7326/0003-4819-107-2-278; HADLER SC, 1991, J INFECT DIS, V163, P454, DOI 10.1093/infdis/163.3.454; HEDIN G, 1986, TREATMENT FULMINANT, P309; HESS G, 1989, DIGESTION, V43, P56, DOI 10.1159/000199861; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; HOOFNAGLE JH, 1993, GASTROENTEROLOGY, V104, P1116, DOI 10.1016/0016-5085(93)90281-G; HOUSSET C, 1992, HEPATOLOGY, V15, P578, DOI 10.1002/hep.1840150404; KAKUMU S, 1993, HEPATOLOGY, V18, P258, DOI 10.1002/hep.1840180206; KORENMAN J, 1991, ANN INTERN MED, V114, P629, DOI 10.7326/0003-4819-114-8-629; LAU JYN, 1992, GASTROENTEROLOGY, V102, P956, DOI 10.1016/0016-5085(92)90182-X; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; LIANG TJ, 1990, HEPATOLOGY, V12, P204, DOI 10.1002/hep.1840120205; LOK ASF, 1987, GASTROENTEROLOGY, V92, P1839, DOI 10.1016/0016-5085(87)90613-5; LOK ASF, 1991, GASTROENTEROLOGY, V100, P182, DOI 10.1016/0016-5085(91)90599-G; LOK ASF, 1989, SEMIN LIVER DIS, V9, P249, DOI 10.1055/s-2008-1040518; LOK ASF, 1991, GASTROENTEROLOGY, V100, P756, DOI 10.1016/0016-5085(91)80022-2; MASON AL, 1993, GASTROENTEROLOGY, V105, P237, DOI 10.1016/0016-5085(93)90032-8; MUTCHNICK MG, 1991, HEPATOLOGY, V14, P409, DOI 10.1002/hep.1840140302; NOVICK DM, 1988, J INFECT DIS, V158, P795, DOI 10.1093/infdis/158.4.795; OGRADY JG, 1992, J HEPATOL, V14, P104, DOI 10.1016/0168-8278(92)90138-F; PATERLINI P, 1993, HEPATOLOGY, V17, P20, DOI 10.1016/0270-9139(93)90186-Q; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; ROINGEARD P, 1990, VIROLOGY, V179, P113, DOI 10.1016/0042-6822(90)90280-5; RUIZMORENO M, 1993, HEPATOLOGY, V18, P264, DOI 10.1016/0270-9139(93)90006-9; SAMUEL D, 1991, LANCET, V337, P813, DOI 10.1016/0140-6736(91)92515-4; SCHAFFNER W, 1993, ANN INTERN MED, V118, P308, DOI 10.7326/0003-4819-118-4-199302150-00011; SCHARSCHMIDT BF, 1992, ANN INTERN MED, V117, P837, DOI 10.7326/0003-4819-117-10-837; TODO S, 1991, HEPATOLOGY, V13, P619, DOI 10.1002/hep.1840130402; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; TYRRELL DLJ, 1993, HEPATOLOGY, V18, pA112, DOI 10.1016/0270-9139(93)91978-2; WEISSBERG JI, 1984, ANN INTERN MED, V101, P613, DOI 10.7326/0003-4819-101-5-613; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; WRIGHT TL, 1992, LANCET, V339, P952, DOI 10.1016/0140-6736(92)91530-L; WRIGHT TL, 1992, WRIGHTS LIVER BILIAR	49	183	192	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 27	1993	342	8883					1340	1344		10.1016/0140-6736(93)92250-W	http://dx.doi.org/10.1016/0140-6736(93)92250-W			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7694023				2022-12-28	WOS:A1993MJ03900013
J	FREEMAN, GJ; GRIBBEN, JG; BOUSSIOTIS, VA; NG, JW; RESTIVO, VA; LOMBARD, LA; GRAY, GS; NADLER, LM				FREEMAN, GJ; GRIBBEN, JG; BOUSSIOTIS, VA; NG, JW; RESTIVO, VA; LOMBARD, LA; GRAY, GS; NADLER, LM			CLONING OF B7-2 - A CTLA-4 COUNTER-RECEPTOR THAT COSTIMULATES HUMAN T-CELL PROLIFERATION	SCIENCE			English	Article							ACTIVATION; INTERLEUKIN-2; ANTIGEN-B7; INDUCTION; ANERGY	Although presentation of antigen to the T cell receptor is necessary for the initiation of an immune response, additional molecules expressed on antigen-presenting cells deliver essential costimulatory signals. T cell activation, in the absence of costimulation, results in T cell anergy. The B7-1 protein is a costimulator molecule that regulates interleukin-2 (IL-2) secretion by signaling through the pathway that uses CD28 and CTLA-4 (hereafter referred to as the CD28 pathway). We have cloned a counter-receptor of CD28 and CTLA-4, termed B7-2. Although only 26 percent identical to B7-1, B7-2 also costimulates IL-2 production and T cell proliferation. Unlike B7-1, B7-2 messenger RNA is constitutively expressed in unstimulated B cells. It is likely that B7-2 provides a critical early costimulatory signal determining if the T cell will contribute to an immune response or become anergic.	REPLIGEN CORP,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	FREEMAN, GJ (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115, USA.		Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616	NCI NIH HHS [CA 40216] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040216] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUSSIOTIS VA, IN PRESS J EXP MED; BOUSSIOTIS VA, IN PRESS P NATL ACAD; FREEDMAN AS, 1987, J IMMUNOL, V139, P3260; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; FREEMAN G, UNPUB; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HATHCOCK KS, 1993, SCIENCE, V262; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; NICKOLOFF BJ, 1993, AM J PATHOL, V142, P1029; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; YOKOCHI T, 1982, J IMMUNOL, V128, P823	18	898	1006	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 5	1993	262	5135					909	911		10.1126/science.7694363	http://dx.doi.org/10.1126/science.7694363			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF438	7694363				2022-12-28	WOS:A1993MF43800039
J	HAO, Y; CRENSHAW, T; MOULTON, T; NEWCOMB, E; TYCKO, B				HAO, Y; CRENSHAW, T; MOULTON, T; NEWCOMB, E; TYCKO, B			TUMOR-SUPPRESSOR ACTIVITY OF H19 RNA	NATURE			English	Article							NORMAL HUMAN CHROMOSOME-11; WILMS-TUMOR; CELL-DIFFERENTIATION; GENE; EXPRESSION; MOUSE; TUMORIGENICITY; ALLELES	Loss of heterozygosity in certain human embryonal tumours implicates a tumour-suppressor gene at chromosome 11p15.5 and selective loss of maternal alleles suggests that this gene is paternally imprinted1-4. The human H19 gene maps to 11p15.5, is expressed in differentiating fetal cells5-11 and is paternally imprinted12-16. We report here that two embryonal tumour cell lines, RD and G401, showed growth retardation and morphological changes when transfected with an H19 expression construct. More importantly, clonogenicity in soft agar and tumorigenicity in nude mice were abrogated in the G401-H19 transfectants. In addition to demonstrating its tumour-suppressor potential, this transfection system should help structural and functional studies of the enigmatic H19 gene.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,DIV ONCOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,DIV NEUROPATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PEDIAT,DIV PEDIAT HEMATOL ONCOL,NEW YORK,NY 10032; NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016	Columbia University; Columbia University; Columbia University; New York University								BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; GARVIN AJ, 1992, AM J PATHOL, V142, P375; HAN DKM, 1992, CIRC RES, V71, P711, DOI 10.1161/01.RES.71.3.711; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PAL N, 1990, ONCOGENE, V5, P1665; PEEBLES PT, 1978, PEDIATR RES, V12, P485, DOI 10.1203/00006450-197804001-00732; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RACHMILEWITZ J, 1992, MOL REPROD DEV, V32, P196, DOI 10.1002/mrd.1080320303; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; REINER S, 1993, NATURE, V362, P747; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WILES MV, 1988, DEVELOPMENT, V104, P403; WILLIAMS JC, 1989, LANCET, V1, P283; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	24	584	600	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 21	1993	365	6448					764	767		10.1038/365764a0	http://dx.doi.org/10.1038/365764a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC812	7692308				2022-12-28	WOS:A1993MC81200067
J	ROSE, J; GERKEN, S; LYNCH, S; PISANI, P; VARVIL, T; OTTERUD, B; LEPPERT, M				ROSE, J; GERKEN, S; LYNCH, S; PISANI, P; VARVIL, T; OTTERUD, B; LEPPERT, M			GENETIC SUSCEPTIBILITY IN FAMILIAL MULTIPLE-SCLEROSIS NOT LINKED TO THE MYELIN BASIC-PROTEIN GENE	LANCET			English	Note								The myelin basic- protein (MBP) gene is a candidate locus for disease susceptibility in familial multiple sclerosis. Amplification of a polymorphic tetranucleotide repeat region immediately 5' to MBP exon 1 demonstrated the presence of eight different alleles among members of 14 multiplex multiple sclerosis families (36 affected individuals). Linkage analysis was performed with autosomal dominant and autosomal recessive models, normal individuals with abnormal magnetic resonance scans being scored as either unknown or affected. Cumulative LOD scores were negative for both models of inheritance. The results do not demonstrate linkage between the MBP gene region and multiple sclerosis.	UNIV UTAH,DEPT NEUROL,SALT LAKE CITY,UT 84112; UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	ROSE, J (corresponding author), VET ADM MED CTR,NEUROVIROL RES LAB 151B,SALT LAKE CITY,UT 84148, USA.							BOYLAN KB, 1990, ANN NEUROL, V27, P291, DOI 10.1002/ana.410270311; EBERS GC, 1986, NEW ENGL J MED, V315, P1638, DOI 10.1056/NEJM198612253152603; ELDRIDGE R, 1984, NEW ENGL J MED, V311, P948, DOI 10.1056/NEJM198410113111504; LYNCH SG, 1990, NEUROLOGY, V40, P900, DOI 10.1212/WNL.40.6.900; LYNCH SG, 1992, NEUROLOGY, V42, P839, DOI 10.1212/WNL.42.4.839; MARTIN R, 1990, J IMMUNOL, V145, P540; MCFARLIN DE, 1982, NEW ENGL J MED, V307, P1183, DOI 10.1056/NEJM198211043071905; NELSON L M, 1986, Neuroepidemiology, V5, P17, DOI 10.1159/000110809; POLYMEROPOULOS MH, 1992, HUM MOL GENET, V1, P658, DOI 10.1093/hmg/1.8.658; TIENARI PJ, 1992, LANCET, V340, P987, DOI 10.1016/0140-6736(92)93007-A	10	67	67	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 8	1993	341	8854					1179	1181		10.1016/0140-6736(93)91003-5	http://dx.doi.org/10.1016/0140-6736(93)91003-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LB017	7683738				2022-12-28	WOS:A1993LB01700005
J	LONGLEY, BJ; MORGANROTH, GS; TYRRELL, L; DING, TG; ANDERSON, DM; WILLIAMS, DE; HALABAN, R				LONGLEY, BJ; MORGANROTH, GS; TYRRELL, L; DING, TG; ANDERSON, DM; WILLIAMS, DE; HALABAN, R			ALTERED METABOLISM OF MAST-CELL GROWTH-FACTOR (C-KIT LIGAND) IN CUTANEOUS MASTOCYTOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONDITIONED MEDIUM; SI-LOCUS; RAT; MOUSE; IDENTIFICATION; TRANSMEMBRANE; RECEPTOR; MUTANT; GENE; RNA	Background and Methods. The lesions of cutaneous mastocytosis are characterized by dermal infiltrates of mast cells and may appear hyperpigmented because of the presence of increased levels of epidermal melanin. Mast-cell growth factor, the ligand for the product of the c-kit proto-oncogene, stimulates the proliferation of mast cells and increases the production of melanin by melanocytes. We therefore looked for the expression of the mast-cell growth factor gene in the skin of patients with cutaneous mastocytosis using immunohistochemical techniques and the polymerase chain reaction. Results. In the skin of normal subjects and those with unrelated diseases, immunoreactive mast-cell growth factor was associated with keratinocytes and scattered dermal cells, a pattern consistent with cell-bound mast-cell growth factor. In skin samples containing lesions and in clinically normal skin from patients with mastocytosis, however, mast-cell growth factor was also found free in the dermis and in the extracellular spaces between keratinocytes, suggesting the presence of a soluble form of this protein. Messenger RNA (mRNA) that can encode soluble mast-cell growth factor was present in the skin of patients as well as in that of normal control subjects. No sequence abnormalities were detected in mRNA for mast-cell growth factor from one patient. Conclusions. The altered distribution of mast-cell growth factor in the skin of patients with cutaneous mastocytosis is consistent with abnormal production ot the soluble form of this factor. This abnormality is probably due to increased proteolytic processing, since it was not explained by differences in the splicing or sequence of mast-cell growth factor mRNA in the patients. Soluble mast-cell growth factor may cause the characteristic accumulation of mast cells and the hyperpigmentation of skin found in cutaneous mastocytosis. These findings suggest that some forms of mastocytosis represent reactive hyperplasia rather than mast-cell neoplasia.	YALE UNIV,SCH MED,DERMATOPATHOL SECT,NEW HAVEN,CT 06510; IMMUNEX CORP,DEPT MOLEC BIOL,SEATTLE,WA; IMMUNEX CORP,DEPT EXPTL HEMATOL,SEATTLE,WA	Yale University; Immunex Corporation; Immunex Corporation	LONGLEY, BJ (corresponding author), YALE UNIV,SCH MED,DEPT DERMATOL,333 CEDAR ST,POB 3333,LCI 500,NEW HAVEN,CT 06510, USA.				NCI NIH HHS [5 R29CA44542-03] Funding Source: Medline; NIAMS NIH HHS [1 R29AR40514-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA044542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040514] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON DM, 1991, CELL GROWTH DIFFER, V2, P373; ANDERSON DM, 1990, CELL, V63, P233; ANDERSON DM, 1990, CELL, V63, P1112; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; LONGLEY J, 1991, J INVEST DERMATOL, V97, P974, DOI 10.1111/1523-1747.ep12491890; LU HS, 1991, J BIOL CHEM, V266, P8102; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; METCALFE DD, 1991, J INVEST DERMATOL, V96, pS2, DOI 10.1111/1523-1747.ep12468882; ONOUE H, 1989, BLOOD, V74, P1557; Sambrook J, 1989, MOL CLONING LABORATO; SOTER NA, 1991, J INVEST DERMATOL, V96, pS32, DOI 10.1111/1523-1747.ep12468973; TSAI M, 1991, J EXP MED, V174, P125, DOI 10.1084/jem.174.1.125; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	23	223	258	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1993	328	18					1302	1307		10.1056/NEJM199305063281803	http://dx.doi.org/10.1056/NEJM199305063281803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KZ640	7682288				2022-12-28	WOS:A1993KZ64000003
J	POPE, SK; WHITESIDE, L; BROOKSGUNN, J; KELLEHER, KJ; RICKERT, VI; BRADLEY, RH; CASEY, PH				POPE, SK; WHITESIDE, L; BROOKSGUNN, J; KELLEHER, KJ; RICKERT, VI; BRADLEY, RH; CASEY, PH			LOW-BIRTH-WEIGHT INFANTS BORN TO ADOLESCENT MOTHERS - EFFECTS OF CORESIDENCY WITH GRANDMOTHER ON CHILD-DEVELOPMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; LONGITUDINAL ANALYSIS; PRETERM INFANTS; PREGNANCY; TEENAGE; PROGRAMS; FAMILY; CHILDBEARING; IMPACT	Objective.-To explore the impact of young maternal age, coresidency with infant's grandmother, and other familial and environmental factors on development of low-birth-weight (LBW) infants. Design.-Prospective cohort analyses. Setting.-Eight medical institutions in different geographical locations participating in the Infant Health and Development Program. Participants.-Control population of 272 LBW, preterm infants enrolled in the Infant Health and Development Program born to mothers aged 15 to 24 years. Main Outcome Measure.-Child cognitive, behavioral, and health outcomes at 36 months' gestation-corrected age. Results.-Maternal age was not significantly related to child development. Coresidence with infant's grandmother was associated with improved cognitive and health outcomes. Maternal ethnicity, maternal verbal ability, and other environmental factors were also associated with child outcomes. Conclusions.-Findings of this study support the need for programs that include the extended family of at-risk infants, providing education and literacy skills to the mothers and encouraging participation of all care givers of the child.	UNIV ARKANSAS MED SCI HOSP,DEPT PEDIAT,LITTLE ROCK,AR 72205; UNIV ARKANSAS MED SCI HOSP,DEPT PEDIAT & PSYCHIAT,LITTLE ROCK,AR 72205; UNIV ARKANSAS,COLL EDUC,LITTLE ROCK,AR 72204; COLUMBIA UNIV TEACHERS COLL,NEW YORK,NY 10027	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Columbia University Teachers College			Kelleher, Kelly/E-3361-2011					ACHENBACH TM, 1987, J ABNORM CHILD PSYCH, V15, P629, DOI 10.1007/BF00917246; ADLER ES, 1985, FAM RELAT, V34, P183, DOI 10.2307/583890; BOYCE WT, 1991, AM J DIS CHILD, V145, P267, DOI 10.1001/archpedi.1991.02160030035017; Bronfenbrenner U., 1983, HDB CHILD PSYCHOL, VVol. 1; BROOKSGUNN J, 1991, PEDIATR ANN, V20, P467, DOI 10.3928/0090-4481-19910901-06; BROOKSGUNN J, 1992, J PEDIATR-US, V120, P350, DOI 10.1016/S0022-3476(05)80896-0; BROOKSGUNN J, IN PRESS CHILD DEV; BROOKSGUNN J, 1987, MALLEABILITY CHILDRE, P171; CARLSON DB, 1986, INT J BEHAV DEV, V9, P1; CASEY PH, 1990, J PEDIATR-US, V117, P298, DOI 10.1016/S0022-3476(05)80551-7; Chase-Lansdale P, 1993, ESCAPE POVERTY WHAT; CHASELANSADLE PL, IN PRESS CHILD DEV; CHASELANSDALE PL, 1991, FAM RELAT, V40, P396, DOI 10.2307/584896; CLAPP DF, 1978, SOC WORK, V23, P149; CLEWELL BC, 1989, FAM RELAT, V38, P201, DOI 10.2307/583676; COLL CG, 1986, J DEV BEHAV PEDIATR, V7, P230, DOI 10.1097/00004703-198608000-00003; DARABI KF, 1984, J MARRIAGE FAM, V46, P993; DUNCAN GJ, IN PRESS CHILD DEV; Dunn L.M., 2007, PEABODY PICTURE VOCA; Eisen MDC, 1990, CONCEPTUALIZATION ME; FIELD TM, 1980, CHILD DEV, V51, P426; FURSTENBERG FF, 1989, AM PSYCHOL, V44, P313, DOI 10.1037/0003-066X.44.2.313; FURSTENBERG FF, 1980, J SOC ISSUES, V36, P64, DOI 10.1111/j.1540-4560.1980.tb01899.x; Goldberg DP., 1972, DETECTION PSYCHIATRI; GROSS RT, 1992, PSYCHOL DEV LOW BIRT, P411; GULLO DF, 1988, CHILD STUDY J, V18, P223; HELD L, 1981, ADOLESCENCE, V16, P905; HUSTON AC, 1991, CHILDREN POVERTY; KING T, 1982, J ADOLESCENCE, V5, P333, DOI 10.1016/S0140-1971(82)80003-1; LANDY S, 1983, ADOLESCENCE, V18, P679; LEE VE, 1988, DEV PSYCHOL, V24, P210, DOI 10.1037/0012-1649.24.2.210; LIAW FR, IN PRESS DEV PSYCHOL; MCCORMICK MC, 1989, JAMA-J AM MED ASSOC, V261, P1767, DOI 10.1001/jama.261.12.1767; MCCORMICK MC, 1992, JAMA-J AM MED ASSOC, V267, P2204, DOI 10.1001/jama.267.16.2204; MCCORMICK MC, 1989, HDB MED SOCIOLOGY, P347; MERCER RT, 1985, ANN REV NURS RES, V3, P49; MILLER KA, 1984, MAYO CLIN PROC, V59, P311, DOI 10.1016/S0025-6196(12)61426-8; PARKER S, 1988, PEDIATR CLIN N AM, V35, P1227; RAMEY CT, 1992, PEDIATRICS, V89, P454; SCOTT DT, 1989, PEDIATR RES, V25, P263; SPENCER MB, 1990, CHILD DEV, V61, P267, DOI 10.1111/j.1467-8624.1990.tb02778.x; STEVENSSIMON C, 1991, PEDIATR ANN, V20, P322, DOI 10.3928/0090-4481-19910601-09; STEVENSSIMON C, 1992, CURR PROBL PEDIATR, P295; TERMAN LM, 1973, STANFORDBINET INTELL; VINCENT ML, 1987, JAMA-J AM MED ASSOC, V257, P3382, DOI 10.1001/jama.257.24.3382; 1990, JAMA-J AM MED ASSOC, V263, P3035	46	37	37	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1396	1400		10.1001/jama.269.11.1396	http://dx.doi.org/10.1001/jama.269.11.1396			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KQ857	7680076				2022-12-28	WOS:A1993KQ85700033
J	BAUMANN, I; TESTA, NG; LANGE, C; DEWYNTER, E; LUFT, T; DEXTER, TM; VANHOEF, MEHM; HOWELL, A				BAUMANN, I; TESTA, NG; LANGE, C; DEWYNTER, E; LUFT, T; DEXTER, TM; VANHOEF, MEHM; HOWELL, A			HEMATOPOIETIC-CELLS MOBILIZED INTO THE CIRCULATION BY LENOGRASTIM AS ALTERNATIVE TO BONE-MARROW FOR ALLOGENEIC TRANSPLANTS	LANCET			English	Letter							COLONY-STIMULATING FACTOR; GRANULOCYTE		CHRISTIE HOSP NHS TRUST,CRC,DEPT MED ONCOL,MANCHESTER,ENGLAND	Christie NHS Foundation Trust; Christie Hospital	BAUMANN, I (corresponding author), CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC,DEPT EXPTL HAEMATOL,MANCHESTER M20 9BX,ENGLAND.			Howell, Anthony/0000-0002-6233-719X				CIVIN IC, 1984, J IMMUNOL, V133, P147; DEMUYNCK H, 1992, EUR J CANCER, V28A, P381; DURHSEN U, 1988, BLOOD, V72, P2074; LOWRY PA, 1992, EXP HEMATOL, V20, P937; MOLINEUX G, 1990, BLOOD, V76, P2153; SHERIDAN WP, 1992, LANCET, V339, P640, DOI 10.1016/0140-6736(92)90795-5; SOCINSKI MA, 1988, LANCET, V1, P1194	7	62	62	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 6	1993	341	8841					369	369		10.1016/0140-6736(93)90166-E	http://dx.doi.org/10.1016/0140-6736(93)90166-E			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KK939	7679177				2022-12-28	WOS:A1993KK93900025
J	FUCHS, CS; STAMPFER, MJ; COLDITZ, GA; GIOVANNUCCI, EL; MANSON, JE; KAWACHI, I; HUNTER, DJ; HANKINSON, SE; HENNEKENS, CH; ROSNER, B; SPEIZER, FE; WILLETT, WC				FUCHS, CS; STAMPFER, MJ; COLDITZ, GA; GIOVANNUCCI, EL; MANSON, JE; KAWACHI, I; HUNTER, DJ; HANKINSON, SE; HENNEKENS, CH; ROSNER, B; SPEIZER, FE; WILLETT, WC			ALCOHOL-CONSUMPTION AND MORTALITY AMONG WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; SELF-ADMINISTERED QUESTIONNAIRE; U-SHAPED CURVE; BREAST-CANCER; RISK-FACTORS; COHORT; MEN; REPRODUCIBILITY; FREQUENCY; DRINKING	Background. Studies in men suggest that light-to-moderate alcohol intake is associated with a reduction in overall mortality, due primarily to a reduced risk of coronary heart disease. Among women with similar levels of alcohol consumption, an increased risk of breast cancer has been noted that complicates the balance of risks and benefits. Methods. We conducted a prospective study among 85,709 women, 34 to 59 years of age and without a history of myocardial infarction, angina, stroke, or cancer, who completed a dietary questionnaire in 1980. During the 12-year follow-up period, 2658 deaths were documented. Results. The relative risks of death in drinkers as compared with nondrinkers were 0.83 (95 percent confidence interval, 0.74 to 0.93) for women who consumed 1.5 to 4.9 g of alcohol per day (one to three drinks per week), 0.88 (95 percent confidence interval, 0.80 to 0.98) for those who consumed 5.0 to 29.9 g per day, and 1.19 (95 percent confidence interval, 1.02 to 1.38) for those who consumed 30 g or more per day, after adjustment for other predictors of mortality. Light-to-moderate drinking (1.5 to 29.9 g per day) was associated with a decreased risk of death from cardiovascular disease; heavier drinking was associated with an increased risk of death from other causes, particularly breast cancer and cirrhosis. The benefit associated with light-to-moderate drinking was most apparent among women with risk factors for coronary heart disease and those 50 years of age or older. Conclusions. Among women, light-to-moderate alcohol consumption is associated with a reduced mortality rate, but this apparent survival benefit appears largely confined to women at greater risk for coronary heart disease.	BRIGHAM & WOMENS HOSP,CHANNING LAB,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH & SOCIAL BEHAV,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	FUCHS, CS (corresponding author), HARVARD UNIV,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009; Sijbrands, Eric/A-1065-2009	Colditz, Graham/0000-0002-7307-0291; Sijbrands, Eric/0000-0001-8857-7389	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; BLACKWELDER WC, 1980, AM J MED, V68, P164, DOI 10.1016/0002-9343(80)90350-2; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; CAMACHO TC, 1987, J CHRON DIS, V40, P229, DOI 10.1016/0021-9681(87)90158-5; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COLDITZ GA, 1987, INT J EPIDEMIOL, V16, P392, DOI 10.1093/ije/16.3.392; COX DR, 1972, J R STAT SOC B, V34, P187; CULLEN KJ, 1993, AM J EPIDEMIOL, V137, P242, DOI 10.1093/oxfordjournals.aje.a116665; DELABRY LO, 1992, J STUD ALCOHOL, V53, P25, DOI 10.15288/jsa.1992.53.25; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; DYER AR, 1977, CIRCULATION, V56, P1067, DOI 10.1161/01.CIR.56.6.1067; FREZZA M, 1990, NEW ENGL J MED, V322, P95, DOI 10.1056/NEJM199001113220205; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GARFINKEL L, 1988, PREV MED, V17, P686, DOI 10.1016/0091-7435(88)90086-2; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GORDON T, 1987, AM J EPIDEMIOL, V125, P263, DOI 10.1093/oxfordjournals.aje.a114525; GRONBAEK M, 1994, BRIT MED J, V308, P302, DOI 10.1136/bmj.308.6924.302; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KITTNER SJ, 1983, AM J EPIDEMIOL, V117, P538, DOI 10.1093/oxfordjournals.aje.a113576; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KONO S, 1986, INT J EPIDEMIOL, V15, P527, DOI 10.1093/ije/15.4.527; KOZARAREVIC DJ, 1980, LANCET, V1, P613; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; MARMOT MG, 1981, LANCET, V1, P580; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; NORTON R, 1987, BMJ-BRIT MED J, V295, P80, DOI 10.1136/bmj.295.6590.80; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; Rothman K, 1986, MODERN EPIDEMIOLOGY; SAUNDERS JB, 1981, BMJ-BRIT MED J, V282, P1140, DOI 10.1136/bmj.282.6270.1140; SCHATZKIN A, 1987, NEW ENGL J MED, V316, P1169, DOI 10.1056/NEJM198705073161901; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILSNACK RW, 1984, AM J PUBLIC HEALTH, V74, P1231, DOI 10.2105/AJPH.74.11.1231; 1968, VITAL STATISTICS US; 1990, LANCET, V335, P634; 1982, HUMAN PROVISIONAL TA; 1967, DHEW PHS1693 PUBL	44	513	521	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 11	1995	332	19					1245	1250		10.1056/NEJM199505113321901	http://dx.doi.org/10.1056/NEJM199505113321901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW600	7708067	Bronze			2022-12-28	WOS:A1995QW60000001
J	ZIDAR, BL				ZIDAR, BL			PERIORBITAL EDEMA IN KAPOSIS-SARCOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											ZIDAR, BL (corresponding author), HAHNEMANN UNIV,MED COLL PENN,ALLEGHENY CAMPUS,PITTSBURGH,PA 15212, USA.								0	7	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 4	1995	332	18					1204	1204		10.1056/NEJM199505043321805	http://dx.doi.org/10.1056/NEJM199505043321805			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV415	7700314				2022-12-28	WOS:A1995QV41500005
J	BLUMBERG, HM; WATKINS, DL; BERSCHLING, JD; ANTLE, A; MOORE, P; WHITE, N; HUNTER, M; GREEN, B; RAY, SM; MCGOWAN, JE				BLUMBERG, HM; WATKINS, DL; BERSCHLING, JD; ANTLE, A; MOORE, P; WHITE, N; HUNTER, M; GREEN, B; RAY, SM; MCGOWAN, JE			PREVENTING THE NOSOCOMIAL TRANSMISSION OF TUBERCULOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						INFECTION CONTROL; TUBERCULOSIS; CROSS INFECTION; HEALTH PERSONNEL; TUBERCULIN TEST	HUMAN-IMMUNODEFICIENCY-VIRUS; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HIV-INFECTED PATIENTS; OUTBREAK	Objective: To study the efficacy of expanded tuberculosis infection control measures consisting primarily of administrative controls. Design: Descriptive case series. Setting: University-affiliated, inner-city hospital. Interventions: Introduction of expanded tuberculosis infection control measures (including an expanded respiratory isolation policy). Measurements: The number of tuberculosis exposure episodes and skin test conversion rates of health care workers were measured before and after implementation of expanded infection control measures. Tuberculosis exposure episodes (the number of patients who were not placed in respiratory isolation at admission but who subsequently had a diagnosis of acid-fast bacilli smear-positive pulmonary tuberculosis during that admission or within 2 weeks of discharge) were compared for two time periods: the 8 months before and the 28 months after implementation of infection control measures. Tuberculin skin test conversion rates among health care workers were evaluated during a 2.5-year period. Results: After expanded infection control measures were implemented, the number of tuberculosis exposure episodes decreased from 4.4 per month (35 episodes among 103 patient admissions for potentially infectious tuberculosis over 8 months) to 0.6 per month (18 episodes among 358 patient admissions for smear-positive pulmonary tuberculosis over 28 months) (odds ratio, 9.72; 95% CI, 4.99 to 19.25 [P < 0.001]). The cumulative number of days per month that potentially infectious patients with tuberculosis were not in isolation decreased from 35.4 to 3.3 (P < 0.001). A concomitant decrease in tuberculin skin test conversion rates in health care workers was seen; 6-month tuberculin skin test conversion rates decreased steadily from 3.3% (118 conversions in 3579 health care workers; 1/92 to 6/92), 1.7%, 1.4%, 0.6%, to 0.4% (23 conversions in 5153 workers [1/94 to 6/94]) (P < 0.001). Conclusions: Infection control measures effectively prevented nosocomial transmission of tuberculosis to health care workers. Administrative controls appear to be the most important component of a tuberculosis infection control program and should be the first focus of such a program, especially at public hospitals, where resources are most likely to be limited.	GRADY MEM HOSP, CLIN MICROBIOL LAB, ATLANTA, GA 30335 USA; GRADY MEM HOSP, DEPT EPIDEMIOL, ATLANTA, GA 30335 USA; GRADY MEM HOSP, OCCUPAT HLTH SERV, ATLANTA, GA 30365 USA		BLUMBERG, HM (corresponding author), EMORY UNIV, SCH MED, DIV INFECT DIS, 69 BUTLER ST SE, ATLANTA, GA 30303 USA.		mcgowan, john e/G-5404-2011; Blumberg, Henry/W-2156-2019	Blumberg, Henry/0000-0002-3110-2443; Ray, Susan/0000-0002-6327-088X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL003078] Funding Source: NIH RePORTER; NHLBI NIH HHS [K07 HL03078-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn J., 1995, Journal of Investigative Medicine, V43, p38A; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BEEKMANN SE, 1993, INFECT CONT HOSP EP, V14, P228; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECKER MD, 1993, INFECT CONT HOSP EP, V14, P689, DOI 10.1086/646671; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FELLA P, 1994, AM J INFECT CONTROL, V22, P100; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FLORA GS, 1990, CHEST, V98, P1056, DOI 10.1378/chest.98.5.1056; GREIFINGER R, 1992, Morbidity and Mortality Weekly Report, V41, P507; HAAS DW, 1994, AM J MED, V96, P439, DOI 10.1016/0002-9343(94)90171-6; HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540; JACOBS RF, 1994, CLIN INFECT DIS, V19, P1, DOI 10.1093/clinids/19.1.1; JARVIS WR, 1993, RES MICROBIOL, V144, P117, DOI 10.1016/0923-2508(93)90025-W; Kent PT, 1985, GUIDE LEVEL 3 LAB; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MATHUR P, 1994, ARCH INTERN MED, V154, P306, DOI 10.1001/archinte.154.3.306; MENZIES D, 1995, NEW ENGL J MED, V332, P92, DOI 10.1056/NEJM199501123320206; NOLTE FS, 1995, IN PRESS MANUAL CLIN; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; ROSNER B, 1990, FUNDAMENTALS BIOSTAT, P305; SEPKOWITZ KA, 1994, ANN INTERN MED, V120, P71, DOI 10.7326/0003-4819-120-1-199401010-00012; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7; ZAZA S, 1992, 1992 WORLD C TUB BET; E74193 AM SOC TEST M; 1992, MMWR-MORBID MORTAL W, V41, P55	32	146	149	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1995	122	9					658	663		10.7326/0003-4819-122-9-199505010-00003	http://dx.doi.org/10.7326/0003-4819-122-9-199505010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV151	7702227				2022-12-28	WOS:A1995QV15100003
J	CROWTHER, CA; HILLER, JE; HASLAM, RR; ROBINSON, JS; GILES, W; GILL, A; WALTERS, W; ROWLEY, M; EVANS, C; HENDERSONSMART, D; CHILD, A; EDWARDS, D; ELLWOOD, D; DOWNE, L; COOK, C; CHIN, M; ARNOLD, J; LESLIE, G; SMITH, D; FISHER, C; GRAVEY, P; CHILTON, H; PERES, M; JOHN, E; TRUDINGER, B; ROBERTS, S; BALLESTY, J; PESCE, A; NICOLL, M; LIKEMAN, R; REYNOLDS, G; WILLIAMS, M; THOMAS, D; KING, J; TUDEHOPE, D; STONE, M; JOHNSON, W; CARTWRIGHT, D; COLDTIZ, P; FORBES, K; DONOVAN, T; HILL, D; BRYCE, R; MARSHALL, P; WHITE, A; WIADROWSKI, T; HOBY, M; PRIDMORE, B; CROWTHER, C; HASLAM, R; THOMAS, A; BURY, G; WATKINS, A; OPIE, G; ASHTON, P; HEALY, D; YU, V; GODFREY, V; BARFIELD, C; TAYLOR, N; BRENNECKE, S; DOYLE, L; MURTON, L; PERMEZEL, M; RUSHFORD, D; BRITT, C; GRAUAUG, A; NEWNHAM, J; MACDONALD, S; MILNER, G				CROWTHER, CA; HILLER, JE; HASLAM, RR; ROBINSON, JS; GILES, W; GILL, A; WALTERS, W; ROWLEY, M; EVANS, C; HENDERSONSMART, D; CHILD, A; EDWARDS, D; ELLWOOD, D; DOWNE, L; COOK, C; CHIN, M; ARNOLD, J; LESLIE, G; SMITH, D; FISHER, C; GRAVEY, P; CHILTON, H; PERES, M; JOHN, E; TRUDINGER, B; ROBERTS, S; BALLESTY, J; PESCE, A; NICOLL, M; LIKEMAN, R; REYNOLDS, G; WILLIAMS, M; THOMAS, D; KING, J; TUDEHOPE, D; STONE, M; JOHNSON, W; CARTWRIGHT, D; COLDTIZ, P; FORBES, K; DONOVAN, T; HILL, D; BRYCE, R; MARSHALL, P; WHITE, A; WIADROWSKI, T; HOBY, M; PRIDMORE, B; CROWTHER, C; HASLAM, R; THOMAS, A; BURY, G; WATKINS, A; OPIE, G; ASHTON, P; HEALY, D; YU, V; GODFREY, V; BARFIELD, C; TAYLOR, N; BRENNECKE, S; DOYLE, L; MURTON, L; PERMEZEL, M; RUSHFORD, D; BRITT, C; GRAUAUG, A; NEWNHAM, J; MACDONALD, S; MILNER, G			AUSTRALIAN COLLABORATIVE TRIAL OF ANTENATAL THYROTROPIN-RELEASING-HORMONE (ACTOBAT) FOR PREVENTION OF NEONATAL RESPIRATORY-DISEASE	LANCET			English	Article							LUNG MATURATION; FETAL SHEEP; INFANTS	The addition of thyrotropin-releasing hormone (TRH) to antenatal glucocorticoid treatment of women at risk of preterm delivery has been reported to lower the risk of respiratory distress syndrome (RDS) in the infant, We have assessed the efficacy of 200 mu g TRH in a multicentre randomised trial. 1234 women at 24 weeks to 31 weeks 6 days of gestation with a singleton or twin pregnancy and at risk of preterm delivery were randomly allocated to groups receiving 200 mu g TRH or placebo intravenously every 12 h up to a maximum of four doses. Randomisation was stratified by duration of gestation and centre. All women received glucocorticoids. Clinical outcome is known for 1231 women and their 1397 infants. The frequencies of the main prespecified study outcomes RDS (relative risk 1.17 [95% CI 1.00-1.36], p=0.05) and need for ventilation (1.15 [1.01-1.31], p=0.04) were higher in TRH-group infants than in control infants. The excess risk in the TRH group was greater in infants who were born more than 10 days after treatment. Multivariate analysis adjusting for duration of gestation at randomisation, time from randomisation to delivery, parity, history of perinatal death, and infant's sex did not affect the risk estimates. TRH administration was associated with increased risks of maternal nausea, vomiting, lightheadedness, and a rise in blood pressure to 140/90 mm Hg or higher. Antenatal TRH given with glucocorticoids to women at high risk of preterm delivery is associated with maternal and perinatal risks and cannot be recommended for widespread clinical use.	JOHN HUNTER HOSP,NEWCASTLE,NSW,AUSTRALIA; PENRITH HOSP,PENRITH,NSW,AUSTRALIA; ROYAL N SHORE HOSP,ST LEONARDS,NSW 2065,AUSTRALIA; SYDNEY ROYAL HOSP WOMEN,SYDNEY,NSW,AUSTRALIA; WESTMEAD HOSP,WESTMEAD,NSW 2145,AUSTRALIA; KIRWAN HOSP,TOWNSVILLE,QLD,AUSTRALIA; MACKAY HOSP,MACKAY,QLD,AUSTRALIA; ROYAL BRISBANE HOSP,BRISBANE,QLD 4029,AUSTRALIA; FLINDERS MED CTR,BEDFORD PK,SA,AUSTRALIA; QUEEN ELIZABETH HOSP,WOODVILLE,SA 5011,AUSTRALIA; QUEEN VICTORIA HOSP,ADELAIDE,SA,AUSTRALIA; ROYAL HOBART HOSP,HOBART,TAS,AUSTRALIA; MERCY HOSP WOMEN,MELBOURNE,VIC,AUSTRALIA; MONASH MED CTR,MELBOURNE,VIC,AUSTRALIA; ROYAL WOMENS HOSP,MELBOURNE,VIC,AUSTRALIA; KING EDWARDS MEM HOSP,PERTH,WA,AUSTRALIA; MATER CHILDRINS HOSP,BRISBANE,QLD,AUSTRALIA	John Hunter Hospital; Royal North Shore Hospital; University of Sydney; Royal Brisbane & Women's Hospital; Flinders Medical Centre; Royal Hobart Hospital; Monash University; King Edward Memorial Hospital	CROWTHER, CA (corresponding author), UNIV ADELAIDE,DEPT OBSTET & GYNAECOL,ADELAIDE,SA 5005,AUSTRALIA.		Brennecke, Shaun/AFV-3919-2022; Cartwright, David W/M-7330-2013; Donovan, Timothy/E-2314-2012; Donovan, Tim/X-9891-2019; Tudehope, David I/G-5123-2013; Gill, Anthony J./M-5015-2019; Hiller, Janet E./A-5633-2008; Cartwright, David W/M-3202-2016; Doyle, Lex/AAJ-5205-2021	Brennecke, Shaun/0000-0003-3070-6971; Donovan, Tim/0000-0002-4710-0186; Hiller, Janet E./0000-0002-8532-4033; Doyle, Lex/0000-0002-7667-7312				ALTHABE F, 1992, PEDIATR RES, V29; BALLARD PL, 1992, PEDIATR RES, V32, P673, DOI 10.1203/00006450-199212000-00009; BALLARD RA, 1992, LANCET, V339, P510, DOI 10.1016/0140-6736(92)90337-3; CERIANI J, 1992, PEDIATR RES, V32, P738; CROWLEY P, 1976, BRIT J OBSTET GYNAEC, V97, P11; CROWTHER CA, IN PRESS AM J OBSTET; CROWTHER CA, 1994, PREGNANCY CHILDB SPR; HALL R, 1976, BRIT MED J, V2, P274; JIKIHARA H, 1990, 6TH P C FED AS OC PE; KNIGHT DB, 1994, AM J OBSTET GYNECOL, V171, P11, DOI 10.1016/S0002-9378(94)70070-2; LIGGINS GC, 1988, J APPL PHYSIOL, V65, P1880, DOI 10.1152/jappl.1988.65.4.1880; LIGGINS GC, 1988, CLIN REPRODUCTIVE ME; Meinert CL, 1986, CLIN TRIALS DESIGN C, P214; MORALES WJ, 1989, OBSTET GYNECOL, V73, P111; Peto R, 1982, TREATMENT CANCER, P867; RODRIGUEZPIERCE M, 1992, PEDIATR RES, V32, P407, DOI 10.1203/00006450-199210000-00008; ROONEY SA, 1979, PEDIATR RES, V13, P623, DOI 10.1203/00006450-197905000-00009; SCHELLENBERG JC, 1988, J APPL PHYSIOL, V65, P94, DOI 10.1152/jappl.1988.65.1.94; SNYDER PJ, 1972, J CLIN ENDOCR METAB, V34, P380, DOI 10.1210/jcem-34-2-380; SOSENKO IRS, 1987, AM J PHYSIOL, V253, pR592, DOI 10.1152/ajpregu.1987.253.4.R592; TABOR B, 1990, AM J OBSTET GYNECOL, V163, P689; WIGGLESWORTH JS, 1980, LANCET, V2, P684; [No title captured]	23	78	79	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 8	1995	345	8954					877	882						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR067	7707809				2022-12-28	WOS:A1995QR06700007
J	MOL, CD; ARVAI, AS; SLUPPHAUG, G; KAVLI, B; ALSETH, I; KROKAN, HE; TAINER, JA				MOL, CD; ARVAI, AS; SLUPPHAUG, G; KAVLI, B; ALSETH, I; KROKAN, HE; TAINER, JA			CRYSTAL-STRUCTURE AND MUTATIONAL ANALYSIS OF HUMAN URACIL-DNA GLYCOSYLASE - STRUCTURAL BASIS FOR SPECIFICITY AND CATALYSIS	CELL			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; VACCINIA VIRUS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; MISMATCH-REPAIR; CODING SEQUENCE; GENE; GENOME; ENZYME	Crystal structures of the DNA repair enzyme human uracil-DNA glycosylase (UDG), combined with mutational analysis, reveal the structural basis for the specificity of the enzyme. Within the classic alpha/beta told of UDG, sequence-conserved residues form a positively charged, active-site groove the width of duplex DNA, at the C-terminal edge of the central four-stranded parallel beta sheet. In the UDG-6-aminouracil complex, uracil binds at the base of the groove within a rigid preformed pocket that confers selectivity for uracil over other bases by shape complementarity and by main chain and Asn-204 side chain hydrogen bonds. Main chain nitrogen atoms are positioned to stabilize the oxyanion intermediate generated by His-268 acting via nucleophilic attack or general base mechanisms. Specific binding of uracil flipped out from a DNA duplex provides a structural mechanism for damaged base recognition.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV TRONDHEIM, UNIGEN CTR MOLEC BIOL, N-7005 TRONDHEIM, NORWAY	Scripps Research Institute			Slupphaug, Geir/AAN-3794-2020; Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; Slupphaug, Geir/0000-0002-7498-3500	NIGMS NIH HHS [GM 46312] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046312] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; Barnes DE, 1993, CURR OPIN CELL BIOL, V5, P424, DOI 10.1016/0955-0674(93)90007-D; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CROUZET J, 1990, J BACTERIOL, V172, P5980, DOI 10.1128/jb.172.10.5980-5990.1990; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DUNCAN BK, 1982, J BACTERIOL, V151, P750, DOI 10.1128/JB.151.2.750-755.1982; ELLIS SR, 1989, MOL CELL BIOL, V9, P1611, DOI 10.1128/MCB.9.4.1611; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; HAUG T, 1994, FEBS LETT, V353, P180, DOI 10.1016/0014-5793(94)01042-0; IMPELLIZZERI KJ, 1991, J BACTERIOL, V173, P6807, DOI 10.1128/jb.173.21.6807-6810.1991; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; KROKAN H, 1981, NUCLEIC ACIDS RES, V9, P2599, DOI 10.1093/nar/9.11.2599; KUHN LA, 1992, J MOL BIOL, V228, P13, DOI 10.1016/0022-2836(92)90487-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MEJEAN V, 1990, NUCLEIC ACIDS RES, V18, P6693, DOI 10.1093/nar/18.22.6693; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MOORE MH, 1994, EMBO J, V13, P1495, DOI 10.1002/j.1460-2075.1994.tb06410.x; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MULLER SJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P197, DOI 10.1016/0167-4781(91)90055-Q; MYERS LC, 1994, CURR OPIN STRUC BIOL, V4, P51, DOI 10.1016/S0959-440X(94)90059-0; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; PERCIVAL KJ, 1989, J BIOL CHEM, V264, P2593; READ RJ, 1975, ACTA CRYSTALLOGR A, V42, P140; RICHARDSON JS, 1990, PREDICTION PROTEIN S, P2; ROSEMAN NA, 1987, J VIROL, V61, P1398, DOI 10.1128/JVI.61.5.1398-1406.1987; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SHCHELKUNOV SN, 1993, DOKL AKAD NAUK+, V328, P629; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SLUPPHAUG G, 1991, NUCLEIC ACIDS RES, V19, P5131, DOI 10.1093/nar/19.19.5131; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; TALPAERTBORLE M, 1982, J BIOL CHEM, V257, P1208; TARTAGLIA J, 1990, J GEN VIROL, V71, P1517, DOI 10.1099/0022-1317-71-7-1517; TELFORD EAR, 1992, VIROLOGY, V189, P304, DOI 10.1016/0042-6822(92)90706-U; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; UPTON C, 1993, P NATL ACAD SCI USA, V90, P4518, DOI 10.1073/pnas.90.10.4518; VARSHNEY U, 1988, J BIOL CHEM, V263, P7776; WITTWER CU, 1985, BIOCHIM BIOPHYS ACTA, V832, P308, DOI 10.1016/0167-4838(85)90264-X; WORRAD DM, 1988, J VIROL, V62, P4774, DOI 10.1128/JVI.62.12.4774-4777.1988; YASUI A, 1992, MUTAT RES, V273, P231, DOI 10.1016/0921-8777(92)90084-G; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	59	339	351	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 24	1995	80	6					869	878		10.1016/0092-8674(95)90290-2	http://dx.doi.org/10.1016/0092-8674(95)90290-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QP612	7697717	Bronze			2022-12-28	WOS:A1995QP61200006
J	BLAND, JM; ALTMAN, DG				BLAND, JM; ALTMAN, DG			CALCULATING CORRELATION-COEFFICIENTS WITH REPEATED OBSERVATIONS .2. CORRELATION BETWEEN SUBJECTS	BRITISH MEDICAL JOURNAL			English	Note									IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	BLAND, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							ARMITAGE P, 1994, STAT METHODS MED RES, P215; BLAND JM, 1994, BRIT MED J, V308, P896, DOI 10.1136/bmj.308.6933.896; BLAND JM, 1995, BRIT MED J, V310, P446, DOI 10.1136/bmj.310.6977.446; BOYD O, 1993, LANCET, V341, P142, DOI 10.1016/0140-6736(93)90005-2	4	371	372	0	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					633	633		10.1136/bmj.310.6980.633	http://dx.doi.org/10.1136/bmj.310.6980.633			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703752	Bronze, Green Published			2022-12-28	WOS:A1995QL98400018
J	PRASAD, B; COSTELLO, AMD				PRASAD, B; COSTELLO, AMD			IMPACT AND SUSTAINABILITY OF A BABY FRIENDLY HEALTH-EDUCATION INTERVENTION AT A DISTRICT HOSPITAL IN BIHAR, INDIA	BRITISH MEDICAL JOURNAL			English	Article							DEVELOPING-COUNTRIES	Objectives-To evaluate the impact and sustainability of a baby friendly training intervention for staff at an Indian district hospital on initiation of breast feeding and use of prelacteal feeds by mothers. Design-Intervention study with assessment by interviewing mothers. Subjects-172 mothers recruited before the intervention, 195 recruited immediately after the intervention, and 101 recruited six months later. Setting-District hospital in a small town in Bihar, India. Main outcome measures-Age of infant when breast feeding started, use of prelacteal feeds, and colostrum feeding. Intervention-10 day training programme for doctors, nurses, and midwives, explaining the benefits and teasibility of early breast feeding and dangers of prelacteal feeds together with instruction on explaining this information to mothers. Results-Breast feeding was started within 24 hours of birth by 53 (29%) of control mothers, 164 (84%) in the early follow up group, and 60 (59%) in the late follow up group. Prelacteal feeds were used by 165 (96%), 84 (43%), and 78 (77%) respectively. Only 36 mothers in the late follow up group reported receiving education on feeding. Mothers in this group who had received the education were significantly more likely than mothers who received no education to breast feed early (28 (78%) v 11 (17%), P < 0.001) and not use prelacteal feeds (21 (58%) v 2 (3%), P < 0.001). Conclusions-Training doctors and midwives greatly improves the feeding practices of mothers. However, the impact of the training fell off quickly and refresher training is needed to sustain the improvement.	INST CHILD HLTH,CTR INT CHILD HLTH,LONDON WC1N 1EH,ENGLAND; MINIST HLTH,KATMANDU,NEPAL	University of London; University College London								ANDERSON S, 1993, J TROP PEDIATRICS, V39, P273, DOI 10.1093/tropej/39.5.273; [Anonymous], 1989, 10 STEPS PROMOTE SUC; BATHIJA C G, 1987, Indian Pediatrics, V24, P933; BHARGAVA SK, 1990, NATIONAL COLLABORATI; BRADLEY JE, 1992, J TROP PEDIATRICS, V38, P228, DOI 10.1093/tropej/38.5.228; COSTELLO AMD, 1993, T ROY SOC TROP MED H, V87, P1; KORAMOA J, 1992, BRIT MED J, V305, P54, DOI 10.1136/bmj.305.6844.54-b; MARTINES JC, 1992, BRIT MED J, V304, P1068, DOI 10.1136/bmj.304.6834.1068; SALARIYA EM, 1978, LANCET, V2, P1141; SINGHANIA R U, 1990, Indian Pediatrics, V27, P591; VANDENBOSCH CA, 1990, ANN TROP PAEDIATR, V10, P347, DOI 10.1080/02724936.1990.11747456; 1990, NATIONAL MED J INDIA, V3, P155; 1989, PROTECTING PROMOTING	13	41	41	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					621	623		10.1136/bmj.310.6980.621	http://dx.doi.org/10.1136/bmj.310.6980.621			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7703747	Green Published			2022-12-28	WOS:A1995QL98400013
J	DURIE, FH; FAVA, RA; FOY, TM; ARUFFO, A; LEDBETTER, JA; NOELLE, RJ				DURIE, FH; FAVA, RA; FOY, TM; ARUFFO, A; LEDBETTER, JA; NOELLE, RJ			PREVENTION OF COLLAGEN-INDUCED ARTHRITIS WITH AN ANTIBODY TO GP39, THE LIGAND FOR CD40	SCIENCE			English	Article							B-CELL ACTIVATION; II COLLAGEN; T-CELLS; PROTEIN; PROLIFERATION; INDUCTION	The ligand for the CD40 antigen is a 39-kilodalton protein, gp39, expressed on the surface of activated CD4+ T cells and is essential for thymus-dependent humoral immunity. The role of gp39-CD40 interactions in autoimmune disease was investigated in vivo with the use of an antibody that blocks their interactions (anti-gp39). Arthritis induced in mice by immunization with type II collagen was inhibited by anti-gp39. Anti-gp39 blocked the development of joint inflammation, serum antibody titers to collagen, the infiltration of inflammatory cells into the subsynovial tissue, and the erosion of cartilage and bone. Thus, interference with gp39-CD40 interactions may have therapeutic potential in the treatment of autoimmune disease.	DARTMOUTH COLL,SCH MED,DEPT MICROBIOL,LEBANON,NH 03756; DEPT VET ADM MED CTR,WHITE RIVER JCT,VT 05009; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; DARTMOUTH COLL,SCH MED,DEPT MED,WHITE RIVER JCT,VT 05009	Dartmouth College; Bristol-Myers Squibb; Dartmouth College					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026296, R37AI026296] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26296] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; CATHCART ES, 1986, LAB INVEST, V54, P26; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; COOPER WO, 1992, CLIN EXP IMMUNOL, V89, P244; COURTENAY JS, 1980, NATURE, V283, P665; CREMER MA, 1992, J IMMUNOL, V149, P1045; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; DURIE FH, UNPUB; FOY TM, UNPUB; FOY TM, IN PRESS J EXP MED; HOLMDAHL R, 1986, AGENTS ACTIONS, V19, P295, DOI 10.1007/BF01971231; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LANE PJL, 1990, J IMMUNOL, V144, P3684; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOELLE RJ, UNPUB; SEKI N, 1992, J IMMUNOL, V148, P3093; SHIZURU JA, 1992, IMMUNOL REV, V129, P105, DOI 10.1111/j.1600-065X.1992.tb01421.x; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; TRENTHAM DE, 1977, J EXP MED, V146, P857, DOI 10.1084/jem.146.3.857	23	443	502	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1328	1330		10.1126/science.7689748	http://dx.doi.org/10.1126/science.7689748			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	7689748				2022-12-28	WOS:A1993LV65600030
J	SCHMID, MF; ROBINSON, JP; DASGUPTA, BR				SCHMID, MF; ROBINSON, JP; DASGUPTA, BR			DIRECT VISUALIZATION OF BOTULINUM NEUROTOXIN-INDUCED CHANNELS IN PHOSPHOLIPID-VESICLES	NATURE			English	Article							TETANUS TOXIN; ELECTRON; MEMBRANES; IMAGES	THE seven botulinum neurotoxin (NT) serotypes produced by strains of Clostridium botulinum inhibit neurotransmitter release from synaptic vesicles. Neurotoxin is synthesized as a roughly 150K single-chain protein. Proteolysis produces two fragments, the 50K L-chain and 100K H-chain, that remain linked by a disulphide bond. Intoxication involves membrane attachment by the C-terminal half of the H-chain, endocytotic/lysosomal internalization, vesicle channel formation mediated by the 50K N-terminal half of the H-chain at low pH, and finally blockade of synaptic vesicle fusion after the L-chain reaches the cytosol1-4 . We report here the visualization of the neurotoxin-membrane complex by electron cryomicroscopy and image processing. Three-dimensional reconstructions show the neurotoxin bound to the exterior of ganglioside/PC lipid vesicles and show channels entirely perforating the vesicle wall. Each channel appears to arise from the interaction of four neurotoxin molecules.	BAYLOR COLL MED,WM KECK CTR COMPUTAT BIOL,HOUSTON,TX 77030; UNIV WISCONSIN,DEPT FOOD MICROBIOL & TOXICOL,MADISON,WI 53706	Baylor College of Medicine; University of Wisconsin System; University of Wisconsin Madison	SCHMID, MF (corresponding author), BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030, USA.		Taylor, Graham/A-4027-2012	Schmid, Michael/0000-0003-1077-5750				BINZ T, 1990, J BIOL CHEM, V265, P9153; CHANG CF, 1988, J ULTRA MOL STRUCT R, V100, P166, DOI 10.1016/0889-1605(88)90023-7; DASGUPTA BR, 1990, J PHYSIOL-PARIS, V84, P220; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; DOLLY JO, 1990, J PHYSIOL-PARIS, V84, P237; DONOVAN JJ, 1986, BIOCHEMISTRY-US, V25, P2872, DOI 10.1021/bi00358a020; GRANT RA, 1986, BIOPHYS J, V49, P251, DOI 10.1016/S0006-3495(86)83638-4; HOCH DH, 1985, ANN NY ACAD SCI, V456, P33, DOI 10.1111/j.1749-6632.1985.tb14841.x; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; KORNBERG RD, 1991, CURR OPIN STRUC BIOL, V1, P632; MONTAL MS, 1992, FEBS LETT, V313, P12, DOI 10.1016/0014-5793(92)81173-J; ROBINSON JP, 1988, J MOL BIOL, V200, P367, DOI 10.1016/0022-2836(88)90247-1; SCHMID MF, 1991, J MOL BIOL, V221, P711, DOI 10.1016/0022-2836(91)80082-6; SCHMID MF, 1990, 12TH P INT C EL MICR, P496; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SIMPSON LL, 1986, ANNU REV PHARMACOL, V26, P427, DOI 10.1146/annurev.pa.26.040186.002235	16	76	76	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					827	830		10.1038/364827a0	http://dx.doi.org/10.1038/364827a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	7689178				2022-12-28	WOS:A1993LU58100063
J	SHAHINIAN, A; PFEFFER, K; LEE, KP; KUNDIG, TM; KISHIHARA, K; WAKEHAM, A; KAWAI, K; OHASHI, PS; THOMPSON, CB; MAK, TW				SHAHINIAN, A; PFEFFER, K; LEE, KP; KUNDIG, TM; KISHIHARA, K; WAKEHAM, A; KAWAI, K; OHASHI, PS; THOMPSON, CB; MAK, TW			DIFFERENTIAL T-CELL COSTIMULATORY REQUIREMENTS IN CD28-DEFICIENT MICE	SCIENCE			English	Article							ACCESSORY MOLECULE CD28; CD4+ LYMPHOCYTES-T; MESSENGER-RNA; SIGNAL TRANSDUCTION; STEM-CELLS; ACTIVATION ANTIGEN-B7; IL-2 PRODUCTION; MURINE HOMOLOG; EXPRESSION; GENE	T cell receptor stimulation without costimulation is insufficient for the induction of an optimal immune response. It is thought that engagement of the CD28 molecule with its ligand B7 provides an essential costimulatory signal without which full activation of T cells cannot occur. A mouse strain with a defective CD28 gene was established. Development of T and B cells in the CD28-deficient mice appeared normal. However, T lymphocytes derived from CD28-/- mutant mice had impaired responses to lectins. Lectin stimulation did not trigger interleukin-2 (IL-2) production, IL-2 receptor alpha expression was significantly decreased, and exogenous IL-2 only partially rescued the CD28 defect. Basal immunoglobulin (Ig) concentrations in CD28-deficient mice were about one-fifth of those found in wild-type controls, with low titers of IgG1 and IgG2b but an increase in IgG2a. In addition, activity of T helper cells in CD28-/- mice was reduced and immunoglobulin class switching was diminished after infection with vesicular stomatitis virus. However, cytotoxic T cells could still be induced and the mice showed delayed-type hypersensitivity after infection with lymphocytic choriomeningitis virus. Thus, CD28 is not required for all T cell responses in vivo, suggesting that alternative costimulatory pathways may exist.	UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS & IMMUNOL, AMGEN INST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Howard Hughes Medical Institute; University of Michigan System; University of Michigan			Kawai, Kazuhiro/D-4998-2011	Kawai, Kazuhiro/0000-0001-9375-0713; Ohashi, Pamela S./0000-0003-2915-9317; Pfeffer, Klaus/0000-0002-5652-6330				ABE R, 1992, J IMMUNOL, V149, P3429; ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; AHMANN GB, 1978, J IMMUNOL, V121, P1981; BRADLEY A, 1986, CURR TOP DEV BIOL, V20, P357, DOI 10.1016/S0070-2153(08)60675-4; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; CERDAN C, 1992, J IMMUNOL, V149, P2255; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; DAMLE NK, 1992, J IMMUNOL, V149, P2541; DAMLE NK, 1992, J IMMUNOL, V148, P1985; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; FREEMAN GJ, 1992, J IMMUNOL, V149, P3795; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GROSS JA, 1990, J IMMUNOL, V144, P3201; GROSS JA, 1992, J IMMUNOL, V149, P380; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HARPER K, 1991, J IMMUNOL, V147, P1037; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LEDBETTER JA, 1990, BLOOD, V75, P1531; LEE KP, 1990, J IMMUNOL, V145, P344; LEIST TP, 1987, J IMMUNOL, V138, P2278; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LIU Y, 1992, EUR J IMMUNOL, V22, P2855, DOI 10.1002/eji.1830221115; LIU Y, 1990, P NATL ACAD SCI USA, V87, P5031; LU YL, 1992, J IMMUNOL, V149, P24; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; NORTON SD, 1992, J IMMUNOL, V149, P1556; PURKERSON J, 1992, FASEB J, V6, P3245, DOI 10.1096/fasebj.6.14.1385241; ROOST H, 1988, EUR J IMMUNOL, V18, P511, DOI 10.1002/eji.1830180404; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHAHINIAN A, UNPUB; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TURKA LA, 1991, J IMMUNOL, V146, P1428; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; VALLE A, 1991, INT IMMUNOL, V3, P229, DOI 10.1093/intimm/3.3.229; VANDENBERGHE P, 1992, J EXP MED, V175, P951, DOI 10.1084/jem.175.4.951; VANSEVENTER GA, 1991, CURR OPIN IMMUNOL, V3, P294, DOI 10.1016/0952-7915(91)90027-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; YANG L, 1992, CURR OPIN IMMUNOL, V4, P265, DOI 10.1016/0952-7915(92)90075-P; YOUNG JW, 1990, J EXP MED, V171, P1315, DOI 10.1084/jem.171.4.1315; YOUNG JW, 1992, J CLIN INVEST, V90, P229, DOI 10.1172/JCI115840	59	1156	1187	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1993	261	5121					609	612		10.1126/science.7688139	http://dx.doi.org/10.1126/science.7688139			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	7688139				2022-12-28	WOS:A1993LP72800039
J	HIDE, M; FRANCIS, DM; GRATTAN, CEH; HAKIMI, J; KOCHAN, JP; GREAVES, MW				HIDE, M; FRANCIS, DM; GRATTAN, CEH; HAKIMI, J; KOCHAN, JP; GREAVES, MW			AUTOANTIBODIES AGAINST THE HIGH-AFFINITY IGE RECEPTOR AS A CAUSE OF HISTAMINE-RELEASE IN CHRONIC URTICARIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-SUBUNIT; MAST-CELLS; ANTIBODIES	Background. Most urticarias are induced by vasoactive mediators such as histamine released from mast cells. Although mast cells are activated by allergens through cross-linking of cell-surface-bound IgE, this mechanism does not appear to explain most cases of chronic urticaria, which, when allergic, infectious, drug-induced, or physical causes cannot be identified, are classified as idiopathic. Methods. We recruited 26 patients with chronic idiopathic urticaria, in whom intradermal injection of autologous serum caused a wheal-and-flare response. Serum from four patients that induced marked histamine release from basophils from a donor with very low serum IgE levels was studied with respect to the IgE dependence of the histamine release, the activity of the IgG fractions, and the neutralizing effect of a recombinant preparation of the soluble extracellular domain of the a subunit of the high-affinity IgE receptor (sFcepsilonRIalpha). Results. The histamine-releasing activity of the serum was abolished by passive sensitization of basophils with myeloma IgE, enhanced after dissociation of IgE by treatment with lactic acid, and induced by IgG fractions from the serum of all four patients. Preincubation of the serum and isolated IgG with sFcepsilonRIalpha resulted in almost complete neutralization. Conclusions. Histamine-releasing IgG autoantibodies against the a subunit of the high-affinity IgE receptor are present in the circulation of some patients with chronic urticaria. Autoantibody-induced cross-linking of IgE receptors may be an important mechanism in the pathogenesis of chronic urticaria and other diseases mediated by mast cells.	HOFFMANN LA ROCHE INC,DEPT MOLEC GENET,NUTLEY,NJ 07110; HOFFMANN LA ROCHE INC,DEPT IMMUNOPHARMACOL,NUTLEY,NJ 07110	Roche Holding; Roche Holding			Hide, Michihiro/H-2519-2019	Hide, Michihiro/0000-0002-1569-6034				ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BAMEZAI A, 1989, J IMMUNOL, V143, P3107; BENDTZEN K, 1990, IMMUNOL TODAY, V11, P167, DOI 10.1016/0167-5699(90)90068-K; BLANK U, 1991, J BIOL CHEM, V266, P2639; BOROS P, 1991, J EXP MED, V173, P1473, DOI 10.1084/jem.173.6.1473; CHAMPION RH, 1990, CLIN EXP ALLERGY, V20, P221, DOI 10.1111/j.1365-2222.1990.tb02671.x; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; GRATTAN CEH, 1986, BRIT J DERMATOL, V114, P583, DOI 10.1111/j.1365-2133.1986.tb04065.x; GRATTAN CEH, 1990, INT ARCH ALLER A IMM, V93, P198, DOI 10.1159/000235301; GRATTAN CEH, 1991, CLIN EXP ALLERGY, V21, P695, DOI 10.1111/j.1365-2222.1991.tb03198.x; GRATTAN CEH, 1992, LANCET, V339, P1078, DOI 10.1016/0140-6736(92)90666-Q; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HOLGATE ST, 1991, INT ARCH ALLER A IMM, V94, P210, DOI 10.1159/000235363; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MACDONALD SM, 1991, INT ARCH ALLER A IMM, V94, P144, DOI 10.1159/000235347; METZGER H, 1991, CLIN EXP ALLERGY, V21, P269, DOI 10.1111/j.1365-2222.1991.tb01658.x; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P57; RISKE F, 1991, J BIOL CHEM, V266, P11245; ROSMAN H, 1962, ACTA ALLERGOL, V17, P168; SCHWARTZ LB, 1991, J AM ACAD DERMATOL, V25, P190, DOI 10.1016/S0190-9622(08)80468-9; SCHWARTZ RS, 1989, FUNDAMENTAL IMMUNOLO, P819; SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SMITH BR, 1974, LANCET, V2, P427; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0	28	697	721	3	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1993	328	22					1599	1604		10.1056/NEJM199306033282204	http://dx.doi.org/10.1056/NEJM199306033282204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE289	7683772				2022-12-28	WOS:A1993LE28900004
J	AMMALA, C; ASHCROFT, FM; RORSMAN, P				AMMALA, C; ASHCROFT, FM; RORSMAN, P			CALCIUM-INDEPENDENT POTENTIATION OF INSULIN RELEASE BY CYCLIC-AMP IN SINGLE BETA-CELLS	NATURE			English	Article							SECRETION; CA-2+; CAMP; EXOCYTOSIS; ACTIVATION; INTERPLAY; CURRENTS	How does cyclic AMP potentiate insulin secretion from pancreatic islet beta-cells? This question is fundamental to understanding how hormones such as glucagon, which elevates cAMP1, stimulate insulin secretion and so contribute to the normal secretory response of the islet2,3. It is well established that a rise in the cytoplasmic Ca2+ concentration ([Ca2+]i) is essential for insulin secretion4 and therefore cAMP has been proposed to act by elevating [Ca2+]i. But studies on permeabilized beta-cells indicate that cAMP increases insulin release even when [Ca2+]i is held constant5,6. We have used microfluorimetry and the patch-clamp technique to measure changes simultaneously in Ca2+ currents, [Ca2+]i and exocytosis7-9 in a single beta-cell in response to cAMP. We show here that cAMP, through activation of protein kinase A, increases Ca2+-influx through voltage-dependent L-type Ca2+ channels, thereby elevating [Ca2+]i and accelerating exocytosis. More importantly, cAMP also promotes insulin release by a direct interaction with the secretory machinery, which accounts for as much as 80% of its effect.	DEPT MED BIOPHYS,MEDICINAREGATAN 11,S-41390 GOTHENBURG,SWEDEN; UNIV OXFORD,PHYSIOL LAB,OXFORD OX1 3PT,ENGLAND	University of Oxford			Rorsman, Patrik/A-4331-2016	Rorsman, Patrik/0000-0001-7578-0767				AMMALA C, 1991, BIOCHIM BIOPHYS ACTA, V1092, P347; AMMALA C, IN PRESS J PHYSL LON; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P1; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P97; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; FIDLERLIM N, 1990, NATURE, V344, P449; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HENQUIN JC, 1985, ARCH INT PHYSIOL BIO, V93, P37, DOI 10.3109/13813458509104514; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HUGHES SJ, 1989, MOL CELL ENDOCRINOL, V65, P35, DOI 10.1016/0303-7207(89)90162-7; JONES PM, 1992, BIOCHEM J, V285, P973, DOI 10.1042/bj2850973; JONES PM, 1988, BIOCHEM J, V254, P397, DOI 10.1042/bj2540397; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; MARTY A, 1982, P NATL ACAD SCI USA, V79, P6712; PERSAUD SJ, 1990, BIOCHEM BIOPH RES CO, V173, P833, DOI 10.1016/S0006-291X(05)80862-9; PIPELEERS D, 1982, P NATL ACAD SCI-BIOL, V79, P7322, DOI 10.1073/pnas.79.23.7322; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P824, DOI 10.1210/endo-117-3-824; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RASMUSSEN H, 1990, DIABETES CARE, V13, P655, DOI 10.2337/diacare.13.6.655; RORSMAN P, 1992, EMBO J, V11, P2877, DOI 10.1002/j.1460-2075.1992.tb05356.x; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; RORSMAN P, 1988, PFLUGERS ARCH, V412, P587; SIKDAR SK, 1990, FEBS LETT, V273, P150, DOI 10.1016/0014-5793(90)81072-V	23	346	351	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 27	1993	363	6427					356	358		10.1038/363356a0	http://dx.doi.org/10.1038/363356a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LD917	7684514				2022-12-28	WOS:A1993LD91700055
J	KENNELL, JC; MORAN, JV; PERLMAN, PS; BUTOW, RA; LAMBOWITZ, AM				KENNELL, JC; MORAN, JV; PERLMAN, PS; BUTOW, RA; LAMBOWITZ, AM			REVERSE-TRANSCRIPTASE ACTIVITY ASSOCIATED WITH MATURASE-ENCODING GROUP-II INTRONS IN YEAST MITOCHONDRIA	CELL			English	Article							CYTOCHROME-OXIDASE; RNA MATURASE; S-CEREVISIAE; SUBUNIT-I; GENE; DNA; EVOLUTION; PROTEINS; ORIGIN; RIBONUCLEOPROTEIN	Group II introns al1 and al2 of the yeast mtDNA cox1 gene encode reverse transcriptase-like proteins that function in RNA splicing and may play a role in intron mobility and excision. We find that ribonucleoprotein particles from yeast mitochondria contain a reverse transcriptase activity that is likely encoded by al1 and al2 and is highly specific for the introns and their flanking exons. Using a mutant strain with elevated activity, we show that the reverse transcriptase uses either excised intron RNA or cox1 pre-mRNA as template and initiates cDNA synthesis near the 3' end of al2 and immediately downstream in E3. Our results suggest that introns al1 and al2 are retroelements, which encode reverse transcriptases that have adapted to function in RNA splicing.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	KENNELL, JC (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.				NIGMS NIH HHS [GM37949, GM31480, GM35510] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031480, R01GM037949, R01GM035510] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER NJ, 1979, J BIOL CHEM, V254, P2471; ANZIANO PQ, 1990, NUCLEIC ACIDS RES, V18, P3233, DOI 10.1093/nar/18.11.3233; BOER PH, 1988, EMBO J, V7, P3501, DOI 10.1002/j.1460-2075.1988.tb03226.x; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; CARIGNANI G, 1986, CURR GENET, V11, P55, DOI 10.1007/BF00389426; CARIGNANI G, 1983, CELL, V35, P733, DOI 10.1016/0092-8674(83)90106-X; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; Dujon B., 1989, MOBILE DNA, P861; FOX TD, 1988, P NATL ACAD SCI USA, V85, P7288, DOI 10.1073/pnas.85.19.7288; Gargouri A., 1983, MITOCHONDRIA 1983, P259; GARRIGA G, 1986, CELL, V46, P669, DOI 10.1016/0092-8674(86)90342-9; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HEBBAR SK, 1992, NUCLEIC ACIDS RES, V20, P1747, DOI 10.1093/nar/20.7.1747; HUDSPETH MES, 1980, BIOCHIM BIOPHYS ACTA, V610, P221, DOI 10.1016/0005-2787(80)90003-9; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; JOHNSTON SA, 1988, SCIENCE, V240, P1538, DOI 10.1126/science.2836954; KUCK U, 1985, CURR GENET, V9, P373, DOI 10.1007/BF00421608; KUIPER MTR, 1988, CELL, V55, P693, DOI 10.1016/0092-8674(88)90228-0; Lambowitz A M, 1979, Methods Enzymol, V59, P421; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAZOWSKA J, 1992, CR ACAD SCI III-VIE, V315, P37; LEVRAJUILLET E, 1989, MOL GEN GENET, V217, P168, DOI 10.1007/BF00330957; MCCLURE MA, 1991, MOL BIOL EVOL, V8, P835; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1985, NATURE, V316, P641, DOI 10.1038/316641a0; NUGENT JM, 1991, CELL, V66, P473, DOI 10.1016/0092-8674(81)90011-8; PEEBLES CL, 1993, IN PRESS J BIOL CHEM; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; Sambrook J, 1989, MOL CLONING LABORATO; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHERMAN F, 1986, LABORATORY COURSE MA; SIPICZKI M, 1977, MOL GEN GENET, V151, P77, DOI 10.1007/BF00446915; SKELLY PJ, 1991, CURR GENET, V20, P115, DOI 10.1007/BF00312773; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WANG H, 1992, MOL CELL BIOL, V12, P5131, DOI 10.1128/MCB.12.11.5131; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WENZLAU JM, 1989, THESIS OHIO STATE U; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	46	115	119	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					133	146		10.1016/0092-8674(93)90166-N	http://dx.doi.org/10.1016/0092-8674(93)90166-N			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	7681727				2022-12-28	WOS:A1993KW75300014
J	COLEMAN, TR; TANG, ZH; DUNPHY, WG				COLEMAN, TR; TANG, ZH; DUNPHY, WG			NEGATIVE REGULATION OF THE WEE1 PROTEIN-KINASE BY DIRECT ACTION OF THE NIM1/CDR1 MITOTIC INDUCER	CELL			English	Article							XENOPUS CDC2 PROTEIN; FISSION YEAST; TYROSINE PHOSPHORYLATION; CELL-CYCLE; ACTIVATES P34CDC2; DNA-REPLICATION; M-PHASE; MITOSIS; DEPHOSPHORYLATION; PHOSPHATASE	The wee1 protein kinase suppresses the entry into mitosis by mediating the inhibitory tyrosine phosphorylation of p34cdc2. Genetic studies have suggested that the nim1 protein kinase (also known as cdr1) acts as a positive regulator of mitosis by down-regulating the wee1 pathway in yeast cells. We have overexpressed the nim1 protein in both bacteria and insect cells. The recombinant nim1 protein autophosphorylates on both tyrosine and serine residues and can phosphorylate the isolated wee1 protein directly in a cell-free system. The nim1-catalyzed phosphorylation of the wee1 protein occurs in its C-terminal region and leads to a substantial drop in its activity as a cdc2-specific tyrosine kinase. This nim1-dependent inhibition of the wee1 protein kinase can be reversed readily in vitro by treatment with a protein phosphatase. These experiments provide direct biochemical evidence that the wee1 protein is subject to negative regulation by phosphorylation and indicate that the nim1 protein acts as an inhibitory, wee1-specific kinase.			COLEMAN, TR (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.							BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FEILOTTER H, 1991, GENETICS, V127, P309; Fleig U N, 1991, Semin Cell Biol, V2, P195; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MILARSKI KL, 1991, COLD SH Q B, V56, P377; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; Nigg E A, 1991, Semin Cell Biol, V2, P261; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60	43	148	150	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 26	1993	72	6					919	929		10.1016/0092-8674(93)90580-J	http://dx.doi.org/10.1016/0092-8674(93)90580-J			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	7681363				2022-12-28	WOS:A1993KU17500012
J	SHEPPARD, DN; RICH, DP; OSTEDGAARD, LS; GREGORY, RJ; SMITH, AE; WELSH, MJ				SHEPPARD, DN; RICH, DP; OSTEDGAARD, LS; GREGORY, RJ; SMITH, AE; WELSH, MJ			MUTATIONS IN CFTR ASSOCIATED WITH MILD-DISEASE-FORM CL- CHANNELS WITH ALTERED PORE PROPERTIES	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; CHLORIDE CHANNEL; EPITHELIAL-CELLS; IDENTIFICATION; EXPRESSION; PHOSPHORYLATION; MEMBRANE	THE cystic fibrosis transmembrane conductance regulator (CFTR) is a phosphorylation-regulated Cl- channel located in the apical membrane of epithelia1-10. Although cystic fibrosis (CF) is caused by mutations in a single gene encoding CFTR11,12, the disease has a variable clinical phenotype13,14. The most common mutation associated with cystic fibrosis, deletion of a phenylalanine at position 508 (frequency, 67%), is associated with severe disease15,17. But some missense mutations, for example ones in which arginine is replaced by histidine at residue at 117 (R117H; 0.8%), tryptophan at 334 (0.4%), or proline at 347 (0.5%), are associated with milder disease15,17,18. These missense mutations affect basic residues located at the external end of the second (M2) and in the sixth (M6) putative membrane-spanning sequences. Here we report that, when expressed in heterologous epithelial cells, all three mutants were correctly processed and generated cyclic AMP-regulated apical Cl- currents. Although the macroscopic current properties were normal, the amount of current was reduced. Patch-clamp analysis revealed that all three mutants had reduced single-channel conductances. In addition, R117H showed altered sensitivity to external pH and had altered single-channel kinetics. These results explain the quantitative decrease in macroscopic Cl- current, and suggest that R117, R334 and R347 contribute to the pore of the CFTR Cl- channel. Our results also suggest why R117H, R334W and R347P produce less severe clinical disease and have implications for our understanding of cystic fibrosis.	UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; GENZYME CORP,FRAMINGHAM,MA 01701	University of Iowa; Sanofi-Aventis; Genzyme Corporation	SHEPPARD, DN (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242, USA.		Sheppard, David N/AAV-4187-2021	Sheppard, David N/0000-0001-5533-9130; Welsh, Michael/0000-0002-1646-6206; Ostedgaard, Lynda/0000-0001-7717-3442				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BOAT TF, 1989, METABOLIC BASIS INHE, V6, P2649; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MCFADDEN ER, 1988, PULMONARY DISEASES D, V2, P1311; NITSCH L, 1980, P NATL ACAD SCI-BIOL, V77, P472, DOI 10.1073/pnas.77.1.472; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J	26	399	409	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					160	164		10.1038/362160a0	http://dx.doi.org/10.1038/362160a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	7680769				2022-12-28	WOS:A1993KR02800061
J	KASSAVETIS, GA; GEIDUSCHEK, EP				KASSAVETIS, GA; GEIDUSCHEK, EP			RNA-POLYMERASE MARCHING BACKWARD	SCIENCE			English	Editorial Material							TRANSCRIPTION ELONGATION; TERNARY COMPLEXES; GENE; TERMINATION; INVITRO; DOMAIN; TFIIS		UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	KASSAVETIS, GA (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; AGARWAL KL, COMMUNICATION; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, IN PRESS CELL; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; HAGLER J, IN PRESS J BIOL CHEM; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, COMMUNICATION; KASSAVETIS GA, 1981, J BIOL CHEM, V256, P2777; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRAKOW JS, 1969, J BIOL CHEM, V244, P5988; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; RAPPAPORT J, 1988, MOL CELL BIOL, V8, P3136, DOI 10.1128/MCB.8.8.3136; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1992, J BIOL CHEM, V267, P2795; REINES D, IN PRESS P NATL ACAD; ROZOVSKAYA TA, 1988, MOL BIOL, V15, P498; SHIRAI T, 1991, P NATL ACAD SCI USA, V88, P9056, DOI 10.1073/pnas.88.20.9056; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; SPARKOWSKI J, 1990, NUCLEIC ACIDS RES, V18, P6443, DOI 10.1093/nar/18.21.6443; SPENCER CA, 1990, ONCOGENE, V5, P777; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	29	82	83	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					944	945		10.1126/science.7679800	http://dx.doi.org/10.1126/science.7679800			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	7679800				2022-12-28	WOS:A1993KL80000034
J	KORTHAUER, U; GRAF, D; MAGES, HW; BRIERE, F; PADAYACHEE, M; MALCOLM, S; UGAZIO, AG; NOTARANGELO, LD; LEVINSKY, RJ; KROCZEK, RA				KORTHAUER, U; GRAF, D; MAGES, HW; BRIERE, F; PADAYACHEE, M; MALCOLM, S; UGAZIO, AG; NOTARANGELO, LD; LEVINSKY, RJ; KROCZEK, RA			DEFECTIVE EXPRESSION OF T-CELL CD40 LIGAND CAUSES X-LINKED IMMUNODEFICIENCY WITH HYPER-IGM	NATURE			English	Article							HUMAN LYMPHOCYTES-B; HYPERIMMUNOGLOBULINEMIA-M; ANTIGEN; PROLIFERATION; FORM	X CHROMOSOME-LINKED immunodeficiency with hyper-IgM (HIGM1, MIM number 308230) is a rare disorder characterized by recurrent bacterial infections, very low or absent IgG, IgA and IgE, and normal to increased IgM and IgD serum levels1-3. HIGM1 has been suggested to result from ineffective T-cell help for B cells4. We and others5-8 have identified a novel, TNF-related activation protein (TRAP) that is exclusively expressed on the surface of stimulated T cells6,8. TRAP, a type II transmembrane protein of M(r) 33,000, is the physiological ligand for CD40 (refs 5-8). Crosslinking of CD40 on B cells induces, in the presence of lymphokines, immunoglobulin class switching from IgM to IgG, IgA or IgE5,9-11. Mapping of the TRAP gene to the X-chromosomal location q26.3-q27.1 (ref. 6) suggested a causal relationship to HIGM1, which had previously been assigned to Xq26 (refs 12-14). Here we present evidence that point mutations in the TRAP gene give rise to nonfunctional or defective expression of TRAP on the surface of T cells in patients with HIGM1. The resultant failure of TRAP to interact with CD40 on functionally intact B cells is responsible for the observed immunoglobulin isotype defect in HIGM1.	UNIV ERLANGEN NURNBERG, INST KLIN IMMUNOL, ARBEITSGRP IMMUNOL, MAX PLANCK GESELLSCH, W-8520 ERLANGEN, GERMANY; SCHERING PLOUGH CORP, IMMUNOL RES LAB, F-69571 DARDILLY, FRANCE; INST CHILD HLTH, LONDON WC1N 1EH, ENGLAND; UNIV BRESCIA, I-25123 BRESCIA, ITALY	Max Planck Society; University of Erlangen Nuremberg; Merck & Company; Schering Plough Corporation; University of London; University College London; University of Brescia			Ugazio, Alberto/AAA-6092-2020; Graf, Daniel/H-1214-2011; Notarangelo, Luigi D/F-9718-2016	Graf, Daniel/0000-0003-1163-8117; Notarangelo, Luigi D/0000-0002-8335-0262				ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BANCHEREAU J, 1991, NATURE, V353, P678, DOI 10.1038/353678a0; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BURTIN P, 1961, REV FR ETUD CLIN BIO, V6, P286; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; HERMANN P, IN PRESS EUR J IMMUN; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MAYER L, 1986, NEW ENGL J MED, V314, P409, DOI 10.1056/NEJM198602133140703; MENSINK EJBM, 1987, HUM GENET, V76, P96; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; PADAYACHEE M, IN PRESS J MED GENET; ROSEN FS, 1961, PEDIATRICS, V28, P182; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543	18	673	696	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 11	1993	361	6412					539	541		10.1038/361539a0	http://dx.doi.org/10.1038/361539a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL714	7679206				2022-12-28	WOS:A1993KL71400061
